PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Ihara, H; Urano, T; Takada, A; Loskutoff, DJ				Ihara, H; Urano, T; Takada, A; Loskutoff, DJ			Induction of plasminogen activator inhibitor 1 gene expression in adipocytes by thiazolidinediones	FASEB JOURNAL			English	Article									Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA; Hamamatsu Univ Sch Med, Dept Physiol, Hamamatsu, Shizuoka 4313192, Japan	Scripps Research Institute; Hamamatsu University School of Medicine	Loskutoff, DJ (corresponding author), Scripps Res Inst, Dept Vasc Biol, VB-3,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	loskutof@scripps.edu							0	29	32	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1233	1235		10.1096/fj.00-0570fje	http://dx.doi.org/10.1096/fj.00-0570fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344098				2022-12-28	WOS:000168655200020
J	O'Brien, CD; Ji, GJ; Wang, YX; Sun, J; Krymskaya, VP; Ruberg, FL; Kotlikoff, MI; Albelda, SM				O'Brien, CD; Ji, GJ; Wang, YX; Sun, J; Krymskaya, VP; Ruberg, FL; Kotlikoff, MI; Albelda, SM			PECAM-1 (CD31) engagement activates a phosphoinositide-independent, nonspecific cation channel in endothelial cells	FASEB JOURNAL			English	Article									Univ Penn, Sch Med, Dept Med, Div Pulm Allergy & Crit Care Med, Philadelphia, PA 19104 USA; Cornell Univ, Coll Vet Med, Dept Biomed Sci, Ithaca, NY 14853 USA	University of Pennsylvania; Cornell University	O'Brien, CD (corresponding author), Univ Penn, Sch Med, Dept Med, Div Pulm Allergy & Crit Care Med, 838 BRB2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.			Ruberg, Frederick/0000-0002-6424-4413; Ji, Guangju/0000-0001-8626-3490					0	19	19	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1257	1260		10.1096/fj.00-0467fje	http://dx.doi.org/10.1096/fj.00-0467fje			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344106				2022-12-28	WOS:000168655200028
J	Pastor, CM; Frossard, JL				Pastor, CM; Frossard, JL			Are genetically modified mice useful for the understanding of acute pancreatitis?	FASEB JOURNAL			English	Article						IL-1; metallothionein; tumor necrosis factor; NK1R; acute pancreatitis; knockout mice	INTERCELLULAR-ADHESION MOLECULE-1; TUMOR-NECROSIS-FACTOR; OXIDATIVE STRESS; KNOCKOUT MICE; LUNG INJURY; GENE-EXPRESSION; TRANSGENIC MICE; NEUROKININ-1 RECEPTOR; SUBSTANCE-P; METALLOTHIONEIN	Treatment of patients with acute pancreatitis has greatly improved due to a better understanding of the pathophysiology of the disease, This pathophysiology includes the activation and release of pancreatic enzymes in the interstitium, the autodigestion of the pancreas, and a multiple organ dysfunction after their release into the systemic circulation, Moreover, significant evidence exists that synthesis and release of proinflammatory cytokines and chemokines are also responsible for the local injury and systemic dispersion of the inflammation, The use of knockout mice devoid of active pro- or anti-inflammatory mediators allows examination of the effects of a specific cytokine without any drawbacks induced by pharmacological manipulations. The results obtained from these genetically modified mice show that numerous mediators have a major role in the pathophysiology of acute pancreatitis, They also clearly demonstrate that a single genetic deletion cannot completely prevent the occurrence of pancreatic or distant organ injury, However, the fact that the immune system is characterized by redundancies of ligands and receptors complicates the full understanding of each report, The utility of such experimental models might have limitations, and a full extrapolation of experimental data from genetically modified mice to humans must be done with caution.	Div Gastroenterol & Hepatol, Geneva, Switzerland	University of Geneva	Pastor, CM (corresponding author), Univ Geneva, Hop Cantonal, Div Gastroenterol & Hepatol, Rue Micheli du Crest 24, CH-1211 Geneva 14, Switzerland.	Catherine.Pastor@medecine.unige.ch						Abcouwer SF, 1996, SURGERY, V120, P255, DOI 10.1016/S0039-6060(96)80296-0; ABEL J, 1989, TOXICOL LETT, V47, P191, DOI 10.1016/0378-4274(89)90075-1; Andrews GK, 2000, BIOCHEM PHARMACOL, V59, P95, DOI 10.1016/S0006-2952(99)00301-9; BARINAGA M, 1994, SCIENCE, V265, P26, DOI 10.1126/science.8016653; Bhatia M, 1998, P NATL ACAD SCI USA, V95, P4760, DOI 10.1073/pnas.95.8.4760; Dabrowski A, 1999, EUR J PHARMACOL, V377, P1, DOI 10.1016/S0014-2999(99)00421-5; Denham W, 1998, ANN SURG, V227, P812, DOI 10.1097/00000658-199806000-00004; Denham W, 1997, GASTROENTEROLOGY, V113, P1741, DOI 10.1053/gast.1997.v113.pm9352880; Denham W, 1997, SURGERY, V122, P295, DOI 10.1016/S0039-6060(97)90021-0; Fink G, 1997, J SURG RES, V67, P94, DOI 10.1006/jsre.1996.4935; Frossard JL, 1999, GASTROENTEROLOGY, V116, P694, DOI 10.1016/S0016-5085(99)70192-7; Fu K, 1998, PANCREAS, V17, P238, DOI 10.1097/00006676-199810000-00003; Gerard C, 1997, J CLIN INVEST, V100, P2022, DOI 10.1172/JCI119734; Gloor B, 1998, J SURG RES, V80, P110, DOI 10.1006/jsre.1997.5289; Grady EF, 2000, BRIT J PHARMACOL, V130, P505, DOI 10.1038/sj.bjp.0703343; Gukovsky I, 1998, AM J PHYSIOL-GASTR L, V275, pG1402, DOI 10.1152/ajpgi.1998.275.6.G1402; Halangk W, 2000, J CLIN INVEST, V106, P773, DOI 10.1172/JCI9411; Kaufmann P, 1996, IMMUNOBIOLOGY, V195, P209, DOI 10.1016/S0171-2985(96)80040-4; Kikuchi Y, 1997, BIOCHEM BIOPH RES CO, V233, P177, DOI 10.1006/bbrc.1997.6421; LAZO JS, 1995, J BIOL CHEM, V270, P5506, DOI 10.1074/jbc.270.10.5506; Levy P, 1997, PANCREAS, V14, P350, DOI 10.1097/00006676-199705000-00004; Majzoub JA, 1996, NEW ENGL J MED, V334, P904, DOI 10.1056/NEJM199604043341407; Norman J, 1997, J INTERF CYTOK RES, V17, P113, DOI 10.1089/jir.1997.17.113; Norman JG, 1996, J SURG RES, V63, P231, DOI 10.1006/jsre.1996.0253; RINDERKNECHT H, 1988, INT J PANCREATOL, V3, P105; Schultz M., 1999, AM J PHYSIOL, V276, P461; Schulz HU, 1999, HEPATO-GASTROENTEROL, V46, P2736; Suzuki S, 2000, PANCREAS, V21, P86, DOI 10.1097/00006676-200007000-00056; Telek G, 1999, J HISTOCHEM CYTOCHEM, V47, P1201, DOI 10.1177/002215549904700912; Werner J, 1999, ANN SURG, V229, P834, DOI 10.1097/00000658-199906000-00010; Whitcomb DC, 1996, NAT GENET, V14, P141, DOI 10.1038/ng1096-141	31	45	46	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2001	15	6					893	897		10.1096/fj.00-0672rev	http://dx.doi.org/10.1096/fj.00-0672rev			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292648	Green Published			2022-12-28	WOS:000167959300002
J	Wartenberg, M; Donmez, F; Ling, FC; Acker, H; Hescheler, J; Sauer, H				Wartenberg, M; Donmez, F; Ling, FC; Acker, H; Hescheler, J; Sauer, H			Tumor-induced angiogenesis studied in confrontation cultures of multicellular tumor spheroids and embryoid bodies grown from pluripotent embryonic stem cells	FASEB JOURNAL			English	Article						VEGF; hypoxia; multidrug resistance; P-glycoprotein; HSP27	LASER-SCANNING MICROSCOPY; IN-VITRO; DRUG-RESISTANCE; GENE-EXPRESSION; P-GLYCOPROTEIN; ENDOTHELIAL-CELLS; PROSTATE-CANCER; HYPOXIA; DOXORUBICIN; PROTEINS	Tumor vascularization is the rate-limiting step for the progression of cancer. Differential steps of tumor-induced angiogenesis were studied by a novel in vitro confrontation culture of avascular multicellular prostate tumor spheroids and embryoid bodies grown from pluripotent embryonic stem (ES) cells. Vascularization in embryoid bodies started on day 5 of cell culture and was paralleled by down-regulation of hypoxia-inducible factor 1 alpha (HIF-1 alpha) and vascular endothelial growth factor (VEGF). In parallel, a dissipation of gradients in the pericellular oxygen pressure was observed as measured by O-2-sensitive microelectrodes. After 24-48 h of confrontation culture, cells positive for platelet endothelial cell adhesion molecule (PECAM-1) became visible in the contact region between the embryoid body and the tumor spheroid and sprouted within the confrontation cultures during subsequent days. Tumor-induced angiogenesis resulted in growth stimulation of tumor spheroids, disappearance of central necrosis and a reduction of the pericellular oxygen pressure. Furthermore, tumor vascularization resulted in elevated levels of HIF-1 alpha, VEGF, heat shock protein 27 (HSP27), and P-glycoprotein. Tumor-induced angiogenesis may augment the oxygen consumption in tumors resulting in an increased expression of hypoxia-related, proangiogenic genes as well as of HSP27 and P-glycoprotein, which are involved in a multidrug resistance phenotype.	Univ Cologne, Dept Neurophysiol, D-50931 Cologne, Germany; Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany	University of Cologne; Max Planck Society	Sauer, H (corresponding author), Univ Cologne, Dept Neurophysiol, Robert Koch Str 39, D-50931 Cologne, Germany.	hs@physiologie.uni-koeln.de	Acker, Helmut Anton Josef/AAS-6841-2020; Acker, Helmut/AAJ-8332-2020	Acker, Helmut Anton Josef/0000-0001-5589-5508; 				BJERKVIG R, 1986, CANCER RES, V46, P4071; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Browder T, 2000, CANCER RES, V60, P1878; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Folkman J, 1992, Semin Cancer Biol, V3, P89; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gassmann M, 1996, P NATL ACAD SCI USA, V93, P2867, DOI 10.1073/pnas.93.7.2867; Grunstein J, 1999, CANCER RES, V59, P1592; HEACOCK CS, 1990, BRIT J CANCER, V62, P217, DOI 10.1038/bjc.1990.264; Hockel M, 1996, SEMIN RADIAT ONCOL, V6, P3, DOI 10.1016/S1053-4296(96)80031-2; HOCKEL M, 1993, RADIOTHER ONCOL, V26, P45, DOI 10.1016/0167-8140(93)90025-4; Jouan V, 1999, BLOOD, V94, P984, DOI 10.1182/blood.V94.3.984.415k31_984_993; Kasimir-Bauer S, 1998, EXP HEMATOL, V26, P1111; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KNEUCHEL R, 1990, AM J PATHOL, V137, P725; KNUCHEL R, 1988, J UROLOGY, V139, P640, DOI 10.1016/S0022-5347(17)42550-X; Koomagi R, 1999, ANTICANCER RES, V19, P4333; Kunz-Schughart LA, 1998, INT J EXP PATHOL, V79, P1, DOI 10.1046/j.1365-2613.1998.00051.x; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; LUK CK, 1990, J NATL CANCER I, V82, P684, DOI 10.1093/jnci/82.8.684; Nygaard SJT, 1995, INVAS METAST, V15, P179; OFFNER FA, 1993, INT J CANCER, V54, P506, DOI 10.1002/ijc.2910540325; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Ratcliffe PJ, 1998, J EXP BIOL, V201, P1153; Richard DE, 1999, BIOCHEM BIOPH RES CO, V266, P718, DOI 10.1006/bbrc.1999.1889; RISAU W, 1988, DEVELOPMENT, V102, P471; SAKATA K, 1991, BRIT J CANCER, V64, P809, DOI 10.1038/bjc.1991.405; SANNA K, 1994, INT J CANCER, V58, P258, DOI 10.1002/ijc.2910580219; Schneider J, 1998, ANTICANCER RES, V18, P2967; SHWEIKI D, 1995, P NATL ACAD SCI USA, V92, P768, DOI 10.1073/pnas.92.3.768; SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290; Tomida A, 1999, ANTI-CANCER DRUG DES, V14, P169; VAUPEL P, 1990, ADV EXP MED BIOL, V277, P895; Vittet D, 1996, BLOOD, V88, P3424, DOI 10.1182/blood.V88.9.3424.bloodjournal8893424; WALEH NS, 1995, CANCER RES, V55, P6222; Wartenberg M, 1998, LAB INVEST, V78, P1301; Wartenberg M, 1996, ANTICANCER RES, V16, P573; Wartenberg M, 1995, MICRON, V26, P395, DOI 10.1016/0968-4328(95)00009-7; Wartenberg M, 1998, INT J CANCER, V75, P855, DOI 10.1002/(SICI)1097-0215(19980316)75:6<855::AID-IJC7>3.3.CO;2-2; Wartenberg M, 1998, CYTOMETRY, V31, P137, DOI 10.1002/(SICI)1097-0320(19980201)31:2<137::AID-CYTO9>3.0.CO;2-J; Wiles Michael V., 1997, Leukemia (Basingstoke), V11, P454; Zhong H, 1998, CANCER RES, V58, P5280; Zhong H, 1999, CANCER RES, V59, P5830; Zhu H, 1999, RESP PHYSIOL, V115, P239, DOI 10.1016/S0034-5687(99)00024-9	45	138	150	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2001	15	6					995	1005		10.1096/fj.00-0350com	http://dx.doi.org/10.1096/fj.00-0350com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292660				2022-12-28	WOS:000167959300014
J	Kawanaka, H; Tomikawa, M; Jones, MK; Pai, R; Szabo, IL; Sugimachi, K; Sarfeh, IJ; Tarnawski, AS				Kawanaka, H; Tomikawa, M; Jones, MK; Pai, R; Szabo, IL; Sugimachi, K; Sarfeh, IJ; Tarnawski, AS			Portal hypertensive gastric mucosa has reduced activation of MAP kinase (ERK2) in response to alcohol injury: A key to impaired healing?	FASEB JOURNAL			English	Article									Dept Vet Affairs Med Ctr, Dept Med, Long Beach, CA USA; Dept Vet Affairs Med Ctr, Dept Surg, Long Beach, CA USA; Univ Calif Irvine, Irvine, CA 90822 USA; Kyushu Univ, Dept Surg 2, Fukuoka 812, Japan	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine; Kyushu University	Tarnawski, AS (corresponding author), DVA Med Ctr, Gastroenterol Sect 111G, 5901 E 7th St, Long Beach, CA 90822 USA.								0	18	19	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					574	576						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259371				2022-12-28	WOS:000167419500009
J	Weaver, BK; Ando, O; Kumar, KP; Reich, NC				Weaver, BK; Ando, O; Kumar, KP; Reich, NC			Apoptosis is promoted by the dsRNA-activated factor (DRAF1) during viral infection independent of the action of interferon or p53	FASEB JOURNAL			English	Article						IRF-3; transcription; defense; gene expression	DOUBLE-STRANDED-RNA; DEPENDENT PROTEIN-KINASE; DNA-DAMAGING AGENTS; VIRUS-INFECTION; SIGNAL-TRANSDUCTION; REGULATORY FACTOR-3; CELL-LINE; TRANSCRIPTION; GENE; BINDING	An apoptotic cellular defense mechanism is triggered in response to viral dsRNA generated during the course of infection by many DNA and RNA viruses. We demonstrate that apoptosis induced by dsRNA or a paramyxovirus is independent of the action of interferon as it can proceed in a variety of cell lines and primary cells deficient in an interferon response. Initiation of apoptosis appears to be triggered by activation of a cellular transcription factor, the dsRNA-activated factor (DRAF1), DRAF1 is composed of interferon regulatory factor 3 (IRF-3) and the transcriptional coactivators CREB binding protein (CBP) or p300. We find that activation of IRF-3 in the absence of viral infection stimulates apoptosis, In addition, a negative interfering mutant blocks both target gene induction and apoptosis, demonstrating a requirement for gene expression by IRF-3/DRAF1 to promote apoptosis. IRF-3/DRAF1 target gene expression is also induced in response to a distinct apoptotic stimulus, the DNA damaging agent: etoposide, The activity of the p53 tumor suppressor does not appear to be required for IRF-3/DRAF1-mediated apoptosis.	SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Reich, NC (corresponding author), SUNY Stony Brook, Dept Pathol, Acad Tower B,Nicolls Rd, Stony Brook, NY 11794 USA.				NCI NIH HHS [R01CA50773, P01CA28146] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA028146, R01CA050773] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arriola EL, 1999, ONCOGENE, V18, P1081, DOI 10.1038/sj.onc.1202391; Bitzer M, 1999, J VIROL, V73, P702, DOI 10.1128/JVI.73.1.702-708.1999; Chiou SK, 1998, VIROLOGY, V244, P108, DOI 10.1006/viro.1998.9077; DALY C, 1993, MOL CELL BIOL, V13, P3756, DOI 10.1128/MCB.13.6.3756; DALY C, 1995, J BIOL CHEM, V270, P23739, DOI 10.1074/jbc.270.40.23739; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Demaeyer E., 1988, INTERFERONS OTHER RE; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUSE A, 1984, JPN J CANCER RES, V75, P379; Gabriele L, 1999, J EXP MED, V190, P411, DOI 10.1084/jem.190.3.411; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GILMOUR KC, 1995, GENE EXPRESSION, V5, P1; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HAINES DS, 1991, J CELL BIOCHEM, V46, P9, DOI 10.1002/jcb.240460104; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; Hande KR, 1998, BBA-GENE STRUCT EXPR, V1400, P173, DOI 10.1016/S0167-4781(98)00134-1; Harada H, 1998, BIOCHIMIE, V80, P641, DOI 10.1016/S0300-9084(99)80017-0; HWANG SY, 1995, P NATL ACAD SCI USA, V92, P11284, DOI 10.1073/pnas.92.24.11284; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; Kibler KV, 1997, J VIROL, V71, P1992, DOI 10.1128/JVI.71.3.1992-2003.1997; Kim T, 1999, J BIOL CHEM, V274, P30686, DOI 10.1074/jbc.274.43.30686; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KUMAR KP, 2000, IN PRESS MOL CELL BI; LAM KM, 1995, MICROB PATHOGENESIS, V19, P169, DOI 10.1006/mpat.1995.0055; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVY D, 1986, P NATL ACAD SCI USA, V83, P8929, DOI 10.1073/pnas.83.23.8929; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Nozawa H, 1999, GENE DEV, V13, P1240, DOI 10.1101/gad.13.10.1240; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Owczarek CM, 1997, J BIOL CHEM, V272, P23865, DOI 10.1074/jbc.272.38.23865; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; Prives C, 1999, J PATHOL, V187, P112; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; REICH N, 1987, P NATL ACAD SCI USA, V84, P3694; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sato M, 1998, FEBS LETT, V425, P112, DOI 10.1016/S0014-5793(98)00210-5; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tanaka N, 1998, GENES CELLS, V3, P29, DOI 10.1046/j.1365-2443.1998.00164.x; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; WATHELET MG, 1992, EUR J BIOCHEM, V206, P901, DOI 10.1111/j.1432-1033.1992.tb16999.x; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; WHITE E, 1990, MOL CELL BIOL, V10, P120, DOI 10.1128/MCB.10.1.120; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Zhou AM, 1998, J INTERF CYTOK RES, V18, P953, DOI 10.1089/jir.1998.18.953	60	60	64	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					501	514		10.1096/fj.00-0222com	http://dx.doi.org/10.1096/fj.00-0222com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156966				2022-12-28	WOS:000166872900032
J	Zheng, YH; Voice, JK; Kong, Y; Goetzl, EJ				Zheng, YH; Voice, JK; Kong, Y; Goetzl, EJ			Altered expression and functional profile of lysophosphatidic acid receptors in mitogen-activated human blood T lymphocytes	FASEB JOURNAL			English	Article									Univ Calif San Francisco, Med Ctr, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Med Ctr, Dept Immunol Microbiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Goetzl, EJ (corresponding author), Univ Calif San Francisco, Med Ctr, Dept Med, UB8B,Box 0711,533 Parnassus & 4th, San Francisco, CA 94143 USA.								0	63	66	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2387	2389						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11024010				2022-12-28	WOS:000165723400006
J	Ganglberger, E; Grunberger, K; Sponer, B; Radauer, C; Breiteneder, H; Boltz-Nitulescu, G; Scheiner, O; Jensen-Jarolim, E				Ganglberger, E; Grunberger, K; Sponer, B; Radauer, C; Breiteneder, H; Boltz-Nitulescu, G; Scheiner, O; Jensen-Jarolim, E			Allergen mimotopes for 3-dimensional epitope search and induction of antibodies inhibiting human IgE	FASEB JOURNAL			English	Article						Bet v 1; IgE epitope; mimotope; phage; biopanning; blocking IgG	BIRCH POLLEN ALLERGEN; BET-V-I; PHAGE-DISPLAYED PEPTIDES; T-CELL CLONES; MONOCLONAL-ANTIBODIES; DISCONTINUOUS EPITOPES; AFFINITY PURIFICATION; OVERLAPPING PEPTIDES; FILAMENTOUS PHAGE; POTENTIAL USE	There is no definite information available on the structural characteristics of IgE binding epitopes on allergenic molecules, although it is widely accepted that most of them are conformational. In the current study we aimed to characterize the IgE epitope of Bet v 1, the major birch pollen allergen, by the application of phage display peptide libraries. We purified IgE specific for Bet v 1 from allergic patients' sera to select mimotopes representing artificial IgE epitopes by biopanning of phage libraries. By linear alignment, it was not possible to attribute mimotope sequences to the primary structure of Bet v 1. We developed a computer-aided, S-dimensional coarse-grained epitope search. The 3-dimensional. search, followed by statistical analysis, revealed an exposed area on the Bet v 1 molecule (located between residues 9-22 and 104-123) as the IgE binding structure. The IgE epitope was located at a 30 Angstrom distance from a previously described IgG epitope and the respective mimotope, designated Bet mim E. Such mimotopes could potentially be used for the induction of IgG capable of interfering with the IgE/allergen interaction. To test this hypothesis, we immunized BALB/c mice with the phage-displayed Bet mim E. Immunizations resulted in the induction of Bet v 1-specific IgG, which was able to block the IgE binding to Bet v 1 in vitro. Based on these observations, we propose that immunotherapy with IgE mimotopes generated by biopannings result in formation of blocking IgG. We conclude that mimotope immunotherapy may represent a new and promising concept for treatment of type I allergic disease.	Univ Vienna, Sch Med, AKH, Dept Pathophysiol, A-1090 Vienna, Austria	University of Vienna	Jensen-Jarolim, E (corresponding author), Univ Vienna, Sch Med, AKH, Dept Pathophysiol, EBO-3Q,Wahringer Gurtel 18-20, A-1090 Vienna, Austria.		Jensen-Jarolim, Erika/C-5120-2018; Radauer, Christian/AAN-6260-2021	Jensen-Jarolim, Erika/0000-0003-4019-5765; Radauer, Christian/0000-0001-9920-4449				BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; Delmastro P, 1997, VACCINE, V15, P1276, DOI 10.1016/S0264-410X(97)00072-8; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; EBNER C, 1993, J IMMUNOL, V150, P1047; EBNER C, 1993, EUR J IMMUNOL, V23, P1523, DOI 10.1002/eji.1830230719; FELICI F, 1993, GENE, V128, P21, DOI 10.1016/0378-1119(93)90148-V; FELICI F, 1991, J MOL BIOL, V222, P301, DOI 10.1016/0022-2836(91)90213-P; Ferreira F, 1998, FASEB J, V12, P231, DOI 10.1096/fasebj.12.2.231; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; Friedl-Hajek R, 1999, MOL IMMUNOL, V36, P639, DOI 10.1016/S0161-5890(99)00078-4; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; JAROLIM E, 1990, J ALLERGY CLIN IMMUN, V85, P996, DOI 10.1016/0091-6749(90)90043-4; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; JAROLIM E, 1989, INT ARCH ALLER A IMM, V90, P54, DOI 10.1159/000235000; Jensen-Jarolim E, 1999, FASEB J, V13, P1586, DOI 10.1096/fasebj.13.12.1586; Jensen-Jarolim E, 1999, INT ARCH ALLERGY IMM, V118, P224, DOI 10.1159/000024078; Jensen-Jarolim E, 1998, FASEB J, V12, P1635, DOI 10.1096/fasebj.12.15.1635; JENSENJAROLIM E, 1992, J ALLERGY CLIN IMMUN, V89, P31, DOI 10.1016/S0091-6749(05)80038-7; KREMSER M, 1989, WIEN MED WSCHR, V6, P135; Lebecque S, 1997, J ALLERGY CLIN IMMUN, V99, P374, DOI 10.1016/S0091-6749(97)70056-3; LICHTENSTEIN LM, 1968, J IMMUNOL, V101, P317; LUZZAGO A, 1993, GENE, V128, P51, DOI 10.1016/0378-1119(93)90152-S; MEOLA A, 1995, J IMMUNOL, V154, P3162; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; Schafer T, 1997, ALLERGY, V52, P14, DOI 10.1111/j.1398-9995.1997.tb04864.x; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; SWOBODA I, 1995, J BIOL CHEM, V270, P2607, DOI 10.1074/jbc.270.6.2607; Visco V, 1996, J IMMUNOL, V157, P956; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330; WUTHRICH B, 1995, INT ARCH ALLERGY IMM, V106, P149, DOI 10.1159/000236836; ZURCHER AW, 1995, IMMUNOL LETT, V46, P49, DOI 10.1016/0165-2478(95)00014-V	33	55	66	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2177	2184		10.1096/fj.99-1000com	http://dx.doi.org/10.1096/fj.99-1000com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053238				2022-12-28	WOS:000165190800010
J	Ron, D; Vagts, AJ; Dohrman, DP; Yaka, R; Jiang, Z; Yao, L; Crabbe, J; Grisel, JE; Diamond, I				Ron, D; Vagts, AJ; Dohrman, DP; Yaka, R; Jiang, Z; Yao, L; Crabbe, J; Grisel, JE; Diamond, I			Uncoupling of beta IIPKC from its targeting protein RACK1 in response to ethanol in cultured cells and mouse brain	FASEB JOURNAL			English	Article						PKC; activated C kinase receptor; cAMP; signal transduction; ethanol; targeting protein	ACTIVATED C-KINASE; A RECEPTORS; RAT-BRAIN; ANCHORING PROTEINS; CALCIUM CHANNELS; PHORBOL ESTERS; UP-REGULATION; MICE LACKING; SUBUNIT; LOCALIZATION	Protein kinase C (PKC) is involved in many neuroadaptive responses to ethanol in the nervous system, PKC activation results in translocation of the enzyme from one intracellular site to another. Compartmentalization of PKC isozymes is regulated by targeting proteins such as receptors for activated C kinase (RACKs), It is possible, therefore, that ethanol-induced changes in the function and compartmentalization of PKC isozymes could be due to changes in PKC targeting proteins. Here we study the response of the targeting protein RACK1 and its corresponding kinase beta IIPKC to ethanol, and propose a novel mechanism to explain how ethanol modulates signaling cascades. In cultured cells, ethanol induces movement of RACK1 to the nucleus without affecting the compartmentalization of beta IIPKC. Ethanol also inhibits beta IIPKC translocation in response to activation, These results suggest that ethanol inhibition of beta IIPKC translocation is due to miscompartmentalization of the targeting protein RACK1. Similar events occurred in mouse brain. In vive exposure to ethanol caused RACK1 to localize to nuclei in specific brain regions, but did not affect the compartmentalization of beta IIPKC, Thus, some of the cellular and neuroadaptive responses to ethanol may be related to ethanol-induced movement of RACK1 to the nucleus, thereby preventing the translocation and corresponding function of beta IIPKC.-Ron, D., Vagts, A. J., Dohrman, D. P., Yaka, R., Jiang, Z., Yao, L., Crabbe, J., Grisel, J. E., Diamond, I, Uncoupling of beta IIPKC from its targeting protein RACK1 in response to ethanol in cultured cells and mouse brain.	Univ Calif San Francisco, Ernest Gallo Res Ctr, Dept Neurol, San Francisco, CA 94110 USA; Univ Calif San Francisco, Ernest Gallo Res Ctr, Dept Cellular & Mol Pharmacol Pediat, San Francisco, CA 94110 USA; Univ Calif San Francisco, Ernest Gallo Res Ctr, Grad Program Neurosci, San Francisco, CA 94110 USA; Univ Calif San Francisco, Ernest Gallo Res Ctr, Ctr Neurobiol & Addict, San Francisco, CA 94110 USA; Oregon Hlth Sci Univ, Dept Behav Neurosci, Portland Alcohol Res Ctr, Portland, OR 97201 USA; Vet Affairs Med Ctr, Portland, OR 97201 USA	University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Ron, D (corresponding author), Ernest Gallo Res Ctr, 5858 Horton St,Suite 200, Emeryville, CA 94608 USA.		Grisel, Judith G./I-6152-2013	Grisel, Judith G./0000-0001-9719-2739	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P60AA010760] Funding Source: NIH RePORTER; NIAAA NIH HHS [P60 AA010760] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BATTAINI F, 1989, ALCOHOL, V6, P169, DOI 10.1016/0741-8329(89)90043-8; Battaini F, 1999, EXP NEUROL, V159, P559, DOI 10.1006/exnr.1999.7151; Battaini F, 1997, TRENDS NEUROSCI, V20, P410, DOI 10.1016/S0166-2236(97)01084-9; Brandon NJ, 1999, J NEUROSCI, V19, P9228; Chandler LJ, 1998, TRENDS PHARMACOL SCI, V19, P491, DOI 10.1016/S0165-6147(98)01268-1; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Constantinescu A, 1999, J BIOL CHEM, V274, P26985, DOI 10.1074/jbc.274.38.26985; Corsini E, 1999, J IMMUNOL, V163, P3468; CRABBLE JC, 1986, J PHARMACOL EXP THER, V239, P3237; Diamond I, 1997, PHYSIOL REV, V77, P1, DOI 10.1152/physrev.1997.77.1.1; DILDYMAYFIELD JE, 1995, J NEUROSCI, V15, P3162; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; Dohrman DP, 1996, P NATL ACAD SCI USA, V93, P10217, DOI 10.1073/pnas.93.19.10217; Escriba PV, 1999, BRIT J PHARMACOL, V127, P343, DOI 10.1038/sj.bjp.0702555; FISHBURN CS, 1995, J BIOL CHEM, V270, P29819; Geijsen N, 1999, ONCOGENE, V18, P5126, DOI 10.1038/sj.onc.1202896; Gerstin EH, 1998, J BIOL CHEM, V273, P16409, DOI 10.1074/jbc.273.26.16409; GORDON AS, 1986, P NATL ACAD SCI USA, V83, P2105, DOI 10.1073/pnas.83.7.2105; Gordon AS, 1997, MOL PHARMACOL, V52, P554, DOI 10.1124/mol.52.4.554; HARRIS RA, 1995, P NATL ACAD SCI USA, V92, P3658, DOI 10.1073/pnas.92.9.3658; Hodge CW, 1999, NAT NEUROSCI, V2, P997, DOI 10.1038/14795; Hundle B, 1997, J BIOL CHEM, V272, P15028, DOI 10.1074/jbc.272.23.15028; KAUER JA, 1988, NATURE, V334, P250, DOI 10.1038/334250a0; KRUGER H, 1993, NEUROCHEM INT, V22, P575, DOI 10.1016/0197-0186(93)90032-Z; LARSSON C, 1995, BIOCHEM PHARMACOL, V50, P647, DOI 10.1016/0006-2952(95)00179-4; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; MACDONALD RL, 1995, P NATL ACAD SCI USA, V92, P3633, DOI 10.1073/pnas.92.9.3633; Mascia MP, 1998, BRIT J PHARMACOL, V125, P263; MESSING RO, 1990, J NEUROCHEM, V55, P1383, DOI 10.1111/j.1471-4159.1990.tb03150.x; Mochly-Rosen D, 1998, FASEB J, V12, P35; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; NAGY LE, 1990, J BIOL CHEM, V265, P1946; Padanilam BJ, 1997, AM J PHYSIOL-RENAL, V272, pF160, DOI 10.1152/ajprenal.1997.272.2.F160; Pascale A, 1996, J NEUROCHEM, V67, P2471; RABIN RA, 1992, J PHARMACOL EXP THER, V262, P257; ROIVAINEN R, 1993, BRAIN RES, V624, P85, DOI 10.1016/0006-8993(93)90063-S; Ron D, 1999, J BIOL CHEM, V274, P27039, DOI 10.1074/jbc.274.38.27039; RON D, 1994, J BIOL CHEM, V269, P21395; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; RON D, 1995, P NATL ACAD SCI USA, V92, P492, DOI 10.1073/pnas.92.2.492; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; SAITO T, 1985, J NEUROCHEM, V44, P1037, DOI 10.1111/j.1471-4159.1985.tb08722.x; STEINER J, 1997, ALCOHOL, V14, P219; Stubbs CD, 1999, ALCOHOL CLIN EXP RES, V23, P1552; TANAKA C, 1992, NEUROCHEM INT, V21, P499, DOI 10.1016/0197-0186(92)90081-2; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; WEINER JL, 1994, J PHARMACOL EXP THER, V268, P1388; Weiner JL, 1997, J NEUROCHEM, V68, P1949; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909; Zheng X, 1997, J NEUROSCI, V17, P8676	52	47	48	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2303	2314		10.1096/fj.00-0143com	http://dx.doi.org/10.1096/fj.00-0143com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053252				2022-12-28	WOS:000165190800024
J	Elliott, DE; Urban, JF; Argo, CK; Weinstock, JV				Elliott, DE; Urban, JF; Argo, CK; Weinstock, JV			Does the failure to acquire helminthic parasites predispose to Crohn's disease?	FASEB JOURNAL			English	Article						ulcerative colitis; helminths; Th1/Th2 response; CD	INFLAMMATORY BOWEL-DISEASE; CYTOKINE-MEDIATED REGULATION; T-CELLS; ULCERATIVE-COLITIS; IMMUNE-RESPONSES; PROTECTIVE IMMUNITY; JEWISH POPULATION; TRICHURIS-MURIS; UNITED-STATES; SCHISTOSOMA-MANSONI	Two polarized patterns (Th1 and Th2) of cytokines regulate inflammatory responses. Each cytokine pattern inhibits production of the opposing pattern. Lymphocytes from inflamed intestine due to Crohn's disease secrete a Th1 pattern of cytokines. Crohn's disease is most prevalent in highly industrialized countries with temperate climates. It occurs rarely in tropical third world countries with poor sanitation. We propose that exposure to an environmental agent predisposes individuals to Crohn's disease. Parasitic worms (helminths) are common in tropical climates and in populations subject to crowding and poor sanitation. Children are most subject to helminthic colonization. Many helminths live within or migrate through the human gut where they interact with the mucosal immune system. The host mounts a mucosal response that includes Th2 cytokine production limiting helminthic colonization. Helminths and their eggs probably are the most potent stimulators of mucosal Th2 responses. The Th2 response provoked by parasitic worms can modulate immune reactions to unrelated parasitic, bacterial, and viral infections. Many people in developed countries now live in increasingly hygienic environments, avoiding exposure to helminths. Perhaps failure to acquire these parasites and experience mucosal Th2 conditioning predisposes to Crohn's disease, which is an overly active Th1 inflammation.	Univ Iowa, Dept Internal Med, Div Gastroenterol Hepatol, Iowa City, IA 52242 USA; USDA, Immunol & Dis Resistance Lab, Beltsville, MD 20705 USA	University of Iowa; United States Department of Agriculture (USDA)	Elliott, DE (corresponding author), Univ Hosp 4611 JCP, Div Gastroenterol Hepatol, 200 Hawkins Dr, Iowa City, IA 52242 USA.	david-elliott@uiowa.edu; joel-weinstock@uiowa.edu		Urban, Joseph/0000-0002-1590-8869; Elliott, David/0000-0002-5359-7125	NIADDK NIH HHS [AM38327] Funding Source: Medline; NIDDK NIH HHS [DK02428] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002428] Funding Source: NIH RePORTER	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON RM, 1982, PARASITOLOGY, V85, P373, DOI 10.1017/S0031182000055347; ASANO K, 1992, EXPERIENTIA, V48, P67, DOI 10.1007/BF01923611; BANCROFT AJ, 1994, EUR J IMMUNOL, V24, P3113, DOI 10.1002/eji.1830241230; Bentwich Z, 1996, CLIN EXP IMMUNOL, V103, P239, DOI 10.1046/j.1365-2249.1996.d01-612.x; Berg DJ, 1996, J CLIN INVEST, V98, P1010, DOI 10.1172/JCI118861; BERGMAN L, 1975, SCAND J GASTROENTERO, V10, P725; BETZ M, 1990, J IMMUNOL, V145, P1046; BLUMENTHAL DS, 1977, NEW ENGL J MED, V297, P1437, DOI 10.1056/NEJM197712292972605; Bortoletti G., 1992, Parassitologia (Rome), V34, P17; BRAHME F, 1975, GASTROENTEROLOGY, V69, P342; Ehrhardt RO, 1997, J IMMUNOL, V158, P566; Elliott DE, 1998, AUTOIMMUNE DISEASES, THIRD EDITION, P477; Elliott DE, 1996, GASTROENTEROL CLIN N, V25, P599, DOI 10.1016/S0889-8553(05)70265-X; Elliott DE, 1999, GASTROENTEROLOGY, V116, pA706; ELSE KJ, 1992, IMMUNOLOGY, V75, P232; ELSE KJ, 1994, J EXP MED, V179, P347, DOI 10.1084/jem.179.1.347; ELSON CO, 1995, GASTROENTEROLOGY, V109, P1344, DOI 10.1016/0016-5085(95)90599-5; ERICKSON RV, 1980, AM J PUBLIC HEALTH, V70, P1003, DOI 10.2105/AJPH.70.9.1003; FELLOWS IW, 1990, GUT, V31, P1262, DOI 10.1136/gut.31.11.1262; FINKELMAN FD, 1994, J EXP MED, V179, P1563, DOI 10.1084/jem.179.5.1563; FIORENTINO DF, 1991, J IMMUNOL, V146, P3444; FIREMAN Z, 1989, AM J GASTROENTEROL, V84, P255; FULMER HS, 1965, AM J TROP MED HYG, V14, P269, DOI 10.4269/ajtmh.1965.14.269; Fuss IJ, 1996, J IMMUNOL, V157, P1261; GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245; Gollob JA, 1997, EUR J IMMUNOL, V27, P647, DOI 10.1002/eji.1830270311; GOLLOP JH, 1988, GUT, V29, P49, DOI 10.1136/gut.29.1.49; GRENCIS RK, 1993, ANN TROP MED PARASIT, V87, P643, DOI 10.1080/00034983.1993.11812823; GROSSMAN A, 1989, HEPATO-GASTROENTEROL, V36, P193; Gusella JF, 1998, GASTROENTEROLOGY, V115, P1286, DOI 10.1016/S0016-5085(98)70103-9; HEALY GR, 1969, PUBLIC HEALTH REP, V84, P907, DOI 10.2307/4593709; HUBBARD DW, 1974, PEDIATR RES, V8, P652, DOI 10.1203/00006450-197406000-00006; Hugot JP, 1996, NATURE, V379, P821, DOI 10.1038/379821a0; HUTT MSR, 1979, ISRAEL J MED SCI, V15, P314; JAYANTHI V, 1992, Q J MED, V82, P125; JEFFERY GM, 1963, PUBLIC HEALTH REP, V78, P45, DOI 10.2307/4591726; JJUMBAMUKASA OR, 1971, AM J TROP MED HYG, V20, P109, DOI 10.4269/ajtmh.1971.20.109; JUNG RC, 1951, PEDIATRICS, V8, P548; KRAWIEC J, 1984, ISRAEL J MED SCI, V20, P16; KUBIN M, 1994, BLOOD, V83, P1847; KULLBERG MC, 1992, J IMMUNOL, V148, P3264; KURATA JH, 1992, GASTROENTEROLOGY, V102, P1940, DOI 10.1016/0016-5085(92)90317-R; KYLE J, 1992, GASTROENTEROLOGY, V103, P392, DOI 10.1016/0016-5085(92)90826-K; Lapidus A, 1997, GUT, V41, P480, DOI 10.1136/gut.41.4.480; LASHNER BA, 1986, GASTROENTEROLOGY, V91, P1396, DOI 10.1016/0016-5085(86)90193-9; Lederer JA, 1996, J EXP MED, V184, P397, DOI 10.1084/jem.184.2.397; Ledingham DL, 1996, TRANSPLANTATION, V61, P184, DOI 10.1097/00007890-199601270-00003; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; LICHTMAN AH, 1987, P NATL ACAD SCI USA, V84, P824, DOI 10.1073/pnas.84.3.824; LINDBERG E, 1991, SCAND J GASTROENTERO, V26, P495, DOI 10.3109/00365529108998572; MALEFYT RD, 1993, J IMMUNOL, V151, P6370; MANSFIELD LS, 1999, EFFECTS MICROBES IMM; Metwali A, 1996, J IMMUNOL, V157, P4546; MEUCCI G, 1992, GASTROENTEROLOGY, V103, P514, DOI 10.1016/0016-5085(92)90841-L; MILLER DS, 1974, LANCET, V2, P691; Mizoguchi A, 1996, J EXP MED, V183, P847, DOI 10.1084/jem.183.3.847; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.iy.11.040193.001121; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MUNKHOLM P, 1992, SCAND J GASTROENTERO, V27, P609, DOI 10.3109/00365529209000127; NEURATH MF, 1995, J EXP MED, V182, P1281, DOI 10.1084/jem.182.5.1281; NIESSNER M, 1995, CLIN EXP IMMUNOL, V101, P428; NIV Y, 1990, AM J GASTROENTEROL, V85, P1580; NOVIS BH, 1975, S AFR MED J, V49, P693; ODES HS, 1991, GUT, V32, P1024, DOI 10.1136/gut.32.9.1024; ODES HS, 1989, SCAND J GASTROENTERO, V24, P36, DOI 10.3109/00365528909091348; ODES HS, 1994, AM J GASTROENTEROL, V89, P1859; ORHOLM M, 1991, NEW ENGL J MED, V324, P84, DOI 10.1056/NEJM199101103240203; PEARLMAN E, 1993, J IMMUNOL, V151, P4857; POWRIE F, 1994, IMMUNITY, V1, P553, DOI 10.1016/1074-7613(94)90045-0; Ramaswamy K, 1996, J IMMUNOL, V156, P4328; ROLON PA, 1979, ISRAEL J MED SCI, V15, P318; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; ROSE JDR, 1988, GUT, V29, P346, DOI 10.1136/gut.29.3.346; ROTH MP, 1989, GASTROENTEROLOGY, V96, P1016, DOI 10.1016/0016-5085(89)91618-1; Sabin EA, 1996, J INFECT DIS, V173, P269, DOI 10.1093/infdis/173.1.269; SALAS SD, 1990, ARCH INTERN MED, V150, P1514, DOI 10.1001/archinte.150.7.1514; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SEGAL I, 1988, INT J COLORECTAL DIS, V3, P222, DOI 10.1007/BF01660719; SHAPIRA M, 1994, EUR J EPIDEMIOL, V10, P231, DOI 10.1007/BF01730377; SHAPIRA M, 1992, J CLIN GASTROENTEROL, V15, P278; Shi HN, 1998, J IMMUNOL, V160, P2449; Shivananda S, 1996, GUT, V39, P690, DOI 10.1136/gut.39.5.690; SINGER HC, 1971, GASTROENTEROLOGY, V61, P423; SONNENBERG A, 1990, GUT, V31, P1037, DOI 10.1136/gut.31.9.1037; SONNENBERG A, 1991, GASTROENTEROLOGY, V101, P122, DOI 10.1016/0016-5085(91)90468-Z; SWAIN SL, 1990, J IMMUNOL, V145, P3796; TAN CC, 1992, J GASTROEN HEPATOL, V7, P360, DOI 10.1111/j.1440-1746.1992.tb00997.x; THOMAS GAO, 1995, EUR J GASTROEN HEPAT, V7, P401; TYSK C, 1988, GUT, V29, P990, DOI 10.1136/gut.29.7.990; URBAN JF, 1993, J IMMUNOL, V151, P7086; URBAN JF, 1991, EXP PARASITOL, V73, P500, DOI 10.1016/0014-4894(91)90074-7; URBAN JF, 1995, J IMMUNOL, V154, P4675; URBAN JF, 1992, IMMUNOL REV, V127, P205, DOI 10.1111/j.1600-065X.1992.tb01415.x; Weinstock JV, 1996, GASTROENTEROL CLIN N, V25, pR11, DOI 10.1016/S0889-8553(05)70256-9; WRIGHT JP, 1983, S AFR MED J, V63, P226; Wright WH, 1955, PUBLIC HEALTH REP, V70, P966, DOI 10.2307/4589255; ZIMMERMANN WJ, 1968, PUBLIC HEALTH REP, V83, P957, DOI 10.2307/4593456	97	187	202	0	35	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2000	14	12					1848	1855		10.1096/fj.99-0885hyp	http://dx.doi.org/10.1096/fj.99-0885hyp			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973934				2022-12-28	WOS:000089212400024
J	Zhou, J; Ng, S; Adesanya-Famuiya, O; Anderson, K; Bondy, CA				Zhou, J; Ng, S; Adesanya-Famuiya, O; Anderson, K; Bondy, CA			Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression	FASEB JOURNAL			English	Article						breast cancer; androgen; tamoxifen; monkey	BREAST-CANCER RISK; POSTMENOPAUSAL WOMEN; MENSTRUAL-CYCLE; HORMONE LEVELS; PRIMATE OVARY; ANDROGEN; TAMOXIFEN; SERUM; THERAPY; GROWTH	This study investigated the effect of sex steroids and tamoxifen on primate mammary epithelial proliferation and steroid receptor gene expression. Ovariectomized rhesus monkeys were treated with placebo, 17 beta estradiol (E2) alone or in combination with progesterone (E2/P) or testosterone (E2/T), or tamoxifen for 3 days. E2 alone increased mammary epithelial proliferation by similar to six-fold (P<0.0001) and increased mammary epithelial estrogen receptor (ER alpha) mRNA expression by similar to 50% (P<0.0001; ER beta mRNA was not detected in the primate mammary gland). Progesterone did not alter E2's proliferative effects, but testosterone reduced E2-induced proliferation by similar to 40% (P<0.002) and entirely abolished E2-induced augmentation of ER alpha expression. Tamoxifen had a significant agonist effect in the ovariectomized monkey, producing a similar to threefold increase in mammary epithelial proliferation (P<0.01), but tamoxifen also reduced ER alpha expression below placebo level.. Androgen receptor (AR) mRNA was detected in mammary epithelium by in situ hybridization. AR mRNA levels were not altered by E2 alone but were significantly reduced by E2/T and tamoxifen treatment. Because combined E2/T and tamoxifen had similar effects on mammary epithelium, we investigated the regulation of known sex steroid-responsive mRNAs in the primate mammary epithelium. E2 alone had no effect on apolipoprotein D (ApoD) or IGF binding protein 5 (IGFBP5) expression, but E2/T and tamoxifen treatment groups both demonstrated identical alterations in these mRNAs (ApoD was decreased and IGFBP5 was increased). These observations showing androgen-induced down-regulation of mammary epithelial proliferation and ER expression suggest that combined estrogen/androgen hormone replacement therapy might reduce the risk of breast cancer associated with estrogen replacement. In addition, these novel findings on tamoxifen's androgen-like effects on primate mammary epithelial sex steroid receptor expression suggest that tamoxifen's protective action on mammary gland may involve androgenic effects.	NICHHD, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Bondy, CA (corresponding author), NICHHD, Dev Endocrinol Branch, NIH, Bldg 10,Rm 10N262, Bethesda, MD 20892 USA.	bondyc@exchange.nih.gov			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000628] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000628] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ayoub JPM, 1997, ANN INTERN MED, V126, P745, DOI 10.7326/0003-4819-126-9-199705010-00033; Berrino F, 1996, JNCI-J NATL CANCER I, V88, P291, DOI 10.1093/jnci/88.5.291; BRYAN RM, 1984, CANCER, V54, P2436, DOI 10.1002/1097-0142(19841201)54:11<2436::AID-CNCR2820541121>3.0.CO;2-H; Cauley JA, 1999, ANN INTERN MED, V130, P270, DOI 10.7326/0003-4819-130-4_Part_1-199902160-00004; DAUVOIS S, 1991, CANCER RES, V51, P3131; Dorgan JF, 1996, CANCER EPIDEM BIOMAR, V5, P533; ENCARNACION CA, 1993, BREAST CANCER RES TR, V26, P237, DOI 10.1007/BF00665801; GERDES J, 1991, AM J PATHOL, V138, P867; GOING JJ, 1988, AM J PATHOL, P130; Hankinson SE, 1998, JNCI-J NATL CANCER I, V90, P1292, DOI 10.1093/jnci/90.17.1292; KEY TJA, 1988, EUR J CANCER CLIN ON, V24, P29, DOI 10.1016/0277-5379(88)90173-3; LABRIE F, 1992, CANCER DETECT PREV, V16, P31; LONGACRE TA, 1986, AM J SURG PATHOL, V10, P382, DOI 10.1097/00000478-198606000-00003; MacGregor JI, 1998, PHARMACOL REV, V50, P151; MELCHOR JC, 1990, ONCOLOGY-BASEL, V47, P467; POTTEN CS, 1988, BRIT J CANCER, V58, P163, DOI 10.1038/bjc.1988.185; Rebbeck TR, 1999, AM J HUM GENET, V64, P1371, DOI 10.1086/302366; SECRETO G, 1991, CANCER RES, V51, P2572; Service RF, 1998, SCIENCE, V279, P1631, DOI 10.1126/science.279.5357.1631; Sfikakis PP, 1998, INT J IMMUNOPHARMACO, V20, P305, DOI 10.1016/S0192-0561(98)00034-4; Shyamala G, 1997, TRENDS ENDOCRIN MET, V8, P34, DOI 10.1016/S1043-2760(96)00207-X; SIMARD J, 1992, ENDOCRINOLOGY, V130, P1115, DOI 10.1210/en.130.3.1115; Simon J, 1999, MENOPAUSE, V6, P138; Staiman VR, 1997, UROLOGY, V50, P929, DOI 10.1016/S0090-4295(97)00457-3; Stomati M, 1996, J ENDOCRINOL INVEST, V19, P535, DOI 10.1007/BF03349013; Vendola KA, 1998, J CLIN INVEST, V101, P2622, DOI 10.1172/JCI2081; Weil SJ, 1998, J CLIN ENDOCR METAB, V83, P2479, DOI 10.1210/jc.83.7.2479; YU H, 1994, BREAST CANCER RES TR, V32, P291, DOI 10.1007/BF00666006; ZHOU J, 2000, IN PRESS J INVEST ME	29	156	163	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2000	14	12					1725	1730		10.1096/fj.99-0863com	http://dx.doi.org/10.1096/fj.99-0863com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973921	Green Submitted			2022-12-28	WOS:000089212400011
J	Zlatanova, J; Caiafa, P; Van Holde, K				Zlatanova, J; Caiafa, P; Van Holde, K			Linker histone binding and displacement: versatile mechanism for transcriptional regulation	FASEB JOURNAL			English	Review						DNA methylation; linker histone modifications; nucleosomal DNA; transcription regulation	NUCLEOSOME CORE PARTICLE; RIBOSOMAL-RNA GENE; DNA-METHYLATION; IN-VITRO; CHROMATIN STRUCTURE; H1E HISTONE; PROTHYMOSIN-ALPHA; CPG SEQUENCES; RICH DNA; VARIANT	In recent years, the connection between chromatin structure and its transcriptional activity has attracted considerable experimental effort. The post-translational modifications to both the core histones and the linker histones are finely tuned through interactions with transcriptional regulators and change chromatin structure in a way to allow transcription to occur. Here we review evidence for the involvement of linker histones in transcriptional regulation and suggest a scenario in which the reversible and controllable binding/displacement of proteins of this class to the nucleosome entry/exit point determine the accessibility of the nucleosomal DNA to the transcriptional machinery.	Argonne Natl Lab, Biochip Technol Ctr, Argonne, IL 60439 USA; Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, I-00161 Rome, Italy; Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	United States Department of Energy (DOE); Argonne National Laboratory; Sapienza University Rome; Oregon State University	Zlatanova, J (corresponding author), Argonne Natl Lab, Biochip Technol Ctr, 9700 S Cass Ave,Bldg 202-A253, Argonne, IL 60439 USA.	zlatanoj@everest.bim.anl.gov	Zlatanova, Jordanka/B-3273-2009		FOGARTY INTERNATIONAL CENTER [R03TW000568] Funding Source: NIH RePORTER; FIC NIH HHS [TW00568] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		ADAMS CC, 1993, CELL, V72, P305, DOI 10.1016/0092-8674(93)90109-4; ADAMS RLP, 1995, BIOESSAYS, V17, P139, DOI 10.1002/bies.950170209; AN W, 1999, BIOCHIMIE PARIS, V81, P1; Bednar J, 1998, P NATL ACAD SCI USA, V95, P14173, DOI 10.1073/pnas.95.24.14173; Belikov S, 1998, FEBS LETT, V441, P161, DOI 10.1016/S0014-5793(98)01512-9; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOUVET P, 1994, GENE DEV, V8, P1147, DOI 10.1101/gad.8.10.1147; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P865, DOI 10.1093/nar/20.4.865; Brown DT, 1996, NUCLEIC ACIDS RES, V24, P486, DOI 10.1093/nar/24.3.486; BROWN DT, 1993, J BIOL CHEM, V268, P713; Brown KS, 1997, J INSECT CONSERV, V1, P25, DOI 10.1023/A:1018422807610; Bruhat A, 1996, NUCLEIC ACIDS RES, V24, P1816, DOI 10.1093/nar/24.10.1816; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CAMPOY FJ, 1995, J BIOL CHEM, V270, P26473, DOI 10.1074/jbc.270.44.26473; CARON F, 1981, J MOL BIOL, V146, P513, DOI 10.1016/0022-2836(81)90045-0; Cirillo LA, 1998, EMBO J, V17, P244, DOI 10.1093/emboj/17.1.244; COLE RD, 1987, INT J PEPT PROT RES, V30, P433; Crane-Robinson C, 1999, BIOESSAYS, V21, P367, DOI 10.1002/(SICI)1521-1878(199905)21:5<367::AID-BIES2>3.0.CO;2-4; CraneRobinson C, 1997, TRENDS BIOCHEM SCI, V22, P75, DOI 10.1016/S0968-0004(97)01013-X; Davie JR, 1998, J CELL BIOCHEM, P203; De Capoa A, 1999, FASEB J, V13, P89; DErme M, 1996, BIOCHEM J, V316, P475, DOI 10.1042/bj3160475; ERARD MS, 1999, EUR J BIOCHEM, V175, P525; Gomez-Marquez J, 1998, BIOCHEM J, V333, P1; Hamiche A, 1996, J MOL BIOL, V257, P30, DOI 10.1006/jmbi.1996.0144; HIGURASHI M, 1991, J BIOL CHEM, V266, P8619; Howe L, 1998, BIOCHEMISTRY-US, V37, P7077, DOI 10.1021/bi980410o; HUANG LHW, 1994, NATURE, V308, P293; JIN YJ, 1986, J BIOL CHEM, V261, P5805; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; JUAN LJ, 1994, EMBO J, V13, P6031, DOI 10.1002/j.1460-2075.1994.tb06949.x; KANDOLF H, 1994, P NATL ACAD SCI USA, V91, P7257, DOI 10.1073/pnas.91.15.7257; Karetsou Z, 1998, NUCLEIC ACIDS RES, V26, P3111, DOI 10.1093/nar/26.13.3111; KASS SU, 1993, MOL CELL BIOL, V13, P7372, DOI 10.1128/MCB.13.12.7372; Kass SU, 1997, CURR BIOL, V7, P157, DOI 10.1016/S0960-9822(97)70086-1; KAWAICHI M, 1981, J BIOL CHEM, V256, P9483; KErmekchiev M, 1997, MOL CELL BIOL, V17, P5833, DOI 10.1128/MCB.17.10.5833; KUMAR NM, 1980, NUCLEIC ACIDS RES, V8, P3535, DOI 10.1093/nar/8.16.3535; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; LARSEN F, 1993, HUM MOL GENET, V2, P775, DOI 10.1093/hmg/2.6.775; Lee HL, 1998, EMBO J, V17, P1454, DOI 10.1093/emboj/17.5.1454; LEVINE A, 1993, J BIOL CHEM, V268, P21754; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; McArthur M, 1996, EMBO J, V15, P1705, DOI 10.1002/j.1460-2075.1996.tb00516.x; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; NIGHTINGALE K, 1995, J BIOL CHEM, V270, P4197, DOI 10.1074/jbc.270.9.4197; PANZETER PL, 1992, BIOCHEMISTRY-US, V31, P1379, DOI 10.1021/bi00120a014; PAPAMARCAKI T, 1994, FEBS LETT, V345, P71, DOI 10.1016/0014-5793(94)00439-0; PERRY CA, 1991, EXP CELL RES, V196, P337, DOI 10.1016/0014-4827(91)90269-Z; POIRIER GG, 1980, CAN J BIOCHEM CELL B, V58, P509, DOI 10.1139/o80-069; POIRIER GG, 1982, P NATL ACAD SCI-BIOL, V79, P3423, DOI 10.1073/pnas.79.11.3423; Polach KJ, 1996, J MOL BIOL, V258, P800, DOI 10.1006/jmbi.1996.0288; POLACH KJ, 1995, J MOL BIOL, V254, P130, DOI 10.1006/jmbi.1995.0606; Ramakrishnan V, 1997, CRIT REV EUKAR GENE, V7, P215, DOI 10.1615/CritRevEukarGeneExpr.v7.i3.20; RIDSDALE JA, 1990, J BIOL CHEM, V265, P5150; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; SANTORO R, 1995, BIOCHEM J, V305, P739, DOI 10.1042/bj3050739; Sera T, 1998, MOL CELL BIOL, V18, P3668, DOI 10.1128/MCB.18.7.3668; Shen XT, 1996, CELL, V86, P475, DOI 10.1016/S0092-8674(00)80120-8; Sweet MT, 1996, J CELL BIOL, V135, P1219, DOI 10.1083/jcb.135.5.1219; SZYF M, 1991, BIOCHEM CELL BIOL, V69, P764, DOI 10.1139/o91-117; Travers A, 1999, TRENDS BIOCHEM SCI, V24, P4, DOI 10.1016/S0968-0004(98)01339-5; TSANEV R, 1992, REPLICATION TRANSCRI; URA K, 1994, J BIOL CHEM, V269, P27171; van Holde K, 1999, BIOESSAYS, V21, P776, DOI 10.1002/(SICI)1521-1878(199909)21:9<776::AID-BIES9>3.3.CO;2-Q; van Holde K.E., 1988, CHROMATIN; vanHolde K, 1996, P NATL ACAD SCI USA, V93, P10548, DOI 10.1073/pnas.93.20.10548; Vignali M, 1998, NAT STRUCT BIOL, V5, P1025, DOI 10.1038/4133; WELLMAN SE, 1994, BIOCHEMISTRY-US, V33, P384, DOI 10.1021/bi00167a049; Widom J, 1998, ANNU REV BIOPH BIOM, V27, P285, DOI 10.1146/annurev.biophys.27.1.285; YANG GL, 1994, NAT STRUCT BIOL, V1, P761, DOI 10.1038/nsb1194-761; Zardo G, 1998, BIOL CHEM, V379, P647; Zardo G, 1998, J BIOL CHEM, V273, P16517, DOI 10.1074/jbc.273.26.16517; Zardo G, 1996, BIOCHEM BIOPH RES CO, V220, P102, DOI 10.1006/bbrc.1996.0364; ZARET KS, 1995, SEMIN CELL BIOL, V6, P209, DOI 10.1006/scel.1995.0029; Zlatanova J, 1996, PROG NUCLEIC ACID RE, V52, P217, DOI 10.1016/S0079-6603(08)60968-X; ZLATANOVA J, 1994, FASEB J, V8, P1260, DOI 10.1096/fasebj.8.15.8001738; ZLATANOVA J, 1990, TRENDS BIOCHEM SCI, V15, P273, DOI 10.1016/0968-0004(90)90053-E	82	122	135	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2000	14	12					1697	1704		10.1096/fj.99-0869rev	http://dx.doi.org/10.1096/fj.99-0869rev			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973918				2022-12-28	WOS:000089212400008
J	Solano, DC; Sironi, M; Bonfini, C; Solerte, SB; Govoni, S; Racchi, M				Solano, DC; Sironi, M; Bonfini, C; Solerte, SB; Govoni, S; Racchi, M			Insulin regulates soluble amyloid precursor protein release via phosphatidyl inositol 3 kinase-dependent pathway	FASEB JOURNAL			English	Article						signal transduction; PI3 kinase; Alzheimer's disease; alpha secretase	SPORADIC ALZHEIMERS-DISEASE; CULTURED SKIN FIBROBLASTS; ENERGY-METABOLISM; PHOSPHOINOSITIDE 3-KINASE; SELECTIVE INHIBITOR; GLUCOSE-TRANSPORT; OXIDATIVE STRESS; GROWTH-FACTOR; LATE-ONSET; SECRETION	Several lines of biochemical evidence correlate the presence of energy metabolic defects with the functional alterations associated with brain aging and with the pathogenesis of neurodegenerative disorders such as Alzheimer's disease. Within this context we tested the ability of insulin to regulate the amyloid precursor protein (APP) processing in SH-SY5Y neuroblastoma cells. Our findings show that insulin promotes APP metabolism by a glucose-independent mechanism, We demonstrate ai novel intracellular pathway that increases the rate of secretion of soluble APP through the activity of phosphatidyl-inositol 3 kinase (PI3-K). This pathway, downstream of insulin receptor tyrosine kinase activity, does not involve either the activation of protein kinase C or the mitogen-activated protein kinase (MAP-K) pathway. Because of the physiological role of PI3-K in the translocation of glucose transporter-containing vesicles, we speculate that PI3-K involvement in APP metabolism may act at the level of vesicular trafficking.	Univ Pavia, Inst Pharmacol, I-27100 Pavia, Italy; Univ Milan, Inst Pharmacol Sci, Milan, Italy; Univ Pavia, Dept Internal Med, Geriatr & Gerontol Clin, I-27100 Pavia, Italy; IRCCS, Ctr S Giovanni di Dio FBF, Brescia, Italy	University of Pavia; University of Milan; University of Pavia; IRCCS Fatebenefratelli	Racchi, M (corresponding author), Univ Pavia, Inst Pharmacol, Viale Taramelli 14, I-27100 Pavia, Italy.	racchi@unipv.it	Racchi, Marco/G-6104-2018; Govoni, Stefano/K-2965-2015	Racchi, Marco/0000-0002-7185-7808; Govoni, Stefano/0000-0002-7243-6837				ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; Bergamaschi S, 1995, NEUROSCI LETT, V201, P1, DOI 10.1016/0304-3940(95)12168-4; Blass J P, 1997, Ann N Y Acad Sci, V826, P382, DOI 10.1111/j.1749-6632.1997.tb48488.x; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; BUXBAUM JD, 1994, P NATL ACAD SCI USA, V91, P4489, DOI 10.1073/pnas.91.10.4489; Chandrasekaran K, 1996, EXP NEUROL, V142, P80, DOI 10.1006/exnr.1996.0180; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; Curti D, 1997, NEUROSCI LETT, V236, P13, DOI 10.1016/S0304-3940(97)00741-6; Davis RE, 1997, P NATL ACAD SCI USA, V94, P4526, DOI 10.1073/pnas.94.9.4526; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Desdouits-Magnen J, 1998, J NEUROCHEM, V70, P524; Dore S, 1997, P NATL ACAD SCI USA, V94, P4772, DOI 10.1073/pnas.94.9.4772; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FUKUYAMA H, 1994, J NUCL MED, V35, P1; GABUZDA D, 1994, J BIOL CHEM, V269, P13623; Gasparini L, 1999, NEUROSCI LETT, V263, P197, DOI 10.1016/S0304-3940(99)00155-X; Gasparini L, 1997, NEUROSCI LETT, V231, P113, DOI 10.1016/S0304-3940(97)00536-3; Gasparini L, 1998, FASEB J, V12, P17, DOI 10.1096/fasebj.12.1.17; Haring R, 1998, J NEUROCHEM, V71, P2094; HOYER S, 1991, J NEURAL TRANSM-PARK, V3, P1, DOI 10.1007/BF02251132; Hoyer S, 1996, ACTA NEUROL SCAND, V93, P18; Jess TJ, 1996, CELL SIGNAL, V8, P297, DOI 10.1016/0898-6568(96)00054-X; LAHIRI DK, 1994, J NEUROSCI RES, V37, P777, DOI 10.1002/jnr.490370612; LeBlanc AC, 1998, J NEUROSCI, V18, P2907; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; Mills J, 1999, J NEUROCHEM, V72, P443, DOI 10.1046/j.1471-4159.1999.0720443.x; Mills J, 1997, J NEUROSCI, V17, P9415; Munch G, 1998, J NEURAL TRANSM, V105, P439, DOI 10.1007/s007020050069; OKADA T, 1994, J BIOL CHEM, V269, P3568; PARKER WD, 1994, NEUROLOGY, V44, P1086, DOI 10.1212/WNL.44.6.1086; Parvathy S, 1998, BIOCHEMISTRY-US, V37, P1680, DOI 10.1021/bi972034y; PETERSON C, 1986, P NATL ACAD SCI USA, V83, P2758, DOI 10.1073/pnas.83.8.2758; Proud CG, 1997, BIOCHEM J, V328, P329; Racchi M, 1999, TRENDS PHARMACOL SCI, V20, P418, DOI 10.1016/S0165-6147(99)01380-2; Racchi M, 1998, BIOCHEM J, V330, P1271, DOI 10.1042/bj3301271; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SIMS NR, 1987, ANN NEUROL, V21, P451, DOI 10.1002/ana.410210507; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; Slack BE, 1997, BIOCHEM J, V327, P245, DOI 10.1042/bj3270245; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TAKADERA T, 1993, NEUROSCI LETT, V161, P41, DOI 10.1016/0304-3940(93)90135-8; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Welsh GI, 1997, FEBS LETT, V410, P418, DOI 10.1016/S0014-5793(97)00579-6; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619	46	144	151	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2000	14	7					1015	1022		10.1096/fasebj.14.7.1015	http://dx.doi.org/10.1096/fasebj.14.7.1015			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	309CG	10783157				2022-12-28	WOS:000086749500021
J	Biroccio, A; Candiloro, A; Mottolese, M; Sapora, O; Albini, A; Zupi, G; Del Bufalo, D				Biroccio, A; Candiloro, A; Mottolese, M; Sapora, O; Albini, A; Zupi, G; Del Bufalo, D			Bcl-2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and in vivo angiogenesis in a breast carcinoma line	FASEB JOURNAL			English	Article						in vivo matrigel assay; MCF7 ADR; metastasis	C-MYC; TUMOR ANGIOGENESIS; CELL-SURVIVAL; GENE-TRANSFER; P53 GENE; IN-VIVO; PRE-B; CANCER; APOPTOSIS; METASTASIS	We have previously demonstrated that bcl-2 overexpression enhances the metastatic potential of the MCF7 ADIR human breast cancer cell line resistant to adriamycin by inducing metastasis-associated properties. To further elucidate the relationship between bcl-2 expression and the metastatic potential of the MCF7 ADR line, we evaluated whether bcl-2 could be also involved in the modulation of the angiogenic phenotype. Four bcl-2-overexpressing clones, a control transfectant clone, and the MCF7 ADR parental Line were used for in vitro and in vivo experiments. Bcl-2 overexpression enhanced the synthesis of the hypoxia-stimulated VEGF protein and mRNA. Northern blot analysis demonstrated an increased VEGF mRNA expression in bcl-2-overexpressing clones, and reverse transcription-polymerase chain reaction showed higher levels of the VEGF(121) and VEGF(165) mRNA isoforms, which are the most active in eliciting angiogenesis. When incorporated into matrigel, supernatants of bcl-2-transfected cells cultured under hypoxic conditions induced an increased angiogenic response in C57BL/6 mice compared with that of control clone. Tumors from bcl-2 transfectants demonstrated increased VEGF expression and neovascularization as compared to the parental line, whereas the apoptosis in in vivo xenografts was similar in control and bcl-2 transfectants. The effect of bcl-2 on angiogenesis was not mediated by p53 protein. These results demonstrate that bcl-2 and hypoxia can act synergistically to modulate VEGF expression and the in vivo angiogenic response in the MCF7 ADR line-Biroccio, A., Candiloro, A., Mottolese, M., Sapora, O., Albini, A., Zupi, G., Del Bufalo, D. Bcl-2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and in vivo angiogenesis in a breast carcinoma line.	Regina Elena Inst Canc Res, Expt Chemotherapy Lab, I-00158 Rome, Italy; Regina Elena Inst Canc Res, Dept Pathol, I-00158 Rome, Italy; Ist Super Sanita, Comparat Toxicol Lab, I-00161 Rome, Italy; Natl Inst Canc Res, Adv Biotechnol Ctr, Genoa, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Istituto Superiore di Sanita (ISS); University of Genoa; IRCCS AOU San Martino IST	Del Bufalo, D (corresponding author), Regina Elena Inst Canc Res, Expt Chemotherapy Lab, Via Messi Oro N156, I-00158 Rome, Italy.		Del Bufalo, Donatella/K-8673-2016; Biroccio, Annamaria/B-2861-2018; Del Bufalo, Donatella/AAC-1594-2021	Del Bufalo, Donatella/0000-0002-3148-6096; Biroccio, Annamaria/0000-0003-3198-3532; Del Bufalo, Donatella/0000-0002-3148-6096; Albini, Adriana/0000-0002-9624-5103				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296-1371; Arriola EL, 1999, ONCOGENE, V18, P1457, DOI 10.1038/sj.onc.1202420; Basolo F, 1999, INT J CANCER, V81, P956, DOI 10.1002/(SICI)1097-0215(19990611)81:6<956::AID-IJC19>3.3.CO;2-E; Biroccio A, 1999, INT J CANCER, V82, P125, DOI 10.1002/(SICI)1097-0215(19990702)82:1<125::AID-IJC21>3.0.CO;2-Q; BOOCOCK CA, 1995, JNCI-J NATL CANCER I, V87, P506, DOI 10.1093/jnci/87.7.506; Bouvet M, 1998, CANCER RES, V58, P2288; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; DelBufalo D, 1997, FASEB J, V11, P947, DOI 10.1096/fasebj.11.12.9337147; DelBufalo D, 1996, J CLIN INVEST, V98, P1165, DOI 10.1172/JCI118900; Ellis LM, 1996, EUR J CANCER, V32A, P2451, DOI 10.1016/S0959-8049(96)00389-9; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1986, CANCER RES, V46, P467; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gasparini G, 1996, CLIN CANCER RES, V2, P1191; GIMBRONE MA, 1972, J EXP MED, V136, P261, DOI 10.1084/jem.136.2.261; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; Harris AL, 1996, BREAST CANCER RES TR, V38, P97, DOI 10.1007/BF01803788; HORAK ER, 1992, LANCET, V340, P1120, DOI 10.1016/0140-6736(92)93150-L; Jager R, 1997, ONCOGENE, V15, P1787, DOI 10.1038/sj.onc.1201353; KIESER A, 1994, ONCOGENE, V9, P963; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Leonetti C, 1999, CLIN CANCER RES, V5, P2588; LIOTTA LA, 1974, CANCER RES, V34, P997; MANDRIOTA SJ, 1995, J BIOL CHEM, V270, P9709, DOI 10.1074/jbc.270.17.9709; Mazure NM, 1996, CANCER RES, V56, P3436; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; PEPPER MS, 1990, CELL DIFFER DEV, V32, P319, DOI 10.1016/0922-3371(90)90046-Y; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; REED JC, 1988, NATURE, V336, P259, DOI 10.1038/336259a0; Riccioni T, 1998, GENE THER, V5, P747, DOI 10.1038/sj.gt.3300681; Risau W, 1992, GROWTH FACTORS, V7, P261, DOI 10.3109/08977199209046408; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SAPORA O, 1991, INT J RADIAT BIOL, V60, P467, DOI 10.1080/09553009114552321; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STRASSER A, 1993, ONCOGENE, V8, P1; Takaoka A, 1997, ONCOGENE, V14, P2971, DOI 10.1038/sj.onc.1201147; Uhlmann EJ, 1996, CANCER RES, V56, P2506; Uhlmann EJ, 1998, J BIOL CHEM, V273, P17926, DOI 10.1074/jbc.273.28.17926; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VIGLIETTO G, 1995, ONCOGENE, V11, P1569; Wang H, 1998, CIRC RES, V83, P832, DOI 10.1161/01.RES.83.8.832; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101	47	110	122	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2000	14	5					652	660		10.1096/fasebj.14.5.652	http://dx.doi.org/10.1096/fasebj.14.5.652			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301DH	10744622				2022-12-28	WOS:000086292700003
J	Fink, C; Ergun, S; Kralisch, D; Remmers, U; Weil, J; Eschenhagen, T				Fink, C; Ergun, S; Kralisch, D; Remmers, U; Weil, J; Eschenhagen, T			Chronic stretch of engineered heart tissue induces hypertrophy and functional improvement	FASEB JOURNAL			English	Article						tissue engineering; cell culture; EHT; atrial natriuretic factor	CARDIAC MYOCYTES; NA+/H+ EXCHANGER; RAT-HEART; EXPRESSION; RECEPTOR; OVEREXPRESSION; INDUCTION; FAILURE; KINASE; SERIES	To examine the influence of chronic mechanical stretch on functional behavior of cardiac myocytes, we reconstituted embryonic chick or neonatal rat cardiac myocytes to a 3-dimensional engineered heart tissue (EHT) by mixing freshly isolated cells with neutralized collagen I and culturing them between two Velcro-coated silicone tubes, held at a fixed distance with a metal spacer. After 4 days, EHTs were subjected to a phasic unidirectional stretch for 6 days in serum-containing medium. Compared to unstretched controls, RNA/DNA and protein/cell ratios increased by 100% and 50%, respectively. ANF mRNA and a-sarcomeric actin increased by 98% and 40%, respectively. Morphologically, stretched EHTs exhibited improved organization of cardiac myocytes into parallel arrays of rod-shaped cells, increased cell length and width, longer myofilaments, and increased mitochondrial density. Thus, stretch induced phenotypic changes, generally referred to as hypertrophy. Concomitantly, force of contraction was two- to fourfold higher both under basal conditions and after stimulation with calcium or the beta-adrenergic agonist isoprenaline. Contraction kinetics were accelerated with a 14-44% decrease in twitch duration under all those conditions. In summary, we have developed a new in vitro model that allows morphological, molecular, and functional consequences of stretch to be studied under defined conditions. The main finding was that stretch of EHTs induced cardiac myocyte hypertrophy, which was accompanied by marked improvement of contractile function.-Fink, C., Ergun, S., Kralisch, D., Remmers, U., Weil, J., Eschenhagen, T. Chronic stretch of engineered heart tissue induces hypertrophy and functional improvement.	Univ Erlangen Nurnberg, Inst Expt & Clin Pharmacol & Toxicol, Fahrstr 17, D-91054 Erlangen, Germany; Univ Hamburg, Hosp Eppendorf, Inst Expt & Clin Pharmacol & Toxicol, D-20246 Hamburg, Germany; Univ Hamburg, Hosp Eppendorf, Inst Anat, D-20246 Hamburg, Germany	University of Erlangen Nuremberg; University of Hamburg; University of Hamburg	Eschenhagen, T (corresponding author), Univ Erlangen Nurnberg, Inst Expt & Clin Pharmacol & Toxicol, Fahrstr 17, D-91054 Erlangen, Germany.	thomas.eschenhagen@pharmakologie.uni-erlangen.de						BOOM S, 1969, CIRC RES, V24, P189; Bowman JC, 1997, J CLIN INVEST, V100, P2189, DOI 10.1172/JCI119755; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALDERONE A, 1995, CIRCULATION, V92, P2385, DOI 10.1161/01.CIR.92.9.2385; Choukroun G, 1999, J CLIN INVEST, V104, P391, DOI 10.1172/JCI6350; COOPER G, 1985, J CLIN INVEST, V75, P1403, DOI 10.1172/JCI111842; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; Eschenhagen T, 1997, FASEB J, V11, P683, DOI 10.1096/fasebj.11.8.9240969; Grimm M, 1998, J MOL CELL CARDIOL, V30, P1917, DOI 10.1006/jmcc.1998.0769; HASENFUSS G, 1994, BRIT HEART J, V72, P10; Hein L, 1997, P NATL ACAD SCI USA, V94, P6391, DOI 10.1073/pnas.94.12.6391; Iwanaga Y, 1998, CIRCULATION, V98, P2065, DOI 10.1161/01.CIR.98.19.2065; Kentish JC, 1999, CIRC RES, V85, P658, DOI 10.1161/01.RES.85.8.658; KOMURO I, 1990, J BIOL CHEM, V265, P3595; Komuro I, 1996, FASEB J, V10, P631, DOI 10.1096/fasebj.10.5.8621062; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; MAUCH C, 1988, EXP CELL RES, V178, P493, DOI 10.1016/0014-4827(88)90417-X; Mazzolai L, 1998, HYPERTENSION, V31, P1324, DOI 10.1161/01.HYP.31.6.1324; MILANO CA, 1994, P NATL ACAD SCI USA, V91, P10109, DOI 10.1073/pnas.91.21.10109; Miyata S, 1996, EUR J PHARMACOL, V307, P81, DOI 10.1016/0014-2999(96)00152-5; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; RONA G, 1959, ARCH PATHOL, V67, P443; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; SCHAIBLE TF, 1986, J APPL PHYSIOL, V60, P1435, DOI 10.1152/jappl.1986.60.4.1435; SCHWARTZ K, 1986, CIRC RES, V59, P551, DOI 10.1161/01.RES.59.5.551; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; SIMPSON PC, 1989, HEART FAILURE, P113; Swynghedauw B, 1999, PHYSIOL REV, V79, P215, DOI 10.1152/physrev.1999.79.1.215; TAKALA T, 1981, BASIC RES CARDIOL, V76, P44, DOI 10.1007/BF01908162; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; WEBSTER KA, 1993, J BIOL CHEM, V268, P16852; Weil J, 1998, AM J PHYSIOL-HEART C, V275, pH378, DOI 10.1152/ajpheart.1998.275.2.H378; Wollert KC, 1996, J BIOL CHEM, V271, P9535, DOI 10.1074/jbc.271.16.9535; Xiao XH, 1999, CIRC RES, V85, P723, DOI 10.1161/01.RES.85.8.723; Yamazaki T, 1998, CIRC RES, V82, P430, DOI 10.1161/01.RES.82.4.430; Yamazaki T, 1996, CARDIOVASC RES, V31, P493; ZAK R, 1974, CIRC RES, V35, P17; ZIMMERMANN WH, 2000, IN PRESS BIOTECH BIO	40	266	283	0	25	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2000	14	5					669	679		10.1096/fasebj.14.5.669	http://dx.doi.org/10.1096/fasebj.14.5.669			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301DH	10744624				2022-12-28	WOS:000086292700005
J	Huang, TY; Chu, TF; Chen, HI; Jen, CYJ				Huang, TY; Chu, TF; Chen, HI; Jen, CYJ			Heterogeneity of [Ca2+](i) signaling in intact rat aortic endothelium	FASEB JOURNAL			English	Article						atherosclerosis; acetylcholine; histamine; blood vessel; endothelial cells	FLUID SHEAR-STRESS; VON-WILLEBRAND-FACTOR; RELAXING FACTOR; CELLS; FLOW; EXPRESSION; GENERATION; HISTAMINE; RECEPTORS; ARTERIES	Most existing knowledge about [Ca2+](i) signaling in vascular endothelium has been based on studies using endothelial cells cultured ii vitro. To examine how endothelial cells behave in situ, we have developed a method to monitor single-cell [Ca2+](i) from Fura-2-loaded rat aortic segments, Fluorescence ratio images from large numbers of endothelial cells were acquired by using a flow chamber mounted on a dual-wavelength fluorescence microscope. Our results showed that either acetylcholine or histamine reversibly activated the vascular endothelium by eliciting M-3 or H-1 receptor-mediated [Ca2+](i) increases, respectively. The acetylcholine-evoked endothelial [Ca2+](i) elevation at the branch site (intercostal orifice) was much more pronounced than that at the non-branch area. However, endothelium at the branch site was relatively insensitive to histamine, Both acetylcholine-sensitive and histamine-sensitive endothelial cells were arranged in belts aligned along flow lines and were intercalated with each other. Data analyzed from 400 endothelial cells located at the non-branch site showed drastically heterogeneous [Ca2+](i) responses to a fixed concentration of either acetylcholine or histamine, differing by two orders of magnitude in individual cells. As a conclusion, vascular endothelial cells appear to have their own characteristic [Ca2+](i) 'fingerprint' to various agonists and they may function coordinately in situ.	Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan 701, Taiwan	National Cheng Kung University	Jen, CYJ (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Physiol, 1 Ta Hsiue Rd, Tainan 701, Taiwan.		Huang, Troy/I-6395-2019					BASSENGE E, 1991, EUR HEART J, V12, P12, DOI 10.1093/eurheartj/12.suppl_E.12; CARO CG, 1971, PROC R SOC SER B-BIO, V177, P109, DOI 10.1098/rspb.1971.0019; CARTER TD, 1994, PFLUG ARCH EUR J PHY, V428, P476, DOI 10.1007/BF00374568; Cheng LJ, 1999, J BIOMED SCI, V6, P22, DOI 10.1159/000025367; Chien S, 1998, HYPERTENSION, V31, P162, DOI 10.1161/01.HYP.31.1.162; Davies PF, 1997, ANNU REV PHYSIOL, V59, P527, DOI 10.1146/annurev.physiol.59.1.527; DEWEY CF, 1981, J BIOMECH ENG-T ASME, V103, P177, DOI 10.1115/1.3138276; ETTER EF, 1994, J BIOL CHEM, V269, P10141; FALCONE JC, 1993, AM J PHYSIOL, V264, pH653, DOI 10.1152/ajpheart.1993.264.2.H653; Fleming I, 1998, CIRC RES, V82, P686, DOI 10.1161/01.RES.82.6.686; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; Garlanda C, 1997, ARTERIOSCL THROM VAS, V17, P1193, DOI 10.1161/01.ATV.17.7.1193; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HELTIANU C, 1982, J CELL BIOL, V93, P357, DOI 10.1083/jcb.93.2.357; JACOB R, 1988, NATURE, V335, P40, DOI 10.1038/335040a0; Jen C J, 1992, Platelets, V3, P145, DOI 10.3109/09537109209013175; Jen CJ, 1996, BLOOD, V87, P3775, DOI 10.1182/blood.V87.9.3775.bloodjournal8793775; JEN CJ, 1994, PROSTAGLANDINS, V47, P109, DOI 10.1016/0090-6980(94)90081-7; KORENAGA R, 1993, CELL STRUCT FUNCT, V18, P95, DOI 10.1247/csf.18.95; KU DN, 1985, ARTERIOSCLEROSIS, V5, P293, DOI 10.1161/01.ATV.5.3.293; LYNCH M, 1992, CELL CALCIUM, V13, P227, DOI 10.1016/0143-4160(92)90011-G; MILLER VM, 1992, ENDOTHELIAL REGULATI, P3; Papadaki M, 1997, BIOTECHNOL PROGR, V13, P209, DOI 10.1021/bp970029f; RISAU W, 1995, FASEB J, V9, P926, DOI 10.1096/fasebj.9.10.7615161; Ruggeri ZM, 1997, J CLIN INVEST, V100, pS41; Senis YA, 1996, BRIT J HAEMATOL, V93, P195, DOI 10.1046/j.1365-2141.1996.4661005.x; Thorin E, 1998, BRIT J PHARMACOL, V125, P1188, DOI 10.1038/sj.bjp.0702199; TRACEY WR, 1992, CIRC RES, V70, P234, DOI 10.1161/01.RES.70.2.234; Usachev YM, 1995, J PHYSIOL-LONDON, V489, P309, DOI 10.1113/jphysiol.1995.sp021052; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1	30	48	48	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2000	14	5					797	804		10.1096/fasebj.14.5.797	http://dx.doi.org/10.1096/fasebj.14.5.797			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301DH	10744636				2022-12-28	WOS:000086292700017
J	Ozaki, M; Deshpande, SS; Angkeow, P; Bellan, J; Lowenstein, CJ; Dinauer, MC; Goldschmidt-Clermont, PJ; Irani, K				Ozaki, M; Deshpande, SS; Angkeow, P; Bellan, J; Lowenstein, CJ; Dinauer, MC; Goldschmidt-Clermont, PJ; Irani, K			Inhibition of the Rac1 GTPase protects against nonlethal ischemia/reperfusion-induced necrosis and apoptosis in vivo	FASEB JOURNAL			English	Article						reactive oxygen species; adenovirus; gene therapy	POSTISCHEMIC TISSUE-INJURY; OXYGEN-FREE-RADICALS; KAPPA-B ACTIVATION; XANTHINE-OXIDASE; REPERFUSION INJURY; NADPH OXIDASE; ARACHIDONATE METABOLISM; SUPEROXIDE PRODUCTION; REOXYGENATION INJURY; MYOCARDIAL-ISCHEMIA	Reperfusion of ischemic tissue results in the generation of reactive oxygen species that contribute to tissue injury. The sources of reactive oxygen species in reperfused tissue are not fully characterized. We hypothesized that the small GTPase Rac1 mediates the oxidative burst in reperfused tissue and thereby contributes to reperfusion injury. Zn an in vivo model of mouse hepatic ischemia/reperfusion injury, recombinant adenoviral expression of a dominant negative Rac1 (Rac1N17) completely suppressed the ischemia/reperfusion-induced production of reactive oxygen species and lipid peroxides, activation of nuclear factor-kappa B, and resulted in a significant reduction of acute liver necrosis, Expression of Rac1N17 also suppressed ischemia/reperfusion-induced acute apoptosis, The protection offered by Rac1N17 was also evident in knockout mice deficient for the gp91phox component of the phagocyte NADPH oxidase. This work demonstrates the crucial role of a Rac1-regulated oxidase in mediating the production of injurious reactive oxygen species, which contribute to acute necrotic and apoptotic cell death induced by ischemia/reperfusion in vivo. Targeted inhibition of this oxidase, which is distinct from the phagocyte NADPH oxidase, should provide a new avenue for in vivo therapy aimed at protecting organs at risk from ischemia/reperfusion injury.	Johns Hopkins Univ, Sch Med, Div Cardiol, Dept Med, Baltimore, MD 21205 USA; Indiana Univ, Sch Med, Indianapolis, IN 46202 USA; Ohio State Univ, Heart & Lung Inst, Columbus, OH 43210 USA	Johns Hopkins University; Indiana University System; Indiana University-Purdue University Indianapolis; University System of Ohio; Ohio State University	Irani, K (corresponding author), Johns Hopkins Univ, Sch Med, Div Cardiol, Dept Med, Ross 1023,720 Rutland Ave, Baltimore, MD 21205 USA.	kirani@jhmi.edu	Ozaki, Michitaka/A-4549-2012	Irani, Kaikobad/0000-0001-9194-7387; Lowenstein, Charles/0000-0003-0485-7514				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ATALLA SL, 1985, TRANSPLANTATION, V40, P584, DOI 10.1097/00007890-198512000-00002; Billadeau DD, 1998, J EXP MED, V188, P549, DOI 10.1084/jem.188.3.549; Burdon RH, 1996, BIOCHEM SOC T, V24, P1028, DOI 10.1042/bst0241028; Chan PH, 1996, STROKE, V27, P1124, DOI 10.1161/01.STR.27.6.1124; Crawford LE, 1996, J BIOL CHEM, V271, P26863, DOI 10.1074/jbc.271.43.26863; Cursio R, 1999, FASEB J, V13, P253, DOI 10.1096/fasebj.13.2.253; D'Souza-Schorey C, 1998, MOL CELL BIOL, V18, P3936, DOI 10.1128/MCB.18.7.3936; DOCTOR RB, 1991, J AM SOC NEPHROL, V1, P959; DOWNEY JM, 1990, ANNU REV PHYSIOL, V52, P487, DOI 10.1146/annurev.ph.52.030190.002415; Gao GP, 1996, J VIROL, V70, P8934, DOI 10.1128/JVI.70.12.8934-8943.1996; Garcia JH, 1996, STROKE, V27, P761, DOI 10.1161/01.STR.27.4.761; Gersh BJ, 1998, AM J CARDIOL, V82, p3P, DOI 10.1016/S0002-9149(98)00659-6; GOODE HF, 1994, HEPATOLOGY, V19, P354; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; GRANGER DN, 1995, ANNU REV PHYSIOL, V57, P311, DOI 10.1146/annurev.ph.57.030195.001523; GRISHAM MB, 1986, AM J PHYSIOL, V251, pG567, DOI 10.1152/ajpgi.1986.251.4.G567; GYLLENHAMMAR H, 1987, J IMMUNOL METHODS, V97, P209, DOI 10.1016/0022-1759(87)90461-3; HASSELGREN PO, 1984, J SURG RES, V37, P409, DOI 10.1016/0022-4804(84)90207-5; HATTORI M, 1990, DNA CELL BIOL, V9, P777, DOI 10.1089/dna.1990.9.777; HEARSE DJ, 1986, ACTA PHYSIOL SCAND, V126, P65; HENSLER T, 1994, INFECT IMMUN, V62, P5281, DOI 10.1128/IAI.62.12.5281-5289.1994; HOTTER G, 1994, J LIPID MEDIAT CELL, V9, P135; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; JAESCHKE H, 1988, BIOCHEM BIOPH RES CO, V150, P568, DOI 10.1016/0006-291X(88)90431-7; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KARWINSKI W, 1993, RES EXP MED, V193, P275, DOI 10.1007/BF02576235; Kim KS, 1998, J CLIN INVEST, V101, P1821, DOI 10.1172/JCI1830; KUZUYA T, 1993, CARDIOVASC RES, V27, P1056, DOI 10.1093/cvr/27.6.1056; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Li YB, 1998, J BIOL CHEM, V273, P2015, DOI 10.1074/jbc.273.4.2015; LINDSAY S, 1991, AM J PHYSIOL, V261, pH2051, DOI 10.1152/ajpheart.1991.261.6.H2051; LUCCHESI BR, 1993, STROKE, V24, pI41; MATHEWS WR, 1994, FREE RADICAL BIO MED, V16, P763, DOI 10.1016/0891-5849(94)90191-0; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MEIER B, 1991, BIOCHEM J, V275, P241, DOI 10.1042/bj2750241; Mohanty PS, 1997, SCI TECHNOL WELD JOI, V2, P133, DOI 10.1179/stw.1997.2.3.133; Muller MJ, 1996, FREE RADICAL BIO MED, V21, P189, DOI 10.1016/0891-5849(96)00028-7; NOHL H, 1993, FREE RADICAL RES COM, V18, P127, DOI 10.3109/10715769309147486; OHTSUKI T, 1995, AM J PHYSIOL-HEART C, V268, pH1249, DOI 10.1152/ajpheart.1995.268.3.H1249; ONEILL PG, 1989, AM J PHYSIOL, V256, pH341, DOI 10.1152/ajpheart.1989.256.2.H341; PODZUWEIT T, 1987, BASIC RES CARDIOL, V82, P493, DOI 10.1007/BF01907097; POLLOCK JD, 1995, NAT GENET, V9, P202, DOI 10.1038/ng0295-202; REIMER KA, 1985, CIRCULATION, V71, P1069, DOI 10.1161/01.CIR.71.5.1069; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Sun JZ, 1996, J CLIN INVEST, V97, P562, DOI 10.1172/JCI118449; SUZUKI S, 1994, TRANSPLANT P, V26, P3695; TADA M, 1988, J MOL CELL CARDIOL, V20, P135, DOI 10.1016/0022-2828(88)90338-0; Walder CE, 1997, STROKE, V28, P2252, DOI 10.1161/01.STR.28.11.2252; Zhang Z, 1998, FREE RADICAL RES, V28, P151, DOI 10.3109/10715769809065801; Zhou MJ, 1997, ANAL BIOCHEM, V253, P169, DOI 10.1006/abio.1997.2392; Zhou MJ, 1997, ANAL BIOCHEM, V253, P162, DOI 10.1006/abio.1997.2391; Zwacka RM, 1998, NAT MED, V4, P698, DOI 10.1038/nm0698-698	56	119	131	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2000	14	2					418	429		10.1096/fasebj.14.2.418	http://dx.doi.org/10.1096/fasebj.14.2.418			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	281WQ	10657998				2022-12-28	WOS:000085184800021
J	Shichiri, M; Hirata, Y				Shichiri, M; Hirata, Y			Antiangiogenesis signals by endostatin	FASEB JOURNAL			English	Article						endostatin; angiogenesis; angiogstatin; c-myc	TARGETED HOMOLOGOUS RECOMBINATION; ENDOTHELIAL-CELL APOPTOSIS; C-MYC EXPRESSION; SURVIVAL FACTOR; TUMOR-GROWTH; NITRIC-OXIDE; ANGIOGENESIS; CYCLE; ADRENOMEDULLIN; MIGRATION	Endostatin is a potent endogenous angiogenesis inhibitor that induces regression of tumors in mice. Neither an extracellular receptor for endostatin nor intracellular signals that result in the regression of tumor vascular beds have been identified. We dem onstrate that endostatin, but not angiostatin, at comparable concentrations to those used in in vivo animal trials, rapidly down-regulates many genes in exponentially growing endothelial cells. These include immediate early response genes, cell cycle-related genes, and genes regulating apoptosis inhibitors, mitogen-activated protein kinases, focal adhesion kinase, G-protein-coupled receptors mediating endothelial growth, a mitogenic factor, adhesion molecules, and cell structure components. Suppression of both apoptosis inhibitors and cell proliferation genes may have a limited contribution to the antiangiogenesis process because endostatin induces neither apoptosis nor growth inhibition, unless studied under reduced serum conditions. In contrast, the antimigratory effect of endostatin was rapid and potent even under serum-supplemented conditions. Endostatin caused gene suppression and migration arrest exclusively in endothelial cells, most profoundly in microvascular endothelial cells. The c-myc null fibroblasts obtained by targeted homologous recombination showed an attenuated migration rate compared with isogenic parental cells, whereas the introduction of the c-myc gene into endothelial cells abrogated the antimigratory effect of endostatin. Inhibition of E-box-driven transcription by overexpressing max or mad suppressed endothelial migration. Thus, rapid down-regulation of gems by endostatin neither restores proliferating endothelial cells to their resting states nor induces apoptosis; rather, it potently inhibits endothelial cell migration partly via suppression of c-myc expression.	Tokyo Med & Dent Univ, Grad Sch, Dept Clin & Mol Endocrinol, Bunkyo Ku, Tokyo 1138519, Japan	Tokyo Medical & Dental University (TMDU)	Shichiri, M (corresponding author), Tokyo Med & Dent Univ, Grad Sch, Dept Clin & Mol Endocrinol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.	mshichiri.cme@tmd.ac.jp		Shichiri, Masayoshi/0000-0002-5704-1378				Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Blezinger P, 1999, NAT BIOTECHNOL, V17, P343, DOI 10.1038/7895; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Dhanabal M, 1999, BIOCHEM BIOPH RES CO, V258, P345, DOI 10.1006/bbrc.1999.0595; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; Dixelius J, 2000, BLOOD, V95, P3403, DOI 10.1182/blood.V95.11.3403.011k07_3403_3411; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Goligorsky MS, 1999, CLIN EXP PHARMACOL P, V26, P269, DOI 10.1046/j.1440-1681.1999.03029.x; HANSON KD, 1994, MOL CELL BIOL, V14, P5748, DOI 10.1128/MCB.14.9.5748; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; Kato H, 1997, ENDOCRINOLOGY, V138, P2615, DOI 10.1210/en.138.6.2615; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Moser TL, 1999, P NATL ACAD SCI USA, V96, P2811, DOI 10.1073/pnas.96.6.2811; Nedelec FJ, 1997, NATURE, V389, P305, DOI 10.1038/38532; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PROUTY SM, 1993, ONCOGENE, V8, P899; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; SHICHIRI M, 1993, CELL GROWTH DIFFER, V4, P93; Shichiri M, 1999, MOL ENDOCRINOL, V13, P1353, DOI 10.1210/me.13.8.1353; Shichiri M, 2000, ARTERIOSCL THROM VAS, V20, P989, DOI 10.1161/01.ATV.20.4.989; SHICHIRI M, 1991, J CLIN INVEST, V87, P1867, DOI 10.1172/JCI115210; Shichiri M, 1998, MOL ENDOCRINOL, V12, P172, DOI 10.1210/me.12.2.172; Shichiri M, 1997, HYPERTENSION, V30, P1198, DOI 10.1161/01.HYP.30.5.1198; Yamaguchi N, 1999, EMBO J, V18, P4414, DOI 10.1093/emboj/18.16.4414	25	190	216	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2001	15	6					1044	1053		10.1096/fj.99-1083com	http://dx.doi.org/10.1096/fj.99-1083com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292666				2022-12-28	WOS:000167959300020
J	Mooren, FC; Turi, S; Gunzel, D; Schlue, WR; Domschke, W; Singh, J; Lerch, MM				Mooren, FC; Turi, S; Gunzel, D; Schlue, WR; Domschke, W; Singh, J; Lerch, MM			Calcium-magnesium interactions in pancreatic acinar cells	FASEB JOURNAL			English	Article						acetylcholine; cholecystokinin-octapeptide (CCK); fura-2 (AM); ion transport; magfura-2 (AM); pancreatic acinar cells	INTRACELLULAR FREE MAGNESIUM; EXTRACELLULAR MG2+ CONCENTRATION; SUBLINGUAL MUCOUS ACINI; CYTOSOLIC-FREE MG2+; SECRETORY RESPONSES; EPITHELIAL-CELLS; RAT PANCREAS; GLAND-CELLS; MG-2+; TRANSPORT	Although the role of calcium (Ca2+) in the signal transduction and pathobiology of the exocrine pancreas is firmly established, the role of magnesium (Mg2+) remains unclear. We have characterized the intracellular distribution of Mg2+ in response to hormone stimulation in isolated mouse pancreatic acinar cells and studied the role of Mg2+ in modulating Ca2+ signaling using microspectrofluorometry and digital imaging of Ca2+- or Mg2+-sensitive fluorescent dyes as well as Mg2+-sensitive intracellular microelectrodes. Our results indicate that an increase in intracellular Mg2+ concentrations reduced the cholecystokinin (CCK) -induced Ca2+ oscillations by inhibiting the capacitive Ca2+ influx. An intracellular Ca2+ mobilization, on the other hand, was paralleled by a decrease in [Mg2+](i), which was reversible upon hormone withdrawal independent of the electrochemical gradients for Mg2+, Ca2+, Na+, and K+, and not caused by Mg2+ efflux from acinar cells. In an attempt to characterize possible Mg2+ stores that would explain the reversible, hormone-induced intracellular Mg2+ movements, we ruled out mitochondria or ATP as potential Mg2+ buffers and found that the CCK-induced [Mg2+](i) decrease was initiated at the basolateral part of the acinar cells, where most of the endoplasmic reticulum (ER) is located, and progressed from there toward the apical pole of the acinar cells in an antiparallel fashion to Ca2+ waves. These experiments represent the first characterization of intracellular Mg2+ movements in the exocrine pancreas, provide evidence for possible Mg2+ stores in the ER, and indicate that the spatial and temporal distribution of intracellular Mg concentrations profoundly affects acinar cell Ca2+ siGnaling.-Mooren, F. C., Turi, S., Gunzel, D., Schlue, W.-R., Domschke, W., Singh, J., Lerch, M. M. Calcium-magnesium interactions in pancreatic acinar cells.	Univ Munster, Dept Med B, D-48129 Munster, Germany; Univ Dusseldorf, Inst Neurobiol, D-4000 Dusseldorf, Germany; Univ Cent Lancashire, Dept Biol Sci, Cell Commun Grp, Preston PR1 2HE, Lancs, England	University of Munster; Heinrich Heine University Dusseldorf; University of Central Lancashire	Lerch, MM (corresponding author), Univ Munster, Dept Med B, Albert Schweitzer Str 33, D-48129 Munster, Germany.		Lerch, Markus M./E-2206-2016	Lerch, Markus M./0000-0002-9643-8263; Gunzel, Dorothee/0000-0002-7998-7164				AGUS Z, 1989, AM J PHYSIOL, V256, P452; ALVAREZLEEFMANS FJ, 1984, J PHYSIOL-LONDON, V354, P303, DOI 10.1113/jphysiol.1984.sp015377; BAUMANN O, 1991, P NATL ACAD SCI USA, V88, P741, DOI 10.1073/pnas.88.3.741; Berridge M, 1999, CURR BIOL, V9, pR157, DOI 10.1016/S0960-9822(99)80101-8; Berridge MJ, 1997, J EXP BIOL, V200, P315; Birch NG, 1993, MAGNESIUM CELL; BOND M, 1987, J BIOL CHEM, V262, P15636; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CORKEY BE, 1986, J BIOL CHEM, V261, P2567; DAI LJ, 1992, AM J PHYSIOL, V262, pF1100; DIWAN JJ, 1987, BIOCHIM BIOPHYS ACTA, V895, P155, DOI 10.1016/S0304-4173(87)80001-0; FLATMAN PW, 1984, J MEMBRANE BIOL, V80, P1, DOI 10.1007/BF01868686; FRANCIS LP, 1990, EXP PHYSIOL, V75, P669, DOI 10.1113/expphysiol.1990.sp003445; FREUDENRICH CC, 1992, AM J PHYSIOL, V262, pC1024, DOI 10.1152/ajpcell.1992.262.4.C1024; GRUBBS RD, 1991, AM J PHYSIOL, V260, pC1158, DOI 10.1152/ajpcell.1991.260.6.C1158; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUKOVSKAYA A, 1994, AM J PHYSIOL, V266, pG350, DOI 10.1152/ajpgi.1994.266.3.G350; GUNTHER T, 1985, BIOCHEM BIOPH RES CO, V130, P540, DOI 10.1016/0006-291X(85)90450-4; Gunzel D, 1997, PFLUG ARCH EUR J PHY, V435, P65, DOI 10.1007/s004240050484; GYLFE E, 1990, BIOCHIM BIOPHYS ACTA, V1055, P82, DOI 10.1016/0167-4889(90)90094-T; HAJNOCZKY G, 1994, J BIOL CHEM, V269, P10280; Hintz K, 1999, PFLUG ARCH EUR J PHY, V437, P354, DOI 10.1007/s004240050789; Hofer AM, 1998, EMBO J, V17, P1986, DOI 10.1093/emboj/17.7.1986; HOFER AM, 1994, AM J PHYSIOL, V267, pG442, DOI 10.1152/ajpgi.1994.267.3.G442; HURLEY TW, 1992, AM J PHYSIOL, V263, pC300, DOI 10.1152/ajpcell.1992.263.2.C300; ISHIJIMA S, 1991, AM J PHYSIOL, V261, pC1074, DOI 10.1152/ajpcell.1991.261.6.C1074; JUNG DW, 1994, J BIOENERG BIOMEMBR, V26, P527, DOI 10.1007/BF00762737; KASAHARA K, 1993, BIOCHEM BIOPH RES CO, V197, P92, DOI 10.1006/bbrc.1993.2445; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; Kruger B, 2000, AM J PATHOL, V157, P43, DOI 10.1016/S0002-9440(10)64515-4; LANSMAN JB, 1986, J GEN PHYSIOL, V88, P321, DOI 10.1085/jgp.88.3.321; LENNARD R, 1992, GEN PHARMACOL, V23, P903, DOI 10.1016/0306-3623(92)90244-E; LENNARD R, 1991, J PHYSIOL-LONDON, V435, P483, DOI 10.1113/jphysiol.1991.sp018520; LERCH MM, 1993, GASTROENTEROLOGY, V104, P1768, DOI 10.1016/0016-5085(93)90658-Y; Mooren FC, 1997, BBA-MOL CELL RES, V1358, P279, DOI 10.1016/S0167-4889(97)00062-1; MUALLEM S, 1990, J BIOL CHEM, V265, P12806; NG LL, 1991, CLIN SCI, V80, P539, DOI 10.1042/cs0800539; Petersen OH, 1999, BIOESSAYS, V21, P851, DOI 10.1002/(SICI)1521-1878(199910)21:10<851::AID-BIES7>3.3.CO;2-6; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; RAJU B, 1989, AM J PHYSIOL, V256, P540; ROMANI A, 1992, FEBS LETT, V296, P135, DOI 10.1016/0014-5793(92)80364-M; ROMANI A, 1990, NATURE, V346, P841, DOI 10.1038/346841a0; Sebille S, 1996, BIOCHEM BIOPH RES CO, V227, P743, DOI 10.1006/bbrc.1996.1579; Sebille S, 1998, BIOCHEM BIOPH RES CO, V246, P111, DOI 10.1006/bbrc.1998.8494; Sueta Carla A., 1995, Magnesium Research, V8, P389; TOESCU EC, 1992, EMBO J, V11, P1623, DOI 10.1002/j.1460-2075.1992.tb05208.x; TOESCU EC, 1993, BIOCHEM BIOPH RES CO, V192, P854, DOI 10.1006/bbrc.1993.1493; TSUNODA Y, 1990, AM J PHYSIOL, V259, pG792, DOI 10.1152/ajpgi.1990.259.5.G792; Turi S, 2000, GASTROENTEROLOGY, V118, pA430, DOI 10.1016/S0016-5085(00)83832-9; vandePut FHMM, 1996, J BIOL CHEM, V271, P4999; WILLIAMS DA, 1990, CELL CALCIUM, V11, P75, DOI 10.1016/0143-4160(90)90061-X; WILLIAMS JA, 1978, AM J PHYSIOL, V235, pE517, DOI 10.1152/ajpendo.1978.235.5.E517; Wisdom DM, 1996, MOL CELL BIOCHEM, V154, P123, DOI 10.1007/BF00226780; Wisdom DM, 1996, EXP PHYSIOL, V81, P367, DOI 10.1113/expphysiol.1996.sp003941; Yoshimura M, 1996, BBA-MOL CELL RES, V1312, P151, DOI 10.1016/0167-4889(96)00034-1; YU HJ, 1995, PHARMACOLOGY, V51, P186, DOI 10.1159/000139334; ZHANG GH, 1994, J BIOL CHEM, V269, P10352; ZHANG GH, 1992, J BIOL CHEM, V267, P20721; ZHU ZM, 1995, BBA-MOL CELL RES, V1265, P89, DOI 10.1016/0167-4889(94)00231-3	59	51	52	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					659	672		10.1096/fj.00-0172com	http://dx.doi.org/10.1096/fj.00-0172com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259384				2022-12-28	WOS:000167419500023
J	Zauli, G; Milani, D; Mirandola, P; Mazzoni, M; Secchiero, P; Miscia, S; Capitani, S				Zauli, G; Milani, D; Mirandola, P; Mazzoni, M; Secchiero, P; Miscia, S; Capitani, S			HIV-1 Tat protein down-regulates CREB transcription factor expression in PC12 neuronal cells through a phosphatidylinositol 3-kinase/AKT/cyclic nucleoside phosphodiesterase pathway	FASEB JOURNAL			English	Article						extracellular Tat; signal transduction; cAMP; PC12; HIV-1-associated dementia	IMMUNODEFICIENCY-VIRUS TYPE-1; INSULIN-INDUCED PHOSPHORYLATION; GENE-TRANSCRIPTION; FRONTAL-CORTEX; GROWTH-FACTOR; BASIC DOMAIN; KINASE AKT; ACTIVATION; AIDS; BINDING	The addition of low concentrations (0.1-1 nM) of extracellular HIV-1 Tat protein to PC12 neuronal cells stimulated a rapid (peak at 5 min) elevation of the cAMP intracellular levels, which in turn induced the phosphorylation of CREB transcription factor (peak at 15 min) on serine-133 (Ser-133). On the contrary, at later time points (60-120 min) Tat induced a significant decline of intracellular cAMP with respect to the basal levels observed in control cells treated with bovine serum albumin. In blocking experiments performed with pharmacological inhibitors, Tat decreased the intracellular levels of cAMP and CREB Ser-133 phosphorylation through a signal transduction pathway involving the sequential activation of phosphatidylinositol 3-kinase, AKT, and cyclic nucleoside phosphodiesterases. Moreover, in transient transfection experiments, Tat inhibited transcription of CREB promoter in a manner strictly dependent on the presence of the cAMP-responsive elements (CRE) in the CREB promoter. Consistently, the expression of endogenous CREB protein was significantly reduced in PC12 cells by prolonged (24-48 h) treatment with Tat. This decline in the expression of CREB, which plays an essential role in the survival and function of neuronal cells, anticipated a progressive increase of apoptosis in Tat-treated cells. Although obtained in a neuronal cell Line, our findings might help to explain some aspects of the pathogenesis of HIV-l-associated dementia.	Univ Chieti, Inst Normal Morphol G Dannunzio, I-66100 Chieti, Italy; Univ Ferrara, Dept Morphol & Embryol, Human Anat Sect, I-44100 Ferrara, Italy	G d'Annunzio University of Chieti-Pescara; University of Ferrara	Zauli, G (corresponding author), Univ Chieti, Inst Normal Morphol G Dannunzio, Via Vestini 6, I-66100 Chieti, Italy.		Zauli, Giorgio/ABE-8001-2020; Mirandola, Prisco/L-3137-2015; Milani, Daniela/G-5579-2015; secchiero, paola/G-9689-2015	Mirandola, Prisco/0000-0002-5058-3924; Milani, Daniela/0000-0002-9540-7801; secchiero, paola/0000-0003-4101-7987; CAPITANI, Silvano/0000-0003-2795-6814; Zauli, Giorgio/0000-0002-3750-8698				ADLEBIASSETTE H, 1995, NEUROPATH APPL NEURO, V21, P218, DOI 10.1111/j.1365-2990.1995.tb01053.x; Albini A, 1998, P NATL ACAD SCI USA, V95, P13153, DOI 10.1073/pnas.95.22.13153; Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296-1371; BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Cafaro A, 1999, NAT MED, V5, P643, DOI 10.1038/9488; Cheng J, 1998, NEUROSCIENCE, V82, P97, DOI 10.1016/S0306-4522(97)00174-7; DIEP A, 1991, GENOMICS, V11, P1161, DOI 10.1016/0888-7543(91)90047-I; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; EVERALL IP, 1991, LANCET, V337, P1119, DOI 10.1016/0140-6736(91)92786-2; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; Filippi CG, 1998, RADIOLOGY, V206, P491, DOI 10.1148/radiology.206.2.9457204; FRANK DA, 1994, CELL, V79, P5, DOI 10.1016/0092-8674(94)90394-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gallo RC, 1999, P NATL ACAD SCI USA, V96, P8324, DOI 10.1073/pnas.96.15.8324; GARRIELI Y, 1992, J CELL BIOL, V119, P493; Gelbard Harris A., 1995, Current Opinion in Pediatrics, V7, P655; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Gringeri A, 1998, J Hum Virol, V1, P293; HOEFFLER JP, 1990, MOL ENDOCRINOL, V4, P920, DOI 10.1210/mend-4-6-920; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; KETZLER S, 1990, ACTA NEUROPATHOL, V80, P92, DOI 10.1007/BF00294228; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; KOLSON DL, 1994, J GEN VIROL, V75, P1927, DOI 10.1099/0022-1317-75-8-1927; Kruman II, 1998, EXP NEUROL, V154, P276, DOI 10.1006/exnr.1998.6958; KURE K, 1990, ACTA NEUROPATHOL, V80, P393, DOI 10.1007/BF00307693; MacKenzie SJ, 1998, P NATL ACAD SCI USA, V95, P3549, DOI 10.1073/pnas.95.7.3549; Maggirwar SB, 1999, J NEUROCHEM, V73, P578, DOI 10.1046/j.1471-4159.1999.0730578.x; MAGNUSON DSK, 1995, ANN NEUROL, V37, P373, DOI 10.1002/ana.410370314; Menegon A, 1997, BIOCHEM BIOPH RES CO, V238, P800, DOI 10.1006/bbrc.1997.7393; MERRILL JE, 1991, FASEB J, V5, P23921; MEYER TE, 1993, ENDOCRINOLOGY, V132, P770, DOI 10.1210/en.132.2.770; Milani D, 1996, J BIOL CHEM, V271, P22961, DOI 10.1074/jbc.271.38.22961; Milani D, 1998, AIDS, V12, P1275, DOI 10.1097/00002030-199811000-00008; Nath A, 1996, J VIROL, V70, P1475, DOI 10.1128/JVI.70.3.1475-1480.1996; Nath A, 1999, J BIOL CHEM, V274, P17098, DOI 10.1074/jbc.274.24.17098; New DR, 1998, J BIOL CHEM, V273, P17852, DOI 10.1074/jbc.273.28.17852; Pauza CD, 2000, P NATL ACAD SCI USA, V97, P3515, DOI 10.1073/pnas.070049797; PETITO CK, 1995, AM J PATHOL, V146, P1121; PHILIPPON V, 1994, VIROLOGY, V205, P519, DOI 10.1006/viro.1994.1673; POWER C, 1993, ANN NEUROL, V34, P339, DOI 10.1002/ana.410340307; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Walker WH, 1998, MOL CELL ENDOCRINOL, V143, P167, DOI 10.1016/S0303-7207(98)00082-3; WEEKS BS, 1995, J NEUROSCI RES, V42, P34, DOI 10.1002/jnr.490420105; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; Wijkander J, 1998, ENDOCRINOLOGY, V139, P219, DOI 10.1210/en.139.1.219; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; ZAULI G, 1995, J ACQ IMMUN DEF SYND, V10, P306; Zauli G, 2000, J BIOL CHEM, V275, P4159, DOI 10.1074/jbc.275.6.4159	56	33	35	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					483	491		10.1096/fj.00-0354com	http://dx.doi.org/10.1096/fj.00-0354com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156964				2022-12-28	WOS:000166872900030
J	Pang, LH; Knox, AJ				Pang, LH; Knox, AJ			Regulation of TNF-alpha-induced eotaxin release from cultured human airway smooth muscle cells by beta(2)-agonists and corticosteroids	FASEB JOURNAL			English	Article						eosinophil; cyclic AMP; asthma; phosphodiesterase; cytokine	PROTEIN-KINASE-A; CYCLIC ADENOSINE-MONOPHOSPHATE; NITRIC-OXIDE SYNTHASE; EOSINOPHIL CHEMOATTRACTANT; BRONCHOALVEOLAR LAVAGE; MOLECULAR-CLONING; ENDOTHELIAL-CELLS; EXPRESSION; RECEPTOR; ASTHMA	Eotaxin is a potent eosinophil chemoattractant that contributes to the eosinophilia seen in asthma and other allergic disorders. Recent studies have identified human airway smooth muscle (HASM) as a rich source of eotaxin, but the factors regulating its production are poorly understood. Here we describe for the first time that beta (2)-agonists can inhibit cytokine-induced eotaxin release. We found that TNF-alpha stimulated eotaxin release (assayed by ELISA) from HASM cells and that the release was partially inhibited by salbutamol and salmeterol. The effect of beta (2)-agonists was mimicked by forskolin and 8-bromo-cAMP and potentiated by the cAMP-dependent phosphodiesterase inhibitor rolipram, suggesting that it is cAMP dependent. We also found that the cAMP inhibition was likely at the transcription stage, although experiments with the PKA. inhibitors H-89 and Rp-cAMP or the PKG inhibitor KT5823 suggested that none of these kinases was involved. Partial inhibition of eotaxin release was also seen with the corticosteroids dexamethasone and fluticasone, The combined use of beta (2)-agonists, rolipram, and steroids abolished TNF-alpha -induced eotaxin release. These results suggest that the combination of a beta (2)-agonist, PDE inhibitor, and a corticosteroid may have additive beneficial effects in the treatment of the eosinophilia associated with asthma and other allergic diseases.	Univ Nottingham, City Hosp, Div Resp Med, Nottingham NG5 1PB, England	Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham	Pang, LH (corresponding author), Univ Nottingham, City Hosp, Div Resp Med, Clin Sci Bldg,Hucknall Rd, Nottingham NG5 1PB, England.			Knox, Alan/0000-0002-5906-4143				BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; Brown JR, 1998, CLIN EXP IMMUNOL, V114, P137; Cass LA, 1999, MOL CELL BIOL, V19, P5882; Chung KF, 1999, BRIT J PHARMACOL, V127, P1145, DOI 10.1038/sj.bjp.0702660; Eickelberg O, 1999, J BIOL CHEM, V274, P1005, DOI 10.1074/jbc.274.2.1005; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; Ghaffar O, 1999, AM J RESP CRIT CARE, V159, P1933, DOI 10.1164/ajrccm.159.6.9805039; Hein H, 1997, BIOCHEM BIOPH RES CO, V237, P537, DOI 10.1006/bbrc.1997.7169; John M, 1998, AM J RESP CELL MOL, V18, P84, DOI 10.1165/ajrcmb.18.1.2813; John M, 1997, J IMMUNOL, V158, P1841; Johnson SR, 1997, TRENDS PHARMACOL SCI, V18, P288, DOI 10.1016/S0165-6147(97)01092-4; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; KNUDSEN PJ, 1986, J IMMUNOL, V137, P3189; Lamkhioued B, 1997, J IMMUNOL, V159, P4593; Lilly CM, 1997, J CLIN INVEST, V99, P1767, DOI 10.1172/JCI119341; MATTOLI S, 1991, J ALLERGY CLIN IMMUN, V87, P794, DOI 10.1016/0091-6749(91)90125-8; Mattoli S, 1997, BIOCHEM BIOPH RES CO, V236, P299, DOI 10.1006/bbrc.1997.6958; Minshall EM, 1997, AM J RESP CELL MOL, V17, P683, DOI 10.1165/ajrcmb.17.6.2865; Mustafa SB, 1998, J BIOL CHEM, V273, P5073, DOI 10.1074/jbc.273.9.5073; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; NEUMANN M, 1995, EMBO J, V14, P1991, DOI 10.1002/j.1460-2075.1995.tb07191.x; Pang LH, 1998, J IMMUNOL, V161, P2509; Pang LH, 1998, BRIT J PHARMACOL, V125, P1320, DOI 10.1038/sj.bjp.0702193; Pang LH, 1997, BIOCHEM PHARMACOL, V53, P493, DOI 10.1016/S0006-2952(96)00737-X; Pang LH, 1997, BRIT J PHARMACOL, V121, P579, DOI 10.1038/sj.bjp.0701152; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; ROTHENBERG ME, 1995, P NATL ACAD SCI USA, V92, P8960, DOI 10.1073/pnas.92.19.8960; Rothenberg ME, 1996, MOL MED, V2, P334, DOI 10.1007/BF03401631; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624; WILLIS SA, 1995, J IMMUNOL, V154, P1399; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590; Yamada H, 1997, BIOCHEM BIOPH RES CO, V231, P365, DOI 10.1006/bbrc.1997.6100; Ying S, 1997, EUR J IMMUNOL, V27, P3507, DOI 10.1002/eji.1830271252	37	119	127	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2001	15	1					261	269		10.1096/fj.00-0103com	http://dx.doi.org/10.1096/fj.00-0103com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149914				2022-12-28	WOS:000166312400035
J	Marshall, HE; Merchant, K; Stamler, JS				Marshall, HE; Merchant, K; Stamler, JS			Nitrosation and oxidation in the regulation of gene expression	FASEB JOURNAL			English	Review						nitric oxide; oxidative stress; nitrosative stress; S-nitrosylation; thiols; transcription factors	NF-KAPPA-B; DNA-BINDING ACTIVITY; NITRIC-OXIDE SYNTHASE; ANTIOXIDANT RESPONSE ELEMENT; EARLY GROWTH RESPONSE-1; WILD-TYPE P53; CONSERVED CYSTEINE RESIDUES; ACTIVATED PROTEIN-KINASES; GLUTATHIONE-S-TRANSFERASE; NECROSIS-FACTOR-ALPHA	A growing body of evidence suggests that the cellular response to oxidative and nitrosative stress is primarily regulated at the level of transcription. Posttranslational modification of transcription factors may provide a mechanism by which cells sense these redox changes. In bacteria, for example, OxyR senses redox-related changes via oxidation or nitrosylation of a free thiol in the DNA binding region. This mode of regulation may serve as a paradigm for redox-sensing by eukaryotic transcription factors as most-including NF-kappa B, AP-1, and p53-contain reactive thiols in their DNA binding regions, the modification of which alters binding in vitro. Several of these transcription factors have been found to be sensitive to both reactive oxygen species and nitric oxide-related species in vivo. It remains entirely unclear, however, if oxidation or nitrosylation of eukaryotic transcription factors is an important mode of regulation, or whether transcriptional activating pathways are principally controlled at other redox-sensitive levels.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute	Stamler, JS (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Room 321,MSRB,DUMC 2612, Durham, NC 27710 USA.	STAML001@mc.duke.edu		Stamler, Jonathan/0000-0002-6866-1572				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ADCOCK IM, 1994, EUR RESPIR J, V7, P2117, DOI 10.1183/09031936.94.07122117; Akamatsu Y, 1997, J BIOL CHEM, V272, P14497, DOI 10.1074/jbc.272.23.14497; Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; AMMENDOLA R, 1994, EUR J BIOCHEM, V225, P483, DOI 10.1111/j.1432-1033.1994.t01-1-00483.x; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Anrather J, 1999, J BIOL CHEM, V274, P13594, DOI 10.1074/jbc.274.19.13594; ARNELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279, DOI 10.1006/abbi.1995.1231; ARNONE MI, 1995, J BIOL CHEM, V270, P12048, DOI 10.1074/jbc.270.20.12048; BANDYOPADHYAY S, 1994, J BIOL CHEM, V269, P29949; Berendji D, 1997, FEBS LETT, V405, P37, DOI 10.1016/S0014-5793(97)00150-6; Bijur GN, 1999, MOL BRAIN RES, V71, P69, DOI 10.1016/S0169-328X(99)00168-0; Brendeford EM, 1998, FEBS LETT, V425, P52, DOI 10.1016/S0014-5793(98)00196-3; Calmels S, 1997, CANCER RES, V57, P3365; CHEN F, 1995, BIOCHEM BIOPH RES CO, V214, P839, DOI 10.1006/bbrc.1995.2363; Chinenov Y, 1998, J BIOL CHEM, V273, P6203, DOI 10.1074/jbc.273.11.6203; Chiu JJ, 1999, CIRC RES, V85, P238, DOI 10.1161/01.RES.85.3.238; CLAIBORNE A, 1993, FASEB J, V7, P1483, DOI 10.1096/fasebj.7.15.8262333; DAS KC, 1995, MOL CELL BIOCHEM, V148, P45, DOI 10.1007/BF00929502; DATTA R, 1992, BIOCHEMISTRY-US, V31, P8300, DOI 10.1021/bi00150a025; Davies KJA, 1995, BIOCHEM SOC SYMP, P1, DOI 10.1042/bss0610001; DelaTorre A, 1997, BIOCHEM BIOPH RES CO, V238, P703, DOI 10.1006/bbrc.1997.7279; DELPHIN C, 1994, EUR J BIOCHEM, V223, P683, DOI 10.1111/j.1432-1033.1994.tb19041.x; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; Duh JL, 1995, J BIOL CHEM, V270, P30499, DOI 10.1074/jbc.270.51.30499; Duhe RJ, 1998, P NATL ACAD SCI USA, V95, P126, DOI 10.1073/pnas.95.1.126; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; ESPOSITO F, 1995, BBA-GENE STRUCT EXPR, V1260, P308, DOI 10.1016/0167-4781(94)00209-L; Eu JP, 2000, BIOCHEMISTRY-US, V39, P1040, DOI 10.1021/bi992046e; FELLEYBOSCO E, 1994, AM J RESP CELL MOL, V11, P159, DOI 10.1165/ajrcmb.11.2.7519434; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Fojta M, 1999, J BIOL CHEM, V274, P25749, DOI 10.1074/jbc.274.36.25749; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; Gaiddon C, 1999, EMBO J, V18, P5609, DOI 10.1093/emboj/18.20.5609; GALANG CK, 1993, MOL CELL BIOL, V13, P4609, DOI 10.1128/MCB.13.8.4609; Galigniana MD, 1999, MOL PHARMACOL, V55, P317, DOI 10.1124/mol.55.2.317; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; Griscavage JM, 1996, P NATL ACAD SCI USA, V93, P3308, DOI 10.1073/pnas.93.8.3308; GUEHMANN S, 1992, NUCLEIC ACIDS RES, V20, P2279, DOI 10.1093/nar/20.9.2279; HABY C, 1994, J NEUROCHEM, V62, P496; HAINAUT P, 1993, CANCER RES, V53, P4469; Hausladen A, 1998, P NATL ACAD SCI USA, V95, P14100, DOI 10.1073/pnas.95.24.14100; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; HENDERSON SA, 1994, J BIOL CHEM, V269, P25239; Hidalgo E, 1997, CELL, V88, P121, DOI 10.1016/S0092-8674(00)81864-4; HIDALGO E, 1995, J BIOL CHEM, V270, P20908, DOI 10.1074/jbc.270.36.20908; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; HUANG RP, 1993, DNA CELL BIOL, V12, P265, DOI 10.1089/dna.1993.12.265; HUTCHISON KA, 1991, J BIOL CHEM, V266, P10505; JacquierSarlin MR, 1996, BIOCHEM J, V318, P187, DOI 10.1042/bj3180187; JAISWAL AK, 1994, BIOCHEM PHARMACOL, V48, P439, DOI 10.1016/0006-2952(94)90272-0; JANSSEN YMW, 1994, AM J RESP CELL MOL, V11, P522, DOI 10.1165/ajrcmb.11.5.7946382; JANSSEN YMW, 1995, CANCER RES, V55, P2085; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Kambe F, 1996, MOL ENDOCRINOL, V10, P801, DOI 10.1210/me.10.7.801; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kim H, 1997, BIOCHEMISTRY-US, V36, P13677, DOI 10.1021/bi970837f; KINNULA VL, 1995, LAB INVEST, V73, P3; Klatt P, 1999, J BIOL CHEM, V274, P15857, DOI 10.1074/jbc.274.22.15857; Klatt P, 1999, FASEB J, V13, P1481, DOI 10.1096/fasebj.13.12.1481; KULLIK I, 1995, J BACTERIOL, V177, P1275, DOI 10.1128/jb.177.5.1275-1284.1995; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; Lander HM, 1996, J BIOL CHEM, V271, P19705, DOI 10.1074/jbc.271.33.19705; LANDER HM, 1993, J IMMUNOL, V150, P1509; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; Lando D, 2000, J BIOL CHEM, V275, P4618, DOI 10.1074/jbc.275.7.4618; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; Makino Y, 1996, J CLIN INVEST, V98, P2469, DOI 10.1172/JCI119065; Makino Y, 1999, J BIOL CHEM, V274, P3182, DOI 10.1074/jbc.274.5.3182; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; Martin ME, 1996, J BIOL CHEM, V271, P25617, DOI 10.1074/jbc.271.41.25617; MATTHEWS JR, 1993, NUCLEIC ACIDS RES, V21, P1727, DOI 10.1093/nar/21.8.1727; MATTHEWS JR, 1995, NUCLEIC ACIDS RES, V23, P3393, DOI 10.1093/nar/23.17.3393; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MESSMER UK, 1994, FEBS LETT, V355, P23; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MITOMO K, 1994, GENE, V145, P197; Mohr S, 1996, J BIOL CHEM, V271, P4209; MOHR S, 1994, FEBS LETT, V348, P223, DOI 10.1016/0014-5793(94)00596-6; Moinova HR, 1998, J BIOL CHEM, V273, P14683, DOI 10.1074/jbc.273.24.14683; MORRIS BJ, 1995, J BIOL CHEM, V270, P24740; Nakshatri H, 1996, J BIOL CHEM, V271, P28784, DOI 10.1074/jbc.271.46.28784; Nikitovic D, 1998, BIOCHEM BIOPH RES CO, V242, P109, DOI 10.1006/bbrc.1997.7930; Norris JL, 1999, J BIOL CHEM, V274, P13841, DOI 10.1074/jbc.274.20.13841; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; NUNOSHIBA T, 1995, INFECT IMMUN, V63, P794, DOI 10.1128/IAI.63.3.794-798.1995; Okamoto K, 1999, J BIOL CHEM, V274, P10363, DOI 10.1074/jbc.274.15.10363; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; Pinkus R, 1996, J BIOL CHEM, V271, P13422, DOI 10.1074/jbc.271.23.13422; POGNONEC P, 1992, J BIOL CHEM, V267, P24563; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; Rao GN, 1999, J BIOL CHEM, V274, P6003, DOI 10.1074/jbc.274.9.6003; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; SATRIANO J, 1994, J CLIN INVEST, V94, P1629, DOI 10.1172/JCI117505; Schafer D, 1996, FEBS LETT, V391, P35, DOI 10.1016/0014-5793(96)00701-6; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHRECK R, 1994, METHOD ENZYMOL, V234, P151; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Sekkai D, 1998, J BIOL CHEM, V273, P3895, DOI 10.1074/jbc.273.7.3895; SHEFFLER LA, 1995, J IMMUNOL, V155, P886; SHIBANUMA M, 1994, FEBS LETT, V353, P62, DOI 10.1016/0014-5793(94)01014-5; Shin WS, 1996, J BIOL CHEM, V271, P11317, DOI 10.1074/jbc.271.19.11317; Shono T, 1996, MOL CELL BIOL, V16, P4231; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Simon DI, 1996, P NATL ACAD SCI USA, V93, P4736, DOI 10.1073/pnas.93.10.4736; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; Stamler JS, 1998, NAT STRUCT BIOL, V5, P247, DOI 10.1038/nsb0498-247; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; TABUCHI A, 1994, FEBS LETT, V351, P123, DOI 10.1016/0014-5793(94)00839-6; Taylor BS, 1997, ARCH SURG-CHICAGO, V132, P1177; Tell G, 1998, BIOCHEM BIOPH RES CO, V252, P178, DOI 10.1006/bbrc.1998.9548; Tell G, 1998, J BIOL CHEM, V273, P25062, DOI 10.1074/jbc.273.39.25062; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; WALKER LJ, 1993, MOL CELL BIOL, V13, P5370, DOI 10.1128/MCB.13.9.5370; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; Wenk J, 1999, J BIOL CHEM, V274, P25869, DOI 10.1074/jbc.274.36.25869; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Wilkinson J, 1998, BIOCHEM BIOPH RES CO, V253, P855, DOI 10.1006/bbrc.1998.9804; Wu HH, 1998, J BIOL CHEM, V273, P18898, DOI 10.1074/jbc.273.30.18898; Wu XS, 1996, MOL CELL BIOL, V16, P1035; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; XIE QW, 1994, J BIOL CHEM, V269, P4705; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718; Zheng M, 2000, BIOCHEM PHARMACOL, V59, P1, DOI 10.1016/S0006-2952(99)00289-0	143	357	371	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2000	14	13					1889	1900		10.1096/fj.00.011rev	http://dx.doi.org/10.1096/fj.00.011rev			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023973				2022-12-28	WOS:000089634400008
J	Gorlach, A; Brandes, RP; Bassus, S; Kronemann, N; Kirchmaier, CM; Busse, R; Schini-Kerth, VB				Gorlach, A; Brandes, RP; Bassus, S; Kronemann, N; Kirchmaier, CM; Busse, R; Schini-Kerth, VB			Oxidative stress and expression of p22phox are involved in the up-regulation of tissue factor in vascular smooth muscle cells in response to activated platelets	FASEB JOURNAL			English	Article						NAD(P)H oxidase; reactive oxygen species; platelet-derived products; vascular injury; antisense technique	MONOCYTE CHEMOATTRACTANT PROTEIN-1; NADPH OXIDASE; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; CORONARY ANGIOPLASTY; BALLOON ANGIOPLASTY; MESSENGER-RNA; FREE-RADICALS; GROWTH; THROMBIN	Vascular injury after balloon angioplasty results in the rapid activation of platelets leading to the release of growth factors and vasoactive substances, In addition, up-regulation of tissue factor (TF) and an increased production of reactive oxygen species (ROS) have been detected at sites of vascular injury. We investigated whether platelet-derived products (PDP) released from activated human platelets increase ROS production, resulting in the induction of TF expression in vascular smooth muscle cells (SMC). PDP induced a time- and concentration-dependent increase in ROS generation in cultured SMC that was mediated mainly by PDGF-AB and TGF-beta 1 and impaired by the flavin inhibitor diphenylene iodonium. Increased ROS formation was associated with enhanced mRNA levels of the small NAD(P)H oxidase subunit p22phox or its smooth muscle isoform. Transient transfection with a p22phox antisense vector decreased PDP-induced ROS generation. PDP up-regulated TF mRNA expression, which was redox sensitive and reduced by transfection of the p22phox antisense vector. In addition, PDP-stimulated reporter gene activity of two TF promoter constructs was decreased by coexpression of the p22phox antisense vector. These results indicate that activated platelets up-regulate TF expression and that this response involves ROS generation and a p22phox-containing NAD(P)H oxidase in SMC.	Univ Frankfurt Klinikum, Inst Kardiovasc Physiol, D-60590 Frankfurt, Germany; Fachbereich Hamostaseol, Stiftung Deutsch Klin Diagnost, D-65191 Wiesbaden, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital	Gorlach, A (corresponding author), Univ Frankfurt Klinikum, Inst Kardiovasc Physiol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.		Gorlach, Agnes/B-3494-2013; Brandes, Ralf P/L-3058-2017	Brandes, Ralf P/0000-0002-8035-0048				Abe J, 1998, TRENDS CARDIOVAS MED, V8, P59, DOI 10.1016/S1050-1738(97)00133-3; Ambrosio G, 1997, CARDIOVASC RES, V34, P445, DOI 10.1016/S0008-6363(97)00101-6; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Bayraktutan U, 1998, CARDIOVASC RES, V38, P256, DOI 10.1016/S0008-6363(98)00003-0; BIERHAUS A, 1995, J BIOL CHEM, V270, P26419, DOI 10.1074/jbc.270.44.26419; Braun M, 1999, CARDIOVASC RES, V41, P395, DOI 10.1016/S0008-6363(98)00302-2; Chakraborti S, 1998, CELL SIGNAL, V10, P675, DOI 10.1016/S0898-6568(98)00014-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Fandrey J, 1997, KIDNEY INT, V51, P492, DOI 10.1038/ki.1997.68; FUKUI T, 1995, BBA-BIOENERGETICS, V1231, P215, DOI 10.1016/0005-2728(95)00098-4; Gallo R, 1998, CIRCULATION, V97, P581; Gardemann A, 1999, ATHEROSCLEROSIS, V145, P315, DOI 10.1016/S0021-9150(99)00083-0; GASPERETTI CM, 1993, CIRCULATION, V88, P2728, DOI 10.1161/01.CIR.88.6.2728; Gong KW, 1996, J VASC RES, V33, P42, DOI 10.1159/000159130; GORLACH A, 1993, BIOCHEM J, V290, P771; HAMON M, 1995, EUR HEART J, V16, P33, DOI 10.1093/eurheartj/16.suppl_I.33; Hannken T, 1998, KIDNEY INT, V54, P1923, DOI 10.1046/j.1523-1755.1998.00212.x; Holland JA, 1998, ENDOTHELIUM-NEW YORK, V6, P113, DOI 10.3109/10623329809072198; Inoue N, 1998, CIRCULATION, V97, P135, DOI 10.1161/01.CIR.97.2.135; JONES SA, 1995, J AM SOC NEPHROL, V5, P1483; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; MACKMAN N, 1995, FASEB J, V9, P883, DOI 10.1096/fasebj.9.10.7615158; MARMUR JD, 1994, J AM COLL CARDIOL, V24, P1484, DOI 10.1016/0735-1097(94)90144-9; MARMUR JD, 1993, J CLIN INVEST, V91, P2253, DOI 10.1172/JCI116452; Marmur JD, 1996, CIRCULATION, V94, P1226, DOI 10.1161/01.CIR.94.6.1226; Marumo T, 1997, CIRCULATION, V96, P2361; McNamara CA, 1996, SEMIN THROMB HEMOST, V22, P139, DOI 10.1055/s-2007-999001; Mechtcheriakova D, 1999, BLOOD, V93, P3811, DOI 10.1182/blood.V93.11.3811.411k40_3811_3823; MURRELL GAC, 1990, BIOCHEM J, V265, P659, DOI 10.1042/bj2650659; Nunes GL, 1997, CIRCULATION, V96, P3593; Pagano PJ, 1998, HYPERTENSION, V32, P331, DOI 10.1161/01.HYP.32.2.331; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; RUGGERI ZM, 1994, SEMIN HEMATOL, V31, P229; Sato Y, 1996, THROMB HAEMOSTASIS, V75, P389; Schecter AD, 1997, J CLIN INVEST, V100, P2276, DOI 10.1172/JCI119765; SchiniKerth VB, 1997, CIRCULATION, V96, P3888; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TAUBMAN MB, 1993, J CLIN INVEST, V91, P547, DOI 10.1172/JCI116234; Taubman MB, 1997, THROMB HAEMOSTASIS, V78, P200; Umemura K, 1996, THROMB HAEMOSTASIS, V76, P799; UshioFukai M, 1996, J BIOL CHEM, V271, P23317, DOI 10.1074/jbc.271.38.23317; WILCOX JN, 1994, CIRC RES, V75, P1029, DOI 10.1161/01.RES.75.6.1029; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P5252, DOI 10.1073/pnas.88.12.5252; Zafari AM, 1998, HYPERTENSION, V32, P488, DOI 10.1161/01.HYP.32.3.488	47	100	103	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2000	14	11					1518	1528		10.1096/fj.14.11.1518	http://dx.doi.org/10.1096/fj.14.11.1518			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CN	10928986				2022-12-28	WOS:000088627800006
J	Kardinal, C; Konkol, B; Schulz, A; Posern, G; Lin, H; Adermann, K; Eulitz, M; Estrov, Z; Talpaz, M; Arlinghaus, RB; Feller, SM				Kardinal, C; Konkol, B; Schulz, A; Posern, G; Lin, H; Adermann, K; Eulitz, M; Estrov, Z; Talpaz, M; Arlinghaus, RB; Feller, SM			Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients	FASEB JOURNAL			English	Article						CRKL; adapter protein; Bcr-Abl; MAP kinase (MAPK)	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; SRC HOMOLOGY-3 DOMAIN; BCR-ABL ONCOGENE; MYELOPROLIFERATIVE DISEASE; PHILADELPHIA-CHROMOSOME; TYROSINE KINASE; CRK; BINDING; MODEL	Bcr-Abl contributes prominently to the development of most chronic myeloid leukemias (CMLs). Prior work has identified the adapter protein CRKL as a major substrate of the Bcr-Abl tyrosine kinase. CRKL can also bind via its first SH3 domain [SH3(1)] to specific sequences in Bcr-Abl. Cell-penetrating peptides were developed that bind with high affinity and selectivity to the SH3(1) domain of CRKL. They disrupt Bcr-Abl-CRKL complexes and strongly reduce the proliferation of primary CML blast cells and cell lines established from Bcr-Abl-positive patients. Activation-specific antibodies against phosphorylated MAP kinase (MAPK) showed that MAPK activity is down-regulated in blast cells treated with the CRKLSH3(1) blocker peptides. We conclude that the Bcr-Abl-CRKL complexes are largely dependent on the CRKLSH3(1) domain, that the central mitogenic cascade is down-regulated as a consequence of the disruption of CRKLSH3(1) interactions, and that CRKL therefore contributes to the proliferation of CML blast cells.	Univ Wurzburg, MSZ, Oncol Mol Lab, D-97078 Wurzburg, Germany; GSF, Klin Mol Biol & Tumorgenet, Munich, Germany; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA	University of Wurzburg; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Texas System; UTMD Anderson Cancer Center	Feller, SM (corresponding author), Univ Wurzburg, MSZ, Oncol Mol Lab, Versbacher Str 5, D-97078 Wurzburg, Germany.			Talpaz, Moshe/0000-0003-3361-3981				Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Arap Wadih, 1998, Current Opinion in Oncology, V10, P560, DOI 10.1097/00001622-199811000-00014; Arlinghaus RB, 1998, CRIT REV ONCOGENESIS, V9, P1; Bocciardi R, 1997, ONCOGENE, V15, P2257, DOI 10.1038/sj.onc.1201413; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; Cussac D, 1999, FASEB J, V13, P31, DOI 10.1096/fasebj.13.1.31; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; Ghaffari S, 1999, LEUKEMIA, V13, P1200, DOI 10.1038/sj.leu.2401467; Groffen J, 1997, BAILLIERE CLIN HAEM, V10, P187, DOI 10.1016/S0950-3536(97)80002-9; Hoyle C, 1998, BLOOD, V92, P3318, DOI 10.1182/blood.V92.9.3318.421k39_3318_3327; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Kolibaba KS, 1999, LEUKEMIA LYMPHOMA, V33, P119, DOI 10.3109/10428199909093732; le Coutre P, 1999, J NATL CANCER I, V91, P163, DOI 10.1093/jnci/91.2.163; Liu XY, 1996, P NATL ACAD SCI USA, V93, P11819, DOI 10.1073/pnas.93.21.11819; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Nguyen JT, 1998, SCIENCE, V282, P2088, DOI 10.1126/science.282.5396.2088; Oehlke J, 1998, BBA-BIOMEMBRANES, V1414, P127, DOI 10.1016/S0005-2736(98)00161-8; Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542; PASQUALINI R, 1995, J CELL BIOL, V130, P1189, DOI 10.1083/jcb.130.5.1189; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Posern G, 1998, ONCOGENE, V16, P1903, DOI 10.1038/sj.onc.1201714; Schulz A, 2000, TETRAHEDRON, V56, P3889, DOI 10.1016/S0040-4020(00)00305-7; Senechal K, 1996, MOL MED TODAY, V2, P503, DOI 10.1016/S1357-4310(97)81454-2; SKORSKI T, 1992, FOLIA HISTOCHEM CYTO, V30, P91; Skorski T, 1998, P NATL ACAD SCI USA, V95, P11858, DOI 10.1073/pnas.95.20.11858; Verfaillie CM, 1998, HEMATOL ONCOL CLIN N, V12, P1, DOI 10.1016/S0889-8588(05)70495-0; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Wang JCY, 1998, BLOOD, V91, P2406, DOI 10.1182/blood.V91.7.2406.2406_2406_2414; Williams EJ, 1997, J BIOL CHEM, V272, P22349, DOI 10.1074/jbc.272.35.22349; WU XD, 1995, STRUCTURE, V3, P215, DOI 10.1016/S0969-2126(01)00151-4; Xu QH, 1999, BIOCHEMISTRY-US, V38, P3491, DOI 10.1021/bi982744j; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829	36	39	41	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2000	14	11					1529	1538		10.1096/fj.14.11.1529	http://dx.doi.org/10.1096/fj.14.11.1529			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CN	10928987				2022-12-28	WOS:000088627800007
J	Hooper, DC; Scott, GS; Zborek, A; Mikheeva, T; Kean, RB; Koprowski, H; Spitsin, SV				Hooper, DC; Scott, GS; Zborek, A; Mikheeva, T; Kean, RB; Koprowski, H; Spitsin, SV			Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood-CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis	FASEB JOURNAL			English	Article						autoimmunity; encephalomyelitis; demyelinating diseases; multiple sclerosis; blood-brain barrier; uric acid	NITRIC-OXIDE SYNTHASE; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; BRAIN-BARRIER; URATE OXIDASE; AUTOIMMUNE ENCEPHALOMYELITIS; PARKINSONS-DISEASE; TYROSINE NITRATION; SUBSTANTIA-NIGRA; EXPRESSION	Peroxynitrite (ONOO-), a toxic product of the free radicals nitric oxide and superoxide, has been implicated in the pathogenesis of CNS inflammatory diseases, including multiple sclerosis and its animal correlate experimental autoimmune encephalomyelitis (EAE). In this study we have assessed the mode of action of uric acid (UA), a purine metabolite and ONOO- scavenger, in the treatment of EAE. We show that if administered to mice before the onset of clinical EAE, UA interferes with the invasion of inflammatory cells into the CNS and prevents development of the disease. In mice with active EAE, exogenously administered UA penetrates the already compromised blood-CNS barrier, blocks ONOO--mediated tyrosine nitration and apoptotic cell death in areas of inflammation in spinal cord tissues and promotes recovery of the animals. Moreover, UA treatment suppresses the enhanced blood-CNS barrier permeability characteristic of EAE. We postulate that UA acts at two levels in EAE: 1) by protecting the integrity of the blood-CNS barrier from ONOO--induced permeability changes such that cell invasion and the resulting pathology is minimized; and 2) through a compromised blood-CNS barrier, by scavenging the ONOO- directly responsible for CNS tissue damage and death.-Hooper, D. C., Scott, G. S., Zborek, A., Mikheeva, T., Kean, R. B., Koprowski, H., Spitsin, S. V. Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood-CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis. FASEB J. 14, 691-698 (2000)	Thomas Jefferson Univ, Dept Microbiol & Immunol, Kimmel Canc Inst, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Biotechnol Fdn Labs, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Hooper, DC (corresponding author), Thomas Jefferson Univ, Dept Microbiol & Immunol, Kimmel Canc Inst, 1020 Locust St, Philadelphia, PA 19107 USA.			Spitsin, Sergei/0000-0002-4231-9437; Hooper, Douglas/0000-0002-8578-5104				ALBERATIGIANI D, 1997, J IMMUNOL, V159, pL419; AMES BN, 1981, P NATL ACAD SCI-BIOL, V78, P6858, DOI 10.1073/pnas.78.11.6858; BACKMAN JS, 1994, BIOL CHEM, V375, P81; Bagasra O, 1995, P NATL ACAD SCI USA, V92, P12041, DOI 10.1073/pnas.92.26.12041; Bauer H, 1997, IMMUNOLOGY, V90, P205, DOI 10.1046/j.1365-2567.1997.00161.x; BO L, 1994, ANN NEUROL, V36, P778, DOI 10.1002/ana.410360515; Campion E W, 1987, Am J Med, V82, P421, DOI 10.1016/0002-9343(87)90441-4; Chou SM, 1996, J NEUROL SCI, V139, P16, DOI 10.1016/0022-510X(96)00090-1; CHURCH WH, 1994, BRAIN RES BULL, V33, P419, DOI 10.1016/0361-9230(94)90285-2; CLAUDIO L, 1995, ACTA NEUROPATHOL, V90, P228; Cross AH, 1998, J NEUROIMMUNOL, V88, P45, DOI 10.1016/S0165-5728(98)00078-2; Cross AH, 1997, J NEUROIMMUNOL, V80, P121, DOI 10.1016/S0165-5728(97)00145-8; Cross AH, 1996, J NEUROIMMUNOL, V71, P145, DOI 10.1016/S0165-5728(96)00147-6; ELIAS JM, 1989, AM J CLIN PATHOL, V92, P62, DOI 10.1093/ajcp/92.1.62; FUNDER J, 1967, LAB INVEST, V19, P310; Greenacre S, 1997, CLIN EXP PHARMACOL P, V24, P880, DOI 10.1111/j.1440-1681.1997.tb02709.x; GUY J, 1994, OPHTHALMIC RES, V26, P310, DOI 10.1159/000267494; HONEGGER CG, 1986, NEUROSCI LETT, V69, P109, DOI 10.1016/0304-3940(86)90424-6; Hooper DC, 1998, P NATL ACAD SCI USA, V95, P675, DOI 10.1073/pnas.95.2.675; HOOPER DC, 1995, P NATL ACAD SCI USA, V92, P5312, DOI 10.1073/pnas.92.12.5312; Hooper DC, 1997, P NATL ACAD SCI USA, V94, P2528, DOI 10.1073/pnas.94.6.2528; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; KEILIN J, 1959, BIOL REV, V34, P265, DOI 10.1111/j.1469-185X.1959.tb01447.x; KOCK R, 1993, EUR J CLIN CHEM CLIN, V31, P303; KOENIG H, 1989, J NEUROCHEM, V52, P101, DOI 10.1111/j.1471-4159.1989.tb10903.x; KOPROWSKI H, 1993, P NATL ACAD SCI USA, V90, P3024, DOI 10.1073/pnas.90.7.3024; Lehniger A. L., 1970, BIOCHEMISTRY; MANGOFF SC, 1978, P SOC EXP BIOL MED, V157, P110; Merrill JE, 1997, BRAIN BEHAV IMMUN, V11, P245, DOI 10.1006/brbi.1997.0496; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; OKUDA Y, 1995, J NEUROIMMUNOL, V62, P103, DOI 10.1016/0165-5728(95)00114-H; PENDER MP, 1991, J NEUROL SCI, V104, P81, DOI 10.1016/0022-510X(91)90219-W; PROCTOR P, 1970, NATURE, V228, P868, DOI 10.1038/228868a0; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RADI R, 1991, J BIOL CHEM, V266, P4244; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SEEGMILLER JE, 1963, NEW ENGL J MED, V268, P712, DOI 10.1056/NEJM196303282681306; Shergill JK, 1996, BIOCHEM BIOPH RES CO, V228, P298, DOI 10.1006/bbrc.1996.1656; Szabo C, 1996, FREE RADICAL BIO MED, V21, P855, DOI 10.1016/0891-5849(96)00170-0; TROUT JJ, 1986, LAB INVEST, V55, P622; USUDA N, 1988, LAB INVEST, V58, P100; vanderVeen RC, 1997, J NEUROIMMUNOL, V77, P1, DOI 10.1016/S0165-5728(97)00013-1; VARELAECHAVARRIA A, 1988, FASEB J, V2, P3092, DOI 10.1096/fasebj.2.15.3192041; Waldner H, 1997, J IMMUNOL, V159, P3100; Wallace MN, 1997, EXP NEUROL, V144, P266, DOI 10.1006/exnr.1996.6373; Whiteman M, 1996, FREE RADICAL RES, V25, P275, DOI 10.3109/10715769609149052; WOLMAN M, 1981, ACTA NEUROPATHOL, V54, P55, DOI 10.1007/BF00691332; WU XW, 1992, J MOL EVOL, V34, P78, DOI 10.1007/BF00163854; YELDANDI AV, 1991, GENE, V109, P281, DOI 10.1016/0378-1119(91)90622-I	49	300	315	0	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2000	14	5					691	698		10.1096/fasebj.14.5.691	http://dx.doi.org/10.1096/fasebj.14.5.691			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301DH	10744626				2022-12-28	WOS:000086292700007
J	Wilson, MH; Grant, PJ; Hardie, LJ; Wild, CP				Wilson, MH; Grant, PJ; Hardie, LJ; Wild, CP			Glutathione S-transferase M1 null genotype is associated with a decreased risk of myocardial infarction	FASEB JOURNAL			English	Article						epoxide hydrolase; acute myocardial infarction; GSTM1; RFLP; case-control study	ARTERIOSCLEROTIC PLAQUE DEVELOPMENT; MICROSOMAL EPOXIDE HYDROLASE; DNA ADDUCT LEVELS; LUNG-CANCER RISK; TOBACCO-SMOKE; GSTM1; GENE; POLYMORPHISM; SUSCEPTIBILITY; DISEASE	Tobacco smoke is a major cause of both cancer and vascular disease. Although its carcinogenic role via induction of DNA damage and mutation is well established, the mechanisms involved in vascular disease remain unclear. One possibility is that DNA damage causes smooth muscle cell proliferation in the intima of arteries, thereby contributing to atherothrombotic processes. The binding of chemicals to DNA is modulated by detoxification enzymes, including glutathione S-transferases (GST) and microsomal epoxide hydrolase (EPXH). We therefore examined whether polymorphisms in these genes influence risk of cardiovascular disease. Blood was obtained from 398 patients admitted for angiographic investigation of chest pain and 196 age- and sex-matched controls. Patients were subdivided into those with and without previous acute myocardial infarction (AMI). DNA was analyzed for deletions in the GSTM1 and T1 genes and for substitutions in EPXH and GSTP1 genes. The GSTM1 null genotype occurred at a significantly lower frequency in the AMI patient group (48%) compared both to patients with no history of AMI (59%) and to the control group (57.2%). When subjects were stratified for smoking status, a significant association was observed only in smokers, suggesting the polymorphism is more important in the presence of tobacco smoke exposure. The association remained significant after adjusting for age, sex, and stenosis (presence or absence). No significant associations were observed between the other genotypes and cardiovascular disease (X-2 test; P>0.1). The results of this study indicate that the GSTM1 null genotype is protective against AMI, an effect that is more marked in smokers. However, further study is required in order to elucidate the as yet unexplained, mechanisms underlying this association.	Univ Leeds, Sch Med, Mol Epidemiol Unit, Leeds LS2 9JT, W Yorkshire, England; Univ Leeds, Sch Med, Mol Vasc Med Unit, Leeds LS2 9JT, W Yorkshire, England	University of Leeds; University of Leeds	Wilson, MH (corresponding author), Univ Leeds, Sch Med, Mol Epidemiol Unit, Algernon Firth Bldg, Leeds LS2 9JT, W Yorkshire, England.		Grant, Peter/HIR-3733-2022; Wild, Christopher/ABC-6260-2020; Hardie, Laura/AAY-6724-2020	Wild, Christopher/0000-0003-0249-8669; Hardie, Laura/0000-0001-5039-2100; Wilson, Michael/0000-0002-6323-6059				AbdelRahman SZ, 1996, CANCER LETT, V107, P229, DOI 10.1016/0304-3835(96)04832-X; ANTTILA S, 1995, CANCER RES, V55, P3305; BRIDGES B A, 1990, Mutation Research, V239, P143, DOI 10.1016/0165-1110(90)90002-S; Collins AR, 1998, FASEB J, V12, P1397, DOI 10.1096/fasebj.12.13.1397; DeFlora S, 1997, FASEB J, V11, P1021, DOI 10.1096/fasebj.11.12.9337155; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Harries LW, 1997, CARCINOGENESIS, V18, P641, DOI 10.1093/carcin/18.4.641; HASSETT C, 1994, HUM MOL GENET, V3, P421, DOI 10.1093/hmg/3.3.421; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; *IARC, 1994, IARC SCI PUBLICATION, V125; IZZOTTI A, 1995, CANCER EPIDEM BIOMAR, V4, P105; IZZOTTI A, 1992, CARCINOGENESIS, V13, P2187, DOI 10.1093/carcin/13.11.2187; KATO S, 1995, J NATL CANCER I, V87, P902, DOI 10.1093/jnci/87.12.902; KIHARA M, 1994, CARCINOGENESIS, V15, P415, DOI 10.1093/carcin/15.2.415; Kohler HP, 1998, THROMB HAEMOSTASIS, V79, P8, DOI 10.1055/s-0037-1614250; Lapenna D, 1998, CIRCULATION, V97, P1930, DOI 10.1161/01.CIR.97.19.1930; MacLeod S, 1997, MUTAT RES-FUND MOL M, V376, P135, DOI 10.1016/S0027-5107(97)00036-5; MANSFIELD MW, 1994, THROMB HAEMOSTASIS, V71, P731; MCWILLIAMS JE, 1995, CANCER EPIDEM BIOMAR, V4, P589; Penn A, 1996, CIRCULATION, V93, P552, DOI 10.1161/01.CIR.93.3.552; PENN A, 1988, CARCINOGENESIS, V9, P2185, DOI 10.1093/carcin/9.12.2185; PESSAHRASMUSSEN H, 1990, J INTERN MED, V228, P17, DOI 10.1111/j.1365-2796.1990.tb00186.x; PESSAHRASMUSSEN H, 1993, INT ANGIOL, V12, P348; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; ROSENBERG L, 1985, NEW ENGL J MED, V313, P1511, DOI 10.1056/NEJM198512123132404; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Ryberg D, 1997, CARCINOGENESIS, V18, P1285, DOI 10.1093/carcin/18.7.1285; Smith CAD, 1997, LANCET, V350, P630, DOI 10.1016/S0140-6736(96)08061-0; Taningher M, 1999, MUTAT RES-REV MUTAT, V436, P227, DOI 10.1016/S1383-5742(99)00005-8; Van Schooten FJ, 1998, FASEB J, V12, P1409, DOI 10.1096/fasebj.12.13.1409	31	106	119	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2000	14	5					791	796		10.1096/fasebj.14.5.791	http://dx.doi.org/10.1096/fasebj.14.5.791			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301DH	10744635				2022-12-28	WOS:000086292700016
J	Barsyte, D; Lovejoy, DA; Lithgow, GJ				Barsyte, D; Lovejoy, DA; Lithgow, GJ			Longevity and heavy metal resistance in daf-2 and age-1 long-lived mutants of Caenorhabditis elegans	FASEB JOURNAL			English	Article						aging; nematode; metallothionein; insulin signaling; stress resistance; age genes	METALLOTHIONEIN-II GENES; LIFE-SPAN; OXIDATIVE STRESS; SUPEROXIDE-DISMUTASE; DIFFERENTIAL DISPLAY; RESPONSIVE GENES; DAUER FORMATION; MICE DEFICIENT; FAMILY MEMBER; RT-PCR	In the nematode Caenorhabditis elegans, dauer formation, stress resistance, and longevity are determined in part by DAF-2 (insulin receptor-like protein), AGE-1 (phosphatidylinositol-3-OH kinase catalytic subunit), and DAF-16 (forkhead transcription factor). Mutations in daf-2 and age-1 result in increased resistance to heat, oxidants, and UV. We have discovered that daf-2 and age-1 mutations result in increased Cd and Cu ion resistance in a 24 h toxicity assay. Lethal concentration (LC50) values for Cd and Cu ions in daf-2 and age-1 mutants were significantly (P<0.001) higher than in wild-type nematodes. However, LC50 values in daf-16;age-1 mutants were not significantly different, implying that metal resistance is influenced by a DAF-16-related function. As metallothionein (MT) proteins play a major role in metal detoxification, we examined the expression of MT genes both under noninducing conditions and after exposure to sublethal and acute heavy metal stress. MT1 mRNA levels were significantly (P<0.05) higher in daf-2 mutants compared to age-1 mutants and wild-type C. elegans under basal conditions. After 10 mM Cd treatment, induction of MT1 and MT2 mRNA was three- and twofold higher, respectively, in daf-2 mutant worms than in wild-type. However, a sublethal concentration of Cd (0.1 mM) resulted in even higher (three- to sevenfold) levels of both MT mRNAs in all strains, Cu did not induce MTI or MT2 mRNAs. These results are consistent with a model in which the insulin-signaling pathway determines life span through regulation of stress protein genes.-Barsyte, D., Lovejoy, D. A., Lithgow, G. J. Longevity and heavy metal resistance in daf-2 and age-1 long-lived mutants of Caenorhabditis elegans.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Lithgow, GJ (corresponding author), Univ Manchester, Sch Biol Sci, 3-239 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.							Barsyte D, 1999, COMP BIOCHEM PHYS C, V122, P287; Beckmann K. B., 1997, OXIDATIVE STRESS MOL, P201; BERNARD A, 1986, CADMIUM, P135; BRENNER S, 1974, GENETICS, V77, P71; Clemens S, 1999, EMBO J, V18, P3325, DOI 10.1093/emboj/18.12.3325; Cohen M., 1991, BIOL EFFECTS HEAVY M, P19; DORMAN JB, 1995, GENETICS, V141, P1399; FABIAN TJ, 1994, J GERONTOL, V49, pB145, DOI 10.1093/geronj/49.4.B145; Finney D J., 1952, PROBIT ANAL STAT TRE, P31; FREEDMAN JH, 1993, J BIOL CHEM, V268, P2554; FREEDMAN JH, 1989, J BIOL CHEM, V264, P5598; FRIEDMAN DB, 1988, J GERONTOL, V43, pB102, DOI 10.1093/geronj/43.4.B102; Ghoshal K, 1999, BIOCHEM BIOPH RES CO, V264, P735, DOI 10.1006/bbrc.1999.1563; Gil EB, 1999, P NATL ACAD SCI USA, V96, P2925, DOI 10.1073/pnas.96.6.2925; GOTTLIEB S, 1994, GENETICS, V137, P107; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HARMAN D, 1992, MUTAT RES, V275, P257, DOI 10.1016/0921-8734(92)90030-S; HARTWIG A, 1995, BIOMETALS, V8, P3; HATCHER EL, 1995, FREE RADICAL BIO MED, V19, P805, DOI 10.1016/0891-5849(95)00099-J; Ho YS, 1997, J BIOL CHEM, V272, P16644, DOI 10.1074/jbc.272.26.16644; Honda Y, 1999, FASEB J, V13, P1385, DOI 10.1096/fasebj.13.11.1385; KAGI JHR, 1988, BIOCHEMISTRY-US, V27, P8509, DOI 10.1021/bi00423a001; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Klaassen CD, 1999, ANNU REV PHARMACOL, V39, P267, DOI 10.1146/annurev.pharmtox.39.1.267; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; LARSEN PL, 1995, GENETICS, V139, P1567; LAZO JS, 1995, J BIOL CHEM, V270, P5506, DOI 10.1074/jbc.270.10.5506; Lee KF, 1999, TOXICOL APPL PHARM, V154, P20, DOI 10.1006/taap.1998.8556; Liao VHC, 1998, J BIOL CHEM, V273, P31962, DOI 10.1074/jbc.273.48.31962; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; LITHGOW GJ, 1995, P NATL ACAD SCI USA, V92, P7540, DOI 10.1073/pnas.92.16.7540; Lithgow Gordon J., 1996, P55; Malone EA, 1996, GENETICS, V143, P1193; MASTERS BA, 1994, P NATL ACAD SCI USA, V91, P584, DOI 10.1073/pnas.91.2.584; Melov S, 2000, SCIENCE, V289, P1567, DOI 10.1126/science.289.5484.1567; MELOV S, 1994, NUCLEIC ACIDS RES, V22, P1075, DOI 10.1093/nar/22.6.1075; MICHALSKA AE, 1993, P NATL ACAD SCI USA, V90, P8088, DOI 10.1073/pnas.90.17.8088; MILLER BJ, 1990, SPORTS MED, V9, P1, DOI 10.2165/00007256-199009010-00001; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Murakami S, 1996, GENETICS, V143, P1207; Muto N, 1999, COMP BIOCHEM PHYS C, V122, P75, DOI 10.1016/S0742-8413(98)10081-6; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Rouault JP, 1999, CURR BIOL, V9, P329, DOI 10.1016/S0960-9822(99)80143-2; SAMUNI A, 1981, J BIOL CHEM, V256, P2632; TAMAI KT, 1993, P NATL ACAD SCI USA, V90, P8013, DOI 10.1073/pnas.90.17.8013; Tawe WN, 1998, NUCLEIC ACIDS RES, V26, P1621, DOI 10.1093/nar/26.7.1621; THORNALLEY PJ, 1985, BIOCHIM BIOPHYS ACTA, V827, P36, DOI 10.1016/0167-4838(85)90098-6; Tissenbaum HA, 1998, GENETICS, V148, P703; Tsang SY, 1996, BIOCHEM J, V317, P13, DOI 10.1042/bj3170013; VANFLETEREN JR, 1995, FASEB J, V9, P1355, DOI 10.1096/fasebj.9.13.7557026; VANTLETEREN JR, 1993, BIOCHEM J, V292, P605; ZHOU JM, 1995, MOL GEN GENET, V248, P318, DOI 10.1007/BF02191599; Zimmermann K, 1996, BIOTECHNIQUES, V21, P268	55	203	221	2	46	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					627	634		10.1096/fj.99-0966com	http://dx.doi.org/10.1096/fj.99-0966com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259381				2022-12-28	WOS:000167419500020
J	Eickelberg, O; Pansky, A; Koehler, E; Bihl, M; Tamm, M; Hildebrand, P; Perruchoud, AP; Kashgarian, M; Roth, M				Eickelberg, O; Pansky, A; Koehler, E; Bihl, M; Tamm, M; Hildebrand, P; Perruchoud, AP; Kashgarian, M; Roth, M			Molecular mechanisms of TGF-beta antagonism by interferon gamma and cyclosporine A in lung fibroblasts	FASEB JOURNAL			English	Article						lung fibrosis; tumor growth factor beta; AP-1; IFN-gamma; Cs-A	GROWTH-FACTOR-BETA; IDIOPATHIC PULMONARY FIBROSIS; TRANSCRIPTIONAL ACTIVATION; COLLAGEN DEPOSITION; T-CELLS; EXPRESSION; GENE; ALVEOLITIS; DISEASE; COMPLEX	Lung fibrosis is a fatal condition of excess extracellular matrix (ECM) deposition associated with increased transforming growth factor beta (TGF-beta) activity. Although much is known about its pathological features, our understanding of the signal transduction pathways resulting in increased ECM and collagen deposition in response to TGF-beta is still incompletely defined. We have previously reported that a JunD homodimer of the transcription factor AP-1 is specifically activated by TGF-beta in lung fibroblasts. Here we demonstrate that JunD is also specifically required for TGF-beta -induced effects. Antisense against JunD, but not c-fos or c-jun, significantly inhibited collagen deposition in response to TGF-beta in primary human lung fibroblasts. We then investigated the ability of pharmacological agents to inhibit TGF-beta -induced signaling and collagen deposition. Cs-A and IFN-gamma, but not glucocorticoids, cyclophosphamide, or azathioprine, inhibited TGF-beta -induced signaling, as assessed by luciferase reporter gene assays, and collagen deposition. TGF-beta antagonism by Cs-A was associated with direct inhibition of JunD activation, as demonstrated by electrophoretic mobility shift analyses. In contrast, the effects of IFN-gamma required signal transducer and activator of transcription (STAT)-1. We thus identify the JunD isoform of AP-1 as an essential mediator of TGF-beta -induced effects in lung fibroblasts. TGF-beta -induced signaling and collagen deposition are efficiently antagonized by Cs-A and IFN-gamma treatment, both of which exhibit distinct molecular mechanisms of action. These observations therefore offer novel targets for future therapy of fibrotic lung disease.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Univ Basel Hosp, Dept Res & Internal Med, CH-4031 Basel, Switzerland	Yale University; University of Basel	Eickelberg, O (corresponding author), Yale Univ, Sch Med, Dept Pathol, 310 Cedar St,LB20, New Haven, CT 06520 USA.	oliver.eickelberg@yale.edu	Roth, Michael/H-8657-2019; Köhler, Eleonore/D-2915-2012; Eickelberg, Oliver/A-5461-2013	Roth, Michael/0000-0002-8139-2821; Köhler, Eleonore/0000-0003-1977-9977; Eickelberg, Oliver/0000-0001-7170-0360				AGELLI M, 1988, METHOD ENZYMOL, V163, P642; ALTON EWFW, 1989, RESP MED, V83, P277, DOI 10.1016/S0954-6111(89)80196-9; Banerjee C, 1996, ENDOCRINOLOGY, V137, P1991, DOI 10.1210/en.137.5.1991; BIENKOWSKI RS, 1995, P SOC EXP BIOL MED, V209, P118; ChanYeung M, 1997, LANCET, V350, P651, DOI 10.1016/S0140-6736(97)06303-4; Coker RK, 1997, AM J PATHOL, V150, P981; CROUCH E, 1990, AM J PHYSIOL, V259, pL159, DOI 10.1152/ajplung.1990.259.4.L159; Egan JJ, 1999, LANCET, V354, P1839, DOI 10.1016/S0140-6736(99)00347-5; Eickelberg O, 1999, AM J PHYSIOL-LUNG C, V276, pL814, DOI 10.1152/ajplung.1999.276.5.L814; Eickelberg O, 1999, CIRCULATION, V99, P2276, DOI 10.1161/01.CIR.99.17.2276; Eickelberg O, 1999, J BIOL CHEM, V274, P12933, DOI 10.1074/jbc.274.18.12933; GAULDIE J, 1993, THORAX, V48, P931, DOI 10.1136/thx.48.9.931; Gay SE, 1998, AM J RESP CRIT CARE, V157, P1063, DOI 10.1164/ajrccm.157.4.9703022; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; GIRI SN, 1993, THORAX, V48, P959, DOI 10.1136/thx.48.10.959; Gorelik L, 2000, IMMUNITY, V12, P171, DOI 10.1016/S1074-7613(00)80170-3; GRUHN WB, 1987, J RHEUMATOL, V14, P1045; GURUJEYALAKSHMI G, 1995, EXP LUNG RES, V21, P791, DOI 10.3109/01902149509050842; Hagimoto N, 1997, AM J RESP CELL MOL, V17, P272, DOI 10.1165/ajrcmb.17.3.2893; HEIN R, 1992, BRIT J DERMATOL, V126, P496, DOI 10.1111/j.1365-2133.1992.tb15122.x; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Hubbard R, 1998, CHEST, V113, P396, DOI 10.1378/chest.113.2.396; JORDANA M, 1988, AM REV RESPIR DIS, V137, P579, DOI 10.1164/ajrccm/137.3.579; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Katzenstein ALA, 1998, AM J RESP CRIT CARE, V157, P1301, DOI 10.1164/ajrccm.157.4.9707039; Kohler E, 1996, J VASC RES, V33, P315, DOI 10.1159/000159159; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; LAURENT GJ, 1985, CIBA F SYMP, V114, P222; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Mapel DW, 1996, CHEST, V110, P1058, DOI 10.1378/chest.110.4.1058; Mason Robert J., 1999, American Journal of Respiratory and Critical Care Medicine, V160, P1771; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MCANULTY RJ, 1995, EXP NEPHROL, V3, P96; McCormick LL, 1999, J IMMUNOL, V163, P5693; MOOLMAN JA, 1991, THORAX, V46, P592, DOI 10.1136/thx.46.8.592; OKADA T, 1993, LYMPHOKINE CYTOK RES, V12, P87; Pansky A, 2000, INT J CANCER, V85, P720, DOI 10.1002/(SICI)1097-0215(20000301)85:5<720::AID-IJC20>3.0.CO;2-O; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; PFEUFFER I, 1994, J IMMUNOL, V153, P5572; RAGHU G, 1989, AM REV RESPIR DIS, V140, P95, DOI 10.1164/ajrccm/140.1.95; Raghu G, 1997, MAYO CLIN PROC, V72, P285, DOI 10.4065/72.3.285; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; Rogers DF, 1998, THORAX, V53, P200, DOI 10.1136/thx.53.3.200; SANTANA A, 1995, AM J RESP CELL MOL, V13, P34, DOI 10.1165/ajrcmb.13.1.7541221; Sauty A, 1997, EUR RESPIR J, V10, P2907, DOI 10.1183/09031936.97.10122907; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Shozu M, 2000, MOL CELL ENDOCRINOL, V160, P123, DOI 10.1016/S0303-7207(99)00233-6; Sime PJ, 1997, J CLIN INVEST, V100, P768, DOI 10.1172/JCI119590; Song CZ, 1999, P NATL ACAD SCI USA, V96, P11776, DOI 10.1073/pnas.96.21.11776; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Tang WL, 1998, J BIOL CHEM, V273, P5506, DOI 10.1074/jbc.273.10.5506; TSUBOI A, 1994, BIOCHEM BIOPH RES CO, V199, P1064, DOI 10.1006/bbrc.1994.1337; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Uria JA, 1998, J BIOL CHEM, V273, P9769, DOI 10.1074/jbc.273.16.9769; VENUTA F, 1993, J HEART LUNG TRANSPL, V12, P909; Virolle T, 1998, J BIOL CHEM, V273, P17318, DOI 10.1074/jbc.273.28.17318; Wang QJ, 1999, THORAX, V54, P805, DOI 10.1136/thx.54.9.805; Wang RQ, 2000, AM J PHYSIOL-LUNG C, V279, pL143, DOI 10.1152/ajplung.2000.279.1.L143; Wang TW, 1996, CELL, V86, P435, DOI 10.1016/S0092-8674(00)80116-6; Ward PA, 1998, AM J RESP CRIT CARE, V157, pS123, DOI 10.1164/ajrccm.157.4.nhlbi-10; WESTERGRENTHORSSON G, 1993, J CLIN INVEST, V92, P632, DOI 10.1172/JCI116631; Wong C, 1999, MOL CELL BIOL, V19, P1821; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YUE J, 2000, IN PRESS J BIOL CHEM; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Ziesche R, 1999, NEW ENGL J MED, V341, P1264, DOI 10.1056/NEJM199910213411703	69	113	126	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2001	15	3					797	806		10.1096/fj.00-0233com	http://dx.doi.org/10.1096/fj.00-0233com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259398				2022-12-28	WOS:000167419500037
J	Walpen, S; Beck, KF; Schaefer, L; Raslik, I; Eberhardt, W; Schaefer, RM; Pfeilschifter, J				Walpen, S; Beck, KF; Schaefer, L; Raslik, I; Eberhardt, W; Schaefer, RM; Pfeilschifter, J			Nitric oxide induces MIP-2 transcription in rat renal mesangial cells and in a rat model of glomerulonephritis	FASEB JOURNAL			English	Article									Univ Frankfurt Klinikum, Zentrum Pharmakol, D-60590 Frankfurt, Germany; Univ Munster, Innere Med Abt, D-4400 Munster, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital; University of Munster	Pfeilschifter, J (corresponding author), Univ Frankfurt Klinikum, Zentrum Pharmakol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.			Schaefer, Liliana/0000-0002-3318-3005					0	49	49	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					571	573						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259370				2022-12-28	WOS:000167419500008
J	Emami, S; Le Floch, N; Bruyneel, E; Thim, L; May, F; Westley, B; Rio, MC; Mareel, M; Gespach, C				Emami, S; Le Floch, N; Bruyneel, E; Thim, L; May, F; Westley, B; Rio, MC; Mareel, M; Gespach, C			Induction of scattering and cellular invasion by trefoil peptides in src- and RhoA-transformed kidney and colonic epithelial cells	FASEB JOURNAL			English	Article						inflammation; pS2; SP; ITF; PI3 '-kinase; phospholipase C; rapamycin	HUMAN SPASMOLYTIC POLYPEPTIDE; EPIDERMAL GROWTH-FACTOR; GTP-BINDING-PROTEIN; PS2 GENE; PHOSPHATIDYLINOSITOL 3-KINASE; COLORECTAL-CANCER; CARCINOMA CELLS; FACTOR RECEPTOR; BETA-CATENIN; MICE LACKING	Trefoil factors (TFFs) are protease-resistant peptides that promote epithelial cell migration and mucosal restitution during inflammatory conditions and wound healing in the gastrointestinal tract. To date, the molecular mechanism of TFFs action and their possible role in tumor progression are unclear. In the present study, we observed that premalignant human colonic PC/AA/C1 and canine kidney MDCK epithelial cells are not competent to invade collagen gels in response to exogenously added TFFs (pS2, spasmolytic polypeptide, and intestinal trefoil factor). In contrast, activated src and RhoA exert permissive induction of invasion by the TFFs that produce similar parallel dose-response curves in src-transformed MDCKts.src and PCmsrc cells (EC50=20-40 nM). Cell scattering is also induced by TFFs in MDCKts.src cells. Stable expression of the pS2 cDNA promotes constitutive invasiveness in MDCKts.src-pS2 cells and human colonic HCT8/S11-pS2 cells established from a sporadic tumor. Furthermore, we found that TEE-mediated cellular invasion is dependent of several signaling pathways implicated in cell transformation and survival, including phosphoinositide PI3'-kinase, phospholipase C, protein kinase C, and the rapamycin target TOR. Constitutive and intense expression of pS2 was revealed by Western blot analyses and immunohistochemistry in human colorectal tumors and their adjacent control mucosa during the neoplastic progression, from the adenoma to the liver metastases. Our studies indicated that TFFs can be involved in cell scattering and tumor invasion via autocrine loops and may serve as potential targets in the control of colon cancer progression.	Hop St Antoine, INSERM Unit U482, F-75571 Paris 12, France; State Univ Ghent Hosp, Expt Cancerol Lab, B-9000 Ghent, Belgium; Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark; Univ Newcastle Upon Tyne, Dept Pathol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Univ Strasbourg 1, INSERM U184, GBMC, F-67404 Illkirch, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Ghent University; Ghent University Hospital; Novo Nordisk; Newcastle University - UK; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Gespach, C (corresponding author), Hop St Antoine, INSERM Unit U482, F-75571 Paris 12, France.		LE FLOCH, Nathalie/I-3415-2015	LE FLOCH, Nathalie/0000-0002-6411-7975				Andre T, 2000, INT J CANCER, V86, P174, DOI 10.1002/(SICI)1097-0215(20000415)86:2<174::AID-IJC5>3.3.CO;2-5; Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; Babyatsky MW, 1996, GASTROENTEROLOGY, V110, P489, DOI 10.1053/gast.1996.v110.pm8566596; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BONKHOFF H, 1995, HUM PATHOL, V26, P824, DOI 10.1016/0046-8177(95)90002-0; BROWN AMC, 1984, P NATL ACAD SCI-BIOL, V81, P6344, DOI 10.1073/pnas.81.20.6344; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chadwick MP, 1997, BIOCHEM J, V327, P117, DOI 10.1042/bj3270117; CHINERY R, 1992, BIOCHEM J, V285, P5, DOI 10.1042/bj2850005; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; Colombel M, 1999, J UROLOGY, V162, P927, DOI 10.1097/00005392-199909010-00092; DELAGE S, 1993, CANCER RES, V53, P2762; DIGNASS A, 1994, J CLIN INVEST, V94, P376, DOI 10.1172/JCI117332; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; Efstathiou JA, 1999, P NATL ACAD SCI USA, V96, P2316, DOI 10.1073/pnas.96.5.2316; Efstathiou JA, 1998, P NATL ACAD SCI USA, V95, P3122, DOI 10.1073/pnas.95.6.3122; Empereur S, 1997, BRIT J CANCER, V75, P241, DOI 10.1038/bjc.1997.40; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Gampel A, 1999, CURR BIOL, V9, P955, DOI 10.1016/S0960-9822(99)80422-9; GESPACH C, 1988, CANCER RES, V48, P5079; Hall CL, 1996, ONCOGENE, V13, P2213; HANBY AM, 1993, GASTROENTEROLOGY, V105, P1110, DOI 10.1016/0016-5085(93)90956-D; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kato K, 1999, AM J PHYSIOL-GASTR L, V276, pG1105, DOI 10.1152/ajpgi.1999.276.5.G1105; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kotelevets L, 1998, J BIOL CHEM, V273, P14138, DOI 10.1074/jbc.273.23.14138; Lalani EN, 1999, LAB INVEST, V79, P537; Lefebvre O, 1996, SCIENCE, V274, P259, DOI 10.1126/science.274.5285.259; Liu D, 1997, LAB INVEST, V77, P557; Machado JC, 2000, J PATHOL, V190, P437; Marchbank T, 1998, J PATHOL, V185, P153; Mashimo H, 1996, SCIENCE, V274, P262, DOI 10.1126/science.274.5285.262; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MICHIYUKI K, 1998, P NATL ACAD SCI USA, V95, P178; Newton JL, 2000, GUT, V46, P312, DOI 10.1136/gut.46.3.312; NUNEZ AM, 1989, EMBO J, V8, P823, DOI 10.1002/j.1460-2075.1989.tb03443.x; Playford RJ, 1996, P NATL ACAD SCI USA, V93, P2137, DOI 10.1073/pnas.93.5.2137; Raymond E, 1997, ANTI-CANCER DRUG, V8, P876, DOI 10.1097/00001813-199710000-00009; RIO MC, 1991, GASTROENTEROLOGY, V100, P375, DOI 10.1016/0016-5085(91)90205-Y; RIO MC, 1988, SCIENCE, V241, P705, DOI 10.1126/science.3041593; Ronnstrand L, 1999, J BIOL CHEM, V274, P22089, DOI 10.1074/jbc.274.31.22089; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sands BE, 1996, ANNU REV PHYSIOL, V58, P253, DOI 10.1146/annurev.ph.58.030196.001345; SUEMORI S, 1991, P NATL ACAD SCI USA, V88, P11017, DOI 10.1073/pnas.88.24.11017; TAKAISHI K, 1994, ONCOGENE, V9, P273; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Taupin DR, 2000, P NATL ACAD SCI USA, V97, P799, DOI 10.1073/pnas.97.2.799; TERMUHLEN PM, 1993, J SURG RES, V54, P293, DOI 10.1006/jsre.1993.1046; THIM L, 1993, FEBS LETT, V318, P345, DOI 10.1016/0014-5793(93)80543-4; THIM L, 1995, BIOCHEMISTRY-US, V34, P4757, DOI 10.1021/bi00014a033; THIM L, 1989, FEBS LETT, V250, P85, DOI 10.1016/0014-5793(89)80690-8; Tomasetto C, 2000, GASTROENTEROLOGY, V118, P70, DOI 10.1016/S0016-5085(00)70415-X; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; Tran CP, 1999, GUT, V44, P636, DOI 10.1136/gut.44.5.636; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; vonEichelStreiber C, 1996, TRENDS MICROBIOL, V4, P375, DOI 10.1016/0966-842X(96)10061-5; Wang DG, 1997, INT J CANCER, V74, P270, DOI 10.1002/(SICI)1097-0215(19970620)74:3<270::AID-IJC6>3.0.CO;2-W; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; Wojciak-Stothard B, 1999, J CELL BIOL, V145, P1293, DOI 10.1083/jcb.145.6.1293; WRIGHT NA, 1993, GASTROENTEROLOGY, V104, P12, DOI 10.1016/0016-5085(93)90830-6; Yoshiji H, 1999, CANCER RES, V59, P4413	64	102	109	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					351	361		10.1096/fj.00-0355com	http://dx.doi.org/10.1096/fj.00-0355com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156951				2022-12-28	WOS:000166872900017
J	Shi, H; Dirienzo, D; Zemel, MB				Shi, H; Dirienzo, D; Zemel, MB			Effects of dietary calcium on adipocyte lipid metabolism and body weight regulation in energy-restricted aP2-agouti transgenic mice	FASEB JOURNAL			English	Article									Univ Tennessee, Knoxville, TN 37996 USA; Natl Dairy Council, Rosemont, IL 60018 USA	University of Tennessee System; University of Tennessee Knoxville	Zemel, MB (corresponding author), Univ Tennessee, 1215 W Cumberland Ave,229, Knoxville, TN 37996 USA.			Zemel, Michael/0000-0003-4104-5750					0	225	231	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					291	293						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156940				2022-12-28	WOS:000166872900006
J	DeMeester, SL; Buchman, TG; Cobb, JP				DeMeester, SL; Buchman, TG; Cobb, JP			The heat shock paradox: does NF-kappa B determine cell fate?	FASEB JOURNAL			English	Article; Proceedings Paper	20th Annual Conference on Shock	JUN 15-18, 1997	INDIAN WELLS, CA			injury; cell death; apoptosis; I kappa B alpha	ENDOTHELIAL-CELLS; INDUCED APOPTOSIS; STRESS-RESPONSE; ACTIVATION; INJURY; SEPSIS; DEATH; ALPHA; INHIBITION; EXPRESSION	Cellular injury induces an adaptive response whether the insult is physical (e.g., heat, radiation), chemical (e.g., reactive oxygen species), infectious (e.g., bacteria), or inflammatory (e.g., lipopolysaccharide), Recent data indicate that the interactions of these responses are not predictable and that sequence permutations can have opposite effects on outcome after injury. Our overarching hypothesis is that interactions among stress responses contribute to the fate of cells, tissues, and organisms and that modulation of these interactions can have important affects on both function and survival. For example, whereas it is well known that a prior heat shock stress can protect cells against inflammatory stress both in vitro and in vivo, we and others have shown that induction of a subsequent heat stress in cells 'primed' by inflammation can precipitate cell death by apoptosis. We call this seemingly paradoxical ability of heat shock to induce cytoprotection and cytotoxicity the heat shock paradox. The molecular mechanisms by which cells integrate responses to these and other stresses are poorly understood. We present data linking the heat shock paradox to the activity of the acute-phase transcription factor nuclear factor kappa B (identifying an 'NF-kappaB paradox') and hypothesize that the mechanism is linked to the downstream effects of induction of NF-kappaB's endogenous inhibitor, I kappaB alpha, a putative heat shock protein.	Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Cellular Injury & Adaptat Lab, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Cobb, JP (corresponding author), Washington Univ, Sch Med, Dept Surg, Campus Box 8109,660 S Euclid Ave, St Louis, MO 63110 USA.	cobb@msnotes.wustl.edu		Buchman, Timothy/0000-0001-7350-5921	NIGMS NIH HHS [GM 59960] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059960] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barinaga M, 1996, SCIENCE, V274, P724, DOI 10.1126/science.274.5288.724; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BUCHMAN TG, 1993, AM J PHYSIOL, V265, pH165, DOI 10.1152/ajpheart.1993.265.1.H165; Cobb JP, 1996, BRIT J ANAESTH, V77, P3, DOI 10.1093/bja/77.1.3; Cobb JP, 1999, CRIT CARE MED, V27, P1695, DOI 10.1097/00003246-199908000-00078; De Maio A, 1995, New Horiz, V3, P198; DeMeester SL, 1997, ARCH SURG-CHICAGO, V132, P1283; DeMeester SL, 1998, CRIT CARE MED, V26, P1500, DOI 10.1097/00003246-199809000-00016; DeMeester SL, 1998, SHOCK, V10, P1, DOI 10.1097/00024382-199807000-00001; DeMeester SL, 1998, SURGERY, V124, P362, DOI 10.1016/S0039-6060(98)70142-4; DEMEESTER SL, 1997, SHOCK S2, V7, P5; Ferran C, 1998, BLOOD, V91, P2249, DOI 10.1182/blood.V91.7.2249.2249_2249_2258; FERRAN C, 1995, BIOCHEM BIOPH RES CO, V214, P212, DOI 10.1006/bbrc.1995.2277; HOTCHKISS R, 1993, AM J PHYSIOL, V265, pR1447, DOI 10.1152/ajpregu.1993.265.6.R1447; Hotchkiss RS, 1999, CRIT CARE MED, V27, P1230, DOI 10.1097/00003246-199907000-00002; Hotchkiss RS, 1997, CRIT CARE MED, V25, P1298, DOI 10.1097/00003246-199708000-00015; MINOWADA G, 1995, J CLIN INVEST, V95, P3, DOI 10.1172/JCI117655; MOORE FA, 1995, SURG CLIN N AM, V75, P257, DOI 10.1016/S0039-6109(16)46587-4; Morishita R, 1997, NAT MED, V3, P894, DOI 10.1038/nm0897-894; Nasraway SA, 1999, CRIT CARE MED, V27, P427, DOI 10.1097/00003246-199902000-00054; PIPER RD, 1997, SEPSIS MULTIORGAN FA, P189; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; SAAD S, 1995, SURGERY, V118, P510, DOI 10.1016/S0039-6060(05)80367-8; VAN AD, 1996, SCIENCE, V274, P787; VILLAR J, 1994, CRIT CARE MED, V22, P914; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang JH, 1997, AM J PHYSIOL-CELL PH, V272, pC1543, DOI 10.1152/ajpcell.1997.272.5.C1543; Wang YR, 1996, SHOCK, V6, P134, DOI 10.1097/00024382-199608000-00009; Wong HR, 1997, J CLIN INVEST, V99, P2423, DOI 10.1172/JCI119425; Wong HR, 1999, SHOCK, V12, P323, DOI 10.1097/00024382-199910000-00012; Wrighton CJ, 1996, J EXP MED, V183, P1013, DOI 10.1084/jem.183.3.1013; Xu DZ, 1996, ARCH SURG-CHICAGO, V131, P1222	34	93	96	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2001	15	1					270	274		10.1096/fj.00-0170hyp	http://dx.doi.org/10.1096/fj.00-0170hyp			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149915				2022-12-28	WOS:000166312400036
J	Haugabook, SJ; Le, T; Yager, D; Zenk, B; Healy, BM; Eckman, EA; Prada, C; Younkin, L; Murphy, P; Pinnix, I; Onstead, L; Sambamurti, K; Golde, TE; Dickson, D; Younkin, SG; Eckman, CB				Haugabook, SJ; Le, T; Yager, D; Zenk, B; Healy, BM; Eckman, EA; Prada, C; Younkin, L; Murphy, P; Pinnix, I; Onstead, L; Sambamurti, K; Golde, TE; Dickson, D; Younkin, SG; Eckman, CB			Reduction of A beta accumulation in the Tg2576 animal model of Alzheimer's disease after oral administration of the phosphatidyl-inositol kinase inhibitor wortmannin	FASEB JOURNAL			English	Article									Mayo Clin, Jacksonville, FL 32224 USA	Mayo Clinic	Eckman, CB (corresponding author), Mayo Clin, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.		Eckman, Elizabeth/AAL-7316-2021; Sambamurti, Kumar/J-6102-2013	Sambamurti, Kumar/0000-0001-9507-9214; Eckman, Elizabeth/0000-0002-5391-4960; Dickson, Dennis W/0000-0001-7189-7917					0	43	48	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2001	15	1					16	18						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11099491				2022-12-28	WOS:000166312400006
J	Shapiro, L; Pott, GB; Ralston, AH				Shapiro, L; Pott, GB; Ralston, AH			Alpha-1-antitrypsin inhibits human immunodeficiency virus type 1	FASEB JOURNAL			English	Article						alpha-1-proteinase inhibitor; serine proteinase inhibitors; HIV-1; NF-kappa B; interleukin 18	TUMOR-NECROSIS-FACTOR; LEUKOCYTE PROTEASE INHIBITOR; NF-KAPPA-B; FACTOR-ALPHA; CELL-LINE; HUMAN LYMPHOCYTES-T4+; CONVERTING-ENZYME; HIV-INFECTION; WHOLE-BLOOD; IN-VITRO	Several observations suggest the existence of potent endogenous suppressors of human immunodeficiency virus type 1 (HIV-l) production, and inhibitors of serine proteases may participate in this effect. Alpha-1-antitrypsin (AAT) is the most abundant circulating serine protease inhibitor. Physiological AAT concentrations inhibited HIV-1 production in chronically infected U1 monocytic cells, reduced virus replication in freshly infected peripheral blood mononuclear cells, and blocked infection of permissive HeLa cells, In U1 cells, AAT suppressed activation of the HIV-1-inducing transcription factor NF-kappaB. Similar results were obtained using CE-2072, a synthetic inhibitor of host serine proteases, HIV-1 did not replicate in blood obtained from healthy volunteers, but marked replication was observed in blood from individuals with hereditary AAT deficiency. These results identify AAT as a candidate circulating HIV-1 inhibitor in vivo. Two different mechanisms of AAT-induced HIV-1 inhibition were identified, including reduced HIV-1 infectivity and blockade of HIV-1 production. A novel host-pathogen interaction is suggested, and an alternative strategy to treat HIV-1-related disease may be possible.	Univ Colorado, Hlth Sci Ctr, Dept Med, Div Infect Dis, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Cellular & Struct Biol, Denver, CO 80262 USA; Amer Red Cross, Plasma Derivat Dept, Holland Lab, Rockville, MD 20855 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; American Red Cross	Shapiro, L (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, Div Infect Dis, Denver, CO 80262 USA.	shapiro@uchsc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015614, R01AI015614] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 15614] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AVRIL LE, 1994, FEBS LETT, V345, P81, DOI 10.1016/0014-5793(94)00410-2; AVRIL LE, 1993, FEBS LETT, V317, P167, DOI 10.1016/0014-5793(93)81515-2; BAYLISS GJ, 1990, J MED VIROL, V31, P161, DOI 10.1002/jmv.1890310215; BLANK CA, 1994, ANN ALLERGY, V72, P105; BRISTOW CL, 1995, INT IMMUNOL, V7, P239, DOI 10.1093/intimm/7.2.239; Bush CE, 1996, J ACQ IMMUN DEF SYND, V13, P23, DOI 10.1097/00042560-199609000-00004; Carpenter CCJ, 2000, JAMA-J AM MED ASSOC, V283, P381, DOI 10.1001/jama.283.3.381; CARRELL RW, 1986, J CLIN INVEST, V78, P1427, DOI 10.1172/JCI112731; COAN MH, 1985, VOX SANG, V48, P333, DOI 10.1111/j.1423-0410.1985.tb00193.x; Coeshott C, 1999, P NATL ACAD SCI USA, V96, P6261, DOI 10.1073/pnas.96.11.6261; CRYSTAL RG, 1990, J CLIN INVEST, V85, P1343, DOI 10.1172/JCI114578; DIMITROV DH, 1990, J CLIN MICROBIOL, V28, P734, DOI 10.1128/JCM.28.4.734-737.1990; Donovan RM, 1996, J INFECT DIS, V174, P401, DOI 10.1093/infdis/174.2.401; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FIORE JR, 1990, MICROBIOLOGICA, V13, P311; FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729; FOX PC, 1988, J AM DENT ASSOC, V116, P635, DOI 10.14219/jada.archive.1988.0002; Gass RJA, 1998, ANTIVIR THER, V3, P97; Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206; HATTORI T, 1989, FEBS LETT, V248, P48, DOI 10.1016/0014-5793(89)80429-6; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; JAPOUR AJ, 1994, J CLIN MICROBIOL, V32, P2291, DOI 10.1128/JCM.32.9.2291-2294.1994; JEPPSSON JO, 1976, FEBS LETT, V65, P195, DOI 10.1016/0014-5793(76)80478-4; KEET IPM, 1992, AIDS, V6, P223, DOI 10.1097/00002030-199202000-00014; KIDO H, 1990, J BIOL CHEM, V265, P21979; KIDO H, 1991, FEBS LETT, V286, P233, DOI 10.1016/0014-5793(91)80981-8; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; KINGSLEY LA, 1987, LANCET, V1, P345; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LYMAN D, 1986, JAMA-J AM MED ASSOC, V255, P1703, DOI 10.1001/jama.1986.03370130059009; MASSI G, 1994, ACTA PAEDIATR, V83, P1, DOI 10.1111/j.1651-2227.1994.tb13197.x; MAYER KH, 1987, ANN INTERN MED, V107, P428, DOI 10.7326/0003-4819-107-2-428_2; MCNEELY TB, 1995, J CLIN INVEST, V96, P456, DOI 10.1172/JCI118056; McNeely TB, 1997, BLOOD, V90, P1141, DOI 10.1182/blood.V90.3.1141.1141_1141_1149; NARAYANAM VR, 1991, J BIOL CHEM, V266, P9540; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; POLI G, 1990, J EXP MED, V172, P151, DOI 10.1084/jem.172.1.151; Shapiro GG, 1998, IMMUNOL ALLERGY CLIN, V18, P1, DOI 10.1016/S0889-8561(05)70343-X; Shapiro L, 1995, P NATL ACAD SCI USA, V92, P12230, DOI 10.1073/pnas.92.26.12230; Shapley R, 1998, NAT NEUROSCI, V1, P95, DOI 10.1038/342; STOLLER RS, 1997, CHEST S6, V111, pS123; TIFFANY TO, 1987, FUNDAMENTALS CLIN CH, P74; TOKARS JI, 1993, ANN INTERN MED, V118, P913, DOI 10.7326/0003-4819-118-12-199306150-00001; WERNER BG, 1982, ANN INTERN MED, V97, P367, DOI 10.7326/0003-4819-97-3-367; WEWERS MD, 1987, NEW ENGL J MED, V316, P1055, DOI 10.1056/NEJM198704233161704; WINKELSTEIN W, 1987, JAMA-J AM MED ASSOC, V257, P321, DOI 10.1001/jama.257.3.321	49	116	124	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2001	15	1					115	122		10.1096/fj.00-0311com	http://dx.doi.org/10.1096/fj.00-0311com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149899				2022-12-28	WOS:000166312400020
J	Berrie, CP; Falasca, M				Berrie, CP; Falasca, M			Patterns within protein/polyphosphoinositide interactions provide specific targets for therapeutic intervention	FASEB JOURNAL			English	Article						phosphoinositide 3-kinase; polyphosphoinositides; inositol polyphosphates; PH/FYVE/HIKE domains; cancer therapy	PLECKSTRIN HOMOLOGY DOMAINS; INOSITOL HEXAKISPHOSPHATE; PHOSPHOINOSITIDE 3-KINASES; SIGNAL-TRANSDUCTION; MEMBRANE TRAFFICKING; PH DOMAIN; BINDING; NEURONS; PENTAKISPHOSPHATE; METABOLISM	Signaling pathways involving the inositol polyphosphates and the polyphosphoinositides have become intricately linked with a number of disease states. More recently, this has principally involved the 3-phosphorylated products of phosphoinositide S-kinase, an enzyme that itself shows oncogenic activity and has hence become of interest in the design of antitumorigenic drugs. The downstream effecters of phosphoinositide 3-kinase are involved in different aspects of cellular signaling and cytoskeleton and trafficking events that are linked to specific polyphosphoinositide binding properties of specific protein domains, which themselves have emerging roles in specific disease states. Our recent findings have demonstrated that there is a selectivity of the intracellular effects of extracellularly applied inositol polyphosphates in their abilities to inhibit a range of growth-related in vivo assay conditions, and that these can themselves be linked to the inhibition of the membrane localization of a green fluorescent protein (GFP) -tagged PH domain. We propose that GFP fusions of the polyphosphoinositides binding domains of specific proteins of interest can be used in high-throughput investigations of the therapeutic value of specific inositol polyphosphates analogs. Inhibition of in vivo membrane targeting of these domains from proteins involved in cell growth and tumorigenesis can thus be used in the search for new anticancer drugs.	Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, I-66030 Santa Maria Imbaro, Chieti, Italy; Univ G DAnnunzio, Sch Med, Dept Oncol & Neurosci, Sect Med Oncol, I-66100 Chieti, Italy	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; G d'Annunzio University of Chieti-Pescara	Berrie, CP (corresponding author), Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, Via Nazl, I-66030 Santa Maria Imbaro, Chieti, Italy.		Falasca, Marco/S-4020-2016	Falasca, Marco/0000-0002-9801-7235	Telethon [E.0841] Funding Source: Medline	Telethon(Fondazione Telethon)		Alberti S, 1998, PROTEINS, V31, P1, DOI 10.1002/(SICI)1097-0134(19980401)31:1<1::AID-PROT1>3.0.CO;2-R; [Anonymous], OMIM ONLINE MENDELIA; Besson A, 1999, EUR J BIOCHEM, V263, P605, DOI 10.1046/j.1432-1327.1999.00542.x; Chalecka-Franaszek E, 1999, P NATL ACAD SCI USA, V96, P8745, DOI 10.1073/pnas.96.15.8745; Ciccarelli FD, 2000, HUM MOL GENET, V9, P1001, DOI 10.1093/hmg/9.6.1001; Corvera S, 1999, CURR OPIN CELL BIOL, V11, P460, DOI 10.1016/S0955-0674(99)80066-0; Dong ZG, 1999, ANTICANCER RES, V19, P3743; Eckmann L, 1997, P NATL ACAD SCI USA, V94, P14456, DOI 10.1073/pnas.94.26.14456; EGGLETON P, 1991, BIOCHIM BIOPHYS ACTA, V1094, P309, DOI 10.1016/0167-4889(91)90091-B; FERGUSON KM, 1995, NAT STRUCT BIOL, V2, P715, DOI 10.1038/nsb0995-715; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fruman DA, 1999, CELL, V97, P817, DOI 10.1016/S0092-8674(00)80792-8; Fukuda M, 1997, BIOESSAYS, V19, P593, DOI 10.1002/bies.950190710; Kassis J, 1999, CLIN CANCER RES, V5, P2251; Kunz J, 2000, MOL CELL, V5, P1, DOI 10.1016/S1097-2765(00)80398-6; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Lemmon MA, 1998, CURR TOP MICROBIOL, V228, P39; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; NICOLETTI F, 1989, J NEUROCHEM, V53, P1026, DOI 10.1111/j.1471-4159.1989.tb07390.x; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; Razzini G, 2000, FASEB J, V14, P1179, DOI 10.1096/fasebj.14.9.1179; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; SASAKAWA N, 1995, BIOCHEM PHARMACOL, V50, P137, DOI 10.1016/0006-2952(95)00059-9; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Shamsuddin AM, 1999, ANTICANCER RES, V19, P3733; SORTINO MA, 1990, EUR J PHARM-MOLEC PH, V189, P115, DOI 10.1016/0922-4106(90)90238-S; Stenmark H, 1999, J CELL SCI, V112, P4175; SUN MK, 1992, EUR J PHARMACOL, V215, P9, DOI 10.1016/0014-2999(92)90601-Y; Tolias KF, 2000, CURR BIOL, V10, P153, DOI 10.1016/S0960-9822(00)00315-8; VALLEJO M, 1987, NATURE, V330, P656, DOI 10.1038/330656a0; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Wang JF, 1999, MOL BRAIN RES, V70, P66, DOI 10.1016/S0169-328X(99)00128-X; Wurmser AE, 1999, J BIOL CHEM, V274, P9129, DOI 10.1074/jbc.274.14.9129; Xie WW, 1996, J BIOL CHEM, V271, P14092, DOI 10.1074/jbc.271.24.14092; Yang XN, 1999, J BIOL CHEM, V274, P18973, DOI 10.1074/jbc.274.27.18973; Yenush L, 2000, FEBS LETT, V467, P321, DOI 10.1016/S0014-5793(00)01183-2; Zheng Y, 1996, J BIOL CHEM, V271, P33169, DOI 10.1074/jbc.271.52.33169; SMART SIMPLE MODULAR; EXPASY EXPERT PROTEI	42	21	22	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2618	2622		10.1096/fj.00-0096hyp	http://dx.doi.org/10.1096/fj.00-0096hyp			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099481				2022-12-28	WOS:000165723400033
J	Krauss, S; Brand, MD				Krauss, S; Brand, MD			Quantitation of signal transduction	FASEB JOURNAL			English	Article						energy metabolism; lymphocytes; metabolic control analysis; mitogenic activation	METABOLIC CONTROL ANALYSIS; PROTEIN-KINASE CASCADE; ENERGY-METABOLISM; ELASTICITY ANALYSIS; CYCLOSPORINE-A; CALCINEURIN; PATHWAYS; CELLS; QUANTIFICATION; MITOCHONDRIA	Conventional qualitative approaches to signal transduction provide powerful ways to explore the architecture and function of signaling pathways, However, at the level of the complete system, they do not fully depict the interactions between signaling and metabolic pathways and fail to give a manageable overview of the complexity that is often a feature of cellular signal transduction, Here, we introduce a quantitative experimental approach to signal transduction that helps to overcome these difficulties. We present a quantitative analysis of signal transduction during early mitogen stimulation of lymphocytes, with steady-state respiration rate as a convenient marker of metabolic stimulation. First, by inhibiting various key signaling pathways, we measure their relative importance in regulating respiration. About 80% of the input signal is conveyed via identifiable routes: 50% through pathways sensitive to inhibitors of protein kinase C and MAP kinase and 30% through pathways sensitive to an inhibitor of calcineurin, Second, we quantify how each of these pathways differentially stimulates functional units of reactions that produce and consume a key intermediate in respiration: the mitochondrial membrane potential. Both the PKC and calcineurin routes stimulate consumption more strongly than production, whereas the unidentified signaling routes stimulate production more than consumption, leading to no change in membrane potential despite increased respiration rate. The approach allows a quantitative description of the relative importance of signal transduction pathways and the routes by which they activate a specific cellular process. It should be widely applicable.	Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; MRC, Dunn Human Nutr Unit, Cambridge, England	University of Cambridge; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research	Krauss, S (corresponding author), Beth Israel Deaconess Med Ctr, Div Endocrinol, 99 Brookline Ave, Boston, MA 02215 USA.		Brand, Martin D/A-9423-2012	Brand, Martin D/0000-0003-4418-6153				Ainscow EK, 1999, BIOSYSTEMS, V49, P151, DOI 10.1016/S0303-2647(98)00040-9; Ainscow EK, 1998, J THEOR BIOL, V194, P223, DOI 10.1006/jtbi.1998.0760; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Brand MD, 1996, J THEOR BIOL, V182, P351, DOI 10.1006/jtbi.1996.0174; Brand MD, 1998, MOL CELL BIOCHEM, V184, P13, DOI 10.1023/A:1006893619101; BROWN GC, 1990, EUR J BIOCHEM, V188, P321, DOI 10.1111/j.1432-1033.1990.tb15406.x; BUTTGEREIT F, 1992, BIOSCIENCE REP, V12, P381, DOI 10.1007/BF01121501; BUTTGEREIT F, 1995, BIOCHEM J, V312, P163, DOI 10.1042/bj3120163; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ENAN E, 1992, BIOCHEM PHARMACOL, V43, P1777, DOI 10.1016/0006-2952(92)90710-Z; Fell D., 1997, UNDERSTANDING CONTRO; Guerini D, 1997, BIOCHEM BIOPH RES CO, V235, P271, DOI 10.1006/bbrc.1997.6802; Horseman ND, 1997, TRENDS ENDOCRIN MET, V8, P123, DOI 10.1016/S1043-2760(97)00001-5; Huang CYF, 1996, P NATL ACAD SCI USA, V93, P10078, DOI 10.1073/pnas.93.19.10078; Karlsson H, 1997, BBA-BIOENERGETICS, V1319, P301, DOI 10.1016/S0005-2728(96)00173-9; Kaufman M, 1999, P NATL ACAD SCI USA, V96, P3894, DOI 10.1073/pnas.96.7.3894; KHOLODENKO BN, 1988, FEBS LETT, V232, P383, DOI 10.1016/0014-5793(88)80775-0; Kholodenko BN, 1997, FEBS LETT, V414, P430, DOI 10.1016/S0014-5793(97)01018-1; Korzeniewski B, 1998, BIOPHYS CHEM, V75, P73, DOI 10.1016/S0301-4622(98)00193-8; Krauss S, 1999, BBA-BIOENERGETICS, V1412, P129, DOI 10.1016/S0005-2728(99)00058-4; KRAUSS S, 1999, THESIS U CAMBRIDGE U; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; PUSZTAI A, 1991, PLANT LECTINS, P78; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; SALISBURY JG, 1979, J BIOCHEM BIOPH METH, V1, P341, DOI 10.1016/0165-022X(79)90025-3; Scott JE, 1997, BIOCHEM J, V324, P597, DOI 10.1042/bj3240597; TOULLEC D, 1991, J BIOL CHEM, V266, P15771	30	19	20	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2581	2588		10.1096/fj.00-0064com	http://dx.doi.org/10.1096/fj.00-0064com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099477				2022-12-28	WOS:000165723400029
J	English, D; Welch, Z; Kovala, AT; Harvey, K; Volpert, OV; Brindley, DN; Garcia, JGN				English, D; Welch, Z; Kovala, AT; Harvey, K; Volpert, OV; Brindley, DN; Garcia, JGN			Sphingosine 1-phosphate released from platelets during clotting accounts for the potent endothelial cell chemotactic activity of blood serum and provides a novel link between hemostasis and angiogenesis	FASEB JOURNAL			English	Article						lipid mediators; vascular endothelium; angiogenesis; endothelial cell migration; hemostasis; SIP	FIBROBLAST GROWTH-FACTOR; COUPLED RECEPTOR EDG-1; LYSOPHOSPHATIDIC ACID; TUMOR ANGIOGENESIS; SPHINGOSINE-1-PHOSPHATE; INHIBITION; MEMBRANE; INVIVO	Recent studies have identified factors responsible for angiogenesis within developing tumors, but mediators of vessel formation at sites of trauma, injury, and wound healing are not clearly established. Here we show that sphingosine l-phosphate (S1P) released by platelets during blood clotting is a potent, specific, and selective endothelial cell chemoattractant that accounts for most of the strong endothelial cell chemotactic activity of blood serum, an activity that is markedly diminished in plasma. Preincubation, of endothelial cells with pertussis toxin inhibited this effect of S1P, demonstrating the involvement of a G(alphai)-coupled receptor, After S1P-induced migration, endothelial cells proliferated avidly and differentiated forming multicellular structures suggestive of early blood vessel formation. SIP was strikingly effective in enhancing the ability of fibroblast growth factor to induce angiogenesis in the avascular mouse cornea, Our results show that blood coagulation initiates endothelial cell angiogenic responses through the release of SIP, a potent endothelial cell chemoattractant that exerts its effects by activating a receptor-dependent process,-English, D., Welch, Z., Kovala, A, T., Harvey, K., Volpert, O. V,, Brindley, D. N., Garcia, J. G. N. Sphingosine l-phosphate released from platelets during clotting accounts for the potent endothelial cell chemotactic activity of blood serum and provides a novel link between hemostasis and angiogenesis.	Methodist Res Inst, Expt Cell Res Program, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Physiol & Biophys, Indianapolis, IN 46202 USA; Northwestern Univ, Sch Med, Dept Immunol Microbiol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, RH Lurie Canc Ctr, Chicago, IL 60611 USA; Univ Alberta, Dept Biochem, Lipid & Lipoprot Res Grp, Edmonton, AB T6H 5M3, Canada; Johns Hopkins Univ, Dept Med, Div Pulm & Crit Care Med, Baltimore, MD 21205 USA	Indiana University System; Indiana University System; Indiana University-Purdue University Indianapolis; Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; University of Alberta; Johns Hopkins University	English, D (corresponding author), Methodist Res Inst, Expt Cell Res Program, 1701 N Senate Ave, Indianapolis, IN 46202 USA.	dkenglish@msn.com	Garcia, Joe GN/E-8862-2010	Kovala, A. Thomas/0000-0002-2908-5613; Volpert, Olga/0000-0003-1381-5543	NHLBI NIH HHS [R01 HL 61751, P0 1 HL 58064] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL058064, R01HL061751] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		DESAI NN, 1991, BIOCHEM BIOPH RES CO, V181, P361, DOI 10.1016/S0006-291X(05)81427-5; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; English D, 1999, J HEMATOTH STEM CELL, V8, P627, DOI 10.1089/152581699319795; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; GERRARD JM, 1989, BIOCHIM BIOPHYS ACTA, V1001, P282, DOI 10.1016/0005-2760(89)90112-4; GROSS JL, 1993, J NATL CANCER I, V85, P121, DOI 10.1093/jnci/85.2.121; HLA T, 1990, J BIOL CHEM, V265, P9308; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Kenyon BM, 1996, INVEST OPHTH VIS SCI, V37, P1625; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lin PN, 1997, J CLIN INVEST, V100, P2072, DOI 10.1172/JCI119740; Martin A, 1997, ONCOGENE, V14, P1571, DOI 10.1038/sj.onc.1200987; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Moore BB, 1998, J LAB CLIN MED, V132, P97, DOI 10.1016/S0022-2143(98)90004-X; NGUYEN M, 1994, J NATL CANCER I, V86, P356, DOI 10.1093/jnci/86.5.356; Nissen NN, 1998, AM J PATHOL, V152, P1445; PASSANITI A, 1992, LAB INVEST, V67, P519; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rusnati M, 1996, INT J CLIN LAB RES, V26, P15, DOI 10.1007/BF02644769; Siddiqui RA, 1997, BBA-LIPID LIPID MET, V1349, P81, DOI 10.1016/S0005-2760(97)00085-4; Spiegel S, 1998, ANN NY ACAD SCI, V845, P11, DOI 10.1111/j.1749-6632.1998.tb09658.x; TIGYI G, 1992, J BIOL CHEM, V267, P21360; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; YATOMI Y, 1995, BLOOD, V86, P193, DOI 10.1182/blood.V86.1.193.bloodjournal861193; Zondag GCM, 1998, BIOCHEM J, V330, P605, DOI 10.1042/bj3300605	31	243	257	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2000	14	14					2255	2265		10.1096/fj.00-0134com	http://dx.doi.org/10.1096/fj.00-0134com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053247				2022-12-28	WOS:000165190800019
J	Flores, I; Jones, DR; Merida, I				Flores, I; Jones, DR; Merida, I			Changes in the balance between mitogenic and antimitogenic lipid second messengers during proliferation, cell arrest, and apoptosis in T lymphocytes	FASEB JOURNAL			English	Article									CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Madrid 28049, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Merida, I (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Campus Univ Autonoma, Madrid 28049, Spain.		Merida, Isabel/A-9713-2014; Flores, Ignacio/E-8304-2016	Merida, Isabel/0000-0003-2762-6241; Flores, Ignacio/0000-0001-8789-6396					0	20	21	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2000	14	13					1873	1875						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023971				2022-12-28	WOS:000089634400006
J	Miller, LE; Justen, HP; Scholmerich, J; Straub, RH				Miller, LE; Justen, HP; Scholmerich, J; Straub, RH			The loss of sympathetic nerve fibers in the synovial tissue of patients with rheumatoid arthritis is accompanied by increased norepinephrine release from synovial macrophages	FASEB JOURNAL			English	Article						osteoarthritis; synovium; norepinephrine; neuroimmunomodulators	TUMOR-NECROSIS-FACTOR; ADJUVANT-INDUCED ARTHRITIS; NITRIC-OXIDE PRODUCTION; GENE-RELATED PEPTIDE; SUBSTANCE-P; MURINE SPLEEN; TNF-ALPHA; ENDOGENOUS NOREPINEPHRINE; INTERLEUKIN-6 SECRETION; PLASMA EXTRAVASATION	Our objective was to investigate sympathetic and sensory nerve fibers in synovial tissue in rheumatoid arthritis (RA) and osteoarthritis (OA) in relation to histological inflammation and synovial cytokine and norepinephrine (NE) secretion. Immunohistochemistry was used to detect nerve fibers and inflammatory parameters. A superfusion technique of synovial tissue pieces was used to investigate cytokine and NE secretion. In RA, we detected 0.2 +/- 0.04 tyrosine hydroxylase-positive (TH-positive=sympathetic) nerve fibers/mm(2) as compared to 4.4 +/- 0.8 nerve fibers/mm(2) in OA (P<0.001). In RA, there was a negative correlation between the number of TH-positive nerve fibers and inflammation index (R-Rank=-0.705, P=0.002) and synovial IL-6 secretion (R-Rank=-0.630, P=0.009), which was not found in OA. Substance P-positive (=sensory) nerve fibers were increased in RA as compared to OA (3.5+/-0.2 vs. 2.3+/-0.3/mm(2), P=0.009). Despite lower numbers of sympathetic nerve fibers in RA than in OA, NE release was similar at baseline (RA, vs. OA: 152+/-36 vs. 106+/-21 pg/ml, n.s.). Basal synovial NE secretions correlate with the number of TH-positive CD 163(+) synovial macrophages (RA: R-Rank=0.622, P=0.031; OA: R-Rank =0.299, n.s.), and synovial macrophages have been shown to produce NE in vitro. Whereas sympathetic innervation is reduced, sensory innervation is increased in the synovium from patients with longstanding RA when compared to the synovium from OA patients. The differential patterns of innervation are dependent on the severity of the inflammation. However, NE secretion from the synovial tissue is maintained by synovial macrophages. This demonstrates a loss of the influence of the sympathetic nervous system on the inflammation, accompanied by an up-regulation of the sensory inputs into the joint, which may contribute to the maintenance of the disease.	Univ Med Ctr Regensburg, Dept Internal Med 1, Lab Neuroendocrinoimmunol, D-93042 Regensburg, Germany; Bavarian Red Cross Hosp, Dept Orthoped Surg, Bad Abbach, Germany	University of Regensburg	Straub, RH (corresponding author), Univ Med Ctr Regensburg, Dept Internal Med 1, Lab Neuroendocrinoimmunol, Franz Josef Strauss Allee 11, D-93042 Regensburg, Germany.			Straub, Rainer H/0000-0003-1165-4555				AHMED M, 1995, ARTHRITIS RHEUM-US, V38, P699, DOI 10.1002/art.1780380519; ANSEL JC, 1993, J IMMUNOL, V150, P4478; Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; BASBAUM AI, 1991, CAN J PHYSIOL PHARM, V69, P647, DOI 10.1139/y91-096; Binder W, 1998, BRIT J PHARMACOL, V124, P647, DOI 10.1038/sj.bjp.0701874; Boyle DL, 1996, ARTHRITIS RHEUM, V39, P923, DOI 10.1002/art.1780390608; Bresnihan B, 1998, BRIT J RHEUMATOL, V37, P636; CALVO CF, 1992, J IMMUNOL, V148, P3498; CODERRE TJ, 1991, NEUROSCIENCE, V40, P185, DOI 10.1016/0306-4522(91)90184-P; Cronstein BN, 1996, ARTHRITIS RHEUM-US, V39, P1951, DOI 10.1002/art.1780391203; CRONSTEIN BN, 1995, ARTHRITIS RHEUM, V38, P1040, DOI 10.1002/art.1780380804; DaSilva JAP, 1996, CLIN EXP RHEUMATOL, V14, P43; Elenkov IJ, 1996, P ASSOC AM PHYSICIAN, V108, P374; GREEN PG, 1991, P NATL ACAD SCI USA, V88, P4162, DOI 10.1073/pnas.88.10.4162; Guirao X, 1997, AM J PHYSIOL-ENDOC M, V273, pE1203, DOI 10.1152/ajpendo.1997.273.6.E1203; Hasko G, 1998, EUR J PHARMACOL, V358, P261, DOI 10.1016/S0014-2999(98)00619-0; Hasko G, 1996, J IMMUNOL, V157, P4634; Heppelmann B, 1997, NEUROSCI LETT, V223, P97, DOI 10.1016/S0304-3940(97)13408-5; HUKKANEN M, 1991, J RHEUMATOL, V18, P177; LAM FY, 1989, ANN RHEUM DIS, V48, P928, DOI 10.1136/ard.48.11.928; LAURENZI MA, 1990, SCAND J IMMUNOL, V31, P529, DOI 10.1111/j.1365-3083.1990.tb02801.x; LEVINE JD, 1984, SCIENCE, V226, P547, DOI 10.1126/science.6208609; LEVINE JD, 1986, J RHEUMATOL, V13, P1040; Lieb K, 1996, J NEUROIMMUNOL, V67, P77; Lieb K, 1997, J IMMUNOL, V159, P4952; LOMBARD MC, 1989, BRAIN RES, V477, P48, DOI 10.1016/0006-8993(89)91393-0; Lorton D, 1996, J NEUROIMMUNOL, V64, P103, DOI 10.1016/0165-5728(95)00150-6; LOTZ M, 1987, SCIENCE, V235, P893, DOI 10.1126/science.2433770; LOTZ M, 1988, SCIENCE, V241, P1218, DOI 10.1126/science.2457950; Malfait AM, 1999, J IMMUNOL, V162, P6278; MAPP PI, 1994, ANN RHEUM DIS, V53, P240, DOI 10.1136/ard.53.4.240; MAPP PI, 1990, NEUROSCIENCE, V37, P143, DOI 10.1016/0306-4522(90)90199-E; PEREIRA DSJ, 1990, J RHEUMATOL, V17, P1592; RAMESHWAR P, 1993, J IMMUNOL, V151, P2484; RENZ H, 1988, J IMMUNOL, V141, P2388; Ritchie PK, 1997, CYTOKINE, V9, P187, DOI 10.1006/cyto.1996.0153; RUSSELL NJW, 1987, NEUROSCI LETT, V76, P107, DOI 10.1016/0304-3940(87)90201-1; Sajjadi FG, 1996, J IMMUNOL, V156, P3435; Sanders VM, 1997, J IMMUNOL, V158, P4200; SERRA MC, 1994, IMMUNOLOGY, V82, P63; Shirvan A, 1999, J NEUROCHEM, V73, P961, DOI 10.1046/j.1471-4159.1999.0730961.x; SLUKA KA, 1994, ANN RHEUM DIS, V53, P309, DOI 10.1136/ard.53.5.309; SPENGLER RN, 1994, J IMMUNOL, V152, P3024; SPENGLER RN, 1990, J IMMUNOL, V145, P1430; STRAUB RH, 1995, J NEUROIMMUNOL, V61, P53, DOI 10.1016/0165-5728(95)00073-B; Straub RH, 1996, J NEUROIMMUNOL, V71, P37, DOI 10.1016/S0165-5728(96)00126-9; Straub RH, 1997, J NEUROCHEM, V68, P1633; Straub RH, 1998, AM J PHYSIOL-REG I, V274, pR997, DOI 10.1152/ajpregu.1998.274.4.R997; Straub RH, 1998, IMMUNOL TODAY, V19, P409, DOI 10.1016/S0167-5699(98)01297-3; Szabo C, 1997, IMMUNOLOGY, V90, P95, DOI 10.1046/j.1365-2567.1997.00137.x; Tanabe T, 1996, RHEUMATOL INT, V16, P159, DOI 10.1007/BF01419729; Tanelian DL, 1997, NAT MED, V3, P1398, DOI 10.1038/nm1297-1398; VarelaEchavarria A, 1997, GENE DEV, V11, P545, DOI 10.1101/gad.11.5.545; WALKER JS, 1995, LIFE SCI, V57, P371, DOI 10.1016/0024-3205(95)00296-I; Watling K. J., 1998, RBI HDB RECEPTOR CLA; WEIHE E, 1988, AGENTS ACTIONS, V25, P255, DOI 10.1007/BF01965027; WIEDERMANN CJ, 1989, N-S ARCH PHARMACOL, V340, P185; [No title captured]	58	215	222	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2000	14	13					2097	2107		10.1096/fj.99-1082com	http://dx.doi.org/10.1096/fj.99-1082com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023994				2022-12-28	WOS:000089634400029
J	Rippo, MR; Malisan, F; Ravagnan, L; Tomassini, B; Condo, I; Costantini, P; Susin, SA; Rufini, A; Todaro, M; Kroemer, G; Testi, R				Rippo, MR; Malisan, F; Ravagnan, L; Tomassini, B; Condo, I; Costantini, P; Susin, SA; Rufini, A; Todaro, M; Kroemer, G; Testi, R			GD3 ganglioside directly targets mitochondria in a bcl-2-controlled fashion	FASEB JOURNAL			English	Article						apoptosis; permeability transition; AIF; cytochrome c; caspase 9	PERMEABILITY TRANSITION PORE; CYTOCHROME-C RELEASE; CERAMIDE-INDUCED APOPTOSIS; ACIDIC SPHINGOMYELINASE; EXPRESSION CLONING; G(D3) SYNTHASE; IN-VIVO; BAX; ACTIVATION; NECROSIS	Lipid and glycolipid diffusible mediators are involved in the intracellular progression and amplification of apoptotic signals. GD3 ganglioside is rapidly synthesized from accumulated ceramide after the clustering of death-inducing receptors and triggers apoptosis. Here we show that GD3 induces dissipation of Delta psi(m), and swelling of isolated mitochondria, which results in the mitochondrial release of cytochrome c, apoptosis inducing factor, and caspase 9. Soluble factors released from GD3-treated mitochondria are sufficient to trigger DNA fragmentation in isolated nuclei. All these effects can be blocked by cyclosporin A, suggesting that GD3 is acting at the level of the permeability transition pore complex. We found that endogenous GD3 accumulates within mitochondria of cells undergoing apoptosis after ceramide exposure. Accordingly, suppression of GD3 synthase (ST8) expression in intact cells substantially prevents ceramide-induced Delta psi(m) dissipation, indicating that endogenously synthesized GD3 induces mitochondrial changes in vivo. Finally, enforced expression of bcl-2 significantly prevents GD3-induced mitochondrial changes, caspase 9 activation, and apoptosis. These results show that mitochondria are a key destination for apoptogenic GD3 ganglioside along the lipid pathway to programmed cell death and indicate that relevant GD3 targets are under bcl-2 control.	Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Lab Signal Transduct, I-00133 Rome, Italy; Inst Gustave Roussy, CNRS, UMR 1599, F-94805 Villejuif, France; Univ Palermo, Sect Anat Sci, I-90133 Palermo, Italy	University of Rome Tor Vergata; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; University of Palermo	Testi, R (corresponding author), Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, Lab Signal Transduct, Via Tor Vergata 135, I-00133 Rome, Italy.		Rufini, Alessandra/Q-9256-2019; KROEMER, Guido/B-4263-2013; Susin, Santos A/Q-6754-2017; Kroemer, Guido/AAY-9859-2020; Rufini, Alessandra/J-2995-2012; Condò, Ivano/B-4783-2010	Rufini, Alessandra/0000-0001-5654-9615; KROEMER, Guido/0000-0002-9334-4405; Susin, Santos A/0000-0002-3366-1628; Condò, Ivano/0000-0001-5421-4846; RIPPO, Maria Rita/0000-0003-3024-3495; MALISAN, FLORENCE/0000-0002-0213-9407				Basu S, 1998, J BIOL CHEM, V273, P30419, DOI 10.1074/jbc.273.46.30419; Basu S, 1998, ONCOGENE, V17, P3277, DOI 10.1038/sj.onc.1202570; Brenner B, 1998, CELL DEATH DIFFER, V5, P29, DOI 10.1038/sj.cdd.4400307; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; COSTANTINI P, 1995, TOXICOLOGY, V99, P77, DOI 10.1016/0300-483X(94)02997-9; De Maria R, 1998, J EXP MED, V187, P897, DOI 10.1084/jem.187.6.897; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; DeMaria R, 1996, J CLIN INVEST, V97, P316, DOI 10.1172/JCI118418; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Fraser A, 1998, TRENDS CELL BIOL, V8, P219, DOI 10.1016/S0962-8924(98)01275-6; Geley S, 1997, FEBS LETT, V400, P15, DOI 10.1016/S0014-5793(96)01284-7; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; HARAGUCHI M, 1994, P NATL ACAD SCI USA, V91, P10455, DOI 10.1073/pnas.91.22.10455; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kristal BS, 1999, J BIOL CHEM, V274, P23169, DOI 10.1074/jbc.274.33.23169; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Nakayama J, 1996, J BIOL CHEM, V271, P3684; NARA K, 1994, P NATL ACAD SCI USA, V91, P7952, DOI 10.1073/pnas.91.17.7952; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; Perry DK, 1998, BBA-MOL CELL BIOL L, V1436, P233, DOI 10.1016/S0005-2760(98)00145-3; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RUSINOL AE, 1994, J BIOL CHEM, V269, P27494; SASAKI K, 1994, J BIOL CHEM, V269, P15950; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Testi R, 1996, TRENDS BIOCHEM SCI, V21, P468, DOI 10.1016/S0968-0004(96)10056-6; Wiegmann K, 1999, J BIOL CHEM, V274, P5267, DOI 10.1074/jbc.274.9.5267; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; ZENG GC, 1995, P NATL ACAD SCI USA, V92, P8670, DOI 10.1073/pnas.92.19.8670; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941	53	154	157	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2000	14	13					2047	2054		10.1096/fj.99-1028com	http://dx.doi.org/10.1096/fj.99-1028com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023989				2022-12-28	WOS:000089634400024
J	Belmant, C; Espinosa, E; Halary, F; Tang, Y; Peyrat, MA; Sicard, H; Kozikowski, A; Buelow, R; Poupot, R; Bonneville, M; Fournie, JJ				Belmant, C; Espinosa, E; Halary, F; Tang, Y; Peyrat, MA; Sicard, H; Kozikowski, A; Buelow, R; Poupot, R; Bonneville, M; Fournie, JJ			A chemical basis for selective recognition of nonpeptide antigens by human delta T cells	FASEB JOURNAL			English	Article									CHU Purpan, INSERM, U395, F-31024 Toulouse, France; Inst Biol, INSERM, U463, F-44035 Nantes, France; Georgetown Univ, GICS, Washington, DC USA; Sang Stat Med Corp, Menlo Pk, CA USA; Innate Pharma, F-13009 Marseille, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Georgetown University	Fournie, JJ (corresponding author), CHU Purpan, INSERM, U395, BP3028, F-31024 Toulouse, France.	fournie@purpan.inserm.fr	Halary, Franck/B-3782-2017; Fournie, Jean-Jacques/J-7805-2013; espinosa, eric/E-4872-2013; halary, franck/AAR-9437-2020	Halary, Franck/0000-0003-0336-9615; Fournie, Jean-Jacques/0000-0001-6542-6908; espinosa, eric/0000-0002-3512-0921; halary, franck/0000-0003-0336-9615					0	68	69	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2000	14	12					1669	1670		10.1096/fj.99-0909fje	http://dx.doi.org/10.1096/fj.99-0909fje			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973912	Bronze			2022-12-28	WOS:000089212400002
J	Ray, A; Norden, B				Ray, A; Norden, B			Peptide nucleic acid (PNA): its medical and biotechnical applications and promise for the future	FASEB JOURNAL			English	Review						DNA; PNA-DNA hybridization; antigene; anti-sense; gene therapy; nucleic acid biosensor	QUARTZ-CRYSTAL MICROBALANCE; DOUBLE-STRANDED DNA; TOF MASS-SPECTROMETRY; THYMINE-SUBSTITUTED POLYAMIDE; IN-VITRO; DICHROISM SPECTROSCOPY; MOLECULAR-DYNAMICS; PCR AMPLIFICATION; HUMAN TELOMERASE; GENE-EXPRESSION	Synthetic molecules that can bind with high sequence specificity to a chosen target in a gene sequence are of major interest in medicinal and biotechnological contexts. They show promise for the development of gene therapeutic agents, diagnostic devices for genetic analysis, and as molecular tools for nucleic acid manipulations. Peptide nucleic acid (PNA) is a nucleic acid analog in which the sugar phosphate backbone of natural nucleic acid has been replaced by a synthetic peptide backbone usually formed from N-(2-amino-ethyl)-glycine units, resulting in an achiral and uncharged mimic. It is chemically stable and resistant to hydrolytic (enzymatic) cleavage and thus not expected to be degraded inside a living cell. PNA is capable of sequence-specific recognition of DNA and RNA obeying the Watson-Crick hydrogen bonding scheme, and the hybrid complexes exhibit extraordinary thermal stability and unique ionic strength effects. It may also recognize duplex homopurine sequences of DNA to which it binds by strand invasion, forming a stable PNA-DNA-PNA tripler with a looped-out DNA strand. Since its discovery, PNA has attracted major attention at the interface of chemistry and biology because of its interesting chemical, physical, and biological properties and its potential to act as an active component for diagnostic as well as pharmaceutical applications. In vitro studies indicate that PNA could inhibit both transcription and translation of genes to which it has been targeted, which holds promise for its use for antigene and antisense therapy. However, as with other high molecular mass drugs, the delivery of PNA, involving passage through the cell membrane, appears to be a general problem.-Ray, A., Norden, B. Peptide nucleic acid (PNA): its medical and biotechnical applications and promise for the future.	Chalmers Univ Technol, Dept Phys Chem, S-41296 Gothenburg, Sweden	Chalmers University of Technology	Norden, B (corresponding author), Chalmers Univ Technol, Dept Phys Chem, S-41296 Gothenburg, Sweden.	ray@phc.chalmers.se; norden@phc.chalmers.se	Norden, Bengt/ABE-3675-2020	Norden, Bengt/0000-0002-7946-200X				Aldrian-Herrada G, 1998, NUCLEIC ACIDS RES, V26, P4910, DOI 10.1093/nar/26.21.4910; ARAKAWA H, 1998, ADV CHROMATOGRAPHIC, P53; Ardhammar M, 1999, J BIOMOL STRUCT DYN, V17, P33, DOI 10.1080/07391102.1999.10508338; Armitage B, 1998, NUCLEIC ACIDS RES, V26, P715, DOI 10.1093/nar/26.3.715; Armitage B, 1998, BIOCHEMISTRY-US, V37, P9417, DOI 10.1021/bi9729458; Basu S, 1997, BIOCONJUGATE CHEM, V8, P481, DOI 10.1021/bc9700650; Bentin T, 1996, BIOCHEMISTRY-US, V35, P8863, DOI 10.1021/bi960436k; Berkenkamp S, 1998, SCIENCE, V281, P260, DOI 10.1126/science.281.5374.260; BETTS L, 1995, SCIENCE, V270, P1838, DOI 10.1126/science.270.5243.1838; Boffa LC, 1996, J BIOL CHEM, V271, P13228, DOI 10.1074/jbc.271.22.13228; BROWN SC, 1994, SCIENCE, V265, P777, DOI 10.1126/science.7519361; Butler JM, 1996, ANAL CHEM, V68, P3283, DOI 10.1021/ac960317a; Carlsson C, 1996, NATURE, V380, P207, DOI 10.1038/380207a0; CHERNY DY, 1993, P NATL ACAD SCI USA, V90, P1667, DOI 10.1073/pnas.90.5.1667; Christensen L, 1998, NUCLEIC ACIDS RES, V26, P2735, DOI 10.1093/nar/26.11.2735; Christensen L, 1995, J Pept Sci, V1, P175; Corey DR, 1997, TRENDS BIOTECHNOL, V15, P224, DOI 10.1016/S0167-7799(97)01037-8; DEMERS DB, 1995, NUCLEIC ACIDS RES, V23, P3050, DOI 10.1093/nar/23.15.3050; DEMIDOV V, 1993, NUCLEIC ACIDS RES, V21, P2103, DOI 10.1093/nar/21.9.2103; DUEHOLM KL, 1994, J ORG CHEM, V59, P5767, DOI 10.1021/jo00098a042; Efimov VA, 1998, NUCLEIC ACIDS RES, V26, P566, DOI 10.1093/nar/26.2.566; EGHOLM M, 1993, NATURE, V365, P566, DOI 10.1038/365566a0; EGHOLM M, 1995, NUCLEIC ACIDS RES, V23, P217, DOI 10.1093/nar/23.2.217; EGHOLM M, 1992, J AM CHEM SOC, V114, P1895, DOI 10.1021/ja00031a062; EGHOLM M, 1992, J AM CHEM SOC, V114, P9677, DOI 10.1021/ja00050a068; Egholm M, 1997, NAT BIOTECHNOL, V15, P1346, DOI 10.1038/nbt1297-1346; Eriksson M, 1998, NEW J CHEM, V22, P1055, DOI 10.1039/a803214i; Eriksson M, 1996, Q REV BIOPHYS, V29, P369, DOI 10.1017/S0033583500005886; Eriksson M, 1996, NAT STRUCT BIOL, V3, P410, DOI 10.1038/nsb0596-410; Falkiewicz B, 1999, NUCLEOS NUCLEOT, V18, P353, DOI 10.1080/15257779908043081; Faruqi AF, 1998, P NATL ACAD SCI USA, V95, P1398, DOI 10.1073/pnas.95.4.1398; GIESEN U, 1998, NUCLEIC ACIDS RES, V26, P1601; GILAR M, 1998, ADV CHROMATOGRAPHIC, P576; Good L, 1998, NAT BIOTECHNOL, V16, P355, DOI 10.1038/nbt0498-355; Good L, 1998, P NATL ACAD SCI USA, V95, P2073, DOI 10.1073/pnas.95.5.2073; Griffin TJ, 1997, NAT BIOTECHNOL, V15, P1368, DOI 10.1038/nbt1297-1368; Haaima G, 1996, ANGEW CHEM INT EDIT, V35, P1939; Hamilton SE, 1999, CHEM BIOL, V6, P343, DOI 10.1016/S1074-5521(99)80046-5; Hansen HF, 1999, NUCLEOS NUCLEOT NUCL, V18, P5, DOI 10.1080/07328319908045589; HANVEY JC, 1992, SCIENCE, V258, P1481, DOI 10.1126/science.1279811; Holmen Anders, 1999, P87; Hyrup B, 1996, BIOORGAN MED CHEM, V4, P5, DOI 10.1016/0968-0896(95)00171-9; Igloi GL, 1998, P NATL ACAD SCI USA, V95, P8562, DOI 10.1073/pnas.95.15.8562; Jensen KK, 1997, BIOCHEMISTRY-US, V36, P5072, DOI 10.1021/bi9627525; KIM SK, 1993, J AM CHEM SOC, V115, P6477, DOI 10.1021/ja00068a001; Kirpekar F, 1998, NUCLEIC ACIDS RES, V26, P2554, DOI 10.1093/nar/26.11.2554; Knudsen H, 1996, NUCLEIC ACIDS RES, V24, P494, DOI 10.1093/nar/24.3.494; KOCH T, 1995, TETRAHEDRON LETT, V36, P6933, DOI 10.1016/00404-0399(50)1373P-; Koppelhus U, 1997, NUCLEIC ACIDS RES, V25, P2167, DOI 10.1093/nar/25.11.2167; Koppitz M, 1998, J AM CHEM SOC, V120, P4563, DOI 10.1021/ja974190y; KROTZ AH, 1995, TETRAHEDRON LETT, V36, P6941, DOI 10.1016/0040-4039(95)01375-R; KROTZ AH, 1995, TETRAHEDRON LETT, V36, P6937, DOI 10.1016/00404-0399(50)1374Q-; Kuhn H, 1998, NUCLEIC ACIDS RES, V26, P582, DOI 10.1093/nar/26.2.582; Lagriffoule P, 1997, CHEM-EUR J, V3, P912, DOI 10.1002/chem.19970030613; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; Larsen HJ, 1996, NUCLEIC ACIDS RES, V24, P458, DOI 10.1093/nar/24.3.458; Lee R, 1998, BIOCHEMISTRY-US, V37, P900, DOI 10.1021/bi972197m; LEIJON M, 1994, BIOCHEMISTRY-US, V33, P9820, DOI 10.1021/bi00199a002; Lu C., 1984, APPL PIEZOELECTRIC Q, DOI 10.1016/B978-0-444-42277-4.50007-7; Lutz MJ, 1999, NUCLEOS NUCLEOT NUCL, V18, P393, DOI 10.1080/15257779908043084; Lutz MJ, 1997, J AM CHEM SOC, V119, P3177, DOI 10.1021/ja9637457; MARKY LA, 1987, BIOPOLYMERS, V26, P1601, DOI 10.1002/bip.360260911; MERRIFIELD B, 1986, SCIENCE, V232, P341, DOI 10.1126/science.3961484; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; Misra HS, 1998, BIOCHEMISTRY-US, V37, P1917, DOI 10.1021/bi971524n; MOLLEGAARD NE, 1994, P NATL ACAD SCI USA, V91, P3892, DOI 10.1073/pnas.91.9.3892; Mologni L, 1998, NUCLEIC ACIDS RES, V26, P1934, DOI 10.1093/nar/26.8.1934; Nielsen PE, 1998, PURE APPL CHEM, V70, P105, DOI 10.1351/pac199870010105; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; Nielsen PE, 1999, CURR OPIN STRUC BIOL, V9, P353, DOI 10.1016/S0959-440X(99)80047-5; Nielsen PE, 1999, CURR OPIN BIOTECH, V10, P71, DOI 10.1016/S0958-1669(99)80013-5; NIELSEN PE, 1993, ANTI-CANCER DRUG DES, V8, P53; NIELSEN PE, 1994, GENE, V149, P139, DOI 10.1016/0378-1119(94)90422-7; NIELSEN PE, 1998, ADV DNA SEQUENCE SPE, V1, P267; NIELSEN PE, 1994, J MOL RECOGNIT, V7, P164; Niikura K, 1998, J AM CHEM SOC, V120, P8537, DOI 10.1021/ja980967r; NOBLE SA, 1995, DRUG DEVELOP RES, V34, P184, DOI 10.1002/ddr.430340208; NORDEN B, 1992, Q REV BIOPHYS, V25, P51, DOI 10.1017/S0033583500004728; Norton JC, 1996, NAT BIOTECHNOL, V14, P615, DOI 10.1038/nbt0596-615; NORTON JC, 1995, BIOORGAN MED CHEM, V3, P437, DOI 10.1016/0968-0896(95)00033-D; Okahata Y, 1998, BIOCHEMISTRY-US, V37, P5666, DOI 10.1021/bi980037k; OKAHATA Y, 1992, J AM CHEM SOC, V114, P8299, DOI 10.1021/ja00047a056; ORUM H, 1993, NUCLEIC ACIDS RES, V21, P5332, DOI 10.1093/nar/21.23.5332; ORUM H, 1995, BIOTECHNIQUES, V19, P472; PEFFER NJ, 1993, P NATL ACAD SCI USA, V90, P10648, DOI 10.1073/pnas.90.22.10648; PENA SDJ, 1994, TRENDS GENET, V10, P204, DOI 10.1016/0168-9525(94)90257-7; PerryOKeefe H, 1996, P NATL ACAD SCI USA, V93, P14670, DOI 10.1073/pnas.93.25.14670; PETERSEN MB, 1990, GENOMICS, V7, P136, DOI 10.1016/0888-7543(90)90531-X; *PHARM BIOS AB, 1996, BIAC X INSTR HDB; Pooga M, 1998, NAT BIOTECHNOL, V16, P857, DOI 10.1038/nbt0998-857; Praseuth D, 1996, BBA-GENE STRUCT EXPR, V1309, P226, DOI 10.1016/S0167-4781(96)00146-7; PUGLISI JD, 1989, METHOD ENZYMOL, V180, P304; Rasmussen H, 1997, NAT STRUCT BIOL, V4, P98, DOI 10.1038/nsb0297-98; Ratilainen T, 1998, BIOCHEMISTRY-US, V37, P12331, DOI 10.1021/bi9808722; RIGHETTI PG, 1996, CRC SER ANAL BIOTECH, P431; ROSE DJ, 1993, ANAL CHEM, V65, P3545, DOI 10.1021/ac00072a003; Ross PL, 1997, ANAL CHEM, V69, P4197, DOI 10.1021/ac9703966; Sen S, 1998, J AM CHEM SOC, V120, P619, DOI 10.1021/ja972234x; Shields GC, 1998, J AM CHEM SOC, V120, P5895, DOI 10.1021/ja9723444; Simmons CG, 1997, BIOORG MED CHEM LETT, V7, P3001, DOI 10.1016/S0960-894X(97)10136-6; Srinivasan AR, 1998, J AM CHEM SOC, V120, P492, DOI 10.1021/ja972721c; Taylor RW, 1997, NAT GENET, V15, P212, DOI 10.1038/ng0297-212; Thiede C, 1996, NUCLEIC ACIDS RES, V24, P983, DOI 10.1093/nar/24.5.983; THOMSON SA, 1995, TETRAHEDRON, V51, P6179, DOI 10.1016/0040-4020(95)00286-H; Tomac S, 1996, J AM CHEM SOC, V118, P5544, DOI 10.1021/ja960495l; Uhlmann E, 1998, ANGEW CHEM INT EDIT, V37, P2797; Uhlmann E, 1996, ANGEW CHEM INT EDIT, V35, P2632, DOI 10.1002/anie.199626321; UHLMANN E, 1996, ANGEW CHEM, V108, P2793; Veselkov AG, 1996, NUCLEIC ACIDS RES, V24, P2483, DOI 10.1093/nar/24.13.2483; VESNAVER G, 1991, P NATL ACAD SCI USA, V88, P3569, DOI 10.1073/pnas.88.9.3569; Walsh P S, 1992, PCR Methods Appl, V1, P241, DOI 10.1101/gr.1.4.241; Wang J, 1997, ANAL CHEM, V69, P5200, DOI 10.1021/ac9706077; Wang J, 1996, J AM CHEM SOC, V118, P7667, DOI 10.1021/ja9608050; WITTUNG P, 1994, NUCLEIC ACIDS RES, V22, P5371, DOI 10.1093/nar/22.24.5371; Wittung P, 1996, J AM CHEM SOC, V118, P7049, DOI 10.1021/ja960521f; Wittung P, 1997, BIOCHEMISTRY-US, V36, P7973, DOI 10.1021/bi963136b; WITTUNG P, 1994, NATURE, V368, P561, DOI 10.1038/368561a0; WITTUNG P, 1995, J AM CHEM SOC, V117, P10167, DOI 10.1021/ja00146a001	118	334	384	1	116	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2000	14	9					1041	1060		10.1096/fasebj.14.9.1041	http://dx.doi.org/10.1096/fasebj.14.9.1041			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834926	Bronze			2022-12-28	WOS:000087427300001
J	Razzini, G; Berrie, CP; Vignati, S; Broggini, M; Mascetta, G; Brancaccio, A; Falasca, M				Razzini, G; Berrie, CP; Vignati, S; Broggini, M; Mascetta, G; Brancaccio, A; Falasca, M			Novel functional PI 3-kinase antagonists inhibit cell growth and tumorigenicity in human cancer cell lines	FASEB JOURNAL			English	Article						antitumor agents; inositol polyphosphates; PH domain-binding antagonists; phosphatidylinositols	PROTEIN-KINASE-B; PLECKSTRIN-HOMOLOGY DOMAINS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; SIGNALING MOLECULES; AKT PROTOONCOGENE; TRANSFORMATION; ACTIVATION; PATHWAY; BINDING	New efforts in cancer therapy are being focused at various levels of signaling pathways. With phosphoinositide 3-kinase (PI3-K) potentially being necessary for a range of cancer-related functions, we have investigated the influence of selected inositol tristo hexakisphosphates on cell growth and tumorigenicity. We show that micromolar concentrations of inositol 1,3,4,5,6-pentakisphosphate and inositol 1,4,5,6-tetrakisphosphate [Ins(1,4,5,6)P-4] inhibit IGF-1-induced [H-3]-thymidine incorporation in human breast cancer (MCF-7) cells and the ability to grow in liquid medium and form colonies in agarose semisolid medium by small cell lung cancer (SCLC) cells, a human cancer cell line containing a constitutively active PI3-K. In an ovarian cancer cell line that also contains a constitutively active PI3-K (SKOV-3 cells), Ins(1,4,5,6)P-4 again inhibited liquid medium growth. Furthermore, when applied extracellularly, inositol 1,3,4,5-tetrakisphosphate was shown indeed to enter SCLC cells. These effects appeared specifically related to PH domains known to bind to phosphatidylinositol 3,4-bisphosphate [PtdIns(3,4)P-2] and phosphatidylinositol 3,4-bisphosphate [PtdIns(3,4,5)P-3], indicating involvement of the PI3-K downstream target protein kinase B (PKB/Akt). This was further supported by inhibition of PKB/Akt PH domain membrane targeting in COS-7 cells by Ins(1,4,5,6)P-4. Thus, we propose that specific inositol polyphosphates inhibit PI3-K by competing with PtdIns(3,4,5)P-3-binding PH domains and that this occurs mainly at: the level of the downstream PI3-K target, PKB/Akt.-Razzini, G., Berrie, C. P., Vignati, S., Broggini, M., Mascetta, G., Brancaccio, A., Falasca, M. Novel functional PI3-kinase antagonists inhibit cell growth and tumorigenicity in human cancer cell lines.	Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Unit Physiopathol Cell Signalling, Dept Cell Biol & Oncol, I-66030 Santa Maria Imbaro, Italy; Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Lab Cell & Mol Endocrinol, Dept Cell Biol & Oncol, I-66030 Santa Maria Imbaro, Italy; Mario Negri Inst Pharmacol Res, Mol Pharmacol Unit, I-20157 Milan, Italy; Fdn CARIPE, Oncol Mol Lab, Pescara, Italy	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Falasca, M (corresponding author), Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Unit Physiopathol Cell Signalling, Dept Cell Biol & Oncol, Via Nazl, I-66030 Santa Maria Imbaro, Italy.	falasca@cmns.mnegri.it	broggini, massimo/AAA-6460-2020; Falasca, Marco/S-4020-2016	BROGGINI, MASSIMO/0000-0002-8138-9358; Falasca, Marco/0000-0002-9801-7235	Telethon [E.0841] Funding Source: Medline	Telethon(Fondazione Telethon)		Alessi DR, 1998, BBA-MOL CELL BIOL L, V1436, P151, DOI 10.1016/S0005-2760(98)00133-7; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Carpenter CL, 1996, BBA-REV CANCER, V1288, pM11, DOI 10.1016/0304-419X(96)00018-2; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; Eckmann L, 1997, P NATL ACAD SCI USA, V94, P14456, DOI 10.1073/pnas.94.26.14456; Falasca M, 1998, ONCOGENE, V16, P2357, DOI 10.1038/sj.onc.1201758; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; Huang CS, 1997, CANCER RES, V57, P2873; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kitchen E, 1996, BRIT J PHARMACOL, V117, P979, DOI 10.1111/j.1476-5381.1996.tb15291.x; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; MACHAMA T, 1999, TRENDS CELL BIOL, V9, P125; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; Moore SM, 1998, CANCER RES, V58, P5239; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; RUSCHKOWSKI S, 1992, FEMS MICROBIOL LETT, V95, P121; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; Takeuchi H, 1997, BBA-MOL CELL RES, V1359, P275, DOI 10.1016/S0167-4889(97)00109-2; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X	35	67	73	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2000	14	9					1179	1187		10.1096/fasebj.14.9.1179	http://dx.doi.org/10.1096/fasebj.14.9.1179			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834940				2022-12-28	WOS:000087427300015
J	Cattaruzza, M; Dimigen, C; Ehrenreich, H; Hecker, M				Cattaruzza, M; Dimigen, C; Ehrenreich, H; Hecker, M			Stretch-induced endothelin B receptor-mediated apoptosis in vascular smooth muscle cells	FASEB JOURNAL			English	Article						vascular remodeling; pressure overload; endothelin system; hypertrophy	SALT HYPERTENSIVE RATS; NITRIC-OXIDE; SIGNAL-TRANSDUCTION; PRESSURE-OVERLOAD; PULSATILE STRETCH; GENE-EXPRESSION; MESSENGER-RNA; HYPERTROPHY; ARTERIES; RELEASE	Growing evidence suggests that a pressure-induced increase in the synthesis of endothelin (ET-1) is involved in arterial remodeling and, as a consequence, in the manifestation of chronic: hypertension. To study potential stretch-induced changes in gene expression and their functional consequences, we have cultured rat aortic smooth muscle cells (raSMC) and porcine aortic endothelial cells (PAEC) on flexible elastomer membranes. The cells were periodically stretched (up to 20% elongation, 0.5 Hz, 6 h) and the expression of prepro-ET-1 and that of the endothelin A and B receptors (ETA-R and ETB-R) were analyzed by semi-quantitative RT-PCR analysis and ELISA (ET-1). In contrast to PAEC where ET-1 synthesis was up-regulated up to eightfold on exposure to cyclic stretch, ET-1 synthesis in raSMC was decreased by more than 80% under these conditions. ETA R -mRNA expression in stretched raSMC declined to 50% whereas ETB R -mRNA levels were increased up to 10-fold. One functional consequence of this apparent shift in receptor abundance was an apoptosis-promoting action of exogenous ET-1 (10 nM), as judged by the appearance of subdiploid peaks during FAGS analysis, caspase-3 activation and chromatin condensation. This ET-1-induced apoptosis appeared to be ETB-R mediated, as it was completely suppressed by the ETB-R antagonist BQ 788 but not by the ETA-R antagonist BQ 123. Moreover, raSMC derived from homozygous spotting lethal rats, which lack a functional ETB-R, showed no signs of apoptosis after exposure to cyclic strain and exogenous ET-1. These findings suggest a central role for the endothelin system in the onset of hypertension-induced remodeling in conduit arteries, which may proceed via an initial stretch-induced apoptosis of the smooth muscle cells.	Univ Gottingen, Dept Cardiovasc Physiol, D-37073 Gottingen, Germany; Univ Gottingen, Max Planck Inst Expt Med, D-37075 Gottingen, Germany; Univ Gottingen, Dept Neurol, D-37075 Gottingen, Germany; Univ Gottingen, Dept Psychiat, D-37075 Gottingen, Germany	University of Gottingen; Max Planck Society; University of Gottingen; University of Gottingen; University of Gottingen	Hecker, M (corresponding author), Univ Gottingen, Dept Cardiovasc Physiol, Humboldtallee 23, D-37073 Gottingen, Germany.	hecker@veg-physiol.med.uni-goettingen.de		Ehrenreich, Hannelore/0000-0001-8371-5711				ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; CECCHERINI I, 1995, HUM MOL GENET, V4, P2089, DOI 10.1093/hmg/4.11.2089; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; Condorelli G, 1999, CIRCULATION, V99, P3071, DOI 10.1161/01.CIR.99.23.3071; DAVENPORT AP, 1995, J CARDIOVASC PHARM, V26, pS265; deBlois D, 1997, HYPERTENSION, V29, P340, DOI 10.1161/01.HYP.29.1.340; Dethlefsen SM, 1996, J VASC RES, V33, P405, DOI 10.1159/000159169; Douglas SA, 1997, J VASC RES, V34, P152, DOI 10.1159/000159219; Ehrenreich H, 1999, NEUROSCIENCE, V91, P1067, DOI 10.1016/S0306-4522(98)00663-0; Gariepy CE, 1996, P NATL ACAD SCI USA, V93, P867, DOI 10.1073/pnas.93.2.867; Hasdai D, 1997, CIRCULATION, V95, P357; JANAKIDEVI K, 1992, AM J PHYSIOL, V263, pC1295, DOI 10.1152/ajpcell.1992.263.6.C1295; KOUREMBANAS S, 1993, J CLIN INVEST, V92, P99, DOI 10.1172/JCI116604; Krzesz R, 1999, FEBS LETT, V453, P191, DOI 10.1016/S0014-5793(99)00683-3; Lauth M, 2000, HYPERTENSION, V35, P648, DOI 10.1161/01.HYP.35.2.648; Lauth M, 2000, ARTERIOSCL THROM VAS, V20, P96, DOI 10.1161/01.ATV.20.1.96; LI JS, 1994, HYPERTENSION, V24, P183, DOI 10.1161/01.HYP.24.2.183; MACARTHUR H, 1994, BIOCHEM BIOPH RES CO, V200, P395, DOI 10.1006/bbrc.1994.1462; MORELAND S, 1992, BIOCHEM BIOPH RES CO, V184, P100, DOI 10.1016/0006-291X(92)91163-K; Nilsson T, 1997, NEUROSURGERY, V40, P346, DOI 10.1097/00006123-199702000-00023; NORIS M, 1995, CIRC RES, V76, P536, DOI 10.1161/01.RES.76.4.536; Okazawa M, 1998, J BIOL CHEM, V273, P12584, DOI 10.1074/jbc.273.20.12584; PREDEL HG, 1992, LANCET, V340, P878; Rosendorff C, 1997, CARDIOVASC DRUG THER, V10, P795, DOI 10.1007/BF00053038; Rudic RD, 1998, J CLIN INVEST, V101, P731, DOI 10.1172/JCI1699; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SHAREFKIN JB, 1991, J VASC SURG, V14, P1; Sharifi AM, 1996, CAN J PHYSIOL PHARM, V74, P934, DOI 10.1139/cjpp-74-8-934; Sharifi AM, 1997, J HYPERTENS, V15, P1441, DOI 10.1097/00004872-199715120-00011; SIHM I, 1995, AM J HYPERTENS, V8, P987, DOI 10.1016/0895-7061(95)00220-0; SUMPIO BE, 1988, J SURG RES, V44, P696, DOI 10.1016/0022-4804(88)90103-5; SUMPIO BE, 1990, SURGERY, V108, P277; Teiger E, 1996, J CLIN INVEST, V97, P2891, DOI 10.1172/JCI118747; WANG DL, 1995, J CELL PHYSIOL, V163, P400, DOI 10.1002/jcp.1041630220; Wang XK, 1996, CIRC RES, V78, P322, DOI 10.1161/01.RES.78.2.322; Yamazaki T, 1996, J BIOL CHEM, V271, P3221, DOI 10.1074/jbc.271.6.3221; ZAMORA MA, 1993, AM J RESP CELL MOL, V9, P429, DOI 10.1165/ajrcmb/9.4.429	38	87	87	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2000	14	7					991	998		10.1096/fasebj.14.7.991	http://dx.doi.org/10.1096/fasebj.14.7.991			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	309CG	10783154				2022-12-28	WOS:000086749500018
J	Fletcher, CF; Tottene, A; Lennon, VA; Wilson, SM; Dubel, SJ; Paylor, R; Hosford, DA; Tessarollo, L; Tessarollo, L; McEnery, MW; Pietrobon, D; Copeland, NG; Jenkins, NA				Fletcher, CF; Tottene, A; Lennon, VA; Wilson, SM; Dubel, SJ; Paylor, R; Hosford, DA; Tessarollo, L; Tessarollo, L; McEnery, MW; Pietrobon, D; Copeland, NG; Jenkins, NA			Dystonia and cerebellar atrophy in Cacna1a null mice lacking P/Q calcium channel activity	FASEB JOURNAL			English	Article									NCI, Mouse Canc Genet Program, FCRDC, Frederick, MD 21702 USA; Univ Padua, Ctr Biomembranes, Dept Biomed Sci, I-35121 Padua, Italy; Univ Padua, Ctr Biomembranes, CNR, I-35121 Padua, Italy; Mayo Clin, Mayo Grad Sch, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin, Mayo Grad Sch, Dept Neurol, Rochester, MN 55905 USA; Mayo Clin, Mayo Med Sch, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin, Mayo Med Sch, Dept Neurol, Rochester, MN 55905 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Glaxo Wellcome Res & Dev Ltd, Clin Genet Dis Sci, Stevenage SG1 2NY, Herts, England	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Case Western Reserve University; Baylor College of Medicine; GlaxoSmithKline	Fletcher, CF (corresponding author), GNF, 3118 Merryfield Row, San Diego, CA 92121 USA.			Wilson, Scott/0000-0001-9376-9430	Telethon [E.1297] Funding Source: Medline	Telethon(Fondazione Telethon)			0	140	146	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1288	1290		10.1096/fj.00-0562fje	http://dx.doi.org/10.1096/fj.00-0562fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344116				2022-12-28	WOS:000168655200038
J	Tsao, TS; Li, J; Chang, KS; Stenbit, AE; Galuska, D; Anderson, JE; Zierath, JR; McCarter, RJ; Charron, MJ				Tsao, TS; Li, J; Chang, KS; Stenbit, AE; Galuska, D; Anderson, JE; Zierath, JR; McCarter, RJ; Charron, MJ			Metabolic adaptations in skeletal muscle overexpressing GLUT4: effects on muscle and physical activity	FASEB JOURNAL			English	Article						free fatty acids; EDL; glycogen synthesis; oleate oxidation	RESPONSIVE GLUCOSE-TRANSPORTER; DEPENDENT DIABETES-MELLITUS; FATTY-ACID OXIDATION; TRANSGENIC MICE; INSULIN-RESISTANCE; SUBSTRATE PATHWAYS; MESSENGER-RNA; MALONYL-COA; RAT MUSCLE; WHOLE-BODY	To understand the long-term metabolic and functional, consequences of increased GLUT4 con tent, intracellular substrate utilization was investigated in isolated muscles of transgenic mice overexpressing GLUT4 selectively in fast-twitch skeletal muscles. Rates of glycolysis, glycogen synthesis, glucose oxidation, and free fatty acid (FFA) oxidation as well as glycogen content were assessed in isolated EDL (fast-twitch) and soleus (slow-twitch) muscles from female and male MLC-GLUT4 transgenic and control mice. In male MLC-GLUT4 EDL, increased glucose influx predominantly led to increased glycolysis. In contrast, in female MLC-GLUT4 EDL increased glycogen synthesis was observed. In both sexes, GLUT4 overexpression resulted in decreased exogenous FFA oxidation rates. The decreased rate of FFA oxidation in male MLC-GLUT4 EDL was associated with increased lipid con tent in liver, but not in muscle or at the whole body level. To determine how changes in substrate metabolism and insulin action may influence energy balance in an environment that encouraged physical activity, we measured voluntary training activity, body weight, and food consumption of MLC-GLUT4 and control mice in cages equipped with training wheels. We observed a small decrease in body weight of MLC-GLUT4 mice that was paradoxically accompanied by a 45% increase in food consumption. The results were explained by a marked fourfold increase in voluntary wheel exercise. The changes in substrate metabolism and physical activity in MLC-GLUT4 mice were not associated with dramatic changes in skeletal muscle morphology. Collectively, results of this study demonstrate the feasibility of altering muscle substrate utilization by overexpression of GLUT4. The results also suggest that as a potential treatment for type II diabetes mellitus, increased skeletal muscle GLUT4 expression may provide benefits in addition to improvement of insulin action.	Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA; Karolinska Hosp, Dept Clin Physiol, S-17176 Stockholm, Sweden; Univ Manitoba, Dept Human Anat & Cell Sci, Winnipeg, MB R3E 0W3, Canada	Yeshiva University; Albert Einstein College of Medicine; University of Texas System; University of Texas Health San Antonio; Karolinska Institutet; Karolinska University Hospital; University of Manitoba	Charron, MJ (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	charron@aecom.yu.edu		Tsao, Tsu-Shuen/0000-0002-1041-9687; Zierath, Juleen/0000-0001-6891-7497	NCI NIH HHS [5P30CA13330] Funding Source: Medline; NHLBI NIH HHS [5T32HL07675, HL58119] Funding Source: Medline; NIA NIH HHS [AG14674] Funding Source: Medline; NIDDK NIH HHS [DK47425] Funding Source: Medline; NIGMS NIH HHS [5T32GM07491] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007675, R01HL058119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007491] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG014674] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aksnes AK, 1996, AM J PHYSIOL-ENDOC M, V271, pE593, DOI 10.1152/ajpendo.1996.271.3.E593; ANDERSEN P, 1977, J PHYSIOL-LONDON, V270, P677, DOI 10.1113/jphysiol.1977.sp011975; ARIANO MA, 1973, J HISTOCHEM CYTOCHEM, V21, P51, DOI 10.1177/21.1.51; ARMSTRONG RB, 1984, AM J ANAT, V171, P259, DOI 10.1002/aja.1001710303; BARON AD, 1988, AM J PHYSIOL, V255, pE769, DOI 10.1152/ajpendo.1988.255.6.E769; Bavenholm PN, 2000, DIABETES, V49, P1078, DOI 10.2337/diabetes.49.7.1078; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BJORNTORP P, 1995, INT J OBESITY, V19, pS6; BOGARDUS C, 1985, AM J PHYSIOL, V248, pE286, DOI 10.1152/ajpendo.1985.248.3.E286; BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; BROOKE MH, 1970, J HISTOCHEM CYTOCHEM, V18, P670, DOI 10.1177/18.9.670; CHAN TM, 1976, ANAL BIOCHEM, V71, P96, DOI 10.1016/0003-2697(76)90014-2; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; Chien D, 2000, AM J PHYSIOL-ENDOC M, V279, pE259, DOI 10.1152/ajpendo.2000.279.2.E259; CUENDET GS, 1976, J CLIN INVEST, V58, P1078, DOI 10.1172/JCI108559; DEEMS RO, 1994, DIABETOLOGIA, V37, P1097, DOI 10.1007/s001250050222; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; DEFRONZO RA, 1981, J CLIN INVEST, V68, P1468, DOI 10.1172/JCI110399; DEVASKAR SU, 1992, PEDIATR RES, V31, P1, DOI 10.1203/00006450-199201000-00001; DOUEN AG, 1990, J BIOL CHEM, V265, P13427; ECKEL RH, 1992, LANCET, V340, P1452, DOI 10.1016/0140-6736(92)92633-Q; FELBER JP, 1993, DIABETOLOGIA, V36, P1221, DOI 10.1007/BF00400798; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; GIBBS EM, 1995, J CLIN INVEST, V95, P1512, DOI 10.1172/JCI117823; GOODMAN MN, 1983, AM J PHYSIOL, V244, pE93, DOI 10.1152/ajpendo.1983.244.1.E93; HALLEN A, 1960, ACTA CHEM SCAND, V14, P2249, DOI 10.3891/acta.chem.scand.14-2249; HANSEN PA, 1995, J BIOL CHEM, V270, P1679; HENRIKSEN EJ, 1990, AM J PHYSIOL, V259, pE593, DOI 10.1152/ajpendo.1990.259.4.E593; HICKEY MS, 1995, AM J PHYSIOL-ENDOC M, V268, pE453, DOI 10.1152/ajpendo.1995.268.3.E453; Holloszy JO, 1996, ANNU REV NUTR, V16, P121, DOI 10.1146/annurev.nu.16.070196.001005; HOLMANG A, 1993, DIABETES, V42, P1073, DOI 10.2337/diabetes.42.7.1073; IKEMOTO S, 1995, P NATL ACAD SCI USA, V92, P865, DOI 10.1073/pnas.92.3.865; IVY JL, 1987, EXERCISE SPORT SCI R, V15, P29; JAMES DE, 1985, AM J PHYSIOL, V248, pE575, DOI 10.1152/ajpendo.1985.248.5.E575; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; Katz EB, 1996, J MOL MED, V74, P639, DOI 10.1007/s001090050068; KAVA RA, 1989, DIABETES, V38, P159, DOI 10.2337/diabetes.38.2.159; KELLEY DE, 1994, J CLIN INVEST, V94, P2349, DOI 10.1172/JCI117600; KRAEGEN EW, 1985, AM J PHYSIOL, V248, pE353; Leturque A, 1996, DIABETES, V45, P23, DOI 10.2337/diabetes.45.1.23; LIU ML, 1993, P NATL ACAD SCI USA, V90, P11346, DOI 10.1073/pnas.90.23.11346; Nyholm B, 1997, DIABETES, V46, P1822, DOI 10.2337/diabetes.46.11.1822; PASSONNEAU JV, 1974, ANAL BIOCHEM, V60, P405, DOI 10.1016/0003-2697(74)90248-6; RANDLE PJ, 1963, LANCET, V1, P785; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; REN JM, 1995, J CLIN INVEST, V95, P429, DOI 10.1172/JCI117673; REN JM, 1993, J BIOL CHEM, V268, P16113; Rincon J, 1996, DIABETES, V45, P615, DOI 10.2337/diabetes.45.5.615; Roberts TJ, 1996, J EXP BIOL, V199, P1651; SALMON DMW, 1985, INT J OBESITY, V9, P443; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; SHULMAN GI, 1990, NEW ENGL J MED, V322, P223, DOI 10.1056/NEJM199001253220403; SWINBURN BA, 1991, J CLIN INVEST, V88, P168, DOI 10.1172/JCI115274; TASKINEN MR, 1985, J CLIN INVEST, V76, P637, DOI 10.1172/JCI112016; THORENS B, 1990, DIABETES CARE, V13, P209, DOI 10.2337/diacare.13.3.209; TREADWAY JL, 1994, J BIOL CHEM, V269, P29956; Tsao TS, 1997, J CLIN INVEST, V100, P671, DOI 10.1172/JCI119579; Tsao TS, 1996, DIABETES, V45, P28, DOI 10.2337/diabetes.45.1.28; Tsao TS, 2000, METABOLISM, V49, P340, DOI 10.1016/S0026-0495(00)90220-8; Tsao TS, 1999, DIABETES, V48, P775, DOI 10.2337/diabetes.48.4.775; Tsuboyama-Kasaoka N, 1999, BIOCHEM BIOPH RES CO, V258, P187, DOI 10.1006/bbrc.1999.0617; Utriainen T, 1996, AM J PHYSIOL-ENDOC M, V270, pE905, DOI 10.1152/ajpendo.1996.270.5.E905; Weber JM, 1996, J EXP BIOL, V199, P1659; YKIJARVINEN H, 1987, J CLIN INVEST, V79, P1713, DOI 10.1172/JCI113011; YOUNG DA, 1990, DIABETES, V39, P1408, DOI 10.2337/diabetes.39.11.1408; Zierath JR, 1996, DIABETOLOGIA, V39, P1180, DOI 10.1007/BF02658504	67	72	74	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2001	15	6					958	969		10.1096/fj.00-0381	http://dx.doi.org/10.1096/fj.00-0381			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292656				2022-12-28	WOS:000167959300010
J	Copin, JC; Gasche, Y; Li, YB; Chan, PH				Copin, JC; Gasche, Y; Li, YB; Chan, PH			Prolonged hypoxia during cell development protects mature manganese superoxide dismutase-deficient astrocytes from damage by oxidative stress	FASEB JOURNAL			English	Article						paraquat; 8-oxo-7.8-dihydro-2 '-deoxyguanosine; mitochondria; adaptation; preconditioning	FREE-RADICAL THEORY; MAMMALIAN-CELLS; OXYGEN-TOXICITY; MUTANT MICE; SACCHAROMYCES-CEREVISIAE; KNOCKOUT MICE; SUSCEPTIBILITY; EXPRESSION; GENERATION; PHENOTYPE	Mouse astrocytes deficient in the mitochondrial form of superoxide dismutase do not grow in culture under 20% atmospheric O-2 levels, By flaw cytometry, immunocytochemistry, and enzymatic analysis we have shown that the oxygen block of cell division is due to a decrease in the number of cells entering the S phase of the cell cycle and is concomitant with higher DNA oxidation and impairment of mitochondrial functions. Seeding the cells under 5% O-2 until the cultures become confluent can circumvent this problem. An initial hypoxic environment increases the resistance of manganese superoxide dismutase-deficient astrocytes to superoxide radicals artificially produced by paraquat treatment, preserves respiratory activity, and allows normoxic division during a subsequent passage. DNA oxidation is then not higher than ill wild-type control cells. However, the adaptation of the cells is not due to compensation by other enzymes of the antioxidant defense system and is specific to cells totally lacking manganese superoxide dismutase, Alteration of the phenotype by prior hypoxia exposure in the SOD2-deficient mutant provide a unique model to study adaptative mechanisms of cellular resistance to oxygen toxicity.	Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Program Neurosci, Stanford, CA 94305 USA; Univ Calif San Francisco, Sch Med, Dept Neurol Surg, San Francisco, CA 94143 USA	Stanford University; Stanford University; Stanford University; University of California System; University of California San Francisco	Chan, PH (corresponding author), Stanford Univ, Neurosurg Labs, 1201 Welch Rd,MSLS P304, Stanford, CA 94305 USA.	phchan@leland.stanford.edu	Copin, Jean-Christophe/K-6890-2012		NINDS NIH HHS [NS36147, NS25372, NS14543] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036147, P01NS014543, P50NS014543, R01NS025372] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLEN RG, 1989, FREE RADICAL BIO MED, V6, P631, DOI 10.1016/0891-5849(89)90071-3; AMMENDOLA R, 1995, FEBS LETT, V371, P209, DOI 10.1016/0014-5793(95)00871-6; Barrientos A, 1999, J BIOL CHEM, V274, P16188, DOI 10.1074/jbc.274.23.16188; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Bohus B, 1998, PROG BRAIN RES, V119, P555; Brosche T, 1998, EXP GERONTOL, V33, P363, DOI 10.1016/S0531-5565(98)00014-X; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; Cadet J, 1999, MUTAT RES-FUND MOL M, V424, P9, DOI 10.1016/S0027-5107(99)00004-4; Carden DL, 2000, J PATHOL, V190, P255, DOI 10.1002/(SICI)1096-9896(200002)190:3<255::AID-PATH526>3.0.CO;2-6; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; Crapo J D, 1978, Methods Enzymol, V53, P382; EGNER PA, 1985, CARCINOGENESIS, V6, P1167, DOI 10.1093/carcin/6.8.1167; FERNANDEZPOL JA, 1982, CANCER RES, V42, P609; Gerhold D, 1999, TRENDS BIOCHEM SCI, V24, P168, DOI 10.1016/S0968-0004(99)01382-1; Gingrich JR, 1998, ANNU REV NEUROSCI, V21, P377, DOI 10.1146/annurev.neuro.21.1.377; GOTO Y, 1992, FREE RADICAL BIO MED, V13, P47, DOI 10.1016/0891-5849(92)90165-D; Grisham MB, 1999, AM J PHYSIOL-GASTR L, V276, pG315, DOI 10.1152/ajpgi.1999.276.2.G315; GUIDOT DM, 1993, J BIOL CHEM, V268, P26699; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Huang TT, 1999, ANN NY ACAD SCI, V893, P95, DOI 10.1111/j.1749-6632.1999.tb07820.x; Huang TT, 1997, ARCH BIOCHEM BIOPHYS, V344, P424, DOI 10.1006/abbi.1997.0237; JOHNSON MH, 1994, BIOESSAYS, V16, P31, DOI 10.1002/bies.950160105; JUURLINK BHJ, 1992, NEUROMETHODS, V23, P269; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KONG XJ, 1993, AM J PHYSIOL, V264, pL365, DOI 10.1152/ajplung.1993.264.4.L365; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; LAPINSKAS PJ, 1995, MOL CELL BIOL, V15, P1382; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; Lee JW, 1996, J BIOL CHEM, V271, P24885, DOI 10.1074/jbc.271.40.24885; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Li YB, 1998, BRAIN RES, V814, P164, DOI 10.1016/S0006-8993(98)01082-8; Luck H., 1974, ESTIMATION CATALASE, V885; MANTHORPE M, 1986, DEV BRAIN RES, V25, P191, DOI 10.1016/0165-3806(86)90208-7; Melov S, 1999, P NATL ACAD SCI USA, V96, P846, DOI 10.1073/pnas.96.3.846; Murakami K, 1998, J NEUROSCI, V18, P205; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; ODONNELLTORMEY J, 1987, J EXP MED, V165, P500, DOI 10.1084/jem.165.2.500; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; Stagliano NE, 1999, J CEREBR BLOOD F MET, V19, P757, DOI 10.1097/00004647-199907000-00005; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; Tomai F, 1999, CIRCULATION, V100, P559, DOI 10.1161/01.CIR.100.5.559; Tsan MF, 1998, AM J RESP CELL MOL, V19, P114, DOI 10.1165/ajrcmb.19.1.3066; UMAOKA Y, 1992, MOL REPROD DEV, V31, P28, DOI 10.1002/mrd.1080310106; VANLOON APGM, 1986, P NATL ACAD SCI USA, V83, P3820; Wiegand F, 1999, J CEREBR BLOOD F MET, V19, P1229, DOI 10.1097/00004647-199911000-00007; WIESE AG, 1995, ARCH BIOCHEM BIOPHYS, V318, P231, DOI 10.1006/abbi.1995.1225; Williams MD, 1998, J BIOL CHEM, V273, P28510, DOI 10.1074/jbc.273.43.28510; Woychik RP, 1998, MUTAT RES-FUND MOL M, V400, P3, DOI 10.1016/S0027-5107(98)00023-2; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; YU BP, 1994, PHYSIOL REV, V74, P139, DOI 10.1152/physrev.1994.74.1.139	53	16	16	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2001	15	2					525	534		10.1096/fj.00-0330com	http://dx.doi.org/10.1096/fj.00-0330com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156968				2022-12-28	WOS:000166872900034
J	Korff, T; Kimmina, S; Martiny-Baron, G; Augustin, HG				Korff, T; Kimmina, S; Martiny-Baron, G; Augustin, HG			Blood vessel maturation in a 3-dimensional spheroidal coculture model: direct contact with smooth muscle cells regulates endothelial cell quiescence and abrogates VEGF responsiveness	FASEB JOURNAL			English	Article						EC; SMC; spheroid; vascular; endothelial growth factor	PDGF-B; EXPRESSION; ANGIOGENESIS; DIFFERENTIATION; ANGIOPOIETIN-2; PERICYTES; BETA; CD34; RECRUITMENT; RECEPTOR	Paracrine interactions between endothelial cells (EC) and mural cells act as critical regulators of vessel wall assembly, vessel maturation and define a plasticity window for vascular remodeling. The present study was aimed at studying blood vessel maturation processes in a novel 3-dimensional spheroidal coculture system of EC and smooth muscle cells (SMC). Coculture spheroids differentiate spontaneously in a calcium-dependent manner to organize into a core of SMC and a surface layer of EC, thus mimicking the physiological assembly of blood vessels with surface lining EC and underlying mural cells. Coculture of EC with SMC induces a mature, quiescent EC phenotype as evidenced by 1) a significant increase in the number of junctional complexes of the EC surface layer, 2) a down-regulation of PDGF-B expression by cocultured EC, and 3) an increased resistance of EC to undergo apoptosis. Furthermore, EC cocultured with SMC become refractory to stimulation with VEGF (lack of CD34 expression on VEGF stimulation; inability to form capillary-like sprouts in a VEGF-dependent manner in a S-dimensional in gel angiogenesis assay). In contrast, costimulation with VEGF and Ang-2 induced sprouting angiogenesis originating from coculture spheroids consistent with a model of Ang-2-mediated vessel destabilization resulting in VEGF responsiveness. Ang-2 on its own was able to stimulate endothelial cells in the absence of Ang-l producing SMC, inducing lateral sheet migration as well as in gel sprouting angiogenesis. Taken together, the data establish the spheroidal EC/SMC system as a powerful cell. culture model to study paracrine interactions in the vessel wall and provide functional evidence for smooth muscle cell-mediated quiescence effects on endothelial cells.	Inst Mol Med, Tumor Biol Ctr, D-79106 Freiburg, Germany; Univ Gottingen, Sch Med, Dept Gynecol & Obstet, Cell Biol Lab, D-37075 Gottingen, Germany	University of Gottingen	Augustin, HG (corresponding author), Inst Mol Med, Tumor Biol Ctr, D-79106 Freiburg, Germany.		Augustin, Hellmut/AAA-5246-2020	Augustin, Hellmut/0000-0002-7173-4242				ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; ANTONELLIORLIDGE A, 1989, P NATL ACAD SCI USA, V86, P4544, DOI 10.1073/pnas.86.12.4544; AUGUSTIN HG, 1994, BIOESSAYS, V16, P901, DOI 10.1002/bies.950161208; Axel DI, 1997, J MOL CELL CARDIOL, V29, P2967, DOI 10.1006/jmcc.1997.0541; BAUMHUETER S, 1994, BLOOD, V84, P2554; Benjamin LE, 1997, P NATL ACAD SCI USA, V94, P8761, DOI 10.1073/pnas.94.16.8761; Benjamin LE, 1998, DEVELOPMENT, V125, P1591; BONIN LR, 1994, AM J PHYSIOL-HEART C, V267, pH1698, DOI 10.1152/ajpheart.1994.267.5.H1698; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; CARMELIET P, 2000, EXP CLIN REGULATION, P34; Cines DB, 1998, BLOOD, V91, P3527; DELIA D, 1993, BLOOD, V81, P1001; Fillinger MF, 1997, J SURG RES, V67, P169, DOI 10.1006/jsre.1996.4978; FINA L, 1990, BLOOD, V75, P2417; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Goede V, 1998, LAB INVEST, V78, P1385; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Hellstrom M, 1999, DEVELOPMENT, V126, P3047; Hirschi KK, 1998, J CELL BIOL, V141, P805, DOI 10.1083/jcb.141.3.805; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; Korff T, 1998, J CELL BIOL, V143, P1341, DOI 10.1083/jcb.143.5.1341; Korff T, 1999, J CELL SCI, V112, P3249; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Mandriota SJ, 1998, CIRC RES, V83, P852, DOI 10.1161/01.RES.83.8.852; POWELL RJ, 1998, AM J PHYSIOL, V274, pH649; RISAU W, 1995, FASEB J, V9, P926, DOI 10.1096/fasebj.9.10.7615161; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; Stratmann A, 1998, AM J PATHOL, V153, P1459, DOI 10.1016/S0002-9440(10)65733-1; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725	33	286	316	4	49	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					447	457		10.1096/fj.00-0139com	http://dx.doi.org/10.1096/fj.00-0139com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156960				2022-12-28	WOS:000166872900026
J	Vasile, E; Tomita, Y; Brown, LF; Kocher, O; Dvorak, HF				Vasile, E; Tomita, Y; Brown, LF; Kocher, O; Dvorak, HF			Differential expression of thymosin beta-10 by early passage and senescent vascular endothelium is modulated by VPF/VEGF: evidence for senescent endothelial cells in vivo at sites of atherosclerosis	FASEB JOURNAL			English	Article						cDNA arrays; lipoproteins; human aorta	LOW-DENSITY-LIPOPROTEIN; MACROPHAGE SCAVENGER RECEPTORS; GROWTH-FACTOR; IN-VIVO; REPLICATIVE SENESCENCE; MICROVASCULAR HYPERPERMEABILITY; TELOMERASE EXPRESSION; GENE OVEREXPRESSION; OXIDIZED LDL; ANGIOGENESIS	VPF/VEGF acts selectively on the vascular endothelium to enhance permeability, induce cell migration and division, and delay replicative senescence. To understand the changes in gene expression during endothelial senescence, we investigated genes that were differentially expressed in early vs, late passage (senescent) human dermal endothelial cells (HDMEC) using cDNA array hybridization, Early passage HDMEC cultured with or without VPF/VEGF overexpressed 9 and underexpressed 6 genes in comparison with their senescent counterparts. Thymosin beta -10 expression was modulated by VPF/VEGF and was strikingly down-regulated in senescent EC, The beta -thymosins are actin G-sequestering peptides that regulate actin dynamics and are overexpressed in neoplastic transformation. We have also identified senescent EC in the human aorta at sites overlying atherosclerotic plaques. These EC expressed senescence-associated neutral beta -galactosidase and, in contrast to adventitial microvessel endothelium, exhibited weak staining for thymosin beta -10. ISH performed on human malignant tumors revealed strong thymosin beta -10 expression in tumor blood vessels. This is the first report that T beta -10 expression is significantly reduced in senescent EC, that VPF/VEGF modulates thymosin beta -10 expression, and that EC can become senescent in vivo, The reduced expression of thymosin beta -10 may contribute to the senescent phenotype by reducing EC plasticity and thus impairing their response to migratory stimuli.	Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Vasile, E (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, RN 280 D,330 Brookline Ave, Boston, MA 02215 USA.	evasile@caregroup.harvard.edu			NCI NIH HHS [CA-50453] Funding Source: Medline; NHLBI NIH HHS [HL-54465] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050453] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054465] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Arthur WT, 1998, MICROVASC RES, V55, P260, DOI 10.1006/mvre.1998.2078; ASHKENAS J, 1993, J LIPID RES, V34, P983; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BOND JA, 1995, CANCER RES, V55, P2404; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; BURRIG KF, 1991, ARTERIOSCLER THROMB, V11, P1678, DOI 10.1161/01.ATV.11.6.1678; Califano D, 1998, CANCER RES, V58, P823; Campisi J, 1996, EXP GERONTOL, V31, P7, DOI 10.1016/0531-5565(95)02024-1; Carpintero P, 1996, FEBS LETT, V394, P103, DOI 10.1016/0014-5793(96)00888-5; Chang BD, 1999, CANCER RES, V59, P3761; de Boer OJ, 1999, CARDIOVASC RES, V41, P443, DOI 10.1016/S0008-6363(98)00255-7; DENEKAMP J, 1990, CANCER METAST REV, V9, P267, DOI 10.1007/BF00046365; DETMAR M, 1990, J INVEST DERMATOL, V95, pS219, DOI 10.1111/1523-1747.ep12875807; DIMRI GP, 1994, COLD SPRING HARB SYM, V59, P67, DOI 10.1101/SQB.1994.059.01.010; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; DVORAK HF, 1995, AM J PATHOL, V146, P1029; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HALL AK, 1995, CELL MOL BIOL RES, V41, P167; HALL AK, 1990, BRAIN RES MOL BRAIN, V8, P1291; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Kraling BM, 1998, IN VITRO CELL DEV-AN, V34, P308; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Levine E M, 1979, Int Rev Cytol Suppl, P67; Maier JAM, 1996, ATHEROSCLEROSIS, V123, P115, DOI 10.1016/0021-9150(95)05793-5; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Muruganandam A, 1997, FASEB J, V11, P1187, DOI 10.1096/fasebj.11.13.9367354; NEGRESALVAYRE A, 1992, FEBS LETT, V299, P60, DOI 10.1016/0014-5793(92)80101-L; PILI R, 1994, JNCI-J NATL CANCER I, V86, P1303, DOI 10.1093/jnci/86.17.1303; PITAS RE, 1990, J BIOL CHEM, V265, P12722; RAJAVASHISTH TB, 1990, NATURE, V344, P254, DOI 10.1038/344254a0; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; Rivard A, 1999, CIRCULATION, V99, P111, DOI 10.1161/01.CIR.99.1.111; Roth LWA, 1999, EUR J NEUROSCI, V11, P3488, DOI 10.1046/j.1460-9568.1999.00715.x; Santelli G, 1999, AM J PATHOL, V155, P799, DOI 10.1016/S0002-9440(10)65178-4; SENGER DR, 1993, CANCER METAST REV, V12, P303, DOI 10.1007/BF00665960; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; SHOLLEY MM, 1976, AM J ANAT, V147, P243, DOI 10.1002/aja.1001470208; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; Sun HQ, 1996, J BIOL CHEM, V271, P9223, DOI 10.1074/jbc.271.16.9223; Vasile E, 1999, J HISTOCHEM CYTOCHEM, V47, P159, DOI 10.1177/002215549904700205; VASILE E, 1991, J SUBMICR CYTOL PATH, V23, P279; VASILE E, 1989, ATHEROSCLEROSIS, V75, P195, DOI 10.1016/0021-9150(89)90177-9; VASILE E, 1983, J CELL BIOL, V96, P1677, DOI 10.1083/jcb.96.6.1677; WANG E, 1995, CANCER RES, V55, P2284; Watanabe Y, 1997, ONCOGENE, V14, P2025, DOI 10.1038/sj.onc.1201033; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; YU FX, 1994, CELL MOTIL CYTOSKEL, V27, P13, DOI 10.1002/cm.970270103; YU FX, 1993, J BIOL CHEM, V268, P502; Zhu WM, 1996, ARTERIOSCL THROM VAS, V16, P1104, DOI 10.1161/01.ATV.16.9.1104	53	177	190	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2001	15	2					458	466		10.1096/fj.00-0051com	http://dx.doi.org/10.1096/fj.00-0051com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156961				2022-12-28	WOS:000166872900027
J	Imam, A; Hoyos, B; Swenson, C; Levi, E; Chua, R; Viriya, E; Hammerling, U				Imam, A; Hoyos, B; Swenson, C; Levi, E; Chua, R; Viriya, E; Hammerling, U			Retinoids as ligands and coactivators of protein kinase C alpha	FASEB JOURNAL			English	Article									Mem Sloan Kettering Canc Ctr, Program Immunol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Hammerling, U (corresponding author), Mem Sloan Kettering Canc Ctr, Program Immunol, 1275 York Ave, New York, NY 10021 USA.								0	59	60	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2001	15	1					28	30						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11099483				2022-12-28	WOS:000166312400010
J	McDonald, MC; Mota-Filipe, M; Paul, A; Cuzzocrea, S; Abdelrahman, M; Harwood, S; Plevin, R; Chatterjee, PK; Yaqoob, MM; Thiemermann, C				McDonald, MC; Mota-Filipe, M; Paul, A; Cuzzocrea, S; Abdelrahman, M; Harwood, S; Plevin, R; Chatterjee, PK; Yaqoob, MM; Thiemermann, C			Calpain inhibitor I reduces the activation of nuclear factor-kappa B and organ injury/dysfunction in hemorrhagic shock	FASEB JOURNAL			English	Article						calpain; cyclo-oxygenase; endotoxin; hemorrhage; multiple organ failure; nitric oxide; reperfusion injury	NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA; TRANSCRIPTION FACTOR; NEUTRAL PROTEASE; CYCLOOXYGENASE-2 EXPRESSION; CIRCULATORY FAILURE; BRIEF ISCHEMIA; RAT-HEART; PROTEOLYSIS; INDUCTION	There is limited evidence that inhibition of the activity of the cytosolic cysteine protease calpain reduces ischemia/reperfusion injury. The multiple organ injury associated with hemorrhagic shock is due at least in part to ischemia (during hemorrhage) and reperfusion (during resuscitation) of target organs. Here we investigate the effects of calpain inhibitor I on the organ injury (kidney, liver, pancreas, lung, intestine) and dysfunction (kidney) associated with hemorrhagic shock in the anesthetized rat. Hemorrhage and resuscitation with shed blood resulted in an increase in calpain activity (heart), activation of NF-kappaB (kidney), expression of iNOS and COX-2 (kidney), and the development of multiple organ injury and dysfunction, all of which were attenuated by calpain inhibitor I (10 mg/kg i.p.), administered 30 min prior to hemorrhage. Chymostatin, a serine protease inhibitor that does not prevent the activation of NF-kappaB, had no effect on the organ injury/failure caused by hemorrhagic shock. Pretreatment (for 1 h) of murine macrophages or rat aortic smooth muscle cells (activated with endotoxin) with calpain inhibitor I attenuated the binding of activated NF-kappaB to DNA and the degradation of I kappaB alpha, I kappaB alpha, and I kappaB epsilon. Selective inhibition of iNOS activity with L-NIL reduced the circulatory failure and liver injury, while selective inhibition of COX-2 activity with SC58635 reduced the renal dysfunction and liver injury caused by hemorrhagic shock. Thus, we provide evidence that the mechanisms by which calpain inhibitor I reduces the circulatory failure as well as the organ injury and dysfunction in hemorrhagic shock include I) inhibition of calpain activity, 2) inhibition of the activation of NF-kappaB and thus prevention of the expression of NF kappaB-dependent genes, 3) prevention of the expression of iNOS, and 4) prevention of the expression of COX-2. Inhibition of calpain activity may represent a novel therapeutic approach for the therapy of hemorrhagic shock.	St Bartholomews & Royal London Sch Med & Dent, William Harvey Res Inst, Dept Expt Med & Nephrol, London EC1M 6BQ, England; Univ Strathclyde, Dept Physiol & Pharmacol, SIBS, Glasgow G4 0NR, Lanark, Scotland; Univ Messina, Sch Med, Inst Pharmacol, I-98123 Messina, Italy	University of London; Queen Mary University London; University of Strathclyde; University of Messina	Thiemermann, C (corresponding author), St Bartholomews & Royal London Sch Med & Dent, William Harvey Res Inst, Dept Expt Med & Nephrol, Charterhouse Sq, London EC1M 6BQ, England.	c.thiemermann@mds.qmw.ac.uk	Mota-Filipe, Helder/M-6298-2013	Mota-Filipe, Helder/0000-0003-3045-2553; Paul, Andrew/0000-0001-5775-2332; Thiemermann, Christoph/0000-0003-4228-9722; Plevin, Robin/0000-0002-7849-1220				APPLEBY SB, 1994, BIOCHEM J, V302, P723, DOI 10.1042/bj3020723; ATSMA DE, 1995, CIRC RES, V76, P1071, DOI 10.1161/01.RES.76.6.1071; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BARTUS RT, 1995, NEUROL RES, V17, P249, DOI 10.1080/01616412.1995.11740322; BAUE AE, 1993, PATHOPHYSIOLOGY SHOC, P1004; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Crofford LJ, 1997, ARTHRITIS RHEUM-US, V40, P226, DOI 10.1002/art.1780400207; Cryer HG, 1997, SHOCK, V8, P26, DOI 10.1097/00024382-199707000-00005; Cuzzocrea S, 1998, FREE RADICAL BIO MED, V24, P450, DOI 10.1016/S0891-5849(97)00280-3; Demetriades D, 1999, J TRAUMA, V46, P667, DOI 10.1097/00005373-199904000-00018; EDELSTEIN CL, 1995, P NATL ACAD SCI USA, V92, P7662, DOI 10.1073/pnas.92.17.7662; ERTEL W, 1992, ARCH SURG-CHICAGO, V127, P70; FENG L, 1995, J CLIN INVEST, V95, P1669, DOI 10.1172/JCI117842; GRISCAVAGE JM, 1995, BIOCHEM BIOPH RES CO, V215, P721, DOI 10.1006/bbrc.1995.2523; Griscavage JM, 1996, P NATL ACAD SCI USA, V93, P3308, DOI 10.1073/pnas.93.8.3308; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HEWETT JA, 1993, AM J PHYSIOL, V265, pG1011, DOI 10.1152/ajpgi.1993.265.6.G1011; IIZUKA K, 1991, BIOCHEM MED METAB B, V46, P427, DOI 10.1016/0885-4505(91)90091-X; IIZUKA K, 1992, JPN HEART J, V33, P707; Iwamoto H, 1999, J CARDIOVASC PHARM, V33, P580, DOI 10.1097/00005344-199904000-00010; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kengatharan M, 1996, BRIT J PHARMACOL, V117, P1163, DOI 10.1111/j.1476-5381.1996.tb16711.x; Kohli V, 1999, GASTROENTEROLOGY, V116, P168, DOI 10.1016/S0016-5085(99)70241-6; Kohli V, 1997, P NATL ACAD SCI USA, V94, P9354, DOI 10.1073/pnas.94.17.9354; Leach M, 1998, BRIT J PHARMACOL, V124, P586, DOI 10.1038/sj.bjp.0701869; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; Liu ZQ, 1996, FEBS LETT, V385, P109, DOI 10.1016/0014-5793(96)00360-2; Markgraf CG, 1998, STROKE, V29, P152, DOI 10.1161/01.STR.29.1.152; MATSUMURA Y, 1993, J CARDIOVASC PHARM, V22, P135, DOI 10.1097/00005344-199307000-00021; MELLONI E, 1989, TRENDS NEUROSCI, V12, P438, DOI 10.1016/0166-2236(89)90093-3; Milligan SA, 1996, ARCH BIOCHEM BIOPHYS, V335, P388, DOI 10.1006/abbi.1996.9998; Morgan WM, 1998, NEW HORIZ-SCI PRACT, V6, P150; Mota-Filipe H, 1999, SHOCK, V12, P255, DOI 10.1097/00024382-199910000-00002; Paul A, 1997, BRIT J PHARMACOL, V120, P1439, DOI 10.1038/sj.bjp.0701070; Plevin R, 1996, BIOCHEM J, V318, P657, DOI 10.1042/bj3180657; PONTREMOLI S, 1988, P NATL ACAD SCI USA, V85, P1740, DOI 10.1073/pnas.85.6.1740; RAMI A, 1993, BRAIN RES, V609, P67, DOI 10.1016/0006-8993(93)90856-I; Regel G, 1996, WORLD J SURG, V20, P422, DOI 10.1007/s002689900067; Ruetten H, 1997, BRIT J PHARMACOL, V121, P695, DOI 10.1038/sj.bjp.0701180; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SASAKI T, 1984, J BIOL CHEM, V259, P2489; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SEUBERT P, 1989, BRAIN RES, V492, P366, DOI 10.1016/0006-8993(89)90921-9; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIROIS J, 1993, J BIOL CHEM, V268, P12199; Sorimachi Y, 1997, J BIOCHEM-TOKYO, V122, P743; SZABO C, 1994, SHOCK, V2, P145, DOI 10.1097/00024382-199408000-00011; THIEMERMANN C, 1993, P NATL ACAD SCI USA, V90, P267, DOI 10.1073/pnas.90.1.267; THIEMERMANN C, 1995, BRIT J PHARMACOL, V116, P2845, DOI 10.1111/j.1476-5381.1995.tb15935.x; TODA G, 1989, JPN HEART J, V30, P375; Wang KKW, 1996, P NATL ACAD SCI USA, V93, P6687, DOI 10.1073/pnas.93.13.6687; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; Wray GM, 1998, SHOCK, V9, P329, DOI 10.1097/00024382-199805000-00003; XIE QW, 1994, J BIOL CHEM, V269, P4705; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; YOSHIDA K, 1993, BIOCHIM BIOPHYS ACTA, V1182, P215, DOI 10.1016/0925-4439(93)90143-O; YOSHIDA K, 1995, CIRC RES, V77, P603, DOI 10.1161/01.RES.77.3.603	59	100	117	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2001	15	1					171	186		10.1096/fj.99-0645com	http://dx.doi.org/10.1096/fj.99-0645com			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149905				2022-12-28	WOS:000166312400026
J	Saemann, MD; Bohmig, GA; Osterreicher, CH; Burtscher, H; Parolini, O; Diakos, C; Stockl, J; Horl, WH; Zlabinger, GJ				Saemann, MD; Bohmig, GA; Osterreicher, CH; Burtscher, H; Parolini, O; Diakos, C; Stockl, J; Horl, WH; Zlabinger, GJ			Anti-inflammatory effects of sodium butyrate on human monocytes: potent inhibition of IL-12 and up-regulation of IL-10 production	FASEB JOURNAL			English	Article									Univ Vienna, Inst Immunol, A-1090 Vienna, Austria; Univ Vienna, Dept Internal Med 3, A-1090 Vienna, Austria	University of Vienna; University of Vienna	Zlabinger, GJ (corresponding author), Univ Vienna, Inst Immunol, Borschkegasse 8A, A-1090 Vienna, Austria.		PAROLINI, ORNELLA/C-7946-2013; PAROLINI, ORNELLA/ABI-7862-2020	PAROLINI, ORNELLA/0000-0002-5211-6430; PAROLINI, ORNELLA/0000-0002-5211-6430; Stockl, Johannes/0000-0002-3304-6975; Zlabinger, Gerhard/0000-0002-7478-4173					0	287	303	1	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2380	2382						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11024006				2022-12-28	WOS:000165723400004
J	Blazquez, C; Galve-Roperh, I; Guzman, M				Blazquez, C; Galve-Roperh, I; Guzman, M			De novo-synthesized ceramide signals apoptosis in astrocytes via extracellular signal-regulated kinase	FASEB JOURNAL			English	Article						cell death; sphingolipids; mitogen-activated protein kinases; neural cells	CARNITINE PALMITOYLTRANSFERASE-I; ACTIVATED PROTEIN-KINASE; DAUNORUBICIN-INDUCED APOPTOSIS; FREE FATTY-ACIDS; CELL-DEATH; SPHINGOMYELIN HYDROLYSIS; RAF-1; INHIBITION; BRAIN; TRANSDUCTION	Recent observations support the importance of ceramide synthesis de novo in the induction of apoptosis. However, the downstream targets of de novo-synthesized ceramide are unknown, Here we show that palmitate incorporated into ceramide and induced apoptotic DNA fragmentation in astrocytes, These effects of palmitate were exacerbated when fatty acid breakdown was uncoupled and were not evident in neurons, which show a very low capacity to take up and metabolize palmitate, Palmitate-induced apoptosis of astrocytes was prevented by L-cycloserine and fumonisin B1, two inhibitors of ceramide synthesis de novo, and by PD098059, an inhibitor of the extracellular signal-regulated kinase (ERK) cascade. Accordingly, palmitate activated ERK by a process that was dependent on ceramide synthesis de novo and Raf-1, but independent of kinase suppressor of Ras, Other potential targets of ceramide in the control of cell fate, namely, c-Jun amino-terminal kinase, p38 mitogen-activated protein kinase, and protein kinase B, were not significantly affected in astrocytes exposed to palmitate. Results show that the Raf-1/ERK cascade is the selective downstream target of de novo-synthesized ceramide in the induction of apoptosis in astrocytes and also highlight the importance of ceramide synthesis de novo in apoptosis of astrocytes, which might have pathophysiological relevance.-Blazquez, C., Galve-Roperh, I., Guzman, M. De novo-synthesized ceramide signals apoptosis in astrocytes via extracellular signal-regulated kinase.	Univ Complutense Madrid, Sch Biol, Dept Biochem & Biol 1, Madrid 28040, Spain	Complutense University of Madrid	Guzman, M (corresponding author), Univ Complutense Madrid, Sch Biol, Dept Biochem & Biol 1, Madrid 28040, Spain.		Galve-Roperh, Ismael/AAG-2369-2020	Guzman, Manuel/0000-0001-7475-118X				Andrieu-Abadie N, 1999, FASEB J, V13, P1501, DOI 10.1096/fasebj.13.12.1501; Ariga T, 1998, J LIPID RES, V39, P1; AVELDANO MI, 1975, BRAIN RES, V100, P99, DOI 10.1016/0006-8993(75)90244-9; Basu S, 1998, J BIOL CHEM, V273, P30419, DOI 10.1074/jbc.273.46.30419; BAZAN NG, 1971, J NEUROCHEM, V18, P1379, DOI 10.1111/j.1471-4159.1971.tb00002.x; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; Blazquez C, 1998, J NEUROCHEM, V71, P1597; Blazquez C, 1999, J NEUROCHEM, V72, P1759, DOI 10.1046/j.1471-4159.1999.721759.x; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; del Pulgar T, 2000, BIOCHEM J, V347, P369, DOI 10.1042/bj3470369; EDMOND J, 1992, CAN J PHYSIOL PHARM, V70, P118; Futerman AH, 1999, BIOCHEM SOC T, V27, P432, DOI 10.1042/bst0270432; Galve-Roperh I, 2000, NAT MED, V6, P313, DOI 10.1038/73171; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Guzman M, 2000, TRENDS ENDOCRIN MET, V11, P49, DOI 10.1016/S1043-2760(99)00223-4; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Huwiler A, 1996, P NATL ACAD SCI USA, V93, P6959, DOI 10.1073/pnas.93.14.6959; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Lehtonen JYA, 1999, J BIOL CHEM, V274, P16901, DOI 10.1074/jbc.274.24.16901; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; Marshall CJ, 1998, NATURE, V392, P553, DOI 10.1038/33293; Michaud NR, 1997, P NATL ACAD SCI USA, V94, P12792, DOI 10.1073/pnas.94.24.12792; Mohr S, 1998, P NATL ACAD SCI USA, V95, P5045, DOI 10.1073/pnas.95.9.5045; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muller G, 1998, EMBO J, V17, P732, DOI 10.1093/emboj/17.3.732; Murray B, 1998, P NATL ACAD SCI USA, V95, P11975, DOI 10.1073/pnas.95.20.11975; Nicotera P, 1999, TRENDS PHARMACOL SCI, V20, P46, DOI 10.1016/S0165-6147(99)01304-8; Paumen MB, 1997, BIOCHEM BIOPH RES CO, V231, P523, DOI 10.1006/bbrc.1997.6089; Paumen MB, 1997, J BIOL CHEM, V272, P3324, DOI 10.1074/jbc.272.6.3324; Price DL, 1999, NATURE, V399, pA3, DOI 10.1038/399a003; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Riboni L, 1999, BIOCHEM J, V338, P147, DOI 10.1042/0264-6021:3380147; Sanchez C, 1998, MOL PHARMACOL, V54, P834, DOI 10.1124/mol.54.5.834; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Tani M, 2000, J BIOL CHEM, V275, P3462, DOI 10.1074/jbc.275.5.3462; Velasco G, 1998, J BIOL CHEM, V273, P21497, DOI 10.1074/jbc.273.34.21497; Xu J, 1998, J BIOL CHEM, V273, P16521, DOI 10.1074/jbc.273.26.16521; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	41	131	135	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2315	2322		10.1096/fj.00-0122com	http://dx.doi.org/10.1096/fj.00-0122com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053253				2022-12-28	WOS:000165190800025
J	Hasko, G; Kuhel, DG; Chen, JF; Schwarzschild, MA; Deitch, EA; Mabley, JG; Marton, A; Szabo, C				Hasko, G; Kuhel, DG; Chen, JF; Schwarzschild, MA; Deitch, EA; Mabley, JG; Marton, A; Szabo, C			Adenosine inhibits IL-12 and TNF-alpha production via adenosine A(2a) receptor-dependent and independent mechanisms	FASEB JOURNAL			English	Article						inflammatory mediators; cytokines; T lymphocytes; inflammation	INTERFERON-GAMMA PRODUCTION; ACTIVATED PROTEIN-KINASE; NECROSIS-FACTOR-ALPHA; A(3) RECEPTORS; SIGNAL-TRANSDUCTION; INDUCED ARTHRITIS; ENDOTOXEMIC MICE; HUMAN MONOCYTES; INTERLEUKIN-12; CYTOKINE	Interleukin 12 (IL-12) is a crucial cytokine in the regulation of T helper 1 vs. T helper 2 immune responses. In the present study, we investigated the effect of the endogenous purine nucleoside adenosine on the production of IL-12, In mouse macrophages, adenosine suppressed 12,12 production. Although the order of potency of adenosine receptor agonists suggested the involvement of A(2a) receptors, data obtained with A(2a) receptor-deficient mice showed that the adenosine suppression of IL-12 and even TNF-alpha production is only partly mediated by A(2a) receptor ligation. Studies with adenosine receptor antagonists or the adenosine uptake blocker dipyridamole showed that adenosine released endogenously also decreases IL-12. Although adenosine increases IL-10 production, the inhibition of IL-12 production is independent of the increased IL-10. The mechanism of action of adenosine was not associated with alterations of the activation of the p38 and p42/p44 mitogen-activated protein kinases or the phosphorylation of the c-Jun terminal kinase. Adenosine failed to affect steady-state levels of either IL-12 p35 or p40 mRNA, but augmented IL-10 mRNA levels. In summary, adenosine inhibits IL-12 production via various adenosine receptors. These results support the notion that adenosine-based therapies might be useful in certain autoimmune and/or inflammatory diseases.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, Newark, NJ 07103 USA; Inotek Corp, Beverly, MA 01915 USA; Massachusetts Gen Hosp, Dept Neurol, Mol Neurobiol Lab, Boston, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA 02129 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Inotek Pharmaceuticals; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Hasko, G (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, 185 S Orange Ave, Newark, NJ 07103 USA.		Mabley, Jon G/D-2296-2010; Szabo, Csaba/ABG-2644-2021; Szabo, Csaba/D-1882-2013	Mabley, Jon/0000-0001-9423-6230	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R43AR046167] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054773, R43GM059560] Funding Source: NIH RePORTER; NIAMS NIH HHS [1R43AR46167-01] Funding Source: Medline; NIGMS NIH HHS [R29GM54773, 1R43GM59560-01] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altare F, 1998, SCIENCE, V280, P1432, DOI 10.1126/science.280.5368.1432; BOUMA MG, 1994, J IMMUNOL, V153, P4159; Cain BS, 1998, J SURG RES, V76, P117, DOI 10.1006/jsre.1998.5304; Chen JF, 1999, J NEUROSCI, V19, P9192, DOI 10.1523/jneurosci.19-21-09192.1999; CRONSTEIN BN, 1995, ARTHRITIS RHEUM, V38, P1040, DOI 10.1002/art.1780380804; Cronstein BN, 1999, P NATL ACAD SCI USA, V96, P6377, DOI 10.1073/pnas.96.11.6377; CRONSTEIN BN, 1991, P NATL ACAD SCI USA, V88, P2441, DOI 10.1073/pnas.88.6.2441; CRONSTEIN BN, 1994, J APPL PHYSIOL, V76, P5, DOI 10.1152/jappl.1994.76.1.5; Daemen MARC, 1999, J IMMUNOL, V162, P5506; de Jong R, 1998, SCIENCE, V280, P1435; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; Eigler A, 1997, SCAND J IMMUNOL, V45, P132, DOI 10.1046/j.1365-3083.1997.d01-377.x; Feoktistov I, 1999, MOL PHARMACOL, V55, P726; Firestein GS, 1999, ARTHRITIS RHEUM-US, V42, P609, DOI 10.1002/1529-0131(199904)42:4<609::AID-ANR3>3.0.CO;2-I; Gadangi P, 1996, J IMMUNOL, V156, P1937; Gately MK, 1998, ANNU REV IMMUNOL, V16, P495, DOI 10.1146/annurev.immunol.16.1.495; GERMANN T, 1995, P NATL ACAD SCI USA, V92, P4823, DOI 10.1073/pnas.92.11.4823; GREEN PG, 1991, P NATL ACAD SCI USA, V88, P4162, DOI 10.1073/pnas.88.10.4162; Hasko G, 1998, BIOCHEM PHARMACOL, V56, P1079, DOI 10.1016/S0006-2952(98)00153-1; Hasko G, 1998, EUR J PHARMACOL, V358, P261, DOI 10.1016/S0014-2999(98)00619-0; Hasko G, 1998, EUR J IMMUNOL, V28, P468, DOI 10.1002/(SICI)1521-4141(199802)28:02<468::AID-IMMU468>3.0.CO;2-Z; Hasko G, 2000, J IMMUNOL, V164, P1013, DOI 10.4049/jimmunol.164.2.1013; Hasko G, 1996, J IMMUNOL, V157, P4634; Hirano D, 1996, BIOCHEM J, V316, P81, DOI 10.1042/bj3160081; Jacobson KA, 1998, DRUG DEVELOP RES, V45, P113, DOI 10.1002/(SICI)1098-2299(199811/12)45:3/4<113::AID-DDR5>3.0.CO;2-S; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; KRAAN TCTMV, 1995, J EXP MED, V181, P775, DOI 10.1084/jem.181.2.775; Krump E, 1996, BRIT J PHARMACOL, V117, P1639, DOI 10.1111/j.1476-5381.1996.tb15334.x; Lee JC, 1996, J LEUKOCYTE BIOL, V59, P152, DOI 10.1002/jlb.59.2.152; LeMoine O, 1996, J IMMUNOL, V156, P4408; Lennon PF, 1998, J EXP MED, V188, P1433, DOI 10.1084/jem.188.8.1433; LEONARD JP, 1995, J EXP MED, V181, P381, DOI 10.1084/jem.181.1.381; LINDEN J, 1994, TRENDS PHARMACOL SCI, V15, P298, DOI 10.1016/0165-6147(94)90011-6; LINDEN J, 1991, FASEB J, V5, P2668, DOI 10.1096/fasebj.5.12.1916091; MARAK GE, 1988, OPHTHALMIC RES, V20, P220; Mayne M, 1999, ANN NEUROL, V45, P633, DOI 10.1002/1531-8249(199905)45:5<633::AID-ANA12>3.0.CO;2-X; MOSMANN TR, 1994, ADV IMMUNOL, V56, P1, DOI 10.1016/S0065-2776(08)60449-6; NEURATH MF, 1995, J EXP MED, V182, P1281, DOI 10.1084/jem.182.5.1281; Ongini E, 1996, TRENDS PHARMACOL SCI, V17, P364, DOI 10.1016/S0165-6147(96)10045-6; OZMEN L, 1994, J EXP MED, V180, P907, DOI 10.1084/jem.180.3.907; PARMELY MJ, 1993, J IMMUNOL, V151, P389; POELSTRA K, 1992, LAB INVEST, V66, P555; PRIEBE T, 1990, CANCER RES, V50, P4328; Ralevic V, 1998, PHARMACOL REV, V50, P413; Resta R, 1997, J CLIN INVEST, V99, P676, DOI 10.1172/JCI119211; Ritchie PK, 1997, CYTOKINE, V9, P187, DOI 10.1006/cyto.1996.0153; Sajjadi FG, 1996, J IMMUNOL, V156, P3435; SALMON JE, 1993, J IMMUNOL, V151, P2775; Schwaninger M, 1997, J NEUROCHEM, V69, P1145; Sullivan GW, 1998, DRUG DEVELOP RES, V45, P103, DOI 10.1002/(SICI)1098-2299(199811/12)45:3/4<103::AID-DDR4>3.0.CO;2-W; Szabo C, 1998, BRIT J PHARMACOL, V125, P379, DOI 10.1038/sj.bjp.0702040; Tracey WR, 1998, CARDIOVASC RES, V40, P138, DOI 10.1016/S0008-6363(98)00112-6; Tremeau A., 1995, Traitement du Signal, V12, P1; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; WYSOCKA M, 1995, EUR J IMMUNOL, V25, P672, DOI 10.1002/eji.1830250307; Xaus J, 1999, J IMMUNOL, V162, P3607	56	395	417	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2000	14	13					2065	2074		10.1096/fj.99-0508com	http://dx.doi.org/10.1096/fj.99-0508com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023991				2022-12-28	WOS:000089634400026
J	Manion, MK; Su, ZC; Villain, M; Blalock, JE				Manion, MK; Su, ZC; Villain, M; Blalock, JE			A new type of Ca2+ channel blocker that targets Ca2+ sensors and prevents Ca2+-mediated apoptosis	FASEB JOURNAL			English	Article						calmodulin; CALP; Fura-2; cation channel; complementary peptide; antisense peptide	METHYL-D-ASPARTATE; CALCIUM-DEPENDENT INACTIVATION; PROGRAMMED CELL-DEATH; HIV COAT PROTEIN; NMDA RECEPTORS; T-CELLS; NEURONAL INJURY; ALPHA-ACTININ; NR1 SUBUNIT; CALMODULIN	Calmodulin (CaM), as well as other Ca2+ binding motifs (i.e., EF hands), have been demonstrated to be Ca2+ sensors for several ion channel types, usually resulting in an inactivation in a negative feedback manner. This provides a novel target for the regulation of such channels. We have designed peptides that interact with EF hands of CaM in a specific and productive manner. Here we have examined whether these peptides block certain Ca2+-permeant channels and inhibit biological activity that is dependent on the influx of Ca2+. We found that these peptides are able to enter the cell and directly, as well as indirectly (through CaM), block the activity of glutamate receptor channels in cultured neocortical neurons and a nonselective cation channel in Jurkat T cells that is activated by HIV-1 gp120. As a consequence, apoptosis mediated by an influx of Ca2+ through these channels was also dose-dependently inhibited by these novel peptides, Thus, this new type of Ca2+ channel blocker may have utility in controlling apoptosis due to HIV infection or neuronal loss due to ischemia.	Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Blalock, JE (corresponding author), Univ Alabama Birmingham, Dept Physiol & Biophys, McCallum Bldg,Rm 898,1918 Univ Blvd, Birmingham, AL 35294 USA.	blalock@uab.edu		Blalock, J. Edwin/0000-0001-5303-8123	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037670, R21AI037670] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH052527] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS029719] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 37670] Funding Source: Medline; NIMH NIH HHS [MH52527] Funding Source: Medline; NINDS NIH HHS [NS 29719] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTMAN SA, 1993, BIOTECHNOL PROGR, V9, P671, DOI 10.1021/bp00024a017; ARMSTRONG DL, 1989, TRENDS NEUROSCI, V12, P117, DOI 10.1016/0166-2236(89)90168-9; BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; BANSAL N, 1990, J CELL PHYSIOL, V143, P105, DOI 10.1002/jcp.1041430114; BARANYI L, 1995, NAT MED, V1, P894, DOI 10.1038/nm0995-894; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Bian XP, 1997, AM J PHYSIOL-CELL PH, V272, pC1241, DOI 10.1152/ajpcell.1997.272.4.C1241; BLALOCK JE, 1995, NAT MED, V1, P876, DOI 10.1038/nm0995-876; Cidlowski JA, 1996, RECENT PROG HORM RES, V51, P457; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P15; DAWSON VL, 1993, P NATL ACAD SCI USA, V90, P3256, DOI 10.1073/pnas.90.8.3256; DELEON M, 1995, SCIENCE, V270, P1502, DOI 10.1126/science.270.5241.1502; DILLON J, 1991, P NATL ACAD SCI USA, V88, P9726, DOI 10.1073/pnas.88.21.9726; DIOP AG, 1994, NEUROSCI LETT, V165, P187, DOI 10.1016/0304-3940(94)90741-2; DREYER EB, 1990, SCIENCE, V248, P364, DOI 10.1126/science.2326646; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; Estacion M, 1999, BIOCHEM J, V341, P41, DOI 10.1042/0264-6021:3410041; Fanger CM, 1999, J BIOL CHEM, V274, P5746, DOI 10.1074/jbc.274.9.5746; FOSTER S, 1995, EUR J IMMUNOL, V25, P1778, DOI 10.1002/eji.1830250644; FRANDSEN A, 1992, P NATL ACAD SCI USA, V89, P2590, DOI 10.1073/pnas.89.7.2590; GARDNER P, 1989, J BIOL CHEM, V264, P1068; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOUGEON ML, 1993, SCIENCE, V260, P1269, DOI 10.1126/science.8098552; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; Grunwald ME, 1998, J BIOL CHEM, V273, P9148, DOI 10.1074/jbc.273.15.9148; HAACK JA, 1994, BIOPHYS J, V66, P1051, DOI 10.1016/S0006-3495(94)80886-0; HAHN JS, 1988, P NATL ACAD SCI USA, V85, P6556, DOI 10.1073/pnas.85.17.6556; KAISER PK, 1990, NEUROLOGY, V40, P1757, DOI 10.1212/WNL.40.11.1757; KEILHOFF G, 1993, NEUROREPORT, V5, P129, DOI 10.1097/00001756-199311180-00008; Krupp JJ, 1999, J NEUROSCI, V19, P1165; LEI SHZ, 1992, BRAIN RES, V598, P196, DOI 10.1016/0006-8993(92)90183-A; Levitan IB, 1999, NEURON, V22, P645, DOI 10.1016/S0896-6273(00)80722-9; LIPTON SA, 1994, MOL NEUROBIOL, V8, P181, DOI 10.1007/BF02780669; LIPTON SA, 1991, NEURON, V7, P111, DOI 10.1016/0896-6273(91)90079-F; McConkey David J., 1996, Scanning Microscopy, V10, P777; OYAIZU N, 1995, CELL ACTIVATION APOP; Peterson BZ, 1999, BIOPHYS J, V76, pA340; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; Philpott NJ, 1996, BLOOD, V87, P2244, DOI 10.1182/blood.V87.6.2244.bloodjournal8762244; Qin N, 1999, P NATL ACAD SCI USA, V96, P2435, DOI 10.1073/pnas.96.5.2435; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; SAVIO T, 1993, J NEUROSCI RES, V34, P265, DOI 10.1002/jnr.490340303; SHERMAN A, 1990, BIOPHYS J, V58, P985, DOI 10.1016/S0006-3495(90)82443-7; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; TRUMP BF, 1995, FASEB J, V9, P219, DOI 10.1096/fasebj.9.2.7781924; Tuosto L, 1995, EUR J IMMUNOL, V25, P2907, DOI 10.1002/eji.1830251030; Villain M, 2000, J BIOL CHEM, V275, P2676, DOI 10.1074/jbc.275.4.2676; Warr CG, 1996, BIOCHEM J, V314, P497, DOI 10.1042/bj3140497; Weissman D, 1997, NATURE, V389, P981, DOI 10.1038/40173; WOODRUFF GN, 1987, NEUROPHARMACOLOGY, V26, P903, DOI 10.1016/0028-3908(87)90068-2; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; YUE DT, 1990, SCIENCE, V250, P1735, DOI 10.1126/science.2176745; Zhang S, 1998, NEURON, V21, P443, DOI 10.1016/S0896-6273(00)80553-X; ZUHKLE RD, 1998, P NATL ACAD SCI USA, V95, P3287	54	15	17	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2000	14	10					1297	1306		10.1096/fj.14.10.1297	http://dx.doi.org/10.1096/fj.14.10.1297			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877822				2022-12-28	WOS:000087932200004
J	Gornikiewicz, A; Sautner, T; Brostjan, C; Schmierer, B; Fugger, R; Roth, E; Muhlbacher, F; Bergmann, M				Gornikiewicz, A; Sautner, T; Brostjan, C; Schmierer, B; Fugger, R; Roth, E; Muhlbacher, F; Bergmann, M			Catecholamines up-regulate lipopolysaccharide-induced IL-6 production in human microvascular endothelial cells	FASEB JOURNAL			English	Article						immunomodulation; transcription; adrenoreceptors	TUMOR-NECROSIS-FACTOR; ANTIINFLAMMATORY CYTOKINE; INTERLEUKIN-10 PRODUCTION; MONONUCLEAR-CELLS; GROWTH-FACTOR; WHOLE-BLOOD; CYCLIC-AMP; SEPSIS; ENDOTOXEMIA; EXPRESSION	The catecholamine-mediated modulation of the cytokine network has primarily been demonstrated for leukocytes, Whereas catecholamines decrease the LPS-induced production of IL-6 by leukocytes, serum levels of IL-6 are dramatically increased by the catecholamine epinephrine in animal endotoxemia models. We now demonstrate that epinephrine as well as norepinephrine can induce IL-6 in an endothelial cell line (HMEC-1). Furthermore, these catecholamines could even potentiate the LPS-induced IL-5 protein production. The synergistic effect of catecholamines and LPS could be reproduced in primary human skin microvascular endothelial cells. The catecholamine-induced IL-6 stimulation is based on increased IL-6 mRNA levels. RNA stability assays revealed that this regulation is not a result of enhanced RNA stability and therefore is most likely due to an increased transcription. Treatment with cycloheximide indicated that new protein synthesis is not necessary for this transcriptional up-regulation of IL-6 mRNA Preincubation with alpha and beta receptor antagonists showed that the effect is mediated by beta(1)- and beta(2)-adrenergic receptors. Thus, endothelial cells might be a possible source of increased IL-6 production observed in situations such as stress or septic shock, in which catecholamines are elevated due to endogenous production or exogenous application.-Gonlikiewicz, A., Sautner, T., Brostjan, C., Schmierer, B., Fugger, R., Roth, E., Muhlbacher, F., Bergmann, M. Catecholamines up-regulate lipopolysaccharide-induced IL-6 production in human microvascular endothelial cells.	Univ Vienna, Dept Surg, A-1090 Vienna, Austria	University of Vienna	Bergmann, M (corresponding author), Univ Vienna, Dept Surg, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	Michael.Bergmann@akh-wien.ac.at	Schmierer, Bernhard/C-1416-2009; Schmierer, Bernhard/P-4208-2019; Sautner, Thomas/AAQ-8899-2021; Bergmann, Michael/GZK-7700-2022	Schmierer, Bernhard/0000-0002-9082-7022; Schmierer, Bernhard/0000-0002-9082-7022; Sautner, Thomas/0000-0003-0033-3414; Bergmann, Michael/0000-0001-8529-1166; Brostjan, Christine/0000-0003-1462-5397				ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Bergmann M, 1999, SHOCK, V12, P421, DOI 10.1097/00024382-199912000-00002; BOGDAN C, 1992, J BIOL CHEM, V267, P23301; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; DENDORFER U, 1994, MOL CELL BIOL, V14, P4443, DOI 10.1128/MCB.14.7.4443; DERIJK RH, 1994, PSYCHONEUROENDOCRINO, V19, P155, DOI 10.1016/0306-4530(94)90005-1; Eickelberg O, 1999, J BIOL CHEM, V274, P12933, DOI 10.1074/jbc.274.18.12933; ERTEL W, 1995, BLOOD, V85, P1341, DOI 10.1182/blood.V85.5.1341.bloodjournal8551341; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HACK CE, 1989, BLOOD, V74, P1704; JIRIK FR, 1989, J IMMUNOL, V142, P144; LeTulzo Y, 1997, J CLIN INVEST, V99, P1516, DOI 10.1172/JCI119314; LIAO JF, 1995, AM J PHYSIOL-REG I, V268, pR896, DOI 10.1152/ajpregu.1995.268.4.R896; MALEFYT RD, 1991, J EXP MED, V174, P1209; MARCHANT A, 1994, LANCET, V343, P707, DOI 10.1016/S0140-6736(94)91584-9; MARUO N, 1992, ENDOCRINOLOGY, V131, P710, DOI 10.1210/en.131.2.710; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; NehlsenCannarella SL, 1997, J APPL PHYSIOL, V82, P1662, DOI 10.1152/jappl.1997.82.5.1662; Papanicolaou DA, 1996, AM J PHYSIOL-ENDOC M, V271, pE601; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; SCHINDLER R, 1990, BLOOD, V75, P40; SEVERN A, 1992, J IMMUNOL, V148, P3441; STEININGER R, 1994, TRANSPLANTATION, V58, P179, DOI 10.1097/00007890-199407270-00008; Szabo C, 1997, IMMUNOLOGY, V90, P95, DOI 10.1046/j.1365-2567.1997.00137.x; THIJS LG, 1995, INTENS CARE MED, V21, pS258, DOI 10.1007/BF01740764; TILG H, 1994, BLOOD, V83, P113; Tilg H, 1997, IMMUNOL TODAY, V18, P428, DOI 10.1016/S0167-5699(97)01103-1; vanderPoll T, 1997, J INFECT DIS, V175, P118, DOI 10.1093/infdis/175.1.118; VANDERPOLL T, 1994, INFECT IMMUN, V62, P2046, DOI 10.1128/IAI.62.5.2046-2050.1994; vanderPoll T, 1996, J CLIN INVEST, V97, P713, DOI 10.1172/JCI118469; Volk HD, 1996, INTENS CARE MED, V22, pS474, DOI 10.1007/BF01743727; Zeni F, 1997, CRIT CARE MED, V25, P1095, DOI 10.1097/00003246-199707000-00001	32	60	68	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2000	14	9					1093	1100		10.1096/fasebj.14.9.1093	http://dx.doi.org/10.1096/fasebj.14.9.1093			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834930				2022-12-28	WOS:000087427300005
J	Giordano, S; Maffe, A; Williams, TA; Artigiani, S; Gual, P; Bardelli, A; Basilico, C; Michieli, P; Comoglio, PM				Giordano, S; Maffe, A; Williams, TA; Artigiani, S; Gual, P; Bardelli, A; Basilico, C; Michieli, P; Comoglio, PM			Different point mutations in the met oncogene elicit distinct biological properties	FASEB JOURNAL			English	Article						tyrosine kinase receptor; mutations; invasive growth; branching morphogenesis	HEPATOCYTE GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; C-MET; ACTIVATING MUTATIONS; CELL-TRANSFORMATION; MET/HGF RECEPTOR; CARCINOMA-CELLS; HGF RECEPTOR; PROTOONCOGENE; EXPRESSION	The MET proto-oncogene, encoding the tyrosine kinase receptor for HGF, controls genetic programs leading to cell growth, invasiveness, and protection from apoptosis. Recently, MET mutations have been identified in hereditary and sporadic forms of papillary renal carcinoma (PRC). Introduction of different naturally occurring mutations into the MET cDNA results in the acquisition of distinct biochemical and biological properties of transfected cells. Some mutations result in a high increase in tyrosine kinase activity and confer transforming ability in focus forming assays. These mutants hyperactivate the Ras signaling pathway. Other mutations are devoid of transforming potential but are effective in inducing protection from apoptosis and sustaining anchorage-independent growth. These Met(PRC) receptors interact more efficiently with the intracellular transducer Pi3Kinase. The reported results show that 2MET(PRC) mutations can be responsible for malignant transformation through different mechanisms, either by increasing the growth ability of cells or by protecting cells from apoptosis and allowing accumulation of other genetic lesions.	Univ Turin, Inst Canc Res & Treatment, Sch Med, IRCC, I-10060 Candiolo, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	Giordano, S (corresponding author), Univ Turin, Canc Res Inst, Dept Mol Oncol, Sch Med, Strada Provinciale 142,Km 395, I-10060 Candiolo, Torino, Italy.		Basilico, Cristina/A-3253-2011; Gual, Philippe/P-9833-2019; Gual, Philippe/M-8787-2017; Williams, Tracy/K-5604-2013; Michieli, Paolo/A-2588-2011; Comoglio, Paolo/G-6323-2011; Giordano, Silvia/J-9858-2018; BARDELLI, Alberto/J-9721-2018	Gual, Philippe/0000-0001-7393-8356; Gual, Philippe/0000-0001-7393-8356; Michieli, Paolo/0000-0002-3093-8871; Giordano, Silvia/0000-0003-1854-1086; Williams, Tracy Ann/0000-0002-2388-6444; BARDELLI, Alberto/0000-0003-1647-5070; Comoglio, Paolo/0000-0002-7056-5328				Bardelli A, 1998, P NATL ACAD SCI USA, V95, P14379, DOI 10.1073/pnas.95.24.14379; Bardelli A, 1999, ONCOGENE, V18, P1139, DOI 10.1038/sj.onc.1202607; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; Beghini A, 1998, BLOOD, V92, P701, DOI 10.1182/blood.V92.2.701; BELLUSCI S, 1994, ONCOGENE, V9, P1091; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; DIRENZO MF, 1995, CANCER RES, V55, P1129; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DIRENZO MF, 1992, ONCOGENE, V7, P2549; FERRACINI R, 1995, ONCOGENE, V10, P739; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Liang TJ, 1996, J CLIN INVEST, V97, P2872, DOI 10.1172/JCI118744; LONGATI P, 1994, ONCOGENE, V9, P49; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; Meiners S, 1998, ONCOGENE, V16, P9, DOI 10.1038/sj.onc.1201486; Michieli P, 1996, ONCOGENE, V12, P775; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NALDINI L, 1991, ONCOGENE, V6, P501; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; PELICCI G, 1995, ONCOGENE, V10, P1631; Piao XH, 1996, BLOOD, V87, P3117, DOI 10.1182/blood.V87.8.3117.bloodjournal8783117; PONZETTO C, 1991, ONCOGENE, V6, P553; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Prat M, 1998, J CELL SCI, V111, P237; RONG S, 1994, COLD SPRING HARB SYM, V59, P629, DOI 10.1101/SQB.1994.059.01.072; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Royal I, 1997, J CELL PHYSIOL, V173, P196, DOI 10.1002/(SICI)1097-4652(199711)173:2<196::AID-JCP20>3.0.CO;2-D; Sachs M, 1996, J CELL BIOL, V133, P1095, DOI 10.1083/jcb.133.5.1095; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Tamagnone Luca, 1997, Cytokine and Growth Factor Reviews, V8, P129, DOI 10.1016/S1359-6101(97)00007-5; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0	43	77	85	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2000	14	2					399	406		10.1096/fasebj.14.2.399	http://dx.doi.org/10.1096/fasebj.14.2.399			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	281WQ	10657996				2022-12-28	WOS:000085184800019
J	Barber, A; Robson, SC; Myatt, L; Bulmer, JN; Lyall, F				Barber, A; Robson, SC; Myatt, L; Bulmer, JN; Lyall, F			Heme oxygenase expression in human placenta and placental bed: reduced expression of placenta endothelial HO-2 in preeclampsia and fetal growth restriction	FASEB JOURNAL			English	Article						pregnancy; HO-1; HO-2; trophoblast; carbon monoxide	NITRIC-OXIDE SYNTHASE; HSP32 MESSENGER-RNA; SPIRAL ARTERIES; CARBON-MONOXIDE; TROPHOBLAST INVASION; MORPHOLOGICAL-CHANGES; PULSATILITY INDEX; OXIDATIVE STRESS; PRE-ECLAMPSIA; BIRTH-WEIGHT	In this study we tested the hypothesis that expression of heme oxygenases HO-1 and HO-2, which are responsible for the production of carbon monoxide, are reduced in the placenta and placental bed of pregnancies complicated by preeclampsia (PE) and fetal growth restriction (FGR) compared with control third-trimester pregnancies. Placental protein expression was determined by Western blotting (n=10 in each group) and immunohistochemistry (controls n=18, PE n=19, FGR n=10), Extravillous trophoblast expression was determined by immunohistochemistry of placental bed biopsy samples (controls n=17, PE n=19, FGR n=10), Western blot analysis of placental homogenates showed no overall differences in HO-2 among groups. However, immunohistochemical analysis showed a reduction in HO-2 expression in endothelial cells in both abnormal groups (PE P<0.01; FGR P<0.0005 vs. control group) but no differences in villous trophoblast staining. HO-I was undetectable by Western blotting in control and abnormal pregnancies and immunoreactivity was very low, suggesting that there is little HO-I in the placenta. Within the placental bed, HO-2 but not HO-1 was detected on all populations of extravillous trophoblast, but expression of HO-2 or HO-1 did not change in PE or FGR, The reduced expression of HO-2 on endothelial cells in PE and FGR may be responsible for reduced placental blood flow in these conditions. The data do not show changes in HO in the placental bed in PE or FGR.	Inst Med Genet, Maternal & Fetal Med Sect, Glasgow G3 8SJ, Lanark, Scotland; Royal Victoria Infirm, Dept Pathol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Royal Victoria Infirm, Dept Obstet & Gynaecol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Univ Cincinnati, Coll Med, Dept Obstet & Gynecol, Cincinnati, OH 45267 USA	University of Glasgow; Newcastle University - UK; Newcastle University - UK; University System of Ohio; University of Cincinnati	Lyall, F (corresponding author), Inst Med Genet, Maternal & Fetal Med Sect, Glasgow G3 8SJ, Lanark, Scotland.							ARDUINI D, 1990, J PERINAT MED, V18, P165, DOI 10.1515/jpme.1990.18.3.165; Barber A, 1999, AM J PATHOL, V155, P831, DOI 10.1016/S0002-9440(10)65182-6; BLANKENSHIP TN, 1993, CELL TISSUE RES, V274, P135, DOI 10.1007/BF00327994; BOWER S, 1993, OBSTET GYNECOL, V82, P78; BROSENS I, 1967, J PATHOL BACTERIOL, V93, P568; BROSENS IA, 1977, CLIN OBSTET GYNAECOL, V4, P573; Conrad KP, 1995, PLACENTA, V16, P691, DOI 10.1016/0143-4004(95)90013-6; CONRAD KP, 1993, FASEB J, V7, P1269, DOI 10.1096/fasebj.7.13.7691671; Craven CM, 1998, PLACENTA, V19, P241, DOI 10.1016/S0143-4004(98)90055-8; CRUSE I, 1988, J BIOL CHEM, V263, P3348; DEWOLF F, 1980, BRIT J OBSTET GYNAEC, V87, P678; DEWOLF F, 1973, AM J OBSTET GYNECOL, V117, P833, DOI 10.1016/0002-9378(73)90500-0; Elbirt KK, 1999, P ASSOC AM PHYSICIAN, V111, P438, DOI 10.1111/paa.1999.111.5.438; EWING JF, 1993, J NEUROCHEM, V60, P1512, DOI 10.1111/j.1471-4159.1993.tb03315.x; GERRETSEN G, 1981, BRIT J OBSTET GYNAEC, V88, P876, DOI 10.1111/j.1471-0528.1981.tb02222.x; GHABOUR MS, 1995, AM J OBSTET GYNECOL, V173, P687, DOI 10.1016/0002-9378(95)90324-0; Hubel CA, 1999, P SOC EXP BIOL MED, V222, P222, DOI 10.1046/j.1525-1373.1999.d01-139.x; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; KHONG TY, 1986, BRIT J OBSTET GYNAEC, V93, P1049, DOI 10.1111/j.1471-0528.1986.tb07830.x; KHONG TY, 1987, BRIT J OBSTET GYNAEC, V94, P649, DOI 10.1111/j.1471-0528.1987.tb03169.x; KHONG TY, 1995, FETUS NEONATE CHANGE, P177; Kingdom J, 1998, PLACENTA, V19, P347, DOI 10.1016/S0143-4004(98)90073-X; Kingdom JCP, 1997, PLACENTA, V18, P613, DOI 10.1016/S0143-4004(97)90000-X; KUTTY RK, 1989, ARCH BIOCHEM BIOPHYS, V268, P100, DOI 10.1016/0003-9861(89)90569-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVERE RD, 1993, AM J HEMATOL, V43, P19, DOI 10.1002/ajh.2830430106; LUNELL NO, 1979, GYNECOL OBSTET INVES, V10, P106, DOI 10.1159/000299924; Lyall F, 2000, FASEB J, V14, P208, DOI 10.1096/fasebj.14.1.208; Lyall F, 1996, PLACENTA, V17, P165, DOI 10.1016/S0143-4004(96)80009-9; LYALL F, 1995, AM J OBSTET GYNECOL, V173, P714, DOI 10.1016/0002-9378(95)90328-3; Lyall F, 1999, AM J PATHOL, V154, P1105, DOI 10.1016/S0002-9440(10)65363-1; Lyall F, 2000, PLACENTA BASIC SCI C, P79; MAINES MD, 1993, MOL CELL NEUROSCI, V4, P389, DOI 10.1006/mcne.1993.1049; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MAINES MD, 1993, J PHARMACOL EXP THER, V264, P457; MANSOURI A, 1982, THROMB HAEMOSTASIS, V48, P286; MATIJEVIC R, 1995, OBSTET GYNECOL, V86, P289, DOI 10.1016/0029-7844(95)00129-F; MCFADYEN IR, 1986, BRIT J OBSTET GYNAEC, V93, P476, DOI 10.1111/j.1471-0528.1986.tb07933.x; MCFAUL SJ, 1987, TOXICOL APPL PHARM, V87, P464, DOI 10.1016/0041-008X(87)90252-3; McLaughlin BE, 2000, PLACENTA, V21, P870, DOI 10.1053/plac.2000.0574; MEEKINS JW, 1994, BRIT J OBSTET GYNAEC, V101, P669, DOI 10.1111/j.1471-0528.1994.tb13182.x; MORITA T, 1995, P NATL ACAD SCI USA, V92, P1475, DOI 10.1073/pnas.92.5.1475; MYATT L, 1992, PLACENTA, V13, P329, DOI 10.1016/0143-4004(92)90057-Z; MYATT L, 1993, PLACENTA, V14, P487, DOI 10.1016/S0143-4004(05)80202-4; MYATT L, 1997, HUM REPROD, V12, P67; OLOFSSON P, 1993, EUR J OBSTET GYN R B, V49, P161, DOI 10.1016/0028-2243(93)90265-E; PIJNENBORG R, 1991, BRIT J OBSTET GYNAEC, V98, P648, DOI 10.1111/j.1471-0528.1991.tb13450.x; PIJNENBORG R, 1983, PLACENTA, V4, P397, DOI 10.1016/S0143-4004(83)80043-5; PIJNENBORG R, 1980, PLACENTA, V1, P3, DOI 10.1016/S0143-4004(80)80012-9; ROBERTS JM, 1993, LANCET, V341, P1447, DOI 10.1016/0140-6736(93)90889-O; Robson SC, 1995, FETUS NEONATE, P297; SHEPPARD BL, 1981, BRIT J OBSTET GYNAEC, V88, P695, DOI 10.1111/j.1471-0528.1981.tb01268.x; SHEPPARD BL, 1976, BRIT J OBSTET GYNAEC, V83, P948, DOI 10.1111/j.1471-0528.1976.tb00781.x; SHIBAHARA S, 1987, J BIOL CHEM, V262, P12889; Tin W, 1997, BRIT J OBSTET GYNAEC, V104, P180, DOI 10.1111/j.1471-0528.1997.tb11041.x; TRAKSHEL GM, 1989, J BIOL CHEM, V264, P1323; TRUDINGER BJ, 1985, BRIT J OBSTET GYNAEC, V92, P23, DOI 10.1111/j.1471-0528.1985.tb01044.x; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; VOIGT HJ, 1992, J PERINAT MED, V20, P139, DOI 10.1515/jpme.1992.20.2.139; Walsh SW, 1998, SEMIN REPROD ENDOCR, V16, P93, DOI 10.1055/s-2007-1016256; Zakhary R, 1996, P NATL ACAD SCI USA, V93, P795, DOI 10.1073/pnas.93.2.795; [No title captured]	62	99	107	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1158	1168		10.1096/fj.00-0376com	http://dx.doi.org/10.1096/fj.00-0376com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344084				2022-12-28	WOS:000168655200006
J	Hoebertz, A; Meghji, S; Burnstock, G; Arnett, TR				Hoebertz, A; Meghji, S; Burnstock, G; Arnett, TR			Extracellular ADP is a powerful osteolytic agent: evidence for signaling through the P2Y(1) receptor on bone cells	FASEB JOURNAL			English	Article						P2 receptors; ADP; ATP; osteoclast; bone resorption; P2Y(1)	PHARMACOLOGICAL CHARACTERIZATION; PURINERGIC RECEPTORS; NONSELECTIVE CATION; ADENINE-NUCLEOTIDES; HUMAN OSTEOBLASTS; RAT OSTEOCLASTS; P2 RECEPTORS; ATP; RESORPTION; PH	There is increasing evidence that extracellular nucleotides act on bone cells via P2 receptors, This study investigated the action of ADP and 2-methylthioADP, a potent ADP analog with selectivity for the P2Y(1) receptor, on osteoclasts, the bone-resorbing multinuclear cells. Using three different assays, we show that ADP and 2-methylthioADP at nanomolar to submicromolar levels caused up to fourfold to sixfold increases in osteoclastic bone resorption, On mature rat osteoclasts, cultured for 1 day on polished dentine disks, peak effects on resorption pit formation were observed between 20 nM and 2 muM of ADP, The same concentrations of ADP also stimulated osteoclast and resorption pit formation in 10-day mouse marrow cultures on dentine disks. In 3-day explant cultures of mouse calvarial bones, the stimulatory effect of ADP on osteoclast-mediated Ca2+ release was greatest at 5-50 muM and equivalent to the maximal effects of prostaglandin E-2. The ADP effects were blocked in a nontoxic manner by MRS 2179, a P2Y(1) receptor antagonist. Using in situ hybridization and immunocytochemistry, we found evidence for P2Y(1) receptor expression on both osteoclasts and osteoblasts; thus, ADP could exert its actions both directly on osteoclasts and indirectly via P2Y(1) receptors on osteoblasts, As a major ATP degradation product, ADP is a novel stimulator of bone resorption that could help mediate inflammatory bone loss in vivo.	UCL, Dept Anat & Dev Biol, London WC1E 6BT, England; UCL, Eastman Dent Inst, Cellular Microbiol Res Grp, London WC1E 6BT, England; UCL, Auton Neurosci Inst, London WC1E 6BT, England	University of London; University College London; University of London; University College London; University of London; University College London	Arnett, TR (corresponding author), UCL, Dept Anat & Dev Biol, Mortimer St, London WC1E 6BT, England.	t.arnett@ucl.ac.uk	Arnett, Tim/AAW-4445-2021					Arnett TR, 1996, BONE, V18, P277, DOI 10.1016/8756-3282(95)00486-6; ARNETT TR, 1986, ENDOCRINOLOGY, V119, P119, DOI 10.1210/endo-119-1-119; Bianchi BR, 1999, EUR J PHARMACOL, V376, P127, DOI 10.1016/S0014-2999(99)00350-7; Bodin P, 1998, INFLAMM RES, V47, P351, DOI 10.1007/s000110050341; Bowler WB, 1999, J BIOL CHEM, V274, P14315, DOI 10.1074/jbc.274.20.14315; Bowler WB, 1998, BONE, V22, P195, DOI 10.1016/S8756-3282(97)00280-9; Boyer JL, 1998, BRIT J PHARMACOL, V124, P1, DOI 10.1038/sj.bjp.0701837; Brown CJ, 1997, BBA-MOL BASIS DIS, V1362, P208, DOI 10.1016/S0925-4439(97)00080-X; Burnstock G, 1997, NEUROPHARMACOLOGY, V36, P1127, DOI 10.1016/S0028-3908(97)00125-1; COADE SB, 1989, CIRC RES, V65, P531, DOI 10.1161/01.RES.65.3.531; Dixon CJ, 2000, BRIT J PHARMACOL, V130, P664, DOI 10.1038/sj.bjp.0703350; Dixon CJ, 1997, BRIT J PHARMACOL, V120, P777; Dixon SJ, 2000, DRUG DEVELOP RES, V49, P187, DOI 10.1002/(SICI)1098-2299(200003)49:3<187::AID-DDR9>3.0.CO;2-F; EVANS RJ, 1995, MOL PHARMACOL, V48, P178; Filippov AK, 2000, BRIT J PHARMACOL, V129, P1063, DOI 10.1038/sj.bjp.0703185; Fuller K, 2000, J CELL SCI, V113, P2445; GOLDHABER P, 1987, AM J PHYSIOL, V253, pE90, DOI 10.1152/ajpendo.1987.253.1.E90; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; Hechler B, 1998, MOL PHARMACOL, V53, P727, DOI 10.1124/mol.53.4.727; Hoebertz A, 2000, BONE, V27, P503, DOI 10.1016/S8756-3282(00)00351-3; Jacobson KA, 1999, PROG BRAIN RES, V120, P119; King BF, 1996, BRIT J PHARMACOL, V117, P1371, DOI 10.1111/j.1476-5381.1996.tb15293.x; King BF, 1998, DEV CARDIOVASC MED, V209, P159; KUMAGAI H, 1991, J BONE MINER RES, V6, P697; LEONG WS, 1994, BBA-GEN SUBJECTS, V1201, P298, DOI 10.1016/0304-4165(94)90054-X; Meghji S, 2001, AM J PHYSIOL-ENDOC M, V280, pE112, DOI 10.1152/ajpendo.2001.280.1.E112; MEGHJI S, 1998, METHODS BONE BIOL, P106; Moran-Jimenez MJ, 2000, MOL BRAIN RES, V78, P50, DOI 10.1016/S0169-328X(00)00067-X; Morrison MS, 1998, J PHYSIOL-LONDON, V511, P495, DOI 10.1111/j.1469-7793.1998.495bh.x; MORRISON MS, 1998, BONE, V22, pS30; MURRILLS RJ, 1998, METHODS BONE BIOL, P64; Naemsch LN, 1999, J CELL SCI, V112, P4425; NEEDLEMAN P, 1974, CIRC RES, V34, P455, DOI 10.1161/01.RES.34.4.455; Ogilvie ALJ, 2000, J INVEST DERMATOL, V114, P226; PEEL NFA, 1991, BRIT J RHEUMATOL, V30, P84; Peerschke EIB, 1998, IMMUNOBIOLOGY, V199, P239, DOI 10.1016/S0171-2985(98)80030-2; RABADJIJA L, 1990, BONE MINER, V11, P295, DOI 10.1016/0169-6009(90)90026-C; Ralevic V, 1998, PHARMACOL REV, V50, P413; REIMER WJ, 1992, AM J PHYSIOL, V263, pC1040, DOI 10.1152/ajpcell.1992.263.5.C1040; SCHOFL C, 1992, J BONE MINER RES, V7, P485; SISTARE FD, 1994, J PHARMACOL EXP THER, V269, P1049; Vigne P, 1998, BRIT J PHARMACOL, V125, P675, DOI 10.1038/sj.bjp.0702115; WEBB TE, 1993, FEBS LETT, V324, P219, DOI 10.1016/0014-5793(93)81397-I; Weidema AF, 1997, J PHYSIOL-LONDON, V503, P303, DOI 10.1111/j.1469-7793.1997.303bh.x; Wildman SS, 1997, BRIT J PHARMACOL, V120, P221, DOI 10.1038/sj.bjp.0700903; YU HS, 1995, J CELL SCI, V108, P3051; YU HS, 1994, CELL SIGNAL, V6, P905, DOI 10.1016/0898-6568(94)90023-X; YU HS, 1993, BIOCHEM BIOPH RES CO, V191, P357, DOI 10.1006/bbrc.1993.1225; Zanellato N, 2000, J BONE MINER RES, V15, pS387	49	68	70	1	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2001	15	7					1139	1148		10.1096/fj.00-0395com	http://dx.doi.org/10.1096/fj.00-0395com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344082				2022-12-28	WOS:000168655200004
J	Choi, DH; Whittier, PS; Oshima, J; Funk, WD				Choi, DH; Whittier, PS; Oshima, J; Funk, WD			Telomerase expression prevents replicative senescence but does not fully reset mRNA expression patterns in Werner syndrome cell strains	FASEB JOURNAL			English	Article							VARIEGATED TRANSLOCATION MOSAICISM; CULTURED SKIN FIBROBLASTS; SYNDROME PROTEIN; SYNDROME GENE; DNA; HELICASE; LINES; TOPOISOMERASE; HYBRIDIZATION; LOCALIZATION	Reduced replicative capacity is a consistent characteristic of cells derived from patients with Werner syndrome, This premature senescence is phenotypically similar to replicative senescence observed in normal cell strains and includes altered cell morphology and gene expression patterns. Telomeres shorten with in vitro passaging of both WRN and normal cell strains; however, the rate of shortening has been reported to be faster in WRN cell strains, and the length of telomeres in senescent WRN cells appears to be longer than that observed in normal strains, leading to the suggestion that senescence in WRN cell strains may not be exclusively associated with telomere effects. We report here that the telomere restriction fragment length in senescent WRN fibroblasts cultures is within the size range observed for normal fibroblasts strains and that the expression of a telomerase transgene in WRN cell strains results in lengthened telomeres and replicative immortalization, thus indicating that telomere effects are the predominant trigger of premature senescence in WRN cells, Microarray analyses showed that mRNA expression patterns induced in senescent WRN cells appeared similar to those in normal strains and that hTERT expression could prevent the induction of most of these genes. However, substantial differences in expression were seen in comparisons of early-passage and telomerase-immortalized derivative lines, indicating that telomerase expression does not prevent the phenotypic drift, or destabilized genotype, resulting from the WRN defect.	Geron Corp, Menlo Park, CA 94025 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA	Geron Corporation; University of Washington; University of Washington Seattle	Choi, DH (corresponding author), Geron Corp, 230 Constitut Dr, Menlo Park, CA 94025 USA.	dchoi@geron.com			NIA NIH HHS [R01 AG14446] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG014446] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Balajee AS, 1999, MOL BIOL CELL, V10, P2655, DOI 10.1091/mbc.10.8.2655; Bennett SE, 1997, CANCER RES, V57, P2956; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; Funk WD, 2000, EXP CELL RES, V258, P270, DOI 10.1006/excr.2000.4945; GEBHART E, 1988, HUM GENET, V80, P135, DOI 10.1007/BF00702855; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; HOEHN H, 1975, CYTOGENET CELL GENET, V15, P282, DOI 10.1159/000130526; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Kodama S, 1998, CANCER RES, V58, P5188; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; Lebel M, 1998, P NATL ACAD SCI USA, V95, P13097, DOI 10.1073/pnas.95.22.13097; LeckaCzernik B, 1996, EXP GERONTOL, V31, P159, DOI 10.1016/0531-5565(95)02014-4; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; Martin GM, 1997, MOL MED, V3, P356, DOI 10.1007/BF03401682; Matsumoto T, 1997, NAT GENET, V16, P335, DOI 10.1038/ng0897-335; Mukherjee AB, 1997, EXP CELL RES, V235, P161, DOI 10.1006/excr.1997.3673; Oshima J, 1996, HUM MOL GENET, V5, P1909, DOI 10.1093/hmg/5.12.1909; Ouellette MM, 2000, HUM MOL GENET, V9, P403, DOI 10.1093/hmg/9.3.403; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; SALK D, 1981, HUM GENET, V58, P310, DOI 10.1007/BF00294930; SCAPPATICCI S, 1982, HUM GENET, V62, P16, DOI 10.1007/BF00295599; SCHONBERG S, 1984, AM J HUM GENET, V36, P387; Schulz VP, 1996, HUM GENET, V97, P750; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; Suzuki N, 1999, NUCLEIC ACIDS RES, V27, P2361, DOI 10.1093/nar/27.11.2361; THOMPSON KVA, 1983, GERONTOLOGY, V29, P73, DOI 10.1159/000213096; Von Zglinicki T, 2000, FREE RADICAL BIO MED, V28, P64, DOI 10.1016/S0891-5849(99)00207-5; VONZGLINICKI T, 1995, EXP CELL RES, V220, P168; Webb DK, 1996, EXP CELL RES, V224, P272, DOI 10.1006/excr.1996.0137; Wyllie FS, 2000, NAT GENET, V24, P16, DOI 10.1038/71630; YANG L, 2000, GENETICS, V154, P357; Yu CE, 1997, AM J HUM GENET, V60, P330; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	39	61	62	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2001	15	6					1014	1020		10.1096/fj.00-0104com	http://dx.doi.org/10.1096/fj.00-0104com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292662				2022-12-28	WOS:000167959300016
J	De Wit, R; Makkinje, M; Boonstra, J; Verkleij, AJ; Post, JA				De Wit, R; Makkinje, M; Boonstra, J; Verkleij, AJ; Post, JA			Hydrogen peroxide reversibly inhibits epidermal growth factor (EGF) receptor internalization and coincident ubiquitination of the EGF receptor and Eps15	FASEB JOURNAL			English	Article									Univ Utrecht, Dept Mol Cell Biol, Inst Biomembranes, NL-3584 CH Utrecht, Netherlands	Utrecht University	De Wit, R (corresponding author), Univ Utrecht, Dept Mol Cell Biol, Inst Biomembranes, Padualaan 8, NL-3584 CH Utrecht, Netherlands.		Post, Jan A/B-7547-2011	Post, Jan A/0000-0003-3048-335X					0	26	27	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					306	308						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156945				2022-12-28	WOS:000166872900011
J	Von Knethen, A; Brune, B				Von Knethen, A; Brune, B			Delayed activation of PPAR gamma by LPS and IFN-gamma attenuates the oxidative burst in macrophages	FASEB JOURNAL			English	Article						anti-inflammatory; sepsis; desensitization; respiratory burst	RECEPTOR-GAMMA; SEPTIC SHOCK; IN-VITRO; EXPRESSION; MECHANISMS; MONOCYTES; APOPTOSIS; ENDOTOXIN; ALPHA; CELLS	Desensitization of macrophages is important during the development of sepsis. It was our intention to identify mechanisms that promote macrophage deactivation upon contact with endotoxin (LPS) and interferon-gamma (IFN-gamma) in vitro. Macrophage activation was achieved with 12-O-tetradecanoylphorbol 13-acetate (TPA), and the oxidative burst (i.e., oxygen radical formation) was followed by oxidation of the redox-sensitive dyes hydroethidine and dichlorodihy-drofluorescein diacetate, Prestimulation of macrophages for 15 h with a combination of LPS/IFN-gamma attenuated oxygen radical formation in response to TPA, Taking the anti-inflammatory properties of the peroxisome proliferator-activating receptory (PPAR gamma) into consideration, we established activation of PPAR gamma in response to LPS/IFN-gamma by an electrophoretic mobility shift, supershift, and a reporter gene assay. The reporter contains a triple PPAR-responsive element (PPRE) in front of a thymidine kinase minimal promoter driving the luciferase gene, We demonstrated that PPRE decoy oligonucleotides, supplied in front of LPS/IFN-gamma, allowed a full oxidative burst to recover upon TPA addition, Furthermore, we suppressed the oxidative burst by using the PPAR gamma agonists 15-deoxy-Delta (12,14)-prostaglandin J(2), BRL. 49653, or ciglitazone. No effect was observed with WY 14643, a PPAR alpha agonist, We conclude that activation of PPARs, most likely PPAR gamma, promotes macrophage desensitization, thus attenuating the oxidative burst, This process appears important during development of sepsis.	Univ Erlangen Nurnberg, Fac Med, Dept Med 4, Expt Div, D-91054 Erlangen, Germany	University of Erlangen Nuremberg	Brune, B (corresponding author), Univ Erlangen Nurnberg, Fac Med, Dept Med 4, Expt Div, Loschgestrasse 8, D-91054 Erlangen, Germany.	mfm423@rzmail.uni-erlangen.de						Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; ALBINA JE, 1993, J IMMUNOL, V150, P5080; Arakawa T, 1996, J BIOL CHEM, V271, P29569, DOI 10.1074/jbc.271.47.29569; Beutler B, 2000, CURR OPIN IMMUNOL, V12, P20, DOI 10.1016/S0952-7915(99)00046-1; BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549; Camandola S, 1996, BIOCHEM BIOPH RES CO, V229, P643, DOI 10.1006/bbrc.1996.1857; CAVAILLON JM, 1995, TRENDS MICROBIOL, V3, P320, DOI 10.1016/S0966-842X(00)88963-5; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; COHEN J, 1991, LANCET, V338, P736, DOI 10.1016/0140-6736(91)91453-2; Colville-Nash PR, 1998, J IMMUNOL, V161, P978; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Gantner F, 1997, BRIT J PHARMACOL, V121, P221, DOI 10.1038/sj.bjp.0701124; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; Herschman HR, 1997, ADV EXP MED BIOL, V407, P61; Hoshino K, 1999, J IMMUNOL, V162, P3749; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Imrich A, 1999, J LEUKOCYTE BIOL, V65, P499, DOI 10.1002/jlb.65.4.499; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Karp CL, 1998, EUR J IMMUNOL, V28, P3128, DOI 10.1002/(SICI)1521-4141(199810)28:10<3128::AID-IMMU3128>3.0.CO;2-T; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kwon G, 1999, J BIOL CHEM, V274, P18702, DOI 10.1074/jbc.274.26.18702; Leininger MT, 1999, BIOCHEM BIOPH RES CO, V263, P749, DOI 10.1006/bbrc.1999.1467; Michalik L, 1999, CURR OPIN BIOTECH, V10, P564, DOI 10.1016/S0958-1669(99)00030-0; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; Paludan SR, 2000, J LEUKOCYTE BIOL, V67, P18, DOI 10.1002/jlb.67.1.18; RAETZ CRH, 1991, FASEB J, V5, P2652, DOI 10.1096/fasebj.5.12.1916089; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Schoonbroodt S, 1997, BIOCHEM J, V321, P777, DOI 10.1042/bj3210777; Schulman IG, 1998, MOL CELL BIOL, V18, P3483, DOI 10.1128/MCB.18.6.3483; Spiegelman BM, 1998, CELL, V93, P153, DOI 10.1016/S0092-8674(00)81567-6; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Thieringer R, 2000, J IMMUNOL, V164, P1046, DOI 10.4049/jimmunol.164.2.1046; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Vadiveloo PK, 1999, J LEUKOCYTE BIOL, V66, P579, DOI 10.1002/jlb.66.4.579; Vamecq J, 1999, LANCET, V354, P141, DOI 10.1016/S0140-6736(98)10364-1; von Knethen A, 1998, ONCOGENE, V17, P387, DOI 10.1038/sj.onc.1201926; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118; Wang LH, 2000, BLOOD, V95, P1249, DOI 10.1182/blood.V95.4.1249.004k39_1249_1257; ZIEGLERHEITBROCK HWL, 1995, J INFLAMM, V45, P13	43	70	70	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2001	15	2					535	544		10.1096/fj.00-0187com	http://dx.doi.org/10.1096/fj.00-0187com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156969				2022-12-28	WOS:000166872900035
J	Freedman, JE; Li, LQ; Sauter, R; Keaney, JF				Freedman, JE; Li, LQ; Sauter, R; Keaney, JF			alpha-tocopherol and protein kinase C inhibition enhance platelet-derived nitric oxide release	FASEB JOURNAL			English	Article									Georgetown Univ, Med Ctr, Dept Pharmacol, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20007 USA; Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Boston Univ, Sch Med, Evans Dept Med, Boston, MA 02118 USA	Georgetown University; Georgetown University; Boston University; Boston University	Freedman, JE (corresponding author), Georgetown Univ, Med Ctr, Dept Pharmacol, Med Dent Bldg,Rm NE 403,3900 Reservoir Rd NW, Washington, DC 20007 USA.								0	54	56	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2377	2379						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11024007				2022-12-28	WOS:000165723400003
J	Miao, HQ; Lee, P; Lin, H; Soker, S; Klagsbrun, M				Miao, HQ; Lee, P; Lin, H; Soker, S; Klagsbrun, M			Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression	FASEB JOURNAL			English	Article						VEGF; VEGF receptors; motility; prostate carcinoma	ENDOTHELIAL GROWTH-FACTOR; FACTOR VEGF; MEMBRANE-PROTEIN; TYROSINE KINASE; FACTOR RECEPTOR; IN-VIVO; IDENTIFICATION; INHIBITION; FACTOR-2; PROLIFERATION	Neuropilin-1 (NRP1) is a VEGF(165) and semaphorin receptor expressed by vascular endothelial cells (EC) and tumor cells. The function of NRP1 in tumor cells is unknown, NRP1 was overexpressed in Dunning rat prostate carcinoma AT2.1 cells using a tetracycline-inducible promoter. Concomitant with increased NRP1 expression in response to a tetracycline homologue, doxycycline (Dox), basal cell. motility, and VEGF(165) binding were increased three- to fourfold in vitro, However, induction of NRP1 did not affect tumor cell proliferation. When rats injected with AT2.1/NRP1 tumor cells were fed Dox, NRP1 synthesis was induced in vivo and AT2.1 cell tumor size was increased 2.5- to 7-fold in a 3-4 wk period compared to controls. The larger tumors with induced NRP1 expression were characterized by markedly increased microvessel density, increased proliferating EC, dilated blood vessels, and notably less tumor cell apoptosis compared to noninduced controls. It was concluded that NRP1 expression results in enlarged tumors associated with substantially enhanced tumor angiogenesis.	Childrens Hosp, Dept Surg Res, Boston, MA 02115 USA; Childrens Hosp, Dept Urol, Boston, MA 02115 USA; Childrens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Klagsbrun, M (corresponding author), Childrens Hosp, Dept Surg Res, Room 1061,300 Longwood Ave, Boston, MA 02115 USA.	klagsbrun@a1.tch.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA037392, R56CA037392, R37CA037392, P01CA045548] Funding Source: NIH RePORTER; NCI NIH HHS [CA45548, CA37392] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bao LR, 1996, NAT MED, V2, P1322, DOI 10.1038/nm1296-1322; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dor Y, 1997, TRENDS CARDIOVAS MED, V7, P289, DOI 10.1016/S1050-1738(97)00091-1; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Fujisawa H, 1995, DEV NEUROSCI-BASEL, V17, P343, DOI 10.1159/000111304; Gagnon ML, 2000, P NATL ACAD SCI USA, V97, P2573, DOI 10.1073/pnas.040337597; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Giger RJ, 1998, NEURON, V21, P1079, DOI 10.1016/S0896-6273(00)80625-X; Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P18040, DOI 10.1074/jbc.M909259199; Goldman CK, 1998, P NATL ACAD SCI USA, V95, P8795, DOI 10.1073/pnas.95.15.8795; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kawakami A, 1996, J NEUROBIOL, V29, P1, DOI 10.1002/(SICI)1097-4695(199601)29:1<1::AID-NEU1>3.0.CO;2-F; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; Kendall RL, 1996, BIOCHEM BIOPH RES CO, V226, P324, DOI 10.1006/bbrc.1996.1355; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Kitsukawa T, 1995, DEVELOPMENT, V121, P4309; Klagsbrun M, 1999, CHEM BIOL, V6, pR217, DOI 10.1016/S1074-5521(99)80081-7; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Kolodkin AL, 1996, TRENDS NEUROSCI, V19, P507, DOI 10.1016/S0166-2236(96)10057-6; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Makinen T, 1999, J BIOL CHEM, V274, P21217, DOI 10.1074/jbc.274.30.21217; Miao HQ, 1997, J CLIN INVEST, V99, P1565, DOI 10.1172/JCI119319; Miao HQ, 1999, J CELL BIOL, V146, P233, DOI 10.1083/jcb.146.1.233; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Presta LG, 1997, CANCER RES, V57, P4593; Salven P, 1998, AM J PATHOL, V153, P103, DOI 10.1016/S0002-9440(10)65550-2; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Soker S, 1997, J BIOL CHEM, V272, P31582, DOI 10.1074/jbc.272.50.31582; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; Sondell M, 1999, BRAIN RES, V846, P219, DOI 10.1016/S0006-8993(99)02056-9; Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Tordjman R, 1999, BLOOD, V94, P2301, DOI 10.1182/blood.V94.7.2301.419k24_2301_2309; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988	48	248	264	1	20	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2000	14	15					2532	2539		10.1096/fj.00-0250com	http://dx.doi.org/10.1096/fj.00-0250com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099472				2022-12-28	WOS:000165723400024
J	Parsons, SM				Parsons, SM			Transport mechanisms in acetylcholine and monoamine storage	FASEB JOURNAL			English	Review						vesicular acetylcholine transporter; vesicular monoamine transporter neurotransmitter transport	CHOLINERGIC SYNAPTIC VESICLES; VESICULAR NEUROTRANSMITTER TRANSPORTERS; CHROMAFFIN GRANULE MEMBRANES; VESAMICOL RECEPTOR; AMINE TRANSPORTER; SUBSTRATE RECOGNITION; RESERPINE BINDING; ACTIVE-TRANSPORT; CATECHOLAMINE TRANSPORTER; RESIDUES CONTRIBUTE	Sequence-related vesicular acetylcholine transporter (VAChT) and vesicular monoamine transporter (VMAT) transport neurotransmitter substrates into secretory vesicles. This review seeks to identify shared and differentiated aspects of the transport mechanisms. VAChT and VMAT exchange two protons per substrate molecule with very similar initial velocity kinetics and pH dependencies. However, vesicular gradients of ACh in vivo are much smaller than the driving force for uptake and vesicular gradients of monoamines, suggesting the existence of a regulatory mechanism in ACh storage not found in monoamine storage, The importance of microscopic rather than macroscopic kinetics in structure-function analysis is described, Transporter regions affecting binding or translocation of substrates, inhibitors, and protons have been found with photoaffinity labeling, chimeras, and single-site mutations, VAChT and VMAT exhibit partial structural and mechanistic homology with lactose permease, which belongs to the same sequence-defined superfamily, despite opposite directions of substrate transport. The vesicular transporters translocate the first proton using homologous aspartates in putative transmembrane domain X (ten), but they translocate the second proton using unknown residues that might not be conserved between them. Comparative analysis of the VAChT and VMAT transport mechanisms will aid understanding of regulation in neurotransmitter storage.	Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Program Biochem & Mol Biol, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Parsons, SM (corresponding author), Univ Calif Santa Barbara, Dept Chem & Biochem, Santa Barbara, CA 93106 USA.	parsons@chem.ucsb.edu		Parsons, Stanley/0000-0001-7097-8221	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015047] Funding Source: NIH RePORTER; NINDS NIH HHS [NS15047] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALFONSO A, 1993, SCIENCE, V261, P617, DOI 10.1126/science.8342028; ANDERSON DC, 1986, J NEUROCHEM, V46, P1207, DOI 10.1111/j.1471-4159.1986.tb00639.x; ANDERSON GC, 1982, RES NURS HEALTH, V5, P21, DOI 10.1002/nur.4770050105; BAGWELL EE, 1989, J PHARMACOL EXP THER, V249, P476; BAHR BA, 1992, BIOCHEMISTRY-US, V31, P5752, DOI 10.1021/bi00140a010; BAHR BA, 1986, P NATL ACAD SCI USA, V83, P2267, DOI 10.1073/pnas.83.7.2267; BAHR BA, 1986, J NEUROCHEM, V46, P1214, DOI 10.1111/j.1471-4159.1986.tb00640.x; CHAPLIN L, 1985, J BIOL CHEM, V260, P981; CLARKSON ED, 1992, J NEUROCHEM, V59, P695, DOI 10.1111/j.1471-4159.1992.tb09424.x; CLARKSON ED, 1993, J NEUROCHEM, V61, P22, DOI 10.1111/j.1471-4159.1993.tb03534.x; DARCHEN F, 1989, BIOCHEMISTRY-US, V28, P1692, DOI 10.1021/bi00430a040; DARCHEN F, 1988, MOL PHARMACOL, V33, P672; DARCHEN F, 1988, BIOCHEM PHARMACOL, V37, P4381, DOI 10.1016/0006-2952(88)90621-1; DIEBLER MF, 1992, NEUROCHEM INT, V21, P83, DOI 10.1016/0197-0186(92)90070-8; Duerr JS, 1999, J NEUROSCI, V19, P72, DOI 10.1523/JNEUROSCI.19-01-00072.1999; Erickson J D, 1998, Adv Pharmacol, V42, P227; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; Finn JP, 1998, J BIOL CHEM, V273, P3943, DOI 10.1074/jbc.273.7.3943; Finn JP, 1997, J BIOL CHEM, V272, P16301, DOI 10.1074/jbc.272.26.16301; FLOOR E, 1995, J NEUROCHEM, V64, P689; GASNIER B, 1986, MOL PHARMACOL, V29, P275; GASNIER B, 1987, FEBS LETT, V222, P215, DOI 10.1016/0014-5793(87)80222-3; GRACZ LM, 1988, BIOCHEMISTRY-US, V27, P5268, DOI 10.1021/bi00414a048; He MM, 1997, BIOCHEMISTRY-US, V36, P13688, DOI 10.1021/bi9715324; Henry J P, 1998, Adv Pharmacol, V42, P236; Henry JP, 1998, NEUROCHEM INT, V32, P227, DOI 10.1016/S0197-0186(97)00092-2; Kaback HR, 1999, ACCOUNTS CHEM RES, V32, P805, DOI 10.1021/ar970256i; KAUFMAN R, 1989, MOL PHARMACOL, V36, P452; Keller JE, 2000, NEUROCHEM INT, V36, P113, DOI 10.1016/S0197-0186(99)00110-2; Keller JE, 2000, J NEUROCHEM, V74, P1739, DOI 10.1046/j.1471-4159.2000.0741739.x; Kim MH, 2000, J BIOL CHEM, V275, P6175, DOI 10.1074/jbc.275.9.6175; Kim MH, 1999, J BIOL CHEM, V274, P673, DOI 10.1074/jbc.274.2.673; KOBOLD G, 1985, N-S ARCH PHARMACOL, V331, P209, DOI 10.1007/BF00634240; KOENIGSBERGER R, 1980, BIOCHEM BIOPH RES CO, V94, P305, DOI 10.1016/S0006-291X(80)80221-X; KORNREICH WD, 1988, BIOCHEMISTRY-US, V27, P5262, DOI 10.1021/bi00414a047; LEWIS K, 1994, TRENDS BIOCHEM SCI, V19, P119, DOI 10.1016/0968-0004(94)90204-6; LINIAL M, 1993, TRENDS BIOCHEM SCI, V18, P248, DOI 10.1016/0968-0004(93)90173-K; Liu YJ, 1996, BEHAV BRAIN RES, V73, P51; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; MERICKEL A, 1995, J BIOL CHEM, V270, P25798, DOI 10.1074/jbc.270.43.25798; Merickel A, 1997, J BIOL CHEM, V272, P5403, DOI 10.1074/jbc.272.9.5403; MERICKEL A, 1995, NEUROPHARMACOLOGY, V34, P1543, DOI 10.1016/0028-3908(95)00148-Y; MICHALKE W, 1990, N-S ARCH PHARMACOL, V342, P312; NEAR JA, 1983, FEBS LETT, V158, P31, DOI 10.1016/0014-5793(83)80670-X; NEAR JA, 1986, MOL PHARMACOL, V30, P252; Nguyen ML, 1998, BIOCHEMISTRY-US, V37, P13400, DOI 10.1021/bi9802263; NGUYEN ML, 1995, J NEUROCHEM, V64, P1137; NOREMBERG K, 1989, J NEUROCHEM, V52, P913, DOI 10.1111/j.1471-4159.1989.tb02542.x; PARSONS SM, 1993, INT REV NEUROBIOL, V35, P279, DOI 10.1016/S0074-7742(08)60572-3; Peter D, 1996, J BIOL CHEM, V271, P2979, DOI 10.1074/jbc.271.6.2979; PETER D, 1994, J BIOL CHEM, V269, P7231; Reimer RJ, 1998, CURR OPIN NEUROBIOL, V8, P405, DOI 10.1016/S0959-4388(98)80068-8; ROGERS GA, 1989, MOL PHARMACOL, V36, P333; ROGERS GA, 1989, J MED CHEM, V32, P1217, DOI 10.1021/jm00126a013; ROGERS GA, 1993, MOL PHARMACOL, V44, P633; Romanenko VG, 1998, ANAL BIOCHEM, V257, P127, DOI 10.1006/abio.1997.2546; Rudnick G, 1998, J BIOENERG BIOMEMBR, V30, P173, DOI 10.1023/A:1020573325823; RUDNICK G, 1990, BIOCHEMISTRY-US, V29, P603, DOI 10.1021/bi00455a002; RUDNICK G, 1989, J BIOL CHEM, V264, P14865; Sagne C, 1997, BIOCHEMISTRY-US, V36, P3345, DOI 10.1021/bi9623439; SCHERMAN D, 1984, MOL PHARMACOL, V25, P113; SCHERMAN D, 1983, MOL PHARMACOL, V23, P431; SCHERMAN D, 1981, EUR J BIOCHEM, V116, P535, DOI 10.1111/j.1432-1033.1981.tb05369.x; SCHULDINER S, 1994, J NEUROCHEM, V62, P2067; Schuldiner S, 1998, Adv Pharmacol, V42, P223; SCHULDINER S, 1995, PHYSIOL REV, V75, P369, DOI 10.1152/physrev.1995.75.2.369; SHIRVAN A, 1994, FEBS LETT, V356, P145, DOI 10.1016/0014-5793(94)01252-0; Sievert MK, 1997, J BIOL CHEM, V272, P26049, DOI 10.1074/jbc.272.41.26049; Song HJ, 1997, NEURON, V18, P815, DOI 10.1016/S0896-6273(00)80320-7; SteinerMordoch S, 1996, J BIOL CHEM, V271, P13048, DOI 10.1074/jbc.271.22.13048; SUCHI R, 1992, BIOCHEMISTRY-US, V31, P12500, DOI 10.1021/bi00164a029; SUCHI R, 1991, BIOCHEMISTRY-US, V30, P6490, DOI 10.1021/bi00240a020; Sulzer D, 2000, REV NEUROSCIENCE, V11, P159; Travis ER, 2000, P NATL ACAD SCI USA, V97, P162, DOI 10.1073/pnas.97.1.162; VANDERKLOOT W, 1991, PROG NEUROBIOL, V36, P93, DOI 10.1016/0301-0082(91)90019-W; VANDYKE RW, 1990, J INTERN MED, V228, P41, DOI 10.1111/j.1365-2796.1990.tb01470.x; Varoqui H, 1997, MOL NEUROBIOL, V15, P165, DOI 10.1007/BF02740633; Varoqui H, 1996, J BIOL CHEM, V271, P27229, DOI 10.1074/jbc.271.44.27229; Varoqui H, 1998, J PHYSIOLOGY-PARIS, V92, P141, DOI 10.1016/S0928-4257(98)80152-6; VIITANEN P, 1986, METHOD ENZYMOL, V125, P429; Wang QD, 1999, BIOCHEMISTRY-US, V38, P16777, DOI 10.1021/bi991853a; WHITTAKER VP, 1987, ANN NY ACAD SCI, V493, P77, DOI 10.1111/j.1749-6632.1987.tb27185.x; Williams J, 1997, NEURON, V18, P683, DOI 10.1016/S0896-6273(00)80308-6; Wu JH, 1998, J MOL BIOL, V282, P959, DOI 10.1006/jmbi.1998.2065	84	131	139	2	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2000	14	15					2423	2434		10.1096/fj.00-0203rev	http://dx.doi.org/10.1096/fj.00-0203rev			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099460				2022-12-28	WOS:000165723400012
J	Rosati, B; Marchetti, P; Crociani, O; Lecchi, M; Lupi, R; Arcangeli, A; Olivotto, M; Wanke, E				Rosati, B; Marchetti, P; Crociani, O; Lecchi, M; Lupi, R; Arcangeli, A; Olivotto, M; Wanke, E			Glucose- and arginine-induced insulin secretion by human pancreatic beta-cells: the role of HERG K+ channels in firing and release	FASEB JOURNAL			English	Article						pancreas; eag gene family; erg gene; nesidioblastosis	PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA; ISLET B-CELLS; POTASSIUM CHANNEL; ELECTRICAL-ACTIVITY; ACTION-POTENTIALS; VENTRICULAR MYOCYTES; I-KR; CURRENTS; CALCIUM; MOUSE	The human ether-a-go-go-related genes (herg) are expressed in tissues other than heart and brain where the HERG K+ channels are known to regulate the repolarization of the heart action potential and the neuronal spike-frequency accommodation. We provide evidence that herg1 transcripts are present in human pancreatic islets that were used to study both insulin secretion and electrical activity with radioimmunoassay and single cell perforated patch-clamp techniques, respectively. Glucose- and arginine-induced islets insulin secretion data suggested a net increase of release under perfusion with antiarrhythmic drug known to selectively block HERG channels. Indeed we could routinely isolate a K+ current that was recognized as biophysically and pharmacologically similar to the HERG current. An analysis of the glucose- and arginine-induced electrical activity (several applications during 30 min) in terms of firing frequency and putative insulin release was done in control and in the presence of selective blockers of HERG channels: the firing frequency and the release increased by 32% and 77%, respectively. It is concluded that HERG channels have a crucial role in regulating insulin secretion and firing of human beta -cells. This raises the possibility that some genetically characterized hyperinsulinemic diseases of unknown origin might involve mutations in the HERG channels.	Univ Milan, Dipartimento Biotecnol & Biosci, I-20126 Milan, Italy; Osped Cisanello, Dept Endocrinol & Metab, Metab Unit, I-56100 Pisa, Italy; Univ Florence, Dept Expt Pathol & Oncol, I-50134 Florence, Italy	University of Milan; University of Florence	Wanke, E (corresponding author), Univ Milan, Dipartimento Biotecnol & Biosci, Piazza Sci 2, I-20126 Milan, Italy.		Marchetti, Piero/J-7439-2013	Marchetti, Piero/0000-0003-4907-0635; Crociani, Olivia/0000-0003-3485-2132	Telethon [1046] Funding Source: Medline	Telethon(Fondazione Telethon)		AMMALA C, 1993, J PHYSIOL-LONDON, V472, P665, DOI 10.1113/jphysiol.1993.sp019966; Arcangeli A, 1995, J PHYSIOL-LONDON, V489, P455, DOI 10.1113/jphysiol.1995.sp021065; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; Barbosa RM, 1998, J PHYSIOL-LONDON, V510, P135, DOI 10.1111/j.1469-7793.1998.135bz.x; Barnett DW, 1995, PFLUG ARCH EUR J PHY, V431, P272, DOI 10.1007/BF00410201; Bolea S, 1997, PFLUG ARCH EUR J PHY, V433, P699, DOI 10.1007/s004240050334; Chiesa N, 1997, J PHYSIOL-LONDON, V501, P313, DOI 10.1111/j.1469-7793.1997.313bn.x; Chouabe C, 1998, MOL PHARMACOL, V54, P695; Conget I, 1997, PANCREAS, V14, P71, DOI 10.1097/00006676-199701000-00011; DIXON JE, 1994, CIRC RES, V75, P252, DOI 10.1161/01.RES.75.2.252; DUNNE MJ, 1990, J MEMBRANE BIOL, V114, P53, DOI 10.1007/BF01869384; FALKE LC, 1989, FEBS LETT, V251, P167, DOI 10.1016/0014-5793(89)81448-6; Faravelli L, 1996, J PHYSIOL-LONDON, V496, P13, DOI 10.1113/jphysiol.1996.sp021661; GILLIS KD, 1992, PFLUG ARCH EUR J PHY, V420, P121, DOI 10.1007/BF00378654; Gopel SO, 1999, J GEN PHYSIOL, V114, P759, DOI 10.1085/jgp.114.6.759; Gurrola GB, 1999, FASEB J, V13, P953, DOI 10.1096/fasebj.13.8.953; KELLY RP, 1991, J PHYSIOL-LONDON, V443, P175, DOI 10.1113/jphysiol.1991.sp018829; KINDMARK H, 1991, FEBS LETT, V291, P310, DOI 10.1016/0014-5793(91)81309-V; Kukuvitis A, 1997, J CLIN ENDOCR METAB, V82, P1192, DOI 10.1210/jc.82.4.1192; LEFEBVRE PJ, 1997, DIABETES MELITUS, P1307; Macfarlane WM, 1997, FEBS LETT, V413, P304, DOI 10.1016/S0014-5793(97)00874-0; MAGISTRETTI J, 1996, TRENDS NEUROSCI, V19, P531; MARCHETTI P, 1995, DIABETES, V44, P375, DOI 10.2337/diabetes.44.4.375; MISLER S, 1992, DIABETES, V41, P1221, DOI 10.2337/diabetes.41.10.1221; Nadal A, 1999, J PHYSIOL-LONDON, V517, P85, DOI 10.1111/j.1469-7793.1999.0085z.x; Paquette T, 1998, BIOPHYS J, V74, P1278, DOI 10.1016/S0006-3495(98)77841-5; PRESSEL DM, 1990, J MEMBRANE BIOL, V116, P273, DOI 10.1007/BF01868466; Pupilli C, 1999, DIABETES, V48, P2309, DOI 10.2337/diabetes.48.12.2309; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; SANTOS RM, 1991, PFLUG ARCH EUR J PHY, V418, P417, DOI 10.1007/BF00550880; Schonherr R, 1999, EUR J NEUROSCI, V11, P753, DOI 10.1046/j.1460-9568.1999.00493.x; Service FJ, 1999, J CLIN ENDOCR METAB, V84, P1582, DOI 10.1210/jc.84.5.1582; Sherman A, 1996, AM J PHYSIOL-ENDOC M, V271, pE362, DOI 10.1152/ajpendo.1996.271.2.E362; Shi WM, 1997, J NEUROSCI, V17, P9423; SMITH PA, 1995, PFLUG ARCH EUR J PHY, V430, P808, DOI 10.1007/BF00386180; SPINELLI W, 1993, CARDIOVASC RES, V27, P1580, DOI 10.1093/cvr/27.9.1580; SUTTON RP, 1991, J PHYSL, V443, P175; Thomas P, 1996, HUM MOL GENET, V5, P1809, DOI 10.1093/hmg/5.11.1809; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; Titus SA, 1997, J NEUROSCI, V17, P875; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438	42	118	122	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2601	2610		10.1096/fj.00-0077com	http://dx.doi.org/10.1096/fj.00-0077com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099479				2022-12-28	WOS:000165723400031
J	Reshkin, SJ; Bellizzi, A; Caldeira, S; Albarani, V; Malanchi, I; Poignee, M; Alunni-Fabbroni, M; Casavola, V; Tommasino, M				Reshkin, SJ; Bellizzi, A; Caldeira, S; Albarani, V; Malanchi, I; Poignee, M; Alunni-Fabbroni, M; Casavola, V; Tommasino, M			Na+/H+ exchanger-dependent intracellular alkalinization is an early event in malignant transformation and plays an essential role in the development of subsequent transformation-associated phenotypes	FASEB JOURNAL			English	Article						cytoplasmic alkalinization; NHE-1; HPV16 E7 oncoprotein	HPV16 E7 PROTEIN; DNA-SYNTHESIS; TUMOR-CELLS; IN-VITRO; PH; FIBROBLASTS; BINDING; REQUIREMENT; INHIBITION; METABOLISM	In this study we investigate the mechanism of intracellular pH change and its role in malignant transformation using the E7 oncogene of human papillomavirus type 16 (HPV16). Infecting NIH3T3 cells with recombinant retroviruses expressing the HPV16 E7 or a transformation deficient mutant we show that alkalinization is transformation specific. In NIH3T3 cells in which transformation can be turned on and followed by induction of the HPV16 E7 oncogene expression, we demonstrate that cytoplasmic alkalinization is an early event and was driven by stimulation of Na+/H+ exchanger activity via an increase in the affinity of the intracellular NHE-1 proton regulatory site. Annulment of the E7-induced cytoplasmic alkalinization by specific inhibition of the NHE-1, acidification of culture medium, or clamping the pHi to nontransformed levels prevented the development of later transformed phenotypes such as increased growth rate, serum-independent growth, anchorage-independent growth, and glycolytic metabolism. These findings were verified in human keratinocytes (HPKIA), the natural host of HPV. Results from both NIH3T3 and HPKIA cells show that alkalinization acts on pathways that are independent of the E2F-mediated transcriptional activation of cell cycle regulator genes. Moreover, we show that the transformation-dependent increase in proliferation is independent of the concomitant stimulation of glycolysis. Finally, treatment of nude mice with the specific inhibitor of NHE-1, DMA, delayed the development of HPV16-keratinocyte tumors. Our data confirm that activation of the NHE-1 and resulting cellular alkalinization is a key mechanism in oncogenic transformation and is necessary for the development and maintenance of the transformed phenotype.	Deutsch Krebsforschungszentrum, Angew Tumorvirol, D-69120 Heidelberg, Germany; Univ Bari, Dept Gen & Environm Physiol, Bari, Italy	Helmholtz Association; German Cancer Research Center (DKFZ); Universita degli Studi di Bari Aldo Moro	Tommasino, M (corresponding author), Deutsch Krebsforschungszentrum, Angew Tumorvirol, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.		Caldeira, Sandra/Y-3652-2019; Reshkin, Stephan/AAI-6680-2020; paradiso, angelo V/J-9457-2018	Caldeira, Sandra/0000-0002-6057-5979; Reshkin, Stephan/0000-0001-9757-5908; CASAVOLA, Valeria/0000-0003-4471-4948				BANKS L, 1990, ONCOGENE, V5, P1383; BARRY MA, 1993, CANCER RES, V53, P2349; BELT JA, 1979, BIOCHEMISTRY-US, V18, P3506, DOI 10.1021/bi00583a011; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; Botz J, 1996, MOL CELL BIOL, V16, P3401; BRANDT RB, 1982, METHOD ENZYMOL, V89, P35; BUSTAMANTE E, 1981, J BIOL CHEM, V256, P8699; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; Durst M, 1995, CANCER GENET CYTOGEN, V85, P105, DOI 10.1016/0165-4608(95)00155-7; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; GILLIES RJ, 1990, P NATL ACAD SCI USA, V87, P7414, DOI 10.1073/pnas.87.19.7414; HAGAG N, 1987, MOL CELL BIOL, V7, P1984, DOI 10.1128/MCB.7.5.1984; HARGUINDEY S, 1995, CRIT REV ONCOGENESIS, V6, P1; HU TH, 1995, INT J ONCOL, V6, P167; KAPLAN DL, 1994, J BIOL CHEM, V269, P4116; KOUZARIDES T, 1995, SEMIN CANCER BIOL, V6, P91, DOI 10.1006/scbi.1995.0012; KRAYERPAWLOWSKA D, 1991, J MEMBRANE BIOL, V120, P173, DOI 10.1007/BF01872400; LALLEMAIN G, 1984, J BIOL CHEM, V259, P4313; LI JF, 1995, J BIOL CHEM, V270, P3203, DOI 10.1074/jbc.270.7.3203; MAIDORN RP, 1993, BRIT J CANCER, V67, P297, DOI 10.1038/bjc.1993.56; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; MONTROSE MH, 1987, J MEMBRANE BIOL, V97, P63, DOI 10.1007/BF01869615; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; PERONA R, 1988, NATURE, V334, P438, DOI 10.1038/334438a0; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; RESHKIN SJ, 1995, INT J ONCOL, V7, P371; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; ROTIN D, 1989, CANCER RES, V49, P205; ROZHIN J, 1994, CANCER RES, V54, P6517; Shrode LD, 1997, J BIOENERG BIOMEMBR, V29, P393, DOI 10.1023/A:1022407116339; SICZKOWSKI M, 1994, AM J PHYSIOL, V267, pC745, DOI 10.1152/ajpcell.1994.267.3.C745; Tedone T, 1996, EUR J CANCER, V32A, P849, DOI 10.1016/0959-8049(95)00660-5; TOMMASINO M, 1993, ONCOGENE, V8, P195; TOMMASINO M, 1995, BIOESSAYS, V17, P509, DOI 10.1002/bies.950170607; Wakabayashi S, 1997, PHYSIOL REV, V77, P51, DOI 10.1152/physrev.1997.77.1.51; WATSON AJM, 1994, BBA-BIOMEMBRANES, V1193, P316, DOI 10.1016/0005-2736(94)90168-6; Webb SD, 1999, J THEOR BIOL, V196, P237, DOI 10.1006/jtbi.1998.0836; Yamagata M, 1996, BRIT J CANCER, V73, P1328, DOI 10.1038/bjc.1996.254	42	297	311	0	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2185	2197		10.1096/fj.00-0029com	http://dx.doi.org/10.1096/fj.00-0029com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053239				2022-12-28	WOS:000165190800011
J	Krebitz, M; Wiedermann, U; Essl, D; Steinkellner, H; Wagner, B; Turpen, TH; Ebner, C; Scheiner, O; Breiteneder, H				Krebitz, M; Wiedermann, U; Essl, D; Steinkellner, H; Wagner, B; Turpen, TH; Ebner, C; Scheiner, O; Breiteneder, H			Rapid production of the major birch pollen allergen Bet v 1 in Nicotiana benthamiana plants and its immunological in vitro and in vivo characterization	FASEB JOURNAL			English	Article						plant expression system; tobacco mosaic virus; recombinant allergen; BALB/c; Th2 response	YEAST PICHIA-PASTORIS; HIGH-LEVEL EXPRESSION; TOBACCO MOSAIC-VIRUS; T-CELL EPITOPES; MURINE MODEL; RECOMBINANT ALLERGENS; OVERLAPPING PEPTIDES; TRANSGENIC PLANTS; IMMUNE-RESPONSE; CDNA CLONING	Type I allergies are immunological disorders that afflict a quarter of the world's population. Improved diagnosis of allergic diseases and the formulation of new therapeutic approaches are based on the use of recombinant allergens. We describe here for the first time the application of a rapid plant-based expression system for a plant-derived allergen and its immunological characterization. We expressed our model allergen Bet v 1, the major birch pollen allergen, in the tobacco-related species Nicotiana benthamiana using a tobacco mosaic virus vector. Two weeks postinoculation, plants infected with recombinant viral RNA containing the Bet v 1 coding sequence accumulated the allergen to levels of 200 mu g/g leaf material. Total nonpurified protein extracts from plants were used for immunological characterizations. IgE immunoblots and ELISA (enzyme-linked immunoassay) inhibition assays showed comparable IgE binding properties for tobacco recombinant (r) Bet v 1 and natural (n) Bet v 1, suggesting that the B cell epitopes were preserved when the allergen was expressed in N. benthamiana plants. Using a murine model of type I allergy, mice immunized with crude leaf extracts containing Bet v 1 with purified rBet v 1 produced in Il: coli or with birch pollen extract generated comparable allergen-specific IgE and IgG1 antibody responses and positive type I skin test reactions. These results demonstrate that nonpurified Bet v 1 overexpressed in N. benthamina has the same immunogenicity as purified Bet v 1 produced in E. coli or nBet v 1. We therefore conclude that this plant expression system offers a viable alternative to fermentation-based production of allergens in bacteria or yeasts. In addition, there may be a broad utility of this system for the development of new and low-cost vaccination strategies against allergy.	Univ Vienna, Dept Pathophysiol, A-1090 Vienna, Austria; Large Scale Biol Corp, Vacaville, CA 95699 USA; Univ Agr Sci, Ctr Appl Genet, A-1190 Vienna, Austria	University of Vienna; University of Natural Resources & Life Sciences, Vienna	Breiteneder, H (corresponding author), Univ Vienna, Dept Pathophysiol, AKH EBO 3Q,Waehringer Guertel 18-20, A-1090 Vienna, Austria.		Steinkellner, Herta/N-4267-2016	Steinkellner, Herta/0000-0003-4823-1505; Wiedermann, Ursula/0000-0002-1302-3223				Arakawa T, 1997, TRANSGENIC RES, V6, P403, DOI 10.1023/A:1018487401810; Bauer L, 1997, CLIN EXP IMMUNOL, V107, P536, DOI 10.1046/j.1365-2249.1997.d01-953.x; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; Casper SJ, 1996, GENE, V173, P69, DOI 10.1016/0378-1119(95)00782-2; EBNER C, 1993, J IMMUNOL, V150, P1047; EBNER C, 1995, J IMMUNOL, V154, P1932; EBNER C, 1993, EUR J IMMUNOL, V23, P1523, DOI 10.1002/eji.1830230719; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; FERREIRA FD, 1993, J BIOL CHEM, V268, P19574; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; GodnicCvar J, 1997, J ALLERGY CLIN IMMUN, V99, P354, DOI 10.1016/S0091-6749(97)70053-8; Hakkaart GAJ, 1998, CLIN EXP ALLERGY, V28, P45, DOI 10.1046/j.1365-2222.1998.00164.x; HAQ TA, 1995, SCIENCE, V268, P714, DOI 10.1126/science.7732379; HoffmannSommergruber K, 1997, PROTEIN EXPRES PURIF, V9, P33, DOI 10.1006/prep.1996.0671; HoffmannSommergruber K, 1997, GENE, V197, P91, DOI 10.1016/S0378-1119(97)00246-1; Hoyne GF, 1996, INT IMMUNOL, V8, P335, DOI 10.1093/intimm/8.3.335; Huecas S, 1999, EUR J BIOCHEM, V261, P539, DOI 10.1046/j.1432-1327.1999.00307.x; IPSEN H, 1983, J ALLERGY CLIN IMMUN, V72, P150, DOI 10.1016/0091-6749(83)90523-7; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; JAROLIM E, 1989, INT ARCH ALLER A IMM, V90, P54, DOI 10.1159/000235000; Koo M, 1999, P NATL ACAD SCI USA, V96, P7774, DOI 10.1073/pnas.96.14.7774; Kraft D, 1999, INT ARCH ALLERGY IMM, V118, P171, DOI 10.1159/000024058; Kraft D, 1998, ALLERGY, V53, P62, DOI 10.1111/j.1398-9995.1998.tb04942.x; KUMAGAI MH, 1993, P NATL ACAD SCI USA, V90, P427, DOI 10.1073/pnas.90.2.427; MASON HS, 1992, P NATL ACAD SCI USA, V89, P11745, DOI 10.1073/pnas.89.24.11745; Mason HS, 1996, P NATL ACAD SCI USA, V93, P5335, DOI 10.1073/pnas.93.11.5335; McCormick AA, 1999, P NATL ACAD SCI USA, V96, P703, DOI 10.1073/pnas.96.2.703; Seymour BWP, 1998, J EXP MED, V187, P721, DOI 10.1084/jem.187.5.721; Smith PM, 1996, J ALLERGY CLIN IMMUN, V98, P331, DOI 10.1016/S0091-6749(96)70158-6; Sowka S, 1998, J BIOL CHEM, V273, P28091, DOI 10.1074/jbc.273.43.28091; Sowka S, 1998, EUR J BIOCHEM, V255, P213, DOI 10.1046/j.1432-1327.1998.2550213.x; SWOBODA I, 1995, J BIOL CHEM, V270, P2607, DOI 10.1074/jbc.270.6.2607; TURPEN TH, 1995, BIO-TECHNOL, V13, P53, DOI 10.1038/nbt0195-53; Vailes LD, 1998, J ALLERGY CLIN IMMUN, V101, P274, DOI 10.1016/S0091-6749(98)70393-8; Valenta R, 1995, CURR OPIN IMMUNOL, V7, P751, DOI 10.1016/0952-7915(95)80043-3; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330; Wen J, 1997, MOL PHYLOGENET EVOL, V8, P317, DOI 10.1006/mpev.1997.0447; Wiedermann U, 1999, J ALLERGY CLIN IMMUN, V103, P1202, DOI 10.1016/S0091-6749(99)70200-9; Wiedermann U, 1998, CLIN EXP IMMUNOL, V111, P144; Wiedermann U, 1999, INT IMMUNOL, V11, P1131, DOI 10.1093/intimm/11.7.1131; Yasue M, 1997, CELL IMMUNOL, V181, P30, DOI 10.1006/cimm.1997.1184	41	40	49	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2000	14	10					1279	1288		10.1096/fj.14.10.1279	http://dx.doi.org/10.1096/fj.14.10.1279			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877820				2022-12-28	WOS:000087932200002
J	Borlado, LR; Redondo, C; Alvarez, B; Jimenez, C; Criado, LM; Flores, J; Marcos, MAR; Martinez, C; Balomenos, D; Carrera, AC				Borlado, LR; Redondo, C; Alvarez, B; Jimenez, C; Criado, LM; Flores, J; Marcos, MAR; Martinez, C; Balomenos, D; Carrera, AC			Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to turner generation in vivo	FASEB JOURNAL			English	Article						lymphoproliferative disease; autoimmunity; cancer; phosphoinositide 3-kinase; PTEN	TUMOR-SUPPRESSOR PTEN; INTERLEUKIN-2 RECEPTOR; T-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHATASE-ACTIVITY; SIGNALING PATHWAYS; MICE; MEMORY; SURVIVAL; LYMPHOCYTES	Alterations in the cell division:cell death ratio induce multiple autoimmune and transformation processes. Phosphoinositide 3-kinase (PI3K) controls cell division and cell death in vitro, but its effect on the function of the cellular immune system and on tumor formation in mammals is poorly characterized. Here we show that transgenic mice expressing in T lymphocytes an active form of PI3K derived from a thymic lymphoma, p65(PI3K), developed an infiltrating lymphoproliferative disorder and autoimmune renal disease with an increased number of T lymphocytes exhibiting a memory phenotype and reduced apoptosis. This pathology was strikingly similar to that described in mice exhibiting heterozygous loss of the tumor suppressor PTEN, a lipid and protein phosphatase. We show that overexpression of PTEN selectively blocks p65(PI3K)-induced 3T3 fibroblast transformation. Moreover, the early development of T cell lymphomas in p65(PI3K) Tg p53(-/-) mice indicated that PI3K contributes to tumor development. These observations demonstrate that constitutive activation of PI3K extends T cell survival in vivo, affects T cell homeostasis, and contributes to tumor generation, supporting a model in which selective increases in one type of PTEN substrate, the PI3K-derived lipid products, induce tumorigenesis. PI3K thus emerges as a potential target in autoimmune disease and cancer therapy.	Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain; Hosp Ramon y Cajal, E-28034 Madrid, Spain; Univ Complutense Madrid, Sch Vet, Dept Anim Pathol, E-28040 Madrid, Spain; Univ Autonoma Madrid, CSIC, Ctr Biol Mol, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Hospital Universitario Ramon y Cajal; Complutense University of Madrid; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Carrera, AC (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, Carretera Colmenar Km 16, E-28049 Madrid, Spain.		Balomenos, Dimitrios/I-3850-2015	Balomenos, Dimitrios/0000-0002-1252-0850; Carrera, Ana/0000-0002-3999-5434; Jimenez, Maria Concepcion/0000-0002-7011-9328				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; BURLINGAME RW, 1993, J CLIN INVEST, V91, P1687, DOI 10.1172/JCI116378; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Furnari FB, 1998, CANCER RES, V58, P5002; GonzalezGarcia A, 1997, J BIOL CHEM, V272, P10220; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Hamann D, 1997, J EXP MED, V186, P1407, DOI 10.1084/jem.186.9.1407; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KLINMAN DM, 1995, IMMUNOL REV, V144, P157; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; REMILLARD B, 1991, J BIOL CHEM, V266, P14167; RODRIGUEZVICIAN.P, 1997, CELL, V89, P475; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; SPRENT J, 1994, SCIENCE, V265, P1395, DOI 10.1126/science.8073282; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; Swain SL, 1996, IMMUNOL REV, V150, P143, DOI 10.1111/j.1600-065X.1996.tb00700.x; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; WATERHOUSE P, 1995, SCIENCE, V270, P895	36	138	152	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2000	14	7					895	903						9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	309CG	10783143				2022-12-28	WOS:000086749500007
J	Raviv, Y; Puri, A; Blumenthal, R				Raviv, Y; Puri, A; Blumenthal, R			P-glycoprotein-overexpressing multidrug-resistant cells are resistant to infection by enveloped viruses that enter via the plasma membrane	FASEB JOURNAL			English	Article						viral invasion; membrane fusion; photosensitized labeling; hydrophobic labeling	VESICULAR STOMATITIS-VIRUS; BIOLOGICAL-MEMBRANES; CONFORMATIONAL-CHANGES; FUSION ACTIVITY; TRANSPORTER; PEPTIDES; HEMAGGLUTININ; FLUORESCENCE; PROTEINS	The multidrug resistance gene product P-glycoprotein confers drug resistance to tumor cells by acting as a transporter that blocks: the entry into the cell of a great variety of drugs and hydrophobic pep tides. In this study we find that in drug-resistant cells, the insertion of the influenza virus fusion protein (hemagglutinin-2) into the plasma membrane is blocked and that the fusion of the viral envelope with the plasma membrane of these cells is impaired. Multidrug-resistant cells display significant resistance to infection by envelope viruses that invade cells by fusion with the plasma membrane, but not to infection by pH-dependent viruses that penetrate cells by fusion with endocytic vesicles, These observations suggest that multidrug resistance phenomena may protect cells from infection by a large group of disease-causing viruses that includes human immunodeficiency virus, herpes simplex virus, and some cancer-inducing retroviruses.	NCI, Intramural Res Support Program, SAIC Frederick,Lab Expt & Computat Biol, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Raviv, Y (corresponding author), NCI, Intramural Res Support Program, SAIC Frederick,Lab Expt & Computat Biol, Frederick Canc Res & Dev Ctr, Bldg 469,Room 211, Frederick, MD 21702 USA.				NATIONAL CANCER INSTITUTE [Z01BC008303, ZIABC008303] Funding Source: NIH RePORTER; PHS HHS [N01-56000] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AKIYAMA SI, 1985, SOMAT CELL MOLEC GEN, V11, P117, DOI 10.1007/BF01534700; Barrett T., 1985, VIROLOGY PRACTICAL A, P119; BLUMENTHAL R, 1987, J BIOL CHEM, V262, P13614; BLUMENTHAL R, 1988, MOL MECHANISMS MEMBR, P367; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; Gottesman MM, 1996, CURR OPIN GENET DEV, V6, P610, DOI 10.1016/S0959-437X(96)80091-8; HEEMELS MT, 1995, ANNU REV BIOCHEM, V64, P463, DOI 10.1146/annurev.bi.64.070195.002335; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Higgins CF, 1997, SEMIN CANCER BIOL, V8, P135, DOI 10.1006/scbi.1997.0067; HOEKSTRA D, 1984, BIOCHEMISTRY-US, V23, P5675, DOI 10.1021/bi00319a002; Licht T, 1997, STEM CELLS, V15, P104, DOI 10.1002/stem.150104; LOE DW, 1994, BBA-BIOMEMBRANES, V1190, P72, DOI 10.1016/0005-2736(94)90035-3; Merezhinskaya N, 1998, BIOCHEM J, V335, P597, DOI 10.1042/bj3350597; NUSSBAUM O, 1993, J VIROL, V67, P7402, DOI 10.1128/JVI.67.12.7402-7405.1993; Pak CC, 1997, BIOCHEMISTRY-US, V36, P8890, DOI 10.1021/bi9702851; PAK CC, 1994, J BIOL CHEM, V269, P14614; PURI A, 1990, J VIROL, V64, P3824, DOI 10.1128/JVI.64.8.3824-3832.1990; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; SHAROM FJ, 1995, J BIOL CHEM, V270, P10334, DOI 10.1074/jbc.270.17.10334; SHEN DW, 1986, J BIOL CHEM, V261, P7762; Ueda K, 1997, SEMIN CANCER BIOL, V8, P151, DOI 10.1006/scbi.1997.0066; vanBelkum MJ, 1997, MOL MICROBIOL, V23, P1293, DOI 10.1046/j.1365-2958.1997.3111677.x; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WILLINGHAM MC, 1987, J HISTOCHEM CYTOCHEM, V35, P1451, DOI 10.1177/35.12.2890686	24	22	23	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2000	14	3					511	515		10.1096/fasebj.14.3.511	http://dx.doi.org/10.1096/fasebj.14.3.511			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	291TJ	10698966				2022-12-28	WOS:000085751900010
J	Mayr, M; Li, CH; Zou, YP; Huemer, U; Hu, YH; Xu, QB				Mayr, M; Li, CH; Zou, YP; Huemer, U; Hu, YH; Xu, QB			Biomechanical stress-induced apoptosis in vein grafts involves p38 mitogen-activated protein kinases	FASEB JOURNAL			English	Article						MAPKs; smooth muscle cell; propidium iodide; cytokine	SMOOTH-MUSCLE CELLS; ENDOTHELIAL-CELLS; SIGNAL-TRANSDUCTION; ATHEROSCLEROTIC PLAQUES; MECHANICAL-STRESS; CELLULAR-RESPONSE; NATIVE CORONARY; DISEASE; PDGF; EXPRESSION	The present study was designed to investigate whether apoptosis occurs in early-stage vein grafts and to determine the mechanisms by which mechanical stress contributes to apoptosis in vascular smooth muscle cells (SMCs). Apoptosis in vessel walls of mouse vein grafts was confirmed by morphological changes and by terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL). TUNEL+ cells in vein grafts 1, 4, and 8 wk postoperatively was 13%, 29%, and 21%, respectively, and apoptosis occurred mainly in veins grafted to arteries, remaining unchanged in vein-to-vein grafts. When mouse, rat, and human arterial SMCs were cultured on a flexible membrane and subjected to cyclic strain stress, apoptosis was observed in a time- and strength-dependent manner. All three types of SMCs showed apoptotic death as confirmed by TUNEL, propidium iodide, and annexin V staining. To further study the signal pathways leading to apoptosis, activities of p38, a subfamily of mitogen-activated protein kinases (MAPKs), were determined. Mechanical stress resulted in p38 MAPK activation, reaching high levels within 8 min. SE 202190, a specific inhibitor for p38 MAPKs, prevented SMC apoptosis in response to mechanical stress. SMC lines stably transfected with a dominant negative rac, an upstream signal transducer, or overexpressing MAPK phosphatase-l, a negative regulator for MAPKs, completely inhibited mechanical stress stimulated p38 activation and abolished mechanical stress-induced apoptosis. Thus, we provide solid evidence that one of the earliest events in venous bypass grafts is apoptosis, in which mechanical stress-induced p38-MAPK activation is responsible for transducing signals leading to apoptosis.	Austrian Acad Sci, Inst Biomed Aging Res, A-6020 Innsbruck, Austria; Univ Innsbruck, Inst Gen & Expt Pathol, Sch Med, A-6020 Innsbruck, Austria	Austrian Academy of Sciences; University of Innsbruck	Xu, QB (corresponding author), Austrian Acad Sci, Inst Biomed Aging Res, Rennweg 10, A-6020 Innsbruck, Austria.	Qingbo.Xu@oeaw.ac.at		Mayr, Manuel/0000-0002-0597-829X				Abe J, 1997, CIRCULATION, V96, P1906, DOI 10.1161/01.CIR.96.6.1906; BENES AJ, 1985, J CELL SCI, V75, P35; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Bennett MR, 1998, ATHEROSCLEROSIS, V138, P3, DOI 10.1016/S0021-9150(98)00013-6; BENNETT MR, 1995, CIRC RES, V77, P266, DOI 10.1161/01.RES.77.2.266; Bennett MR, 1998, CIRC RES, V82, P704, DOI 10.1161/01.RES.82.6.704; Best PJM, 1999, ARTERIOSCL THROM VAS, V19, P14, DOI 10.1161/01.ATV.19.1.14; Bjorkerud S, 1996, AM J PATHOL, V149, P367; Bryant SR, 1999, CIRC RES, V84, P323, DOI 10.1161/01.RES.84.3.323; Chien S, 1998, HYPERTENSION, V31, P162, DOI 10.1161/01.HYP.31.1.162; Force T, 1996, CIRC RES, V78, P947, DOI 10.1161/01.RES.78.6.947; Furukawa Y, 1999, CIRC RES, V84, P306, DOI 10.1161/01.RES.84.3.306; Geng YJ, 1996, ARTERIOSCL THROM VAS, V16, P19, DOI 10.1161/01.ATV.16.1.19; GIBBONS GH, 1994, NEW ENGL J MED, V330, P1431; Granville DJ, 1998, LAB INVEST, V78, P893; Horino K, 1998, LAB INVEST, V78, P603; Hu YH, 1999, CIRCULATION, V100, P861, DOI 10.1161/01.CIR.100.8.861; Hu YH, 1998, FASEB J, V12, P1135, DOI 10.1096/fasebj.12.12.1135; Hu YH, 1997, ARTERIOSCL THROM VAS, V17, P2808, DOI 10.1161/01.ATV.17.11.2808; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ishida T, 1996, CIRC RES, V79, P310, DOI 10.1161/01.RES.79.2.310; ISNER JM, 1995, CIRCULATION, V91, P2703, DOI 10.1161/01.CIR.91.11.2703; KOCKX MM, 1994, HISTOPATHOLOGY, V25, P365, DOI 10.1111/j.1365-2559.1994.tb01355.x; Lehoux S, 1998, HYPERTENSION, V32, P338, DOI 10.1161/01.HYP.32.2.338; LI C, 2000, IN PRESS ARTERIOSCLE; Li CH, 1999, J BIOL CHEM, V274, P25273, DOI 10.1074/jbc.274.36.25273; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; MAUTNER SL, 1992, AM J CARDIOL, V70, P1380, DOI 10.1016/0002-9149(92)90285-7; Mehta D, 1998, NAT MED, V4, P235, DOI 10.1038/nm0298-235; Metzler B, 1999, ARTERIOSCL THROM VAS, V19, P1862, DOI 10.1161/01.ATV.19.8.1862; MIYASHITA T, 1995, CELL, V80, P293; Motwani JG, 1998, CIRCULATION, V97, P916, DOI 10.1161/01.CIR.97.9.916; Newby AC, 1996, CURR OPIN CARDIOL, V11, P574, DOI 10.1097/00001573-199611000-00004; Nishiura H, 1998, LAB INVEST, V78, P1615; Okada M, 1998, ARTERIOSCL THROM VAS, V18, P894, DOI 10.1161/01.ATV.18.6.894; Pollman MJ, 1998, NAT MED, V4, P222, DOI 10.1038/nm0298-222; Pollman MJ, 1999, CIRC RES, V84, P113; Ridley A, 1999, CURR BIOL, V9, pR156, DOI 10.1016/S0960-9822(99)80100-6; SCHWARTZ SM, 1995, AM J PATHOL, V147, P229; Shyy JYJ, 1997, CURR OPIN CELL BIOL, V9, P707, DOI 10.1016/S0955-0674(97)80125-1; Sumpio BE, 1998, ARTERIOSCL THROM VAS, V18, P349, DOI 10.1161/01.ATV.18.3.349; Takahashi E, 1998, ACTA PHYSIOL SCAND, V164, P611, DOI 10.1111/j.1365-201X.1998.tb10705.x; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; WILSON APR, 1995, J ANTIMICROB CHEMOTH, V36, P1, DOI 10.1093/jac/36.1.1; WILSON E, 1993, J CELL BIOL, V123, P741, DOI 10.1083/jcb.123.3.741; Xu QB, 1996, J CLIN INVEST, V97, P508, DOI 10.1172/JCI118442; XU QB, 1995, CIRCULATION, V92, P1223, DOI 10.1161/01.CIR.92.5.1223; Yang ZH, 1998, CIRCULATION, V97, P181, DOI 10.1161/01.CIR.97.2.181; Zou YP, 1998, AM J PATHOL, V153, P1301, DOI 10.1016/S0002-9440(10)65675-1; Zou YP, 1998, INT J MOL MED, V1, P827	52	132	139	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2000	14	2					261	270		10.1096/fasebj.14.2.261	http://dx.doi.org/10.1096/fasebj.14.2.261			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	281WQ	10660448	Green Submitted			2022-12-28	WOS:000085184800005
J	Pibiri, M; Ledda-Columbano, GM; Cossu, C; Simbula, G; Menegazzi, M; Shinozuka, H; Columbano, A				Pibiri, M; Ledda-Columbano, GM; Cossu, C; Simbula, G; Menegazzi, M; Shinozuka, H; Columbano, A			Cyclin D1 is an early target in hepatocyte proliferation induced by thyroid hormone (T3)	FASEB JOURNAL			English	Article						nuclear receptor; cell cycle; liver	TUMOR-NECROSIS-FACTOR; ALPHA C/EBP-ALPHA; LIVER-REGENERATION; IN-VIVO; CELL-PROLIFERATION; DEPENDENT KINASES; GENE-EXPRESSION; HEPATIC REGENERATION; CYPROTERONE-ACETATE; PARTIAL-HEPATECTOMY	The thyroid hormone (T3) affects cell growth, differentiation, and regulates metabolic functions via its interaction with the thyroid hormone nuclear receptors (TRs). The mechanism by which TRs mediate cell growth is unknown. To investigate the mechanisms responsible for the mitogenic effect of T3, we have determined changes in activation of transcription factors, mRNA levels of immediate early genes, and levels of proteins involved in the progression from G1 to S phase of the cell cycle. We show that hepatocyte proliferation induced by a single administration of T3 to Wistar rats occurred in the absence of activation of AP-1, NF-kappaB, and STAT3 or changes in the mRNA levels of the immediate early genes c-fos, c-jun, and c-myc These genes are considered to be essential for liver regeneration after partial hepatectomy (PH). On the other hand, T3 treatment caused an increase in cyclin D1 mRNA and protein levels that occurred much more rapidly compared to liver regeneration after 2/3 PH. The early increase in cyclin D1 expression was associated with accelerated onset of DNA synthesis, as demonstrated by a 20-fold increase of bromodeoxyuridine-positive hepatocytes at 12 h after T3 treatment and by a 20-fold increase in mitotic activity at 18 h. An early increase of cyclin D1 expression was also observed after treatment with nafenopin, a ligand of a nuclear receptor (peroxisome proliferator-activated receptor alpha) of the same superfamily of steroid/thyroid receptors. T3 treatment also resulted in increased expression of cyclin E, E2F, and p107 and enhanced phosphorylation of pRb, the ultimate substrate in the pathway leading to transition from G1 to S phase. The results demonstrate that cyclin D1 induction is one of the earlier events in hepatocyte proliferation induced by T3 and suggest that this cyclin might be a common target responsible for the mitogenic activity of ligands of nuclear receptors.	Univ Cagliari, Dept Toxicol, Oncol & Mol Pathol Unit, Sez Oncol & Patol Mol, I-09124 Cagliari, Italy; Univ Verona, Dept Neurol Sci, I-37100 Verona, Italy; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15260 USA	University of Cagliari; University of Verona; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Columbano, A (corresponding author), Univ Cagliari, Dept Toxicol, Oncol & Mol Pathol Unit, Sez Oncol & Patol Mol, Via Porcell 4, I-09124 Cagliari, Italy.	columbano@unica.it	Simbula, Gabriella/AAN-4390-2020; Menegazzi, Marta/AAE-7079-2019; Columbano, Amedeo/C-7463-2011	Simbula, Gabriella/0000-0003-4946-532X; Menegazzi, Marta/0000-0003-1310-9227; Columbano, Amedeo/0000-0002-6956-9030; PIBIRI, MONICA/0000-0002-9660-9616				AKERMAN P, 1992, AM J PHYSIOL, V263, pG579, DOI 10.1152/ajpgi.1992.263.4.G579; Albrecht JH, 1998, ONCOGENE, V16, P2141, DOI 10.1038/sj.onc.1201728; Albrecht JH, 1997, HEPATOLOGY, V25, P557, DOI 10.1002/hep.510250311; Barrera-Hernandez G, 1999, ENDOCRINOLOGY, V140, P5267, DOI 10.1210/en.140.11.5267; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Columbano A, 1996, FASEB J, V10, P1118, DOI 10.1096/fasebj.10.10.8751714; Columbano A, 1997, ONCOGENE, V14, P857, DOI 10.1038/sj.onc.1200891; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; DAKSIS JI, 1994, ONCOGENE, V9, P3635; Fausto N, 1995, FASEB J, V9, P1527, DOI 10.1096/fasebj.9.15.8529831; Forbes SJ, 1998, GENE THER, V5, P552, DOI 10.1038/sj.gt.3300613; FRANCAVILLA A, 1994, HEPATOLOGY, V20, P1237, DOI 10.1002/hep.1840200521; GRANA X, 1995, ONCOGENE, V11, P211; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; Higgins GM, 1931, ARCH PATHOL, V12, P186; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; Ledda-Columbano GM, 2000, AM J PATHOL, V156, P91, DOI 10.1016/S0002-9440(10)64709-8; Ledda-Columbano GM, 1998, ONCOGENE, V17, P1039, DOI 10.1038/sj.onc.1202018; Lee SK, 2000, J BIOL CHEM, V275, P12470, DOI 10.1074/jbc.275.17.12470; LEVINE WG, 1977, BIOCHEM PHARMACOL, V26, P939, DOI 10.1016/0006-2952(77)90470-1; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; MANGELSDORF DJ, 1984, RETINOIDS BIOL CHEM, P319; Martin-Castellanos C, 1997, TRENDS CELL BIOL, V7, P95, DOI 10.1016/S0962-8924(96)10055-6; Menegazzi M, 1997, HEPATOLOGY, V25, P585, DOI 10.1002/hep.510250316; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Oppenheimer Jack H., 1996, P162; Oren R, 1999, HEPATOLOGY, V30, P903, DOI 10.1002/hep.510300418; PEREZ P, 1993, J BIOL CHEM, V268, P135; Peters JM, 1997, CARCINOGENESIS, V18, P2029, DOI 10.1093/carcin/18.11.2029; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; Rao MS, 1996, ANN NY ACAD SCI, V804, P573, DOI 10.1111/j.1749-6632.1996.tb18646.x; SAMUELS HH, 1988, J CLIN INVEST, V81, P957, DOI 10.1172/JCI113449; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHORT J, 1972, J BIOL CHEM, V247, P1757; Skrtic S, 1997, J HEPATOL, V27, P903, DOI 10.1016/S0168-8278(97)80329-7; Taub R, 1996, FASEB J, V10, P413, DOI 10.1096/fasebj.10.4.8647340; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; TRAUTWEIN C, 1994, GUT, V35, P1163, DOI 10.1136/gut.35.9.1163; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441	48	114	121	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2001	15	6					1006	1013		10.1096/fj.00-0416com	http://dx.doi.org/10.1096/fj.00-0416com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292661				2022-12-28	WOS:000167959300015
J	Taraseviciene-Stewart, L; Kasahara, Y; Alger, L; Hirth, P; McMahon, G; Waltenberger, J; Voelkel, NF; Tuder, RM				Taraseviciene-Stewart, L; Kasahara, Y; Alger, L; Hirth, P; McMahon, G; Waltenberger, J; Voelkel, NF; Tuder, RM			Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension	FASEB JOURNAL			English	Article						apoptosis; survival; selection; pulmonary vascular remodeling; angiogenesis	NITRIC-OXIDE; FLK-1/KDR ACTIVATION; SURVIVAL FACTOR; GROWTH; PROSTACYCLIN; INFLAMMATION; EXPRESSION; APOPTOSIS; VESSELS; THERAPY	Our understanding of the pathobiology of severe pulmonary hypertension, usually a fatal disease, has been hampered by the lack of information of its natural history. We have demonstrated that, in human severe pulmonary hypertension, the precapillary pulmonary arteries show occlusion by proliferated endothelial cells. Vascular endothelial growth factor (VEGF) and its receptor 2 (VEGFR-2) are involved in proper maintenance, differentiation, and function of endothelial cells. We demonstrate here that VEGFR-2 blockade with SU5416 in combination with chronic hypobaric hypoxia causes severe pulmonary hypertension associated with precapillary arterial occlusion by proliferating endothelial cells. Prior to and concomitant with the development of severe pulmonary hypertension, lungs of chronically hypoxic SU5416-treated rats show significant pulmonary endothelial cell death, as demonstrated by activated caspase 3 immunostaining and TUNEL. The broad caspase inhibitor Z-Asp-CH2-DCB prevents the development of intravascular pulmonary endothelial cell growth and severe pulmonary hypertension caused by the combination of SU5416 and chronic hypoxia.	Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Div Pulm Sci & Crit Care Med, Denver, CO 80262 USA; SUGEN Inc, S San Francisco, CA 94080 USA; Univ Ulm, Med Ctr, Dept Internal Med 2, D-89081 Ulm, Germany; Univ Colorado, Hlth Sci Ctr, Pulm Hypertens Ctr, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Pfizer; Ulm University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Tuder, RM (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pathol, Campus Box B216,4200 E 9th Ave, Denver, CO 80262 USA.		Waltenberger, Johannes/I-1813-2013	Waltenberger, Johannes/0000-0002-2417-9880	NHLBI NIH HHS [R01 HL60195-01, 1RO1 HL60913-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060195, R01HL060913] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; Barst RJ, 1996, NEW ENGL J MED, V334, P296, DOI 10.1056/NEJM199602013340504; Cool CD, 1999, AM J PATHOL, V155, P411, DOI 10.1016/S0002-9440(10)65137-1; Daemen MARC, 1999, J CLIN INVEST, V104, P541, DOI 10.1172/JCI6974; Dimmeler S, 1999, CELL DEATH DIFFER, V6, P964, DOI 10.1038/sj.cdd.4400581; Feng YY, 1999, BIOCHEM BIOPH RES CO, V256, P192, DOI 10.1006/bbrc.1998.9790; Fong TAT, 1999, CANCER RES, V59, P99; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gerber HP, 1999, DEVELOPMENT, V126, P1149; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; HALBOWER AC, 1994, LAB INVEST, V71, P149; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; Jones PL, 1997, AM J PATHOL, V150, P1349; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Kroll J, 1998, BIOCHEM BIOPH RES CO, V252, P743, DOI 10.1006/bbrc.1998.9719; Lee SD, 1998, J CLIN INVEST, V101, P927, DOI 10.1172/JCI1910; MEYRICK B, 1980, AM J PATHOL, V100, P151; Morbidelli L, 1996, AM J PHYSIOL-HEART C, V270, pH411, DOI 10.1152/ajpheart.1996.270.1.H411; Murohara T, 1998, CIRCULATION, V97, P99, DOI 10.1161/01.CIR.97.1.99; Rabinovitch M, 1999, AM J PHYSIOL-LUNG C, V277, pL5, DOI 10.1152/ajplung.1999.277.1.L5; REID LM, 1989, PULMONARY PHYSL PATH; Scalia R, 1999, FASEB J, V13, P1039, DOI 10.1096/fasebj.13.9.1039; Shaheen RM, 1999, CANCER RES, V59, P5412; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Srinivasan A, 1998, CELL DEATH DIFFER, V5, P1004, DOI 10.1038/sj.cdd.4400449; Tuder RM, 1999, CIRCULATION, V100, P241; TUDER RM, 1994, AM J PATHOL, V144, P275; TUDER RM, 1996, CIRCULATION, V94, P64; VOELKEL NF, 1994, AM J RESP CELL MOL, V11, P664, DOI 10.1165/ajrcmb.11.6.7946395; Voelkel NF, 1999, EUR RESPIR J, V14, P1246, DOI 10.1183/09031936.99.14612469; WAGENVOORT CA, 1970, CIRCULATION, V42, P1163, DOI 10.1161/01.CIR.42.6.1163; Yeager ME, 1999, CIRCULATION, V100, P587	32	581	600	0	30	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					427	438		10.1096/fj.00-0343com	http://dx.doi.org/10.1096/fj.00-0343com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156958				2022-12-28	WOS:000166872900024
J	Wang, ZW; Pan, WT; Lee, Y; Kakuma, T; Zhou, YT; Unger, RH				Wang, ZW; Pan, WT; Lee, Y; Kakuma, T; Zhou, YT; Unger, RH			The role of leptin resistance in the lipid abnormalities of aging	FASEB JOURNAL			English	Article						high-fat diet; hyperleptinemia; SOCS-3; fatty acids; hypothalamus; lipotoxicity	OBESE RATS; EXERCISE; DISEASE; SOCS-3; CELLS	Leptin resistance has been implicated in the pathogenesis of obesity-related complications involving abnormalities of lipid metabolism that resemble those of old age. To determine whether development of leptin resistance in advancing age might account for such abnormalities, we compared the effects of hyperleptinemia (>40 ng/ml) induced in 2-month-old and 18-month-old lean wild-type (+/+) Zucker diabetic fatty rats by adenovirus gene transfer. The decline in food intake, body weight, and body fat in old rats was only 25%, 50%, and 16%, respectively, of the young rats. Whereas in young rats plasma free fatty acids fell 44% and triacylglycerol (TG) 94%, neither changed in the rats. In hyperleptinemic young rats, adipocyte expression of preadipocyte factor 1 increased dramatically and leptin mRNA virtually disappeared; there was increased expression of acyl CoA oxidase, carnitine palmitoyl transferase 1, and their transcription factor peroxisome proliferator-activated receptor alpha, accounting for the reduction in body fat. These hyperleptinemia-induced changes were profoundly reduced in the old rats. On a high-fat diet, old rats consumed 28% more calories than the young and gained 1.5x as much fat, despite greater endogenous hyperleptinemia. Expression of a candidate leptin resistance factor, suppressor of cytokine signaling 3 (SOCS-3), was compared in the hypothalamus and white adipocytes of young and old rats before and after induction of hyperleptinemia; hypothalamic SOCS-3 mRNA was similar to 3x higher in old rats before, whereas it was 3x higher in WAT after, hyperleptinemia. We conclude that the anorexic and antilipopenic actions of leptin decline with age, possibly through increased SOCS-3 expression, and that this could account for the associated abnormalities in lipid metabolism of the elderly.	Univ Texas, SW Med Ctr, Ctr Diabet Res, Gifford Labs,Dept Internal Med, Dallas, TX 75290 USA; VA N Texas Hlth Care Syst, Dallas, TX 75216 USA	Diabetes & Endocrine Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA North Texas Health Care System	Unger, RH (corresponding author), Univ Texas, SW Med Ctr, Touchstone Ctr Diabet Res, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	Runger@mednet.Swmed.edu			NIDDK NIH HHS [DK02700-37] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK002700, R01DK002700] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessio HM, 1997, RES Q EXERCISE SPORT, V68, P292, DOI 10.1080/02701367.1997.10608010; Barzilai N, 1999, J GERONTOL A-BIOL, V54, pB89, DOI 10.1093/gerona/54.3.B89; Bjorbaek C, 1999, J BIOL CHEM, V274, P30059, DOI 10.1074/jbc.274.42.30059; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Chen GX, 1996, P NATL ACAD SCI USA, V93, P14795, DOI 10.1073/pnas.93.25.14795; Das UN, 1999, PROSTAG LEUKOTR ESS, V61, P157, DOI 10.1054/plef.1999.0085; EVANS WJ, 1995, J GERONTOL A-BIOL, V50, P5, DOI 10.1093/gerona/50A.Special_Issue.5; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; Higa M, 1999, P NATL ACAD SCI USA, V96, P11513, DOI 10.1073/pnas.96.20.11513; Koyama K, 1997, AM J PHYSIOL-ENDOC M, V273, pE708, DOI 10.1152/ajpendo.1997.273.4.E708; Lakowski B, 1996, SCIENCE, V272, P1010, DOI 10.1126/science.272.5264.1010; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; LEE Y, 1994, P NATL ACAD SCI USA, V91, P10878, DOI 10.1073/pnas.91.23.10878; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; POEHLMAN ET, 1995, INT J OBESITY, V19, pS93; Qian H, 1998, P SOC EXP BIOL MED, V219, P160, DOI 10.3181/00379727-219-44330; Shimabukuro M, 1998, J BIOL CHEM, V273, P32487, DOI 10.1074/jbc.273.49.32487; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Shimabukuro M, 1997, P NATL ACAD SCI USA, V94, P4637, DOI 10.1073/pnas.94.9.4637; Shimizu M, 1996, DIABETES CARE, V19, P8, DOI 10.2337/diacare.19.1.8; SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092-8674(93)90252-L; STEIN DT, 1995, INT J OBESITY, V19, P804; STRATTON JR, 1994, CIRCULATION, V89, P1648, DOI 10.1161/01.CIR.89.4.1648; Unger RH, 1997, TRENDS ENDOCRIN MET, V8, P276, DOI 10.1016/S1043-2760(97)00094-5; Unger RH, 1999, P NATL ACAD SCI USA, V96, P2327, DOI 10.1073/pnas.96.5.2327; Zhou YT, 2000, P NATL ACAD SCI USA, V97, P1784, DOI 10.1073/pnas.97.4.1784; Zhou YT, 1998, P NATL ACAD SCI USA, V95, P8898, DOI 10.1073/pnas.95.15.8898; Zhou YT, 1999, P NATL ACAD SCI USA, V96, P2391, DOI 10.1073/pnas.96.5.2391	28	113	126	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2001	15	1					108	114		10.1096/fj.00-0310com	http://dx.doi.org/10.1096/fj.00-0310com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149898				2022-12-28	WOS:000166312400019
J	Carofano, A; Czernichow, P; Breant, B				Carofano, A; Czernichow, P; Breant, B			Impaired beta-cell regeneration in perinatally malnourished rats: a study with STZ	FASEB JOURNAL			English	Article						malnutrition; beta-cell mass; proliferation; morphometry	DEPENDENT DIABETES-MELLITUS; TREATED NEWBORN RATS; GROWTH-FACTOR-II; LOW-PROTEIN-DIET; ENDOCRINE PANCREAS; NEONATAL-RAT; GLUCOSE-TOLERANCE; FETAL-GROWTH; ADULT-RATS; STREPTOZOTOCIN	We investigated the mechanisms implicated in beta -cell mass reduction observed during late fetal and early postnatal malnutrition in the rat. Beta-cell regeneration, including proliferation and neogenesis, was studied after neonatal beta -cell destruction by streptozotocin (STZ). STZ was injected at birth and maternal food restriction was continued until weaning. Beta-cell mass, proliferation, and islet number were quantified by morphometrical measurements on pancreatic sections in STZ-injected normal (C-STZ) and malnourished (R-STZ) rats, with noninjected C and R rats as controls. At day 4, only 20% of the beta cell-mass remained in C-STZ rats. It regenerated to 50% that of noninjected controls, mainly through active neogenesis, as shown by the entire recovery of islet number/cm(2), and also through moderately increased beta -cell proliferation. In contrast, beta -cell mass from R-STZ animals poorly regenerated, despite a dramatic increase of beta -cell proliferation, because islet number/cm(2) recovered insufficiently. In conclusion, perinatal malnutrition impairs neogenesis and the capacity of beta -cell regeneration by neogenesis but preserves beta -cell proliferation, which remains the elective choice to increase beta -cell mass. These results provide an explanation for the impaired capacity of malnourished animals to adapt their beta -cell mass during aging or pregnancy, which aggravate glucose tolerance.	Hop Robert Debre, INSERM, U457, F-75019 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Breant, B (corresponding author), Hop Robert Debre, INSERM, U457, 48 Blvd Serurier, F-75019 Paris, France.	bbreant@infobiogen.fr						BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; Blondeau B, 1999, ENDOCRINOLOGY, V140, P4208, DOI 10.1210/en.140.9.4208; BONNERWEIR S, 1993, DIABETES, V42, P1715, DOI 10.2337/diabetes.42.12.1715; BONNERWEIR S, 1994, TRENDS ENDOCRIN MET, V5, P60, DOI 10.1016/1043-2760(94)90003-5; BONNERWEIR S, 1981, DIABETES, V30, P64, DOI 10.2337/diabetes.30.1.64; BONNEVIENIELSEN V, 1981, DIABETES, V30, P424, DOI 10.2337/diabetes.30.5.424; CANTENYS D, 1981, VIRCHOWS ARCH B, V35, P109; DUTRILLAUX MC, 1982, VIRCHOWS ARCH B, V39, P173, DOI 10.1007/BF02892846; FERRAND N, 1995, AM J PHYSIOL-CELL PH, V269, pC1250, DOI 10.1152/ajpcell.1995.269.5.C1250; FINEGOOD DT, 1995, DIABETES, V44, P249, DOI 10.2337/diabetes.44.3.249; Garofano A, 1998, DIABETOLOGIA, V41, P1114, DOI 10.1007/s001250051038; Garofano A, 1999, DIABETOLOGIA, V42, P711, DOI 10.1007/s001250051219; Garofano A, 1998, BIOL NEONATE, V73, P89, DOI 10.1159/000013964; Garofano A, 1997, DIABETOLOGIA, V40, P1231, DOI 10.1007/s001250050812; GU DL, 1993, DEVELOPMENT, V118, P33; HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; Hoorens A, 1996, J CLIN INVEST, V98, P1568, DOI 10.1172/JCI118950; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; Movassat J, 1999, DIABETOLOGIA, V42, P1098, DOI 10.1007/s001250051277; PANG K, 1994, P NATL ACAD SCI USA, V91, P9559, DOI 10.1073/pnas.91.20.9559; Petrik J, 1999, ENDOCRINOLOGY, V140, P4861, DOI 10.1210/en.140.10.4861; Petrik J, 1998, ENDOCRINOLOGY, V139, P2994, DOI 10.1210/en.139.6.2994; PHIPPS K, 1993, DIABETOLOGIA, V36, P225, DOI 10.1007/BF00399954; Pick A, 1998, DIABETES, V47, P358, DOI 10.2337/diabetes.47.3.358; PORTHA B, 1974, DIABETES, V23, P889, DOI 10.2337/diab.23.11.889; ROSENBERG L, 1983, J SURG RES, V35, P63, DOI 10.1016/0022-4804(83)90127-0; SCAGLIA L, 1995, ENDOCRINOLOGY, V136, P5461, DOI 10.1210/en.136.12.5461; Scaglia L, 1997, ENDOCRINOLOGY, V138, P1736, DOI 10.1210/en.138.4.1736; SCHNEDL WJ, 1994, DIABETES, V43, P1326, DOI 10.2337/diabetes.43.11.1326; SNOECK A, 1990, BIOL NEONATE, V57, P107, DOI 10.1159/000243170; SWENNE I, 1982, DIABETES, V31, P745; VINIK A, 1996, DIABETES REV, V4, P235; WANG RN, 1995, DIABETOLOGIA, V38, P1405, DOI 10.1007/BF00400600; WANG RN, 1994, DIABETOLOGIA, V37, P1088; Wang RN, 1996, DIABETOLOGIA, V39, P548, DOI 10.1007/BF00403301	36	39	41	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2000	14	15					2611	2617		10.1096/fj.00-0015com	http://dx.doi.org/10.1096/fj.00-0015com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099480				2022-12-28	WOS:000165723400032
J	Schildmeyer, LA; Braun, R; Taffet, G; Debiasi, M; Burns, AE; Bradley, A; Schwartz, RJ				Schildmeyer, LA; Braun, R; Taffet, G; Debiasi, M; Burns, AE; Bradley, A; Schwartz, RJ			Impaired vascular contractility and blood pressure homeostasis in the smooth muscle alpha-actin null mouse	FASEB JOURNAL			English	Article						SM alpha-actin gene; homologous recombination; vascular tone	PHENOL-CHLOROFORM EXTRACTION; AMINO-ACID SEQUENCE; SINGLE-STEP METHOD; SKELETAL-MUSCLE; MESSENGER-RNA; GAMMA-ACTIN; SARCOMERIC ACTIN; TRANSGENIC MICE; STROMAL CELLS; CARDIAC ACTIN	The smooth muscle (SM) alpha -actin gene activated during the early stages of embryonic cardiovascular development is switched off in late stage heart tissue and replaced by cardiac and skeletal alpha -actins. SM alpha -actin also appears during vascular development, but becomes the single most abundant protein in adult vascular smooth muscle cells. Tissue-specific expression of SM alpha -actin is thought to be required for the principal force-generating capacity of the vascular smooth muscle cell. We wanted to determine whether SM alpha -actin gene expression actually relates to an actin isoform's function. Analysis of SM alpha -actin null mice indicated that SM alpha -actin is not required for the formation of the cardiovascular system. Also, SM alpha -actin null mice appeared to have no difficulty feeding or reproducing. Survival in the absence of SM alpha -actin may result from other actin isoforms partially substituting for this isoform. In fact, skeletal alpha -actin gene, an actin isoform not usually expressed in vascular smooth muscle, was activated in the aortas of these SM alpha -actin null mice. However, even with a modest increase in skeletal alpha -actin activity, highly compromised vascular contractility, tone, and blood flow were detected in SM alpha -actin-defective mice. This study supports the concept that SM alpha -actin has a central role in regulating vascular contractility and blood pressure homeostasis, but is not required for the formation of the cardiovascular system.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Cardiovasc Sci Sect, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Physiol & Mol Biophys, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Dept Genet, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute	Schwartz, RJ (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	schwartz@bcm.tmc.edu	De Biasi, Mariella/M-7646-2017	De Biasi, Mariella/0000-0002-0687-8872				BABAI F, 1990, DIFFERENTIATION, V44, P132, DOI 10.1111/j.1432-0436.1990.tb00546.x; BARJA F, 1986, LAB INVEST, V55, P226; CARROLL SL, 1986, J BIOL CHEM, V261, P8965; CHANG KS, 1984, MOL CELL BIOL, V4, P2498, DOI 10.1128/MCB.4.11.2498; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CINTORINO M, 1991, INT J CANCER, V47, P843, DOI 10.1002/ijc.2910470609; COLEMAN ME, 1995, J BIOL CHEM, V270, P12109, DOI 10.1074/jbc.270.20.12109; DIAMOND JR, 1995, AM J PATHOL, V146, P121; EINAT P, 1990, DIFFERENTIATION, V44, P36, DOI 10.1111/j.1432-0436.1990.tb00534.x; GABBIANI G, 1994, PATHOL RES PRACT, V190, P851; Gunning P, 1997, CELL STRUCT FUNCT, V22, P173, DOI 10.1247/csf.22.173; HEWETT TE, 1994, CIRC RES, V74, P740, DOI 10.1161/01.RES.74.4.740; KREGEL KC, 1988, J APPL PHYSIOL, V64, P2582, DOI 10.1152/jappl.1988.64.6.2582; Kumar A, 1997, P NATL ACAD SCI USA, V94, P4406, DOI 10.1073/pnas.94.9.4406; LLOYD C, 1992, J CELL BIOL, V117, P787, DOI 10.1083/jcb.117.4.787; Makino H, 1996, DIABETES, V45, P488, DOI 10.2337/diabetes.45.4.488; MCHUGH KM, 1988, MOL CELL BIOL, V8, P5224, DOI 10.1128/MCB.8.12.5224; MCHUGH KM, 1991, DEV BIOL, V148, P442, DOI 10.1016/0012-1606(91)90263-3; MIANO JM, 1994, CIRC RES, V75, P803, DOI 10.1161/01.RES.75.5.803; MIN BH, 1990, J BIOL CHEM, V265, P16667; OWENS GK, 1986, J BIOL CHEM, V261, P3373; OWENS GK, 1995, PHYSIOL REV, V75, P487; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; RubbiaBrandt L, 1997, TRANSPLANT P, V29, P2390, DOI 10.1016/S0041-1345(97)00415-6; RUZICKA DL, 1988, J CELL BIOL, V107, P2575, DOI 10.1083/jcb.107.6.2575; SAPPINO AP, 1988, INT J CANCER, V41, P707, DOI 10.1002/ijc.2910410512; SCHEVZOV G, 1992, J CELL BIOL, V117, P775, DOI 10.1083/jcb.117.4.775; SCHLAGER G, 1994, CLIN EXP HYPERTENS, V16, P809, DOI 10.3109/10641969409078027; SKALLI O, 1988, AM J PATHOL, V130, P515; SKALLI O, 1986, J CELL BIOL, V103, P2787, DOI 10.1083/jcb.103.6.2787; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUGI Y, 1992, DEV DYNAM, V193, P116, DOI 10.1002/aja.1001930203; Sun Y, 1996, J LAB CLIN MED, V127, P94, DOI 10.1016/S0022-2143(96)90170-5; VANDEKERCKHOVE J, 1978, J MOL BIOL, V126, P783, DOI 10.1016/0022-2836(78)90020-7; VANDEKERCKHOVE J, 1978, P NATL ACAD SCI USA, V75, P1106, DOI 10.1073/pnas.75.3.1106; VANDEKERCKHOVE J, 1981, EUR J BIOCHEM, V113, P595, DOI 10.1111/j.1432-1033.1981.tb05104.x; VANDEKERCKHOVE J, 1979, DIFFERENTIATION, V14, P123, DOI 10.1111/j.1432-0436.1979.tb01021.x; WOODCOCKMITCHELL J, 1988, DIFFERENTIATION, V39, P161, DOI 10.1111/j.1432-0436.1988.tb00091.x	39	151	155	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2000	14	14					2213	2220		10.1096/fj.99-0927com	http://dx.doi.org/10.1096/fj.99-0927com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053242				2022-12-28	WOS:000165190800014
J	Shiels, A; MacKay, D; Bassnett, S; Al-Ghoul, K; Kuszak, J				Shiels, A; MacKay, D; Bassnett, S; Al-Ghoul, K; Kuszak, J			Disruption of lens fiber cell architecture in mice expressing a chimeric AQP0-LTR protein	FASEB JOURNAL			English	Article						lens; major intrinsic protein; water channel; cataract; mouse	NEPHROGENIC DIABETES-INSIPIDUS; MAJOR INTRINSIC PROTEIN; AQUAPORIN-1 NULL MICE; WATER CHANNELS; CONGENITAL CATARACT; GENE; MOUSE; INSERTION; MUTATIONS; MUTANT	Aquaporin-0 (AQP0) is the major intrinsic protein of lens fiber cells and the founder member of the water channel gene family. Here we show that disruption of the AQP0 gene by an early transposon (ETn) element results in expression of a chimeric protein, comprised of similar to 75% AQP0 and similar to 25% ETn long terminal repeat (LTR) sequence, in the cataract Eraser (Cat(Fr)) mouse lens, Immunoblot analysis showed that mutant AQP0-LTR was similar in mass to wild-type AQP0, However, immunofluorescence microscopy revealed that AQP0-LTR was localized to intracellular membranes rather than to plasma membranes of lens fiber cells. Heterozygous Cat(Fr) lenses were similar in size to wild-type but displayed abnormal regions of translucence and light scattering, Scanning electron microscopy further revealed that mature fiber cells within the core of the heterozygous Cat(Fr) lens failed to stratify into uniform, concentric growth shells, suggesting that the AQP0 water channel facilitates the development of the unique cellular architecture of the crystalline lens.	Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Rush Presbyterian St Lukes Med Ctr, Dept Pathol, Chicago, IL 60612 USA; Rush Presbyterian St Lukes Med Ctr, Dept Ophthalmol, Chicago, IL 60612 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Rush University; Rush University	Shiels, A (corresponding author), Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, Box 8096,660 S Euclid Ave, St Louis, MO 63110 USA.			Mackay, Donna/0000-0002-2499-1203; Bassnett, Steven/0000-0002-8337-2760	NEI NIH HHS [EY11411, EY09852, P30 EY002687, EY06642] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009852, R01EY011411, P30EY002687] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Berry V, 2000, NAT GENET, V25, P15, DOI 10.1038/75538; Borgnia M, 1999, ANNU REV BIOCHEM, V68, P425, DOI 10.1146/annurev.biochem.68.1.425; Chou CL, 1999, J CLIN INVEST, V103, P491, DOI 10.1172/JCI5704; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; FRASER FC, 1962, GENET RES, V3, P383, DOI 10.1017/S0016672300003220; Froger A, 1998, PROTEIN SCI, V7, P1458, DOI 10.1002/pro.5560070623; HAMAI Y, 1975, INVEST OPHTH VISUAL, V14, P517; JUNG JS, 1994, J BIOL CHEM, V269, P14648; Kamsteeg EJ, 1999, EMBO J, V18, P2394, DOI 10.1093/emboj/18.9.2394; Kuszak J R, 1989, Lens Eye Toxic Res, V6, P639; KUSZAK JR, 1994, EXP EYE RES, V59, P521, DOI 10.1006/exer.1994.1138; LYON MF, 1981, GENET RES, V38, P337, DOI 10.1017/S0016672300020668; Ma TH, 1999, J BIOL CHEM, V274, P20071, DOI 10.1074/jbc.274.29.20071; Moon BC, 1997, GENOMICS, V42, P152, DOI 10.1006/geno.1997.4701; MUGGLETONHARRIS AL, 1987, GENET RES, V49, P235, DOI 10.1017/S0016672300027129; Mulders SM, 1998, J CLIN INVEST, V102, P57, DOI 10.1172/JCI2605; PRESTON GM, 1994, SCIENCE, V265, P1585, DOI 10.1126/science.7521540; SAKURAGAWA M, 1975, EXP EYE RES, V21, P381, DOI 10.1016/0014-4835(75)90048-2; Schey KL, 1997, INVEST OPHTH VIS SCI, V38, P2508; Schnermann J, 1998, P NATL ACAD SCI USA, V95, P9660, DOI 10.1073/pnas.95.16.9660; SHELL BE, 1990, GENE, V86, P269, DOI 10.1016/0378-1119(90)90289-4; SHIELS A, 1991, BIOCHIM BIOPHYS ACTA, V1097, P318, DOI 10.1016/0925-4439(91)90087-P; SHIELS A, 1993, CURR EYE RES, V12, P913, DOI 10.3109/02713689309020398; Shiels A, 1996, NAT GENET, V12, P212, DOI 10.1038/ng0296-212; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0; Tamarappoo BK, 1998, J CLIN INVEST, V101, P2257, DOI 10.1172/JCI2303; Varadaraj K, 1999, J MEMBRANE BIOL, V170, P191, DOI 10.1007/s002329900549; VERRUSIO AC, 1966, GENET RES, V8, P377, DOI 10.1017/S0016672300010223; ZWAAN J, 1968, J EXP ZOOL, V169, P407, DOI 10.1002/jez.1401690404; ZWAAN J, 1969, EXP EYE RES, V8, P161, DOI 10.1016/S0014-4835(69)80027-8	32	55	56	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2207	2212		10.1096/fj.99-1071com	http://dx.doi.org/10.1096/fj.99-1071com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053241				2022-12-28	WOS:000165190800013
J	Botchkarev, VA; Botchkareva, NV; Albers, KM; Chen, LH; Welker, P; Paus, R				Botchkarev, VA; Botchkareva, NV; Albers, KM; Chen, LH; Welker, P; Paus, R			A role for p75 neurotrophin receptor in the control of apoptosis-driven hair follicle regression	FASEB JOURNAL			English	Article						p75NTR; kerotinocyte catagen; NGF; NT-3; BDNF; alopecia	NERVE GROWTH-FACTOR; CHEMOTHERAPY-INDUCED ALOPECIA; CELL-DEATH; DIFFERENTIAL DEPENDENCY; CATAGEN TRANSFORMATION; SIGNAL-TRANSDUCTION; CYCLOSPORINE-A; TRK RECEPTORS; HIGH-AFFINITY; MURINE SKIN	To examine the mechanisms that underlie the neurotrophin-induced, apoptosis-driven hair follicle involution (catagen), the expression and function of p75 neurotrophin receptor (p75NTR), which is implicated iu apoptosis control, were studied during spontaneous catagen development in murine skin. By RT-PCR, high steady-state p75NTR mRNA skin levels were found during the anagen-catagen transition of the hair follicle. By immunohistochemistry, p75NTR alone was strongly expressed in TUNEL+/Bcl2- keratinocytes of the regressing outer root sheath, but both p75NTR and TrkB and/or TrkC were expressed by the nonregressing TUNEL/Bcl2+ secondary hair germ keratinocytes. To determine whether p75NTR is functionally involved in catagen control, spontaneous catagen development was compared in vivo between p75NTR knockout (-/-) and wild-type mice. There was significant catagen retardation in p75NTR knockout mice as compared to wild-type controls (P<0.05). Instead, transgenic mice-overexpressing NGF (promoter: K14) showed substantial acceleration of catagen (P<0.001). Although NGF, brain-derived neurotrophic factor (BDNF), and neurotrophin 3 (NT-3) accelerated catagen in the organ-cultured skin of C57BL/6 mice, these neurotrophins failed to promote catagen development in the organ-cultured p75NTR null skin. These findings suggest that p75NTR signaling is involved in the control of kerotinocyte apoptosis during catagen and that pharmacological manipulation of p75NTR signaling may prove useful for the treatment of hair disorders that display premature entry into catagen.	Univ Hamburg, Hosp Eppendorf, Dept Dermatol, D-20246 Hamburg, Germany; Univ Kentucky, Med Ctr, Dept Pathol & Lab Med, Lexington, KY 40536 USA; Humboldt Univ, Charite, Dept Dermatol, Berlin, Germany	University of Hamburg; University of Kentucky; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Paus, R (corresponding author), Univ Hamburg, Hosp Eppendorf, Dept Dermatol, Martinistr 52, D-20246 Hamburg, Germany.	paus@uke.uni-hamburg.de	Paus, Ralf/F-6243-2011	Botchkarev, Vladimir/0000-0002-5212-5353; Albers, Kathryn/0000-0003-4597-9323				ALBERS KM, 1994, J NEUROSCI, V14, P1422, DOI 10.1523/JNEUROSCI.14-03-01422.1994; Albers KM, 1996, J CELL BIOL, V134, P487, DOI 10.1083/jcb.134.2.487; Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; Bergmann I, 1997, EUR J NEUROSCI, V9, P18, DOI 10.1111/j.1460-9568.1997.tb01349.x; Botchkarev VA, 1999, NAT CELL BIOL, V1, P158, DOI 10.1038/11078; Botchkarev VA, 1998, AM J PATHOL, V153, P785, DOI 10.1016/S0002-9440(10)65621-0; Botchkarev VA, 1998, J INVEST DERMATOL, V111, P279, DOI 10.1046/j.1523-1747.1998.00277.x; Botchkarev VA, 1999, FASEB J, V13, P395, DOI 10.1096/fasebj.13.2.395; BOTCHKAREVA NV, 1998, ARCH DERMATOL RES, V290, P71; Bothwell M, 1996, SCIENCE, V272, P506, DOI 10.1126/science.272.5261.506; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; Bowden PE, 1998, J INVEST DERMATOL, V110, P158, DOI 10.1046/j.1523-1747.1998.00097.x; BRONZETTI E, 1996, ITAL J ANAT EMBRY S1, V100, P565; BulfonePaus S, 1997, NAT MED, V3, P1124, DOI 10.1038/nm1097-1124; Carter BD, 1997, NEURON, V18, P187, DOI 10.1016/S0896-6273(00)80259-7; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; Cece R, 1996, LAB INVEST, V75, P601; Chao M, 1998, BRAIN RES REV, V26, P295, DOI 10.1016/S0165-0173(97)00036-2; CHAO MV, 1994, J NEUROBIOL, V25, P1373, DOI 10.1002/neu.480251106; CHASE HB, 1954, PHYSIOL REV, V34, P113, DOI 10.1152/physrev.1954.34.1.113; Chou TT, 1997, J NEUROSCI RES, V49, P522, DOI 10.1002/(SICI)1097-4547(19970901)49:5<522::AID-JNR2>3.3.CO;2-M; Commo S, 1997, BRIT J DERMATOL, V137, P31, DOI 10.1046/j.1365-2133.1997.17641854.x; Davies AM, 1997, CURR BIOL, V7, pR38, DOI 10.1016/S0960-9822(06)00016-9; Dechant G, 1997, J NEUROSCI, V17, P5281; Dechant G, 1997, CURR OPIN NEUROBIOL, V7, P413, DOI 10.1016/S0959-4388(97)80071-2; Foitzik K, 2000, FASEB J, V14, P752, DOI 10.1096/fasebj.14.5.752; Frade JM, 1998, NEURON, V20, P35, DOI 10.1016/S0896-6273(00)80432-8; Frade JM, 1996, NATURE, V383, P166; Fuchs E, 1995, ANNU REV CELL DEV BI, V11, P123, DOI 10.1146/annurev.cb.11.110195.001011; Fundin BT, 1997, DEV BIOL, V190, P94, DOI 10.1006/dbio.1997.8658; HANDJISKI BK, 1994, BRIT J DERMATOL, V131, P303, DOI 10.1111/j.1365-2133.1994.tb08515.x; HANSEN LS, 1984, ANAT REC, V210, P569, DOI 10.1002/ar.1092100404; HARDY MH, 1992, TRENDS GENET, V8, P55, DOI 10.1016/0168-9525(92)90350-D; Huang EJ, 1999, DEVELOPMENT, V126, P2869; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; LI LN, 1992, IN VITRO CELL DEV-AN, V28A, P695; Lindner G, 1997, AM J PATHOL, V151, P1601; Maurer M, 1997, AM J PATHOL, V150, P1433; Maurer M, 1997, LAB INVEST, V77, P319; Muragaki Y, 1997, J NEUROSCI, V17, P530; Panteleyev AA, 1998, J INVEST DERMATOL, V110, P902, DOI 10.1046/j.1523-1747.1998.00219.x; Panteleyev AA, 1999, AM J PATHOL, V155, P159, DOI 10.1016/S0002-9440(10)65110-3; PARAKKAL PF, 1970, Z ZELLFORSCH MIK ANA, V107, P174, DOI 10.1007/BF00335223; PAUS R, 1994, AM J PATHOL, V144, P719; Paus R, 1997, J INVEST DERMATOL, V109, P518, DOI 10.1111/1523-1747.ep12336635; PAUS R, 1994, J INVEST DERMATOL, V103, P143, DOI 10.1111/1523-1747.ep12392542; PAUS R, 1994, BRIT J DERMATOL, V130, P174, DOI 10.1111/j.1365-2133.1994.tb02896.x; PAUS R, 1994, BRIT J DERMATOL, V130, P281, DOI 10.1111/j.1365-2133.1994.tb02922.x; PAUS R, 1990, BRIT J DERMATOL, V122, P777, DOI 10.1111/j.1365-2133.1990.tb06266.x; Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; PAUS R, 1996, CURR OPIN DERMATOL, V3, P248; Philpott M, 1998, MOL BASIS EPITHELIAL, P75; Philpott M P, 1994, J Dermatol Sci, V7 Suppl, pS55, DOI 10.1016/0923-1811(94)90036-1; PHILPOTT MP, 1994, J INVEST DERMATOL, V102, P857, DOI 10.1111/1523-1747.ep12382494; Pincelli C, 1997, J INVEST DERMATOL, V109, P757, DOI 10.1111/1523-1747.ep12340768; Poukka H, 1996, BIOCHEM BIOPH RES CO, V229, P565, DOI 10.1006/bbrc.1996.1844; Rice FL, 1998, DEV BIOL, V198, P57, DOI 10.1006/dbio.1998.8861; Rudman SM, 1997, J INVEST DERMATOL, V109, P770, DOI 10.1111/1523-1747.ep12340934; Schilli MB, 1997, J INVEST DERMATOL, V108, P928, DOI 10.1111/1523-1747.ep12294690; SEIBERG M, 1995, J INVEST DERMATOL, V104, P78, DOI 10.1111/1523-1747.ep12613555; Seidl K, 1998, J CELL PHYSIOL, V176, P10, DOI 10.1002/(SICI)1097-4652(199807)176:1<10::AID-JCP2>3.0.CO;2-B; Shibayama E, 1996, AM J PATHOL, V148, P1807; Soma T, 1998, J INVEST DERMATOL, V111, P948, DOI 10.1046/j.1523-1747.1998.00408.x; Stenn K., 1998, MOL BASIS EPITHELIAL, P111; STENN KS, 1994, J INVEST DERMATOL, V103, P107, DOI 10.1111/1523-1747.ep12391844; STENN KS, 2000, IN PRESS PHYSL REV; STRAILE WE, 1961, J EXP ZOOL, V148, P205, DOI 10.1002/jez.1401480304; WEEDON D, 1981, ACTA DERM-VENEREOL, V61, P335; Yaar M, 1998, J Investig Dermatol Symp Proc, V3, P47; Yaar M, 1997, J CLIN INVEST, V100, P2333, DOI 10.1172/JCI119772; Yoon SO, 1998, J NEUROSCI, V18, P3273	75	79	80	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2000	14	13					1931	1942		10.1096/fj.99-0930com	http://dx.doi.org/10.1096/fj.99-0930com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023977				2022-12-28	WOS:000089634400012
J	Reznikov, K; Kolesnikova, L; Pramanik, A; Tan-no, K; Gileva, I; Yakovleva, T; Rigler, R; Terenius, L; Bakalkin, G				Reznikov, K; Kolesnikova, L; Pramanik, A; Tan-no, K; Gileva, I; Yakovleva, T; Rigler, R; Terenius, L; Bakalkin, G			Clustering of apoptotic cells via bystander killing by peroxides	FASEB JOURNAL			English	Article						intercellular communications; cell death; reactive oxygen species	HYDROGEN-PEROXIDE; NITRIC-OXIDE; IN-VITRO; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; OXIDATIVE STRESS; INDUCED P53; EXPRESSION; GROWTH; DEATH	Clustering of apoptotic cells is a characteristic of many developing or renewing systems, suggesting that apoptotic cells kill bystanders. Bystander killing can be triggered experimentally by inducing apoptosis in single cells and may be based on the exchange of as yet unidentified chemical cell death signals between nearby cells without the need for cell-to-cell communication via gap junctions. Here we demonstrate that apoptotic cell clusters occurred spontaneously, after serum deprivation or p53 transfection in cell monolayers in vitro. Clustering was apparently induced through bystander killing by primary apoptotic cells. Catalase, a peroxide scavenger, suppressed bystander killing, suggesting that hydrogen peroxide generated by apoptotic cells is the death signal. Although p53 expression increased the number of apoptoses, clustering was found to be similar around apoptotic cells whether or not p53 was expressed, indicating that there is no specific p53 contribution to bystander killing. Bystander killing through peroxides emitted by apoptotic cells may propagate tissue injury in different pathological situations and be relevant in chemo-, gamma-ray, and gene therapy of cancer.	Karolinska Inst, Dept Clin Neurosci, Expt Alcohol & Drug Addict Res Sect, S-17176 Stockholm, Sweden; Karolinska Inst, Dept Med Biochem & Biophys, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Bakalkin, G (corresponding author), Karolinska Inst, Dept Clin Neurosci, Sect Alcohol & Drug Addict Res, CMM L8-01, S-17176 Stockholm, Sweden.	Gregory.Bakalkin@cmm.ki.se		Bakalkin, Georgy/0000-0002-8074-9833; Tan-No, Koichi/0000-0001-6724-848X				Bedner E, 1999, CYTOMETRY, V35, P181, DOI 10.1002/(SICI)1097-0320(19990301)35:3<181::AID-CYTO1>3.0.CO;2-5; Boonen G, 2000, PLANTA MED, V66, P7, DOI 10.1055/s-2000-11112; Booth C, 1995, CELL PROLIFERAT, V28, P581, DOI 10.1111/j.1365-2184.1995.tb00046.x; Bouvet M, 1998, CANCER RES, V58, P2288; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CIVITELLI R, 1993, J CLIN INVEST, V91, P1888, DOI 10.1172/JCI116406; CLARK PJ, 1954, ECOLOGY, V35, P445, DOI 10.2307/1931034; Collins JA, 1997, J HISTOCHEM CYTOCHEM, V45, P923, DOI 10.1177/002215549704500702; Davies KJA, 1999, IUBMB LIFE, V48, P41, DOI 10.1080/152165499307404; Dilber MS, 1997, GENE THER, V4, P273, DOI 10.1038/sj.gt.3300389; DONAHUE HJ, 1995, J BONE MINER RES, V10, P881; Dumont A, 1999, ONCOGENE, V18, P747, DOI 10.1038/sj.onc.1202325; EDELSTEINKESHET L, 1990, DIFFERENTIATION, V45, P147, DOI 10.1111/j.1432-0436.1990.tb00468.x; Favrot M, 1998, GENE THER, V5, P728, DOI 10.1038/sj.gt.3300661; Frank DK, 1998, CLIN CANCER RES, V4, P2521; Goldkorn T, 1998, J CELL SCI, V111, P3209; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; Haugland R.P., 1996, HDB FLUORESCENT PROB, P491; Hendry JH, 1998, INT J RADIAT BIOL, V73, P575; HICKMAN AW, 1994, CANCER RES, V54, P5797; Hiraoka W, 1998, J CLIN INVEST, V102, P1961, DOI 10.1172/JCI3437; Ijiri K., 1987, P326; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Kaneko K, 1997, B MATH BIOL, V59, P139, DOI 10.1016/S0092-8240(96)00044-4; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Komarova EA, 1998, ONCOGENE, V17, P1089, DOI 10.1038/sj.onc.1202303; Kravtsov VD, 1999, AM J PATHOL, V155, P1327, DOI 10.1016/S0002-9440(10)65235-2; Kuzin B, 1996, CELL, V87, P639, DOI 10.1016/S0092-8674(00)81384-7; LANG R, 1994, DEVELOPMENT, V120, P3395; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; Lin JHC, 1998, NAT NEUROSCI, V1, P494, DOI 10.1038/2210; Matsumoto H, 1999, CANCER RES, V59, P3239; Maxeiner H, 1998, J EXP MED, V188, P2257, DOI 10.1084/jem.188.12.2257; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; Milan M, 1997, P NATL ACAD SCI USA, V94, P5691, DOI 10.1073/pnas.94.11.5691; MORITA I, 1995, BIOCHEMISTRY-US, V34, P7194, DOI 10.1021/bi00021a034; Mothersill C, 1998, RADIAT RES, V149, P256, DOI 10.2307/3579958; Narayanan PK, 1997, CANCER RES, V57, P3963; NATHAN CF, 1987, J CLIN INVEST, V80, P1550, DOI 10.1172/JCI113241; NIKOTERA P, 1997, ADV NEUROIMMUNOL, V5, P411; Ogino T, 1997, FREE RADICAL BIO MED, V23, P445, DOI 10.1016/S0891-5849(97)00115-9; Olejnicka BT, 1999, APMIS, V107, P747, DOI 10.1111/j.1699-0463.1999.tb01469.x; PAILLARD F, 1997, GENE THER, V4, P273; Peunova N, 1996, COLD SPRING HARB SYM, V61, P417; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Potten C S, 1981, Int Rev Cytol, V69, P271; Pramanik A., 1999, Biomedical Chromatography, V13, P119, DOI 10.1002/(SICI)1099-0801(199904)13:2<119::AID-BMC835>3.0.CO;2-P; Prise KM, 1998, INT J RADIAT BIOL, V74, P793, DOI 10.1080/095530098141087; QUI XB, 1997, FREE RADICAL BIO MED, V24, P848; REZNIKOV K, 1995, J COMP NEUROL, V360, P536, DOI 10.1002/cne.903600313; REZNIKOV KY, 1991, ADV ANAT EMBRYOL CEL, V122, P1; REZNIKOV KY, 1984, ANAT EMBRYOL, V170, P99, DOI 10.1007/BF00319464; Rigler R, 1999, P NATL ACAD SCI USA, V96, P13318, DOI 10.1073/pnas.96.23.13318; RIGLER R, 1995, J BIOTECHNOL, V41, P177, DOI 10.1016/0168-1656(95)00054-T; Rollet-Labelle E, 1998, FREE RADICAL BIO MED, V24, P563, DOI 10.1016/S0891-5849(97)00292-X; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Simizu S, 1998, J BIOL CHEM, V273, P26900, DOI 10.1074/jbc.273.41.26900; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012; VANDISSEL JT, 1987, J IMMUNOL, V138, P4428; Wilson JW, 1998, AM J PATHOL, V153, P899, DOI 10.1016/S0002-9440(10)65631-3	62	31	34	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2000	14	12					1754	1764		10.1096/fj.99-0890com	http://dx.doi.org/10.1096/fj.99-0890com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973925				2022-12-28	WOS:000089212400015
J	Yu, XX; Mao, WG; Zhong, A; Schow, P; Brush, J; Sherwood, SW; Adams, SH; Pan, GH				Yu, XX; Mao, WG; Zhong, A; Schow, P; Brush, J; Sherwood, SW; Adams, SH; Pan, GH			Characterization of novel UCP5/BMCP1 isoforms and differential regulation of UCP4 and UCP5 expression through dietary or temperature manipulation	FASEB JOURNAL			English	Article						uncoupling proteins; metabolism; thermoregulation; mitochondrial membrane potential	MITOCHONDRIAL UNCOUPLING PROTEIN; THYROID-HORMONE; IN-VITRO; OBESITY; GENE; MICE; LEPTIN; FAT; THERMOGENESIS; GENERATION	Mitochondrial uncoupling proteins have been implicated in the maintenance of metabolic rate and adaptational thermoregulation, We recently reported the identification of a brain-specific mitochondrial uncoupling protein homologue, UCP4, Here we; characterized another newly described member of the uncoupling protein family, termed UCP5 (also called BMCP1). UCP5 transcripts are present in multiple human and mouse tissues, with an especially high abundance in the brain and testis, Expression of UCP5 in mammalian cells reduces the mitochondrial membrane potential, Multiple isoforms of UCP5 were identified and exhibited tissue-specific distribution and different potency in reduction of membrane potential. Furthermore, the mRNA abundance of both UCP4 and UCP5 is modulated by nutritional status or temperature in a tissue-specific manner in mice. Brain UCP4 and UCP5 mRNA transcripts rose by 1.5- and 1.7-fold, respectively, and liver UCP5 expression increased by 1.8-fold in response to acute cold exposure. A high-fat diet increased UCP5 mRNA in liver by 1.6-fold selectively in the obesity-resistant A/J but not in the obesity-prone C57BL/6J mouse strain, Liver UCP5 expression decreased significantly with a 24 h fast and was restored to the normal level after refeeding. In contrast, brain transcripts for both genes were not significantly altered by fasting or high-fat diet. These findings are consistent with the notion that UCP4 and UCP5 may be involved in tissue-specific thermoregulation and metabolic changes associated with nutritional status.	Genentech Inc, Dept Endocrinol, S San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Biol, S San Francisco, CA 94080 USA; Genentech Inc, Dept Bioassay & Bioimage, S San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Pan, GH (corresponding author), Genentech Inc, Dept Endocrinol, M-S-37,1 DNA Way, S San Francisco, CA 94080 USA.		ADAMS, SEAN/N-9262-2018	ADAMS, SEAN/0000-0002-9515-2319				Argyropoulos G, 1998, J CLIN INVEST, V102, P1345, DOI 10.1172/JCI4115; Boss O, 1998, J BIOL CHEM, V273, P5, DOI 10.1074/jbc.273.1.5; Bouchard C, 1997, HUM MOL GENET, V6, P1887, DOI 10.1093/hmg/6.11.1887; BUSCIGLIO J, 1995, NATURE, V378, P776, DOI 10.1038/378776a0; Chavin KD, 1999, J BIOL CHEM, V274, P5692, DOI 10.1074/jbc.274.9.5692; DONHOFFER D, 1959, NATURE, V184, P993; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; Gong DW, 1999, BIOCHEM BIOPH RES CO, V256, P27, DOI 10.1006/bbrc.1999.0239; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; King KL, 1998, ENDOCRINE, V9, P45, DOI 10.1385/ENDO:9:1:45; Larkin S, 1997, BIOCHEM BIOPH RES CO, V240, P222, DOI 10.1006/bbrc.1997.7636; Liu QY, 1998, GENE, V207, P1, DOI 10.1016/S0378-1119(97)00596-9; Mao WG, 1999, FEBS LETT, V443, P326, DOI 10.1016/S0014-5793(98)01713-X; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; Richard D, 1998, J COMP NEUROL, V397, P549; Ricquier D, 1997, PROG NUCLEIC ACID RE, V56, P83, DOI 10.1016/S0079-6603(08)61003-X; Rolfe DFS, 1996, AM J PHYSIOL-CELL PH, V271, pC1380, DOI 10.1152/ajpcell.1996.271.4.C1380; ROLFE DFS, 1994, BIOCHIM BIOPHYS ACTA, V1118, P405; Sanchis D, 1998, J BIOL CHEM, V273, P34611, DOI 10.1074/jbc.273.51.34611; Scarpace PJ, 1998, J ENDOCRINOL, V159, P349, DOI 10.1677/joe.0.1590349; Solanes G, 1997, J BIOL CHEM, V272, P25433, DOI 10.1074/jbc.272.41.25433; STEINBERGER A, 1991, ADV EXP MED BIOL, V286, P33; SURWIT RS, 1995, METABOLISM, V44, P645, DOI 10.1016/0026-0495(95)90123-X; Surwit RS, 1998, P NATL ACAD SCI USA, V95, P4061, DOI 10.1073/pnas.95.7.4061; Taylor BA, 1996, GENOMICS, V34, P389, DOI 10.1006/geno.1996.0302; Thomas SA, 1997, NATURE, V387, P94, DOI 10.1038/387094a0; WARDEN CH, 1995, J CLIN INVEST, V95, P1545, DOI 10.1172/JCI117827; Weigle DS, 1998, DIABETES, V47, P298, DOI 10.2337/diabetes.47.2.298; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P6386, DOI 10.1073/pnas.94.12.6386	32	133	142	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2000	14	11					1611	1618		10.1096/fj.14.11.1611	http://dx.doi.org/10.1096/fj.14.11.1611			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CN	10928996				2022-12-28	WOS:000088627800016
J	Guo, YJ; Higazi, AA; Arakelian, A; Sachais, BS; Cines, D; Goldfarb, RH; Jones, TR; Kwaan, H; Mazar, AP; Rabbani, SA				Guo, YJ; Higazi, AA; Arakelian, A; Sachais, BS; Cines, D; Goldfarb, RH; Jones, TR; Kwaan, H; Mazar, AP; Rabbani, SA			A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo	FASEB JOURNAL			English	Article						apoptosis; breast cancer; endothelial cell; tumor necrosis	BOUND REACTANTS; GROWTH-FACTOR; RECEPTOR; SYSTEM; METASTASIS; EXPRESSION; INVASION; CANCER; CARCINOMA; COMPLEXES	Urokinase plasminogen activator (uPA) plays an important role in the progression of several malignancies including breast cancer. We have identified a noncompetitive antagonist of the uPA-uPAR interaction derived from a nonreceptor binding region of uPA (amino acids 136-143). This 8-mer capped peptide (Angstrom 6) inhibited breast cancer cell invasion and endothelial cell migration in a dose-dependent manner in vitro without altering cell doubling time. Intraperitoneal administration of Angstrom 6 resulted in a significant inhibition of tumor growth and suppressed the development of lymph node metastases in several models of breast cancer cell growth and metastasis, Large areas of tumor necrosis and extensive positive staining by TUNEL were observed on histological and inmunohistochemical analysis of experimental tumor sections from Angstrom 6-treated animals.;is treatment also resulted in a decrease in factor VIII-positive tumor microvessel hot-spots. These results identify a new epitope in uPA that is involved in the uPA-uPAR interaction and indicate that an antagonist based on this epitope is able to inhibit tumor progression by modulating the tumor microenvironment in the absence of direct cytotoxic effects in vivo.	McGill Univ, Ctr Hlth, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hlth, Dept Oncol, Montreal, PQ H3A 1A1, Canada; Royal Victoria Hosp, Montreal, PQ H3A 1A1, Canada; Univ Penn, Dept Pathol, Philadelphia, PA 19104 USA; Hadassah Med Sch, Dept Clin Biochem, IL-91120 Jerusalem, Israel; Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Ft Worth, TX 76107 USA; Angstrom Pharmaceut Inst, Dept Biol, San Diego, CA 92121 USA; Northwestern Univ, Sch Med, Chicago, IL 60611 USA; Univ N Texas, Inst Canc Res, Ft Worth, TX 76107 USA	McGill University; McGill University; McGill University; Royal Victoria Hospital; University of Pennsylvania; Hebrew University of Jerusalem; University of North Texas System; University of North Texas Health Science Center; Northwestern University; University of North Texas System; University of North Texas Health Science Center	Rabbani, SA (corresponding author), McGill Univ, Ctr Hlth, Dept Med, Room H4-67,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.		Sachais, Bruce/D-1236-2009	rabbani, shafaat/0000-0001-5594-3899	NHLBI NIH HHS [T32 HL007775, HL60169] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060169, T32HL007775] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Blancher C, 1998, CANCER METAST REV, V17, P187, DOI 10.1023/A:1006002419244; Choi HJ, 1998, ONCOLOGY-BASEL, V55, P575, DOI 10.1159/000011915; Dumler I, 1998, J BIOL CHEM, V273, P315, DOI 10.1074/jbc.273.1.315; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; Faller DV, 1999, CLIN EXP PHARMACOL P, V26, P74, DOI 10.1046/j.1440-1681.1999.02992.x; Franco P, 1998, J BIOL CHEM, V273, P27734, DOI 10.1074/jbc.273.42.27734; FRANCO P, 1997, J CELL BIOL, V137, P777; Haj-Yehia A, 2000, FASEB J, V14, P1411, DOI 10.1096/fj.14.10.1411; Higazi AA, 1998, BLOOD, V92, P2075, DOI 10.1182/blood.V92.6.2075.418k08_2075_2083; JOHNSSON B, 1995, J MOL RECOGNIT, V8, P125, DOI 10.1002/jmr.300080122; Knoop A, 1998, BRIT J CANCER, V77, P932, DOI 10.1038/bjc.1998.154; LIU DF, 1995, PROSTATE, V27, P269, DOI 10.1002/pros.2990270506; Mandriota SJ, 1997, J CELL SCI, V110, P2293; Mazar A P, 1999, Angiogenesis, V3, P15, DOI 10.1023/A:1009095825561; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; Mignatti P, 1996, ENZYME PROTEIN, V49, P117, DOI 10.1159/000468621; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; Min HY, 1996, CANCER RES, V56, P2428; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; ODEKON LE, 1994, J CELL PHYSIOL, V158, P398, DOI 10.1002/jcp.1041580303; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; PYKE C, 1993, CANCER RES, V53, P1911; QUATTRONE A, 1995, CANCER RES, V55, P90; Rabbani SA, 1997, J CELL PHYSIOL, V172, P137, DOI 10.1002/(SICI)1097-4652(199708)172:2<137::AID-JCP1>3.0.CO;2-P; Reuning U, 1998, INT J ONCOL, V13, P893; Schmitt M, 1997, THROMB HAEMOSTASIS, V78, P285; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; Tang H, 1998, J BIOL CHEM, V273, P18268, DOI 10.1074/jbc.273.29.18268; Tozer GM, 1999, CANCER RES, V59, P1626; YAMAMOTO M, 1994, CANCER RES, V54, P5016	33	127	143	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2000	14	10					1400	1410		10.1096/fj.14.10.1400	http://dx.doi.org/10.1096/fj.14.10.1400			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877833				2022-12-28	WOS:000087932200015
J	Bhatia, R; Lin, H; Lal, R				Bhatia, R; Lin, H; Lal, R			Fresh and globular amyloid beta protein (1-42) induces rapid cellular degeneration: evidence for A beta P channel-mediated cellular toxicity	FASEB JOURNAL			English	Article						AFM; scanning probe microscopy; real-time cellular imaging; endothelial cells; amyloid beta protein; neurotoxicity; Alzheimer's disease; calcium imaging; cytoskeletal reorganization	ALZHEIMERS-DISEASE; IN-VITRO; ZN2+-SENSITIVE CHANNEL; PRECURSOR PROTEIN; CORTICAL-NEURONS; PC12 CELLS; PEPTIDE; NEUROTOXICITY; APOPTOSIS; VASOACTIVITY	Amyloid beta peptides (A beta P) deposit as plaques in vascular and parenchymal areas of Alzheimer's disease (AD) tissues and Down's syndrome patients. Although neuronal toxicity is a feature of late stages of AD, vascular pathology appears to be a feature of all stages of AD. Globular and nonfibrillar A beta Ps are continuously released during normal cellular metabolism, form calcium-permeable channels, and alter cellular calcium level. We used atomic force microscopy, laser confocal microscopy, and calcium imaging to examine the real-time and acute effects of fresh and globular A beta P1-42, A beta P1-40, and A beta P25-35 on cultured endothelial cells. A beta Ps induced morphological changes that were observed within minutes after A beta P treatment and led to eventual cellular degeneration. Cellular morphological changes were most sensitive to A beta P1-42. APP(1-42)-induced morphological changes were observed at nanomolar concentrations and were accompanied by an elevated cellular calcium level. Morphological changes were prevented by anti-A beta P antibody, A beta P-channel antagonist zinc, and the removal of extracellular calcium, but not by tachykinin neuropeptide, voltage-sensitive calcium channel blocker cadmium, or antioxidants DTT and Trolox. Thus, nanomolar fresh and globular A beta P1-42 induces rapid cellular degeneration by elevating intracellular calcium, most likely via calcium-permeable A beta P channels and not by its interaction with membrane receptors or by activating oxidative pathways. Such rapid degeneration also suggests that the plaques, and especially fibrillar A beta Ps, may not have a direct causative role in AD pathogenic cascades.-Bhatia, R., Lin H., Lal, R. Fresh and globular amyloid beta protein (1-42) induces rapid cellular degeneration: evidence for APE channel-mediated cellular toxicity.	Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara	Bhatia, R (corresponding author), Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA.	bhatia@lifesci.ucsb.edu						Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; ARISPE N, 1993, P NATL ACAD SCI USA, V90, P10573, DOI 10.1073/pnas.90.22.10573; Arispe N, 1996, P NATL ACAD SCI USA, V93, P1710, DOI 10.1073/pnas.93.4.1710; BARBEE KA, 1995, AM J PHYSIOL-HEART C, V268, pH1765, DOI 10.1152/ajpheart.1995.268.4.H1765; BENZI G, 1995, NEUROBIOL AGING, V16, P661, DOI 10.1016/0197-4580(95)00066-N; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; Blanc EM, 1997, J NEUROCHEM, V68, P1870; BUEE L, 1994, ACTA NEUROPATHOL, V87, P469; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; Crawford F, 1998, EXP NEUROL, V150, P159, DOI 10.1006/exnr.1997.6743; Dikalov SI, 1999, J BIOL CHEM, V274, P9392, DOI 10.1074/jbc.274.14.9392; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; ETCHEBERRIGARAY R, 1994, SCIENCE, V264, P276, DOI 10.1126/science.8146663; Geula C, 1998, NAT MED, V4, P827, DOI 10.1038/nm0798-827; Good TA, 1996, BIOPHYS J, V70, P296, DOI 10.1016/S0006-3495(96)79570-X; GRAMMAS P, 1995, DEMENTIA, V6, P126, DOI 10.1159/000106934; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Hirakura Y, 1999, J NEUROSCI RES, V57, P458, DOI 10.1002/(SICI)1097-4547(19990815)57:4<458::AID-JNR5>3.0.CO;2-4; Hirakura Y, 1999, BIOPHYS J, V76, pA443; ITO E, 1994, P NATL ACAD SCI USA, V91, P534, DOI 10.1073/pnas.91.2.534; Ivins KJ, 1999, J BIOL CHEM, V274, P2107, DOI 10.1074/jbc.274.4.2107; Janson J, 1999, DIABETES, V48, P491, DOI 10.2337/diabetes.48.3.491; Kawahara M, 1997, BIOPHYS J, V73, P67, DOI 10.1016/S0006-3495(97)78048-2; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; KOSIK K, 1992, NEUROBIOL AGING, V13, P535, DOI 10.1016/0197-4580(92)90052-Y; LAL R, 1994, AM J PHYSIOL, V266, pC1, DOI 10.1152/ajpcell.1994.266.1.C1; LAL R, 1995, AM J PHYSIOL-CELL PH, V269, pC275, DOI 10.1152/ajpcell.1995.269.1.C275; Lane NJ, 1998, J NEUROCYTOL, V27, P707, DOI 10.1023/A:1006976400227; Li JH, 1997, CELL, V90, P917, DOI 10.1016/S0092-8674(00)80356-6; Lin H, 1999, BIOCHEMISTRY-US, V38, P11189, DOI 10.1021/bi982997c; Lin MX, 1997, J BIOL CHEM, V272, P44; Liu YB, 1998, J NEUROCHEM, V71, P2322; LOCKHART BP, 1994, J NEUROSCI RES, V39, P494, DOI 10.1002/jnr.490390416; MAESTRE GE, 1993, BRAIN RES, V621, P145, DOI 10.1016/0006-8993(93)90311-A; MATTILA KM, 1994, ACTA NEUROL SCAND, V89, P192; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; MECOCCI P, 1995, J NEUROIMMUNOL, V57, P165, DOI 10.1016/0165-5728(94)00180-V; Mirzabekov TA, 1996, J BIOL CHEM, V271, P1988, DOI 10.1074/jbc.271.4.1988; NASLUND J, 1995, NEURON, V15, P219, DOI 10.1016/0896-6273(95)90079-9; Pallitto MM, 1999, BIOCHEMISTRY-US, V38, P3570, DOI 10.1021/bi982119e; PERLMUTTER LS, 1994, MOL NEUROBIOL, V9, P33, DOI 10.1007/BF02816103; Perry G, 1998, BRAIN RES, V791, P63, DOI 10.1016/S0006-8993(98)00006-7; Rhee SK, 1998, J BIOL CHEM, V273, P13379, DOI 10.1074/jbc.273.22.13379; Sanderson KL, 1997, BRAIN RES, V744, P7, DOI 10.1016/S0006-8993(96)01060-8; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Seilheimer B, 1997, J STRUCT BIOL, V119, P59, DOI 10.1006/jsbi.1997.3859; SHEARMAN MS, 1994, P NATL ACAD SCI USA, V91, P1470, DOI 10.1073/pnas.91.4.1470; Suo ZM, 1997, BRAIN RES, V762, P144, DOI 10.1016/S0006-8993(97)00383-1; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; White AR, 1998, J NEUROSCI, V18, P6207; WHITSON JS, 1995, NEUROBIOL AGING, V16, P5, DOI 10.1016/0197-4580(95)80002-9; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; Zhu YJ, 2000, FASEB J, V14, P1244, DOI 10.1096/fasebj.14.9.1244	56	207	217	0	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2000	14	9					1233	1243		10.1096/fasebj.14.9.1233	http://dx.doi.org/10.1096/fasebj.14.9.1233			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834945				2022-12-28	WOS:000087427300020
J	Albanese, C; Reutens, AT; Bouzahzah, B; Fu, MF; D'Amico, M; Link, T; Nicholson, R; Depinho, RA; Pestell, RG				Albanese, C; Reutens, AT; Bouzahzah, B; Fu, MF; D'Amico, M; Link, T; Nicholson, R; Depinho, RA; Pestell, RG			Sustained mammary gland-directed, ponasterone A-inducible expression in transgenic mice	FASEB JOURNAL			English	Article						ecdysteroids; gland-specific transgenics; DNA binding site	SITE-SPECIFIC RECOMBINATION; GENE-EXPRESSION; MAMMALIAN-CELLS; TRANSCRIPTIONAL ACTIVATION; ECDYSONE RECEPTOR; MOUSE; INDUCTION; ONCOGENE; LIGANDS; PRODUCT	The ability to regulate temporal- and spatial-specific expression of target genes in transgenic mice will facilitate analysis of gene function and enable the generation of murine models of human diseases. The genetic analysis of mammary gland tumorigenesis requires the development of mammary gland-specific transgenics, which are tightly regulated throughout the adult mammary epithelium. Analysis of genes implicated in mammary gland tumorigenesis has been hampered by mosaic transgene expression and the findings that homozygous deletion of several candidate genes (cyclin D1, Stat5A, prolactin receptor) abrogates normal mammary gland development. We describe the development of transgenic mouse lines in which sustained transgene expression was inducibly regulated, both specifically and homogeneously, in the adult mammary gland epithelium. Transgenes encoding RXR alpha and a chimeric ecdysone receptor under control of a modified MMTV-LTR, which targets mammary gland expression, were used. These transgenic 'receptor' lines were crossed with transgenic 'enhancer' lines in which the ecdysone/RXR binding site induced ligand-dependent expression of transgenic beta-galactoxidase. Pharmacokinetic analysis of a highly bioactive ligand (ponasterone A), identified through screening ecdysteroids from local plants, demonstrated sustained release and transgene expression in vivo. This transgenic model with both tightly regulated and homogeneous transgene expression, which was sustained in vivo using ligands readily extracted from local flora, has broad practical applicability for genetic analysis of mammary gland disease.	Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Smith Coll Lyman Conservatory, Northampton, MA 01636 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Smith College; Harvard University; Dana-Farber Cancer Institute	Pestell, RG (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Med, 1300 Morris Pk Ave,Chanin 302, Bronx, NY 10461 USA.			Link, Todd/0000-0003-1939-9755; DePinho, Ronald/0000-0002-5625-577X	NATIONAL CANCER INSTITUTE [R01CA075503, P30CA013330, R29CA070896] Funding Source: NIH RePORTER; NCI NIH HHS [5-P30-CA13330-26, R29CA70896-01, R01CA75503] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brocard J, 1997, P NATL ACAD SCI USA, V94, P14559, DOI 10.1073/pnas.94.26.14559; BURDON T, 1991, J BIOL CHEM, V266, P6909; BYRNE GW, 1989, P NATL ACAD SCI USA, V86, P5473, DOI 10.1073/pnas.86.14.5473; CHERBAS P, 1982, J CHEM SOC CHEM COMM, P1307, DOI 10.1039/c39820001307; COHEN PE, 1993, J REPROD FERTIL, V99, P219, DOI 10.1530/jrf.0.0990219; Danielian PS, 1998, CURR BIOL, V8, P1323, DOI 10.1016/S0960-9822(07)00562-3; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; Feil R, 1996, P NATL ACAD SCI USA, V93, P10887, DOI 10.1073/pnas.93.20.10887; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hennighausen L, 1995, J CELL BIOCHEM, V59, P463, DOI 10.1002/jcb.240590407; Ho SN, 1996, NATURE, V382, P822, DOI 10.1038/382822a0; IMAI S, 1967, STEROIDS, V10, P557, DOI 10.1016/0039-128X(67)90129-8; KALANT H, 1998, PRINCIPLES MED PHARM, P55; Kellendonk C, 1999, J MOL BIOL, V285, P175, DOI 10.1006/jmbi.1998.2307; KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147; LI BL, 1994, CELL GROWTH DIFFER, V5, P711; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Pestell RG, 1999, ENDOCR REV, V20, P501, DOI 10.1210/er.20.4.501; Redfern CH, 1999, NAT BIOTECHNOL, V17, P165, DOI 10.1038/6165; Rossant J, 1999, GENE DEV, V13, P142, DOI 10.1101/gad.13.2.142; Rundle CH, 1998, BBA-GENE STRUCT EXPR, V1398, P164, DOI 10.1016/S0167-4781(98)00046-3; Sawicki JA, 1998, BIOTECHNIQUES, V25, P868, DOI 10.2144/98255rr01; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; Wang Y, 1997, GENE THER, V4, P432, DOI 10.1038/sj.gt.3300402; WANG YL, 1994, P NATL ACAD SCI USA, V91, P8180, DOI 10.1073/pnas.91.17.8180; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F	34	47	52	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2000	14	7					877	884		10.1096/fasebj.14.7.877	http://dx.doi.org/10.1096/fasebj.14.7.877			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	309CG	10783141				2022-12-28	WOS:000086749500005
J	Gorza, L; Vitadello, M				Gorza, L; Vitadello, M			Reduced amount of the glucose-regulated protein GRP94 in skeletal myoblasts results in loss of fusion competence	FASEB JOURNAL			English	Article						heat-shock protein; skeletal-muscle growth and differentiation; antisense-elements physiology; cell fusion; gene expression and regulation	ENDOPLASMIC-RETICULUM PROTEINS; CELL-SURFACE; INDUCIBLE EXPRESSION; MOLECULAR CHAPERONE; GENE-EXPRESSION; MYOGENIN GENE; MUSCLE; DIFFERENTIATION; CALRETICULIN; STRESS	We previously showed that skeletal myocytes of the adult rabbit do not accumulate the endoplasmic reticulum glucose-regulated protein GRP94, neither constitutively nor inducibly, at variance with skeletal myocytes during perinatal development (5), Here we show that C2C12 cells upregulate GRP94 during differentiation and, similarly to primary cultures of murine skeletal myocytes, specifically display GRP94 immunoreactivity on the cell surface. Stable transfection of C2C12 cells with grp94 antisense cDNA shows lack of myotube formation in clones displaying >40% reduction in GRP94 amount. The same result is obtained after irt vivo injection of grp94-antisense myoblasts, Conversely, GRP94 overexpression is accompanied by accelerated myotube formation. Analyses of BrdU incorporation, p21 nuclear translocation, and muscle-gene expression show that muscle differentiation is not apparently affected in grp94-antisense clones. In contrast, cell-surface GRP94 is greatly reduced in grp94-antisense clones, as shown by immunocytochemistry and precipitation of cell-surface biotinylated proteins. Thus, cell-surface expression of GRP94 is necessary for maintenance of fusion competence. Furthermore, differentiating C2C12 cells grown in the presence of anti-GRP94 antibody show decreased myotube number suggesting that cell-surface GRP94 is directly involved in myoblast fusion process.	Univ Padua, Dept Biomed Sci, CNR, Unit Muscle Biol & Physiopathol, I-35121 Padua, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Padua	Vitadello, M (corresponding author), Univ Padua, Dept Biomed Sci, CNR, Unit Muscle Biol & Physiopathol, Via G Colombo 3, I-35121 Padua, Italy.			GORZA, LUISA/0000-0003-4897-400X	NIAAA NIH HHS [AA07573, AA05551] Funding Source: Medline; NIGMS NIH HHS [GM 07040-20] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007040] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [F31AA005551] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Altmeyer A, 1996, INT J CANCER, V69, P340, DOI 10.1002/(SICI)1097-0215(19960822)69:4<340::AID-IJC18>3.0.CO;2-9; Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; Blaschuk KL, 1997, DEV BIOL, V184, P266, DOI 10.1006/dbio.1997.8527; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; Charlton CA, 1997, J CELL BIOL, V138, P331, DOI 10.1083/jcb.138.2.331; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163-7258(98)00013-8; DHAWAN J, 1991, SCIENCE, V254, P1509, DOI 10.1126/science.1962213; Dourdin N, 1997, EXP CELL RES, V235, P385, DOI 10.1006/excr.1997.3684; FASSLER R, 1995, GENE DEV, V9, P1896, DOI 10.1101/gad.9.15.1896; Gogos JA, 1996, J CELL BIOL, V134, P837, DOI 10.1083/jcb.134.4.837; GORZA L, 1993, DEV BIOL, V156, P253, DOI 10.1006/dbio.1993.1074; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HIRANO N, 1995, EUR J BIOCHEM, V234, P336, DOI 10.1111/j.1432-1033.1995.336_c.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Krause KH, 1997, CELL, V88, P439, DOI 10.1016/S0092-8674(00)81884-X; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; Lambert N, 1997, BIOTECHNOL BIOENG, V54, P165, DOI 10.1002/(SICI)1097-0290(19970420)54:2<165::AID-BIT8>3.0.CO;2-J; LEWIS MJ, 1985, J BIOL CHEM, V260, P3050; LI H, 1994, J CELL BIOL, V124, P827, DOI 10.1083/jcb.124.5.827; LI LJ, 1992, J CELL PHYSIOL, V153, P575, DOI 10.1002/jcp.1041530319; LIN HY, 1993, MOL BIOL CELL, V4, P1109, DOI 10.1091/mbc.4.11.1109; LITTLE E, 1995, J BIOL CHEM, V270, P9526, DOI 10.1074/jbc.270.16.9526; Little Edward, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P1; Liu H, 1997, J BIOL CHEM, V272, P21751, DOI 10.1074/jbc.272.35.21751; Loones MT, 1997, CELL MOL LIFE SCI, V53, P179, DOI 10.1007/PL00000590; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; Muresan Z, 1997, J BIOL CHEM, V272, P26095, DOI 10.1074/jbc.272.42.26095; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; Nicchitta CV, 1998, CURR OPIN IMMUNOL, V10, P103, DOI 10.1016/S0952-7915(98)80039-3; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; Ruddon RW, 1997, J BIOL CHEM, V272, P3125, DOI 10.1074/jbc.272.6.3125; Russo S, 1998, J CELL SCI, V111, P691; SAGGIN L, 1990, DEVELOPMENT, V110, P547; Tamura Y, 1997, SCIENCE, V278, P117, DOI 10.1126/science.278.5335.117; VILLA A, 1993, EXP CELL RES, V209, P140, DOI 10.1006/excr.1993.1294; Vitadello M, 1998, BIOCHEM J, V332, P351, DOI 10.1042/bj3320351; VITADELLO M, 1990, J CELL SCI, V97, P11; VITADELLO M, 1994, HUM GENE THER, V5, P11, DOI 10.1089/hum.1994.5.1-11; WHITE TK, 1995, J BIOL CHEM, V270, P15926, DOI 10.1074/jbc.270.27.15926; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; Yogalingam G, 1997, DNA CELL BIOL, V16, P1189, DOI 10.1089/dna.1997.16.1189; Zaretsky JZ, 1997, HUM GENE THER, V8, P1555, DOI 10.1089/hum.1997.8.13-1555	45	41	44	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2000	14	3					461	475		10.1096/fasebj.14.3.461	http://dx.doi.org/10.1096/fasebj.14.3.461			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	291TJ	10698961				2022-12-28	WOS:000085751900005
J	Lee, CGL; Ramachandra, M; Jeang, KT; Martin, MA; Pastan, I; Gottesman, MM				Lee, CGL; Ramachandra, M; Jeang, KT; Martin, MA; Pastan, I; Gottesman, MM			Effect of ABC transporters on HIV-1 infection: inhibition of virus production by the MDR1 transporter	FASEB JOURNAL			English	Article						ABC transporters; acquired immunodeficiency syndrome; AIDS; P-glycoprotein; virus entry	BICISTRONIC EXPRESSION SYSTEM; MULTIDRUG TRANSPORTER; P-GLYCOPROTEIN; SALMONELLA-TYPHIMURIUM; OLIGOPEPTIDE PERMEASE; HYDROPHOBIC PEPTIDES; PROTEASE INHIBITORS; MAMMALIAN-CELLS; GENE; BINDING	(3)The MDR1 multidrug transporter P-gp (P-glycoprotein) is an efflux pump that extrudes diverse hydrophobic drugs and peptides from cells. Since the entry of HIV-1 into cells involves an initial interaction of the viral gp41 hydrophobic peptide with the plasma membrane, a potential effect of P-gp on HIV-1 infectivity was explored. Virus production was greatly decreased when P-gp was overexpressed at the surface of a continuous CD4(+) human T-leukemic cell line (12D7) infected with HIV-1(NL4-3) a T-tropic molecular clone of HIV-1. P-gp overexpression did not significantly alter the surface expression or distribution of either the HIV-1 receptor CD4 or the coreceptor CXCR4. Reduction of HIV-1 infectivity in P-gp-expressing cells occurred both during the fusion of viral and plasma membranes and at subsequent step(s) in the HIV-1 life cycle.	NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; NCI, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Gottesman, MM (corresponding author), NCI, Cell Biol Lab, NIH, Bldg 37,Room 1A09,37 Convent Dr MSC 4255, Bethesda, MD 20892 USA.		pastan, ira/P-9319-2019; Jeang, Kuan-Teh/A-2424-2008; Lee, Caroline G/M-8918-2019	pastan, ira/0000-0002-9223-0270; Lee, Caroline G/0000-0002-4323-3635; Ramachandra, Murali/0000-0003-4039-1491	NATIONAL CANCER INSTITUTE [ZIABC005598, Z01BC008714, ZIABC008714, Z01BC005598] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000547, Z01AI000190, ZIAAI000547, ZIAAI000190] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [Z01OD010491] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; CHAUDHARY PM, 1991, CELL, V66, P85, DOI 10.1016/0092-8674(91)90141-K; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Germann UA, 1996, J BIOL CHEM, V271, P1708, DOI 10.1074/jbc.271.3.1708; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; HIGGINS CF, 1990, J BIOENERG BIOMEMBR, V22, P571, DOI 10.1007/BF00762962; HILES ID, 1987, MOL GEN GENET, V206, P101, DOI 10.1007/BF00326543; HILES ID, 1987, J MOL BIOL, V195, P125, DOI 10.1016/0022-2836(87)90332-9; HUANG LM, 1994, EMBO J, V13, P2886, DOI 10.1002/j.1460-2075.1994.tb06583.x; Lee CGL, 1998, METHOD ENZYMOL, V292, P557; Lee CGL, 1998, J CLIN INVEST, V101, P287, DOI 10.1172/JCI2575; Lee CGL, 1997, ANTISENSE NUCLEIC A, V7, P511, DOI 10.1089/oli.1.1997.7.511; Lee CGL, 1998, BIOCHEMISTRY-US, V37, P3594, DOI 10.1021/bi972709x; LOEFFLER JP, 1990, J NEUROCHEM, V54, P1812, DOI 10.1111/j.1471-4159.1990.tb01240.x; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; NUSSBAUM O, 1994, J VIROL, V68, P5411, DOI 10.1128/JVI.68.9.5411-5422.1994; OSTEDGAARD LS, 1992, J BIOL CHEM, V267, P26142; ROSS EK, 1991, J VIROL, V65, P4350, DOI 10.1128/JVI.65.8.4350-4358.1991; SARKADI B, 1994, FASEB J, V8, P766, DOI 10.1096/fasebj.8.10.7914178; SHARMA RC, 1992, J BIOL CHEM, V267, P5731; Sharom FJ, 1996, BIOCHEM J, V320, P421, DOI 10.1042/bj3200421; SHEN HM, 1998, AM SOC GENE THER SEA, pA211; Shoshani T, 1998, MOL PHARMACOL, V54, P623; STEIN WD, 1994, MOL PHARMACOL, V45, P763; TAME JRH, 1994, SCIENCE, V264, P1578, DOI 10.1126/science.8202710; Zhang SD, 1998, METHOD ENZYMOL, V292, P474	28	60	62	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2000	14	3					516	522		10.1096/fasebj.14.3.516	http://dx.doi.org/10.1096/fasebj.14.3.516			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	291TJ	10698967				2022-12-28	WOS:000085751900011
J	Vieira, O; Escargueil-Blanc, I; Jurgens, G; Borner, C; Almeida, L; Salvayre, R; Negre-Salvayre, A				Vieira, O; Escargueil-Blanc, I; Jurgens, G; Borner, C; Almeida, L; Salvayre, R; Negre-Salvayre, A			Oxidized LDLs alter the activity of the ubiquitin-proteasome pathway: potential role in oxidized LDL-induced apoptosis	FASEB JOURNAL			English	Article						oxidized LDL; 4-hydroxynonenal; proteasome; ubiquitin; apoptosis	LOW-DENSITY-LIPOPROTEIN; ACTIVATED PROTEIN-KINASE; HUMAN-ENDOTHELIAL-CELLS; VASCULAR SMOOTH-MUSCLE; OXIDATIVE STRESS; ATHEROSCLEROTIC LESIONS; LIPID-PEROXIDATION; KAPPA-B; DEGRADATION; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE	Oxidized low-density lipoproteins (oxLDL) play a role in the genesis of atherosclerosis. OxLDL are able to induce apoptosis of vascular cells, which is potentially involved in the formation of the necrotic center of atherosclerotic lesions, plaque rupture, and subsequent thrombotic events, Because oxLDL may induce structural modifications of cell protein and altered proteins may impair cell viability, the present work aimed to evaluate the extent of protein alterations, the degradation of modified proteins through the ubiquitin-proteasome system (a major degradative pathway for altered and oxidatively modified proteins) and their role during apoptosis induced by oxLDL. This paper reports the following: 1) oxLDL induce derivatization of cell proteins by 4-hydroxynonenal (4-HNE) and ubiquitination. 2) Toxic concentrations of oxLDL elicit a biphasic effect on proteasome activity. An early and transient activation of endogenous proteolysis is followed rapidly by a subsequent decay (resulting probably from the 26S proteasome inhibition) and followed later by the inhibition of the 20S proteasome las assessed by inhibition of sLLVY-MCA hydrolysis). 3) Specific inhibitors of proteasome (lactacystin and proteasome inhibitor I) potentiated considerably the toxicity of oxLDL (nontoxic doses of oxLDL became severely toxic). The defect of the ubiquitination pathway tin temperature-sensitive mutants) also potentiated the toxicity of oxLDL. This suggests that the ubiquitin-proteasome pathway plays a role in the cellular defenses against oxLDL-induced toxicity. 4) Dinitrophenylhydrazine (DNPH), an aldehyde reagent, prevented both the oxLDL- induced derivatization of cell proteins and subsequent cytotoxicity. Altogether, the reported data suggest that both derivatization of cell proteins (by 4-HNE and other oxidized lipids) and inhibition of the proteasome pathway are involved in the mechanism of of oxLDL-induced apoptosis.	Univ Toulouse 3, Dept Biochem, INSERM, U466, Toulouse, France; Univ Coimbra, Fac Farm, Lab Bioquim, P-3000 Coimbra, Portugal; Univ Coimbra, Ctr Neurociencias, P-3000 Coimbra, Portugal; Karl Franzens Univ Graz, Inst Med Biochem, Graz, Austria; Univ Fribourg, Inst Biochem, CH-1700 Fribourg, Switzerland	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universidade de Coimbra; Universidade de Coimbra; University of Graz; University of Fribourg	Negre-Salvayre, A (corresponding author), CHU Rangueil, INSERM, U456, 1 Ave Jean Poulhes, F-31403 Toulouse 04, France.		Jürgens, Günther/B-8818-2011; Vieira, O V/C-4860-2013; Vieira, Otilia V/O-8660-2017	Vieira, Otilia V/0000-0003-4924-1780; Negre-Salvayre, Anne/0000-0003-2136-5706; Almeida, Leonor Martins/0000-0002-7769-4712				Auge N, 1998, J BIOL CHEM, V273, P12893, DOI 10.1074/jbc.273.21.12893; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Brand K, 1997, ARTERIOSCL THROM VAS, V17, P1901, DOI 10.1161/01.ATV.17.10.1901; Chait Alan, 1994, Current Opinion in Lipidology, V5, P365, DOI 10.1097/00041433-199410000-00008; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Dean RT, 1997, BIOCHEM J, V324, P1; DEE G, 1991, FEBS LETT, V294, P38, DOI 10.1016/0014-5793(91)81338-9; Deigner HP, 1996, FEBS LETT, V385, P149, DOI 10.1016/0014-5793(96)00371-7; Dimmeler S, 1997, CIRCULATION, V95, P1760; EscargueilBlanc I, 1997, ARTERIOSCL THROM VAS, V17, P331, DOI 10.1161/01.ATV.17.2.331; ESCARGUEILBLANC I, 1994, FASEB J, V8, P1075, DOI 10.1096/fasebj.8.13.7926374; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; ESTERBAUER H, 1990, CHEM RES TOXICOL, V3, P77, DOI 10.1021/tx00014a001; ESTERBAUER H, 1985, BIOCHEM J, V228, P363, DOI 10.1042/bj2280363; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; FRIGUET B, 1994, J BIOL CHEM, V269, P21639; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; Grune T, 1996, J BIOL CHEM, V271, P15504, DOI 10.1074/jbc.271.26.15504; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; Haas AL, 1997, FASEB J, V11, P1257; HABERLAND ME, 1988, SCIENCE, V241, P215, DOI 10.1126/science.2455346; HENRIKSEN T, 1979, SCAND J CLIN LAB INV, V39, P361, DOI 10.3109/00365517909106120; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HESSLER JR, 1979, ATHEROSCLEROSIS, V32, P213, DOI 10.1016/0021-9150(79)90166-7; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Li NX, 1996, BIOCHEM BIOPH RES CO, V225, P855, DOI 10.1006/bbrc.1996.1263; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; Meilhac O, 1999, FASEB J, V13, P485, DOI 10.1096/fasebj.13.3.485; Monney L, 1998, J BIOL CHEM, V273, P6121, DOI 10.1074/jbc.273.11.6121; NATARAJAN V, 1993, FREE RADICAL BIO MED, V15, P365, DOI 10.1016/0891-5849(93)90036-T; NEGRESALVAYRE A, 1990, BIOCHIM BIOPHYS ACTA, V1045, P224, DOI 10.1016/0005-2760(90)90124-G; PENN MS, 1994, ATHEROSCLEROSIS, V108, pS21, DOI 10.1016/0021-9150(94)90150-3; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; PRICE P, 1990, CANCER RES, V50, P1392; Reinheckel T, 1998, BIOCHEM J, V335, P637, DOI 10.1042/bj3350637; ROSENFELD ME, 1991, J CLIN INVEST, V87, P90, DOI 10.1172/JCI115006; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROSSI MA, 1990, BIOCHEM PHARMACOL, V39, P1715, DOI 10.1016/0006-2952(90)90116-3; SCHMITT A, 1995, BRIT J PHARMACOL, V116, P1985, DOI 10.1111/j.1476-5381.1995.tb16402.x; STAROS JV, 1986, ANAL BIOCHEM, V156, P220, DOI 10.1016/0003-2697(86)90176-4; STARY HC, 1990, EUR HEART J, V11, P3, DOI 10.1093/eurheartj/11.suppl_E.3; STEINBRECHER UP, 1990, FREE RADICAL BIO MED, V9, P155, DOI 10.1016/0891-5849(90)90119-4; Strack PR, 1996, BIOCHEMISTRY-US, V35, P7142, DOI 10.1021/bi9518048; Suc I, 1998, FASEB J, V12, P665, DOI 10.1096/fasebj.12.9.665; SZWEDA LI, 1993, J BIOL CHEM, V268, P3342; Tanaka K, 1998, BIOCHEM BIOPH RES CO, V247, P537, DOI 10.1006/bbrc.1998.8617; Uchida K, 1995, ARCH BIOCHEM BIOPHYS, V324, P241, DOI 10.1006/abbi.1995.0036; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Vieira O, 1998, BRIT J PHARMACOL, V123, P565, DOI 10.1038/sj.bjp.0701624; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; WOLFF SP, 1994, METHOD ENZYMOL, V233, P182; YAGI K, 1987, CHEM PHYS LIPIDS, V45, P337, DOI 10.1016/0009-3084(87)90071-5	54	106	112	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2000	14	3					532	542		10.1096/fasebj.14.3.532	http://dx.doi.org/10.1096/fasebj.14.3.532			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	291TJ	10698969				2022-12-28	WOS:000085751900013
J	Zahler, S; Kupatt, C; Becker, BF				Zahler, S; Kupatt, C; Becker, BF			Endothelial preconditioning by transient oxidative stress reduces inflammatory responses of cultured endothelial cells to TNF-alpha	FASEB JOURNAL			English	Article						cytokine; adhesion molecule; NF kappa B; glutathione	MYOCARDIAL ISCHEMIA-REPERFUSION; OXYGEN RADICALS; RABBIT HEARTS; NITRIC-OXIDE; P-SELECTIN; KAPPA-B; INJURY; CARDIOPROTECTION; DYSFUNCTION; INVOLVEMENT	Brief episodes of ischemia can render an organ resistant to subsequent severe ischemia, This 'ischemic preconditioning' is ascribed to various mechanisms, including oxidative stress. We investigated whether preconditioning exists on an endothelial level. Human umbilical vein endothelial cells (HUVECs) were transiently confronted with oxidative stress (1 mM H2O2, 5 min). Adhesion molecules ICAM-1 and E-selectin and release of cytokines IL-6 and IL-8 to subsequent stimulation with TNF-alpha (2.5 ng/ml, 4 h) were measured (flow cytometry and immunoassay), as were nuclear translocation of the transcription factor NF kappa B (Western blotting, confocal microscopy) and redox status of HUVECs (quantification of glutathione by HPLC). TNF-alpha elevated IL-6 in the cell supernatant from 8.8 +/- 1 to 41 +/- 3 pg/ml and IL-8 from 0.5 +/- 0.03 to 3 +/- 0.2 ng/ml. ICAM-1 was increased threefold and E-selectin rose eightfold. Oxidative stress (decrease of glutathione by 50%) reduced post-TNF-alpha levels of IL-6 to 14 +/- 3 and IL-8 to 1 +/- 0.2; the rise of ICAM-1 was completely blocked and E-selectin was only doubled, The anti-inflammatory effects of preconditioning via oxidative stress were paralleled by reduction of the translocation of NF kappa B on stimulation with TNF-alpha, and antagonized by the intracellular radical scavenger N-acetylcysteine, 'Anti-inflammatory preconditioning' of endothelial cells by oxidative stress may account for the inhibitory effects of preconditioning on leukocyte adhesion in vivo.	Univ Munich, Dept Physiol, D-8000 Munich, Germany	University of Munich	Zahler, S (corresponding author), Inst Physiol, Schillerstr 44, D-80336 Munich, Germany.			Kupatt, Christian/0000-0002-3611-1218; Zahler, Stefan/0000-0002-5140-7287				Akimitsu T, 1996, AM J PHYSIOL-HEART C, V271, pH2052, DOI 10.1152/ajpheart.1996.271.5.H2052; Baines CP, 1997, J MOL CELL CARDIOL, V29, P207, DOI 10.1006/jmcc.1996.0265; BANERJEE A, 1993, CIRC RES, V73, P656, DOI 10.1161/01.RES.73.4.656; BAXTER GF, 1994, CIRCULATION, V90, P2993, DOI 10.1161/01.CIR.90.6.2993; CHATELAIN P, 1987, CIRCULATION, V75, P1083, DOI 10.1161/01.CIR.75.5.1083; CHEN W, 1995, CIRC RES, V77, P424, DOI 10.1161/01.RES.77.2.424; Crestanello JA, 1996, J SURG RES, V65, P53, DOI 10.1006/jsre.1996.0342; DEFILY DV, 1993, AM J PHYSIOL, V265, pH700, DOI 10.1152/ajpheart.1993.265.2.H700; Ferdinandy P, 1996, ANN NY ACAD SCI, V793, P489, DOI 10.1111/j.1749-6632.1996.tb33547.x; Friedrichs B, 1998, ARTERIOSCL THROM VAS, V18, P1829, DOI 10.1161/01.ATV.18.12.1829; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GOTO M, 1995, CIRC RES, V77, P611, DOI 10.1161/01.RES.77.3.611; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; HEARSE DJ, 1977, J MOL CELL CARDIOL, V9, P605, DOI 10.1016/S0022-2828(77)80357-X; HOSHIDA S, 1994, CARDIOVASC RES, V28, P1083, DOI 10.1093/cvr/28.7.1083; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JEROME SN, 1995, AM J PHYSIOL-HEART C, V268, pH2063, DOI 10.1152/ajpheart.1995.268.5.H2063; Jordan JE, 1999, CARDIOVASC RES, V43, P860, DOI 10.1016/S0008-6363(99)00187-X; Kokura S, 1999, CIRC RES, V84, P516, DOI 10.1161/01.RES.84.5.516; Kubes P, 1998, AM J PHYSIOL-HEART C, V274, pH1230, DOI 10.1152/ajpheart.1998.274.4.H1230; Kupatt C, 1999, CIRC RES, V84, P392, DOI 10.1161/01.RES.84.4.392; Li CF, 1999, AM J PHYSIOL-HEART C, V276, pH543, DOI 10.1152/ajpheart.1999.276.2.H543; LIU YG, 1995, J MOL CELL CARDIOL, V27, P883, DOI 10.1016/0022-2828(95)90038-1; LOMBARDI L, 1995, NUCLEIC ACIDS RES, V23, P2328, DOI 10.1093/nar/23.12.2328; MA XL, 1991, J CLIN INVEST, V88, P1237, DOI 10.1172/JCI115427; MARBER MS, 1993, CIRCULATION, V88, P1264, DOI 10.1161/01.CIR.88.3.1264; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Pan JL, 1998, J BIOL CHEM, V273, P10058, DOI 10.1074/jbc.273.16.10058; RICHARD V, 1994, CIRCULATION, V89, P1254, DOI 10.1161/01.CIR.89.3.1254; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHCULZ R, 1994, AM J PHYSIOL, V267, pH1341; SIEGFRIED MR, 1992, J PHARMACOL EXP THER, V260, P668; SQUADRITO F, 1993, EUR J PHARMACOL, V237, P223, DOI 10.1016/0014-2999(93)90272-J; Tritto I, 1997, CIRC RES, V80, P743, DOI 10.1161/01.RES.80.5.743; YAO ZH, 1993, AM J PHYSIOL, V264, pH2221, DOI 10.1152/ajpheart.1993.264.6.H2221; Yellon DM, 1998, CARDIOVASC RES, V37, P21, DOI 10.1016/S0008-6363(97)00214-9; Zahler S, 1997, J MOL CELL CARDIOL, V29, P2953, DOI 10.1006/jmcc.1997.0530; Zhou XB, 1996, CIRCULATION, V93, P1177, DOI 10.1161/01.CIR.93.6.1177	38	80	85	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2000	14	3					555	564		10.1096/fasebj.14.3.555	http://dx.doi.org/10.1096/fasebj.14.3.555			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	291TJ	10698971	Green Submitted			2022-12-28	WOS:000085751900015
J	Grishko, V; Solomon, M; Breit, JF; Killilea, DW; Ledoux, SP; Wilson, GL; Gillespie, MN				Grishko, V; Solomon, M; Breit, JF; Killilea, DW; Ledoux, SP; Wilson, GL; Gillespie, MN			Hypoxia promotes oxidative base modifications in the pulmonary artery endothelial cell VEGF gene	FASEB JOURNAL			English	Article									Univ S Alabama, Coll Med, Dept Pharmacol & Cell Biol, Mobile, AL 36688 USA; Univ S Alabama, Coll Med, Dept Neurosci, Mobile, AL 36688 USA	University of South Alabama; University of South Alabama	Gillespie, MN (corresponding author), Univ S Alabama, Coll Med, Dept Pharmacol, MSB 3130, Mobile, AL 36688 USA.	mgillesp@jaguar1.usouthal.edu		Killilea, David/0000-0002-8929-6527				CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253	1	62	63	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2001	15	7					1267	1269		10.1096/fj.00-0755fje	http://dx.doi.org/10.1096/fj.00-0755fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344109	Bronze			2022-12-28	WOS:000168655200031
J	Leitinger, N; Huber, J; Rizza, C; Mechtcheriakova, D; Bochkov, V; Koshelnick, Y; Berliner, JA; Binder, BR				Leitinger, N; Huber, J; Rizza, C; Mechtcheriakova, D; Bochkov, V; Koshelnick, Y; Berliner, JA; Binder, BR			The isoprostane 8-iso-PGF(2 alpha) stimulates endothelial cells to bind monocytes: differences from thromboxane-mediated endothelial activation	FASEB JOURNAL			English	Article									Univ Vienna, Dept Vasc Biol & Thrombosis Res, A-1090 Vienna, Austria; Univ Calif Los Angeles, Dept Med Cardiol, Los Angeles, CA 90095 USA	University of Vienna; University of California System; University of California Los Angeles	Leitinger, N (corresponding author), Univ Vienna, Dept Vasc Biol & Thrombosis Res, Schwarzspanierstr 17, A-1090 Vienna, Austria.			Mechtcheriakova, Diana/0000-0002-8737-3592					0	53	53	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1254	1256		10.1096/fj.00-0498fje	http://dx.doi.org/10.1096/fj.00-0498fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344105				2022-12-28	WOS:000168655200027
J	Masaki, I; Yonemitsu, Y; Komori, K; Ueno, H; Nakashima, Y; Nakagawa, K; Fukumura, M; Kato, A; Hasan, MK; Nagai, Y; Sugimachi, K; Hasegawa, M; Sueishi, K				Masaki, I; Yonemitsu, Y; Komori, K; Ueno, H; Nakashima, Y; Nakagawa, K; Fukumura, M; Kato, A; Hasan, MK; Nagai, Y; Sugimachi, K; Hasegawa, M; Sueishi, K			Recombinant Sendai virus-mediated gene transfer to vasculature: a new class of efficient gene transfer vector to the vascular system	FASEB JOURNAL			English	Article									Kyushu Univ, Grad Sch Med Sci, Dept Pathol, Div Pathophysiol & Expt Pathol,Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Cardiovasc Med, Higashi Ku, Fukuoka 8128582, Japan; DNAVEC Res Inc, Tsukuba, Ibaraki, Japan; Natl Inst Infect Dis, Dept Viral Infect & Vaccine Control, Tokyo, Japan; Natl Inst Infect Dis, AIDS Res Ctr, Tokyo, Japan	Kyushu University; Kyushu University; Kyushu University; DNAVEC Corporation; National Institute of Infectious Diseases (NIID); National Institute of Infectious Diseases (NIID)	Yonemitsu, Y (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Pathol, Div Pathophysiol & Expt Pathol,Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.		KOMORI, Kimihiro/M-8870-2014						0	60	65	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1294	1296		10.1096/fj.00-0460fje	http://dx.doi.org/10.1096/fj.00-0460fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344118				2022-12-28	WOS:000168655200040
J	Oberholzer, C; Oberholzer, A; Clare-Salzler, M; Moldawer, LL				Oberholzer, C; Oberholzer, A; Clare-Salzler, M; Moldawer, LL			Apoptosis in sepsis: a new target for therapeutic exploration	FASEB JOURNAL			English	Review						Bcl-2; caspases; lymphocytes; neutrophils	TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; PROGRAMMED CELL-DEATH; INFLAMMATORY RESPONSE SYNDROME; BCL-2 FAMILY PROTEINS; ACTIVATION-INDUCED APOPTOSIS; DELAYS NEUTROPHIL APOPTOSIS; FULMINANT LIVER DESTRUCTION; SOLUBLE FAS LIGAND; CYTOCHROME-C	The treatment of sepsis and septic shock remains a clinical conundrum, and recent prospective trials with biological response modifiers aimed at the inflammatory response have shown only modest clinical benefit. Recently, interest has shifted toward therapies aimed at reversing the accompanying periods of immune suppression. Studies in experimental animals and critically ill patients have demonstrated that increased apoptosis of lymphoid organs and some parenchymal tissues contributes to this immune suppression, anergy, and organ system dysfunction, During sepsis syndromes, lymphocyte apoptosis can be triggered by the absence of IL-2 or by the release of glucocorticoids, granzymes, or the so-called 'death' cytokines: tumor necrosis factor alpha or Fas ligand, Apoptosis proceeds via auto-activation of cytosolic and/or mitochondrial caspases, which can be influenced by the pro- and anti-apoptotic members of the Bcl-2 family, In experimental animals, not only can treatment with inhibitors of apoptosis prevent lymphoid cell apoptosis; it may also improve outcome. Although clinical trials with anti-apoptotic agents remain distant due in large part to technical difficulties associated with their administration and tissue targeting, inhibition of lymphocyte apoptosis represents an attractive therapeutic target for the septic patient.	Univ Florida, Coll Med, Dept Surg, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Moldawer, LL (corresponding author), Univ Florida, Shands Hosp, Coll Med, Dept Surg, Room 6116,1600 SW Archer Rd,POB 100286, Gainesville, FL 32610 USA.	moldawer@surgery.ufl.edu		Moldawer, Lyle/0000-0002-9041-9838	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008912] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM040586] Funding Source: NIH RePORTER; NHLBI NIH HHS [P30 HL-08912] Funding Source: Medline; NIGMS NIH HHS [R37 GM-40586] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Ayala A, 1999, SHOCK, V11, P211, DOI 10.1097/00024382-199903000-00010; Ayala A, 1999, IMMUNOLOGY, V97, P45; Ayala A, 1996, BLOOD, V87, P4261, DOI 10.1182/blood.V87.10.4261.bloodjournal87104261; AYALA A, 1995, SHOCK, V3, P359; Bazzoni F, 1996, NEW ENGL J MED, V334, P1717, DOI 10.1056/NEJM199606273342607; Biffl WL, 1996, ARCH SURG-CHICAGO, V131, P24; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Bohlinger I, 1996, AM J PATHOL, V149, P1381; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; Bone RC, 1996, CRIT CARE MED, V24, P1125, DOI 10.1097/00003246-199607000-00010; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CASEY LC, 1993, ANN INTERN MED, V119, P771, DOI 10.7326/0003-4819-119-8-199310150-00001; Castelino DJ, 1997, AUST NZ J MED, V27, P170, DOI 10.1111/j.1445-5994.1997.tb00934.x; CHEADLE WG, 1993, J TRAUMA, V35, P844, DOI 10.1097/00005373-199312000-00007; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Chung CS, 1998, ARCH SURG-CHICAGO, V133, P1213, DOI 10.1001/archsurg.133.11.1213; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; COLOTTA F, 1992, BLOOD, V80, P2012; Coopersmith CM, 1999, AM J PHYSIOL-GASTR L, V276, pG677, DOI 10.1152/ajpgi.1999.276.3.G677; COX G, 1996, AM J PHYSIOL, V271, P566; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Ertel W, 1997, J NEUROIMMUNOL, V80, P93, DOI 10.1016/S0165-5728(97)00139-2; ERTEL W, 1995, J TRAUMA, V39, P879, DOI 10.1097/00005373-199511000-00011; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Fanning NF, 1999, SHOCK, V11, P167, DOI 10.1097/00024382-199903000-00003; Faubion WA, 1999, HEPATOLOGY, V29, P1, DOI 10.1002/hep.510290101; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Fukuzuka K, 1999, ANN SURG, V229, P851, DOI 10.1097/00000658-199906000-00012; Fukuzuka K, 2000, AM J PHYSIOL-REG I, V278, pR1005, DOI 10.1152/ajpregu.2000.278.4.R1005; Giordano C, 1997, SCIENCE, V275, P960, DOI 10.1126/science.275.5302.960; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grell M, 1998, P NATL ACAD SCI USA, V95, P570, DOI 10.1073/pnas.95.2.570; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hiramatsu M, 1997, SHOCK, V7, P247, DOI 10.1097/00024382-199704000-00002; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; HORGAN AF, 1994, ANN SURG, V220, P342, DOI 10.1097/00000658-199409000-00010; Hotchkiss RS, 1999, CRIT CARE MED, V27, P1230, DOI 10.1097/00003246-199907000-00002; Hotchkiss RS, 1999, J IMMUNOL, V162, P4148; Hotchkiss RS, 1999, P NATL ACAD SCI USA, V96, P14541, DOI 10.1073/pnas.96.25.14541; Hotchkiss RS, 1997, CRIT CARE MED, V25, P1298, DOI 10.1097/00003246-199708000-00015; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Ito A, 1999, BBA-MOL CELL RES, V1452, P263, DOI 10.1016/S0167-4889(99)00131-7; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Jaeschke H, 1996, SHOCK, V6, P351, DOI 10.1097/00024382-199611000-00009; Jaeschke H, 1998, J IMMUNOL, V160, P3480; JAMESON SC, 1994, NATURE, V369, P750, DOI 10.1038/369750a0; Jimenez MF, 1997, ARCH SURG-CHICAGO, V132, P1263; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Karima R, 1999, MOL MED TODAY, V5, P123, DOI 10.1016/S1357-4310(98)01430-0; KATO Y, 1995, FEMS IMMUNOL MED MIC, V12, P195, DOI 10.1016/0928-8244(95)00067-8; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; Keel M, 1997, BLOOD, V90, P3356, DOI 10.1182/blood.V90.9.3356; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; LEIST M, 1995, AM J PATHOL, V146, P1220; Lenardo M, 1999, ANNU REV IMMUNOL, V17, P221, DOI 10.1146/annurev.immunol.17.1.221; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LILES WC, 1995, BLOOD, V86, P3181; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; Martin C, 1997, CRIT CARE MED, V25, P1813, DOI 10.1097/00003246-199711000-00018; Matute-Bello G, 1999, J IMMUNOL, V163, P2217; MatuteBello G, 1997, AM J RESP CRIT CARE, V156, P1969, DOI 10.1164/ajrccm.156.6.96-12081; Medema JP, 1997, EUR J IMMUNOL, V27, P3492, DOI 10.1002/eji.1830271250; MEMON SA, 1995, J IMMUNOL, V155, P4644; Mignon A, 1999, AM J RESP CRIT CARE, V159, P1308, DOI 10.1164/ajrccm.159.4.9712012; MIYAWAKI T, 1992, J IMMUNOL, V149, P3753; Moldawer LL, 1999, CRIT CARE MED, V27, P1381, DOI 10.1097/00003246-199907000-00035; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; NAKGAWA T, 2000, NATURE, V403, P98; Nolan B, 2000, J TRAUMA, V48, P599, DOI 10.1097/00005373-200004000-00004; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OSULLIVAN ST, 1995, ANN SURG, V222, P482; Ottonello L, 1999, J IMMUNOL, V162, P3601; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; PARRILLO JE, 1990, ANN INTERN MED, V113, P227, DOI 10.7326/0003-4819-113-3-227; RANGELFRAUSTO MS, 1995, JAMA-J AM MED ASSOC, V273, P117, DOI 10.1001/jama.273.2.117; Rodriguez I, 1996, J EXP MED, V183, P1031, DOI 10.1084/jem.183.3.1031; Rodriguez I, 1996, J EXP MED, V184, P2067, DOI 10.1084/jem.184.5.2067; Rogers HW, 1996, J IMMUNOL, V156, P679; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schendel SL, 1998, CELL DEATH DIFFER, V5, P372, DOI 10.1038/sj.cdd.4400365; SCHUTZE S, 1994, J LEUKOCYTE BIOL, V56, P533, DOI 10.1002/jlb.56.5.533; SCHWARTZ LM, 1993, IMMUNOL TODAY, V14, P582, DOI 10.1016/0167-5699(93)90197-S; Shenkar R, 1999, J IMMUNOL, V163, P954; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STONE R, 1994, SCIENCE, V264, P365, DOI 10.1126/science.8153620; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Tannahill CL, 1999, SURGERY, V126, P349, DOI 10.1016/S0039-6060(99)70176-5; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TEODORCZYKINJEYAN JA, 1995, J CLIN IMMUNOL, V15, P318, DOI 10.1007/BF01541322; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsujimoto Y, 1998, GENES CELLS, V3, P697, DOI 10.1046/j.1365-2443.1998.00223.x; Varfolomeev EE, 1996, J EXP MED, V183, P1271, DOI 10.1084/jem.183.3.1271; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Wagner JG, 1999, J LEUKOCYTE BIOL, V66, P10, DOI 10.1002/jlb.66.1.10; WANG SD, 1994, J IMMUNOL, V152, P5014; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zedler S, 1999, CRIT CARE MED, V27, P66, DOI 10.1097/00003246-199901000-00028; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang H, 2000, P NATL ACAD SCI USA, V97, P2597, DOI 10.1073/pnas.97.6.2597; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0; Zheng LX, 1998, J IMMUNOL, V160, P763	126	230	260	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2001	15	6					879	892		10.1096/fj.00-058rev	http://dx.doi.org/10.1096/fj.00-058rev			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292647				2022-12-28	WOS:000167959300001
J	Barbe, P; Larrouy, D; Boulanger, C; Chevillotte, E; Viguerie, N; Thalamas, C; Trastoy, MO; Roques, M; Vidal, H; Langin, D				Barbe, P; Larrouy, D; Boulanger, C; Chevillotte, E; Viguerie, N; Thalamas, C; Trastoy, MO; Roques, M; Vidal, H; Langin, D			Triiodothyronine-mediated up-regulation of UCP2 and UCP3 mRNA expression in human skeletal muscle without coordinated induction of mitochondrial respiratory chain genes	FASEB JOURNAL			English	Article									Univ Toulouse 3, INSERM, U317, Inst Louis Bugnard,Hop Rangueil, Toulouse, France; Fac Med RTH Laennec, INSERM, U449, Lyon, France; Hop Purpan, Ctr Invest Clin, Toulouse, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Langin, D (corresponding author), CHU Rangueil, INSERM, U317, Inst Louis Bugnard, Batiment L3, F-31403 Toulouse 4, France.		Vidal, Hubert/M-6674-2017; Viguerie, Nathalie/M-2422-2017	Vidal, Hubert/0000-0002-9467-0317; Viguerie, Nathalie/0000-0002-1730-9915; Larrouy, Dominique/0000-0002-4120-5593; Langin, Dominique/0000-0002-2669-7825					0	87	91	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2001	15	1					13	15						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11099489				2022-12-28	WOS:000166312400005
J	Wilkinson, MG; Millar, JBA				Wilkinson, MG; Millar, JBA			Control of the eukaryotic cell cycle by MAP kinase signaling pathways	FASEB JOURNAL			English	Review						CDK; proliferation; MAPK; signal transduction	ATF1 TRANSCRIPTION FACTOR; FOCAL ADHESION KINASE; ACTIVATED PROTEIN-KINASES; RECEPTOR TYROSINE KINASES; EPIDERMAL GROWTH-FACTOR; DEPENDENT KINASE; C-JUN; TRANSDUCTION PATHWAY; FISSION YEAST; SACCHAROMYCES-CEREVISIAE	In an often rapidly changing environment, cells must adapt by monitoring and reacting quickly to extracellular stimuli detected by membrane-bound receptors and proteins, Reversible phosphorylation of intracellular regulatory proteins has emerged as a crucial mechanism effecting the transmission and modulation of such signals and is determined by the relative activities of protein kinases and phosphatases within the cell, These are often arranged into complex signaling networks that may function independently or be subject to cross-regulation. Recently, genetic and biochemical analyses have identified the universally conserved mitogen-activated protein (MAP) kinase cascade as one of the most ubiquitous signal transduction systems. This pathway is activated after a variety of cellular stimuli and regulates numerous physiological processes, particularly the cell division cycle, Progression through the cell cycle is critically dependent on the presence of environmental growth factors and stress stimuli, and failure to correctly integrate such signals into the cell cycle machinery can lead to the accumulation of genetic damage and genomic instability characteristic of cancer cells. Here we focus on the MAP kinase cascade and discuss the molecular mechanisms by which these extensively studied signaling pathways influence cell growth and proliferation.	SmithKline Beecham Pharmaceut PLC, Dept Mol Neurobiol, Harlow CM19 5AW, Essex, England; Natl Inst Med Res, Div Yeast Genet, London NW7 1AA, England	GlaxoSmithKline; MRC National Institute for Medical Research	Wilkinson, MG (corresponding author), SmithKline Beecham Pharmaceut PLC, Dept Mol Neurobiol, New Frontiers Sci Pk,Coldharbour Rd, Harlow CM19 5AW, Essex, England.			Millar, Jonathan/0000-0002-9930-3989	MRC [MC_U117531948] Funding Source: UKRI; Medical Research Council [MC_U117531948] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abbott DW, 1999, J BIOL CHEM, V274, P2732, DOI 10.1074/jbc.274.5.2732; Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; ADLER V, 1995, P NATL ACAD SCI USA, V92, P10585, DOI 10.1073/pnas.92.23.10585; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Bohmer RM, 1996, MOL BIOL CELL, V7, P101; Bottazzi ME, 1999, J CELL BIOL, V146, P1255, DOI 10.1083/jcb.146.6.1255; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; Chao TH, 1999, J BIOL CHEM, V274, P36035, DOI 10.1074/jbc.274.51.36035; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Cherkasova V, 1999, GENETICS, V151, P989; CHOI KY, 1994, CELL, V78, P499; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Degols G, 1997, MOL CELL BIOL, V17, P3356, DOI 10.1128/MCB.17.6.3356; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Ellinger-Ziegelbauer H, 1999, MOL CELL BIOL, V19, P3857; English JM, 1999, J BIOL CHEM, V274, P31588, DOI 10.1074/jbc.274.44.31588; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; Gartner A, 1998, MOL CELL BIOL, V18, P3681, DOI 10.1128/MCB.18.7.3681; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; Graves LM, 2000, NATURE, V403, P328, DOI 10.1038/35002111; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Henchoz S, 1997, GENE DEV, V11, P3046, DOI 10.1101/gad.11.22.3046; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Igishi T, 1999, J BIOL CHEM, V274, P30738, DOI 10.1074/jbc.274.43.30738; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kang JS, 1996, MOL CELL BIOL, V16, P3370; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Leone G, 1997, NATURE, V387, P932, DOI 10.1038/43230; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lin TH, 1997, J BIOL CHEM, V272, P8849; Liu Z, 1995, WIREL NETW, V1, P1, DOI 10.1007/BF01196254; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; Mahanty SK, 1999, CELL, V98, P501, DOI 10.1016/S0092-8674(00)81978-9; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; MCKINNEY JD, 1995, MOL CELL BIOL, V15, P2509; MILLAR JBA, 1995, GENE DEV, V9, P2117, DOI 10.1101/gad.9.17.2117; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; Mittnacht S, 1997, CURR BIOL, V7, P219, DOI 10.1016/S0960-9822(97)70094-0; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Oehlen LJWM, 1996, MOL CELL BIOL, V16, P2830; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; PETER M, 1994, SCIENCE, V265, P1228, DOI 10.1126/science.8066461; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; Rausch O, 1997, MOL CELL BIOL, V17, P1170, DOI 10.1128/MCB.17.3.1170; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; SHULZE A, 1996, MOL CELL BIOL, V16, P4632; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TYERS M, 1993, MOL CELL BIOL, V13, P5659, DOI 10.1128/MCB.13.9.5659; Wang S, 1999, EMBO J, V18, P1559, DOI 10.1093/emboj/18.6.1559; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Wilkinson MG, 1999, EMBO J, V18, P4210, DOI 10.1093/emboj/18.15.4210; Wilkinson MG, 1998, GENE DEV, V12, P1391, DOI 10.1101/gad.12.10.1391; Wilkinson MG, 1996, GENE DEV, V10, P2289, DOI 10.1101/gad.10.18.2289; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665; Zhu X, 1996, MOL BIOL CELL, V7, P1001; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	106	236	252	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2147	2157		10.1096/fj.00-0102rev	http://dx.doi.org/10.1096/fj.00-0102rev			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053235				2022-12-28	WOS:000165190800007
J	Pinto, YM; Bader, M; Pesquero, JB; Tschope, C; Scholtens, E; Van Gilst, WH; Buikema, H				Pinto, YM; Bader, M; Pesquero, JB; Tschope, C; Scholtens, E; Van Gilst, WH; Buikema, H			Increased kallikrein expression protects against cardiac ischemia	FASEB JOURNAL			English	Article									Univ Groningen Hosp, Dept Cardiol, NL-9713 GZ Groningen, Netherlands; Univ Groningen Hosp, Dept Clin Pharmacol, NL-9713 GZ Groningen, Netherlands; Max Delbruck Ctr Mol Med, Berlin, Germany; Univ Fed Sao Paulo, Escola Paulista Med, Dept Biophys, Sao Paulo, Brazil	University of Groningen; University of Groningen; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Universidade Federal de Sao Paulo (UNIFESP)	Pinto, YM (corresponding author), Univ Groningen Hosp, Dept Cardiol, Zone S4 Kamer 4-252,Hanzepl 1, NL-9713 GZ Groningen, Netherlands.		Bader, Michael/K-2124-2013; Pesquero, Joao/C-1470-2012; van Gilst, Wiek H/C-3828-2008; van Gilst, Wiek/R-1806-2019	Pesquero, Joao/0000-0002-4507-632X; van Gilst, Wiek/0000-0003-2968-8585; Tschope, Carsten/0000-0001-5243-8985; Bader, Michael/0000-0003-4780-4164					0	34	34	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2000	14	13					1861	1863						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023968				2022-12-28	WOS:000089634400002
J	Salcedo, R; Resau, JH; Halverson, D; Hudson, EA; Dambach, M; Powell, D; Wasserman, K; Oppenheim, JJ				Salcedo, R; Resau, JH; Halverson, D; Hudson, EA; Dambach, M; Powell, D; Wasserman, K; Oppenheim, JJ			Differential expression and responsiveness of chemokine receptors (CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cells	FASEB JOURNAL			English	Article						chemokines; angiogenesis	INTERFERON-BETA; INDUCIBLE PROTEIN-10; GROWTH-FACTOR; IFN-BETA; IN-VIVO; ANGIOGENESIS; INTERLEUKIN-8; METASTASIS; IL-8; TUMORIGENICITY	The basis for the angiogenic effects of CXC chemokines such as interleukin 8 (IL-8) and for angiostatic chemokines such as interferon-inducible protein 10 (IP-10) has been difficult to assess. We recently reported, based on an RNase protection assay, that human umbilical vein endothelial cells (HUVECs) did not express detectable mRNA for the IL-8 receptors CXCR1 and CXCR2. This raised the possibility of heterogeneity of receptor expression by different endothelial cell (ECs) types. Since systemic angiogenesis induced by IL-8 would more likely involve microvessel ECs, we investigated CXC receptor expression on human microvascular dermal endothelial cells (HMECs). By confocal microscopy and immunofluorescence we observed that HMECs consistently expressed high levels of CXCR1 and CXCR4 (mean fluorescence intensity of 261+/-22.1 and 306.2+/-19, respectively) and intermediate levels of CXCR3 and CXCR2 (173.9+/-30.2 and 156+/-30.9, respectively). In contrast, only a small proportion of HUVEC preparations expressed low levels of CXCR1, -2; and -3 (66+/-19.9; 49+/-15, and 81.4+/-17.9, respectively). However, both HMECs and HUVECs expressed equal levels of CXCR4. As expected, HMECs had more potent chemotactic responses to IL-8 than HUVECs, and this was correlated with the levels of IL-8 receptors on the ECs. Antibodies to CXCR1 and CXCR2 each had inhibitory effects on chemotaxis of HMECs to IL-8, indicating that both IL-8 receptors contributed to the migratory response of these cells toward IL-8. Assessment of the functional capacity of CXCR3 unexpectedly revealed that HMECs migrated in response to relatively higher concentrations (100-500 ng/ml) of each of the 'angiostatic' chemokines IP-10, ITAC, and MIG. Despite this, the 'angiostatic' chemokines inhibited the chemotactic response of HMECs to IL-8. IL-8 and SDF-1 alpha but not IP-10 induced calcium mobilization in adherent ECs, suggesting that signaling events associated with calcium mobilization are separable from those required for chemotaxis. Taken together, our data indicated that functional differences among EC types is dependent on the level of the expression of CXC chemokine receptors. Whether this heterogeneity in receptor expression by ECs reflects distinct differentiation pathways remains to be established.	NCI, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; Data Management Serv Inc, ABL BRP, Mol Immunoregulat Lab, Frederick, MD 21702 USA; Data Management Serv Inc, ABL BRP, Div Basic Sci, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Oppenheim, JJ (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Bldg 560,Rm 21-89A, Frederick, MD 21702 USA.				NATIONAL CANCER INSTITUTE [Z01BC009369, ZIABC009369] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGIOLILLO AL, 1995, J EXP MED, V182, P155, DOI 10.1084/jem.182.1.155; ASANG QX, 1998, CELL RES, V8, P171; Balbay MD, 1999, CLIN CANCER RES, V5, P783; BENDER JR, 1987, J CLIN INVEST, V79, P1679, DOI 10.1172/JCI113007; Bielenberg DR, 1999, INT J ONCOL, V14, P401; Bielenberg DR, 1999, J INVEST DERMATOL, V112, P802, DOI 10.1046/j.1523-1747.1999.00566.x; Dong ZY, 1998, CANCER IMMUNOL IMMUN, V46, P137, DOI 10.1007/s002620050472; Dong ZY, 1999, CANCER RES, V59, P872; Ellis LM, 1996, EUR J CANCER, V32A, P2451, DOI 10.1016/S0959-8049(96)00389-9; Engelhardt E, 1998, AM J PATHOL, V153, P1849, DOI 10.1016/S0002-9440(10)65699-4; Feil C, 1998, BIOCHEM BIOPH RES CO, V247, P38, DOI 10.1006/bbrc.1998.8499; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Garlanda C, 1997, ARTERIOSCL THROM VAS, V17, P1193, DOI 10.1161/01.ATV.17.7.1193; Gupta SK, 1998, J BIOL CHEM, V273, P4282, DOI 10.1074/jbc.273.7.4282; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HU DE, 1993, INFLAMMATION, V17, P135, DOI 10.1007/BF00916100; Keane MP, 1997, J IMMUNOL, V159, P1437; KLINEBERG E, 1996, CELL VISION, V3, P402; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; Luca M, 1997, AM J PATHOL, V151, P1105; Mason JC, 1997, AM J PHYSIOL-CELL PH, V273, pC1233, DOI 10.1152/ajpcell.1997.273.4.C1233; PAGE C, 1992, AM J PATHOL, V141, P673; PETZELBAUER P, 1995, CYTOKINE, V7, P267, DOI 10.1006/cyto.1995.0031; PETZELBAUER P, 1993, J IMMUNOL, V151, P5062; Salcedo R, 1999, AM J PATHOL, V154, P1125, DOI 10.1016/S0002-9440(10)65365-5; SCHONBECK U, 1995, J IMMUNOL, V154, P2375; STRIETER RM, 1995, BIOCHEM BIOPH RES CO, V210, P51, DOI 10.1006/bbrc.1995.1626; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; STRIETER RM, 1992, AM J PATHOL, V141, P1279; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Taraboletti G, 1992, EXS, V61, P210; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; Xie KP, 1997, CLIN CANCER RES, V3, P2283	34	212	221	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2000	14	13					2055	2064		10.1096/fj.99-0963com	http://dx.doi.org/10.1096/fj.99-0963com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023990				2022-12-28	WOS:000089634400025
J	Yamamoto, Y; Zolfaghari, R; Ross, AC				Yamamoto, Y; Zolfaghari, R; Ross, AC			Regulation of CYP26 (cytochrome P450RAI) mRNA expression and retinoic acid metabolism by retinoids and dietary vitamin A in liver of mice and rats	FASEB JOURNAL			English	Article						retinoic acid oxidation; vitamin A status; aging	AGING LEWIS RATS; ALL-TRANS; BINDING PROTEINS; MESSENGER-RNA; IN-VIVO; MOUSE; CELLS; 4-HYDROXYLASE; MICROSOMES; RECEPTORS	Retinoic acid (RA), through nuclear retinoid receptors, regulates the expression of numerous genes. However, little is known of the biochemical mechanisms that regulate RA concentration in vivo. CYP26 (P450RAI), a novel cytochrome P450, is expressed during embryonic development, induced by all-trans RA, and capable of catalyzing the oxidation of [H-3]RA to polar retinoids including 4-oxo-RA. Here we report that CYP26 expression in adult liver is regulated by all-trans RA and dietary vitamin A, and is correlated with the metabolism of all-trans RA to polar metabolites. In normal mouse and rat liver, CYP26 mRNA was barely detectable; however, after acute treatment with all-trans RA CYP26 mRNA and RA metabolism by liver microsomes were significantly induced. Aqueous-soluble RA metabolites were detected, but their formation was not induced. The expression of retinoid receptors, RAR-gamma and RXR-alpha, was not changed after RA treatment in vivo. In a model of chronic vitamin A ingestion during aging, CYP26 mRNA expression, determined by Northern blot and RT-PCR analysis, increased progressively with dietary vitamin A (P<0.0001; marginal < control < supplemented) and age (P<0.003). The relative expression of CYP26 mRNA was positively correlated with liver total retinol (log(10)), ranging from undetectable CYP26 expression at liver retinol concentrations below similar to 20 nmol/g to a three- to fourfold elevation at concentrations >10,000 nmol/g (r=0.90, P<0.0001). We conclude that CYP26 expression and RA metabolism are regulated in adult liver not only acutely by RA administration, as may be relevant to retinoid therapy but under chronic dietary conditions relevant to vitamin A nutrition in humans.	Penn State Univ, Dept Nutr, University Pk, PA 16802 USA; Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Ross, AC (corresponding author), Penn State Univ, Dept Nutr, 126-S Henderson Bldg, University Pk, PA 16802 USA.	acr6@psu.edu			NIA NIH HHS [AG09839] Funding Source: Medline; NIDDK NIH HHS [DK46869] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009839] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abu-Abed SS, 1998, J BIOL CHEM, V273, P2409, DOI 10.1074/jbc.273.4.2409; Blaner William S., 1994, P229; BLOMHOFF R, 1982, P NATL ACAD SCI-BIOL, V79, P7326, DOI 10.1073/pnas.79.23.7326; BLOMHOFF R, 1992, ANNU REV NUTR, V12, P37, DOI 10.1146/annurev.nu.12.070192.000345; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Dawson HD, 2000, J NUTR, V130, P1280, DOI 10.1093/jn/130.5.1280; Dawson HD, 1999, J NUTR, V129, P1510, DOI 10.1093/jn/129.8.1510; de Roos K, 1999, MECH DEVELOP, V82, P205, DOI 10.1016/S0925-4773(99)00016-7; DECICCO KL, 2000, J INFECT DIS, V130, P1280; Duester G, 1996, BIOCHEMISTRY-US, V35, P12221, DOI 10.1021/bi961176+; DUNAGIN PE, 1966, BIOCHIM BIOPHYS ACTA, V124, P71, DOI 10.1016/0304-4165(66)90314-X; EDWARDS RB, 1992, EXP EYE RES, V54, P481, DOI 10.1016/0014-4835(92)90126-D; FIORELLA PD, 1994, J BIOL CHEM, V269, P10538; Fujii H, 1997, EMBO J, V16, P4163, DOI 10.1093/emboj/16.14.4163; Gaemers IC, 1996, ENDOCRINOLOGY, V137, P479, DOI 10.1210/en.137.2.479; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; HARRISON EH, 1995, J LIPID RES, V36, P1498; Kang S, 1996, J INVEST DERMATOL, V107, P183, DOI 10.1111/1523-1747.ep12329579; KATO S, 1992, BIOCHEM J, V286, P755, DOI 10.1042/bj2860755; KURLANDSKY SB, 1995, J BIOL CHEM, V270, P17850, DOI 10.1074/jbc.270.30.17850; LEO MA, 1989, J NUTR, V119, P993, DOI 10.1093/jn/119.7.993; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MUINDI JRF, 1994, LEUKEMIA, V8, P1807; Nadin L, 1999, BIOCHEM PHARMACOL, V58, P1201, DOI 10.1016/S0006-2952(99)00192-6; NAPOLI JL, 1987, ARCH BIOCHEM BIOPHYS, V255, P95, DOI 10.1016/0003-9861(87)90298-0; NAPOLI JL, 1991, BIOMED PHARMACOTHER, V45, P131, DOI 10.1016/0753-3322(91)90101-X; Napoli JL, 1999, BBA-MOL CELL BIOL L, V1440, P139, DOI 10.1016/S1388-1981(99)00117-1; OLSON JA, 1984, J NATL CANCER I, V73, P1439; Ong David E., 1994, P283; Raner GM, 1996, MOL PHARMACOL, V49, P515; Ray WJ, 1997, J BIOL CHEM, V272, P18702, DOI 10.1074/jbc.272.30.18702; REEVES PG, 1993, J NUTR, V123, P1939, DOI 10.1093/jn/123.11.1939; RIAZULHAQ, 1991, P NATL ACAD SCI USA, V88, P8272, DOI 10.1073/pnas.88.18.8272; ROBERTS AB, 1980, ARCH BIOCHEM BIOPHYS, V199, P374, DOI 10.1016/0003-9861(80)90293-3; ROBERTS ES, 1992, MOL PHARMACOL, V41, P427; ROSS AC, 1993, FASEB J, V7, P317, DOI 10.1096/fasebj.7.2.8440409; ROSS AC, 1982, J BIOL CHEM, V257, P2453; Ross AC, 2000, MODERN NUTR HLTH DIS, P305; SCHWARTZ EL, 1995, BIOCHEM PHARMACOL, V50, P923, DOI 10.1016/0006-2952(95)00213-J; Sonneveld E, 1999, DEV BIOL, V213, P390, DOI 10.1006/dbio.1999.9381; Teerlink T, 1997, J CHROMATOGR B, V694, P83, DOI 10.1016/S0378-4347(97)00109-6; VECCHINI F, 1994, BIOCHEM BIOPH RES CO, V201, P1205, DOI 10.1006/bbrc.1994.1833; Westin S, 1997, MOL CELL ENDOCRINOL, V129, P169, DOI 10.1016/S0303-7207(97)04055-0; White JA, 1997, J BIOL CHEM, V272, P18538, DOI 10.1074/jbc.272.30.18538; White JA, 1996, J BIOL CHEM, V271, P29922, DOI 10.1074/jbc.271.47.29922; ZACHMAN RD, 1966, J LIPID RES, V7, P3; ZOLFAGHARI R, 1995, ARCH BIOCHEM BIOPHYS, V323, P258, DOI 10.1006/abbi.1995.9966	48	65	68	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2000	14	13					2119	2127		10.1096/fj.00-0061com	http://dx.doi.org/10.1096/fj.00-0061com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023996				2022-12-28	WOS:000089634400031
J	Roeb, E; Behrmann, I; Grotzinger, J; Breuer, B; Matern, S				Roeb, E; Behrmann, I; Grotzinger, J; Breuer, B; Matern, S			An MMP-9 mutant without gelatinolytic activity as a novel TIMP-1-antagonist	FASEB JOURNAL			English	Article									Rhein Westfal TH Aachen, Med Klin 3, D-52057 Aachen, Germany; Inst Biochem, D-52057 Aachen, Germany	RWTH Aachen University	Roeb, E (corresponding author), Rhein Westfal TH Aachen, Med Klin 3, Pauwelsstr 30, D-52057 Aachen, Germany.			Behrmann, Iris/0000-0003-3688-3645					0	34	36	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2000	14	12					1671	1673						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973913				2022-12-28	WOS:000089212400003
J	Akaike, T; Fujii, S; Kato, A; Yoshitake, J; Miyamoto, Y; Sawa, T; Okamoto, S; Suga, M; Asakawa, M; Nagai, Y; Maeda, H				Akaike, T; Fujii, S; Kato, A; Yoshitake, J; Miyamoto, Y; Sawa, T; Okamoto, S; Suga, M; Asakawa, M; Nagai, Y; Maeda, H			Viral mutation accelerated by nitric oxide production during infection in vivo	FASEB JOURNAL			English	Article						NO; peroxynitrite; oxidative stress	SENDAI VIRUS; VESICULAR STOMATITIS; OXYGEN RADICALS; PEROXYNITRITE; MICE; PATHOGENESIS; MUTAGENESIS; SUPEROXIDE; CARCINOGENESIS; FREQUENCIES	Nitric oxide (NO), superoxide (O-2(-)), and their reaction product peroxynitrite (ONOO-) are generated in excess during a host's response against viral infection, and contribute to viral pathogenesis by promoting oxidative stress and tissue injury. Here we demonstrate that NO and peroxynitrite greatly accelerates the mutation of Sendai virus (SeV), a nonsegmented negative-strand RNA virus, by using green fluorescent protein (GFP) inserted into and expressed by a recombinant SeV (GFP-SeV) as an indicator for mutation. GFP-SeV mutation frequencies were much higher in the wild-type mice than in those lacking inducible NO synthase, suggesting that mutation of the virus in vivo is NO dependent. High levels of NO and NO-mediated oxidative stress were induced by GFP-SeV infection in the lung of the wild-type mice, but not in the iNOS-deficient mice, as evidenced by electron spin resonance spectroscopy and immunohistochemical analysis for nitrotyrosine formation as well as histopathological examination. Furthermore, peroxynitrite, an NO-derived reactive nitrogen intermediate, enhanced viral mutation in vitro. These results indicate that the oxidative stress induced by NO produced during the natural course of viral infection increases mutation, expands the quasispecies spectrum, and facilitates evolution of RNA viruses.	Kumamoto Univ, Sch Med, Dept Microbiol, Kumamoto 8600811, Japan; Kumamoto Univ, Sch Med, Dept Med 1, Kumamoto 8600811, Japan; Univ Tokyo, Inst Ind Sci, Dept Viral Infect, Tokyo 1080071, Japan; DNAVEC Res Inst, Tsukuba, Ibaraki, Japan	Kumamoto University; Kumamoto University; University of Tokyo; DNAVEC Corporation	Akaike, T (corresponding author), Kumamoto Univ, Sch Med, Dept Microbiol, Kumamoto 8600811, Japan.							AKAIKE T, 1992, ARCH BIOCHEM BIOPHYS, V294, P55, DOI 10.1016/0003-9861(92)90136-K; AKAIKE T, 1990, J CLIN INVEST, V85, P739, DOI 10.1172/JCI114499; Akaike T, 1996, P NATL ACAD SCI USA, V93, P2448, DOI 10.1073/pnas.93.6.2448; Akaike T, 1998, P SOC EXP BIOL MED, V217, P64; Beck MA, 1998, FASEB J, V12, P1143, DOI 10.1096/fasebj.12.12.1143; BECK MA, 1995, NAT MED, V1, P433, DOI 10.1038/nm0595-433; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; CARP RI, 1962, VIROLOGY, V17, P99, DOI 10.1016/0042-6822(62)90086-7; Denicola A, 1998, P NATL ACAD SCI USA, V95, P3566, DOI 10.1073/pnas.95.7.3566; Domingo E, 1997, REV MED VIROL, V7, P87, DOI 10.1002/(SICI)1099-1654(199707)7:2<87::AID-RMV188>3.0.CO;2-0; Fujii S, 1999, VIROLOGY, V256, P203, DOI 10.1006/viro.1999.9610; Gal A, 1996, P NATL ACAD SCI USA, V93, P15102, DOI 10.1073/pnas.93.26.15102; GRANOFF A, 1961, VIROLOGY, V13, P402, DOI 10.1016/0042-6822(61)90270-7; HARRIS CC, 1991, CANCER RES, V51, pS5023; HASSAN MK, 1997, J GEN VIROL, V78, P2813; HOLLAND JJ, 1990, J VIROL, V64, P3960, DOI 10.1128/JVI.64.8.3960-3962.1990; HOMMA M, 1973, J VIROL, V12, P1457, DOI 10.1128/JVI.12.6.1457-1465.1973; Inoue K, 1999, J BIOL CHEM, V274, P27069, DOI 10.1074/jbc.274.38.27069; Juedes MJ, 1996, MUTAT RES-FUND MOL M, V349, P51, DOI 10.1016/0027-5107(95)00152-2; Karupiah G, 1998, J EXP MED, V188, P1541, DOI 10.1084/jem.188.8.1541; Kato A, 1996, GENES CELLS, V1, P569, DOI 10.1046/j.1365-2443.1996.d01-261.x; LAUBACH VE, 1995, P NATL ACAD SCI USA, V92, P10688, DOI 10.1073/pnas.92.23.10688; LIU RH, 1995, MUTAT RES-REV GENET, V339, P73, DOI 10.1016/0165-1110(95)90004-7; Marla SS, 1997, P NATL ACAD SCI USA, V94, P14243, DOI 10.1073/pnas.94.26.14243; NISHIKAWA K, 1983, VIROLOGY, V130, P318, DOI 10.1016/0042-6822(83)90086-7; ODA T, 1989, SCIENCE, V244, P974, DOI 10.1126/science.2543070; OHSHIMA H, 1994, MUTAT RES, V305, P253, DOI 10.1016/0027-5107(94)90245-3; Okamoto T, 1997, ARCH BIOCHEM BIOPHYS, V342, P261, DOI 10.1006/abbi.1997.0127; PORTNER A, 1980, VIROLOGY, V104, P235, DOI 10.1016/0042-6822(80)90382-7; RADI R, 1991, J BIOL CHEM, V266, P4244; Rubbo H, 1996, CHEM RES TOXICOL, V9, P809, DOI 10.1021/tx960037q; SCHEID A, 1976, VIROLOGY, V69, P265, DOI 10.1016/0042-6822(76)90213-0; Schwarz KB, 1996, FREE RADICAL BIO MED, V21, P641, DOI 10.1016/0891-5849(96)00131-1; SINGER B, 1969, VIROLOGY, V39, P395, DOI 10.1016/0042-6822(69)90087-7; SMITH DB, 1987, J GEN VIROL, V68, P2729, DOI 10.1099/0022-1317-68-11-2729; Szabo C, 1997, NITRIC OXIDE-BIOL CH, V1, P373, DOI 10.1006/niox.1997.0143; TSUGITA A, 1962, J MOL BIOL, V4, P73, DOI 10.1016/S0022-2836(62)80039-4; VUILLAUME M, 1987, MUTAT RES, V186, P43, DOI 10.1016/0165-1110(87)90014-5; WEITZMAN SA, 1981, SCIENCE, V212, P546, DOI 10.1126/science.6259738; Zhuang JC, 1998, P NATL ACAD SCI USA, V95, P8286, DOI 10.1073/pnas.95.14.8286	40	80	82	2	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2000	14	10					1447	1454		10.1096/fj.14.10.1447	http://dx.doi.org/10.1096/fj.14.10.1447			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877838				2022-12-28	WOS:000087932200020
J	Dahlstedt, AJ; Katz, A; Wieringa, B; Westerblad, H				Dahlstedt, AJ; Katz, A; Wieringa, B; Westerblad, H			Is creatine kinase responsible for fatigue? Studies of isolated skeletal muscle deficient in creatine kinase	FASEB JOURNAL			English	Article						calcium; excitation-contraction coupling; inorganic phosphate; low-frequency fatigue; muscle metabolism	SINGLE FIBERS; MOUSE MUSCLE; SARCOPLASMIC-RETICULUM; INTRACELLULAR CALCIUM; CA2+ RELEASE; RABBIT SKELETAL; RELAXATION RATE; PHOSPHATE; MECHANISMS; FORCE	Creatine kinase (CK) is a key enzyme for maintaining a constant ATP/ADP ratio during rapid energy turnover. To investigate the role of CK in skeletal muscle fatigue, we used isolated whole muscles and intact single fibers from CK-deficient mice (CK-/-). With high-intensity electrical stimulation, single fibers from CK-/- mice displayed a transient decrease in both tetanic free myoplasmic [Ca2+] ([Ca2+](i) measured with the fluorescent dye indo-1) and force that was not observed in wild-type fibers. With less intense, repeated tetanic stimulation single fibers and EDL muscles, both of which are fast-twitch, fatigued more slowly in CK-/- than in wild-type mice; on the other hand, the slow-twitch soleus muscle fatigued more rapidly in CK-/- mice. In single wild-type fibers, tetanic force decreased and [Ca2+](i) increased during the first 10 fatiguing tetani, but this was not observed in CK-/- fibers. Fatigue was not accompanied by phosphocreatine breakdown and accumulation of inorganic phosphate in CK-/- muscles. In conclusion, CK is important for avoiding fatigue at the onset of high-intensity stimulation, However, during more prolonged stimulation, CK may contribute to the fatigue process by increasing the myoplasmic concentration of inorganic phosphate.	Karolinska Inst, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden; Univ Nijmegen, Fac Med Sci, Dept Cell Biol & Histol, NL-6500 HB Nijmegen, Netherlands	Karolinska Institutet; Radboud University Nijmegen	Westerblad, H (corresponding author), Karolinska Inst, Dept Physiol & Pharmacol, von Eulers Vag 4, S-17177 Stockholm, Sweden.	Hakan.Westerblad@fyfa.ki.se	Wieringa, Berend/A-5346-2011; Katz, Abram/AAL-2244-2020	Wieringa, Berend/0000-0001-9192-8020; Westerblad, Hakan/0000-0002-8180-3029				ALLEN DG, 1989, J PHYSIOL-LONDON, V415, P433, DOI 10.1113/jphysiol.1989.sp017730; ALLEN DG, 1995, EXP PHYSIOL, V80, P497, DOI 10.1113/expphysiol.1995.sp003864; Andrade FH, 1998, J PHYSIOL-LONDON, V509, P565, DOI 10.1111/j.1469-7793.1998.565bn.x; BESSMAN SP, 1985, ANNU REV BIOCHEM, V54, P831, DOI 10.1146/annurev.bi.54.070185.004151; Bruton JD, 1997, AM J PHYSIOL-CELL PH, V272, pC870; Bruton JD, 1998, J APPL PHYSIOL, V85, P478, DOI 10.1152/jappl.1998.85.2.478; Chin ER, 1997, AM J PHYSIOL-CELL PH, V272, pC550, DOI 10.1152/ajpcell.1997.272.2.C550; DAWSON MJ, 1980, J PHYSIOL-LONDON, V299, P465, DOI 10.1113/jphysiol.1980.sp013137; DEHAAN A, 1989, PFLUG ARCH EUR J PHY, V413, P422, DOI 10.1007/BF00584493; FRUEN BR, 1994, J BIOL CHEM, V269, P192; FRYER MW, 1995, J PHYSIOL-LONDON, V482, P123, DOI 10.1113/jphysiol.1995.sp020504; GODT RE, 1989, J PHYSIOL-LONDON, V412, P155, DOI 10.1113/jphysiol.1989.sp017609; GUTH K, 1987, J BIOL CHEM, V262, P13627; HAN JW, 1992, BIOCHEMISTRY-US, V31, P377, DOI 10.1021/bi00117a010; Hultman E, 1980, Exerc Sport Sci Rev, V8, P41; LaBella JJ, 1998, J APPL PHYSIOL, V84, P1166, DOI 10.1152/jappl.1998.84.4.1166; LAMB GD, 1991, J PHYSIOL-LONDON, V434, P507, DOI 10.1113/jphysiol.1991.sp018483; LANNERGREN J, 1991, J PHYSIOL-LONDON, V434, P307; LANNERGREN J, 1987, J PHYSIOL-LONDON, V390, P285; MEYER RA, 1984, AM J PHYSIOL, V246, pC365, DOI 10.1152/ajpcell.1984.246.5.C365; MILLAR NC, 1990, J BIOL CHEM, V265, P20234; Owen VJ, 1996, J PHYSIOL-LONDON, V493, P309, DOI 10.1113/jphysiol.1996.sp021385; Posterino GS, 1998, J PHYSIOL-LONDON, V512, P97, DOI 10.1111/j.1469-7793.1998.097bf.x; SMITH JS, 1985, NATURE, V316, P446, DOI 10.1038/316446a0; Steeghs K, 1998, MOL CELL BIOCHEM, V184, P183, DOI 10.1023/A:1006811717709; Steeghs K, 1997, CELL, V89, P93, DOI 10.1016/S0092-8674(00)80186-5; Tullson PC, 1998, AM J PHYSIOL-CELL PH, V274, pC1411, DOI 10.1152/ajpcell.1998.274.5.C1411; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; Watchko JF, 1997, J APPL PHYSIOL, V82, P1416, DOI 10.1152/jappl.1997.82.5.1416; WESTERBLAD H, 1994, J PHYSIOL-LONDON, V474, P291, DOI 10.1113/jphysiol.1994.sp020022; Westerblad H, 1998, J PHYSIOL-LONDON, V510, P269, DOI 10.1111/j.1469-7793.1998.269bz.x; WESTERBLAD H, 1992, J PHYSIOL-LONDON, V453, P413, DOI 10.1113/jphysiol.1992.sp019236; Westerblad H, 1996, PFLUG ARCH EUR J PHY, V431, P964, DOI 10.1007/s004240050092; WESTERBLAD H, 1991, J GEN PHYSIOL, V98, P615, DOI 10.1085/jgp.98.3.615; Westerblad H, 1998, ACTA PHYSIOL SCAND, V162, P253, DOI 10.1046/j.1365-201X.1998.0301f.x; WESTERBLAD H, 1993, J APPL PHYSIOL, V75, P382, DOI 10.1152/jappl.1993.75.1.382	36	79	81	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2000	14	7					982	990		10.1096/fasebj.14.7.982	http://dx.doi.org/10.1096/fasebj.14.7.982			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	309CG	10783153				2022-12-28	WOS:000086749500017
J	Rohan, RM; Fernandez, A; Udagawa, T; Wan, J; D'Amato, RJ				Rohan, RM; Fernandez, A; Udagawa, T; Wan, J; D'Amato, RJ			Genetic heterogeneity of angiogenesis in mice	FASEB JOURNAL			English	Article						growth factors; blood vessels; endothelial cells; inbred strains	GROWTH; MODEL	Many diseases, including cancer, are dependent on the growth of new blood vessels, a process known as angiogenesis, Differences in an individual's ability to grow new blood vessels may influence the rate of progression of these diseases. Here we show that different strains of inbred mice have an similar to 10-fold range of response to growth factor-stimulated angiogenesis in the corneal micropocket assay. The in vitro migratory activity of endothelial cells from aortic rings of selected strains correlated with the in vivo responsiveness. Further, a differential sensitivity to angiogenesis inhibitors was seen between strains, with one strain demonstrating resistance to both TNP-470 and thalidomide. These results suggest the presence of genetic factors that control individual angiogenic potential.	Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	D'Amato, RJ (corresponding author), Childrens Hosp, 300 Longwood Ave,Enders 1006, Boston, MA 02115 USA.							ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0; Cheung DSM, 1997, ANN PLAS SURG, V38, P269, DOI 10.1097/00000637-199703000-00014; DAMERON KM, 1994, COLD SPRING HARB SYM, V59, P483, DOI 10.1101/SQB.1994.059.01.053; ENGERMAN RL, 1967, LAB INVEST, V17, P738; EZEKOWITZ RAB, 1992, NEW ENGL J MED, V326, P1456, DOI 10.1056/NEJM199205283262203; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1975, ANN INTERN MED, V82, P96, DOI 10.7326/0003-4819-82-1-96; GREGOR Z, 1978, BRIT J OPHTHALMOL, V62, P547, DOI 10.1136/bjo.62.8.547; Griep AE, 1998, INVEST OPHTH VIS SCI, V39, P2723; Kenyon BM, 1997, EXP EYE RES, V64, P971, DOI 10.1006/exer.1997.0292; Kenyon BM, 1996, INVEST OPHTH VIS SCI, V37, P1625; Michaelson I.C., 1948, T OPHTHALMOL SOC, V68, P137; NICOSIA RF, 1990, LAB INVEST, V63, P115; POOLE TJ, 1989, J EXP ZOOL, V251, P224, DOI 10.1002/jez.1402510210; Redmer D A, 1996, Rev Reprod, V1, P182; Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597-19; Thurston G, 1998, AM J PATHOL, V153, P1099, DOI 10.1016/S0002-9440(10)65654-4; [No title captured]	19	180	182	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2000	14	7					871	876		10.1096/fasebj.14.7.871	http://dx.doi.org/10.1096/fasebj.14.7.871			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	309CG	10783140				2022-12-28	WOS:000086749500004
J	D'Aniello, A; Di Fiore, MM; Fisher, GH; Milone, A; Seleni, A; D'Aniello, S; Perna, AF; Ingrosso, D				D'Aniello, A; Di Fiore, MM; Fisher, GH; Milone, A; Seleni, A; D'Aniello, S; Perna, AF; Ingrosso, D			Occurrence of D-aspartic acid and N-methyl-D-aspartic acid in rat neuroendocrine tissues and their role in the modulation of luteinizing hormone and growth hormone release	FASEB JOURNAL			English	Article						D-Asp; NMDA; methyltransferase; S-adenosylmethionine; NMDA synthase; testosterone; progesterone; endocrine glands; nervous system	PERFORMANCE LIQUID-CHROMATOGRAPHY; D-AMINO ACIDS; OCTOPUS-VULGARIS LAM; N-METHYL-D,L-ASPARTATE MODULATION; PROLACTIN SECRETION; LH-RELEASE; GONADOTROPIN; OXIDASE; DERIVATIZATION; INVOLVEMENT	Using two specific and sensitive fluorometric/HPLC methods and a GC-MS method, alone and in combination with D-aspartate oxidase, we have demonstrated for the first time that N-methyl-D-aspartate (NMDA), in addition to D-aspartate (D-Asp), is endogenously present as a natural molecule in rat nervous system and endocrine glands. Both of these amino acids are mostly concentrated at nmol/g levels in the adenohypophysis, hypothalamus, brain, and testis. The adenohypophysis maximally showed the ability to accumulate D-Asp when the latter is exogenously administered. In vivo experiments, consisting of the i.p. injection of D-Asp, showed that D-Asp induced both growth hormone and luteinizing hormone (LH) release. However, in vitro experiments showed that D-Asp was able to induce LH release from adenohypophysis only when this gland was co-incubated with the hypothalamus. This is because D-Asp also induces the release of GnRH from the hypothalamus, which in turn is directly responsible for the D-Asp-induced LH secretion from the pituitary gland. Compared to D-Asp, NMDA elicits its hormone release action at concentrations similar to 100-fold lower than D-Asp. D-AP5, a specific NMDA receptor antagonist, inhibited D-Asp and NMDA hormonal activity, demonstrating that these actions are mediated by NMDA receptors. NMDA is biosynthesized from D-Asp by an S-adeno- sylmethionine-dependent enzyme, which we tentatively denominated as NMDA synthase.-D'Aniello, A., Di Fiore, M. M., Fisher, G. H., Milone, A., Seleni, A., D'Aniello, S., Perna, A. F., Ingrosso, D. Occurrence of D-aspartic acid and N-methyl-D-aspartic acid in rat neuroendocrine tissues and their role in the modulation of luteinizing hormone and growth hormone release.	Staz Zool Anton Dohrn, Dept Biochem & Mol Biol & Neurobiol, I-80121 Naples, Italy; Univ Naples 2, Dept Sci Vita, I-81100 Caserta, Italy; Barry Univ, Dept Chem, Miami Shores, FL 33161 USA; CNR, Ist Chim Mol Interesse Biol, I-80072 Arco Felice Napoli, Italy; Dept Radioimmunol, Lab Igea, I-80027 Naples, Italy; Univ Naples 2, Inst Nephrol, Sch Med, I-80131 Naples, Italy; Univ Naples 2, Inst Biochem Macromol, Sch Med, I-80138 Naples, Italy	Stazione Zoologica Anton Dohrn di Napoli; Universita della Campania Vanvitelli; Consiglio Nazionale delle Ricerche (CNR); Universita della Campania Vanvitelli; Universita della Campania Vanvitelli	D'Aniello, A (corresponding author), Staz Zool Anton Dohrn, Dept Biochem & Mol Biol & Neurobiol, Villa Comunale 1, I-80121 Naples, Italy.	daniello@alpha.snz.it	Ingrosso, Diego/AHE-4980-2022; Di Fiore, Maria Maddalena/ABE-4398-2020; Perna, Alessandra F/AAC-3952-2022	PERNA, Alessandra/0000-0003-4048-9392; Di Fiore, Maria Maddalena/0000-0003-4673-6729	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM045455] Funding Source: NIH RePORTER; NIGMS NIH HHS [SO6GM45455, GM TW00033] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arias P, 1996, BRAIN RES, V740, P234, DOI 10.1016/S0006-8993(96)00862-1; ARSLAN M, 1988, NEUROENDOCRINOLOGY, V47, P465, DOI 10.1159/000124951; ARSLAN M, 1992, LIFE SCI, V50, P295, DOI 10.1016/0024-3205(92)90337-O; ASWAD DW, 1984, ANAL BIOCHEM, V137, P405, DOI 10.1016/0003-2697(84)90106-4; BARB CR, 1993, LIFE SCI, V53, P1157, DOI 10.1016/0024-3205(93)90552-E; Bettendorf M, 1999, HORM RES, V51, P25, DOI 10.1159/000023309; BOURGUIGNON JP, 1989, NEUROENDOCRINOLOGY, V49, P402, DOI 10.1159/000125145; BRANN DW, 1991, ENDOCRINOLOGY, V128, P1541, DOI 10.1210/endo-128-3-1541; CHANG WJ, 1993, DOMEST ANIM ENDOCRIN, V10, P305, DOI 10.1016/0739-7240(93)90034-9; D'Aniello A, 1998, FEBS LETT, V436, P23, DOI 10.1016/S0014-5793(98)01087-4; DAniello A, 1996, LIFE SCI, V59, P97, DOI 10.1016/0024-3205(96)00266-4; DANIELLO A, 1978, J NEUROCHEM, V31, P1107, DOI 10.1111/j.1471-4159.1978.tb00155.x; DANIELLO A, 1977, J NEUROCHEM, V29, P1053, DOI 10.1111/j.1471-4159.1977.tb06508.x; DANIELLO A, 1993, ANAL BIOCHEM, V213, P290, DOI 10.1006/abio.1993.1423; DANIELLO A, 1993, J BIOL CHEM, V268, P26941; DANIELLO A, 1995, GEN COMP ENDOCR, V100, P69, DOI 10.1006/gcen.1995.1134; DANIELLO A, 1992, COMP BIOCHEM PHYS B, V102, P795, DOI 10.1016/0305-0491(92)90082-3; DANIELLO A, 1992, LIFE SCI, V52, P733; Di Fiore MM, 1998, J ENDOCRINOL, V157, P199, DOI 10.1677/joe.0.1570199; DOWNING JA, 1996, J ENDOCRINOL, V149, P63; DUNLOP DS, 1986, BIOCHEM BIOPH RES CO, V141, P27, DOI 10.1016/S0006-291X(86)80329-1; ESTIENNE MJ, 1989, LIFE SCI, V44, P1527, DOI 10.1016/0024-3205(89)90445-1; Estienne MJ, 1998, J ANIM SCI, V76, P2162; Estienne MJ, 1996, J ANIM SCI, V74, P597; FISHER GH, 1994, MOL CHEM NEUROPATHOL, V23, P115, DOI 10.1007/BF02815405; FISHER GH, 1991, BRAIN RES BULL, V26, P983, DOI 10.1016/0361-9230(91)90266-M; Fitzgerald BP, 1997, BIOL REPROD, V57, P36, DOI 10.1095/biolreprod57.1.36; GAY VL, 1987, ENDOCRINOLOGY, V120, P2289, DOI 10.1210/endo-120-6-2289; GODEL H, 1984, J CHROMATOGR, V297, P49, DOI 10.1016/S0021-9673(01)89028-2; HALLOWAY AC, 1997, ONCORHYNCHUS MYKISS, V107, P32; HASHIMOTO A, 1993, J NEUROCHEM, V61, P348, DOI 10.1111/j.1471-4159.1993.tb03575.x; HASHIMOTO A, 1993, FEBS LETT, V331, P4, DOI 10.1016/0014-5793(93)80286-4; ILPO T, 1984, HORMONE ACTION TESTI, V438, P283; NEGRI A, 1987, J BIOL CHEM, V262, P10026; NEGRI A, 1999, IN PRESS BIOCH BIOPH; NEIDLE A, 1990, LIFE SCI, V46, P1517, DOI 10.1016/0024-3205(90)90424-P; OKUMA E, 1994, J CHROMATOGR B, V660, P243, DOI 10.1016/0378-4347(94)00304-1; OLDENDORF WH, 1971, AM J PHYSIOL, V221, P1629, DOI 10.1152/ajplegacy.1971.221.6.1629; ONDO JG, 1988, LIFE SCI, V43, P2283, DOI 10.1016/0024-3205(88)90422-5; PERNA AF, 1993, J CLIN INVEST, V91, P2497; PING L, 1994, ENDOCRINOLOGY, V135, P113, DOI 10.1210/en.135.1.113; Pinilla L, 1999, NEUROENDOCRINOLOGY, V69, P11, DOI 10.1159/000054398; POHL CR, 1989, ENDOCRINOLOGY, V124, P1905, DOI 10.1210/endo-124-4-1905; PRICE MT, 1978, NEUROENDOCRINOLOGY, V26, P352, DOI 10.1159/000122790; PRICE MT, 1978, BRAIN RES, V158, P461, DOI 10.1016/0006-8993(78)90690-X; SATO M, 1987, BIOCHEM J, V241, P309, DOI 10.1042/bj2410309; SCHAINKER BA, 1980, BRAIN RES, V184, P425, DOI 10.1016/0006-8993(80)90810-0; SCHELL MJ, 1997, P NATL ACAD SCI USA, V94, P2113; TEDESCHI G, 1994, BBA-PROTEIN STRUCT M, V1207, P217, DOI 10.1016/0167-4838(94)00071-9; URBANSKI HF, 1987, NEUROENDOCRINOLOGY, V46, P273, DOI 10.1159/000124831; WILSON RC, 1982, BRAIN RES, V248, P177, DOI 10.1016/0006-8993(82)91160-X; ZANISI M, 1991, J STEROID BIOCHEM, V40, P155, DOI 10.1016/0960-0760(91)90178-8; ZUCKER I, 1983, HDB BEHAVIORAL NEURO, P3	53	202	212	2	27	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2000	14	5					699	714		10.1096/fasebj.14.5.699	http://dx.doi.org/10.1096/fasebj.14.5.699			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301DH	10744627				2022-12-28	WOS:000086292700008
J	Wuttge, DM; Romert, A; Eriksson, U; Torma, H; Hansson, GK; Sirsjo, A				Wuttge, DM; Romert, A; Eriksson, U; Torma, H; Hansson, GK; Sirsjo, A			Induction of CD36 by all-trans retinoic acid: retinoic acid receptor signaling in the pathogenesis of atherosclerosis	FASEB JOURNAL			English	Article									Karolinska Inst, Ctr Mol Med, Stockholm, Sweden; Karolinska Inst, Dept Med, Stockholm, Sweden; Ludwig Inst Canc Res, Stockholm Branch, S-10401 Stockholm, Sweden; Univ Uppsala Hosp, Dept Med Sci, Dermatol Sect, Uppsala, Sweden	Karolinska Institutet; Karolinska Institutet; Ludwig Institute for Cancer Research; Uppsala University; Uppsala University Hospital	Sirsjo, A (corresponding author), Karolinska Hosp, Ctr Mol Med, Cardiovasc Res Unit, S-17176 Stockholm, Sweden.		Hansson, Goran K/B-7423-2012; Törmä, Hans/F-8152-2011	Törmä, Hans/0000-0002-3617-8551; Hansson, Goran/0000-0003-4148-5190					0	35	35	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1221	1223		10.1096/fj.00-0488fje	http://dx.doi.org/10.1096/fj.00-0488fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344094				2022-12-28	WOS:000168655200016
J	Morris, MA; Liu, JX; Kumar, V; Bennett, M				Morris, MA; Liu, JX; Kumar, V; Bennett, M			The B6 strain-Ly491 NK inhibitory gene expression on T Cells in FVB.LY491(B6) transgenic mice fails to prevent normal T cell functions.	FASEB JOURNAL			English	Meeting Abstract									Univ Texas, SW Med Ctr, Dallas, TX 75390 USA; Univ Chicago, Chicago, IL 60637 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Chicago									0	14	15	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR 8	2001	15	5	2				A1026	A1026		10.1096/fj.00-0603fje	http://dx.doi.org/10.1096/fj.00-0603fje			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410TA	11292674				2022-12-28	WOS:000167454201807
J	Liu, YY; Han, TY; Giuliano, AE; Cabot, MC				Liu, YY; Han, TY; Giuliano, AE; Cabot, MC			Ceramide glycosylation potentiates cellular multidrug resistance	FASEB JOURNAL			English	Article						glucosylceramide synthase; antisense; breast cancer; apoptosis; chemotherapy	BREAST-CANCER-CELLS; GLUCOSYLCERAMIDE SYNTHASE; P-GLYCOPROTEIN; INDUCED APOPTOSIS; GLYCOSPHINGOLIPID SYNTHESIS; ADRIAMYCIN RESISTANCE; GLUCOSPHINGOLIPID SYNTHESIS; GENE-EXPRESSION; CYCLOSPORINE-A; SDZ PSC-833	Ceramide glycosylation, through glucosylceramide synthase (GCS), allows cellular escape from ceramide-induced programmed cell death. This glycosylation event confers cancer cell resistance to cytotoxic anticancer agents [Liu, Y. Y., Han, T. Y., Giuliano, A. E., and M. C. Cabot. (1999) J. Biol. Qlem. 274, 1140-1146]. We previously found that glucosylceramide, the glycosylated form of ceramide, accumulates in adriamycin-resistant breast carcinoma cells, in vinblastine-resistant epithelioid carcinoma cells, and in tumor specimens from patients showing poor response to chemotherapy, Here we show that multidrug resistance can be increased over baseline and then totally reversed in human breast cancer cells by GCS gene targeting. In adriamycin-resistant MCF-7-AdrR cells, transfection of GCS upgraded multidrug resistance, whereas transfection of GCS antisense markedly restored cellular sensitivity to anthracyclines, Vinca alkaloids, taxanes, and other anticancer drugs. Sensitivity to the various drugs by GCS antisense transfection increased 7- to 240-fold and was consistent with the resumption of ceramide-caspase-apoptotic signaling. CCS targeting had Little influence on cellular sensitivity to either 5-FU or cisplatin, nor did it modify P-glyco-protein expression or rhodamine-123 efflux, GCS antisense transfection did enhance rhodamine-123 uptake compared with parent MCF-7-AdrR cells. This study reveals that GCS is a novel mechanism of multidrug resistance and positions GCS antisense as an innovative force to overcome multidrug resistance in cancer chemotherapy.-Liu, Y.-Y., Han, T.-Y., Giuliano, A. E., and Cabot, M, C, Ceramide glycosylation potentiates cellular multidrug resistance.	St Johns Hlth Ctr, John Wayne Canc Inst, Santa Monica, CA 90404 USA	John Wayne Cancer Institute	Cabot, MC (corresponding author), St Johns Hlth Ctr, John Wayne Canc Inst, 2200 Santa Monica Blvd, Santa Monica, CA 90404 USA.	Cabot@jwci.org		Liu, Yong-Yu/0000-0002-7968-0162	NATIONAL CANCER INSTITUTE [R01CA077632] Funding Source: NIH RePORTER; NCI NIH HHS [CA77632] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASU S, 1968, J BIOL CHEM, V243, P5802; BATIST G, 1986, J BIOL CHEM, V261, P5544; Birkle S, 2000, J NEUROCHEM, V74, P547, DOI 10.1046/j.1471-4159.2000.740547.x; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BROUTYBOYE D, 1995, CANCER RES, V55, P1633; Cabot MC, 1999, CANCER RES, V59, P880; Cabot MC, 1998, FEBS LETT, V431, P185, DOI 10.1016/S0014-5793(98)00744-3; CABOT MC, 1997, BREAST CANC RES TREA, V46, P283; Chen JH, 1998, P NATL ACAD SCI USA, V95, P2648, DOI 10.1073/pnas.95.5.2648; COWAN KH, 1986, P NATL ACAD SCI USA, V83, P9328, DOI 10.1073/pnas.83.24.9328; DARVIS WD, 1998, CURR OPIN ONCOL, V10, P552; DATTA SC, 1988, LIPIDS, V23, P508, DOI 10.1007/BF02535529; Dbaibo GS, 1998, J CLIN INVEST, V102, P329, DOI 10.1172/JCI1180; DECKER DA, 1995, ANN CLIN LAB SCI, V25, P52; FAIRCHILD CR, 1990, MOL PHARMACOL, V37, P801; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; Ferte J, 2000, EUR J BIOCHEM, V267, P277, DOI 10.1046/j.1432-1327.2000.01046.x; Fukumoto H, 1996, INT J CANCER, V67, P676, DOI 10.1002/(SICI)1097-0215(19960904)67:5<676::AID-IJC14>3.0.CO;2-3; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Hakamori S, 1998, ACTA ANAT, V161, P79; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Ichikawa S, 1996, P NATL ACAD SCI USA, V93, P4638, DOI 10.1073/pnas.93.10.4638; INOKUCHI J, 1990, CANCER RES, V50, P6731; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; JONES JB, 1985, CIBA F SYMP, V111, P3; Kim HM, 1997, FEBS LETT, V412, P201, DOI 10.1016/S0014-5793(97)00777-1; Kok JW, 2000, INT J CANCER, V87, P172, DOI 10.1002/1097-0215(20000715)87:2<172::AID-IJC3>3.0.CO;2-K; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kolter T, 1998, BRAIN PATHOL, V8, P79; Kyogashima M, 1996, CANCER LETT, V101, P25, DOI 10.1016/0304-3835(95)04106-0; Lala P, 2000, J BIOL CHEM, V275, P6246, DOI 10.1074/jbc.275.9.6246; Lavie Y, 1999, LIPIDS, V34, pS57, DOI 10.1007/BF02562229; Lavie Y, 1997, J BIOL CHEM, V272, P1682, DOI 10.1074/jbc.272.3.1682; Lavie Y, 1996, J BIOL CHEM, V271, P19530, DOI 10.1074/jbc.271.32.19530; Lehnert M, 1996, EUR J CANCER, V32A, P912, DOI 10.1016/0959-8049(96)00069-X; Liu YY, 2000, J BIOL CHEM, V275, P7138, DOI 10.1074/jbc.275.10.7138; Liu YY, 1999, EXP CELL RES, V252, P464, DOI 10.1006/excr.1999.4649; Liu YY, 1999, J BIOL CHEM, V274, P1140, DOI 10.1074/jbc.274.2.1140; Luberto C, 1998, J BIOL CHEM, V273, P14550, DOI 10.1074/jbc.273.23.14550; Lucci A, 1999, INT J ONCOL, V15, P541; Lucci A, 1999, CANCER-AM CANCER SOC, V86, P300, DOI 10.1002/(SICI)1097-0142(19990715)86:2<300::AID-CNCR14>3.0.CO;2-H; Lucci A, 1998, ANTICANCER RES, V18, P475; MARSH NL, 1995, J CLIN INVEST, V95, P2903, DOI 10.1172/JCI117997; Mizutani A, 1996, BIOCHEM BIOPH RES CO, V222, P494, DOI 10.1006/bbrc.1996.0772; Mutoh T, 1998, J BIOL CHEM, V273, P26001, DOI 10.1074/jbc.273.40.26001; Myrick D, 1999, LEUKEMIA RES, V23, P569, DOI 10.1016/S0145-2126(99)00048-X; Nicholson KM, 1999, BRIT J CANCER, V81, P423, DOI 10.1038/sj.bjc.6690711; Perales M, 1998, LEUKEMIA LYMPHOMA, V31, P609, DOI 10.3109/10428199809057621; PETERSON RHF, 1983, CANCER RES, V43, P222; Radford IR, 1999, INT J RADIAT BIOL, V75, P521, DOI 10.1080/095530099140168; Radin NS, 1999, BIOCHEM PHARMACOL, V57, P589; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; RIORDAN JR, 1979, J BIOL CHEM, V254, P2701; ROSENWALD AG, 1994, J LIPID RES, V35, P1232; SCHNEIDER J, 1995, ANTICANCER RES, V15, P1117; SHUKLA GS, 1990, ARCH BIOCHEM BIOPHYS, V283, P372, DOI 10.1016/0003-9861(90)90657-K; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Stein U, 1997, INT J CANCER, V72, P885, DOI 10.1002/(SICI)1097-0215(19970904)72:5<885::AID-IJC28>3.0.CO;2-6; Watanabe R, 1998, J BIOL CHEM, V273, P9651, DOI 10.1074/jbc.273.16.9651; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yamashita T, 1999, P NATL ACAD SCI USA, V96, P9142, DOI 10.1073/pnas.96.16.9142; Yokoyama K, 1997, EUR J BIOCHEM, V249, P450, DOI 10.1111/j.1432-1033.1997.00450.x	65	233	252	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2001	15	3					719	730		10.1096/fj.00-0223com	http://dx.doi.org/10.1096/fj.00-0223com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259390				2022-12-28	WOS:000167419500029
J	Massfelder, T; Taesch, N; Endlich, N; Eichinger, A; Escande, B; Endlich, K; Barthelmebs, M; Helwig, JJ				Massfelder, T; Taesch, N; Endlich, N; Eichinger, A; Escande, B; Endlich, K; Barthelmebs, M; Helwig, JJ			Paradoxical actions of exogenous and endogenous parathyroid hormone-related protein on renal vascular smooth muscle cell proliferation: reversion in the SHR model of genetic hypertension	FASEB JOURNAL			English	Article						mitogenesis; intracrine; nucleolus	PTH/PTHRP RECEPTOR; BLOOD-PRESSURE; MESSENGER-RNA; PEPTIDE; EXPRESSION; PTHRP; ARTERIES; KIDNEY; RATS; BINDING	In previous studies, added parathyroid hormone-related protein (PTHrP) inhibits whereas transfected PTHrP stimulates the proliferation of A10 aortic smooth muscle cells by nuclear translocation of the peptide. In the present studies, we asked whether these paradoxical trophic actions of PTHrP occur in smooth muscle cells (SMC) cultured from small intrarenal arteries of, and whether they are altered in, 12-wk-old spontaneously hypertensive rats (SHR) as compared to normotensive Wistar-Kyoto (WKY) rats, SHR cells grew faster than WKY cells. PTHrP transcript was increased in SHR-derived cells whereas PTH1 receptor (PTH1R) transcripts were similar in both cell Lines. In both strains of cells, stable transfection with human PTHrP(1-139) cDNA did not further induce proliferation, suggesting maximal effect of endogenous PTHrP in wild cells. In contrast, transfection with antisense hPTHrP(1-139) DNA, which abolished PTHrP mRNA, decreased WKY but increased SHR cell proliferation. Added PTHrP(1-36) (1-100 pM) decreased WKY and increased SHR cell proliferation, Additional studies indicated that the preferential coupling of PTH1-R to G-protein Gi was responsible for the proliferative effect of exogenous PTHrP in SHR cells. Moreover, PTHrP was detected in the nucleolus of a fraction of WKY and SHR renal SMC, in vitro as well as in situ, suggesting that the nucleolar translocation of PTHrP might be involved in the proliferative effects of endogenous PTHrP. In renovascular SMC, added PTHrP is antimitogenic, whereas endogenously produced PTHrP is mitogenic, These paradoxical effects of PTHrP on renovascular SMC proliferation appear to be reversed in the SHR model of genetic hypertension, A new concept emerges from these results, according to which a single molecule may have opposite effects on VSMC proliferation under physiological and pathophysiological conditions.-Mass-felder, T., Taesch, N., Endlich, N., Eichinger, A., Escande, B., Endlich, K., Barthelmebs, M., Helwig, J.-J. Paradoxical actions of exogenous and endogenous parathyroid hormone-related protein on renal vascular smooth muscle cell proliferation: reversion in the SHR model of genetic hypertension.	Univ Louis Pasteur Strasbourg 1, Sect Renovasc Pharmacol & Physiol, INSERM, Sch Med, Strasbourg, France	CHU Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Universite de Franche-Comte	Helwig, JJ (corresponding author), INSERM, Equipe 0015, MENRT, Equipe 2307, 11 Rue Humann,Batiment 4,1 Etage, F-67085 Strasbourg, France.	Jean-Jacques.Helwig@pharmaco-ulp.u-strasbg.fr	Massfelder, Thierry/I-1260-2016; Endlich, Karlhans/G-5485-2013	Endlich, Karlhans/0000-0001-6052-6061				Aarts MM, 1999, J BONE MINER RES, V14, P1493, DOI 10.1359/jbmr.1999.14.9.1493; Aarts MM, 1999, J BIOL CHEM, V274, P4832, DOI 10.1074/jbc.274.8.4832; ABOUSAMRA AB, 1989, ENDOCRINOLOGY, V125, P2594; ANANDSRIVASTAVA MB, 1992, BIOCHEM J, V288, P79, DOI 10.1042/bj2880079; Broadus Arthur E., 1994, P259; BUKOSKI RD, 1990, J HYPERTENS, V8, P37, DOI 10.1097/00004872-199001000-00007; Celic S, 1996, J ENDOCRINOL, V150, P299, DOI 10.1677/joe.0.1500299; Diez J, 1998, EUR HEART J, V19, pG29; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Endlich N, 2000, KIDNEY INT, V57, P2468, DOI 10.1046/j.1523-1755.2000.00105.x; Fiaschi-Taesch N, 1998, KIDNEY INT, V54, pS207, DOI 10.1046/j.1523-1755.1998.06749.x; HADRAVA V, 1992, BIOCHEM CELL BIOL, V70, P599, DOI 10.1139/o92-091; HENDERSON JE, 1995, MOL CELL BIOL, V15, P4064; Ishikawa M, 1998, ATHEROSCLEROSIS, V136, P59, DOI 10.1016/S0021-9150(97)00187-1; JIANG BB, 1995, MINER ELECTROL METAB, V21, P157; Joun H, 1997, ENDOCRINOLOGY, V138, P1742, DOI 10.1210/en.138.4.1742; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; Kett MM, 1996, CLIN EXP PHARMACOL P, V23, pS132, DOI 10.1111/j.1440-1681.1996.tb03074.x; Lam MHC, 1999, J BIOL CHEM, V274, P7391, DOI 10.1074/jbc.274.11.7391; LAM MHC, 1999, ASBMR ANN M ST LOUIS; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maeda S, 1996, ENDOCRINOLOGY, V137, P3154, DOI 10.1210/en.137.8.3154; Maeda S, 1999, ENDOCRINOLOGY, V140, P1815, DOI 10.1210/en.140.4.1815; Massfelder T, 1998, CURR OPIN NEPHROL HY, V7, P27, DOI 10.1097/00041552-199801000-00005; Massfelder T, 1996, BRIT J PHARMACOL, V118, P1995, DOI 10.1111/j.1476-5381.1996.tb15635.x; Massfelder T, 1999, ENDOCRINOLOGY, V140, P1507, DOI 10.1210/en.140.4.1507; Massfelder T, 1996, KIDNEY INT, V50, P1591, DOI 10.1038/ki.1996.475; Massfelder T, 1997, P NATL ACAD SCI USA, V94, P13630, DOI 10.1073/pnas.94.25.13630; MASSFELDER T, 1995, J PHYSIOL-LONDON, V483, P481; NAKAYAMA T, 1994, BIOCHEM BIOPH RES CO, V200, P1028, DOI 10.1006/bbrc.1994.1553; NICKOLS GA, 1990, ENDOCRINOLOGY, V126, P721, DOI 10.1210/endo-126-2-721; Noda M, 1997, HYPERTENSION, V30, P1284, DOI 10.1161/01.HYP.30.5.1284; ORLOFF JJ, 1995, ENDOCRINOLOGY, V136, P3016, DOI 10.1210/en.136.7.3016; Orloff JJ, 1996, ENDOCRINOLOGY, V137, P5376, DOI 10.1210/en.137.12.5376; Ozeki S, 1996, ARTERIOSCL THROM VAS, V16, P565, DOI 10.1161/01.ATV.16.4.565; Pederson T, 1998, J CELL BIOL, V143, P279, DOI 10.1083/jcb.143.2.279; Pederson T, 1998, NUCLEIC ACIDS RES, V26, P3871, DOI 10.1093/nar/26.17.3871; Philbrick WM, 1996, PHYSIOL REV, V76, P127, DOI 10.1152/physrev.1996.76.1.127; PIROLA CJ, 1994, ENDOCRINOLOGY, V134, P2230, DOI 10.1210/en.134.5.2230; PIROLA CJ, 1993, J BIOL CHEM, V268, P1987; Qian J, 1999, ENDOCRINOLOGY, V140, P1826, DOI 10.1210/en.140.4.1826; Rettig R, 1996, J HUM HYPERTENS, V10, P641; RETTIG R, 1990, CLIN EXP HYPERTENS A, V12, P957, DOI 10.3109/10641969009073513; RETTIG R, 1993, J HUM HYPERTENS, V7, P177; SAUSSINE C, 1993, KIDNEY INT, V44, P764, DOI 10.1038/ki.1993.311; Schwindinger WF, 1998, ENDOCRINE, V8, P201, DOI 10.1385/ENDO:8:2:201; STUART WD, 1999, ASBMR ANN M ST LOUIS; TAKAHASHI K, 1995, BIOCHEM BIOPH RES CO, V208, P447, DOI 10.1006/bbrc.1995.1358; TREMBLAY J, 1992, CAN J PHYSIOL PHARM, V70, P565, DOI 10.1139/y92-071; Valin A, 1997, J CELL PHYSIOL, V170, P209, DOI 10.1002/(SICI)1097-4652(199702)170:2<209::AID-JCP13>3.3.CO;2-Y; Vasavada RC, 1998, RECENT PROG HORM RES, V53, P305; Wu TL, 1996, J BIOL CHEM, V271, P24371, DOI 10.1074/jbc.271.40.24371; Wysolmerski JJ, 1998, ANNU REV PHYSIOL, V60, P431, DOI 10.1146/annurev.physiol.60.1.431; YANG TX, 1997, AM J PHYSIOL, V41, pF751	56	18	18	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2001	15	3					707	718		10.1096/fj.00-0053com	http://dx.doi.org/10.1096/fj.00-0053com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259389				2022-12-28	WOS:000167419500028
J	Fruhbeck, G; Gomez-Ambrosi, J; Salvador, J				Fruhbeck, G; Gomez-Ambrosi, J; Salvador, J			Leptin-induced lipolysis opposes the tonic inhibition of endogenous adenosine in white adipocytes	FASEB JOURNAL			English	Article						OB protein; catecholamines; G-proteins; obesity; lipid metabolism	ADENYLATE-CYCLASE ACTIVITY; DEPENDENT PROTEIN-KINASE; FAT-CELLS; IN-VIVO; RAT ADIPOCYTES; OB/OB MICE; BROWN FAT; OBESE; ACTIVATION; GTP	The aim of the present study was to gain insight into the signaling pathway used by leptin to stimulate lipolysis. The lipolytic rate of white adipocytes from sex- and age-matched lean (+/+) and fa/fa rats was determined in the absence or presence of leptin together with a number of agents acting at different levels of the signaling cascade. Leptin did not modify FSK-, dbcAMP-, and IBMX-stimulated lipolysis. Lipolysis can also be maximally stimulated by lowering media adenosine levels with adenosine deaminase (ADA), i.e., in the ligand-free state. Although ADA produced near maximal lipolysis in adipocytes of lean animals, only half of the maximal lipolytic rate (50.9+/-3.2%) was achieved in fat cells from fa/fa rats (P=0.0034). In adipocytes from lean animals preincubated with ADA, leptin caused a concentration-related stimulation of lipolysis (P=0.0001). However, leptin had no effect on the lipolytic activity of adipocytes in the ligand-free state from fa/fa rats. The adenosine A(1) receptor agonist CPA effectively inhibited basal lipolysis in both lean and obese adipocytes (P=0.0001 and P=0.0090, respectively). Leptin had no effect on the lipolytic rate of adipocytes isolated from fa/fa rats and preincubated with CPA. When adipocytes were incubated with the A(1) receptor antagonist DPCPX, a significant increase in glycerol release was observed in fa/fa fat cells (P=0.009), whereas cells isolated from lean rats showed no differences to ADA-stimulated lipolysis. After pretreatment with PTX, which inactivates receptor-mediated G(i) function, adipocytes of obese rats became as responsive to the stimulatory actions of ISO as cells from lean rats (P=0.0090 vs. ISO in fa/fa rats; P=0.2416 vs. lean rats, respectively). PTX treatment of lean cells, however, did not alter their response to this lipolytic agent. It can be concluded that the lipolytic effect of leptin is located at the adenylate cyclase/G(i) proteins level and that leptin-induced lipolysis opposes the tonic inhibition of endogenous adenosine in white adipocytes.	Univ Navarra, Metab Res Lab, Pamplona 31008, Spain; Univ Navarra Clin, Dept Endocrinol, Pamplona 31008, Spain	University of Navarra; University of Navarra	Fruhbeck, G (corresponding author), Univ Navarra Clin, Dept Endocrinol, Pamplona 31008, Spain.	gfruhbeck@unav.es	Gómez-Ambrosi, Javier/D-2984-2017	Gómez-Ambrosi, Javier/0000-0001-5601-1604				BEGINHEICK N, 1985, J BIOL CHEM, V260, P6187; BEGINHEICK N, 1990, BIOCHEM J, V268, P83, DOI 10.1042/bj2680083; BEGINHEICK N, 1992, AM J PHYSIOL, V263, pC121, DOI 10.1152/ajpcell.1992.263.1.C121; BERKICH DA, 1995, AM J PHYSIOL-ENDOC M, V268, pE693, DOI 10.1152/ajpendo.1995.268.4.E693; Bottini E, 1999, METABOLISM, V48, P949, DOI 10.1016/S0026-0495(99)90187-7; Bray G, 1997, FASEB J, V11, P937, DOI 10.1096/fasebj.11.12.9337146; CARO JF, 1994, J CELL BIOCHEM, V54, P309, DOI 10.1002/jcb.240540307; Chagnon YC, 2000, OBES RES, V8, P89, DOI 10.1038/oby.2000.12; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Chen GX, 1996, P NATL ACAD SCI USA, V93, P14795, DOI 10.1073/pnas.93.25.14795; Cheng JT, 2000, DIABETES, V49, P20, DOI 10.2337/diabetes.49.1.20; Cioffi JA, 1996, NAT MED, V2, P585, DOI 10.1038/nm0596-585; Crist GH, 1998, FASEB J, V12, P1301, DOI 10.1096/fasebj.12.13.1301; DOLE VP, 1960, J BIOL CHEM, V235, P2595; Fruhbeck G, 1999, DIABETES, V48, P903, DOI 10.2337/diabetes.48.4.903; Fruhbeck G, 2000, DIABETOLOGIA, V43, P3, DOI 10.1007/s001250050002; Fruhbeck G, 1998, BIOCHEM BIOPH RES CO, V250, P99, DOI 10.1006/bbrc.1998.9277; Fruhbeck G, 1997, BIOCHEM BIOPH RES CO, V240, P590, DOI 10.1006/bbrc.1997.7716; GALITZKY J, 1993, AM J PHYSIOL, V264, pE403, DOI 10.1152/ajpendo.1993.264.3.E403; GETTYS TW, 1991, J BIOL CHEM, V266, P15949; GREENBERG AS, 1987, J BIOL CHEM, V262, P4564; HONNOR RC, 1985, J BIOL CHEM, V260, P5122; HONNOR RC, 1985, J BIOL CHEM, V260, P5130; KAARTINEN JM, 1994, BBA-GEN SUBJECTS, V1201, P69, DOI 10.1016/0304-4165(94)90153-8; Kenan Y, 1997, AM J PHYSIOL-ENDOC M, V272, pE1043, DOI 10.1152/ajpendo.1997.272.6.E1043; LAFONTAN M, 1993, J LIPID RES, V34, P1057; LANOUE KF, 1994, FASEB J, V8, P72, DOI 10.1096/fasebj.8.1.8299893; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; MALBON CC, 1985, J BIOL CHEM, V260, P2558; MARTIN LF, 1990, SURGERY, V108, P228; MILLIGAN G, 1990, BIOCHEM J, V270, P765, DOI 10.1042/bj2700765; Moxham CM, 1996, NATURE, V379, P840, DOI 10.1038/379840a0; MOXHAM CM, 1993, DEV GENET, V14, P266, DOI 10.1002/dvg.1020140404; OHISALO JJ, 1989, BIOCHEM J, V260, P843, DOI 10.1042/bj2600843; Rice AM, 2000, ENDOCRINOLOGY, V141, P1442, DOI 10.1210/en.141.4.1442; RODBELL M, 1964, J BIOL CHEM, V239, P375; Shimabukuro M, 1997, P NATL ACAD SCI USA, V94, P4637, DOI 10.1073/pnas.94.9.4637; Siegrist-Kaiser CA, 1997, J CLIN INVEST, V100, P2858, DOI 10.1172/JCI119834; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; VANNUCCI SJ, 1990, INT J OBESITY, V14, P125; VANNUCCI SJ, 1989, AM J PHYSIOL, V257, pE871, DOI 10.1152/ajpendo.1989.257.6.E871; Wang MY, 1999, J BIOL CHEM, V274, P17541, DOI 10.1074/jbc.274.25.17541; Wang ZW, 1999, BIOCHEM BIOPH RES CO, V260, P653, DOI 10.1006/bbrc.1999.0918; WIELAND O, 1957, BIOCHEM Z, V329, P313; Xu BY, 1998, AM J PHYSIOL-ENDOC M, V274, pE271, DOI 10.1152/ajpendo.1998.274.2.E271; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zhao AZ, 1998, J CLIN INVEST, V102, P869, DOI 10.1172/JCI3920	48	83	86	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2001	15	2					333	340		10.1096/fj.00-0249com	http://dx.doi.org/10.1096/fj.00-0249com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156949				2022-12-28	WOS:000166872900015
J	L'Heureux, N; Stoclet, JC; Auger, FA; Lagaud, GJL; Germain, L; Andriantsitohaina, R				L'Heureux, N; Stoclet, JC; Auger, FA; Lagaud, GJL; Germain, L; Andriantsitohaina, R			A human tissue-engineered vascular media: a new model for pharmacological studies of contractile responses	FASEB JOURNAL			English	Article						tissue engineering; blood vessel; pharmacol; calcium; purinoceptors; cyclic nucleotides; contraction	SMOOTH-MUSCLE-CELLS; DEPENDENT PROTEIN-KINASE; NITRIC-OXIDE; ISOMETRIC CONTRACTION; NUCLEOTIDE RECEPTOR; CYCLIC-GMP; EXPRESSION; ATP; CULTURE; MECHANISM	Our method for producing tissue-engineered blood vessels based exclusively on the use of human cells, i.e., without artificial scaffolding, has previously been described (1). In this report, a tissue-engineered vascular media (TEVM) was specifically produced for pharmacological studies from cultured human vascular smooth muscle cells (VSMC). The VSMC displayed a differentiated phenotype as demonstrated by the re-expression of VSMC-specific markers and actual tissue contraction in response to physiological stimuli. Because of their physiological shape and mechanical strength, rings of human TEVM could be mounted on force transducers in organ baths to perform standard pharmacological experiments. Concentration-response curves to vasoconstrictor agonists (histamine, bradykinin, ATP, and UTP) were established, with or without selective antagonists, allowing pharmacological characterization of receptors (H-1, B-2, and P-2Y1, and pyrimidinoceptors). Sustained agonist-induced contractions were associated with transient increases in cytosolic Ca2+ concentration, suggesting sensitization of the contractile machinery to Ca2+.ATP caused both Ca2+ entry and Ca2+ release from a ryanodine- and caffeine-sensitive store. Increased cyclic AMP or cyclic GMP levels caused relaxation. This human TEVM displays many of functional characters of the normal vessel from which the cells were originally isolated, including contractile/relaxation responses, cyclic nucleotide sensitivity, and Ca2+ handling mechanisms comparable to those of the normal vessel from which the cells were originally isolated. These results demonstrate the potential of this human model as a versatile new tool for pharmacological research.	Hop St Sacrament CHA, Lab Organogenese Expt, Ste Foy, PQ G1S 4L8, Canada; Univ Laval, Dept Surg, Quebec City, PQ, Canada; Univ Strasbourg 1, Fac Pharm, Lab Pharmacol & Physicochim Interact Cellulaires, UMR CNRS 7034, F-67401 Illkirch Graffenstaden, France	Laval University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Germain, L (corresponding author), Hop St Sacrament CHA, Lab Organogenese Expt, 1050 Chemin, Ste Foy, PQ G1S 4L8, Canada.	Lucie.germain@chg.ulaval.ca	ANDRIANTSITOHAINA, Ramaroson/H-5286-2018; L'Heureux, Nicolas/K-8669-2015	L'Heureux, Nicolas/0000-0001-8602-3948; Germain, Lucie/0000-0001-8883-6491; andriantsitohaina, ramaroson/0000-0002-4770-3585				ALLEN BG, 1994, TRENDS BIOCHEM SCI, V19, P362, DOI 10.1016/0968-0004(94)90112-0; ALTURA BM, 1972, AM J PHYSIOL, V222, P345, DOI 10.1152/ajplegacy.1972.222.2.345; ANDRIANTSITOHAINA R, 1995, AM J PHYSIOL-HEART C, V268, pH1223, DOI 10.1152/ajpheart.1995.268.3.H1223; BIRUKOV KG, 1993, EXP CELL RES, V204, P46, DOI 10.1006/excr.1993.1007; Bo XN, 1998, EUR J PHARMACOL, V353, P59, DOI 10.1016/S0014-2999(98)00383-5; Boerth NJ, 1997, J VASC RES, V34, P245, DOI 10.1159/000159231; BOSWELL CA, 1992, MICROVASC RES, V43, P178, DOI 10.1016/0026-2862(92)90015-H; BRINER VA, 1993, AM J HYPERTENS, V6, P268, DOI 10.1093/ajh/6.4.268; Brown C, 1999, CIRC RES, V84, P655, DOI 10.1161/01.RES.84.6.655; CAILLA HL, 1976, ANAL BIOCHEM, V70, P195, DOI 10.1016/S0378-5173(83)90100-X; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; Charlton SJ, 1996, BRIT J PHARMACOL, V119, P1301, DOI 10.1111/j.1476-5381.1996.tb16038.x; CHEN TR, 1977, EXP CELL RES, V104, P255, DOI 10.1016/0014-4827(77)90089-1; Communi D, 1995, J BIOL CHEM, V270, P30849, DOI 10.1074/jbc.270.52.30849; CORNWELL TL, 1994, J VASC RES, V31, P330, DOI 10.1159/000159061; Delaey C, 1997, EUR J PHARMACOL, V325, P41, DOI 10.1016/S0014-2999(97)00097-6; DRUMMOND GR, 1995, BRIT J PHARMACOL, V116, P2746; DUBEY RK, 1995, J CLIN INVEST, V96, P141, DOI 10.1172/JCI118014; DUBEY RK, 1992, CIRC RES, V71, P1143, DOI 10.1161/01.RES.71.5.1143; EASTWOOD M, 1994, BBA-GEN SUBJECTS, V1201, P186, DOI 10.1016/0304-4165(94)90040-X; Erlinge D, 1998, GEN PHARMACOL-VASC S, V31, P1, DOI 10.1016/S0306-3623(97)00420-5; Erlinge D, 1998, BIOCHEM BIOPH RES CO, V248, P864, DOI 10.1006/bbrc.1998.9083; FELETOU M, 1995, EUR J PHARMACOL, V274, P57, DOI 10.1016/0014-2999(94)00709-G; FUKURODA T, 1994, J APPL PHYSIOL, V76, P1976, DOI 10.1152/jappl.1994.76.5.1976; Gessi S, 1997, BRIT J PHARMACOL, V122, P1450, DOI 10.1038/sj.bjp.0701536; Groschner K, 1996, BIOCHEM J, V318, P513, DOI 10.1042/bj3180513; GRYNKIEWICZ G, 1985, J BIOL CHEM, V360, P3110; Harper S, 1998, BRIT J PHARMACOL, V124, P703, DOI 10.1038/sj.bjp.0701895; JIANG H, 1992, J BIOL CHEM, V267, P1015; Kleschyov AL, 1998, BRIT J PHARMACOL, V124, P623, DOI 10.1038/sj.bjp.0701916; KOLODNEY MS, 1992, J CELL BIOL, V117, P73, DOI 10.1083/jcb.117.1.73; Kunapuli SP, 1998, BIOCHEM J, V336, P513, DOI 10.1042/bj3360513; L'Heureux N, 1998, FASEB J, V12, P47, DOI 10.1096/fasebj.12.1.47; Lagaud GJL, 1996, J PHYSIOL-LONDON, V492, P689, DOI 10.1113/jphysiol.1996.sp021338; LHEUREUX N, 1993, J VASC SURG, V17, P499, DOI 10.1016/0741-5214(93)90150-K; LINCOLN TM, 1991, BLOOD VESSELS, V28, P129; LOIRAND G, 1995, PFLUG ARCH EUR J PHY, V430, P429, DOI 10.1007/BF00373919; MARCEAU F, 1995, IMMUNOPHARMACOLOGY, V30, P1, DOI 10.1016/0162-3109(95)00011-H; Moy AB, 1996, J CLIN INVEST, V97, P1020, DOI 10.1172/JCI118493; MURRAY TR, 1990, J CELL PHYSIOL, V143, P26, DOI 10.1002/jcp.1041430105; Murthy KS, 1998, J BIOL CHEM, V273, P4695, DOI 10.1074/jbc.273.8.4695; Nguyen T, 1995, J BIOL CHEM, V270, P30845, DOI 10.1074/jbc.270.52.30845; Nicholas RA, 1996, J AUTON PHARMACOL, V16, P319, DOI 10.1111/j.1474-8673.1996.tb00044.x; Nicholas RA, 1996, MOL PHARMACOL, V50, P224; Niklason LE, 1999, SCIENCE, V284, P489, DOI 10.1126/science.284.5413.489; OKADA K, 1991, AM J PHYSIOL, V260, pF39, DOI 10.1152/ajprenal.1991.260.1.F39; OSOL G, 1995, J VASC RES, V32, P275, DOI 10.1159/000159102; OWENS GK, 1995, PHYSIOL REV, V75, P487; PACAUD P, 1995, AM J PHYSIOL-HEART C, V269, pH30, DOI 10.1152/ajpheart.1995.269.1.H30; PARR CE, 1994, P NATL ACAD SCI USA, V91, P13067, DOI 10.1073/pnas.91.26.13067; PARR CE, 1994, P NATL ACAD SCI USA, V91, P3275, DOI 10.1073/pnas.91.8.3275; Petitclerc E, 1996, J IMMUNOL, V156, P3426; Pfitzer G, 1998, ACTA PHYSIOL SCAND, V164, P449, DOI 10.1111/j.1365-201X.1998.tb10698.x; PILCHER BK, 1995, PLAST RECONSTR SURG, V96, P1188, DOI 10.1097/00006534-199510000-00029; RICHARD S, 1992, BIOCHIM BIOPHYS ACTA, V1160, P95, DOI 10.1016/0167-4838(92)90042-C; Robaye B, 1997, EUR J PHARMACOL, V329, P231, DOI 10.1016/S0014-2999(97)89184-4; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SHIRINSKY VP, 1992, AM J HYPERTENS, V5, pS124, DOI 10.1093/ajh/5.6.124S; SKALLI O, 1986, J CELL BIOL, V103, P2787, DOI 10.1083/jcb.103.6.2787; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; Strobaek D, 1996, BRIT J PHARMACOL, V118, P1645, DOI 10.1111/j.1476-5381.1996.tb15587.x; THYBERG J, 1990, ARTERIOSCLEROSIS, V10, P966, DOI 10.1161/01.ATV.10.6.966; Zhao M, 1996, PULM PHARMACOL THER, V9, P167, DOI 10.1006/pulp.1996.0019	63	129	132	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2001	15	2					515	524		10.1096/fj.00-0283com	http://dx.doi.org/10.1096/fj.00-0283com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156967				2022-12-28	WOS:000166872900033
J	Kamencic, H; Griebel, RW; Lyon, AW; Paterson, PG; Juurlink, BHJ				Kamencic, H; Griebel, RW; Lyon, AW; Paterson, PG; Juurlink, BHJ			Promoting glutathione synthesis after spinal cord trauma decreases secondary damage and promotes retention of function	FASEB JOURNAL			English	Article						central nervous system; functional recovery; neurotrauma; oxidative stress; paraplegia	RANDOMIZED CONTROLLED TRIAL; LIPID-PEROXIDATION PRODUCT; TIRILAZAD MESYLATE; OXIDATIVE STRESS; ISOLATED HEPATOCYTES; N-ACETYLCYSTEINE; INJURY; RAT; METHYLPREDNISOLONE; REDUCTASE	The study aimed to 1) quantify oxidative stress in spinal cord after crush injury at T6, 2) determine whether the administration of the procysteine compound L-2-oxothiazolidine-4-carboxylate (OTC) would up-regulate glutathione (GSH) synthesis and decrease oxidative stress, and 3) determine whether decreased oxidative stress results in better tissue and function retention. We demonstrate that spinal cord compression (5 s with a 50 g aneurysm clip) at T6 in rats results in oxidative stress that is extensive (significant increases in oxidative stress seen at C3 and L4) and rapid in onset. Indices of oxidative stress used were GSH content, protein carbonyl content, and inactivation of glutathione reductase. Administration of OTC resulted in a marked decrease in oxidative stress associated with a sparing of white matter at T6 (16 +/-1.9% retained in OTC-treated animals vs, less than 1% in saline-treated). Behavioral indices in control, saline-treated, and OTC-treated animals after 6 wk were respectively: angle board scores (59 degrees, 32 degrees, and 42 degrees), modified Tarlov score (7, 2.4, and 4.1), and Basso-Beattie-Bresnahan score (21, 5.3, and 12.9). We conclude that administration of OTC after spinal cord trauma greatly decreases oxidative stress and allows tissue preservation, thereby enabling otherwise paraplegic animals to locomote.	Univ Saskatchewan, Dept Anat & Cell Biol, Saskatoon, SK S7N 5E5, Canada; Univ Saskatchewan, Dept Surg Neurosurg, Saskatoon, SK S7N 5E5, Canada; Univ Saskatchewan, Dept Pathol, Saskatoon, SK S7N 5E5, Canada; Univ Saskatchewan, Coll Pharm & Nutr, Saskatoon, SK S7N 5E5, Canada	University of Saskatchewan; University of Saskatchewan; University of Saskatchewan; University of Saskatchewan	Juurlink, BHJ (corresponding author), Univ Saskatchewan, Dept Anat & Cell Biol, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.							ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; ANDERSON ME, 1989, FASEB J, V3, P1632, DOI 10.1096/fasebj.3.5.2920877; Barker JE, 1996, BRAIN RES, V716, P118, DOI 10.1016/0006-8993(96)00003-0; BARTHOLDI D, 1995, BRAIN RES, V672, P177, DOI 10.1016/0006-8993(94)01410-J; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; BELLOMO G, 1987, BIOCHEM PHARMACOL, V36, P1313, DOI 10.1016/0006-2952(87)90087-6; Bernard GR, 1997, CHEST, V112, P164, DOI 10.1378/chest.112.1.164; Bethea JR, 1998, J NEUROSCI, V18, P3251; Blakeman DP, 1998, J BIOCHEM MOL TOXIC, V12, P185, DOI 10.1002/(SICI)1099-0461(1998)12:3<185::AID-JBT7>3.0.CO;2-H; BLAKYTNY R, 1992, BIOCHEM J, V288, P303, DOI 10.1042/bj2880303; Bracken MB, 1998, J NEUROSURG, V89, P699, DOI 10.3171/jns.1998.89.5.0699; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; BROWN SA, 1992, J AM VET MED ASSOC, V200, P1849; Burcham PC, 1996, BIOCHEM BIOPH RES CO, V220, P996, DOI 10.1006/bbrc.1996.0521; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Christman JW, 2000, BRAIN PATHOL, V10, P153; EKLOW L, 1984, EUR J BIOCHEM, V138, P459, DOI 10.1111/j.1432-1033.1984.tb07938.x; FEHLINGS MG, 1995, EXP NEUROL, V132, P220, DOI 10.1016/0014-4886(95)90027-6; GALANDIUK S, 1993, ANN SURG, V218, P419, DOI 10.1097/00000658-199310000-00003; HALL ED, 1992, J NEUROSURG, V76, P13, DOI 10.3171/jns.1992.76.1.0013; Huang DW, 1999, NEURON, V24, P639, DOI 10.1016/S0896-6273(00)81118-6; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; Juurlink BHJ, 1999, NEUROTOX RES, V1, P119, DOI 10.1007/BF03033276; Juurlink BHJ, 1998, GLIA, V22, P371, DOI 10.1002/(SICI)1098-1136(199804)22:4<371::AID-GLIA6>3.0.CO;2-6; KALAYJIAN RC, 1994, J ACQ IMMUN DEF SYND, V7, P369; KHAN M, 1983, CAN J NEUROL SCI, V10, P161, DOI 10.1017/S031716710004484X; Koc RK, 1999, SPINAL CORD, V37, P29, DOI 10.1038/sj.sc.3100732; KOMURO C, 1985, J CHROMATOGR, V338, P209, DOI 10.1016/0378-4347(85)80087-6; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; Lucas JH, 1998, J NEUROPATH EXP NEUR, V57, P937, DOI 10.1097/00005072-199810000-00006; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; MCLELLAN LI, 1995, CARCINOGENESIS, V16, P2099, DOI 10.1093/carcin/16.9.2099; MEISTER A, 1989, GLUTATHIONE CHEM BIO, VA, P367; MESINA JE, 1989, BRAIN RES, V478, P181, DOI 10.1016/0006-8993(89)91494-7; Miyata T, 1998, FEBS LETT, V437, P24, DOI 10.1016/S0014-5793(98)01079-5; Nesathurai S, 1998, J TRAUMA, V45, P1088, DOI 10.1097/00005373-199812000-00021; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; RIVLIN AS, 1979, SURG NEUROL, V9, P39; SCHUPPE I, 1992, BIOCHEM PHARMACOL, V44, P1757, DOI 10.1016/0006-2952(92)90069-U; SHIVAKUMAR BR, 1995, J PHARMACOL EXP THER, V274, P1167; Springer JE, 1997, J NEUROCHEM, V68, P2469; TABATABAIE T, 1994, ARCH BIOCHEM BIOPHYS, V314, P112, DOI 10.1006/abbi.1994.1418; Taoka Y, 1997, NEUROSCIENCE, V79, P1177, DOI 10.1016/S0306-4522(97)00011-0; Tariq M, 1998, J NEUROTRAUM, V15, P239, DOI 10.1089/neu.1998.15.239; Vita JA, 1998, J CLIN INVEST, V101, P1408, DOI 10.1172/JCI1155	46	89	91	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2001	15	1					243	250		10.1096/fj.00-0228com	http://dx.doi.org/10.1096/fj.00-0228com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149912				2022-12-28	WOS:000166312400033
J	Efange, SMN				Efange, SMN			In vivo imaging of the vesicular acetylcholine transporter and the vesicular monoamine transporter	FASEB JOURNAL			English	Review						choline acetyltransferase; positron emission tomography; single photon emission computed tomography radiotracer	POSITRON-EMISSION-TOMOGRAPHY; CHOLINE-ACETYLTRANSFERASE ACTIVITY; H-3 VESAMICOL BINDING; BASAL FOREBRAIN LESIONS; IN-VIVO; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; RAT-BRAIN; SYNAPTIC VESICLES; NERVE-TERMINALS	Validation of the vesicular acetylcholine transporter (VAChT) and the neuronal vesicular monoamine transporter (VMAT2) as important molecular targets in the cholinergic and dopamine neurons, respectively, has sparked interest in the development of radiotracers for studying these markers in vitro and in vivo. Currently, a number of selective high-affinity radiotracers are available for studying these targets in vivo with positron emission tomography (PET) or single photon emission computed tomography (SPECT), PET studies of VMAT2 in neuropathology reveal changes in the density of this marker that can be verified independently. Similarly, in vivo studies with VAChT ligands suggest that the latter are potentially useful in detecting cholinergic lesions in vivo; however, additional development is required to fully realize the potential of these radioligands.	Univ Minnesota, Dept Radiol, Acad Hlth Ctr, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Med Chem, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Neurosurg, Minneapolis, MN 55455 USA; Univ Minnesota, Grad Program Neurosci, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Efange, SMN (corresponding author), Univ Minnesota, Dept Radiol, Acad Hlth Ctr, Mayo Box 292,420 Delaware St SE, Minneapolis, MN 55455 USA.	efang001@maroon.tc.umn.edu						ALTAR CA, 1988, SYNAPSE, V2, P486, DOI 10.1002/syn.890020504; BAHR BA, 1986, P NATL ACAD SCI USA, V83, P2267, DOI 10.1073/pnas.83.7.2267; BALDWIN RM, 1997, J NUCL MED S, V38; BEJANIN S, 1994, J BIOL CHEM, V269, P21944; BERRARD S, 1995, J NEUROCHEM, V65, P939; BERSE B, 1995, J BIOL CHEM, V270, P22101, DOI 10.1074/jbc.270.38.22101; BRITTAIN RT, 1969, EUR J PHARMACOL, V8, P93, DOI 10.1016/0014-2999(69)90133-2; Chan GLY, 1999, J NUCL MED, V40, P283; CONSOLO S, 1993, PROG BRAIN RES, V98, P201; DASILVA JN, 1993, SYNAPSE, V14, P128, DOI 10.1002/syn.890140205; DASILVA JN, 1994, NUCL MED BIOL, V21, P151, DOI 10.1016/0969-8051(94)90003-5; Efange SMN, 1997, NEUROBIOL AGING, V18, P407, DOI 10.1016/S0197-4580(97)00038-9; Efange SMN, 1996, J NUCL MED, V37, P1192; EFANGE SMN, 1995, BIOCHEM PHARMACOL, V49, P791, DOI 10.1016/0006-2952(94)00541-S; Efange SMN, 1996, LIFE SCI, V58, P1367, DOI 10.1016/0024-3205(96)00103-8; EFANGE SMN, 1992, 9TH INT S RAD CHEM, P311; ERICKSON JD, 1994, J BIOL CHEM, V269, P21929; Frey KA, 1996, ANN NEUROL, V40, P873, DOI 10.1002/ana.410400609; Gage HD, 1999, J COMPUT ASSIST TOMO, V23, P25, DOI 10.1097/00004728-199901000-00007; GAGE HD, IN PRESS PAIN; Gilman S, 1999, ANN NEUROL, V45, P769, DOI 10.1002/1531-8249(199906)45:6<769::AID-ANA11>3.0.CO;2-G; Gilman S, 1996, ANN NEUROL, V40, P885, DOI 10.1002/ana.410400610; Gilman S, 1998, ANN NEUROL, V44, P326, DOI 10.1002/ana.410440307; Gilmor ML, 1998, J NEUROCHEM, V71, P2411; Gilmor ML, 1999, J COMP NEUROL, V411, P693; Gilmor ML, 1996, J NEUROSCI, V16, P2179; HENRY JP, 1989, BIOCHEM PHARMACOL, V38, P2395, DOI 10.1016/0006-2952(89)90082-8; Holler T, 1996, NEUROSCI LETT, V212, P107, DOI 10.1016/0304-3940(96)12808-1; HOLLEY LA, 1993, BRAIN RES, V610, P181, DOI 10.1016/0006-8993(93)91399-D; Ichikawa T, 1997, J CHEM NEUROANAT, V13, P23, DOI 10.1016/S0891-0618(97)00021-5; INGVAR M, 1993, NEUROREPORT, V4, P1311, DOI 10.1097/00001756-199309150-00006; Kasa P, 1997, PROG NEUROBIOL, V52, P511, DOI 10.1016/S0301-0082(97)00028-2; Kilbourn M, 1997, EUR J PHARMACOL, V331, P161, DOI 10.1016/S0014-2999(97)01054-6; Kilbourn MR, 1997, NUCL MED BIOL, V24, P615, DOI 10.1016/S0969-8051(97)00101-7; KILBOURN MR, 1995, NUCL MED BIOL, V22, P565, DOI 10.1016/0969-8051(95)00005-I; KISH SJ, 1990, NEUROSCI LETT, V117, P347, DOI 10.1016/0304-3940(90)90689-7; KISH SJ, 1988, J NEUROL NEUROSUR PS, V51, P544, DOI 10.1136/jnnp.51.4.544; Kitamoto T, 1998, J BIOL CHEM, V273, P2706, DOI 10.1074/jbc.273.5.2706; Koeppe RA, 1997, J CEREBR BLOOD F MET, V17, P919, DOI 10.1097/00004647-199709000-00001; Koeppe RA, 1996, J CEREBR BLOOD F MET, V16, P1288, DOI 10.1097/00004647-199611000-00025; KUHL DE, 1994, J NUCL MED, V35, P405; Kuhl DE, 1996, ANN NEUROL, V40, P399, DOI 10.1002/ana.410400309; KUNG MP, 1994, SYNAPSE, V18, P225, DOI 10.1002/syn.890180308; Little KY, 1999, AM J PSYCHIAT, V156, P238; Mach RH, 1997, SYNAPSE, V25, P368, DOI 10.1002/(SICI)1098-2396(199704)25:4<368::AID-SYN8>3.0.CO;2-8; MARIEN MR, 1987, P NATL ACAD SCI USA, V84, P876, DOI 10.1073/pnas.84.3.876; MARSHALL IG, 1970, BRIT J PHARMACOL, V38, P503, DOI 10.1111/j.1476-5381.1970.tb10592.x; Matsuura J, 1997, NEUROSCI LETT, V236, P95, DOI 10.1016/S0304-3940(97)00763-5; Meyer P, 1999, NEUROLOGY, V53, P371, DOI 10.1212/WNL.53.2.371; Miller GW, 1999, EXP NEUROL, V156, P138, DOI 10.1006/exnr.1998.7008; MISAWA H, 1995, NEUROREPORT, V6, P965, DOI 10.1097/00001756-199505090-00004; MOUNTJOY CQ, 1984, BRAIN, V107, P507, DOI 10.1093/brain/107.2.507; Naciff JM, 1997, NEUROREPORT, V8, P3467, DOI 10.1097/00001756-199711100-00011; Nagao M, 1998, J NEUROPATH EXP NEUR, V57, P329, DOI 10.1097/00005072-199804000-00004; Paans AMJ, 1997, ACTA NEUROL BELG, V97, P150; PERRY EK, 1978, BRIT MED J, V2, P1457, DOI 10.1136/bmj.2.6150.1457; Perry R, 1997, J NEURAL TRANSM-SUPP, P95; PERRY RH, 1982, NEUROSCI LETT, V33, P311, DOI 10.1016/0304-3940(82)90391-3; PETER D, 1995, J NEUROSCI, V15, P6179; PIKE VW, 1997, DRUG INF J, V31, P997; Rehavi M, 1998, MOL BRAIN RES, V57, P31, DOI 10.1016/S0169-328X(98)00058-8; ROGERS GA, 1993, MOL PHARMACOL, V44, P633; ROGHANI A, 1994, P NATL ACAD SCI USA, V91, P10620, DOI 10.1073/pnas.91.22.10620; RUBERG M, 1990, NEUROSCIENCE, V35, P327, DOI 10.1016/0306-4522(90)90086-J; SCHAFER MKH, 1994, J MOL NEUROSCI, V5, P1, DOI 10.1007/BF02736691; Schafer MKH, 1995, J MOL NEUROSCI, V6, P225, DOI 10.1007/BF02736782; SLOTKIN TA, 1990, P NATL ACAD SCI USA, V87, P2452, DOI 10.1073/pnas.87.7.2452; Sorger D, 2000, NUCL MED BIOL, V27, P23, DOI 10.1016/S0969-8051(99)00087-6; Staley JK, 1997, BRAIN RES, V747, P219, DOI 10.1016/S0006-8993(96)01196-1; Staley JK, 1997, EUR J PHARMACOL, V338, P159, DOI 10.1016/S0014-2999(97)81944-9; STOOF JC, 1992, NEUROSCIENCE, V47, P755, DOI 10.1016/0306-4522(92)90027-Y; Sun XY, 1997, NEUROREPORT, V8, P891, DOI 10.1097/00001756-199703030-00015; THIBAUT F, 1995, BRAIN RES, V692, P233, DOI 10.1016/0006-8993(95)00674-F; USDIN TB, 1995, TRENDS NEUROSCI, V18, P218, DOI 10.1016/0166-2236(95)93906-E; VANDERBORGHT TM, 1995, NEUROSCIENCE, V68, P955, DOI 10.1016/0306-4522(95)00167-H; VANDERBORGHT TM, 1995, J NUCL MED, V36, P2252; VAROQUI H, 1994, FEBS LETT, V342, P97, DOI 10.1016/0014-5793(94)80592-X; VOYTKO ML, 2000, IN PRESS SYNAPSE; Weihe E, 1996, P NATL ACAD SCI USA, V93, P3547, DOI 10.1073/pnas.93.8.3547; Wenk GL, 1996, NEUROSCIENCE, V73, P79, DOI 10.1016/0306-4522(96)00019-X; WIDEN L, 1993, J CEREB BLOOD FLO S1, V13, pS300; Wilson JM, 1996, J NEUROSCI, V16, P3507	82	44	44	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2000	14	15					2401	2413		10.1096/fj.00-0204rev	http://dx.doi.org/10.1096/fj.00-0204rev			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099458				2022-12-28	WOS:000165723400010
J	Saurin, AT; Martin, JL; Heads, RJ; Foley, C; Mockridge, JW; Wright, MJ; Wang, YB; Marber, MS				Saurin, AT; Martin, JL; Heads, RJ; Foley, C; Mockridge, JW; Wright, MJ; Wang, YB; Marber, MS			The role of differential activation of p38-mitogen-activated protein kinase in preconditioned ventricular myocytes	FASEB JOURNAL			English	Article						myocardial ischemia; cardioprotection; ischemic preconditioning; cytoprotection	N-TERMINAL KINASES; ISOLATED RABBIT CARDIOMYOCYTES; IN-VITRO MODEL; P38 MAP KINASE; CARDIAC MYOCYTES; ISCHEMIC MYOCARDIUM; SIMULATED ISCHEMIA; STRESS PROTEINS; A(3) RECEPTOR; RAT-HEART	Activation of protein kinase C (PKC) and more recently mitogen-activated protein kinases (MAPKs) have been associated with the cardioprotective effect of ischemic preconditioning. We examined the interplay between these kinases in a characterized model of ischemic preconditioning in cultured rat neonatal ventricular cardiocytes where ectopic expression of active PKC-delta results in protection. Two members of the MAPK family, p38 and p42/44, were activated transiently during preconditioning by brief simulated ischemia/reoxygenation. Overexpression of active PKC-delta, rather than augmenting, completely abolished this activation. We therefore determined whether a similar process occurred during lethal prolonged simulated ischemia. In contrast to ischemia, brief, lethal-simulated ischemia activated only p38 (2.8+/-0.45 vs, basal, P<0.01), which was attenuated by expression of active PKC-<delta> or by preconditioning (0.48+/-0.1 vs. ischemia, P<0.01). To determine whether reduced p38 activation was the cause or an effect of protection, we used SB203580, a p38 inhibitor. SB203580 reduced ischemic injury (CK release 38.0+/-3.1%, LDH release 77.3+/-4.0%, and MTT bioreduction 127.1+/-4.8% of control, n=20, P<0.05). To determine whether p38 activation was isoform selective, myocytes were infected with adenoviruses encoding wild-type p38 alpha or p38 beta. Transfected p38 alpha and beta show differential activation (P<0.001) during sustained simulated ischemia, with p38<alpha> remaining activated (1.48+/-0.36 vs, basal) but p38 beta deactivated (0.36+/-0.1 vs, basal, P<0.01). Prior preconditioning prevented the activation of p38<alpha> (0.65+/-0.11 vs. ischemia, P<0.05). Moreover, cells expressing a dominant negative p38<alpha>, which prevented ischemic p38 activation, were resistant to lethal. simulated ischemia (CK release 82.9+/-3.9% and MTT bioreduction 130.2+/-6.5% of control, n=8, P<0.05). Thus, inhibition of p38<alpha> activation during ischemia reduces injury and may contribute to preconditioning-induced cardioprotection in this model.	St Thomas Hosp, Rayne Inst, Dept Cardiol, KCL, London SE1 7EH, England; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University System of Maryland; University of Maryland Baltimore	Marber, MS (corresponding author), St Thomas Hosp, Rayne Inst, Dept Cardiol, KCL, London SE1 7EH, England.		marber, michael/AAW-7916-2021	Saurin, Adrian/0000-0001-9317-2255; Marber, Michael/0000-0002-3463-7128; Wright, Matthew/0000-0002-0541-7556; Wang, Yibin/0000-0003-0852-0767				ARMSTRONG S, 1994, CARDIOVASC RES, V28, P1049, DOI 10.1093/cvr/28.7.1049; ARMSTRONG S, 1994, CARDIOVASC RES, V28, P72, DOI 10.1093/cvr/28.1.72; Armstrong SC, 1999, J MOL CELL CARDIOL, V31, P555, DOI 10.1006/jmcc.1998.0891; Arstall MA, 1998, J MOL CELL CARDIOL, V30, P1019, DOI 10.1006/jmcc.1998.0666; Barancik M, 2000, J CARDIOVASC PHARM, V35, P474, DOI 10.1097/00005344-200003000-00019; Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; Clerk A, 1998, FEBS LETT, V426, P93, DOI 10.1016/S0014-5793(98)00324-X; COHEN MV, 1994, CIRC RES, V74, P998, DOI 10.1161/01.RES.74.5.998; Cumming DVE, 1996, J MOL CELL CARDIOL, V28, P2343, DOI 10.1006/jmcc.1996.0227; DECOCK JBJ, 1994, FEBS LETT, V356, P275, DOI 10.1016/0014-5793(94)01283-0; Dougherty C, 1998, FASEB J, V12, P1785, DOI 10.1096/fasebj.12.15.1785; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; GOTO M, 1995, CIRC RES, V77, P611, DOI 10.1161/01.RES.77.3.611; Gray MO, 1997, J BIOL CHEM, V272, P30945, DOI 10.1074/jbc.272.49.30945; GROSS GJ, 1995, BASIC RES CARDIOL, V90, P85, DOI 10.1007/BF00789438; Gross GJ, 1999, CIRC RES, V84, P973, DOI 10.1161/01.RES.84.9.973; Hart SL, 1998, HUM GENE THER, V9, P575, DOI 10.1089/hum.1998.9.4-575; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; IKONOMIDIS JS, 1994, CARDIOVASC RES, V28, P1285, DOI 10.1093/cvr/28.8.1285; Kalmes A, 1999, FEBS LETT, V444, P71, DOI 10.1016/S0014-5793(99)00034-4; Kitakaze M, 1996, CIRCULATION, V93, P781, DOI 10.1161/01.CIR.93.4.781; Kloner RA, 1998, CIRCULATION, V97, P1848, DOI 10.1161/01.CIR.97.18.1848; Lali FV, 2000, J BIOL CHEM, V275, P7395, DOI 10.1074/jbc.275.10.7395; Lasley RD, 1997, J MOL CELL CARDIOL, V29, P3345, DOI 10.1006/jmcc.1997.0559; Liang BT, 1999, CIRC RES, V84, P1396; Liu Y, 1996, BASIC RES CARDIOL, V91, P450, DOI 10.1007/BF00788726; LIU YG, 1995, J MOL CELL CARDIOL, V27, P883, DOI 10.1016/0022-2828(95)90038-1; Ma XL, 1999, CIRCULATION, V99, P1685, DOI 10.1161/01.CIR.99.13.1685; Mackay K, 1999, J BIOL CHEM, V274, P6272, DOI 10.1074/jbc.274.10.6272; Marber MS, 2000, CIRC RES, V86, P926, DOI 10.1161/01.RES.86.9.926; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; Maulik N, 1998, FEBS LETT, V429, P365, DOI 10.1016/S0014-5793(98)00632-2; Maulik N, 1998, AM J PHYSIOL-HEART C, V275, pH1857, DOI 10.1152/ajpheart.1998.275.5.H1857; MITCHELL MB, 1995, CIRC RES, V76, P73, DOI 10.1161/01.RES.76.1.73; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Nagarkatti DS, 1998, J MOL CELL CARDIOL, V30, P1651, DOI 10.1006/jmcc.1998.0733; Nakano A, 2000, CIRC RES, V86, P144, DOI 10.1161/01.RES.86.2.144; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ovelgonne JH, 1996, J MOL CELL CARDIOL, V28, P1617, DOI 10.1006/jmcc.1996.0152; Ping PP, 1997, CIRC RES, V81, P404, DOI 10.1161/01.RES.81.3.404; SCHULTZ JEJ, 1995, AM J PHYSIOL-HEART C, V268, pH2157, DOI 10.1152/ajpheart.1995.268.5.H2157; Shirai T, 1998, J THORAC CARDIOV SUR, V115, P210, DOI 10.1016/S0022-5223(98)70459-3; Strickler J, 1996, J CLIN INVEST, V98, P1773, DOI 10.1172/JCI118976; Sugden PH, 1998, CIRC RES, V83, P345, DOI 10.1161/01.RES.83.4.345; TSUCHIDA A, 1994, CIRC RES, V75, P576, DOI 10.1161/01.RES.75.3.576; Vanden Hoek TL, 1998, J BIOL CHEM, V273, P18092, DOI 10.1074/jbc.273.29.18092; VANWINKLE DM, 1999, CORONARY HEART DIS, V2, P613; WALSH RS, 1994, CARDIOVASC RES, V28, P1337, DOI 10.1093/cvr/28.9.1337; Wang PP, 1996, J MOL CELL CARDIOL, V28, P579, DOI 10.1006/jmcc.1996.0054; Wang Y, 1996, P NATL ACAD SCI USA, V93, P3932, DOI 10.1073/pnas.93.9.3932; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; WEBSTER KA, 1995, J MOL CELL CARDIOL, V27, P453, DOI 10.1016/S0022-2828(08)80041-7; Weinbrenner C, 1997, J MOL CELL CARDIOL, V29, P2383, DOI 10.1006/jmcc.1997.0473; Wu S, 1999, CIRC RES, V84, P1388; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Yue TL, 2000, CIRC RES, V86, P692, DOI 10.1161/01.RES.86.6.692; Zhao J, 1998, J BIOL CHEM, V273, P23072, DOI 10.1074/jbc.273.36.23072	58	135	137	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2237	2246		10.1096/fj.99-0671com	http://dx.doi.org/10.1096/fj.99-0671com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053245				2022-12-28	WOS:000165190800017
J	Trusolino, L; Cavassa, S; Angelini, P; Ando, M; Bertotti, A; Comoglio, PM; Boccaccio, C				Trusolino, L; Cavassa, S; Angelini, P; Ando, M; Bertotti, A; Comoglio, PM; Boccaccio, C			HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity	FASEB JOURNAL			English	Article						growth factors; tyrosine kinase receptors; MET; adhesion; integrin activation	HEPATOCYTE GROWTH-FACTOR; TYROSINE KINASE RECEPTOR; SCATTER FACTOR; EPITHELIAL-CELLS; MET RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SOMATIC MUTATIONS; MET/HGF RECEPTOR; CARCINOMA-CELLS; METASTASIS	Hepatocyte growth factor/scatter factor (HGF/SF) controls a genetic program known as 'invasive growth', which involves as critical steps cell adhesion, migration, and trespassing of basement membranes. We show here that in MDA-MD-231 carcinoma cells, these steps are elicited by HGF/SF but not by epidermal growth factor (EGF). Neither factor substantially alters the production or activity of extracellular matrix proteases. HGF/SF, but not EGF, selectively promotes cell adhesion on laminins 1 and 5, fibronectin, and vitronectin through a PI3-K-dependent mechanism. Increased adhesion is followed by enhanced invasiveness through isolated matrix proteins as well as through reconstituted basement membranes. Inhibition assays using function-blocking antibodies show that this phenomenon is mediated by multiple integrins including beta 1, beta 3, beta 4, and beta 5. HGF/SF triggers clustering of all these integrins at actin-rich adhesive sites and lamellipodia but does not quantitatively modify their membrane expression. These data suggest that HGF/SF promotes cell adhesion and invasiveness by increasing the avidity of integrins for their specific ligands.	Univ Turin, Sch Med, Inst Canc Res & Treatment, I-10060 Turin, Italy	University of Turin	Boccaccio, C (corresponding author), Inst Canc Res, Div Mol Oncol, Str Prov 142, I-10060 Turin, Italy.		Boccaccio, Carla/AHE-7875-2022; Comoglio, Paolo/G-6323-2011; Trusolino, Livio/A-3896-2011	Boccaccio, Carla/0000-0003-2620-9083; Bertotti, Andrea/0000-0001-8196-7608; Trusolino, Livio/0000-0002-6379-3365; Comoglio, Paolo/0000-0002-7056-5328				ALBINI A, 1987, CANCER RES, V47, P3239; Amicone L, 1997, EMBO J, V16, P495, DOI 10.1093/emboj/16.3.495; ARROYO AG, 1993, J BIOL CHEM, V268, P9863; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; Bardelli A, 1998, P NATL ACAD SCI USA, V95, P14379, DOI 10.1073/pnas.95.24.14379; Bardelli A, 1999, ONCOGENE, V18, P1139, DOI 10.1038/sj.onc.1202607; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; BIRCHMEIER W, 1995, CANCER SURV, V24, P129; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; CAPCO DG, 1982, CELL, V29, P847, DOI 10.1016/0092-8674(82)90446-9; DELUCA M, 1990, P NATL ACAD SCI USA, V87, P6888, DOI 10.1073/pnas.87.17.6888; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; FABBRO D, 1986, CANCER RES, V46, P2720; FERRACINI R, 1995, ONCOGENE, V10, P739; Ferracini R, 1996, ONCOGENE, V12, P1697; FEY EG, 1984, J CELL BIOL, V98, P1973, DOI 10.1083/jcb.98.6.1973; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Gilmore AP, 1996, STRUCTURE, V4, P647, DOI 10.1016/S0969-2126(96)00069-X; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Juliano RL, 1993, CURR OPIN CELL BIOL, V5, P812, DOI 10.1016/0955-0674(93)90030-T; LI R, 1995, J CELL BIOL, V129, P1143, DOI 10.1083/jcb.129.4.1143; Longati P, 1996, CELL DEATH DIFFER, V3, P23; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; McCawley LJ, 1998, J CELL PHYSIOL, V176, P255, DOI 10.1002/(SICI)1097-4652(199808)176:2<255::AID-JCP4>3.0.CO;2-N; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; Meiners S, 1998, ONCOGENE, V16, P9, DOI 10.1038/sj.onc.1201486; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; Park WS, 1999, CANCER RES, V59, P307; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; Rabinovitz I, 1999, J CELL BIOL, V146, P1147, DOI 10.1083/jcb.146.5.1147; Rabinovitz I, 1997, J CELL BIOL, V139, P1873, DOI 10.1083/jcb.139.7.1873; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Tamagnone Luca, 1997, Cytokine and Growth Factor Reviews, V8, P129, DOI 10.1016/S1359-6101(97)00007-5; Trusolino L, 1998, J CELL BIOL, V142, P1145, DOI 10.1083/jcb.142.4.1145; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; YEDNOCK TA, 1995, J BIOL CHEM, V270, P28740, DOI 10.1074/jbc.270.48.28740	59	106	107	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2000	14	11					1629	1640		10.1096/fj.14.11.1629	http://dx.doi.org/10.1096/fj.14.11.1629			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CN	10928998				2022-12-28	WOS:000088627800018
J	Wang, TG; Gotoh, Y; Jennings, MH; Rhoads, CA; Aw, TY				Wang, TG; Gotoh, Y; Jennings, MH; Rhoads, CA; Aw, TY			Lipid hydroperoxide-induced apoptosis in human colonic CaCo-2 cells is associated with an early loss of cellular redox balance	FASEB JOURNAL			English	Article						GSH/GSSG ratio; intestinal cell death; redox shifts; peroxidized lipids; intestinal oxidative stress; diamide and GSH oxidation	PERFORMANCE LIQUID-CHROMATOGRAPHY; MITOCHONDRIAL-DNA; SMALL-INTESTINE; GLUTATHIONE; DEATH; RAT; PROLIFERATION; ACTIVATION; PEROXIDES; RADICALS	Apoptosis plays a critical role in maintaining homeostasis of the intestinal epithelium, Dietary oxidants like peroxidized lipids could perturb cellular redox status and disrupt mucosal turnover. The objective of this study,vas to delineate the role of lipid hydroperoxide (LOOH) -induced redox shifts in intestinal apoptosis using the human colonic CaCo-2 cell. We found that subtoxic concentrations of LOOM increased CaCo-2 cell apoptosis, This LOOM-induced apoptosis was associated with a significant decrease in the ratio of reduced glutathione-to-oxidized glutathione (GSH/GSSG), which preceded DNA fragmentation by 12 to 14 h, suggesting a temporal relationship between the two events. Oxidation of GSM with the thiol oxidant diamide caused significant decreases in cellular GSH and GSH/GSSG at 15 min that correlated with the activation of caspase 3 (60 min) and cleavage of PARP (120 min), confirming a temporal link between induction of cellular redox imbalance and initiation of apoptotic cell death. These kinetic studies further reveal that oxidant-mediated early redox change (within 1 h) was a primary inciting event of the apoptotic cascade, Once initiated, the recovery of redox balance did not prevent the progression of CaCo-2 cell apoptosis to its biological end point at 24 h. Collectively, the study shows that subtoxic levels of LOOM disrupt intestinal redox homeostasis, which contributes to apoptosis, These results provide insights into the mechanism of hydroperoxide-induced mucosal turnover that have important implications for understanding oxidant-mediated genesis of gut pathology.	Louisiana State Univ, Med Ctr, Dept Mol & Cellular Physiol, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Aw, TY (corresponding author), Louisiana State Univ, Med Ctr, Dept Mol & Cellular Physiol, 1501 Kings Hwy, Shreveport, LA 71130 USA.				NIDDK NIH HHS [R01 DK044510, R01 DK044510-07, DK 44510] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044510] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; ANDREWS JS, 1960, J NUTR, V70, P199, DOI 10.1093/jn/70.2.199; Aw T. Y., 1997, FASEB Journal, V11, pA219; AW TY, 1992, AM J PHYSIOL, V262, pG99, DOI 10.1152/ajpgi.1992.262.1.G99; BEACH D, 1988, CURRENT COMMUNICATIO; Bloom P D, 1996, Semin Gastrointest Dis, V7, P151; BULL AW, 1984, CANCER RES, V44, P4924; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; CEPINSKAS G, 1994, GASTROENTEROLOGY, V107, P80, DOI 10.1016/0016-5085(94)90063-9; CONTGREAVE IA, 1998, BIOCHEM BIOPH RES CO, V242, P1; Depraetere V, 1997, Semin Immunol, V9, P93, DOI 10.1006/smim.1997.0062; Esteve JM, 1999, FASEB J, V13, P1055, DOI 10.1096/fasebj.13.9.1055; Flores S. C., 1997, Oxidative stress and the molecular biology of antioxidant defenses., P117; Garland JM, 1997, BRIT J HAEMATOL, V99, P756, DOI 10.1046/j.1365-2141.1997.4733277.x; Hara H, 1996, J NUTR, V126, P800, DOI 10.1093/jn/126.4.800; Jiang SN, 1999, J BIOL CHEM, V274, P29905, DOI 10.1074/jbc.274.42.29905; KANEDA T, 1955, J BIOCHEM-TOKYO, V42, P561; KAPLOWITZ N, 1985, ANNU REV PHARMACOL, V25, P715, DOI 10.1146/annurev.pa.25.040185.003435; KIMURA T, 1984, J NUTR SCI VITAMINOL, V30, P125, DOI 10.3177/jnsv.30.125; KORNBERG A, 1955, METHOD ENZYMOL, V1, P441, DOI 10.1016/0076-6879(55)01072-0; KOSOWER NS, 1995, METHOD ENZYMOL, V251, P123, DOI 10.1016/0076-6879(95)51116-4; McConkey DJ, 1996, STEM CELLS, V14, P619, DOI 10.1002/stem.140619; MEUNIER V, 1995, CELL BIOL TOXICOL, V11, P187, DOI 10.1007/BF00756522; MILLER DL, 1977, GASTROENTEROLOGY, V73, P1326; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; PARKS DA, 1983, SURGERY, V94, P415; Pritchard DM, 1996, PHARMACOL THERAPEUT, V72, P149, DOI 10.1016/S0163-7258(96)00102-7; Que FG, 1996, GASTROENTEROLOGY, V110, P1238, DOI 10.1053/gast.1996.v110.pm8613014; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; SHIGENAGA MK, 1994, METHOD ENZYMOL, V234, P16; Stefanis L, 1998, J NEUROSCI, V18, P9204; Tortorella D, 1998, J CELL BIOL, V142, P365, DOI 10.1083/jcb.142.2.365; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; WATSON AJM, 1995, ALIMENT PHARM THER, V9, P215; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	37	79	80	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2000	14	11					1567	1576		10.1096/fj.14.11.1567	http://dx.doi.org/10.1096/fj.14.11.1567			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CN	10928991				2022-12-28	WOS:000088627800011
J	Sawada, H; Ibi, M; Kihara, T; Urushitani, M; Honda, K; Nakanishi, M; Akaike, A; Shimohama, S				Sawada, H; Ibi, M; Kihara, T; Urushitani, M; Honda, K; Nakanishi, M; Akaike, A; Shimohama, S			Mechanisms of antiapoptotic effects of estrogens in nigral dopaminergic neurons	FASEB JOURNAL			English	Article						estrogen receptor beta; AP-1 element; Parkinson's disease; neuroprotection	PROGRAMMED CELL-DEATH; ACTIVATED PROTEIN-KINASE; PRIMARY CORTICAL-NEURONS; NF-KAPPA-B; PARKINSONS-DISEASE; OXIDATIVE STRESS; INDUCED APOPTOSIS; NEUROBLASTOMA-CELLS; MEDIATED APOPTOSIS; ALZHEIMERS-DISEASE	Parkinson's disease is characterized by the mesencephalic dopaminergic neuronal loss, possibly by apoptosis, and the prevalence is higher in males than in females. The estrogen receptor (ER) subtype in the mesencephalon is exclusively ER beta, a recently cloned novel subtype. Bound with estradiol, it enhances gene transcription through the estrogen response element (ERE) or inhibits it through the activator protein-1 (AP-1) site. We demonstrated that 17 beta-estradiol provided protection against nigral neuronal apoptosis caused by exposure to either bleomycin sulfate (BLM) or buthionine sulfoximine (BSO). BLM and BSO-induced nigral apoptosis was blocked by inhibitors for caspase-3 or c-Jun/AP-1. The antiapoptotic effect by estradiol was blocked by ICI 182,780, an antagonist for ER, but not by a synthesized peptide that inhibits binding of the ER to the ERE. Estradiol had no effects on caspase-3 activation and c-Jun NH2-terminal kinase (JNK), which were activated by BLM. It also suppressed apoptosis by serum deprivation, which was independent of caspase-3 activation. Therefore, the antiapoptotic neuroprotection by estradiol is mediated by transcription through AP-1 site downstream from JNK and caspase-3 activation. Furthermore, 17 alpha-estradiol, a stereoisomer without female hormone activity, also provided an antiapoptotic effect. Therefore, the antiapoptotic effect is independent of female hormone activity.-Sawada, H., Ibi, M., Kihara, T., Urushitani, M., Honda, K, Nakanishi, M., Akaike, A., Shimohama, S. Mechanisms of antiapoptotic effects of estrogens in nigral dopaminergic neurons.	Kyoto Univ, Grad Sch Med, Dept Neurol, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University; Kyoto University	Shimohama, S (corresponding author), Kyoto Univ, Grad Sch Med, Dept Neurol, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.			Urushitani, Makoto/0000-0003-2773-9836; Sawada, Hideyuki/0000-0002-5909-3366; Ibi, Masakazu/0000-0003-1414-100X				Amato SF, 1998, CANCER RES, V58, P241; AMBANI LM, 1975, ARCH NEUROL-CHICAGO, V32, P114, DOI 10.1001/archneur.1975.00490440064010; [Anonymous], 1996, PHYSIOLOGIST; ARNOLD SF, 1995, P NATL ACAD SCI USA, V92, P7475, DOI 10.1073/pnas.92.16.7475; Barkhem T, 1998, MOL PHARMACOL, V54, P105, DOI 10.1124/mol.54.1.105; BAUER RB, 1982, J AM GERIATR SOC, V30, P322, DOI 10.1111/j.1532-5415.1982.tb05621.x; Bayne K, 1996, Physiologist, V39, P208; Behl C, 1997, MOL PHARMACOL, V51, P535, DOI 10.1124/mol.51.4.535; Birge SJ, 1996, J AM GERIATR SOC, V44, P865, DOI 10.1111/j.1532-5415.1996.tb03749.x; Birge SJ, 1997, NEUROLOGY, V48, pS36, DOI 10.1212/WNL.48.5_Suppl_7.36S; CASPARY WJ, 1982, BIOCHEMISTRY-US, V21, P334, DOI 10.1021/bi00531a021; CharriautMarlangue C, 1995, NEUROREPORT, V7, P61, DOI 10.1097/00001756-199512290-00014; Clark J. H., 1992, TXB ENDOCRINOLOGY, P35; DMELLO SR, IN PRESS J NEUROSCI; Dubal DB, 1999, J NEUROSCI, V19, P6385; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FAHN S, 1992, ANN NEUROL, V32, P804, DOI 10.1002/ana.410320616; Garcia-Segura LM, 1998, NEUROREPORT, V9, P593, DOI 10.1097/00001756-199803090-00006; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GRASLKRAUPP B, 1995, HEPATOLOGY, V21, P1465, DOI 10.1016/0270-9139(95)90071-3; Green PS, 1998, NEUROSCIENCE, V84, P7, DOI 10.1016/S0306-4522(97)00595-2; Green PS, 1997, J NEUROSCI, V17, P511; Green PS, 1996, NEUROSCI LETT, V218, P165, DOI 10.1016/S0304-3940(96)13148-7; Gridley KE, 1998, MOL PHARMACOL, V54, P874, DOI 10.1124/mol.54.5.874; GRIFFITH OW, 1979, P NATL ACAD SCI USA, V76, P5606, DOI 10.1073/pnas.76.11.5606; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; HAMILTON RF, 1995, AM J PHYSIOL-LUNG C, V269, pL318, DOI 10.1152/ajplung.1995.269.3.L318; Henderson Victor W., 1997, American Journal of Medicine, V103, p11S, DOI 10.1016/S0002-9343(97)00261-1; Higuchi Y, 1997, FREE RADICAL BIO MED, V23, P90, DOI 10.1016/S0891-5849(96)00589-8; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; Ishikawa Y, 1997, BIOCHEM BIOPH RES CO, V240, P496, DOI 10.1006/bbrc.1997.7665; Jacobs-Helber SM, 1998, MOL CELL BIOL, V18, P3699, DOI 10.1128/MCB.18.7.3699; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KISH SJ, 1985, NEUROSCI LETT, V58, P343, DOI 10.1016/0304-3940(85)90078-3; KUIPER GG, 1996, P NATL ACAD SCI USA, V39, P5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; KYPRIANOU N, 1991, CANCER RES, V51, P162; LI SC, 1985, ARCH NEUROL-CHICAGO, V42, P655, DOI 10.1001/archneur.1985.04060070045013; Li YH, 1997, J CELL BIOL, V139, P1317, DOI 10.1083/jcb.139.5.1317; Liebermann DA, 1998, INT J ONCOL, V12, P685; Marini M, 1996, BIOCHEM BIOPH RES CO, V229, P910, DOI 10.1006/bbrc.1996.1901; Matsura T, 1999, FREE RADICAL RES, V30, P73, DOI 10.1080/10715769900300081; MAYEUX R, 1995, AM J EPIDEMIOL, V142, P820, DOI 10.1093/oxfordjournals.aje.a117721; Mochizuki H, 1996, J NEUROL SCI, V137, P120, DOI 10.1016/0022-510X(95)00336-Z; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; PERRY TL, 1982, NEUROSCI LETT, V33, P305, DOI 10.1016/0304-3940(82)90390-1; Pike BR, 1998, J NEUROSCI RES, V52, P505, DOI 10.1002/(SICI)1097-4547(19980601)52:5<505::AID-JNR3>3.0.CO;2-G; POLLARD JW, 1987, CELL TISSUE RES, V249, P533; Rano TA, 1997, CHEM BIOL, V4, P149, DOI 10.1016/S1074-5521(97)90258-1; RATAN RR, 1994, J NEUROCHEM, V62, P376; RINK A, 1995, AM J PATHOL, V147, P1575; Saraste A, 1999, HERZ, V24, P189, DOI 10.1007/BF03044961; Sawada H, 1996, J NEUROSCI RES, V46, P509, DOI 10.1002/(SICI)1097-4547(19961115)46:4<509::AID-JNR13>3.0.CO;2-T; Sawada H, 1998, ANN NEUROL, V44, P110, DOI 10.1002/ana.410440117; Sawada H, 2000, J NEUROCHEM, V74, P1175; Sawada H, 1996, J NEUROSCI RES, V43, P503, DOI 10.1002/(SICI)1097-4547(19960215)43:4<503::AID-JNR12>3.0.CO;2-2; Sawada H, 1998, J NEUROSCI RES, V54, P707, DOI 10.1002/(SICI)1097-4547(19981201)54:5<707::AID-JNR16>3.0.CO;2-T; Sawada H, 2000, NEUROSCI BIOBEHAV R, V24, P143, DOI 10.1016/S0149-7634(99)00059-7; SAWAI H, 1995, J BIOL CHEM, V270, P27326, DOI 10.1074/jbc.270.45.27326; Sengpiel B, 1998, EUR J NEUROSCI, V10, P1903, DOI 10.1046/j.1460-9568.1998.00202.x; Shughrue PJ, 1997, J COMP NEUROL, V388, P507, DOI 10.1002/(SICI)1096-9861(19971201)388:4<507::AID-CNE1>3.0.CO;2-6; Singer CA, 1999, J NEUROSCI, V19, P2455; Singer CA, 1998, NEUROREPORT, V9, P2565, DOI 10.1097/00001756-199808030-00025; Singer CA, 1996, NEUROSCI LETT, V212, P13, DOI 10.1016/0304-3940(96)12760-9; Singh M, 1999, J NEUROSCI, V19, P1179; Srivastava RK, 1999, MOL CELL BIOL, V19, P5659; Tan SL, 1998, J NEUROCHEM, V71, P95; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; Watabe M, 1998, ONCOGENE, V16, P779, DOI 10.1038/sj.onc.1201592; Watters JJ, 1997, ENDOCRINOLOGY, V138, P4030, DOI 10.1210/en.138.9.4030; Weaver CE, 1997, BRAIN RES, V761, P338, DOI 10.1016/S0006-8993(97)00449-6	73	131	139	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2000	14	9					1202	1214		10.1096/fasebj.14.9.1202	http://dx.doi.org/10.1096/fasebj.14.9.1202			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834942				2022-12-28	WOS:000087427300017
J	Iida, R; Saito, K; Yamada, K; Basile, AS; Sekikawa, K; Takemura, M; Fujii, H; Wada, H; Seishima, M; Nabeshima, T				Iida, R; Saito, K; Yamada, K; Basile, AS; Sekikawa, K; Takemura, M; Fujii, H; Wada, H; Seishima, M; Nabeshima, T			Suppression of neurocognitive damage in LP-BM5-infected mice with a targeted deletion of the TNF-alpha gene	FASEB JOURNAL			English	Article						animal model; AIDS; TNF-alpha-(-/-) mice; dementia; learning; behavior	TUMOR-NECROSIS-FACTOR; CENTRAL-NERVOUS-SYSTEM; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; RETROVIRUS-INDUCED IMMUNODEFICIENCY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; PERIPHERAL BENZODIAZEPINE RECEPTORS; MURINE MODEL; LEUKEMIA-VIRUS; DEFICIENT MICE; MESSENGER-RNA	Brain levels of TNF-alpha increase in many including HIV-1 infection and may contribute to neurodegenerative processes. The paucity of agents that can selectively and potently block TNF-alpha processing or its receptors has led us to investigate the role of TNF-alpha in chronic neurodegeneration associated with retroviral infection using mice with targeted deletions of the TNF-alpha gene, Infection of wild-type C57BL/6 mice with the LP-BM5 murine leukemia retrovirus mixture leads to the development of a severe immunodeficiency as well as cognitive deficits and neuronal damage. TNF-alpha-(-/-) mice infected with LP-BM5 developed a systemic immunopathology indistinguishable in severity from that observed in contemporaneously infected wild-type mice. In contrast, the performance of infected TNF-alpha-(-/-) mice in the Y-maze and Morris water maze was not different from that of uninfected TNF-alpha-(-/-) mice. The extent of glial activation in the striatum, as indicated by the increase in density of peripheral benzodiazepine receptors, was equivalent in both groups of LP-BM5-infected mice. However, the decrease in striatal MAP-2 expression, a marker of neurodegeneration observed in infected wild-type mice, was not found in infected TNF-alpha-(-/-) mice. While the loss of TNF-alpha appeared to have no effect on the course or severity of the central or peripheral immunopathology resulting from LP-BM5 infection, the behavioral and biochemical manifestations were substantially curtailed in the TNF-alpha-(-/-) mice. These findings directly support a role for TNF-ai in the neurodegenerative processes associated with viral infections such as HIV-1.	Gifu Univ, Sch Med, Dept Lab Med, Gifu 5008705, Japan; Nagoya Univ, Grad Sch Med, Dept Neuropsychopharmacol & Hosp Pharm, Nagoya, Aichi 4668560, Japan; JBC Inc, Gifu Res Lab, Gifu 5030628, Japan; NIDDK, Bioorgan Chem Lab, Bethesda, MD 20892 USA; Natl Inst Anim Hlth, Dept Immunol, Tsukuba, Ibaraki 3050856, Japan	Gifu University; Nagoya University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Agriculture & Food Research Organization - Japan; National Institute of Animal Health - Japan	Saito, K (corresponding author), Gifu Univ, Sch Med, Dept Lab Med, Gifu 5008705, Japan.	saito@cc.gifu-u.ac.jp; tnabeshi@.med.nagoya-u.ac.jp	Sokabe, Masahiro/I-1565-2012; Yamada, Kiyofumi/I-7487-2014	Yamada, Kiyofumi/0000-0002-5280-5180	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK032200] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGGARWAL BB, 1992, TUMOR NECROSIS FACTO; ANDERSSON PB, 1992, J EXP MED, V176, P255, DOI 10.1084/jem.176.1.255; BASILE AS, 1987, J PHARMACOL METHOD, V17, P149, DOI 10.1016/0160-5402(87)90025-8; BOURDIOL F, 1991, BRAIN RES, V543, P194, DOI 10.1016/0006-8993(91)90028-T; BREDER CD, 1993, J COMP NEUROL, V337, P543, DOI 10.1002/cne.903370403; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; BULLER RML, 1987, J VIROL, V61, P383, DOI 10.1128/JVI.61.2.383-387.1987; CHAO CC, 1994, DEV NEUROSCI-BASEL, V16, P172, DOI 10.1159/000112104; Childs EA, 1999, NEUROLOGY, V52, P607, DOI 10.1212/WNL.52.3.607; CLAUDIO L, 1994, LAB INVEST, V70, P850; Devan BD, 1996, NEUROBIOL LEARN MEM, V66, P305, DOI 10.1006/nlme.1996.0072; English JA, 1998, FASEB J, V12, P175, DOI 10.1096/fasebj.12.2.175; Espey MG, 1998, J NEUROCHEM, V71, P2079; Fine SM, 1996, J BIOL CHEM, V271, P15303, DOI 10.1074/jbc.271.26.15303; FREI K, 1990, ANN NY ACAD SCI, V594, P326; Furukawa K, 1998, J NEUROCHEM, V70, P1876; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; HITOSHI Y, 1993, J EXP MED, V177, P621, DOI 10.1084/jem.177.3.621; Iida R, 1999, J NEUROIMMUNOL, V95, P65, DOI 10.1016/S0165-5728(98)00259-8; Korner H, 1997, EUR J IMMUNOL, V27, P1973, DOI 10.1002/eji.1830270822; Kustova Y, 1998, BRAIN BEHAV IMMUN, V12, P308, DOI 10.1006/brbi.1998.0546; Kustova Y, 1998, MOL CHEM NEUROPATHOL, V35, P39, DOI 10.1007/BF02815115; Kustova Y, 1998, BRAIN RES, V793, P119, DOI 10.1016/S0006-8993(98)00167-X; Kustova Y, 1996, BRAIN RES, V742, P271, DOI 10.1016/S0006-8993(96)01014-1; Li Y, 1997, BRAIN RES, V752, P107, DOI 10.1016/S0006-8993(96)01459-X; MAKINO M, 1990, J IMMUNOL, V144, P4347; Manabe T, 1998, NATURE, V394, P577, DOI 10.1038/29073; MERRILL JE, 1991, FASEB J, V5, P2391, DOI 10.1096/fasebj.5.10.2065887; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORSE HC, 1995, SPRINGER SEMIN IMMUN, V17, P231; MORSE HC, 1992, AIDS, V6, P607, DOI 10.1097/00002030-199207000-00001; Nishida K, 1996, J NEUROCHEM, V66, P433; Parks CL, 1998, P NATL ACAD SCI USA, V95, P10734, DOI 10.1073/pnas.95.18.10734; Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397; PROBERT L, 1995, P NATL ACAD SCI USA, V92, P11294, DOI 10.1073/pnas.92.24.11294; Saito K, 1996, NEUROSCI LETT, V206, P149, DOI 10.1016/S0304-3940(96)12460-5; Sei Y, 1996, FASEB J, V10, P339, DOI 10.1096/fasebj.10.2.8641568; SEI Y, 1992, FASEB J, V6, P3008, DOI 10.1096/fasebj.6.11.1644264; SELMAJ KW, 1990, J IMMUNOL, V144, P129; SPENCER DC, 1992, ANNU REV MICROBIOL, V46, P655; STADLER I, 1994, J PHARMACOL EXP THER, V268, P10; STEPHENSON DT, 1995, J NEUROSCI, V15, P5263; Taniguchi T, 1997, LAB INVEST, V77, P647; TYOR WR, 1992, ANN NEUROL, V31, P349, DOI 10.1002/ana.410310402; Vowinckel E, 1997, J NEUROSCI RES, V50, P345, DOI 10.1002/(SICI)1097-4547(19971015)50:2<345::AID-JNR22>3.0.CO;2-5; Wesselingh SL, 1997, J NEUROIMMUNOL, V74, P1, DOI 10.1016/S0165-5728(96)00160-9; WESSELINGH SL, 1993, ANN NEUROL, V33, P576, DOI 10.1002/ana.410330604; Whitaker-Azmitia PM, 1997, BRAIN RES, V776, P51, DOI 10.1016/S0006-8993(97)01002-0; Yamada K, 1996, NEUROSCIENCE, V74, P365, DOI 10.1016/0306-4522(96)00161-3; Zhou T, 1996, J IMMUNOL, V156, P2661	50	26	27	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2000	14	7					1023	1031		10.1096/fasebj.14.7.1023	http://dx.doi.org/10.1096/fasebj.14.7.1023			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	309CG	10783158				2022-12-28	WOS:000086749500022
J	Van der Lee, KAJM; Willemsen, PHM; Van der Vusse, GJ; Van Bilsen, M				Van der Lee, KAJM; Willemsen, PHM; Van der Vusse, GJ; Van Bilsen, M			Effects of fatty acids on uncoupling protein-2 expression in the rat heart	FASEB JOURNAL			English	Article						cardiomyocytes; metabolism; UCP; gene expression	PROLIFERATOR-ACTIVATED RECEPTOR; BROWN ADIPOSE-TISSUE; PALMITOYLTRANSFERASE-I GENE; SKELETAL-MUSCLE; DIFFERENTIAL REGULATION; MESSENGER-RNA; UP-REGULATION; ALPHA; METABOLISM; GAMMA	Fatty acids are thought to play a role in the activity of uncoupling proteins (UCP) and have been shown to regulate the expression of genes encoding proteins involved in fatty acid handling. Therefore, we investigated whether fatty acids, which are the main substrates for the heart, affect rat cardiac UCP-2 expression in vivo and in vitro. After birth, when the contribution of fatty acid oxidation to cardiac energy conversion increases, UCP-2 expression enhanced rapidly. In the adult heart, however, UCP-2 mRNA levels did not alter during conditions associated with either enhanced (fasting, diabetes) or decreased (hypertrophy) fatty acid utilization. Exposure of neonatal cardiomyocytes and embryonic rat heart-derived H9c2 cells to fatty acids (palmitic and oleic acid) for 48 h strongly induced UCP-2 expression. Stimulation of neonatal cardiomyocytes with triiodothyronine also increased UCP-2 mRNA levels, though only in the presence of fatty acids. Ligands specific to the fatty acid-activated transcription factor PPAR alpha, but not to PPAR gamma, acted as inducers of cardiomyocyte UCP-2 expression. It is concluded that fatty acids promote UCP-2 expression in neonatal cardiomyocytes, which might explain the rapid increase in UCP-2 mRNA in the postnatal heart. However, UCP-2 mRNA levels in the adult heart appear to be insensitive to changes in cardiac fatty acid handling under various pathological conditions.	Maastricht Univ, Cardiovasc Res Inst Maastricht, Dept Physiol, NL-6200 MD Maastricht, Netherlands	Maastricht University	Van der Lee, KAJM (corresponding author), Maastricht Univ, Cardiovasc Res Inst Maastricht, Dept Physiol, POB 616, NL-6200 MD Maastricht, Netherlands.	Karin.vdLee@FYS.Unimaas.NL	van Bilsen, Marc/E-8342-2016					Aubert J, 1997, BIOCHEM BIOPH RES CO, V238, P606, DOI 10.1006/bbrc.1997.7348; BACHMANN E, 1990, PHARMACOL TOXICOL, V67, P49, DOI 10.1111/j.1600-0773.1990.tb00781.x; Boss O, 1997, FEBS LETT, V412, P111, DOI 10.1016/S0014-5793(97)00755-2; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; Brandt JM, 1998, J BIOL CHEM, V273, P23786, DOI 10.1074/jbc.273.37.23786; Brun S, 1999, DIABETES, V48, P1217, DOI 10.2337/diabetes.48.6.1217; Camirand A, 1998, ENDOCRINOLOGY, V139, P428, DOI 10.1210/en.139.1.428; Carmona MC, 1998, FEBS LETT, V441, P447, DOI 10.1016/S0014-5793(98)01598-1; Carmona MC, 1998, BIOCHEM BIOPH RES CO, V243, P224, DOI 10.1006/bbrc.1998.8088; CHALLONE.DR, 1966, AM J PHYSIOL, V210, P280, DOI 10.1152/ajplegacy.1966.210.2.280; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; deVries JE, 1997, J LIPID RES, V38, P1384; Engels W, 1999, MOL CELL BIOCHEM, V192, P53, DOI 10.1023/A:1006855214237; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; GHEZZI C, 1990, ARCH INT PHYSIOL BIO, V98, P269, DOI 10.3109/13813459009113987; GIRARD J, 1992, PHYSIOL REV, V72, P507, DOI 10.1152/physrev.1992.72.2.507; Hidaka S, 1999, DIABETES, V48, P430, DOI 10.2337/diabetes.48.2.430; KAGAYA Y, 1990, CIRCULATION, V81, P1353, DOI 10.1161/01.CIR.81.4.1353; Kelly LJ, 1998, ENDOCRINOLOGY, V139, P4920, DOI 10.1210/en.139.12.4920; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Korshunov SS, 1998, FEBS LETT, V435, P215, DOI 10.1016/S0014-5793(98)01073-4; Lanni A, 1997, FEBS LETT, V418, P171, DOI 10.1016/S0014-5793(97)01375-6; LOPASCHUK GD, 1992, CARDIOVASC RES, V26, P1172, DOI 10.1093/cvr/26.12.1172; LOPASCHUK GD, 1992, HEART DIABETES, P215; Makinde AO, 1998, MOL CELL BIOCHEM, V188, P49, DOI 10.1023/A:1006860104840; Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210; Mascaro C, 1998, J BIOL CHEM, V273, P8560, DOI 10.1074/jbc.273.15.8560; MENAHAN LA, 1983, COMP BIOCHEM PHYS B, V74, P859, DOI 10.1016/0305-0491(83)90157-8; Millet L, 1997, J CLIN INVEST, V100, P2665, DOI 10.1172/JCI119811; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; Ricquier D, 1997, PROG NUCLEIC ACID RE, V56, P83, DOI 10.1016/S0079-6603(08)61003-X; Sack MN, 1996, CIRCULATION, V94, P2837, DOI 10.1161/01.CIR.94.11.2837; Samec S, 1998, DIABETES, V47, P1693, DOI 10.2337/diabetes.47.11.1693; Samec S, 1998, FASEB J, V12, P715, DOI 10.1096/fasebj.12.9.715; Savontaus E, 1998, BIOCHEM BIOPH RES CO, V246, P899, DOI 10.1006/bbrc.1998.8721; Sears IB, 1996, MOL CELL BIOL, V16, P3410; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; SNOECKX LHEH, 1990, J MOL CELL CARDIOL, V22, P1439, DOI 10.1016/0022-2828(90)90987-D; Teshima Y, 1999, BBA-MOL CELL RES, V1448, P409, DOI 10.1016/S0167-4889(98)00154-2; Tsuboyama-Kasaoka N, 1999, BIOCHEM BIOPH RES CO, V257, P879, DOI 10.1006/bbrc.1999.0555; van der Lee KAJM, 2000, J LIPID RES, V41, P41; Van Nieuwenhoven FA, 1999, INT J BIOCHEM CELL B, V31, P489, DOI 10.1016/S1357-2725(98)00122-8; VANBILSEN M, 1999, CARDIOVASCULAR SPECI, P257; VANBILSEN M, 1997, PROSTAGLANDINS LEUKO, V57, P30; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1; Willemsen Peter H. M., 1999, Journal of Molecular and Cellular Cardiology, V31, pA89; WINKLER E, 1994, J BIOL CHEM, V269, P2508	50	50	53	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2000	14	3					495	502		10.1096/fasebj.14.3.495	http://dx.doi.org/10.1096/fasebj.14.3.495			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	291TJ	10698964				2022-12-28	WOS:000085751900008
J	Noma, T; Nishiyama, A; Mizushige, K; Murakami, K; Tsuji, T; Kohno, M; Rahman, M; Fukui, T; Abe, Y; Kimura, S				Noma, T; Nishiyama, A; Mizushige, K; Murakami, K; Tsuji, T; Kohno, M; Rahman, M; Fukui, T; Abe, Y; Kimura, S			Possible role of uncoupling protein in regulation of myocardial energy metabolism in aortic regurgitation model rats	FASEB JOURNAL			English	Article									Kagawa Med Univ, Dept Pharmacol, Kagawa 7610793, Japan; Kagawa Med Univ, Dept Internal Med 2, Kagawa 7610793, Japan	Kagawa University; Kagawa University	Kimura, S (corresponding author), Kagawa Med Univ, Dept Pharmacol, 1750-1 Miki, Kagawa 7610793, Japan.		Rahman, Moazur/C-5515-2019	Rahman, Moazur/0000-0003-2892-1250					0	33	34	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1206	1208		10.1096/fj.000569fje	http://dx.doi.org/10.1096/fj.000569fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344089				2022-12-28	WOS:000168655200011
J	Reinmuth, N; Liu, WB; Jung, YD; Ahmad, SA; Shaheen, RM; Fan, F; Bucana, CD; McMahon, G; Gallick, GE; Ellis, LM				Reinmuth, N; Liu, WB; Jung, YD; Ahmad, SA; Shaheen, RM; Fan, F; Bucana, CD; McMahon, G; Gallick, GE; Ellis, LM			Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival	FASEB JOURNAL			English	Article									Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; SUGEN Inc, S San Francisco, CA 94080 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Pfizer	Ellis, LM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, 1515 Holcombe Blvd,Box 444, Houston, TX 77030 USA.								0	185	195	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1239	1241		10.1096/fj.00-0693fje	http://dx.doi.org/10.1096/fj.00-0693fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344100				2022-12-28	WOS:000168655200022
J	Lambert, V; Munaut, C; Noel, A; Frankenne, F; Bajou, K; Gerard, R; Carmeliet, P; Defresne, MP; Foidart, JM; Rakic, JM				Lambert, V; Munaut, C; Noel, A; Frankenne, F; Bajou, K; Gerard, R; Carmeliet, P; Defresne, MP; Foidart, JM; Rakic, JM			Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization	FASEB JOURNAL			English	Article						angiogenesis; retinal disease; proteases; viral vector; macular degeneration	ENDOTHELIAL GROWTH-FACTOR; RETINAL NEOVASCULARIZATION; DIABETIC-RETINOPATHY; MACULAR DEGENERATION; INTEGRIN ALPHA(V)BETA(3); CANCER INVASION; MURINE MODEL; TISSUE; GENE; ANGIOGENESIS	High levels of the plasminogen activators, but also their inhibitor, plasminog en activator inhibitor 1 (PAI-1), have been documented in neovascularization of severe ocular pathologies such as diabetic retinopathy or age-related macular degeneration (AMD). AMD is the primary cause of irreversible photoreceptors loss, and current therapies are limited. PAI-1 has recently been shown to be essential for tumoral angiogenesis. We report here that deficient PAI-1 expression in mice prevented the development of subretinal choroidal angiogenesis induced by laser photocoagulation. When systemic and local PAI-1 expression was achieved by intravenous injection of a replication-defective adenoviral vector expressing human PAI-1 cDNA, the wild-type pattern of choroidal angiogenesis was restored. These observations demonstrate the proangiogenic activity of PAI-1 not only in tumoral models, but also in choroidal experimental neovascularization sharing similarities with human AMD. They identify therefore PAI-1 as a potential target for therapeutic ocular anti-angiogenic strategies.	Univ Liege, Lab Tumor & Dev Biol, B-4000 Liege, Belgium; Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium; Univ Liege, Lab Cytol & Histol, B-4000 Liege, Belgium; Univ Hosp, Dept Ophthalmol, B-4000 Liege, Belgium	University of Liege; Flanders Institute for Biotechnology (VIB); KU Leuven; University of Liege; University of Liege	Lambert, V (corresponding author), Univ Liege, Lab Tumor & Dev Biol, Pathol Tower,B23, B-4000 Liege, Belgium.	vincent.lambert@ulg.ac.be	Munaut, Carine/K-8138-2019; Carmeliet, Peter/AAQ-5140-2020	Carmeliet, Peter/0000-0001-7961-1821; Bajou, Khalid/0000-0002-5529-9228; Noel, Agnes/0000-0002-7670-6179				AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; BEHRINGER RR, 1993, DEVELOPMENT, V117, P823; Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3; Blasi F, 1999, THROMB HAEMOSTASIS, V82, P298; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BULLARD LE, 1999, INVEST OPHTH VIS SCI, V40, P3255; Carmeliet P, 1997, CIRCULATION, V96, P3180, DOI 10.1161/01.CIR.96.9.3180; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764; Gately S, 1997, P NATL ACAD SCI USA, V94, P10868, DOI 10.1073/pnas.94.20.10868; Grant MB, 1996, EXP EYE RES, V63, P233, DOI 10.1006/exer.1996.0112; Hammes HP, 1996, NAT MED, V2, P529, DOI 10.1038/nm0596-529; Hattenbach LO, 1999, RETINA-J RET VIT DIS, V19, P383, DOI 10.1097/00006982-199909000-00003; Iijima H, 1999, AM J OPHTHALMOL, V127, P477, DOI 10.1016/S0002-9394(98)00378-X; Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367; Kaplan HJ, 1999, NAT MED, V5, P292, DOI 10.1038/6509; Kosano H, 1999, LIFE SCI, V64, P2307, DOI 10.1016/S0024-3205(99)00184-8; Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929; Luna J, 1996, LAB INVEST, V75, P563; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; Noel A, 1999, FIBRINOLYSIS PROTEOL, V13, P220, DOI 10.1054/fipr.2000.0043; Okamoto N, 1997, AM J PATHOL, V151, P281; PEDERSEN H, 1994, CANCER RES, V54, P4671; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; Plantner JJ, 1998, EXP EYE RES, V67, P637, DOI 10.1006/exer.1998.0552; SMALLEY DM, 1994, INVEST OPHTH VIS SCI, V35, P48; Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194; Steinkamp G. W. K., 1993, Ophthalmologe, V90, P73; Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352	33	80	84	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2001	15	6					1021	1027		10.1096/fj.00-0393com	http://dx.doi.org/10.1096/fj.00-0393com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292663	Green Submitted			2022-12-28	WOS:000167959300017
J	Fessele, S; Boehlk, S; Mojaat, A; Miyamoto, NG; Werner, T; Nelson, EL; Schlondorff, D; Nelson, PJ				Fessele, S; Boehlk, S; Mojaat, A; Miyamoto, NG; Werner, T; Nelson, EL; Schlondorff, D; Nelson, PJ			Molecular and in silico characterization of a promoter module and C/EBP element that mediate LPS-induced RANTES/CCL5 expression in monocytic cells	FASEB JOURNAL			English	Article									Univ Munich, Klinikum Innenstadt, Med Poliklin, D-8000 Munich, Germany; Beriex Biosci, Dept Immunol, Richmond, CA USA; GSF, Natl Res Ctr Environm & Hlth, Inst Mammalian Genet, Neuherberg, Germany; Genomatix Software GmbH, Munich, Germany; NCI, Frederick Canc Res & Dev Ctr, Frederick, MD USA	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Nelson, PJ (corresponding author), Univ Munich, Med Poliklin, Schillerstr 42, D-80336 Munich, Germany.			Nelson, Edward/0000-0001-7887-032X; Fessele, Sabine/0000-0002-5399-3574					0	48	48	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					577	579						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259372				2022-12-28	WOS:000167419500010
J	Oviedo-Orta, E; Gasque, P; Evans, WH				Oviedo-Orta, E; Gasque, P; Evans, WH			Immunoglobulin and cytokine expression in mixed lymphocyte cultures is reduced by disruption of gap junction intercellular communication	FASEB JOURNAL			English	Article						connexins; intercellular communication; interleukins; mimetic peptides; interferon gamma	ENDOTHELIUM-DEPENDENT RELAXATIONS; ADHESION MOLECULES; PERIPHERAL-BLOOD; IMMUNE-SYSTEM; CELL-ADHESION; B-CELLS; INHIBITION; IL-2; PROTEINS; CONNEXIN-43	Connexins (Cx), the protein subunits assembled into gap junction intercellular communication channels, are expressed in primary lymphoid or organs and by circulating leukocytes, Human tonsil-derived T and B lymphocytes express Cx40 and 43; circulating human T, B, and NK lymphocytes express Cx43 and directly transfer between each other a low molecular dye indicative that functional gap junctions exist. We now identify specific properties in the immune system underwritten by gap junctions. Mixed lymphocytes cultured in the presence of two reagents with independent inhibitory action on gap junction communication, a connexin mimetic peptide and 18-alpha -glycyrrhetinic acid, markedly reduced the secretion of IgM, Igc, and IgA. The secretion of these immunoglobulins by purified B cells was also reduced by the two classes of gap junction inhibitors. Complex temporal inhibitory effects on the expression of mRNA encoding interleukins, especially IL-10, were also observed, The results indicate that intercellular signaling across gap junctions is an important component of the mechanisms underlying metabolic cooperation in the immune system.	Univ Wales Coll Cardiff, Coll Med, Dept Biochem Med, Cardiff CF14 4XN, S Glam, Wales; Wales Heart Res Inst, Cardiff CF14 4XN, S Glam, Wales	Cardiff University; Cardiff University	Oviedo-Orta, E (corresponding author), Bristol Royal Infirm & Gen Hosp, Bristol Heart Inst, Level 7,Upper Maudlin St, Bristol BS2 8HW, Avon, England.	e.oviedo-orta@bristol.ac.uk	OVIEDO-ORTA, Ernesto/L-4846-2018	OVIEDO-ORTA, Ernesto/0000-0003-1323-3316				AbouHashieh I, 1996, J HEPATOL, V24, P360; Alves LA, 1998, IMMUNOL TODAY, V19, P269, DOI 10.1016/S0167-5699(98)01256-0; Angelopoulou MK, 1999, SEMIN HEMATOL, V36, P178; Bain G, 1998, SEMIN IMMUNOL, V10, P143, DOI 10.1006/smim.1998.0116; BASTIDE B, 1995, PFLUG ARCH EUR J PHY, V429, P386, DOI 10.1007/BF00374154; BASTIDE B, 1993, CIRC RES, V73, P1138, DOI 10.1161/01.RES.73.6.1138; Bayon Y, 1998, CYTOKINES CELL MOL T, V4, P275; BECK E, 1995, BOT ACTA, V108, P1; BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; BEREK C, 1993, IMMUNOL TODAY, V14, P400, DOI 10.1016/0167-5699(93)90143-9; Boitano S, 2000, AM J PHYSIOL-LUNG C, V279, pL623, DOI 10.1152/ajplung.2000.279.4.L623; Briscoe DM, 1998, CURR OPIN IMMUNOL, V10, P525, DOI 10.1016/S0952-7915(98)80218-5; Buckley CD, 1998, MOL MEMBR BIOL, V15, P167, DOI 10.3109/09687689709044318; CALLAGHAN M, 1993, CLIN EXP IMMUNOL, V93, P212; Chaytor AT, 1997, J PHYSIOL-LONDON, V503, P99, DOI 10.1111/j.1469-7793.1997.099bi.x; Chaytor AT, 1998, J PHYSIOL-LONDON, V508, P561, DOI 10.1111/j.1469-7793.1998.561bq.x; Chaytor AT, 1999, J PHYSIOL-LONDON, V520, P539, DOI 10.1111/j.1469-7793.1999.00539.x; Chaytor AT, 1997, J PHYSIOL-LONDON, V503, P699; Chia MC, 1998, CRIT REV CL LAB SCI, V35, P573, DOI 10.1080/10408369891234282; Cooper EL, 1999, MICROSC RES TECHNIQ, V44, P237, DOI 10.1002/(SICI)1097-0029(19990215)44:4<237::AID-JEMT4>3.0.CO;2-0; DAVIDSON JS, 1988, J PHARMACOL EXP THER, V246, P1104; DEUTSCH DE, 1995, AM J PHYSIOL-GASTR L, V269, pG779, DOI 10.1152/ajpgi.1995.269.5.G779; Dora KA, 1999, BIOCHEM BIOPH RES CO, V254, P27, DOI 10.1006/bbrc.1998.9877; EVANS WH, 1988, BIOESSAYS, V8, P3; Fabbri M, 1999, INFLAMM RES, V48, P239, DOI 10.1007/s000110050454; Freitas AA, 1999, CURR OPIN IMMUNOL, V11, P152, DOI 10.1016/S0952-7915(99)80026-0; Gonzalez-Amaro R, 1998, DRUGS, V56, P977, DOI 10.2165/00003495-199856060-00003; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; GUO YH, 1999, AM J PHYSIOL, V20, pL1018; He DS, 1998, MOL BIOL CELL, V9, p325A; HULSER DF, 1972, EXP CELL RES, V74, P319, DOI 10.1016/0014-4827(72)90383-7; JARA PI, 1995, P NATL ACAD SCI USA, V92, P7011, DOI 10.1073/pnas.92.15.7011; JAVID PJ, 1995, FASEB J, V9, pA914; KAUL R, 1995, CLIN IMMUNOL IMMUNOP, V74, P271, DOI 10.1006/clin.1995.1039; KRENACS T, 1995, J HISTOCHEM CYTOCHEM, V43, P1125, DOI 10.1177/43.11.7560895; Krenacs T, 1997, EUR J IMMUNOL, V27, P1489, DOI 10.1002/eji.1830270627; Kwak BR, 1999, J PHYSIOL-LONDON, V516, P679, DOI 10.1111/j.1469-7793.1999.0679u.x; Mambetisaeva ET, 1999, J NEUROSCI RES, V57, P166, DOI 10.1002/(SICI)1097-4547(19990715)57:2<166::AID-JNR2>3.3.CO;2-P; Martin PEM, 1998, J BIOL CHEM, V273, P1719, DOI 10.1074/jbc.273.3.1719; MILSTEIN C, 1991, IMMUNOL TODAY, V12, P93, DOI 10.1016/0167-5699(91)90164-O; MIYAJIMA H, 1991, J IMMUNOL, V146, P457; NONOYAMA S, 1994, CLIN IMMUNOL IMMUNOP, V72, P373, DOI 10.1006/clin.1994.1155; Oviedo-Orta E, 2000, IMMUNOLOGY, V99, P578, DOI 10.1046/j.1365-2567.2000.00991.x; REVEL JP, 1986, TRENDS BIOCHEM SCI, V11, P375, DOI 10.1016/0968-0004(86)90208-2; Taylor HJ, 1998, BRIT J PHARMACOL, V125, P1, DOI 10.1038/sj.bjp.0702078; WARNER A, 1995, J PHYSIOL-LONDON, V488, P721, DOI 10.1113/jphysiol.1995.sp021003	46	71	74	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2001	15	3					768	774		10.1096/fj.00-0288com	http://dx.doi.org/10.1096/fj.00-0288com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259395				2022-12-28	WOS:000167419500034
J	Watanabe, H; Tran, QK; Takeuchi, K; Fukao, M; Liu, MY; Kanno, M; Hayashi, T; Iguchi, A; Seto, M				Watanabe, H; Tran, QK; Takeuchi, K; Fukao, M; Liu, MY; Kanno, M; Hayashi, T; Iguchi, A; Seto, M			Myosin light-chain kinase regulates endothelial calcium entry and endothelium-dependent vasodilation	FASEB JOURNAL			English	Article									Hamamatsu Univ Sch Med, Dept Clin Pharmacol & Therapeut, Hamamatsu, Shizuoka 4313192, Japan; Hokkaido Univ, Sch Med, Dept Pharmacol, Sapporo, Hokkaido 0608638, Japan; Asahi Chem Ind Co Ltd, Life Sci Res Ctr, Fuji, Shizuoka 4160934, Japan; Nagoya Univ, Sch Med, Dept Geriatr Med, Nagoya, Aichi 4668560, Japan	Hamamatsu University School of Medicine; Hokkaido University; Nagoya University	Watanabe, H (corresponding author), Hamamatsu Univ Sch Med, Dept Clin Pharmacol & Therapeut, 3600 Handa Cho, Hamamatsu, Shizuoka 4313192, Japan.	hwat@hama-med.ac.jp		Tran, Kim/0000-0003-1881-1357					0	24	25	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2001	15	2					282	284		10.1096/fj.00-0587fje	http://dx.doi.org/10.1096/fj.00-0587fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156937				2022-12-28	WOS:000166872900003
J	Elkin, M; Miao, HQ; Nagler, A; Aingorn, E; Reich, R; Hemo, I; Dou, HL; Pines, M; Vlodavsky, I				Elkin, M; Miao, HQ; Nagler, A; Aingorn, E; Reich, R; Hemo, I; Dou, HL; Pines, M; Vlodavsky, I			Halofuginone: a potent inhibitor of critical steps in angiogenesis progression	FASEB JOURNAL			English	Article						neovascularization; type I collagen; halofuginone; matrix metalloproteinase-2; extracellular matrix	SMALL-INTESTINAL SUBMUCOSA; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; TUMOR ANGIOGENESIS; COLLAGEN-SYNTHESIS; GROWTH; PROLIFERATION; EXPRESSION; METALLOPROTEINASES; DIFFERENTIATION	We have previously demonstrated that halofuginone, a low molecular weight quinazolinone alkaloid, is a potent inhibitor of collagen alpha1(I) and matrix metalloproteinase 2 (MMP-2) gene expression. Halofuginone also effectively suppresses tumor progression and metastasis in mice. These results together with the well-documented role of extracellular matrix (ECM) components and matrix degrading enzymes in formation of new blood vessels led us to investigate the effect of halofuginone on the angiogenic process. In a variety of experimental system, representing sequential events in the angiogenic cascade, halofuginone treatment resulted in profound inhibitory effect. Among these are the abrogation of endothelial cell MMP-2 expression and basement membrane invasion, capillary tube formation, and vascular sprouting, as well as deposition of subendothelial ECM. The most conclusive anti-angiogenic activity of halofuginone was demonstrated in vivo (mouse corneal micropocket assay) by showing a marked inhibition of basic fibroblast growth factor (bFGF) -induced neovascularization in response to systemic administration of halofuginone, either i.p. or in the diet. The ability of halofuginone to interfere with key events in neovascularization, together with its oral bioavailability and safe use as an anti-parasitic agent, make it a promising drug for further evaluation in the treatment of a wide range of diseases associated with pathological angiogenesis.	Hadassah Univ Hosp, Dept Oncol, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Dept Bone Marrow Transplantat, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Dept Pharmacol, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Dept Ophthalmol, IL-91120 Jerusalem, Israel; Agr Res Org, Volcani Ctr, Inst Anim Sci, IL-50250 Bet Dagan, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH	Vlodavsky, I (corresponding author), Hadassah Univ Hosp, Dept Oncol, POB 12000, IL-91120 Jerusalem, Israel.	vlodavsk@cc.huji.ac.il						ABRAMOVITCH R, 1999, NEOPLASIA, V32, P321; ALBINI A, 1987, CANCER RES, V47, P3239; Badylak S, 1999, BIOMATERIALS, V20, P2257, DOI 10.1016/S0142-9612(99)00156-8; Badylak SF, 1998, J BIOMAT SCI-POLYM E, V9, P863, DOI 10.1163/156856298X00208; BENELLI R, 1994, ONCOL RES, V6, P251; BENEZRA M, 1994, ARTERIOSCLER THROMB, V14, P1992, DOI 10.1161/01.ATV.14.12.1992; Brower V, 1999, NAT BIOTECHNOL, V17, P963, DOI 10.1038/13654; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Elkin M, 1999, CANCER RES, V59, P4111; Elkin M, 1999, CLIN CANCER RES, V5, P1982; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FOLKMAN J, 1972, ANN SURG, V175, P409, DOI 10.1097/00000658-197203000-00014; FOUSER L, 1991, J BIOL CHEM, V266, P18345; GOSPODAROWICZ D, 1976, P NATL ACAD SCI USA, V73, P4120, DOI 10.1073/pnas.73.11.4120; GOSPODAROWICZ D, 1980, J SUPRAMOL STR CELL, V13, P339, DOI 10.1002/jss.400130307; GRANOT I, 1991, POULTRY SCI, V70, P1559, DOI 10.3382/ps.0701559; GRANOT I, 1993, BIOCHIM BIOPHYS ACTA, V1156, P107, DOI 10.1016/0304-4165(93)90123-P; Grant D S, 1997, EXS, V79, P317; Halevy O, 1996, BIOCHEM PHARMACOL, V52, P1057, DOI 10.1016/0006-2952(96)00427-3; HERRON GS, 1986, J BIOL CHEM, V261, P2814; INGBER D, 1991, J CELL BIOCHEM, V47, P236, DOI 10.1002/jcb.240470309; INGBER D, 1988, LAB INVEST, V59, P44; IRUELAARISPE ML, 1991, LAB INVEST, V64, P174; Itoh T, 1998, CANCER RES, V58, P1048; JACKSON CJ, 1991, EXP CELL RES, V192, P319, DOI 10.1016/0014-4827(91)90194-Y; Kenyon BM, 1996, INVEST OPHTH VIS SCI, V37, P1625; Keshet E, 1999, J CLIN INVEST, V104, P1497, DOI 10.1172/JCI8849; LIOTTA LA, 1981, BIOCHEMISTRY-US, V20, P100, DOI 10.1021/bi00504a017; Maekawa R, 1999, CANCER RES, V59, P1231; Nagler A, 1997, KIDNEY INT, V52, P1561, DOI 10.1038/ki.1997.486; Nagler A, 1997, ARTERIOSCL THROM VAS, V17, P194, DOI 10.1161/01.ATV.17.1.194; NICOSIA RF, 1990, LAB INVEST, V63, P115; NICOSIA RF, 1991, IN VITRO CELL DEV B, V27, P961; Pines M, 1998, GEN PHARMACOL, V30, P445, DOI 10.1016/S0306-3623(97)00307-8; RISAU W, 1995, FASEB J, V9, P926, DOI 10.1096/fasebj.9.10.7615161; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; ROONEY P, 1993, J CELL SCI, V105, P213; Rooney R, 1997, TUMOUR ANGIOGENESIS, P141; SCHNAPER HW, 1993, J CELL PHYSIOL, V156, P235, DOI 10.1002/jcp.1041560204; Stetler-Stevenson WG, 1999, J CLIN INVEST, V103, P1237, DOI 10.1172/JCI6870; Voytik-Harbin SL, 1998, TISSUE ENG, V4, P157, DOI 10.1089/ten.1998.4.157; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	44	86	89	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2000	14	15					2477	2485		10.1096/fj.00-0292com	http://dx.doi.org/10.1096/fj.00-0292com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099465				2022-12-28	WOS:000165723400017
J	Kang, TB; Yi, J; Yang, WR; Wang X; Jiang, AX; Pei, DQ				Kang, TB; Yi, J; Yang, WR; Wang, X; Jiang, AX; Pei, DQ			Functional characterization of MT3-MMP in transfected MDCK cells: progelatinase A activation and tubulogenesis in 3-D collagen lattice	FASEB JOURNAL			English	Article						ECM; zymogen; membrane-bound MMP; 3-D collagen; tubulogenesis	3 MATRIX METALLOPROTEINASES; MEMBRANE-TYPE 1; HEPATOCYTE GROWTH-FACTOR; SMOOTH-MUSCLE-CELLS; TISSUE LOCALIZATION; MT-MMPS; INTRACELLULAR ACTIVATION; HUMAN STROMELYSIN-3; BREAST-CARCINOMA; IV COLLAGENASE	MT3-MMP, a membrane-anchored matrix metalloproteinase, has been proposed to participate in the remodeling of extracellular matrix either by direct proteolysis or via activating other enzymes such as progelatinase A. To test this hypothesis, we analyzed the effect of exogenously transfected MT3-MMP in a tissue remodeling system: growth and tubulogenesis of Madin-Darby canine kidney (MDCK) cells in collagen gels. Although the parental cells require MMP activities for both growth and tubulogenesis, over-expression of wild-type MT3-MMP, but not its catalytically inactive mutant, leads to further enhancement of both processes, independent of its downstream substrate, progelatinase A, Mechanistically, MT3-MMP accomplishes such an effect by displaying on cell surfaces as active species, ready to activate progelatinase A or degrade ECM molecules. These data strongly suggest that MT3-MMP possesses the potential to directly enhance the growth and invasiveness of cells in vivo, two critical processes for development and carcinogenesis.	Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Pei, DQ (corresponding author), Univ Minnesota, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	peixx003@tc.umn.edu	Wang, Xing/G-2917-2015	Jiang, Aixiang/0000-0002-6153-7595	NCI NIH HHS [CA76308] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076308, R29CA076308] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Deryugina EI, 1998, CANCER RES, V58, P3743; Goss KJH, 1998, INT J CANCER, V78, P629; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Itoh T, 1997, J BIOL CHEM, V272, P22389, DOI 10.1074/jbc.272.36.22389; Itoh Y, 1999, J BIOL CHEM, V274, P34260, DOI 10.1074/jbc.274.48.34260; Kadono Y, 1998, BIOCHEM BIOPH RES CO, V251, P681, DOI 10.1006/bbrc.1998.9531; Kajita M, 1999, FEBS LETT, V457, P353, DOI 10.1016/S0014-5793(99)01065-0; KAWAHARA E, 1993, JPN J CANCER RES, V84, P409, DOI 10.1111/j.1349-7006.1993.tb00151.x; Kitagawa Y, 1999, J UROLOGY, V162, P905, DOI 10.1097/00005392-199909010-00088; Kitagawa Y, 1998, J UROLOGY, V160, P1540, DOI 10.1016/S0022-5347(01)62609-0; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Konaka H, 1999, J UROLOGY, V161, P342, DOI 10.1016/S0022-5347(01)62143-8; KONO T, 1990, Journal of Dermatology (Tokyo), V17, P2; Lee AY, 1997, P NATL ACAD SCI USA, V94, P4424, DOI 10.1073/pnas.94.9.4424; Llano E, 1999, CANCER RES, V59, P2570; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAGASE H, 1986, J BIOL CHEM, V261, P1421; Nakada M, 1999, AM J PATHOL, V154, P417, DOI 10.1016/S0002-9440(10)65288-1; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; Pei DQ, 1998, PROTEIN EXPRES PURIF, V13, P277, DOI 10.1006/prep.1998.0894; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Pei DQ, 1999, CELL RES, V9, P291, DOI 10.1038/sj.cr.7290028; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; PEI DQ, 1994, J BIOL CHEM, V269, P25849; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Polette M, 1998, INT J BIOCHEM CELL B, V30, P1195, DOI 10.1016/S1357-2725(98)00083-1; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Puente XS, 1996, CANCER RES, V56, P944; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1997, THROMB HAEMOSTASIS, V78, P497; Schlessinger J, 1997, CELL, V91, P869, DOI 10.1016/S0092-8674(00)80477-8; Seiki M, 1999, APMIS, V107, P137, DOI 10.1111/j.1699-0463.1999.tb01536.x; Shimada T, 1999, EUR J BIOCHEM, V262, P907, DOI 10.1046/j.1432-1327.1999.00459.x; Shofuda K, 1998, LAB INVEST, V78, P915; Shofuda K, 1997, J BIOL CHEM, V272, P9749; STOKER M, 1985, J CELL SCI, V77, P209; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; TURKSEN K, 1991, CELL REGUL, V2, P613, DOI 10.1091/mbc.2.8.613; Ueno H, 1997, CANCER RES, V57, P2055; Werb Z, 1998, ANN NY ACAD SCI, V857, P110, DOI 10.1111/j.1749-6632.1998.tb10111.x; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Yoshiyama Y, 1998, ACTA NEUROPATHOL, V96, P347, DOI 10.1007/s004010050904	47	43	49	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2559	2568		10.1096/fj.00-0269com	http://dx.doi.org/10.1096/fj.00-0269com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099475				2022-12-28	WOS:000165723400027
J	Weihe, E; Eiden, LE				Weihe, E; Eiden, LE			Chemical neuroanatomy of the vesicular amine transporters	FASEB JOURNAL			English	Review						aminergic neuron; endocrine cell; CNS; amine-handling cell; autonomic; immune; inflammatory	CENTRAL-NERVOUS-SYSTEM; CHOLINERGIC GENE LOCUS; ACETYLCHOLINE TRANSPORTER; MONOAMINE TRANSPORTER; ENDOCRINE-CELLS; NEUROTRANSMITTER PHENOTYPE; TYROSINE-HYDROXYLASE; ALZHEIMERS-DISEASE; SYNAPTIC VESICLES; MESSENGER-RNAS	Acetylcholine, catecholamines, serotonin, and histamine are classical neurotransmitters, These small molecules also play important roles in the endocrine and immune/inflammatory systems, Serotonin secreted from enterochromaffin cells of the gut epithelium regulates gut motility; histamine secreted from basophils and mast cells is a major regulator of vascular permeability and skin inflammatory responses; epinephrine is a classical hormone released from the adrenal medulla, Each of these molecules is released from neural, endocrine, or immune/inflammatory cells only in response to specific physiological stimuli. Regulated secretion is possible because amines are stored in secretory vesicles and released via a stimulus-dependent exocytotic event. Amine storage-at concentrations orders of magnitude higher than in the cytoplasm-is accomplished in turn by specific secretory vesicle transporters that recognize the amines and move them from the cytosol into the vesicle. Immunohistochemical visualization of specific vesicular amine transporters (VATs) in neuronal, endocrine, and inflammatory cells provides important new information about how amine-handling cell phenotypes arise during development and how vesicular transport is regulated during homeostatic response events, Comparison of the chemical neuroanatomy of VATs and amine biosynthetic enzymes has also revealed cell groups that express vesicular transporters but not enzymes for monoamine synthesis, and vice versa: their function and regulation is a new topic of investigation in mammalian neurobiology, The chemical neuroanatomy of the vesicular amine transporters is reviewed here. These and similar data emerging from the study of the localization of the recently characterized vesicular inhibitory and excitatory amino acid transporters will contribute to understanding chemically coded synaptic circuitry in the brain, and amine-handling neuroendocrine and immune/inflammatory cell regulation.	Univ Marburg, Dept Mol Neuroimmunol, Inst Anat & Cell Biol, D-35033 Marburg, Germany; NIMH, Mol Neurosci Sect, Lab Cellular & Mol Regulat, Bethesda, MD 20892 USA	Philipps University Marburg; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Weihe, E (corresponding author), Univ Marburg, Dept Mol Neuroimmunol, Inst Anat & Cell Biol, Robt Koch Str 6, D-35033 Marburg, Germany.			Eiden, Lee/0000-0001-7524-944X	NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH002386, ZIAMH002386] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Arvidsson U, 1997, J COMP NEUROL, V378, P454; Asmus SE, 2000, J NEUROSCI, V20, P1495; Bellocchio EE, 2000, SCIENCE, V289, P957, DOI 10.1126/science.289.5481.957; Bennett MR, 1997, PROG NEUROBIOL, V52, P159, DOI 10.1016/S0301-0082(97)00012-9; BERRARD S, 1995, J NEUROCHEM, V65, P939; BERSE B, 1995, J BIOL CHEM, V270, P22101, DOI 10.1074/jbc.270.38.22101; BJORKLUND A, 1984, HDB CHEM NEUROANATOM, V3; BROWNSTEIN M, 1975, J NEUROCHEM, V24, P35, DOI 10.1111/j.1471-4159.1975.tb07624.x; Chalfie M, 1998, TRENDS GENET, V14, P506, DOI 10.1016/S0168-9525(98)01623-0; Chaudhry FA, 1998, J NEUROSCI, V18, P9733; Cho JY, 1996, J COMP NEUROL, V369, P264; COCHARD P, 1978, P NATL ACAD SCI USA, V75, P2986, DOI 10.1073/pnas.75.6.2986; Debeir T, 1999, P NATL ACAD SCI USA, V96, P4067, DOI 10.1073/pnas.96.7.4067; DeGiorgio R, 1996, NEUROSCI LETT, V217, P77, DOI 10.1016/S0304-3940(96)13051-2; Depboylu C., 1999, Society for Neuroscience Abstracts, V25, P44; Dimaline R, 1996, J PHYSIOL-LONDON, V490, P249, DOI 10.1113/jphysiol.1996.sp021140; Duerr JS, 1999, J NEUROSCI, V19, P72, DOI 10.1523/JNEUROSCI.19-01-00072.1999; Dumoulin A, 1999, J CELL SCI, V112, P811; Efange SMN, 2000, FASEB J, V14, P2401, DOI 10.1096/fj.00-0204rev; Efange SMN, 1997, NEUROBIOL AGING, V18, P407, DOI 10.1016/S0197-4580(97)00038-9; Eiden LE, 1998, J NEUROCHEM, V70, P2227; Eissele R, 1999, DIGESTION, V60, P428, DOI 10.1159/000007688; Erickson JD, 1996, P NATL ACAD SCI USA, V93, P5166, DOI 10.1073/pnas.93.10.5166; Erickson JD, 1995, J MOL NEUROSCI, V6, P277, DOI 10.1007/BF02736786; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; Ernsberger U, 1999, CELL TISSUE RES, V297, P339, DOI 10.1007/s004410051363; EVANS GS, 1994, ANNU REV PHYSIOL, V56, P399; Fon EA, 1997, NEURON, V19, P1271, DOI 10.1016/S0896-6273(00)80418-3; GALLIN JI, 1984, INFLAMMATION BASIC P; Gershon MD, 1999, ALIMENT PHARM THER, V13, P15; Gilmor ML, 1999, J COMP NEUROL, V411, P693; Gilmor ML, 1996, J NEUROSCI, V16, P2179; Guidry G, 1998, DEV BIOL, V199, P175, DOI 10.1006/dbio.1998.8929; HALASZ N, 1977, BRAIN RES, V126, P455, DOI 10.1016/0006-8993(77)90597-2; Hansson SR, 1998, DEV BRAIN RES, V110, P135, DOI 10.1016/S0165-3806(98)00104-7; Holler T, 1996, NEUROSCI LETT, V212, P107, DOI 10.1016/0304-3940(96)12808-1; Hunyady B, 1998, ENDOCRINOLOGY, V139, P4404, DOI 10.1210/en.139.10.4404; Hussain I, 1999, J PHYSIOL-LONDON, V517, P495, DOI 10.1111/j.1469-7793.1999.00495.x; Ichikawa T, 1997, J CHEM NEUROANAT, V13, P23, DOI 10.1016/S0891-0618(97)00021-5; JACOBSSON G, 1994, P NATL ACAD SCI USA, V91, P12487, DOI 10.1073/pnas.91.26.12487; Jonas P, 1998, SCIENCE, V281, P419, DOI 10.1126/science.281.5375.419; KIRSHENBAUM AS, 1991, J IMMUNOL, V146, P1410; Kuhl DE, 1996, ANN NEUROL, V40, P399, DOI 10.1002/ana.410400309; LANDIS SC, 1990, TRENDS NEUROSCI, V13, P344, DOI 10.1016/0166-2236(90)90147-3; Lebrand C, 1996, NEURON, V17, P823, DOI 10.1016/S0896-6273(00)80215-9; Lebrand C, 1998, J COMP NEUROL, V401, P506; Liu YJ, 1997, J CELL BIOL, V139, P907, DOI 10.1083/jcb.139.4.907; Matsuura J, 1997, NEUROSCI LETT, V236, P95, DOI 10.1016/S0304-3940(97)00763-5; McClung C, 1999, CURR BIOL, V9, P853, DOI 10.1016/S0960-9822(99)80389-3; McIntire SL, 1997, NATURE, V389, P870, DOI 10.1038/39908; MERICKEL A, 1995, NEUROPHARMACOLOGY, V34, P1543, DOI 10.1016/0028-3908(95)00148-Y; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; Monastirioti M, 1996, J NEUROSCI, V16, P3900; Nagao M, 1998, J NEUROPATH EXP NEUR, V57, P329, DOI 10.1097/00005072-199804000-00004; PATERSON IA, 1990, J NEUROCHEM, V55, P1827, DOI 10.1111/j.1471-4159.1990.tb05764.x; PETER D, 1995, J NEUROSCI, V15, P6179; Rindi G, 2000, VIRCHOWS ARCH, V436, P217, DOI 10.1007/s004280050033; Roghani A, 1998, NEUROSCIENCE, V82, P1195; Sagne C, 1997, FEBS LETT, V417, P177, DOI 10.1016/S0014-5793(97)01279-9; SCHAFER MKH, 1994, J MOL NEUROSCI, V5, P1, DOI 10.1007/BF02736691; Schafer MKH, 1998, NEUROSCIENCE, V84, P331, DOI 10.1016/S0306-4522(97)00516-2; Schafer MKH, 1997, P NATL ACAD SCI USA, V94, P4149, DOI 10.1073/pnas.94.8.4149; SCHOTZINGER R, 1994, J NEUROBIOL, V25, P620, DOI 10.1002/neu.480250605; Takamori S, 2000, NATURE, V407, P189, DOI 10.1038/35025070; TALLMAN JF, 1976, J PHARMACOL EXP THER, V199, P216; Tian XT, 1996, NEUROSCI LETT, V209, P134, DOI 10.1016/0304-3940(96)12629-X; TISCHLER AS, 1985, LIFE SCI, V37, P1881, DOI 10.1016/0024-3205(85)90005-0; Tooyama I, 2000, J CHEM NEUROANAT, V17, P217, DOI 10.1016/S0891-0618(99)00043-5; TYRRELL S, 1992, NEUROSCIENCE, V47, P985, DOI 10.1016/0306-4522(92)90046-5; Watson F, 1999, BIOCHEM J, V337, P193, DOI 10.1042/0264-6021:3370193; Weihe E, 1998, J PHYSIOLOGY-PARIS, V92, P385, DOI 10.1016/S0928-4257(99)80010-2; WEIHE E, 1994, J MOL NEUROSCI, V5, P149, DOI 10.1007/BF02736730; Weihe E, 1996, P NATL ACAD SCI USA, V93, P3547, DOI 10.1073/pnas.93.8.3547	74	109	120	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2435	2449		10.1096/fj.00-0202rev	http://dx.doi.org/10.1096/fj.00-0202rev			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099461				2022-12-28	WOS:000165723400013
J	Colussi, C; Albertini, MC; Coppola, S; Rovidati, S; Galli, F; Ghibelli, L				Colussi, C; Albertini, MC; Coppola, S; Rovidati, S; Galli, F; Ghibelli, L			H2O2-induced block of glycolysis as an active ADP-ribosylation reaction protecting cells from apoptosis	FASEB JOURNAL			English	Article						NAD; oxidative stress; hydrogen peroxide; 3-aminobenzamide	NICOTINAMIDE ADENINE-DINUCLEOTIDE; ISLET-ACTIVATING PROTEIN; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; HYDROGEN-PEROXIDE; NITRIC-OXIDE; COVALENT MODIFICATION; MAMMALIAN-CELLS; S-NITROSYLATION; INDUCED INJURY; GSH EXTRUSION	H2O2 treatment on U937 cells leads to the block of glycolytic flux and the inactivation of glyceraldehyde-3-phosphate-dehydrogenase by a posttranslational modification (possibly ADP-ribosylation), Glycolysis spontaneously reactivates after 2 h of recovery from oxidative stress; thereafter cells begin to undergo apoptosis, The specific ADP-ribosylation inhibitor 3-aminobenzamide inhibits the stress-induced inactivation of glyceraldehyde-3-phosphate-dehydrogenase and the block of glycolysis; concomitantly, it anticipates and increases apoptosis, Exogenous block of glycolysis (i.e., by culture in glucose-free medium or with glucose analogs or after NAD depletion), turns the transient block into a stable one: this results in protection from apoptosis, even when downstream cell metabolism is kept active by the addition of pyruvate, All this evidence indicates that the stress-induced block of glycolysis is not the result of a passive oxidative damage, but rather an active cell reaction programmed via ADP-ribosylation for cell self-defense.-Colussi, C., Albertini, M. C., Coppola, S., Rovidati, S., Galli, F., Ghibelli, L. H2O2-induced block of glycolysis as an active ADP-ribosylation reaction protecting cells from apoptosis.	Univ Roma Tor Vergata, Dipartimento Biol, I-00133 Rome, Italy; Univ Urbino, Ist Biochim G Fornaini, Rome, Italy	University of Rome Tor Vergata; University of Urbino	Ghibelli, L (corresponding author), Univ Roma Tor Vergata, Dipartimento Biol, Via Ric Sci, I-00133 Rome, Italy.		Colussi, Claudia/H-8609-2019; Galli, Francesco/K-5048-2016; Albertini, Maria Cristina/AAG-6980-2019; Coppola, Simona/A-6638-2015	Galli, Francesco/0000-0003-3626-051X; Albertini, Maria Cristina/0000-0003-4549-1475; Coppola, Simona/0000-0001-7851-9409; Colussi, Claudia/0000-0002-7727-8911				ALVAREZGONZALEZ R, 1989, MUTAT RES, V218, P67, DOI 10.1016/0921-8777(89)90012-8; ARGILES JM, 1990, MED HYPOTHESES, V32, P151, DOI 10.1016/0306-9877(90)90039-H; BANASIK M, 1992, J BIOL CHEM, V267, P1569; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; BERVOFSKI C, 1973, ANAL BIOCHEM, V53, P452; BOKOCH GM, 1983, J BIOL CHEM, V258, P2072; BOUCHERIE H, 1995, FEMS MICROBIOL LETT, V125, P127; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P2669, DOI 10.1073/pnas.75.6.2669; CLANCY RM, 1993, BIOCHEM BIOPH RES CO, V191, P847, DOI 10.1006/bbrc.1993.1294; CLEAVER JE, 1991, MUTAT RES, V257, P1, DOI 10.1016/0165-1110(91)90016-O; COPPOLA S, 1995, EXP CELL RES, V221, P462, DOI 10.1006/excr.1995.1397; Coppola S, 2000, BIOCHEM SOC T, V28, P56, DOI 10.1042/bst0280056; DEMATTEIS MA, 1994, P NATL ACAD SCI USA, V91, P1114, DOI 10.1073/pnas.91.3.1114; DIMMELER S, 1992, J BIOL CHEM, V267, P16771; Dini L, 1996, EXP CELL RES, V223, P340, DOI 10.1006/excr.1996.0089; Ghibelli L, 1999, FASEB J, V13, P2031, DOI 10.1096/fasebj.13.14.2031; GHIBELLI L, 1995, BIOCHEM BIOPH RES CO, V216, P313, DOI 10.1006/bbrc.1995.2626; Ghibelli L, 1998, FASEB J, V12, P479, DOI 10.1096/fasebj.12.6.479; HARLAN JM, 1984, J CLIN INVEST, V73, P706, DOI 10.1172/JCI111263; HINSHAW DB, 1988, AM J PATHOL, V132, P479; HUITOREL P, 1985, EUR J BIOCHEM, V150, P265, DOI 10.1111/j.1432-1033.1985.tb09016.x; HYSLOP PA, 1986, J CELL PHYSIOL, V129, P356, DOI 10.1002/jcp.1041290314; HYSLOP PA, 1988, J BIOL CHEM, V263, P1665; KATADA T, 1982, J BIOL CHEM, V257, P7210; KLIMAN HJ, 1980, J BIOL CHEM, V255, P6314; KOTS AY, 1992, FEBS LETT, V300, P9, DOI 10.1016/0014-5793(92)80153-8; MCDONALD LJ, 1993, P NATL ACAD SCI USA, V90, P6238, DOI 10.1073/pnas.90.13.6238; MEYERSIEGLER K, 1991, P NATL ACAD SCI USA, V88, P8460, DOI 10.1073/pnas.88.19.8460; Mohr S, 1996, J BIOL CHEM, V271, P4209; MORGENEGG G, 1986, J NEUROCHEM, V47, P54; MOSS J, 1977, J BIOL CHEM, V252, P2455; NATH KA, 1994, KIDNEY INT, V45, P166, DOI 10.1038/ki.1994.20; NATH KA, 1995, AM J PHYSIOL-CELL PH, V268, pC227, DOI 10.1152/ajpcell.1995.268.1.C227; Neermann J, 1996, J CELL PHYSIOL, V166, P152; NOSSERI C, 1994, EXP CELL RES, V212, P367, DOI 10.1006/excr.1994.1156; OMANN GM, 1994, ARCH BIOCHEM BIOPHYS, V308, P407, DOI 10.1006/abbi.1994.1057; Petronini PG, 1996, J CELL PHYSIOL, V169, P175, DOI 10.1002/(SICI)1097-4652(199610)169:1<175::AID-JCP18>3.0.CO;2-C; RANKIN PW, 1989, J BIOL CHEM, V264, P4312; RONAI Z, 1993, INT J BIOCHEM, V25, P1073, DOI 10.1016/0020-711X(93)90123-V; RUBIN R, 1984, ARCH BIOCHEM BIOPHYS, V228, P450, DOI 10.1016/0003-9861(84)90010-9; SCHLAFER M, 1994, J NEUROCHEM, V63, P1924; SCHRAUFSTATTER IU, 1986, P NATL ACAD SCI USA, V83, P4908, DOI 10.1073/pnas.83.13.4908; SCHRAUFSTATTER IU, 1986, J CLIN INVEST, V77, P1312, DOI 10.1172/JCI112436; SCHRAUFSTATTER IU, 1985, J CLIN INVEST, V76, P1131, DOI 10.1172/JCI112068; SCHUPPEKOISTINEN I, 1994, EUR J BIOCHEM, V221, P1033, DOI 10.1111/j.1432-1033.1994.tb18821.x; SHALL S, 1995, BIOCHIMIE, V77, P313, DOI 10.1016/0300-9084(96)88140-5; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; Soukri A, 1996, BBA-PROTEIN STRUCT M, V1292, P177, DOI 10.1016/0167-4838(95)00200-6; SPRAGG RG, 1985, J CLIN INVEST, V76, P1471, DOI 10.1172/JCI112126; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; Vertessy BG, 1996, FEBS LETT, V379, P191, DOI 10.1016/0014-5793(95)01510-8; WIESE AG, 1995, ARCH BIOCHEM BIOPHYS, V318, P231, DOI 10.1006/abbi.1995.1225; Wright SC, 1996, J EXP MED, V183, P463, DOI 10.1084/jem.183.2.463; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; ZHANG J, 1992, P NATL ACAD SCI USA, V89, P9382, DOI 10.1073/pnas.89.20.9382	55	125	129	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2266	2276		10.1096/fj.00-0074com	http://dx.doi.org/10.1096/fj.00-0074com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053248				2022-12-28	WOS:000165190800020
J	Aoki, Y; Huang, ZH; Thomas, SS; Bhide, PG; Huang, I; Moskowitz, MA; Reeves, SA				Aoki, Y; Huang, ZH; Thomas, SS; Bhide, PG; Huang, I; Moskowitz, MA; Reeves, SA			Increased susceptibility to ischemia-induced brain damage in transgenic mice overexpressing a dominant negative form of SHP2	FASEB JOURNAL			English	Article						protein tyrosine phosphatase; cell survival; cerebral ischemia; neuron	PROTEIN-TYROSINE-PHOSPHATASE; FOCAL CEREBRAL-ISCHEMIA; TRANSIENT FOREBRAIN ISCHEMIA; NERVE GROWTH-FACTOR; REACTIVE ASTROCYTES; PROGENITOR CELLS; MESSENGER-RNA; RAT-BRAIN; DIFFERENTIAL REGULATION; SIGNAL-TRANSDUCTION	Cell culture studies have established SH2 domain-containing protein tyrosine phosphatase-2 (SHP2) as an important factor in growth factor and cytokine-activated signaling pathways. However, the significance of SHP2 in the mammalian central nervous system (CNS) is not known since early embryonic lethality occurs in shp2 null mice. To bypass this embryonic lethality, transgenic animals containing a catalytically inactive mutant of SHP2 (SHP2-CS) under the control of a nestin intron II/thymidiue kinase minimal promoter were generated. In the developing CNS of these animals, although high-level transgene expression was detected in the neuroepithelium, there was no obvious abnormality in progenitor cell proliferation or migration. In the adult brain, high-level transgene expression was detected in the subventricular zone, rostral migratory stream, dentate gyrus of hippocampus, and cerebellum. Because SHP2 function is Likely important in cell survival pathways, we used a focal cerebral ischemia model to examined whether SHP2 is important during CNS injury. Ischemia-induced damage and neuronal death was found to be significantly greater in nestin-SHP2-CS mice than in wildtype littermates. These findings indicate that SHP2 is a required factor in signaling pathway(s) important for neuronal survival.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, CNS Signaling Lab, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	Reeves, SA (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, CNS Signaling Lab, 149 13th St, Charlestown, MA 02129 USA.		Moskowitz, Michael A/D-9916-2011	Bhide, Pradeep/0000-0003-4236-9415	NINDS NIH HHS [R01NS3599601] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035996] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; Arrandale JM, 1996, J BIOL CHEM, V271, P21353, DOI 10.1074/jbc.271.35.21353; Beck KD, 1996, NEURON, V16, P665, DOI 10.1016/S0896-6273(00)80085-9; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BETZ AL, 1983, J CEREBR BLOOD F MET, V3, P193, DOI 10.1038/jcbfm.1983.26; Chan KM, 1996, NEUROCHEM RES, V21, P763, DOI 10.1007/BF02532298; Doetsch F, 1997, J NEUROSCI, V17, P5046; Duggal N, 1997, BRAIN RES, V768, P1, DOI 10.1016/S0006-8993(97)00588-X; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FINKLESTEIN SP, 1990, STROKE, V21, P122; Frearson JA, 1998, J EXP MED, V187, P1417, DOI 10.1084/jem.187.9.1417; Fujii M, 1997, STROKE, V28, P1805, DOI 10.1161/01.STR.28.9.1805; Gage FH, 1998, J NEUROBIOL, V36, P249, DOI 10.1002/(SICI)1097-4695(199808)36:2<249::AID-NEU11>3.0.CO;2-9; GLUCKMAN P, 1992, BIOCHEM BIOPH RES CO, V182, P593, DOI 10.1016/0006-291X(92)91774-K; Guegan C, 1998, MOL BRAIN RES, V55, P133, DOI 10.1016/S0169-328X(97)00372-0; Hogan B, 1994, MANIPULATING MOUSE E; Huang ZH, 1996, J CEREBR BLOOD F MET, V16, P981, DOI 10.1097/00004647-199609000-00023; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KLEMPT ND, 1992, MOL BRAIN RES, V13, P93, DOI 10.1016/0169-328X(92)90048-G; KOKETSU N, 1994, ANN NEUROL, V35, P451, DOI 10.1002/ana.410350413; LEE WH, 1993, ANN NY ACAD SCI, V679, P418, DOI 10.1111/j.1749-6632.1993.tb18332.x; Li Y, 1999, BRAIN RES, V838, P1, DOI 10.1016/S0006-8993(99)01502-4; LIN RCS, 1995, NEUROBIOL DIS, V2, P79, DOI 10.1006/nbdi.1995.0008; Lin TN, 1998, MOL BRAIN RES, V55, P71, DOI 10.1016/S0169-328X(97)00367-7; Lin TN, 1997, MOL BRAIN RES, V49, P255, DOI 10.1016/S0169-328X(97)00152-6; LINDVALL O, 1992, P NATL ACAD SCI USA, V89, P648, DOI 10.1073/pnas.89.2.648; Lothian C, 1997, EUR J NEUROSCI, V9, P452, DOI 10.1111/j.1460-9568.1997.tb01622.x; Neel B G, 1993, Semin Cell Biol, V4, P419, DOI 10.1006/scel.1993.1050; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; O'Reilly AM, 1998, MOL CELL BIOL, V18, P161, DOI 10.1128/MCB.18.1.161; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; Reeves SA, 1996, NEUROSCIENCE, V71, P1037, DOI 10.1016/0306-4522(95)00491-2; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; Sakakibara S, 1997, J NEUROSCI, V17, P8300; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Servidei T, 1998, NEUROSCIENCE, V82, P529; Servidei T, 1998, J BIOL CHEM, V273, P6233, DOI 10.1074/jbc.273.11.6233; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; TAKAHASHI T, 1992, J NEUROCYTOL, V21, P185, DOI 10.1007/BF01194977; TAKAHASHI T, 1993, J NEUROSCI, V13, P820; TAKAMI K, 1992, EXP BRAIN RES, V90, P1; TAKEDA A, 1992, BRAIN RES, V569, P177, DOI 10.1016/0006-8993(92)90388-P; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; Thomas LB, 1996, GLIA, V17, P1; VANUITERT RL, 1978, STROKE, V9, P67, DOI 10.1161/01.STR.9.1.67; Wright JH, 1997, MOL BIOL CELL, V8, P1575, DOI 10.1091/mbc.8.8.1575; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, J BIOL CHEM, V270, P14871, DOI 10.1074/jbc.270.25.14871; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; ZHU CZ, 1994, J CEREBR BLOOD F MET, V14, P237, DOI 10.1038/jcbfm.1994.30; ZIMMERMAN L, 1994, NEURON, V12, P11, DOI 10.1016/0896-6273(94)90148-1	52	40	43	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2000	14	13					1965	1973		10.1096/fj.00-0105com	http://dx.doi.org/10.1096/fj.00-0105com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023980				2022-12-28	WOS:000089634400015
J	Schroder, HC; Krasko, A; Batel, R; Skorokhod, A; Pahler, S; Kruse, M; Muller, IM; Muller, WEG				Schroder, HC; Krasko, A; Batel, R; Skorokhod, A; Pahler, S; Kruse, M; Muller, IM; Muller, WEG			Stimulation of protein (collagen) synthesis in sponge cells by a cardiac myotrophin-related molecule from Suberites domuncula	FASEB JOURNAL			English	Article						Porifera; myotrophin-like molecule; collagen; primmorphs; signal transduction	GEODIA-CYDONIUM; ADHESION RECEPTORS; GENE-EXPRESSION; MARINE SPONGES; ORIGIN; CLONING; SEQUENCE; SYSTEMS; IDENTIFICATION; INVERTEBRATES	The body wall of sponges (Porifera), the lowest metazoan phylum, is formed by two epithelial cell layers of exopinacocytes and endopinacocytes, both of which are associated with collagen fibrils. Here we show that a myotrophin-like polypeptide from the sponge Suberites domuncula causes the expression of collagen in cells from the same sponge in vitro. The cDNA of the sponge myotrophin was isolated; the potential open reading frame of 360 nt encodes a 120 aa long protein (M-r of 12,837). The sequence SUBDOMYOL shares high similarity with the known metazoan myotrophin sequences. The expression of SUBDOMYOL is lo tv in single cells but high after formation of primmorph aggregates as well as in intact animals. Recombinant myotrophin was found to stimulate protein synthesis by fivefold, as analyzed by incorporation studies using [H-3] lysine. In addition, it is shown that after incubation of single cells with myotrophin, the primmorphs show an unusual elongated, oval-shaped appearance. It is demonstrated that in the presence of recombinant myotrophin, the cells up-regulate the expression of the collagen gene. The cDNA for S. domuncula collagen was isolated; the deduced aa sequence shows that the collagenous internal domain is rather short, with only 24 G-x-y collagen triplets. We conclude that the sponge myotrophin causes in homologous cells the same/similar effect as the cardiac myotrophin in mammalian cells, where it is involved in initiation of cardial ventricular hypertrophy. We assume that an understanding of sponge molecular cell biology will also contribute to a further elucidation of human diseases, here of the cardiovascular system.	Johannes Gutenberg Univ Mainz, Inst Physiol Chem, Angew Mol Biol Abt, D-55099 Mainz, Germany; Rudjer Boskovic Inst, Ctr Marine Res, HR-52210 Rovinj, Croatia; Max Planck Inst Zuchtungsforsch, D-50829 Cologne, Germany	Johannes Gutenberg University of Mainz; Rudjer Boskovic Institute; Max Planck Society	Muller, WEG (corresponding author), Johannes Gutenberg Univ Mainz, Inst Physiol Chem, Angew Mol Biol Abt, Duesbergweg 6, D-55099 Mainz, Germany.	WMUELLER@mail.UNI-Mainz.DE	Müller, W. E. G./AAR-8651-2020	Müller, W. E. G./0000-0002-8223-3689; Schroder, Heinz C./0000-0003-0992-6427				Asahina K, 1999, DEV DYNAM, V216, P59, DOI 10.1002/(SICI)1097-0177(199909)216:1<59::AID-DVDY8>3.0.CO;2-B; Asahina K, 1999, MATRIX BIOL, V18, P89, DOI 10.1016/S0945-053X(99)00005-0; Bisoffi M, 1996, PARASITOLOGY, V113, P145, DOI 10.1017/S0031182000066397; Blumbach B, 1999, IMMUNOGENETICS, V49, P751, DOI 10.1007/s002510050549; Blumbach B, 1998, J CELL SCI, V111, P2635; Brooks WW, 1997, HYPERTENSION, V30, P1362, DOI 10.1161/01.HYP.30.6.1362; Celerin M, 1996, EMBO J, V15, P4445, DOI 10.1002/j.1460-2075.1996.tb00821.x; Chan SL, 1999, J BIOL CHEM, V274, P32461, DOI 10.1074/jbc.274.45.32461; Custodio MR, 1998, MECH AGEING DEV, V105, P45, DOI 10.1016/S0047-6374(98)00078-5; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; Eble J.A., 1997, INTEGRIN LIGAND INTE; EXPOSITO JY, 1991, J BIOL CHEM, V266, P21923; EXPOSITO JY, 1990, P NATL ACAD SCI USA, V87, P6669, DOI 10.1073/pnas.87.17.6669; Felsenstein J., 1993, PHYLIP VER 3 5; FIELD KG, 1988, SCIENCE, V239, P748, DOI 10.1126/science.3277277; Garrone R, 1998, Prog Mol Subcell Biol, V21, P119; Garrone R., 1978, PHYLOGENESIS CONNECT; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; *INT INC, 1995, PC GENE DAT BANKS CD; KOROTKOVA GP, 1970, BIOL PORIFERA, V25, P423; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Koziol C, 1998, MECH AGEING DEV, V100, P107, DOI 10.1016/S0047-6374(97)00120-6; Kruse M, 1997, MOL BIOL EVOL, V14, P1326, DOI 10.1093/oxfordjournals.molbev.a025742; KURZ EM, 1991, J CELL BIOL, V115, P1159, DOI 10.1083/jcb.115.4.1159; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lorenz B, 1996, CELL SIGNAL, V8, P517, DOI 10.1016/S0898-6568(96)00108-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAYNE R, 1985, ANN NY ACAD SCI, V460, P38, DOI 10.1111/j.1749-6632.1985.tb51155.x; Moore DD, 1995, GLOB MOB SURV; MUKHERJEE D, 1992, CIRCULATION S1, V86, P1; Muller WEG, 1999, DNA CELL BIOL, V18, P885, DOI 10.1089/104454999314746; MULLER WEG, 1977, CANCER RES, V37, P3824; Muller WEG, 1999, TRANSPLANTATION, V68, P1215; Muller WEG, 1999, MAR ECOL PROG SER, V178, P205, DOI 10.3354/meps178205; Muller WEG, 1997, CELL TISSUE RES, V289, P383, DOI 10.1007/s004410050885; MULLER WEG, 1995, NATURWISSENSCHAFTEN, V82, P321; MUNRO HN, 1966, ANALYST, V91, P78, DOI 10.1039/an9669100078; Nicholas KB., 1997, GENEDOC TOOL EDITING; Pahler S, 1998, P ROY SOC B-BIOL SCI, V265, P421, DOI 10.1098/rspb.1998.0311; Pancer Z, 1997, MOL BIOL EVOL, V14, P391, DOI 10.1093/oxfordjournals.molbev.a025775; Perovic S, 1999, CELL TISSUE RES, V296, P395, DOI 10.1007/s004410051299; PFEIFER K, 1993, GLYCOBIOLOGY, V3, P179, DOI 10.1093/glycob/3.2.179; Sawada K, 1996, INT J DEV BIOL, V40, P531; SCHACKE H, 1994, IMMUNOL TODAY, V15, P497, DOI 10.1016/0167-5699(94)90198-8; SCHWARTZ K, 1986, CIRC RES, V59, P551, DOI 10.1161/01.RES.59.5.551; SEN S, 1990, J BIOL CHEM, V265, P16635; Sil P, 1998, CIRC RES, V82, P1173, DOI 10.1161/01.RES.82.11.1173; Simpson T., 1984, CELL BIOL SPONGES; Sivasubramanian N, 1996, J BIOL CHEM, V271, P2812, DOI 10.1074/jbc.271.5.2812; STANLEY PE, 1990, BIOLUMINESCENCE CHEM; TAKAHARA K, 1991, J BIOL CHEM, V266, P13124; TAOKA M, 1994, J BIOL CHEM, V269, P9946; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vacelet Jean, 1999, Memoirs of the Queensland Museum, V44, P27; Westheide W, 1996, SPEZIELLE ZOOLOGIE 1; Wiens M, 2000, CELL DEATH DIFFER, V7, P461, DOI 10.1038/sj.cdd.4400671; Wiens M, 1999, FEBS LETT, V462, P12, DOI 10.1016/S0014-5793(99)01478-7; Wiens M, 1998, MAR ECOL PROG SER, V165, P247, DOI 10.3354/meps165247; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Wimmer W, 1999, EUR J BIOCHEM, V260, P156, DOI 10.1046/j.1432-1327.1999.00146.x; Yang JJ, 1997, TOP GERIATR REHABIL, V13, P13	61	61	66	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2000	14	13					2022	2031		10.1096/fj.00-0043com	http://dx.doi.org/10.1096/fj.00-0043com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023986				2022-12-28	WOS:000089634400021
J	Biessen, EAL; Valentijn, ARPM; De Vrueh, RLA; Van de Bilt, E; Sliedregt, LAJM; Prince, P; Bijsterbosch, MK; Van Boom, JH; Van der Marel, GA; Abrahams, PJ; Van Berkel, TJC				Biessen, EAL; Valentijn, ARPM; De Vrueh, RLA; Van de Bilt, E; Sliedregt, LAJM; Prince, P; Bijsterbosch, MK; Van Boom, JH; Van der Marel, GA; Abrahams, PJ; Van Berkel, TJC			Novel hepatotrophic prodrugs of the antiviral nucleoside 9-(2-phosphonylmethoxyethyl)adenine with improved pharmacokinetics and antiviral activity	FASEB JOURNAL			English	Article						asialoglycoprotein; HBV; HSV-1; drug targeting; liver	CHRONIC HEPATITIS-B; LOW-DENSITY-LIPOPROTEIN; HERPES-SIMPLEX VIRUS; POLY-L-LYSINE; ASIALOGLYCOPROTEIN RECEPTOR; LIVER-CELLS; HIGH-AFFINITY; LAMIVUDINE RESISTANCE; CLUSTER GALACTOSIDES; LIPOPHILIC PRODRUG	The device of new hepatotrophic prodrugs of the antiviral nucleoside 9-(2-phosphonylmethoxyethyl)adenine (PMEA) with specificity for the asialoglycoprotein receptor on parenchymal liver cells is described. PMEA was conjugated to bi- and trivalent cluster glycosides (K(GN)(2) and K-2 (GN)(3), respectively) with nanomolar affinity for the asialoglycoprotein receptor. The liver uptake of the PMEA prodrugs was more than 10-fold higher than that of the parent drug (52+/-6% and 62+/-3% vs. 4.8+/-0.7% of the injected dose for PMEA) and could be attributed for 90% to parenchymal cells. Accumulation of the PMEA prodrugs in extrahepatic tissue (e.g., kidney, skin) was substantially reduced. The ratio of parenchymal liver cell-to-kidney uptake-a measure of the prodrugs therapeutic window-was increased from 0.058 +/- 0.01 for PMEA to 1.86 +/- 0.57 for K(GN)(2)-PMEA and even 2.69 +/- 0.24 for K-2 (GN)(3)-PMEA. Apparently both glycosides have a similar capacity to redirect (antiviral) drugs to the liver. After cellular uptake, both PMEA prodrugs were converted into the parent drug, PMEA, during acidification of the lysosomal milieu (t(1/2) approximate to 100 min), and the released PMEA was rapidly translocated into the cytosol. The antiviral activity of the prodrugs in vitro was dramatically enhanced as compared to the parent drug (5- and 52-fold for K(GN)(2)-PMEA and K-2 (GN)(3)-PMEA, respectively). Given the 15-fold enhanced liver uptake of the prodrugs, we anticipate that the potency in vivo will be similarly increased. We conclude that PMEA prodrugs have been developed with greatly improved pharmacokinetics and therapeutic activity against viral infections that implicate the liver parenchyma (e.g., HBV). In addition, the significance of the above prodrug concept also extends to drugs that intervene in other liver disorders such as cholestasis and dyslipidemia.	Leiden Amsterdam Ctr Drug Res, Sylvius Labs, Div Biopharmaceut, Leiden, Netherlands; Leiden Univ, LIC, Dept Bioorgan Chem, Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Radiat Genet & Chem Mutagenesis, Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Biessen, EAL (corresponding author), Leiden Amsterdam Ctr Drug Res, Sylvius Labs, Div Biopharmaceut, Wassenaarseweg 72, Leiden, Netherlands.	biessen@lacdr.leidenuniv.nl	Van Berkel, Theo/ABD-7677-2021; de Vrueh, Remco/ABE-3053-2020					ABRAHAMS PJ, 1984, MOL CELL BIOL, V4, P2341, DOI 10.1128/MCB.4.11.2341; Angus PW, 1997, J GASTROEN HEPATOL, V12, P217, DOI 10.1111/j.1440-1746.1997.tb00411.x; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; Atkins M, 1998, J HEPATOL, V28, P169, DOI 10.1016/S0168-8278(98)80219-5; BIESSEN EAL, 1995, J MED CHEM, V38, P1538, DOI 10.1021/jm00009a014; BIESSEN EAL, 1994, J HEPATOL, V21, P806, DOI 10.1016/S0168-8278(94)80243-2; Bijsterbosch MK, 1996, BIOCHEM PHARMACOL, V52, P113, DOI 10.1016/0006-2952(96)00170-0; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BISCHOFBERGER N, 1994, ANTIMICROB AGENTS CH, V38, P2387, DOI 10.1128/AAC.38.10.2387; BURGESS JB, 1992, HEPATOLOGY, V15, P702, DOI 10.1002/hep.1840150425; CASTER WO, 1955, AM J PHYSIOL, V183, P317, DOI 10.1152/ajplegacy.1955.183.2.317; Cerenzia MT, 1996, HEPATOLOGY, V23, P657, DOI 10.1002/hep.510230401; CIHLAR T, 1995, ANTIMICROB AGENTS CH, V39, P117, DOI 10.1128/AAC.39.1.117; de Vrueh RLA, 1999, PHARMACEUT RES, V16, P1179, DOI 10.1023/A:1018933126885; DECLERCQ E, 1993, ADV VIRUS RES, V42, P1, DOI 10.1016/S0065-3527(08)60082-2; DIENSTAG JL, 1995, NEW ENGL J MED, V333, P1657, DOI 10.1056/NEJM199512213332501; EISENBERG C, 1991, J HEPATOL, V13, P305, DOI 10.1016/0168-8278(91)90073-K; ENRIQUEZ PM, 1995, BIOCONJUGATE CHEM, V6, P195, DOI 10.1021/bc00032a007; FIUME L, 1995, HEPATOLOGY, V22, P1072, DOI 10.1002/hep.1840220409; Fiume L, 1997, J VIRAL HEPATITIS, V4, P363, DOI 10.1046/j.1365-2893.1997.00067.x; FIUME L, 1986, BIOCHEM PHARMACOL, V35, P967, DOI 10.1016/0006-2952(86)90084-5; FOSTER SA, 1991, J BIOL CHEM, V266, P238; Hangeland JJ, 1997, ANTISENSE NUCLEIC A, V7, P141, DOI 10.1089/oli.1.1997.7.141; HOLY A, 1987, COLLECT CZECH CHEM C, V52, P2801, DOI 10.1135/cccc19872801; Honkoop P, 1997, J HEPATOL, V26, P1393, DOI 10.1016/S0168-8278(97)80476-X; Hoofnagle JH, 1997, J VIRAL HEPATITIS, V4, P41, DOI 10.1111/j.1365-2893.1997.tb00159.x; JANSEN RW, 1993, HEPATOLOGY, V18, P146, DOI 10.1016/0270-9139(93)90518-R; KROGSGAARD K, 1994, J HEPATOL, V21, P646, DOI 10.1016/S0168-8278(94)80114-2; KRUINING J, 1995, J HEPATOL, V22, P263, DOI 10.1016/0168-8278(95)80277-0; Kuznetsova E V, 1995, Mol Biol (Mosk), V29, P415; Lee RT, 1997, BIOCONJUGATE CHEM, V8, P762, DOI 10.1021/bc9700796; Ling R, 1996, HEPATOLOGY, V24, P711, DOI 10.1053/jhep.1996.v24.pm0008781347; MIDOUX P, 1990, BIOCHEM BIOPH RES CO, V167, P1044, DOI 10.1016/0006-291X(90)90628-Z; MYERS BM, 1995, HEPATOLOGY, V22, P1519, DOI 10.1016/0270-9139(95)90160-4; Naesens L, 1997, ANTIVIR CHEM CHEMOTH, V8, P1; NAESENS L, 1992, DRUG METAB DISPOS, V20, P747; NAGELKERKE JF, 1983, J BIOL CHEM, V258, P2221; Nevens F, 1997, GASTROENTEROLOGY, V113, P1258, DOI 10.1053/gast.1997.v113.pm9322520; RAHIL J, 1981, J AM CHEM SOC, V103, P1723, DOI 10.1021/ja00397a024; RENSEN PCN, 1995, NAT MED, V1, P221, DOI 10.1038/nm0395-221; SCHALM SW, 1995, J HEPATOL, V22, P52; Smeijsters LJJW, 1996, ANTIMICROB AGENTS CH, V40, P1584, DOI 10.1128/AAC.40.7.1584; Valentijn ARPM, 1997, TETRAHEDRON, V53, P759, DOI 10.1016/S0040-4020(96)01018-6; Van Berkel Theo J. C., 1994, Current Opinion in Lipidology, V5, P331, DOI 10.1097/00041433-199410000-00004; VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282; VANBERKEL TJC, 1987, BIOCHEM J, V243, P715, DOI 10.1042/bj2430715; WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011	47	15	31	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2000	14	12					1784	1792		10.1096/fj.99-0887com	http://dx.doi.org/10.1096/fj.99-0887com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973928	Bronze			2022-12-28	WOS:000089212400018
J	Mikulits, W; Pradet-Balade, B; Habermann, B; Beug, H; Garcia-Sanz, JA; Mullner, EW				Mikulits, W; Pradet-Balade, B; Habermann, B; Beug, H; Garcia-Sanz, JA; Mullner, EW			Isolation of translationally controlled mRNAs by differential screening	FASEB JOURNAL			English	Article						T cell activation; translational control; array hybridization	T-CELL ACTIVATION; TRANSCRIPTION FACTOR CHOP; P38 MAP KINASE; MESSENGER-RNA; POSTTRANSCRIPTIONAL REGULATION; PROTEIN-SYNTHESIS; CYTOPLASMIC POLYADENYLATION; LYMPHOCYTE STIMULATION; TRANSFERRIN RECEPTOR; GENE-EXPRESSION	Translational regulation plays an important role in the control of gene expression, Changes in translation initiation rates are the most common translation-regulating mechanisms, resulting in alterations in mRNA loading of ribosomes. This differential mobilization of mRNAs onto polyribosomes tvas used in differential screening to directly identify cDNAs whose transcripts are translationally controlled during antigenic stimulation of primary human T lymphocytes. Ribosome-free and polysome-bound mRNAs were prepared from quiescent and activated T cells and used as templates to synthesize four cDNA pools, These in turn were used as probes to hybridize four identical replicas of a T cell library or, alternatively, four cDNA arrays. Translational activation was indicated by redistribution of the hybridization signals from the ribosome-free fraction in resting T cells to the polysome-associated fraction in activated T cells. Translational repression corresponded to the opposite hybridization pattern. Fifty-two cDNAs were identified as translationally controlled by screening 472 genes in a cDNA array; 12 additional ones were obtained by screening a cDNA library. Several of the transcripts corresponded to mRNAs previously reported to be translationally controlled, thus validating the method. For the majority, however, such regulation had not yet been described, Translational control was verified for representative examples by demonstrating the redistribution of the corresponding mRNAs on polysome gradients in response to T cell activation, Our strategy therefore provides an efficient tool to directly isolate or identify translationally controlled mRNAs in a variety of physiological situations, Moreover, differential screening using arrays enables simultaneous analysis of both transcriptional and translational regulation, further enhancing the power of gene expression analysis.	Univ Vienna, Bioctr, Inst Mol Biol, A-1030 Vienna, Austria; Univ Vienna, Bioctr, Inst Mol Pathol, A-1030 Vienna, Austria; Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain	University of Vienna; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); University of Vienna; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Mullner, EW (corresponding author), Univ Vienna, Bioctr, Inst Mol Biol, Dr Bohr-Gasse, A-1030 Vienna, Austria.	jasanz@cnb.uam.es	Garcia-Sanz, Jose A/E-7684-2011; Mikulits, Wolfgang/AAH-4043-2021; Habermann, Bianca/N-4886-2016; Garcia-Sanz, Jose A./AAA-2956-2019	Garcia-Sanz, Jose A/0000-0002-1153-6025; Habermann, Bianca/0000-0002-2457-7504; Garcia-Sanz, Jose A./0000-0002-1153-6025; Mikulits, Wolfgang/0000-0003-4612-7106				AHERN T, 1974, NATURE, V248, P519, DOI 10.1038/248519a0; AHERN T, 1975, EXP CELL RES, V92, P513, DOI 10.1016/0014-4827(75)90410-3; AMATRUDA TT, 1988, J BIOL CHEM, V263, P5008; Anderson NL, 1998, ELECTROPHORESIS, V19, P1853, DOI 10.1002/elps.1150191103; AVNI D, 1994, MOL CELL BIOL, V14, P3822, DOI 10.1128/MCB.14.6.3822; AZIZ N, 1986, NUCLEIC ACIDS RES, V14, P915, DOI 10.1093/nar/14.2.915; BERGER SL, 1978, BIOCHIM BIOPHYS ACTA, V517, P84, DOI 10.1016/0005-2787(78)90036-9; BRUNET JF, 1986, NATURE, V322, P268, DOI 10.1038/322268a0; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; CIOCCA DR, 1993, JNCI-J NATL CANCER I, V85, P1558, DOI 10.1093/jnci/85.19.1558; COHEN RB, 1990, EMBO J, V9, P3831, DOI 10.1002/j.1460-2075.1990.tb07601.x; Coutts M, 1999, BLOOD, V93, P3369, DOI 10.1182/blood.V93.10.3369.410k11_3369_3378; DeSilva DR, 1997, CELL IMMUNOL, V180, P116, DOI 10.1006/cimm.1997.1182; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Espel E, 1996, EUR J IMMUNOL, V26, P2417, DOI 10.1002/eji.1830261023; ESTES SD, 1995, EXP CELL RES, V220, P47, DOI 10.1006/excr.1995.1290; EVMIN B, 1997, CANCER RES, V57, P686; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; Fawcett TW, 1996, J BIOL CHEM, V271, P14285, DOI 10.1074/jbc.271.24.14285; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Friedman AD, 1996, CANCER RES, V56, P3250; Garcia-Sanz JA, 1998, FASEB J, V12, P299, DOI 10.1096/fasebj.12.3.299; GarciaSanz JA, 1996, J EXP MED, V184, P159, DOI 10.1084/jem.184.1.159; Gonalons E, 1998, J IMMUNOL, V161, P1837; GRABTREE GR, 1989, SCIENCE, V243, P355; Grant KR, 1997, IMMUNOLOGY, V90, P564, DOI 10.1046/j.1365-2567.1997.00196.x; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Guyton KZ, 1996, BIOCHEM J, V314, P547, DOI 10.1042/bj3140547; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Hershey JWB, 1996, TRANSLATIONAL CONTRO; Jung S, 1999, CURR OPIN IMMUNOL, V11, P319, DOI 10.1016/S0952-7915(99)80051-X; KASPAR RL, 1992, J BIOL CHEM, V267, P508; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; Landry J, 1995, BIOCHEM CELL BIOL, V73, P703, DOI 10.1139/o95-078; LAURENZI MA, 1994, EUR J BIOCHEM, V223, P733, DOI 10.1111/j.1432-1033.1994.tb19047.x; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Lin TA, 1996, J BIOL CHEM, V271, P30199, DOI 10.1074/jbc.271.47.30199; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; LOWENTHAL JW, 1985, J IMMUNOL, V134, P931; LUETHY JD, 1992, CANCER RES, V52, P5; MACDONALD HR, 1986, ANNU REV CELL BIOL, V2, P231; MAO XH, 1992, J BIOL CHEM, V267, P20444; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; MELEFORS O, 1993, BIOESSAYS, V15, P85, DOI 10.1002/bies.950150203; Meyuhas Oded, 1996, V30, P363; Mikulits W, 1999, BIOTECHNIQUES, V26, P846, DOI 10.2144/99265bm09; Morley SJ, 1997, FEBS LETT, V418, P327, DOI 10.1016/S0014-5793(97)01405-1; Mullner E. W., 1997, MANUAL IMMUNOLOGICAL, V1, P457; MULLNER EW, 1997, MANUAL IMMUNOLOGICAL, V1, P389; MULLNER EW, 1997, IMMUNOLOGY METHODS M, V1, P407; Neumann F, 1997, EXP CELL RES, V230, P252, DOI 10.1006/excr.1996.3417; NEUMANN F, 1995, NUCLEIC ACIDS RES, V23, P195, DOI 10.1093/nar/23.2.195; NIELSEN FC, 1995, NATURE, V377, P358, DOI 10.1038/377358a0; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Penninger JM, 1999, CELL, V96, P9, DOI 10.1016/S0092-8674(00)80954-X; Richter JD, 1999, MICROBIOL MOL BIOL R, V63, P446, DOI 10.1128/MMBR.63.2.446-456.1999; RICHTER JD, 1993, DEV GENET, V14, P407, DOI 10.1002/dvg.1020140602; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Rosenwald IB, 1995, CELL PROLIFERAT, V28, P631, DOI 10.1111/j.1365-2184.1995.tb00050.x; ROUAULT TA, 1996, TRANSLATIONAL CONTRO, P335; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; SAFER D, 1997, BIOCHEMISTRY-US, V36, P2806; Salmon RA, 1997, J IMMUNOL, V159, P5309; SARGENT TD, 1987, METHOD ENZYMOL, V152, P423; SCHOBITZ B, 1990, J BIOL CHEM, V265, P15387; SEISER C, 1993, J BIOL CHEM, V268, P13074; SHEETS MD, 1994, GENE DEV, V8, P926, DOI 10.1101/gad.8.8.926; Shimizu M, 1998, EXP CELL RES, V239, P93, DOI 10.1006/excr.1997.3884; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; Tanaka T, 1998, GENES CELLS, V3, P801, DOI 10.1046/j.1365-2443.1998.00230.x; TEIXEIRA S, 1991, EUR J BIOCHEM, V202, P819, DOI 10.1111/j.1432-1033.1991.tb16438.x; TRACHSEL H, 1996, TRANSLATIONAL CONTRO, P113; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; VARESIO L, 1980, J IMMUNOL, V124, P2288; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WEINBERG AD, 1990, J IMMUNOL, V144, P4712; Welsh GI, 1996, J BIOL CHEM, V271, P11410, DOI 10.1074/jbc.271.19.11410; WICKENS M, 1992, SEM DEV BIOL, V3, P399; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Wolfgang CD, 1997, MOL CELL BIOL, V17, P6700, DOI 10.1128/MCB.17.11.6700; Wormington M, 1993, CURR OPIN CELL BIOL, V5, P950, DOI 10.1016/0955-0674(93)90075-2; Zhang J, 1999, J IMMUNOL, V162, P3819	86	90	95	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2000	14	11					1641	1652		10.1096/fj.14.11.1641	http://dx.doi.org/10.1096/fj.14.11.1641			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CN	10928999				2022-12-28	WOS:000088627800019
J	Puskas, F; Gergely, P; Banki, K; Perl, A				Puskas, F; Gergely, P; Banki, K; Perl, A			Stimulation of the pentose phosphate pathway and glutathione levels by dehydroascorbate, the oxidized form of vitamin C	FASEB JOURNAL			English	Article						DHA; transaldolase; glucose 6-phosphate dehydrogenase; GSH; apoptosis	NECROSIS-FACTOR-ALPHA; ASCORBIC-ACID; INDUCED APOPTOSIS; CELL-DEATH; ENDOTHELIAL-CELLS; RAT-LIVER; EXPRESSION; MITOCHONDRIA; ACTIVATION; PHOSPHATIDYLSERINE	Ascorbic acid, or vitamin C, generally functions as an antioxidant by directly reacting with reactive oxygen intermediates and has a vital role in defenses against oxidative stress. However, ascorbic acid also has pro-oxidant properties and may cause apoptosis of lymphoid and myeloid cells. The present study shows that dehydroascorbate, the oxidized form of vitamin C, stimulates the antioxidant defenses of cells,preferentially importing dehydroascorbate over ascorbate. While 200-800 mu M vitamin C caused apoptosis of Jurkat and H9 human T lymphocytes, pretreatment with 200-1000 mu M dehydroascorbate stimulated activity of pentose phosphate pathway enzymes glucose 6-phosphate dehydrogenase, 6-phosphogluconate dehydrogenase, and transaldolase, elevated intracellular glutathione levels, and inhibited H2O2-induced changes in mitochondrial transmembrane potential and cell death. A 3.3-fold maximal glutathione elevation was observed after 48 h stimulation with 800 mu M dehydroascorbate. In itself, dehydroascorbate did not affect cytosolic or mitochondrial reactive oxygen intermediate levels as monitored by flow cytometry using oxidation-sensitive fluorescent probes. The data reveal a novel mechanism for increasing glutathione levels through stimulation of the pentose phosphate pathway and identify dehydroascorbate as an antioxidant for cells susceptible to the pro-oxidant and proapoptotic properties of vitamin C.	SUNY Hlth Sci Ctr, Coll Med, Dept Med, Syracuse, NY 13210 USA; SUNY Hlth Sci Ctr, Coll Med, Dept Pathol, Syracuse, NY 13210 USA; SUNY Hlth Sci Ctr, Coll Med, Dept Microbiol & Immunol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Perl, A (corresponding author), SUNY Hlth Sci Ctr, Coll Med, Dept Med, 750 E Adams St, Syracuse, NY 13210 USA.			Perl, Andras/0000-0002-5017-1348	FIC NIH HHS [1FO5TW05421] Funding Source: Medline; NIDDK NIH HHS [R01 DK 49221] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F05TW005421] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049221] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amano Y, 1998, ANTICANCER RES, V18, P2503; Banhegyi G, 1997, FREE RADICAL BIO MED, V23, P793, DOI 10.1016/S0891-5849(97)00062-2; Banki K, 1998, J BIOL CHEM, V273, P11944, DOI 10.1074/jbc.273.19.11944; Banki K, 1996, J BIOL CHEM, V271, P32994, DOI 10.1074/jbc.271.51.32994; Banki K, 1999, J IMMUNOL, V162, P1466; BARBIERI D, 1994, BIOCHEM BIOPH RES CO, V201, P1109, DOI 10.1006/bbrc.1994.1820; Benov L, 1998, J BIOL CHEM, V273, P25741, DOI 10.1074/jbc.273.40.25741; BEYER RE, 1994, J BIOENERG BIOMEMBR, V26, P349, DOI 10.1007/BF00762775; Braun L, 1996, FEBS LETT, V390, P183, DOI 10.1016/0014-5793(96)00654-0; BUROW S, 1987, EUR J CELL BIOL, V43, P128; Carr A, 1999, FASEB J, V13, P1007, DOI 10.1096/fasebj.13.9.1007; Constantini P., 1996, J BIOL CHEM, V271, P6746; COSSARIZZA A, 1995, EXP CELL RES, V220, P232, DOI 10.1006/excr.1995.1311; Cramer C T, 1995, J Biochem Toxicol, V10, P293, DOI 10.1002/jbt.2570100603; Devamanoharan PS, 1996, MOL CELL BIOCHEM, V156, P131, DOI 10.1007/BF00426335; Doiron B, 1996, J BIOL CHEM, V271, P5321, DOI 10.1074/jbc.271.10.5321; FARISS MW, 1987, METHOD ENZYMOL, V143, P101; GOLDENBERG H, 1994, J BIOENERG BIOMEMBR, V26, P359, DOI 10.1007/BF00762776; HARAPANHALLI RS, 1993, J CHROMATOGR-BIOMED, V614, P233, DOI 10.1016/0378-4347(93)80314-T; HEINRICH PC, 1976, CANCER RES, V36, P3189; INGEBRETSEN OC, 1982, BIOCHIM BIOPHYS ACTA, V684, P21, DOI 10.1016/0005-2736(82)90044-X; KANFER J, 1960, J BIOL CHEM, V235, P2518; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Massillon D, 1998, J BIOL CHEM, V273, P228, DOI 10.1074/jbc.273.1.228; Mayes P., 1993, HARPERS BIOCH, P201; MEISTER A, 1994, J BIOL CHEM, V269, P9397; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NISHIKIMI M, 1991, AM J CLIN NUTR, V54, pS1203, DOI 10.1093/ajcn/54.6.1203s; Parker J.E., 1979, NATURE, V278, P737; PETIT PX, 1990, EUR J BIOCHEM, V194, P389, DOI 10.1111/j.1432-1033.1990.tb15632.x; Podmore ID, 1998, NATURE, V392, P559, DOI 10.1038/33308; PONTREMOLI S, 1961, P NATL ACAD SCI USA, V47, P1942, DOI 10.1073/pnas.47.12.1942; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; RUDACK D, 1971, J BIOL CHEM, V246, P1249; Sakagami H, 1997, ANTICANCER RES, V17, P3513; Salvemini F, 1999, J BIOL CHEM, V274, P2750, DOI 10.1074/jbc.274.5.2750; SMILEY ST, 1991, P NATL ACAD SCI USA, V88, P3671, DOI 10.1073/pnas.88.9.3671; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Szent-Gyorgyi A, 1928, BIOCHEM J, V22, P1387, DOI 10.1042/bj0221387; TANNER MK, 1993, CYTOMETRY, V14, P59, DOI 10.1002/cyto.990140111; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; UDENFRIEND S, 1954, J BIOL CHEM, V208, P731; Urata Y, 1996, J BIOL CHEM, V271, P15146, DOI 10.1074/jbc.271.25.15146; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; VERA JC, 1993, NATURE, V364, P79, DOI 10.1038/364079a0; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; WINKLER BS, 1994, FREE RADICAL BIO MED, V17, P333, DOI 10.1016/0891-5849(94)90019-1; WOOD T, 1985, PENTOSE PHOSPHATE PA; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	53	90	96	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2000	14	10					1352	1361		10.1096/fj.14.10.1352	http://dx.doi.org/10.1096/fj.14.10.1352			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877828				2022-12-28	WOS:000087932200010
J	Almeida, OFX; Conde, GL; Crochemore, C; Demeneix, BA; Fischer, D; Hassan, AHS; Meyer, M; Holsboer, F; Michaelidis, TM				Almeida, OFX; Conde, GL; Crochemore, C; Demeneix, BA; Fischer, D; Hassan, AHS; Meyer, M; Holsboer, F; Michaelidis, TM			Subtle shifts in the ratio between pro- and antiapoptotic molecules after activation of corticosteroid receptors decide neuronal fate	FASEB JOURNAL			English	Article						apoptosis; Bcl-2; Bax; Bax knockout mouse; corticosterone; dexamethasone; mineralocorticoid receptor; glucocorticoid receptor	STEROID-HORMONE RECEPTORS; PROGRAMMED CELL-DEATH; TUMOR-SUPPRESSOR P53; BCL-2 GENE FAMILY; DENTATE GYRUS; IN-VIVO; GLUCOCORTICOID RECEPTOR; NERVOUS-SYSTEM; UP-REGULATION; DNA FRAGMENTATION	Glucocorticoid receptor (GR) activation induces apoptosis of granule cells in the hippocampus. In contrast, neuroprotection is seen after mineralocorticoid receptor (MR) activation. To date there is no in vivo evidence for direct interactions between corticosteroids and any of the key regulatory molecules of programmed cell death. In this report, we show that the opposing actions of MR and GR on neuronal survival result from their ability to differentially influence the expression of members of the bcl-2 gene family; specifically; in the rat hippocampus, activation of GR induces cell death by increasing the ratio of the proapoptotic molecule Bax relative to the antiapoptotic molecules Bcl-2 or Bcl-x(L); the opposite effect is oh served after stimulation of MR. The same results were obtained in both young and aged animals; however, older subjects (which were more susceptible to GR-mediated apoptosis) tended to express the antiapoptotic genes more robustly. Using a loss-of-function mouse model, we corroborated the observations made in the rat, demonstrating Bax to be essential in the GR-mediated cell death-signaling cascade. In addition, we show that GR activation increases and MR activation decreases levels of the tumor suppressor protein p53 (a direct transcriptional regulator of bax and bcl-2 genes), thus providing new information on the early genetic events linking corticosteroid receptors with apoptosis in the nervous system.	Max Planck Inst Psychiat, Dept Neuroendocrinol, D-80804 Munich, Germany; CNRS, Lab Gen & Comparat Physiol, UMR 8572, Museum Natl Hist Nat, F-75231 Paris, France; Max Planck Inst Neurobiol, Dept Neurobiochem, D-82152 Martinsried, Germany	Max Planck Society; Centre National de la Recherche Scientifique (CNRS); Museum National d'Histoire Naturelle (MNHN); Max Planck Society	Almeida, OFX (corresponding author), Max Planck Inst Psychiat, Dept Neuroendocrinol, Kraepelinstr 2-10, D-80804 Munich, Germany.		Almeida, Osborne F.X. F/E-8402-2010	Almeida, Osborne F.X. F/0000-0001-7331-6928				Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BAYER SA, 1974, J COMP NEUROL, V158, P55, DOI 10.1002/cne.901580105; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Bernier PJ, 1998, NEUROSCIENCE, V82, P635; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Cameron HA, 1998, NEUROSCIENCE, V82, P349; CASTREN E, 1994, NEUROSCIENCE, V61, P165, DOI 10.1016/0306-4522(94)90069-8; Chen J, 1996, J NEUROCHEM, V67, P64; Clark RSB, 1997, J NEUROSCI, V17, P9172; De Kloet ER, 1998, ENDOCR REV, V19, P269, DOI 10.1210/er.19.3.269; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Farrow SN, 1996, CURR OPIN GENET DEV, V6, P45, DOI 10.1016/S0959-437X(96)90009-X; FRANKOWSKI H, 1995, NEUROREPORT, V6, P1917, DOI 10.1097/00001756-199510020-00023; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gillardon F, 1996, MOL BRAIN RES, V40, P254, DOI 10.1016/0169-328X(96)00059-9; GONZALEZGARCIA M, 1995, P NATL ACAD SCI USA, V92, P4304, DOI 10.1073/pnas.92.10.4304; Gould E, 1996, DEV NEUROSCI-BASEL, V18, P22, DOI 10.1159/000111392; Gould E, 1998, P NATL ACAD SCI USA, V95, P3168, DOI 10.1073/pnas.95.6.3168; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; Hassan AHS, 1999, FASEB J, V13, P115, DOI 10.1096/fasebj.13.1.115; Hassan AHS, 1996, EXP NEUROL, V140, P43, DOI 10.1006/exnr.1996.0113; Heck S, 1997, EMBO J, V16, P4698, DOI 10.1093/emboj/16.15.4698; Hengartner MO, 1998, NATURE, V391, P441, DOI 10.1038/35036; Hu ZT, 1997, J NEUROSCI, V17, P3981; KAPLAN MS, 1984, J NEUROSCI, V4, P1429; Keller JN, 1998, J NEUROSCI, V18, P687; Kempermann G, 1998, J NEUROSCI, V18, P3206; KNUDSON MC, 1997, NAT GENET, V16, P358; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; KRAJEWSKI S, 1995, J NEUROSCI, V15, P6364; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; Lupien SJ, 1998, NAT NEUROSCI, V1, P69, DOI 10.1038/271; MacGibbon GA, 1997, BRAIN RES, V750, P223, DOI 10.1016/S0006-8993(96)01351-0; Maiyar AC, 1997, MOL ENDOCRINOL, V11, P312, DOI 10.1210/me.11.3.312; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Marshall KA, 1997, BIOCHEM BIOPH RES CO, V240, P84, DOI 10.1006/bbrc.1997.7604; McKay LI, 1998, MOL ENDOCRINOL, V12, P45, DOI 10.1210/mend.12.1.0044; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; MIASHITA T, 1994, ONCOGENE, V9, P1799; Michaelidis TM, 1996, NEURON, V17, P75, DOI 10.1016/S0896-6273(00)80282-2; MIYASHITA T, 1995, CELL, V80, P293; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Parsadanian AS, 1998, J NEUROSCI, V18, P1009; PAXINOS G, 1998, RAT BRIN STEREOTAXIC; Porter NM, 1998, NAT NEUROSCI, V1, P3, DOI 10.1038/196; Reagan LP, 1997, J CHEM NEUROANAT, V13, P149, DOI 10.1016/S0891-0618(97)00031-8; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Sapolsky, 1996, Stress, V1, P1, DOI 10.3109/10253899609001092; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHIMAZAKI K, 1994, NEUROSCI RES, V20, P95, DOI 10.1016/0168-0102(94)90026-4; Shindler KS, 1997, J NEUROSCI, V17, P3112; SLOVITER RS, 1993, J COMP NEUROL, V330, P324, DOI 10.1002/cne.903300304; Sousa N, 1998, STRESS, V2, P237, DOI 10.3109/10253899809167288; Sousa N, 1999, NEUROSCIENCE, V89, P1079, DOI 10.1016/S0306-4522(98)00311-X; SPENCER RL, 1993, ENDOCRINOLOGY, V133, P1941, DOI 10.1210/en.133.5.1941; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; TILLY JL, 1995, ENDOCRINOLOGY, V136, P232, DOI 10.1210/en.136.1.232; Trapp T, 1996, TRENDS PHARMACOL SCI, V17, P145, DOI 10.1016/0165-6147(96)81590-2; TZIMAGIORGIS G, 1996, NUCLEIC ACIDS RES, V24, P3467; Vekrellis K, 1997, DEVELOPMENT, V124, P1239; White FA, 1998, J NEUROSCI, V18, P1428; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WOOLLEY CS, 1991, BRAIN RES, V554, P312, DOI 10.1016/0006-8993(91)90207-C; Wyllie A, 1997, NATURE, V389, P237, DOI 10.1038/38405; Xiang H, 1998, J NEUROSCI, V18, P1363; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Yu CL, 1997, CANCER LETT, V116, P191, DOI 10.1016/S0304-3835(97)00186-9; ZEINER M, 1995, P NATL ACAD SCI USA, V92, P11465, DOI 10.1073/pnas.92.25.11465; Zuo Z, 1999, BIOCHEMISTRY-US, V38, P8849, DOI 10.1021/bi990842e	75	234	260	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2000	14	5					779	790		10.1096/fasebj.14.5.779	http://dx.doi.org/10.1096/fasebj.14.5.779			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301DH	10744634				2022-12-28	WOS:000086292700015
J	Cuzzocrea, S; Mazzon, E; Dugo, L; Serraino, I; Ciccolo, A; Centorrino, T; De Sarro, A; Caputi, AP				Cuzzocrea, S; Mazzon, E; Dugo, L; Serraino, I; Ciccolo, A; Centorrino, T; De Sarro, A; Caputi, AP			Protective effects of n-acetylcysteine on lung injury and red blood cell modification induced by carrageenan in the rat	FASEB JOURNAL			English	Article						inflammation; nitric oxide; peroxynitrite; n-acetylcysteine; superoxide	OBSTRUCTIVE PULMONARY-DISEASE; NITRIC-OXIDE SYNTHASE; ADP-RIBOSE SYNTHETASE; DNA STRAND-BREAKS; HYDROGEN-PEROXIDE; INDUCED PLEURISY; KAPPA-B; SUPEROXIDE-DISMUTASE; TRANSCRIPTION FACTOR; LOCAL INFLAMMATION	Oxidative stress has been suggested as a potential mechanism in the pathogenesis of lung inflammation. The pharmacological profile of n-acetylcysteine (NAC), a free radical scavenger, was evaluated in an experimental model of lung injury (carrageenan-induced pleurisy). Injection of carrageenan into the pleural cavity of rats elicited an acute inflammatory response characterized by fluid accumulation in the pleural cavity that contained many neutrophils (PMNs), an infiltration of PMNs in lung tissues and subsequent lipid peroxidation, and increased production of nitrite/nitrate, tumor necrosis factor alpha, and interleukin 1 beta. All parameters of inflammation were attenuated by NAC treatment. Furthermore, carrageenan induced an up-regulation of the adhesion molecules ICAM-1 and P-selectin, as well as nitrotyrosine and poly (ADP-ribose) synthetase (PARS), as determined by immunohistochemical analysis of lung tissues. The degree of staining for the ICAM-1, P-selectin, nitrotyrosine, and PARS was reduced by NAG. In vivo NAC treatment significantly reduced peroxynitrite formation as measured by the oxidation of the fluorescent dihydrorhodamine-123, prevented the appearance of DNA damage, an decrease in mitochondrial respiration, and partially restored the cellular level of NAD+ in ex vivo macrophages harvested from the pleural cavity of rats subjected to carrageenan-induced pleurisy. A significant alteration in the morphology of red blood cells was observed 24 h after carrageenan administration. NAC treatment has the ability to significantly diminish the red blood cell alteration. Our results clearly demonstrate that NAC treatment exerts a protective effect and clearly indicate that NAC offers a novel therapeutic approach for the management of lung injury where radicals have been postulated to play a role.	Univ Messina, Sch Med, Inst Pharmacol, I-98100 Messina, Italy; Univ Messina, Sch Med, Dept Biomorphol, I-98100 Messina, Italy; Univ Messina, Inst Gen Surg, I-98100 Messina, Italy	University of Messina; University of Messina; University of Messina	Cuzzocrea, S (corresponding author), Univ Messina, Sch Med, Inst Pharmacol, Torre Biol Policlin Univ Via C Valeria Gazzi, I-98100 Messina, Italy.		Mazzon, Emanuela/AAL-4334-2020	mazzon, emanuela/0000-0002-5073-717X; Dugo, Laura/0000-0001-5527-0364				ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; BONE RC, 1991, CHEST, V100, P802, DOI 10.1378/chest.100.3.802; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; BRITTON JR, 1995, AM J RESP CRIT CARE, V151, P1383, DOI 10.1164/ajrccm.151.5.7735589; Brown BB, 1995, MOL DIVERS, V1, P4, DOI 10.1007/BF01715804; CARSON DA, 1986, EXP CELL RES, V164, P273, DOI 10.1016/0014-4827(86)90028-5; Cuzzocrea S, 1998, IMMUNOLOGY, V93, P96; Cuzzocrea S, 1998, EUR J PHARMACOL, V342, P67, DOI 10.1016/S0014-2999(97)01417-9; Cuzzocrea S, 1997, J PINEAL RES, V23, P106, DOI 10.1111/j.1600-079X.1997.tb00342.x; DAMOTTA JIB, 1994, BRIT J PHARMACOL, V112, P111; DARLEYUSMAR V, 1995, FEBS LETT, V369, P131, DOI 10.1016/0014-5793(95)00764-Z; DAWSON J, 1991, INT J TISSUE REACT, V13, P171; Dix TA, 1996, BIOCHEMISTRY-US, V35, P4578, DOI 10.1021/bi952010w; DROST EM, 1992, AM J RESP CELL MOL, V6, P287, DOI 10.1165/ajrcmb/6.3.287; DROST EM, 1993, AM REV RESPIR DIS, V148, P1277, DOI 10.1164/ajrccm/148.5.1277; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Flohe L, 1997, FREE RADICAL BIO MED, V22, P1115, DOI 10.1016/S0891-5849(96)00501-1; Galley HF, 1997, FREE RADICAL BIO MED, V23, P768, DOI 10.1016/S0891-5849(97)00059-2; GROENEVELD ABJ, 1990, CIRC SHOCK, V30, P185; HARRISON PM, 1991, NEW ENGL J MED, V324, P1852, DOI 10.1056/NEJM199106273242604; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; HYSLOP PA, 1988, J BIOL CHEM, V263, P1665; INOUE S, 1995, FEBS LETT, V371, P86, DOI 10.1016/0014-5793(95)00873-8; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; Ischiropoulos H, 1999, METHOD ENZYMOL, V301, P367; KOOY NW, 1994, FREE RADICAL BIO MED, V16, P149, DOI 10.1016/0891-5849(94)90138-4; LAIGHT DW, 1994, EUR J PHARM-ENVIRON, V292, P81, DOI 10.1016/0926-6917(94)90029-9; LINDEN M, 1989, INFLAMMATION, V13, P651, DOI 10.1007/BF00914309; MacMillan-Crow LA, 1999, ARCH BIOCHEM BIOPHYS, V366, P82, DOI 10.1006/abbi.1999.1202; MACNEE W, 1989, NEW ENGL J MED, V321, P924, DOI 10.1056/NEJM198910053211402; MACNEE W, 1993, THORAX, V48, P79, DOI 10.1136/thx.48.1.79; MEISTER A, 1983, SCIENCE, V220, P472, DOI 10.1126/science.6836290; Noguera A, 1998, AM J RESP CRIT CARE, V158, P1664, DOI 10.1164/ajrccm.158.5.9712092; Ogino M, 1996, INFLAMM RES, V45, P335, DOI 10.1007/BF02252946; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Parmentier M, 1999, AM J RESP CRIT CARE, V159, pA286; PESKAR BM, 1991, AGENTS ACTIONS, V33, P240, DOI 10.1007/BF01986569; POSTMA DS, 1988, AM REV RESPIR DIS, V137, P57, DOI 10.1164/ajrccm/137.1.57; POUWELL RJ, 1991, AM SURGEON, V57, P86; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; Rahman I, 1996, AM J RESP CRIT CARE, V154, P1055, DOI 10.1164/ajrccm.154.4.8887607; Rahman I, 1997, THORAX, V52, P565, DOI 10.1136/thx.52.6.565; Repine JE, 1997, AM J RESP CRIT CARE, V156, P341, DOI 10.1164/ajrccm.156.2.9611013; RUBBO H, 1994, J BIOL CHEM, V269, P26066; SALGO MG, 1995, ARCH BIOCHEM BIOPHYS, V322, P500, DOI 10.1006/abbi.1995.1493; Salvemini D, 1999, BRIT J PHARMACOL, V127, P685, DOI 10.1038/sj.bjp.0702604; Salvemini D, 1996, BRIT J PHARMACOL, V118, P829, DOI 10.1111/j.1476-5381.1996.tb15475.x; Salzman AL, 1996, AM J PHYSIOL-GASTR L, V270, pG565, DOI 10.1152/ajpgi.1996.270.4.G565; SCHILLIER HJ, 1993, CRIT CARE MED, V21, P92; SCHMIDT KN, 1995, CHEM BIOL, V2, P13, DOI 10.1016/1074-5521(95)90076-4; SCHRAUFSTATTER IU, 1986, J CLIN INVEST, V77, P1312, DOI 10.1172/JCI112436; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SELBY C, 1991, AM REV RESPIR DIS, V143, P1359, DOI 10.1164/ajrccm/143.6.1359; SRIDHAR MK, 1994, EUR RESPIR J, V7, P720, DOI 10.1183/09031936.94.07040720; Steinberg FM, 1998, AM J CLIN NUTR, V68, P319, DOI 10.1093/ajcn/68.2.319; Szabo C, 1997, J EXP MED, V186, P1041, DOI 10.1084/jem.186.7.1041; SZABO C, 1993, BRIT J PHARMACOL, V108, P786, DOI 10.1111/j.1476-5381.1993.tb12879.x; TRACEY WR, 1995, J PHARMACOL EXP THER, V273, P1295; VILLA LM, 1994, P NATL ACAD SCI USA, V91, P12383, DOI 10.1073/pnas.91.26.12383; Watchorn T., 1998, AM J RESP CRIT CARE, V157, pA889; WEGNER CD, 1992, LUNG, V170, P267, DOI 10.1007/BF00566679; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0; WIZEMANN TM, 1994, J LEUKOCYTE BIOL, V56, P759, DOI 10.1002/jlb.56.6.759; Yamakura F, 1998, J BIOL CHEM, V273, P14085, DOI 10.1074/jbc.273.23.14085; ZIMENT I, 1988, BIOMED PHARMACOTHER, V42, P513; Zingarelli B, 1996, J IMMUNOL, V156, P350	69	92	99	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1187	1200		10.1096/fj.00-0526hyp	http://dx.doi.org/10.1096/fj.00-0526hyp			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344087				2022-12-28	WOS:000168655200009
J	Butikofer, P; Malherbe, T; Boschung, M; Roditi, I				Butikofer, P; Malherbe, T; Boschung, M; Roditi, I			GPI-anchored proteins: now you see 'em, now you don't	FASEB JOURNAL			English	Article						trypanosome; toxoplasma; CD52; CD59; vaccine; conformational epitope	PHOSPHATIDYLINOSITOL MEMBRANE ANCHOR; VARIANT SURFACE GLYCOPROTEIN; TRYPANOSOMA-BRUCEI; PHOSPHOLIPASE-C; PLASMODIUM-FALCIPARUM; PLASMA-MEMBRANE; GLYCOSYLPHOSPHATIDYLINOSITOL; ANTIGEN; PROCYCLIN; ACTIVATION	Many cell surface proteins are attached to membranes via covalent glycosylphosphatidylinositol (GPI) anchors that are posttranslationally linked to the carboxy-terminus of the protein. Removal of the GPI lipid moieties by enzymes such as GPI-specific phospholipases or by chemical treatments generates a soluble form of the protein that no longer associates with lipid bilayers, We have found that the removal of lipid moieties from the anchor can also have a second, unexpected effect on the antigenicity of a variety of GPI-anchored surface molecules, suggesting that they undergo major conformational changes. Several antibodies raised against GPI-anchored proteins from protozoa and mammalian cells were no longer capable of binding the corresponding antigens once the lipid moieties had been removed. Conversely, antibodies raised against soluble (delipidated) forms reacted poorly with intact GPI-anchored proteins, but showed enhanced binding after treatment with phospholipases. In the light of these findings, we have reevaluated a number of publications on GPI-anchored proteins. Many of the results are best explained by lipid-dependent changes in antigenicity, indicating this might be a widespread phenomenon. Since many pathogen surface proteins are GPI-anchored, researchers should be aware that the presence or absence of the GPI lipid moieties may have a major impact on the host immune response to infection or vaccination.	Univ Bern, Inst Cell Biol, CH-3012 Bern, Switzerland; Univ Bern, Inst Cell Biol, CH-3012 Bern, Switzerland	University of Bern; University of Bern	Roditi, I (corresponding author), Univ Bern, Inst Cell Biol, Baltzerstr 4, CH-3012 Bern, Switzerland.	isabel.roditi@izb.unibe.ch		Roditi, Isabel/0000-0003-2812-6513				BARBONI E, 1995, J CELL SCI, V108, P487; Blanco ARA, 1999, MOL BIOCHEM PARASIT, V98, P163, DOI 10.1016/S0166-6851(98)00162-5; BRAUNBRETON C, 1988, NATURE, V332, P457, DOI 10.1038/332457a0; BRAUNBRETON C, 1992, EXP PARASITOL, V74, P452, DOI 10.1016/0014-4894(92)90207-Q; BREWIS IA, 1994, BIOCHEM J, V303, P633, DOI 10.1042/bj3030633; Butikofer P, 1997, BIOCHEM J, V326, P415; Butikofer P, 1999, J CELL SCI, V112, P1785; CAPDEVILLE Y, 1987, J CELL SCI, V88, P553; Costagliola S, 1998, FEBS LETT, V436, P427, DOI 10.1016/S0014-5793(98)01177-6; DEALMEIDA MLC, 1983, NATURE, V302, P349, DOI 10.1038/302349a0; DURBIN H, 1994, P NATL ACAD SCI USA, V91, P4313, DOI 10.1073/pnas.91.10.4313; GMACHL M, 1993, FEBS LETT, V336, P545, DOI 10.1016/0014-5793(93)80873-S; Hale G, 1995, IMMUNOTECHNOLOGY, V1, P175, DOI 10.1016/1380-2933(95)00017-8; Letho MT, 1998, BIOCHEM J, V332, P101, DOI 10.1042/bj3320101; MASTERSON WJ, 1988, J IMMUNOL, V140, P3194; MILLER EN, 1984, MOL BIOCHEM PARASIT, V13, P67, DOI 10.1016/0166-6851(84)90102-6; MULLER G, 1994, ARCH BIOCHEM BIOPHYS, V308, P504, DOI 10.1006/abbi.1994.1071; RICHARDSON JP, 1988, MOL BIOCHEM PARASIT, V31, P203, DOI 10.1016/0166-6851(88)90150-8; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; Ruepp S, 1997, J CELL BIOL, V137, P1369, DOI 10.1083/jcb.137.6.1369; TOMAVO S, 1993, BIOL CELL, V78, P155, DOI 10.1016/0248-4900(93)90126-Y; TOZEREN A, 1992, J CELL BIOL, V116, P997, DOI 10.1083/jcb.116.4.997; TREUMANN A, 1995, J BIOL CHEM, V270, P6088, DOI 10.1074/jbc.270.11.6088; Tsujioka H, 1999, BIOCHEM J, V342, P449, DOI 10.1042/0264-6021:3420449; Wang GS, 1996, BIOCHEMISTRY-US, V35, P10358, DOI 10.1021/bi960934t; ZAMZE SE, 1988, EUR J BIOCHEM, V176, P527, DOI 10.1111/j.1432-1033.1988.tb14310.x	26	72	75	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2001	15	2					545	548		10.1096/fj.00-0415hyp	http://dx.doi.org/10.1096/fj.00-0415hyp			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156970				2022-12-28	WOS:000166872900036
J	Lavigne, MC; Malech, HL; Holland, SM; Leto, TL				Lavigne, MC; Malech, HL; Holland, SM; Leto, TL			Genetic requirement of p47phox for superoxide production by murine microglia	FASEB JOURNAL			English	Article									NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Leto, TL (corresponding author), NIH, Bldg 10,Room 11N106, Bethesda, MD 20982 USA.			Malech, Harry/0000-0001-5874-5775	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000614, ZIAAI000646, Z01AI000614, ZIAAI000644, Z01AI000646, Z01AI000644] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))			0	48	50	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					285	287						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156938				2022-12-28	WOS:000166872900004
J	Takacs, P; Kauma, SW; Sholley, MM; Walsh, SW; Dinsmoor, MJ; Green, K				Takacs, P; Kauma, SW; Sholley, MM; Walsh, SW; Dinsmoor, MJ; Green, K			Increased circulating lipid peroxides in severe preeclampsia activate NF-kappa B and upregulate ICAM-1 in vascular endothelial cells	FASEB JOURNAL			English	Article									Virginia Commonwealth Univ, Med Coll Virginia, Dept Obstet & Gynecol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Microbiol & Immunol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Physiol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Kauma, SW (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Obstet & Gynecol, 1101 E Marshal St,Sanger Hall,Rm 11-029,Box 98003, Richmond, VA 23298 USA.								0	81	98	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					279	281						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156936				2022-12-28	WOS:000166872900002
J	Dabbeni-Sala, F; Di Santo, S; Franceschini, D; Skaper, SD; Giusti, P				Dabbeni-Sala, F; Di Santo, S; Franceschini, D; Skaper, SD; Giusti, P			Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity	FASEB JOURNAL			English	Article						Parkinson's disease; neurodegeneration; pineal hormone; neuroprotection; oxidative phosphorylation	KAINATE-INDUCED EXCITOTOXICITY; DEPENDENT LIPID-PEROXIDATION; PARKINSONS-DISEASE; CELL-DEATH; ROTATIONAL BEHAVIOR; SUBSTANTIA-NIGRA; OXIDATIVE STRESS; ACTIVITY RHYTHMS; ANIMAL-MODELS; VITAMIN-E	Unilateral injection into the right substantia nigra of the catecholaminergic neurotoxin 6-hydroxydopamine (6-OHDA) produces extensive loss of dopaminergic cells ('hemi-parkinsonian rat'). The pineal hormone melatonin, which is a potent antioxidant against different reactive oxygen species and has been reported to be neuroprotective in vivo and in vitro, was evaluated for potential anti-Parkinson effects in this model. Imbalance in dopaminergic innervation between the striata produced by intranigral administration of 6-OHDA results in a postural asymmetry causing rotation away from the nonlesioned side. Melatonin given systemically prevented apomorphine-induced circling behavior in 6-OHDA-lesioned rats. Reduced activity of mitochondrial oxidative phosphorylation enzymes has been suggested in some neurodegenerative diseases; in particular, selective decrease in complex I activity is observed in the substantia nigra of Parkinson's disease patients. Analysis of mitochondrial oxidative phosphorylation enzyme activities in nigral tissue from 6-OHDA-lesioned rats by a novel BN-PAGE histochemical procedure revealed a clear loss of complex I activity, which was protected against in melatonin-treated animals. A good correlation between behavioral parameters and enzymatic (complex I) analysis was observed independent of melatonin administration. A deficit in mitochondrial complex I could conceivably contribute to cell death in parkinsonism via free radical mechanisms, both directly via reactive oxygen species production and by decreased ATP synthesis and energy failure. Melatonin may have potential utility in the treatment of neurodegenerative disorders where oxidative stress is a participant.	Univ Padua, Dept Pharmacol, I-35131 Padua, Italy; SmithKline Beecham Pharmaceut, Dept Neurosci Res, Harlow CM19 5AW, Essex, England	University of Padua; GlaxoSmithKline	Giusti, P (corresponding author), Univ Padua, Dept Pharmacol, Largo E Meneghetti 2, I-35131 Padua, Italy.	giusti@uxl.unipd.it		GIUSTi, Pietro/0000-0001-9352-4046				Acuna-Castroviejo Dario, 1997, Life Sciences, V60, pPL23; ADAMS JD, 1993, FREE RADICAL BIO MED, V15, P181, DOI 10.1016/0891-5849(93)90057-2; ANDREW R, 1993, NEUROCHEM RES, V18, P1175, DOI 10.1007/BF00978370; ANTONTAY F, 1971, LIFE SCI, V10, P841, DOI 10.1016/0024-3205(71)90155-X; Beal MF, 1999, BIOFACTORS, V9, P261, DOI 10.1002/biof.5520090222; BENSHACHAR D, 1991, J NEUROCHEM, V57, P1609, DOI 10.1111/j.1471-4159.1991.tb06358.x; BENSHACHAR D, 1995, J NEUROCHEM, V64, P718, DOI 10.1046/j.1471-4159.1995.64020718.x; BURTON S, 1991, EXPERIENTIA, V47, P466, DOI 10.1007/BF01959946; CAGNOLI CM, 1995, J PINEAL RES, V18, P222, DOI 10.1111/j.1600-079X.1995.tb00163.x; CARMAN LS, 1991, BRAIN RES, V553, P275, DOI 10.1016/0006-8993(91)90835-J; Chanut E, 1998, J CHROMATOGR B, V709, P11, DOI 10.1016/S0378-4347(98)00041-3; CHESWORTH MJ, 1987, AM J PHYSIOL, V253, pR101, DOI 10.1152/ajpregu.1987.253.1.R101; COSTALL B, 1975, PSYCHOPHARMACOLOGIA, V43, P53, DOI 10.1007/BF00437615; COTZIAS GC, 1971, SCIENCE, V173, P450, DOI 10.1126/science.173.3995.450; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Davey GP, 1998, J BIOL CHEM, V273, P12753, DOI 10.1074/jbc.273.21.12753; Ebadi M, 1996, PROG NEUROBIOL, V48, P1, DOI 10.1016/0301-0082(95)00029-1; Floreani M, 1997, FASEB J, V11, P1309, DOI 10.1096/fasebj.11.14.9409550; Gerlach M, 1996, J NEURAL TRANSM, V103, P987, DOI 10.1007/BF01291788; GIUSTI P, 1995, EXP NEUROL, V131, P39, DOI 10.1016/0014-4886(95)90005-5; Giusti P, 1996, FASEB J, V10, P891, DOI 10.1096/fasebj.10.8.8666166; Giusti P, 1996, J PINEAL RES, V20, P226, DOI 10.1111/j.1600-079X.1996.tb00263.x; GLINKA YY, 1995, EUR J PHARM-ENVIRON, V292, P329, DOI 10.1016/0926-6917(95)90040-3; Gu M, 1998, ANN NEUROL, V44, P177, DOI 10.1002/ana.410440207; HASEGAWA E, 1990, BIOCHEM BIOPH RES CO, V170, P1049, DOI 10.1016/0006-291X(90)90498-C; HEFFNER TG, 1980, PHARMACOL BIOCHEM BE, V13, P453, DOI 10.1016/0091-3057(80)90254-3; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5299, DOI 10.1021/bi00695a011; Hou JGG, 1997, J NEUROCHEM, V69, P76; ICHITANI Y, 1994, EXP NEUROL, V130, P269, DOI 10.1006/exnr.1994.1205; Jenner P, 1996, NEUROLOGY, V47, pS161, DOI 10.1212/WNL.47.6_Suppl_3.161S; JENNER P, 1992, NEUROLOGY, V42, P2241, DOI 10.1212/WNL.42.12.2241; Kim YS, 1998, NEUROREPORT, V9, P2387, DOI 10.1097/00001756-199807130-00043; KUMAR R, 1995, J NEUROCHEM, V64, P1703; Maney H., 1995, Society for Neuroscience Abstracts, V21, P1518; Matuszak Z, 1997, FREE RADICAL BIO MED, V23, P367, DOI 10.1016/S0891-5849(96)00614-4; Mayo JC, 1998, J PINEAL RES, V24, P179, DOI 10.1111/j.1600-079X.1998.tb00531.x; Melchiorri D, 1996, BIOCHEM PHARMACOL, V51, P1095, DOI 10.1016/0006-2952(96)00055-X; MELCHIORRI D, 1995, FASEB J, V9, P1205, DOI 10.1096/fasebj.9.12.7672513; MONTEIRO HP, 1989, BIOCHEM PHARMACOL, V38, P4177, DOI 10.1016/0006-2952(89)90512-1; NAVEILHAN P, 1994, J NEUROCHEM, V62, P2178; Offen D, 1996, EXP NEUROL, V141, P32, DOI 10.1006/exnr.1996.0136; OGAWA N, 1993, ADV NEUROL, V60, P242; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; PAPAVASILIOU PS, 1972, J AMER MED ASSOC, V221, P88, DOI 10.1001/jama.221.1.88; PERUMAL AS, 1992, BRAIN RES BULL, V29, P699, DOI 10.1016/0361-9230(92)90142-K; PIERI C, 1994, LIFE SCI, V55, pPL271, DOI 10.1016/0024-3205(94)00666-0; PIERREFICHE G, 1995, EXP GERONTOL, V30, P213, DOI 10.1016/0531-5565(94)00036-3; PRZEDBORSKI S, 1993, ANN NEUROL, V34, P715, DOI 10.1002/ana.410340515; PYCOCK CJ, 1980, NEUROSCIENCE, V5, P461, DOI 10.1016/0306-4522(80)90048-2; REDMAN J, 1983, SCIENCE, V219, P1089, DOI 10.1126/science.6823571; Reiter R, 1997, LIFE SCI, V60, P2255, DOI 10.1016/S0024-3205(97)00030-1; Reiter RJ, 1998, PROG NEUROBIOL, V56, P359, DOI 10.1016/S0301-0082(98)00052-5; Reiter RJ, 1996, TRENDS ENDOCRIN MET, V7, P22, DOI 10.1016/1043-2760(95)00192-1; Rojas P, 1996, NEUROTOXICOLOGY, V17, P323; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Schapira AHV, 1998, BBA-BIOENERGETICS, V1364, P261, DOI 10.1016/S0005-2728(98)00032-2; Schapira AHV, 1999, BBA-BIOENERGETICS, V1410, P159, DOI 10.1016/S0005-2728(98)00164-9; SEWERYNEK E, 1995, J PINEAL RES, V19, P51, DOI 10.1111/j.1600-079X.1995.tb00170.x; SHAW KM, 1973, LANCET, V1, P271; SILVERMAN PB, 1993, EUR J PHARMACOL, V242, P31, DOI 10.1016/0014-2999(93)90006-4; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Tenn CC, 1997, NEUROPHARMACOLOGY, V36, P1659, DOI 10.1016/S0028-3908(97)00165-2; UNGERSTEDT U, 1971, ACTA PHYSIOL SCAND, P69; Willis GL, 1999, PHYSIOL BEHAV, V66, P785, DOI 10.1016/S0031-9384(99)00023-2; Wolden-Hanson T, 2000, ENDOCRINOLOGY, V141, P487, DOI 10.1210/en.141.2.487; Yeleswaram K, 1997, J PINEAL RES, V22, P45, DOI 10.1111/j.1600-079X.1997.tb00302.x; Zamostiano R, 1999, NEUROSCI LETT, V264, P9, DOI 10.1016/S0304-3940(99)00168-8; Zerbetto E, 1997, ELECTROPHORESIS, V18, P2059, DOI 10.1002/elps.1150181131; ZIV I, 1994, NEUROSCI LETT, V170, P136, DOI 10.1016/0304-3940(94)90258-5	69	159	166	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2001	15	1					164	170		10.1096/fj.00-0129com	http://dx.doi.org/10.1096/fj.00-0129com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149904				2022-12-28	WOS:000166312400025
J	Federici, M; Hribal, ML; Ranalli, M; Marselli, L; Porzio, O; Lauro, D; Borboni, P; Lauro, R; Marchetti, P; Melino, G; Sesti, G				Federici, M; Hribal, ML; Ranalli, M; Marselli, L; Porzio, O; Lauro, D; Borboni, P; Lauro, R; Marchetti, P; Melino, G; Sesti, G			The common Arg(972) polymorphism in insulin receptor substrate-1 causes apoptosis of human pancreatic islets	FASEB JOURNAL			English	Article									Univ Roma Tor Vergata, Dept Internal Med, Mol Med Lab, I-00133 Rome, Italy; Univ Roma Tor Vergata, Dept Expt Med, Biochem Lab, IDI,IRCCS, Rome, Italy; Univ Pisa, Dept Endocrinol & Metab, I-56100 Pisa, Italy	University of Rome Tor Vergata; IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Rome Tor Vergata; University of Pisa	Sesti, G (corresponding author), Univ Roma Tor Vergata, Dept Internal Med, Mol Med Lab, Via Tor Vergata 135, I-00133 Rome, Italy.		Sesti, Giorgio/B-1509-2012; Marchetti, Piero/J-7439-2013; Federici, Massimo/G-9940-2012; Lauro, Davide/K-4683-2018	Marchetti, Piero/0000-0003-4907-0635; Federici, Massimo/0000-0003-4989-5194; PORZIO, OTTAVIA/0000-0001-5931-8679; Lauro, Davide/0000-0002-8597-4415; Sesti, Giorgio/0000-0002-1618-7688; Marselli, Lorella/0000-0002-6698-2962	Telethon [E.0695] Funding Source: Medline	Telethon(Fondazione Telethon)			0	81	81	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2001	15	1					22	24						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11099486				2022-12-28	WOS:000166312400008
J	Laflamme, N; Rivest, S				Laflamme, N; Rivest, S			Toll-like receptor 4: the missing link of the cerebral innate immune response triggered by circulating gram-negative bacterial cell wall components	FASEB JOURNAL			English	Article						circumventricular organs; innate immune response; in situ hybridization histochemistry; inflammation; lipopolysaccharide; proinflammatory cytokines; microglia; macrophages; NF-kappa B; septic shock	RAT-BRAIN; LIPOPOLYSACCHARIDE; ENDOTOXIN; MICE; CD14; POPULATIONS	The recent characterization of human homologues of Toll may be the missing link for the transduction events leading to NF-kappaB activity and proinflammatory gene transcription during innate immune response. Indeed, CD14 is not thought to participate directly in the cell signaling, but rather one or more of the mammalian Toll-like receptors (TLRs) acts in concert with the lipopolysaccharide (LPS) receptor to discriminate between microbial pathogens or their products and initiate transmembrane signaling. Mammalian cells may express as many as 10 distinct TLRs, although the importance of TLR4 in response to gram-negative bacteria and LPS is now supported by the fact that TLR4-mutated mice are LPS resistant. We investigated the expression of TLR4 across the rat brain under basal conditions and in response to systemic LPS and IL-1 beta injection. We first cloned the rat TLR4 cDNA via RNA isolation and polymerase chain reaction (PCR) amplification with a proofreading polymerase. Total RNA was isolated from the rat liver tissue using Tri-Reagent and reverse transcribed into cDNA using Superscript II reverse transcriptase and an oligonucleotide primer with a degenerate 3' end of sequence 5'-T12(GAC)N-3'. Positive hybridization signal was found in the leptomeninges, choroid plexus (chp), subfornical organ, organum vasculosum of the lamina terminalis, median eminence, and area postrema. Scattered small cells also displayed a convincing hybridization signal within the brain parenchyma. Few well-defined nuclei exhibited positive TLR4 transcript: the supramamillary nucleus, cochlear nucleus, and the lateral reticular nucleus. The circumventricular organs, the leptomeninges, and chp also exhibited constitutive expression of the LPS receptor mCD14. In contrast to the strong up-regulation of the gene encoding mCD14 during endotoxemia, neither LPS nor IL-1 beta caused a convincing increase in the TLR4 mRNA levels across the CNS. A down-regulation of the gene encoding TLR4 was found in the cerebral tissue of immune-challenged animals. The constitutive expression of both mCD 14 and TLR4 may explain the innate immune response in the brain, which originates from the structures devoid of blood-brain barrier in presence of circulating LPS.	Univ Laval, CHUL, Res Ctr, Mol Endocrinol Lab, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Dept Anat & Physiol, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University	Rivest, S (corresponding author), Univ Laval, CHUL, Res Ctr, Mol Endocrinol Lab, 2705 Boul Laurier, Quebec City, PQ G1V 4G2, Canada.			Rivest, Serge/0000-0002-6082-770X				Anderson KV, 2000, CURR OPIN IMMUNOL, V12, P13, DOI 10.1016/S0952-7915(99)00045-X; ANDERSSON J, 1992, IMMUNOL REV, V127, P69, DOI 10.1111/j.1600-065X.1992.tb01409.x; Beutler B, 2000, CURR OPIN IMMUNOL, V12, P20, DOI 10.1016/S0952-7915(99)00046-1; Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Lacroix S, 1998, BRAIN PATHOL, V8, P625, DOI 10.1111/j.1750-3639.1998.tb00189.x; Laflamme N, 1999, J NEUROCHEM, V73, P309, DOI 10.1046/j.1471-4159.1999.0730309.x; Laflamme N, 1999, J NEUROSCI, V19, P10923, DOI 10.1523/JNEUROSCI.19-24-10923.1999; Muzio M, 2000, J LEUKOCYTE BIOL, V67, P450, DOI 10.1002/jlb.67.4.450; Nadeau S, 1999, J NEUROPATH EXP NEUR, V58, P61, DOI 10.1097/00005072-199901000-00008; Nadeau S, 2000, J NEUROSCI, V20, P3456, DOI 10.1523/JNEUROSCI.20-09-03456.2000; Nomura F, 2000, J IMMUNOL, V164, P3476, DOI 10.4049/jimmunol.164.7.3476; Oldfield Brian J., 1995, P391; Perera PY, 1997, J IMMUNOL, V158, P4422; Quan N, 1998, NEUROSCIENCE, V83, P281, DOI 10.1016/S0306-4522(97)00350-3; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Vallieres L, 1997, J NEUROCHEM, V69, P1668, DOI 10.1046/j.1471-4159.1997.69041668.x; Wright SD, 1999, J EXP MED, V189, P605, DOI 10.1084/jem.189.4.605; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	19	395	431	0	35	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2001	15	1					155	163		10.1096/fj.00-0339com	http://dx.doi.org/10.1096/fj.00-0339com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149903				2022-12-28	WOS:000166312400024
J	Virag, L; Szabo, C				Virag, L; Szabo, C			Purines inhibit poly(ADP-ribose) polymerase activation and modulate oxidant-induced cell death	FASEB JOURNAL			English	Article						nitric oxide; free radicals; antioxidants; shock; knockout; ADP-RT	PERFORMANCE LIQUID-CHROMATOGRAPHY; INDUCED BACTERIAL TRANSLOCATION; ISCHEMIA-REPERFUSION INJURY; ADENOSINE RECEPTOR AGONISTS; ADP-RIBOSE POLYMERASE; NITRIC-OXIDE; XANTHINE-OXIDASE; URIC-ACID; SYNTHETASE ACTIVATION; ADENINE-NUCLEOTIDES	Purines such as adenosine, inosine, and hypoxanthine are known to have potent antiinflammatory effects. These effects generally are believed to be mediated by cell surface adenosine receptors. Here we provide evidence that purines protect against oxidant-induced cell injury by inhibiting the activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP). Upon binding to broken DNA, PARP cleaves NAD(+) into nicotinamide and ADP-ribose and polymerizes the latter on nuclear acceptor tor proteins such as histones and PARP itself. Overactivation of PARP depletes cellular NAD(+) and ATP stores and causes necrotic cell death. We have identified some purines (hypoxanthine, inosine, and adenosine) as potential endogenous PARP inhibitors, We have found that purines (hypoxanthine > inosine > adenosine) dose-dependently inhibited PARP activation in peroxynitrite-treated macrophages and also inhibited the activity of the purified PARP enzyme. Consistently with their PARP inhibitory effects, the purines also protected interferon gamma + endotoxin (IFN/LPS) -stimulated RAW macrophages from the inhibition of mitochondrial respiration and inhibited nitrite production from IFN/LPS-stimulated macrophages. We have selected hypoxanthine as the most potent cytoprotective agent and PARP inhibitor among the three purine compounds, and investigated the mechanism of its cytoprotective effect. We have found that hypoxanthine protects thymocytes from death induced by the cytotoxic oxidant peroxynitrite, In line with the PARP inhibitory effect of purines, hypoxanthine has prevented necrotic cell death while increasing caspase activity and DNA fragmentation, As previously shown with other PARP inhibitors, hypoxanthine acted proximal to mitochondrial alterations as hypoxanthine inhibited the peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Our data imply that purines may serve as endogenous PARP inhibitors. We propose that, by affecting PARP activation, purines may modulate the pattern of cell death during shock, inflammation, and reperfusion injury.	Inotek Corp, Cummings Ctr 100, Beverly, MA 01915 USA	Inotek Pharmaceuticals	Szabo, C (corresponding author), Inotek Corp, Cummings Ctr 100, Suite 419E, Beverly, MA 01915 USA.	szabocsaba@aol.com	Szabo, Csaba/ABG-2644-2021; Virag, Laszlo/E-6124-2010; Szabo, Csaba/D-1882-2013	Virag, Laszlo/0000-0002-7099-6718	NIGMS NIH HHS [R01-GM60915] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060915] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASEN AO, 1979, CIRC SHOCK, V6, P277; Ar'Rajab A, 1996, New Horiz, V4, P224; Bell MJ, 1998, J NEUROTRAUM, V15, P163, DOI 10.1089/neu.1998.15.163; Bouma MG, 1997, SHOCK, V8, P313, DOI 10.1097/00024382-199711000-00001; COCHRANE CG, 1991, MOL ASPECTS MED, V12, P137, DOI 10.1016/0098-2997(91)90009-B; CRONSTEIN BN, 1995, J INVEST MED, V43, P50; CRONSTEIN BN, 1994, J APPL PHYSIOL, V76, P5, DOI 10.1152/jappl.1994.76.1.5; Degenring F H, 1975, Recent Adv Stud Cardiac Struct Metab, V10, P455; DEITCH EA, 1988, SURGERY, V104, P191; DEITCH EA, 1992, J TRAUMA, V32, P141; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; DEVOUS MD, 1979, CARDIOLOGY, V64, P149; Dougherty C, 1998, FASEB J, V12, P1785, DOI 10.1096/fasebj.12.15.1785; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Fujimura M, 1997, NEUROSCI LETT, V228, P107, DOI 10.1016/S0304-3940(97)00373-X; Gizzi F, 1998, ADV EXP MED BIOL, V431, P777; GUDBJORNSSON B, 1991, ANN RHEUM DIS, V50, P669, DOI 10.1136/ard.50.10.669; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; HARKNESS RA, 1988, J CHROMATOGR-BIOMED, V429, P255, DOI 10.1016/S0378-4347(00)83873-6; Hasko G, 2000, J IMMUNOL, V164, P1013, DOI 10.4049/jimmunol.164.2.1013; Hasko G, 1996, J IMMUNOL, V157, P4634; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; HAUSCHILDT S, 1992, BIOCHEM J, V288, P255, DOI 10.1042/bj2880255; KLEIN HH, 1981, BASIC RES CARDIOL, V76, P612, DOI 10.1007/BF01908051; KOGURE K, 1980, ANN NEUROL, V8, P278, DOI 10.1002/ana.410080310; Krump E, 1999, ADV EXP MED BIOL, V447, P107; Maguire MH, 1998, J CHROMATOGR B, V707, P33, DOI 10.1016/S0378-4347(97)00581-1; MAINOUS MR, 1993, CIRC SHOCK, V40, P99; MARAK GE, 1988, OPHTHALMIC RES, V20, P220; Mei DA, 1996, ANAL BIOCHEM, V238, P34, DOI 10.1006/abio.1996.0246; MIRASPORTUGAL MT, 1986, J BIOL CHEM, V261, P1712; MORIMOTO K, 1982, J NEUROCHEM, V38, P833, DOI 10.1111/j.1471-4159.1982.tb08706.x; NISHINO T, 1994, J BIOCHEM, V116, P1; Nyce JW, 1999, TRENDS PHARMACOL SCI, V20, P79, DOI 10.1016/S0165-6147(99)01305-X; Oldner A, 1999, CRIT CARE MED, V27, P790, DOI 10.1097/00003246-199904000-00037; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Perretti M, 1997, TRENDS PHARMACOL SCI, V18, P418; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; POELSTRA K, 1992, LAB INVEST, V66, P555; POLASEK PM, 1989, J PHARM PHARMACOL, V41, P216, DOI 10.1111/j.2042-7158.1989.tb06437.x; Quinlan GJ, 1999, J CARDIOVASC SURG, V40, P65; SAUGSTAD OD, 1977, SCAND J CLIN LAB INV, V37, P517, DOI 10.3109/00365517709101840; Sitkovsky M V, 1998, Nihon Ika Daigaku Zasshi, V65, P351; SMISETH OA, 1983, CARDIOVASC RES, V17, P192, DOI 10.1093/cvr/17.4.192; STIPEK S, 1989, BIOMED BIOCHIM ACTA, V48, pS194; Stover JF, 1997, NEUROSCI LETT, V238, P25, DOI 10.1016/S0304-3940(97)00840-9; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Szabo C, 1998, EUR J PHARMACOL, V350, P1, DOI 10.1016/S0014-2999(98)00249-0; Szabo C, 1998, BRIT J PHARMACOL, V125, P379, DOI 10.1038/sj.bjp.0702040; Szabo C, 1997, J EXP MED, V186, P1041, DOI 10.1084/jem.186.7.1041; Szabo C, 1998, P NATL ACAD SCI USA, V95, P3867, DOI 10.1073/pnas.95.7.3867; Szabo C, 1996, SHOCK, V6, P79, DOI 10.1097/00024382-199608000-00001; Szabo C., 2000, CELL DEATH ROLE PARP; TARANTOLA M, 1991, J MOL CELL CARDIOL, V23, P77, DOI 10.1016/0022-2828(91)90040-S; THIRINGER K, 1983, ACTA PAEDIATR SCAND, V72, P231, DOI 10.1111/j.1651-2227.1983.tb09703.x; Tighe D, 1996, New Horiz, V4, P426; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; VanWay CW, 1996, J SURG RES, V66, P159; Virag L, 1998, FREE RADICAL BIO MED, V25, P1075, DOI 10.1016/S0891-5849(98)00139-7; Virag L, 1999, MOL PHARMACOL, V56, P824; Virag L, 1999, BRIT J PHARMACOL, V126, P769, DOI 10.1038/sj.bjp.0702332; Virag L, 1998, J IMMUNOL, V161, P3753; Virag L, 1998, IMMUNOLOGY, V94, P345, DOI 10.1046/j.1365-2567.1998.00534.x; Zingarelli B, 1996, J IMMUNOL, V156, P350	64	100	113	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2001	15	1					99	107		10.1096/fj.00-0299com	http://dx.doi.org/10.1096/fj.00-0299com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149897				2022-12-28	WOS:000166312400018
J	Bloch, W; Huggel, K; Sasaki, T; Grose, R; Bugnon, P; Addicks, K; Timpl, R; Werner, S				Bloch, W; Huggel, K; Sasaki, T; Grose, R; Bugnon, P; Addicks, K; Timpl, R; Werner, S			The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing	FASEB JOURNAL			English	Article									ETH Honggerberg, Inst Cell Biol, Swiss Fed Inst Technol, CH-8093 Zurich, Switzerland; Univ Cologne, Inst Anat, D-50931 Cologne, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Cologne; Max Planck Society	Werner, S (corresponding author), ETH Honggerberg, Inst Cell Biol, Swiss Fed Inst Technol, CH-8093 Zurich, Switzerland.			Werner, Sabine/0000-0001-7397-8710; Grose, Richard/0000-0002-4738-0173					0	140	149	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2373	2376						4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11024009				2022-12-28	WOS:000165723400002
J	Roth, W; Deussing, J; Botchkarev, VA; Pauly-Evers, M; Saftig, P; Hafner, A; Schmidt, P; Schmahl, W; Scherer, J; Anton-Lamprecht, I; Von Figura, K; Paus, R; Peters, C				Roth, W; Deussing, J; Botchkarev, VA; Pauly-Evers, M; Saftig, P; Hafner, A; Schmidt, P; Schmahl, W; Scherer, J; Anton-Lamprecht, I; Von Figura, K; Paus, R; Peters, C			Cathepsin L deficiency as molecular defect of furless: hyperproliferation of keratinocytes and pertubation of hair follicle cycling	FASEB JOURNAL			English	Article						epidermal hyperplasia; hair follicle development; lysosomal cysteine proteinase	CYSTEINE PROTEASE INHIBITORS; AMINO-ACID SEQUENCES; MHC CLASS-II; GROWTH-FACTOR; FUNCTIONAL EXPRESSION; REGRESSION CATAGEN; ENZYMATIC CHARACTERIZATION; CHROMOSOMAL LOCALIZATION; TISSUE DISTRIBUTION; LYMPHOID-CELLS	Lysosomal cysteine proteinases of the papain family are involved in lysosomal bulk proteolysis, major histocompatibility complex class II mediated antigen presentation, prohormone processing, and extracellular matrix remodeling. Cathepsin L (CTSL) is a ubiquitously expressed major representative of the papain-like family of cysteine proteinases. To investigate CTSL in vivo functions, the gene was inactivated by gene targeting in embryonic stem cells. CTSL-deficient mice develop periodic hair loss and epidermal hyperplasia, acanthosis, and hyperkeratosis. The hair loss is due to alterations of hair follicle morphogenesis and cycling, dilatation of hair follicle canals, and disturbed club hair formation. Hyperproliferation of hair follicle epithelial cells and basal epidermal keratinocytes-both of ectodermal origin-are the primary characteristics underlying the mutant phenotype. Pathological inflammatory responses have been excluded as a putative cause of the skin and hair disorder. The phenotype of CTSL-deficient mice is reminiscent of the spontaneous mouse mutant furless (fs). Analyses of the cfsl gene of fs mice revealed a G149R mutation inactivating the proteinase activity. CTSL is the first lysosomal proteinase shown to be essential for epidermal homeostasis id regular hair follicle morphogenesis and cycling.	Univ Freiburg, Inst Mol Med & Zellforsch, D-79106 Freiburg, Germany; Humboldt Univ, Charite, Hautklin, D-10117 Berlin, Germany; Univ Gottingen, Zentrum Biochem & Mol Zellbiol, Biochem Abt 2, D-37073 Gottingen, Germany; Univ Munich, Tierarztliche Fak, D-80539 Munich, Germany; Univ Heidelberg, Hautklin, Inst Ultrastrukturforsch Haut, D-69115 Heidelberg, Germany	University of Freiburg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Gottingen; University of Munich; Ruprecht Karls University Heidelberg	Peters, C (corresponding author), Univ Freiburg, Inst Mol Med & Zellforsch, Hugstetter Str 55, D-79106 Freiburg, Germany.		Paus, Ralf/F-6243-2011; Deussing, Jan M/ABB-5993-2021; Saftig, Paul/A-7966-2010	Botchkarev, Vladimir/0000-0002-5212-5353; Deussing, Jan/0000-0002-9329-5252				ARTELT P, 1988, GENE, V68, P213, DOI 10.1016/0378-1119(88)90023-6; BANDO Y, 1986, J BIOCHEM-TOKYO, V100, P35, DOI 10.1093/oxfordjournals.jbchem.a121703; BARRETT AJ, 1992, ANN NY ACAD SCI, V674, P1; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BERTI PJ, 1995, J MOL BIOL, V246, P273, DOI 10.1006/jmbi.1994.0083; Blake JA, 1997, NUCLEIC ACIDS RES, V25, P85, DOI 10.1093/nar/25.1.85; Botchkarev VA, 1998, AM J PATHOL, V153, P785, DOI 10.1016/S0002-9440(10)65621-0; Botchkarev VA, 1998, J INVEST DERMATOL, V111, P279, DOI 10.1046/j.1523-1747.1998.00277.x; Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126; Bromme D, 1999, BIOCHEMISTRY-US, V38, P2377, DOI 10.1021/bi982175f; BRYCE SD, 1994, GENOMICS, V24, P568, DOI 10.1006/geno.1994.1667; CALKINS CC, 1995, BIOL CHEM H-S, V376, P71; CHAN SJ, 1986, P NATL ACAD SCI USA, V83, P7721, DOI 10.1073/pnas.83.20.7721; Chapman HA, 1997, ANNU REV PHYSIOL, V59, P63, DOI 10.1146/annurev.physiol.59.1.63; CHAUHAN SS, 1993, J BIOL CHEM, V268, P1039; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Deussing J, 1997, MAMM GENOME, V8, P241, DOI 10.1007/s003359900401; FAN YS, 1989, CYTOGENET CELL GENET, V51, P996; Fuchs E, 1995, ANNU REV CELL DEV BI, V11, P123, DOI 10.1146/annurev.cb.11.110195.001011; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; FUCHS R, 1989, NUCLEIC ACIDS RES, V17, P9471, DOI 10.1093/nar/17.22.9471; Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236; Gerdes Johannes, 1997, European Journal of Cell Biology, V72, P88; GREEN EL, 1954, J HERED, V45, P115, DOI 10.1093/oxfordjournals.jhered.a106453; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; HANDJISKI BK, 1994, BRIT J DERMATOL, V131, P303, DOI 10.1111/j.1365-2133.1994.tb08515.x; HANSEN LS, 1984, ANAT REC, V210, P569, DOI 10.1002/ar.1092100404; HARDY MH, 1992, TRENDS GENET, V8, P55, DOI 10.1016/0168-9525(92)90350-D; HEBERT JM, 1994, CELL, V78, P1017, DOI 10.1016/0092-8674(94)90276-3; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; Janeway CA., 2001, IMMUNOBIOLOGY IMMUNE, V5th edition; JOSEPH LJ, 1988, J CLIN INVEST, V81, P1621, DOI 10.1172/JCI113497; Kasper D, 1996, J CELL BIOL, V134, P615, DOI 10.1083/jcb.134.3.615; KATUNUMA N, 1995, METHOD ENZYMOL, V251, P382, DOI 10.1016/0076-6879(95)51142-3; KIRSCHKE H, 1987, LYSOSOMES THEIR ROLE, P193; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; Laufer TM, 1996, NATURE, V383, P81, DOI 10.1038/383081a0; LI LN, 1992, IN VITRO CELL DEV-AN, V28A, P695; Lindner G, 1997, AM J PATHOL, V151, P1601; Linnevers C, 1997, FEBS LETT, V405, P253, DOI 10.1016/S0014-5793(97)00118-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; LYONS K, 1989, P NATL ACAD SCI USA, V86, P4554, DOI 10.1073/pnas.86.12.4554; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; Nakagawa T, 1998, SCIENCE, V280, P450, DOI 10.1126/science.280.5362.450; Nakagawa TY, 1999, IMMUNITY, V10, P207, DOI 10.1016/S1074-7613(00)80021-7; OWNES JW, 1975, ARCH BIOCHEM BIOPHYS, V166, P258; PARIS A, 1995, FEBS LETT, V369, P326, DOI 10.1016/0014-5793(95)00777-7; Paus R, 1997, J INVEST DERMATOL, V109, P518, DOI 10.1111/1523-1747.ep12336635; PAUS R, 1994, J INVEST DERMATOL, V103, P143, DOI 10.1111/1523-1747.ep12392542; PAUS R, 1994, BRIT J DERMATOL, V130, P174, DOI 10.1111/j.1365-2133.1994.tb02896.x; PAUS R, 1994, BRIT J DERMATOL, V130, P281, DOI 10.1111/j.1365-2133.1994.tb02922.x; PAUS R, 1990, BRIT J DERMATOL, V122, P777, DOI 10.1111/j.1365-2133.1990.tb06266.x; PAUS R, 1996, CURR OPIN DERMATOL, V3, P248; Pelsue SC, 1998, EUR J IMMUNOL, V28, P1379, DOI 10.1002/(SICI)1521-4141(199804)28:04<1379::AID-IMMU1379>3.0.CO;2-3; PHILPOTT MF, 1998, MOL BIOL SKIN APPEND; PILZ A, 1995, GENOMICS, V25, P139, DOI 10.1016/0888-7543(95)80119-7; Riese RJ, 1996, IMMUNITY, V4, P357, DOI 10.1016/S1074-7613(00)80249-6; SAFTIG P, 1995, EMBO J, V14, P3599, DOI 10.1002/j.1460-2075.1995.tb00029.x; Santamaria I, 1998, CANCER RES, V58, P1624; Santamaria I, 1998, J BIOL CHEM, V273, P16816, DOI 10.1074/jbc.273.27.16816; SCHUERMANN M, 1990, NUCLEIC ACIDS RES, V18, P4945, DOI 10.1093/nar/18.16.4945; SHAW E, 1980, BIOCHEM J, V186, P385, DOI 10.1042/bj1860385; Shi GP, 1999, IMMUNITY, V10, P197, DOI 10.1016/S1074-7613(00)80020-5; STENN K, 1998, MOL BASIS EPITHELIAL; Stenn KS, 1996, DERMATOL CLIN, V14, P543, DOI 10.1016/S0733-8635(05)70383-1; STRAILE WE, 1961, J EXP ZOOL, V148, P205, DOI 10.1002/jez.1401480304; Sundberg, 1994, HDB MOUSE MUTATIONS; Sundberg JP., 1994, HDB MOUSE MUTATIONS, P57; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Tisljar K, 1999, FEBS LETT, V459, P299, DOI 10.1016/S0014-5793(99)01263-6; TROEN BR, 1987, BIOCHEM J, V246, P731, DOI 10.1042/bj2460731; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; VELASCO G, 1994, J BIOL CHEM, V269, P27136; VIELKIND U, 1995, ACTA ANAT, V152, P93; Wang B, 1998, J BIOL CHEM, V273, P32000, DOI 10.1074/jbc.273.48.32000	77	264	271	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2000	14	13					2075	2086		10.1096/fj.99-0970com	http://dx.doi.org/10.1096/fj.99-0970com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023992				2022-12-28	WOS:000089634400027
J	Rusnati, M; Taraboletti, G; Urbinati, C; Tulipano, G; Giuliani, R; Molinari-Tosatti, MP; Sennino, B; Giacca, M; Tyagi, M; Albini, A; Noonan, D; Giavazzi, R; Presta, M				Rusnati, M; Taraboletti, G; Urbinati, C; Tulipano, G; Giuliani, R; Molinari-Tosatti, MP; Sennino, B; Giacca, M; Tyagi, M; Albini, A; Noonan, D; Giavazzi, R; Presta, M			Thrombospondin-1/HIV-1 Tat protein interaction: modulation of the biological activity of extracellular Tat	FASEB JOURNAL			English	Article						AIDS; extracellular matrix; angiogenesis; oncogenesis	IMMUNODEFICIENCY-VIRUS TYPE-1; HEPARAN-SULFATE PROTEOGLYCANS; VASCULAR ENDOTHELIAL-CELLS; FIBROBLAST GROWTH-FACTOR; HIV-1 TAT; KAPOSIS-SARCOMA; TRANSGENIC MICE; IN-VITRO; TYROSINE PHOSPHORYLATION; PLATELET THROMBOSPONDIN	Tat protein, a trans-activating factor of the human immunodeficiency virus type 1, acts also as an extracellular molecule modulating gene expression, cell survival, growth, transformation, and angiogenesis. Here we demonstrate that human thrombospondin-1 (TSP), a plasma glycoprotein and constituent of the extracellular matrix, binds to glutathione-S-transferase (GST)-Tat protein but not to GST. Scatchard plot analysis of the binding of free GST-Tat to immobilized TSP reveals a high-affinity interaction (K-d equal to 25 nM). Accordingly, TSP inhibits cell internalization and HIV-1 LTR trans-activating activity of extracellular Tat in HL3T1 cells with ID50 equal to 10-30 nM. Also, TSP inhibits cell interaction and mitogenic activity of extracellular Tat in T53 Tat-less cells. TSP is instead ineffective when administered after the interaction of Tat with cell surface heparan-sulfate proteoglycans has occurred, in keeping with its ability to prevent but not disrupt Tat/heparin interaction in vitro. Finally, TSP inhibits the autocrine loop of stimulation exerted by endogenous Tat in parental T53 cells. Accordingly, TSP overexpression inhibits cell proliferation, angiogenic activity, and tumorigenic capacity of stable T53 transfectants. Our data demonstrate the ability of TSP to bind to Tat protein and to affect its LTR trans-activating, mitogenic, angiogenic, and tumorigenic activity. These findings suggest that TSP may be implicated in the progression of AIDS and in AIDS-associated pathologies by modulating the bioavailability and biological activity of extracellular Tat.	Univ Brescia, Sch Med, Dept Biomed Sci & Biotechnol, Chair Gen Pathol & Immunol, I-25123 Brescia, Italy; Univ Brescia, Sch Med, Dept Biomed Sci & Biotechnol, Unit Histol & Cytol, I-25123 Brescia, Italy; Ist Ric Farmacol Mario Negri, I-24125 Bergamo, Italy; Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Ist Nazl Ric Canc, I-16132 Genoa, Italy	University of Brescia; University of Brescia; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; International Center for Genetic Engineering & Biotechnology (ICGEB); University of Genoa; IRCCS AOU San Martino IST	Presta, M (corresponding author), Univ Brescia, Sch Med, Dept Biomed Sci & Biotechnol, Chair Gen Pathol & Immunol, Via Valsabbina 19, I-25123 Brescia, Italy.		Giavazzi, Raffaella/J-7424-2018; Giacca, Mauro/J-9287-2016; Giavazzi, Raffaella/ABB-9768-2020; Noonan, Douglas M/A-8620-2010; Rusnati, Marco/F-1168-2010; Presta, Marco/B-4345-2010; Taraboletti, Giulia/J-4089-2018	Giacca, Mauro/0000-0003-2927-7225; Giavazzi, Raffaella/0000-0001-5249-8208; Noonan, Douglas M/0000-0001-8058-0719; Rusnati, Marco/0000-0001-9968-5908; Taraboletti, Giulia/0000-0001-8780-5001; Albini, Adriana/0000-0002-9624-5103; PRESTA, Marco/0000-0002-4398-8376; Urbinati, Chiara Eva/0000-0002-0138-7871				ALBINI A, 1994, AIDS, V8, P1237, DOI 10.1097/00002030-199409000-00004; Albini A, 1996, ONCOGENE, V12, P289; Albini A, 1998, P NATL ACAD SCI USA, V95, P13153, DOI 10.1073/pnas.95.22.13153; Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296-1371; ALBO D, 1994, BIOCHEM BIOPH RES CO, V203, P857, DOI 10.1006/bbrc.1994.2262; Auvinen M, 1997, CANCER RES, V57, P3016; BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; Bleuel K, 1999, P NATL ACAD SCI USA, V96, P2065, DOI 10.1073/pnas.96.5.2065; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; BORNSTEIN P, 1994, METHOD ENZYMOL, V245, P62; Cafaro A, 1999, NAT MED, V5, P643, DOI 10.1038/9488; CAMPIONI D, 1995, AIDS RES HUM RETROV, V11, P1039, DOI 10.1089/aid.1995.11.1039; Castle VP, 1997, LAB INVEST, V77, P51; Chang HC, 1997, AIDS, V11, P1421, DOI 10.1097/00002030-199712000-00006; CORALLINI A, 1993, CANCER RES, V53, P5569; Corallini A, 1996, AIDS, V10, P701, DOI 10.1097/00002030-199606001-00003; Crombie R, 1998, J EXP MED, V187, P25, DOI 10.1084/jem.187.1.25; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; Demarchi F, 1996, J VIROL, V70, P4427, DOI 10.1128/JVI.70.7.4427-4437.1996; ElSolh A, 1997, IMMUNOL INVEST, V26, P351, DOI 10.3109/08820139709022692; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; Ensoli B, 1998, CRIT REV ONCOGENESIS, V9, P107, DOI 10.1615/CritRevOncog.v9.i2.20; Gallo RC, 1998, SCIENCE, V282, P1837, DOI 10.1126/science.282.5395.1837; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GIBELLINI D, 1995, BRIT J HAEMATOL, V89, P24, DOI 10.1111/j.1365-2141.1995.tb08915.x; Gibellini D, 1998, J IMMUNOL, V160, P3891; GOLDER H, 1996, ARION, V4, P1; Hamy F, 1998, BIOCHEMISTRY-US, V37, P5086, DOI 10.1021/bi972947s; HAVERSTICK DM, 1984, BIOCHEMISTRY-US, V23, P5597, DOI 10.1021/bi00318a033; HOGG PJ, 1994, THROMB HAEMOSTASIS, V72, P787; Hogg PJ, 1997, BIOCHEM J, V326, P709, DOI 10.1042/bj3260709; Holme PA, 1998, FASEB J, V12, P79, DOI 10.1096/fasebj.12.1.79; Incardona F, 1996, J CELL BIOCHEM, V62, P431, DOI 10.1002/(SICI)1097-4644(19960915)62:4<431::AID-JCB1>3.0.CO;2-N; IRUELAARISPE ML, 1991, P NATL ACAD SCI USA, V88, P5026, DOI 10.1073/pnas.88.11.5026; JEANG KT, 1996, HUMAN RETROVIRUSES A; Kaaya EE, 1996, HISTOPATHOLOGY, V29, P337, DOI 10.1111/j.1365-2559.1996.tb01417.x; KIM CM, 1992, ONCOGENE, V7, P1525; Lamszus K, 1996, AM J PATHOL, V149, P805; LI CJ, 1995, P NATL ACAD SCI USA, V92, P5461, DOI 10.1073/pnas.92.12.5461; LONGO F, 1995, BIOCHEM BIOPH RES CO, V206, P326, DOI 10.1006/bbrc.1995.1045; Lyon M, 1997, J BIOL CHEM, V272, P18000, DOI 10.1074/jbc.272.29.18000; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; Marzio G, 1998, P NATL ACAD SCI USA, V95, P13519, DOI 10.1073/pnas.95.23.13519; MCCROHAN MB, 1987, THROMB HAEMOSTASIS, V58, P850; Menegon A, 1997, BIOCHEM BIOPH RES CO, V238, P800, DOI 10.1006/bbrc.1997.7393; Milani D, 1996, J BIOL CHEM, V271, P22961, DOI 10.1074/jbc.271.38.22961; Milani D, 1998, AIDS, V12, P1275, DOI 10.1097/00002030-199811000-00008; Mitola S, 1997, BLOOD, V90, P1365, DOI 10.1182/blood.V90.4.1365.1365_1365_1372; MOSHER DF, 1990, ANNU REV MED, V41, P85; MOULIGNIER A, 1994, CANCER, V74, P686, DOI 10.1002/1097-0142(19940715)74:2<686::AID-CNCR2820740222>3.0.CO;2-K; MURPHYULLRICH JE, 1992, MOL BIOL CELL, V3, P181, DOI 10.1091/mbc.3.2.181; NICOSIA RF, 1994, J CELL BIOL, V124, P183, DOI 10.1083/jcb.124.1.183; POTASH MJ, 1992, BIOCHEM BIOPH RES CO, V189, P250, DOI 10.1016/0006-291X(92)91551-Z; Ribatti D, 1999, J PATHOL, V189, P590; ROBERTS DD, 1988, CANCER RES, V48, P6785; Rusnati M, 1997, AIDS, V11, P727, DOI 10.1097/00002030-199706000-00005; Rusnati M, 1998, J BIOL CHEM, V273, P16027, DOI 10.1074/jbc.273.26.16027; Rusnati M, 1999, J BIOL CHEM, V274, P28198, DOI 10.1074/jbc.274.40.28198; Rusnati M, 1996, INT J CLIN LAB RES, V26, P15, DOI 10.1007/BF02644769; Rusnati M, 1997, J BIOL CHEM, V272, P11313, DOI 10.1074/jbc.272.17.11313; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHON P, 1992, EUR J CELL BIOL, V59, P329; SCHWARTZ S, 1990, J VIROL, V64, P2519, DOI 10.1128/JVI.64.6.2519-2529.1990; SHEIBANI N, 1995, P NATL ACAD SCI USA, V92, P6788, DOI 10.1073/pnas.92.15.6788; Shugars DC, 1999, J INFECT DIS, V179, pS431, DOI 10.1086/314799; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Streit M, 1999, AM J PATHOL, V155, P441, DOI 10.1016/S0002-9440(10)65140-1; TARABOLETTI G, 1992, LAB INVEST, V67, P566; Taraboletti G, 1999, J PATHOL, V188, P76, DOI 10.1002/(SICI)1096-9896(199905)188:1<76::AID-PATH312>3.0.CO;2-A; Taraboletti G, 1997, CELL GROWTH DIFFER, V8, P471; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; TORNESELLO ML, 1993, INTERVIROLOGY, V36, P57, DOI 10.1159/000150322; VECCHI A, 1994, EUR J CELL BIOL, V63, P247; VOGEL J, 1991, CANCER RES, V51, P6686; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; Volpert OV, 1998, P NATL ACAD SCI USA, V95, P6343, DOI 10.1073/pnas.95.11.6343; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504; WRIGHT CM, 1986, SCIENCE, V234, P988, DOI 10.1126/science.3490693; Wu ZH, 1998, AM J PATHOL, V152, P1599; YABKOWITZ R, 1989, J BIOL CHEM, V264, P10888; Zagury J F, 1998, J Hum Virol, V1, P282	82	25	26	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2000	14	13					1917	1930		10.1096/fj.99-0902com	http://dx.doi.org/10.1096/fj.99-0902com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023976				2022-12-28	WOS:000089634400011
J	Machwe, A; Orren, DK; Bohr, VA				Machwe, A; Orren, DK; Bohr, VA			Accelerated methylation of ribosomal RNA genes during the cellular senescence of Werner syndrome fibroblasts	FASEB JOURNAL			English	Article						life span; aging; population doubling; rDNA	REPLICATIVE LIFE-SPAN; AGE-DEPENDENT LOSS; DNA METHYLATION; HUMAN-CELLS; RESTRICTION ENDONUCLEASE; SYNDROME PROTEIN; HELICASE; SEQUENCES; SGS1; RDNA	Ribosomal DNA (rDNA) metabolism has been implicated in cellular and organismal aging. The role of rDNA in premature and normal human aging was investigated by measuring rDNA gene copy number, the level of rDNA methylation, and rRNA expression during the in vitro senescence of primary fibroblasts from normal (young and old) donors and from Werner syndrome (WS) patients, In comparison to their normal counterparts, WS fibroblasts grew slowly and reached senescence after fewer doublings. The rDNA copy number did not change significantly throughout the life span of both normal and WS fibroblasts, However, in senescent WS and normal old fibroblasts, we detected rDNA species with unusually slow electrophoretic mobility, Cellular aging in Saccharomyces cerevisiae is accompanied by the formation and accumulation of rDNA circles. Our analysis revealed that the rDNA species observed in this study were longer, linear rDNA molecules attributable to the inhibition of EcoRI cleavage by methylation. Furthermore, isoschizomeric restriction analysis confirmed that in vitro senescence of fibroblasts is accompanied by significant increases in cytosine methylation within rDNA genes, This increased methylation is maximal during the abbreviated life span of WS fibroblasts. Despite increased methylation of rDNA in senescent cells, the steady-state levels of 28S rRNA remained constant over the life span of both normal and WS fibroblasts.	NIA, Mol Genet Lab, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Bohr, VA (corresponding author), NIA, Mol Genet Lab, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		Bohr, Vilhelm/AAP-5931-2020					ALVES J, 1984, EUR J BIOCHEM, V140, P83, DOI 10.1111/j.1432-1033.1984.tb08069.x; ARKING R, 1998, BIOL AGING, P415; Battey, 1986, BASIC METHODS MOL BI; Bennett RJ, 1998, J BIOL CHEM, V273, P9644, DOI 10.1074/jbc.273.16.9644; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BRENNAN CA, 1986, J BIOL CHEM, V261, P7270; BROWN TC, 1987, CELL, V50, P945, DOI 10.1016/0092-8674(87)90521-6; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; CHIKARAISHI DM, 1983, NUCLEIC ACIDS RES, V11, P6437, DOI 10.1093/nar/11.18.6437; Cristofalo Vincent J., 1995, P53; Cristofalo VJ, 1998, P NATL ACAD SCI USA, V95, P10614, DOI 10.1073/pnas.95.18.10614; Epstein CJ, 1996, BIOESSAYS, V18, P1025, DOI 10.1002/bies.950181214; Finch CE, 1990, LONGEVITY SENESCENCE; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GAUBATZ JW, 1978, GERONTOLOGY, V24, P179, DOI 10.1159/000212250; Goto M, 1997, MECH AGEING DEV, V98, P239, DOI 10.1016/S0047-6374(97)00111-5; Gray MD, 1998, EXP CELL RES, V242, P487, DOI 10.1006/excr.1998.4124; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Guarente L, 1997, GENE DEV, V11, P2449, DOI 10.1101/gad.11.19.2449; Halle JP, 1997, EUR J CELL BIOL, V74, P281; HO L, 1989, MOL CELL BIOL, V9, P1594, DOI 10.1128/MCB.9.4.1594; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; JOHNSON R, 1972, NATURE, V240, P412, DOI 10.1038/240412a0; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; Kochanek S, 1996, FEBS LETT, V388, P192, DOI 10.1016/0014-5793(96)00506-6; MACLEOD D, 1983, NATURE, V306, P200, DOI 10.1038/306200a0; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; Martin GM, 1996, EXP GERONTOL, V31, P49, DOI 10.1016/0531-5565(95)02021-7; MARTIN GM, 1970, LAB INVEST, V23, P86; MCCLELLAND M, 1992, NUCLEIC ACIDS RES, V20, P2145, DOI 10.1093/nar/20.suppl.2145; Moser MJ, 1999, HUM MUTAT, V13, P271, DOI 10.1002/(SICI)1098-1004(1999)13:4<271::AID-HUMU2>3.0.CO;2-Q; PENNOCK DG, 1984, NUCLEIC ACIDS RES, V12, P2225, DOI 10.1093/nar/12.4.2225; PETERSON CRD, 1984, ARCH GERONTOL GERIAT, V3, P115, DOI 10.1016/0167-4943(84)90004-9; Rattan SIS, 1996, EXP GERONTOL, V31, P33, DOI 10.1016/0531-5565(95)02022-5; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; SALK D, 1981, CYTOGENET CELL GENET, V30, P108, DOI 10.1159/000131597; Sambrook J., 2002, MOL CLONING LAB MANU; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STREHLER BL, 1979, MECH AGEING DEV, V11, P379, DOI 10.1016/0047-6374(79)90013-7; STREHLER BL, 1979, MECH AGEING DEV, V11, P371, DOI 10.1016/0047-6374(79)90012-5; SWISSHELM K, 1990, MUTAT RES, V237, P131, DOI 10.1016/0921-8734(90)90019-N; TASSERONDEJONG JG, 1988, GENE, V74, P147, DOI 10.1016/0378-1119(88)90272-7; Van Remmen Holly, 1995, P171; VERTINO PM, 1994, CELL GROWTH DIFFER, V5, P1395; WANG RYH, 1982, BIOCHIM BIOPHYS ACTA, V697, P371, DOI 10.1016/0167-4781(82)90101-4; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; WILSON V L, 1983, Science (Washington D C), V220, P1055, DOI 10.1126/science.6844925; WILSON VL, 1987, J BIOL CHEM, V262, P9948; Yan H, 1998, NAT GENET, V19, P375, DOI 10.1038/1263; YANG JK, 1984, J MOL BIOL, V176, P169, DOI 10.1016/0022-2836(84)90419-4; Yu CE, 1997, AM J HUM GENET, V60, P330; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	56	38	41	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2000	14	12					1715	1724		10.1096/fj.99-0926com	http://dx.doi.org/10.1096/fj.99-0926com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973920				2022-12-28	WOS:000089212400010
J	Conner, SD; Wessel, GM				Conner, SD; Wessel, GM			A rab3 homolog in sea urchin functions in cell division	FASEB JOURNAL			English	Article						GTP binding protein; vesicle dynamics; membrane fusion; cytokinesis	CORTICAL GRANULE EXOCYTOSIS; ENDOCYTIC MEMBRANE-FUSION; ENDOPLASMIC-RETICULUM; PROTEIN; GOLGI; GTPASE; EFFECTOR; RABPHILIN-3A; SUBFAMILY; TRANSPORT	Rabs are monomeric GTP binding proteins belonging to the ras superfamily that function throughout the secretory pathway. Members of the rab3 family function in the final steps of the secretory pathway, vesicle fusion with the plasma membrane, In contrast to mammalian systems with several rab3 isoforms (rab3A-D), a single family member homologue of rab3 is present in the rapidly dividing cleavage stage sea urchin embryo that localizes to numerous vesicles enriched at the cell cortex. We hypothesized that whereas the contents of these rab3-positive vesicles may contribute to the embryonic extracellular matrix, the membrane and its constituent proteins may be important for other aspects of cell division. We tested the function of rab3 in cell, division by the microinjection of either antibodies or competing effector domain peptides to interfere with its function, We found that perturbing rab3 function results in cessation of cell division, whereas cells injected with either heat-inactivated antibodies or control scrambled peptides develop as normal. Moreover, neither endocytosis nor general membrane topology are affected by rab3 perturbation, Thus, we conclude that rab3-associated vesicles and/or their contents are critical for cell division.	Brown Univ, Dept Biochem & Mol Cell Biol, Providence, RI 02912 USA	Brown University	Wessel, GM (corresponding author), Brown Univ, Dept Biochem & Mol Cell Biol, 69 Brown St, Providence, RI 02912 USA.	rhet@brown.edu						ANTONY C, 1992, J CELL SCI, V103, P785; Bean AJ, 1997, NEURON, V19, P751, DOI 10.1016/S0896-6273(00)80957-5; Burgess RW, 1997, J CELL BIOL, V138, P861, DOI 10.1083/jcb.138.4.861; BURTON JL, 1994, EMBO J, V13, P5547, DOI 10.1002/j.1460-2075.1994.tb06892.x; Burton JL, 1997, J BIOL CHEM, V272, P3663, DOI 10.1074/jbc.272.6.3663; Conner S, 1998, DEV BIOL, V203, P334, DOI 10.1006/dbio.1998.9057; Conner S, 1997, MOL REPROD DEV, V48, P106; Conner SD, 1999, MOL BIOL CELL, V10, P2735, DOI 10.1091/mbc.10.8.2735; Deretic D, 1997, ELECTROPHORESIS, V18, P2537, DOI 10.1002/elps.1150181408; Echard A, 1998, SCIENCE, V279, P580, DOI 10.1126/science.279.5350.580; FELDMANN G, 1995, BIOL CELL, V83, P121, DOI 10.1016/0248-4900(96)81299-8; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Harlow E., 1988, ANTIBODIES LAB MANUA; Jahn R, 1998, NATURE, V393, P14, DOI 10.1038/29871; Johannes L, 1996, J CELL SCI, V109, P2875; KIEHART DP, 1982, METHOD CELL BIOL, V25, P13, DOI 10.1016/S0091-679X(08)61418-1; LAIDLAW M, 1994, DEVELOPMENT, V120, P1325; Lauber MH, 1997, J CELL BIOL, V139, P1485, DOI 10.1083/jcb.139.6.1485; LEPAGE T, 1992, DEV BIOL, V150, P23, DOI 10.1016/0012-1606(92)90004-Z; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LLEDO PM, 1994, TRENDS NEUROSCI, V17, P426, DOI 10.1016/0166-2236(94)90017-5; LUCOCQ JM, 1987, EMBO J, V6, P3239, DOI 10.1002/j.1460-2075.1987.tb02641.x; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; Martinez O, 1998, BBA-MOL CELL RES, V1404, P101, DOI 10.1016/S0167-4889(98)00050-0; MCCLAY DR, 1986, EMBRYO DISSOCIATION, V27; OBERHAUSER AF, 1992, NATURE, V360, P270, DOI 10.1038/360270a0; Ostermeier C, 1999, CELL, V96, P363, DOI 10.1016/S0092-8674(00)80549-8; Rappaport R., 1996, CYTOKINESIS ANIMAL C; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; Schimmoller F, 1998, J BIOL CHEM, V273, P22161, DOI 10.1074/jbc.273.35.22161; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; Terasaki M, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P501; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; Turner MD, 1997, J BIOL CHEM, V272, P13479, DOI 10.1074/jbc.272.21.13479; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; WARREN G, 1989, NATURE, V342, P857, DOI 10.1038/342857a0; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WHALLEY T, 1995, J CELL BIOL, V131, P1183, DOI 10.1083/jcb.131.5.1183	40	16	16	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2000	14	11					1559	1566		10.1096/fj.14.11.1559	http://dx.doi.org/10.1096/fj.14.11.1559			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CN	10928990				2022-12-28	WOS:000088627800010
J	Hong, SH; Ondrey, FG; Avis, IM; Chen, Z; Loukinova, E; Cavanaugh, PF; Van Waes, C; Mulshine, JL				Hong, SH; Ondrey, FG; Avis, IM; Chen, Z; Loukinova, E; Cavanaugh, PF; Van Waes, C; Mulshine, JL			Cyclooxygenase regulates human oropharyngeal carcinomas via the proinflammatory cytokine IL-6: a general role for inflammation?	FASEB JOURNAL			English	Article						colon cancer; arachidonic acid; inflammatory disease; COX inhibitors	SQUAMOUS-CELL CARCINOMA; PROSTAGLANDIN E(2) PRODUCTION; HOST ENVIRONMENT PROMOTES; FACTOR-KAPPA-B; CANCER CELLS; ADULT PERIODONTITIS; TUMOR PROGRESSION; EPITHELIAL-CELLS; LUNG-CANCER; BONE LOSS	High levels of prostaglandins are produced in human oropharyngeal carcinoma (OPC), Five human OPC cell lines tested expressed both isoforms of cyclooxygenases (COX), The pan-COX inhibitor ketorolac continuously and significantly decreased PGE(2) production and IL-6 and IL-8 levels in all OPC cell lines tested, but did not affect IL-1 alpha, GM-CSF levels, or in vitro tumor cell growth. In contrast, ketorolac reduced OPC growth in vivo. The OPC cell lines used express the IL-6 receptor, and IL-6 stimulation of these cells causes transduction to occur via STAT3 pathway activation. Coincubation with OPC cell lines with conditioned medium from a TPA-exposed HL-60 cells stimulated growth proportional to the IL-6 levels measured in the conditioned medium. This growth effect was specifically inhibited by anti-IL-6 antibody. These results are consistent with cytokine products of inflammatory cells having paracrine growth effects on OPC, If chronic inflammation plays a role in promoting the development of OPC, this mechanism may also apply to other epithelial tumor systems modulated by COX activity.	NCI, Med Branch, Div Clin Sci, Cell & Canc Biol Dept,Intervent Sect, Bethesda, MD 20892 USA; NIH, Natl Inst Deafness & Other Commun Disorders, Head & Neck Surg Branch, Bethesda, MD 20892 USA; Procter & Gamble Oral Hlth Care Technol Div, Cincinnati, OH USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Procter & Gamble	Mulshine, JL (corresponding author), NCI, Med Branch, Div Clin Sci, Cell & Canc Biol Dept,Intervent Sect, Bldg 10-12N226,9000 Rockville Pike, Bethesda, MD 20892 USA.	mulshinej@bprb.nci.nih.gov	Cavanaugh, Paul/AAY-4856-2021	Cavanaugh, Paul/0000-0002-7874-7249	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000016, ZIADC000016] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Ahnen DJ, 1998, EUR J SURG, V164, P111, DOI 10.1080/11024159850191544; Avis IM, 1996, J CLIN INVEST, V97, P806, DOI 10.1172/JCI118480; Beck J D, 1998, Ann Periodontol, V3, P127, DOI 10.1902/annals.1998.3.1.127; Cavanaugh P. F. Jr., 1995, Inflammopharmacology, V3, P313, DOI 10.1007/BF02668026; Cavanaugh PF, 1998, J PERIODONTAL RES, V33, P75; Chan G, 1999, CANCER RES, V59, P991; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; Chen Z, 1997, CLIN EXP METASTAS, V15, P527, DOI 10.1023/A:1018474910432; Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318; DEMARINI DM, 1983, MUTAT RES, V114, P59, DOI 10.1016/0165-1110(83)90019-2; Dong G, 1999, CANCER RES, V59, P3495; Dongari-Bagtzoglou AI, 1998, J PERIODONTOL, V69, P899, DOI 10.1902/jop.1998.69.8.899; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Duffey DC, 1999, CANCER RES, V59, P3468; ELATTAR TMA, 1987, J ORAL PATHOL MED, V16, P483; EUGUI EM, 1993, ANN NY ACAD SCI, V685, P309, DOI 10.1111/j.1749-6632.1993.tb35881.x; Ghosh J, 1997, BIOCHEM BIOPH RES CO, V235, P418, DOI 10.1006/bbrc.1997.6799; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; GOODWIN JS, 1983, J CLIN IMMUNOL, V3, P295, DOI 10.1007/BF00915791; GU L, 1987, PHARMACEUT RES, V4, P255, DOI 10.1023/A:1016420514689; HEDGES S, 1995, ADV EXP MED BIOL, V371, P189; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; Hida T, 1998, CANCER RES, V58, P3761; Hong SH, 1999, CANCER RES, V59, P2223; Hong WK, 1997, SCIENCE, V278, P1073, DOI 10.1126/science.278.5340.1073; JEFFCOAT MK, 1995, J PERIODONTOL, V66, P329, DOI 10.1902/jop.1995.66.5.329; Kelley DJ, 1997, CARCINOGENESIS, V18, P795, DOI 10.1093/carcin/18.4.795; KRAUSE CJ, 1981, ARCH OTOLARYNGOL, V107, P703; Liu XH, 1996, CANCER RES, V56, P5125; Mitchell JA, 1998, INFLAMM RES, V47, pS88; NAKANISHI Y, 1988, EXP CELL BIOL, V56, P74; OTTO JC, 1995, J LIPID MEDIAT CELL, V12, P139, DOI 10.1016/0929-7855(95)00015-I; PANJE WR, 1981, ARCH OTOLARYNGOL, V107, P658; PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064; Potter M, 1997, HEMATOL ONCOL CLIN N, V11, P323, DOI 10.1016/S0889-8588(05)70434-2; Prescott SM, 1996, CELL, V87, P783, DOI 10.1016/S0092-8674(00)81983-2; Rainsford KD, 1997, J PHARM PHARMACOL, V49, P991, DOI 10.1111/j.2042-7158.1997.tb06030.x; Reed JC, 1999, J NATL CANCER I, V91, P1099, DOI 10.1093/jnci/91.13.1099; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; ROOKS WH, 1985, DRUG EXP CLIN RES, V11, P479; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; SCHREY MP, 1995, BRIT J CANCER, V72, P1412, DOI 10.1038/bjc.1995.523; Slavkin HC, 1999, J AM DENT ASSOC, V130, P109, DOI 10.14219/jada.archive.1999.0038; Smith CW, 1998, CLIN EXP METASTAS, V16, P655, DOI 10.1023/A:1006559811429; Smith T, 1893, B BUREAU ANIM IND, P1; SNYDER DS, 1986, BLOOD, V67, P1675; SNYDERMAN CH, 1995, HEAD NECK-J SCI SPEC, V17, P108, DOI 10.1002/hed.2880170206; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Tucker ON, 1999, CANCER RES, V59, P987; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Vane JR, 1998, INT J TISSUE REACT, V20, P3; Wallace JL, 1998, GASTROENTEROLOGY, V115, P101, DOI 10.1016/S0016-5085(98)70370-1; Williams JA, 1997, J BIOL CHEM, V272, P25693, DOI 10.1074/jbc.272.41.25693	53	73	78	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2000	14	11					1499	1507		10.1096/fj.99-0802com	http://dx.doi.org/10.1096/fj.99-0802com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CN	10928984				2022-12-28	WOS:000088627800004
J	Santucci-Darmanin, S; Walpita, D; Lespinasse, F; Desnuelle, C; Ashley, T; Paquis-Flucklinger, V				Santucci-Darmanin, S; Walpita, D; Lespinasse, F; Desnuelle, C; Ashley, T; Paquis-Flucklinger, V			MSH4 acts in conjunction with MLH1 during mammalian meiosis	FASEB JOURNAL			English	Article						MSH proteins; MLH proteins; protein interaction; synapsis; meiotic recombination; mismatch DNA repair	DNA MISMATCH REPAIR; CROSSING-OVER; MUTS HOMOLOG; SACCHAROMYCES-CEREVISIAE; SYNAPTONEMAL COMPLEXES; CHROMOSOME SYNAPSIS; MICE; GENE; PROTEIN; YEAST	MSH4 is a meiosis-specific MutS homolog, In yeast, it is required for reciprocal recombination and proper segregation of homologous chromosomes at meiosis I. MLH1 (MutL homolog 1) facilitates both mismatch repair and crossing over during meiosis in yeast. Germ-line mutations in the MLH1 human gene are responsible for hereditary nonpolyposis cancer, but the analysis of MLH1-deficient mice has revealed that MLH1 is also required for reciprocal recombination in mammals. Here we show that hMSH4 interacts with hMLH1. The two proteins are coimmunoprecipitated regardless of the presence of DNA or ATP, suggesting that the interaction does not require the binding of MSH4 to DNA, The domain of hMSH4 responsible for the interaction is in the amino-terminal part of the protein whereas the region that contains the ATP binding site and helix-turn-helix motif does not bind to hMLH1. Immunolocalization analysis shows that MSH4 is present at sites along the synaptonemal complex as soon as homologous chromosomes synapse. The number of MSH4 foci decreases gradually as pachynema progresses, During this transition, MLH1 foci begin to appear and colocalize with MSH4, These results suggest that MSH4 is first required for chromosome synapsis and that this MutS homologue is involved later with MLH1 in meiotic reciprocal recombination.	Fac Med, UMR CNRS UNSA 6549, Neurobiol Lab Cellulaire, F-06107 Nice 2, France; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA	UDICE-French Research Universities; Universite Cote d'Azur; Yale University	Paquis-Flucklinger, V (corresponding author), Fac Med, UMR CNRS UNSA 6549, Neurobiol Lab Cellulaire, Ave Valombrose, F-06107 Nice 2, France.			LESPINASSE, francoise/0000-0001-7710-0649; Santucci-Darmanin, Sabine/0000-0001-5354-6988	NIGMS NIH HHS [GM55300, GM47797] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R13GM047797] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson LK, 1999, GENETICS, V151, P1569; ASHLEY T, 1995, CHROMOSOMA, V104, P19, DOI 10.1007/BF00352222; Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; Barlow AL, 1998, EUR J HUM GENET, V6, P350, DOI 10.1038/sj.ejhg.5200200; BROCKER TA, 1999, CANCER RES, V59, P816; de Vries SS, 1999, GENE DEV, V13, P523, DOI 10.1101/gad.13.5.523; Edelmann W, 1999, NAT GENET, V21, P123, DOI 10.1038/5075; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; Fishel R, 1997, CURR OPIN GENET DEV, V7, P105, DOI 10.1016/S0959-437X(97)80117-7; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Guerrette S, 1999, J BIOL CHEM, V274, P6336, DOI 10.1074/jbc.274.10.6336; Habraken Y, 1998, J BIOL CHEM, V273, P9837, DOI 10.1074/jbc.273.16.9837; HOLLINGSWORTH NM, 1995, GENE DEV, V9, P1728, DOI 10.1101/gad.9.14.1728; Hunter N, 1997, GENE DEV, V11, P1573, DOI 10.1101/gad.11.12.1573; LAMMERS JHM, 1994, MOL CELL BIOL, V14, P1137, DOI 10.1128/MCB.14.2.1137; Moses MJ, 1980, ANIMAL MODELS HUMAN, P169; PaquisFlucklinger V, 1997, GENOMICS, V44, P188, DOI 10.1006/geno.1997.4857; Peters AHFM, 1997, CHROMOSOME RES, V5, P66, DOI 10.1023/A:1018445520117; Pochart P, 1997, J BIOL CHEM, V272, P30345, DOI 10.1074/jbc.272.48.30345; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; ROSSMACDONALD P, 1994, CELL, V79, P1069, DOI 10.1016/0092-8674(94)90037-X; Santucci-Darmanin S, 1999, MAMM GENOME, V10, P423, DOI 10.1007/s003359901016; Winand NJ, 1998, GENOMICS, V53, P69, DOI 10.1006/geno.1998.5447; Woods LM, 1999, J CELL BIOL, V145, P1395, DOI 10.1083/jcb.145.7.1395	26	112	114	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2000	14	11					1539	1547		10.1096/fj.14.11.1539	http://dx.doi.org/10.1096/fj.14.11.1539			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CN	10928988				2022-12-28	WOS:000088627800008
J	Di Marzo, V; Hill, MP; Bisogno, T; Crossman, AR; Brotchie, JM				Di Marzo, V; Hill, MP; Bisogno, T; Crossman, AR; Brotchie, JM			Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease	FASEB JOURNAL			English	Article						anandamide; 2-arachidonoyl glycerol; cannabinoids; dopamine; receptors	MOUSE NEUROBLASTOMA-CELLS; BASAL GANGLIA; RECEPTOR AGONIST; BRAIN; ANANDAMIDE; RAT; NEURONS; 2-ARACHIDONOYLGLYCEROL; ENDOCANNABINOIDS; BIOSYNTHESIS	In recent years, cannabinoid receptors and their endogenous ligands (endocannabinoids) have been identified within the brain. The high density of CB1 cannabinoid receptors within the basal ganglia suggests a potential role for endocannabinoids in the control of voluntary movement and in basal ganglia-related movement disorders such as Parkinson's disease. However, whether endocannabinoids play a role in regulating motor behavior in health and disease is unknown. Here we report the presence in two regions of the basal ganglia, the g-lobus pallidus and substantia nigra, of the endocannabinoids 2-arachidonoylglycerol (2AG) and anandamide. The levels of the latter compound are similar to threefold higher than those previously reported in any other brain region. In the reserpine-treated rat, an animal model of Parkinson's disease, suppression of locomotion is accompanied by a sevenfold increase in the levels of the 2AG in the globus pallidus, but not in the other five brain regions analyzed. Stimulation of locomotion in the reserpine-treated rat by either of the two selective agonists of D2 and D1 dopamine receptors, quinpirole and R-(+/-)-3-allyl-6-chloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide (Cl-APB), respectively, results in the reduction of both anandamide and 2AG levels in the g-lobus pallidus. Finally, full restoration of locomotion in the reserpine-treated rat is obtained by coadministration of quinpirole and the selective antagonist of the cannabinoid CB1 receptor subtype, SR141716A. These findings indicate a link between endocannabinoid signaling in the globus pallidus and symptoms of Parkinson's disease in the reserpine-treated rat, and suggest that modulation of the endocannabinoid signaling system might prove useful in treating this or other basal ganglia-related movement disorders.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; CNR, Ist Chim Mol Interesse Biol, I-80072 Arco, Naples, Italy; Motac Neurosci Ltd, Manchester M13 9XX, Lancs, England	University of Manchester; Consiglio Nazionale delle Ricerche (CNR)	Di Marzo, V (corresponding author), Univ Manchester, Sch Biol Sci, 1-124 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.		Bisogno, Tiziana/B-7891-2015; Di Marzo, Vincenzo/AAD-7742-2019	Di Marzo, Vincenzo/0000-0002-1490-3070; Brotchie, Jonathan/0000-0003-2337-0816				Bisogno T, 1999, J NEUROCHEM, V72, P2113, DOI 10.1046/j.1471-4159.1999.0722113.x; Bisogno T, 1999, BIOCHEM BIOPH RES CO, V256, P377, DOI 10.1006/bbrc.1999.0254; Bisogno T, 1997, BIOCHEM J, V322, P671, DOI 10.1042/bj3220671; CARLSSON A, 1957, NATURE, V180, P1200, DOI 10.1038/1801200a0; COLPAERT FC, 1987, NEUROPHARMACOLOGY, V26, P1431, DOI 10.1016/0028-3908(87)90110-9; Consroe P, 1998, NEUROBIOL DIS, V5, P534, DOI 10.1006/nbdi.1998.0220; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 1998, TRENDS NEUROSCI, V21, P521, DOI 10.1016/S0166-2236(98)01283-1; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; DiMarzo V, 1996, BIOCHEM BIOPH RES CO, V227, P281, DOI 10.1006/bbrc.1996.1501; Felder CC, 1996, FEBS LETT, V393, P231, DOI 10.1016/0014-5793(96)00891-5; FERRE S, 1991, EUR J PHARMACOL, V192, P25, DOI 10.1016/0014-2999(91)90064-W; GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780; Giuffrida A, 1999, NAT NEUROSCI, V2, P358, DOI 10.1038/7268; Glass M, 1997, EUR J NEUROSCI, V9, P199, DOI 10.1111/j.1460-9568.1997.tb01390.x; HERKENHAM M, 1991, BRAIN RES, V547, P267, DOI 10.1016/0006-8993(91)90970-7; Landsman RS, 1997, EUR J PHARMACOL, V334, pR1, DOI 10.1016/S0014-2999(97)01160-6; Maneuf YP, 1996, EUR J PHARMACOL, V308, P161, DOI 10.1016/0014-2999(96)00326-3; Maneuf YP, 1997, EXP NEUROL, V148, P265, DOI 10.1006/exnr.1997.6645; Maneuf YP, 1996, SYNAPSE, V22, P382; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Penney J B Jr, 1986, Mov Disord, V1, P3, DOI 10.1002/mds.870010102; Pertwee RG, 1997, PHARMACOL THERAPEUT, V74, P129, DOI 10.1016/S0163-7258(97)82001-3; PERTWEE RG, 1991, NEUROPHARMACOLOGY, V30, P237, DOI 10.1016/0028-3908(91)90150-A; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; ROMERO J, 1995, LIFE SCI, V56, P2033, DOI 10.1016/0024-3205(95)00186-A; Smith Y, 1998, NEUROSCIENCE, V86, P353; Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; TRUGMAN JM, 1991, BRAIN, V114, P1429, DOI 10.1093/brain/114.3.1429; USHIJIMA I, 1988, PSYCHOPHARMACOLOGY, V95, P29	31	248	258	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2000	14	10					1432	1438		10.1096/fj.14.10.1432	http://dx.doi.org/10.1096/fj.14.10.1432			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877836				2022-12-28	WOS:000087932200018
J	Albrecht, D; Nitschke, T; von Bohlen und Halbach, O				Albrecht, D; Nitschke, T; von Bohlen und Halbach, O			Various effects of angiotensin II on amygdaloid neuronal activity in normotensive control and hypertensive transgenic [TGR(mREN-2)27] rats	FASEB JOURNAL			English	Article						amygdala; angiotensin II; AT(1); AT(2); bicuculline; extracellular recording; urethane; iontophoresis	CONVERTING ENZYME; AT(2) RECEPTORS; LIMBIC SYSTEM; BRAIN; MODULATION; RESPONSIVENESS; MECHANISMS; PEPTIDES; BEHAVIOR; AT(1)	The effects: of iontophoretically ejected angiotensin II (Ang II) on the firing rate of neurons in the basolateral complex and the central and cortical amygdala were investigated in two strains of urethane anesthetized rats. hi normotensive Sprague-Dawley rats, Ang II induced a significant increase in the discharge rate of responsive amygdaloid neurons. In contrast, in the hypertensive transgenic [TGR(mREN-2)27] rats with higher brain Ang II level, Ang II more often caused inhibitory effects on the amygdaloid firing rate in comparison with controls. The distribution of nonresponsive, excited, and inhibited neurons differed significantly in the two rat strains. Moreover, the responsiveness of amygdaloid neurons was significantly higher in transgenic rats in comparison with controls. Both the increase and the decrease in the firing rate caused by Ang II could be blocked either by angiotensin AT(1) or by AT(2) receptor-specific antagonists. In many cases, the Ang II-induced decrease in the firing rate was antagonized by bicuculline, a gamma-aminobutyric acid (GABA(A)) antagonist. The higher responsiveness of amygdaloid neurons in transgenic rats as well as the predominance of inhibitory effects, presumedly mediated by GABAergic interneurons, could change the output of the amygdala and its influence on thirst, kidney, and cardiovascular function or on processes of learning and anxiety.	Humboldt Univ, Fac Med Charite, Inst Physiol, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Albrecht, D (corresponding author), Humboldt Univ, Fac Med Charite, Inst Physiol, Tucholskystr 2, D-10117 Berlin, Germany.	doris.albrecht@charite.de	von Bohlen und Halbach, Oliver/A-1060-2008; von Bohlen und Halbach, Oliver/R-3464-2019	von Bohlen und Halbach, Oliver/0000-0002-6265-9156; von Bohlen und Halbach, Oliver/0000-0002-2613-2517				ALBRECHT D, 1989, BRAIN RES BULL, V22, P923, DOI 10.1016/0361-9230(89)90001-4; Albrecht D, 1997, J HYPERTENS, V15, P1151, DOI 10.1097/00004872-199715100-00013; Albrecht D, 1997, EUR J PHARMACOL, V332, P53, DOI 10.1016/S0014-2999(97)01062-5; AMBUHL P, 1992, REGUL PEPTIDES, V41, P19, DOI 10.1016/0167-0115(92)90510-2; ANDERSON KM, 1993, AM J PHYSIOL, V264, pC179, DOI 10.1152/ajpcell.1993.264.1.C179; BARNES JM, 1992, J CARDIOVASC PHARM, V19, pS63, DOI 10.1097/00005344-199219006-00011; CAMPBELL DJ, 1995, HYPERTENSION, V25, P1014, DOI 10.1161/01.HYP.25.5.1014; CHAI SY, 1987, NEUROSCIENCE, V20, P615; CHAN RKW, 1991, BRAIN RES, V556, P145, DOI 10.1016/0006-8993(91)90559-E; Chorvatova A, 1996, CELL SIGNAL, V8, P525, DOI 10.1016/S0898-6568(96)00117-9; HARDING JW, 1987, J NEUROSCI METH, V19, P209, DOI 10.1016/S0165-0270(87)80004-3; HICKS TP, 1984, PROG NEUROBIOL, V22, P185; Jacinto SM, 1999, AM J PHYSIOL-RENAL, V276, pF315, DOI 10.1152/ajprenal.1999.276.2.F315; Johnson AK, 1997, FRONT NEUROENDOCRIN, V18, P292, DOI 10.1006/frne.1997.0153; Johren O, 1996, AM J PHYSIOL-ENDOC M, V271, pE104, DOI 10.1152/ajpendo.1996.271.1.E104; KAISER FC, 1992, NEUROREPORT, V3, P922, DOI 10.1097/00001756-199210000-00026; Kanashiro CA, 1995, J PHARMACOL EXP THER, V275, P1543; KANG J, 1992, BRAIN RES, V580, P317, DOI 10.1016/0006-8993(92)90960-H; LeDoux J E, 1992, Curr Opin Neurobiol, V2, P191, DOI 10.1016/0959-4388(92)90011-9; Lienard F, 1996, REGUL PEPTIDES, V66, P59, DOI 10.1016/S0167-0115(96)00060-2; MULLINS JJ, 1990, NATURE, V344, P541, DOI 10.1038/344541a0; Okuyama S, 1999, BRAIN RES, V821, P150, DOI 10.1016/S0006-8993(99)01098-7; PHILLIPS MI, 1987, ANNU REV PHYSIOL, V49, P413, DOI 10.1146/annurev.physiol.49.1.413; REAGAN LP, 1994, BRAIN RES, V662, P45, DOI 10.1016/0006-8993(94)90794-3; SAAVEDRA JM, 1992, ENDOCR REV, V13, P329, DOI 10.1210/er.13.2.329; Sanvitto GL, 1997, AM J PHYSIOL-ENDOC M, V273, pE156, DOI 10.1152/ajpendo.1997.273.1.E156; SENANAYAKE PD, 1994, PEPTIDES, V15, P919; SONG K, 1992, J COMP NEUROL, V316, P467, DOI 10.1002/cne.903160407; Sumners C, 1998, CELL SIGNAL, V10, P303, DOI 10.1016/S0898-6568(97)00133-2; SUMNERS C, 1994, FRONT NEUROENDOCRIN, V15, P203; Swanson LW, 1998, TRENDS NEUROSCI, V21, P323, DOI 10.1016/S0166-2236(98)01265-X; von Bohlen und Halbach O, 1998, PEPTIDES, V19, P1031, DOI 10.1016/S0196-9781(98)00044-8; von Bohlen und Halbach O, 1998, NEUROPEPTIDES, V32, P241, DOI 10.1016/S0143-4179(98)90043-9; von Bohlen und Halbach O, 1998, BRAIN RES BULL, V47, P311, DOI 10.1016/S0361-9230(98)00073-2; von Bohlen und Halbach O, 1998, REGUL PEPTIDES, V78, P51, DOI 10.1016/S0167-0115(98)00109-8; Wilson W, 1996, BRAIN RES, V729, P1; WINNICKA MM, 1988, POL J PHARMACOL PHAR, V40, P129; WRIGHT JW, 1995, FRONT NEUROENDOCRIN, V16, P23, DOI 10.1006/frne.1995.1002; ZHAO Y, 1993, AM J PHYSIOL, V265, pE699, DOI 10.1152/ajpendo.1993.265.5.E699	39	32	32	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2000	14	7					925	931		10.1096/fasebj.14.7.925	http://dx.doi.org/10.1096/fasebj.14.7.925			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	309CG	10783146				2022-12-28	WOS:000086749500010
J	Zeidler, R; Csanady, M; Gires, O; Lang, S; Schmitt, B; Wollenberg, B				Zeidler, R; Csanady, M; Gires, O; Lang, S; Schmitt, B; Wollenberg, B			Tumor cell-derived prostaglandin E2 inhibits monocyte function by interfering with CCR5 and Mac-1	FASEB JOURNAL			English	Article						immune evasion; prostaglandins; migration; adhesion	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; HUMAN COLON-CANCER; COLORECTAL-CANCER; ASPIRIN USE; SELECTIVE EXPRESSION; CHEMOKINE RECEPTORS; LEUKOCYTE ADHESION; DENDRITIC CELLS; DOWN-REGULATION; MESSENGER-RNA	The cyclooxygenases (COX)-1 and COX-2 are key enzymes in the conversion of arachidonic acid to prostaglandins and other eicosanoids. 'Whereas COX-1 is expressed ubiquitously, COX-2 is an immediate-early gene often associated with malignant transformation, and a role for the COX enzymes in tumor initiation and promotion is discussed. Nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin and indomethacin that block COX-1 and -2 have been shown to have beneficial effects for tumor patients. Therefore, these compounds have gained interest also among oncologists. However, the molecular mechanism by which NSAIDs inhibit carcinogenesis is not clearly understood. The prostaglandin-dependent and -independent effect may both account for their antineoplastic action. We show here that tumor cells derived from different tumors regularly produce prostaglandin E-2 (PGE,) interfering with the function of monocytes. in particular, PGE, inhibits the potential of monocytes to migrate in the direction of a chemotactic stimulus and to adhere to endothelial cell. This inhibition is most probably due to a modulation of the chemokine receptor CCR5 and the beta 2-integrin Mac-1. Both down-regulation of CCR5 and reduced expression of Mac-1 may diminish the potential of peripheral blood monocytes to leave blood vessels and invade target tissues. Since both dysfunctions can be restored with NSAIDs, our findings help to explain the molecular chemopreventive action of NSAIDs on tumor formation and progession.- Zeidler, R., Csanady, M., Gires, O., Lang, S., Schmitt, B., Wollenberg, B. Tumor cell-derived prostaglandin E2 inhibits monocyte function by interfering with CCR5 and Mac-1.	Univ Munich, Dept Otolaryngol, D-81377 Munich, Germany	University of Munich	Zeidler, R (corresponding author), Univ Munich, Dept Otolaryngol, Marchioninistr 15, D-81377 Munich, Germany.	rzeidler@hno.med.uni-muenchen.de	Zeidler, Reinhard/M-9837-2014; Wollenberg, Barbara/E-7435-2010; Wollenberg, Barbara/AAK-7272-2020; Gires, Olivier/V-2689-2017	Zeidler, Reinhard/0000-0002-3357-4954; Gires, Olivier/0000-0002-2292-7064				ALLEVA DG, 1994, J IMMUNOL, V153, P1674; ARNAOUT MA, 1990, BLOOD, V75, P1037; Carlos Timothy M., 1994, Blood, V84, P2068; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CROSS DS, 1992, ARCH OTOLARYNGOL, V118, P526; Dilloo D, 1996, NAT MED, V2, P1090, DOI 10.1038/nm1096-1090; Dong ZG, 1997, J BIOL CHEM, V272, P9962; Fioretti F, 1998, J IMMUNOL, V161, P342; Gahmberg CG, 1997, EUR J BIOCHEM, V245, P215, DOI 10.1111/j.1432-1033.1997.00215.x; GOODWIN JS, 1983, J CLIN IMMUNOL, V3, P295, DOI 10.1007/BF00915791; Huang M, 1996, J IMMUNOL, V157, P5512; HUANG SY, 1994, CANCER IMMUNOL IMMUN, V39, P231, DOI 10.1007/BF01525986; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Kune GA, 2007, INT J EPIDEMIOL, V36, P951, DOI 10.1093/ije/dym193; Loetscher P, 1998, NATURE, V391, P344, DOI 10.1038/34814; LUSTER AD, 1993, J EXP MED, V178, P1057, DOI 10.1084/jem.178.3.1057; MCLEMORE TL, 1988, CANCER RES, V48, P3140; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; MORISAKI T, 1991, CLIN IMMUNOL IMMUNOP, V59, P474, DOI 10.1016/0090-1229(91)90042-9; Murata H, 1999, AM J GASTROENTEROL, V94, P451; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; NAKAGOMI H, 1995, INT J CANCER, V63, P366, DOI 10.1002/ijc.2910630311; Narko K, 1997, J BIOL CHEM, V272, P21455, DOI 10.1074/jbc.272.34.21455; Okajima E, 1998, CANCER RES, V58, P3028; ONEILL GP, 1993, FEBS LETT, V330, P156, DOI 10.1016/0014-5793(93)80263-T; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Piazza GA, 1997, CANCER RES, V57, P2452; PISA P, 1992, P NATL ACAD SCI USA, V89, P7708, DOI 10.1073/pnas.89.16.7708; PUNNONEN J, 1993, J IMMUNOL, V151, P1280; RAO CV, 1995, CANCER RES, V55, P1464; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; RIGAS B, 1993, J LAB CLIN MED, V122, P518; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; ROLLINS BJ, 1991, MOL CELL BIOL, V11, P3125, DOI 10.1128/MCB.11.6.3125; SCHREINEMACHERS DM, 1994, EPIDEMIOLOGY, V5, P138, DOI 10.1097/00001648-199403000-00003; Shiff SJ, 1999, J EXP MED, V190, P445, DOI 10.1084/jem.190.4.445; Sica A, 1997, J EXP MED, V185, P969, DOI 10.1084/jem.185.5.969; Smalley W E, 1997, Adv Pharmacol, V39, P1, DOI 10.1016/S1054-3589(08)60067-8; SNYDERMAN CH, 1994, OTOLARYNG HEAD NECK, V111, P189, DOI 10.1016/S0194-5998(94)70590-9; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; TAGA K, 1993, BLOOD, V81, P2964; TAUB DD, 1995, J IMMUNOL, V155, P3877; Thivierge M, 1998, BLOOD, V92, P40, DOI 10.1182/blood.V92.1.40.413k43_40_45; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; VADDI K, 1994, J IMMUNOL, V153, P4721; vanBergen CAM, 1996, ANN HEMATOL, V72, P245, DOI 10.1007/s002770050167; Williams CS, 1997, J CLIN INVEST, V100, P1325, DOI 10.1172/JCI119651; Xu LL, 1996, J LEUKOCYTE BIOL, V60, P365, DOI 10.1002/jlb.60.3.365; YAMAMURA M, 1993, J CLIN INVEST, V91, P1005, DOI 10.1172/JCI116256; Young MRI, 1996, INT J CANCER, V67, P333, DOI 10.1002/(SICI)1097-0215(19960729)67:3<333::AID-IJC5>3.3.CO;2-R; Zeidler R, 1997, BLOOD, V90, P2390; ZEMBALA M, 1994, INT J CANCER, V56, P269, DOI 10.1002/ijc.2910560221; Zhang L, 1997, J IMMUNOL, V158, P4855	54	45	52	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2000	14	5					661	668		10.1096/fasebj.14.5.661	http://dx.doi.org/10.1096/fasebj.14.5.661			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301DH	10744623				2022-12-28	WOS:000086292700004
J	Matsuzaki, H; Tamatani, M; Yamaguchi, A; Namikawa, K; Kiyama, H; Vitek, MP; Mitsuda, N; Tohyama, M				Matsuzaki, H; Tamatani, M; Yamaguchi, A; Namikawa, K; Kiyama, H; Vitek, MP; Mitsuda, N; Tohyama, M			Vascular endothelial growth factor rescues hippocampal neurons from glutamate-induced toxicity: signal transduction cascades	FASEB JOURNAL			English	Article									Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, Suita, Osaka 5650871, Japan; Asahikawa Med Coll, Dept Anat, Asahikawa, Hokkaido 0788510, Japan; Duke Univ, Med Ctr, Div Neurol, Durham, NC 27710 USA; Japan Sci & Technol, CREST, Tokyo, Japan	Osaka University; Asahikawa Medical College; Duke University; Japan Science & Technology Agency (JST)	Tamatani, M (corresponding author), Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Kiyama, Hiroshi/M-8867-2014; MATSUZAKI, HIDEO/AAE-5246-2020	Kiyama, Hiroshi/0000-0001-5963-046X; MATSUZAKI, HIDEO/0000-0002-6869-1261; Vitek, Michael/0000-0001-8140-8048					0	232	252	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1218	1220		10.1096/fj.00-0495fje	http://dx.doi.org/10.1096/fj.00-0495fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344093				2022-12-28	WOS:000168655200015
J	Sakiyama-Elbert, SE; Panitch, A; Hubbell, JA				Sakiyama-Elbert, SE; Panitch, A; Hubbell, JA			Development of growth factor fusion proteins for cell-triggered drug delivery	FASEB JOURNAL			English	Article									ETH Zurich, Inst Biomed Engn, CH-8044 Zurich, Switzerland; ETH Zurich, Dept Mat, CH-8044 Zurich, Switzerland; Univ Zurich, Zurich, Switzerland; CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA; Arizona State Univ, Dept Bioengn, Tempe, AZ 85287 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; California Institute of Technology; Arizona State University; Arizona State University-Tempe	Hubbell, JA (corresponding author), ETH Zurich, Inst Biomed Engn, Moussonstr 18, CH-8044 Zurich, Switzerland.		Panitch, Alyssa/F-4413-2012; Hubbell, Jeffrey A/A-9266-2008; Sakiyama-Elbert, Shelly/A-6753-2008	Hubbell, Jeffrey A/0000-0003-0276-5456; Sakiyama-Elbert, Shelly/0000-0003-4832-5851					0	129	140	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1300	1302		10.1096/fj.00-0564fje	http://dx.doi.org/10.1096/fj.00-0564fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344120				2022-12-28	WOS:000168655200042
J	Zhang, JH; Underwood, LE; D'Ercole, AJ				Zhang, JH; Underwood, LE; D'Ercole, AJ			Hepatic mRNAs up-regulated by starvation: an expression profile determined by suppression subtractive hybridization	FASEB JOURNAL			English	Article									Univ N Carolina, Dept Pediat, Div Endocrinol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Zhang, JH (corresponding author), Univ N Carolina, Dept Pediat, Div Endocrinol, 509 Burnett Womack Bldg,CB 7220, Chapel Hill, NC 27599 USA.								0	14	14	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1261	1263		10.1096/fj.00-0717fje	http://dx.doi.org/10.1096/fj.00-0717fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344107				2022-12-28	WOS:000168655200029
J	Horino, K; Kindezelskii, AL; Elner, VM; Hughes, BA; Petty, HR				Horino, K; Kindezelskii, AL; Elner, VM; Hughes, BA; Petty, HR			Tumor cell invasion of model 3-dimensional matrices: demonstration of migratory pathways, collagen disruption, and intercellular cooperation	FASEB JOURNAL			English	Article						transmigration; metalloproteinase; HT1080 cells; T-47D cells; gelatin-nylon mesh matrix	PLASMINOGEN-ACTIVATOR; EXTRACELLULAR-MATRIX; BASEMENT-MEMBRANE; INVITRO ASSAY; METALLOPROTEINASES; METASTASIS; UROKINASE; PROTEOLYSIS; PROTEASE; RECEPTOR	We report a novel 3-dimensional model for visualizing tumor cell migration across a nylon mesh-supported gelatin matrix. To visualize migration across these model barriers, cell proteolytic activity of the pericellular matrix was detected using Bodipy-BSA (fluorescent upon proteolysis) and DQ (TM) collagen (fluorescent upon collagenase activity). For 3-dimensional image reconstruction, multiple optical images at sequential z axis positions were deconvoluted by computer analysis. Specificity was indicated using well known inhibitors. Using these fluorescent proteolysis markers and imaging methods, we have directly demonstrated proteolytic and collagenolytic activity during tumor cell invasion. Moreover, it is possible to visualize migratory pathways followed by tumor cells during matrix invasion. Using cells of differing invasive potentials (uPAR-negative T-47D wild-type and uPAR-positive T-47D A2-1 cells), we show that the presence of the T47D-A2-1 cells facilitates the entry of T-47D wild-type cells into the matrix. In some cases, wild-type cells follow T-47D A2-1 cells into the matrix whereas other T-47D-wild-type cells appear to enter without the direct intervention of T-47D AZ-l cells. Thus, we have developed a new 3-dimensional model of tumor cell invasion, demonstrated protein and collagen disruption, mapped the pathways followed by tumor cells during migration through an extracellular matrix, and illustrated cross-talk among tumor cell populations during invasion.	Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA; Univ Michigan, Dept Ophthalmol, Ann Arbor, MI USA	Wayne State University; University of Michigan System; University of Michigan	Petty, HR (corresponding author), Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA.	hpetty@biology.biosci.wayne.edu		Hughes, Bret/0000-0002-6913-4467; Elner, Victor/0000-0001-7708-1898	NEI NIH HHS [EY09441, EY007003] Funding Source: Medline; NIAID NIH HHS [AI27409] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009441] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027409] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBINI A, 1987, CANCER RES, V47, P3239; BARAMOVA E, 1995, CELL BIOL INT, V19, P239; Curran S, 1999, J PATHOL, V189, P300, DOI 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C; Dano K, 1999, APMIS, V107, P120, DOI 10.1111/j.1699-0463.1999.tb01534.x; DeClerck YA, 1996, ENZYME PROTEIN, V49, P72, DOI 10.1159/000468617; Ellerbroek SM, 1999, BIOESSAYS, V21, P940, DOI 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.3.CO;2-A; ERKELL LJ, 1988, CANCER RES, V48, P6933; Garbett EA, 1999, BRIT J CANCER, V81, P287, DOI 10.1038/sj.bjc.6690689; GOLDBERG GI, 1990, ANN NY ACAD SCI, V580, P375, DOI 10.1111/j.1749-6632.1990.tb17945.x; HADDOX JL, 1991, J IMMUNOL METHODS, V141, P41, DOI 10.1016/0022-1759(91)90208-W; Kennedy S, 1998, BRIT J CANCER, V77, P1638, DOI 10.1038/bjc.1998.268; Kindzelskii AL, 2000, J IMMUNOL, V164, P953, DOI 10.4049/jimmunol.164.2.953; Kindzelskii AL, 1998, BIOPHYS J, V74, P90, DOI 10.1016/S0006-3495(98)77770-7; Kuriyama S, 1998, ANTICANCER RES, V18, P4181; LIOTTA LA, 1980, CANCER LETT, V11, P141, DOI 10.1016/0304-3835(80)90105-6; MACKAY AR, 1990, CANCER RES, V50, P5997; McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MONSKY WL, 1994, CANCER RES, V54, P5702; MONTGOMERY AMP, 1993, CANCER RES, V53, P693; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; OSSOWSKI L, 1980, CANCER RES, V40, P2300; PARK JK, 1992, J CARDIOVASC ELECTR, V3, P306, DOI 10.1111/j.1540-8167.1992.tb00976.x; POSTE G, 1980, CANCER RES, V40, P1636; REICH R, 1988, CANCER RES, V48, P3307; ROMER J, 1994, INT J CANCER, V57, P553, DOI 10.1002/ijc.2910570419; STARKEY JR, 1984, CANCER RES, V44, P1585; SZATROWSKI TP, 1991, CANCER RES, V51, P794; TOWLE MJ, 1993, CANCER RES, V53, P2553; Xue W, 1997, CANCER RES, V57, P1682	30	22	23	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2001	15	6					932	939		10.1096/fj.00-0392com	http://dx.doi.org/10.1096/fj.00-0392com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292653	Green Submitted			2022-12-28	WOS:000167959300007
J	Hagedorn, M; Zilberberg, L; Lozano, RM; Cuevas, P; Canron, X; Redondo-Horcajo, M; Gimenez-Gallego, G; Bikfalvi, A				Hagedorn, M; Zilberberg, L; Lozano, RM; Cuevas, P; Canron, X; Redondo-Horcajo, M; Gimenez-Gallego, G; Bikfalvi, A			A short peptide domain of platelet factor 4 blocks angiogenic key events induced by FGF-2	FASEB JOURNAL			English	Article									Univ Bordeaux 1, Growth Factor & Cell Differentiat Lab, F-33405 Talence, France; CSIC, Lab Estructura & Func Prot, E-28006 Madrid, Spain; Hosp Ramon y Cajal, Dept Hist, E-28034 Madrid, Spain	UDICE-French Research Universities; Universite de Bordeaux; Consejo Superior de Investigaciones Cientificas (CSIC); Hospital Universitario Ramon y Cajal	Bikfalvi, A (corresponding author), Univ Bordeaux 1, Growth Factor & Cell Differentiat Lab, F-33405 Talence, France.		Hagedorn, Martin/B-4272-2008	Lozano, Rosa Maria/0000-0003-2762-6938; Hagedorn, Martin/0000-0002-0960-5116					0	61	71	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					550	552						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259363				2022-12-28	WOS:000167419500001
J	Zhang, JC; Claffey, K; Sakthivel, R; Darzynkiewicz, Z; Shaw, DE; Leal, J; Wang, YC; Lu, FM; McCrae, KR				Zhang, JC; Claffey, K; Sakthivel, R; Darzynkiewicz, Z; Shaw, DE; Leal, J; Wang, YC; Lu, FM; McCrae, KR			Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5	FASEB JOURNAL			English	Article						angiogenesis; coagulation; neovascularization; tumor; endothelium	TUMOR ANGIOGENESIS; BINDING-PROTEIN; HUMAN ANGIOSTATIN; CONTACT SYSTEM; IN-VITRO; RECEPTOR; MECHANISM; PLASMA; GROWTH; METASTASIS	We previously reported that the binding of two-chain high molecular weight kininogen (HKa) to endothelial cells may occur through interactions with endothelial urokinase receptors. Since the binding of urokinase to urokinase receptors activates signaling responses and may stimulate mitogenesis, we assessed the effect of HKa binding on endothelial cell proliferation. Unexpectedly, HKa inhibited proliferation in response to several growth factors, with 50% inhibition caused by similar to 10 nM HKa. This activity was Zn2+ dependent and not shared by either single-chain high molecular weight kininogen (HK) or low molecular weight kininogen. HKa selectively inhibited the proliferation of human umbilical vein and dermal microvascular endothelial cells, but did not affect that of umbilical vein or human aortic smooth muscle cells, trophoblasts, fibroblasts, or carcinoma cells. Inhibition of endothelial proliferation by HKa was associated with endothelial cell apoptosis and unaffected by antibodies that block the binding of HK or HKa to any of their known endothelial receptors. Recombinant HK domain 5 displayed activity similar to that of HKa. In vivo, HKa inhibited neovascularization of subcutaneously implanted Matrigel plugs, as well as rat corneal angiogenesis. These results demonstrate that HKa is a novel inhibitor of angiogenesis, whose activity is dependent on the unique conformation of the two-chain molecule.	Case Western Reserve Univ, Sch Med, Div Hematol Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Med, Cleveland, OH 44106 USA; Univ Connecticut, Sch Med, Ctr Vasc Biol, Dept Physiol, Farmington, CT USA; New York Med Coll, Valhalla, NY 10595 USA; DE Shaw & Co Inc, New York, NY USA; Attenuon LLC, San Diego, CA USA; Abbott Labs, Div Pharmaceut Prod, Dept Chemotherapeut, Abbott Pk, IL 60064 USA; Allegheny Univ Hlth Sci, Ctr Neurovirol & Neurooncol, Philadelphia, PA 19102 USA	Case Western Reserve University; Case Western Reserve University; University of Connecticut; New York Medical College; Abbott Laboratories; Drexel University	McCrae, KR (corresponding author), Case Western Reserve Univ, Sch Med, Div Hematol Oncol, BRB 3,10900 Euclid Ave, Cleveland, OH 44106 USA.	kxm71@po.cwru.edu		Darzynkiewicz, Zbigniew/0000-0002-2040-7081	NATIONAL CANCER INSTITUTE [R01CA083134, R01CA028704] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050827] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA028704, CA83134, R01 CA028704-23] Funding Source: Medline; NHLBI NIH HHS [HL50827] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARENDS MJ, 1990, AM J PATHOL, V136, P593; Asakura S, 1998, J BIOCHEM-TOKYO, V124, P473, DOI 10.1093/oxfordjournals.jbchem.a022138; ASAKURA S, 1992, J CELL BIOL, V116, P465, DOI 10.1083/jcb.116.2.465; BERRETTINI M, 1986, BLOOD, V68, P455; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Browder T, 2000, J BIOL CHEM, V275, P1521, DOI 10.1074/jbc.275.3.1521; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; CLAPP C, 1993, ENDOCRINOLOGY, V133, P1292, DOI 10.1210/en.133.3.1292; Colman RW, 1997, J CLIN INVEST, V100, P1481, DOI 10.1172/JCI119669; Colman RW, 1997, BLOOD, V90, P3819, DOI 10.1182/blood.V90.10.3819; Colman RW, 2000, BLOOD, V95, P543, DOI 10.1182/blood.V95.2.543; CONRAD TJ, 1994, LAB INVEST, V70, P426; Ding YH, 1998, P NATL ACAD SCI USA, V95, P10443, DOI 10.1073/pnas.95.18.10443; DISS EM, 1992, AM J OBSTET GYNECOL, V167, P1046, DOI 10.1016/S0002-9378(12)80036-6; EWALD GA, 1995, CIRCULATION, V91, P28, DOI 10.1161/01.CIR.91.1.28; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOURNIER GA, 1981, INVEST OPHTH VIS SCI, V21, P351; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HASAN AAK, 1995, J BIOL CHEM, V270, P19256, DOI 10.1074/jbc.270.33.19256; Hasan AAK, 1998, P NATL ACAD SCI USA, V95, P3615, DOI 10.1073/pnas.95.7.3615; Herwald H, 1996, J BIOL CHEM, V271, P13040, DOI 10.1074/jbc.271.22.13040; HOFFMEISTER HM, 1995, CIRCULATION, V91, P2520, DOI 10.1161/01.CIR.91.10.2520; HOMANDBERG GA, 1985, AM J PATHOL, V120, P327; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; Joseph K, 1996, P NATL ACAD SCI USA, V93, P8552, DOI 10.1073/pnas.93.16.8552; Kamphaus GD, 2000, J BIOL CHEM, V275, P1209, DOI 10.1074/jbc.275.2.1209; KAPLAN AP, 1987, BLOOD, V70, P1; Karlsrud TS, 1996, INTENS CARE MED, V22, P760; KIRCHHEIMER JC, 1987, FASEB J, V1, P125, DOI 10.1096/fasebj.1.2.3038646; KLENIEWSKI J, 1992, J LAB CLIN MED, V120, P129; Kozik A, 1998, J BIOL CHEM, V273, P33224, DOI 10.1074/jbc.273.50.33224; Lee TH, 1998, J BIOL CHEM, V273, P28805, DOI 10.1074/jbc.273.44.28805; MERRIFIELD RB, 1969, ADV ENZYMOL RAMB, V32, P221; MORI K, 1981, J BIOCHEM-TOKYO, V89, P1465, DOI 10.1093/oxfordjournals.jbchem.a133339; Motta G, 1998, BLOOD, V91, P516, DOI 10.1182/blood.V91.2.516.516_516_528; O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926; Obermair A, 1998, AM J OBSTET GYNECOL, V178, P314, DOI 10.1016/S0002-9378(98)80018-5; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Parangi S, 1996, P NATL ACAD SCI USA, V93, P2002, DOI 10.1073/pnas.93.5.2002; Pavord S, 1997, BRIT J HAEMATOL, V97, P762, DOI 10.1046/j.1365-2141.1997.1282947.x; Pike SE, 1998, J EXP MED, V188, P2349, DOI 10.1084/jem.188.12.2349; POLVERINI PJ, 1991, METHOD ENZYMOL, V198, P440; Ramchandran R, 1999, BIOCHEM BIOPH RES CO, V255, P735, DOI 10.1006/bbrc.1999.0248; REDDIGARI SR, 1993, BLOOD, V81, P1306; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; Sage EH, 1997, TRENDS CELL BIOL, V7, P182; Sanders RJ, 1998, CANCER INVEST, V16, P329, DOI 10.3109/07357909809084653; Shariat-Madar Z, 1999, J BIOL CHEM, V274, P7137, DOI 10.1074/jbc.274.11.7137; SILVA MRE, 1949, AM J PHYSIOL, V156, P261, DOI 10.1152/ajplegacy.1949.156.2.261; Sim BKL, 1997, CANCER RES, V57, P1329; Soff GA, 1995, J CLIN INVEST, V96, P2593, DOI 10.1172/JCI118323; TAKAGAKI Y, 1985, J BIOL CHEM, V260, P8601; Tang H, 1998, J BIOL CHEM, V273, P18268, DOI 10.1074/jbc.273.29.18268; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; VANIWAARDEN F, 1988, J BIOL CHEM, V263, P4698; Varner JA, 1995, CELL ADHES COMMUN, V3, P367, DOI 10.3109/15419069509081020; VOGEL R, 1988, J BIOL CHEM, V263, P12661; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WEIDNER N, 1993, AM J PATHOL, V143, P401; WEISEL JW, 1994, J BIOL CHEM, V269, P10100; Wu ZG, 1997, BIOCHEM BIOPH RES CO, V236, P651, DOI 10.1006/bbrc.1997.7032; Zhang JC, 1996, BLOOD, V88, P3880, DOI 10.1182/blood.V88.10.3880.bloodjournal88103880; Zhang JC, 1998, J BIOL CHEM, V273, P32273, DOI 10.1074/jbc.273.48.32273	69	97	111	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2000	14	15					2589	2600		10.1096/fj.99-1025com	http://dx.doi.org/10.1096/fj.99-1025com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099478				2022-12-28	WOS:000165723400030
J	Belanger, H; Fleysh, N; Cox, S; Bartman, G; Deka, D; Trudel, M; Koprowski, H; Yusibov, V				Belanger, H; Fleysh, N; Cox, S; Bartman, G; Deka, D; Trudel, M; Koprowski, H; Yusibov, V			Human respiratory syncytial virus vaccine antigen produced in plants	FASEB JOURNAL			English	Article						G-protein; alfalfa mosaic virus; respiratory tract; RSV	MOSAIC-VIRUS; MONOCLONAL-ANTIBODIES; SYNTHETIC PEPTIDE; G-GLYCOPROTEIN; F-PROTEIN; SEROPOSITIVE CHILDREN; FUSION GLYCOPROTEIN; FOREIGN PEPTIDES; INFECTION; MICE	Human respiratory syncytial virus (RSV) is the primary cause of respiratory infection in infants worldwide. Currently there is no available vaccine, although studies in animal models have demonstrated protective immunity induced by an epitope of the RSV G-protein representing amino acids 174-187. Two peptides containing amino acids 174-187 of the G-protein of the human RSV A2 strain (NF1-RSV/172-187 and NF2-RSV/170-191) were separately engineered as translational fusions with the alfalfa mosaic virus coat protein and individually expressed in Nicotiana tabacum cv. Samsun NN plants through virus infection. RSV G-protein peptides were expressed in infected plant tissues at significant levels within 2 wk of inoculation and purified as part of recombinant alfalfa mosaic virions. BALB/c mice immunized intraperitoneally with three doses of the purified recombinant viruses showed high levels of serum antibody specific for RSV G-protein and were protected against infection with RSV Long strain.-Belanger, H., Fleysh, N., Cox, S., Bartman, G., Deka, D., Trudel, M., Koprowski, H., Yusibov, V. Human respiratory syncytial virus vaccine antigen produced in plants.	Thomas Jefferson Univ, Biotechnol Fdn Labs, Philadelphia, PA 19107 USA; Univ Quebec, Inst Armand Frappier, INRS, Ctr Rech Santehumaine, Laval, PQ, Canada	Jefferson University; University of Quebec; Institut national de la recherche scientifique (INRS)	Yusibov, V (corresponding author), Thomas Jefferson Univ, Biotechnol Fdn Labs, 1020 Locust St,Room 346 JAH, Philadelphia, PA 19107 USA.		Yusibov, Vidadi/AAA-7408-2019					AKERLINDSTOPNER B, 1995, J MED VIROL, V47, P120, DOI 10.1002/jmv.1890470203; AKERLINDSTOPNER B, 1990, J VIROL, V64, P5143, DOI 10.1128/JVI.64.10.5143-5148.1990; ANDERSON LJ, 1995, J INFECT DIS, V171, P1, DOI 10.1093/infdis/171.1.1; ARBIZA J, 1992, J GEN VIROL, V73, P2225, DOI 10.1099/0022-1317-73-9-2225; Bastien N, 1999, VACCINE, V17, P832, DOI 10.1016/S0264-410X(98)00267-9; BRANDT CD, 1973, AM J EPIDEMIOL, V98, P355, DOI 10.1093/oxfordjournals.aje.a121565; Buraphacheep W, 1997, J CLIN MICROBIOL, V35, P354, DOI 10.1128/JCM.35.2.354-357.1997; CHANOCK RM, 1965, PEDIATRICS, V36, P21; CONNORS M, 1991, J VIROL, V65, P1634, DOI 10.1128/JVI.65.3.1634-1637.1991; DEDIEU JF, 1992, J VIROL, V66, P3161, DOI 10.1128/JVI.66.5.3161-3167.1992; ELANGO N, 1986, P NATL ACAD SCI USA, V83, P1906, DOI 10.1073/pnas.83.6.1906; GREENWOOD J, 1991, J MOL BIOL, V220, P821, DOI 10.1016/0022-2836(91)90354-9; Groothuis JR, 1998, J INFECT DIS, V177, P467, DOI 10.1086/517377; HAMAMOTO H, 1993, BIO-TECHNOL, V11, P930, DOI 10.1038/nbt0893-930; Joelson T, 1997, J GEN VIROL, V78, P1213, DOI 10.1099/0022-1317-78-6-1213; KAPIKIAN AZ, 1969, AM J EPIDEMIOL, V89, P405, DOI 10.1093/oxfordjournals.aje.a120954; KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955; Modelska A, 1998, P NATL ACAD SCI USA, V95, P2481, DOI 10.1073/pnas.95.5.2481; MUFSON MA, 1991, J CLIN MICROBIOL, V29, P162, DOI 10.1128/JCM.29.1.162-165.1991; PORTA C, 1994, VIROLOGY, V202, P949, DOI 10.1006/viro.1994.1417; Sambrook S, 1989, MOL CLONING LAB MANU; SCOPES GE, 1990, J GEN VIROL, V71, P53, DOI 10.1099/0022-1317-71-1-53; Simard C, 1997, VACCINE, V15, P423, DOI 10.1016/S0264-410X(97)00189-8; STOTT EJ, 1986, J VIROL, V60, P607, DOI 10.1128/JVI.60.2.607-613.1986; Sullender WM, 1996, J GEN VIROL, V77, P641, DOI 10.1099/0022-1317-77-4-641; SULLENDER WM, 1990, VIROLOGY, V178, P195, DOI 10.1016/0042-6822(90)90394-7; TASCHNER PEM, 1991, VIROLOGY, V181, P445, DOI 10.1016/0042-6822(91)90876-D; TAYLOR G, 1992, J GEN VIROL, V73, P2217, DOI 10.1099/0022-1317-73-9-2217; TAYLOR G, 1984, IMMUNOLOGY, V52, P137; TRISTRAM DA, 1993, J INFECT DIS, V167, P191, DOI 10.1093/infdis/167.1.191; TRUDEL M, 1987, J GEN VIROL, V68, P2273, DOI 10.1099/0022-1317-68-9-2273; TRUDEL M, 1991, ARCH VIROL, V117, P59, DOI 10.1007/BF01310492; TRUDEL M, 1991, VIROLOGY, V185, P749, DOI 10.1016/0042-6822(91)90546-N; USHA R, 1993, VIROLOGY, V197, P366, DOI 10.1006/viro.1993.1598; Verch T, 1998, J IMMUNOL METHODS, V220, P69, DOI 10.1016/S0022-1759(98)00149-5; WERTZ GW, 1987, J VIROL, V61, P293, DOI 10.1128/JVI.61.2.293-301.1987; Yusibov V, 1997, P NATL ACAD SCI USA, V94, P5784, DOI 10.1073/pnas.94.11.5784; YUSIBOV VM, 1995, VIROLOGY, V208, P405, DOI 10.1006/viro.1995.1168	38	37	50	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2323	2328		10.1096/fj.00-0144com	http://dx.doi.org/10.1096/fj.00-0144com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053254				2022-12-28	WOS:000165190800026
J	Matesic, LE; Niemitz, EL; De Maio, A; Reeves, RH				Matesic, LE; Niemitz, EL; De Maio, A; Reeves, RH			Quantitative trait loci modulate neutrophil infiltration in the liver during LPS-induced inflammation	FASEB JOURNAL			English	Article						mapping; quantitative trait loci; inbred strains (A/J and C57BL/6J); sepsis; multiple organ dysfunction syndrome	NECROSIS-FACTOR-ALPHA; INTERCELLULAR-ADHESION MOLECULE-1; DROSOPHILA TOLL; ORGAN FAILURE; SEVERE SEPSIS; MICE; ENDOTOXIN; LIPOPOLYSACCHARIDE; POLYMORPHISM; IMMUNE	A crucial aspect of the inflammatory response is the recruitment of activated neutrophils (PMN) to the site of damage. Lytic enzymes and oxygen radicals released by PMN are important in clearing an infection or cellular debris, but can also produce host tissue damage. Failure to properly regulate the inflammatory response contributes to a variety of human diseases like sepsis and multiple organ dysfunction syndrome, the leading cause of morbidity and mortality in surgical intensive care units. Many aspects of human disease pathology, including hepatic PMN infiltration, can be recapitulated in mice using an endotoxic shock model. Six quantitative trait loci that predispose to high infiltration of PMN in hepatic sinusoids after high-dose endotoxin administration were provisionally identified. Two of these loci, Hpi1 and Hpi2 on mouse chromosomes 5 and 13, were mapped to the significant and highly significant level using a lo cv-resolution genome scan on 122 intercross animals. These loci interact epistatically to produce a high degree of PMN infiltration. Intercross and recombinant inbred strain mice with a specific genotype at these loci always had a high infiltration response, indicating that genotype analysis at just these two loci can accurately predict a high PMN infiltration response. Genetic predisposition to the degree of PMN infiltration in the inflammatory response in mice suggests that analogous genetic mechanisms occur in human beings that could be used for diagnostic purposes.-Matesic, L. E., Niemitz, E. L., De Maio, A., Reeves, R. H. Quantitative trait loci modulate neutrophil infiltration in the liver during LPS-induced inflammation.	Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Div Pediat Surg, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Reeves, RH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Physiol, 725 N Wolfe St,Biophys 203, Baltimore, MD 21205 USA.				NIGMS NIH HHS [GM57317] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUCKLIN SE, 1993, INFECT IMMUN, V61, P3184, DOI 10.1128/IAI.61.8.3184-3189.1993; CERRA FB, 1987, SURGERY, V101, P1; CHURCHILL GA, 1994, GENETICS, V138, P963; Cox A, 1996, J PEDIATR ENDOCR MET, V9, P129; De Maio A, 1998, SHOCK, V10, P319; DEITCH EA, 1992, ANN SURG, V216, P117, DOI 10.1097/00000658-199208000-00002; Eakes AT, 1997, AM J PHYSIOL-GASTR L, V272, pG605, DOI 10.1152/ajpgi.1997.272.3.G605; ESSANI NA, 1995, HEPATOLOGY, V21, P1632, DOI 10.1002/hep.1840210623; Fang XM, 1999, CRIT CARE MED, V27, P1330, DOI 10.1097/00003246-199907000-00024; FATTORI E, 1994, J EXP MED, V180, P1243, DOI 10.1084/jem.180.4.1243; HEWETT JA, 1992, LAB INVEST, V66, P347; Hierholzer C, 1998, AM J PHYSIOL-LUNG C, V275, pL611, DOI 10.1152/ajplung.1998.275.3.L611; HOEKZEMA R, 1992, INVEST OPHTH VIS SCI, V33, P532; JACOB CO, 1991, CYTOKINE, V3, P551, DOI 10.1016/1043-4666(91)90481-R; Jaeschke H, 1996, SHOCK, V6, P351, DOI 10.1097/00024382-199611000-00009; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Livingston D H, 1995, New Horiz, V3, P257; MAEMURA K, 1994, BIOCHEM BIOPH RES CO, V201, P538, DOI 10.1006/bbrc.1994.1735; Manly KF, 1999, MAMM GENOME, V10, P327, DOI 10.1007/s003359900997; Matesic LE, 1999, GENOMICS, V62, P34, DOI 10.1006/geno.1999.5986; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Mochida S, 1996, HEPATOLOGY, V23, P320; Nussler AK, 1999, LANGENBECK ARCH SURG, V384, P222, DOI 10.1007/s004230050196; O'Malley J, 1998, J HERED, V89, P525, DOI 10.1093/jhered/89.6.525; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; ROSENBLOOM AJ, 1995, JAMA-J AM MED ASSOC, V274, P58, DOI 10.1001/jama.274.1.58; Sampson SB, 1998, MAMM GENOME, V9, P688, DOI 10.1007/s003359900849; SHANLEY TP, 1995, MOL MED TODAY, V1, P40, DOI 10.1016/1357-4310(95)80019-0; SORENSEN TIA, 1988, NEW ENGL J MED, V318, P727, DOI 10.1056/NEJM198803243181202; Stuber F, 1996, CRIT CARE MED, V24, P381, DOI 10.1097/00003246-199603000-00004; THOMAS KR, 1992, MOL CELL BIOL, V12, P2919, DOI 10.1128/MCB.12.7.2919; VINCEK V, 1993, CANCER RES, V53, P728; WENZEL RP, 1992, NEW ENGL J MED, V326, P1151, DOI 10.1056/NEJM199204233261710; Zivot J B, 1995, New Horiz, V3, P267	37	26	27	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2247	2254		10.1096/fj.99-1051com	http://dx.doi.org/10.1096/fj.99-1051com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053246				2022-12-28	WOS:000165190800018
J	Yamauchi, H; Desgranges, P; Lecerf, L; Papy-Garcia, D; Tournaire, MC; Moczar, M; Loisance, D; Barritault, D				Yamauchi, H; Desgranges, P; Lecerf, L; Papy-Garcia, D; Tournaire, MC; Moczar, M; Loisance, D; Barritault, D			New agents for the treatment of infarcted myocardium	FASEB JOURNAL			English	Article									Univ Paris 12, UPRES CNRS 7053, CRRET Lab, F-94000 Creteil, France; Hop Henri Mondor, UPRES CNRS 7054, Assoc Claude Bernard, Ctr Rech Chirurg, F-94010 Creteil, France	Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	Barritault, D (corresponding author), Univ Paris 12, UPRES CNRS 7053, CRRET Lab, Ave Gal Gaulle, F-94000 Creteil, France.			LECERF, LAURE/0000-0001-8342-5298					0	33	36	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2133	2134						2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11024002				2022-12-28	WOS:000165190800002
J	Sato, Y; Yamauchi, N; Takahashi, M; Sasaki, K; Fukaura, J; Neda, H; Fujii, S; Hirayama, M; Itoh, Y; Koshita, Y; Kogawa, K; Kato, J; Sakamaki, S; Niitsu, Y				Sato, Y; Yamauchi, N; Takahashi, M; Sasaki, K; Fukaura, J; Neda, H; Fujii, S; Hirayama, M; Itoh, Y; Koshita, Y; Kogawa, K; Kato, J; Sakamaki, S; Niitsu, Y			In vivo gene delivery to tumor cells by transferrin-streptavidin-DNA conjugate	FASEB JOURNAL			English	Article						plasmid DNA; gene therapy; transferrin receptor; tumor targeting; metastasis	RECEPTOR-MEDIATED ENDOCYTOSIS; PLASMID DNA; EXPRESSION; ADENOVIRUS; TRANSFECTION; CYTOTOXICITY; ENHANCEMENT; EFFICIENT; DIFFERENTIATION; PURIFICATION	To target disseminated tumors in vivo, transgenes [beta-galactosidase gene, green fluorescence protein (GFP) gene, herpes simplex virus thymidine kinase (HSV-TK)] were conjugated to transferrin (Tf) by a biotin-streptavidin bridging, which is stoichiometrically controllable, and Tf receptor (Tf-R) affinity chromatography, which selects Tf conjugates with intact receptor bindings sites from reacting with the linker. Tf-beta-galactosidase plasmid conjugate thus constructed was specifically transfected to human erythroleukemia cells (K562) via Tf-R without the aid of any lysosomotropic agents. The transfection efficiency of the conjugate was superior to those of lipofection (1% staining) and retroviral vector (5%) and slightly lower than that of adenovirus (70%). The high level of expression with our conjugate was confirmed using other tumor cells (M7609, TMK-1) whereas in normal diploid cells (HEL), which express low levels of Tf-R, expression was negligible. When GFP gene conjugates were systemically administered through the tail vein to nude mice subcutaneously inoculated with tumor, expression of GFP mRNA was found almost exclusively in tumors and to a much lesser extent in muscles, whereas GFP revealed by fluorescence microscopy was detected only in the former. To exploit a therapeutic applicability of this method, suicide gene therapy using Tf-HSV-TK gene conjugate for massively metastasized k562 tumors in severe combined immune-deficient mice was conducted, and a marked prolongation of survival and significant reduction of tumor burden were confirmed. Thus, this method could also be used for gene therapy to disseminated tumors.	Sapporo Med Univ, Sch Med, Dept Internal Med 4, Chuo Ku, Sapporo, Hokkaido 0608543, Japan	Sapporo Medical University	Niitsu, Y (corresponding author), Sapporo Med Univ, Sch Med, Dept Internal Med 4, Chuo Ku, South 1,West 16, Sapporo, Hokkaido 0608543, Japan.	niitsu@sapmed.ac.jp		KOSHITA, YOSHIKAZU/0000-0002-4597-9334; Sato, Yasushi/0000-0002-6776-4609				Ban N, 1996, CANCER RES, V56, P3577; BARABAS K, 1992, J BIOL CHEM, V267, P9437; BERGAMASCHI G, 1988, BRIT J HAEMATOL, V68, P379, DOI 10.1111/j.1365-2141.1988.tb04218.x; Cheng PW, 1996, HUM GENE THER, V7, P275, DOI 10.1089/hum.1996.7.3-275; COTTEN M, 1992, P NATL ACAD SCI USA, V89, P6094, DOI 10.1073/pnas.89.13.6094; COTTEN M, 1993, METHOD ENZYMOL, V217, P618; Cristiano RJ, 1996, CANCER GENE THER, V3, P49; CURIEL DT, 1991, P NATL ACAD SCI USA, V88, P8850, DOI 10.1073/pnas.88.19.8850; FAULK WP, 1980, LANCET, V2, P390; FOSTER AC, 1985, NUCLEIC ACIDS RES, V13, P745; GATTER KC, 1983, J CLIN PATHOL, V36, P539, DOI 10.1136/jcp.36.5.539; GREEN NM, 1980, BIOCHEM J, V94, P1; Hirayama Y, 1998, BLOOD, V92, P46, DOI 10.1182/blood.V92.1.46.413k44_46_52; JEFFERIES WA, 1984, NATURE, V312, P162, DOI 10.1038/312162a0; KARLSSON GB, 1991, ANAL BIOCHEM, V199, P219, DOI 10.1016/0003-2697(91)90093-9; KLAUSNER RD, 1983, J BIOL CHEM, V258, P4715; KOHGO Y, 1987, BLOOD, V70, P1955; KOHGO Y, 1990, JPN J CANCER RES, V81, P91, DOI 10.1111/j.1349-7006.1990.tb02512.x; Kuan CT, 1996, BIOCHEMISTRY-US, V35, P2872, DOI 10.1021/bi952047g; Kuriyama S, 1995, HEPATOLOGY, V22, P1838, DOI 10.1002/hep.1840220633; LARRICK JW, 1979, J SUPRAMOL STR CELL, V11, P579, DOI 10.1002/jss.400110415; Laske DW, 1997, NAT MED, V3, P1362, DOI 10.1038/nm1297-1362; Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947; MULFORD CA, 1988, J BIOL CHEM, V263, P5455; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; OKEEFE DO, 1985, J BIOL CHEM, V260, P932; PANACCIO M, 1987, IMMUNOL CELL BIOL, V65, P461, DOI 10.1038/icb.1987.55; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RASO V, 1984, J BIOL CHEM, V259, P1143; SAKAMAKI S, 1999, BLOOD, V94, P1; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SASAKI K, 1993, JPN J CANCER RES, V84, P191, DOI 10.1111/j.1349-7006.1993.tb02854.x; Sato Y, 1996, HUM GENE THER, V7, P1895, DOI 10.1089/hum.1996.7.15-1895; Schmidt W, 1997, GENE, V190, P211, DOI 10.1016/S0378-1119(96)00537-9; SCHOEMAN R, 1995, J DRUG TARGET, V2, P509, DOI 10.3109/10611869509015921; SHINTANI N, 1994, BLOOD, V83, P1209, DOI 10.1182/blood.V83.5.1209.bloodjournal8351209; SHPITZ B, 1994, ANTICANCER RES, V14, P1927; Suzuki M, 1999, NAT BIOTECHNOL, V17, P265, DOI 10.1038/7010; Takahashi M, 1996, J BIOL CHEM, V271, P26536, DOI 10.1074/jbc.271.43.26536; THEUER CP, 1993, CANCER RES, V53, P340; TURKEWITZ AP, 1988, J BIOL CHEM, V263, P8318; VANAGTHOVEN A, 1984, EUR J BIOCHEM, V140, P433; VANDRIEL IR, 1984, J IMMUNOL, V133, P3220; VANRENSWOUDE J, 1982, P NATL ACAD SCI-BIOL, V79, P6186; VITETTA ES, 1987, SCIENCE, V238, P1098, DOI 10.1126/science.3317828; WAGNER E, 1991, P NATL ACAD SCI USA, V88, P4255, DOI 10.1073/pnas.88.10.4255; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P6099, DOI 10.1073/pnas.89.13.6099; WAGNER E, 1990, P NATL ACAD SCI USA, V87, P3410, DOI 10.1073/pnas.87.9.3410; Wolff Jon A., 1992, Human Molecular Genetics, V1, P363, DOI 10.1093/hmg/1.6.363; Xu LN, 1997, HUM GENE THER, V8, P467, DOI 10.1089/hum.1997.8.4-467; Zauner W, 1997, EXP CELL RES, V232, P137, DOI 10.1006/excr.1997.3486; Zauner W, 1996, BIOTECHNIQUES, V20, P905; ZENKE M, 1990, P NATL ACAD SCI USA, V87, P3655, DOI 10.1073/pnas.87.10.3655; Zhang GF, 1999, HUM GENE THER, V10, P1735, DOI 10.1089/10430349950017734	55	45	48	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2000	14	13					2108	2118		10.1096/fj.99-1052com	http://dx.doi.org/10.1096/fj.99-1052com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023995				2022-12-28	WOS:000089634400030
J	Silva, JA; Araujo, RC; Baltatu, O; Oliveira, SM; Tschope, C; Fink, E; Hoffmann, S; Plehm, R; Chai, KX; Chao, L; Chao, J; Ganten, D; Pesquero, JB; Bader, M				Silva, JA; Araujo, RC; Baltatu, O; Oliveira, SM; Tschope, C; Fink, E; Hoffmann, S; Plehm, R; Chai, KX; Chao, L; Chao, J; Ganten, D; Pesquero, JB; Bader, M			Reduced cardiac hypertrophy and altered blood pressure control in transgenic rats with the human tissue kallikrein gene	FASEB JOURNAL			English	Article									Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Escola Paulista Med, Dept Biophys, Sao Paulo, Brazil; Free Univ Berlin, Univ Hosp Benjamin Franklin, Dept Cardiol, D-1000 Berlin, Germany; Free Univ Berlin, Univ Hosp Benjamin Franklin, Dept Clin Pharmacol, D-1000 Berlin, Germany; Univ Munich, Dept Clin Chem & Clin Biochem, D-80539 Munich, Germany; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Universidade Federal de Sao Paulo (UNIFESP); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Munich; Medical University of South Carolina	Bader, M (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.		Baltatu, Ovidiu Constantin/E-5890-2011; Bader, Michael/K-2124-2013; Araujo, Ronaldo C/H-1618-2012; Pesquero, Joao/C-1470-2012; Silva, Jose A/B-9399-2012; Araujo, Ronaldo Carvalho/O-7569-2019; Silva, Jose Antonio/AAA-8100-2019	Baltatu, Ovidiu Constantin/0000-0001-9732-6039; Pesquero, Joao/0000-0002-4507-632X; Araujo, Ronaldo Carvalho/0000-0003-0095-4608; Silva, Jose Antonio/0000-0001-6904-9185; Tschope, Carsten/0000-0001-5243-8985; Bader, Michael/0000-0003-4780-4164					0	93	98	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2000	14	13					1858	1860						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023967				2022-12-28	WOS:000089634400001
J	Thannickal, VJ; Day, RM; Klinz, SG; Bastien, MC; Larios, JM; Fanburg, BL				Thannickal, VJ; Day, RM; Klinz, SG; Bastien, MC; Larios, JM; Fanburg, BL			Ras-dependent and -independent regulation of oxygen species by mitogenic growth factors and TGF-beta 1	FASEB JOURNAL			English	Article						superoxide anion; hydrogen peroxide; cell growth; fibroblasts	TRANSFORMING GROWTH-FACTOR-BETA-1; HYDROGEN-PEROXIDE; NADPH OXIDASE; LYSYL OXIDASE; FACTOR-BETA; TYROSINE PHOSPHORYLATION; HORSERADISH-PEROXIDASE; SUPEROXIDE PRODUCTION; SIGNAL-TRANSDUCTION; CELL-PROLIFERATION	Mitogenic growth factors and transforming growth factor beta 1 (TGF-beta 1) induce the generation of reactive oxygen species (ROS) in non phagocytic cells, but their enzymatic source(s) and regulatory mechanisms are largely unknown. We previously reported on the ability of TGF-beta 1 to activate a cell surface-associated NADH:flavin:O-2 oxidoreductase (NADH oxidase) that generates extracellular H2O2. In this study, we compared the ROS-generating enzymatic systems activated by mitogenic growth factors and TGF-beta 1 with respect to the primary reactive species produced (O-2(.-) vs. H2O2), the site of generation (intracellular vs. extracellular) and regulation by Ras. We find that the mitogenic growth factors PDGF-BB, FGF-2, and TGF-alpha tan EGF receptor ligand) are able to rapidly (within 5 min) induce the generation of intracellular O-2(.-) without detectable NADH oxidase activity or extracellular H2O2 release. In contrast, TGF-beta 1 does not stimulate intracellular O-2(.-) production and the delayed induction of extracellular H2O2 release is not associated with O-2(.-) production. Expression of dominant-negative Ras (N17Ras) protein by herpes simplex virus-mediated gene transfer blocks mitogen-stimulated intracellular O-2(.-) generation but has no effect on TGF-beta 1-induced NADH oxidase activation/H2O2 production. These results demonstrate that there are at least two distinctly different ROS-generating enzymatic systems in lung fibroblasts regulated by mitogenic growth factors and TGF-beta 1 via Ras-dependent and -independent mechanisms, respectively. In addition, these findings suggest that endogenous production of ROS by growth factors/ cytokines may have different biological effects depending on the primary reactive species generated and site of production.	New England Med Ctr, Div Pulm & Crit Care, Dept Med, Tupper Res Inst, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA	Tufts Medical Center; Tufts University	Thannickal, VJ (corresponding author), New England Med Ctr, Div Pulm & Crit Care, Dept Med, Tupper Res Inst, 750 Washington St,NEMC 257, Boston, MA 02111 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003552, R01HL042376] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08 HL-03552, HL-42376] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Barrett WC, 1999, J BIOL CHEM, V274, P34543, DOI 10.1074/jbc.274.49.34543; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Feres EJ, 1995, J BIOL CHEM, V270, P30797, DOI 10.1074/jbc.270.51.30797; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; GYLLENHAMMAR H, 1987, J IMMUNOL METHODS, V97, P209, DOI 10.1016/0022-1759(87)90461-3; Halliwell B, 1989, FREE RADICAL BIO MED, P22; Hartsough MT, 1996, J BIOL CHEM, V271, P22368, DOI 10.1074/jbc.271.37.22368; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Jones SA, 1996, AM J PHYSIOL-HEART C, V271, pH1626, DOI 10.1152/ajpheart.1996.271.4.H1626; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; KAGAN HM, 1991, AM J RESP CELL MOL, V5, P206, DOI 10.1165/ajrcmb/5.3.206; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Lim F, 1996, BIOTECHNIQUES, V20, P460; Liochev SI, 1997, ARCH BIOCHEM BIOPHYS, V337, P115, DOI 10.1006/abbi.1997.9766; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; MASSEY V, 1994, J BIOL CHEM, V269, P22459; MEIER B, 1993, BIOCHEM J, V289, P481, DOI 10.1042/bj2890481; Mills EM, 1998, J BIOL CHEM, V273, P22165, DOI 10.1074/jbc.273.35.22165; MULDER KM, 1992, J BIOL CHEM, V267, P5029; ODONNELL VB, 1993, BIOCHEM J, V290, P41, DOI 10.1042/bj2900041; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; PANUS PC, 1993, FREE RADICAL BIO MED, V14, P217, DOI 10.1016/0891-5849(93)90013-K; PINNELL SR, 1968, P NATL ACAD SCI USA, V61, P708, DOI 10.1073/pnas.61.2.708; Rota C, 1999, J BIOL CHEM, V274, P28161, DOI 10.1074/jbc.274.40.28161; RUCH W, 1983, J IMMUNOL METHODS, V63, P347, DOI 10.1016/S0022-1759(83)80008-8; SAUNDERS BC, 1964, PEROXIDASE PROPERTIE; Spasojevic I, 2000, ARCH BIOCHEM BIOPHYS, V373, P447, DOI 10.1006/abbi.1999.1579; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; THANNICKAL VJ, 1993, AM J PHYSIOL, V265, pL622, DOI 10.1152/ajplung.1993.265.6.L622; Thannickal VJ, 1998, J BIOL CHEM, V273, P23611, DOI 10.1074/jbc.273.36.23611; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; TSUNAWAKI S, 1988, NATURE, V334, P260, DOI 10.1038/334260a0; UshioFukai M, 1996, J BIOL CHEM, V271, P23317, DOI 10.1074/jbc.271.38.23317; Wang SX, 1996, SCIENCE, V273, P1078, DOI 10.1126/science.273.5278.1078	43	114	118	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2000	14	12					1741	1748		10.1096/fj.99-0878com	http://dx.doi.org/10.1096/fj.99-0878com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973923				2022-12-28	WOS:000089212400013
J	Morgan, H; Smith, M; Burke, Z; Carter, D				Morgan, H; Smith, M; Burke, Z; Carter, D			The transactivation-competent carboxyl-terminal domain of AF-9 is expressed within a sexually dimorphic transcript in rat pituitary	FASEB JOURNAL			English	Article						leukemia; estrogen; oncogene	POLYMERASE CHAIN-REACTION; HORMONE-RELEASING FACTOR; SACCHAROMYCES-CEREVISIAE; ACUTE-LEUKEMIA; NUCLEAR-PROTEIN; GROWTH; GENE; CHROMATIN; RECEPTOR; ENL	We have investigated the biological role of the cellular counterpart of the leukemogenic AF-9 gene by cloning the rat AF-9 (rAF-9) cDNA and defining the regulation of an anterior pituitary-specific rAF-9 transcript that is expressed in a sexually dimorphic manner. Expression of this transcript is down-regulated after puberty in females and can be subsequently up-regulated in adults by ovariectomy. Hormone replacement studies have provided direct evidence that rAF-9 mRNA expression is suppressed by estrogen, Mapping the 1.9 kb anterior pituitary transcript has shown that it corresponds in size to the rAF-9 cDNA clone, which contains an open reading frame (ORF) that is truncated compared with the human AF-9 ORF, but encodes a previously defined transcriptional activation domain. Thus, the cellular AF-9 gene is alternatively expressed in a manner that reflects the presence of translocated, functionally active (oncogenic) AF-9 sequences in leukemias. Using a novel antisera raised against a rAF-9 peptide, we have also demonstrated tissue- and sex-specific expression of a nuclear 41 kDa anterior pituitary protein and have localized this protein to a major population of growth hormone synthesizing cells. By localizing the expression and defining the physiological regulation of rAF-9, our studies have provided novel insights into the AF-9 gene that will facilitate an understanding of both oncogenic and endocrine roles.-Morgan, H., Smith, M., Burke, Z., Carter, D. The transactivation-competent carboxyl-terminal domain of AF-9 is expressed within a sexually dimorphic transcript in rat pituitary.	Cardiff Univ, Sch Biosci, Cardiff CF1 3US, S Glam, Wales	Cardiff University	Carter, D (corresponding author), Cardiff Univ, Sch Biosci, Biomed Bldg,Museum Ave, Cardiff CF1 3US, S Glam, Wales.		Carter, David/A-4479-2010	Carter, David/0000-0002-8419-3975; Morgan, Helen E/0000-0003-2470-9746				Aizawa A, 1996, J BIOCHEM-TOKYO, V119, P296, DOI 10.1093/oxfordjournals.jbchem.a021238; Allen DL, 1997, ENDOCRINOLOGY, V138, P2128, DOI 10.1210/en.138.5.2128; Armstrong JA, 1998, CURR OPIN GENET DEV, V8, P165, DOI 10.1016/S0959-437X(98)80137-8; BERCHTOLD MW, 1989, NUCLEIC ACIDS RES, V17, P453, DOI 10.1093/nar/17.1.453; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cairns BR, 1996, MOL CELL BIOL, V16, P3308; CARTER DA, 1994, NEUROSCIENCE, V62, P1267, DOI 10.1016/0306-4522(94)90358-1; CARTER DA, 1989, J BIOL CHEM, V264, P6601; CHARLTON HM, 1988, J ENDOCRINOL, V119, P51, DOI 10.1677/joe.0.1190051; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; CLARK RG, 1987, J ENDOCRINOL, V114, P399, DOI 10.1677/joe.0.1140399; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DUKAS K, 1993, ANAL BIOCHEM, V215, P66, DOI 10.1006/abio.1993.1555; FISHMAN A, 1993, NEUROENDOCRINOLOGY, V57, P782, DOI 10.1159/000126437; IIDA S, 1993, ONCOGENE, V8, P3085; Jacobson S, 1999, CURR OPIN GENET DEV, V9, P175, DOI 10.1016/S0959-437X(99)80027-6; JOH T, 1996, ONCOGENE, V13, P1845; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; ONO M, 1995, BIOCHEM BIOPH RES CO, V216, P1060, DOI 10.1006/bbrc.1995.2728; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; RUBNITZ JE, 1994, BLOOD, V84, P1747; Sambrook J., 2002, MOL CLONING LAB MANU; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; WEHRENBERG WB, 1986, ENDOCRINOLOGY, V118, P489, DOI 10.1210/endo-118-2-489; WELCH MD, 1994, MOL BIOL CELL, V5, P617, DOI 10.1091/mbc.5.6.617; ZENG Q, 1994, J NEUROENDOCRINOL, V6, P469, DOI 10.1111/j.1365-2826.1994.tb00610.x; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	32	5	5	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2000	14	9					1109	1116		10.1096/fasebj.14.9.1109	http://dx.doi.org/10.1096/fasebj.14.9.1109			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834932				2022-12-28	WOS:000087427300007
J	Biggiogera, M; Pellicciari, C				Biggiogera, M; Pellicciari, C			Heterogeneous ectopic RNP-derived structures (HERDS) are markers of transcriptional arrest	FASEB JOURNAL			English	Article						ribonucleoproteins; transcriptional arrest; immunocytochemistry; heterogeneous ectopic RNP-derived structures	EARLY PREIMPLANTATION EMBRYOS; NUCLEAR RIBONUCLEOPROTEIN; IMMUNOELECTRON MICROSCOPY; CELL-NUCLEUS; ULTRASTRUCTURAL DISTRIBUTION; PERICHROMATIN FIBRILS; GENE-EXPRESSION; COILED BODIES; MITOSIS; MOUSE	We have reviewed the reports in the literature concerning the segregation and clustering of ribonucleoprotein (RNP) -containing nuclear structures in either physiological or experimentally induced conditions (i.e., spermiogenesis and erythropoiesis in mammals, early embryonic development, hibernation, spontaneous and drug-induced apoptosis, treatment with different drugs). Irrespective of the biological system or the experimental conditions, heterogeneous ectopic RNP-derived structures (HERDS) are always found. We hypothesize that the common event at the basis of this phenomenon might be the block in transcription; this is also consistent with our own and others' results on cultured cells after actinomycin D treatment. HERDS may therefore be considered as the morphological sign of transcriptional arrest. Based on the evidence that the restructuring/relocation of RNPs may be reversible, we also hypothesize that HERDS may serve as storage sites from which RNPs may be eventually retrieved, as soon as transcription restarts. Under acute stress conditions or during apoptotic cell death, the same reorganization of RNP-containing structures would be an adaptively suitable mechanism to induce an irreversible arrest in RNA processing, thus effectively blocking protein synthesis.	Univ Pavia, Dipartimento Biol Anim, Lab Biol Cellulare, I-27100 Pavia, Italy; Univ Pavia, Ctr Studio Istochim, CNR, I-27100 Pavia, Italy	University of Pavia; Consiglio Nazionale delle Ricerche (CNR); University of Pavia	Biggiogera, M (corresponding author), Univ Pavia, Dipartimento Biol Anim, Lab Biol Cellulare, Piazza Botta 10, I-27100 Pavia, Italy.		Biggiogera, Marco/AAH-3543-2019; Pellicciari, Carlo/Q-1481-2016	Pellicciari, Carlo/0000-0001-7684-0469				BIGGIOGERA M, 1990, DEVELOPMENT, V110, P1263; Biggiogera M, 1998, J HISTOCHEM CYTOCHEM, V46, P999, DOI 10.1177/002215549804600903; Biggiogera M, 1997, EXP CELL RES, V234, P512, DOI 10.1006/excr.1997.3657; BIGGIOGERA M, 1993, MOL REPROD DEV, V35, P261, DOI 10.1002/mrd.1080350308; Biggiogera M, 1997, HISTOCHEM CELL BIOL, V107, P331, DOI 10.1007/s004180050118; BIGGIOGERA M, 1994, EXP CELL RES, V213, P55, DOI 10.1006/excr.1994.1172; Biggiogera M, 1999, HISTOCHEM CELL BIOL, V112, P473, DOI 10.1007/s004180050431; Billings P B, 1978, Methods Cell Biol, V17, P349, DOI 10.1016/S0091-679X(08)61154-1; BRITO M, 1992, COMP BIOCHEM PHYS B, V103, P197, DOI 10.1016/0305-0491(92)90431-P; CARMOFONSECA M, 1993, J CELL BIOL, V120, P841, DOI 10.1083/jcb.120.4.841; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; Casiano CA, 1996, J EXP MED, V184, P765, DOI 10.1084/jem.184.2.765; Cmarko D, 1999, MOL BIOL CELL, V10, P211, DOI 10.1091/mbc.10.1.211; COURTENS JL, 1981, J ULTRA MOL STRUCT R, V74, P327, DOI 10.1016/S0022-5320(81)80124-4; CZAKER R, 1985, ANDROLOGIA, V17, P42; CZAKER R, 1984, EXPERIENTIA, V40, P960, DOI 10.1007/BF01946459; CZAKER R, 1985, ANDROLOGIA, V17, P547; EARNSHAW WC, 1991, CHROMOSOMA, V100, P139, DOI 10.1007/BF00337241; FAKAN S, 1986, J CELL BIOL, V103, P1153, DOI 10.1083/jcb.103.4.1153; FAKAN S, 1984, J CELL BIOL, V98, P358, DOI 10.1083/jcb.98.1.358; FAKAN S, 1980, BIOL CELLULAIRE, V37, P211; Fakan Stanislav, 1994, Trends in Cell Biology, V4, P86, DOI 10.1016/0962-8924(94)90180-5; Flechon JE, 1998, ZYGOTE, V6, P183, DOI 10.1017/S0967199498000112; Fomproix N, 1998, J CELL SCI, V111, P359; GAUTIER T, 1992, J CELL SCI, V102, P729; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; HERNANDEZVERDUN D, 1994, BIOESSAYS, V16, P179, DOI 10.1002/bies.950160308; Kopecny V, 1996, EUR J CELL BIOL, V70, P361; Kopecny V, 1996, CHROMOSOMA, V104, P561, DOI 10.1007/BF00352296; Kopecny V, 1996, REPROD NUTR DEV, V36, P667; KOPENCY V, 1991, MOL REPROD DEV, V29, P209, DOI 10.1002/mrd.1080290302; LAZARUS SS, 1966, CANCER RES, V26, P2229; LESER GP, 1989, EUR J CELL BIOL, V50, P376; Lorenz P, 1998, MOL BIOL CELL, V9, P1007, DOI 10.1091/mbc.9.5.1007; MALATESTA M, 1994, EUR J CELL BIOL, V65, P82; MALATESTA M, 1995, CHROMOSOMA, V104, P121, DOI 10.1007/s004120050099; MALATESTA M, 1994, EXP CELL RES, V211, P415, DOI 10.1006/excr.1994.1106; MARTIN T, 1979, MOL BIOL REP, V5, P37, DOI 10.1007/BF00777486; Matera AG, 1998, J CELL BIOCHEM, V70, P181; Misteli T, 1998, CURR OPIN CELL BIOL, V10, P323, DOI 10.1016/S0955-0674(98)80007-0; Misteli T, 1997, TRENDS CELL BIOL, V7, P135, DOI 10.1016/S0962-8924(96)20043-1; MONNERON A, 1968, CR ACAD SCI D NAT, V267, P2053; Puvion E, 1996, EXP CELL RES, V229, P217, DOI 10.1006/excr.1996.0363; SIMARD R, 1974, CELL NUCLEUS, V3, P447; Spector DL, 1996, EXP CELL RES, V229, P189, DOI 10.1006/excr.1996.0358; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; Tamburini M, 1996, HISTOCHEM CELL BIOL, V106, P581; ZWEIER M, 1997, EXP CELL RES, V230, P325	49	46	55	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2000	14	5					828	834		10.1096/fasebj.14.5.828	http://dx.doi.org/10.1096/fasebj.14.5.828			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301DH	10744640				2022-12-28	WOS:000086292700021
J	Foitzik, K; Lindner, G; Mueller-Roever, S; Maurer, M; Botchkareva, N; Botchkarev, V; Handjiski, B; Metz, M; Hibino, T; Soma, T; Dotto, GP; Paus, R				Foitzik, K; Lindner, G; Mueller-Roever, S; Maurer, M; Botchkareva, N; Botchkarev, V; Handjiski, B; Metz, M; Hibino, T; Soma, T; Dotto, GP; Paus, R			Control of murine hair follicle regression (catagen) by TGF-beta 1 in vivo	FASEB JOURNAL			English	Article						in vivo; apoptosis; TGF-beta receptor	GROWTH-FACTOR-BETA; TGF-BETA; IN-VIVO; TRANSFORMING GROWTH-FACTOR-BETA-1; DEPENDENT CHANGES; TRANSGENIC MICE; MAST-CELLS; SKIN; EXPRESSION; APOPTOSIS	The regression phase of the hair cycle (catagen) is an apoptosis-driven process accompanied by terminal differentiation, proteolysis, and matrix remodeling. As an inhibitor of keratinocyte proliferation and inductor of keratinocyte apoptosis, transforming growth factor beta 1 (TGF-beta 1) has been proposed to play an important role in catagen regulation. This is suggested, for example, by maximal expression of TGF-beta 1 and its receptors during late anagen and the onset of catagen of the hair cycle. We examined the potential involvement of TGF-beta 1 in catagen control. We compared the first spontaneous entry of hair follicles into catagen between TGF-beta 1 null mice and age-matched wild-type littermates, and assessed the effects of TGF-beta 1 injection on murine anagen hair follicles in vivo. At day 18 p.p., hair follicles in TGF-beta 1 -/- mice were still in early catagen, whereas hair follicles of +/+ littermates had already entered the subsequent resting phase (telogen). TGF-beta 1 -/- mice displayed more Ki-67-positive cells and fewer apoptotic cells than comparable catagen follicles from +/+ mice. In contrast, injection of TGF-beta 1 into the back skin of mice induced premature catagen development. In addition, the number of proliferating follicle keratinocytes was reduced and the number of TUNEL + cells was increased in the TGF-beta 1-treated mice compared to controls. Double visualization of TGF-beta type II receptor (TGFRII) and TUNEL reactivity revealed colocalization of apoptotic nuclei and TGFRII in catagen follicles. These data strongly support that TGF-beta 1 ranks among the elusive endogenous regulators of catagen induction in vivo, possibly via the inhibition of keratinocyte proliferation and induction of apoptosis. Thus, TCF-beta RII agonists and antagonists may provide useful therapeutic tools for human hair growth disorders based on premature or retarded catagen development (effluvium, alopecia, hirsutism).	Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; Humboldt Univ, Dept Dermatol, Berlin, Germany; Univ London Queen Mary Coll, Ctr Cutaneous Res, London E1 4NS, England; Univ Mainz, Dept Dermatol, D-6500 Mainz, Germany; Boston Univ, Dept Dermatol, Boston, MA 02118 USA; Shiseido Res Ctr, Yokohama, Kanagawa, Japan	Harvard University; Massachusetts General Hospital; Harvard University; Humboldt University of Berlin; University of London; Queen Mary University London; Johannes Gutenberg University of Mainz; Boston University; Shiseido Company, Limited	Paus, R (corresponding author), Univ Hamburg, Dept Dermatol, UKE, Martinistr 52, D-20246 Hamburg, Germany.		Metz, Martin/M-5237-2013; Maurer, Marcus/ABG-2174-2020; Metz, Martin/B-8799-2009; Hendrix, Sven/F-4059-2010	Metz, Martin/0000-0002-4070-9976; Maurer, Marcus/0000-0002-4121-481X; Metz, Martin/0000-0002-4070-9976; Hendrix, Sven/0000-0003-2344-7369; Botchkarev, Vladimir/0000-0002-5212-5353; Lindner, Gerd/0000-0003-2336-2058	NATIONAL CANCER INSTITUTE [P01CA016038, R01CA073796] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039190] Funding Source: NIH RePORTER; NCI NIH HHS [CA73796, CA 16038] Funding Source: Medline; NIAMS NIH HHS [AR39190] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Baker JC, 1997, CURR OPIN GENET DEV, V7, P467, DOI 10.1016/S0959-437X(97)80072-X; Botchkarev VA, 1998, AM J PATHOL, V153, P785, DOI 10.1016/S0002-9440(10)65621-0; Botchkarev VA, 1997, ARCH DERMATOL RES, V289, P292, DOI 10.1007/s004030050195; BulfonePaus S, 1997, NAT MED, V3, P1124, DOI 10.1038/nm1097-1124; Cotsarelis G, 1997, AM J PATHOL, V151, P1505; Cotton SA, 1998, J PATHOL, V184, P4, DOI 10.1002/(SICI)1096-9896(199801)184:1<4::AID-PATH968>3.0.CO;2-0; Dawber R., 1997, DIS HAIR SCALP; Frank J, 1999, NATURE, V398, P473, DOI 10.1038/18997; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; Hoodless PA, 1998, CURR TOP MICROBIOL, V228, P235; Kim JW, 1998, GYNECOL ONCOL, V69, P230, DOI 10.1006/gyno.1998.5003; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Letterio JJ, 1996, J LEUKOCYTE BIOL, V59, P769, DOI 10.1002/jlb.59.6.769; Li J, 1999, J BIOL CHEM, V274, P4213, DOI 10.1074/jbc.274.7.4213; Lindner G, 1997, AM J PATHOL, V151, P1601; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASSAGUE J, 1992, CANCER SURV, V12, P81; Maurer M, 1997, LAB INVEST, V77, P319; Moses HL, 1996, CURR OPIN GENET DEV, V6, P581, DOI 10.1016/S0959-437X(96)80087-6; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Munger JS, 1997, KIDNEY INT, V51, P1376, DOI 10.1038/ki.1997.188; Panteleyev AA, 1999, AM J PATHOL, V155, P159, DOI 10.1016/S0002-9440(10)65110-3; Panteleyev AA, 1998, EXP DERMATOL, V7, P249, DOI 10.1111/j.1600-0625.1998.tb00295.x-i1; PAUS R, 1994, AM J PATHOL, V144, P719; Paus R, 1997, J INVEST DERMATOL, V109, P518, DOI 10.1111/1523-1747.ep12336635; PAUS R, 1990, BRIT J DERMATOL, V122, P777, DOI 10.1111/j.1365-2133.1990.tb06266.x; Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; PAUS R, 1996, CURR OPIN DERMATOL, V3, P248; Philpott M P, 1994, J Dermatol Sci, V7 Suppl, pS55, DOI 10.1016/0923-1811(94)90036-1; PROETZEL G, 1995, NAT GENET, V11, P409, DOI 10.1038/ng1295-409; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROBERTS AB, 1990, PHILOS T R SOC B, V327, P145, DOI 10.1098/rstb.1990.0050; ROBERTS AB, 1992, KIDNEY INT, V41, P557, DOI 10.1038/ki.1992.81; Sanford LP, 1997, DEVELOPMENT, V124, P2659; Schilli MB, 1997, J INVEST DERMATOL, V108, P928, DOI 10.1111/1523-1747.ep12294690; SEIBERG M, 1995, J INVEST DERMATOL, V104, P78, DOI 10.1111/1523-1747.ep12613555; SELLHEYER K, 1993, P NATL ACAD SCI USA, V90, P5237, DOI 10.1073/pnas.90.11.5237; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Slominski A, 1996, J INVEST DERMATOL, V106, P1203, DOI 10.1111/1523-1747.ep12348479; Soma T, 1998, J INVEST DERMATOL, V111, P948, DOI 10.1046/j.1523-1747.1998.00408.x; Stenn KS, 1996, DERMATOL CLIN, V14, P543, DOI 10.1016/S0733-8635(05)70383-1; Tobin DJ, 1998, J INVEST DERMATOL, V111, P941, DOI 10.1046/j.1523-1747.1998.00417.x; Wang XJ, 1997, P NATL ACAD SCI USA, V94, P2386, DOI 10.1073/pnas.94.6.2386; WEEDON D, 1981, ACTA DERM-VENEREOL, V61, P335; Welker P, 1997, ARCH DERMATOL RES, V289, P554, DOI 10.1007/s004030050239; Wollina U, 1996, HISTOL HISTOPATHOL, V11, P431	46	247	271	3	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2000	14	5					752	760		10.1096/fasebj.14.5.752	http://dx.doi.org/10.1096/fasebj.14.5.752			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301DH	10744631				2022-12-28	WOS:000086292700012
J	Pins, GD; Toner, M; Morgan, JR				Pins, GD; Toner, M; Morgan, JR			Microfabrication of an analog of the basal lamina: biocompatible membranes with complex topographies	FASEB JOURNAL			English	Article						tissue engineering; basal lamina; dermal analog; polyimide chip	HUMAN EPIDERMAL-KERATINOCYTES; SKIN-EQUIVALENT; FULL-THICKNESS; BARRIER LIPIDS; TISSUE; DIFFERENTIATION; REGENERATION; COLLAGEN; INVITRO; GROWTH	A microfabrication approach was used to produce novel analogs of the basal lamina with complex topographic features. A test pattern of ridges and channels with length scales (40 to 310 mu m) similar to the invaginations found in a native basal lamina was laser machined into the surface of a polyimide master chip. Negative replicates of the chip were produced using polydimethylsiloxane silicone elastomer and these replicates were used as templates for the production of thin (similar to 21 mu m) membranes of collagen or gelatin. The resulting membranes had a complex topography of ridges and channels that recapitulated the features of the master chip. To demonstrate their utility, these complex membranes were laminated to type I collagen sponges and their surfaces were seeded with cultured human epidermal keratinocytes to form a skin equivalent, The keratinocytes formed a differentiated and stratified epidermis that conformed to the features of the microfabricated membrane. The topography of the membrane influenced the differentiation of the keratinocytes because stratification was enhanced in the deeper channels. Membrane topography also controlled the gross surface features of the skin equivalent; infolds of the epidermis increased as channel depth increased. These novel microfabricated analogs of the basal lamina will help to elucidate the influence of topography on epithelial cell proliferation and differentiation and should have applications in the tissue engineering of skin equivalents as well as other basal lamina-containing tissues.	Shriners Burns Hosp Children, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Surg Serv, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Morgan, JR (corresponding author), Shriners Burns Hosp Children, 51 Blossom St, Boston, MA 02114 USA.			Morgan, Jeffrey/0000-0002-7546-3443; Pins, George/0000-0002-8844-8074	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR042012] Funding Source: NIH RePORTER; NIAMS NIH HHS [R29 AR42012-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BELL E, 1981, SCIENCE, V211, P1052, DOI 10.1126/science.7008197; Black AF, 1998, FASEB J, V12, P1331, DOI 10.1096/fasebj.12.13.1331; BOYCE ST, 1993, J INVEST DERMATOL, V101, P180, DOI 10.1111/1523-1747.ep12363678; BOYCE ST, 1988, SURGERY, V103, P421; BOYCE ST, 1988, J BIOMED MATER RES, V22, P939, DOI 10.1002/jbm.820221008; BOYCE ST, 1995, ANN SURG, V222, P743, DOI 10.1097/00000658-199512000-00008; BRITTBERG M, 1994, NEW ENGL J MED, V331, P889, DOI 10.1056/NEJM199410063311401; BURGESON RE, 1987, DERMATOLOGY GENERAL, P288; BURGESON RE, 1993, MOL CELLULAR ASPECTS, P49; Carter William G., 1992, P299; CHAMBERLAIN LJ, 1988, TISSUE ENG METHODS P, P3; EKBLOM P, 1993, MOL CELLULAR ASPECTS, P359; EMING SA, 1995, J INVEST DERMATOL, V105, P756, DOI 10.1111/1523-1747.ep12325550; Falanga V, 1998, ARCH DERMATOL, V134, P293, DOI 10.1001/archderm.134.3.293; Farquhar M. G., 1991, CELL BIOL EXTRACELLU, P365; FREED LE, 1993, J BIOMED MATER RES, V27, P11, DOI 10.1002/jbm.820270104; FREED LE, 1995, BIOMEDICAL ENG HDB, P1788; JONES PH, 1995, CELL, V80, P83, DOI 10.1016/0092-8674(95)90453-0; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; LAVKER RM, 1983, J INVEST DERMATOL S, V81, P121; Medalie DA, 1997, TRANSPLANTATION, V64, P454, DOI 10.1097/00007890-199708150-00015; Morgan J., 1997, SCI MED, V4, P6; ODLAND GF, 1950, ANAT REC, V108, P399, DOI 10.1002/ar.1091080305; Ponec M, 1997, J INVEST DERMATOL, V109, P348, DOI 10.1111/1523-1747.ep12336024; RHEINWALD JG, 1975, CELL, V6, P317, DOI 10.1016/0092-8674(75)90183-X; STERN R, 1990, Journal of Burn Care and Rehabilitation, V11, P7, DOI 10.1097/00004630-199001000-00003; Teumer J., 1998, FRONTIERS TISSUE ENG, P664; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; VRACKO R, 1974, AM J PATHOL, V77, P313; WAKE MC, 1994, CELL TRANSPLANT, V3, P339, DOI 10.1177/096368979400300411; YANNAS IV, 1982, SCIENCE, V215, P174, DOI 10.1126/science.7031899; YANNAS IV, 1980, J BIOMED MATER RES, V14, P107, DOI 10.1002/jbm.820140203; YANNAS IV, 1989, P NATL ACAD SCI USA, V86, P933, DOI 10.1073/pnas.86.3.933	33	78	83	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2000	14	3					593	602		10.1096/fasebj.14.3.593	http://dx.doi.org/10.1096/fasebj.14.3.593			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	291TJ	10698975				2022-12-28	WOS:000085751900019
J	Ristori, G; Salvetti, M; Pesole, G; Attimonelli, M; Buttinelli, C; Martin, R; Riccio, P				Ristori, G; Salvetti, M; Pesole, G; Attimonelli, M; Buttinelli, C; Martin, R; Riccio, P			Compositional bias and mimicry toward the nonself proteome in immunodominant T cell epitopes of self and nonself antigens	FASEB JOURNAL			English	Article						T lymphocytes; tolerance; molecular mimicry; immunogenicity; vaccine design	MYELIN BASIC-PROTEIN; MAJOR HISTOCOMPATIBILITY COMPLEX; C VIRUS-ANTIGENS; MULTIPLE-SCLEROSIS; MOLECULAR MIMICRY; POSITIVE SELECTION; INNATE IMMUNITY; CYTOCHROME-C; RECOGNITION; SEQUENCE	We investigated whether and how molecular mimicry affects the shaping of the helper T cell repertoire. We implemented an algorithm that measures the probability of mimicry between epitopes of known immunogenicity and self or nonself proteomes. This algorithm yields 'similarity profiles', which represent the probability of matching between all contiguous overlapping peptides of the antigen under examination and those in the proteome(s) considered. Similarity profiles between helper T cell epitopes (of self or microbial antigens and allergens) and human or microbial SWISSPROT collections were produced. For each antigen, both collections yielded largely overlapping profiles, demonstrating that self-nonself discrimination does not rely on qualitative features that distinguish human from microbial peptides. However, epitopes whose probability of mimicry with self or nonself prevails are, respectively, tolerated or immunodominant and coexist within the same (auto-)antigen regardless of its self/nonself nature. Epitopes ton self and nonself antigens) can cross-stimulate T cells at increasing potency as their similarity with nonself augments. Mimicry, rather than complicating self-nonself discrimination, assists in the shaping of the immune repertoire and helps define the defensive or autoreactive potential of a T cell. Being a predictor of epitope immunogenicity, it bears relevance to vaccine design.	Univ La Sapienza, Dipartimento Sci Neurol, I-00185 Rome, Italy; Univ Basilicata, Dipartimento Biol DBAF, I-85100 Potenza, Italy; Univ Bari, Dip Biochim & Biol Mol, Bari, Italy; NINCDS, Cellular Immunol Sect, Neuroimmunol Branch, NIH, Bethesda, MD 20892 USA	Sapienza University Rome; University of Basilicata; Universita degli Studi di Bari Aldo Moro; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Salvetti, M (corresponding author), Univ La Sapienza, Dipartimento Sci Neurol, V Univ 30, I-00185 Rome, Italy.		Attimonelli, Marcella/AAK-1644-2020; Pesole, Graziano/E-9051-2014; Pesole, Graziano/C-1408-2009; Pesole, Graziano/K-5283-2019	Pesole, Graziano/0000-0003-3663-0859; Pesole, Graziano/0000-0003-3663-0859; RISTORI, Giovanni/0000-0002-6598-6777	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002205] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARNABA V, 1996, IMMUNOL REV, V152, P46; BARNETT LA, 1992, FASEB J, V6, P840, DOI 10.1096/fasebj.6.3.1740233; Barton GM, 1999, SCIENCE, V283, P67, DOI 10.1126/science.283.5398.67; BAUMHUTER S, 1987, EUR J IMMUNOL, V17, P651, DOI 10.1002/eji.1830170511; Bevan MJ, 1997, IMMUNITY, V7, P175, DOI 10.1016/S1074-7613(00)80520-8; BURNET FM, 1959, CLONAL SELECTION THE; CARBALLIDO JM, 1993, J IMMUNOL, V150, P3582; COHEN IR, 1992, IMMUNOL TODAY, V13, P441, DOI 10.1016/0167-5699(92)90071-E; EVAVOLD BD, 1995, IMMUNITY, V2, P655, DOI 10.1016/1074-7613(95)90010-1; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; FUJINAMI RS, 1985, SCIENCE, V230, P1043, DOI 10.1126/science.2414848; GOUY M, 1985, COMPUT APPL BIOSCI, V1, P167; Grillo G, 1996, COMPUT APPL BIOSCI, V12, P1; Hemmer B, 1997, J EXP MED, V185, P1651, DOI 10.1084/jem.185.9.1651; Hemmer B, 1998, IMMUNOL TODAY, V19, P163, DOI 10.1016/S0167-5699(97)01217-6; HOFFMANN RM, 1995, HEPATOLOGY, V21, P632, DOI 10.1002/hep.1840210305; JUNG G, 1992, ANGEW CHEM INT EDIT, V31, P367, DOI 10.1002/anie.199203673; KOLASKAR AS, 1990, FEBS LETT, V276, P172, DOI 10.1016/0014-5793(90)80535-Q; Landry SJ, 1997, IMMUNOL TODAY, V18, P527, DOI 10.1016/S0167-5699(97)01152-3; Lechmann M, 1996, HEPATOLOGY, V24, P790; Liu CP, 1997, J EXP MED, V186, P1441, DOI 10.1084/jem.186.9.1441; Lucas B, 1999, IMMUNITY, V10, P367, DOI 10.1016/S1074-7613(00)80036-9; MAMULA MJ, 1992, J IMMUNOL, V149, P789; MARGALIT H, 1987, J IMMUNOL, V138, P2213; MARTIN R, 1992, J IMMUNOL, V148, P1359; Mason D, 1998, IMMUNOL TODAY, V19, P395, DOI 10.1016/S0167-5699(98)01299-7; MATZINGER P, 1994, NATURE, V369, P605, DOI 10.1038/369605a0; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; MEINL E, 1993, J CLIN INVEST, V92, P2633, DOI 10.1172/JCI116879; Moudgil KD, 1997, J IMMUNOL, V159, P2574; Nakano N, 1997, SCIENCE, V275, P678, DOI 10.1126/science.275.5300.678; NANDA NK, 1995, J EXP MED, V182, P531, DOI 10.1084/jem.182.2.531; Oldstone MBA, 1998, FASEB J, V12, P1255, DOI 10.1096/fasebj.12.13.1255; OTA K, 1990, NATURE, V346, P183, DOI 10.1038/346183a0; PESOLE G, 1994, TRENDS BIOTECHNOL, V12, P401, DOI 10.1016/0167-7799(94)90028-0; REYES VE, 1989, J BIOL CHEM, V264, P12854; REYES VE, 1990, MOL IMMUNOL, V27, P1021, DOI 10.1016/0161-5890(90)90125-J; ROTHBARD JB, 1988, EMBO J, V7, P93, DOI 10.1002/j.1460-2075.1988.tb02787.x; SALVETTI M, 1993, EUR J IMMUNOL, V23, P1232, DOI 10.1002/eji.1830230606; SantAngelo DB, 1997, IMMUNITY, V7, P517, DOI 10.1016/S1074-7613(00)80373-8; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SETTE A, 1989, P NATL ACAD SCI USA, V86, P3296, DOI 10.1073/pnas.86.9.3296; Steinman RM, 1997, IMMUNOL REV, V156, P25, DOI 10.1111/j.1600-065X.1997.tb00956.x; VALLI A, 1993, J CLIN INVEST, V91, P616, DOI 10.1172/JCI116242; Viret C, 1999, IMMUNITY, V10, P559, DOI 10.1016/S1074-7613(00)80055-2; Williams O, 1997, IMMUNOL TODAY, V18, P121, DOI 10.1016/S0167-5699(97)01029-3; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8	48	20	27	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2000	14	3					431	438		10.1096/fasebj.14.3.431	http://dx.doi.org/10.1096/fasebj.14.3.431			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	291TJ	10698957				2022-12-28	WOS:000085751900001
J	Ammit, AJ; Hastie, AT; Edsall, LC; Hoffman, RK; Amrani, Y; Krymskaya, VP; Kane, SA; Peters, SP; Penn, RB; Spiegel, S; Panettieri, RA				Ammit, AJ; Hastie, AT; Edsall, LC; Hoffman, RK; Amrani, Y; Krymskaya, VP; Kane, SA; Peters, SP; Penn, RB; Spiegel, S; Panettieri, RA			Sphingosine 1-phosphate modulates human airway smooth muscle cell functions that promote inflammation and airway remodeling in asthma	FASEB JOURNAL			English	Article									Univ Penn, Med Ctr, Dept Med, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Div Pulm & Crit Care Med, Philadelphia, PA 19107 USA; Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	University of Pennsylvania; Jefferson University; Georgetown University; Jefferson University	Panettieri, RA (corresponding author), Univ Penn, Med Ctr, Dept Med, Pulm Allergy & Crit Care Div, 805 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.		Amrani, Yassine/Q-6323-2019; panettieri, reynold/AAG-9485-2019; Amrani, Yassine/A-1826-2013	Amrani, Yassine/0000-0002-7042-6926; Ammit, Alaina/0000-0003-0555-2544					0	259	268	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1212	1214		10.1096/fj.00-0742fje	http://dx.doi.org/10.1096/fj.00-0742fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344091				2022-12-28	WOS:000168655200013
J	Navarro-Antolin, J; Lopez-Munoz, MJ; Klatt, P; Soria, J; Michel, T; Lamas, S				Navarro-Antolin, J; Lopez-Munoz, MJ; Klatt, P; Soria, J; Michel, T; Lamas, S			Formation of peroxynitrite in vascular endothelial cells exposed to cyclosporine A	FASEB JOURNAL			English	Article									CSIC, Ctr Invest Biol, E-28006 Madrid, Spain; CSIC, Inst Reina Sofia Invest Nefrol, E-28006 Madrid, Spain; CSIC, Inst Catalisis & Petroleoquim, E-28006 Madrid, Spain; Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Consejo Superior de Investigaciones Cientificas (CSIC); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Catalisis y Petroleoquimica (ICP); Harvard University; Brigham & Women's Hospital; Harvard Medical School	Lamas, S (corresponding author), CSIC, Ctr Invest Biol, C Velazquez 144, E-28006 Madrid, Spain.		Lamas, Santiago/G-7308-2015	Lamas, Santiago/0000-0001-5166-4155; Lopez-Munoz, Maria-Jose/0000-0002-8323-7315					0	45	49	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1291	1293		10.1096/fj.00-0636fje	http://dx.doi.org/10.1096/fj.00-0636fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344117				2022-12-28	WOS:000168655200039
J	Zangger, K; Oz, G; Haslinger, E; Kunert, O; Armitage, IM				Zangger, K; Oz, G; Haslinger, E; Kunert, O; Armitage, IM			Nitric oxide selectively releases metals from the amino-terminal domain of metallothioneins: potential role at inflammatory sites	FASEB JOURNAL			English	Article									Graz Univ, Inst Pharmaceut Chem, A-8010 Graz, Austria; Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA	University of Graz; University of Minnesota System; University of Minnesota Twin Cities	Zangger, K (corresponding author), Graz Univ, Inst Chem Organ & Bioorgan Chem, Heinrichstr 28, A-8010 Graz, Austria.		Oz, Gulin/L-1306-2016	Oz, Gulin/0000-0002-5769-183X; Kunert, Olaf/0000-0002-7091-5973; Zangger, Klaus/0000-0003-1682-1594					0	85	89	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1303	1305		10.1096/fj.00-0641fje	http://dx.doi.org/10.1096/fj.00-0641fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344121				2022-12-28	WOS:000168655200043
J	Mojena, M; Hortelano, S; Castrillo, A; Diaz-Guerra, MJM; Garcia-Barchino, MJ; Saez, GT; Bosca, L				Mojena, M; Hortelano, S; Castrillo, A; Diaz-Guerra, MJM; Garcia-Barchino, MJ; Saez, GT; Bosca, L			Protection by nitric oxide against liver inflammatory injury in animals carrying a nitric oxide synthase-2 transgene	FASEB JOURNAL			English	Article									Univ Complutense Madrid, Fac Farm, CSIC, Inst Bioquim, E-28040 Madrid, Spain; Merck Sharp & Dohme Ltd, CIBE, Madrid, Spain; Fac Med, Dept Bioquim, Albacete 02071, Spain; Univ Valencia, Fac Med, Dept Bioquim & Biol Mol, Valencia 46010, Spain	Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Merck & Company; University of Valencia	Bosca, L (corresponding author), Univ Complutense Madrid, Fac Farm, CSIC, Inst Bioquim, E-28040 Madrid, Spain.		Bosca, Lisardo/A-2059-2008; Díaz-Guerra, María José M/M-2855-2014; Hortelano, Sonsoles/A-7954-2010	Bosca, Lisardo/0000-0002-0253-5469; Díaz-Guerra, María José M/0000-0003-3843-3912; Hortelano, Sonsoles/0000-0003-2528-0072; Saez, Guillermo/0000-0002-8164-4048; Mojena, Marina/0000-0002-5371-8118					0	44	46	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					583	585						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259374				2022-12-28	WOS:000167419500012
J	Ticchioni, M; Raimondi, V; Lamy, L; Wijdenes, J; Lindberg, FP; Brown, EJ; Bernard, A				Ticchioni, M; Raimondi, V; Lamy, L; Wijdenes, J; Lindberg, FP; Brown, EJ; Bernard, A			Integrin-associated protein (CD47/IAP) contributes to T cell arrest on inflammatory vascular endothelium under flow	FASEB JOURNAL			English	Article						adhesion; T cell circulation; integrin	NEURAL ADHESION MOLECULE; RED-BLOOD-CELLS; L-SELECTIN; SIGNAL-TRANSDUCTION; IMMOBILIZED THROMBOSPONDIN; HUMAN MONOCYTES; BINDING DOMAIN; SHEAR-FLOW; RECEPTOR; EXPRESSION	Integrin-associated protein (CD47/IAP) is a pentaspan molecule that regulates integrin functions. We prepared a CD47-deficient Jurkat T cell line to assess its role in the arrest of T cells on inflammatory endothelium. Under flow conditions, constitutive arrest of CD47-deficient cells is strongly decreased as compared to the original cell line, whereas reexpression of CD47 reestablishes their ability to stop. Moreover, cells transfected with a chimera made with the extracellular portion of CD47 and the transmembrane domain of CD7 or several truncated forms of CD47 show that the first transmembrane domain and a short cytoplasmic loop are sufficient for this process. CD47 effect is indirect and depends mainly on the alpha4 beta1/VCAM-1 pathway, as shown by blocking antibodies. We detected on endothelium the two CD47 counter receptors known to date: thrombospondin and SIRP1 alpha, Blocking experiments show that both are involved. Overall, CD47 participates in the constitutive arrest of T lymphocytes on inflamed vascular endothelium by up-regulating alpha 4 beta1 integrins.	Hop Archet, Unite INERM U343, F-06202 Nice 3, France; Immunol Lab, F-06202 Nice, France; Diaclone Res, F-25020 Besancon, France; Washington Univ, Sch Med, Div Infect Dis, St Louis, MO 63110 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); Washington University (WUSTL); University of California System; University of California San Francisco	Bernard, A (corresponding author), Hop Archet, Unite INERM U343, Route St Antoine Ginestiere,BP 3079, F-06202 Nice 3, France.		Ticchioni, Michel/P-8095-2016		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057573] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM57573-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe Y, 1996, J IMMUNOL, V157, P5061; ADAMS J, 1993, CURR BIOL, V3, P188, DOI 10.1016/0960-9822(93)90270-X; ALON R, 1995, J CELL BIOL, V128, P1243, DOI 10.1083/jcb.128.6.1243; Aplin AE, 1998, PHARMACOL REV, V50, P197; Babic I, 2000, J IMMUNOL, V164, P3652, DOI 10.4049/jimmunol.164.7.3652; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Barabino GA, 1997, BLOOD, V89, P2560, DOI 10.1182/blood.V89.7.2560; BERLIN C, 1995, CELL, V80, P413, DOI 10.1016/0092-8674(95)90491-3; Blanks JE, 1998, EUR J IMMUNOL, V28, P433, DOI 10.1002/(SICI)1521-4141(199802)28:02<433::AID-IMMU433>3.0.CO;2-U; BLYSTONE SD, 1995, J CELL BIOL, V130, P745, DOI 10.1083/jcb.130.3.745; BLYSTONE SD, 1994, J CELL BIOL, V127, P1129, DOI 10.1083/jcb.127.4.1129; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; BROWN EJ, 1990, J CELL BIOL, P2785; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CAMPBELL IG, 1992, CANCER RES, V52, P5416; Chen C, 1999, J IMMUNOL, V162, P1084; Chung J, 1997, J BIOL CHEM, V272, P14740, DOI 10.1074/jbc.272.23.14740; Chung J, 1999, BLOOD, V94, P642, DOI 10.1182/blood.V94.2.642.414k35_642_648; Comu S, 1997, J NEUROSCI, V17, P8702; COOKE BM, 1994, BRIT J HAEMATOL, V87, P162, DOI 10.1111/j.1365-2141.1994.tb04887.x; COOPER D, 1995, P NATL ACAD SCI USA, V92, P3978, DOI 10.1073/pnas.92.9.3978; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Frazier WA, 1999, J BIOL CHEM, V274, P8554, DOI 10.1074/jbc.274.13.8554; Furusawa T, 1998, J BIOCHEM-TOKYO, V123, P101; Gao AG, 1996, J CELL BIOL, V135, P533, DOI 10.1083/jcb.135.2.533; GAO AG, 1994, J BIOL CHEM, V269, P29650; GAO AG, 1996, J BIOL CHEM, V271, P12; Giblin PA, 1997, J IMMUNOL, V159, P3498; Gopalan PK, 1997, J IMMUNOL, V158, P367; Green JM, 1999, J CELL BIOL, V146, P673, DOI 10.1083/jcb.146.3.673; GRESHAM HD, 1992, J BIOL CHEM, V267, P13885; Hermann P, 1999, J CELL BIOL, V144, P767, DOI 10.1083/jcb.144.4.767; Huang AM, 1998, J NEUROSCI, V18, P4305; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Imhof BA, 1997, EUR J IMMUNOL, V27, P3242, DOI 10.1002/eji.1830271223; JAKUBOWSKI A, 1995, CELL ADHES COMMUN, V3, P131, DOI 10.3109/15419069509081282; Jiang PH, 1999, J BIOL CHEM, V274, P559, DOI 10.1074/jbc.274.2.559; Joneckis CC, 1996, BLOOD, V87, P4862, DOI 10.1182/blood.V87.11.4862.bloodjournal87114862; KANSAS GS, 1993, J EXP MED, V177, P833, DOI 10.1084/jem.177.3.833; KOSFELD MD, 1993, J BIOL CHEM, V268, P8808; Li XP, 1996, AM J RESP CELL MOL, V14, P398, DOI 10.1165/ajrcmb.14.4.8600945; Lindberg FP, 1996, J CELL BIOL, V134, P1313, DOI 10.1083/jcb.134.5.1313; Lindberg FP, 1996, SCIENCE, V274, P795, DOI 10.1126/science.274.5288.795; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; MACKINNON M, 1990, DIABETIC MED, V7, P171, DOI 10.1111/j.1464-5491.1990.tb01356.x; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; MCPHERSON J, 1981, J BIOL CHEM, V256, P1330; Mi ZP, 2000, J COMP NEUROL, V416, P335; MODDERMAN PW, 1992, LEUKOCYTE TYPING 4, P1025; MOSHER DF, 1982, J CELL BIOL, V93, P343, DOI 10.1083/jcb.93.2.343; MURPHYULLRICH JE, 1987, J CELL BIOL, V105, P1603, DOI 10.1083/jcb.105.4.1603; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; Parkos CA, 1996, J CELL BIOL, V132, P437, DOI 10.1083/jcb.132.3.437; Pettersen RD, 1999, J IMMUNOL, V162, P7031; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; PITZALIS C, 1991, EUR J IMMUNOL, V21, P369, DOI 10.1002/eji.1830210218; Porter JC, 1997, J CELL BIOL, V138, P1437, DOI 10.1083/jcb.138.6.1437; Reinhold MI, 1997, J EXP MED, V185, P1, DOI 10.1084/jem.185.1.1; Reinhold MI, 1999, INT IMMUNOL, V11, P707, DOI 10.1093/intimm/11.5.707; REINHOLD MI, 1995, J CELL SCI, V108, P3419; ROSALES C, 1995, J LEUKOCYTE BIOL, V57, P189, DOI 10.1002/jlb.57.2.189; Saginario C, 1998, MOL CELL BIOL, V18, P6213, DOI 10.1128/MCB.18.11.6213; SALTINI C, 1990, J EXP MED, V171, P1123, DOI 10.1084/jem.171.4.1123; SCHON P, 1992, EUR J CELL BIOL, V59, P329; SCHWARTZ MA, 1993, J BIOL CHEM, V268, P19931; Seiffert M, 1999, BLOOD, V94, P3633, DOI 10.1182/blood.V94.11.3633.423k01_3633_3643; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SIMON SI, 1995, J IMMUNOL, V155, P1502; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Steeber DA, 1997, J IMMUNOL, V159, P952; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; TAUB DD, 1993, J EXP MED, V177, P1809, DOI 10.1084/jem.177.6.1809; Ticchioni M, 1997, J IMMUNOL, V158, P677; TSAO PW, 1995, J BIOL CHEM, V270, P23747, DOI 10.1074/jbc.270.40.23747; Vallejo AN, 2000, J IMMUNOL, V164, P2947, DOI 10.4049/jimmunol.164.6.2947; VISCHER P, 1988, EUR J CELL BIOL, V47, P36; Waclavicek M, 1997, J IMMUNOL, V159, P5345; Ward SG, 1998, IMMUNITY, V9, P1, DOI 10.1016/S1074-7613(00)80583-X; ZHOU MJ, 1993, J EXP MED, V178, P1165, DOI 10.1084/jem.178.4.1165	81	47	48	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					341	350		10.1096/fj.99-0833com	http://dx.doi.org/10.1096/fj.99-0833com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156950				2022-12-28	WOS:000166872900016
J	Jafrezou, JP; Bruno, AP; Moisand, A; Levade, T; Laurent, G				Jafrezou, JP; Bruno, AP; Moisand, A; Levade, T; Laurent, G			Activation of a nuclear sphingomyelinase in radiation-induced apoptosis	FASEB JOURNAL			English	Article						myeloid cells; nuclear signaling; ionizing radiation; resistance	CERAMIDE-INDUCED APOPTOSIS; IONIZING-RADIATION; NEUTRAL SPHINGOMYELINASE; RAT-LIVER; ACID SPHINGOMYELINASE; CONFERS RESISTANCE; DNA FRAGMENTATION; CELLS; GENERATION; DISEASE	The subcellular origin of ceramide signaling in ionizing radiation-triggered apoptosis was investigated using two previously described subclones of the autonomous erythro-myeloblastic cell line TF-1, radio-resistant and -sensitive TF-1-34 and TF-1-33, respectively. We show in nuclei-free lysates and cytoplasts that both cell lines failed to generate ceramide in response to ionizing radiation, Moreover, whereas cytoplasts did respond to anti-Fas stimulation through phosphatidylserine externalization, no effect was observed with ionizing radiation. Only in highly purified nuclei preparations did we observe ceramide generation, neutral sphingomyelinase activation, and apoptotic features (PARP cleavage, nuclear fragmentation, DNA laddering) in TF-1-33, but not in TF-1-34 cells, These observations suggest that nuclear sphingomyelinase and ceramide formation may contribute to ionizing radiation-triggered apoptosis.	Inst Claudius Regaud, INSERM E9910, F-31052 Toulouse, France; CNRS, UPR 9062, Inst Pharmacol & Biol Struct, Toulouse, France; CHU Rangueil, INSERM, U466, Lab Biochim Med, F-31403 Toulouse, France; CHU Purpan, Serv Hematol, F-31059 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse	Jafrezou, JP (corresponding author), Inst Claudius Regaud, INSERM E9910, 20 Rue Pont St Pierre, F-31052 Toulouse, France.	jaffrezou@icr.fnclcc.fr	Levade, Thierry/O-8948-2014					Albi E, 1997, BIOCHEM BIOPH RES CO, V236, P29, DOI 10.1006/bbrc.1997.6803; ALESSENKO A, 1995, MOL CELL BIOCHEM, V143, P169, DOI 10.1007/BF01816950; Andrieu N, 1996, EUR J BIOCHEM, V236, P738, DOI 10.1111/j.1432-1033.1996.00738.x; Bezombes C, 1998, FASEB J, V12, P101, DOI 10.1096/fasebj.12.1.101; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; Bruno AP, 1998, CELL DEATH DIFFER, V5, P172, DOI 10.1038/sj.cdd.4400330; BSTTCHER CJF, 1961, ANAL CHIM ACTA, V699, P57; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Chmura SJ, 1997, CANCER RES, V57, P1270; COCCO L, 1980, BIOCHEM BIOPH RES CO, V96, P890, DOI 10.1016/0006-291X(80)91439-4; DATTA R, 1995, CELL GROWTH DIFFER, V6, P363; DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; ESCARGUEILBLANC I, 1994, FASEB J, V8, P1075, DOI 10.1096/fasebj.8.13.7926374; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FOLCH J, 1957, J BIOL CHEM, V226, P497; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; KAPUSCINSKI J, 1977, ANAL BIOCHEM, V83, P252, DOI 10.1016/0003-2697(77)90533-4; KASTAN MB, 1991, CANCER RES, V51, P6304; Kharbanda S, 1996, CANCER RES, V56, P3617; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; LEHNERT S, 1995, RADIAT RES, V141, P108; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; Levade T, 1996, J LIPID RES, V37, P2525; LEVADE T, 1993, FEBS LETT, V329, P306, DOI 10.1016/0014-5793(93)80243-N; LINARDIC CM, 1994, J BIOL CHEM, V269, P23530; LING CC, 1994, RADIOTHER ONCOL, V32, P129; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MARTIN SJ, 1995, CELL DEATH DIFFER, V2, P253; MEYN RE, 1993, INT J RADIAT BIOL, V64, P583, DOI 10.1080/09553009314551801; Michael JM, 1997, CANCER RES, V57, P3600; MORRE DJ, 1971, METHOD ENZYMOL, V22, P130; OJCIUS DM, 1991, MOL IMMUNOL, V28, P1011, DOI 10.1016/0161-5890(91)90187-O; PENNINGTON R, 1961, BIOCHEM J, V80, P649, DOI 10.1042/bj0800649; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; RADFORD IR, 1986, INT J RADIAT BIOL, V49, P611; RADFORD JR, 1994, INT J RADIAT BIOL, V66, P329; Rusakov S A, 1993, Biokhimiia, V58, P724; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPANGLER M, 1975, CANCER RES, V35, P3131; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; TAMIYAKOIZUMI K, 1989, J BIOCHEM, V106, P593, DOI 10.1093/oxfordjournals.jbchem.a122901; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tsugane K, 1999, J HEPATOL, V31, P8, DOI 10.1016/S0168-8278(99)80158-5; WENGER DA, 1976, LIFE SCI, V19, P413, DOI 10.1016/0024-3205(76)90047-3; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	54	44	46	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2001	15	1					123	133		10.1096/fj.00-0305com	http://dx.doi.org/10.1096/fj.00-0305com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149900	Bronze			2022-12-28	WOS:000166312400021
J	Sallese, M; Salvatore, L; D'Urbano, E; Sala, G; Storto, M; Launey, T; Nicoletti, F; Knopfel, T; De Blasi, A				Sallese, M; Salvatore, L; D'Urbano, E; Sala, G; Storto, M; Launey, T; Nicoletti, F; Knopfel, T; De Blasi, A			The G-protein-coupled receptor kinase GRK4 mediates homologous desensitization of metabotropic glutamate receptor 1	FASEB JOURNAL			English	Article						Purkinje cells; mGlu(1) receptor; receptor internalization; GRK; antisense knock down	CEREBELLAR PURKINJE-CELLS; LONG-TERM DEPRESSION; SPLICE VARIANTS; RGS PROTEINS; IDENTIFICATION; EXPRESSION; MGLUR1; MICE; PHOSPHORYLATION; LOCALIZATION	G-protein-coupled receptor kinases (GRKs) are involved in the regulation of many G-protein-coupled receptors. As opposed to the other GRKs, such as rhodopsin kinase (GRK1) or beta -adrenergic receptor kinase (beta ARK, GRK2), no receptor substrate for GRK4 has been so far identified. Here we show that GRK4 is expressed in cerebellar Purkinje cells, where it regulates mGlu(1) metabotropic glutamate receptors, as indicated by the following: I) When coexpressed in heterologous cells (HEK293), mGlu(1) receptor signaling was desensitized by GRK4 in an agonist-dependent manner (homologous desensitization). 2) In transfected HEK293 and in cultured Purkinje cells, the exposure to glutamate agonists induced internalization of the receptor and redistribution of GRK4. There was a substantial colocalization of the receptor and kinase both under basal condition and after internalization. 3) Kinase activity was necessary for desensitizing mGlu(1a) receptor and agonist-dependent phosphorylation of this receptor was also documented. 4) Antisense treatment of cultured Purkinje cells, which significantly reduced the levels of GRK4 expression, induced a marked modification of the mGlu(1)-mediated functional response, consistent with an impaired receptor desensitization. The critical role for GRK4 in regulating mGlu(1) receptors implicates a major involvement of this kinase in the physiology of Purkinje cell, and in motor learning.	Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Mol Pharmacol & Pathol, I-66030 Santa Maria Imbaro, Italy; RIKEN, Brain Sci Inst, Wako, Saitama 35101, Japan; INM Neuromed, Pozzilli, Italy	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; RIKEN; IRCCS Neuromed	De Blasi, A (corresponding author), Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Mol Pharmacol & Pathol, Via Nazl, I-66030 Santa Maria Imbaro, Italy.		Storto, Marianna/G-8745-2012; Nicoletti, Ferdinando/K-4410-2016; Nicoletti, Ferdinando/T-4898-2019; Knöpfel, Thomas/B-1128-2008; Sallese, Michele/J-5347-2016; Sala, Gianluca/C-2056-2017; Launey, Thomas/A-2605-2010; Nicoletti, Ferdinando/A-2446-2010	Knöpfel, Thomas/0000-0002-5718-0765; Sallese, Michele/0000-0002-2555-3571; Sala, Gianluca/0000-0002-4494-915X; Launey, Thomas/0000-0001-9153-9260; NICOLETTI, Ferdinando/0000-0003-3366-7269; marianna, storto/0000-0002-0159-7449; Nicoletti, Ferdinando/0000-0003-0917-443X	Telethon [1238] Funding Source: Medline	Telethon(Fondazione Telethon)		AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; Ambrose Christine, 1992, Human Molecular Genetics, V1, P697, DOI 10.1093/hmg/1.9.697; Aragay AM, 1998, P NATL ACAD SCI USA, V95, P2985, DOI 10.1073/pnas.95.6.2985; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Carruthers AM, 1997, MOL PHARMACOL, V52, P406, DOI 10.1124/mol.52.3.406; CATANIA MV, 1991, J NEUROCHEM, V56, P1329, DOI 10.1111/j.1471-4159.1991.tb11429.x; Chuang TT, 1996, TRENDS PHARMACOL SCI, V17, P416, DOI 10.1016/S0165-6147(96)10048-1; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; CONQUET F, 1994, NATURE, V372, P237, DOI 10.1038/372237a0; CONTRERA JG, 1993, J PHARMACOL EXP THER, V265, P433; Flor PJ, 1996, J NEUROCHEM, V67, P58; Furuya S, 1998, BRAIN RES PROTOC, V3, P192, DOI 10.1016/S1385-299X(98)00040-3; Gereau RW, 1998, NEURON, V20, P143, DOI 10.1016/S0896-6273(00)80442-0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hepler JR, 1999, TRENDS PHARMACOL SCI, V20, P376, DOI 10.1016/S0165-6147(99)01369-3; Iacovelli L, 1999, MOL PHARMACOL, V56, P316, DOI 10.1124/mol.56.2.316; Iacovelli L, 1999, FASEB J, V13, P1; Inoue T, 1998, J NEUROSCI, V18, P5366, DOI 10.1523/JNEUROSCI.18-14-05366.1998; KANAI Y, 1994, J BIOL CHEM, V269, P20599; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; Lazari MDM, 1999, MOL ENDOCRINOL, V13, P866, DOI 10.1210/me.13.6.866; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Offermanns S, 1997, P NATL ACAD SCI USA, V94, P14089, DOI 10.1073/pnas.94.25.14089; PANNESE M, 1995, DEVELOPMENT, V121, P707; PICKERING DS, 1993, J NEUROCHEM, V61, P85, DOI 10.1111/j.1471-4159.1993.tb03540.x; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; PITCHER J, 1992, BIOCHEMISTRY-US, V31, P3193, DOI 10.1021/bi00127a021; Premont RT, 1996, J BIOL CHEM, V271, P6403, DOI 10.1074/jbc.271.11.6403; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; Prezeau L, 1996, MOL PHARMACOL, V49, P422; Sallese M, 1997, J BIOL CHEM, V272, P10188; SALLESE M, 1994, BIOCHEM BIOPH RES CO, V199, P848, DOI 10.1006/bbrc.1994.1306; Salvatore L, 1999, FEBS LETT, V449, P146, DOI 10.1016/S0014-5793(99)00420-2; Saugstad JA, 1998, J NEUROSCI, V18, P905; Smitt PS, 2000, NEW ENGL J MED, V342, P21, DOI 10.1056/NEJM200001063420104; STAUB C, 1992, EUR J NEUROSCI, V4, P832, DOI 10.1111/j.1460-9568.1992.tb00193.x; Virlon B, 1998, ENDOCRINOLOGY, V139, P2784, DOI 10.1210/en.139.6.2784; YUZAKI M, 1992, J NEUROSCI, V12, P4253	39	109	112	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2569	2580		10.1096/fj.00-0072com	http://dx.doi.org/10.1096/fj.00-0072com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099476				2022-12-28	WOS:000165723400028
J	Inui, A				Inui, A			Transgenic study of energy homeostasis equation: implications and confounding influences	FASEB JOURNAL			English	Review						melanocortin; neuropeptide Y; arcuate nucleus; body mass	CORTICOTROPIN-RELEASING HORMONE; MELANIN-CONCENTRATING HORMONE; RECEPTOR-DEFICIENT MICE; GLUCAGON-LIKE PEPTIDE-1; CENTRAL-NERVOUS-SYSTEM; BODY-WEIGHT REGULATION; AGOUTI-RELATED PROTEIN; INBRED MOUSE STRAINS; EARLY-ONSET OBESITY; NEUROPEPTIDE-Y	Recently novel molecular mediators and regulatory pathways for feeding and body weight regulation have been identified in the brain and the periphery. Mice lacking or overexpressing these mediators or receptors have been produced by molecular genetic techniques, and observations on mutant mice have shed new light on the role of each element in the homeostatic loop of body weight regulation. However, the interpretation of the phenotype is under the potential influence of developmental compensation and other genetic and environmental confounds. Specific alterations of the mediators and the consequences of the altered expression patterns are reviewed here and discussed in the context of their functions as suggested from conventional pharmacological studies. Advanced gene targeting strategies in which genes can be turned on or off at desired tissues and times would undoubtedly lead to a better understanding of the highly integrated and redundant systems for energy homeostasis equation.	Kobe Univ, Sch Med, Dept Internal Med 2, Chuo Ku, Kobe, Hyogo 6500017, Japan	Kobe University	Inui, A (corresponding author), Kobe Univ, Sch Med, Dept Internal Med 2, Chuo Ku, Kobe, Hyogo 6500017, Japan.							Adan RAH, 1997, PEPTIDES, V18, P1279, DOI 10.1016/S0196-9781(97)00078-8; Bale TL, 2000, NAT GENET, V24, P410, DOI 10.1038/74263; Beattie JH, 1998, P NATL ACAD SCI USA, V95, P358, DOI 10.1073/pnas.95.1.358; Blomqvist AG, 1997, TRENDS NEUROSCI, V20, P294, DOI 10.1016/S0166-2236(96)01057-0; Blundell JE, 1995, OBES RES, V3, pS471, DOI 10.1002/j.1550-8528.1995.tb00214.x; Boston BA, 1997, SCIENCE, V278, P1641, DOI 10.1126/science.278.5343.1641; Bray GA, 1999, ENDOCR REV, V20, P805, DOI 10.1210/er.20.6.805; Bray GA, 1998, RECENT PROG HORM RES, V53, P95; BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0; Brunner D, 1997, ANN NY ACAD SCI, V836, P81, DOI 10.1111/j.1749-6632.1997.tb52356.x; Burrows HL, 1998, J CLIN INVEST, V101, P1439, DOI 10.1172/JCI1963; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Caro JF, 1996, DIABETES, V45, P1455, DOI 10.2337/diab.45.11.1455; Caro JF, 1996, LANCET, V348, P159, DOI 10.1016/S0140-6736(96)03173-X; Chua S, 1997, DIABETES REV, V5, P2; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Coste SC, 2000, NAT GENET, V24, P403, DOI 10.1038/74255; Crabbe JC, 1999, SCIENCE, V284, P1670, DOI 10.1126/science.284.5420.1670; Crabbe JC, 1996, NAT GENET, V14, P98, DOI 10.1038/ng0996-98; Crawley JN, 1996, TRENDS NEUROSCI, V19, P181, DOI 10.1016/S0166-2236(96)20021-9; Crawley JN, 1997, PSYCHOPHARMACOLOGY, V132, P107, DOI 10.1007/s002130050327; Criscione L, 1998, J CLIN INVEST, V102, P2136, DOI 10.1172/JCI4188; Crusio WE, 1996, TRENDS NEUROSCI, V19, P186, DOI 10.1016/S0166-2236(96)20023-2; Cummings DE, 1996, NATURE, V382, P622, DOI 10.1038/382622a0; Curzon G, 1997, TRENDS PHARMACOL SCI, V18, P21, DOI 10.1016/S0165-6147(96)01003-6; Dong ZM, 1997, P NATL ACAD SCI USA, V94, P7526, DOI 10.1073/pnas.94.14.7526; Drago J, 1998, DEV NEUROSCI-BASEL, V20, P188, DOI 10.1159/000017313; DRAGO J, 1994, P NATL ACAD SCI USA, V91, P12564, DOI 10.1073/pnas.91.26.12564; Drucker DJ, 1998, DIABETES, V47, P159, DOI 10.2337/diabetes.47.2.159; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Elmquist JK, 1999, NEURON, V22, P221, DOI 10.1016/S0896-6273(00)81084-3; Elmquist JK, 1998, NAT NEUROSCI, V1, P445, DOI 10.1038/2164; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Flier JS, 1998, J CLIN ENDOCR METAB, V83, P1407, DOI 10.1210/jc.83.5.1407; Flier JS, 1998, CELL, V92, P437, DOI 10.1016/S0092-8674(00)80937-X; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; Frenette PS, 1996, NEW ENGL J MED, V335, P43, DOI 10.1056/NEJM199607043350108; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Garrick D, 1998, NAT GENET, V18, P56, DOI 10.1038/ng0198-56; Gerald C, 1996, NATURE, V382, P168, DOI 10.1038/382168a0; Gerlai R, 1996, TRENDS NEUROSCI, V19, P177, DOI 10.1016/S0166-2236(96)20020-7; Good DJ, 1997, NAT GENET, V15, P397, DOI 10.1038/ng0497-397; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Graham M, 1997, NAT GENET, V17, P273, DOI 10.1038/ng1197-273; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; GUTZWILLER JP, 1994, GASTROENTEROLOGY, V106, P1168, DOI 10.1016/0016-5085(94)90006-X; Hahm S, 1999, NEURON, V23, P537, DOI 10.1016/S0896-6273(00)80806-5; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Hamann A, 1996, ENDOCRINOLOGY, V137, P21, DOI 10.1210/en.137.1.21; Hampton LL, 1998, P NATL ACAD SCI USA, V95, P3188, DOI 10.1073/pnas.95.6.3188; Heinrichs SC, 1998, VITAM HORM, V54, P51, DOI 10.1016/S0083-6729(08)60921-8; Heinrichs SC, 1999, TRENDS PHARMACOL SCI, V20, P311, DOI 10.1016/S0165-6147(99)01335-8; HIMMSHAGEN J, 1992, OBESITY, P15; Hirsch E, 1996, P NATL ACAD SCI USA, V93, P11008, DOI 10.1073/pnas.93.20.11008; Hollopeter G, 1998, REGUL PEPTIDES, V75-6, P383, DOI 10.1016/S0167-0115(98)00092-5; Hollopeter G, 1998, INT J OBESITY, V22, P506, DOI 10.1038/sj.ijo.0800615; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Ibrahimi A, 1999, J BIOL CHEM, V274, P26761, DOI 10.1074/jbc.274.38.26761; Inui A, 1999, CANCER RES, V59, P4493; Inui A, 1999, TRENDS PHARMACOL SCI, V20, P43, DOI 10.1016/S0165-6147(99)01303-6; Inui A, 1999, TRENDS NEUROSCI, V22, P62, DOI 10.1016/S0166-2236(98)01292-2; Inui A, 1998, P ASSOC AM PHYSICIAN, V110, P171; Jacobson L, 1999, ENDOCRINOLOGY, V140, P310, DOI 10.1210/en.140.1.310; Jensen DR, 1997, AM J PHYSIOL-REG I, V273, pR683, DOI 10.1152/ajpregu.1997.273.2.R683; Kalra SP, 1999, ENDOCR REV, V20, P68, DOI 10.1210/er.20.1.68; Karolyi IJ, 1999, P NATL ACAD SCI USA, V96, P11595, DOI 10.1073/pnas.96.20.11595; KATZ EB, 1995, NATURE, V377, P151, DOI 10.1038/377151a0; Kieffer BL, 1999, TRENDS PHARMACOL SCI, V20, P19, DOI 10.1016/S0165-6147(98)01279-6; King PJ, 1998, DRUG NEWS PERSPECT, V11, P402, DOI 10.1358/dnp.1998.11.7.659946; Kishimoto T, 2000, NAT GENET, V24, P415, DOI 10.1038/74271; Klaus S, 1998, AM J PHYSIOL-REG I, V274, pR287, DOI 10.1152/ajpregu.1998.274.2.R287; KLEBIG ML, 1995, P NATL ACAD SCI USA, V92, P4728, DOI 10.1073/pnas.92.11.4728; KOZAK LP, 1991, GENE DEV, V5, P2256, DOI 10.1101/gad.5.12a.2256; Krude H, 1998, NAT GENET, V19, P155, DOI 10.1038/509; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Kushi A, 1998, P NATL ACAD SCI USA, V95, P15659, DOI 10.1073/pnas.95.26.15659; Lathe R, 1996, TRENDS NEUROSCI, V19, P183, DOI 10.1016/S0166-2236(96)20022-0; LEIBOWITZ SF, 1992, TRENDS NEUROSCI, V15, P491, DOI 10.1016/0166-2236(92)90101-D; LEIBSON PJ, 1995, IMMUNITY, V3, P5, DOI 10.1016/1074-7613(95)90153-1; LEVI A, 1985, SCIENCE, V229, P393, DOI 10.1126/science.3839317; Levin BE, 1998, AM J PHYSIOL-REG I, V274, pR412, DOI 10.1152/ajpregu.1998.274.2.R412; Levin BE, 1999, AM J PHYSIOL-REG I, V276, pR382, DOI 10.1152/ajpregu.1999.276.2.R382; Levine AS, 1997, ANNU REV NUTR, V17, P597, DOI 10.1146/annurev.nutr.17.1.597; Levine AS, 1998, CURR BIOL, V8, pR251, DOI 10.1016/S0960-9822(98)70153-8; Lipworth BJ, 1996, BRIT J CLIN PHARMACO, V42, P291, DOI 10.1046/j.1365-2125.1996.04222.x; Liu S, 1999, J CLIN INVEST, V103, P207, DOI 10.1172/JCI4243; Lovejoy DA, 1998, J NEUROENDOCRINOL, V10, P483; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; Lowell BB, 1998, ENDOCR J, V45, pS9, DOI 10.1507/endocrj.45.Suppl_S9; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Marsh DJ, 1998, NAT MED, V4, P718, DOI 10.1038/nm0698-718; Marsh DJ, 1999, NAT GENET, V21, P119, DOI 10.1038/5070; Martinez V, 1998, AM J PHYSIOL-GASTR L, V274, pG965, DOI 10.1152/ajpgi.1998.274.5.G965; McKnight GS, 1991, CURR OPIN CELL BIOL, V3, P213; Meeran K, 1999, ENDOCRINOLOGY, V140, P244, DOI 10.1210/en.140.1.244; Melnyk A, 1998, AM J PHYSIOL-REG I, V274, pR1131, DOI 10.1152/ajpregu.1998.274.4.R1131; MERALI Z, 1993, AM J PHYSIOL, V264, pR1031, DOI 10.1152/ajpregu.1993.264.5.R1031; Miltenberger RJ, 1997, J NUTR, V127, pS1902, DOI 10.1093/jn/127.9.1902S; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; MUGLIA L, 1995, NATURE, V373, P427, DOI 10.1038/373427a0; Muglia LJ, 1997, J CLIN INVEST, V99, P2923, DOI 10.1172/JCI119487; Murphy DL, 1999, TRENDS PHARMACOL SCI, V20, P246, DOI 10.1016/S0165-6147(99)01325-5; Murray I, 2000, ENDOCRINOLOGY, V141, P1041, DOI 10.1210/en.141.3.1041; Mynatt RL, 1997, P NATL ACAD SCI USA, V94, P919, DOI 10.1073/pnas.94.3.919; NAHON JL, 1994, CRIT REV NEUROBIOL, V8, P221; Naveilhan P, 1999, NAT MED, V5, P1188, DOI 10.1038/13514; Nonogaki K, 1998, NAT MED, V4, P1152, DOI 10.1038/2647; O'Rahilly S, 1998, NATURE, V392, P330, DOI 10.1038/32769; Ogawa Y, 1999, DIABETES, V48, P1822, DOI 10.2337/diabetes.48.9.1822; OhkiHamazaki H, 1997, NATURE, V390, P165, DOI 10.1038/36568; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; Olson EN, 1996, CELL, V85, P1, DOI 10.1016/S0092-8674(00)81073-9; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; Pedrazzini T, 1998, NAT MED, V4, P722, DOI 10.1038/nm0698-722; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; PEPIN MC, 1992, NATURE, V355, P725, DOI 10.1038/355725a0; Presse F, 1996, NEUROSCIENCE, V71, P735, DOI 10.1016/0306-4522(95)00481-5; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; Ren JM, 1998, DIABETES, V47, P493, DOI 10.2337/diabetes.47.3.493; Revelli JP, 1997, J CLIN INVEST, V100, P1098, DOI 10.1172/JCI119620; RICHARD D, 1993, AM J PHYSIOL, V265, pR146, DOI 10.1152/ajpregu.1993.265.1.R146; Rohrer DK, 1998, PHYSIOL REV, V78, P35, DOI 10.1152/physrev.1998.78.1.35; Rubinstein M, 1996, P NATL ACAD SCI USA, V93, P3995, DOI 10.1073/pnas.93.9.3995; Salton SRJ, 2000, NEURON, V25, P265, DOI 10.1016/S0896-6273(00)80892-2; Samanin R, 1996, THERAPIE, V51, P107; SAUDOU F, 1994, SCIENCE, V265, P1875, DOI 10.1126/science.8091214; Schaapveld RQJ, 1997, DEV BIOL, V188, P134, DOI 10.1006/dbio.1997.8630; Schwartz MW, 1997, NEW ENGL J MED, V336, P1802, DOI 10.1056/NEJM199706193362507; Scrocchi LA, 1996, NAT MED, V2, P1254, DOI 10.1038/nm1196-1254; Scrocchi LA, 1998, ENDOCRINOLOGY, V139, P3127, DOI 10.1210/en.139.7.3127; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; Shimada M, 1998, NATURE, V396, P670, DOI 10.1038/25341; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; Silva AJ, 1997, NEURON, V19, P755, DOI 10.1016/S0896-6273(00)80958-7; Simonin F, 1998, EMBO J, V17, P886, DOI 10.1093/emboj/17.4.886; Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597-19; Smagin GN, 1998, NEUROREPORT, V9, P1601, DOI 10.1097/00001756-199805110-00063; Snyder SE, 1998, J COMP NEUROL, V394, P91; Soloveva V, 1997, MOL ENDOCRINOL, V11, P27, DOI 10.1210/me.11.1.27; Son JH, 1997, MOL PSYCHIATR, V2, P26, DOI 10.1038/sj.mp.4000181; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Spina M, 1996, SCIENCE, V273, P1561, DOI 10.1126/science.273.5281.1561; Stanley B.G., 1993, BIOL NEUROPEPTIDE RE, P457, DOI [10.1007/978-1-59259-465-8_11, DOI 10.1007/978-1-59259-465-8_11]; STENZELPOORE MP, 1992, ENDOCRINOLOGY, V130, P3378, DOI 10.1210/en.130.6.3378; STENZELPOORE MP, 1994, J NEUROSCI, V14, P2579; Strader CD, 1998, DRUG DISCOV TODAY, V3, P250, DOI 10.1016/S1359-6446(98)01189-1; Strobel A, 1998, NAT GENET, V18, P213, DOI 10.1038/ng0398-213; Strosberg AD, 1999, TRENDS PHARMACOL SCI, V20, P227, DOI 10.1016/S0165-6147(99)01313-9; SUSULIC VS, 1995, J BIOL CHEM, V270, P29483, DOI 10.1074/jbc.270.49.29483; Szczypka MS, 1999, P NATL ACAD SCI USA, V96, P12138, DOI 10.1073/pnas.96.21.12138; TACHE Y, 1982, TRENDS NEUROSCI, V5, P431, DOI 10.1016/0166-2236(82)90234-X; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; TECOTT LH, 1995, NATURE, V374, P542, DOI 10.1038/374542a0; TEMPEL DL, 1994, J NEUROENDOCRINOL, V6, P479, DOI 10.1111/j.1365-2826.1994.tb00611.x; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Tordoff MG, 1999, SCIENCE, V285, P2069; Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703; Tsien JZ, 1996, CELL, V87, P1317, DOI 10.1016/S0092-8674(00)81826-7; Turnbull AV, 1997, P SOC EXP BIOL MED, V215, P1; Turton MD, 1996, NATURE, V379, P69, DOI 10.1038/379069a0; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Ueno N, 1999, GASTROENTEROLOGY, V117, P1427, DOI 10.1016/S0016-5085(99)70293-3; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; VAUGHAN J, 1995, NATURE, V378, P287, DOI 10.1038/378287a0; VAUGHAN JM, 1989, ENDOCRINOLOGY, V125, P1660, DOI 10.1210/endo-125-3-1660; Ventre J, 1997, DIABETES, V46, P1526, DOI 10.2337/diabetes.46.9.1526; Weinstock PH, 1995, J CLIN INVEST, V96, P2555, DOI 10.1172/JCI118319; Weinstock PH, 1997, P NATL ACAD SCI USA, V94, P10261, DOI 10.1073/pnas.94.19.10261; Wieland HA, 1998, BRIT J PHARMACOL, V125, P549, DOI 10.1038/sj.bjp.0702084; Wilson BD, 1999, MOL MED TODAY, V5, P250, DOI 10.1016/S1357-4310(99)01471-9; Wilson MA, 1997, TRENDS NEUROSCI, V20, P102, DOI 10.1016/S0166-2236(96)01023-5; Woods SC, 1998, SCIENCE, V280, P1378, DOI 10.1126/science.280.5368.1378; XU M, 1994, CELL, V79, P729, DOI 10.1016/0092-8674(94)90557-6; Yamada M, 1997, P NATL ACAD SCI USA, V94, P10862, DOI 10.1073/pnas.94.20.10862; Yaswen L, 1999, NAT MED, V5, P1066, DOI 10.1038/12506; YORK DA, 1998, HDB OBESITY, P191; Yu SH, 2000, J CLIN INVEST, V105, P615, DOI 10.1172/JCI8437; ZARJEVSKI N, 1993, ENDOCRINOLOGY, V133, P1753, DOI 10.1210/en.133.4.1753; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; ZHENG H, 1995, IMMUNITY, V3, P9, DOI 10.1016/1074-7613(95)90154-X; Zhou QY, 1995, CELL, V83, P1197, DOI 10.1016/0092-8674(95)90145-0	189	40	41	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2158	2170		10.1096/fj.00-0291rev	http://dx.doi.org/10.1096/fj.00-0291rev			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053236				2022-12-28	WOS:000165190800008
J	Canitrot, Y; Hoffmann, JS; Calsou, P; Hayakawa, H; Salles, B; Cazaux, C				Canitrot, Y; Hoffmann, JS; Calsou, P; Hayakawa, H; Salles, B; Cazaux, C			Nucleotide excision repair DNA synthesis by excess DNA polymerase beta: a potential source of genetic instability in cancer cells	FASEB JOURNAL			English	Article						cell variants; DNA repair; mutagenesis	IN-VITRO; MUTATOR PHENOTYPE; MAMMALIAN-CELLS; FREE-EXTRACTS; LINEAR DNA; LIGASE-I; PROTEIN; REPLICATION; EXPRESSION; COMPLEX	The nucleotide excision repair pathway contributes to genetic stability by removing a wide range of DNA damage through an error-free reaction. When the lesion is located, the altered strand is incised on both sides of the lesion and a damaged oligonucleotide excised, A repair patch is then synthesized and the repaired strand is ligated. It is assumed that only DNA polymerases delta and/or epsilon participate to the repair DNA synthesis step. Using UV and cisplatin-modified DNA templates, we measured in vitro that extracts from cells overexpressing the error-prone DNA polymerase beta exhibited a five- to sixfold increase of the ultimate DNA synthesis activity compared with control extracts and demonstrated the specific involvement of Pol beta in this step, By using a 28 nt gapped, double-stranded DNA substrate mimicking the product of the incision step, we showed that pol beta is able to catalyze strand displacement downstream of the gap, We discuss these data within the scope of a hypothesis previously presented proposing that excess error-prone Pol beta in cancer cells could perturb the well-defined specific functions of DNA polymerases during error-free DNA transactions.	Inst Pharmacol & Biol Struct, Grp Instabil Genet & Canc, CNRS, UMR 5089, F-31077 Toulouse 4, France; Inst Pharmacol & Biol Struct, Grp Toxicoresistance, CNRS, UMR 5089, F-31077 Toulouse, France; Kyushu Univ, Sch Med, Dept Biochem, Fukuoka 8128582, Japan	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Kyushu University	Salles, B (corresponding author), Inst Pharmacol & Biol Struct, Grp Instabil Genet & Canc, CNRS, UMR 5089, 205 Route Narbonne, F-31077 Toulouse 4, France.		salles, bernard/B-8531-2008; calsou, patrick/AAB-5123-2020; Hoffmann, Jean-Sebastien/O-9183-2014	Hoffmann, Jean-Sebastien/0000-0003-2222-354X; Calsou, Patrick/0000-0001-7951-9806				APPLEGREN N, 1995, J CELL BIOCHEM, V59, P91, DOI 10.1002/jcb.240590111; Araujo SJ, 1999, MUTAT RES-DNA REPAIR, V435, P23, DOI 10.1016/S0921-8777(99)00042-7; BARBOULE N, 1995, INT J CANCER, V63, P611, DOI 10.1002/ijc.2910630502; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; BIGGERSTAFF M, 1991, MUTAT RES, V254, P217, DOI 10.1016/0921-8777(91)90059-X; Bouayadi K, 1997, CANCER RES, V57, P110; CALSOU P, 1994, NUCLEIC ACIDS RES, V22, P4937, DOI 10.1093/nar/22.23.4937; CALSOU P, 1992, NUCLEIC ACIDS RES, V20, P6363, DOI 10.1093/nar/20.23.6363; CALSOU P, 1994, BIOCHEM BIOPH RES CO, V202, P788, DOI 10.1006/bbrc.1994.1999; Canitrot Y, 1999, FASEB J, V13, P1107, DOI 10.1096/fasebj.13.9.1107; Canitrot Y, 1999, ONCOGENE, V18, P2676, DOI 10.1038/sj.onc.1202619; Canitrot Y, 1998, P NATL ACAD SCI USA, V95, P12586, DOI 10.1073/pnas.95.21.12586; COPELAND WC, 1992, J BIOL CHEM, V267, P21459; DACOSTA LT, 1995, NAT GENET, V9, P10, DOI 10.1038/ng0195-10; DeMott MS, 1998, J BIOL CHEM, V273, P27492, DOI 10.1074/jbc.273.42.27492; Dianov GL, 1999, J BIOL CHEM, V274, P13741, DOI 10.1074/jbc.274.20.13741; Dimitriadis EK, 1998, J BIOL CHEM, V273, P20540, DOI 10.1074/jbc.273.32.20540; Flohr T, 1999, INT J CANCER, V80, P919, DOI 10.1002/(SICI)1097-0215(19990315)80:6<919::AID-IJC19>3.0.CO;2-U; FORNACE AJ, 1989, MOL CELL BIOL, V9, P851, DOI 10.1128/MCB.9.2.851; Frit P, 1998, J MOL BIOL, V284, P963, DOI 10.1006/jmbi.1998.2257; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; Gomi A, 1996, BIOCHEM BIOPH RES CO, V227, P558, DOI 10.1006/bbrc.1996.1545; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; HANSSON J, 1989, NUCLEIC ACIDS RES, V17, P8073, DOI 10.1093/nar/17.20.8073; HAUSER J, 1986, MOL CELL BIOL, V6, P277, DOI 10.1128/MCB.6.1.277; HOFFMANN J, 1997, INT J ONCOL, V12, P377; Hoffmann JS, 1996, P NATL ACAD SCI USA, V93, P13766, DOI 10.1073/pnas.93.24.13766; HOFFMANN JS, 1995, P NATL ACAD SCI USA, V92, P5356, DOI 10.1073/pnas.92.12.5356; JOZAN S, 1992, IN VITRO CELL DEV-AN, V28A, P687; KamathLoeb AS, 1997, J BIOL CHEM, V272, P5892, DOI 10.1074/jbc.272.9.5892; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kornberg A., 1992, DNA REPLICATION; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; KUMAR A, 1990, J BIOL CHEM, V265, P2124; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; KUNKEL TA, 1986, J BIOL CHEM, V261, P3581; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LOEB L, 1997, CANC SURVEYS, V28, P329; Macdonald F., 1997, MOL BIOL CANC; Marintchev A, 1999, NAT STRUCT BIOL, V6, P884; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; Narayan S, 1996, J BIOL CHEM, V271, P18508, DOI 10.1074/jbc.271.31.18508; Osheroff WP, 1999, J BIOL CHEM, V274, P3642, DOI 10.1074/jbc.274.6.3642; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; Plug AW, 1997, P NATL ACAD SCI USA, V94, P1327, DOI 10.1073/pnas.94.4.1327; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; Radman M, 1999, NATURE, V401, P866, DOI 10.1038/44738; SCANLON KJ, 1989, CANCER INVEST, V7, P581, DOI 10.3109/07357908909017533; SHIJVI MKK, 1992, CELL, V69, P367; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1999, CARCINOGENESIS, V20, P1049, DOI 10.1093/carcin/20.6.1049; Torkelson J, 1997, EMBO J, V16, P3303, DOI 10.1093/emboj/16.11.3303; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; Wood RD, 1997, CARCINOGENESIS, V18, P605, DOI 10.1093/carcin/18.4.605; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036; Yoon JH, 1999, BIOCHEMISTRY-US, V38, P4809, DOI 10.1021/bi990105i; ZMUDZKA BZ, 1988, NUCLEIC ACIDS RES, V16, P9589	62	54	60	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2000	14	12					1765	1774		10.1096/fj.99-1063com	http://dx.doi.org/10.1096/fj.99-1063com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973926				2022-12-28	WOS:000089212400016
J	Taraboletti, G; Morbidelli, L; Donnini, S; Parenti, A; Granger, HJ; Giavazzi, R; Ziche, M				Taraboletti, G; Morbidelli, L; Donnini, S; Parenti, A; Granger, HJ; Giavazzi, R; Ziche, M			The heparin binding 25 kDa fragment of thrombospondin-1 promotes angiogenesis and modulates gelatinase and TIMP-2 production in endothelial cells	FASEB JOURNAL			English	Article									Univ Siena, Inst Pharmacol Sci, I-53100 Siena, Italy; Univ Florence, Dept Pharmacol, Florence, Italy; Mario Negri Inst Pharmacol Res, Dept Oncol, Bergamo, Italy; Texas A&M Univ, Hlth Sci Ctr, Microcirculat Res Inst, College Stn, TX USA; Texas A&M Univ, Hlth Sci Ctr, Dept Physiol, College Stn, TX USA	University of Siena; University of Florence; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Ziche, M (corresponding author), Univ Siena, Inst Pharmacol Sci, Vial Piccolomini 140, I-53100 Siena, Italy.		Morbidelli, Lucia/AAC-7858-2020; Morbidelli, Lucia/K-4053-2016; Giavazzi, Raffaella/ABB-9768-2020; Donnini, Sandra/K-9252-2019; Taraboletti, Giulia/J-4089-2018; Giavazzi, Raffaella/J-7424-2018	Morbidelli, Lucia/0000-0001-8148-7049; Giavazzi, Raffaella/0000-0001-5249-8208; Donnini, Sandra/0000-0001-6617-1644; Taraboletti, Giulia/0000-0001-8780-5001; Parenti, Astrid/0000-0002-7980-6853					0	117	123	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2000	14	12					1674	1676						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973914				2022-12-28	WOS:000089212400004
J	Foehr, ED; Tatavos, A; Tanabe, E; Raffioni, S; Goetz, S; Dimarco, E; De Luca, M; Bradshaw, RA				Foehr, ED; Tatavos, A; Tanabe, E; Raffioni, S; Goetz, S; Dimarco, E; De Luca, M; Bradshaw, RA			Discoidin domain receptor 1 (DDR1) signaling in PC12 cells: activation of juxtamembrane domains in PDGFR/DDR/TrkA chimeric receptors	FASEB JOURNAL			English	Article						tyrosine kinase; collagen receptor; signal transduction	NORMAL HUMAN KERATINOCYTES; GROWTH-FACTOR RECEPTOR; TYROSINE KINASE; ADAPTER PROTEINS; BINDING-SITES; TRANSDUCTION; COLLAGEN; SHC; DIFFERENTIATION; IDENTIFICATION	The discoidin domain receptor (DDR1) is characterized by a discoidin I motif in the extracellular domain, an unusually long cytoplasmic juxtamembrane (JM) region, and a kinase domain that is 45% identical to that of the NGF receptor, TrkA. DDR1 also has a major splice form, which has a 37 amino acid insert in the JM region with a consensus Shc PTB site that is lacking in the shorter receptor. One class of ligands for the DDR receptors has recently been identified as being derived from the collagen family, but neither native PC12 cells, which express modest amounts of DDR1, nor transfected PC12 cells, which express much larger amounts of DDR1, respond to this ligand. A chimeric receptor, containing the extracellular domain of hPDGFR beta fused to the transmembrane and intracellular regions of DDR1, also fails to mediate neuronal-like differentiation in stably transfected PC12 cells and is only weakly autophosphorylated. However, chimeric receptors, which are composed of combinations of intracellular regions from DDR1 and TrkA (with the extracellular domain of hPDGFR beta), in some cases provided ligand (PDGF) -inducible receptor responses. Those with the TrkA kinase domain and the DDR1 JM regions were able to produce differentiation to varying degrees, whereas the opposite combination did not. Analysis of the signaling responses of the two chimeras with DDR1 JM sequences (with and without the insert) indicated that the shorter sequence bound and activated FRS2 whereas the insert-containing form activated Shc instead. Both activated PLC gamma through the carboxyl-terminal tyrosine of the TrkA domain (Y785 in TrkA residue numbering). Mutation of this site (Y-->F) eliminated PLC gamma activation (indicating there are no other cryptic binding sites for PI,Cy in the DDR1 sequences) and markedly reduced the differentiative activity of the receptor. This is in contrast to TrkA (or PDGFR beta/TrkA chimeras), where ablation of this pathway has no notable effect on PC12 cell morphogenic responses. Thus, the activation of FRS2 and Shc (leading to MAPK activation) is weaker in the DDR1/TrkA chimeras than in TrkA alone, and the PLC gamma contribution becomes essential for full response. Nonetheless, both DDR1 JM regions contain potentially usable signaling sites, albeit they apparently are not activated directly in DDR1 (or DDR1 chimeras) in a ligand-dependent fashion. These findings suggest that the DDR1 receptors do have signaling capacity but may require additional components or altered conditions to fully activate their kinase domains and/or sustain the activation of the JM sites.	Univ Calif Irvine, Coll Med, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Dept Anat & Neurobiol, Irvine, CA 92697 USA; Ist Nazl Ric Canc, Ctr Biotechnol Avanzate, I-16132 Genoa, Italy	University of California System; University of California Irvine; University of California System; University of California Irvine; University of Genoa; IRCCS AOU San Martino IST	Bradshaw, RA (corresponding author), Univ Calif Irvine, Coll Med, Dept Physiol & Biophys, Med Sci 1 D238, Irvine, CA 92697 USA.	rablab@uci.edu	De Luca, Michele/N-5883-2014; Bradshaw, Ralph A/K-1515-2013	De Luca, Michele/0000-0002-0850-8445; 	NIA NIH HHS [AG09735] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG009735] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALVES F, 1995, ONCOGENE, V10, P609; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DIMARCO E, 1993, J BIOL CHEM, V268, P24290; DIMARCO E, 1993, J BIOL CHEM, V268, P22838; Foehr ED, 1998, IMMUNOL CELL BIOL, V76, P406, DOI 10.1046/j.1440-1711.1998.00775.x; Harmer SL, 1997, MOL CELL BIOL, V17, P4087, DOI 10.1128/MCB.17.7.4087; Heldin C.-H., 1996, SIGNAL TRANSDUCTION; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; JOHNSON JD, 1993, P NATL ACAD SCI USA, V90, P5677, DOI 10.1073/pnas.90.12.5677; JOHNSON JD, 1993, P NATL ACAD SCI USA, V90, P10891, DOI 10.1073/pnas.90.22.10891; KARN T, 1993, ONCOGENE, V8, P3433; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LAVAL S, 1994, CELL GROWTH DIFFER, V5, P1173; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; Marais R, 1998, SCIENCE, V280, P989; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Perez JL, 1996, ONCOGENE, V12, P1469; Plowman GD, 1999, P NATL ACAD SCI USA, V96, P13603, DOI 10.1073/pnas.96.24.13603; Raffioni S, 1999, P NATL ACAD SCI USA, V96, P7178, DOI 10.1073/pnas.96.13.7178; Raffioni S, 1998, J BIOL CHEM, V273, P35250, DOI 10.1074/jbc.273.52.35250; SANCHEZ MP, 1994, P NATL ACAD SCI USA, V91, P1819, DOI 10.1073/pnas.91.5.1819; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Schlessinger J, 1997, CELL, V91, P869, DOI 10.1016/S0092-8674(00)80477-8; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; SPRINGER WR, 1984, CELL, V39, P557, DOI 10.1016/0092-8674(84)90462-8; Thomas D, 1997, J BIOL CHEM, V272, P22293, DOI 10.1074/jbc.272.35.22293; VAMBUTAS V, 1995, J BIOL CHEM, V270, P25629, DOI 10.1074/jbc.270.43.25629; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987; Yoon SO, 1997, J BIOL CHEM, V272, P23231, DOI 10.1074/jbc.272.37.23231; ZERLIN M, 1993, ONCOGENE, V8, P2731	35	34	34	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2000	14	7					973	981		10.1096/fasebj.14.7.973	http://dx.doi.org/10.1096/fasebj.14.7.973			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	309CG	10783152				2022-12-28	WOS:000086749500016
J	Sasaki, T; Hohenester, E; Zhang, RZ; Gotta, S; Speer, MC; Tandan, R; Timpl, R; Chu, ML				Sasaki, T; Hohenester, E; Zhang, RZ; Gotta, S; Speer, MC; Tandan, R; Timpl, R; Chu, ML			A Bethlem myopathy Gly to Glu mutation in the von Willebrand factor A domain N2 of the collagen alpha 3(VI) chain interferes with protein folding	FASEB JOURNAL			English	Article						haploin sufficiency; inherited disease; protein misfolding; recombinant production	FACTOR A1 DOMAIN; VI COLLAGEN; CRYSTAL-STRUCTURE; IN-VITRO; BINDING; MATRIX; EXPRESSION; CALCIUM; GLYCOPROTEIN; LOCALIZATION	A single G1679E mutation in the amino-terminal globular domain N2 of the alpha 3 chain of type VI collagen tvas found in a large family affected with Bethlem myopathy, Recombinant production of N2 (similar to 200 residues) in transfected mammalian cells has now been used to examine the possibility that the mutation interfered with protein folding. The wild-type form and a G1679A mutant were produced at high levels and shown to fold into a stable globular structure. Only a small amount of secretion was observed for mutants G1679E and G1679Q, which apparently were efficiently degraded within the cells. Homology modeling onto the related von Willebrand factor A1 structure indicated that substitution of G1679 by the bulky E or Q cannot be accommodated without considerable changes in the folding pattern, This suggests protein misfolding as a molecular basis for this particular mutation in Bethlem myopathy, in agreement with radioimmunoassay data showing reduced levels of domain N2 in cultured fibroblasts from two patients.	Max Planck Inst Biochem, D-82152 Martinsried, Germany; Univ London Imperial Coll Sci Technol & Med, Blackett Lab, Biophys Sect, London SW7 2AZ, England; Univ London Imperial Coll Sci Technol & Med, Div Med, London SW7 2AZ, England; Thomas Jefferson Univ, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA; Duke Univ, Med Ctr, Dept Med, Med Genet Sect, Durham, NC 27710 USA; Univ Vermont, Coll Med, Dept Neurol, Burlington, VT 05405 USA	Max Planck Society; Imperial College London; Imperial College London; Jefferson University; Duke University; University of Vermont	Timpl, R (corresponding author), Max Planck Inst Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038912] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS026630] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR38912] Funding Source: Medline; NINDS NIH HHS [NS26630] Funding Source: Medline; Wellcome Trust [054334] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Wellcome Trust(Wellcome TrustEuropean Commission)		Andac Z, 1999, J MOL BIOL, V287, P253, DOI 10.1006/jmbi.1999.2606; BETHLEM J, 1976, BRAIN, V99, P91, DOI 10.1093/brain/99.1.91; Bonaldo P, 1998, HUM MOL GENET, V7, P2135, DOI 10.1093/hmg/7.13.2135; Branden C., 1999, INTRO PROTEIN STRUCT; Brodsky B, 1995, FASEB J, V9, P1537, DOI 10.1096/fasebj.9.15.8529832; Brodsky B, 1997, MATRIX BIOL, V15, P545, DOI 10.1016/S0945-053X(97)90030-5; Bruckner-Tuderman L, 1999, MATRIX BIOL, V18, P43, DOI 10.1016/S0945-053X(98)00007-9; Celikel R, 1998, NAT STRUCT BIOL, V5, P189, DOI 10.1038/nsb0398-189; CHAN D, 1995, J BIOL CHEM, V270, P4558, DOI 10.1074/jbc.270.9.4558; CHU ML, 1990, EMBO J, V9, P385, DOI 10.1002/j.1460-2075.1990.tb08122.x; DIETZ HC, 1995, HUM MOL GENET, V4, P1799, DOI 10.1093/hmg/4.suppl_1.1799; Dublet B, 1999, J BIOL CHEM, V274, P18909, DOI 10.1074/jbc.274.27.18909; Emsley J, 1998, J BIOL CHEM, V273, P10396, DOI 10.1074/jbc.273.17.10396; ENGEL J, 1994, METHOD ENZYMOL, V245, P469; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jobsis GJ, 1996, NEUROLOGY, V46, P779, DOI 10.1212/WNL.46.3.779; Jobsis GJ, 1996, NAT GENET, V14, P113, DOI 10.1038/ng0996-113; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; Lamande SR, 1998, J BIOL CHEM, V273, P7423, DOI 10.1074/jbc.273.13.7423; Lamande SR, 1998, HUM MOL GENET, V7, P981, DOI 10.1093/hmg/7.6.981; Loo TW, 1998, J BIOL CHEM, V273, P32373, DOI 10.1074/jbc.273.49.32373; Marks DS, 1999, J BIOL CHEM, V274, P3632, DOI 10.1074/jbc.274.6.3632; Pan TC, 1998, HUM MOL GENET, V7, P807, DOI 10.1093/hmg/7.5.807; Pepe G, 1999, BIOCHEM BIOPH RES CO, V258, P802, DOI 10.1006/bbrc.1999.0680; Pepe G, 1999, NEUROMUSCULAR DISORD, V9, P264, DOI 10.1016/S0960-8966(99)00014-0; POTTGIESSER J, 1994, J MOL BIOL, V238, P563, DOI 10.1006/jmbi.1994.1315; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Pulkkinen L, 1999, MATRIX BIOL, V18, P29, DOI 10.1016/S0945-053X(98)00005-5; Ramirez F, 1996, CURR OPIN GENET DEV, V6, P309, DOI 10.1016/S0959-437X(96)80007-4; Sasaki T, 1996, J CELL SCI, V109, P2895; SPECKS U, 1992, EMBO J, V11, P4281, DOI 10.1002/j.1460-2075.1992.tb05527.x; Speer MC, 1996, HUM MOL GENET, V5, P1043, DOI 10.1093/hmg/5.7.1043; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; Talts JF, 1998, FEBS LETT, V426, P71, DOI 10.1016/S0014-5793(98)00312-3; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TILLET E, 1994, EUR J BIOCHEM, V221, P177, DOI 10.1111/j.1432-1033.1994.tb18727.x; Timpl R, 1994, EXTRACELLULAR MATRIX, P207, DOI 10.1016/B978-0-12-775170-2.50012-3; TIMPL R, 1982, IMMUNOCHEMISTRY EXTR, V1, P199; WEIL D, 1988, AM J HUM GENET, V42, P435; Whiteman P, 1998, J BIOL CHEM, V273, P7807, DOI 10.1074/jbc.273.14.7807	42	27	27	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2000	14	5					761	768		10.1096/fasebj.14.5.761	http://dx.doi.org/10.1096/fasebj.14.5.761			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301DH	10744632				2022-12-28	WOS:000086292700013
J	Huang, DY; Shenoy, A; Cui, JK; Huang, WY; Liu, PK				Huang, DY; Shenoy, A; Cui, JK; Huang, WY; Liu, PK			In situ detection of AP sites and DNA strand breaks bearing 3 '-phosphate termini in ischemic mouse brain	FASEB JOURNAL			English	Article						aging; apoptosis; oxidative DNA damage; DNA repair; stroke	NITRIC-OXIDE SYNTHASE; MITOCHONDRIAL-DNA; OXIDATIVE DAMAGE; FOREBRAIN ISCHEMIA; CELL-DEATH; NUCLEAR; 7-NITROINDAZOLE; REPAIR; EXCITOTOXICITY; MUTAGENESIS	Our aims were to examine whether oxidative DNA damage was elevated in brain cells of male C57BL/6 mice after oxidative stress, and to determine whether neuronal nitric oxide synthase (nNOS) was involved in such damage. Oxidative stress was induced by occluding both common carotid arteries for 90 min, followed by reperfusion, Escherichia coli exonuclease LII (Exo III) removes apyrimidinic or apurinic (AP) sites and 3'-phosphate termini in single-strand breaks, and converts these lesions to 3'OH termini. These ExoIII-sensitive sites (EXOSS) can then be postlabeled using digoxigenin11-dUTP and Klenow DNA polymerase-I, and detected using fluorescein isothiocyanate-IgG against digoxigenin, Compared with the non-ischemia controls, the density of EXOSS-positive cells was elevated at least 20-fold (P < 0.01) at 15 min of reperfusion, and remained elevated for another 30 min. EXOSS mainly occurred in the cell nuclei of the astrocytes and neurons. Signs of cell death were detected at 24 h of reperfusion and occurred mostly in the neurons. Both DNA damage and cell death in the cerebral cortical neurons were abolished by treatment with 3-bromo-7-nitroindazole (30 mg/kg, intraperitoneal), which specifically inhibited nNOS. Our results suggest that nNOS, its activator (calcium), and peroxynitrite exacerbate oxidative DNA damage after brain ischemia.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA	Baylor College of Medicine	Liu, PK (corresponding author), Baylor Coll Med, Dept Neurosurg, 6560 Fannin St,Suite 944, Houston, TX 77030 USA.	philipl@bcm.tmc.edu			NINDS NIH HHS [R01 NS034810-04, NS34810, R01 NS034810-04S1] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034810] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ayata C, 1997, J NEUROSCI, V17, P6908; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Chen J, 1997, J NEUROCHEM, V69, P232; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; Cork RJ, 1998, PROG BRAIN RES, V118, P37; CUI J, 1999, J NEUROCHEM, V73, P1; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DeLaAsuncion JG, 1996, FASEB J, V10, P333, DOI 10.1096/fasebj.10.2.8641567; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; Du C, 1996, J CEREBR BLOOD F MET, V16, P195, DOI 10.1097/00004647-199603000-00003; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gobbel GT, 1998, J NEUROSCI, V18, P147; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HENNER WD, 1982, J BIOL CHEM, V257, P1750; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; Iadecola C, 1997, J NEUROSCI, V17, P9157; INOUE S, 1995, FEBS LETT, V371, P86, DOI 10.1016/0014-5793(95)00873-8; KAMII H, 1994, J CEREB BLOOD FLOW M, V16, P153; Kawase M, 1999, STROKE, V30, P441, DOI 10.1161/01.STR.30.2.441; Kisby GE, 1997, NEUROREPORT, V8, P1337, DOI 10.1097/00001756-199704140-00004; KOH JY, 1988, J NEUROSCI, V8, P2153, DOI 10.1523/jneurosci.08-06-02153.1988; KORNBERG A, 1980, EXONUCLEASE, V3, P324; LIN L, 2000, IN PRESS J NEUROCHEM; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Liu JK, 1996, FASEB J, V10, P1532, DOI 10.1096/fasebj.10.13.8940299; Liu PK, 1999, STROKE THERAPY, P299; LIU PK, 1994, ANN NEUROL, V36, P566, DOI 10.1002/ana.410360405; Liu PK, 1996, J NEUROSCI, V16, P6795; LIU TH, 1989, AM J PHYSIOL, V256, pH589, DOI 10.1152/ajpheart.1989.256.2.H589; MECOCCI P, 1993, ANN NEUROL, V34, P609, DOI 10.1002/ana.410340416; Murakami K, 1998, J NEUROSCI, V18, P205; Nanri K, 1998, STROKE, V29, P1248, DOI 10.1161/01.STR.29.6.1248; Nunomura A, 1999, J NEUROSCI, V19, P1959; ONeill MJ, 1996, EUR J PHARMACOL, V310, P115, DOI 10.1016/0014-2999(96)00387-1; Parshad R, 1996, P NATL ACAD SCI USA, V93, P5146, DOI 10.1073/pnas.93.10.5146; READON JT, 1997, P NATL ACAD SCI USA, V94, P9463; Schulz JB, 1995, J NEUROSCI, V15, P8419; SHALL S, 1995, BIOCHIMIE, V77, P313, DOI 10.1016/0300-9084(96)88140-5; Shimizu-Sasamata M, 1998, J NEUROSCI, V18, P9564; Suzuki M, 1997, J BIOL CHEM, V272, P11228; Taffe BG, 1996, MUTAT RES-DNA REPAIR, V364, P183, DOI 10.1016/S0921-8777(96)00031-6; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; YOSHIDA T, 1994, J CEREBR BLOOD F MET, V14, P924, DOI 10.1038/jcbfm.1994.123; Zhuang JC, 1998, P NATL ACAD SCI USA, V95, P8286, DOI 10.1073/pnas.95.14.8286	48	53	59	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2000	14	2					407	417		10.1096/fasebj.14.2.407	http://dx.doi.org/10.1096/fasebj.14.2.407			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	281WQ	10657997	Green Accepted			2022-12-28	WOS:000085184800020
J	Ravanti, L; Toriseva, M; Penttinen, R; Chrombleholme, T; Foschi, M; Han, JH; Kahari, VM				Ravanti, L; Toriseva, M; Penttinen, R; Chrombleholme, T; Foschi, M; Han, JH; Kahari, VM			Expression of human collagenase-3 (MMP-13) by fetal skin fibroblasts is induced by transforming growth factor-beta via p38 mitogen-activated protein kinase	FASEB JOURNAL			English	Article						matrix metalloproteinase; collagenase; fibroblast	MATRIX-METALLOPROTEINASE EXPRESSION; SQUAMOUS-CELL CARCINOMAS; TGF-BETA; NEUTRALIZING ANTIBODY; EXTRACELLULAR-MATRIX; ADULT FIBROBLASTS; BREAST CARCINOMAS; TISSUE INHIBITOR; WOUND REPAIR; KERATINOCYTES	Human collagenase-3 (MMP-13) is characterized by wide substrate specificity and limited tissue specific expression. We have previously noted that human collagenase-3 (MMP-13) is expressed by gingival fibroblasts in culture and during gingival wound repair characterized by minimal scarring. Here we show that human MMP-13 is expressed by dermal fibroblasts during early wound repair in fetal skin grafted on SCID mice. The expression of MMP-13 by fetal skin fibroblasts in monolayer culture was enhanced by transforming growth factor b1 (TGF-beta 1) and TGF-beta 3, whereas MMP-13 expression was not detected in neonatal skin fibroblasts. Treatment of fetal skin fibroblasts with TGF-beta 1 potently activated p38 mitogen-activated protein kinase (MAPK). Induction of MMP-13 expression by TGF-beta 1 was blocked by p38 MAPK inhibitor SB203580, and by adenovirally delivered dominant negative form of p38 alpha. These observations demonstrate a remarkable difference in the regulation of collagenolytic capacity between fetal and neonatal skin fibroblasts, which suggests a role for MMP-13 in rapid turnover of collagenous matrix during repair of fetal cutaneous wounds, which heal without scar.	Univ Turku, Turku Ctr Biotechnol, FIN-20520 Turku, Finland; Univ Turku, Dept Med Biochem, FIN-20520 Turku, Finland; Univ Turku, Dept Dermatol, FIN-20520 Turku, Finland; Univ Penn, Sch Med, Childrens Inst Surg Sci, Philadelphia, PA USA; Univ Florence, Dept Internal Med, Florence, Italy; Scripps Res Inst, Dept Immunol, La Jolla, CA USA	University of Turku; University of Turku; University of Turku; University of Pennsylvania; University of Florence; Scripps Research Institute	Kahari, VM (corresponding author), Univ Turku, Turku Ctr Biotechnol, Tykistokuta 6B, FIN-20520 Turku, Finland.	veli-matti.hahari@btk.utu.fi	Kahari, Veli-Matti/T-4925-2019; Kähäri, Veli-Matti/E-5144-2011; Han, J/G-4671-2010	Kahari, Veli-Matti/0000-0003-2421-9368; Kähäri, Veli-Matti/0000-0003-2421-9368; Toriseva, Mervi/0000-0003-3024-6282				Airola K, 1999, BRIT J CANCER, V80, P733, DOI 10.1038/sj.bjc.6690417; Airola K, 1997, J INVEST DERMATOL, V109, P225, DOI 10.1111/1523-1747.ep12319441; Ashworth JL, 1999, BIOCHEM J, V340, P171, DOI 10.1042/0264-6021:3400171; BOSTROM PJ, 2000, INT J CANCE IN PRESS; Broker BJ, 1999, ARCH OTOLARYNGOL, V125, P676, DOI 10.1001/archotol.125.6.676; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Clark RAF, 1997, J CELL PHYSIOL, V170, P69; Cullen B, 1997, INT J BIOCHEM CELL B, V29, P241, DOI 10.1016/S1357-2725(96)00137-9; Eickelberg O, 1999, AM J PHYSIOL-LUNG C, V276, pL814, DOI 10.1152/ajplung.1999.276.5.L814; Ellis I, 1997, DEVELOPMENT, V124, P1593; Ellis IR, 1998, CYTOKINE, V10, P281, DOI 10.1006/cyto.1997.0294; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; Giambernardi TA, 1998, MATRIX BIOL, V16, P483, DOI 10.1016/S0945-053X(98)90019-1; INOUE M, 1995, J INVEST DERMATOL, V104, P479, DOI 10.1111/1523-1747.ep12605917; Johansson N, 1999, AM J PATHOL, V154, P469, DOI 10.1016/S0002-9440(10)65293-5; Johansson N, 1997, DEV DYNAM, V208, P387, DOI 10.1002/(SICI)1097-0177(199703)208:3<387::AID-AJA9>3.0.CO;2-E; Johansson N, 1997, CELL GROWTH DIFFER, V8, P243; Johansson N, 1997, AM J PATHOL, V151, P499; Kahari VM, 1999, ANN MED, V31, P34, DOI 10.3109/07853899909019260; Khorramizadeh MR, 1999, MOL CELL BIOCHEM, V194, P99, DOI 10.1023/A:1006909021352; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Knauper V, 1997, J BIOL CHEM, V272, P7608, DOI 10.1074/jbc.272.12.7608; Lanning DA, 1999, J PEDIATR SURG, V34, P695, DOI 10.1016/S0022-3468(99)90358-5; LORENZ HP, 1992, DEVELOPMENT, V114, P253; Mao DL, 1999, BIOCHEM BIOPH RES CO, V261, P904, DOI 10.1006/bbrc.1999.1142; McCallion RL, 1996, MOL CELLULAR BIOL WO, P561; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; NIKKOLA J, 2000, MELANOMA RE IN PRESS; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; Ravanti L, 2000, INT J MOL MED, V6, P391; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; SAARIALHOKERE UK, 1993, J CLIN INVEST, V92, P2858, DOI 10.1172/JCI116906; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Schor S L, 1996, Oral Dis, V2, P155; SHAH M, 1994, J CELL SCI, V107, P1137; SHAH M, 1992, LANCET, V339, P213, DOI 10.1016/0140-6736(92)90009-R; Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5; StahleBackdahl M, 1997, LAB INVEST, V76, P717; Sukhova GK, 1999, CIRCULATION, V99, P2503, DOI 10.1161/01.CIR.99.19.2503; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Sylvester KG, 2000, WOUND REPAIR REGEN, V8, P36, DOI 10.1046/j.1524-475x.2000.00036.x; Uitto VJ, 1998, AM J PATHOL, V152, P1489; Uria JA, 1998, J BIOL CHEM, V273, P9769, DOI 10.1074/jbc.273.16.9769; Uria JA, 1998, AM J PATHOL, V153, P91, DOI 10.1016/S0002-9440(10)65549-6; Uria JA, 1997, CANCER RES, V57, P4882; Vaalamo M, 1998, AM J PATHOL, V152, P1005; Vaalamo M, 1997, J INVEST DERMATOL, V109, P96, DOI 10.1111/1523-1747.ep12276722; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; WILKINSON GWG, 1992, NUCLEIC ACIDS RES, V20, P2233, DOI 10.1093/nar/20.9.2233; Wu LC, 1997, ARCH SURG-CHICAGO, V132, P753; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	60	66	81	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2001	15	6					1098	+		10.1096/fj.00-0588fje	http://dx.doi.org/10.1096/fj.00-0588fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292680				2022-12-28	WOS:000167959300023
J	Jo, DG; Kim, MJ; Choi, YH; Kim, IK; Song, YH; Woo, HN; Chung, CW; Jung, YK				Jo, DG; Kim, MJ; Choi, YH; Kim, IK; Song, YH; Woo, HN; Chung, CW; Jung, YK			Pro-apoptotic function of calsenilin/DREAM/KChIP3	FASEB JOURNAL			English	Article									Kwangju Inst Sci & Technol, Dept Life Sci, Puk Gu, Kwangju 500712, South Korea	Gwangju Institute of Science & Technology (GIST)	Jung, YK (corresponding author), Kwangju Inst Sci & Technol, Dept Life Sci, Puk Gu, 1 Oryong Dong, Kwangju 500712, South Korea.		Jo, Dong-Gyu/AAN-9278-2021	Jo, Dong-Gyu/0000-0003-2271-1076; Woo, Ha-Na/0000-0002-6771-8151; Jung, Yong-Keun/0000-0002-9686-3120					0	67	71	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					589	591						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259376				2022-12-28	WOS:000167419500014
J	Li, LH; McCarthy, P; Hui, SW				Li, LH; McCarthy, P; Hui, SW			High-efficiency electrotransfection of human primary hematopoietic stem cells	FASEB JOURNAL			English	Article									New York State Dept Hlth, Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA; New York State Dept Hlth, Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA	Roswell Park Cancer Institute; Roswell Park Cancer Institute	Hui, SW (corresponding author), New York State Dept Hlth, Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA.	sekwen.hui@roswellpark.org							0	35	40	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2001	15	3					586	588		10.1096/fj.00-0447fje	http://dx.doi.org/10.1096/fj.00-0447fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259375				2022-12-28	WOS:000167419500013
J	Zouki, C; Zhang, SL; Chan, JSD; Filep, JG				Zouki, C; Zhang, SL; Chan, JSD; Filep, JG			Peroxynitrite induces integrin-dependent adhesion of human neutrophils to endothelial cells via activation of the Raf-1/MEK/Erk pathway	FASEB JOURNAL			English	Article									Hop Maison Neuve Rosemont, Res Ctr, Montreal, PQ H1T 2M4, Canada; Univ Montreal, Dept Med, Montreal, PQ H1T 2M4, Canada	Universite de Montreal; Universite de Montreal	Filep, JG (corresponding author), Hop Maison Neuve Rosemont, Res Ctr, 5415 Blvd Assompt, Montreal, PQ H1T 2M4, Canada.								0	79	84	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2001	15	1					25	27						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11099490				2022-12-28	WOS:000166312400009
J	Goldring, CEP; Reveneau, S; Chantome, A; Pance, A; Fleury, C; Hume, DA; Sester, D; Mignotte, B; Jeannin, JF				Goldring, CEP; Reveneau, S; Chantome, A; Pance, A; Fleury, C; Hume, DA; Sester, D; Mignotte, B; Jeannin, JF			Heat shock enhances transcriptional activation of the murine-inducible nitric oxide synthase gene	FASEB JOURNAL			English	Article									Univ Bourgogne, Canc Immunotherapy Lab, Ecole Prat Hautes Etud, Fac Med, F-21000 Dijon, France; Univ Bourgogne, INSERM U517, Fac Med, F-21000 Dijon, France; Univ Versailles, CNRS, UPRESA 8087, F-78035 Versailles, France; Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia	Universite de Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Queensland	Reveneau, S (corresponding author), Univ Bourgogne, Canc Immunotherapy Lab, Ecole Prat Hautes Etud, Fac Med, 7 Blvd Jeanne dArc, F-21000 Dijon, France.		Hume, David A/C-7695-2013; Pance, Alena/AAH-2878-2021; Mignotte, Bernard/A-3499-2009; Sester, David/GLR-2942-2022	Pance, Alena/0000-0002-9017-2644; Mignotte, Bernard/0000-0002-8512-8518; Hume, David/0000-0002-2615-1478					0	33	36	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2393	2395						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11024011				2022-12-28	WOS:000165723400008
J	Solanes, G; Pedraza, N; Iglesias, R; Giralt, M; Villarroya, F				Solanes, G; Pedraza, N; Iglesias, R; Giralt, M; Villarroya, F			The human uncoupling protein-3 gene promoter requires MyoD and is induced by retinoic acid in muscle cells	FASEB JOURNAL			English	Article									Univ Barcelona, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain	University of Barcelona	Villarroya, F (corresponding author), Univ Barcelona, Dept Bioquim & Biol Mol, Avda Diagonal 645, E-08028 Barcelona, Spain.		Giralt, Marta/A-4756-2013; Pedraza González, Neus/C-6390-2011; Iglesias, Roser/C-5561-2017; Villarroya, Francesc/K-4357-2014	Giralt, Marta/0000-0001-7968-4190; Pedraza González, Neus/0000-0003-4749-5111; Iglesias, Roser/0000-0002-7107-8097; Villarroya, Francesc/0000-0003-1266-9142					0	49	49	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2141	2143						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11024001				2022-12-28	WOS:000165190800005
J	Woods, M; Bobanovic, F; Brown, D; Alexander, DR				Woods, M; Bobanovic, F; Brown, D; Alexander, DR			Lyn and Syk tyrosine kinases are not activated in B-lineage lymphoid cells exposed to low-energy electromagnetic fields	FASEB JOURNAL			English	Article						neoplasia; cancer; protein tyrosine phosphorylation	FREQUENCY MAGNETIC-FIELDS; CHILDHOOD-CANCER; SIGNAL-TRANSDUCTION; POWER-LINES; RECEPTOR; RISK; CHILDREN; STIMULATION; PATHWAYS	Exposure of B-lineage lymphoid cells to a 100 muT 60 Hz AC magnetic field has been reported to stimulate the rapid activation of Lyn and Syk tyrosine kinases and the induction of protein tyrosine phosphorylation. These findings are significant because of the critical role played by these B cell signaling events in the control of growth and differentiation, and therefore the potential of electromagnetic field (EMF) exposure to induce cancer. We report the first study carried out with the aim of reproducing the reported EMF effects on Lyn and Syk tyrosine kinases, The system used enabled EMF exposure conditions to be carefully controlled and also allowed experiments to be performed blind. The effects of a 100 mur 60 Hz AC magnetic field on protein tyrosine phosphorylation and on Lyn and Syk tyrosine kinase activities were investigated in Nalm-6 and DT40 B cells in the absence and presence of a 46 muT DC magnetic field. However, no significant effects of low-energy electromagnetic fields on tyrosine kinase activities or protein phosphorylation were observed.-Woods, M., Bobanovic, F., Brown, D., Alexander, D. R. Lyn and Syk tyrosine kinases are not activated in B-lineage lymphoid cells exposed to low-energy electromagnetic fields.	Babraham Inst, Lab Lymphocyte Signalling & Dev, Cambridge CB2 4AT, England; Babraham Inst, Mol Signalling Lab, Cambridge CB2 4AT, England; Babraham Inst, Lab Computat Neurosci, Cambridge CB2 4AT, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Alexander, DR (corresponding author), Babraham Inst, Lab Lymphocyte Signalling & Dev, Babraham Hall, Cambridge CB2 4AT, England.							Benschop RJ, 1999, CURR OPIN IMMUNOL, V11, P143, DOI 10.1016/S0952-7915(99)80025-9; Cheng KK, 1999, LANCET, V354, P1925, DOI 10.1016/S0140-6736(99)10074-6; DeFranco AL, 1997, CURR OPIN IMMUNOL, V9, P296, DOI 10.1016/S0952-7915(97)80074-X; Dibirdik I, 1998, J BIOL CHEM, V273, P4035, DOI 10.1074/jbc.273.7.4035; Feychting M, 1995, EUR J CANCER, V31A, P2035, DOI 10.1016/0959-8049(95)00472-6; FEYCHTING M, 1993, AM J EPIDEMIOL, V138, P467, DOI 10.1093/oxfordjournals.aje.a116881; FEYCHTING M, 1992, 692 IMM SWED NAT I O; Kristupaitis D, 1998, J BIOL CHEM, V273, P12397, DOI 10.1074/jbc.273.20.12397; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; Kurosaki T, 1999, ANNU REV IMMUNOL, V17, P555, DOI 10.1146/annurev.immunol.17.1.555; Lacy-Hulbert A, 1998, FASEB J, V12, P395, DOI 10.1096/fasebj.12.6.395; LACYHULBERT A, 1995, RADIAT RES, V144, P9, DOI 10.2307/3579230; LEDNEV VV, 1991, BIOELECTROMAGNETICS, V12, P71, DOI 10.1002/bem.2250120202; LONDON SJ, 1991, AM J EPIDEMIOL, V134, P923, DOI 10.1093/oxfordjournals.aje.a116176; Miller SC, 1998, J BIOL CHEM, V273, P32618, DOI 10.1074/jbc.273.49.32618; MYERS A, 1990, BRIT J CANCER, V62, P1008, DOI 10.1038/bjc.1990.428; OLSEN JH, 1993, BRIT MED J, V307, P891, DOI 10.1136/bmj.307.6909.891; SAVITZ DA, 1988, AM J EPIDEMIOL, V128, P21, DOI 10.1093/oxfordjournals.aje.a114943; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TOMENIUS L, 1986, BIOELECTROMAGNETICS, V7, P191, DOI 10.1002/bem.2250070209; UCKUN FM, 1995, J BIOL CHEM, V270, P27666, DOI 10.1074/jbc.270.46.27666; UCKUN FM, 1993, J BIOL CHEM, V268, P21172; VERKASALO PK, 1993, BRIT MED J, V307, P895, DOI 10.1136/bmj.307.6909.895	23	10	11	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2284	2290		10.1096/fj.00-0164com	http://dx.doi.org/10.1096/fj.00-0164com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053250				2022-12-28	WOS:000165190800022
J	Duval, D; Reinhardt, S; Kedinger, C; Boeuf, H				Duval, D; Reinhardt, S; Kedinger, C; Boeuf, H			Role of suppressors of cytokine signaling (Socs) in leukemia inhibitory factor (LIF) -dependent embryonic stem cell survival	FASEB JOURNAL			English	Article						pluripotency; apoptosis; early response genes; transcription	STAT3 ACTIVATION; TARGETED DISRUPTION; POLY(ADP-RIBOSE) POLYMERASE; NEGATIVE REGULATORS; CIS FAMILY; BOX MOTIF; APOPTOSIS; GENE; PROTEINS; MICE	Mouse embryonic stem (ES) cells remain pluripotent in vitro when grown in the presence of leukemia inhibitory factor (LIF), LIF withdrawal results in progressive ES cell differentiation. Here we show that during this differentiation process, part of the cells undergo apoptosis concomitant with an activation of the p38 MAP kinase. To gain insight into events mediated by LIF in ES cells, the expression of potential candidate genes was analyzed in the absence or presence of this cytokine by using a semiquantitative RT-PCR assay, We focused on early response genes and on a new type of cytokine repressors (the Socs proteins), some of which exhibit anti-apoptotic properties, We found that expression of c-Fos, c-Jun, and JunB was induced upon LIF treatment whereas that of JunD, the tyrosine phosphatase ESP, and the components of the LIF receptor remained unaffected, Expression of Socs-3, but not Socs-1 or Socs-2, was stimulated in the presence of LIF. Finally, uncontrolled overexpression of Socs-1 and Socs-3 led to repression of LIF-dependent transcription and severely reduced cell viability, suggesting that the disturbance of a well balanced Socs protein content has adverse effects on cell survival.	IGBMC, Inst genet & Biol Mol & Cellulaire, CNRS, INSERM,ULP, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Kedinger, C (corresponding author), IGBMC, Inst genet & Biol Mol & Cellulaire, CNRS, INSERM,ULP, 1 Rue Laurent Fries,BP 163, F-67404 Illkirch Graffenstaden, France.	kedinger@igbmc.u-strasbg.fr	DUVAL, David/B-8586-2011	Duval, David/0000-0001-6933-3354				ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Auernhammer CJ, 1999, P NATL ACAD SCI USA, V96, P6964, DOI 10.1073/pnas.96.12.6964; Boeuf H, 1997, J CELL BIOL, V138, P1207, DOI 10.1083/jcb.138.6.1207; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; COFFER P, 1995, ONCOGENE, V10, P985; Cohen-Tannoudji M, 1998, MOL HUM REPROD, V4, P929, DOI 10.1093/molehr/4.10.929; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; De Sepulveda P, 1999, EMBO J, V18, P904; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; EDWARDS DR, 1994, TRENDS PHARMACOL SCI, V15, P239, DOI 10.1016/0165-6147(94)90318-2; Eferl R, 1999, J CELL BIOL, V145, P1049, DOI 10.1083/jcb.145.5.1049; Ernst M, 1999, J BIOL CHEM, V274, P9729, DOI 10.1074/jbc.274.14.9729; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gardner RL, 1997, INT J DEV BIOL, V41, P235; GRIGORIADIS AE, 1995, TRENDS GENET, V11, P436, DOI 10.1016/S0168-9525(00)89142-8; Hansen JA, 1999, MOL ENDOCRINOL, V13, P1832, DOI 10.1210/me.13.11.1832; Heim MH, 1999, J RECEPT SIGNAL TR R, V19, P75, DOI 10.3109/10799899909036638; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Hirano Toshio, 1997, Cytokine and Growth Factor Reviews, V8, P241, DOI 10.1016/S1359-6101(98)80005-1; Hoey T, 1998, CURR OPIN GENET DEV, V8, P582, DOI 10.1016/S0959-437X(98)80015-4; Ihle JN, 1996, BIOESSAYS, V18, P95, DOI 10.1002/bies.950180204; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kitanaka C, 1999, CELL DEATH DIFFER, V6, P508, DOI 10.1038/sj.cdd.4400526; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; KROWCZYNSKA AM, 1989, NUCLEIC ACIDS RES, V17, P6408, DOI 10.1093/nar/17.15.6408; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Lee K, 1996, MECH DEVELOP, V59, P153, DOI 10.1016/0925-4773(96)00586-2; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; Masuhara M, 1997, BIOCHEM BIOPH RES CO, V239, P439, DOI 10.1006/bbrc.1997.7484; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Narazaki M, 1998, P NATL ACAD SCI USA, V95, P13130, DOI 10.1073/pnas.95.22.13130; Nichols J, 1996, MECH DEVELOP, V57, P123, DOI 10.1016/0925-4773(96)00531-X; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; PESCE M, 1993, DEVELOPMENT, V118, P1089; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Raz R, 1999, P NATL ACAD SCI USA, V96, P2846, DOI 10.1073/pnas.96.6.2846; Rich T, 1999, NAT CELL BIOL, V1, pE69, DOI 10.1038/11038; Robertson E. J., 1987, TERATOCARCINOMAS EMB; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; Sendtner M, 1996, CURR BIOL, V6, P686, DOI 10.1016/S0960-9822(09)00450-3; Shellard J, 1996, EUR CYTOKINE NETW, V7, P699; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1999, BIOESSAYS, V21, P47, DOI 10.1002/(SICI)1521-1878(199901)21:1<47::AID-BIES6>3.0.CO;2-N; Suzuki R, 1998, ONCOGENE, V17, P2271, DOI 10.1038/sj.onc.1202143; Takeda K, 1998, J IMMUNOL, V161, P4652; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Taupin J L, 1998, Int Rev Immunol, V16, P397, DOI 10.3109/08830189809043003; Tone E, 1998, BIOCHEM BIOPH RES CO, V253, P147, DOI 10.1006/bbrc.1998.9767; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WARE CB, 1995, DEVELOPMENT, V121, P1283; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407; Yoshimura A, 1998, LEUKEMIA, V12, P1851, DOI 10.1038/sj.leu.2401238; Yoshimura A, 1998, CYTOKINE GROWTH F R, V9, P197, DOI 10.1016/S1359-6101(98)00019-7; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	67	98	100	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2000	14	11					1577	1584		10.1096/fj.14.11.1577	http://dx.doi.org/10.1096/fj.14.11.1577			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CN	10928992				2022-12-28	WOS:000088627800012
J	Bouche, M; Canipari, R; Melchionna, R; Willems, D; Senni, MI; Molinaro, M				Bouche, M; Canipari, R; Melchionna, R; Willems, D; Senni, MI; Molinaro, M			TGF-beta autocrine loop regulates cell growth and myogenic differentiation in human rhabdomyosarcoma cells	FASEB JOURNAL			English	Article						TPA; serine-protease system; muscle regulatory factors; RD cells	UROKINASE PLASMINOGEN-ACTIVATOR; SOFT-TISSUE TUMORS; MESSENGER-RNA; 12-O-TETRADECANOYLPHORBOL-13-ACETATE-INDUCED DIFFERENTIATION; FACTOR RECEPTOR; DNA-BINDING; EXPRESSION; PROTEIN; LOCALIZATION; INHIBITION	Transforming growth factor beta (TGF) is a well-known inhibitor of myogenic differentiation as well as an autocrine product of rhabdomyosarcoma cells. We studied the role of the TGF-beta autocrine loop in regulating growth and myogenic differentiation in the human rhabdomyosarcoma cell, line, RD. We previously reported that the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) induces growth arrest and myogenic differentiation in these cells, which constitutively express muscle regulatory factors. We show that TPA inhibits the activation of secreted latent TGF-beta, thus decreasing the concentration of active TGF-beta to which the cells are exposed. This event is mediated by the TPA-induced alteration of the uPA/ PAI serine-protease system. Complete removal of TGF-beta, mediated by the ectopic expression of a soluble type II TGF-beta receptor dominant negative cDNA, induces growth arrest, but does not trigger differentiation. In contrast, a reduction in the TGF-beta concentration, to a range of 0.14-0.20 x 10(-2) ng/ml (which is similar to that measured in TPA-treated cells), mimics TPA-induced differentiation. Taken together, these data demonstrate that cell growth and suppression of differentiation in rhabdomyosarcoma cells require overproduction of active TGF-beta; furthermore, they show that a 'critical' concentration of TGF-beta is necessary for myogenic differentiation to occur, whereas myogenesis is abolished below and above this concentration. By impairing the TGF-beta autocrine loop, TPA stabilizes the factor concentration within the range compatible for differentiation to occur. In contrast, in human primary muscle cells a much higher concentration of exogenous TGF-beta is required for the differentiation inhibitory effect and TPA inhibits differentiation in these cells probably through a TGF-beta independent mechanism. These data thus clarify the mechanism underlying the multiple roles of TGF-beta in the regulation of both the transformed and differentiated phenotype.-Bouche, M., Canipari, R., Melchionna, R., Willems, D., Senni, M. I., Molinaro, M. TGF-beta autocrine loop regulates cell growth and myogenic differentiation in human rhabdomyosarcoma cells.	Univ Roma La Sapienza, Dept Histol & Med Embryol, I-00161 Rome, Italy	Sapienza University Rome	Bouche, M (corresponding author), Univ Roma La Sapienza, Dept Histol & Med Embryol, Via A Scarpa 14, I-00161 Rome, Italy.	bouche@uniroma1.it	melchionna, Roberta/G-2479-2011; SENNI, MICHELE/J-9380-2018	Melchionna, Roberta/0000-0002-8410-9681; SENNI, MICHELE/0000-0001-5502-7882; Bouche, Marina/0000-0002-0938-5360; CANIPARI, Rita/0000-0003-3481-6908	Telethon [859] Funding Source: Medline	Telethon(Fondazione Telethon)		ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; AGUANNO S, 1990, CANCER RES, V50, P3377; ANDREASEN PA, 1990, MOL CELL ENDOCRINOL, V68, P1, DOI 10.1016/0303-7207(90)90164-4; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BAKER JB, 1980, CELL, V21, P37, DOI 10.1016/0092-8674(80)90112-9; BELIN D, 1984, EMBO J, V3, P1901, DOI 10.1002/j.1460-2075.1984.tb02065.x; BLASI F, 1993, BIOESSAYS, V15, P105, DOI 10.1002/bies.950150206; BOUCHE M, 1995, CELL GROWTH DIFFER, V6, P845; BOUCHE M, 1993, EXP CELL RES, V208, P209, DOI 10.1006/excr.1993.1239; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; CHEN RH, 1994, J BIOL CHEM, V269, P22868; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DeGiovanni C, 1996, CANCER RES, V56, P3898; DEGIOVANNI C, 1995, BRIT J CANCER, V72, P1224, DOI 10.1038/bjc.1995.490; DERYNCK R, 1987, CANCER RES, V47, P707; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; FILVAROFF EH, 1994, DEVELOPMENT, V120, P1085; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; MALONE M, 1994, HISTOPATHOLOGY, V24, P197, DOI 10.1111/j.1365-2559.1994.tb01309.x; MALONE M, 1993, HISTOPATHOLOGY, V23, P203, DOI 10.1111/j.1365-2559.1993.tb01192.x; MARTIN JF, 1992, J BIOL CHEM, V267, P10956; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MAYER M, 1988, J BIOL CHEM, V263, P15688; MIGNATTI P, 1991, J CELL BIOL, V113, P1193, DOI 10.1083/jcb.113.5.1193; MunozCanoves P, 1997, THROMB HAEMOSTASIS, V77, P526; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; PLOUG M, 1991, J BIOL CHEM, V266, P1926; QUAX PHA, 1992, DEV BIOL, V151, P166, DOI 10.1016/0012-1606(92)90224-5; ROBERTS AB, 1988, RECENT PROG HORM RES, V44, P157; SAPPINO AP, 1989, J CELL BIOL, V109, P2471, DOI 10.1083/jcb.109.5.2471; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; VERDE P, 1984, P NATL ACAD SCI-BIOL, V81, P4727, DOI 10.1073/pnas.81.15.4727; WELLS JM, 1994, DEVELOPMENT, V120, P3639; Wells JM, 1997, J CELL PHYSIOL, V171, P217, DOI 10.1002/(SICI)1097-4652(199705)171:2<217::AID-JCP13>3.0.CO;2-A; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	42	42	48	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2000	14	9					1147	1158		10.1096/fasebj.14.9.1147	http://dx.doi.org/10.1096/fasebj.14.9.1147			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834937				2022-12-28	WOS:000087427300012
J	Damjanovski, S; Puzianowska-Kuznicka, M; Ishuzuya-Oka, A; Shi, YB				Damjanovski, S; Puzianowska-Kuznicka, M; Ishuzuya-Oka, A; Shi, YB			Differential regulation of three thyroid hormone-responsive matrix metalloproteinase genes implicates distinct functions during frog embryogenesis	FASEB JOURNAL			English	Article						apoptosis; extracellular matrix; Xenopus laevis; morphogenesis; organogenesis	EXTRACELLULAR-MATRIX; TRANSCRIPTIONAL ACTIVATION; XENOPUS-LAEVIS; CELL-DEATH; EXPRESSION; TAIL; METAMORPHOSIS; APOPTOSIS; MORPHOGENESIS; HYBRIDIZATION	Matrix metalloproteinases (MMPs) are a family of Zn2+-dependent extracellular proteases capable of degrading various proteinaceous components of the extracellular matrix (ECM), They are expressed in developmental and pathological processes such as postlactation mammary gland involution and tumor metastasis, Relatively few studies have been carried out to investigate the function of MMPs during embryogenesis and postembryonic organ development. Using Xenopus development as a model system, we and others have previously isolated three MMP gems as thyroid hormone response genes, They have distinct temporal and organ-specific regulations during thyroid hormone-dependent metamorphosis, We demonstrate here that three MMPs-stromelysin-3 (ST3), collagenases-3 (Col3), and collagenases-4 (Col4)-also have distinct spatial and temporal expression profiles during embryogenesis, Consistent with earlier suggestions that ST3 is a direct thyroid hormone response gem whereas Col3 and Col4 are not, we show that precocious overexpression of thyroid hormone receptors in the presence of thyroid hormone lead to increased expression of ST3, but not Col3, Furthermore, our whole-mount in situ hybridizations reveal a tight but distinct association of individual MMPs with tissue remodeling in different regions of the animal during embryogenesis, These results suggest that ST3 is likely to play a role in ECM remodeling that facilitate apoptotic tissue remodeling or resorption, whereas Col3 and Col4 appear to participate in connective tissue degradation during development.	NICHHD, Mol Embryol Lab, NIH, Bethesda, MD 20892 USA; Dokkyo Univ, Sch Med, Dept Histol & Neurobiol, Mibu, Tochigi 32102, Japan	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Dokkyo Medical University	Shi, YB (corresponding author), NICHHD, Mol Embryol Lab, NIH, Bldg 18T,Rm 106, Bethesda, MD 20892 USA.		Damjanovski, Sashko/N-8728-2015	Damjanovski, Sashko/0000-0002-3479-721X; Shi, Yun-Bo/0000-0002-6330-0639; Puzianowska-Kuznicka, Monika/0000-0001-5295-3848	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001901] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001901] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alexander CM, 1991, CELL BIOL EXTRACELLU, P255; Beck CW, 1998, MECH DEVELOP, V72, P41, DOI 10.1016/S0925-4773(98)00015-X; Berry DL, 1998, DEV BIOL, V203, P24, DOI 10.1006/dbio.1998.8975; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Chin JR, 1997, DEVELOPMENT, V124, P1519; Dodd M.H.I., 1976, P467; Gilbert L, 1981, METAMORPHOSIS PROBLE; GROSS J, 1966, J INVEST DERMATOL, V47, P274, DOI 10.1038/jid.1966.141; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HAUSEN P, 1991, EARLY DEV XENOPUS; Hay ED, 1993, CURR OPIN CELL BIOL, V5, P1029, DOI 10.1016/0955-0674(93)90088-8; Hensey C, 1998, DEV BIOL, V203, P36, DOI 10.1006/dbio.1998.9028; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; LELOUP J, 1977, CR ACAD SCI D NAT, V284, P2261; Li JW, 1998, NUCLEIC ACIDS RES, V26, P3018, DOI 10.1093/nar/26.12.3018; Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962-8924(98)01362-2; Lund LR, 1996, DEVELOPMENT, V122, P181; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MAYOR R, 1995, DEVELOPMENT, V121, P767; MURPHY G, 1994, ANN NY ACAD SCI, V732, P31, DOI 10.1111/j.1749-6632.1994.tb24722.x; Nagase H, 1992, Matrix Suppl, V1, P237; Nagase H, 1998, Cell Res, V8, P179; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; OOFUSA K, 1994, INT J DEV BIOL, V38, P345; PATTERTON D, 1995, DEV BIOL, V167, P252, DOI 10.1006/dbio.1995.1021; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Puzianowska-Kuznicka M, 1997, MOL CELL BIOL, V17, P4738, DOI 10.1128/MCB.17.8.4738; RADICE G P, 1989, International Journal of Developmental Biology, V33, P325; RANJAN M, 1994, J BIOL CHEM, V269, P24699; Sang QXA, 1996, J PROTEIN CHEM, V15, P137, DOI 10.1007/BF01887395; Schmidt J W, 1993, Semin Cell Biol, V4, P161, DOI 10.1006/scel.1993.1020; Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5; Shi YB, 1998, INT J DEV BIOL, V42, P107; Shi Yun-Bo, 1996, Journal of Biomedical Science, V3, P307, DOI 10.1007/BF02257960; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Stolow MA, 1996, MOL BIOL CELL, V7, P1471, DOI 10.1091/mbc.7.10.1471; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; TUCKER AS, 1995, CURR BIOL, V5, P807, DOI 10.1016/S0960-9822(95)00158-8; Uria J A, 1998, Cell Res, V8, P187; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WANG Z, 1993, J BIOL CHEM, V268, P16270; Werb Z, 1998, ANN NY ACAD SCI, V857, P110, DOI 10.1111/j.1749-6632.1998.tb10111.x; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WONG JM, 1995, J BIOL CHEM, V270, P18479, DOI 10.1074/jbc.270.31.18479; WU M, 1991, METHOD CELL BIOL, V36, P3; Yaoita Y, 1997, J BIOL CHEM, V272, P5122, DOI 10.1074/jbc.272.8.5122	47	34	34	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2000	14	3					503	510		10.1096/fasebj.14.3.503	http://dx.doi.org/10.1096/fasebj.14.3.503			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	291TJ	10698965				2022-12-28	WOS:000085751900009
J	De Felice, FG; Houzel, JC; Garcia-Abreu, J; Louzada, PRF; Afonso, RC; Meirelles, MNL; Lent, R; Neto, VM; Ferreira, ST				De Felice, FG; Houzel, JC; Garcia-Abreu, J; Louzada, PRF; Afonso, RC; Meirelles, MNL; Lent, R; Neto, VM; Ferreira, ST			Inhibition of Alzheimer's disease beta-amyloid aggregation, neurotoxicity, and in vivo deposition by nitrophenols: implications for Alzheimer's therapy	FASEB JOURNAL			English	Article									Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, BR-21944590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Anat, BR-21944590 Rio De Janeiro, Brazil; FIOCRUZ, Inst Oswaldo Cruz, Dept Ultraestrutura & Biol Celular, BR-21045900 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Fundacao Oswaldo Cruz	Ferreira, ST (corresponding author), Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, BR-21944590 Rio De Janeiro, Brazil.		De Felice, Fernanda G/M-1074-2017; Houzel, Jean Christophe/M-7936-2019; Abreu, Jose G/ABB-1199-2021; Houzel, Jean Christophe/G-3723-2010; Abreu, Jose G/G-6159-2010; Moura-Neto, VIVALDO/V-9913-2019; Ferreira, Sergio/AAZ-1576-2020	Houzel, Jean Christophe/0000-0001-5128-438X; Abreu, Jose G/0000-0002-1363-1755; Houzel, Jean Christophe/0000-0001-5128-438X; Abreu, Jose G/0000-0002-9875-7786; Moura-Neto, VIVALDO/0000-0002-6266-043X; Ferreira, Sergio/0000-0001-7160-9866					0	95	109	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1297	1299		10.1096/fj.00-0676fje	http://dx.doi.org/10.1096/fj.00-0676fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344119				2022-12-28	WOS:000168655200041
J	Ho, MCY; Lo, ACY; Kurihara, H; Yu, ACH; Chung, SSM; Chung, SK				Ho, MCY; Lo, ACY; Kurihara, H; Yu, ACH; Chung, SSM; Chung, SK			Endothelin-1 protects astrocytes from hypoxic/ischemic injury	FASEB JOURNAL			English	Article						Endothelin-3; endothelin receptors; cell survival; lactate dehydrogenase; ET-1-deficient mice	TRANSIENT FOREBRAIN ISCHEMIA; RECEPTOR-DEFICIENT MICE; SMOOTH-MUSCLE CELLS; ETB RECEPTORS; DNA-SYNTHESIS; GLIAL-CELLS; RAT; EXPRESSION; VASOCONSTRICTOR; BRAIN	Under pathological conditions such as ischemia (I), subarachnoid hemorrhage, and Alzheimer's disease, astrocytes show a large increase in endothelin (ET) -like immunoreactivity. However, it is not clear whether ET is protective or destructive to these cells during brain injury. Using astrocytes from ET-1-deficient mice, we determined the effect of ET-1 on these cells under normal, hypoxic (H), and hypoxic/ ischemic (H/I) conditions. Under normal culture conditions, astrocytes from wild-type and ET-l-deficient mice showed no difference in their morphology and cell proliferation rates. ET-3 and ETA receptor mRNAs were up-regulated whereas ETB receptor mRNA was down-regulated in ET-1-deficient astrocytes, suggesting that ET-1 and ET-3 may complement each other's functions and that the expressions of these endothelins and their receptors are regulated by a complex feedback mechanism. Under H and H/I conditions, ET-1 peptide and mRNA were up-regulated in wild-type astrocytes, and the astrocytes without ET-1 died faster than the wild-type astrocytes, as indicated by greater efflux of lactate dehydrogenase, The present study suggests that astrocytes without ET-1 are more vulnerable to H and H/I injuries and that the up-regulation of astrocytic ET-1 is essential for the survival of astrocytes.-Ho, M. C. Y., Lo, A. C. Y., Kurihara, H., Yu, A. C. H., Chung, S. S. M., Chung, S. K. Endothelin-1 protects astrocytes from hypoxic/ischemic injury.	Univ Hong Kong, Inst Mol Biol, Hong Kong, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Dept Biol, Hong Kong, Hong Kong, Peoples R China; Univ Tokyo, Grad Sch Med, Dept Cardiovasc Res, Tokyo, Japan	University of Hong Kong; Hong Kong University of Science & Technology; University of Tokyo	Chung, SK (corresponding author), Univ Hong Kong, Inst Mol Biol, South Wing,8-F Kadoorie,Biol Sci Bldg,Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.		Lo, Amy C. Y./C-1195-2009	Lo, Amy C. Y./0000-0003-4239-6851; Kurihara, Hiroki/0000-0002-6476-5593				ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; Chan TSK, 1995, EUR J BIOCHEM, V234, P819, DOI 10.1111/j.1432-1033.1995.819_a.x; CLARKE JG, 1989, AM J PHYSIOL, V257, pH2033, DOI 10.1152/ajpheart.1989.257.6.H2033; Clouthier DE, 1998, DEVELOPMENT, V125, P813; Clouthier DE, 2000, DEV BIOL, V217, P10, DOI 10.1006/dbio.1999.9527; DENUCCI G, 1988, P NATL ACAD SCI USA, V85, P9797; DUGAN LL, 1995, J NEUROSCI, V15, P4545; FUXE K, 1991, NEUROSCI LETT, V123, P107, DOI 10.1016/0304-3940(91)90169-T; HIRATA Y, 1989, ATHEROSCLEROSIS, V78, P225, DOI 10.1016/0021-9150(89)90227-X; Hu J, 1998, BIOCHEM BIOPH RES CO, V245, P894, DOI 10.1006/bbrc.1998.8543; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; Ishikawa N, 1997, EUR J NEUROSCI, V9, P895, DOI 10.1111/j.1460-9568.1997.tb01440.x; JIANG MH, 1993, NEUROREPORT, V4, P935, DOI 10.1097/00001756-199307000-00024; KAKU DA, 1991, BRAIN RES, V554, P344, DOI 10.1016/0006-8993(91)90214-G; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; Kuwaki T, 1997, PROG NEUROBIOL, V51, P545, DOI 10.1016/S0301-0082(96)00063-9; LEE ME, 1990, J CLIN INVEST, V86, P141, DOI 10.1172/JCI114677; MACCUMBER MW, 1990, P NATL ACAD SCI USA, V87, P2359, DOI 10.1073/pnas.87.6.2359; MACNULTY EE, 1990, BIOCHEM J, V272, P761, DOI 10.1042/bj2720761; MAKAR TK, 1994, J NEUROCHEM, V62, P45; NAKAMURA S, 1993, ENDOCRINOLOGY, V132, P530, DOI 10.1210/en.132.2.530; Pluta RM, 1997, J NEUROSURG, V87, P287, DOI 10.3171/jns.1997.87.2.0287; RANSOM BR, 1992, PROG BRAIN RES, V94, P37; RAPS SP, 1989, BRAIN RES, V493, P398, DOI 10.1016/0006-8993(89)91178-5; ROSENBERG PA, 1990, NEUROSCI LETT, V116, P399; ROSENBERG PA, 1989, NEUROSCI LETT, V103, P162, DOI 10.1016/0304-3940(89)90569-7; Ruffolo RR., 1995, ENDOTHELIN RECEPTORS; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; Sasaki Y, 1998, EUR J NEUROSCI, V10, P2984, DOI 10.1111/j.1460-9568.1998.00305.x; Shichiri M, 1998, J CARDIOVASC PHARM, V31, pS138, DOI 10.1097/00005344-199800001-00041; Shichiri M, 1997, HYPERTENSION, V30, P1198, DOI 10.1161/01.HYP.30.5.1198; SIMONSON MS, 1989, J CLIN INVEST, V83, P708, DOI 10.1172/JCI113935; SUPATTAPONE S, 1989, BIOCHEM BIOPH RES CO, V165, P1115, DOI 10.1016/0006-291X(89)92718-6; TSANG M, 1995, NEUR ABSTR, V22; VIGNE P, 1990, BIOCHEM J, V266, P415, DOI 10.1042/bj2660415; Wu-Wong JR, 1997, BIOCHEM J, V328, P733, DOI 10.1042/bj3280733; YAMASHITA K, 1993, CELL MOL NEUROBIOL, V13, P15, DOI 10.1007/BF00712986; YAMASHITA K, 1994, J NEUROCHEM, V63, P1042; Yamashita Kimihiro, 1995, Clinical and Experimental Pharmacology and Physiology, V22, pS277, DOI 10.1111/j.1440-1681.1995.tb02915.x; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; Yu ACH, 2000, NEUROCHEM INT, V36, P369, DOI 10.1016/S0197-0186(99)00145-X; YU ACH, 1993, J NEUROSCI RES, V34, P295, DOI 10.1002/jnr.490340306; ZHANG WW, 1994, J NEUROL SCI, V122, P90, DOI 10.1016/0022-510X(94)90057-4	43	49	51	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					618	626		10.1096/fj.99-1022com	http://dx.doi.org/10.1096/fj.99-1022com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259380				2022-12-28	WOS:000167419500019
J	Schaefer, L; Raslik, I; Grone, HJ; Schonherr, E; Macakova, K; Ugorcakova, J; Budny, S; Schaefer, RM; Kresse, H				Schaefer, L; Raslik, I; Grone, HJ; Schonherr, E; Macakova, K; Ugorcakova, J; Budny, S; Schaefer, RM; Kresse, H			Small proteoglycans in human diabetic nephropathy: Discrepancy between glomerular expression and protein accumulation of decorin, biglycan, lumican, and fibromodulin	FASEB JOURNAL			English	Article									Univ Munster, Dept Internal Med, D-4400 Munster, Germany; Univ Munster, Dept Physiol Chem & Pathobiochem, D-4400 Munster, Germany; German Canc Res Ctr, Dept Cellular & Mol Pathol, D-6900 Heidelberg, Germany; Slovak Acad Sci, Inst Mol Biol, Bratislava 84251, Slovakia	University of Munster; University of Munster; Helmholtz Association; German Cancer Research Center (DKFZ); Slovak Academy of Sciences	Schaefer, L (corresponding author), Med Poliklin, Albert Schweitzer Str 33, D-48129 Munster, Germany.			Ugorcakova, Jana/0000-0003-4019-9221					0	117	123	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					559	561						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259366				2022-12-28	WOS:000167419500004
J	Watchorn, TM; Waddell, I; Dowidar, N; Ross, JA				Watchorn, TM; Waddell, I; Dowidar, N; Ross, JA			Proteolysis-inducing factor regulates hepatic gene expression via the transcription factors NF-kappa B and STAT3	FASEB JOURNAL			English	Article									Univ Edinburgh, Dept Clin & Surg Sci, Mol Immunol Grp, Edinburgh EH8 9YL, Midlothian, Scotland; Astrazeneca, Cardiovasc & Gastrointestinal Discovery Dept, Macclesfield, Cheshire, England	University of Edinburgh; AstraZeneca	Waddell, I (corresponding author), RIE, Lister Res Labs, Lauriston Pl, Edinburgh EH3 9YW, Midlothian, Scotland.								0	75	85	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					562	564						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259367				2022-12-28	WOS:000167419500005
J	Young, ME; Patil, S; Ying, J; Depre, C; Ahuja, HS; Shipley, GL; Stepkowski, SM; Davies, PJA; Taegtmeyer, H				Young, ME; Patil, S; Ying, J; Depre, C; Ahuja, HS; Shipley, GL; Stepkowski, SM; Davies, PJA; Taegtmeyer, H			Uncoupling protein 3 transcription is regulated by peroxisome proliferator-activated receptor alpha in the adult rodent heart	FASEB JOURNAL			English	Article						diabetes; fasting; fatty acids; hypertrophy; unloading	NECROSIS-FACTOR-ALPHA; BROWN ADIPOSE-TISSUE; SKELETAL-MUSCLE; GENE-EXPRESSION; FATTY-ACIDS; CARDIAC-HYPERTROPHY; MESSENGER-RNA; PPAR-ALPHA; RAT-HEART; MECHANISM	Relatively little is known concerning the regulation of uncoupling proteins (UCPs) in the heart. We investigated in the adult rodent heart 1) whether changes in workload, substrate supply, or cytokine (TNF-alpha) administration affect UCP-2 and UCP-3 expression, and 2) whether peroxisome proliferator-activated receptor alpha (PPAR alpha) regulates the expression of either UCP-2 or UCP-3. Direct comparisons were made between cardiac and skeletal muscle. UCP-2, UCP-3, and PPAR alpha expression were reduced when cardiac workload was either increased (pressure overload by aortic constriction) or decreased (mechanical unloading by heterotopic transplantation). Similar results were observed during cytokine administration. Reduced dietary fatty acid availability resulted in decreased expression of both cardiac UCP-2 and UCP-3. However, when fatty acid (the natural ligand for PPAR alpha) supply was increased thigh-fat feeding, fasting, and STZ-induced diabetes), cardiac UCP-3 but not UCP-2 expression increased. Comparable results were observed in rats treated with the specific PPAR alpha agonist WY-14,643, The level of cardiac UCP-3 but not UCP-2 expression was severely reduced (20-fold) in PPAR alpha (-/-) mice compared to wild-type mice. These results suggest that in the adult rodent heart, UCP-3 expression is regulated by PPAR alpha, In contrast, cardiac UCP-2 expression is regulated in part by a fatty acid-dependent, PPAR alpha -independent mechanism.	Univ Texas, Sch Med, Div Cardiol, Ctr Med, Houston, TX 77030 USA; Univ Texas, Med Ctr, Dept Integrat Biol, Houston, TX 77030 USA; Univ Texas, Med Ctr, Div Organ Transplantat, Houston, TX 77030 USA	University of Texas System; University of Texas System; University of Texas System	Taegtmeyer, H (corresponding author), Univ Texas, Sch Med, Div Cardiol, Ctr Med, 6431 Fannin,MSB 1-246, Houston, TX 77030 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043133, R01HL061483] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-61483, HL-43133] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLARD MF, 1994, AM J PHYSIOL, V267, pH742, DOI 10.1152/ajpheart.1994.267.2.H742; Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; ARMSTRONG RB, 1983, J PHYSIOL-LONDON, V344, P189, DOI 10.1113/jphysiol.1983.sp014933; Barger PM, 2000, J CLIN INVEST, V105, P1723, DOI 10.1172/JCI9056; Boss O, 2000, DIABETES, V49, P143, DOI 10.2337/diabetes.49.2.143; Boss O, 1998, FASEB J, V12, P335, DOI 10.1096/fasebj.12.3.335; Boss O, 1999, BIOCHEM BIOPH RES CO, V261, P870, DOI 10.1006/bbrc.1999.1145; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; Brandt JM, 1998, J BIOL CHEM, V273, P23786, DOI 10.1074/jbc.273.37.23786; Brun S, 1999, DIABETES, V48, P1217, DOI 10.2337/diabetes.48.6.1217; Busquets S, 1998, FEBS LETT, V440, P348, DOI 10.1016/S0014-5793(98)01485-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Depre C, 1998, NAT MED, V4, P1269, DOI 10.1038/3253; Deswal A, 1999, CIRCULATION, V99, P3224, DOI 10.1161/01.CIR.99.25.3224; Doenst T, 1999, CIRCULATION, V100, P344; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; HEGEWISCH S, 1990, LANCET, V335, P294, DOI 10.1016/0140-6736(90)90115-L; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hidaka S, 1999, DIABETES, V48, P430, DOI 10.2337/diabetes.48.2.430; HORN F, 1984, DIABETES, V33, P153; Jaburek M, 1999, J BIOL CHEM, V274, P26003, DOI 10.1074/jbc.274.37.26003; KAGAYA Y, 1990, CIRCULATION, V81, P1353, DOI 10.1161/01.CIR.81.4.1353; Kageyama H, 1998, FEBS LETT, V440, P450, DOI 10.1016/S0014-5793(98)01506-3; Katz Arnold M., 1998, Cardiology Clinics, V16, P633, DOI 10.1016/S0733-8651(05)70040-0; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; KLEINMAN LH, 1978, AM J PHYSIOL, V234, pH515, DOI 10.1152/ajpheart.1978.234.5.H515; Korshunov SS, 1998, FEBS LETT, V435, P215, DOI 10.1016/S0014-5793(98)01073-4; Krook A, 1998, DIABETES, V47, P1528, DOI 10.2337/diabetes.47.9.1528; Larkin S, 1997, BIOCHEM BIOPH RES CO, V240, P222, DOI 10.1006/bbrc.1997.7636; LEGATO MJ, 1979, CIRC RES, V44, P263, DOI 10.1161/01.RES.44.2.263; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; MEERSON FZ, 1972, J MOL CELL CARDIOL, V4, P571, DOI 10.1016/0022-2828(72)90113-7; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; ONO K, 1969, J THORAC CARDIOV SUR, V57, P225, DOI 10.1016/S0022-5223(19)42744-X; Palou A, 1998, INT J BIOCHEM CELL B, V30, P7, DOI 10.1016/S1357-2725(97)00065-4; RICQUIER D, 1983, J BIOL CHEM, V258, P6675; Sack MN, 1996, CIRCULATION, V94, P2837, DOI 10.1161/01.CIR.94.11.2837; Samec S, 1999, DIABETES, V48, P436, DOI 10.2337/diabetes.48.2.436; Schoonjans K, 1996, BBA-LIPID LIPID MET, V1302, P93, DOI 10.1016/0005-2760(96)00066-5; Schrauwen P, 1999, OBES RES, V7, P97, DOI 10.1002/j.1550-8528.1999.tb00396.x; TorreAmione G, 1996, CIRCULATION, V93, P704, DOI 10.1161/01.CIR.93.4.704; Van der Lee KAJM, 2000, FASEB J, V14, P495, DOI 10.1096/fasebj.14.3.495; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; Wu PF, 1999, DIABETES, V48, P1593, DOI 10.2337/diabetes.48.8.1593; Wu PF, 1998, BIOCHEM J, V329, P197, DOI 10.1042/bj3290197; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Zhou YT, 2000, P NATL ACAD SCI USA, V97, P1784, DOI 10.1073/pnas.97.4.1784	50	181	186	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					833	845		10.1096/fj.00-0351com	http://dx.doi.org/10.1096/fj.00-0351com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259402				2022-12-28	WOS:000167419500041
J	Baker, D; Pryce, G; Croxford, JL; Brown, P; Pertwee, RG; Makriyannis, A; Khanolkar, A; Layward, L; Fezza, F; Bisogno, T; Di Marzo, V				Baker, D; Pryce, G; Croxford, JL; Brown, P; Pertwee, RG; Makriyannis, A; Khanolkar, A; Layward, L; Fezza, F; Bisogno, T; Di Marzo, V			Endocannabinoids control spasticity in a multiple sclerosis model	FASEB JOURNAL			English	Article									CNR, Ist Chim Mol Interesse Biol, Endocannabinoid Res Grp, I-80072 Arco Felice Napoli, Naples, Italy; UCL, Inst Neurol, Neuroinflammat Grp, London, England; Natl Hosp Neurol & Neurosurg, MRC, Human Movement & Balance Unit, London WC1N 3BG, England; Univ Aberdeen, Inst Med Sci, Aberdeen AB9 1FX, Scotland; Univ Connecticut, Dept Pharmaceut Sci & Mol & Cell Biol, Ctr Drug Discovery, Storrs, CT USA; Multiple Sclerosis Soc Great Britain & No Ireland, London, England	Consiglio Nazionale delle Ricerche (CNR); University of London; King's College London; University College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of Aberdeen; University of Connecticut	Di Marzo, V (corresponding author), CNR, Ist Chim Mol Interesse Biol, Endocannabinoid Res Grp, Via Toiano 6, I-80072 Arco Felice Napoli, Naples, Italy.	vdimarzo@icmib.na.cnr.it	Brown, Peter/J-4307-2016; Pertwee, Roger Guy/E-1312-2011; Di Marzo, Vincenzo/AAD-7742-2019; Bisogno, Tiziana/B-7891-2015; Makriyannis, Alexandros/GRF-1518-2022	Brown, Peter/0000-0002-5201-3044; Di Marzo, Vincenzo/0000-0002-1490-3070; Makriyannis, Alexandros/0000-0003-3272-3687; Pertwee, Roger/0000-0003-3227-2783	Multiple Sclerosis Society [541] Funding Source: Medline	Multiple Sclerosis Society(National Multiple Sclerosis Society)			0	314	337	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					300	302		10.1096/fj.00-0399fje	http://dx.doi.org/10.1096/fj.00-0399fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156943				2022-12-28	WOS:000166872900009
J	Smith, U; Gogg, S; Johansson, A; Olausson, T; Rotter, V; Svalstedt, B				Smith, U; Gogg, S; Johansson, A; Olausson, T; Rotter, V; Svalstedt, B			Thiazolidinediones (PPAR gamma agonists) but not PPAR alpha agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes	FASEB JOURNAL			English	Article; Proceedings Paper	60th Annual Meeting of the American-Diabetes-Association	JUN 09-13, 2000	SAN ANTONIO, TEXAS	Amer Diabet Assoc		insulin signaling; insulin action; gene transcription; IRS-2; PPAR	INSULIN-RECEPTOR SUBSTRATE-2; OBESE ZUCKER RATS; TYROSINE PHOSPHORYLATION; ADIPOSE-TISSUE; C/EBP-ALPHA; PATHWAY; ORGANIZATION; TROGLITAZONE; SENSITIVITY; FIBROBLASTS	Thiazolidinediones (TZD) improve insulin sensitivity in human as well as in different animal models of insulin resistance and Type 2 diabetes. However, no clear link to the insulin signaling events has been identified, Using differentiated 3T3-L1 adipocytes, we found that TZD rapidly and markedly increased IRS-2 gene expression. This effect was specific for PPAR gamma agonists and was not seen with PPAR alpha agonists. It was rapidly induced (within 4 h) and maintained throughout the observation period of 48 h. It was also concentration dependent (EC50 similar to 50 nM) and not inhibited by cycloheximide, suggesting a direct effect on the IRS-2 promoter. There was no evidence that TZD altered IRS-2 mRNA stability, supporting that the increased mRNA levels were due to an increased gene transcription. IRS-2 protein expression was increased similar to 30% after 48 h and similar to 50% after 96 h. No effects of TZD were seen on IRS-1, PKB/Akt, or GLUT4 gene expression. TZD also increased IRS-2 mRNA levels in cultured human adipose tissue. These data show the first direct Link between TZD and a critical molecule in insulin's signaling cascade in both 3T3-L1 and human adipocytes, and indicate a novel mode of action of these compounds.	Univ Gothenburg, Sahlgrenska Hosp, Dept Internal Med, Lundberg Lab Diabet Res, S-41345 Gothenburg, Sweden	Sahlgrenska University Hospital; University of Gothenburg	Smith, U (corresponding author), Univ Gothenburg, Sahlgrenska Hosp, Dept Internal Med, Lundberg Lab Diabet Res, Guldhetsgatan, S-41345 Gothenburg, Sweden.		Gogg, Silvia/R-4549-2019					BOWEN L, 1991, METABOLISM, V40, P1025, DOI 10.1016/0026-0495(91)90124-F; CHAIKEN RL, 1995, DIABETOLOGIA, V38, P1307; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIGOLINI M, 1979, METABOLISM, V28, P502, DOI 10.1016/0026-0495(79)90189-6; El-Jack AK, 1999, J BIOL CHEM, V274, P7946, DOI 10.1074/jbc.274.12.7946; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; FUJIWARA T, 1988, DIABETES, V37, P1549, DOI 10.2337/diabetes.37.11.1549; Lefebvre AM, 1997, ARTERIOSCL THROM VAS, V17, P1756, DOI 10.1161/01.ATV.17.9.1756; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Mastick CC, 1997, J BIOL CHEM, V272, P20706, DOI 10.1074/jbc.272.33.20706; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; Okuno A, 1998, J CLIN INVEST, V101, P1354, DOI 10.1172/JCI1235; Peraldi P, 1997, J CLIN INVEST, V100, P1863, DOI 10.1172/JCI119715; Ribon V, 1998, P NATL ACAD SCI USA, V95, P14751, DOI 10.1073/pnas.95.25.14751; RICORT JM, 1995, DIABETOLOGIA, V38, P1148, DOI 10.1007/s001250050406; Rondinone CM, 1997, P NATL ACAD SCI USA, V94, P4171, DOI 10.1073/pnas.94.8.4171; RUBIN CS, 1977, J BIOL CHEM, V252, P3554; SMITH U, 1976, DIABETOLOGIA, V12, P137, DOI 10.1007/BF00428979; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Sun XJ, 1999, DIABETES, V48, P1359, DOI 10.2337/diabetes.48.7.1359; TOBACK FG, 1974, J CLIN INVEST, V54, P91, DOI 10.1172/JCI107754; Vassen L, 1999, MOL ENDOCRINOL, V13, P485; Vassen L, 1999, DIABETES, V48, P1877, DOI 10.2337/diabetes.48.9.1877; Withers DJ, 1999, NAT GENET, V23, P32, DOI 10.1038/12631; Wu ZD, 1998, J CLIN INVEST, V101, P22, DOI 10.1172/JCI1244; Zierath JR, 1998, ENDOCRINOLOGY, V139, P5034, DOI 10.1210/en.139.12.5034	27	108	114	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2001	15	1					215	220		10.1096/fj.00-0020com	http://dx.doi.org/10.1096/fj.00-0020com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149909				2022-12-28	WOS:000166312400030
J	Tegeder, I; Niederberger, E; Israr, E; Guhring, H; Brune, K; Euchenhofer, C; Grosch, S; Geisslinger, G				Tegeder, I; Niederberger, E; Israr, E; Guhring, H; Brune, K; Euchenhofer, C; Grosch, S; Geisslinger, G			Inhibition of NF-kappa B and AP-1 activation by R- and S-flurbiprofen	FASEB JOURNAL			English	Article									Goethe Univ Frankfurt, Ctr Pharmacol, D-60590 Frankfurt, Germany; Univ Erlangen Nurnberg, Inst Expt Pharmakol & Toxikol, D-91054 Erlangen, Germany	Goethe University Frankfurt; University of Erlangen Nuremberg	Geisslinger, G (corresponding author), Goethe Univ Frankfurt, Ctr Pharmacol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	geisslinger@em.uni-frankfurt.de	Groesch, Sabine/H-4251-2018; Tegeder, Irmgard/AAM-2246-2020; Tegeder, Irmgard/AAM-2266-2020	Groesch, Sabine/0000-0002-7262-6307; Tegeder, Irmgard/0000-0001-7524-8025; Tegeder, Irmgard/0000-0001-7524-8025					0	75	78	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2001	15	1					2	4		10.1096/fasebj.15.1.2	http://dx.doi.org/10.1096/fasebj.15.1.2			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11099482	Bronze			2022-12-28	WOS:000166312400001
J	Berns, H; Humar, R; Hengerer, B; Kiefer, FN; Battegay, EJ				Berns, H; Humar, R; Hengerer, B; Kiefer, FN; Battegay, EJ			RACK1 is up-regulated in angiogenesis and human carcinomas	FASEB JOURNAL			English	Article						receptor for activated PKC beta; signaling; angiogenic process; endothelium; cancer	PROTEIN-KINASE-C; ENDOTHELIAL-CELLS; IN-VITRO; GROWTH-FACTOR; INTRACELLULAR RECEPTOR; EXTRACELLULAR-MATRIX; GENE-EXPRESSION; ESTROUS-CYCLE; MESSENGER-RNA; CORPORA-LUTEA	Angiogenesis is crucial for many biological and pathological processes including the ovarian cycle and tumor growth, To identify molecules relevant for angiogenesis, we performed mRNA fingerprinting and subsequent Northern blot analysis using bovine cord-forming vs, monolayer-forming endothelial cells (EC) in vitro and staged bovine corpora lutea in vivo. We detected the receptor for activated C kinase 1 (RACK1), the specific receptor for activated protein kinase C beta (PKC beta), to be up-regulated in bovine cord-forming EC in vitro and in angiogenically active stages of bovine corpora lutea in vivo, Thereafter we established and determined the complete bovine RACK1 cDNA sequence. RACK1 was massively induced in subconfluent vs. contact-inhibited bovine EC, during angiogenesis in vitro, active phases of the murine ovarian cycle, human tumor angiogenesis, and in cancer cells in vivo as assessed by quantitative PCR and in situ hybridization, RACK1 transcripts were localized to proliferating EC in vitro and the endothelium of tumor neovascularizations in vivo by in situ hybridization, PKC beta plays an important role in angiogenesis and cancer growth. Our data suggest that downstream signaling of PKC beta in angiogenically active vs. inactive tissues and endothelium is affected by the availability of RACK1.	Univ Basel Hosp, Dept Res, Head Lab Vasc Biol, Cardiovasc Res Grp, CH-4031 Basel, Switzerland; Univ Basel Hosp, Med Outpatient Div, CH-4031 Basel, Switzerland; Novartis, Nervous Syst Therapeut Area, CH-4002 Basel, Switzerland	University of Basel; University of Basel; Novartis	Battegay, EJ (corresponding author), Univ Basel Hosp, Dept Res, Head Lab Vasc Biol, Cardiovasc Res Grp, Petersgraben 3, CH-4031 Basel, Switzerland.							Battegay EJ, 1996, TRENDS GLYCOSCI GLYC, V8, P231, DOI 10.4052/tigg.8.231; BATTEGAY EJ, 1995, J MOL MED, V73, P333; BATTEGAY EJ, 1994, J CELL BIOL, V125, P917, DOI 10.1083/jcb.125.4.917; CHAMPLIN AK, 1973, BIOL REPROD, V8, P491, DOI 10.1093/biolreprod/8.4.491; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COTTAPEREIRA G, 1980, J CELL PHYSIOL, V102, P183, DOI 10.1002/jcp.1041020209; Csukai M, 1999, PHARMACOL RES, V39, P253, DOI 10.1006/phrs.1998.0418; Doanes AM, 1999, BIOCHEM BIOPH RES CO, V255, P545, DOI 10.1006/bbrc.1999.0227; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Frueh FW, 1997, MOL PHARMACOL, V51, P363; GarciaHiguera I, 1996, BIOCHEMISTRY-US, V35, P13985, DOI 10.1021/bi9612879; HENGERER B, 1993, BIOTECHNIQUES, V14, P522; HU DE, 1995, INFLAMMATION, V19, P39, DOI 10.1007/BF01534379; IMAI Y, 1994, MOL BRAIN RES, V24, P313, DOI 10.1016/0169-328X(94)90144-9; IRELAND JJ, 1980, J DAIRY SCI, V63, P155, DOI 10.3168/jds.S0022-0302(80)82901-8; IRUELAARISPE ML, 1991, ARTERIOSCLER THROMB, V11, P805, DOI 10.1161/01.ATV.11.4.805; IRUELAARISPE ML, 1993, J CELL BIOCHEM, V52, P414, DOI 10.1002/jcb.240520406; Jones MK, 1998, BIOCHEM BIOPH RES CO, V249, P118, DOI 10.1006/bbrc.1998.9095; Kanashiro CA, 1998, CLIN EXP PHARMACOL P, V25, P974, DOI 10.1111/j.1440-1681.1998.tb02170.x; Kolarova H, 1996, BIOTECHNIQUES, V20, P196; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIAW L, 1993, ARTERIOSCLER THROMB, V13, P985, DOI 10.1161/01.ATV.13.7.985; Martelli AM, 1999, J CELL BIOCHEM, V74, P499, DOI 10.1002/(SICI)1097-4644(19990915)74:4<499::AID-JCB1>3.0.CO;2-X; MIETTINEN M, 1983, AM J CLIN PATHOL, V79, P32, DOI 10.1093/ajcp/79.1.32; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; ONO Y, 1986, FEBS LETT, V206, P347, DOI 10.1016/0014-5793(86)81010-9; REYNOLDS LP, 1992, FASEB J, V6, P886, DOI 10.1096/fasebj.6.3.1371260; RICKEN AM, 1995, HISTOCHEM CELL BIOL, V103, P345, DOI 10.1007/BF01457809; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Ron D, 1999, J BIOL CHEM, V274, P27039, DOI 10.1074/jbc.274.38.27039; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Rosales OR, 1998, CELL SIGNAL, V10, P589, DOI 10.1016/S0898-6568(98)00002-3; Schenk S, 1999, MOL BIOL CELL, V10, P2933, DOI 10.1091/mbc.10.9.2933; SPANELBOROWSKI K, 1987, ACTA ANAT, V128, P227; Thommen R, 1997, J CELL BIOCHEM, V64, P403; TSOPANOGLOU NE, 1993, J VASC RES, V30, P202, DOI 10.1159/000158995; VERNON RB, 1995, AM J PATHOL, V147, P873; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Yoshiji H, 1999, CANCER RES, V59, P4413; Zhou LY, 1996, J INVEST DERMATOL, V107, P248, DOI 10.1111/1523-1747.ep12329733	44	100	106	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2549	2558		10.1096/fj.99-1038com	http://dx.doi.org/10.1096/fj.99-1038com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099474				2022-12-28	WOS:000165723400026
J	Rand, JB; Duerr, JS; Frisby, DL				Rand, JB; Duerr, JS; Frisby, DL			Neurogenetics of vesicular transporters in C-elegans	FASEB JOURNAL			English	Review							NEMATODE CAENORHABDITIS-ELEGANS; INORGANIC-PHOSPHATE TRANSPORTER; GLUTAMIC-ACID DECARBOXYLASE; CHOLINERGIC GENE LOCUS; MALE MATING-BEHAVIOR; MONOAMINE TRANSPORTER; ACETYLCHOLINE TRANSPORTER; CHLORIDE CHANNEL; NERVOUS-SYSTEM; GLUTAMATERGIC NEUROTRANSMISSION	The nematode Caenorhabditis elegans has a number of advantages for the analysis of synaptic molecules. These include a simple nervous system in which all cells are identified and synaptic connectivity is known and reproducible, a large collection of mutants and powerful methods of genetic analysis, simple methods for the generation and analysis of transgenic animals, and a number of relatively simple quantifiable behaviors. Studies in C. elegans have made major contributions to our understanding of vesicular transmitter transporters. Two of the four classes of vesicular transporters so far identified (VAChT and VGAT) were first described and cloned in C. elegans; in both cases, the genes were first identified and cloned by means of mutations causing a suggestive phenotype (1, 2). The phenotypes of eat-4 mutants and the cell biology of the EAT-4 protein were critical in the identification of this protein as the vesicular glutamate transporter (3, 4). In addition, the unusual gem structure associated with the cholinergic locus was first described in C. elegans (5). The biochemical properties of the nematode transporters are surprisingly similar to their vertebrate counterparts, and they can be assayed under similar conditions using the same types of mammalian cells (6, 7). In addition, mild and severe mutants (including knockouts) are available for each of the four C. elegans vesicular transporters, which has permitted a careful evaluation of the role(s) of vesicular transport in transmitter-specific behaviors. Accordingly, it seems appropriate at this time to present the current status of the field. In this review, we will first discuss the properties of C. elegans vesicular transporters and transporter mutants, and then explore some of the lessons and insights C. elegans research has provided to the field of vesicular transport.	Oklahoma Med Res Fdn, Program Mol & Cell Biol, Oklahoma City, OK 73104 USA	Oklahoma Medical Research Foundation	Rand, JB (corresponding author), Oklahoma Med Res Fdn, Program Mol & Cell Biol, 825 Ne 13Th St, Oklahoma City, OK 73104 USA.	James-Rand@omrf.ouhsc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038679] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS010031] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38679, R01 GM038679] Funding Source: Medline; NINDS NIH HHS [NS10031] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBERTSON DG, 1976, PHILOS T ROY SOC B, V275, P299, DOI 10.1098/rstb.1976.0085; ALFONSO A, 1994, J MOL BIOL, V241, P627, DOI 10.1006/jmbi.1994.1538; ALFONSO A, 1993, SCIENCE, V261, P617, DOI 10.1126/science.8342028; AVERY L, 1993, GENETICS, V133, P897; BEJANIN S, 1994, J BIOL CHEM, V269, P21944; Bellocchio EE, 1998, J NEUROSCI, V18, P8648; Bellocchio EE, 2000, SCIENCE, V289, P957, DOI 10.1126/science.289.5481.957; BRENNER S, 1974, GENETICS, V77, P71; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Chaudhry FA, 1998, J NEUROSCI, V18, P9733; CULLY DF, 1994, NATURE, V371, P707, DOI 10.1038/371707a0; DELCASTILLO J, 1963, ARCH INT PHYS BIOCH, V71, P741, DOI 10.3109/13813456309092194; Dent JA, 2000, P NATL ACAD SCI USA, V97, P2674, DOI 10.1073/pnas.97.6.2674; Dent JA, 1997, EMBO J, V16, P5867, DOI 10.1093/emboj/16.19.5867; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; Duerr JS, 1999, J NEUROSCI, V19, P72, DOI 10.1523/JNEUROSCI.19-01-00072.1999; Dumoulin A, 1999, J CELL SCI, V112, P811; Eastman C, 1999, J NEUROSCI, V19, P6225; Eiden LE, 1998, J NEUROCHEM, V70, P2227; ERICKSON JD, 1993, J NEUROCHEM, V61, P2314, DOI 10.1111/j.1471-4159.1993.tb07476.x; Erickson JD, 1996, P NATL ACAD SCI USA, V93, P5166, DOI 10.1073/pnas.93.10.5166; ERICKSON JD, 1994, J BIOL CHEM, V269, P21929; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; HALL DH, 1991, J NEUROSCI, V11, P1; HART AC, 1995, NATURE, V378, P82, DOI 10.1038/378082a0; HORVITZ HR, 1982, SCIENCE, V216, P1012, DOI 10.1126/science.6805073; HOSONO R, 1989, ZOOL SCI, V6, P697; HOSONO R, 1987, J NEUROCHEM, V49, P1820, DOI 10.1111/j.1471-4159.1987.tb02442.x; HOSONO R, 1991, NEUROSCI LETT, V128, P243, DOI 10.1016/0304-3940(91)90270-4; HOWELL M, 1994, FEBS LETT, V338, P16, DOI 10.1016/0014-5793(94)80108-8; ISAAC RE, 1991, PARASITOLOGY, V102, P445, DOI 10.1017/S0031182000064428; Jin YS, 1999, J NEUROSCI, V19, P539; Johnson C.D., 1980, P159; JOHNSON CD, 1983, J NEUROCHEM, V41, P30, DOI 10.1111/j.1471-4159.1983.tb11811.x; Kawano T, 1996, BIOCHEM BIOPH RES CO, V228, P415, DOI 10.1006/bbrc.1996.1676; Kawano T, 1997, BIOSCI BIOTECH BIOCH, V61, P927, DOI 10.1271/bbb.61.927; Kitamoto T, 1998, J BIOL CHEM, V273, P2706, DOI 10.1074/jbc.273.5.2706; KOLSON DL, 1985, J NEUROGENET, V2, P93, DOI 10.3109/01677068509100145; Lee RYN, 1999, J NEUROSCI, V19, P159, DOI 10.1523/JNEUROSCI.19-01-00159.1999; Li HY, 1997, P NATL ACAD SCI USA, V94, P5912, DOI 10.1073/pnas.94.11.5912; Lints R, 1999, DEVELOPMENT, V126, P5819; LIU KS, 1995, NEURON, V14, P79, DOI 10.1016/0896-6273(95)90242-2; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; LOER CM, 1993, J NEUROSCI, V13, P5407, DOI 10.1523/JNEUROSCI.13-12-05407.1993; MARICQ AV, 1995, NATURE, V378, P78, DOI 10.1038/378078a0; McIntire SL, 1997, NATURE, V389, P870, DOI 10.1038/39908; MCINTIRE SL, 1993, NATURE, V364, P337, DOI 10.1038/364337a0; MCINTIRE SL, 1993, NATURE, V364, P334, DOI 10.1038/364334a0; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; Mello C, 1995, METHOD CELL BIOL, V48, P451; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Miller DM, 1999, BIOTECHNIQUES, V26, P914, DOI 10.2144/99265rr01; Miller KG, 1996, P NATL ACAD SCI USA, V93, P12593, DOI 10.1073/pnas.93.22.12593; MUIMO R, 1993, COMP BIOCHEM PHYS B, V106, P969, DOI 10.1016/0305-0491(93)90059-E; NGUYEN M, 1995, GENETICS, V140, P527; NI BH, 1994, P NATL ACAD SCI USA, V91, P5607, DOI 10.1073/pnas.91.12.5607; Radice AD, 1996, MOL BIOCHEM PARASIT, V80, P41, DOI 10.1016/0166-6851(96)02667-9; RAIZEN DM, 1994, NEURON, V12, P483, DOI 10.1016/0896-6273(94)90207-0; Rand James B., 1997, Cold Spring Harbor Monograph Series, V33, P611; RAND JB, 1985, J NEUROCHEM, V44, P189, DOI 10.1111/j.1471-4159.1985.tb07130.x; RAND JB, 1984, GENETICS, V106, P227; RAND JB, 1989, GENETICS, V122, P73; Rankin CH, 2000, J NEUROSCI, V20, P4337; Sagne C, 1997, FEBS LETT, V417, P177, DOI 10.1016/S0014-5793(97)01279-9; Sawin ER, 2000, NEURON, V26, P619, DOI 10.1016/S0896-6273(00)81199-X; Schafer WR, 1996, GENETICS, V143, P1219; SEGALAT L, 1995, SCIENCE, V267, P1648, DOI 10.1126/science.7886454; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SULSTON J, 1975, J COMP NEUROL, V163, P215, DOI 10.1002/cne.901630207; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; Sze JY, 2000, NATURE, V403, P560, DOI 10.1038/35000609; THOMAS JH, 1990, GENETICS, V124, P855; VAROQUI H, 1994, FEBS LETT, V342, P97, DOI 10.1016/0014-5793(94)80592-X; Vassilatis DK, 1997, J BIOL CHEM, V272, P33167, DOI 10.1074/jbc.272.52.33167; WATERSTON R, 1995, P NATL ACAD SCI USA, V92, P10836, DOI 10.1073/pnas.92.24.10836; WEINSHENKER D, 1995, J NEUROSCI, V15, P6975; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WHITE JG, 1976, PHILOS T R SOC B, V275, P327, DOI 10.1098/rstb.1976.0086; Wolstenholme AJ, 1997, BIOCHEM SOC T, V25, P830, DOI 10.1042/bst0250830	81	33	51	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2000	14	15					2414	2422		10.1096/fj.00-0313rev	http://dx.doi.org/10.1096/fj.00-0313rev			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099459				2022-12-28	WOS:000165723400011
J	Burke, LJ; Baniahmad, A				Burke, LJ; Baniahmad, A			Co-repressors 2000	FASEB JOURNAL			English	Review							HISTONE DEACETYLASE COMPLEX; NUCLEAR RECEPTOR COREPRESSOR; ACUTE PROMYELOCYTIC LEUKEMIA; THYROID-HORMONE RECEPTOR; PLZF-RAR-ALPHA; ADRENAL HYPOPLASIA CONGENITA; MEDIATES TRANSCRIPTIONAL REPRESSION; NEGATIVE-FEEDBACK-REGULATION; ACUTE MYELOID-LEUKEMIA; ZINC-FINGER PROTEINS	In the last 5 years, many co-repressors have been identified in eukaryotes that function in a wide range of species, from yeast to Drosophila and humans. Co-repressors are coregulators that are recruited by DNA-bound transcriptional silencers and play essential roles in many pathways including differentiation, proliferation, programmed cell death, and cell cycle. Accordingly, it has been shown that aberrant interactions of co-repressors with transcriptional silencers provide the molecular basis of a variety of human diseases. Co-repressors mediate transcriptional silencing by mechanisms that include direct inhibition of the basal transcription machinery and recruitment of chromatin-modifying enzymes. Chromatin modification includes histone deacetylation, which is thought to lead to a compact chromatin structure to which the accessibility of transcriptional activators is impaired. In a general mechanistic view, the overall picture suggests that transcriptional silencers and co-repressors act in analogy to transcriptional activators and coactivators, but with the opposite effect leading to gene silencing. We provide a comprehensive overview of the currently known higher eukaryotic co-repressors, their mechanism of action, and their involvement in biological and pathophysiological pathways. We also show the different pathways that lead to the regulation of corepressor-silencer complex formation.	Univ Giessen, Inst Genet, D-35392 Giessen, Germany	Justus Liebig University Giessen	Baniahmad, A (corresponding author), Univ Giessen, Inst Genet, Heinrich Buff Ring 58-62, D-35392 Giessen, Germany.	Aria.Baniahmad@gen.bio.uni-giessen.de		Burke, Lez/0000-0002-2932-6843				Agata Y, 1999, J BIOL CHEM, V274, P16412, DOI 10.1074/jbc.274.23.16412; Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Altincicek B, 2000, J BIOL CHEM, V275, P7662, DOI 10.1074/jbc.275.11.7662; Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Andres ME, 1999, P NATL ACAD SCI USA, V96, P9873, DOI 10.1073/pnas.96.17.9873; Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; Asahara H, 1999, MOL CELL BIOL, V19, P8219; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Bach I, 1999, NAT GENET, V22, P394, DOI 10.1038/11970; Bailey P, 1999, MOL ENDOCRINOL, V13, P1155, DOI 10.1210/me.13.7.1155; Baniahmad A, 1998, MOL ENDOCRINOL, V12, P504, DOI 10.1210/me.12.4.504; BANIAHMAD A, 1992, P NATL ACAD SCI USA, V89, P10633, DOI 10.1073/pnas.89.22.10633; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BECKPECCOZ P, 1994, THYROID, V4, P225, DOI 10.1089/thy.1994.4.225; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Brannon M, 1999, DEVELOPMENT, V126, P3159; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Choi CY, 1999, J BIOL CHEM, V274, P31543, DOI 10.1074/jbc.274.44.31543; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; CLASS CK, 2000, GENE DEV, V14, P121; Crawford PA, 1998, MOL CELL BIOL, V18, P2949, DOI 10.1128/MCB.18.5.2949; Dang CV, 1999, EXP CELL RES, V253, P63, DOI 10.1006/excr.1999.4686; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dhordain P, 1998, NUCLEIC ACIDS RES, V26, P4645, DOI 10.1093/nar/26.20.4645; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Dressel U, 1999, MOL CELL BIOL, V19, P3383; Dubnicoff T, 1997, GENE DEV, V11, P2952, DOI 10.1101/gad.11.22.2952; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Furusawa T, 1999, MOL CELL BIOL, V19, P8581; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Georgopoulos K, 1997, CURR OPIN IMMUNOL, V9, P222, DOI 10.1016/S0952-7915(97)80139-2; Ghosh AK, 1999, BIOCHEM BIOPH RES CO, V260, P405, DOI 10.1006/bbrc.1999.0921; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; Guo WW, 1996, J CLIN ENDOCR METAB, V81, P2481, DOI 10.1210/jc.81.7.2481; Habiby RL, 1996, J CLIN INVEST, V98, P1055, DOI 10.1172/JCI118866; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Holmes M, 1999, J BIOL CHEM, V274, P23491, DOI 10.1074/jbc.274.33.23491; Hong SH, 1998, MOL ENDOCRINOL, V12, P1161, DOI 10.1210/me.12.8.1161; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hsieh JJD, 1999, P NATL ACAD SCI USA, V96, P23, DOI 10.1073/pnas.96.1.23; Huang EY, 2000, GENE DEV, V14, P45; Huang YF, 1999, NAT NEUROSCI, V2, P867, DOI 10.1038/13165; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Jimenez G, 1997, GENE DEV, V11, P3072, DOI 10.1101/gad.11.22.3072; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kadosh D, 1998, GENE DEV, V12, P797, DOI 10.1101/gad.12.6.797; Kao HY, 2000, GENE DEV, V14, P55; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Koipally J, 1999, EMBO J, V18, P3090, DOI 10.1093/emboj/18.11.3090; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Laj A, 1999, MOL CELL BIOL, V19, P6632; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mannervik M, 1999, SCIENCE, V284, P606, DOI 10.1126/science.284.5414.606; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Muscat GEO, 1998, NUCLEIC ACIDS RES, V26, P2899, DOI 10.1093/nar/26.12.2899; MUSCATELLI F, 1994, NATURE, V372, P672, DOI 10.1038/372672a0; Muto A, 1998, EMBO J, V17, P5734, DOI 10.1093/emboj/17.19.5734; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Naruse Y, 1999, P NATL ACAD SCI USA, V96, P13691, DOI 10.1073/pnas.96.24.13691; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Nibu Y, 1998, EMBO J, V17, P7009, DOI 10.1093/emboj/17.23.7009; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; Olson DP, 1998, J BIOL CHEM, V273, P3375, DOI 10.1074/jbc.273.6.3375; Ordentlich P, 1999, P NATL ACAD SCI USA, V96, P2639, DOI 10.1073/pnas.96.6.2639; Park EJ, 1999, P NATL ACAD SCI USA, V96, P3519, DOI 10.1073/pnas.96.7.3519; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; Rao G, 1996, ONCOGENE, V12, P1165; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; Refetoff S, 1994, Curr Ther Endocrinol Metab, V5, P117; Refetoff Samuel, 1994, Acta Paediatrica Japonica (Overseas Edition), V36, P1; Ren B, 1999, GENE DEV, V13, P125, DOI 10.1101/gad.13.1.125; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; RUSSO MW, 1995, P NATL ACAD SCI USA, V92, P6873, DOI 10.1073/pnas.92.15.6873; Sasaki S, 1999, EMBO J, V18, P5389, DOI 10.1093/emboj/18.19.5389; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Sparrow DB, 1999, EMBO J, V18, P5085, DOI 10.1093/emboj/18.18.5085; Stiegler P, 1998, CANCER RES, V58, P5049; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Svaren J, 1996, MOL CELL BIOL, V16, P3545; Tagami T, 1998, ENDOCRINOLOGY, V139, P640, DOI 10.1210/en.139.2.640; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tenbaum S, 1997, INT J BIOCHEM CELL B, V29, P1325, DOI 10.1016/S1357-2725(97)00087-3; Thormeyer D, 1999, INT J MOL MED, V4, P351; Tokitou F, 1999, J BIOL CHEM, V274, P4485, DOI 10.1074/jbc.274.8.4485; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Tsai CC, 1999, MOL CELL, V4, P175, DOI 10.1016/S1097-2765(00)80365-2; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Tyler JK, 1999, CELL, V99, P443, DOI 10.1016/S0092-8674(00)81530-5; Valentine SA, 1998, MOL CELL BIOL, V18, P6584, DOI 10.1128/MCB.18.11.6584; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; Vogel G, 1999, SCIENCE, V286, P665, DOI 10.1126/science.286.5440.665; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang JX, 1999, CANCER RES, V59, P2766; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; Wong CW, 1998, MOL CELL BIOL, V18, P5500, DOI 10.1128/MCB.18.9.5500; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yang Q, 2000, BIOCHEM J, V345, P335, DOI 10.1042/0264-6021:3450335; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yoh SM, 1997, MOL ENDOCRINOL, V11, P470, DOI 10.1210/me.11.4.470; Zamir I, 1997, P NATL ACAD SCI USA, V94, P14400, DOI 10.1073/pnas.94.26.14400; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4; Zhang YH, 1998, AM J HUM GENET, V62, P855, DOI 10.1086/301782	164	170	173	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2000	14	13					1876	1888		10.1096/fj.99-0943rev	http://dx.doi.org/10.1096/fj.99-0943rev			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023972				2022-12-28	WOS:000089634400007
J	Theilmeier, G; De Geest, B; Van Veldhoven, PP; Stengel, D; Michiels, C; Lox, M; Landeloos, M; Chapman, MJ; Ninio, E; Collen, D; Himpens, B; Holvoet, P				Theilmeier, G; De Geest, B; Van Veldhoven, PP; Stengel, D; Michiels, C; Lox, M; Landeloos, M; Chapman, MJ; Ninio, E; Collen, D; Himpens, B; Holvoet, P			HDL-associated PAF-AH reduces endothelial adhesiveness in apoE(-/-) mice	FASEB JOURNAL			English	Article						atherosclerosis; lipoproteins; leukocytes; cell adhesion molecules; signal transduction	HIGH-DENSITY-LIPOPROTEIN; ACTIVATING-FACTOR-ACETYLHYDROLASE; E-DEFICIENT MICE; CELL-ADHESION MOLECULE-1; CORONARY-ARTERY DISEASE; GENE-TRANSFER; EXPRESSION; ATHEROSCLEROSIS; PLASMA; PROGRESSION	Macrophage infiltration into the subendothelial space at lesion prone sites is the primary event in atherogenesis. Inhibition of macrophage homing might therefore prevent atherosclerosis. Since HDL levels are inversely correlated with cardiovascular risk, their effect on macrophage homing was assessed in apoE-deficient (apoE(-/-)) mice. Overexpression of human apolipoprotein AI in apoE(-/-) mice increased HDL levels 3-fold and reduced macrophage accumulation in an established assay of leukocyte homing to aortic root endothelium 3.2-fold (P<0.005). This was due to reduced in vivo beta VLDL oxidation, reduced beta VLDL triggered endothelial cytosolic Ca2+ signaling through PAF-like bioactivity, lower ICAM-1 and VCAM-1 expression, and diminished ex vivo leukocyte adhesion. Adenoviral gene transfer of human PAF-acetylhydrolase (PAF-AH) in apoE(-/-) mice increased PAF-AH activity 1.5-fold (P<0.001), reduced beta VLDL-induced ex vivo macrophage adhesion 3.5-fold (P<0.01), and reduced in vivo macrophage homing 2.6-fold (P<0.02). These inhibitory effects were observed in the absence of increased HDL cholesterol levels. In conclusion, HDL reduces macrophage homing to endothelium by reducing oxidative stress via its associated PAF-AH activity. This protective mechanism is independent of the function of HDL as cholesterol acceptor. Modulation of lipoprotein oxidation by PAF-AH may prevent leukocyte recruitment to the vessel wall, a key feature in atherogenesis.	Katholieke Univ Leuven, Ctr Mol & Vasc Biol, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Dept Pharmacol, B-3000 Louvain, Belgium; FUNDP, Lab Biochim & Biol Cellulaire, Namur, Belgium; Hop Pitie, INSERM, U321, F-75651 Paris, France; Katholieke Univ Leuven, Dept Physiol, B-3000 Louvain, Belgium	KU Leuven; KU Leuven; University of Namur; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; KU Leuven	Holvoet, P (corresponding author), Katholieke Univ Leuven, Ctr Expt Surg & Anesthesiol, Herestr 49, B-3000 Louvain, Belgium.		, Van Veldhoven Paul/U-6359-2019; De Geest, Bart/AHB-0394-2022; chapman, john/Y-2742-2019; HOLVOET, PAUL/T-8434-2017	, Van Veldhoven Paul/0000-0002-4478-2564; HOLVOET, PAUL/0000-0001-9201-0772; De Geest, Bart/0000-0001-5580-686X; Lox, Marleen/0000-0002-0837-7852				Benoit P, 1999, CIRCULATION, V99, P105, DOI 10.1161/01.CIR.99.1.105; COCKERILL GW, 1995, ARTERIOSCL THROM VAS, V15, P1987, DOI 10.1161/01.ATV.15.11.1987; Dansky HM, 1999, J CLIN INVEST, V104, P31, DOI 10.1172/JCI6577; DeGeest B, 1997, CIRCULATION, V96, P4349; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; Holvoet P, 1998, CIRCULATION, V98, P1487, DOI 10.1161/01.CIR.98.15.1487; Holvoet P, 1998, J CLIN INVEST, V102, P379, DOI 10.1172/JCI3038; HOLVOET P, 1995, J CLIN INVEST, V95, P2611, DOI 10.1172/JCI117963; KINASHI T, 1995, J LEUKOCYTE BIOL, V57, P168, DOI 10.1002/jlb.57.1.168; Lee C, 1999, ARTERIOSCL THROM VAS, V19, P1437, DOI 10.1161/01.ATV.19.6.1437; MACKNESS MI, 1993, ATHEROSCLEROSIS, V104, P129, DOI 10.1016/0021-9150(93)90183-U; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; MAZER B, 1991, J IMMUNOL, V146, P1914; MILLER NE, 1985, NATURE, V314, P109, DOI 10.1038/314109a0; NAVAB M, 1991, J CLIN INVEST, V88, P2039, DOI 10.1172/JCI115532; PALINSKI W, 1994, ARTERIOSCLER THROMB, V14, P605, DOI 10.1161/01.ATV.14.4.605; Patel SS, 1998, CIRCULATION, V97, P75, DOI 10.1161/01.CIR.97.1.75; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; PLUMP AS, 1994, P NATL ACAD SCI USA, V91, P9607, DOI 10.1073/pnas.91.20.9607; RUBIN EM, 1991, P NATL ACAD SCI USA, V88, P434, DOI 10.1073/pnas.88.2.434; SCHEYNIUS A, 1993, J IMMUNOL, V150, P655; Serebruany VL, 1998, CARDIOLOGY, V90, P127, DOI 10.1159/000006831; SHAH PK, 1992, CIRCULATION, V85, P1279, DOI 10.1161/01.CIR.85.4.1279; Shah PK, 1998, CIRCULATION, V97, P780, DOI 10.1161/01.CIR.97.8.780; Staley D, 1997, COMPR PSYCHIAT, V38, P6, DOI 10.1016/S0010-440X(97)90047-X; Theilmeier G, 1999, BLOOD, V94, P2725, DOI 10.1182/blood.V94.8.2725.420k18_2725_2734; THOMAS JE, 1993, ONCOGENE, V8, P2521; TSELEPIS AD, 1995, ARTERIOSCL THROM VAS, V15, P1764, DOI 10.1161/01.ATV.15.10.1764; WATSON AD, 1995, J CLIN INVEST, V95, P774, DOI 10.1172/JCI117726; Watson AD, 1995, J CLIN INVEST, V96, P2882, DOI 10.1172/JCI118359; Yamada Y, 1998, METABOLISM, V47, P177, DOI 10.1016/S0026-0495(98)90216-5	32	126	135	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2000	14	13					2032	2039		10.1096/fj.99-1029com	http://dx.doi.org/10.1096/fj.99-1029com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023987				2022-12-28	WOS:000089634400022
J	Martin, M; Macias, M; Escames, G; Leon, J; Acuna-Castroviejo, D				Martin, M; Macias, M; Escames, G; Leon, J; Acuna-Castroviejo, D			Melatonin but not vitamins C and E maintains glutathione homeostasis in t-butyl hydroperoxide-induced mitochondrial oxidative stress	FASEB JOURNAL			English	Article									Univ Granada, Inst Biotecnol, Dept Fisiol, E-18012 Granada, Spain	University of Granada	Acuna-Castroviejo, D (corresponding author), Fac Med, Dept Fisiol, Avda Madrid 11, E-18012 Granada, Spain.		Acuña-Castroviejo, Dario/N-7456-2016; Leon, Pepi/K-8972-2014; Escames, Germaine/N-7501-2016	Acuña-Castroviejo, Dario/0000-0002-9680-1560; Leon, Pepi/0000-0002-0543-4823; Escames, Germaine/0000-0003-1256-7656					0	287	298	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2000	14	12					1677	1679						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973915				2022-12-28	WOS:000089212400005
J	Tan, NS; Ng, MLP; Yau, YH; Chong, PKW; Ho, B; Ding, JL				Tan, NS; Ng, MLP; Yau, YH; Chong, PKW; Ho, B; Ding, JL			Definition of endotoxin binding sites in horseshoe crab Factor C recombinant sushi proteins and neutralization of endotoxin by sushi peptides	FASEB JOURNAL			English	Article						Limulus ameboclyte lysate; lipid A; Drosophila S2 cells; LPS	SERINE-PROTEASE ZYMOGEN; LIPOPOLYSACCHARIDE (LPS)-BINDING PROTEIN; GRAM-NEGATIVE BACTERIA; INCREASING PROTEIN; LIPID-A; LIMULUS; HEMOCYTES; LPS; PERMEABILITY; PURIFICATION	Three truncated fragments, harboring different sushi domains, namely, sushi123, sushi1, and sushi3 domains, of Factor C were produced as biologically active secreted recombinant proteins. Sushil and 3 each has a high-affinity LPS binding site with K-d of 10(-9) to 10(-10) M. Positive cooperativity in sushi123 resulted in a 1000-fold increase in K(d)2. The core LPS binding region of sushi and 3 reside in two 34-mer peptides, S1 and S3. A rigidly held disulfide-bonded structure is not essential but is important for LPS binding, as confirmed by a 100- to 10000-fold decrease in affinity. Both SI and S3 can inhibit LAL reaction and LPS-induced hTNF-alpha secretion with different potency. LAL assay revealed that at least two molecules of S1 bind cooperatively to one LPS molecule, with Hill's coefficient of 2.42. The LPS binding by S3 is independent and noncooperative. The modified S Delta 1 and S Delta 3 peptides exhibited increased LPS neutralization potential although its LPS binding affinities indicated only a 10-fold improvement. Hence, the structural difference of the four sushi peptides conferred different efficiencies in LPS neutralization without altering their binding affinity for LPS. Circular dichroism spectrometry revealed that the four peptides underwent conformational change in the presence of lipid A, transitioning from a random coil to either an cu-helical or P-sheet structure. Two factors are critical for the sensitivity of Factor C to LPS: 1) the presence of multiple binding sites for LPS on a single Factor C molecule; and 2) high positive cooperativity in LPS binding. The results showed that in the design of an improved LPS binding and neutralizing peptide, charge balance of the peptide is a critical parameter in addition to its structure.	Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore; Natl Univ Singapore, Dept Microbiol, Singapore 117543, Singapore	National University of Singapore; National University of Singapore	Ding, JL (corresponding author), Natl Univ Singapore, Dept Biol Sci, 10 Kent Ridge Crescent, Singapore 117543, Singapore.		Hoe, YAU Yin/A-2817-2011; Tan, Nguan Soon/A-2220-2011; Ng, Patricia ML/B-3939-2008; Ding, Jeak/H-8057-2012	Hoe, YAU Yin/0000-0001-8136-2393; Tan, Nguan Soon/0000-0003-0136-7341; Ng, Patricia ML/0000-0001-5043-5596; 				CHEN CP, 1995, FEBS LETT, V370, P46, DOI 10.1016/0014-5793(95)00792-8; CORY AH, 1991, CANCER COMMUN, V3, P207, DOI 10.3727/095535491820873191; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; de Haas CJC, 1998, BIOCHEM BIOPH RES CO, V252, P492, DOI 10.1006/bbrc.1998.9675; Ding Jeak L., 1995, Molecular Marine Biology and Biotechnology, V4, P90; GALANOS C, 1979, P NATL ACAD SCI USA, V76, P5939, DOI 10.1073/pnas.76.11.5939; GAZZANOSANTORO H, 1994, INFECT IMMUN, V62, P1185, DOI 10.1128/IAI.62.4.1185-1191.1994; GRAY PW, 1989, J BIOL CHEM, V264, P9505; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; HAN JH, 1994, J BIOL CHEM, V269, P8172; Heinrichs DE, 1998, MOL MICROBIOL, V30, P221, DOI 10.1046/j.1365-2958.1998.01063.x; Hill A.V, 1910, J PHYSL, V40, piv, DOI DOI 10.1113/JPHYSIOL.1910.SP001386; Hong SY, 1998, ANTIMICROB AGENTS CH, V42, P2534, DOI 10.1128/AAC.42.10.2534; IWANAGA S, 1993, CURR OPIN IMMUNOL, V5, P74, DOI 10.1016/0952-7915(93)90084-6; IWANAGA S, 1992, THROMB RES, V68, P1, DOI 10.1016/0049-3848(92)90124-S; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Karima R, 1999, MOL MED TODAY, V5, P123, DOI 10.1016/S1357-4310(98)01430-0; MANNION BA, 1989, J IMMUNOL, V142, P2807; MINETTI CASA, 1991, J BIOL CHEM, V266, P20773; MORITA T, 1985, J BIOCHEM, V97, P1611, DOI 10.1093/oxfordjournals.jbchem.a135218; Muta T., 1996, Progress in Molecular and Subcellular Biology, V15, P154; MUTA T, 1991, J BIOL CHEM, V266, P6554; Myszka DG, 1998, TRENDS BIOCHEM SCI, V23, P149, DOI 10.1016/S0968-0004(98)01183-9; NAKAMURA T, 1988, J BIOCHEM, V103, P370, DOI 10.1093/oxfordjournals.jbchem.a122276; NAKAMURA T, 1986, EUR J BIOCHEM, V154, P511, DOI 10.1111/j.1432-1033.1986.tb09427.x; NAKAMURA T, 1988, EUR J BIOCHEM, V176, P89, DOI 10.1111/j.1432-1033.1988.tb14254.x; RISS TL, 1992, MOL BIOL CELL, V3, pA184; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; Tan NS, 2000, FASEB J, V14, P859, DOI 10.1096/fasebj.14.7.859; TOBIAS PS, 1995, J BIOL CHEM, V270, P10482, DOI 10.1074/jbc.270.18.10482; TSUCHIYA S, 1982, CANCER RES, V42, P1530; VAARA M, 1985, ANTIMICROB AGENTS CH, V27, P548, DOI 10.1128/AAC.27.4.548; VAARA M, 1992, MICROBIOL REV, V56, P395, DOI 10.1128/MMBR.56.3.395-411.1992; ZAHRINGER U, 1994, ADV CARBOHYD CHEM BI, V50, P211, DOI 10.1016/S0065-2318(08)60152-3	35	88	105	2	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2000	14	12					1801	1813		10.1096/fj.99-0866com	http://dx.doi.org/10.1096/fj.99-0866com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973930				2022-12-28	WOS:000089212400020
J	Ishii, K; Muelhauser, F; Liebl, U; Picard, M; Kuhl, S; Penke, B; Bayer, T; Wiessler, M; Hennerici, M; Beyreuther, K; Hartmann, T; Fassbender, K				Ishii, K; Muelhauser, F; Liebl, U; Picard, M; Kuhl, S; Penke, B; Bayer, T; Wiessler, M; Hennerici, M; Beyreuther, K; Hartmann, T; Fassbender, K			Subacute NO generation induced by Alzheimer's beta-amyloid in the living brain: reversal by inhibition of the inducible NO synthase	FASEB JOURNAL			English	Article						amyloid peptide; nitric oxide; iNOS; brain; in vivo microdialysis	NITRIC-OXIDE SYNTHASE; INTERFERON-GAMMA; MOUSE-BRAIN; IN-VIVO; DISEASE; MICROGLIA; PROTEIN; NEUROTOXICITY; EXPRESSION; DAMAGE	Glial activation contiguous to deposits of amyloid peptide (A beta) is a characteristic feature in Alzheimer's disease. We performed complementary in vitro and in vivo experiments to study the extent, kinetics, and mechanisms of microglial generation of nitric oxide (NO) induced by challenge with A beta. We showed that A beta fibrils dose-dependently induced a marked release of stable metabolites of NO in vivo that was strikingly similar regarding extent and temporal profile to the one in the parallel designed microglial cell culture experiments. However, costimulation with interferon gamma, which was a prerequisite for A beta-induced NO generation in vitro, was not required in vivo, demonstrating that factors are present in the living brain that activate glial cells synergistically with A beta. Therefore, in Alzheimer's disease, deposits of A beta fibrils alone may be sufficient to induce a chronic release of neurotoxic microglial products, explaining the progressive neurodegeneration associated with this disease. Our observation that systemic administration of selective iNOS inhibitors abolishes A beta-induced NO generation in vivo may have implications for therapy of Alzheimer's disease.	Univ Heidelberg, Dept Neurol, D-68135 Mannheim, Germany; Univ Heidelberg, ZMBH, Ctr Mol Biol, D-68135 Mannheim, Germany; Albert Szent Gyorgyi Med Univ, Dept Med Chem, Szeged, Hungary; Univ Bonn, Dept Psychiat, D-5300 Bonn, Germany; German Canc Res Ctr, D-6900 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Szeged University; University of Bonn; Helmholtz Association; German Cancer Research Center (DKFZ)	Fassbender, K (corresponding author), Univ Heidelberg, Dept Neurol, Theodor Kutzer Ufer 1-3, D-68135 Mannheim, Germany.		Hartmann, Tobias/AAB-8297-2022	Hartmann, Tobias/0000-0001-7481-6430; Fassbender, Klaus/0000-0003-3596-868X				Beyreuther K, 1996, ANN NY ACAD SCI, V777, P74, DOI 10.1111/j.1749-6632.1996.tb34403.x; Chao CC, 1996, GLIA, V16, P276, DOI 10.1002/(SICI)1098-1136(199603)16:3<276::AID-GLIA10>3.0.CO;2-X; DAWSON VL, 1994, NEUROPHARMACOLOGY, V33, P1425, DOI 10.1016/0028-3908(94)90045-0; Della Bianca V, 1999, J BIOL CHEM, V274, P15493, DOI 10.1074/jbc.274.22.15493; DING AH, 1988, J IMMUNOL, V141, P2407; Ding MZ, 1997, J BIOL CHEM, V272, P11327; ElKhoury J, 1996, NATURE, V382, P716; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Geula C, 1998, NAT MED, V4, P827, DOI 10.1038/nm0798-827; GOODWIN JL, 1995, BRAIN RES, V692, P207, DOI 10.1016/0006-8993(95)00646-8; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Heales SJR, 1999, BBA-BIOENERGETICS, V1410, P215, DOI 10.1016/S0005-2728(98)00168-6; Hensley K, 1998, J NEUROSCI, V18, P8126; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; KLEGERIS A, 1994, BIOCHEM BIOPH RES CO, V199, P984, DOI 10.1006/bbrc.1994.1326; Knauber J, 1999, J NEURAL TRANSM, V106, P35, DOI 10.1007/s007020050139; Lee SC, 1999, J NEUROPATH EXP NEUR, V58, P1163, DOI 10.1097/00005072-199911000-00006; LEE SC, 1993, J NEUROIMMUNOL, V46, P19, DOI 10.1016/0165-5728(93)90229-R; London JA, 1996, P NATL ACAD SCI USA, V93, P4147, DOI 10.1073/pnas.93.9.4147; MACMICKING JD, 1995, NATURE, V375, P408; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; Netland EE, 1998, NEUROBIOL AGING, V19, P201, DOI 10.1016/S0197-4580(98)00047-5; O'Mahony D, 1999, J NEUROL NEUROSUR PS, V67, P1, DOI 10.1136/jnnp.67.1.1; PAXINOS G, 1982, RAT BRAIN STEREOTACT; PETERSON PK, 1994, J INFECT DIS, V170, P457, DOI 10.1093/infdis/170.2.457; Smith MA, 1997, J NEUROSCI, V17, P2653; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; SUZUMURA A, 1987, J NEUROIMMUNOL, V15, P263, DOI 10.1016/0165-5728(87)90121-4; Vitek MP, 1997, BIOCHEM BIOPH RES CO, V240, P391, DOI 10.1006/bbrc.1997.7408; Weldon DT, 1998, J NEUROSCI, V18, P2161; Xia MQ, 1998, AM J PATHOL, V153, P31, DOI 10.1016/S0002-9440(10)65542-3; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Yun HY, 1996, CRIT REV NEUROBIOL, V10, P291, DOI 10.1615/CritRevNeurobiol.v10.i3-4.20	34	59	71	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2000	14	11					1485	1489		10.1096/fj.14.11.1485	http://dx.doi.org/10.1096/fj.14.11.1485			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CN	10928982				2022-12-28	WOS:000088627800002
J	Maasch, C; Wagner, S; Lindschau, C; Alexander, G; Buchner, K; Gollasch, M; Luft, FC; Haller, H				Maasch, C; Wagner, S; Lindschau, C; Alexander, G; Buchner, K; Gollasch, M; Luft, FC; Haller, H			Protein kinase C alpha targeting is regulated by temporal and spatial changes in intracellular free calcium concentration [Ca2+](i)	FASEB JOURNAL			English	Article						isoforms; green fluorescent protein; vascular smooth muscle cells; receptor coupling; translocation; mutation	SMOOTH-MUSCLE CELLS; ENDOTHELIAL-CELLS; RBL-2H3 CELLS; TRANSLOCATION; ISOZYMES; DIACYLGLYCEROL; LOCALIZATION; PERSPECTIVES; ACTIVATION; EXOCYTOSIS	Protein kinase C (PKC) isoforms exert specific intracellular functions, but the different isoforms display little substrate specificity in vitro. Selective PKC isoform targeting may be a mechanism to achieve specificity. We used a green fluorescent fusion protein (GFP) to test the hypothesis that local changes in [Ca2+](i); regulate translocation of PKC alpha and that different modes of Ca2+ and Ca2+ release play a role in PKCa targeting. We constructed deletion mutants of PKC alpha. to analyze the Ca2+-sensitive domains and their role in targeting. Confocal microscopy was used and [Ca2+](i) was measured by fluo-3. The fusion protein PKC alpha-GFP was expressed in vascular smooth muscle cells and showed a cytosolic distribution similar to the wildtype PKC alpha protein. The Ca2+ ionophore ionomycin induced a speckled cytosolic PKC alpha-GFP distribution, followed by membrane translocation, while depolarization by KCI induced primarily membrane translocation. Selective voltage-operated Ca2+ channel opening led to a localized accumulation of PKC alpha-GFP near the plasma membrane. Opening Ca2+ stores with InsP(3), thapsigargin, or ryanodine induced a specific PKC alpha-GFP targeting to distinct intracellular areas. The G-protein-coupled receptor agonist thrombin induced a rapid translocation of the fusion protein to focal domains. The tyrosine kinase receptor agonist PDGF induced Ca2+ influx and led to a linear PKC alpha-GFP membrane association. PKC alpha-GFP deletion mutants demonstrated that the C2 domain, but not the catalytic subunit, is necessary for Ca2+-induced PKC alpha targeting. Targeting was also abolished when the ATP binding site was deleted. We conclude that PKC alpha can rapidly be translocated to distinct intracellular or membrane domains by local increases in [Ca2+](i). The targeting mechanism is dependent on the C2 and ATP binding site of the enzyme. Localized [Ca2+](i) changes determine the spatial and temporal targeting of PKC alpha.	Med Hsch Hannover, D-30625 Hannover, Germany; Free Univ Berlin, Inst Biochem, D-1000 Berlin, Germany; Humboldt Univ, Charite, Fak Med, Franz Volhard Clin, Berlin, Germany; Humboldt Univ, Charite, Fak Med, Max Delbruck Ctr Mol Med, Berlin, Germany	Hannover Medical School; Free University of Berlin; Franz-Volhard Clinical Research Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Haller, H (corresponding author), Med Hsch Hannover, OE 6840,Carl-Neuberg-Str 1, D-30625 Hannover, Germany.		Lindschau, Carsten/AAE-6721-2020; Lindschau, Carsten/G-1798-2011	Lindschau, Carsten/0000-0003-1960-099X; Luft, Friedrich/0000-0002-8635-1199				CANNELL MB, 1994, BIOPHYS J, V67, P1942, DOI 10.1016/S0006-3495(94)80677-0; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; HA KS, 1993, J BIOL CHEM, V268, P10534; Haller H, 1998, CIRC RES, V82, P157; HALLER H, 1995, CIRC RES, V76, P21, DOI 10.1161/01.RES.76.1.21; HALLER H, 1994, KIDNEY INT, V46, P1653, DOI 10.1038/ki.1994.465; HALLER H, 1989, J BIOCH, V270, P375; Hofmann J, 1997, FASEB J, V11, P649, DOI 10.1096/fasebj.11.8.9240967; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; Keranen LM, 1997, J BIOL CHEM, V272, P25959, DOI 10.1074/jbc.272.41.25959; KHALIL RA, 1994, AM J PHYSIOL, V266, pC1544, DOI 10.1152/ajpcell.1994.266.6.C1544; KHALIL RA, 1992, J PHYSIOL-LONDON, V455, P585, DOI 10.1113/jphysiol.1992.sp019317; KHALIL RA, 1992, AM J PHYSIOL, V263, pC714, DOI 10.1152/ajpcell.1992.263.3.C714; KILEY SC, 1995, BIOCHEM SOC T, V23, P601, DOI 10.1042/bst0230601; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; LUO JH, 1993, J BIOL CHEM, V268, P23580; Mineo C, 1998, J CELL BIOL, V141, P601, DOI 10.1083/jcb.141.3.601; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1986, JNCI-J NATL CANCER I, V76, P363; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; ONO Y, 1988, NUCLEIC ACIDS RES, V16, P5199, DOI 10.1093/nar/16.11.5199; OZAWA K, 1993, J BIOL CHEM, V268, P2280; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; Porter VA, 1998, AM J PHYSIOL-CELL PH, V274, pC1346; Quest AFG, 1996, ENZYME PROTEIN, V49, P231, DOI 10.1159/000468635; RASMUSSEN H, 1986, NEW ENGL J MED, V314, P1164; ROSALES OR, 1992, BIOCHEM BIOPH RES CO, V189, P40, DOI 10.1016/0006-291X(92)91522-R; ROSEN DM, 1998, FASEB J, V12, P35; Tang SQ, 1997, J BIOL CHEM, V272, P28704, DOI 10.1074/jbc.272.45.28704	38	69	69	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2000	14	11					1653	1663		10.1096/fj.14.11.1653	http://dx.doi.org/10.1096/fj.14.11.1653			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CN	10929000				2022-12-28	WOS:000088627800020
J	Matsuo, K; Shintani, S; Tsuji, T; Nagata, E; Lerman, M; McBride, J; Nakahara, Y; Ohyama, H; Todd, R; Wong, DTW				Matsuo, K; Shintani, S; Tsuji, T; Nagata, E; Lerman, M; McBride, J; Nakahara, Y; Ohyama, H; Todd, R; Wong, DTW			p12(DOC-1), a growth suppressor, associates with DNA polymerase alpha/primase	FASEB JOURNAL			English	Article						pol-alpha; primase complex; cell cycle regulator; DNA replication	SIMIAN VIRUS-40 DNA; REPLICATION IN-VITRO; TUMOR-SUPPRESSOR; CELL-CYCLE; ENZYMOLOGICAL CHARACTERIZATION; MUTATION ANALYSIS; ALPHA-PRIMASE; GENE; PHOSPHORYLATION; DOC-1	p12(DOC-1) is a growth suppressor identified and isolated from normal keratinocytes. Ectopic expression of p12(DOC-1) in squamous carcinoma cells led to the reversion of in vitro transformation phenotypes including anchorage independence, doubling time, and morphology. Here we report that p12(DOC-1) associates with DNA polymerase alpha/primase (pol-alpha: primase) in vitro and in cells. The pol-alpha:primase binding domain in p12(DOC-1) is mapped to the amino-terminal six amino acid (MSYKPN). The biological effect of p12(DOC-1) on pol-alpha:primase was examined using in vitro DNA replication assays. Using the SV40 DNA replication assay, p12(DOC-1) suppresses DNA replication, leveling at similar to 50%. Similar results were obtained using the M13 single-stranded DNA synthesis assay. Analysis of the DNA replication products revealed that p12(DOC-1) affects the initiation step, not the elongation phase. The p12(DOC-1) suppression of DNA replication is likely to be mediated either by a direct inhibitory effect on pol-alpha:primase or by its effect on cyclin-dependent kinase 2 (CDK2), a recently identified p12(DOC-1)-associated protein known to stimulate DNA replication by phosphorylating pol-alpha:primase. p12(DOC-1) suppresses CDK2-mediated phosphorylation of pol-alpha:primase. These data support a role of p12(DOC-1) as a regulator of DNA replication by direct inhibition of pol-alpha:primase or by negatively regulating the CDK2-mediated phosphorylation of pol-alpha:primase.	Harvard Univ, Sch Dent Med, Div Oral Pathol, Lab Mol Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Dent Med, Lab Oral & Maxillofacial Surg, Boston, MA 02115 USA; NCI, Immunobiol Lab, DBS, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA	Harvard University; Harvard School of Dental Medicine; Harvard University; Harvard School of Dental Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Wong, DTW (corresponding author), Harvard Univ, Sch Dent Med, Div Oral Pathol, Lab Mol Pathol, 188 Longwood Ave, Boston, MA 02115 USA.				NIDCR NIH HHS [R01 DE08680, P01 DE12467, R29 DE 11983] Funding Source: Medline	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		COPELAND WC, 1991, J BIOL CHEM, V266, P22739; CRIPPSWOLFMAN J, 1989, J BIOL CHEM, V264, P19478; Daigo Y, 1997, GENE CHROMOSOME CANC, V20, P204, DOI 10.1002/(SICI)1098-2264(199710)20:2<204::AID-GCC12>3.0.CO;2-Q; DONALDSON RW, 1987, P NATL ACAD SCI USA, V84, P759, DOI 10.1073/pnas.84.3.759; DORNREITER I, 1993, MOL CELL BIOL, V13, P809, DOI 10.1128/MCB.13.2.809; DUTTA A, 1996, CELL CYCLE MAT METHO, P175; GORDON HM, 1992, J IMMUNOL, V148, P4021; Harlow ED., 1999, USING ANTIBODIES; LEHMAN IR, 1989, J BIOL CHEM, V264, P4265; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; MILLER MA, 1988, NUCLEIC ACIDS RES, V16, P7961, DOI 10.1093/nar/16.16.7961; NASHEUER HP, 1991, J BIOL CHEM, V266, P7893; Sambrook J, 1989, MOL CLONING LAB MANU, VII; STADLBAUER F, 1994, EUR J BIOCHEM, V222, P781, DOI 10.1111/j.1432-1033.1994.tb18925.x; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; TODD R, 1995, FASEB J, V9, P1362, DOI 10.1096/fasebj.9.13.7557027; Tsuji T, 1998, J BIOL CHEM, V273, P6704, DOI 10.1074/jbc.273.12.6704; Voitenleitner C, 1997, ONCOGENE, V14, P1611, DOI 10.1038/sj.onc.1200975; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAHL AF, 1988, MOL CELL BIOL, V8, P5016, DOI 10.1128/MCB.8.11.5016; WONG SW, 1986, J BIOL CHEM, V261, P7958; Zhang X, 1999, BIOCHEM BIOPH RES CO, V255, P59, DOI 10.1006/bbrc.1999.0148	22	47	54	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2000	14	10					1318	1324		10.1096/fj.14.10.1318	http://dx.doi.org/10.1096/fj.14.10.1318			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877824				2022-12-28	WOS:000087932200006
J	Straub, RH; Linde, HJ; Mannel, DN; Scholmerich, J; Falk, W				Straub, RH; Linde, HJ; Mannel, DN; Scholmerich, J; Falk, W			A bacteria-induced switch of sympathetic effector mechanisms augments local inhibition of TNF-alpha and IL-6 secretion in the spleen	FASEB JOURNAL			English	Article						Pseudomonas aeruginosa; macrophage; tumor necrosis factor alpha; interleukin 6; norepinephrine; adrenoreceptor	GRAM-NEGATIVE BACTERIA; NECROSIS-FACTOR-ALPHA; MURINE SPLEEN; INTERLEUKIN-6 SECRETION; NERVOUS-SYSTEM; TRANSLOCATION; EXPRESSION; SHOCK; LIPOPOLYSACCHARIDE; GLUCOCORTICOIDS	It is believed that an inflammation-induced activation of the CNS leads to an inhibition of overshooting immune responses to prevent extensive local cytokine secretion. However, immunosuppression by the sympathetic nervous system may be unfavorable when bacteria are present locally and when TNF-alpha is necessary to overcome infection. We now report in a superfusion model, using mouse spleen slices, that although local Pseudomonas aeruginosa increased splenic TNF-alpha and IL-6 secretion severalfold over basal levels, electrically released neurotransmitters attenuated cytokine secretion to similar basal level as under bacteria-free conditions. Bacteria reversed noradrenergic inhibitory effector mechanisms: Under bacteria-free conditions, TNF-alpha secretion was very low and IL-6 secretion was mainly inhibited by alpha(2)-adrenoreceptor ligation. In the presence of bacteria, TNF-alpha and IL-6 secretion were high and IL-6 secretion was mainly inhibited by beta-adrenoreceptor ligation. The alpha- to beta-adrenoswitch of IL-6 inhibition in the presence of bacteria was mediated by the prior adrenergic regulation of TNF-alpha. In vivo, chemical abrogation of sympathetic inhibition reduced accumulation of bacteria in the spleen, which depended at least in part on TNF-alpha. This suggests that activation of the sympathetic nervous system may be a forerunner for accumulation of bacteria in tissue and consecutively sepsis due to intensified inhibition of TNF-alpha secretion.	Univ Regensburg, Dept Internal Med 1, Lab Neuroendocrinoimmunol, D-93042 Regensburg, Germany; Univ Regensburg, Inst Med Microbiol, D-93042 Regensburg, Germany; Univ Regensburg, Inst Pathol Immunol, D-93042 Regensburg, Germany	University of Regensburg; University of Regensburg; University of Regensburg	Straub, RH (corresponding author), Univ Regensburg, Dept Internal Med 1, Lab Neuroendocrinoimmunol, Franz Josef Strauss Allee 11, D-93042 Regensburg, Germany.	rainer.straub@klinik.uni-regensburg.de		Straub, Rainer H/0000-0003-1165-4555				BAKER JW, 1988, J TRAUMA, V28, P896, DOI 10.1097/00005373-198807000-00002; Benzing T, 1999, NAT MED, V5, P913, DOI 10.1038/11354; Berg Rodney D., 1995, Trends in Microbiology, V3, P149, DOI 10.1016/S0966-842X(00)88906-4; Besedovsky HO, 1996, ENDOCR REV, V17, P64, DOI 10.1210/er.17.1.64; COTECCHIA S, 1984, LIFE SCI, V35, P2359, DOI 10.1016/0024-3205(84)90528-9; De Luigi A, 1998, NEUROSCIENCE, V83, P1245, DOI 10.1016/S0306-4522(97)00381-3; Docke WD, 1997, NAT MED, V3, P678, DOI 10.1038/nm0697-678; ECHTENACHER B, 1990, J IMMUNOL, V145, P3762; FERNANDES LB, 1988, EUR J PHARMACOL, V157, P135, DOI 10.1016/0014-2999(88)90376-7; Freestone PPE, 1999, FEMS MICROBIOL LETT, V172, P53, DOI 10.1111/j.1574-6968.1999.tb13449.x; Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X; ICHIJO T, 1994, BRAIN RES BULL, V34, P547, DOI 10.1016/0361-9230(94)90139-2; JONES WG, 1990, ANN SURG, V211, P399, DOI 10.1097/00000658-199004000-00004; Kalb A, 1996, J BIOL CHEM, V271, P28097, DOI 10.1074/jbc.271.45.28097; Kale IT, 1998, J TRAUMA, V44, P171, DOI 10.1097/00005373-199801000-00024; Kinney KS, 1999, MICROB PATHOGENESIS, V26, P85, DOI 10.1006/mpat.1998.0251; Koch T, 1996, INTENS CARE MED, V22, P637; Korn SH, 1998, BIOCHEM PHARMACOL, V56, P1561, DOI 10.1016/S0006-2952(98)00179-8; Licinio J, 1997, J CLIN INVEST, V100, P2941, DOI 10.1172/JCI119846; LYTE M, 1992, LIFE SCI, V50, P203, DOI 10.1016/0024-3205(92)90273-R; MAK JCW, 1995, J CLIN INVEST, V96, P99, DOI 10.1172/JCI118084; MCCONKEY DJ, 1993, FASEB J, V7, P580, DOI 10.1096/fasebj.7.6.8386120; MCMAHON A, 1992, J NEUROCHEM, V59, P2040; Munck A, 1986, Adv Exp Med Biol, V196, P81; NIIJIMA A, 1991, J AUTONOM NERV SYST, V36, P183, DOI 10.1016/0165-1838(91)90042-2; Obermeier F, 1999, CLIN EXP IMMUNOL, V116, P238; Panetta R, 1999, BIOCHEM BIOPH RES CO, V259, P550, DOI 10.1006/bbrc.1999.0817; REITHMANN C, 1991, EUR J PHARM-MOLEC PH, V206, P53, DOI 10.1016/0922-4106(91)90146-9; RENZ H, 1988, J IMMUNOL, V141, P2388; RICE P, 1999, NEUROIMMUNOMODULAT, V6, P244; SEVERN A, 1992, J IMMUNOL, V148, P3441; Sparwasser T, 1997, NATURE, V386, P336, DOI 10.1038/386336a0; STRAUB RH, 1995, J NEUROIMMUNOL, V61, P53, DOI 10.1016/0165-5728(95)00073-B; Straub RH, 1996, J NEUROIMMUNOL, V71, P37, DOI 10.1016/S0165-5728(96)00126-9; Straub RH, 1997, J NEUROCHEM, V68, P1633; Straub RH, 1998, AM J PHYSIOL-REG I, V274, pR997, DOI 10.1152/ajpregu.1998.274.4.R997; Straub RH, 1998, IMMUNOL TODAY, V19, P409, DOI 10.1016/S0167-5699(98)01297-3; TANNENBAUM CS, 1989, J IMMUNOL, V142, P1274; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; ZHANG YH, 1988, J BIOL CHEM, V263, P6177	40	48	53	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2000	14	10					1380	1388		10.1096/fj.14.10.1380	http://dx.doi.org/10.1096/fj.14.10.1380			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877831				2022-12-28	WOS:000087932200013
J	Mei, JM; Hord, NG; Winterstein, DF; Donald, SP; Phang, JM				Mei, JM; Hord, NG; Winterstein, DF; Donald, SP; Phang, JM			Expression of prostaglandin endoperoxide H synthase-2 induced by nitric oxide in conditionally immortalized murine colonic epithelial cells	FASEB JOURNAL			English	Article						PGHS-2; NOSII; nitric oxide; colonic epithelial cells	INFLAMMATORY BOWEL-DISEASE; FAMILIAL ADENOMATOUS POLYPOSIS; TRANSCRIPTION FACTOR LEF-1; TUMOR-SUPPRESSOR PROTEIN; BETA-CATENIN; CYCLOOXYGENASE-2 LEVELS; SMALL-INTESTINE; APC GENE; CANCER; ACTIVATION	Increased expression of prostaglandin endoperoxide H synthase-2 (PGHS-2) has been implicated in pathological conditions such as inflammatory bowel diseases and colon cancer. Recently, it has been demonstrated that inducible nitric oxide synthase (NOS II) expression and nitric oxide (NO) production are up-regulated in these diseases as well. However, the apparent link between PGHS-2 and NOS II has not been thoroughly investigated in nontransformed and nontumorigenic colonic epithelial cells. In the present study, we examined the concomitant expression of PGHS-2 and NOS II as well as the production of prostaglandin E2 (PGE2) and NO in conditionally immortalized mouse colonic epithelial cells, namely YAMC (Apc(+/+)). We found that the induction of PGHS-2 and generation of PGE2 in these cells by IFN-gamma and lipopolysaccharide (LPS) were greatly reduced by two selective NOS II inhibitors, L-NIL and SMT. To ascertain the effect of NO on PGHS-2 overexpression, we tested NO-releasing compounds, NOR-1 and SNAP, and found that they caused PGHS-2 expression and PGE2 production. This effect was abolished by hemoglobin, a NO scavenger. Using electrophoretic mobility shift assays, we found that both NOR-1 and SNAP caused beta-catenin/LEF-1 DNA complex formation. Supershift by anti-beta-catenin antibody confirmed the presence of beta-catenin in the complex. Cell fractionation studies indicated that NO donors caused an increase in free soluble cytoplasmic beta-catenin. This is further corroborated by the immunocytochemistry data showing the redistribution of beta-catenin from the predominantly membrane localization into the cytoplasm and nucleus after treatment with NO donors. To further explore the possible connection between PGHS-2 expression and beta-catenin/LEF-1 DNA complex formation, we studied IMCE (Apc(Min/+)) cells, a sister cell line of YAMC with similar genetic background but differing in Ape genotype and, consequently, their beta-catenin levels. We found that IMCE cells, in comparison with YAMC cells, had markedly higher beta-catenin/LEF-1 DNA complex formation under both resting conditions as well as after induction with NO. In parallel fashion, IMCE cells ex pressed significantly higher levels of PGHS-2 mRNA and protein, and generated more PGE2. Overall, this study suggests that NO may be involved in PGHS-2 overexpression in conditionally immortalized mouse colonic epithelial cells. Although the molecular mechanism of the link is still under investigation, this effect of NO appears directly or indirectly to be a result of the increase in free soluble beta-catenin and the formation of nuclear beta-catenin/LEF-1 DNA complex.-Mei, J. M., Hord, N. G., Winterstein, D. F., Donald, S. P., and Phang, J. M. Expression of prostaglandin endoperoxide H synthase-2 induced by nitric oxide in conditionally immortalized murine colonic epithelial cells.	NCI, Metab & Canc Susceptibil Sect, Basic Res Lab, Div Basic Sci, Frederick, MD 21702 USA; NCI, Intramural Res Support Program, SAIC Frederick, FCRDC, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Mei, JM (corresponding author), NCI, Metab & Canc Susceptibil Sect, Basic Res Lab, Div Basic Sci, Rm 12-90,Bldg 560, Frederick, MD 21702 USA.				DIVISION OF BASIC SCIENCES - NCI [Z01BC010005] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Ambs S, 1998, CANCER RES, V58, P334; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Boolbol SK, 1996, CANCER RES, V56, P2556; BROUET I, 1995, BIOCHEM BIOPH RES CO, V206, P533, DOI 10.1006/bbrc.1995.1076; Dabadie A, 1996, ARCH PEDIATRIE, V3, P884, DOI 10.1016/0929-693X(96)87579-8; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DuBois RN, 1996, GASTROENTEROLOGY, V110, P1259, DOI 10.1053/gast.1996.v110.pm8613017; DuBois RN, 1996, CANCER RES, V56, P733; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Hendel J, 1997, AM J GASTROENTEROL, V92, P1170; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; Howe LR, 1999, CANCER RES, V59, P1572; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; JACOBY RF, 1995, GASTROENTEROLOGY, V109, P73, DOI 10.1016/0016-5085(95)90270-8; Jacoby RF, 1996, CANCER RES, V56, P710; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Lander HM, 1996, J BIOL CHEM, V271, P19705, DOI 10.1074/jbc.271.33.19705; Landino LM, 1996, P NATL ACAD SCI USA, V93, P15069, DOI 10.1073/pnas.93.26.15069; LIU RH, 1995, MUTAT RES-REV GENET, V339, P73, DOI 10.1016/0165-1110(95)90004-7; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Mei JM, 1999, CARCINOGENESIS, V20, P737, DOI 10.1093/carcin/20.4.737; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; MOSER AR, 1995, EUR J CANCER, V31A, P1061, DOI 10.1016/0959-8049(95)00181-H; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; OHSHIMA H, 1994, MUTAT RES, V305, P253, DOI 10.1016/0027-5107(94)90245-3; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Porfiri E, 1997, ONCOGENE, V15, P2833, DOI 10.1038/sj.onc.1201462; Prescott SM, 1996, CELL, V87, P783, DOI 10.1016/S0092-8674(00)81983-2; Rao CV, 1999, CARCINOGENESIS, V20, P641, DOI 10.1093/carcin/20.4.641; RAO CV, 1995, CANCER RES, V55, P259; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1997, CANCER RES, V57, P4624; Ryuto M, 1997, JPN J CANCER RES, V88, P982, DOI 10.1111/j.1349-7006.1997.tb00319.x; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; SALVEMINI D, 1993, P NATL ACAD SCI USA, V90, P7240, DOI 10.1073/pnas.90.15.7240; Salvemini D, 1997, CELL MOL LIFE SCI, V53, P576, DOI 10.1007/s000180050074; Schmitz FJ, 1997, INT J ANTIMICROB AG, V9, P1, DOI 10.1016/S0924-8579(97)00027-7; Sheng HM, 1998, CANCER RES, V58, P362; Shoemaker AR, 1997, CANCER RES, V57, P1999; Shoemaker AR, 1997, BBA-REV CANCER, V1332, pF25, DOI 10.1016/S0304-419X(96)00041-8; Singer II, 1996, GASTROENTEROLOGY, V111, P871, DOI 10.1016/S0016-5085(96)70055-0; Singer II, 1998, GASTROENTEROLOGY, V115, P297, DOI 10.1016/S0016-5085(98)70196-9; Subbaramaiah K, 1997, P SOC EXP BIOL MED, V216, P201; terSteege J, 1997, LAB INVEST, V77, P29; Thomsen LL, 1997, CANCER RES, V57, P3300; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; VonKnethen A, 1997, FASEB J, V11, P887; WHITEHEAD RH, 1993, P NATL ACAD SCI USA, V90, P587, DOI 10.1073/pnas.90.2.587; WHITEHEAD RH, 1994, EPITHELIAL CELL BIOL, V3, P119; Williams CS, 1996, GASTROENTEROLOGY, V111, P1134, DOI 10.1016/S0016-5085(96)70083-5	62	42	42	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2000	14	9					1188	1201		10.1096/fasebj.14.9.1188	http://dx.doi.org/10.1096/fasebj.14.9.1188			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834941				2022-12-28	WOS:000087427300016
J	Nunez, F; Chipchase, MD; Clarke, AR; Melton, DW				Nunez, F; Chipchase, MD; Clarke, AR; Melton, DW			Nucleotide excision repair gene (ERCC1) deficiency causes G(2) arrest in hepatocytes and a reduction in liver binucleation: the role of p53 and p21	FASEB JOURNAL			English	Article						DNA repair; cancer; knockout mice; cell cycle arrest	CELL-CYCLE ARREST; DNA-REPAIR; MICE LACKING; MAMMALIAN-CELLS; S-PHASE; NUCLEAR ABNORMALITIES; GROWTH FAILURE; ULTRAVIOLET-B; GROUP-A; EXPRESSION	A wide range of DNA lesions, both UV and chemically induced, are dealt with by the nucleotide excision repair (NER) pathway. Defects in NER result in human syndromes such as xeroderma pigmentosum (XP) where there is a 1000-fold increased incidence of skin cancer. The ERCC1 protein is essential for NER, but ERCC1 knockout mice are not a model for XP, In the absence of exogenous DNA-damaging agents, these mice are runted and die before weaning, with dramatically accelerated liver polyploidy and elevated levels of p53, Here we present a morphological, immunological, and molecular study to understand the mechanism for the unusual liver pathology in ERCC1-deficient mice. We show that the enlarged ERCC1-deficient hepatocytes are arrested in G(2) and that DNA replication and the normal process of binucleation are both reduced. This is associated with a p53-independent increase in expression of the cyclin-dependent kinase inhibitor p21, The most dramatic feature of the ERCC1-deficient liver phenotype, the accelerated polyploidy, is not rescued by p53 deficiency, but we show that p53 is responsible for the reduced DNA replication and binucleation. We consider that the liver phenotype is a response to unrepaired endogenous DNA damage, which may reflect an additional non-NER-related function for the ERCC1 protein.-Nunez, F,, Chipchase, M. D., Clarke, A. R., Melton, D. W. Nucleotide excision repair gene (ERCC1) deficiency causes G(2) arrest in hepatocytes and a reduction in liver binucleation: the role of p53 and p21.	Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Univ Edinburgh, Dept Pathol, Edinburgh EH9 3JR, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Melton, DW (corresponding author), Univ Edinburgh, Inst Cell & Mol Biol, Darwin Bldg,Kings Bldg,Mayfield Rd, Edinburgh EH9 3JR, Midlothian, Scotland.		clarke, alan r/P-2820-2014; Clarke, Alan R/A-6256-2008	Clarke, Alan/0000-0002-4281-426X				ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; BASI G, 1995, CELL CYCLE CONTROL, P106; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; BRENNER S, 1981, J CELL BIOL, V91, P95, DOI 10.1083/jcb.91.1.95; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; BRUGAL G, 1992, CYTOMETRY, V13, P109, DOI 10.1002/cyto.990130202; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cox LS, 1997, J PATHOL, V183, P134, DOI 10.1002/(SICI)1096-9896(199710)183:2<134::AID-PATH960>3.0.CO;2-D; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; EARNSHAW WC, 1985, CHROMOSOMA, V91, P313, DOI 10.1007/BF00328227; EPSTEIN CJ, 1967, P NATL ACAD SCI USA, V57, P327, DOI 10.1073/pnas.57.2.327; Fisher PB, 1996, MOL CELL DIFFER, V4, pU7; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENSI; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; Harada YN, 1999, MOL CELL BIOL, V19, P2366, DOI 10.1128/mcb.19.3.2366; Jacks T, 1996, NATURE, V381, P643, DOI 10.1038/381643a0; JIANG HP, 1994, ONCOGENE, V9, P3397; Kaufmann WK, 1996, FASEB J, V10, P238, DOI 10.1096/fasebj.10.2.8641557; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MCWHIR J, 1993, NAT GENET, V5, P217, DOI 10.1038/ng1193-217; MEDVEDEV ZA, 1986, EXP GERONTOL, V21, P277, DOI 10.1016/0531-5565(86)90037-9; Melton DW, 1998, J CELL SCI, V111, P395; MURRAY A, 1994, CURR OPIN CELL BIOL, V6, P872, DOI 10.1016/0955-0674(94)90059-0; NAKANE H, 1995, NATURE, V377, P165, DOI 10.1038/377165a0; PARK CH, 1995, J BIOL CHEM, V270, P22657, DOI 10.1074/jbc.270.39.22657; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Pellegata NS, 1996, P NATL ACAD SCI USA, V93, P15209, DOI 10.1073/pnas.93.26.15209; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; RODEL C, 1992, NUCLEIC ACIDS RES, V20, P6347, DOI 10.1093/nar/20.23.6347; Sakata H, 1996, CELL GROWTH DIFFER, V7, P1513; SANCHEZ Y, 1995, BIOESSAYS, V17, P545, DOI 10.1002/bies.950170611; SANDS AT, 1995, NATURE, V377, P162, DOI 10.1038/377162a0; Sargent RG, 1997, P NATL ACAD SCI USA, V94, P13122, DOI 10.1073/pnas.94.24.13122; Savio M, 1996, ONCOGENE, V13, P1591; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; SOAMES AR, 1994, J HISTOCHEM CYTOCHEM, V42, P939, DOI 10.1177/42.7.8014477; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; VANDUIN M, 1986, CELL, V44, P913, DOI 10.1016/0092-8674(86)90014-0; VANDUIN M, 1988, MUTAT RES, V193, P123, DOI 10.1016/0167-8817(88)90042-9; VANDUIN M, 1989, MUTAT RES, V217, P83, DOI 10.1016/0921-8777(89)90059-1; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Weeda G, 1997, CURR BIOL, V7, P427, DOI 10.1016/S0960-9822(06)00190-4; WESTERVELD A, 1984, NATURE, V310, P425, DOI 10.1038/310425a0; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245	49	47	49	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2000	14	9					1073	1082		10.1096/fasebj.14.9.1073	http://dx.doi.org/10.1096/fasebj.14.9.1073			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834928				2022-12-28	WOS:000087427300003
J	Schneider, MR; Lahm, H; Wu, MY; Hoeflich, A; Wolf, E				Schneider, MR; Lahm, H; Wu, MY; Hoeflich, A; Wolf, E			Transgenic mouse models for studying the functions of insulin-like growth factor-binding proteins	FASEB JOURNAL			English	Review						IGFBP; insulin-like growth factors; transgenic mice; overexpression; knockout	SMOOTH-MUSCLE CELLS; FACTOR-I RECEPTOR; MESSENGER-RNA EXPRESSION; CENTRAL-NERVOUS-SYSTEM; IGF-II; CIRCULATING LEVELS; FACTOR BINDING-PROTEIN-1; INTRAUTERINE GROWTH; PERINATAL LETHALITY; TARGETED DISRUPTION	The insulin-like growth factor-binding proteins (IGFBPs) comprise a family of six related peptides that interact with high affinity with IGFs. IGFBPs compete with IGF receptors for IGF binding, and as a consequence of this competition they can affect cell growth. In addition, IGF-independent regulatory mechanisms of IGFBPs have been described. Despite their common property to interact with IGFs every IGFBP is expressed in a tightly regulated time- and tissue-specific manner suggesting that each protein may have its own distinct functions. Several transgenic mouse models overexpressing IGFBP-1, -2, -3, or -4 were developed in the past few years. Brain abnormalities were a common feature of IGFBP-1 transgenic models. Individual strains showed alterations in glucose homeostasis, reproductive performance, and a reduction of somatic growth as the most prominent phenotypes. The latter was also the main effect observed in IGFBP-2 transgenic mice. The overexpression of IGFBP-3 under the control of an ubiquitous promoter resulted in selective organomegaly, whereas mammary gland-targeted expression of this protein caused an altered involution after pregnancy in this organ. Tissue-specific overexpression of IGFBP-4 resulted in hypoplasia and reduced weight of smooth muscle-rich tissues such as bladder, aorta, and stomach. This review summarizes the current knowledge about the actions of IGFBPs in vivo based on the presently established transgenic mice.-Schneider, hi. R., Lahm, H., Wu, M., Hoeflich, A., Wolf, E. Transgenic mouse models for studying the functions of insulin-like growth factor-binding proteins.	Gene Ctr, Inst Mol Anim Breeding, D-81377 Munich, Germany	University of Munich	Wolf, E (corresponding author), Gene Ctr, Inst Mol Anim Breeding, Feodor Lynen Str 25, D-81377 Munich, Germany.	ewolf@lmb.uni-muenchen.de		Hoeflich, Andreas/0000-0003-2018-2836; Wolf, Eckhard/0000-0002-0430-9510; Schneider, Marlon/0000-0002-9570-3491				Accili D, 1998, INT CONGR SER, V1151, P71; AMARNANI S, 1993, J BONE MINER RES, V8, P157; Bach LA, 1999, HORM METAB RES, V31, P226, DOI 10.1055/s-2007-978723; BARTLETT WP, 1991, DEV BIOL, V147, P239, DOI 10.1016/S0012-1606(05)80021-1; BAUTISTA CM, 1991, BIOCHEM BIOPH RES CO, V176, P756, DOI 10.1016/S0006-291X(05)80249-9; Baxter RC, 1998, ENDOCRINOLOGY, V139, P4036, DOI 10.1210/en.139.10.4036; Blackburn A, 1997, EUR J ENDOCRINOL, V137, P701, DOI 10.1530/eje.0.1370701; BLUM WF, 1993, GROWTH REGULAT, V3, P100; BLUNDELL TL, 1980, NATURE, V287, P781, DOI 10.1038/287781a0; Braulke T, 1999, HORM METAB RES, V31, P235, DOI 10.1055/s-2007-978724; Butt AJ, 1999, IMMUNOL CELL BIOL, V77, P256, DOI 10.1046/j.1440-1711.1999.00822.x; CARSON MJ, 1993, NEURON, V10, P729, DOI 10.1016/0896-6273(93)90173-O; CLAUSSEN M, 1995, MOL ENDOCRINOL, V9, P902, DOI 10.1210/me.9.7.902; Clemmons David R., 1997, Cytokine and Growth Factor Reviews, V8, P45, DOI 10.1016/S1359-6101(96)00053-6; COHICK WS, 1993, J CELL PHYSIOL, V157, P52, DOI 10.1002/jcp.1041570107; CONOVER CA, 1993, J CLIN INVEST, V91, P1129, DOI 10.1172/JCI116272; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; DAI ZH, 1994, ENDOCRINOLOGY, V135, P1316, DOI 10.1210/en.135.4.1316; DEMEYTS P, 1994, HORM RES, V42, P152, DOI 10.1159/000184188; DERCOLE AJ, 1994, DEV BRAIN RES, V82, P213; Dheen ST, 1997, J ENDOCRINOL, V155, P551, DOI 10.1677/joe.0.1550551; Dheen ST, 1996, DIABETOLOGIA, V39, P1249, DOI 10.1007/s001250050566; DROP SLS, 1979, ACTA ENDOCRINOL-COP, V90, P505, DOI 10.1530/acta.0.0900505; Duvillie B, 1997, P NATL ACAD SCI USA, V94, P5137, DOI 10.1073/pnas.94.10.5137; ERNST M, 1990, ENDOCRINOLOGY, V127, P807, DOI 10.1210/endo-127-2-807; Ewton DZ, 1998, J CELL PHYSIOL, V177, P47, DOI 10.1002/(SICI)1097-4652(199810)177:1<47::AID-JCP5>3.0.CO;2-E; FANT M, 1993, REGUL PEPTIDES, V48, P29, DOI 10.1016/0167-0115(93)90333-4; Ferry RJ, 1999, HORM RES, V51, P53; Flyvbjerg A, 1997, KIDNEY INT S, V60, pS12; Gay E, 1997, ENDOCRINOLOGY, V138, P2937, DOI 10.1210/en.138.7.2937; Glantschnig H, 1998, DNA CELL BIOL, V17, P51, DOI 10.1089/dna.1998.17.51; GORDON JW, 1993, METHOD ENZYMOL, V225, P747; Grellier P, 1998, CANCER RES, V58, P1670; GutierrezOspina G, 1996, ENDOCRINOLOGY, V137, P5484, DOI 10.1210/en.137.12.5484; Hakeda Y, 1996, J CELL PHYSIOL, V166, P370; Hoeflich A, 1999, ENDOCRINOLOGY, V140, P5488, DOI 10.1210/en.140.12.5488; Hoeflich A, 1998, GROWTH HORM IGF RES, V8, P113, DOI 10.1016/S1096-6374(98)80101-9; Hoeflich A, 1996, AM J PHYSIOL-ENDOC M, V271, pE922, DOI 10.1152/ajpendo.1996.271.5.E922; Hoflich A, 1998, FEBS LETT, V434, P329, DOI 10.1016/S0014-5793(98)01011-4; Hogan B, 1994, MANIPULATING MOUSE E; Huang H, 1997, J ENDOCRINOL, V152, P99, DOI 10.1677/joe.0.1520099; Huang H, 1997, BIOL REPROD, V56, P284, DOI 10.1095/biolreprod56.1.284; Joyner A. L., 1995, GENE TARGETING PRACT; Kelley KM, 1996, INT J BIOCHEM CELL B, V28, P619, DOI 10.1016/1357-2725(96)00005-2; KLEMPT M, 1993, MOL BRAIN RES, V17, P347, DOI 10.1016/0169-328X(93)90021-G; KOU K, 1994, GENOMICS, V20, P412, DOI 10.1006/geno.1994.1195; LAHM H, 1994, INT J CANCER, V58, P452, DOI 10.1002/ijc.2910580325; LATOUR D, 1990, MOL ENDOCRINOL, V4, P1806, DOI 10.1210/mend-4-12-1806; LAU MMH, 1994, GENE DEV, V8, P2953, DOI 10.1101/gad.8.24.2953; LEE PDK, 1993, P SOC EXP BIOL MED, V204, P4; Lee PDK, 1997, P SOC EXP BIOL MED, V216, P319; LEE YL, 1988, MOL ENDOCRINOL, V2, P404, DOI 10.1210/mend-2-5-404; LEWITT MS, 1991, ENDOCRINOLOGY, V129, P2254, DOI 10.1210/endo-129-4-2254; Li YM, 1996, J IMMUNOL, V156, P64; LIN T, 1993, ENDOCRINOLOGY, V132, P1898, DOI 10.1210/en.132.5.1898; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; Ludwig T, 1996, DEV BIOL, V177, P517, DOI 10.1006/dbio.1996.0182; MA JX, 1994, NEUROCHEM RES, V19, P1363, DOI 10.1007/BF00972464; MATHEWS LS, 1988, ENDOCRINOLOGY, V123, P2827, DOI 10.1210/endo-123-6-2827; MIN BH, 1990, J BIOL CHEM, V265, P16667; Mohan S, 1996, HORM RES, V45, P59, DOI 10.1159/000184833; MULLER EE, 1998, IGFS NERVOUS SYSTEM; Muller U, 1999, MECH DEVELOP, V82, P3, DOI 10.1016/S0925-4773(99)00021-0; MURPHY LJ, 1995, J MOL ENDOCRINOL, V15, P293, DOI 10.1677/jme.0.0150293; Murphy LJ, 1998, J MOL ENDOCRINOL, V21, P97, DOI 10.1677/jme.0.0210097; Neuenschwander S, 1996, J CLIN INVEST, V97, P2225, DOI 10.1172/JCI118663; Ni W, 1997, BRAIN RES, V769, P97, DOI 10.1016/S0006-8993(97)00676-8; OH Y, 1993, J BIOL CHEM, V268, P26045; OH YM, 1993, J BIOL CHEM, V268, P14964; PARKER A, 1995, ENDOCRINOLOGY, V136, P2470, DOI 10.1210/en.136.6.2470; Pintar J, 1998, INT CONGR SER, V1151, P65; Pintar JE, 1996, HORM RES, V45, P172, DOI 10.1159/000184782; Pintar John E., 1995, Progress in Growth Factor Research, V6, P437, DOI 10.1016/0955-2235(95)00029-1; Powell David R., 1995, Progress in Growth Factor Research, V6, P93, DOI 10.1016/0955-2235(95)00034-8; Pucilowski O, 1996, EUR J PHARMACOL, V305, P57, DOI 10.1016/0014-2999(96)00177-X; Putzer P, 1998, MOL CELL ENDOCRINOL, V137, P69, DOI 10.1016/S0303-7207(97)00233-5; Rajaram S, 1997, ENDOCR REV, V18, P801, DOI 10.1210/er.18.6.801; Rajkumar K, 1999, BBA-GEN SUBJECTS, V1426, P491, DOI 10.1016/S0304-4165(98)00162-7; RAJKUMAR K, 1995, ENDOCRINOLOGY, V136, P4029, DOI 10.1210/en.136.9.4029; Rajkumar K, 1996, J CLIN INVEST, V98, P1818, DOI 10.1172/JCI118982; Rajkumar K, 1996, AM J PHYSIOL-ENDOC M, V270, pE565, DOI 10.1152/ajpendo.1996.270.4.E565; Rees C, 1998, ENDOCRINOLOGY, V139, P4182, DOI 10.1210/en.139.10.4182; Rosen CJ, 1999, CLIN CHEM, V45, P1384; Roths JB, 1999, LAB ANIM SCI, V49, P12; SCHULLER AGP, 1993, ENDOCRINOLOGY, V132, P2544, DOI 10.1210/en.132.6.2544; SCHULLER AGP, 1994, MOL CELL ENDOCRINOL, V104, P57, DOI 10.1016/0303-7207(94)90051-5; SEAMARK RF, 1991, BAILLIERE CLIN ENDOC, V5, P833, DOI 10.1016/S0950-351X(10)80017-5; SHIMASAKI S, 1989, BIOCHEM BIOPH RES CO, V165, P907, DOI 10.1016/S0006-291X(89)80052-X; SINGH P, 1992, CANCER RES, V54, P6563; SPORN MB, 1990, PEPTIDE GROWTH FACTO, P3; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; TAPANAINEN PJ, 1994, PEDIATR RES, V36, P152, DOI 10.1203/00006450-199408000-00004; Tazuke SI, 1998, P NATL ACAD SCI USA, V95, P10188, DOI 10.1073/pnas.95.17.10188; Twigg SM, 1998, J BIOL CHEM, V273, P6074, DOI 10.1074/jbc.273.11.6074; UNTERMAN TG, 1993, ENDOCRINOLOGY, V132, P327, DOI 10.1210/en.132.1.327; van Kleffens M, 1998, MOL CELL ENDOCRINOL, V138, P151, DOI 10.1016/S0303-7207(98)00007-0; Wallen LD, 1997, J ENDOCRINOL, V155, P313, DOI 10.1677/joe.0.1550313; Wang JW, 1998, ENDOCRINOLOGY, V139, P2605, DOI 10.1210/en.139.5.2605; Wang JW, 1997, J CLIN INVEST, V100, P1425, DOI 10.1172/JCI119663; WANG ZQ, 1994, NATURE, V372, P464, DOI 10.1038/372464a0; Werner H, 1997, CRIT REV ONCOGENESIS, V8, P71, DOI 10.1615/CritRevOncog.v8.i1.40; Wolf E, 1998, GROWTH HORM IGF RES, V8, P185, DOI 10.1016/S1096-6374(98)80110-X; WOLF E, 1994, ENDOCRINOLOGY, V135, P1877, DOI 10.1210/en.135.5.1877; Wolf E, 1997, ENDOCRINOLOGY, V138, P307, DOI 10.1210/en.138.1.307; WOOD TL, 1995, AM J PHYSIOL-ENDOC M, V269, pE613, DOI 10.1152/ajpendo.1995.269.4.E613; WOOD TL, 1993, GROWTH REGULAT, V3, P5; YE P, 1995, J NEUROSCI, V15, P7344; Ye P, 1995, NEUROSCI LETT, V201, P235, DOI 10.1016/0304-3940(95)12194-3; Zadeh SM, 1997, ENDOCRINOLOGY, V138, P3069, DOI 10.1210/en.138.7.3069	110	108	110	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2000	14	5					629	640		10.1096/fasebj.14.5.629	http://dx.doi.org/10.1096/fasebj.14.5.629			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301DH	10744620				2022-12-28	WOS:000086292700001
J	Pezzi, N; Prieto, I; Kremer, L; Jurado, LAP; Valero, C; Del Mazo, J; Martinez, C; Barbero, JL				Pezzi, N; Prieto, I; Kremer, L; Jurado, LAP; Valero, C; Del Mazo, J; Martinez, C; Barbero, JL			STAG3, a novel gene encoding a protein involved in meiotic chromosome pairing and location of STAG3-related genes flanking the Williams-Beuren syndrome deletion	FASEB JOURNAL			English	Article						stromal antigens; stromalin; meiosis; cohesins	7Q11.23 DELETIONS; MOLECULAR-CLONING; C-ELEGANS; MOUSE; SYNAPSIS; SPERMATOGENESIS; MEIOSIS; REGIONS; PHOSPHORYLATION; IDENTIFICATION	Chromatin rearrangements in the meiotic prophase are characterized by the assembly and disassembly of synaptonemal complexes (SC), a protein structure that stabilizes the pairing of homologous chromosomes in prophase. We report the identification of human and mouse cDNA coding for stromalin 3 (STAG3), a new mammalian stromalin member of the synaptonemal complex. The stromalins are a group of highly conserved proteins, represented in several organisms from yeast to humans. Stromalins are characterized by the stromalin conservative domain (SCD), a specific motif found in all proteins of the family described to date. STAG3 is expressed specifically in testis, and immunolocalization experiments show that STAG3 is associated to the synaptonemal complex. As the protein encoded by the homologous gene (Scc3p) in Saccharomyces cerevisiae was found to be a subunit of a cohesin complex that binds chromosomes until the onset of anaphase, our data suggest that STAG3 is involved in chromosome pairing and maintenance of synaptonemal complex structure during the pachytene phase of meiosis in a cohesin-like manner. We have mapped the human STAG3 gene to the 7q22 region of chromosome 7; six human STAG3-related genes have also been mapped: two at 7q22 near the functional gene, one at 7q11.22, and three at 7q11.23, two of them flanking the breakpoints commonly associated with the Williams-Beuren syndrome (WBS) deletion. Since the WBS deletion occurs as a consequence of unequal meiotic crossing over, we suggest that STAG3 duplications predispose to germline chromosomal rearrangement within this region.	Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain; CSIC, CIB, Dept Biol Celular & Desarrollo, E-28006 Madrid, Spain; Hosp Univ La Paz, Serv Genet, E-28046 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Hospital Universitario La Paz	Barbero, JL (corresponding author), Ctr Nacl Biotecnol, Dept Immunol & Oncol, UAM Campus Cantoblanco, E-28049 Madrid, Spain.		Pérez Jurado, Luis Alberto/M-7706-2015; Barbero, Jose Luis/J-9833-2014; del Mazo, Jesus/L-3156-2015; Kremer, Leonor/L-5445-2015	del Mazo, Jesus/0000-0003-3269-3895; Kremer, Leonor/0000-0002-2235-2010; BARBERO, JOSE LUIS/0000-0002-1226-0323				BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; Barlow AL, 1997, EMBO J, V16, P5207, DOI 10.1093/emboj/16.17.5207; Baumer A, 1998, HUM MOL GENET, V7, P887, DOI 10.1093/hmg/7.5.887; BURN J, 1986, J MED GENET, V23, P389, DOI 10.1136/jmg.23.5.389; CANTU JM, 1981, HUM GENET, V59, P380, DOI 10.1007/BF00295476; Carramolino L, 1997, GENE, V195, P151, DOI 10.1016/S0378-1119(97)00121-2; CHAGANTI RSK, 1980, AM J HUM GENET, V32, P833; Chua PR, 1998, CELL, V93, P349, DOI 10.1016/S0092-8674(00)81164-2; Cobb J, 1998, SEMIN CELL DEV BIOL, V9, P445, DOI 10.1006/scdb.1998.0202; DELMAZO J, 1986, CYTOGENET CELL GENET, V43, P201, DOI 10.1159/000132321; Dernburg AF, 1998, CELL, V94, P387, DOI 10.1016/S0092-8674(00)81481-6; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Dutly F, 1996, HUM MOL GENET, V5, P1893, DOI 10.1093/hmg/5.12.1893; Edelmann W, 1999, NAT GENET, V21, P123, DOI 10.1038/5075; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; EWART AK, 1993, NAT GENET, V5, P11, DOI 10.1038/ng0993-11; GILALBERDI L, 1992, CYTOGENET CELL GENET, V59, P1, DOI 10.1159/000133185; Gorlach A, 1997, J CLIN INVEST, V100, P1907, DOI 10.1172/JCI119721; GREENBERG F, 1991, AM J MED GENET S, V6, P85; Ishwad CS, 1997, GENE CHROMOSOME CANC, V19, P156, DOI 10.1002/(SICI)1098-2264(199707)19:3<156::AID-GCC4>3.0.CO;2-X; Jurado LAP, 1998, HUM MOL GENET, V7, P325, DOI 10.1093/hmg/7.3.325; KURLANDZKA A, 1995, YEAST, V11, P885, DOI 10.1002/yea.320110910; LAMMERS JHM, 1994, MOL CELL BIOL, V14, P1137, DOI 10.1128/MCB.14.2.1137; Leu JY, 1998, CELL, V94, P375, DOI 10.1016/S0092-8674(00)81480-4; LILFORD R, 1994, BMJ-BRIT MED J, V309, P570, DOI 10.1136/bmj.309.6954.570; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; MAYSHOOPES LL, 1995, BIOL REPROD, V53, P1003, DOI 10.1095/biolreprod53.5.1003; MEUWISSEN RLJ, 1992, EMBO J, V11, P5091, DOI 10.1002/j.1460-2075.1992.tb05616.x; MORRIS CA, 1988, J PEDIATR-US, V113, P318, DOI 10.1016/S0022-3476(88)80272-5; NICOLAIDES NC, 1995, GENOMICS, V29, P329, DOI 10.1006/geno.1995.9997; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; Osborne LR, 1997, GENOMICS, V45, P402, DOI 10.1006/geno.1997.4923; Pereira MM, 1996, J SOL-GEL SCI TECHN, V7, P59, DOI 10.1007/BF00401884; REIJO R, 1995, NAT GENET, V10, P383, DOI 10.1038/ng0895-383; Rhodes M, 1998, GENOME RES, V8, P531, DOI 10.1101/gr.8.5.531; Robinson WP, 1996, GENOMICS, V34, P17, DOI 10.1006/geno.1996.0237; SAMBROOK J, 1989, MOL CLONING LAB MANU, P846; Tang TTL, 1998, GENE DEV, V12, P3843, DOI 10.1101/gad.12.24.3843; ULLOA L, 1993, J NEUROCHEM, V61, P961, DOI 10.1111/j.1471-4159.1993.tb03609.x; Urban Z, 1996, AM J HUM GENET, V59, P958; Valdeolmillos A, 1998, DNA CELL BIOL, V17, P699, DOI 10.1089/dna.1998.17.699; Watson ML, 1998, P NATL ACAD SCI USA, V95, P14361, DOI 10.1073/pnas.95.24.14361; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Wu YQ, 1998, AM J MED GENET, V78, P82, DOI 10.1002/(SICI)1096-8628(19980616)78:1<82::AID-AJMG17>3.0.CO;2-K; Yen PH, 1996, HUM MOL GENET, V5, P2013, DOI 10.1093/hmg/5.12.2013	46	110	121	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2000	14	3					581	592		10.1096/fasebj.14.3.581	http://dx.doi.org/10.1096/fasebj.14.3.581			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	291TJ	10698974				2022-12-28	WOS:000085751900018
J	Standridge, M; Alemzadeh, R; Zemel, M; Koontz, J; Moustaid-Moussa, N				Standridge, M; Alemzadeh, R; Zemel, M; Koontz, J; Moustaid-Moussa, N			Diazoxide down-regulates leptin and lipid metabolizing enzymes in adipose tissue of Zucker rats	FASEB JOURNAL			English	Article						lipoprotein lipase; fatty acid synthase; insulin; glucose; adipocytes	LIPOPROTEIN-LIPASE ACTIVITY; FATTY-ACID SYNTHETASE; INSULIN-RESISTANCE; HORMONAL-REGULATION; SYNTHASE GENE; OBESE GENE; EXPRESSION; SECRETION; LIVER; CELLS	We have previously reported that attenuation of hyperinsulinemia by diazoxide (DZ), an inhibitor of glucose-mediated insulin secretion, increased insulin sensitivity and reduced body weight in obese Zucker rats. These findings prompted us to investigate the effects of DZ on key insulin-sensitive enzymes regulating adipose tissue metabolism, fatty acid synthase (FAS), and lipoprotein lipase (LPL), as well as on circulating levels of leptin. We also determined the direct effects of diazoxide on FAS in 3T3-L1 adipocytes, Seven-week-old female obese and lean Zucker rats were treated with DZ (150 mg/kg/d) or vehicle (C, control) for a period of 6 wk, Changes in plasma parameters by DZ include significant decreases in triglycerides, free fatty acids, glucose, and insulin, consistent with our previous reports, DZ obese rats exhibited lower plasma leptin levels (P<0.03) com pared to their C animals. DZ significantly reduced adipose tissue FAS activity in both lean (P< 0.0001) and obese (P<0.01) animals, LPL mRNA content was also decreased significantly in DZ-treated obese animals (P<0.009) as compared to their respective controls without a significant effect on lean animals, The possibility that DZ exerted a direct effect on adipocytes was further tested in cultured 3T3-L1 adipocytes, Although diazoxide (5 mu M) alone did not change FAS activity in cultured 3T3-L1 adipocytes, it significantly attenuated insulin's effect on FAS activity (P<0.001). We demonstrate that DZ regulates key insulin-sensitive enzymes involved in regulation of adipose tissue metabolism, These findings suggest that modification of insulin-sensitive pathways can be therapeutically beneficial in obesity management.	Univ Tennessee, Dept Nutr JHB 229, Knoxville, TN 37996 USA; Univ Tennessee, Dept Biochem Cellular & Mol Biol, Knoxville, TN 37996 USA; Univ Tennessee, Med Ctr, Dept Pediat, Knoxville, TN 37920 USA	University of Tennessee System; University of Tennessee Knoxville; University of Tennessee System; University of Tennessee Knoxville; University of Tennessee System; University of Tennessee Health Science Center	Moustaid-Moussa, N (corresponding author), Univ Tennessee, Dept Nutr JHB 229, 1215 Cumberland Ave, Knoxville, TN 37996 USA.	moustaid@utk.edu	Moustaid-Moussa, Naima/B-9067-2014	Moustaid-Moussa, Naima/0000-0002-7508-8030; Zemel, Michael/0000-0003-4104-5750				Alemzadeh R, 1996, METABOLISM, V45, P334, DOI 10.1016/S0026-0495(96)90287-5; ALEMZADEH R, 1993, ENDOCRINOLOGY, V133, P705, DOI 10.1210/en.133.2.705; ALEMZADEH R, 1999, IN PRESS ENDOCRINOLO; APPEL B, 1992, AM J PHYSIOL, V262, pE695, DOI 10.1152/ajpendo.1992.262.5.E695; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; Caro JF, 1996, DIABETES, V45, P1455, DOI 10.2337/diab.45.11.1455; CARO JF, 1989, DIABETES METAB REV, V5, P665, DOI 10.1002/dmr.5610050804; Claycombe KJ, 1998, AM J PHYSIOL-REG I, V274, pR1253, DOI 10.1152/ajpregu.1998.274.5.R1253; CRYER A, 1981, INT J BIOCHEM, V13, P525, DOI 10.1016/0020-711X(81)90177-4; Ewart HS, 1997, BIOCHEM J, V327, P439, DOI 10.1042/bj3270439; GRUEN RK, 1981, AM J PHYSIOL, V241, pE76, DOI 10.1152/ajpendo.1981.241.1.E76; GUICHARD C, 1992, J LIPID RES, V33, P679; HALAAS JL, 1997, NATL ACAD SCI US, V16, P8878; JEANRENAUD B, 1978, METABOLISM, V27, P1881, DOI 10.1016/S0026-0495(78)80006-7; JEANRENAUD B, 1979, RECENT ADV OBES RES, V2, P111; Jones BH, 1996, AM J PHYSIOL-ENDOC M, V270, pE192, DOI 10.1152/ajpendo.1996.270.1.E192; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Kim JH, 1996, FASEB J, V10, P1646, DOI 10.1096/fasebj.10.14.9002558; Kraemer FB, 1998, METABOLISM, V47, P555, DOI 10.1016/S0026-0495(98)90239-6; LAKSHMAN.MR, 1972, P NATL ACAD SCI USA, V69, P3516, DOI 10.1073/pnas.69.12.3516; LESTUNFF C, 1994, DIABETES, V43, P696, DOI 10.2337/diabetes.43.5.696; MAGGIO C A, 1990, FASEB Journal, V4, pA511; Mariot P, 1998, DIABETES, V47, P365, DOI 10.2337/diabetes.47.3.365; MOUSTAID N, 1991, J BIOL CHEM, V266, P18550; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; PAULAUSKIS JD, 1988, J BIOL CHEM, V263, P7049; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; PENICAUD L, 1989, AM J PHYSIOL, V257, pE255, DOI 10.1152/ajpendo.1989.257.2.E255; Picard F, 1999, DIABETES, V48, P452, DOI 10.2337/diabetes.48.3.452; Shi H, 1999, FASEB J, V13, P1833, DOI 10.1096/fasebj.13.13.1833; Tenenbaum R., 1994, International Journal of Obesity, V18, P67; VOLPE JJ, 1976, PHYSIOL REV, V56, P339, DOI 10.1152/physrev.1976.56.2.339; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; Woods S C, 1983, Adv Metab Disord, V10, P457; ZEMEL MB, 1995, P NATL ACAD SCI USA, V92, P4733, DOI 10.1073/pnas.92.11.4733; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; ZUCKER LM, 1975, P SOC EXP BIOL MED, V148, P498, DOI 10.3181/00379727-148-38569	38	38	44	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2000	14	3					455	460		10.1096/fasebj.14.3.455	http://dx.doi.org/10.1096/fasebj.14.3.455			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	291TJ	10698960				2022-12-28	WOS:000085751900004
J	Kallio, J; Pesonen, U; Kaipio, K; Karvonen, MK; Jaakkola, U; Heinonen, OJ; Uusitupa, MIJ; Koulu, M				Kallio, J; Pesonen, U; Kaipio, K; Karvonen, MK; Jaakkola, U; Heinonen, OJ; Uusitupa, MIJ; Koulu, M			Altered intracellular processing and release of neuropeptide Y due to leucine 7 to proline 7 polymorphism in the signal peptide of preproneuropeptide Y in humans	FASEB JOURNAL			English	Article									Univ Turku, Dept Pharmacol & Clin Pharmacol, FIN-20520 Turku, Finland; Univ Turku, Dept Physiol, Paavo Nurmi Ctr, FIN-20520 Turku, Finland; Univ Kuopio, Dept Clin Nutr, FIN-70211 Kuopio, Finland	University of Turku; University of Turku; University of Eastern Finland	Kallio, J (corresponding author), Univ Turku, Dept Pharmacol & Clin Pharmacol, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.		Uusitupa, Matti Ilmari Julius/AAX-4929-2020; Heinonen, Olli/AAG-7298-2019	Heinonen, Olli/0000-0002-1722-1729; Pesonen, Ullamari/0000-0002-9962-212X					0	116	119	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1242	1244		10.1096/fj.00-0436fje	http://dx.doi.org/10.1096/fj.00-0436fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344101				2022-12-28	WOS:000168655200023
J	Lee, FJS; Liu, F; Pristupa, ZB; Niznik, HB				Lee, FJS; Liu, F; Pristupa, ZB; Niznik, HB			Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis	FASEB JOURNAL			English	Article						DA uptake; cell death; coimmunoprecipitation; GST fusion proteins; Parkinson's disease	A-BETA COMPONENT; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; LEWY BODIES; SUBSTANTIA-NIGRA; CELL-DEATH; CYTOCHROME-C; MICE LACKING; IN-VITRO	Mutations in alpha -synuclein, a protein highly enriched in presynaptic terminals, have been implicated in the expression of familial forms of Parkinson's disease (PD) whereas native alpha -synuclein is a major component of intraneuronal inclusion bodies characteristic of PD and other neurodegenerative disorders. Although overexpression of human a-synuclein induces dopaminergic nerve terminal degeneration, the molecular mechanism by which alpha -synuclein contributes to the degeneration of these pathways remains enigmatic, We report here that alpha -synuclein complexes with the presynaptic human dopamine transporter (hDAT) in both neurons and cotransfected cells through the direct binding of the non-A beta amyloid component of alpha -synuclein to the carboxyl-terminal tail of the hDAT, alpha -Synuclein-hDAT complex formation facilitates the membrane clustering of the DAT, thereby accelerating cellular dopamine uptake and dopamine-induced cellular apoptosis, Since the selective vulnerability of dopaminergic neurons in PD has been ascribed in part to oxidative stress as a result of the cellular overaccumulation of dopamine or dopamine-like molecules by the presynaptic DAT, these data provide mechanistic insight into the mode by which the activity of these two proteins may give rise to this process.	Ctr Addict & Mental Hlth, Mol Neurobiol Lab, Toronto, ON M5T 1R8, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto; University of Toronto	Lee, FJS (corresponding author), Ctr Addict & Mental Hlth, Mol Neurobiol Lab, 250 Coll St, Toronto, ON M5T 1R8, Canada.	f.lee@utoronto.ca	Lee, Frank J.S./D-5899-2017	Lee, Frank J.S./0000-0002-5768-3776				Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Baba M, 1998, AM J PATHOL, V152, P879; Beckman ML, 1998, J NEUROSCI, V18, P6103; Bennett MC, 1999, J BIOL CHEM, V274, P33855, DOI 10.1074/jbc.274.48.33855; Berman SB, 1996, J NEUROCHEM, V67, P593; Berman SB, 1999, J NEUROCHEM, V73, P1127, DOI 10.1046/j.1471-4159.1999.0731127.x; Bodles AM, 2000, EUR J BIOCHEM, V267, P2186, DOI 10.1046/j.1432-1327.2000.01219.x; Bunn RC, 1999, MOL BIOL CELL, V10, P819, DOI 10.1091/mbc.10.4.819; Ciliax BJ, 1999, J COMP NEUROL, V409, P38, DOI 10.1002/(SICI)1096-9861(19990621)409:1<38::AID-CNE4>3.0.CO;2-1; Clayton DF, 1999, J NEUROSCI RES, V58, P120, DOI 10.1002/(SICI)1097-4547(19991001)58:1<120::AID-JNR12>3.3.CO;2-5; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Copeland BJ, 1996, J PHARMACOL EXP THER, V277, P1527; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Dougherty DD, 1999, LANCET, V354, P2132, DOI 10.1016/S0140-6736(99)04030-1; Dunnett SB, 1999, NATURE, V399, pA32, DOI 10.1038/399a032; El-Agnaf OMA, 1998, FEBS LETT, V440, P67, DOI 10.1016/S0014-5793(98)01419-7; El-Agnaf OMA, 1998, FEBS LETT, V440, P71, DOI 10.1016/S0014-5793(98)01418-5; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; Fang YA, 1999, J NEUROSCI, V19, P8966, DOI 10.1523/JNEUROSCI.19-20-08966.1999; Forloni G, 2000, ANN NEUROL, V47, P632, DOI 10.1002/1531-8249(200005)47:5<632::AID-ANA11>3.3.CO;2-E; Gainetdinov RR, 1999, BIOL PSYCHIAT, V46, P303, DOI 10.1016/S0006-3223(99)00122-5; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; Halestrap AP, 2000, BIOCHEM SOC T, V28, P170, DOI 10.1042/bst0280170; HAN HY, 1995, CHEM BIOL, V2, P163, DOI 10.1016/1074-5521(95)90071-3; Hashimoto M, 1999, J BIOL CHEM, V274, P28849, DOI 10.1074/jbc.274.41.28849; Hashimoto M, 1999, NEUROREPORT, V10, P717, DOI 10.1097/00001756-199903170-00011; Hersch SM, 1997, J COMP NEUROL, V388, P211; Hornykiewicz O, 1998, NEUROLOGY, V51, pS2, DOI 10.1212/WNL.51.2_Suppl_2.S2; Irizarry MC, 1998, J NEUROPATH EXP NEUR, V57, P334, DOI 10.1097/00005072-199804000-00005; Irizarry MC, 1996, J NEUROPATH EXP NEUR, V55, P889, DOI 10.1097/00005072-199608000-00004; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; JAVITCH JA, 1985, P NATL ACAD SCI USA, V82, P2173, DOI 10.1073/pnas.82.7.2173; Jellinger KA, 2000, J NEURAL TRANSM, V107, P1, DOI 10.1007/s007020050001; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jenner P, 1998, MOVEMENT DISORD, V13, P24; Jensen PH, 1997, BIOCHEM J, V323, P539, DOI 10.1042/bj3230539; Jensen PH, 1999, J BIOL CHEM, V274, P25481, DOI 10.1074/jbc.274.36.25481; Jones SR, 1998, P NATL ACAD SCI USA, V95, P4029, DOI 10.1073/pnas.95.7.4029; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kaytor MD, 1999, J BIOL CHEM, V274, P37507, DOI 10.1074/jbc.274.53.37507; Kholodilov NG, 1999, NEUROSCI LETT, V275, P105, DOI 10.1016/S0304-3940(99)00740-5; Kosel S, 1999, BIOL CHEM, V380, P865, DOI 10.1515/BC.1999.106; Kowall NW, 2000, NEUROREPORT, V11, P211, DOI 10.1097/00001756-200001170-00041; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Laruelle M, 1996, P NATL ACAD SCI USA, V93, P9235, DOI 10.1073/pnas.93.17.9235; Lavedan C, 1998, GENOME RES, V8, P871, DOI 10.1101/gr.8.9.871; Lee FJS, 1996, J BIOL CHEM, V271, P20885, DOI 10.1074/jbc.271.34.20885; Lippa CF, 1998, AM J PATHOL, V153, P1365, DOI 10.1016/S0002-9440(10)65722-7; Little KY, 1999, AM J PSYCHIAT, V156, P238; Liu F, 2000, NATURE, V403, P274, DOI 10.1038/35002014; Luo YQ, 1999, MOL PHARMACOL, V56, P254, DOI 10.1124/mol.56.2.254; Luo YQ, 1998, J BIOL CHEM, V273, P3756, DOI 10.1074/jbc.273.6.3756; Maruyama W, 1998, J NEUROCHEM, V70, P2510; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Melikian HE, 1999, J NEUROSCI, V19, P7699; Mezey E, 1998, NAT MED, V4, P755, DOI 10.1038/nm0798-755; MICHEL PP, 1990, J NEUROSCI RES, V26, P428, DOI 10.1002/jnr.490260405; Miller GW, 1999, TRENDS PHARMACOL SCI, V20, P424, DOI 10.1016/S0165-6147(99)01379-6; Neystat M, 1999, MOVEMENT DISORD, V14, P417, DOI 10.1002/1531-8257(199905)14:3<417::AID-MDS1005>3.0.CO;2-X; Nirenberg MJ, 1997, J NEUROSCI, V17, P5255; Nirenberg MJ, 1996, J NEUROSCI, V16, P436; Offen D, 1999, Adv Neurol, V80, P265; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; OLANOW CW, 1994, CURR OPIN NEUROL, V7, P548, DOI 10.1097/00019052-199412000-00013; Oliver JD, 1996, J BIOL CHEM, V271, P13691, DOI 10.1074/jbc.271.23.13691; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Pristupa ZB, 1998, SYNAPSE, V30, P79, DOI 10.1002/(SICI)1098-2396(199809)30:1<79::AID-SYN10>3.3.CO;2-I; Reith MEA, 1997, EUR J PHARMACOL, V324, P1, DOI 10.1016/S0014-2999(97)00065-4; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Surguchov A, 1999, MOL CELL NEUROSCI, V13, P95, DOI 10.1006/mcne.1999.0735; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Trojanowski JQ, 1998, ARCH NEUROL-CHICAGO, V55, P151, DOI 10.1001/archneur.55.2.151; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Vaughan RA, 1997, J BIOL CHEM, V272, P15541, DOI 10.1074/jbc.272.24.15541; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Withers GS, 1997, DEV BRAIN RES, V99, P87, DOI 10.1016/S0165-3806(96)00210-6; WU RM, 1993, EUR J PHARMACOL, V243, P241, DOI 10.1016/0014-2999(93)90181-G; YOSHIMOTO M, 1995, P NATL ACAD SCI USA, V92, P9141, DOI 10.1073/pnas.92.20.9141; Zhang L, 1997, BIOCHEM PHARMACOL, V53, P677, DOI 10.1016/S0006-2952(96)00898-2	84	356	378	0	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2001	15	6					916	926		10.1096/fj.00-0334com	http://dx.doi.org/10.1096/fj.00-0334com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292651				2022-12-28	WOS:000167959300005
J	Gibson, JS; Khan, A; Speake, PF; Ellory, JC				Gibson, JS; Khan, A; Speake, PF; Ellory, JC			O-2 dependence of K+ transport in sickle cells: the effect of different cell populations and the substituted benzaldehyde 12C79	FASEB JOURNAL			English	Article						oxygen; potassium; HbS; HbA; red cells	INDUCED CATION FLUXES; ANEMIA RED-CELLS; CL-COTRANSPORT; KCL-COTRANSPORT; ION-TRANSPORT; VOLUME; DEOXYGENATION; RETICULOCYTES; DEHYDRATION; HEMOGLOBIN	The molecular basis of sickle cell disease (SCD) is well known but the pathophysiology is poorly understood. It remains intractable to therapy, Hyperactivity of several membrane transport systems, including the K+-Cl- cotransporter (termed KCC), cause HbS-containing red cells (termed HbS cells) to dehydrate and sickle, leading to the development of sickle cell crises (SCCs), Contrary to normal red cells (HbA cells), KCC in HbS cells is active at low O-2 tensions (PO(2)s), remaining responsive to low pH or urea. Since these stimuli are usually encountered in hypoxic regions, the abnormal O-2 dependence increases the contribution of KCC to dehydration, and hence development of SCCs, These differences with HbA cells may be due to the younger population of cells or to polymerization of HbS, We used Rb-86(+) as a K+ congener to investigate the activity of KCC at different PO(2)s, and density gradient separation to investigate different red cell fractions. We found no correlation of O-2 dependence with cell fractions. We also used the substituted benzaldehyde 12C79 to increase the O-2 affinity of HbS and found that its effect on HbS O-2 saturation and cell sickling correlated with that on both Cl--independent and Cl--dependent K+ transport, implying that, at low PO(2)s, KCC activity correlated with HbS polymerization, The importance of these results to understanding the pathophysiology of SCD, and for the design of chemotherapeutic agents to ameliorate or prevent SCC, is discussed.	Univ London St Georges Hosp, Sch Med, Dept Physiol, Tooting SW17 0RE, England; Univ Oxford, Physiol Lab, Oxford OX1 3PT, England; Univ Manchester, Acad Unit Child Hlth, Manchester M13, Lancs, England	St Georges University London; University of Oxford; University of Manchester	Gibson, JS (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Physiol, Tooting SW17 0RE, England.	jsgibson@sghms.ac.uk						APOVO M, 1994, BBA-MOL BASIS DIS, V1225, P255, DOI 10.1016/0925-4439(94)90003-5; BEDDELL CR, 1984, BRIT J PHARMACOL, V82, P397, DOI 10.1111/j.1476-5381.1984.tb10775.x; BERKOWITZ LR, 1985, AM J PHYSIOL, V249, pC208, DOI 10.1152/ajpcell.1985.249.3.C208; Beutler E, 1982, GLUTATHIONE RED CELL, V3 rd; BOOKCHIN RM, 1991, J CLIN INVEST, V87, P113, DOI 10.1172/JCI114959; BOOKCHIN RM, 1993, BLOOD, V82, pA350; BORGESE F, 1991, BIOCHIM BIOPHYS ACTA, V1066, P252, DOI 10.1016/0005-2736(91)90194-D; BRUGNARA C, 1985, J CLIN INVEST, V75, P1608, DOI 10.1172/JCI111867; BRUGNARA C, 1987, AM J PHYSIOL, V252, pC269, DOI 10.1152/ajpcell.1987.252.3.C269; BRUGNARA C, 1986, SCIENCE, V232, P388, DOI 10.1126/science.3961486; BRUGNARA C, 1993, J CLIN INVEST, V92, P520, DOI 10.1172/JCI116597; BRUGNARA C, 1989, BLOOD, V74, P487; Bunn HF, 1986, HEMOGLOBIN MOL GENET; Campbell EH, 1998, J PHYSIOL-LONDON, V506, P679, DOI 10.1111/j.1469-7793.1998.679bv.x; CANESSA M, 1987, J MEMBRANE BIOL, V97, P97, DOI 10.1007/BF01869416; CANESSA M, 1986, FEBS LETT, V200, P197, DOI 10.1016/0014-5793(86)80538-5; COSSINS AR, 1994, AM J PHYSIOL-CELL PH, V267, pC1641, DOI 10.1152/ajpcell.1994.267.6.C1641; Cossins AR, 1997, J EXP BIOL, V200, P343; Culliford SJ, 1998, PFLUG ARCH EUR J PHY, V435, P740, DOI 10.1007/s004240050576; DUNHAM PB, 1981, J PHYSIOL-LONDON, V318, P511; EATON WA, 1987, BLOOD, V70, P1245; Ellory JC, 1998, CONTRIB NEPHROL, V123, P220, DOI 10.1159/000059915; ELLORY JC, 1988, COMP BIOCHEM PHYS A, V90, P533, DOI 10.1016/0300-9629(88)90663-9; ELLORY JC, 1989, CLIN HEMORHEOL, V9, P1009; ELLORY JC, 1989, J PHYSL, V420, pP149; ETZION Z, 1993, J CLIN INVEST, V92, P2489, DOI 10.1172/JCI116857; FABRY ME, 1982, BLOOD CELLS, V8, P9; FABRY ME, 1991, BLOOD, V78, P217; Flatman PW, 1996, AM J PHYSIOL-CELL PH, V271, pC255, DOI 10.1152/ajpcell.1996.271.1.C255; FRANCIS RB, 1991, BLOOD, V77, P1405; Franco RS, 1996, BLOOD, V88, P4359; GARAY RP, 1988, MOL PHARMACOL, V33, P696; GARDOS G, 1958, BIOCHIM BIOPHYS ACTA, V30, P653, DOI 10.1016/0006-3002(58)90124-0; Gibson JS, 1999, PFLUG ARCH EUR J PHY, V437, P498, DOI 10.1007/s004240050807; Gibson JS, 2000, J EXP BIOL, V203, P1395; Gibson JS, 1998, J PHYSIOL-LONDON, V511, P225, DOI 10.1111/j.1469-7793.1998.225bi.x; GIBSON JS, 1994, EXP PHYSIOL, V79, P997, DOI 10.1113/expphysiol.1994.sp003824; HALL AC, 1986, BIOCHIM BIOPHYS ACTA, V858, P317, DOI 10.1016/0005-2736(86)90338-X; HALL AC, 1986, J MEMBRANE BIOL, V94, P1, DOI 10.1007/BF01901009; Hoffmann EK, 1995, INT REV CYTOL, V161, P173; HORIUCHI K, 1988, BLOOD, V71, P46; Ishii TM, 1997, P NATL ACAD SCI USA, V94, P11651, DOI 10.1073/pnas.94.21.11651; JOINER CH, 1993, AM J PHYSIOL, V264, pC251, DOI 10.1152/ajpcell.1993.264.2.C251; JOINER CH, 1988, BLOOD CELLS, V13, P339; JOINER CH, 1993, AM J PHYSIOL, V264, pC734, DOI 10.1152/ajpcell.1993.264.3.C734; Joiner CH, 1998, AM J PHYSIOL-CELL PH, V274, pC1466, DOI 10.1152/ajpcell.1998.274.6.C1466; KAJI DM, 1995, AM J PHYSIOL-CELL PH, V268, pC1018, DOI 10.1152/ajpcell.1995.268.4.C1018; LAUF PK, 1992, AM J PHYSIOL, V263, pC917, DOI 10.1152/ajpcell.1992.263.5.C917; Lew VL, 1997, J CLIN INVEST, V99, P2727, DOI 10.1172/JCI119462; LEW VL, 1991, J CLIN INVEST, V87, P100, DOI 10.1172/JCI114958; MINTON AP, 1992, P NATL ACAD SCI USA, V89, P10504, DOI 10.1073/pnas.89.21.10504; NARLA M, 1986, BLOOD, V68, P450; NIELSEN OB, 1992, AM J PHYSIOL, V263, pC1057, DOI 10.1152/ajpcell.1992.263.5.C1057; OHNISHI ST, 1986, BIOCHIM BIOPHYS ACTA, V886, P119, DOI 10.1016/0167-4889(86)90217-X; ORTIZ OE, 1986, BLOOD, V67, P710; ORTIZ OE, 1990, J PHYSIOL-LONDON, V427, P211, DOI 10.1113/jphysiol.1990.sp018168; PARKER JC, 1993, AM J PHYSIOL, V265, pC447, DOI 10.1152/ajpcell.1993.265.2.C447; PAULING L, 1949, SCIENCE, V110, P543, DOI 10.1126/science.110.2865.543; SERJANT GR, 1992, SICKLE CELL DIS; Serjeant GR, 1997, LANCET, V350, P725, DOI 10.1016/S0140-6736(97)07330-3; Speake PF, 1997, AM J PHYSIOL-CELL PH, V273, pC1811, DOI 10.1152/ajpcell.1997.273.6.C1811; Speake PF, 1997, PFLUG ARCH EUR J PHY, V434, P104, DOI 10.1007/s004240050369; STARKE LC, 1993, AM J PHYSIOL, V264, pC118, DOI 10.1152/ajpcell.1993.264.1.C118; STUART J, 1988, BRIT J HAEMATOL, V69, P1, DOI 10.1111/j.1365-2141.1988.tb07593.x; TOSTESON DC, 1955, J GEN PHYSIOL, V39, P55, DOI 10.1085/jgp.39.1.55; TUCKER VA, 1967, J APPL PHYSIOL, V23, P410, DOI 10.1152/jappl.1967.23.3.410; VITOUX D, 1989, P NATL ACAD SCI USA, V86, P4273, DOI 10.1073/pnas.86.11.4273; WOLFF D, 1988, J MEMBRANE BIOL, V106, P243, DOI 10.1007/BF01872162	68	21	21	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2001	15	3					823	832		10.1096/fj.00-0177com	http://dx.doi.org/10.1096/fj.00-0177com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259401				2022-12-28	WOS:000167419500040
J	Lindenthal, B; Holleran, AL; Aldaghlas, TA; Ruan, BF; Schroepfer, GJ; Wilson, WK; Kelleher, JK				Lindenthal, B; Holleran, AL; Aldaghlas, TA; Ruan, BF; Schroepfer, GJ; Wilson, WK; Kelleher, JK			Progestins block cholesterol synthesis to produce meiosis-activating sterols	FASEB JOURNAL			English	Article						progesterone; 17-hydroxyprogesterone; cholesterol precursors; GC-MS; isotopomer spectral analysis; HepG2 cells	PLASMA-MEMBRANE CHOLESTEROL; EMPTY FOLLICLE SYNDROME; RECEPTOR LXR-ALPHA; ENDOPLASMIC-RETICULUM; DOCOSAHEXAENOIC ACID; GRANULOSA-CELLS; OOCYTE MEIOSIS; CULTURED-CELLS; CACO-2 CELLS; IN-VITRO	The resumption of meiosis is regulated by meiosis-preventing and meiosis-activating substances in testes and ovaries. Certain C-29 precursors of cholesterol are present at elevated levels in gonadal tissue, but the mechanism by which these meiosis-activating sterols (MAS) accumulate has remained an unresolved question. Here we report that progestins alter cholesterol synthesis in HepG2 cells and rat testes to increase levels of major MAS (FF-MAS and T-MAS), These C-29 sterols accumulated as a result of inhibition of Delta 24-reduction and 4 alpha -demethylation, Progesterone, pregnenolone, and 17 alpha -OH-pregnenolone were potent inhibitors of Delta 24-reduction in an in vitro cell assay and led to the accumulation of desmosterol, a Delta5,24 sterol precursor of cholesterol, A markedly different effect was observed for 17 alpha -OH-progesterone, which caused the accumulation of sterols associated with inhibition of 4 alpha -demethylation. The flux of C-13-acetate into lathosterol and cholesterol was decreased by progestins as measured by isotopomer spectral analysis, whereas newly synthesized MAS accumulated, The combined evidence that MAS concentrations can be regulated by physiological levels of progestins and their specific combination provides a plausible explanation for the elevated concentration of MAS in gonads and suggests a new role for progestins in fertility.	George Washington Univ, Sch Med & Hlth Sci, Dept Physiol & Expt Med, Washington, DC 20037 USA; Univ Bonn, Dept Clin Pharmacol, D-53105 Bonn, Germany; Rice Univ, Dept Chem, Houston, TX 77251 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77251 USA	George Washington University; University of Bonn; Rice University; Rice University	Lindenthal, B (corresponding author), Schering AG, Female Hlth Care Res, Muellerstr 170-178, D-13342 Berlin, Germany.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045164] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-49122] Funding Source: Medline; NIDDK NIH HHS [DK-45164] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSEN CY, 1992, HUM REPROD, V7, P765, DOI 10.1093/oxfordjournals.humrep.a137734; BRAILLY S, 1981, J CLIN ENDOCR METAB, V53, P128, DOI 10.1210/jcem-53-1-128; Byskov AG, 1999, J EXP ZOOL, V285, P237, DOI 10.1002/(SICI)1097-010X(19991015)285:3&lt;237::AID-JEZ6&gt;3.0.CO;2-S; BYSKOV AG, 1995, NATURE, V374, P559, DOI 10.1038/374559a0; BYSKOV AG, 1976, DEV BIOL, V52, P193, DOI 10.1016/0012-1606(76)90239-6; Byskov AG, 1998, J MOL MED-JMM, V76, P818, DOI 10.1007/s001090050286; CHANNING CP, 1978, CLIN ENDOCRINOL META, V7, P601, DOI 10.1016/S0300-595X(78)80011-5; Connor WE, 1997, J CLIN ENDOCR METAB, V82, P1911, DOI 10.1210/jc.82.6.1911; Enien WM, 1995, HUM REPROD, V10, P2840, DOI 10.1093/oxfordjournals.humrep.a135804; FIELD FJ, 1995, J LIPID RES, V36, P1533; Field FJ, 1998, J LIPID RES, V39, P333; Forman BM, 1997, P NATL ACAD SCI USA, V94, P10588, DOI 10.1073/pnas.94.20.10588; Gerst N, 1997, J LIPID RES, V38, P1685; Gondos B, 1996, ANN CLIN LAB SCI, V26, P421; Grondahl C, 1998, BIOL REPROD, V58, P1297, DOI 10.1095/biolreprod58.5.1297; HAKSAR A, 1967, STEROIDS, V9, P405, DOI 10.1016/0039-128X(67)90028-1; HASHIMOTO F, 1991, BIOCHIM BIOPHYS ACTA, V1086, P115, DOI 10.1016/0005-2760(91)90162-B; Holleran AL, 1998, METABOLISM, V47, P1504, DOI 10.1016/S0026-0495(98)90078-6; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; KALLIO MJT, 1989, AM J CLIN NUTR, V50, P782, DOI 10.1093/ajcn/50.4.782; KASE NG, 1983, J REPROD MED, V28, P239; KELLEHER JK, 1994, AM J PHYSIOL, V266, pE384, DOI 10.1152/ajpendo.1994.266.3.E384; KRITCHEVSKY D, 1965, J AM OIL CHEM SOC, V42, P1024, DOI 10.1007/BF02636896; LANGE Y, 1994, J BIOL CHEM, V269, P3411; LANGE Y, 1994, J BIOL CHEM, V269, P29371; LANGE Y, 1988, ENDOCRINOLOGY, V123, P81, DOI 10.1210/endo-123-1-81; LEINONEN P, 1981, J CLIN ENDOCR METAB, V53, P569, DOI 10.1210/jcem-53-3-569; LEINONEN P, 1980, J CLIN ENDOCR METAB, V51, P423, DOI 10.1210/jcem-51-3-423; LIN DS, 1993, J LIPID RES, V34, P491; LISCUM L, 1995, J BIOL CHEM, V270, P15443, DOI 10.1074/jbc.270.26.15443; MCNATTY KP, 1979, J CLIN ENDOCR METAB, V49, P687, DOI 10.1210/jcem-49-5-687; Metherall JE, 1996, J BIOL CHEM, V271, P2627, DOI 10.1074/jbc.271.5.2627; Metherall JE, 1996, J BIOL CHEM, V271, P2634, DOI 10.1074/jbc.271.5.2634; Nikkila K, 1996, J LIPID RES, V37, P2687; PANINI SR, 1987, J BIOL CHEM, V262, P14435; RODRIGUEZRIGAU LJ, 1978, ACTA ENDOCRINOL-COP, V87, P400, DOI 10.1530/acta.0.0870400; Ruan BF, 1998, J LIPID RES, V39, P2005; SCHUETZ AW, 1977, ANN NY ACAD SCI, V286, P408, DOI 10.1111/j.1749-6632.1977.tb29433.x; SEIBEL MM, 1982, AM J OBSTET GYNECOL, V142, P568, DOI 10.1016/0002-9378(82)90763-3; Stromstedt M, 1998, ENDOCRINOLOGY, V139, P2314, DOI 10.1210/en.139.5.2314; TSUIKI A, 1988, FERTIL STERIL, V49, P104; WESTERGAARD L, 1984, FERTIL STERIL, V41, P377; Yoshida Y, 1996, BIOCHEM BIOPH RES CO, V223, P534, DOI 10.1006/bbrc.1996.0929; ZEGERSHOCHSCHILD F, 1995, HUM REPROD, V10, P2262	44	44	45	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					775	784		10.1096/fj.00-0214com	http://dx.doi.org/10.1096/fj.00-0214com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259396				2022-12-28	WOS:000167419500035
J	Unger, RH; Orci, L				Unger, RH; Orci, L			Diseases of liporegulation: new perspective on obesity and related disorders	FASEB JOURNAL			English	Review							ACTIVATED RECEPTOR-ALPHA; NITRIC-OXIDE SYNTHASE; LEPTIN GENE-EXPRESSION; PANCREATIC BETA-CELLS; GROWTH-FACTOR-BETA; CALORIC RESTRICTION; INSULIN-RESISTANCE; FATTY-ACIDS; DIABETES-MELLITUS; PREDIABETIC RATS	Obesity-related diseases now threaten to reach epidemic proportions in the United States, Here we review in a rodent model of genetic obesity, the fa/fa Zucker diabetic fatty (ZDF) rat, the mechanisms involved in the most common complications of diet-induced human obesity, i.e., noninsulin-dependent diabetes mellitus, and myocardial dysfunction. In ZDF rats, hyperphagia leads to hyperinsulinemia, which upregulates transcription factors that stimulate lipogenesis. This causes ectopic deposition of triacylglycerol in nonadipocytes, providing fatty acid (FA) substrate for damaging pathways of nonoxidative metabolism, such as ceramide synthesis, In beta cells and myocardium, the resulting functional impairment and apoptosis cause diabetes and cardiomyopathy, Interventions that lower ectopic lipid accumulation or block nonoxidative metabolism of FA and ceramide formation completely prevent these complications, Given the evidence for a similar etiology for the complications of human obesity, it would be appropriate to develop strategies to avert the predicted epidemic of lipotoxic disorders.	Univ Texas, SW Med Ctr, Gifford Labs, Touchstone Ctr Diabet Res,Dept Internal Med, Dallas, TX 75216 USA; Vet Affairs N Texas Hlth Care Syst, Dallas, TX USA; Univ Geneva, Sch Med, Dept Morphol, Geneva, Switzerland	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA North Texas Health Care System; University of Geneva	Unger, RH (corresponding author), Univ Texas, SW Med Ctr, Gifford Labs, Touchstone Ctr Diabet Res,Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75216 USA.	runger@mednet.swmed.edu			NIDDK NIH HHS [DK02700-37] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK002700, R01DK002700] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AILHAUD G, 2000, INT J OBES RELAT M S, pS1; ALPERT MA, 1993, AM J MED SCI, V306, P117, DOI 10.1097/00000441-199308000-00011; Berkalp B, 1995, INT J CARDIOL, V52, P23, DOI 10.1016/0167-5273(95)02431-U; Bielawska AE, 1997, AM J PATHOL, V151, P1257; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Bjornstad PG, 1996, ACTA PAEDIATR, V85, P39, DOI 10.1111/j.1651-2227.1996.tb14264.x; BROWN MS, 1978, J BIOL CHEM, V253, P1121; BROWN MS, 1976, SCIENCE, V191, P150, DOI 10.1126/science.174194; Cavaghan MK, 1997, J CLIN INVEST, V100, P530, DOI 10.1172/JCI119562; CHIEN KR, 1983, AM J PATHOL, V112, P68; CHU KC, 1969, J PATHOL, V97, P99, DOI 10.1002/path.1710970113; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Cnop M, 2000, AM J PATHOL, V156, P237, DOI 10.1016/S0002-9440(10)64724-4; Coughlin SS, 1996, EPIDEMIOLOGY, V7, P629, DOI 10.1097/00001648-199611000-00011; deVries JE, 1997, J LIPID RES, V38, P1384; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; DUFLOU J, 1995, AM HEART J, V130, P306, DOI 10.1016/0002-8703(95)90445-X; Egbert AM, 1996, NUTR REV, V54, pS25; Ghafourifar P, 1999, J BIOL CHEM, V274, P31185, DOI 10.1074/jbc.274.44.31185; HERRERA MF, 1991, CAN J SURG, V34, P431; Higa M, 1999, P NATL ACAD SCI USA, V96, P11513, DOI 10.1073/pnas.96.20.11513; HIMMSHAGEN J, 1989, CAN J PHYSIOL PHARM, V67, P394, DOI 10.1139/y89-063; Iida M, 1996, BIOCHEM BIOPH RES CO, V224, P597, DOI 10.1006/bbrc.1996.1070; Itoh H, 1996, INTERNAL MED, V35, P876, DOI 10.2169/internalmedicine.35.876; Jaquet D, 1999, EUR J ENDOCRINOL, V140, P107, DOI 10.1530/eje.0.1400107; Kakuma T, 2000, P NATL ACAD SCI USA, V97, P8536, DOI 10.1073/pnas.97.15.8536; Katsuyama K, 1998, ENDOCRINOLOGY, V139, P4506, DOI 10.1210/en.139.11.4506; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KEYS A, 1988, ANN CLIN RES, V20, P97; KHALIL N, 1991, AM J RESP CELL MOL, V5, P155, DOI 10.1165/ajrcmb/5.2.155; Kim JB, 1998, P NATL ACAD SCI USA, V95, P4333, DOI 10.1073/pnas.95.8.4333; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Kim JK, 2000, J BIOL CHEM, V275, P8456, DOI 10.1074/jbc.275.12.8456; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KNOWLER WC, 1978, AM J EPIDEMIOL, V108, P497, DOI 10.1093/oxfordjournals.aje.a112648; Koyama K, 1997, AM J PHYSIOL-ENDOC M, V273, pE708, DOI 10.1152/ajpendo.1997.273.4.E708; LaRosa JC, 1999, JAMA-J AM MED ASSOC, V282, P2340, DOI 10.1001/jama.282.24.2340; Lee AY, 1997, BELL LABS TECH J, V2, P46, DOI 10.1002/bltj.2065; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; LEE Y, 1994, P NATL ACAD SCI USA, V91, P10878, DOI 10.1073/pnas.91.23.10878; LIN KT, 1995, J BIOL CHEM, V270, P16487, DOI 10.1074/jbc.270.28.16487; Marceau P, 1999, J CLIN ENDOCR METAB, V84, P1513, DOI 10.1210/jc.84.5.1513; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; MCGARRY JD, 1994, J CELL BIOCHEM, V55, P29, DOI 10.1002/jcb.240550005; MILBURN JL, 1995, J BIOL CHEM, V270, P1295, DOI 10.1074/jbc.270.3.1295; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; NAKAJIMA T, 1989, AM J CARDIOL, V64, P369, DOI 10.1016/0002-9149(89)90537-7; Neel JV, 1999, NUTR REV, V57, pS2, DOI 10.1111/j.1753-4887.1999.tb01782.x; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OHNEDA M, 1995, DIABETOLOGIA, V38, P173, DOI 10.1007/BF00400091; Pahan K, 1998, J BIOL CHEM, V273, P2591, DOI 10.1074/jbc.273.5.2591; Perez-Campo R, 1998, J COMP PHYSIOL B, V168, P149, DOI 10.1007/s003600050131; PETRIE JR, 1998, DIABET MED S5, V15, P529; Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18; POEHLMAN ET, 1995, INT J OBESITY, V19, pS93; Poynter ME, 1998, J BIOL CHEM, V273, P32833, DOI 10.1074/jbc.273.49.32833; Qian H, 1998, P SOC EXP BIOL MED, V219, P160, DOI 10.3181/00379727-219-44330; Randolph DL, 1998, PSYCHOLOGY, V35, P33; REAVEN GM, 1995, PHYSIOL REV, V75, P473, DOI 10.1152/physrev.1995.75.3.473; REAVEN GM, 1993, ANNU REV MED, V44, P121, DOI 10.1146/annurev.me.44.020193.001005; Roulot D, 1999, HEPATOLOGY, V29, P1730, DOI 10.1002/hep.510290622; Scarpace PJ, 1998, J ENDOCRINOL, V159, P349, DOI 10.1677/joe.0.1590349; Schoonjans K, 1996, BBA-LIPID LIPID MET, V1302, P93, DOI 10.1016/0005-2760(96)00066-5; SEGAL KR, 1985, J CLIN INVEST, V76, P1107, DOI 10.1172/JCI112065; Seip M, 1996, ACTA PAEDIATR, V85, P2, DOI 10.1111/j.1651-2227.1996.tb14262.x; Shimabukuro M, 1998, J BIOL CHEM, V273, P32487, DOI 10.1074/jbc.273.49.32487; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Shimabukuro M, 1997, J CLIN INVEST, V100, P290, DOI 10.1172/JCI119534; Shimabukuro M, 1998, J BIOL CHEM, V273, P3547, DOI 10.1074/jbc.273.6.3547; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Torra IP, 1999, CURR OPIN LIPIDOL, V10, P151, DOI 10.1097/00041433-199904000-00009; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; VidalPuig AJ, 1997, J CLIN INVEST, V99, P2416, DOI 10.1172/JCI119424; Vincent HK, 1999, INT J OBESITY, V23, P67, DOI 10.1038/sj.ijo.0800761; Walford R L, 1985, Clin Geriatr Med, V1, P29; Wang ZW, 2001, FASEB J, V15, P108, DOI 10.1096/fj.00-0310com; WEICHSELBAUM A, 1902, WIEN KLIN WCHNSCHR, V15, P969; Weichselbaum A., 1910, SITZUNGSBER KAIS MN, V119, P73; Weiss B, 1997, EUR J BIOCHEM, V249, P239, DOI 10.1111/j.1432-1033.1997.00239.x; Williams RS, 1999, NEW ENGL J MED, V341, P759, DOI 10.1056/NEJM199909023411012; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zhou YT, 2000, P NATL ACAD SCI USA, V97, P1784, DOI 10.1073/pnas.97.4.1784; Zhou YT, 1998, P NATL ACAD SCI USA, V95, P8898, DOI 10.1073/pnas.95.15.8898; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P6386, DOI 10.1073/pnas.94.12.6386	90	340	365	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2001	15	2					312	321		10.1096/fj.00-0590	http://dx.doi.org/10.1096/fj.00-0590			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156947				2022-12-28	WOS:000166872900013
J	Genini, D; Sheeter, D; Rought, S; Zaunders, JJ; Susin, SA; Kroemer, G; Richman, DD; Carson, DA; Corbeil, J; Leoni, LM				Genini, D; Sheeter, D; Rought, S; Zaunders, JJ; Susin, SA; Kroemer, G; Richman, DD; Carson, DA; Corbeil, J; Leoni, LM			HIV induces lymphocyte apoptosis by a p53-initiated, mitochondrial-mediated mechanism	FASEB JOURNAL			English	Article									Univ Calif San Diego, Dept Med 0663, La Jolla, CA 92093 USA; Univ Calif San Diego, Sam & Rose Stein Inst Res Aging, La Jolla, CA 92093 USA; San Diego Hlth Care Syst & Vet Med Res Fdn, La Jolla, CA 92161 USA; Inst Gustave Roussy, CNRS, UMR1599, F-94805 Villejuif, France	University of California System; University of California San Diego; University of California System; University of California San Diego; Veterans Medical Research Foundation; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Leoni, LM (corresponding author), Univ Calif San Diego, Dept Med 0663, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Zaunders, John/J-6553-2012; Corbeil, Jacques/AAW-9739-2020; Susin, Santos A/Q-6754-2017; KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020	Zaunders, John/0000-0002-5912-5989; Corbeil, Jacques/0000-0002-9973-2740; Susin, Santos A/0000-0002-3366-1628; KROEMER, Guido/0000-0002-9334-4405; 					0	95	98	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2001	15	1					5	6						2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11099484				2022-12-28	WOS:000166312400002
J	See, V; Boutiller, AL; Bito, H; Loeffler, JP				See, V; Boutiller, AL; Bito, H; Loeffler, JP			Calcium/calmodulin-dependent protein kinase type IV (CaMKIV) inhibits apoptosis induced by potassium deprivation in cerebellar granule neurons	FASEB JOURNAL			English	Article						CPP32/caspase-3; cAMP-responsive element binding protein (CREB); calcium channels; nuclear condensation; gene transfer	GENE-EXPRESSION; SIGNALING PATHWAY; TRANSGENIC MICE; CELL-SURVIVAL; MESSENGER-RNA; CALCIUM; CREB; ACTIVATION; TRANSCRIPTION; DEATH	The neuroprotective mechanisms of the Ca2+/calmodulin kinase (CaMK) signaling pathway were studied in primary cerebellar neurons in vitro. When switched from depolarizing culture conditions HX (extracellular Kf 30 mM) to LK (Kf 5 mM), these neurons rapidly undergo nuclear fragmentation, a typical feature of apoptosis. We present evidence that blockade of L-type Ca2+ channels (nifedipine sensitive) but not N/P/Q-type Ca2+ channels (omega-conotoxin MVIIC sensitive) triggered apoptosis and CPP32/ caspase-3-like activity. The entry into apoptosis was associated with a progressive caspase-3-dependent cleavage of CaMKIV, but not of CaMKII. CaMKIV function in neuronal apoptosis was further investigated by overexpression of CaMKIV mutants by gene transfer. A dominant-active CaMKIV mutant inhibited LK-induced apoptosis whereas a dominant-negative form induced apoptosis in HK, suggesting that CaMKIV exerts neuroprotective effects. The transcription factor CREB is a well-described nuclear target of CaMKIV in neurons. When switched to LK, the level of phosphorylation of CREB, after an initial drop, further declined progressively with kinetics comparable to those of CaMKIV degradation. This decrease was abolished by caspase-3 inhibitor. These data are compatible with a model where Ca2+ influx via L-type Ca2+ channels prevents caspase-dependent cleavage of CaMKIV and promotes neuronal survival by maintaining a constitutive level of CaMKIV/CREB-dependent gene expression.	Univ Strasbourg, UMR 7519, CNRS, IPCB, F-67084 Strasbourg, France; Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068315, Japan	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Kyoto University	Loeffler, JP (corresponding author), Univ Strasbourg, UMR 7519, CNRS, IPCB, 21 Rue Rene Descartes, F-67084 Strasbourg, France.	loeffler@neurochem.u-strasbg.fr	LOEFFLER, Jean-Philippe/AAS-4401-2020; Bito, Haruhiko/A-8635-2008	Bito, Haruhiko/0000-0001-6315-9594				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Anderson KA, 1997, MOL ENDOCRINOL, V11, P725, DOI 10.1210/me.11.6.725; Armstrong RC, 1997, J NEUROSCI, V17, P553; Barthel F, 1996, NEUROSCIENCE, V70, P1053, DOI 10.1016/0306-4522(95)00411-4; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Bito H, 1997, CURR OPIN NEUROBIOL, V7, P419, DOI 10.1016/S0959-4388(97)80072-4; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Boutillier AL, 1999, EUR J NEUROSCI, V11, P441, DOI 10.1046/j.1460-9568.1999.00451.x; Brugg B, 1996, J NEUROCHEM, V66, P733; Campard PK, 1997, DNA CELL BIOL, V16, P323, DOI 10.1089/dna.1997.16.323; CHURN SB, 1993, STROKE, V24, P271, DOI 10.1161/01.STR.24.2.271; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; Eldadah BA, 1997, J NEUROSCI, V17, P6105; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; GALLO V, 1987, J NEUROSCI, V7, P2203; HACK N, 1993, NEUROSCIENCE, V57, P9, DOI 10.1016/0306-4522(93)90108-R; HAJIMOHAMMADREZA I, 1995, J NEUROSCI, V15, P4093; Hardingham GE, 1999, NEURON, V22, P789, DOI 10.1016/S0896-6273(00)80737-0; Heist EK, 1998, CELL CALCIUM, V23, P103; Kohara K, 1998, BRAIN RES, V809, P231, DOI 10.1016/S0006-8993(98)00894-4; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; Marks N, 1999, NEUROCHEM INT, V35, P195, DOI 10.1016/S0197-0186(99)00061-3; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; McGinnis KM, 1998, J BIOL CHEM, V273, P19993, DOI 10.1074/jbc.273.32.19993; Mermelstein PG, 2000, J NEUROSCI, V20, P266, DOI 10.1523/JNEUROSCI.20-01-00266.2000; Moran J, 1999, J NEUROCHEM, V73, P568, DOI 10.1046/j.1471-4159.1999.0730568.x; Murray KD, 1998, EUR J NEUROSCI, V10, P377, DOI 10.1046/j.1460-9568.1998.00019.x; Nardi N, 1997, J NEUROCHEM, V68, P750; Ono T, 1997, NEUROSCI LETT, V228, P123, DOI 10.1016/S0304-3940(97)00383-2; PORTERA CC, 1995, J NEUROSCI, P3775; Przywara DA, 1998, J NEUROCHEM, V71, P1889; RANDALL A, 1995, J NEUROSCI, V15, P2995; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Schousboe A., 1989, DISSECTION TISSUE CU, P203; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; Schulz JB, 1996, J NEUROSCI, V16, P4696; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; Shieh PB, 1998, NEURON, V20, P727, DOI 10.1016/S0896-6273(00)81011-9; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Tanabe H, 1997, EUR J NEUROSCI, V9, P848, DOI 10.1111/j.1460-9568.1997.tb01434.x; Tanabe H, 1998, EUR J NEUROSCI, V10, P1403, DOI 10.1046/j.1460-9568.1998.00148.x; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; VILLARROEL A, 1997, TRENDS GENET, V13, P164; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Wright SC, 1997, FASEB J, V11, P843, DOI 10.1096/fasebj.11.11.9285482; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147	50	123	129	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2001	15	1					134	144		10.1096/fj.00-0106com	http://dx.doi.org/10.1096/fj.00-0106com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149901				2022-12-28	WOS:000166312400022
J	Tomatis, L; Melnick, RL; Haseman, J; Barrett, JC; Huff, J				Tomatis, L; Melnick, RL; Haseman, J; Barrett, JC; Huff, J			Alleged 'misconceptions' distort perceptions of environmental cancer risks	FASEB JOURNAL			English	Article						environmental carcinogens; assessment of risks; cancer prevention; carcinogenesis bioassay	CARCINOGENIC POTENCY; AVOIDABLE RISKS; LUNG-CANCER; PREVENTION; CHEMICALS; PESTICIDES; POLLUTION; EXPOSURE; TESTS	In a series of papers, Ames and col leagues allege that the scientific and public health communities have perpetuated a series of 'misconceptions' that resulted in inaccurate identification of chemicals that pose potential human cancer risks, and misguided cancer prevention strategies and regulatory policies. They conclude that exposures to industrial and synthetic chemicals represent negligible cancer risks and that animal studies have little or no scientific value for assessing human risks, Their conclusions are based on flawed and untested assumptions. For instance, they claim that synthetic residues on food can be ignored because 99.99% of pesticides humans eat are natural, chemicals in plants are pesticides, and their potential to cause cancer equals that of synthetic pesticides. Similarly, Ames does not offer any convincing scientific evidence to justify discrediting bioassays for identifying human carcinogens. Ironically, their arguments center on a ranking procedure that relies on the same experimental data and extrapolation methods they criticize as being unreliable for evaluating cancer risks. We address their inconsistencies and flaws, and present scientific facts and our perspectives surrounding Ames' nine alleged misconceptions. Our conclusions agree with the International Agency for Research on Cancer, the National Toxicology Program, and other respected scientific organizations: in the absence of human data, animal studies are the most definitive for assessing human cancer risks, Animal data should not be ignored, and precautions should be taken to lessen human exposures, Dismissing animal carcinogenicity findings would lead to human cancer cases as the only means of demonstrating carcinogenicity of environmental agents. This is unacceptable public health policy.	NIEHS, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Huff, J (corresponding author), NIEHS, 111 Alexander Dr, Res Triangle Pk, NC 27709 USA.	huffl@niehs.nih.gov			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES045004, Z01ES045004] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; *AM CANC SOC, 2000, ACS CANC FACTS FIG; AMES BN, 1995, P NATL ACAD SCI USA, V92, P5258, DOI 10.1073/pnas.92.12.5258; AMES BN, 1990, P NATL ACAD SCI USA, V87, P7772, DOI 10.1073/pnas.87.19.7772; AMES BN, 1987, SCIENCE, V236, P271, DOI 10.1126/science.3563506; Ames BN, 2000, MUTAT RES-FUND MOL M, V447, P3, DOI 10.1016/S0027-5107(99)00194-3; AMES BN, 1990, MED ONCOL TUMOR PHAR, V7, P69; Ames BN, 1997, FASEB J, V11, P1041, DOI 10.1096/fasebj.11.13.9367339; AMES BN, 1990, P NATL ACAD SCI USA, V87, P7777, DOI 10.1073/pnas.87.19.7777; Ames BN, 1997, ENVIRON HEALTH PERSP, V105, P865, DOI 10.2307/3433296; AMES BN, 1976, SCREENING TESTS CHEM, V12, P493; Bailar JC, 1997, NEW ENGL J MED, V336, P1569, DOI 10.1056/NEJM199705293362206; Bartsch H, 1996, EUR J CANCER PREV, V5, P11, DOI 10.1097/00008469-199609001-00003; BLUM A, 1977, SCIENCE, V195, P17, DOI 10.1126/science.831254; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; Doll R, 1967, PREVENTION CANC POIN; *EPA, 1997, CHEM PROG, V18, P1; FUNG VA, 1993, FUND APPL TOXICOL, V20, P413, DOI 10.1006/faat.1993.1053; FUNG VA, 1995, ENVIRON HEALTH PERSP, V103, P680, DOI 10.2307/3432858; Gold L.S., 1997, HDB CARCINOGENIC POT; GOLD LS, 1992, SCIENCE, V258, P261, DOI 10.1126/science.1411524; GOLD LS, 1984, ENVIRON HEALTH PERSP, V58, P9, DOI 10.2307/3429857; Gold LS, 1998, DRUG METAB REV, V30, P359, DOI 10.3109/03602539808996318; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Herbst A. L., 1981, DEV EFFECTS DIETHYLS; HIGGINSON J, 1979, JNCI-J NATL CANCER I, V63, P1291; Huff J, 1999, CARCINOGENICITY, P21; HUFF J, 1993, ENVIRON HEALTH PERSP, V100, P201, DOI 10.2307/3431526; HUFF JE, 1994, CARCINOGENESIS, P35; *IARC, 1987, MON EV CARC RISK H S, V7; IARC, 1993, IARC MON EV CARC RIS, V56; *IARC, 1995, MON EV CARC RISK HUM, V63; *IARC PREAMBL, 2000, IARC MON EV CARC RIS, V77; Jasny BR, 1998, SCIENCE, V280, P1507; McCann J., 1977, ORIGINS HUMAN CANCER, P1431; McMichael AJ, 1992, IARC SCI PUBL, V116; National Toxicology Program, 2000, 9 NAT TOX PROGR; NRC National Research Council, 1993, PEST DIETS INF CHILD; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; PETO R, 1984, ENVIRON HEALTH PERSP, V58, P1, DOI 10.2307/3429856; SCHMAHL D, 1989, KLIN WOCHENSCHR, V67, P1169, DOI 10.1007/BF01716203; SUGIMURA T, 1992, SCIENCE, V258, P603, DOI 10.1126/science.1411570; TOMATIS L, 1993, NEW FRONTIERS IN CANCER CAUSATION, P371; Tomatis L, 1997, CARCINOGENESIS, V18, P97, DOI 10.1093/carcin/18.1.97; TOMATIS L, 1979, ANNU REV PHARMACOL, V19, P511, DOI 10.1146/annurev.pa.19.040179.002455; TOMATIS L, 1990, IARC SCI PUB, V100; Wingo PA, 1999, J NATL CANCER I, V91, P675, DOI 10.1093/jnci/91.8.675; WYNDER EL, 1977, JNCI-J NATL CANCER I, V58, P825, DOI 10.1093/jnci/58.4.825; 1990, WASHINGTON POST 0831, pA3; 1991, FOOD CHEM NEWS  0805, P6; 1993, FORBES          1025, P104; 1991, FOOD CHEM NEWS  0826, P23; 1990, BUSINESS WEEK   1015, P58	53	36	36	1	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2001	15	1					195	203		10.1096/fj.99-1056com	http://dx.doi.org/10.1096/fj.99-1056com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149907				2022-12-28	WOS:000166312400028
J	Gallucci, RM; Simeonova, PP; Matheson, JM; Kommineni, C; Guriel, JL; Sugawara, T; Luster, MI				Gallucci, RM; Simeonova, PP; Matheson, JM; Kommineni, C; Guriel, JL; Sugawara, T; Luster, MI			Impaired cutaneous wound healing in interleukin-6-deficient and immunosuppressed mice	FASEB JOURNAL			English	Article						inflammation; cytokines; gene therapy	TRANSCRIPTION FACTORS C/EBP; GROWTH-FACTOR EXPRESSION; IN-VIVO INTRODUCTION; CULTURED FIBROBLASTS; GENE-EXPRESSION; KERATINOCYTE DIFFERENTIATION; INFLAMMATORY CYTOKINES; STAT3 ACTIVATION; BINDING-PROTEINS; IL-6 GENE	It has been postulated that an inflammatory response after cutaneous wounding is a prerequisite for healing, and inflammatory cytokines, such as interleukin-6 (IL-6), might be intimately involved in this process. IL-6-deficient transgenic mice (IL-6 KO) displayed significantly delayed cutaneous wound healing compared with wild-type control animals, requiring up to threefold longer to heal. This was characterized by minimal epithelial bridge formation, decreased inflammation, and granulation tissue formation. Using electrophoretic mobility shift assays of wound tissue from IL-6 KO mice, decreased AP-1 transcription factor activation was shown compared with wild-type mice 16 h after wounding. lit situ hybridization of wound tissue from wild-type mice revealed IL-6 mRNA expression primarily in the epidermis at the leading edge of the wound. Delayed wound healing in IL-6 KO mice was reversed with a single dose of recombinant murine IL-6 or intradermal injection of an expression plasmid containing the full-length murine IL-6 cDNA. Treatment with rmIL-6 also reconstituted wound healing in dexamethasone-treated immunosuppressed mice. The results of this study may indicate a potential use for IL-6 therapeutically where cutaneous wound healing is impaired.	NIOSH, Toxicol & Mol Biol Branch, Hlth Effects Lab Div, Morgantown, WV 26505 USA; Daiichi Pharmaceut Co Ltd, Drug Safety Res Lab, Tokyo, Japan	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); Daiichi Sankyo Company Limited	Luster, MI (corresponding author), NIOSH, Toxicol & Mol Biol Branch, Hlth Effects Lab Div, MS 3014,1095 Willowdale Rd, Morgantown, WV 26505 USA.	myl6@cdc.gov						Adcock I M, 1997, Monaldi Arch Chest Dis, V52, P178; Aragane Y, 1996, J INVEST DERMATOL, V106, P1192, DOI 10.1111/1523-1747.ep12347985; BAXTER JD, 1972, AM J MED, V53, P573, DOI 10.1016/0002-9343(72)90154-4; Bello YM, 2000, JAMA-J AM MED ASSOC, V283, P716, DOI 10.1001/jama.283.6.716; BLUETHMANN H, 1994, J LEUKOCYTE BIOL, V56, P565, DOI 10.1002/jlb.56.5.565; BRAUCHLE M, 1994, ONCOGENE, V9, P3199; BRAUCHLE M, 1995, J INVEST DERMATOL, V105, P579, DOI 10.1111/1523-1747.ep12323521; Bruccoleri A, 1997, HEPATOLOGY, V25, P133, DOI 10.1002/hep.510250125; CASATORRES J, 1994, J BIOL CHEM, V269, P20489; CHEDID M, 1994, J BIOL CHEM, V269, P10753; CHENKIANG S, 1993, CURR OPIN IMMUNOL, V5, P124, DOI 10.1016/0952-7915(93)90091-6; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; CRESSMAN DE, 1995, HEPATOLOGY, V21, P1443, DOI 10.1016/0270-9139(95)90068-3; FAHEY TJ, 1991, J SURG RES, V50, P308, DOI 10.1016/0022-4804(91)90196-S; FORD HR, 1989, ARCH SURG-CHICAGO, V124, P1422; FUGGER L, 1989, J IMMUNOGENET, V16, P461; GIULIANI AL, 1993, CELL IMMUNOL, V149, P208, DOI 10.1006/cimm.1993.1148; GOODMAN L, 1994, J BIOL CHEM, V269, P19250; GROSSMAN RM, 1989, P NATL ACAD SCI USA, V86, P6367, DOI 10.1073/pnas.86.16.6367; Hauser PJ, 1998, CELL GROWTH DIFFER, V9, P847; Howie S E, 1992, Exp Dermatol, V1, P230, DOI 10.1111/j.1600-0625.1992.tb00081.x; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Hubner G, 1996, EXP CELL RES, V228, P106, DOI 10.1006/excr.1996.0305; KOCH AE, 1993, PATHOBIOLOGY, V61, P239, DOI 10.1159/000163802; Kondo T, 1996, INT J LEGAL MED, V108, P231, DOI 10.1007/BF01369816; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; LEIBOVICH SJ, 1975, AM J PATHOL, V78, P71; MATEO RB, 1994, AM J PHYSIOL, V266, pR1840, DOI 10.1152/ajpregu.1994.266.6.R1840; Maytin EV, 1999, DEV BIOL, V216, P164, DOI 10.1006/dbio.1999.9460; Maytin EV, 1998, J INVEST DERMATOL, V110, P238, DOI 10.1046/j.1523-1747.1998.00123.x; MORAIN WD, 1990, CLIN PLAST SURG, V17, P493; NAVARRO JM, 1995, J BIOL CHEM, V270, P21362, DOI 10.1074/jbc.270.36.21362; Oh HS, 1998, J INVEST DERMATOL, V110, P939, DOI 10.1046/j.1523-1747.1998.00199.x; Oyama N, 1998, J DERMATOL SCI, V16, P120, DOI 10.1016/S0923-1811(97)00040-6; Paquet P, 1996, INT ARCH ALLERGY IMM, V109, P308, DOI 10.1159/000237257; Rincon M, 1996, MOL CELL BIOL, V16, P1074; Sato M, 1999, ARCH DERMATOL RES, V291, P400, DOI 10.1007/s004030050429; Sawamura D, 1998, J IMMUNOL, V161, P5633; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEHGAL PB, 1990, J INVEST DERMATOL, V94, pS2, DOI 10.1111/1523-1747.ep12874963; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Solis-Herruzo JA, 1999, J BIOL CHEM, V274, P30919, DOI 10.1074/jbc.274.43.30919; Takeda K, 1998, J IMMUNOL, V161, P4652; TURKSEN K, 1992, P NATL ACAD SCI USA, V89, P5068, DOI 10.1073/pnas.89.11.5068; Vogel JC, 1999, P ASSOC AM PHYSICIAN, V111, P190, DOI 10.1046/j.1525-1381.1999.99223.x; Zhu SY, 1999, MOL CELL BIOL, V19, P7181	46	315	333	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2000	14	15					2525	2531		10.1096/fj.00-0073com	http://dx.doi.org/10.1096/fj.00-0073com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099471				2022-12-28	WOS:000165723400023
J	Galun, E; Zeira, E; Pappo, O; Peters, M; Rose-John, S				Galun, E; Zeira, E; Pappo, O; Peters, M; Rose-John, S			Liver regeneration induced by a designer human IL-6/sIL-6R fusion protein reverses severe hepatocellular injury	FASEB JOURNAL			English	Article						interleukin 6; chimeric protein; hyper-IL-6; cytokines; hepatotoxicity; liver failure	TUMOR-NECROSIS-FACTOR; FULMINANT HEPATIC-FAILURE; IN-VIVO; IL-6 RECEPTOR; TRANSGENIC MICE; D-GALACTOSAMINE; INTERLEUKIN-6 RECEPTOR; GENE-TRANSCRIPTION; INDUCED APOPTOSIS; CELLS	The cytokine IL-6 plays a significant role in liver regeneration in conjunction with additional growth factors (HGF, TNF-alpha, and TGF-alpha). Many IL-6 effects depend on a naturally occurring soluble IL-6 receptor (sIL-6R). Here, the chimeric protein hyper-IL-6, constructed from the human IL-6 protein fused to a truncated form of its receptor, was found to have superagonistic IL-6 properties, and as such, enhanced liver cell regeneration. Hyper-IL-6 reversed the state of hepatotoxicity and enhanced the survival rates of rats suffering from fulminant hepatic failure after D-galactosamine administration. The hyper-IL-6 protein has a significant potential for use in the treatment of set ere human liver diseases.	Hadassah Univ Hosp, Goldyne Savad Inst Gene therapy, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Liver Unit, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Dept Pathol, IL-91120 Jerusalem, Israel; Univ Mainz, Med Klin 1, Abt Pathophysiol, D-6500 Mainz, Germany	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Johannes Gutenberg University of Mainz	Galun, E (corresponding author), Hadassah Univ Hosp, Goldyne Savad Inst Gene therapy, IL-91120 Jerusalem, Israel.		Rose-John, Stefan/A-7998-2010; Galun, Eithan/AAD-9117-2022	Rose-John, Stefan/0000-0002-7519-3279; Galun, Eithan/0000-0002-6243-6702				ATILLASOY E, 1995, ANNU REV MED, V46, P181; Bruck R, 1998, HEPATOLOGY, V27, P1013, DOI 10.1002/hep.510270417; BulfonePaus S, 1997, NAT MED, V3, P1124, DOI 10.1038/nm1097-1124; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; Fausto Nelson, 1994, P1059; Fischer M, 1997, NAT BIOTECHNOL, V15, P142, DOI 10.1038/nbt0297-142; Hellerbrand C, 1998, HEPATOLOGY, V27, P1285, DOI 10.1002/hep.510270514; Itokazu Y, 1999, BIOL PHARM BULL, V22, P1127; Katz A, 1998, CYTOKINES CELL MOL T, V4, P221; Leist M, 1997, GASTROENTEROLOGY, V112, P923, DOI 10.1053/gast.1997.v112.pm9041255; LUST J, 1995, CURR TOP MICROBIOL I, V194, P194; Maezono K, 1996, HEPATOLOGY, V24, P1211; Maione D, 1998, EMBO J, V17, P5588, DOI 10.1093/emboj/17.19.5588; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MULLBERG J, 1994, J IMMUNOL, V152, P4958; MURAKAMI M, 1993, SCIENCE, V260, P1080; Okano J, 1997, HEPATOLOGY, V26, P1241; Oritani K, 1999, BLOOD, V93, P1346, DOI 10.1182/blood.V93.4.1346.404k15_1346_1354; Overturf K, 1996, NAT GENET, V12, P266, DOI 10.1038/ng0396-266; Peters M, 1996, J EXP MED, V183, P1399, DOI 10.1084/jem.183.4.1399; Peters M, 1998, BLOOD, V92, P3495, DOI 10.1182/blood.V92.10.3495.422k47_3495_3504; Peters M, 1998, J IMMUNOL, V161, P3575; Rakemann T, 1999, J BIOL CHEM, V274, P1257, DOI 10.1074/jbc.274.3.1257; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; Schirmacher P, 1998, AM J PATHOL, V153, P639, DOI 10.1016/S0002-9440(10)65605-2; Shirin H, 1998, J HEPATOL, V29, P60, DOI 10.1016/S0168-8278(98)80179-7; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; Stachlewitz RF, 1999, HEPATOLOGY, V29, P737, DOI 10.1002/hep.510290335; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; Taub R, 1998, HEPATOLOGY, V27, P1445, DOI 10.1002/hep.510270538; Trautwein C, 1996, GASTROENTEROLOGY, V110, P1854, DOI 10.1053/gast.1996.v110.pm8964411; Webber EM, 1998, HEPATOLOGY, V28, P1226, DOI 10.1002/hep.510280509; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441	35	102	113	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2000	14	13					1979	1987		10.1096/fj.99-0913com	http://dx.doi.org/10.1096/fj.99-0913com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023982				2022-12-28	WOS:000089634400017
J	Esfandyari, T; Macnaughton, WK; Quirion, R; St Pierre, S; Junien, JL; Sharkey, KA				Esfandyari, T; Macnaughton, WK; Quirion, R; St Pierre, S; Junien, JL; Sharkey, KA			A novel receptor for calcitonin gene-related peptide (CGRP) mediates secretion in the rat colon: implications for secretory function in colitis	FASEB JOURNAL			English	Article						TNBS; ion transport; CGRP receptors; adrenomedullin; amylin; mast cells; secretion	ALPHA-CALCITONIN; LIGAND SPECIFICITY; ION-TRANSPORT; ADRENOMEDULLIN; EXPRESSION; BRAIN; AMYLIN; IDENTIFICATION; INFLAMMATION; JUNCTIONS	The receptor responsible for CGRP-induced ion transport and permeability was examined in tissues from animals treated 7 days previously with trinitrobenzenesulfonic acid to induce colitis or in controls. CGRP caused a concentration-dependent increase in short circuit current (I-sc, EC50 21 nM), which was abolished in chloride-free buffer but was not blocked by CGRP(8-37) or tetrodotoxin (TTX). Amylin and adrenomedullin caused only a modest increase in I-sc. The responses to the linear CGRP(2) receptor agonists [Cys(Et)(2,7)] hCGRP alpha and [Cys(Acm)(2,7)] hCGRP alpha were considerably smaller than the response to CGRP. These responses were abolished in chloride-free buffer and were TTX sensitive. Atropine, doxantrazole, and indomethacin did not block the effects of CGRP or the CGRP, agonists. The response to [Cys(Et)(2,7)] hCGRP alpha was not affected by prior desensitization of the CGRP receptor and vice versa, Inflamed rats had a similar secretory response to CGRP (I-sc, EC50 15 nM) and [Cys(Et)(2,7)] hCGRP alpha as control tissues, while being hyporesponsive to carbachol, CGRP application increased electrical conductance of inflamed preparations. Taken together, these data suggest that CGRP may play an important role in the maintenance of host defense in colitis through an apparently novel CGRP receptor located on the colonic enterocyte.	Univ Calgary, Hlth Sci Ctr, Dept Physiol & Biophys, Neurosci Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Physiol & Biophys, Gastrointestinal Res Grp, Calgary, AB T2N 4N1, Canada; McGill Univ, Dept Psychiat, Douglas Hosp, Res Ctr, Verdun, PQ H4H 1R3, Canada; Univ Quebec, Dept Chem, Montreal, PQ H3C 3P8, Canada; Ferring Res Inst, Paris, France	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary; McGill University; University of Quebec; University of Quebec Montreal	Sharkey, KA (corresponding author), Univ Calgary, Hlth Sci Ctr, Dept Physiol & Biophys, Neurosci Res Grp, Room 2113,3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	ksharkey@ucalgary.ca		Sharkey, Keith/0000-0001-9560-1711				Aiyar N, 1996, J BIOL CHEM, V271, P11325, DOI 10.1074/jbc.271.19.11325; AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; AMARA SG, 1985, SCIENCE, V229, P1094, DOI 10.1126/science.2994212; Asfaha S, 1999, AM J PHYSIOL-GASTR L, V276, pG703, DOI 10.1152/ajpgi.1999.276.3.G703; BELL CJ, 1995, AM J PHYSIOL-GASTR L, V268, pG622, DOI 10.1152/ajpgi.1995.268.4.G622; Belloni AS, 1999, ENDOCR RES, V25, P29, DOI 10.1080/07435809909066127; Berin MC, 1999, AM J TROP MED HYG, V60, P16, DOI 10.4269/ajtmh.1999.60.16; Buhlmann N, 1999, ENDOCRINOLOGY, V140, P2883, DOI 10.1210/en.140.6.2883; Bulloch K, 1998, ANN NY ACAD SCI, V840, P551, DOI 10.1111/j.1749-6632.1998.tb09594.x; CHATTERJEE TK, 1995, CAN J PHYSIOL PHARM, V73, P968, DOI 10.1139/y95-134; COOKE HJ, 1992, ANN NY ACAD SCI, V657, P313, DOI 10.1111/j.1749-6632.1992.tb22778.x; COX HM, 1989, BRIT J PHARMACOL, V97, P996, DOI 10.1111/j.1476-5381.1989.tb12553.x; COX HM, 1995, CAN J PHYSIOL PHARM, V73, P974, DOI 10.1139/y95-135; DENNIS T, 1991, BRAIN RES, V539, P59, DOI 10.1016/0006-8993(91)90686-P; DENNIS T, 1989, J PHARMACOL EXP THER, V251, P718; Dumont Y, 1997, CAN J PHYSIOL PHARM, V75, P671, DOI 10.1139/cjpp-75-6-671; ENTZEROTH M, 1995, LIFE SCI, V56, P19; EVANGELISTA S, 1992, LIFE SCI, V50, pPL13, DOI 10.1016/0024-3205(92)90441-Q; Fries W, 1999, LAB INVEST, V79, P49; GIULIANI S, 1992, BRIT J PHARMACOL, V107, P510, DOI 10.1111/j.1476-5381.1992.tb12775.x; Hall JM, 1998, TRENDS PHARMACOL SCI, V19, P303, DOI 10.1016/S0165-6147(98)01234-6; Hallgren A, 1998, AM J PHYSIOL-GASTR L, V275, pG95, DOI 10.1152/ajpgi.1998.275.1.G95; HOKFELT T, 1992, ANN NY ACAD SCI, V657, P119; HOLZER P, 1995, ADV EXP MED BIOL, V371, P891; Holzer P, 1998, DIGESTION, V59, P269, DOI 10.1159/000007504; JOLICOEUR FB, 1992, ANN NY ACAD SCI, V657, P155, DOI 10.1111/j.1749-6632.1992.tb22764.x; KACHUR JF, 1995, INFLAMMATION, V19, P245, DOI 10.1007/BF01534465; Kapas S, 1995, BIOCHEM BIOPH RES CO, V217, P832, DOI 10.1006/bbrc.1995.2847; KRAWISZ JE, 1984, GASTROENTEROLOGY, V87, P1344; LIBERT F, 1990, NUCLEIC ACIDS RES, V18, P1917, DOI 10.1093/nar/18.7.1917; LONGMORE J, 1994, EUR J PHARMACOL, V265, P53, DOI 10.1016/0014-2999(94)90222-4; MacNaughton WK, 1998, AM J PHYSIOL-GASTR L, V275, pG1353, DOI 10.1152/ajpgi.1998.275.6.G1353; Madara JL, 1998, ANNU REV PHYSIOL, V60, P143, DOI 10.1146/annurev.physiol.60.1.143; MAGGI CA, 1991, EUR J PHARMACOL, V192, P85, DOI 10.1016/0014-2999(91)90072-X; McCafferty DM, 1997, AM J PHYSIOL-GASTR L, V272, pG272, DOI 10.1152/ajpgi.1997.272.2.G272; MCCULLOCH CR, 1989, REGUL PEPTIDES, V24, P87, DOI 10.1016/0167-0115(89)90214-0; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Miampamba M, 1999, NEUROGASTROENT MOTIL, V11, P193; MORRIS GP, 1989, GASTROENTEROLOGY, V96, P795, DOI 10.1016/0016-5085(89)90904-9; MUFF R, 1995, EUR J ENDOCRINOL, V133, P17, DOI 10.1530/eje.0.1330017; NJUKI F, 1993, CLIN SCI, V85, P385, DOI 10.1042/cs0850385; NUKI C, 1993, BIOCHEM BIOPH RES CO, V196, P245, DOI 10.1006/bbrc.1993.2241; PHILLIPS TE, 1987, CELL TISSUE RES, V247, P547, DOI 10.1007/BF00215748; Poyner D, 1995, TRENDS PHARMACOL SCI, V16, P424, DOI 10.1016/S0165-6147(00)89093-8; QUIRION R, 1992, ANN NY ACAD SCI, V657, P88, DOI 10.1111/j.1749-6632.1992.tb22759.x; ROSENFELD MG, 1992, ANN NY ACAD SCI, V657, P1, DOI 10.1111/j.1749-6632.1992.tb22754.x; Sarkar A, 1997, J NEUROCHEM, V69, P455; Sato A, 1997, BIOCHEM BIOPH RES CO, V230, P311, DOI 10.1006/bbrc.1996.5952; Saunders PR, 1997, AM J PHYSIOL-GASTR L, V273, pG486, DOI 10.1152/ajpgi.1997.273.2.G486; SEXTON PM, 1988, NEUROCHEM INT, V12, P323, DOI 10.1016/0197-0186(88)90171-4; STANGL D, 1993, ENDOCRINOLOGY, V132, P744, DOI 10.1210/en.132.2.744; STERNINI C, 1992, ANN NY ACAD SCI, V657, P170, DOI 10.1111/j.1749-6632.1992.tb22766.x; Tu Y, 1998, EUR J GASTROEN HEPAT, V10, P317, DOI 10.1097/00042737-199804000-00008; VanRossum D, 1997, NEUROSCI BIOBEHAV R, V21, P649, DOI 10.1016/S0149-7634(96)00023-1; Wimalawansa SJ, 1996, ENDOCR REV, V17, P533, DOI 10.1210/er.17.5.533; Wimalawansa SJ, 1997, CRIT REV NEUROBIOL, V11, P167, DOI 10.1615/CritRevNeurobiol.v11.i2-3.40	56	21	21	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2000	14	10					1439	1446		10.1096/fj.14.10.1439	http://dx.doi.org/10.1096/fj.14.10.1439			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877837				2022-12-28	WOS:000087932200019
J	Walsh, SW; Vaughan, JE; Wang, Y; Roberts, LJ				Walsh, SW; Vaughan, JE; Wang, Y; Roberts, LJ			Placental isoprostane is significantly increased in preeclampsia	FASEB JOURNAL			English	Article						placenta; malondialdehyde; oxidative stress; isoprostanes	LIPID-PEROXIDATION; SUPEROXIDE-DISMUTASE; THROMBOXANE; PLASMA; VASOCONSTRICTION; PROSTACYCLIN; ENDOTHELIN; PREGNANCY; F2-ALPHA; PRODUCTS	We determined placental tissue levels, production rates, and secretion rates of isoprostanes for placentas obtained from women with normal pregnancies and women with preeclampsia, a hypertensive disorder of pregnancy. Isoprostanes are markers of oxidative stress that exert biological actions such as vasoconstriction. Placental tissue was rinsed and immediately frozen in liquid nitrogen to determine tissue levels of total and free isoprostane. Placental tissue pieces were also incubated in serum-free DMEM for 48 h at 37 degrees C in 95% air/5% CO2 to determine production rates. Isolated placental cotyledons were perfused for the determination of secretion rates. All samples were analyzed by EIA for isoprostane using an antibody specific for 8-Iso-PGF(2) (15-F-2t-IsoP). In addition, medium samples were analyzed for malondialdehyde (MDA), a breakdown product of lipid peroxidation. We found that tissue levels of free isoprostane and total isoprostane (free plus esterified forms) were significantly higher for preeclamptic placentas than for normal placentas. Concentrations of isoprostane and MDA in the medium increased progressively during 48 h of incubation of placental explants, At 48 h of incubation, the mean concentrations of both isoprostane and MDA were significantly higher for the placentas from preeclamptic women than for the placentas from normal pregnant women. Concentrations of MDA were highly correlated with those of isoprostane. Induction of oxidative stress with xanthine plus xanthine oxidase increased placental production of isoprostane by normal tissue to a level similar to that of preeclamptic tissue. Placental secretion of isoprostane was eightfold greater toward the maternal side of the placenta than toward the fetal side, and was increased sixfold on the maternal side and twofold on the fetal side by inducing oxidative stress with t-butyl hydroperoxide. This study presents new information that isoprostanes are formed and secreted by the human placenta and provides convincing evidence that oxidative stress and lipid peroxidation are abnormally increased in placentas of preeclamptic women.	Virginia Commonwealth Univ, Dept Obstet & Gynecol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Physiol, Richmond, VA 23298 USA; Vanderbilt Univ, Dept Pharmacol, Sch Med, Nashville, TN 37232 USA	Virginia Commonwealth University; Virginia Commonwealth University; Vanderbilt University	Walsh, SW (corresponding author), Virginia Commonwealth Univ, Dept Obstet & Gynecol, Sanger Hall,Rm 11-039,1101 E Marshall St, Richmond, VA 23298 USA.				NICHD NIH HHS [HD20973] Funding Source: Medline; NIGMS NIH HHS [GM42056, GM15431] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R55HD020973, R01HD020973] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042056, P01GM015431, R37GM042056, P50GM015431] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bachi A, 1996, FREE RADICAL BIO MED, V20, P619, DOI 10.1016/0891-5849(95)02087-X; Barden A, 1996, CLIN SCI, V91, P711, DOI 10.1042/cs0910711; Cueto SM, 1997, J SOC GYNECOL INVEST, V4, P64, DOI 10.1016/S1071-5576(97)00010-5; FUKUNAGA M, 1995, J CARDIOVASC PHARM, V26, pS51; FUKUNAGA M, 1993, AM J PHYSIOL, V264, pC1619, DOI 10.1152/ajpcell.1993.264.6.C1619; Hoffman SW, 1997, STROKE, V28, P844, DOI 10.1161/01.STR.28.4.844; JENDRYCZKO A, 1990, ZBL GYNAKOL, V112, P889; Jentzsch AM, 1996, FREE RADICAL BIO MED, V20, P251, DOI 10.1016/0891-5849(95)02043-8; KANG KH, 1993, J APPL PHYSIOL, V74, P460, DOI 10.1152/jappl.1993.74.1.460; Leitch I, 1999, J SOC GYNECOL INVEST, V6, p195A; Lynch SM, 1997, ARTERIOSCL THROM VAS, V17, P2975, DOI 10.1161/01.ATV.17.11.2975; Mobert J, 1997, J CARDIOVASC PHARM, V29, P789, DOI 10.1097/00005344-199706000-00012; Moore K, 1998, FREE RADICAL RES, V28, P659, DOI 10.3109/10715769809065821; MORROW JD, 1995, NEW ENGL J MED, V332, P1198, DOI 10.1056/NEJM199505043321804; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; Morrow JD, 1996, BIOCHEM PHARMACOL, V51, P1, DOI 10.1016/0006-2952(95)02072-1; Morrow JD, 1997, PROG LIPID RES, V36, P1, DOI 10.1016/S0163-7827(97)00001-5; NOVA A, 1991, AM J OBSTET GYNECOL, V165, P724, DOI 10.1016/0002-9378(91)90317-K; Roberts LJ, 1997, BBA-LIPID LIPID MET, V1345, P121, DOI 10.1016/S0005-2760(96)00162-2; Taber DF, 1997, PROSTAGLANDINS, V53, P63, DOI 10.1016/S0090-6980(97)00005-1; TAYLOR RN, 1990, J CLIN ENDOCR METAB, V71, P1675, DOI 10.1210/jcem-71-6-1675; Walsh SW, 1996, HYPERTENS PREGNANCY, V15, P101, DOI 10.3109/10641959609015693; WALSH SW, 1993, AM J OBSTET GYNECOL, V169, P1007, DOI 10.1016/0002-9378(93)90044-J; WALSH SW, 1994, HYPERTENS PREGNANCY, V13, P1, DOI 10.3109/10641959409084168; WALSH SW, 1985, AM J OBSTET GYNECOL, V152, P335, DOI 10.1016/S0002-9378(85)80223-4; WALSH SW, 1993, AM J OBSTET GYNECOL, V169, P1462, DOI 10.1016/0002-9378(93)90419-J; Wang YP, 1996, J SOC GYNECOL INVEST, V3, P179, DOI 10.1016/1071-5576(96)00015-9	28	193	202	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2000	14	10					1289	1296		10.1096/fj.14.10.1289	http://dx.doi.org/10.1096/fj.14.10.1289			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877821				2022-12-28	WOS:000087932200003
J	Li, J; Houseknecht, KL; Stenbit, AE; Katz, EB; Charron, MJ				Li, J; Houseknecht, KL; Stenbit, AE; Katz, EB; Charron, MJ			Reduced glucose uptake precedes insulin signaling defects in adipocytes from heterozygous GLUT4 knockout mice	FASEB JOURNAL			English	Article						adipocyte glucose transport; NIDDM; hyperglycemia; PI3 kinase	PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; 60-KDA PHOSPHOTYROSINE PROTEIN; RECEPTOR SUBSTRATE-1; DIABETES-MELLITUS; ADIPOSE-TISSUE; ANIMAL-MODELS; MUSCLE; OBESE; TRANSPORTER; RESISTANCE	Decreased GLUT4 expression, impaired insulin receptor (IR), TRS-l, and pp60/IRS-3 tyrosine phosphorylation are characteristics of adipocytes from insulin-resistant animal models and obese NIDDM humans. However, the sequence of events leading to the development of insulin signaling defects and the significance of decreased GLUT4 expression in causing adipocyte insulin resistance are unknown. The present study used male heterozygous GLUT4 knockout mice (GLUT4(+/-)) as a novel model of diabetes to study the development of insulin signaling defects in adipocytes with the progression of whole body insulin resistance and diabetes. Male GLUT4(+/-) mice with normal fed glycemia and insulinemia (N/N), normal fed glycemia and hyperinsulinemia (N/H), and fed hyperglycemia with hyperinsulinemia (H/H) exist at all ages. The expression of GLUT4 protein and the maximal insulin-stimulated glucose transport was 50% decreased in adipocytes from all three groups. Insulin signaling was normal in N/N adipose cells. From 35 to 70% reductions in insulin-stimulated tyrosine phosphorylation of IR, IRS-1, and pp60/IRS-3 were noted with no changes in the cellular content of IR, IRS-1, and p85 in N/H adipocytes. Insulin-stimulated protein tyrosine phosphorylation was further decreased to 12-23% in H/H adipose cells accompanied by 42% decreased IR and 80% increased p85 expression. Insulin-stimulated, IRS-1-associated PI3 kinase activity was decreased by 20% in N/H and 68% reduced in H/H GLUT4(+/-) adipocytes. However, total insulin-stimulated PI3 kinase activity was normal in H/H GLUT4(+/-) adipocytes. Taken together, these results strongly suggest that hyperinsulinemia triggers a reduction of IR tyrosine kinase activity that is further exacerbated by the appearance of hyperglycemia. However, the insulin signaling cascade has sufficient plasticity to accommodate significant changes in specific components without further reducing glucose uptake. Furthermore, the data indicate that the cellular content of GLUT4 is the rate-limiting factor in mediating maximal insulin-stimulated glucose uptake in GLUT4(+/-) adipocytes.-Li, J., Houseknecht, K. L., Stenbit, A. E., Katz, E. B., Charron, M. J. Reduced glucose uptake precedes insulin signaling defects in adipocytes from heterozygous GLUT4: knockout mice.	Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Purdue Univ, Dept Anim Sci, W Lafayette, IN 47907 USA	Yeshiva University; Albert Einstein College of Medicine; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Charron, MJ (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	charron@aecom.yu.edu			NHLBI NIH HHS [HL 58119] Funding Source: Medline; NIDDK NIH HHS [DK 47425] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047425] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; CUSHMAN SW, 1978, J LIPID RES, V19, P269; CZECH MP, 1995, ANNU REV NUTR, V15, P441, DOI 10.1146/annurev.nu.15.070195.002301; FOLLI F, 1993, J CLIN INVEST, V92, P1787, DOI 10.1172/JCI116768; FREIDENBERG GR, 1987, J CLIN INVEST, V79, P240, DOI 10.1172/JCI112789; GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; HEYDRICK SJ, 1995, AM J PHYSIOL-ENDOC M, V268, pE604, DOI 10.1152/ajpendo.1995.268.4.E604; HIRSCH J, 1968, J LIPID RES, V9, P110; Houseknecht KL, 1996, J BIOL CHEM, V271, P11347, DOI 10.1074/jbc.271.19.11347; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; KATZ EB, 1995, NATURE, V377, P151, DOI 10.1038/377151a0; Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872; KORANYI L, 1990, J CLIN INVEST, V85, P962, DOI 10.1172/JCI114526; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; Lavan BE, 1997, J BIOL CHEM, V272, P11439; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; Morris AJ, 1996, P NATL ACAD SCI USA, V93, P8401, DOI 10.1073/pnas.93.16.8401; OLEFSKY JM, 1995, AM J CLIN NUTR, V61, p980S, DOI 10.1093/ajcn/61.4.980S; REAVEN GM, 1995, PHYSIOL REV, V75, P473, DOI 10.1152/physrev.1995.75.3.473; Rondinone CM, 1997, P NATL ACAD SCI USA, V94, P4171, DOI 10.1073/pnas.94.8.4171; Rossetti L, 1997, J CLIN INVEST, V100, P1831, DOI 10.1172/JCI119711; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; SAAD MJA, 1993, J CLIN INVEST, V92, P2065, DOI 10.1172/JCI116803; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Sharma PM, 1997, MOL CELL BIOL, V17, P7386, DOI 10.1128/MCB.17.12.7386; Shepherd PR, 1996, J MOL ENDOCRINOL, V17, P175, DOI 10.1677/jme.0.0170175; Shepherd PR, 1997, BIOCHEM SOC T, V25, P978, DOI 10.1042/bst0250978; SmithHall J, 1997, BIOCHEMISTRY-US, V36, P8304, DOI 10.1021/bi9630974; Staubs PA, 1998, J BIOL CHEM, V273, P25139, DOI 10.1074/jbc.273.39.25139; Stenbit AE, 1997, NAT MED, V3, P1096, DOI 10.1038/nm1097-1096; STEPHENS JM, 1995, ENDOCR REV, V16, P529, DOI 10.1210/er.16.4.529; THIES RS, 1990, DIABETES, V39, P250, DOI 10.2337/diabetes.39.2.250; WHITE MF, 1994, J BIOL CHEM, V269, P1; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074; Zierath JR, 1996, SEMIN CELL DEV BIOL, V7, P295, DOI 10.1006/scdb.1996.0038	38	45	51	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2000	14	9					1117	1125		10.1096/fasebj.14.9.1117	http://dx.doi.org/10.1096/fasebj.14.9.1117			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834933				2022-12-28	WOS:000087427300008
J	Naganuma, A; Miura, N; Kaneko, S; Mishina, T; Hosoya, S; Miyairi, S; Furuchi, T; Kuge, S				Naganuma, A; Miura, N; Kaneko, S; Mishina, T; Hosoya, S; Miyairi, S; Furuchi, T; Kuge, S			GFAT as a target molecule of methylmercury toxicity in Saccharomyces cerevisiae	FASEB JOURNAL			English	Article						gene screening; glucosamine; glucosamine-6-phosphate; resistance; p-chloromercuribenzoate	FRUCTOSE-6-PHOSPHATE AMIDOTRANSFERASE; CELL-LINES; GLUTAMINE; RESISTANT; SYNTHASE; MERCURY; GENE; NEUROTOXICITY; AMPLIFICATION; TRANSCRIPTION	Using a genomic library constructed from Saccharomyces cerevisiae, we have identified a gene GFA1 that confers resistance to methylmercury toxicity. GFA1 encodes L-glutamine:D-fructose-6-phosphate amidotransferase (GFAT) and catalyzes synthesis of glucosamine-6-phosphate. Transformed yeast cells expressing GFA1 demonstrated resistance to methylmercury but no resistance to p-chloromercuribenzoate, a GFAT inhibitor. The cytotoxicity of methylmercury was inhibited by loading- excess glucosamine 6-phosphate into yeast. Considering that GFAT is an essential cellular enzyme, our findings suggest that GFAT is the major target molecule of methylmercury in yeasts. This report is the first to identify the target molecule of methylmercury toxicity in eukaryotic cells.	Tohoku Univ, Grad Sch Pharmaceut Sci, Lab Mol & Biochem Toxicol, Sendai, Miyagi 9808578, Japan; Univ Tokyo, Inst Med Sci, Dept Microbiol, Minato Ku, Tokyo 1088639, Japan	Tohoku University; University of Tokyo	Naganuma, A (corresponding author), Tohoku Univ, Grad Sch Pharmaceut Sci, Lab Mol & Biochem Toxicol, Sendai, Miyagi 9808578, Japan.		NAGANUMA, AKIRA/V-2918-2019					AKAGI H, 1996, BRAZIL ENV SCI, V4, P199; ATCHISON WD, 1994, FASEB J, V8, P622, DOI 10.1096/fasebj.8.9.7516300; BADET B, 1987, BIOCHEMISTRY-US, V26, P1940, DOI 10.1021/bi00381a023; CARLBERG I, 1975, J BIOL CHEM, V250, P5475; Clarkson TW, 1997, CRIT REV CL LAB SCI, V34, P369, DOI 10.3109/10408369708998098; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; Duffy L K, 1998, Alaska Med, V40, P75; FREEMANTLE SJ, 1995, BRIT J CANCER, V71, P925, DOI 10.1038/bjc.1995.179; GHOSH S, 1960, J BIOL CHEM, V235, P1265; Grandjean P, 1999, ENVIRON HEALTH PERSP, V107, P587, DOI 10.2307/3434402; HARADA M, 1995, CRIT REV TOXICOL, V25, P1, DOI 10.3109/10408449509089885; Holsbeek L, 1997, SCI TOTAL ENVIRON, V198, P201, DOI 10.1016/S0048-9697(97)05453-3; Jaffe R, 1997, B ENVIRON CONTAM TOX, V59, P99; JENH CH, 1985, MOL PHARMACOL, V28, P80; Lebel J, 1998, ENVIRON RES, V79, P20, DOI 10.1006/enrs.1998.3846; Malm O, 1998, ENVIRON RES, V77, P73, DOI 10.1006/enrs.1998.3828; MCKNIGHT GL, 1992, J BIOL CHEM, V267, P25208; MOCHIZUKI Y, 1977, J BIOCHEM, V81, P1849, DOI 10.1093/oxfordjournals.jbchem.a131646; MORTON RK, 1964, J BIOL CHEM, V239, P1614; Nierenberg DW, 1998, NEW ENGL J MED, V338, P1672, DOI 10.1056/NEJM199806043382305; PATERSON AJ, 1995, ENDOCRINOLOGY, V136, P2809, DOI 10.1210/en.136.7.2809; QULALI M, 1991, ARCH BIOCHEM BIOPHYS, V288, P406, DOI 10.1016/0003-9861(91)90213-3; SRIMATKANDADA S, 1983, BIOCHEMISTRY-US, V22, P5774, DOI 10.1021/bi00294a015; WATZELE G, 1989, J BIOL CHEM, V264, P8753; WINTERBURN PJ, 1971, BIOCHEM J, V121, P721, DOI 10.1042/bj1210721; YEN Y, 1994, CANCER RES, V54, P3686; ZALKIN H, 1985, METHOD ENZYMOL, V113, P278	27	37	38	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2000	14	7					968	972		10.1096/fasebj.14.7.968	http://dx.doi.org/10.1096/fasebj.14.7.968			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	309CG	10783151				2022-12-28	WOS:000086749500015
J	Vos, IHC; Govers, R; Grone, HJ; Kleij, L; Schurink, M; De Weger, RA; Goldschmeding, R; Rabelink, TJ				Vos, IHC; Govers, R; Grone, HJ; Kleij, L; Schurink, M; De Weger, RA; Goldschmeding, R; Rabelink, TJ			NF kappa B decoy oligodeoxynucleotides reduce monocyte infiltration in renal allografts	FASEB JOURNAL			English	Article						transplantation; adhesion molecules; macrophages; endothelium	INITIAL ISCHEMIA/REPERFUSION INJURY; CELL-ADHESION MOLECULES; TRANSCRIPTION FACTOR; ANTISENSE OLIGONUCLEOTIDES; REPERFUSION INJURY; REJECTION; ACTIVATION; KIDNEY; RAT; TRANSPLANTATION	Monocyte influx secondary to ischemia-reperfusion conditions the renal allograft to rejection by presentation of antigens and production of cytokines. Monocyte influx depends on NF kappa B-dependent transcription of genes encoding adhesion molecules and chemokines, Here we demonstrate that cationic liposomes containing phosphorothioated oligodeoxynucleotides (ODN) with the kappa B binding site serving as competitive binding decoy, can prevent TNF-alpha-induced NF kappa B activity in endothelial cells in vitro, In an allogenic rat kidney transplantation model (BN to LEW), we show that perfusing the renal allograft with this decoy prior to transplantation abolishes nuclear NF kappa B activity hi vivo and inhibits VCAM-1 expression in the donor endothelium (P<0.05), At 24 h postreperfusion, periarterial infiltration of monocytes/macrophages was significantly reduced in decoy ODN-treated allografts compared to control allografts (3.7 +/- 0.7 vs. 9.2+/-1.2 macrophages/vessel; P<0.01), At 72 h, there was a reduction of tubulointerstitial macrophage infiltration in decoy ODN-treated kidneys compared to controls (75.6+/-13.9 vs. 120.0+/-11.2 macrophages/tubulointerstitial area; P<0.05), In conclusion, perfusion of the renal allograft with NF kappa B decoy ODN prior to transplantation decreases the initial inflammatory response in a stringent, nonimmunosuppressed allogenic transplantation model. Therefore, the NF kappa B decoy approach may be useful to explore the role of endothelium and macrophages in graft rejection and may be developed into a graft-specific immunosuppressive strategy allowing reduction of systemic immunosuppression on organ transplantation.	Univ Utrecht, Med Ctr, Dept Vasc Med, NL-3584 CX Utrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Hypertens & Nephrol, NL-3584 CX Utrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Pathol, NL-3584 CX Utrecht, Netherlands; German Canc Res Ctr, D-6900 Heidelberg, Germany	Utrecht University; Utrecht University; Utrecht University; Helmholtz Association; German Cancer Research Center (DKFZ)	Rabelink, TJ (corresponding author), Univ Utrecht, Med Ctr, Dept Vasc Med, G02-228,Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.		Rabelink, Ton J./A-5316-2008; Goldschmeding, Roel/I-1723-2014; Govers, Roland/O-5782-2016	Rabelink, Ton J./0000-0001-6780-5186; Govers, Roland/0000-0003-1359-5333				ALCALDE G, 1995, TRANSPLANTATION, V59, P1695, DOI 10.1097/00007890-199506270-00009; ANDREWS NC, 1991, SCIENCE, V154, P1662; Azuma H, 1997, TRANSPL P, V29, P1528, DOI 10.1016/S0041-1345(96)00662-8; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BENNETT CF, 1994, J IMMUNOL, V152, P3530; Brand K, 1997, EXP PHYSIOL, V82, P297, DOI 10.1113/expphysiol.1997.sp004025; BROCKMEYER C, 1993, TRANSPLANTATION, V55, P610; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Dragun D, 1998, KIDNEY INT, V54, P590, DOI 10.1046/j.1523-1755.1998.00026.x; FONTIJN R, 1995, EXP CELL RES, V216, P199, DOI 10.1006/excr.1995.1025; HANCOCK WW, 1983, TRANSPLANTATION, V35, P458, DOI 10.1097/00007890-198305000-00013; Kajiwara I, 1996, NEPHRON, V73, P536; Meldrum DR, 1998, AM J PHYSIOL-REG I, V274, pR577, DOI 10.1152/ajpregu.1998.274.3.R577; Morishita R, 1997, NAT MED, V3, P894, DOI 10.1038/nm0897-894; Nagano H, 1997, TRANSPLANTATION, V63, P1101, DOI 10.1097/00007890-199704270-00009; Paul LC, 1996, TRANSPLANT INT, V9, P420, DOI 10.1007/BF00335706; Perkins ND, 1997, INT J BIOCHEM CELL B, V29, P1433, DOI 10.1016/S1357-2725(97)00088-5; RUSSELL ME, 1995, TRANSPLANTATION, V59, P572; Sakurai H, 1996, BBA-MOL BASIS DIS, V1316, P132, DOI 10.1016/0925-4439(96)00022-1; Sawa Y, 1997, CIRCULATION, V96, P280; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Solez K, 1997, KIDNEY INT, V51, P1476, DOI 10.1038/ki.1997.202; STEPKOWSKI SM, 1994, J IMMUNOL, V153, P5336; Stojanovic T, 1996, LAB INVEST, V74, P496; Takada M, 1997, J CLIN INVEST, V99, P2682, DOI 10.1172/JCI119457; Takada M, 1997, TRANSPLANTATION, V64, P1520, DOI 10.1097/00007890-199712150-00003; Thurston G, 1998, J CLIN INVEST, V101, P1401, DOI 10.1172/JCI965; Tomita N, 1998, J HYPERTENS, V16, P993, DOI 10.1097/00004872-199816070-00013; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998	34	97	118	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2000	14	5					815	822		10.1096/fasebj.14.5.815	http://dx.doi.org/10.1096/fasebj.14.5.815			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301DH	10744638				2022-12-28	WOS:000086292700019
J	Latasa, MU; Boukaba, A; Garcia-Trevijano, ER; Torres, L; Rodriguez, JL; Caballeria, J; Lu, SC; Lopez-Rodas, G; Franco, L; Mato, JM; Avila, MA				Latasa, MU; Boukaba, A; Garcia-Trevijano, ER; Torres, L; Rodriguez, JL; Caballeria, J; Lu, SC; Lopez-Rodas, G; Franco, L; Mato, JM; Avila, MA			Hepatocyte growth factor induces MAT2A expression and histone acetylation in rat hepatocytes: role in liver regeneration	FASEB JOURNAL			English	Article									Univ Navarra, Fac Med, Edificio Castanos, Dept Med Interna,Unidad Hepatol & Terapia Gen, Pamplona 31008, Spain; Univ Valencia, Dept Bioquim & Biol Mol, E-46100 Valencia, Spain; Hosp Clin & Prov, Serv Hepatol, Barcelona 08036, Spain; Univ So Calif, Sch Med, Dept Med, Ctr Liver Dis Res, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Med, Div Gastrointestinal Liver Dis, Los Angeles, CA 90033 USA	University of Navarra; University of Valencia; University of Barcelona; Hospital Clinic de Barcelona; University of Southern California; University of Southern California	Mato, JM (corresponding author), Univ Navarra, Fac Med, Edificio Castanos, Dept Med Interna,Unidad Hepatol & Terapia Gen, Pamplona 31008, Spain.		MATO, JOSE/A-5187-2011; Torres, Luis/AAB-2403-2019; Avila, Matias A/Y-6342-2019; Ruiz García-Trevijano, Elena R./ABE-1014-2021; LOPEZ-RODAS, GERARDO/I-1349-2015	MATO, JOSE/0000-0003-1264-3153; Avila, Matias A/0000-0001-6570-3557; Ruiz García-Trevijano, Elena R./0000-0002-3985-1270; LOPEZ-RODAS, GERARDO/0000-0001-8367-653X; Latasa, Maria Ujue/0000-0002-0878-1337; Franco, Luis/0000-0001-9610-6448					0	48	49	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1248	1250		10.1096/fj.00-0556fjev1	http://dx.doi.org/10.1096/fj.00-0556fjev1			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344103				2022-12-28	WOS:000168655200025
J	Lepple-Wienhues, A; Wieland, U; Laun, T; Heil, L; Stern, M; Lang, F				Lepple-Wienhues, A; Wieland, U; Laun, T; Heil, L; Stern, M; Lang, F			A src-like kinase activates outwardly rectifying chloride channels in CFTR-defective lymphocytes	FASEB JOURNAL			English	Article						cystic fibrosis; tyrosine kinase; human lymphocytes; cyclic adenosine monophosphate; cell volume	TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS AIRWAY; APICAL-MEMBRANE; EPITHELIAL-CELLS; T-LYMPHOCYTES; CL CHANNEL; RESPIRATORY EPITHELIUM; ION CHANNELS; CAMP; PROTEIN	Defective activation of chloride channels is a hallmark of cystic fibrosis (CF). Recently we have described activation of a volume-sensitive, outwardly rectifying chloride conductance (I-OR) through the src-like tyrosine kinase p56(lck). Here we show that p56(lck) activates I-OR independently of CFTR. In lymphocytes from healthy donors, chloride channels could be opened by either intracellular cAMP, p56(lck) or osmotic swelling. In CF lymphocytes, p56(lck) and cell swelling but not cAMP could activate chloride channels. Regulation of I-OR by p56(lck) thus represents an alternative pathway of stimulating membrane chloride conductance that is left intact in cystic fibrosis.	Univ Tubingen, Inst Physiol, Dept Physiol, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Lepple-Wienhues, A (corresponding author), Univ Tubingen, Inst Physiol, Dept Physiol, Gmelinstr 5, D-72076 Tubingen, Germany.	alepplew@uni-tuebingen.de						ALLERT N, 1992, PFLUG ARCH EUR J PHY, V421, P403, DOI 10.1007/BF00374233; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; ANDERSON MP, 1992, AM J PHYSIOL, V263, pL1, DOI 10.1152/ajplung.1992.263.1.L1; BERGER HA, 1993, J BIOL CHEM, V268, P2037; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; CHEN JH, 1989, SCIENCE, V243, P657, DOI 10.1126/science.2464852; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CLARKE LL, 1994, P NATL ACAD SCI USA, V91, P479, DOI 10.1073/pnas.91.2.479; COTTON CU, 1987, J CLIN INVEST, V79, P80, DOI 10.1172/JCI112812; CUNNINGHAM SA, 1992, AM J PHYSIOL, V262, P783; CUTHBERT AW, 1994, BRIT J PHARMACOL, V112, P31, DOI 10.1111/j.1476-5381.1994.tb13024.x; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; Fischer H, 1996, BIOPHYS J, V71, P3073, DOI 10.1016/S0006-3495(96)79501-2; GABRIEL SE, 1993, NATURE, V363, P263, DOI 10.1038/363263a0; Greger R, 1996, J MOL MED-JMM, V74, P527; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KNOWLES MR, 1983, SCIENCE, V221, P1067, DOI 10.1126/science.6308769; KRAUSS RD, 1992, EMBO J, V11, P875, DOI 10.1002/j.1460-2075.1992.tb05125.x; KROUSE ME, 1994, AM J PHYSIOL, V267, pC642, DOI 10.1152/ajpcell.1994.267.2.C642; KUNZELMANN K, 1989, PFLUG ARCH EUR J PHY, V415, P172, DOI 10.1007/BF00370589; KUNZELMANN K, 1995, PFLUG ARCH EUR J PHY, V431, P1, DOI 10.1007/BF00374371; Kunzelmann K, 1997, FEBS LETT, V400, P341, DOI 10.1016/S0014-5793(96)01414-7; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Lepple-Wienhues A, 1998, J CELL BIOL, V141, P281, DOI 10.1083/jcb.141.1.281; LEWIS RS, 1993, J GEN PHYSIOL, V101, P801, DOI 10.1085/jgp.101.6.801; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; MCDONALD TV, 1992, J BIOL CHEM, V267, P3242; PUSCH M, 1988, PFLUG ARCH EUR J PHY, V411, P204, DOI 10.1007/BF00582316; RATCLIFF R, 1993, NAT GENET, V4, P35, DOI 10.1038/ng0593-35; Reddy MM, 1999, NATURE, V402, P301, DOI 10.1038/46297; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; ROSS PE, 1994, BIOPHYS J, V66, P169, DOI 10.1016/S0006-3495(94)80754-4; SCHOUMACHER RA, 1987, NATURE, V330, P752, DOI 10.1038/330752a0; Schwiebert EM, 1998, P NATL ACAD SCI USA, V95, P3879, DOI 10.1073/pnas.95.7.3879; Seidler U, 1997, J PHYSIOL-LONDON, V505, P411, DOI 10.1111/j.1469-7793.1997.411bb.x; SMITH JJ, 1992, J CLIN INVEST, V89, P1148, DOI 10.1172/JCI115696; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; SOLC CK, 1991, AM J PHYSIOL, V261, pC658, DOI 10.1152/ajpcell.1991.261.4.C658; Sorota S, 1995, PFLUG ARCH EUR J PHY, V431, P178, DOI 10.1007/BF00410189; SOROTA S, 1992, CIRC RES, V70, P679, DOI 10.1161/01.RES.70.4.679; Szabo I, 1998, P NATL ACAD SCI USA, V95, P6169, DOI 10.1073/pnas.95.11.6169; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TILLY BC, 1993, J BIOL CHEM, V268, P19919; Voets T, 1998, J PHYSIOL-LONDON, V506, P341, DOI 10.1111/j.1469-7793.1998.341bw.x; WELSH MJ, 1986, SCIENCE, V232, P1648, DOI 10.1126/science.2424085; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; WELSH MJ, 1989, ANN NY ACAD SCI, V574, P44; Zabner J, 1998, MOL CELL, V2, P397, DOI 10.1016/S1097-2765(00)80284-1	51	21	23	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2001	15	6					927	931		10.1096/fj.00-0264com	http://dx.doi.org/10.1096/fj.00-0264com			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292652				2022-12-28	WOS:000167959300006
J	Kenakin, T				Kenakin, T			Inverse, protean, and ligand-selective agonism: matters of receptor conformation	FASEB JOURNAL			English	Review						G-protein-coupled receptors; receptor activation; inverse agonism; receptor theory; constitutive receptor activity	VASOACTIVE-INTESTINAL-PEPTIDE; IMMUNODEFICIENCY-VIRUS TYPE-1; COUPLED SIGNAL-TRANSDUCTION; GASTRIN-RELEASING-PEPTIDE; BETA-ADRENERGIC-RECEPTOR; DELTA-OPIOID RECEPTORS; OCCUPANCY MODEL; ALPHA(1B)-ADRENERGIC RECEPTOR; ALPHA(2)-ADRENERGIC RECEPTOR; ALPHA-1B-ADRENERGIC RECEPTOR	Concepts regarding the mechanisms by which drugs activate receptors to produce physiological response have progressed beyond considering the receptor as a simple on-off switch. Current evidence suggests that the idea that agonists produce only varying degrees of receptor activation is obsolete and must be reconciled with data to show that agonist efficacy has texture as well as magnitude. Thus, agonists can block system constitutive response (inverse agonists), behave as positive and inverse agonists on the same receptor (protean agonists), and differ in the stimulus pattern they produce in physiological systems (ligand-selective agonists), The molecular mechanism for this seemingly diverse array of activities is the same, namely, the selective microaffinity of ligands for different conformational states of the receptor. This paper reviews evidence for the existence of the various types of agonism and the potential therapeutic utility of different agonist types.-Kenakin, T, Inverse, protean, and ligand-selective agonism: matters of receptor conformation.	Glaxo SmithKline Res & Dev, Dept Receptor Biochem, Res Triangle Pk, NC 27709 USA	GlaxoSmithKline	Kenakin, T (corresponding author), GlaxoWellcome Res & Dev, Dept Receptor Biochem, 5 Moore Dr, Res Triangle Pk, NC 27709 USA.	tpk1348@glaxo.com						ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; [Anonymous], 2000, HANDB EXP PHARM; ARMOUR SL, 2000, IN PRESS J PHARM TOX; AVANITAKIS L, 1997, NATURE, V385, P347; Bai M, 1999, P NATL ACAD SCI USA, V96, P2834, DOI 10.1073/pnas.96.6.2834; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; BELLAN C, 1992, EXP CELL RES, V200, P34, DOI 10.1016/S0014-4827(05)80068-0; Berg KA, 1999, MOL PHARMACOL, V55, P863; Berg KA, 1998, MOL PHARMACOL, V54, P94, DOI 10.1124/mol.54.1.94; Blake AD, 1997, J BIOL CHEM, V272, P782, DOI 10.1074/jbc.272.2.782; Bonhaus DW, 1998, J PHARMACOL EXP THER, V287, P884; BRAESTRUP C, 1982, SCIENCE, V216, P1241, DOI 10.1126/science.6281892; Chen G, 2000, MOL PHARMACOL, V57, P125; Chidiac P, 1996, MOL PHARMACOL, V50, P662; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; Christopoulos G, 1999, MOL PHARMACOL, V56, P235, DOI 10.1124/mol.56.1.235; Ciruela F, 1997, MOL PHARMACOL, V52, P788, DOI 10.1124/mol.52.5.788; Clifford EE, 1997, AM J PHYSIOL-CELL PH, V273, pC973, DOI 10.1152/ajpcell.1997.273.3.C973; COHN J, 1987, AM J PHYSIOL, V16, pG420; COSTA T, 1989, P NATL ACAD SCI USA, V86, P7321, DOI 10.1073/pnas.86.19.7321; COUGHLIN SR, 1994, CURR OPIN CELL BIOL, V6, P191, DOI 10.1016/0955-0674(94)90135-X; COUVINEAU A, 1985, J CLIN ENDOCR METAB, V61, P50, DOI 10.1210/jcem-61-1-50; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; de Ligt RAF, 2000, BRIT J PHARMACOL, V130, P1, DOI 10.1038/sj.bjp.0703311; DEAKIN M, 1992, DRUGS, V44, P709, DOI 10.2165/00003495-199244050-00003; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Domingo E, 1997, Prog Drug Res, V48, P99; Donaldson LF, 1997, TRENDS PHARMACOL SCI, V18, P171, DOI 10.1016/S0165-6147(97)90614-3; ELBATTARI A, 1988, J BIOL CHEM, V263, P17685; Foord SM, 1999, TRENDS PHARMACOL SCI, V20, P184, DOI 10.1016/S0165-6147(99)01347-4; Fraser NJ, 1999, MOL PHARMACOL, V55, P1054, DOI 10.1124/mol.55.6.1054; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; FRAUENFELDER H, 1988, ANNU REV BIOPHYS BIO, V17, P451; GESPACH C, 1988, CANCER RES, V48, P5079; GETHER U, 1995, J BIOL CHEM, V270, P28268; GOZES I, 1991, J PHARMACOL EXP THER, V257, P959; HAEGERSTRAND A, 1989, P NATL ACAD SCI USA, V86, P5993, DOI 10.1073/pnas.86.15.5993; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Harrigan PR, 1998, J VIROL, V72, P3773, DOI 10.1128/JVI.72.5.3773-3778.1998; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HEDIN KE, 1993, CELL SIGNAL, V5, P505, DOI 10.1016/0898-6568(93)90046-O; HORNE WC, 1994, TRENDS ENDOCRIN MET, V5, P395, DOI 10.1016/1043-2760(95)92521-J; IKEZU T, 1992, FEBS LETT, V311, P29, DOI 10.1016/0014-5793(92)81359-T; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P232, DOI 10.1016/S0165-6147(00)89032-X; Kenakin T, 1999, TRENDS PHARMACOL SCI, V20, P400, DOI 10.1016/S0165-6147(99)01361-9; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P256, DOI 10.1016/S0165-6147(00)89037-9; Kenakin T, 1997, TRENDS PHARMACOL SCI, V18, P416, DOI 10.1016/S0165-6147(97)01127-9; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P188, DOI 10.1016/S0165-6147(00)89020-3; Kenakin T, 1997, ANN NY ACAD SCI, V812, P116, DOI 10.1111/j.1749-6632.1997.tb48151.x; KENAKIN TP, 1998, PHARM NEWS, V5, P20; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KORMAN LY, 1986, CANCER RES, V46, P1214; Kovoor A, 1997, J BIOL CHEM, V272, P27605, DOI 10.1074/jbc.272.44.27605; KRENNING EP, 1989, LANCET, V1, P242; KROOG GS, 1995, MED RES REV, V15, P389, DOI 10.1002/med.2610150502; Krumins AM, 1997, MOL PHARMACOL, V52, P144, DOI 10.1124/mol.52.1.144; Kudo M, 1996, J BIOL CHEM, V271, P22470, DOI 10.1074/jbc.271.37.22470; Kuhmann SE, 2000, J VIROL, V74, P7005, DOI 10.1128/JVI.74.15.7005-7015.2000; LAMBERTS SWJ, 1990, NEW ENGL J MED, V323, P1246, DOI 10.1056/NEJM199011013231805; Law PY, 2000, MOL PHARMACOL, V58, P388, DOI 10.1124/mol.58.2.388; LEE M, 1990, PEPTIDES, V11, P1205, DOI 10.1016/0196-9781(90)90153-V; LEE TW, 1997, UP REGULATION LEVELS; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MacEwan DJ, 1996, MOL PHARMACOL, V50, P1479; Mack M, 1998, J EXP MED, V187, P1215, DOI 10.1084/jem.187.8.1215; MAHMOUD S, 1991, CANCER RES, V51, P1798; MARUNO K, 1989, CANCER RES, V49, P629; McCune DF, 2000, MOL PHARMACOL, V57, P659, DOI 10.1124/mol.57.4.659; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; MELLER E, 1992, J PHARMACOL EXP THER, V263, P462; Mhaouty-Kodja S, 1999, MOL PHARMACOL, V55, P339, DOI 10.1124/mol.55.2.339; Milligan G, 1997, TRENDS PHARMACOL SCI, V18, P468, DOI 10.1016/S0165-6147(97)90685-4; MITSUHASHI M, 1987, LIFE SCI, V40, P853, DOI 10.1016/0024-3205(87)90034-8; MOODY TW, 1993, P NATL ACAD SCI USA, V90, P4345, DOI 10.1073/pnas.90.10.4345; Mukhopadhyay S, 2000, MOL PHARMACOL, V57, P162; MULLER JM, 1989, J BIOL CHEM, V264, P3647; MUNCH G, 1991, EUR J BIOCHEM, V198, P357, DOI 10.1111/j.1432-1033.1991.tb16023.x; Nagaraja S, 1999, BRIT J PHARMACOL, V127, P1099, DOI 10.1038/sj.bjp.0702645; NWOLKO CU, 1991, GUT, V32, P1455; NWOLOKO CU, 1990, ALIMENT PHARM THE S1, V4, P29; ODORISIO MS, 1992, REGUL PEPTIDES, V37, P213; PINCUS DW, 1990, NATURE, V343, P564, DOI 10.1038/343564a0; Porter JE, 1996, J BIOL CHEM, V271, P28318, DOI 10.1074/jbc.271.45.28318; ROBB S, 1994, EMBO J, V13, P1325, DOI 10.1002/j.1460-2075.1994.tb06385.x; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; Rodriguez-Frade JM, 1999, J CELL BIOL, V144, P755, DOI 10.1083/jcb.144.4.755; Roettger BF, 1997, MOL PHARMACOL, V51, P357; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Rosenkilde MM, 2000, MOL PHARMACOL, V57, P602, DOI 10.1124/mol.57.3.602; Rossier O, 1999, MOL PHARMACOL, V56, P858, DOI 10.1124/mol.56.5.858; Sagan S, 1999, J BIOL CHEM, V274, P23770, DOI 10.1074/jbc.274.34.23770; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Schols D, 1998, J VIROL, V72, P4032, DOI 10.1128/JVI.72.5.4032-4037.1998; Schwartz TW, 1996, TRENDS PHARMACOL SCI, V17, P213, DOI 10.1016/0165-6147(96)10017-1; Seifert R, 1999, MOL PHARMACOL, V56, P348, DOI 10.1124/mol.56.2.348; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; Smit MJ, 1996, P NATL ACAD SCI USA, V93, P6802, DOI 10.1073/pnas.93.13.6802; Spalding TA, 1995, J PHARMACOL EXP THER, V275, P1274; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; SPIEGEL AM, 1993, J CLIN INVEST, V92, P1119, DOI 10.1172/JCI116680; Spiegel AM, 1996, ANNU REV PHYSIOL, V58, P143, DOI 10.1146/annurev.ph.58.030196.001043; SREEDHARAN SP, 1991, P NATL ACAD SCI USA, V88, P4986, DOI 10.1073/pnas.88.11.4986; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SVOBODA M, 1988, EUR J BIOCHEM, V176, P707, DOI 10.1111/j.1432-1033.1988.tb14334.x; TIAN WN, 1994, MOL PHARMACOL, V45, P524; Ullmer C, 1998, FEBS LETT, V424, P63, DOI 10.1016/S0014-5793(98)00141-0; vanHooft JA, 1996, BRIT J PHARMACOL, V117, P839; VIRGOLINI I, 1994, CANCER RES, V54, P690; VIRGOLINI I, 1994, NEW ENGL J MED, V331, P1116, DOI 10.1056/NEJM199410273311703; Wade SM, 1999, MOL PHARMACOL, V56, P1005, DOI 10.1124/mol.56.5.1005; Ward DT, 1998, J BIOL CHEM, V273, P14476, DOI 10.1074/jbc.273.23.14476; WATSON CA, 2000, IN PRESS MOL PHARM; WEINSTEIN LS, 1992, GENOMICS, V13, P1319, DOI 10.1016/0888-7543(92)90056-X; Weiss JM, 1996, J THEOR BIOL, V178, P169, DOI 10.1006/jtbi.1996.0015; Weiss JM, 1996, J THEOR BIOL, V178, P151, DOI 10.1006/jtbi.1996.0014; Weiss JM, 1996, J THEOR BIOL, V181, P381, DOI 10.1006/jtbi.1996.0139; WESTPHAL RS, 1995, MOL PHARMACOL, V48, P200; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Wiens BL, 1998, MOL PHARMACOL, V54, P435, DOI 10.1124/mol.54.2.435; WILDERSMITH CH, 1990, DIGEST DIS SCI, V35, P976, DOI 10.1007/BF01537246; WOOD PL, 1984, J PHARMACOL EXP THER, V231, P572; WYMAN J, 1975, P NATL ACAD SCI USA, V72, P3983, DOI 10.1073/pnas.72.10.3983; Yu YK, 1997, J BIOL CHEM, V272, P28869, DOI 10.1074/jbc.272.46.28869; ZURIER RB, 1988, EXP CELL RES, V176, P155, DOI 10.1016/0014-4827(88)90129-2	131	325	339	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2001	15	3					598	611		10.1096/fj.00-0438rev	http://dx.doi.org/10.1096/fj.00-0438rev			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259378	Green Submitted			2022-12-28	WOS:000167419500017
J	Vohradsky, J				Vohradsky, J			Neural network model of gene expression	FASEB JOURNAL			English	Article						genetic network; regulation of gene expression; mathematical modeling	BACTERIAL CHEMOTAXIS; MESSENGER-RNA; SIMULATION; PROTEIN; CELLS	Many natural processes consist of networks of interacting elements that, over time, affect each other's state. Their dynamics depend on the pattern of connections and the updating rules for each element. Genomic regulatory networks are networks of this sort. In this paper we use artificial neural networks as a model of the dynamics of gene expression. The significance of the regulatory effect of one gene product on the expression of other genes of the system is defined by a weight matrix. The model considers multigenic regulation including positive and/or negative feedback. The process of gene expression is described by a single network and by two linked networks where transcription and translation are modeled independently. Each of these processes is described by different network controlled by different weight matrices. Methods for computing the parameters of the model from experimental data are discussed. Results computed by means of the model are compared with experimental observations, Generalization to a 'black box' concept, where the molecular processes occurring in the cell are considered as signal processing units forming a global regulatory network, is discussed.	CAS, Inst Microbiol, CZ-14220 Prague, Czech Republic	Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences	Vohradsky, J (corresponding author), CAS, Inst Microbiol, Videnska 1083, CZ-14220 Prague, Czech Republic.							Akutsu T, 1999, Pac Symp Biocomput, P17; ARKIN A, 1994, BIOPHYS J, V67, P560, DOI 10.1016/S0006-3495(94)80516-8; BOSE NK, 1996, NEURAL NETWORK FUNDA, P323; BOSE NK, 1996, NEURAL NETWORK FUNDA, P312; BOSE NK, 1996, NEURAL NETWORK FUNDA, P335; BRAY D, 1995, NATURE, V376, P307, DOI 10.1038/376307a0; BRAY D, 1993, MOL BIOL CELL, V4, P469, DOI 10.1091/mbc.4.5.469; BRAY D, 1995, MOL BIOL CELL, V6, P1367, DOI 10.1091/mbc.6.10.1367; BRAY D, 1999, BACTERIAL NEURAL NET, P48; CHEN T, 1999, P PAC S BIOC, V4, P29; D'haeseleer P, 1999, Pac Symp Biocomput, P41; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; HAURI DC, 1995, BIOPHYS J, V68, P708, DOI 10.1016/S0006-3495(95)80232-8; HOEL DG, 1970, J BIOL CHEM, V245, P5811; McAdams HH, 2000, CURR BIOL, V10, pR318, DOI 10.1016/S0960-9822(00)00440-1; MCADAMS HH, 1995, SCIENCE, V269, P650, DOI 10.1126/science.7624793; McAdams HH, 1998, ANNU REV BIOPH BIOM, V27, P199, DOI 10.1146/annurev.biophys.27.1.199; PINEDA FJ, 1987, PHYS REV LETT, V59, P2229, DOI 10.1103/PhysRevLett.59.2229; SAMSONOVA MG, 1999, P PAC S BIOC, V4, P102; Somogyi R, 1997, NONLINEAR ANAL-THEOR, V30, P1815, DOI 10.1016/S0362-546X(97)00217-4; Somogyi R, 1996, COMPLEXITY, V1, P45, DOI DOI 10.1002/CPLX.6130010612; THOMAS R, 1978, J THEOR BIOL, V73, P631, DOI 10.1016/0022-5193(78)90127-3; THOMAS R, 1973, J THEOR BIOL, V42, P563, DOI 10.1016/0022-5193(73)90247-6; VanBogelen RA, 1999, TRENDS MICROBIOL, V7, P320, DOI 10.1016/S0966-842X(99)01540-1; Weaver D C, 1999, Pac Symp Biocomput, P112; Wuensche A, 1998, Pac Symp Biocomput, P89; WUENSCHE A, 1993, SFI STUDIES SCI COMP, P465; Yagil G, 1975, Curr Top Cell Regul, V9, P183	29	141	150	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					846	854		10.1096/fj.00-0361com	http://dx.doi.org/10.1096/fj.00-0361com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259403				2022-12-28	WOS:000167419500042
J	Tsai, JC; Liu, LX; Cooley, BC; Dichiara, MR; Topper, JN; Aird, WC				Tsai, JC; Liu, LX; Cooley, BC; Dichiara, MR; Topper, JN; Aird, WC			The Egr-1 promoter contains information for constitutive and inducible expression in transgenic mice	FASEB JOURNAL			English	Article									Beth Israel Deaconess Med Ctr, Dept Mol Med, Boston, MA 02215 USA; Med Coll Wisconsin, Dept Orthopaed Surg, Milwaukee, WI 53226 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA	Harvard University; Beth Israel Deaconess Medical Center; Medical College of Wisconsin; Stanford University	Aird, WC (corresponding author), Beth Israel Deaconess Med Ctr, Dept Mol Med, RW-663,330 Brookline Ave, Boston, MA 02215 USA.								0	22	23	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2000	14	13					1870	1872						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023970				2022-12-28	WOS:000089634400005
J	Akdis, CA; Joss, A; Akdis, M; Faith, A; Blaser, K				Akdis, CA; Joss, A; Akdis, M; Faith, A; Blaser, K			A molecular basis for T cell suppression by IL-10: CD28-associated IL-10 receptor inhibits CD28 tyrosine phosphorylation and phosphatidylinositol 3-kinase binding	FASEB JOURNAL			English	Article									Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland	Swiss Institute of Allergy & Asthma Research	Akdis, CA (corresponding author), Swiss Inst Allergy & Asthma Res, Obere Str 22, CH-7270 Davos, Switzerland.		Akdis, Cezmi/AAV-4844-2020	Akdis, Cezmi/0000-0001-8020-019X					0	129	133	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2000	14	12					1666	1668						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973911				2022-12-28	WOS:000089212400001
J	Barrett, P; Choi, WS; Morris, M; Morgan, P				Barrett, P; Choi, WS; Morris, M; Morgan, P			A role for tyrosine phosphorylation in the regulation and sensitization of adenylate cyclase by melatonin	FASEB JOURNAL			English	Article						pars tuberalis; tyrosine kinase; G-protein; receptors	OVINE PARS-TUBERALIS; PROTEIN-KINASE-C; SIGNAL-TRANSDUCTION; HERBIMYCIN-A; INHIBITORY RECEPTORS; CAMP ACCUMULATION; PINEAL MELATONIN; CELLS; ACTIVATION; PITUITARY	Mimicking short photoperiod melatonin signals (16 h exposure) on primary cell cultures of melatonin target cells of the ovine pars tuberalis (PT) results in an enhanced cAMP response to forskolin stimulation relative to untreated cells, a phenomenon termed sensitization. The sensitized response of PT cells may be an important aspect of the interpretation of the melatonin signal to initiate appropriate seasonal physiological responses. The aim of this study is to add to our understanding of the molecular mechanisms involved in the sensitization of PT cells by melatonin, We demonstrate that sensitization of PT cells by melatonin is mediated via a G(i)-coupled melatonin receptor. The sensitized cAMP response is not only obtained with the pharmacological tool forskolin, but also with cholera toxin, an activator of G(s alpha). Changes in the level of G(s alpha) or G(i alpha) G-protein subunits are ruled out as part of the sensitization mechanism. However, changes in tyrosine phosphorylation may be involved as tyrosine kinase inhibitors sensitize ovine PT cells and tyrosine phosphatase inhibitors significantly blunt adenylate cyclase activity, including the sensitized response to melatonin. The adenylate cyclase isoforms mediating the sensitized response may be broad as 7 of the 9 isoforms of adenylate cyclase are expressed in the PT.	Rowett Res Inst, Aberdeen AB21 9SB, Scotland	University of Aberdeen	Barrett, P (corresponding author), Rowett Res Inst, Greenburn Rd, Aberdeen AB21 9SB, Scotland.			Morgan, Peter/0000-0002-5071-6512; Barrett, Perry/0000-0003-3604-2950				Ammer H, 1996, BRAIN RES, V707, P235, DOI 10.1016/0006-8993(95)01265-6; Ammer H, 1997, MOL PHARMACOL, V52, P993, DOI 10.1124/mol.52.6.993; AVIDORREISS T, 1995, J BIOL CHEM, V270, P29732; Barrett P, 1996, MOL ENDOCRINOL, V10, P892, DOI 10.1210/me.10.7.892; BARRETT P, 1994, J NEUROENDOCRINOL, V6, P509, DOI 10.1111/j.1365-2826.1994.tb00613.x; Barrett P, 1998, ENDOCRINOLOGY, V139, P163, DOI 10.1210/en.139.1.163; BARTNESS TJ, 1989, EXPERIENTIA, V45, P939, DOI 10.1007/BF01953051; BATES MD, 1991, MOL PHARMACOL, V39, P55; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buc HA, 1996, INT J IMMUNOPHARMACO, V18, P135, DOI 10.1016/0192-0561(95)00116-6; CARLSON LL, 1989, ENDOCRINOLOGY, V125, P2670, DOI 10.1210/endo-125-5-2670; Drake PG, 1996, ENDOCRINOLOGY, V137, P4960, DOI 10.1210/en.137.11.4960; FUKAZAWA H, 1991, BIOCHEM PHARMACOL, V42, P1661; GOLDMAN B, 1981, BIOL REPROD, V24, P778, DOI 10.1095/biolreprod24.4.778; HAZLERIGG DG, 1993, ENDOCRINOLOGY, V132, P285, DOI 10.1210/en.132.1.285; HAZLERIGG DG, 1994, J ENDOCRINOL, V142, P127, DOI 10.1677/joe.0.1420127; Hazlerigg DG, 1996, ENDOCRINOLOGY, V137, P210, DOI 10.1210/en.137.1.210; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; MCNULTY S, 1995, J ENDOCRINOL, V145, P471, DOI 10.1677/joe.0.1450471; MCNULTY S, 1994, J NEUROENDOCRINOL, V6, P523, DOI 10.1111/j.1365-2826.1994.tb00615.x; MCNULTY S, 1994, MOL CELL ENDOCRINOL, V99, P73, DOI 10.1016/0303-7207(94)90148-1; MORGAN PJ, 1990, J NEUROENDOCRINOL, V2, P773, DOI 10.1111/j.1365-2826.1990.tb00639.x; MORGAN PJ, 1989, J MOL ENDOCRINOL, V3, pR5, DOI 10.1677/jme.0.003R005; Morgan PJ, 1998, J NEUROENDOCRINOL, V10, P319, DOI 10.1046/j.1365-2826.1998.00232.x; MORGAN PJ, 1995, J NEUROENDOCRINOL, V7, P361, DOI 10.1111/j.1365-2826.1995.tb00770.x; MURAKAMI Y, 1988, CANCER RES, V48, P1587; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; Nevo I, 1998, MOL PHARMACOL, V54, P419, DOI 10.1124/mol.54.2.419; Ogiwara T, 1997, J ENDOCRINOL, V152, P193, DOI 10.1677/joe.0.1520193; Ross AW, 1998, ENDOCRINOLOGY, V139, P1723, DOI 10.1210/en.139.4.1723; SCHWABE U, 1979, NATURE, V277, P143, DOI 10.1038/277143a0; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P3092, DOI 10.1073/pnas.72.8.3092; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; Tang H, 1999, J BIOL CHEM, V274, P12401, DOI 10.1074/jbc.274.18.12401; Thomas JM, 1996, MOL PHARMACOL, V49, P907; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UEHARA Y, 1988, VIROLOGY, V164, P294, DOI 10.1016/0042-6822(88)90649-6; Watts VJ, 1996, MOL PHARMACOL, V50, P966; Witt-Enderby PA, 1998, ENDOCRINOLOGY, V139, P3064, DOI 10.1210/en.139.7.3064; YUNG LY, 1995, FEBS LETT, V372, P99, DOI 10.1016/0014-5793(95)00963-A	42	25	25	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2000	14	11					1619	1628		10.1096/fj.14.11.1619	http://dx.doi.org/10.1096/fj.14.11.1619			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CN	10928997				2022-12-28	WOS:000088627800017
J	Puddicombe, SM; Polosa, R; Richter, A; Krishna, MT; Howarth, PH; Holgate, ST; Davies, DE				Puddicombe, SM; Polosa, R; Richter, A; Krishna, MT; Howarth, PH; Holgate, ST; Davies, DE			Involvement of the epidermal growth factor receptor in epithelial repair in asthma	FASEB JOURNAL			English	Article						phosphorylation; tyrphostin; remodeling; TGF-beta; c-erbB1	BRONCHOALVEOLAR LAVAGE FLUID; SUBEPITHELIAL FIBROSIS; BRONCHIAL-ASTHMA; FACTOR-ALPHA; AIRWAY RESPONSIVENESS; BASEMENT-MEMBRANE; MUCOSAL BIOPSIES; EXPRESSION; CELLS; LUNG	Epithelial damage and airway remodeling are consistent features of bronchial asthma and are correlated with disease chronicity, severity, and bronchial hyperreactivity. To examine the mechanisms that control bronchial epithelial repair, we investigated expression of the epidermal growth factor receptor (c-erbB1, EGFR) in asthmatic bronchial mucosa and studied repair responses in vitro. In biopsies from asthmatic subjects, areas of epithelial damage were frequently observed and exhibited strong EGFR immunostaining. EGFR expression was also high in morphologically intact asthmatic epithelium. Using image analysis, EGFR immunoreactivity (% of total epithelial area, median (range) was found to increase from 9.4 (4.1-20.4) in normal subjects (n=10) to 18.4 (9.3-28.9) in mild asthmatics (P<0.01, n=13) and 25.4 (15.4-31.8) in severe asthmatics (P<0.00, n=5). Epithelial EGFR immunoreactivity remained elevated in patients treated with corticosteroids and was positively correlated with subepithelial reticular membrane thickening. Using 16HBE 14o- bronchial epithelial cells, we found that EGF accelerated repair of scrape-wounded monolayers and that the EGFR-selective inhibitor, tyrphostin AG1478, inhibited both EGF-stimulated and basal wound closure whereas dexamethasone was without effect. Intrinsic activation of the EGFR was confirmed by analysis of tyrosine phosphorylated proteins, which revealed a rapid, damage-induced phosphorylation of the EGFR, irrespective of the presence of exogenous EGF. To assess the relationship between EGFR-mediated repair and tissue remodeling, release of the profibrogenic mediator TGF-beta 2 was also measured. Scrape wounding increased release of TGF-beta 2 from epithelial monolayers and EGF had no additional stimulatory effect. However, when repair was retarded with AG1478, the amount of TGF-beta 2 increased significantly. These data indicate that the EGFR may play an important role in bronchial epithelial repair in asthma and that impairment of this function may augment airway remodeling.	Southampton Gen Hosp, Sch Med, Div Resp Cell & Mol Biol, Southampton SO16 6YD, Hants, England	University of Southampton	Davies, DE (corresponding author), Southampton Gen Hosp, Sch Med, Div Resp Cell & Mol Biol, Med Specialties Level D,Ctr Block 810,Tremona Rd, Southampton SO16 6YD, Hants, England.		Davies, Donna E/H-2993-2012	Davies, Donna/0000-0002-5117-2991; Howarth, Peter/0000-0003-0619-7927				AIDA S, 1994, RESPIRATION, V61, P161; Altraja A, 1996, AM J RESP CELL MOL, V15, P482, DOI 10.1165/ajrcmb.15.4.8879182; Amishima M, 1998, AM J RESP CRIT CARE, V157, P1907, DOI 10.1164/ajrccm.157.6.9609040; ANTONIADES HN, 1993, AM J PATHOL, V142, P1099; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BARROW RE, 1993, LUNG, V171, P335, DOI 10.1007/BF00165699; Barsky SH, 1998, JNCI-J NATL CANCER I, V90, P1198, DOI 10.1093/jnci/90.16.1198; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; Boulet LP, 1997, CHEST, V112, P45, DOI 10.1378/chest.112.1.45; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; BRITTEN KM, 1993, BIOTECH HISTOCHEM, V68, P271, DOI 10.3109/10520299309105629; Campbell AM, 1997, ALLERGY, V52, P483, DOI 10.1111/j.1398-9995.1997.tb02591.x; CARPENTER G, 1991, PEPTIDE GROWTH FACTO, P69; COZENS AL, 1994, AM J RESP CELL MOL, V10, P38, DOI 10.1165/ajrcmb.10.1.7507342; Davies DE, 1999, ALLERGY, V54, P771; DEMOLY P, 1994, AM J RESP CRIT CARE, V150, P214, DOI 10.1164/ajrccm.150.1.7912988; DJUKANOVIC R, 1991, AM REV RESPIR DIS, V143, P772, DOI 10.1164/ajrccm/143.4_Pt_1.772; DUNNILL MS, 1969, THORAX, V24, P176, DOI 10.1136/thx.24.2.176; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; ERJEFALT JS, 1995, CELL TISSUE RES, V281, P305, DOI 10.1007/BF00583399; EVANS MJ, 1993, AM J RESP CELL MOL, V8, P188, DOI 10.1165/ajrcmb/8.2.188; Gizycki MJ, 1997, AM J RESP CELL MOL, V16, P664, DOI 10.1165/ajrcmb.16.6.9191468; Helmrath MA, 1998, J PEDIATR SURG, V33, P229, DOI 10.1016/S0022-3468(98)90437-7; HOLGATE ST, 1996, CIBA FDN S, V206, P5; Hoshino M, 1998, THORAX, V53, P21, DOI 10.1136/thx.53.1.21; Huang RP, 1996, J CELL BIOL, V133, P211, DOI 10.1083/jcb.133.1.211; HURD S, 1992, EUR RESPIR J, V5, P115; IRWIN CR, 1991, J PERIODONTAL RES, V26, P388, DOI 10.1111/j.1600-0765.1991.tb01727.x; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745, DOI 10.1164/ajrccm/140.6.1745; KHERADMAND F, 1994, AM J PHYSIOL-LUNG C, V267, pL728, DOI 10.1152/ajplung.1994.267.6.L728; Kumar RK, 1996, LUNG, V174, P171, DOI 10.1007/BF00173309; Laitinen A, 1997, AM J RESP CRIT CARE, V156, P951, DOI 10.1164/ajrccm.156.3.9610084; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599, DOI 10.1164/arrd.1985.131.4.599; LAWRENCE WT, 1994, CLIN DERMATOL, V12, P157, DOI 10.1016/0738-081X(94)90266-6; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; MADTES DK, 1994, AM J RESP CELL MOL, V11, P540, DOI 10.1165/ajrcmb.11.5.7524566; McCarthy DW, 1996, J INVEST DERMATOL, V106, P49, DOI 10.1111/1523-1747.ep12327214; MINOO P, 1994, ANNU REV PHYSIOL, V56, P13; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326, DOI 10.1165/ajrcmb.17.3.2733; MITAMURA T, 1995, J BIOL CHEM, V270, P1015, DOI 10.1074/jbc.270.3.1015; MONTEFORT S, 1992, THORAX, V47, P499, DOI 10.1136/thx.47.7.499; NANNEY LB, 1986, J INVEST DERMATOL, V86, P260, DOI 10.1111/1523-1747.ep12285389; Pohunek P., 1997, European Respiratory Journal Supplement, V10, p160S; Polosa R., 1998, European Respiratory Journal, V12, p317S; POLOSA R, 1990, J ALLERGY CLIN IMMUN, V86, P265, DOI 10.1016/S0091-6749(05)80075-2; Polosa R, 1999, AM J RESP CELL MOL, V20, P914, DOI 10.1165/ajrcmb.20.5.3308; POLOSA R, 2000, IN PRESS AM J RESP C; Redington AE, 1997, AM J RESP CRIT CARE, V156, P642, DOI 10.1164/ajrccm.156.2.9605065; RICHTER A, 1995, BIOCHEM PHARMACOL, V49, P367, DOI 10.1016/0006-2952(94)00423-J; ROCHE WR, 1989, LANCET, V1, P520; RUSCH V, 1993, CANCER RES, V53, P2379; SCHMIEGEL W, 1993, P NATL ACAD SCI USA, V90, P863, DOI 10.1073/pnas.90.3.863; Takeyama K, 1999, P NATL ACAD SCI USA, V96, P3081, DOI 10.1073/pnas.96.6.3081; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALYINAGY I, 1992, J INVEST DERMATOL, V99, P350, DOI 10.1111/1523-1747.ep12616672; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591, DOI 10.1164/ajrccm.156.2.9609066; Zhang SL, 1999, LAB INVEST, V79, P395	59	419	438	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2000	14	10					1362	1374		10.1096/fj.14.10.1362	http://dx.doi.org/10.1096/fj.14.10.1362			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877829				2022-12-28	WOS:000087932200011
J	Zhu, YJ; Lin, H; Lal, R				Zhu, YJ; Lin, H; Lal, R			Fresh and nonfibrillar amyloid beta protein(1-40) induces rapid cellular degeneration in aged human fibroblasts: evidence for A beta P-channel-mediated cellular toxicity	FASEB JOURNAL			English	Article						atomic force microscope; scanning probe microscopy; amyloid beta protein; ion channels; Alzheimer's disease	ATOMIC-FORCE MICROSCOPY; FAMILIAL ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; ZN2+-SENSITIVE CHANNEL; ENDOTHELIAL-CELLS; CORTICAL-NEURONS; PEPTIDE; NEUROTOXICITY; BRAIN; AGGREGATION	Alzheimer's disease (AD) is primarily nonfamilial or sporadic (SAD) in origin, although several genetic linkages are reported. Tissues from AD patients contain fibrillar plaques made of 39 to 43 amino acid-long amyloid beta peptide (A beta P), although the mechanisms of A beta P toxicity are poorly understood. A beta P1-40 is the most prevalent A beta P present in the neuronal and non-neuronal tissues from SAD patients. A beta P1-40 toxicity has been examined mainly after prolonged incubation and correlates with the age and fibrillar morphology of A beta P1-40. Globular and nonfibrillar A beta Ps are released continually during normal cellular metabolism; they elevate cellular Ca2+ and form cation-permeable channels. However, their role in cellular toxicity is poorly understood. We have used an integrated atomic force and light fluorescence microscopy (AFM-LFM), laser confocal microscopy, and calcium imaging to examine real-time and acute effect of fresh and globular A beta P1-40 on cultured, aged human, AD-free fibroblasts. AFM images show that freshly prepared A beta P1-40 in phosphate-buffered saline (PBS) are globular and do not form fiber for an extended time period. A beta P1-40 induced rapid structural modifications, including cytoskeletal reorganization, retraction of cellular processes, and loss of cell-cell contacts, within minutes of incubation. This led to eventual cellular degeneration A beta P1-40-induced degeneration was prevented by anti-A beta P antibody, zinc, and Tris, but not by tachykinin neuropeptides. In Ca2+-free extracellular medium, A beta P1-40, did not induce cellular degeneration. In the presence of extracellular Ca2+, A beta P1-40 induced a sustained increase in the cellular Ca2+. Thus, short-term and acute A beta P1-40 toxicity is mediated by Ca2+ uptake, most likely via calcium-permeable A beta P pores. Such rapid degeneration does not require fibrillar plaques, suggesting that the plaques may not have any causative role.-Zhu, Y. J., Lin, H., Lal, R. Fresh and nonfibrillar amyloid beta protein(1-40) induces rapid cellular degeneration in aged human fibroblasts: evidence for A beta P-channel-mediated cellular toxicity.	Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara	Lal, R (corresponding author), Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA.	rlal@physics.ucsb.edu						ARISPE N, 1993, P NATL ACAD SCI USA, V90, P10573, DOI 10.1073/pnas.90.22.10573; Arispe N, 1996, P NATL ACAD SCI USA, V93, P1710, DOI 10.1073/pnas.93.4.1710; BENZI G, 1995, NEUROBIOL AGING, V16, P661, DOI 10.1016/0197-4580(95)00066-N; Bhatia R, 2000, FASEB J, V14, P1233, DOI 10.1096/fasebj.14.9.1233; Blanc EM, 1997, J NEUROCHEM, V68, P1870; CALINGASAN NY, 1995, BRAIN RES, V677, P50, DOI 10.1016/0006-8993(95)00136-E; ChooSmith LP, 1997, J BIOL CHEM, V272, P22987, DOI 10.1074/jbc.272.37.22987; DICKSON DW, 1992, NEUROBIOL AGING, V13, P179, DOI 10.1016/0197-4580(92)90027-U; DURELL SR, 1994, BIOPHYS J, V67, P2137, DOI 10.1016/S0006-3495(94)80717-9; ETCHEBERRIGARAY R, 1994, SCIENCE, V264, P276, DOI 10.1126/science.8146663; GarzonRodriguez W, 1997, J BIOL CHEM, V272, P21037, DOI 10.1074/jbc.272.34.21037; Gasparini L, 1998, FASEB J, V12, P17, DOI 10.1096/fasebj.12.1.17; Geula C, 1998, NAT MED, V4, P827, DOI 10.1038/nm0798-827; Good TA, 1996, BIOPHYS J, V70, P296, DOI 10.1016/S0006-3495(96)79570-X; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; Hirakura Y, 1999, J NEUROSCI RES, V57, P458, DOI 10.1002/(SICI)1097-4547(19990815)57:4<458::AID-JNR5>3.0.CO;2-4; ITO E, 1994, P NATL ACAD SCI USA, V91, P534, DOI 10.1073/pnas.91.2.534; JOACHIM CL, 1989, NATURE, V341, P226, DOI 10.1038/341226a0; Kawahara M, 1997, BIOPHYS J, V73, P67, DOI 10.1016/S0006-3495(97)78048-2; Kawahara M, 1999, BIOPHYS J, V76, pA396; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; KOSIK K, 1992, NEUROBIOL AGING, V13, P535, DOI 10.1016/0197-4580(92)90052-Y; LAL R, 1994, AM J PHYSIOL, V266, pC1, DOI 10.1152/ajpcell.1994.266.1.C1; Lal R, 1997, INT J IMAG SYST TECH, V8, P293, DOI 10.1002/(SICI)1098-1098(1997)8:3<293::AID-IMA7>3.0.CO;2-5; LAL R, 1995, AM J PHYSIOL-CELL PH, V269, pC275, DOI 10.1152/ajpcell.1995.269.1.C275; Lane NJ, 1998, J NEUROCYTOL, V27, P707, DOI 10.1023/A:1006976400227; Li JH, 1997, CELL, V90, P917, DOI 10.1016/S0092-8674(00)80356-6; Lin H, 1999, BIOCHEMISTRY-US, V38, P11189, DOI 10.1021/bi982997c; Lin H, 2000, BIOPHYS J, V78, p177A; Liu YB, 1998, J NEUROCHEM, V71, P2322; MAESTRE GE, 1992, BRAIN RES, V599, P64, DOI 10.1016/0006-8993(92)90853-2; MAESTRE GE, 1993, BRAIN RES, V621, P145, DOI 10.1016/0006-8993(93)90311-A; MARTINS RN, 1995, NEUROREPORT, V6, P1513, DOI 10.1097/00001756-199507310-00012; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; MIRZABEKOV T, 1994, BIOCHEM BIOPH RES CO, V202, P1142, DOI 10.1006/bbrc.1994.2047; NASLUND J, 1995, NEURON, V15, P219, DOI 10.1016/0896-6273(95)90079-9; Pallitto MM, 1999, BIOCHEMISTRY-US, V38, P3570, DOI 10.1021/bi982119e; Rhee SK, 1998, J BIOL CHEM, V273, P13379, DOI 10.1074/jbc.273.22.13379; Salinero O, 1997, J NEUROSCI RES, V47, P216; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Seilheimer B, 1997, J STRUCT BIOL, V119, P59, DOI 10.1006/jsbi.1997.3859; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; Shao ZF, 1996, ADV PHYS, V45, P1, DOI 10.1080/00018739600101467; SHEARMAN MS, 1994, P NATL ACAD SCI USA, V91, P1470, DOI 10.1073/pnas.91.4.1470; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; STGEORGEHYSLOP PH, 1990, NATURE, V347, P194, DOI 10.1038/347194a0; Suo ZM, 1997, BRAIN RES, V762, P144, DOI 10.1016/S0006-8993(97)00383-1; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; Waiter MF, 1997, BIOCHEM BIOPH RES CO, V233, P760, DOI 10.1006/bbrc.1997.6547; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; ZHAO B, 1995, J NEUROSCI RES, V40, P261, DOI 10.1002/jnr.490400215	55	133	139	1	27	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2000	14	9					1244	1254		10.1096/fasebj.14.9.1244	http://dx.doi.org/10.1096/fasebj.14.9.1244			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834946				2022-12-28	WOS:000087427300021
J	Frigeri, A; Nicchia, GP; Desaphy, JF; Pierno, S; De Luca, A; Camerino, DC; Svelto, M				Frigeri, A; Nicchia, GP; Desaphy, JF; Pierno, S; De Luca, A; Camerino, DC; Svelto, M			Muscle loading modulates aquaporin-4 expression in skeletal muscle	FASEB JOURNAL			English	Article									Univ Bari, Dept Gen & Environm Physiol, I-70126 Bari, Italy; Univ Bari, Dept Pharmacobiol, Pharmacol Unit, I-70126 Bari, Italy	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro	Frigeri, A (corresponding author), Univ Bari, Dept Gen & Environm Physiol, Via Amendola 165-A, I-70126 Bari, Italy.		frigeri, Antonio/AAC-6336-2022; Desaphy, Jean-Francois/T-6191-2019; Svelto, Maria/P-6186-2014	Desaphy, Jean-Francois/0000-0001-8816-9369; De Luca, Annamaria/0000-0002-5652-7341; Svelto, Maria/0000-0002-5584-9541; Frigeri, Antonio/0000-0002-5284-2934; Conte, Diana/0000-0003-0162-9698; Pierno, Sabata/0000-0003-3121-2666	Telethon [983] Funding Source: Medline	Telethon(Fondazione Telethon)			0	45	45	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1282	1284		10.1096/fj.00-0525fje	http://dx.doi.org/10.1096/fj.00-0525fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344114				2022-12-28	WOS:000168655200036
J	Pfeifer, H; Conrad, M; Roethlein, D; Kyriakopoulos, A; Brielmeier, M; Bornkamm, GW; Behne, D				Pfeifer, H; Conrad, M; Roethlein, D; Kyriakopoulos, A; Brielmeier, M; Bornkamm, GW; Behne, D			Identification of a specific sperm nuclei selenoenzyme necessary for protamine thiol cross-linking during sperm maturation	FASEB JOURNAL			English	Article									Hahn Meitner Inst Kernforsch Berlin GmbH, Dept Mol Trace Element Res Life Sci, D-14109 Berlin, Germany; GSF, Res Ctr Environm & Hlth, Inst Clin Mol Biol & Tumor Genet, D-81377 Munich, Germany	Helmholtz Association; Helmholtz-Zentrum fuer Materialien und Energie GmbH (HZB); Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Behne, D (corresponding author), Hahn Meitner Inst Kernforsch Berlin GmbH, Dept Mol Trace Element Res Life Sci, Glienicker Str 100, D-14109 Berlin, Germany.		Conrad, Marcus/E-8792-2015; Brielmeier, Markus/M-7352-2014	Conrad, Marcus/0000-0003-1140-5612; Brielmeier, Markus/0000-0002-8715-869X					0	208	218	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1236	1238		10.1096/fj.00-0655fje	http://dx.doi.org/10.1096/fj.00-0655fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344099	Bronze			2022-12-28	WOS:000168655200021
J	Stark, LA; Din, FVN; Zwacka, RM; Dunlop, MG				Stark, LA; Din, FVN; Zwacka, RM; Dunlop, MG			Aspirin-induced activation of the NF-kappa B signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells	FASEB JOURNAL			English	Article									Western Gen Hosp, MRC, Human Genet Unit, Colon Canc Genet Grp, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Edinburgh, Dept Oncol, Div Clin & Mol Med, Colon Canc Genet Grp, Edinburgh, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Stark, LA (corresponding author), Western Gen Hosp, MRC, Human Genet Unit, Colon Canc Genet Grp, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.		Dunlop, Malcolm G/F-1973-2011; Din, Farhat/A-1944-2015	Dunlop, Malcolm G/0000-0002-3033-5851; Zwacka, Ralf/0000-0003-2821-0387					0	164	172	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1273	1275		10.1096/fj.00-0529fje	http://dx.doi.org/10.1096/fj.00-0529fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344111				2022-12-28	WOS:000168655200033
J	Zhang, CH; Hein, TW; Wang, W; Chang, CI; Kuo, L				Zhang, CH; Hein, TW; Wang, W; Chang, CI; Kuo, L			Constitutive expression of arginase in microvascular endothelial cells counteracts nitric oxide-mediated vasodilatory function	FASEB JOURNAL			English	Article									Texas A&M Univ Syst, Hlth Sci Ctr, Cardiovasc Res Inst, Dept Med Physiol, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Kuo, L (corresponding author), Texas A&M Univ Syst, Hlth Sci Ctr, Cardiovasc Res Inst, Dept Med Physiol, College Stn, TX 77843 USA.			Kuo, Lih/0000-0002-4912-6910					0	169	174	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1264	1266		10.1096/fj.00-0681fje	http://dx.doi.org/10.1096/fj.00-0681fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344108				2022-12-28	WOS:000168655200030
J	Izzotti, A; Cartiglia, C; Lewtas, J; De Flora, S				Izzotti, A; Cartiglia, C; Lewtas, J; De Flora, S			Increased DNA alterations in atherosclerotic lesions of individuals lacking the GSTM1 genotype	FASEB JOURNAL			English	Article						metabolic polymorphisms; glutathione S-transferases; smooth muscle cells; DNA adducts	TRANSFERASE M1 GSTM1; GLUTATHIONE S-TRANSFERASES; LUNG-CANCER PATIENTS; ADDUCT LEVELS; SUPERGENE FAMILY; SUSCEPTIBILITY; POLYMORPHISMS; RISK; GENE; SMOKING	Reduced glutathione (GSH) plays a critical role as an intracellular defense system providing detoxification of a broad spectrum of reactive species and their excretion as water-soluble conjugates, Conjugation of GSH with electrophiles is catalyzed by GSH S-transferases (GST), which constitute a broad family of phase II isoenzymes, Two of the GST encoding genes, GSTM1 (mu) and GSTT1 (0), have a null genotype due to their homozygous deletion that results in lack of active protein, Polymorphisms within GSTT1 and especially GSTM1 have often been associated with cancer in various organs as well as with elevated levels of DNA adducts in various cell types. We recently demonstrated that DNA adducts are consistently detectable in smooth muscle cells (SMC) of human abdominal aorta affected by atherosclerotic lesions. Here we provide evidence that levels: of adducts to SMC DNA from atherosclerotic lesions are consistently increased in individuals having the null GSTM1 genotype, whereas no association was established with the GSTT1 polymorphism. The influence of GSTM1 deletion was better expressed in never-smokers and ex-smokers than in current smokers. These findings bear relevance to the epidemiology of atherosclerosis and suggest that metabolic polymorphisms may contribute to the interindividual variability in susceptibility not only to carcinogens, but also to DNA binding atherogens.	Univ Genoa, Dept Hlth Sci, I-16132 Genoa, Italy; US EPA, Seattle, WA USA	University of Genoa; United States Environmental Protection Agency	De Flora, S (corresponding author), Univ Genoa, Dept Hlth Sci, Via A Pastore 1, I-16132 Genoa, Italy.	sdf@unige.it		izzotti, alberto/0000-0002-8588-0347				ANTTILA S, 1995, CANCER RES, V55, P3305; BELL DA, 1993, J NATL CANCER I, V85, P1159, DOI 10.1093/jnci/85.14.1159; BINKOVA B, 1999, HOMEOSTASIS HLTH DIS, V39, P168; BRIDGES B A, 1990, Mutation Research, V239, P143, DOI 10.1016/0165-1110(90)90002-S; Butkiewicz D, 1999, EUR J CANCER PREV, V8, P315, DOI 10.1097/00008469-199908000-00008; Chasseaud L F, 1979, Adv Cancer Res, V29, P175, DOI 10.1016/S0065-230X(08)60848-9; Chen L, 1996, HUM GENET, V98, P551, DOI 10.1007/s004390050258; DeFlora S, 1997, FASEB J, V11, P1021, DOI 10.1096/fasebj.11.12.9337155; DeFlora S, 1996, MUTAT RES-REV GENET, V366, P197, DOI 10.1016/S0165-1110(96)00043-7; dErrico A, 1996, BIOMARKERS, V1, P149, DOI 10.3109/13547509609079352; GUPTA RC, 1988, CARCINOGENESIS, V9, P1687, DOI 10.1093/carcin/9.9.1687; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; He NG, 1999, TOXICOL APPL PHARM, V158, P177, DOI 10.1006/taap.1999.8700; He NG, 1998, TOXICOL APPL PHARM, V152, P83, DOI 10.1006/taap.1998.8511; Hou SM, 2000, CARCINOGENESIS, V21, P49, DOI 10.1093/carcin/21.1.49; Izzotti A, 1998, FREE RADICAL RES, V28, P165, DOI 10.3109/10715769809065802; KATO S, 1995, J NATL CANCER I, V87, P902, DOI 10.1093/jnci/87.12.902; KETTERER B, 1992, ENVIRON HEALTH PERSP, V98, P87, DOI 10.2307/3431252; Kleyn PW, 1998, SCIENCE, V281, P1820, DOI 10.1126/science.281.5384.1820; Li RL, 2000, ATHEROSCLEROSIS, V149, P451, DOI 10.1016/S0021-9150(99)00483-9; Margaglione M, 1996, ARTERIOSCL THROM VAS, V16, P304, DOI 10.1161/01.ATV.16.2.304; MCWILLIAMS JE, 1995, CANCER EPIDEM BIOMAR, V4, P589; Meister A., 1989, GLUTATHIONE CHEM BIO, P361; Mooney LA, 1997, CARCINOGENESIS, V18, P503, DOI 10.1093/carcin/18.3.503; NELSON HH, 1995, CARCINOGENESIS, V16, P1243, DOI 10.1093/carcin/16.5.1243; PEMBLE S, 1994, BIOCHEM J, V300, P271, DOI 10.1042/bj3000271; Perera FP, 1997, SCIENCE, V278, P1068, DOI 10.1126/science.278.5340.1068; PESSAHRASMUSSEN H, 1990, INT ANGIOL, V9, P70; Peyser PA, 1997, EPIDEMIOL REV, V19, P80, DOI 10.1093/oxfordjournals.epirev.a017949; Rojas M, 2000, CARCINOGENESIS, V21, P35, DOI 10.1093/carcin/21.1.35; Rollinson S, 2000, CARCINOGENESIS, V21, P43, DOI 10.1093/carcin/21.1.43; SEIDEGARD J, 1988, P NATL ACAD SCI USA, V85, P7293, DOI 10.1073/pnas.85.19.7293; SHIELDS PG, 1993, CANCER RES, V53, P3486; SING CF, 1985, AM J HUM GENET, V37, P268; Taningher M, 1999, MUTAT RES-REV MUTAT, V436, P227, DOI 10.1016/S1383-5742(99)00005-8; ToFigueras J, 1997, CARCINOGENESIS, V18, P1529, DOI 10.1093/carcin/18.8.1529; Van Schooten FJ, 1998, FASEB J, V12, P1409, DOI 10.1096/fasebj.12.13.1409; Wilson MH, 2000, FASEB J, V14, P791, DOI 10.1096/fasebj.14.5.791; ZHONG S, 1993, CARCINOGENESIS, V14, P1821, DOI 10.1093/carcin/14.9.1821	39	74	76	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2001	15	3					752	757		10.1096/fj.00-0312com	http://dx.doi.org/10.1096/fj.00-0312com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259393				2022-12-28	WOS:000167419500032
J	Tonko, M; Ausserlechner, MJ; Bernhard, D; Helmberg, A; Kofler, R				Tonko, M; Ausserlechner, MJ; Bernhard, D; Helmberg, A; Kofler, R			Gene expression profiles of proliferating vs. G1/G0 arrested human leukemia cells suggest a mechanism for glucocorticoid-induced apoptosis	FASEB JOURNAL			English	Article						glucocorticoid-induced gene regulation; DNA chip expression profiling; acute lymphoid leukemia; pathophysiology	RECEPTOR EXPRESSION; T-CELLS; LYMPHOBLASTS; METABOLISM; RESISTANCE; BCL-2; LINES	Glucocorticoids (GC) have pronounced effects on metabolism, differentiation, proliferation, and cell survival (1). In certain lymphocytes and lymphocyte-related malignancies, GC inhibit proliferation and induce apoptotic cell. death, which has led to their extensive use in the therapy of malignant lymphoproliferative disorders (2). Most of these effects result from regulation of gene expression via the GC receptor (GI), a ligand-activated transcription factor (3). Although hundreds of genes are regulated by GC (1), how certain biological GC effects relate to individual gene regulation remains enigmatic. To address this question with respect to GC-induced cell cycle arrest and apoptosis, we applied DNA chip technology (4, 5) to determine gene expression profiles in proliferating and G1/G0-arrested (by conditional expression of the CDK inhibitor p16/INK4a) acute lymphoblastic T cells undergoing GC-induced apoptosis. Of 7074 genes tested, 163 were found to be regulated by dexamethasone in the first 8 h in proliferating cells and 66 genes in G1/G0-arrested cells. An almost nonoverlapping set of genes (i.e., only eight genes) was coordinately regulated in proliferating and arrested cells. Analysis of the regulated genes supports the concept that GC-induced apoptosis results from positive GR autoregulation entailing persistent down-regulation of metabolic pathways critical for survival.-Tonko, Ml, Ausserlechner, M. J., Bernhard, D., Helmberg, A., Kofler, R. Gene expression profiles of proliferating vs. G1/G0 arrested human leukemia cells suggest a mechanism for glucocorticoid-induced apoptosis.	Univ Innsbruck, Tyrolean Canc Res Inst, A-6020 Innsbruck, Austria; Univ Innsbruck, Inst Gen & Expt Pathol, Div Mol Pathophysiol, A-6020 Innsbruck, Austria	University of Innsbruck; University of Innsbruck	Kofler, R (corresponding author), Univ Innsbruck, Tyrolean Canc Res Inst, Innrain 66, A-6020 Innsbruck, Austria.	Reinhard.Kofler@uibk.ac.at		Ausserlechner, Michael/0000-0002-1015-2302; Bernhard, David/0000-0002-2383-6607				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; AUSSERLECHNER MJ, 2001, IN PRESS J BIOL CHEM; BANSAL N, 1991, FASEB J, V5, P211, DOI 10.1096/fasebj.5.2.2004665; Bernhard D, 1999, FASEB J, V13, P1991, DOI 10.1096/fasebj.13.14.1991; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; EISEN LP, 1988, J BIOL CHEM, V263, P12044; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J; Geley S, 1996, REV PHYSIOL BIOCH P, V128, P1; Geley S, 1996, CANCER RES, V56, P5033; Hartmann BL, 1999, ONCOGENE, V18, P713, DOI 10.1038/sj.onc.1202339; HELMBERG A, 1990, J IMMUNOL, V145, P4332; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Kalenik JL, 1997, NUCLEIC ACIDS RES, V25, P843, DOI 10.1093/nar/25.4.843; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Mellitzer G, 1999, NATURE, V400, P77, DOI 10.1038/21907; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Ramdas J, 1999, CANCER RES, V59, P1378; SCHMIDT TJ, 1994, RECEPTOR, V4, P229; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; SIMONET WS, 1989, J BIOL CHEM, V264, P569; STEPHENS JL, 1984, BIOCHEM J, V219, P689, DOI 10.1042/bj2190689; STOOLMAN LM, 1993, J CELL PHYSIOL, V154, P593, DOI 10.1002/jcp.1041540318; Strasser-Wozak EMC, 1998, CELL DEATH DIFFER, V5, P687, DOI 10.1038/sj.cdd.4400402; STRASSERWOZAK EMC, 1995, CANCER RES, V55, P348; Vogel P, 1996, BBA-GENE STRUCT EXPR, V1309, P200, DOI 10.1016/S0167-4781(96)00177-7; WARBURG O, 1926, METABOLISM TUMORS	27	94	96	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					693	699		10.1096/fj.00-0327com	http://dx.doi.org/10.1096/fj.00-0327com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259387				2022-12-28	WOS:000167419500026
J	Wei, L; Wang, L; Carson, JA; Agan, JE; Imanaka-Yoshida, K; Schwartz, RJ				Wei, L; Wang, L; Carson, JA; Agan, JE; Imanaka-Yoshida, K; Schwartz, RJ			beta 1 integrin and organized actin filaments facilitate cardiomyocyte-specific RhoA-dependent activation of the skeletal alpha-actin promoter	FASEB JOURNAL			English	Article						serum response factor; cardiac hypertrophy; actin polymerization	SERUM RESPONSE FACTOR; CARDIAC MYOCYTE HYPERTROPHY; RAT VENTRICULAR MYOCYTES; BINDING PROTEIN-RHO; GENE-TRANSCRIPTION; FOCAL ADHESIONS; CELL-ADHESION; STRESS FIBERS; F-ACTIN; GROWTH	Activation of RhoA GTPase causes actin filament bundling into stress fibers, integrin clustering, and focal adhesion formation through its action on actin cytoskeleton organization, RhoA also regulates transcriptional activity of serum response factor (SRF), Recent studies in NM 3T3 fibroblasts have shown that SRF activation by RhoA does not require an organized cytoskeleton and may be regulated by G-actin level, In cardiac myocytes, the organization of actin fibers into myofibrils is one of the primary characteristics of cardiac differentiation and hypertrophy, The primary purpose of this study was to examine if RhoA regulates SRF-dependent gene expression in neonatal cardiomyocytes in a manner different from that observed in fibroblasts, Our results show that RhoA-dependent skeletal alpha -actin promoter activation requires beta1 integrin and a functional cytoskeleton in cardiomyocytes but not in NM 3T3 fibroblasts, Activation of the alpha -actin promoter by RhoA is greatly potentiated (up to 15-fold) by coexpression of the integrin beta 1A or beta 1D isoform but is significantly reduced by 70% with a coexpressed dominant negative mutant of beta1 integrin, Furthermore, clustering of beta1 integrin with anti-beta1 integrin antibodies potentiates synergistic RhoA and beta1 integrin activation of the alpha -actin promoter. Cytochalasin D and latrunculin B, inhibitors of actin polymerization, significantly reduced RhoA-induced activation of the alpha -actin promoter, Jasplakinolide, an actin polymerizing agent, mimics the synergistic effect of RhoA and beta1 integrin on the actin promoter, These observations support the concept that RhoA regulates SRF-dependent cardiac gene expression through cross-talk with beta1 integrin signal pathway via an organized actin cytoskeleton.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Univ S Carolina, Sch Publ Hlth, Dept Exercise Sci, Columbia, SC 29208 USA; Mie Univ, Sch Med, Dept Pathol, Tsu, Mie 514, Japan	Baylor College of Medicine; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Mie University	Schwartz, RJ (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza,Room 145E, Houston, TX 77030 USA.		Carson, James/Q-5693-2019	Carson, James/0000-0003-3733-8796	NHLBI NIH HHS [R01 HL50422, P01 HL49953] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049953] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aikawa R, 1999, CIRC RES, V84, P458, DOI 10.1161/01.RES.84.4.458; AKIYAMA SK, 1994, J BIOL CHEM, V269, P15961; Aoki H, 1998, CIRC RES, V82, P666, DOI 10.1161/01.RES.82.6.666; Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; BELAGULI NS, 2000, IN PRESS MOL CELL BI; Belkin AM, 1996, J CELL BIOL, V132, P211, DOI 10.1083/jcb.132.1.211; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; BUBB MR, 1994, J BIOL CHEM, V269, P14869; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Chen CY, 1996, MOL CELL BIOL, V16, P6372; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; Cone M, 1987, FEBS LETT, V213, P316; Dabiri GA, 1997, P NATL ACAD SCI USA, V94, P9493, DOI 10.1073/pnas.94.17.9493; DLUGOSZ AA, 1984, J CELL BIOL, V99, P2268, DOI 10.1083/jcb.99.6.2268; FLANAGAN MD, 1980, J BIOL CHEM, V255, P835; Groisman R, 1996, J BIOL CHEM, V271, P5258; GROUX H, 1989, NATURE, V339, P152, DOI 10.1038/339152a0; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HILENSKI LL, 1992, CELL MOTIL CYTOSKEL, V21, P87, DOI 10.1002/cm.970210202; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hoshijima M, 1998, J BIOL CHEM, V273, P7725, DOI 10.1074/jbc.273.13.7725; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; LAFLAMME SE, 1992, J CELL BIOL, V117, P437, DOI 10.1083/jcb.117.2.437; LEE TC, 1991, MOL CELL BIOL, V11, P5090, DOI 10.1128/MCB.11.10.5090; LUKASHEV ME, 1994, J BIOL CHEM, V269, P18311; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MUSCAT GEO, 1987, MOL CELL BIOL, V7, P4089, DOI 10.1128/MCB.7.11.4089; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; Paradis P, 1996, J BIOL CHEM, V271, P10827, DOI 10.1074/jbc.271.18.10827; PARKER TG, 1992, J BIOL CHEM, V267, P3343; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RHEE D, 1994, CELL MOTIL CYTOSKEL, V28, P1, DOI 10.1002/cm.970280102; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 1999, NAT CELL BIOL, V1, pE64, DOI 10.1038/11034; Ross RS, 1998, CIRC RES, V82, P1160, DOI 10.1161/01.RES.82.11.1160; Sah VP, 1996, J BIOL CHEM, V271, P31185, DOI 10.1074/jbc.271.49.31185; SCHWARTZ K, 1986, CIRC RES, V59, P551, DOI 10.1161/01.RES.59.5.551; Sharp WW, 1997, AM J PHYSIOL-HEART C, V273, pH546, DOI 10.1152/ajpheart.1997.273.2.H546; SIMPSON PC, 1989, J MOL CELL CARDIOL, V21, P79, DOI 10.1016/0022-2828(89)90774-8; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; Takano H, 1998, MOL CELL BIOL, V18, P1580, DOI 10.1128/MCB.18.3.1580; Taylor JM, 2000, J BIOL CHEM, V275, P19250, DOI 10.1074/jbc.M909099199; TERRACIO L, 1991, CIRC RES, V68, P734, DOI 10.1161/01.RES.68.3.734; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; VanderFlier A, 1997, DEV DYNAM, V210, P472, DOI 10.1002/(SICI)1097-0177(199712)210:4<472::AID-AJA10>3.0.CO;2-9; Wei L, 1998, J BIOL CHEM, V273, P30287, DOI 10.1074/jbc.273.46.30287; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	52	62	65	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					785	796		10.1096/fj.00-026com	http://dx.doi.org/10.1096/fj.00-026com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259397				2022-12-28	WOS:000167419500036
J	Andley, UP; Song, Z; Wawrousek, EF; Brady, JP; Bassnett, S; Fleming, TP				Andley, UP; Song, Z; Wawrousek, EF; Brady, JP; Bassnett, S; Fleming, TP			Lens epithelial cells derived from alpha B-crystallin knockout mice demonstrate hyperproliferation and genomic instability	FASEB JOURNAL			English	Article						molecular chaperone; nuclear; immortalization; ploidy	NIH 3T3 FIBROBLASTS; LARGE-T-ANTIGEN; A-CRYSTALLIN; MOLECULAR CHAPERONE; SPINDLE CHECKPOINT; CYCLE REGULATION; MOUSE LENS; HA-RAS; V-MOS; EXPRESSION	alphaB-crystallin is a member of the small heat shock protein family and can act as a molecular chaperone preventing the in vitro aggregation of other proteins denatured by heat or other stress conditions. Expression of alphaB-crystallin increases in cells exposed to stress and enhanced in tumors of neuroectodermal origin and in many neurodegenerative diseases. In the present study, we examined the properties of lens epithelial cells derived from mice in which the alphaB-crystallin gene had been knocked out. Primary rodent cells immortalize spontaneously in tissue culture with a frequency of 10(-5) to 10(-6). Primary lens epithelial cells derived from alphaB-crystallin(-/-) mice produced hyperproliferative clones at a frequency of 7.6 x 10(-2), four orders of magnitude greater than predicted by spontaneous immortalization (1), Hyperproliferative alphaB-crystallin(-/-) cells were shown to be truly immortal since they have been passaged for more than 100 population doublings without any diminution in growth potential. In striking contrast to the wild-type cells, which were diploid, the alphaB-crystallin(-/-) cultures had a high proportion of tetraploid and higher ploidy cells, indicating that the loss of alphaB-crystallin is associated with an increase in genomic instability. Further evidence of genomic instability of alphaB-crystallin(-/-) cells was observed when primary cultures were infected with Ad12SV40 hybrid virus. In striking contrast to wild-type cells, alphaB-crystallin(-/-) cells expressing SV40 T antigen exhibited a widespread cytocidal response 2 to 3 days after attaining confluence, indicating that SV40 T antigen enhanced the intrinsic genomic instability of alphaB-crystallin(-/-) lens epithelial cells. These observations suggest that the widely distributed molecular chaperone alphaB-crystallin may play an important nuclear role in maintaining genomic integrity.	Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; NEI, NIH, Bethesda, MD 20892 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Andley, UP (corresponding author), Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, 660 S Euclid Ave,Campus Box 8096, St Louis, MO 63110 USA.		Wawrousek, Eric/A-4547-2008	Bassnett, Steven/0000-0002-8337-2760; Andley, Usha/0000-0001-7049-7591	NATIONAL EYE INSTITUTE [R01EY009852, Z01EY000286, P30EY002687, R01EY005681] Funding Source: NIH RePORTER; NEI NIH HHS [R01EY05681, P30 EY002687, EY02687, R01EY09852] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Andley UP, 1998, J BIOL CHEM, V273, P31252, DOI 10.1074/jbc.273.47.31252; ANDLEY UP, 1994, INVEST OPHTH VIS SCI, V35, P3094; Arrigo AP, 1995, NEUROPATH APPL NEURO, V21, P488, DOI 10.1111/j.1365-2990.1995.tb01094.x; BASSNETT S, 1994, J CELL SCI, V107, P799; Bhat SP, 1999, EUR J CELL BIOL, V78, P143, DOI 10.1016/S0171-9335(99)80016-8; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; Brady JP, 1997, P NATL ACAD SCI USA, V94, P884, DOI 10.1073/pnas.94.3.884; CHIESA R, 1989, BIOCHEM BIOPH RES CO, V162, P1494, DOI 10.1016/0006-291X(89)90843-7; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DEJONG WW, 1993, MOL BIOL EVOL, V10, P103; Djabali K, 1999, EXP CELL RES, V253, P649, DOI 10.1006/excr.1999.4679; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; Fleming TP, 1998, INVEST OPHTH VIS SCI, V39, P1387; Gennarelli M, 1998, CELL BIOCHEM FUNCT, V16, P117, DOI 10.1002/(SICI)1099-0844(199806)16:2<117::AID-CBF776>3.0.CO;2-X; Gonin S, 1997, CELL STRESS CHAPERON, V2, P238, DOI 10.1379/1466-1268(1997)002<0238:TBTAAO>2.3.CO;2; GRIEP AE, 1993, J VIROL, V67, P1373, DOI 10.1128/JVI.67.3.1373-1384.1993; GRIEP AE, 1989, GENE DEV, V3, P1075, DOI 10.1101/gad.3.7.1075; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hopfer U, 1996, AM J PHYSIOL-CELL PH, V270, pC1, DOI 10.1152/ajpcell.1996.270.1.C1; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Iwaki A, 1997, GENOMICS, V45, P386, DOI 10.1006/geno.1997.4956; IWAKI T, 1991, AM J PATHOL, V139, P1303; IWAKI T, 1991, CANCER, V68, P2230, DOI 10.1002/1097-0142(19911115)68:10<2230::AID-CNCR2820681023>3.0.CO;2-7; KANTOROW M, 1995, J BIOL CHEM, V270, P17215, DOI 10.1074/jbc.270.29.17215; Kappler R, 1999, CARCINOGENESIS, V20, P1433, DOI 10.1093/carcin/20.8.1433; KLEMENZ R, 1991, MOL CELL BIOL, V11, P803, DOI 10.1128/MCB.11.2.803; KLEMENZ R, 1989, ONCOGENE, V4, P799; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Peterson W D Jr, 1979, Methods Enzymol, V58, P164; PIATIGORSKY J, 1994, EXS, V71, P241; Rakic JM, 1997, EXP EYE RES, V64, P67, DOI 10.1006/exer.1996.0179; Reddan J R, 1989, Lens Eye Toxic Res, V6, P687; REDDAN JR, 1982, CELL BIOL EYE, P299; Renkawek K, 1999, NEUROREPORT, V10, P2273, DOI 10.1097/00001756-199908020-00009; RHIM JS, 1993, CRIT REV ONCOGENESIS, V4, P313; Robinson ML, 1996, INVEST OPHTH VIS SCI, V37, P2276; RUSSELL P, 1977, INVEST OPHTH VIS SCI, V21, P169; Sax C M, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P155; Schmutte C, 1999, ANTICANCER RES, V19, P4665; SEABRIGH.M, 1971, LANCET, V2, P971; SPECTOR A, 1985, P NATL ACAD SCI USA, V82, P4712, DOI 10.1073/pnas.82.14.4712; Thornton C, 1999, SEMIN NEUROL, V19, P25, DOI 10.1055/s-2008-1040823; Tlsty TD, 1998, CURR OPIN CELL BIOL, V10, P647, DOI 10.1016/S0955-0674(98)80041-0; VANNOORT JM, 1995, NATURE, V375, P798, DOI 10.1038/375798a0; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Wawrousek E. F., 1998, IOVS, V39, pS523; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; YAMADA T, 1990, CURR EYE RES, V9, P31, DOI 10.3109/02713689009000052; Yin XY, 1999, ONCOGENE, V18, P1177, DOI 10.1038/sj.onc.1202410; Zelenka PS, 1997, PROG RETIN EYE RES, V16, P303, DOI 10.1016/S1350-9462(96)00024-9	52	60	62	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2001	15	1					221	229		10.1096/fj.00-0296com	http://dx.doi.org/10.1096/fj.00-0296com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149910				2022-12-28	WOS:000166312400031
J	Albrecht-Buehler, G				Albrecht-Buehler, G			Reversible, excitation light-induced enhancement of fluorescence of live mammalian mitochondria	FASEB JOURNAL			English	Article									Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA	Northwestern University	Albrecht-Buehler, G (corresponding author), Northwestern Univ, Sch Med, Dept Cell & Mol Biol, 305 E Chicago Ave, Chicago, IL 60611 USA.	g-buehler@nwu.edu							0	9	18	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2000	14	13					1864	1866		10.1096/fj.00-0028fje	http://dx.doi.org/10.1096/fj.00-0028fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023966				2022-12-28	WOS:000089634400003
J	Egashira, K; Koyanagi, M; Kitamoto, S; Ni, WH; Kataoka, C; Morishita, R; Kaneda, Y; Akiyama, C; Nishida, KI; Sueishi, K; Takeshita, A				Egashira, K; Koyanagi, M; Kitamoto, S; Ni, WH; Kataoka, C; Morishita, R; Kaneda, Y; Akiyama, C; Nishida, KI; Sueishi, K; Takeshita, A			Anti-monocyte chemoattractant protein-1 gene therapy inhibits vascular remodeling in rats: blockade of MCP-1 activity after intramuscular transfer of a mutant gene inhibits vascular remodeling induced by chronic blockade of NO synthesis	FASEB JOURNAL			English	Article						endothelium-derived relaxing factors; remodeling; growth substances; inflammation; adhesion molecule; monocyte chemoattractant protein-1; gene transfer	NITRIC-OXIDE SYNTHESIS; ATHEROSCLEROTIC LESIONS; EXPRESSION; CHEMOKINES; INDUCTION; MICE	Monocyte chemoattractant protein-1 (MCP-1) may play an essential part in the formation of arteriosclerosis by recruiting monocytes into the arterial wall. Thus, we devised a new strategy for anti-MCP-1 gene therapy against arteriosclerosis by transfecting an amino-terminal deletion mutant (missing the amino-terminal amino acids 2 to 8) of the human MCP-1 gene into a remote organ (skeletal muscles), Intramuscular transduction with the mutant MCP-1 gene blocked monocyte recruitment induced by a subcutaneous injection of recombinant MCP-1. In a rat model in which the chronic inhibition of endothelial nitric oxide synthesis induces early vascular inflammation as well as subsequent coronary vascular remodeling, this strategy suppressed monocyte recruitment into the coronary vessels and the development of vascular medial thickening, but did not reduce perivascular fibrosis. Thus, MCP-1 is necessary far the development of medial thickening but not for fibrosis in this model. This new strategy may be a useful and feasible gene therapy against arteriosclerosis.	Kyushu Univ, Grad Sch Med Sci, Dept Cardiovasc Med, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Pathol, Higashi Ku, Fukuoka 8128582, Japan; Osaka Univ, Sch Med, Div Gene Therapy Sci, Osaka, Japan; Daiichi Pharmaceut Co Ltd, New Prod Res Labs, Tokyo, Japan	Kyushu University; Kyushu University; Osaka University; Daiichi Sankyo Company Limited	Egashira, K (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Cardiovasc Med, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.							Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; DE CR, 1995, J CLIN INVEST, V96, P60; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; Katoh M, 1998, CIRC RES, V83, P743, DOI 10.1161/01.RES.83.7.743; Kumar AG, 1997, CIRCULATION, V95, P693, DOI 10.1161/01.CIR.95.3.693; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Takemoto M, 1997, J CLIN INVEST, V99, P278, DOI 10.1172/JCI119156; TAKEYA M, 1993, HUM PATHOL, V24, P534, DOI 10.1016/0046-8177(93)90166-E; Tomita H, 1998, ARTERIOSCL THROM VAS, V18, P1456, DOI 10.1161/01.ATV.18.9.1456; Tsao PS, 1997, CIRCULATION, V96, P934; Ueki T, 1999, NAT MED, V5, P226, DOI 10.1038/5593; Usui M, 2000, CIRCULATION, V101, P305, DOI 10.1161/01.CIR.101.3.305; Yamashiro S, 1998, INT ARCH ALLERGY IMM, V115, P15, DOI 10.1159/000023825; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P5252, DOI 10.1073/pnas.88.12.5252; ZEIHER AM, 1995, CIRC RES, V76, P980, DOI 10.1161/01.RES.76.6.980; ZHANG YJ, 1995, MOL CELL BIOL, V15, P4851	19	75	80	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2000	14	13					1974	1978		10.1096/fj.00-0141com	http://dx.doi.org/10.1096/fj.00-0141com			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023981				2022-12-28	WOS:000089634400016
J	Rauen, U; Petrat, F; Li, TJ; De Groot, H				Rauen, U; Petrat, F; Li, TJ; De Groot, H			Hypothermia injury/cold-induced apoptosis - evidence of an increase in chelatable iron causing oxidative injury in spite of low O-2(-)/H2O2 formation	FASEB JOURNAL			English	Article						hydrogen peroxide; superoxide anion radical; hydroxyl radical; Fenton reaction; transition metal ions	LIVER ENDOTHELIAL-CELLS; ELECTRON-PARAMAGNETIC-RESONANCE; DESFERRIOXAMINE-AVAILABLE IRON; CULTURED RAT HEPATOCYTES; MOLECULAR-WEIGHT-IRON; REACTIVE OXYGEN; LIPID-PEROXIDATION; REOXYGENATION INJURY; REPERFUSION INJURY; HYDROGEN-PEROXIDE	When incubated at 4 degrees C, cultured rat hepatocytes or liver endothelial cells exhibit pronounced injury and, during earlier rewarming, marked apoptosis. Both processes are mediated by reactive oxygen species, and marked protective effects of iron chelators as well as the protection provided by various other antioxidants suggest that hydroxyl radicals, formed by classical Fenton chemistry, are involved. However, when we measured the Fenton chemistry educt hydrogen peroxide and its precursor, the superoxide anion radical, formation of both had markedly decreased and steady-state levels of hydrogen peroxide did not alter during cold incubation of either liver endothelial cells or hepatocytes. Similarly, there was no evidence of an increase in O-2(-)/H2O2 release contributing to cold-induced apoptosis occurring on rewarming. In contrast to the release/ level of O-2(-) and H2O2, cellular homeostasis of the transition metal iron is likely to play a key role during cold incubation of cultured hepatocytes: the hepatocellular pool of chelatable iron, measured on a single-cell level using laser scanning microscopy and the fluorescent indicator phen green, increased from 3.1 +/- 2.3 mu M (before cold incubation) to 7.7 +/- 2.4 mu M within 90 min after initiation of cold incubation. This increase in the cellular chelatable iron pool was reversible on rewarming after short periods of cold incubation. The cold-induced increase in the hepatocellular chelatable iron pool was confirmed using the calcein method. These data suggest that free radical-mediated hypothermia injury/cold-induced apoptosis is primarily evoked by alterations in the cellular iron homeostasis/a rapid increase in the cellular chelatable iron pool and not by increased formation of O-2(-)/H2O2.	Univ Klinikum Essen, Inst Physiol Chem, D-45132 Essen, Germany	University of Duisburg Essen	Rauen, U (corresponding author), Univ Klinikum Essen, Inst Physiol Chem, Hufelandstr 55, D-45132 Essen, Germany.	ursula.rauen@uni-essen.de	Li, Tongju/AAX-4655-2020; Rauen, Ursula/N-2137-2014	Li, Tongju/0000-0001-8896-5840; 				BALIGA R, 1993, BIOCHEM J, V291, P901, DOI 10.1042/bj2910901; BALLA G, 1990, J LAB CLIN MED, V116, P546; BLOUIN A, 1977, J CELL BIOL, V72, P441, DOI 10.1083/jcb.72.2.441; BREUER W, 1995, AM J PHYSIOL-CELL PH, V268, pC1354, DOI 10.1152/ajpcell.1995.268.6.C1354; BREUER W, 1995, J BIOL CHEM, V270, P24209, DOI 10.1074/jbc.270.41.24209; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; CAIRO G, 1995, J BIOL CHEM, V270, P700, DOI 10.1074/jbc.270.2.700; DEGROOT H, 1994, HEPATO-GASTROENTEROL, V41, P328; DEGROOT H, 1992, TOXICOL LETT, V63, P111, DOI 10.1016/0378-4274(92)90002-2; DEGROOT H, 1991, BIOL CHEM H-S, V372, P35, DOI 10.1515/bchm3.1991.372.1.35; Dieter P, 1995, BIOL SIGNAL, V4, P331; FRIED R, 1974, METHODEN ENZYMATISCH, P682; FULLER BJ, 1987, TRANSPLANTATION, V43, P604; Garner B, 1998, FREE RADICAL RES, V29, P103, DOI 10.1080/10715769800300121; Garner B, 1997, FREE RADICAL RES, V27, P487, DOI 10.3109/10715769709065788; Ghersi-Egea JF, 1998, FREE RADICAL BIO MED, V24, P1074, DOI 10.1016/S0891-5849(97)00387-0; GOWER JD, 1989, ANAL BIOCHEM, V180, P126, DOI 10.1016/0003-2697(89)90099-7; HALLEZ P, 1890, REV BIOL NORD FRANCE, V2, P1; HEALING G, 1990, BIOCHEM PHARMACOL, V39, P1239, DOI 10.1016/0006-2952(90)90269-Q; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; KOZLOV AV, 1992, FREE RADICAL BIO MED, V13, P9, DOI 10.1016/0891-5849(92)90159-E; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; Kuznetsov AV, 1999, TRANSPLANT P, V31, P992, DOI 10.1016/S0041-1345(98)01871-5; LITTAUER A, 1992, AM J PHYSIOL, V262, pG1015, DOI 10.1152/ajpgi.1992.262.6.G1015; MAGNI F, 1994, FREE RADICAL BIO MED, V16, P465, DOI 10.1016/0891-5849(94)90124-4; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; NIELSEN P, 1993, INT J BIOCHEM, V25, P223, DOI 10.1016/0020-711X(93)90010-C; NOLL T, 1987, ARCH BIOCHEM BIOPHYS, V252, P284, DOI 10.1016/0003-9861(87)90033-6; Ollinger K, 1997, J BIOL CHEM, V272, P23707, DOI 10.1074/jbc.272.38.23707; Peters SMA, 1998, TRANSPLANTATION, V65, P625, DOI 10.1097/00007890-199803150-00005; Petrat F, 1999, HEPATOLOGY, V29, P1171, DOI 10.1002/hep.510290435; Petrat F, 2000, ARCH BIOCHEM BIOPHYS, V376, P74, DOI 10.1006/abbi.2000.1711; Qian SY, 1999, FREE RADICAL BIO MED, V26, P1447, DOI 10.1016/S0891-5849(99)00002-7; RAUEN U, 1994, ZBL CHIR, V119, P322; Rauen U, 1997, FREE RADICAL BIO MED, V22, P17, DOI 10.1016/S0891-5849(96)00273-0; Rauen U, 1997, FREE RADICAL BIO MED, V23, P392, DOI 10.1016/S0891-5849(96)00618-1; Rauen U, 1998, FREE RADICAL BIO MED, V24, P1316, DOI 10.1016/S0891-5849(97)00456-5; Rauen U, 1997, HEPATOLOGY, V26, P351, DOI 10.1002/hep.510260215; RAUEN U, 1993, TRANSPLANTATION, V55, P469, DOI 10.1097/00007890-199303000-00002; Rauen U, 1999, FASEB J, V13, P155, DOI 10.1096/fasebj.13.1.155; ROOT RK, 1975, J CLIN INVEST, V55, P945, DOI 10.1172/JCI108024; ROSSER BG, 1995, GASTROENTEROLOGY, V108, P252, DOI 10.1016/0016-5085(95)90032-2; RYAN TP, 1992, CRIT REV TOXICOL, V22, P119, DOI 10.3109/10408449209146308; SERGENT O, 1995, BIOL TRACE ELEM RES, V47, P185, DOI 10.1007/BF02790116; Staubli A, 1998, AM J PHYSIOL-GASTR L, V274, pG1031, DOI 10.1152/ajpgi.1998.274.6.G1031; SteinlechnerMaran R, 1997, TRANSPLANTATION, V63, P136, DOI 10.1097/00007890-199701150-00025; Thomas F, 1999, J BIOL CHEM, V274, P13375, DOI 10.1074/jbc.274.19.13375; Turner CP, 1998, FREE RADICAL BIO MED, V24, P401, DOI 10.1016/S0891-5849(97)00270-0; Vreugdenhil PK, 1997, TRANSPLANT INT, V10, P379, DOI 10.1007/s001470050074; WOLFF SP, 1994, METHOD ENZYMOL, V233, P182; Young Stephen P., 1994, P597	51	158	164	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2000	14	13					1953	1964		10.1096/fj.00-0071com	http://dx.doi.org/10.1096/fj.00-0071com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023979				2022-12-28	WOS:000089634400014
J	Stulnig, TM; Berger, M; Roden, M; Stingl, H; Raederstorff, D; Waldhausl, W				Stulnig, TM; Berger, M; Roden, M; Stingl, H; Raederstorff, D; Waldhausl, W			Elevated serum free fatty acid concentrations inhibit T lymphocyte signaling	FASEB JOURNAL			English	Article						signal transduction; calcium signaling; lipids; antigen receptors; glycosylphosphatidylinositols	INSULIN-RESISTANCE; CELLS; ALBUMIN; TRANSDUCTION; METABOLISM; RECEPTOR; BINDING; PLASMA; MECHANISMS; RESPONSES	Unbound cis-unsaturated free (i.e., nonesterified) fatty acids (FFA) inhibit T lymphocyte activation in vitro and therefore may exert immunosuppressive effects. However, in blood serum the major proportion of FFA is tightly bound to albumin, whereas unbound FFA are hardly detectable, Since serum FFA elevation occurs under pathological conditions like insulin resistance or cancer, which are often associated with a disturbed immune response, we addressed the question of whether increased serum EFA concentrations could affect T lymphocyte activation under in vivo conditions. Our studies revealed that 1) addition of pure long-chain cis-unsaturated EFA in the absence of albumin inhibited calcium response in cultured Jurkat T cells. 2) In healthy volunteers, serum FFA elevation by a lipid/heparin infusion, including predominantly unsaturated fatty acids, decreased calcium response of cultured T cells in contrast to studies without heparin, 3) Most notably, stepwise increasing serum FFA by lipid/heparin infusion also inhibited calcium response of simultaneously isolated autologous peripheral blood T lymphocytes as well as their CD4(+) and CD8(+) subsets. In conclusion, our data emphasize that serum EEA elevation is able to exert immunosuppressive effects in vivo.	Univ Vienna, Dept Internal Med 3, Div Endocrinol & Metab, A-1090 Vienna, Austria; F Hoffmann La Roche & Co Ltd, Basel, Switzerland	University of Vienna; Roche Holding	Stulnig, TM (corresponding author), Univ Vienna, Dept Internal Med 3, Div Endocrinol & Metab, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.		Roden, Michael/AAD-3843-2019	Stulnig, Thomas/0000-0003-3300-6161				ABUMRAD NA, 1981, J BIOL CHEM, V256, P9183; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BODEN G, 1991, J CLIN INVEST, V88, P960, DOI 10.1172/JCI115399; BOJESEN IN, 1994, J LIPID RES, V35, P770; BREITTMAYER JP, 1993, J BIOL CHEM, V268, P20812; BROWN RE, 1983, J IMMUNOL, V131, P1011; CHANDRA RK, 1992, NUTR RES, V12, pS137, DOI 10.1016/S0271-5317(05)80458-0; CHOW SC, 1990, BIOCHEM J, V267, P727, DOI 10.1042/bj2670727; Gamberucci A, 1997, CELL CALCIUM, V21, P375, DOI 10.1016/S0143-4160(97)90031-2; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guse AH, 1998, CRIT REV IMMUNOL, V18, P419, DOI 10.1615/CritRevImmunol.v18.i5.20; HAMAZAKI T, 1984, KIDNEY INT, V26, P81, DOI 10.1038/ki.1984.137; Hendrickson SC, 1997, MOL CELL BIOCHEM, V166, P85, DOI 10.1023/A:1006886601825; HEROLD PM, 1986, AM J CLIN NUTR, V43, P566, DOI 10.1093/ajcn/43.4.566; HULTIN M, 1992, BIOCHIM BIOPHYS ACTA, V1125, P97, DOI 10.1016/0005-2760(92)90161-N; LEGASPI A, 1987, METABOLISM, V36, P958, DOI 10.1016/0026-0495(87)90132-6; Levey DL, 1996, IMMUNOL TODAY, V17, P365, DOI 10.1016/0167-5699(96)10013-X; Lommi J, 1998, AM J CARDIOL, V81, P45, DOI 10.1016/S0002-9149(97)00804-7; MIWA H, 1987, J CHROMATOGR-BIOMED, V416, P237, DOI 10.1016/0378-4347(87)80507-8; MOUTSCHEN MP, 1992, DIABETES METAB, V18, P187; POTTER BJ, 1989, ANNU REV NUTR, V9, P253, DOI 10.1146/annurev.nu.09.070189.001345; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; RAEDERSTORFF D, 1991, LIPIDS, V26, P781, DOI 10.1007/BF02536158; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; REAVEN GM, 1988, DIABETES, V37, P1020, DOI 10.2337/diabetes.37.8.1020; RICHIERI GV, 1995, J LIPID RES, V36, P229; RICHIERI GV, 1993, BIOCHEMISTRY-US, V32, P7574, DOI 10.1021/bi00080a032; RICHIERI GV, 1990, J IMMUNOL, V145, P1074; RICHIERI GV, 1989, J IMMUNOL, V143, P2302; RICHIERI GV, 1990, J IMMUNOL, V144, P671; Roden M, 1996, J CLIN INVEST, V97, P2859, DOI 10.1172/JCI118742; Roden M, 1999, DIABETES, V48, P358, DOI 10.2337/diabetes.48.2.358; ROSE H, 1994, BBA-LIPID LIPID MET, V1215, P321, DOI 10.1016/0005-2760(94)90060-4; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SPECTOR AA, 1975, J LIPID RES, V16, P165; Steinberg HO, 1997, J CLIN INVEST, V100, P1230, DOI 10.1172/JCI119636; Stulnig TM, 1998, J CELL BIOL, V143, P637, DOI 10.1083/jcb.143.3.637; Stulnig TM, 1997, J BIOL CHEM, V272, P19242, DOI 10.1074/jbc.272.31.19242; STULNIG TM, 1995, ARTERIOSCL THROM VAS, V15, P872, DOI 10.1161/01.ATV.15.7.872; TISCHLER MD, 1994, CIRCULATION, V89, P132, DOI 10.1161/01.CIR.89.1.132; TRAILL KN, 1984, IMMUNOL TODAY, V5, P70, DOI 10.1016/0167-5699(84)90169-5; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4	43	43	43	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2000	14	7					939	947		10.1096/fasebj.14.7.939	http://dx.doi.org/10.1096/fasebj.14.7.939			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	309CG	10783148				2022-12-28	WOS:000086749500012
J	Podesta, M; Zocchi, E; Pitto, A; Usai, C; Franco, L; Bruzzone, S; Guida, L; Bacigalupo, A; Scadden, DT; Walseth, TF; De Flora, A; Daga, A				Podesta, M; Zocchi, E; Pitto, A; Usai, C; Franco, L; Bruzzone, S; Guida, L; Bacigalupo, A; Scadden, DT; Walseth, TF; De Flora, A; Daga, A			Extracellular cyclic ADP-ribose increases intracellular free calcium concentration and stimulates proliferation of human hemopoietic progenitors	FASEB JOURNAL			English	Article						bone marrow cells; intracellular calcium homeostasis; cytokine-like activity of cyclic ADP-ribose; expansion of hemopoietic progenitors	HEMATOPOIETIC STEM-CELLS; INOSITOL TRISPHOSPHATE; CYCLASE ACTIVITY; RYANODINE RECEPTORS; ENDOGENOUS LEVELS; MICE LACKING; HUMAN CD38; RADIOIMMUNOASSAY; DIFFERENTIATION; GLYCOPROTEIN	Cyclic ADP-ribose (cADPR) is a universal second messenger that regulates many calcium-related cellular events by releasing calcium from intracellular stores. Since these events include enhanced cell proliferation and since the bone marrow harbors both ectoenzymes that generate cADPR from NAD(+) (CD38 and BST-1), we investigated the effects of extracellular cADPR on human hemopoietic progenitors (HP). Exposure of HE to 100 mu M cADPR for 24 h induced a significant increase in colony output (P<0.01) and colony size (P<0.003). A horizontal expansion of HP, as demonstrated by a markedly increased replating efficiency in semisolid medium (up to 700 times compared to controls), was also observed, indicating that cADPR priming can affect cell growth for multiple generations over several weeks after exposure. Influx of extracellular cADPR into the cells was demonstrated, and a causal relationship between the functional effects and the increase of intracellular free calcium concentration induced by cADPR on HP was established through the use of specific antagonists. Similar effects on HP were produced by nanomolar concentrations of the nonhydrolyzable cADPR analog 3-deaza-cADPR, These data demonstrate that extracellular cADPR behaves as a cytokine enhancing the proliferation of human HP, a finding that may have biomedical applications for the ex vivo expansion of hemopoietic cells.-Podesta, M., Zocchi, E., Pitto, A, Usai, C., Franco, L., Bruzzone, S., Guida, L., Bacigalupo, A., Scadden, D. T., Walseth, T. F., De Flora, A., Daga, A Extracellular cyclic ADP-ribose increases intracellular free calcium concentration and stimulates proliferation of human hemopoietic progenitors.	Univ Genoa, Dept Expt Med, Biochem Sect, I-16132 Genoa, Italy; San Martino Hosp, Dept Hematol, Genoa, Italy; CNR, Inst Cybernet & Biophys, Genoa, Italy; Harvard Univ, Sch Med, Dept Expt Hematol, Massachusetts Gen Hosp, Boston, MA 02115 USA; Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA; Natl Inst Canc Res, IST, Genoa, Italy	University of Genoa; University of Genoa; IRCCS AOU San Martino IST; Consiglio Nazionale delle Ricerche (CNR); Istituto di Cibernetica "Eduardo Caianiello" (ICIB-CNR); Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Minnesota System; University of Minnesota Twin Cities; University of Genoa; IRCCS AOU San Martino IST	De Flora, A (corresponding author), Univ Genoa, Dept Expt Med, Biochem Sect, Viale Benedetto XV-1, I-16132 Genoa, Italy.	toninodf@unige.it	Daga, Antonio/Z-2417-2019; Walseth, Timothy F/F-9518-2010; Podestà, Marina/K-3875-2016; Daga, Antonio/C-3041-2008; Bruzzone, Santina/A-4264-2015	Daga, Antonio/0000-0001-5845-8530; Walseth, Timothy F/0000-0003-2558-7859; Podestà, Marina/0000-0002-6755-613X; Bruzzone, Santina/0000-0003-2034-3716; Usai, Cesare/0000-0001-8863-7759	NATIONAL INSTITUTE ON DRUG ABUSE [P50DA011806] Funding Source: NIH RePORTER; NIDA NIH HHS [P50 DA011806] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Albrieux M, 1998, J BIOL CHEM, V273, P14566, DOI 10.1074/jbc.273.23.14566; AYABE T, 1995, DEVELOPMENT, V121, P2233; Cairo MS, 1997, BLOOD, V90, P4665, DOI 10.1182/blood.V90.12.4665.4665_4665_4678; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; Cockayne DA, 1998, BLOOD, V92, P1324, DOI 10.1182/blood.V92.4.1324.416k26_1324_1333; da Silva CP, 1998, J CHROMATOGR B, V707, P43, DOI 10.1016/S0378-4347(97)00622-1; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; DeFlora A, 1996, BIOCHEM J, V320, P665, DOI 10.1042/bj3200665; DRESCH C, 1983, EXP HEMATOL, V11, P187; Franco L, 1998, FASEB J, V12, P1507; Gothot A, 1997, BLOOD, V90, P4384, DOI 10.1182/blood.V90.11.4384.4384_4384_4393; Graeff RM, 1997, METHOD ENZYMOL, V280, P230; Graeff RM, 1998, J BIOL CHEM, V273, P118, DOI 10.1074/jbc.273.1.118; HIRATA Y, 1994, FEBS LETT, V356, P244, DOI 10.1016/0014-5793(94)01279-2; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; Ikemoto T, 1997, J PHYSIOL-LONDON, V501, P305, DOI 10.1111/j.1469-7793.1997.305bn.x; JACKSON DG, 1990, J IMMUNOL, V144, P2811; Krause DS, 1996, BLOOD, V87, P1; KUEMMERLE JF, 1995, J BIOL CHEM, V270, P25488, DOI 10.1074/jbc.270.43.25488; Lansdorp P M, 1997, Biol Blood Marrow Transplant, V3, P171; LEE CK, 1993, J MATER CHEM, V3, P191, DOI 10.1039/jm9930300191; LEE HC, 1994, VITAM HORM, V48, P199, DOI 10.1016/S0083-6729(08)60499-9; Masuda W, 1997, FEBS LETT, V405, P104, DOI 10.1016/S0014-5793(97)00168-3; Mehta K, 1996, FASEB J, V10, P1408, DOI 10.1096/fasebj.10.12.8903511; Mehta K, 1999, LEUKEMIA LYMPHOMA, V32, P441, DOI 10.3109/10428199909058401; OGAWA M, 1993, BLOOD, V81, P2844; TAKAHASHI K, 1995, FEBS LETT, V371, P204, DOI 10.1016/0014-5793(95)00914-U; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; Takeshima H, 1998, EMBO J, V17, P3309, DOI 10.1093/emboj/17.12.3309; TERSTAPPEN LWMM, 1991, BLOOD, V77, P1218; Walseth TF, 1997, METHOD ENZYMOL, V280, P294; WALSETH TF, 1991, BIOCHIM BIOPHYS ACTA, V1094, P113, DOI 10.1016/0167-4889(91)90032-S; Wong L, 1999, BBA-GEN SUBJECTS, V1472, P555, DOI 10.1016/S0304-4165(99)00161-0; Zocchi E, 1999, FASEB J, V13, P273, DOI 10.1096/fasebj.13.2.273; Zocchi E, 1998, J BIOL CHEM, V273, P8017, DOI 10.1074/jbc.273.14.8017; ZOCCHI E, 1995, FEBS LETT, V359, P35, DOI 10.1016/0014-5793(95)00005-T	37	63	73	0	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2000	14	5					680	690		10.1096/fasebj.14.5.680	http://dx.doi.org/10.1096/fasebj.14.5.680			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301DH	10744625				2022-12-28	WOS:000086292700006
J	Koya, D; Haneda, M; Nakagawa, H; Isshiki, K; Sato, H; Maeda, S; Sugimoto, T; Yasuda, H; Kashiwagi, A; Ways, DK; King, GL; Kikkawa, R				Koya, D; Haneda, M; Nakagawa, H; Isshiki, K; Sato, H; Maeda, S; Sugimoto, T; Yasuda, H; Kashiwagi, A; Ways, DK; King, GL; Kikkawa, R			Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes	FASEB JOURNAL			English	Article						transforming growth factor beta (TGF-beta); fibronectin; type IV collagen; diabetic nephropathy	PROTEIN-KINASE-C; GROWTH-FACTOR-BETA; HIGH GLUCOSE CONDITIONS; MESSENGER-RNA LEVELS; GENE-EXPRESSION; POSSIBLE MEDIATION; GLOMERULAR CELLS; RESPONSE ELEMENT; IDDM PATIENTS; TGF-BETA	Activation of protein kinase C (PKC) is implicated as an important mechanism by which diabetes causes vascular complications. We have recently shown that a PKC beta inhibitor ameliorates not only early diabetes-induced glomerular dysfunction such as glomerular hyperfiltration and albuminuria, but also overexpression of glomerular mRNA for transforming growth factor beta 1 (TGF-beta 1) and extracellular matrix (ECM) proteins in streptozotocin-induced diabetic rats, a model for type 1 diabetes. In this study, we examined the long-term effects of a PKC beta inhibitor on glomerular histology as well as on biochemical and functional abnormalities in glomeruli of db/db mice, a model for type 2 diabetes. Administration of a PKC beta inhibitor reduced urinary albumin excretion rates and inhibited glomerular PKC activation in diabetic db/db mice. Administration of a PKC beta inhibitor also prevented the mesangial expansion observed in diabetic db/db mice, possibly through attenuation of glomerular expression of TGF-beta and ECM proteins such as fibronectin and type TV collagen. These findings provide the first in vivo evidence that the long-term inhibition of PKC activation in the renal glomeruli can ameliorate glomerular pathologies in diabetic state, and thus suggest that a PKC beta inhibitor might be an useful therapeutic strategy for the treatment of diabetic nephropathy.	Shiga Univ Med Sci, Dept Med 3, Shiga 5202192, Japan; Otowa Hosp, Dept Pathol, Kyoto 6078062, Japan; Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA; Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Shiga University of Medical Science; Eli Lilly; Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Haneda, M (corresponding author), Shiga Univ Med Sci, Dept Med 3, Shiga 5202192, Japan.	haneda@belle.shiga-med.ac.jp	Kashiwagi, Atsunori/H-8712-2019; Koya, Daisuke/J-3257-2014					ADLER S, 1994, J AM SOC NEPHROL, V5, P1165; ANDERSEN AR, 1983, DIABETOLOGIA, V25, P496; AYO SH, 1991, AM JP HYSL, V261, pF57; Babazono T, 1998, DIABETES, V47, P668, DOI 10.2337/diabetes.47.4.668; BALLARD DJ, 1988, DIABETES, V37, P405, DOI 10.2337/diabetes.37.4.405; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; COHEN MP, 1995, J CLIN INVEST, V95, P2338, DOI 10.1172/JCI117926; Cohen MP, 1998, EXP NEPHROL, V6, P226; CRAVEN PA, 1989, J CLIN INVEST, V83, P1667, DOI 10.1172/JCI114066; CRAVEN PA, 1990, DIABETES, V39, P667, DOI 10.2337/diabetes.39.6.667; DEAN DC, 1990, J BIOL CHEM, V265, P3522; DERUBERTIS FR, 1994, DIABETES, V43, P1, DOI 10.2337/diabetes.43.1.1; ELLIS EN, 1986, KIDNEY INT, V29, P889, DOI 10.1038/ki.1986.82; FALK RJ, 1983, DIABETES, V32, P34, DOI 10.2337/diab.32.2.S34; FIORETTO P, 1994, DIABETES, V43, P1358, DOI 10.2337/diabetes.43.11.1358; Fioretto P, 1998, NEW ENGL J MED, V339, P69, DOI 10.1056/NEJM199807093390202; FUKUI M, 1992, DIABETES, V41, P1520, DOI 10.2337/diabetes.41.12.1520; GEISER AG, 1991, MOL CELL BIOL, V11, P84, DOI 10.1128/MCB.11.1.84; GREENE DA, 1987, NEW ENGL J MED, V316, P599; HANEDA M, 1990, METABOLISM, V39, P40, DOI 10.1016/0026-0495(90)90145-3; Haneda M, 1997, DIABETES, V46, P847, DOI 10.2337/diabetes.46.5.847; Hugo C, 1996, J CLIN INVEST, V97, P2499, DOI 10.1172/JCI118697; IHM CG, 1992, KIDNEY INT, V41, P768, DOI 10.1038/ki.1992.120; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; KIKKAWA R, 1987, DIABETES, V36, P240, DOI 10.2337/diabetes.36.2.240; KIKKAWA R, 1994, DIABETOLOGIA, V37, P838, DOI 10.1007/BF00404342; KIM SJ, 1989, J BIOL CHEM, V264, P19373; Koya D, 1997, J CLIN INVEST, V100, P115, DOI 10.1172/JCI119503; Koya D, 1997, J AM SOC NEPHROL, V8, P426; Koya D, 1998, DIABETES, V47, P859, DOI 10.2337/diabetes.47.6.859; KREISBERG JI, 1994, KIDNEY INT, V46, P105, DOI 10.1038/ki.1994.249; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; KUNZELMAN CL, 1989, KIDNEY INT, V35, P681, DOI 10.1038/ki.1989.39; LEDBETTER S, 1990, DIABETES, V39, P196, DOI 10.2337/diabetes.39.2.196; LEE SM, 1980, EXP MOL PATHOL, V33, P323, DOI 10.1016/0014-4800(80)90030-1; MAUER SM, 1984, J CLIN INVEST, V74, P1143, DOI 10.1172/JCI111523; MURO AF, 1992, J BIOL CHEM, V267, P12767; Murphy M, 1998, CURR OPIN NEPHROL HY, V7, P563, DOI 10.1097/00041552-199809000-00013; Nakao N, 1998, AM J PATHOL, V152, P1237; *NAT I DIAB DIG KI, 1998, NIH PUBL; PETEN EP, 1992, J EXP MED, V176, P1571, DOI 10.1084/jem.176.6.1571; ROSSING P, 1995, DIABETES, V44, P739, DOI 10.2337/diabetes.44.7.739; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SHARMA K, 1994, AM J PHYSIOL-RENAL, V267, pF1094, DOI 10.1152/ajprenal.1994.267.6.F1094; SHARMA K, 1995, BIOCHEM BIOPH RES CO, V207, P80, DOI 10.1006/bbrc.1995.1156; Sharma K, 1996, DIABETES, V45, P522, DOI 10.2337/diabetes.45.4.522; SHARMA K, 1995, DIABETES, V44, P1139, DOI 10.2337/diabetes.44.10.1139; STEFFES MW, 1989, DIABETES, V38, P1077, DOI 10.2337/diabetes.38.9.1077; Suzuki D, 1999, J AM SOC NEPHROL, V10, P822; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; WILLIAMSON JR, 1993, DIABETES, V42, P801, DOI 10.2337/diabetes.42.6.801; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; YAMAMOTO T, 1993, P NATL ACAD SCI USA, V90, P1814, DOI 10.1073/pnas.90.5.1814; YOSHIMURA A, 1991, KIDNEY INT, V40, P470, DOI 10.1038/ki.1991.234; YOUNG BA, 1995, KIDNEY INT, V47, P935, DOI 10.1038/ki.1995.139; ZHU D, 1994, KIDNEY INT, V45, P425, DOI 10.1038/ki.1994.55; ZIYADEH FN, 1994, J CLIN INVEST, V93, P536, DOI 10.1172/JCI117004	60	364	388	0	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2000	14	3					439	447		10.1096/fasebj.14.3.439	http://dx.doi.org/10.1096/fasebj.14.3.439			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	291TJ	10698958				2022-12-28	WOS:000085751900002
J	Eriksson, EE; Xie, X; Werr, J; Thoren, P; Lindbom, L				Eriksson, EE; Xie, X; Werr, J; Thoren, P; Lindbom, L			Direct viewing of atherosclerosis in vivo: plaque invasion by leukocytes is initiated by the endothelial selectins	FASEB JOURNAL			English	Article						intravital; atherosclerosis; inflammation; selectin; neutrophils	CELL-ADHESION MOLECULE-1; P-SELECTIN; T-LYMPHOCYTES; FOAM CELLS; MACROPHAGES; EXPRESSION; LOCALIZATION; LESIONS; ACCUMULATION; PLATELETS	Leukocyte infiltration in atherosclerosis has been extensively investigated by using histological techniques on fixed tissues. In this study, intravital microscopic observations of leukocyte recruitment in the aorta of atherosclerotic mice were performed. Interactions between leukocytes and atherosclerotic endothelium were highly transient, thereby limiting the ability for rolling leukocytes to firmly adhere. Leukocyte rolling was abolished by function inhibition of P-selectin (P<0.001, n=8), whereas antibody blockage of E-selectin (n=10) decreased rolling leukocyte flux to 51 +/- 9.9% (mean+/-SE, P<0.01) and increased leukocyte rolling velocity to 162 +/- 18% (P<0.01) of pretreatment values. Notably, function inhibition of the integrin at, subunit (n=5) had no effect on rolling flux (107+/-25%, P=0.782) or rolling velocity (89+/-6.1%, P=0.147), despite endothelial expression of vascular cell adhesion molecule 1 (VCAM-1). Leukocytes interacting with atherosclerotic endothelium were predominantly neutrophils, because treatment with antineutrophil serum decreased rolling and neutrophil counts in peripheral blood to the same extent. In conclusion, we present the first direct observations of atherosclerosis in vivo. We show that transient dynamics of leukocyte-endothelium interactions are important regulators of arterial leukocyte recruitment and that leukocyte rolling in atherosclerosis is critically dependent on the endothelial selectins. This experimental technique and the data presented introduce a novel perspective for the study of pathophysiological events involved in large-vessel disease.	Karolinska Inst, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden	Karolinska Institutet	Eriksson, EE (corresponding author), Karolinska Inst, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden.	einar.eriksson@fyfa.ki.se		Lindbom, Lennart/0000-0001-9243-257X				ARFORS KE, 1987, BLOOD, V69, P338; Barnathan ES, 1997, AM J PATHOL, V150, P1009; CARLOS TM, 1994, BLOOD, V84, P2068; Collins RG, 2000, J EXP MED, V191, P189, DOI 10.1084/jem.191.1.189; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; Diacovo TG, 1998, J EXP MED, V187, P197, DOI 10.1084/jem.187.2.197; Dong ZM, 1998, J CLIN INVEST, V102, P145, DOI 10.1172/JCI3001; Eriksson EE, 2000, CIRC RES, V86, P526, DOI 10.1161/01.RES.86.5.526; Gautam N, 2000, J EXP MED, V191, P1829, DOI 10.1084/jem.191.11.1829; GERRITY RG, 1981, AM J PATHOL, V103, P181; HANSSON GK, 1991, ARTERIOSCLER THROMB, V11, P745, DOI 10.1161/01.ATV.11.3.745; Iiyama K, 1999, CIRC RES, V85, P199, DOI 10.1161/01.RES.85.2.199; Jung U, 1997, MICROCIRCULATION-LON, V4, P311, DOI 10.3109/10739689709146794; Jung U, 1998, J CLIN INVEST, V102, P1526, DOI 10.1172/JCI119893; KISHIKAWA H, 1993, VIRCHOWS ARCH A, V423, P433, DOI 10.1007/BF01606532; Kunkel EJ, 2000, J IMMUNOL, V164, P3301, DOI 10.4049/jimmunol.164.6.3301; Kunkel EJ, 1997, AM J PHYSIOL-HEART C, V272, pH1391, DOI 10.1152/ajpheart.1997.272.3.H1391; Kunkel EJ, 1996, CIRC RES, V79, P1196, DOI 10.1161/01.RES.79.6.1196; LAWRENCE MB, 1993, J IMMUNOL, V151, P6338; LEHR HA, 1994, LAB INVEST, V71, P380; Lei X, 1996, ATHEROSCLEROSIS, V125, P81, DOI 10.1016/0021-9150(96)05863-7; LEY K, 1995, J EXP MED, V181, P669, DOI 10.1084/jem.181.2.669; Lorenzon P, 1998, J CELL BIOL, V142, P1381, DOI 10.1083/jcb.142.5.1381; Nakashima Y, 1998, ARTERIOSCL THROM VAS, V18, P842, DOI 10.1161/01.ATV.18.5.842; OBrien KD, 1996, CIRCULATION, V93, P672, DOI 10.1161/01.CIR.93.4.672; Ramos CL, 1999, CIRC RES, V84, P1237, DOI 10.1161/01.RES.84.11.1237; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sakai A, 1997, ARTERIOSCL THROM VAS, V17, P310, DOI 10.1161/01.ATV.17.2.310; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SQUIER MKT, 1995, J LEUKOCYTE BIOL, V57, P2, DOI 10.1002/jlb.57.1.2; TRILLO AA, 1982, ATHEROSCLEROSIS, V43, P259, DOI 10.1016/0021-9150(82)90027-2; van der Wal AC, 1999, CARDIOVASC RES, V41, P334, DOI 10.1016/S0008-6363(98)00276-4; Wang N, 1996, J BIOL CHEM, V271, P8837, DOI 10.1074/jbc.271.15.8837; Yoshida M, 1998, J IMMUNOL, V161, P933	34	109	110	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2001	15	7					1149	1157		10.1096/fj.00-0537com	http://dx.doi.org/10.1096/fj.00-0537com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344083				2022-12-28	WOS:000168655200005
J	Andreadis, ST; Hamoen, KE; Yarmush, ML; Morgan, JR				Andreadis, ST; Hamoen, KE; Yarmush, ML; Morgan, JR			Keratinocyte growth factor induces hyperproliferation and delays differentiation in a skin equivalent model system	FASEB JOURNAL			English	Article						KGF; fibroblast growth factor; cell proliferation; rete ridges	HUMAN EPIDERMAL-CELLS; TERMINAL DIFFERENTIATION; FACTOR EXPRESSION; ELECTRICAL CAPACITANCE; DEVELOPMENT SUGGESTS; LAMELLAR ICHTHYOSIS; BARRIER FUNCTION; ATHYMIC MICE; GENE; RECEPTOR	Keratinocyte growth factor (KGF) is a paracrine mediator of epithelial cell growth. To examine the direct effects of KGF on the morphogenesis of the epidermis, we generated skin equivalents in vitro by seeding human keratinocytes on the papillary surface of acellular dermis and raising them up to the air-liquid interface. KGF was either added exogenously or expressed by keratinocytes via a recombinant retrovirus encoding KGF. KGF induced dramatic changes to the 3-dimensional organization of the epidermis including pronounced hyperthickening, crowding, and elongation of the basal cells, flattening of the rete ridges, and a ripple-like pattern in the junction of stratum corneum and granular layers. Quantitative immunostaining for the proliferation antigen, Ki67, revealed that in addition to increasing basal proliferation, KGF extended the proliferative compartment by inducing suprabasal cell proliferation. KGF also induced expression of the integrin alpha5 beta1 and delayed expression of keratin 10 and transglutaminase, However, barrier formation of the epidermis was not disrupted. These results demonstrate for the first time that a single growth factor can alter the 3-dimensional organization and proliferative function of an in vitro epidermis, In addition to new strategies for tissue engineering, such a well-defined system will be useful for analyzing growth factor effects on the complex links between cell proliferation, cell movement and differentiation within a stratified tissue.	Shriners Burn Hosp, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Surg Serv, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Morgan, JR (corresponding author), Shriners Hosp Children, 51 Blossom St, Boston, MA 02114 USA.	jmorgan@sbi.org		Yarmush, Martin/0000-0003-4986-8444; Morgan, Jeffrey/0000-0002-7546-3443	NICHD NIH HHS [HD-28528] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD028528] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AARONSON SA, 1991, ANN NY ACAD SCI, V638, P62, DOI 10.1111/j.1749-6632.1991.tb49018.x; Abrams JR, 1999, J CLIN INVEST, V103, P1243, DOI 10.1172/JCI5857; ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; BELL E, 1981, SCIENCE, V211, P1052, DOI 10.1126/science.7008197; BOYCE ST, 1993, J INVEST DERMATOL, V101, P180, DOI 10.1111/1523-1747.ep12363678; Boyce ST, 1996, J INVEST DERMATOL, V107, P82, DOI 10.1111/1523-1747.ep12298286; BRAUCHLE M, 1995, J INVEST DERMATOL, V105, P579, DOI 10.1111/1523-1747.ep12323521; Choate KA, 1996, HUM GENE THER, V7, P2247, DOI 10.1089/hum.1996.7.18-2247; Choate KA, 1996, NAT MED, V2, P1263, DOI 10.1038/nm1196-1263; Dellambra E, 1998, HUM GENE THER, V9, P1359, DOI 10.1089/hum.1998.9.9-1359; DISTANTE F, 1995, BIOENGINEERING SKIN, P5; EMING SA, 1995, J INVEST DERMATOL, V105, P756, DOI 10.1111/1523-1747.ep12325550; Falanga V, 1998, ARCH DERMATOL, V134, P293, DOI 10.1001/archderm.134.3.293; Fenjves ES, 1996, J INVEST DERMATOL, V106, P576, DOI 10.1111/1523-1747.ep12344976; FINCH PW, 1995, DEV DYNAM, V203, P223, DOI 10.1002/aja.1002030210; Finch PW, 1997, AM J PATHOL, V151, P1619; Goretsky Michael J., 1995, Wound Repair and Regeneration, V3, P419, DOI 10.1046/j.1524-475X.1995.30406.x; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; GUO LF, 1993, EMBO J, V12, P973, DOI 10.1002/j.1460-2075.1993.tb05738.x; HANSBROUGH JF, 1989, JAMA-J AM MED ASSOC, V262, P2125, DOI 10.1001/jama.262.15.2125; Madlener M, 1996, BIOCHEM J, V320, P659, DOI 10.1042/bj3200659; MASON IJ, 1994, MECH DEVELOP, V45, P15, DOI 10.1016/0925-4773(94)90050-7; Medalie DA, 1997, TRANSPLANTATION, V64, P454, DOI 10.1097/00007890-199708150-00015; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MORGAN JR, 1987, SCIENCE, V237, P1476; OHASHI T, 1992, P NATL ACAD SCI USA, V89, P11332, DOI 10.1073/pnas.89.23.11332; Page SM, 1997, J INVEST DERMATOL, V109, P139, DOI 10.1111/1523-1747.ep12319194; PELLEGRINI G, 1992, J CLIN INVEST, V89, P1783, DOI 10.1172/JCI115782; Pilcher BK, 1997, J BIOL CHEM, V272, P18147, DOI 10.1074/jbc.272.29.18147; Ponec M, 1997, J INVEST DERMATOL, V109, P348, DOI 10.1111/1523-1747.ep12336024; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RUBIN JS, 1995, CELL BIOL INT, V19, P399, DOI 10.1006/cbir.1995.1085; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; SIMON M, 1985, CELL, V40, P677, DOI 10.1016/0092-8674(85)90216-8; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; TSUBOI R, 1993, J INVEST DERMATOL, V101, P49, DOI 10.1111/1523-1747.ep12358892; WATT FM, 1982, NATURE, V295, P434, DOI 10.1038/295434a0; WERNER S, 1994, J INVEST DERMATOL, V103, P469, DOI 10.1111/1523-1747.ep12395564; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; WICKETT RR, 1995, SKIN PHARMACOL, V8, P179; YANNAS IV, 1982, SCIENCE, V215, P174, DOI 10.1126/science.7031899	44	114	130	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2001	15	6					898	906		10.1096/fj.00-0324com	http://dx.doi.org/10.1096/fj.00-0324com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292649				2022-12-28	WOS:000167959300003
J	Brockmann, GA; Haley, CS; Wolf, E; Karle, S; Kratzsch, J; Renne, U; Schwerin, M; Hoeflich, A				Brockmann, GA; Haley, CS; Wolf, E; Karle, S; Kratzsch, J; Renne, U; Schwerin, M; Hoeflich, A			Genome-wide search for loci controlling serum IGF binding protein levels of mice	FASEB JOURNAL			English	Article						IGFBP-2; IGFBP-3; IGFBP-4; linkage	GROWTH-FACTOR-I; FOCAL ADHESION KINASE; QUANTITATIVE TRAIT LOCI; BODY-WEIGHT; TRANSGENIC MICE; TYROSINE PHOSPHORYLATION; DIABETES-MELLITUS; GENE-EXPRESSION; INSULIN; RECEPTOR	A segregating F-2 pedigree based on two mouse Lines (DU6i and DBA/2) with extremely different growth characteristics was generated to search for loci affecting serum levels of insulin-like growth factor (IGF) binding proteins (IGFBPs) and to estimate their effects on growth and body composition. DU6i is characterized by high body mass and obesity associated with hyperinsulinemia, hyperleptinemia, and elevated serum IGF-I concentrations. Furthermore, significantly elevated serum levels of IGFBP-2, IGFBP-3, and IGFBP-4 were found in DU6i vs. DBA/2 mice. Linkage analysis identified loci with major effects on the serum level of IGFBP-3 on Chromosome 5 at 58 cM (Igfbp3q1; F = 9.9) and on Chromosome 10 at 46 cM (Igfbp3q2; F = 33.8). A locus significantly influencing serum IGFBP-2 levels in males was found on Chromosome 7. Additional linkage was detected in males and females for IGFBP-2 on Chromosomes 8, 11, 14, 17, and X, and for ICFBP-4 on Chromosome 4. Additional loci affecting IGFBPs acted in a sex-specific manner. The identified loci coincide in part with chromosomal regions controlling growth and obesity. Thus, multiple genes or pleiotropic gene effects may be assumed for these chromosomal regions. The identification of quantitative trait loci for IGFBPs as subcomponents of growth regulation and differentiation will further improve the understanding of complex trait regulation.	Res Inst Biol Farm Anim, Dept Biol Mol, D-18196 Dummerstorf, Germany; Roslin Inst, Roslin EH25 9PS, Midlothian, Scotland; Univ Munich, Dept Mol Anim Breeding, D-81377 Munich, Germany; Univ Leipzig, Dept Clin Chem, D-04103 Leipzig, Germany; Univ Leipzig, Dept Pathobiochem, D-04103 Leipzig, Germany	Forschungsinstitut fur Nutztierbiologie (FBN); UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; University of Munich; Leipzig University; Leipzig University	Brockmann, GA (corresponding author), Res Inst Biol Farm Anim, Dept Biol Mol, Wilhelm Stahl Allee 2, D-18196 Dummerstorf, Germany.	Gudrun.Brockmann@fbn-dummerstorf.de	Haley, Chris S/F-3110-2013	Wolf, Eckhard/0000-0002-0430-9510; Haley, Chris/0000-0002-9811-0210; Hoeflich, Andreas/0000-0003-2018-2836				BEREKET A, 1995, J CLIN ENDOCR METAB, V80, P3647, DOI 10.1210/jc.80.12.3647; Bohe J, 1998, KIDNEY INT, V54, P1070, DOI 10.1046/j.1523-1755.1998.00096.x; BRADFORD GE, 1984, GENET RES, V44, P293, DOI 10.1017/S0016672300026537; Brockmann GA, 1998, GENETICS, V150, P369; Brockmann GA, 2000, GENOME RES, V10, P1941, DOI 10.1101/gr.GR1499R; BUNGER L, 1990, P 4 WORLD C GEN APPL, V13, P321; CAMACHOHUBNER C, 1991, ENDOCRINOLOGY, V129, P1201, DOI 10.1210/endo-129-3-1201; Casamassima A, 1998, J BIOL CHEM, V273, P26149, DOI 10.1074/jbc.273.40.26149; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; CHURCHILL GA, 1994, GENETICS, V138, P963; COHEN P, 1993, MOL ENDOCRINOL, V7, P380, DOI 10.1210/me.7.3.380; Coverley JA, 2000, ENDOCRINOLOGY, V141, P564, DOI 10.1210/en.141.2.564; Dahlfors G, 2000, ENDOCRINOLOGY, V141, P2062, DOI 10.1210/en.141.6.2062; Das P, 1996, ARCH TIERZUCHT, V39, P185; de Angelis MH, 2000, NAT GENET, V25, P444, DOI 10.1038/78146; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; DOMENE HM, 1994, REGUL PEPTIDES, V52, P215, DOI 10.1016/0167-0115(94)90056-6; Erondu NE, 1996, GROWTH REGULAT, V6, P1; GARGOSKY SE, 1994, ENDOCRINOLOGY, V134, P2267, DOI 10.1210/en.134.5.2267; Grimberg A, 2000, J CELL PHYSIOL, V183, P1, DOI 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J; Grimberg A, 2000, MOL GENET METAB, V70, P85, DOI 10.1006/mgme.2000.3008; HALEY CS, 1994, GENETICS, V136, P1195; Hise MK, 1995, AM J PHYSIOL-RENAL, V269, pF817, DOI 10.1152/ajprenal.1995.269.6.F817; Hoeflich A, 1999, ENDOCRINOLOGY, V140, P5488, DOI 10.1210/en.140.12.5488; Hoeflich A, 1998, GROWTH HORM IGF RES, V8, P113, DOI 10.1016/S1096-6374(98)80101-9; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; JUUL A, 1995, J CLIN ENDOCR METAB, V80, P2534, DOI 10.1210/jc.80.8.2534; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LANDER ES, 1987, P NATL ACAD SCI USA, V84, P2363, DOI 10.1073/pnas.84.8.2363; Legare ME, 2000, GENOME RES, V10, P42; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; Liu BR, 2000, J BIOL CHEM, V275, P33607, DOI 10.1074/jbc.M002547200; Liu JL, 1999, ENDOCRINOLOGY, V140, P5178, DOI 10.1210/en.140.11.5178; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; Manes S, 1999, MOL CELL BIOL, V19, P3125; Martin JL, 2000, ENDOCRINOLOGY, V141, P2401, DOI 10.1210/en.141.7.2401; MATHEWS LS, 1988, ENDOCRINOLOGY, V123, P2827, DOI 10.1210/endo-123-6-2827; MEDRANO JF, 1991, GENET RES, V58, P67, DOI 10.1017/S0016672300029621; Metcalf D, 2000, NATURE, V405, P1069, DOI 10.1038/35016611; Mitsui S, 1997, BRIT J DERMATOL, V137, P693; MURPHY LJ, 1995, J MOL ENDOCRINOL, V15, P293, DOI 10.1677/jme.0.0150293; Rajaram S, 1997, ENDOCR REV, V18, P801, DOI 10.1210/er.18.6.801; Richardson RL, 1998, GROWTH DEVELOP AGING, V62, P3; RIESNER D, 1989, ELECTROPHORESIS, V10, P377, DOI 10.1002/elps.1150100516; SCHULER L, 1985, ARCH TIERZUCHT, V28, P357; Shakibaei M, 1999, BIOCHEM J, V342, P615, DOI 10.1042/0264-6021:3420615; Shi ZD, 2000, J BIOL CHEM, V275, P18574, DOI 10.1074/jbc.M002172200; SHIMASAKI S, 1991, Progress in Growth Factor Research, V3, P243, DOI 10.1016/0955-2235(91)90003-M; STRASSERVOGEL B, 1995, J CLIN ENDOCR METAB, V80, P1207, DOI 10.1210/jc.80.4.1207; Timtchenko D, 1999, INT J OBESITY, V23, P586, DOI 10.1038/sj.ijo.0800872; Yap OWS, 1997, FERTIL STERIL, V68, P252	52	13	15	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2001	15	6					978	987		10.1096/fj.00-0391com	http://dx.doi.org/10.1096/fj.00-0391com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292658				2022-12-28	WOS:000167959300012
J	Thurnher, M; Zelle-Rieser, C; Ramoner, R; Bartsch, G; Holtl, L				Thurnher, M; Zelle-Rieser, C; Ramoner, R; Bartsch, G; Holtl, L			The disabled dendritic cell	FASEB JOURNAL			English	Article						interleukin-4; phospholipase A2; eicosanoids; platelet-activating factor	COLONY-STIMULATING FACTOR; PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-2; ACTIVATION-INDUCED APOPTOSIS; PERIPHERAL-BLOOD MONOCYTES; T-HELPER-CELL; FACTOR-BETA 1; ARACHIDONIC-ACID; INFLAMMATORY CYTOKINES; IMMUNE-RESPONSES; GENE-EXPRESSION	Dendritic cells are important antigen-presenting cells of the immune system that induce and modulate immune responses. They interact with T and B lymphocytes as well as with natural killer cells to promote activation and differentiation of these cells. Dendritic cells generated in vitro from monocytes by use of the cytokines GM-CSF and IL-4 are increasingly used clinically to enhance antitumor immunity in cancer patients. However, recent studies revealed that the functional repertoire of monocyte-derived dendritic cells may be incomplete. important functions of monocyte-derived dendritic cells such as migration or the ability to induce natural killer cell activation or type 2 T helper cell differentiation appear to be impaired. We propose that ah these deficiencies relate to a single biochemical deficiency of monocyte derived dendritic cells. IL-4, which is used to generate monocyte-derived dendritic cells, suppresses phospholipase A2, the enzyme that liberates arachidonic acid from membrane phospholipids and contributes to the synthesis of platelet-activating factor. Monocyte-derived dendritic cells must therefore fail to generate platelet-activating factor as well as arachidonic acid derivatives such as prostaglandins, leukotrienes, and lipoxins, collectively referred to as eicosanoids, Since eicosanoids and platelet-activating factor are known to play an important role in processes such as leukocyte migration, natural killer cell activation, and type 2 T helper cell differentiation, the deficiency in eicosanoid and platelet-activating factor biosynthesis may be responsible for the observed handicaps of monocyte-derived dendritic cells.	Univ Innsbruck, Dept Urol, A-6020 Innsbruck, Austria	University of Innsbruck	Thurnher, M (corresponding author), Univ Innsbruck, Dept Urol, Anichstr 35, A-6020 Innsbruck, Austria.	martin.thurnher@uibk.ac.at	Thurnher, Martin/AAD-5922-2020	Thurnher, Martin/0000-0001-9940-7326				Albert ML, 1998, J EXP MED, V188, P1359, DOI 10.1084/jem.188.7.1359; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BETZ M, 1991, J IMMUNOL, V146, P108; Borkowski TA, 1996, J EXP MED, V184, P2417, DOI 10.1084/jem.184.6.2417; BRAY RA, 1986, J IMMUNOL, V136, P1783; Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030; Chavis C, 1996, J EXP MED, V183, P1633, DOI 10.1084/jem.183.4.1633; CIFONE MG, 1993, CELL IMMUNOL, V148, P247, DOI 10.1006/cimm.1993.1109; Coffey MJ, 1999, BLOOD, V94, P3897, DOI 10.1182/blood.V94.11.3897.423k12_3897_3905; CONRAD DJ, 1992, P NATL ACAD SCI USA, V89, P217, DOI 10.1073/pnas.89.1.217; CORCORAN ML, 1992, J BIOL CHEM, V267, P515; Corry DB, 1999, CURR OPIN IMMUNOL, V11, P610, DOI 10.1016/S0952-7915(99)00025-4; Demeure CE, 1997, EUR J IMMUNOL, V27, P3526, DOI 10.1002/eji.1830271254; Dhodapkar MV, 1999, J CLIN INVEST, V104, P173, DOI 10.1172/JCI6909; Dubois B, 1997, J EXP MED, V185, P941, DOI 10.1084/jem.185.5.941; Fernandez NC, 1999, NAT MED, V5, P405, DOI 10.1038/7403; GAGNON L, 1987, CELL IMMUNOL, V110, P243, DOI 10.1016/0008-8749(87)90120-1; Geissmann F, 1998, J EXP MED, V187, P961, DOI 10.1084/jem.187.6.961; Godson C, 2000, J IMMUNOL, V164, P1663, DOI 10.4049/jimmunol.164.4.1663; GOETZL EJ, 1995, J IMMUNOL, V154, P1041; Gronert K, 1998, J EXP MED, V187, P1285, DOI 10.1084/jem.187.8.1285; HANNIGAN GE, 1991, SCIENCE, V251, P204, DOI 10.1126/science.1898993; Holtl L, 1998, LANCET, V352, P1358, DOI 10.1016/S0140-6736(05)60748-9; Holtl L, 1999, J UROLOGY, V161, P777, DOI 10.1016/S0022-5347(01)61767-1; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Hung K, 1998, J EXP MED, V188, P2357, DOI 10.1084/jem.188.12.2357; Jonuleit H, 1997, EUR J IMMUNOL, V27, P3135, DOI 10.1002/eji.1830271209; Kitamura S, 1999, JPN J CANCER RES, V90, P75, DOI 10.1111/j.1349-7006.1999.tb00668.x; Kugler A, 2000, NAT MED, V6, P332, DOI 10.1038/73193; Kuroda A, 1997, BIOCHEM BIOPH RES CO, V230, P40, DOI 10.1006/bbrc.1996.5885; Kuroda E, 2000, J IMMUNOL, V164, P2386, DOI 10.4049/jimmunol.164.5.2386; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Mehindate K, 1996, LAB INVEST, V75, P529; Morse MA, 1999, CANCER RES, V59, P56; MURAKAMI M, 1995, P NATL ACAD SCI USA, V92, P6107, DOI 10.1073/pnas.92.13.6107; Murphy GP, 1999, PROSTATE, V38, P73; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; OBIRI NI, 1993, J CLIN INVEST, V91, P88, DOI 10.1172/JCI116205; PHIPPS RP, 1991, IMMUNOL TODAY, V12, P349, DOI 10.1016/0167-5699(91)90064-Z; Porter BO, 1999, EUR J IMMUNOL, V29, P2360, DOI 10.1002/(SICI)1521-4141(199907)29:07<2360::AID-IMMU2360>3.0.CO;2-A; POULIOT M, 1994, J EXP MED, V179, P1225, DOI 10.1084/jem.179.4.1225; Pouliot M, 1998, FASEB J, V12, P1109, DOI 10.1096/fasebj.12.12.1109; Randolph GJ, 1998, P NATL ACAD SCI USA, V95, P6924, DOI 10.1073/pnas.95.12.6924; Rey A, 1998, BBA-LIPID LIPID MET, V1393, P244, DOI 10.1016/S0005-2760(98)00080-0; Rieser C, 1999, UROL INT, V63, P151, DOI 10.1159/000030438; Rieser C, 1997, J EXP MED, V186, P1603, DOI 10.1084/jem.186.9.1603; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; Rocca B, 1999, J CLIN INVEST, V103, P1469, DOI 10.1172/JCI6400; Romani N, 1996, J IMMUNOL METHODS, V196, P137, DOI 10.1016/0022-1759(96)00078-6; Sallusto F, 1999, EUR J IMMUNOL, V29, P1617, DOI 10.1002/(SICI)1521-4141(199905)29:05<1617::AID-IMMU1617>3.0.CO;2-3; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Santini SM, 2000, J EXP MED, V191, P1777, DOI 10.1084/jem.191.10.1777; Schuler T, 1999, J EXP MED, V189, P803, DOI 10.1084/jem.189.5.803; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; Serhan CN, 1999, CLIN CHEM LAB MED, V37, P299, DOI 10.1515/CCLM.1999.052; SNYDER F, 1995, BIOCHEM J, V305, P689, DOI 10.1042/bj3050689; Spanbroek R, 1998, P NATL ACAD SCI USA, V95, P663, DOI 10.1073/pnas.95.2.663; STEINHILBER D, 1993, P NATL ACAD SCI USA, V90, P5984, DOI 10.1073/pnas.90.13.5984; Steinman RM, 2000, J EXP MED, V191, P411, DOI 10.1084/jem.191.3.411; THIVIERGE M, 1991, AM REV RESPIR DIS, V144, P272, DOI 10.1164/ajrccm/144.2.272; Thurner B, 1999, J EXP MED, V190, P1669, DOI 10.1084/jem.190.11.1669; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Wijnholds J, 1997, NAT MED, V3, P1275, DOI 10.1038/nm1197-1275; YAMAOKA KA, 1989, J IMMUNOL, V143, P1996	65	44	48	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2001	15	6					1054	1061		10.1096/fj.00-0508hyp	http://dx.doi.org/10.1096/fj.00-0508hyp			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292667				2022-12-28	WOS:000167959300021
J	Zhang, ZL; Oliver, P; Lancaster, JR; Schwarzenberger, PO; Joshi, MS; Cork, J; Kolls, JK				Zhang, ZL; Oliver, P; Lancaster, JR; Schwarzenberger, PO; Joshi, MS; Cork, J; Kolls, JK			Reactive oxygen species mediate tumor necrosis factor alpha-converting, enzyme-dependent ectodomain shedding induced by phorbol myristate acetate	FASEB JOURNAL			English	Article									Tulane Univ, Sch Med, LSUMC Gene Therapy Program, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Dept Pediat, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Dept Physiol, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Dept Med, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Dept Surg, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Dept Anat & Cell Biol, New Orleans, LA 70112 USA	Tulane University; Tulane University; Tulane University; Tulane University; Tulane University; Tulane University	Kolls, JK (corresponding author), 533 Bolivar St,Room 601, New Orleans, LA 70112 USA.		Schwarzenberger, Paul/AAZ-2174-2021; Kolls, Jay/AAH-1829-2019	Kolls, Jay/0000-0001-5151-6304					0	152	163	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					303	305						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156944				2022-12-28	WOS:000166872900010
J	Frigeri, A; Nicchia, GP; Nico, B; Quondamatteo, F; Herken, R; Roncali, L; Svelto, M				Frigeri, A; Nicchia, GP; Nico, B; Quondamatteo, F; Herken, R; Roncali, L; Svelto, M			Aquaporin-4 deficiency in skeletal muscle and brain of dystrophic mdx mice	FASEB JOURNAL			English	Article						muscular dystrophy; aquaporins; orthogonal arrays of particles; AQP4; mdx mice; water channels	DUCHENNE MUSCULAR-DYSTROPHY; INSENSITIVE WATER CHANNEL; PLASMA-MEMBRANES; RAT-BRAIN; MOLECULAR CHARACTERIZATION; FREEZE-FRACTURE; EXPRESSION; PROTEIN; MOUSE; ASTROCYTES	We report a detailed study of AQP4 expression in the neuromuscular system of mdx mice. Immunocytochemical analysis performed by double immunostaining revealed that mdx mice manifest a progressive reduction in AQP4 at the sarcolemmal level of skeletal muscle fast fibers and that type IIB fibers are the first to manifest this reduction in AQP4 expression. No labeling was observed in the cytoplasm of muscle fibers, indicating that the reduction in sarcolemma staining is not associated with an intracellular compartmentalization of mistargeted protein. By Western blot and RT-PCR analysis, we found that whereas the total content of AQP4 protein decreased (by 90% in adult mdx mice), mRNA levels for AQP4 remained unchanged. A similar age-related reduction in AQP4 expression was found in brain astrocytic end-feet surrounding capillaries of mdx mice. Morphometric analysis performed after immunogold electron microscopy indicated a reduction of similar to 85% in gold particles (32 +/-2/mum vs. 4.7 +/-0.61/mum). Western blot experiments conducted using membrane fractions from brain cortex revealed a strong reduction (of 70%) in AQP4 protein in adult mdx mice, and RT-PCR experiments demonstrated that the reduction was not at transcription level. More interesting was the finding that AQP4 reduction was associated with swelling of astrocytic perivascular processes whose ultrastructural modifications are commonly indicated as an important and early event in the development of brain edema. No apparent reduction in AQP4 was found in mdx stomach and kidney. Our data provide evidence that dystrophin deficiency in mdx mice leads to disturbances in AQP4 assembly in the plasma membrane of fast skeletal muscle fibers and brain astrocytic end-feet, suggesting that changes in the osmotic equilibrium of the neuromuscular apparatus may be involved in the pathology of muscular dystrophy.	Univ Bari, Dipartimento Fisiol Gen & Ambientale, I-70126 Bari, Italy; Policlin Bari, Ist Anat Umana Normale, I-70124 Bari, Italy; Univ Gottingen, Zentrum Anat, Abt Histol, D-37075 Gottingen, Germany	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro; University of Gottingen	Frigeri, A (corresponding author), Univ Bari, Dipartimento Fisiol Gen & Ambientale, Via Amendola 165-A, I-70126 Bari, Italy.		Svelto, Maria/P-6186-2014; frigeri, Antonio/AAC-6336-2022	Frigeri, Antonio/0000-0002-5284-2934; Svelto, Maria/0000-0002-5584-9541	Telethon [983] Funding Source: Medline	Telethon(Fondazione Telethon)		ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; Anderson LVB, 1999, HUM MOL GENET, V8, P855, DOI 10.1093/hmg/8.5.855; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; Culligan KG, 1998, INT J MOL MED, V2, P639; DeVries HE, 1997, PHARMACOL REV, V49, P143; Dunn JF, 1999, MUSCLE NERVE, V22, P1367, DOI 10.1002/(SICI)1097-4598(199910)22:10<1367::AID-MUS5>3.3.CO;2-8; EMERY AEH, 1987, OXFORD MONOGRAPHS ME, V15; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; Finn DM, 1998, BIOCHEM BIOPH RES CO, V249, P231, DOI 10.1006/bbrc.1998.9119; FRIGERI A, 1995, P NATL ACAD SCI USA, V92, P4328, DOI 10.1073/pnas.92.10.4328; Frigeri A, 1998, J CLIN INVEST, V102, P695, DOI 10.1172/JCI2545; FRIGERI A, 1995, J CELL SCI, V108, P2993; GORECKI DC, 1992, HUM MOL GENET, V1, P505, DOI 10.1093/hmg/1.7.505; HASEGAWA H, 1994, J BIOL CHEM, V269, P5497; HIRCHE H, 1980, PFLUG ARCH EUR J PHY, V387, P231, DOI 10.1007/BF00580975; HOFFMAN EP, 1988, NEURON, V1, P411, DOI 10.1016/0896-6273(88)90191-2; Jancsik V, 1999, BRAIN RES, V831, P200, DOI 10.1016/S0006-8993(99)01445-6; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; KOWALCHUK JM, 1988, J APPL PHYSIOL, V65, P2080, DOI 10.1152/jappl.1988.65.5.2080; Ma TH, 1997, J CLIN INVEST, V100, P957, DOI 10.1172/JCI231; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; MEHTA JR, 1989, RES VET SCI, V47, P17, DOI 10.1016/S0034-5288(18)31225-6; MENKE A, 1991, NATURE, V349, P69, DOI 10.1038/349069a0; MISRA L K, 1982, Magnetic Resonance Imaging, V1, P75, DOI 10.1016/0730-725X(82)90222-3; Muntoni F, 1991, Neuromuscul Disord, V1, P121, DOI 10.1016/0960-8966(91)90059-2; Neely JD, 1999, BIOCHEMISTRY-US, V38, P11156, DOI 10.1021/bi990941s; Newman Eric A., 1995, P717; Nielsen S, 1997, J NEUROSCI, V17, P171; OZAWA E, 1995, HUM MOL GENET, V4, P1711, DOI 10.1093/hmg/4.suppl_1.1711; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; Rash JE, 1998, P NATL ACAD SCI USA, V95, P11981, DOI 10.1073/pnas.95.20.11981; SCHIAFFINO S, 1989, J MUSCLE RES CELL M, V10, P197, DOI 10.1007/BF01739810; SHIBUYA S, 1991, NEUROPATH APPL NEURO, V17, P335, DOI 10.1111/j.1365-2990.1991.tb00730.x; SJOGAARD G, 1985, AM J PHYSIOL, V248, P190; Straub V, 1997, J CELL BIOL, V139, P375, DOI 10.1083/jcb.139.2.375; Sun DD, 1995, AM J PHYSIOL-CELL PH, V269, pC1506, DOI 10.1152/ajpcell.1995.269.6.C1506; Tracey I, 1996, J NEUROL SCI, V141, P13, DOI 10.1016/0022-510X(96)00135-9; Tracey I, 1996, BRAIN, V119, P1039, DOI 10.1093/brain/119.3.1039; Tsukaguchi H, 1998, J BIOL CHEM, V273, P24737, DOI 10.1074/jbc.273.38.24737; Verbavatz JM, 1997, J CELL SCI, V110, P2855; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246; WAKAYAMA Y, 1989, J NEUROL SCI, V91, P191, DOI 10.1016/0022-510X(89)90087-7; WALZ W, 1985, BRAIN RES, V343, P44, DOI 10.1016/0006-8993(85)91156-4; WEBSTER C, 1988, CELL, V52, P503, DOI 10.1016/0092-8674(88)90463-1; Wen H, 1999, EUR J NEUROSCI, V11, P935, DOI 10.1046/j.1460-9568.1999.00502.x; Yaffe D., 1996, Cellular Pharmacology, V3, P331; Yokota T, 2000, P JPN ACAD B-PHYS, V76, P22, DOI 10.2183/pjab.76.22	50	158	168	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2001	15	1					90	98		10.1096/fj.00-0260com	http://dx.doi.org/10.1096/fj.00-0260com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149896				2022-12-28	WOS:000166312400017
J	Garcia-Trevijano, ER; Latasa, MU; Carretero, MV; Berasain, C; Mato, JM; Avila, MA				Garcia-Trevijano, ER; Latasa, MU; Carretero, MV; Berasain, C; Mato, JM; Avila, MA			S-Adenosylmethionine regulates MAT1A and MAT2A gene expression in cultured rat hepatocytes: a new role for S-adenosylmethionine in the maintenance of the differentiated status of the liver	FASEB JOURNAL			English	Article						biological methylation; hepatocarcinoma; methionine metabolism; gene expression	ADENOSYL-L-METHIONINE; ALBUMIN GENE; SYNTHETASE; ADENOSYLTRANSFERASE; METHYLATION; METABOLISM; ADENOSYLHOMOCYSTEINE; CARCINOGENESIS; INDUCTION; PROMOTION	Methionine metabolism starts with the formation of S-adenosylmethionine (AdoMet), the most important biological methyl donor. This reaction is catalyzed by methionine adenosyltransferase (MAT). MAT is the product of two different genes: MAT1A, which is expressed only in the adult liver, and 2MAT2A, which is widely distributed, expressed in the fetal liver, and replaces MAT1A in hepatocarcinoma. In the liver, preservation of high expression of MAT1A and low expression of MAT2A is critical for the maintenance of a functional and differentiated organ. Here we describe that in cultured rat hepatocytes MAT1A expression progressively decreased, as described for other liver-specific genes, and MAT2A expression was induced. We find that this switch in gene expression was prevented by adding AdoMet to the culture medium. We also show that in cultured hepatocytes with decreased MAT1A expression AdoMet addition markedly increased MAT1A transcription in a dose-dependent fashion. This effect of AdoMet was mimicked by methionine, and blocked by 3-deazaadenosine and L-ethionine, but not D-ethionine, indicating that the effect was specific and mediated probably by a methylation reaction. These findings identify AdoMet as a key molecule that differentially regulates MAT1A and MAT2A expression and helps to maintain the differentiated status of the hepatocyte.	Univ Navarra, Fac Med, Dept Med Interna, Unidad Hepatol & Terapia Genica, Pamplona 31008, Spain	University of Navarra	Mato, JM (corresponding author), Univ Navarra, Fac Med, Dept Med Interna, Unidad Hepatol & Terapia Genica, Edificio Los Castanos, Pamplona 31008, Spain.	jmmato@unav.es	Avila, Matias A/Y-6342-2019; Berasain, Carmen/E-4139-2016; MATO, JOSE/A-5187-2011; Ruiz García-Trevijano, Elena R./ABE-1014-2021	Avila, Matias A/0000-0001-6570-3557; Berasain, Carmen/0000-0001-7075-2476; MATO, JOSE/0000-0003-1264-3153; Ruiz García-Trevijano, Elena R./0000-0002-3985-1270; Latasa, Maria Ujue/0000-0002-0878-1337	NIAAA NIH HHS [AA12677-01A1] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA012677] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Alvarez L, 1997, J BIOL CHEM, V272, P22875, DOI 10.1074/jbc.272.36.22875; ALVAREZ L, 1991, FEBS LETT, V290, P142, DOI 10.1016/0014-5793(91)81245-4; AVILA MA, 1995, ONCOGENE, V10, P963; Avila MA, 1998, GASTROENTEROLOGY, V114, P364, DOI 10.1016/S0016-5085(98)70489-5; Bontemps F, 1997, BIOCHEM J, V327, P383, DOI 10.1042/bj3270383; BRADA Z, 1988, CANCER RES, V48, P4464; BRADA Z, 1981, RES COMMUN CHEM PATH, V31, P357; Cai JX, 1998, CANCER RES, V58, P1444; Cai JX, 1996, HEPATOLOGY, V24, P1090; CANTONI GL, 1975, ANNU REV BIOCHEM, V44, P435, DOI 10.1146/annurev.bi.44.070175.002251; CARON JM, 1990, MOL CELL BIOL, V10, P1239, DOI 10.1128/MCB.10.3.1239; Carretero MV, 1998, FEBS LETT, V439, P55, DOI 10.1016/S0014-5793(98)01335-0; Chawla RK, 1998, AM J PHYSIOL-GASTR L, V275, pG125, DOI 10.1152/ajpgi.1998.275.1.G125; Chiang PK, 1998, PHARMACOL THERAPEUT, V77, P115, DOI 10.1016/S0163-7258(97)00089-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Counts JL, 1996, CARCINOGENESIS, V17, P1251, DOI 10.1093/carcin/17.6.1251; ENGSTROM MA, 1987, J NUTR, V117, P1820, DOI 10.1093/jn/117.11.1820; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; FINKELSTEIN JD, 1986, J BIOL CHEM, V261, P1582; GARCEA R, 1989, CANCER RES, V49, P1850; Gil B, 1997, ENDOCRINOLOGY, V138, P1251, DOI 10.1210/en.138.3.1251; Gil B, 1996, HEPATOLOGY, V24, P876; HENNING SM, 1989, J NUTR, V119, P1478, DOI 10.1093/jn/119.10.1478; HIROKAWA S, 1993, FEBS LETT, V334, P69, DOI 10.1016/0014-5793(93)81682-P; Hoffman Jerald L., 1994, V27, P449; HORIKAWA S, 1990, J BIOL CHEM, V265, P13683; Huang ZZ, 1998, AM J PHYSIOL-GASTR L, V275, pG14, DOI 10.1152/ajpgi.1998.275.1.G14; Kimura K, 1999, FEBS LETT, V457, P75, DOI 10.1016/S0014-5793(99)00987-4; Kotb M, 1997, TRENDS GENET, V13, P51, DOI 10.1016/S0168-9525(97)01013-5; KOTB M, 1993, PHARMACOL THERAPEUT, V59, P125, DOI 10.1016/0163-7258(93)90042-C; Mato JM, 1997, PHARMACOL THERAPEUT, V73, P265, DOI 10.1016/S0163-7258(96)00197-0; Mato JM, 1999, J HEPATOL, V30, P1081, DOI 10.1016/S0168-8278(99)80263-3; MATSUMOTO C, 1984, J BIOCHEM-TOKYO, V95, P287, DOI 10.1093/oxfordjournals.jbchem.a134596; MUDD SH, 1975, METABOLISM, V24, P721, DOI 10.1016/0026-0495(75)90040-2; NEWBERNE PM, 1986, ANNU REV NUTR, V6, P407, DOI 10.1146/annurev.nu.06.070186.002203; Nozawa K, 1999, J BIOCHEM, V126, P361, DOI 10.1093/oxfordjournals.jbchem.a022458; PASCALE RM, 1992, CANCER RES, V52, P4979; Ruiz F, 1998, HEPATOLOGY, V28, P1051, DOI 10.1002/hep.510280420; SARGENT TD, 1979, P NATL ACAD SCI USA, V76, P3256, DOI 10.1073/pnas.76.7.3256; SCHUETZ EG, 1988, J CELL PHYSIOL, V134, P309, DOI 10.1002/jcp.1041340302; Torres L, 2000, FASEB J, V14, P95, DOI 10.1096/fasebj.14.1.95; TORRES L, 2000, IN PRESS INT J BIOCH; Watson WH, 1999, BIOCHEM J, V342, P21, DOI 10.1042/0264-6021:3420021	43	92	95	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2000	14	15					2511	2518		10.1096/fj.00-0121com	http://dx.doi.org/10.1096/fj.00-0121com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099469				2022-12-28	WOS:000165723400021
J	McLendon, C; Xin, TP; Ziani-Cherif, C; Murphy, MP; Findlay, KA; Lewis, PA; Pinnix, I; Sambamurti, K; Wang, R; Fauq, A; Golde, TE				McLendon, C; Xin, TP; Ziani-Cherif, C; Murphy, MP; Findlay, KA; Lewis, PA; Pinnix, I; Sambamurti, K; Wang, R; Fauq, A; Golde, TE			Cell-free assays for gamma-secretase activity	FASEB JOURNAL			English	Article									Mayo Clin Jacksonville, Dept Pharmacol, Jacksonville, FL 32224 USA; Rockefeller Univ, Lab Mass Spect, New York, NY 10021 USA	Mayo Clinic; Rockefeller University	Golde, TE (corresponding author), Mayo Clin Jacksonville, Dept Pharmacol, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.		Lewis, Patrick A./C-3674-2009; Wang, Rong/A-8721-2009; Sambamurti, Kumar/J-6102-2013	Sambamurti, Kumar/0000-0001-9507-9214; Lewis, Patrick/0000-0003-4537-0489; ziani-cherif, chewki/0000-0001-5759-8275					0	105	120	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2383	2386						4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11024004				2022-12-28	WOS:000165723400005
J	Uhl, GR; Li, S; Takahashi, N; Itokawa, K; Lin, ZC; Hazama, M; Sora, I				Uhl, GR; Li, S; Takahashi, N; Itokawa, K; Lin, ZC; Hazama, M; Sora, I			The VMAT2 gene in mice and humans: amphetamine responses, locomotion, cardiac arrhythmias, aging, and vulnerability to dopaminergic toxins	FASEB JOURNAL			English	Review						VMAT2; serotonin; histamine; dopamine; norepinephrine; synaptic vesicle; Parkinsonism; MPTP	VESICULAR MONOAMINE TRANSPORTER-2; CHROMAFFIN GRANULES; MOLECULAR-CLONING; KNOCKOUT MICE; COCAINE; ADDICTION; TOXICITY; DEATH	Monoamine compartmentalization in monoaminergic neurons uses serial action of the plasma membrane and vesicular monoamine (VAMT2) transporters. We can now define the sequences of the genes encoding these transporters in mice and humans, examine influences of deletions of this gene and alteration in its expression levels in transgenic mice, and identify sequence polymorphisms in the human VMAT2 gene. Examination of VMAT2 variants can provide potential insights into roles for allelic variants at these loci in variant drug responses and in diseases linked to monoaminergic systems, including substance abuse and Parkinson's disease.	NIDA, Mol Neurobiol Branch, IRP, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA)	Uhl, GR (corresponding author), NIDA, Mol Neurobiol Branch, IRP, NIH, Rm 302,5500 Nathan Shock Dr, Baltimore, MD 21224 USA.							ELLINWOO.EH, 1971, SCIENCE, V171, P420, DOI 10.1126/science.171.3969.420; Fon EA, 1997, NEURON, V19, P1271, DOI 10.1016/S0896-6273(00)80418-3; Fumagalli F, 1999, J NEUROSCI, V19, P2424; HENRY JP, 1994, J EXP BIOL, V196, P251; Itokawa K, 1999, MOL BRAIN RES, V71, P354, DOI 10.1016/S0169-328X(99)00194-1; JOHNSON RG, 1988, PHYSIOL REV, V68, P232, DOI 10.1152/physrev.1988.68.1.232; Kuczenski R, 1994, AMPHETAMINE ITS ANAL, P81; LIU L, 1994, MOL BRAIN RES, V25, P90, DOI 10.1016/0169-328X(94)90282-8; NESTLER EJ, 1992, J NEUROSCI, V12, P2439; Persico AM, 1995, AM J MED GENET, V60, P563, DOI 10.1002/ajmg.1320600616; POST RM, 1976, NATURE, V260, P731, DOI 10.1038/260731a0; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; SURRATT CK, 1993, FEBS LETT, V318, P325, DOI 10.1016/0014-5793(93)80539-7; Takahashi N, 1997, MOL BRAIN RES, V49, P7, DOI 10.1016/S0169-328X(97)00116-2; Takahashi N, 1997, P NATL ACAD SCI USA, V94, P9938, DOI 10.1073/pnas.94.18.9938; Travis ER, 2000, P NATL ACAD SCI USA, V97, P162, DOI 10.1073/pnas.97.1.162; Wang YM, 1997, NEURON, V19, P1285, DOI 10.1016/S0896-6273(00)80419-5; Watson F, 1999, BIOCHEM J, V337, P193, DOI 10.1042/0264-6021:3370193; Wilson JM, 1996, ANN NEUROL, V40, P428, DOI 10.1002/ana.410400312; Xu WM, 1997, MOL BRAIN RES, V45, P41, DOI 10.1016/S0169-328X(96)00218-5	20	44	46	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2459	2465		10.1096/fj.00-0205rev	http://dx.doi.org/10.1096/fj.00-0205rev			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099463				2022-12-28	WOS:000165723400015
J	Attoub, S; Noe, V; Pirola, L; Bruyneel, E; Chastre, E; Mareel, M; Wymann, MP; Gespach, C				Attoub, S; Noe, V; Pirola, L; Bruyneel, E; Chastre, E; Mareel, M; Wymann, MP; Gespach, C			Leptin promotes invasiveness of kidney and colonic epithelial cells via phosphoinositide 3-kinase-, Rho-, and Rac-dependent signaling pathways	FASEB JOURNAL			English	Article						wortmannin; PI3 '-kinase; MDCK cells; leptin signaling; pertussis toxin	PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; CONSTITUTIVE ACTIVATION; COLORECTAL-CANCER; NEUROPEPTIDE-Y; 3-OH KINASE; OBESE GENE; RECEPTOR; INVASION; SRC	Leptin plays a key role regulating food intake, body weight and fat mass. These critical parameters are associated with an increased risk for digestive and mammary gland cancer in the Western population. Here we determined whether leptin contributes to the invasive phenotype of colonic and kidney epithelial cells at various stages of the neoplastic progression. First, leptin potently (EC50 10-30 ng/ml) induces invasion of collagen gels by premalignant familial adenomatous colonic cells PC/AA/C1 and nontumorigenic MDCK kidney epithelial cells, their src-transformed counterparts, and the human adenocarcinoma colonic cells LoVo and HCT-8/S11. Leptin and its Ob-Rb receptors were consistently identified by RT-PCR and immunoblotting in these cell, lines, as well as in human colonic epithelial crypts, polyps, colonic tumor resections, and adjacent mucosa. Leptin-induced invasion was effectively blocked by pharmacological inhibitors of several downstream signaling pathways involved in cell transformation, namely, JAK2 tyrosine kinase (AG490), phosphoinositide PI3'-kinase (wortmannin and LY294002), mTOR kinase (rapamycin), and protein kinases C (GF109203X, Go6976). Accordingly, leptin induces transient elevation of the PI3'-kinase Lipid products in JAK2 immunoprecipitates prepared from parental MDCK cells. The leptin effect on invasion was potentiated by the activated form of the small GTPase RhoA and was abrogated by dominant negative mutants of RhoA, Rad, and the p110 alpha of PI3'-K. Our data indicate that leptin may exert a local and beneficial effect on migration of normal colonic epithelial cells and reparation of the inflamed or wounded digestive mucosa. We also emphasize a new role for leptin, linking- the nutritional and body fat status to digestive cancer susceptibility by stimulating the invasive capacity of colonic epithelial cells at early stages of neoplasia. This finding has potential clinical implications for colon cancer progression and management of obesity.-Attoub, S., Noe, V., Pirola, L., Bruyneel, E., Chastre, E., Mareel, M., Wymann, M. P., Gespach, C. Leptin promotes invasiveness of kidney and colonic epithelial cells via phosphoinositide 3-kinase-, Rho-, and pac-dependent signaling pathways.	Hop St Antoine, INSERM Unit U482, F-75571 Paris 12, France; Hop St Antoine, IFR65, F-75571 Paris, France; State Univ Ghent, Expt Cancerol Lab, B-9000 Ghent, Belgium; Inst Biochem, CH-1700 Fribourg, Switzerland	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Ghent University	Gespach, C (corresponding author), Hop St Antoine, INSERM Unit U482, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France.		Pirola, Luciano/I-5250-2018; Wymann, Matthias P/C-3227-2008; CHASTRE, Eric/L-8446-2018; Attoub, Samir/N-6852-2018	Wymann, Matthias P/0000-0003-3349-4281; CHASTRE, Eric/0000-0002-8993-1228; Pirola, Luciano/0000-0001-6539-5435				Andre T, 2000, INT J CANCER, V86, P174, DOI 10.1002/(SICI)1097-0215(20000415)86:2<174::AID-IJC5>3.3.CO;2-5; Bado A, 1998, NATURE, V394, P790, DOI 10.1038/29547; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Bennett BD, 1996, CURR BIOL, V6, P1170, DOI 10.1016/S0960-9822(02)70684-2; Bjorbaek C, 1999, J BIOL CHEM, V274, P30059, DOI 10.1074/jbc.274.42.30059; Bjorbaek C, 1997, J BIOL CHEM, V272, P32686, DOI 10.1074/jbc.272.51.32686; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; CHIOU MM, 1996, CELL, V85, P573; CLARK JT, 1984, ENDOCRINOLOGY, V115, P427, DOI 10.1210/endo-115-1-427; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Empereur S, 1997, BRIT J CANCER, V75, P241, DOI 10.1038/bjc.1997.40; Farooqi IS, 1999, NEW ENGL J MED, V341, P879, DOI 10.1056/NEJM199909163411204; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Gainsford T, 1996, P NATL ACAD SCI USA, V93, P14564, DOI 10.1073/pnas.93.25.14564; Ghilardi N, 1997, MOL ENDOCRINOL, V11, P393, DOI 10.1210/me.11.4.393; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kotelevets L, 1998, J BIOL CHEM, V273, P14138, DOI 10.1074/jbc.273.23.14138; LeMarchand L, 1997, CANCER RES, V57, P4787; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; Martinez ME, 1999, J NATL CANCER I, V91, P950, DOI 10.1093/jnci/91.11.950; MAYAN N, 1996, NATURE, V379, P645; Morsy MA, 1998, P NATL ACAD SCI USA, V95, P7866, DOI 10.1073/pnas.95.14.7866; Morton NM, 1998, J BIOL CHEM, V273, P26194, DOI 10.1074/jbc.273.40.26194; Murakami Y, 1998, J CELL PHYSIOL, V175, P220, DOI 10.1002/(SICI)1097-4652(199805)175:2<220::AID-JCP12>3.0.CO;2-C; Noe V., 1996, Clinical and Experimental Metastasis, V14, P71; PRETZEL N, 1999, NATURE, V402, P884; Prunier C, 1999, J BIOL CHEM, V274, P22919, DOI 10.1074/jbc.274.33.22919; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sarraf P, 1997, J EXP MED, V185, P171, DOI 10.1084/jem.185.1.171; Schoen RE, 1999, JNCI-J NATL CANCER I, V91, P1147, DOI 10.1093/jnci/91.13.1147; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; Takahashi Y, 1997, J BIOL CHEM, V272, P12897, DOI 10.1074/jbc.272.20.12897; Taouis M, 1998, GENE, V208, P239, DOI 10.1016/S0378-1119(97)00670-7; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wang MY, 1998, P NATL ACAD SCI USA, V95, P714, DOI 10.1073/pnas.95.2.714; Wasan HS, 1997, P NATL ACAD SCI USA, V94, P3308, DOI 10.1073/pnas.94.7.3308; Xue LX, 1996, JNCI-J NATL CANCER I, V88, P1586, DOI 10.1093/jnci/88.21.1586; Yamauchi T, 1998, J BIOL CHEM, V273, P15719, DOI 10.1074/jbc.273.25.15719; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	54	209	221	1	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2329	2338		10.1096/fj.00-0162	http://dx.doi.org/10.1096/fj.00-0162			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053255				2022-12-28	WOS:000165190800027
J	Farber, SA; Slack, BE; Blusztajn, JK				Farber, SA; Slack, BE; Blusztajn, JK			Acceleration of phosphatidylcholine synthesis and breakdown by inhibitors of mitochondrial function in neuronal cells: a model of the membrane defect of Alzheimer's disease	FASEB JOURNAL			English	Article						PC 12 cells; membrane turnover; phospholipase; CTP-phosphorylcholine cytidylyltransferase; glycerophosphorylcholine	AMYLOID PRECURSOR PROTEIN; CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; DIFFERENTIATED PC12 CELLS; ENERGY-METABOLISM; OXIDATIVE-PHOSPHORYLATION; NEURODEGENERATIVE DISEASES; PHOSPHOLIPASE A(2); CYTOSOLIC CALCIUM; CHEMICAL HYPOXIA; GENE-EXPRESSION	Brain cells in Alzheimer's disease (AD) exhibit a membrane defect characterized by accelerated phospholipid turnover, The mechanism responsible for this defect remains unknown. Recent studies indicate that impairment of mitochondrial function is frequently observed in AD and may be responsible for certain aspects of its pathophysiology, We show that when PC12 cells are exposed to inhibitors of mitochondrial bioenergetics, the turnover of their major membrane phospholipid, phosphatidylcholine, is accelerated, producing a pattern of metabolic changes that mimics that observed in brains of AD patients, Abnormalities of mitochondrial function may therefore underlie the membrane defect in AD.	Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA; Thomas Jefferson Univ, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Boston University; Jefferson University	Blusztajn, JK (corresponding author), Boston Univ, Sch Med, Dept Pathol & Lab Med, 85 E Newton St,Room M1009, Boston, MA 02118 USA.	jbluszta@bu.edu	Slack, Barbara/AAU-9917-2021; Farber, Steven A/G-5851-2012	Farber, Steven A/0000-0002-8037-7312; /0000-0001-8438-3122; Slack, Barbara/0000-0002-7619-410X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030791, F32NS010326] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG009525] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG09525] Funding Source: Medline; NINDS NIH HHS [F32 NS10326, R01 NS30791] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Araki W, 1997, P NATL ACAD SCI USA, V94, P11946, DOI 10.1073/pnas.94.22.11946; BARANY M, 1985, LANCET, V1, P517; Beal MF, 1998, BBA-BIOENERGETICS, V1366, P211, DOI 10.1124/jpet.112.192138; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BLASS JP, 1990, ARCH NEUROL-CHICAGO, V47, P864, DOI 10.1001/archneur.1990.00530080046009; BLUSZTAJN JK, 1990, BRAIN RES, V536, P240, DOI 10.1016/0006-8993(90)90030-F; Bonilla E, 1999, BBA-BIOENERGETICS, V1410, P171, DOI 10.1016/S0005-2728(98)00165-0; BUSH ML, 1995, P NATL ACAD SCI USA, V92, P1861, DOI 10.1073/pnas.92.6.1861; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; CARROLL JM, 1992, J NEUROCHEM, V59, P1836, DOI 10.1111/j.1471-4159.1992.tb11017.x; CHAGNON P, 1995, NEUROREPORT, V6, P711, DOI 10.1097/00001756-199503270-00002; CHANDRASEKARAN K, 1994, MOL BRAIN RES, V24, P336, DOI 10.1016/0169-328X(94)90147-3; Chandrasekaran K, 1996, EXP NEUROL, V142, P80, DOI 10.1006/exnr.1996.0180; CORNELL R, 1987, BIOCHIM BIOPHYS ACTA, V919, P26, DOI 10.1016/0005-2760(87)90214-1; Davis JN, 1998, BIOCHEM BIOPH RES CO, V244, P877, DOI 10.1006/bbrc.1998.8353; ELLISON DW, 1987, BRAIN RES, V417, P389, DOI 10.1016/0006-8993(87)90471-9; Farber SA, 1996, BRAIN RES, V723, P90, DOI 10.1016/0006-8993(96)00221-1; Farooqui AA, 1997, J NEUROCHEM, V69, P889; FELDMAN DA, 1981, BIOCHIM BIOPHYS ACTA, V665, P53, DOI 10.1016/0005-2760(81)90231-9; FOLCH J, 1957, J BIOL CHEM, V226, P497; GABUZDA D, 1994, J BIOL CHEM, V269, P13623; GEDDES JW, 1985, SCIENCE, V230, P1179, DOI 10.1126/science.4071042; Gibson G, 1997, J NEUROCHEM, V69, P603; GIBSON GE, 1988, ARCH NEUROL-CHICAGO, V45, P836, DOI 10.1001/archneur.1988.00520320022009; Gibson GE, 1998, ANN NEUROL, V44, P676, DOI 10.1002/ana.410440414; GINSBERG L, 1993, MOL CHEM NEUROPATHOL, V19, P37, DOI 10.1007/BF03160167; GINSBERG L, 1995, BRAIN RES, V698, P223, DOI 10.1016/0006-8993(95)00931-F; GREENBERG SM, 1994, P NATL ACAD SCI USA, V91, P7104, DOI 10.1073/pnas.91.15.7104; HASHAM MI, 1994, CAN J PHYSIOL PHARM, V72, P728, DOI 10.1139/y94-104; Hoyer S, 1993, J Geriatr Psychiatry Neurol, V6, P3; HOYER S, 1992, MOL CHEM NEUROPATHOL, V16, P207, DOI 10.1007/BF03159971; JOHNSON JD, 1987, TOXICOL APPL PHARM, V88, P217, DOI 10.1016/0041-008X(87)90007-X; Jope RS, 1997, NEUROBIOL AGING, V18, P111, DOI 10.1016/S0197-4580(96)00205-9; JOPE RS, 1994, NEUROBIOL AGING, V15, P221, DOI 10.1016/0197-4580(94)90116-3; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; KLEIN J, 1993, BRAIN RES, V630, P337, DOI 10.1016/0006-8993(93)90674-C; Klunk WE, 1996, NEUROBIOL AGING, V17, P349, DOI 10.1016/0197-4580(96)00035-8; Klunk WE, 1998, NEUROBIOL AGING, V19, P511, DOI 10.1016/S0197-4580(98)00105-5; LISCOVITCH M, 1985, ANAL BIOCHEM, V151, P182, DOI 10.1016/0003-2697(85)90069-7; LOPEZ G, 1992, J NEUROCHEM, V59, P338; Luo Y, 1997, P NATL ACAD SCI USA, V94, P9705, DOI 10.1073/pnas.94.18.9705; MADUH EU, 1991, J APPL TOXICOL, V11, P97, DOI 10.1002/jat.2550110205; MASON RP, 1995, NEUROBIOL AGING, V16, P531, DOI 10.1016/0197-4580(95)00057-L; MCCLURE RJ, 1994, ANN NY ACAD SCI, V747, P110; Mills EM, 1996, J NEUROCHEM, V67, P1039; NITSCH RM, 1992, P NATL ACAD SCI USA, V89, P1671, DOI 10.1073/pnas.89.5.1671; PARKER WD, 1994, NEUROLOGY, V44, P1090, DOI 10.1212/WNL.44.6.1090; PARKER WD, 1991, ANN NY ACAD SCI, V640, P59; Pedersen WA, 1997, J BIOL CHEM, V272, P22397, DOI 10.1074/jbc.272.36.22397; PELECH SL, 1983, J BIOL CHEM, V258, P6782; Pettegrew JW, 1997, ANN NY ACAD SCI, V826, P282, DOI 10.1111/j.1749-6632.1997.tb48480.x; Poirier J, 1999, J PSYCHIATR NEUROSCI, V24, P147; Purdon AD, 1998, BIOCHEM J, V335, P313, DOI 10.1042/bj3350313; RABIZADEH S, 1994, P NATL ACAD SCI USA, V91, P10703, DOI 10.1073/pnas.91.22.10703; Rapoport SI, 1996, NEURODEGENERATION, V5, P473, DOI 10.1006/neur.1996.0065; Redjems-Bennani N, 1998, GERONTOLOGY, V44, P300, DOI 10.1159/000022031; Ross BM, 1998, J NEUROCHEM, V70, P786; Satlin A, 1997, AM J PSYCHIAT, V154, P1459; SCHUBERT D, 1988, SCIENCE, V241, P223, DOI 10.1126/science.2968652; SCHUBERT D, 1989, P NATL ACAD SCI USA, V86, P2066, DOI 10.1073/pnas.86.6.2066; SHEU KFR, 1985, ANN NEUROL, V17, P444; SIMS NR, 1987, ANN NEUROL, V21, P451, DOI 10.1002/ana.410210507; SIMS NR, 1983, J NEUROCHEM, V41, P1329, DOI 10.1111/j.1471-4159.1983.tb00829.x; SLACK BE, 1991, J BIOL CHEM, V266, P24503; SLACK BE, 1992, BRAIN RES, V585, P169, DOI 10.1016/0006-8993(92)91203-Q; SORBI S, 1995, ALZ DIS ASSOC DIS, V9, P73, DOI 10.1097/00002093-199509020-00003; STOKES CE, 1987, J NEUROCHEM, V48, P1018, DOI 10.1111/j.1471-4159.1987.tb05619.x; TOUCHSTONE JC, 1980, LIPIDS, V15, P61, DOI 10.1007/BF02534120; Webster MT, 1998, J NEURAL TRANSM, V105, P839, DOI 10.1007/s007020050098; WEINHOLD PA, 1984, J BIOL CHEM, V259, P315; Wells K, 1995, NEUROCHEM RES, V20, P1329, DOI 10.1007/BF00992508; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; YANG XM, 1994, J RARE EARTH, V12, P124; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; ZUBENKO GS, 1992, NEUROPSYCHOPHARMACOL, V6, P77; Zubenko GS, 1999, AM J PSYCHIAT, V156, P50, DOI 10.1176/ajp.156.1.50	78	54	56	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2000	14	14					2198	2206		10.1096/fj.99-0853	http://dx.doi.org/10.1096/fj.99-0853			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053240				2022-12-28	WOS:000165190800012
J	Napoli, C; Quehenberger, O; De Nigris, F; Abete, P; Glass, CK; Palinski, W				Napoli, C; Quehenberger, O; De Nigris, F; Abete, P; Glass, CK; Palinski, W			Mildly oxidized low density lipoprotein activates multiple apoptotic signaling pathways in human coronary cells	FASEB JOURNAL			English	Article						oxidized LDL; atherosclerosis; FasL; TNF receptors; caspases; MAPK; JunK	HUMAN ATHEROSCLEROTIC PLAQUES; SMOOTH-MUSCLE CELLS; NF-KAPPA-B; IN-VITRO; OXYGEN RADICALS; LDL; DEATH; MACROPHAGES; EXPRESSION; OXIDATION	Apoptosis of arterial cells induced by oxidized low density lipoproteins (OxLDL) is thought to contribute to the progression of atherosclerosis. However, most data on apoptotic effects and mechanisms of OxLDL were obtained with extensively oxidized LDL unlikely to occur in early stages of atherosclerotic lesions. We now demonstrate that mildly oxidized LDL generated by incubation with oxygen radical-producing xanthine/xanthine oxidase (X/XO) induces apoptosis in primary cultures of human coronary endothelial and SMC, as determined by TUNEL technique, DNA laddering, and FAGS analysis. Apoptosis was markedly reduced when X/XO-LDL was generated in the presence of different oxygen radical scavengers. Apoptotic signals were mediated by intramembrane domains of both Fas and tumor necrosis factor (TNF) receptors I and II. Blocking of Fas ligand (FasL) reduced apoptosis by 50% and simultaneous blocking of FasL and TNF receptors by 70%. Activation of apoptotic receptors was accompanied by an increase of proapoptotic and a decrease in antiapoptotic proteins of the Bcl-2 family: and resulted in marked activation of class I and II caspases. Mildly oxidized LDL also activated MAP and Jun kinases and increased p53 and other transcription factors (ATF-2, ELK-1, CREB, AP-1). Inhibitors of Map and Jun kinase significantly reduced apoptosis. Our results provide the first evidence that OxLDL-induced apoptosis involves TNF receptors and Jun activation. More important, they demonstrate that even mildly oxidized LDL formed in atherosclerotic lesions may activate a broad cascade of oxygen radical-sensitive signaling pathways affecting apoptosis and other processes influencing the evolution of plaques. Thus, we suggest that extensive oxidative modifications of LDL are not necessary to influence signal transduction and transcription in vivo.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Naples Federico II, Dept Clin & Expt Med, I-80131 Naples, Italy; Univ Naples Federico II, Dept Gerontol, I-80131 Naples, Italy	University of California System; University of California San Diego; University of Naples Federico II; University of Naples Federico II	Palinski, W (corresponding author), Univ Calif San Diego, Dept Med, 0682,9500 Gilman Dr,MTF 110, La Jolla, CA 92093 USA.	wpalinski@ucsd.edu/cnapoli.ucsd.edu	Glass, Christopher/AAI-3933-2021; Abete, Pasquale/AAC-2455-2022; Palinski, Wulf/AAW-8032-2021	Glass, Christopher/0000-0003-4344-3592; Abete, Pasquale/0000-0002-4585-5390; Palinski, Wulf/0000-0002-5113-0169; de nigris, filomena/0000-0002-2322-1557; Napoli, Claudio/0000-0002-5455-555X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056989] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56989] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMBROSIO G, 1994, J CLIN INVEST, V93, P2408, DOI 10.1172/JCI117248; Aravind L, 1999, TRENDS BIOCHEM SCI, V24, P47, DOI 10.1016/S0968-0004(98)01341-3; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Battista S, 1998, ONCOGENE, V17, P377, DOI 10.1038/sj.onc.1201953; BJORKERUD S, 1995, AM J PATHOL, V147, P267; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; de Nigris F, 2000, BIOCHEM PHARMACOL, V59, P1477, DOI 10.1016/S0006-2952(00)00275-6; Dimmeler S, 1997, CIRCULATION, V95, P1760; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Fruebis J, 1997, ARTERIOSCL THROM VAS, V17, P1289, DOI 10.1161/01.ATV.17.7.1289; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GENG YJ, 1995, AM J PATHOL, V147, P251; Geng YJ, 1997, ARTERIOSCL THROM VAS, V17, P2200, DOI 10.1161/01.ATV.17.10.2200; Hamilton TA, 1998, J LEUKOCYTE BIOL, V64, P667, DOI 10.1002/jlb.64.5.667; Harada-Shiba M, 1998, J BIOL CHEM, V273, P9681, DOI 10.1074/jbc.273.16.9681; HARLOW E, 1989, IMMUNOBLOTTING LAB M; Jovinge S, 1997, ARTERIOSCL THROM VAS, V17, P2225, DOI 10.1161/01.ATV.17.10.2225; Kinscherf R, 1998, FASEB J, V12, P461, DOI 10.1096/fasebj.12.6.461; Kockx MM, 2000, CARDIOVASC RES, V45, P736, DOI 10.1016/S0008-6363(99)00235-7; Kockx MM, 1998, CIRCULATION, V97, P2307, DOI 10.1161/01.CIR.97.23.2307; Kolodgie FD, 1999, APOPTOSIS, V4, P5, DOI 10.1023/A:1009645730270; Kusuhara M, 1997, ARTERIOSCL THROM VAS, V17, P141, DOI 10.1161/01.ATV.17.1.141; Lee JW, 1999, J MOL CELL CARDIOL, V31, P113, DOI 10.1006/jmcc.1998.0850; LI D, 1998, AM J PHYSIOL, V275, P568; Liguori A, 1999, EUR J CLIN PHARMACOL, V55, P117, DOI 10.1007/s002280050605; Mallat Z, 1997, CIRCULATION, V96, P424; Maziere C, 1999, FEBS LETT, V448, P49, DOI 10.1016/S0014-5793(99)00324-5; Meilhac O, 1999, FASEB J, V13, P485, DOI 10.1096/fasebj.13.3.485; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Napoli C, 1996, J AM COLL CARDIOL, V28, P1637, DOI 10.1016/S0735-1097(96)90208-9; Napoli C, 1997, STROKE, V28, P2266, DOI 10.1161/01.STR.28.11.2266; Napoli C, 1997, AM HEART J, V133, P585, DOI 10.1016/S0002-8703(97)70155-8; Napoli C, 1997, J BIOCHEM-TOKYO, V121, P1096; Napoli C, 2000, P NATL ACAD SCI USA, V97, P3678, DOI 10.1073/pnas.97.7.3678; Napoli C, 1999, LANCET, V354, P1234, DOI 10.1016/S0140-6736(99)02131-5; Napoli C, 1995, ATHEROSCLEROSIS, V118, P259, DOI 10.1016/0021-9150(95)05612-2; Palinski W, 2000, J INTERN MED, V247, P371, DOI 10.1046/j.1365-2796.2000.00656.x; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; REID VC, 1993, J PATHOL, V171, P321, DOI 10.1002/path.1711710413; REID VC, 1993, FEBS LETT, V332, P218, DOI 10.1016/0014-5793(93)80635-8; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sata M, 1998, J BIOL CHEM, V273, P33103, DOI 10.1074/jbc.273.50.33103; Sata M, 1998, J CLIN INVEST, V102, P1682, DOI 10.1172/JCI3531; SHARAD K, 1999, TRENDS BIOCHEM SCI, V24, P1; Siow RCM, 1999, ARTERIOSCL THROM VAS, V19, P2387, DOI 10.1161/01.ATV.19.10.2387; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; Vieira O, 2000, FASEB J, V14, P532, DOI 10.1096/fasebj.14.3.532; von Harsdorf R, 1999, CIRCULATION, V99, P2934, DOI 10.1161/01.CIR.99.22.2934; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0	53	181	188	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2000	14	13					1996	2007		10.1096/fj.99-0986com	http://dx.doi.org/10.1096/fj.99-0986com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023984				2022-12-28	WOS:000089634400019
J	Harms, C; Lautenschlager, M; Bergk, A; Freyer, D; Weih, M; Dirnagl, U; Weber, JR; Hortnagl, H				Harms, C; Lautenschlager, M; Bergk, A; Freyer, D; Weih, M; Dirnagl, U; Weber, JR; Hortnagl, H			Melatonin is protective in necrotic but not in caspase-dependent, free radical-independent apoptotic neuronal cell death in primary neuronal cultures	FASEB JOURNAL			English	Article						ethylcholine aziridinium (AF64A); staurosporine; oxygen-glucose deprivation; cortex; oxidative stress	ETHYLCHOLINE AZIRIDINIUM AF64A; RAT CORTICAL-NEURONS; NF-KAPPA-B; HIPPOCAMPAL-NEURONS; OXIDATIVE STRESS; CHOLINERGIC HYPOFUNCTION; DOPAMINERGIC-NEURONS; EMBRYONIC NEURONS; HYDROGEN-PEROXIDE; AMYLOID PEPTIDE	To assess the neuroprotective potential of melatonin in apoptotic neuronal cell death, we investigated the efficacy of melatonin in serum-free primary neuronal cultures of rat cortex by using three different models of caspase-dependent apoptotic, excitotoxin-independent neurodegeneration and com pared it to that in necrotic neuronal damage. Neuronal apoptosis was induced by either staurosporine or the neurotoxin ethylcholine aziridinium (AF64A) with a delayed occurrence of apoptotic cell death (within 72 h). The apoptotic component of oxygen-glucose deprivation (OGD) unmasked by glutamate antagonists served as a third model. As a model for necrotic cell death, OGD was applied. Neuronal injury was quantified by LDH release and loss of metabolic activity. Although melatonin (0.5 mM) partly protected cortical neurons from OGD-induced necrosis, as measured by a significant reduction in LDH release, it was not effective in all three models of apoptotic cell death. In contrast, exaggeration of neuronal damage by melatonin was observed in native cultures as well as after induction of apoptosis. The present data suggest that the neuroprotectiveness of melatonin strongly depends on the model of neuronal cell death applied. As demonstrated in three different models of neuronal apoptosis, the progression of the apoptotic type of neuronal cell death cannot be withhold or is even exaggerated by melatonin, in contrast to its beneficial effect in the necrotic type of cell death.	Humboldt Univ, Fac Med Charite, Inst Pharmacol & Toxicol, D-10098 Berlin, Germany; Humboldt Univ, Fac Med Charite, Dept Neurol, D-10098 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Hortnagl, H (corresponding author), Humboldt Univ, Fac Med Charite, Inst Pharmacol & Toxicol, Dorotheensr 94, D-10098 Berlin, Germany.	heide.hoertnagl@charite.de	Harms, Christoph/AAD-7895-2021; Harms, Christoph/HIK-2989-2022	Harms, Christoph/0000-0002-2063-2860; Dirnagl, Ulrich/0000-0003-0755-6119				ACUNACASTROVIEJ.D, 1997, LIFE SCI, V60, P23; Ahlemeyer B, 1998, NEUROSCI LETT, V246, P93, DOI 10.1016/S0304-3940(98)00242-0; Antolin I, 1996, FASEB J, V10, P882, DOI 10.1096/fasebj.10.8.8666165; Barsacchi R, 1998, FREE RADICAL BIO MED, V24, P1187, DOI 10.1016/S0891-5849(97)00431-0; Behan WMH, 1999, BRIT J PHARMACOL, V128, P1754, DOI 10.1038/sj.bjp.0702940; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BENITEZKING G, 1993, EXPERIENTIA, V49, P635; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; BREWER GJ, 1995, J NEUROSCI RES, V42, P674, DOI 10.1002/jnr.490420510; Bruer U, 1997, FEBS LETT, V414, P117, DOI 10.1016/S0014-5793(97)00954-X; Cazevieille C, 1997, BRAIN RES, V768, P120, DOI 10.1016/S0006-8993(97)00611-2; Chen ST, 1999, EXP BRAIN RES, V124, P241, DOI 10.1007/s002210050619; Cho S, 1997, BRAIN RES, V755, P335, DOI 10.1016/S0006-8993(97)00188-1; COHEN G, 1974, J BIOL CHEM, V249, P2447; COPANI A, 1995, MOL PHARMACOL, V47, P890; Copin JC, 1998, BRAIN RES, V784, P25, DOI 10.1016/S0006-8993(97)00972-4; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; Dodel RC, 1999, MOL BRAIN RES, V64, P141, DOI 10.1016/S0169-328X(98)00318-0; FALCIERI E, 1993, BIOCHEM BIOPH RES CO, V193, P19, DOI 10.1006/bbrc.1993.1584; FISHER A, 1982, J PHARMACOL EXP THER, V222, P140; Floreani M, 1997, FASEB J, V11, P1309, DOI 10.1096/fasebj.11.14.9409550; Gibb JW, 1997, J PHARMACOL EXP THER, V283, P630; Gilad E, 1998, FASEB J, V12, P685, DOI 10.1096/fasebj.12.9.685; Giusti P, 1996, FASEB J, V10, P891, DOI 10.1096/fasebj.10.8.8666166; Gottron FJ, 1997, MOL CELL NEUROSCI, V9, P159, DOI 10.1006/mcne.1997.0618; GSCHWIND M, 1995, J NEUROCHEM, V65, P292; Gulyaeva NV, 1996, BRAIN RES, V726, P174; Hanin I, 1996, LIFE SCI, V58, P1955, DOI 10.1016/0024-3205(96)00185-3; HORTNAGL H, 1991, N-S ARCH PHARMACOL, V344, P213, DOI 10.1007/BF00167221; HUERTODELGADILLO L, 1994, J PINEAL RES, V17, P55, DOI 10.1111/j.1600-079X.1994.tb00114.x; Iacovitti L, 1997, BRAIN RES, V768, P317, DOI 10.1016/S0006-8993(97)00668-9; IANAS O, 1991, ROM J ENDOCRINOL, V29, P147; Jin BK, 1998, NEUROSCI LETT, V245, P61, DOI 10.1016/S0304-3940(98)00170-0; Kabuto H, 1998, EPILEPSIA, V39, P237, DOI 10.1111/j.1528-1157.1998.tb01367.x; Kim YS, 1998, NEUROREPORT, V9, P2387, DOI 10.1097/00001756-199807130-00043; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; Lapin IP, 1998, J PINEAL RES, V24, P215; Lautenschlager M, 1998, ADV BEHAV BIOL, V49, P681; Lautenschlager M, 2000, NEUROSCIENCE, V97, P383, DOI 10.1016/S0306-4522(99)00599-0; Lezoualch F, 1996, NEUROREPORT, V7, P2071, DOI 10.1097/00001756-199609020-00003; Lotharius J, 1999, J NEUROSCI, V19, P1284; Manev H, 1996, FASEB J, V10, P1546, DOI 10.1096/fasebj.10.13.8940301; Mayo JC, 1999, BRAIN RES, V818, P221, DOI 10.1016/S0006-8993(98)01262-1; Medina-Navarro R, 1999, ENDOCR RES, V25, P263, DOI 10.1080/07435809909066147; MELCHIORRI D, 1995, FASEB J, V9, P1205, DOI 10.1096/fasebj.9.12.7672513; Mevissen M, 1998, NEUROSCI LETT, V257, P13, DOI 10.1016/S0304-3940(98)00790-3; Mohan N, 1995, BIOCHEM MOL BIOL INT, V37, P1063; Nathan L, 1998, SEMIN REPROD ENDOCR, V16, P309, DOI 10.1055/s-2007-1016289; Paolini M, 1999, LIFE SCI, V64, pPL273, DOI 10.1016/S0024-3205(99)00167-8; Pappolla M, 1998, J BIOL CHEM, V273, P7185, DOI 10.1074/jbc.273.13.7185; Pappolla MA, 1997, J NEUROSCI, V17, P1683; POLLARD H, 1994, NEUROSCIENCE, V63, P7, DOI 10.1016/0306-4522(94)90003-5; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Reiter R, 1997, LIFE SCI, V60, P2255, DOI 10.1016/S0024-3205(97)00030-1; Reiter RJ, 1998, PROG NEUROBIOL, V56, P359, DOI 10.1016/S0301-0082(98)00052-5; REITER RJ, 1995, FASEB J, V9, P526, DOI 10.1096/fasebj.9.7.7737461; Rinner WA, 1997, NEUROSCIENCE, V79, P535, DOI 10.1016/S0306-4522(96)00687-2; Sheldon SH, 1998, LANCET, V351, P1254, DOI 10.1016/S0140-6736(05)79321-1; Skaper SD, 1998, FASEB J, V12, P725, DOI 10.1096/fasebj.12.9.725; Southgate GS, 1998, J CHEM NEUROANAT, V14, P151, DOI 10.1016/S0891-0618(98)00026-X; Tan DX, 1998, J NEUROSCI RES, V54, P382, DOI 10.1002/(SICI)1097-4547(19981101)54:3<382::AID-JNR9>3.0.CO;2-Y; Uz T, 1996, NEUROSCIENCE, V73, P631, DOI 10.1016/0306-4522(96)00155-8; Wiesner DA, 1996, J NEUROCHEM, V66, P1418; WONG SHY, 1987, CLIN CHEM, V33, P214	65	50	54	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2000	14	12					1814	1824		10.1096/fj.99-0899com	http://dx.doi.org/10.1096/fj.99-0899com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973931				2022-12-28	WOS:000089212400021
J	Si-Hoe, SL; De Bree, FM; Nijenhuis, M; Davies, JE; Howell, LMC; Tinley, H; Waller, SJ; Zeng, Q; Zalm, R; Sonnemans, M; Van Leeuwen, FW; Burbach, JPH; Murphy, D				Si-Hoe, SL; De Bree, FM; Nijenhuis, M; Davies, JE; Howell, LMC; Tinley, H; Waller, SJ; Zeng, Q; Zalm, R; Sonnemans, M; Van Leeuwen, FW; Burbach, JPH; Murphy, D			Endoplasmic reticulum derangement in hypothalamic neurons of rats expressing a familial neurohypophyseal diabetes insipidus mutant vasopressin transgene	FASEB JOURNAL			English	Article									Univ Bristol, Bristol Royal Infirm, Dept Med, Mol Neuroendocrinol Res Grp, Bristol BS2 8HW, Avon, England; Natl Univ Singapore, Inst Mol & Cell Biol, Neuropeptide Lab, Singapore 117609, Singapore; Rudolf Magnus Inst Neurosci, Dept Med Pharmacol, NL-3584 CG Utrecht, Netherlands; Netherlands Inst Brain Res, NL-1105 AZ Amsterdam, Netherlands	Bristol Royal Infirmary; University of Bristol; Agency for Science Technology & Research (ASTAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Utrecht University; Utrecht University Medical Center; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW)	Murphy, D (corresponding author), Univ Bristol, Bristol Royal Infirm, Dept Med, Mol Neuroendocrinol Res Grp, Marlborough St, Bristol BS2 8HW, Avon, England.		Murphy, David/C-3967-2012; ZENG, Qi/E-9812-2010	Murphy, David/0000-0003-2946-0353; 					0	41	41	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2000	14	12					1680	1684						5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973916				2022-12-28	WOS:000089212400006
J	Haj-Yehia, A; Nassar, T; Sachais, BS; Kuo, A; Bdeir, K; Al-Mehdi, AB; Mazar, A; Cines, DB; Higazi, AA				Haj-Yehia, A; Nassar, T; Sachais, BS; Kuo, A; Bdeir, K; Al-Mehdi, AB; Mazar, A; Cines, DB; Higazi, AA			Urokinase-derived peptides regulate vascular smooth muscle contraction in vitro and in vivo	FASEB JOURNAL			English	Article						smooth muscle cell; intracellular calcium; vascular contractility; rat aorta	SINGLE-CHAIN UROKINASE; ACTIVATOR INHIBITOR TYPE-1; PLASMINOGEN-ACTIVATOR; ENDOTHELIAL-CELLS; COMPLEMENT RECEPTOR-TYPE-3; PROTEOLYTIC CLEAVAGE; MELANOMA-CELLS; PRO-UROKINASE; IN-VITRO; EXPRESSION	We examined the effect of urokinase (uPA) and its fragments on vascular smooth muscle cell contraction, Single-chain uPA inhibits phenylepherine (PE) -induced contraction of rat aortic rings, whereas two-chain uPA exerts the opposite effect. Two independent epitopes mediating these opposing activities were identified. Angstrom 6, a capped peptide corresponding to amino acids 136-143 (KPSSPPEE) of uPA, increased the EC50 of PE induced vascular contraction sevenfold by inhibiting the release of calcium from intracellular stores. Angstrom 6 activity was abolished by deleting the carboxyl-terminal Glu or by mutating the Ser corresponding to position 138 in uPA to Glu. A single-chain uPA variant lacking amino acids 136-143 did not induce vasorelaxation, A second epitope within the kringle of uPA potentiated PE-induced vasoconstriction. This epitope was exposed when single-chain uPA was converted to a two-chain molecule by plasmin. The isolated uPA kringle augmented vasoconstriction, whereas uPA variant lacking the kringle had no procontractile activity. These studies reveal previously undescribed vasoactive domains within urokinase and its naturally derived fragments.	Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Inst Environm Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Hebrew Univ Jerusalem, Hadassah Med Ctr, Sch Pharm, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Clin Biochem, IL-91120 Jerusalem, Israel; Angstrom Pharmaceut Inc, Dept Biol, San Diego, CA 92121 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Hadassah University Medical Center	Higazi, AA (corresponding author), Univ Penn, Dept Pathol & Lab Med, 513A Stellar Chance,422 Curie Blvd, Philadelphia, PA 19104 USA.	higazi@mail.med.upenn.edu	Al-Mehdi, Abu-Bakr/A-8636-2009; Sachais, Bruce/D-1236-2009		NHLBI NIH HHS [HL-60169, T32 HL007775] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007775, R01HL060169] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AXELROD JH, 1989, MOL CELL BIOL, V9, P2133, DOI 10.1128/MCB.9.5.2133; BACHARACH E, 1992, P NATL ACAD SCI USA, V89, P10686, DOI 10.1073/pnas.89.22.10686; Bugge TH, 1996, P NATL ACAD SCI USA, V93, P5899, DOI 10.1073/pnas.93.12.5899; CAO DR, 1995, J IMMUNOL, V154, P1817; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; Carmeliet P, 1998, J CELL BIOL, V140, P233, DOI 10.1083/jcb.140.1.233; Carmeliet P, 1997, CIRC RES, V81, P829; Carmeliet P, 1996, HAEMOSTASIS, V26, P132; CHANG KSK, 1992, BRIT J PHARMACOL, V107, P983, DOI 10.1111/j.1476-5381.1992.tb13395.x; Christow SP, 1999, EUR J BIOCHEM, V265, P264, DOI 10.1046/j.1432-1327.1999.00729.x; CLOWES AW, 1990, CIRC RES, V67, P61, DOI 10.1161/01.RES.67.1.61; Degryse B, 1999, BLOOD, V94, P649, DOI 10.1182/blood.V94.2.649.414k34_649_662; DEPETRO G, 1994, EXP CELL RES, V213, P286, DOI 10.1006/excr.1994.1200; Franco P, 1998, J BIOL CHEM, V273, P27734, DOI 10.1074/jbc.273.42.27734; Franco P, 1997, J CELL BIOL, V137, P779, DOI 10.1083/jcb.137.3.779; Gibson A, 1998, TRENDS PHARMACOL SCI, V19, P266; Graier WF, 1998, J PHYSIOL-LONDON, V506, P109, DOI 10.1111/j.1469-7793.1998.109bx.x; Guo YJ, 2000, FASEB J, V14, P1400, DOI 10.1096/fj.14.10.1400; GUREWICH V, 1987, SEMIN THROMB HEMOST, V13, P146, DOI 10.1055/s-2007-1003485; Gyetko MR, 1996, J CLIN INVEST, V97, P1818, DOI 10.1172/JCI118611; HIGAZI AA, 1995, J BIOL CHEM, V270, P17375, DOI 10.1074/jbc.270.29.17375; Higazi AA, 1998, BLOOD, V92, P2075, DOI 10.1182/blood.V92.6.2075.418k08_2075_2083; Higazi AAR, 1996, THROMB RES, V84, P243, DOI 10.1016/S0049-3848(96)00184-3; Higazi AAR, 1996, BLOOD, V88, P542, DOI 10.1182/blood.V88.2.542.bloodjournal882542; Higazi AAR, 1996, BLOOD, V87, P3545, DOI 10.1182/blood.V87.9.3545.bloodjournal8793545; Higazi AAR, 1996, BIOCHEMISTRY-US, V35, P6884, DOI 10.1021/bi9514774; HUSAIN SS, 1991, BIOCHEMISTRY-US, V30, P5797, DOI 10.1021/bi00237a024; Ikeda M, 1998, CELL CALCIUM, V24, P49, DOI 10.1016/S0143-4160(98)90088-4; JOHNSSON B, 1995, J MOL RECOGNIT, V8, P125, DOI 10.1002/jmr.300080122; Kanse SM, 1997, ARTERIOSCL THROM VAS, V17, P2848, DOI 10.1161/01.ATV.17.11.2848; Kanse SM, 1996, EXP CELL RES, V224, P344, DOI 10.1006/excr.1996.0144; KIRSCHHEIMER JC, 1987, FED AM SOC EXP BIOL, V1, P125; KOIZUMI T, 1994, J CLIN INVEST, V94, P2275, DOI 10.1172/JCI117590; Koopman JL, 1998, J BIOL CHEM, V273, P33267, DOI 10.1074/jbc.273.50.33267; KYONG SK, 1992, BRIT J PHARMACOL, V107, P983; Li CH, 1995, J BIOL CHEM, V270, P30282, DOI 10.1074/jbc.270.51.30282; Lijnen HR, 1998, ARTERIOSCL THROM VAS, V18, P1035, DOI 10.1161/01.ATV.18.7.1035; MANCHANDA N, 1995, J BIOL CHEM, V270, P20032, DOI 10.1074/jbc.270.34.20032; MARCOTTE PA, 1992, J BIOL CHEM, V267, P13803; MAZAR AP, 1995, FIBRINOLYSIS S1, V6, P49; Min HY, 1996, CANCER RES, V56, P2428; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; NODAHEINY H, 1995, ARTERIOSCL THROM VAS, V15, P37, DOI 10.1161/01.ATV.15.1.37; NUSRAT AR, 1991, J CLIN INVEST, V87, P1091, DOI 10.1172/JCI115070; ODEKON LE, 1992, J CELL PHYSIOL, V150, P258, DOI 10.1002/jcp.1041500206; OYAMA Y, 1986, EUR J PHARMACOL, V132, P75, DOI 10.1016/0014-2999(86)90013-0; PANNELL R, 1987, BLOOD, V69, P22; Pedersen TL, 1996, BRIT J HAEMATOL, V95, P45; PEPPER MS, 1990, J CELL BIOL, V111, P743, DOI 10.1083/jcb.111.2.743; Pinsky DJ, 1998, J CLIN INVEST, V102, P919, DOI 10.1172/JCI307; QUAX PHA, 1991, CELL REGUL, V2, P793, DOI 10.1091/mbc.2.10.793; RABBANI SA, 1992, J BIOL CHEM, V267, P14151; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; SCHWARTZ BS, 1994, J BIOL CHEM, V269, P8319; Shireman PK, 1997, J VASC SURG, V25, P157, DOI 10.1016/S0741-5214(97)70333-1; Simon DI, 1996, BLOOD, V88, P3185, DOI 10.1182/blood.V88.8.3185.bloodjournal8883185; Sitrin RG, 1999, J IMMUNOL, V163, P6193; STAHL A, 1994, CANCER RES, V54, P3066; Tozawa K, 1999, ANTIOXID REDOX SIGN, V1, P145, DOI 10.1089/ars.1999.1.2-145; Ugwu F, 1998, BIOCHEMISTRY-US, V37, P7231, DOI 10.1021/bi9728708; URANO T, 1988, ARCH BIOCHEM BIOPHYS, V264, P222, DOI 10.1016/0003-9861(88)90588-7; van Hinsbergh V W, 1997, EXS, V79, P391; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; XUE W, 1994, J IMMUNOL, V152, P4630; Yebra M, 1996, J BIOL CHEM, V271, P29393, DOI 10.1074/jbc.271.46.29393; YOHTARO O, 1987, EUR J PHARMACOL, V131, P75; Zlatnik MG, 1999, AM J OBSTET GYNECOL, V180, P1191, DOI 10.1016/S0002-9378(99)70615-0	68	36	40	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2000	14	10					1411	1422		10.1096/fj.14.10.1411	http://dx.doi.org/10.1096/fj.14.10.1411			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877834				2022-12-28	WOS:000087932200016
J	Manev, H; Uz, T; Sugaya, K; Qu, TY				Manev, H; Uz, T; Sugaya, K; Qu, TY			Putative role of neuronal 5-lipoxygenase in an aging brain	FASEB JOURNAL			English	Article						5-LOX; aged-associated CNS alterations; neuronal degeneration; cyclooxygenase; COX	MESSENGER-RNA; KAINIC ACID; RAT PINEAL; ANTIINFLAMMATORY DRUGS; MELATONIN-DEFICIENT; ACTIVATING PROTEIN; GENE-EXPRESSION; UP-REGULATION; PATHWAY; 12-LIPOXYGENASE	Aging is associated with increased incidence and/or severity of neurodegenerative pathologies. Oxygen-mediated events are being considered as possible mechanisms responsible for the increasing neuronal vulnerability. Lipoxygenases are enzymes that, as cyclooxygenases (COX), can insert oxygen into the molecule of arachidonic acid and thereby synthesize inflammatory eicosanoids: leukotrienes [due to 5-lipoxygenase (5-LOX) activity] and prostaglandins (via COX activity), It appears that 5-LOX is expressed in central nervous system neurons and may participate in neurodegeneration. 5-LOX-triggered cell death may be initiated by the enzymatic activity of 5-LOX but could also occur via the nonenzymatic actions of the 5-LOX protein; new data point to the possibility that 5-LOX protein exerts actions such as interaction with tyrosine kinase receptors, cytoskeletal proteins, and the nucleus. The expression of neuronal 5-LOX is susceptible to hormonal regulation, presumably due to the presence of hormone-responsive elements in the structure of the 5-LOX gene promoter. The expression of the 5-LOX gene and the activity of the 5-LOX pathway are increased in elderly subjects. One possible mechanism of such 5-LOX up-regulation implies the contribution of aging-associated hormonal changes: relative melatonin deficiency and/or hyperglucocorticoidemia. Thus, the 5-LOX pathway could become a promising target of neuroprotective therapies for the aging brain.	Univ Illinois, Inst Psychiat, Dept Psychiat, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Manev, H (corresponding author), Univ Illinois, Inst Psychiat, Dept Psychiat, 1601 W Taylor St,MC 912, Chicago, IL 60612 USA.	HManev@psych.uic.edu	qu, tingyu/AGX-7752-2022; qu, tingyu/AHA-0840-2022	Sugaya, Kiminobu/0000-0002-2788-5457	NATIONAL INSTITUTE ON AGING [R01AG015347] Funding Source: NIH RePORTER; NIA NIH HHS [R01-AG15347] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARAN H, 1994, BRAIN RES, V646, P201, DOI 10.1016/0006-8993(94)90078-7; Bigby TD, 1999, CLIN REV ALLERG IMMU, V17, P43, DOI 10.1007/BF02737596; Cattaneo E, 1998, TRENDS NEUROSCI, V21, P476, DOI 10.1016/S0166-2236(98)01282-X; Chakraborti T, 1999, BIOCHEM MOL BIOL INT, V47, P501; Chen XS, 1998, J BIOL CHEM, V273, P31237, DOI 10.1074/jbc.273.47.31237; Christie MJ, 1999, INFLAMM RES, V48, P1, DOI 10.1007/s000110050367; Chyb S, 1999, NATURE, V397, P255, DOI 10.1038/16703; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Drazen JM, 1999, NAT GENET, V22, P168, DOI 10.1038/9680; Funder JW, 1997, ANNU REV MED, V48, P231, DOI 10.1146/annurev.med.48.1.231; Geula C, 1998, NAT MED, V4, P827, DOI 10.1038/nm0798-827; HARMAN D, 1999, J ANTI-AGING MED, V2, P15, DOI DOI 10.1089/rej.1.1999.2.15; HOSHIKO S, 1990, P NATL ACAD SCI USA, V87, P9073, DOI 10.1073/pnas.87.23.9073; Ibe BO, 1997, BIOCHEM MOL MED, V61, P63, DOI 10.1006/bmme.1997.2579; In KH, 1999, CLIN REV ALLERG IMMU, V17, P59, DOI 10.1007/BF02737597; INTVELD BA, 1998, NEUROBIOL AGING, V119, P607; Kawajiri H, 1997, BIOCHEM BIOPH RES CO, V238, P229, DOI 10.1006/bbrc.1997.7213; Kilic E, 1999, J CEREBR BLOOD F MET, V19, P511, DOI 10.1097/00004647-199905000-00005; Lammers CH, 1996, J NEUROCHEM, V66, P147; LANDFIELD PW, 1978, SCIENCE, V202, P1098, DOI 10.1126/science.715460; Lepley RA, 1998, ARCH BIOCHEM BIOPHYS, V356, P71, DOI 10.1006/abbi.1998.0744; LEPLEY RA, 1994, J BIOL CHEM, V269, P24163; Lepley RA, 1996, J BIOL CHEM, V271, P6179, DOI 10.1074/jbc.271.11.6179; Li YH, 1997, NEURON, V19, P453, DOI 10.1016/S0896-6273(00)80953-8; LINDGREN JA, 1984, P NATL ACAD SCI-BIOL, V81, P6212, DOI 10.1073/pnas.81.19.6212; LU MC, 1996, AM J PHYSIOL, V271, pL545; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; Lupien SJ, 1998, NAT NEUROSCI, V1, P69, DOI 10.1038/271; Lynch MA, 1998, PROG NEUROBIOL, V56, P571, DOI 10.1016/S0301-0082(98)00054-9; Maccarrone M, 1998, BIOCHEM J, V333, P45, DOI 10.1042/bj3330045; Manev H, 1996, FASEB J, V10, P1546, DOI 10.1096/fasebj.10.13.8940301; Manev H, 1999, ANN NY ACAD SCI, V890, P183, DOI 10.1111/j.1749-6632.1999.tb07994.x; Manev H, 1998, RESTOR NEUROL NEUROS, V12, P81; Manev H., 1997, Society for Neuroscience Abstracts, V23, P533; Mayatepek E, 1998, LANCET, V352, P1514, DOI 10.1016/S0140-6736(98)01186-6; McEwen BS, 1999, FRONT NEUROENDOCRIN, V20, P49, DOI 10.1006/frne.1998.0173; McGill KA, 1996, LANCET, V348, P519, DOI 10.1016/S0140-6736(95)12297-4; OHTSUKI T, 1995, AM J PHYSIOL-HEART C, V268, pH1249, DOI 10.1152/ajpheart.1995.268.3.H1249; PALLUY O, 1994, CR ACAD SCI III-VIE, V317, P813; Peters-Golden M, 1998, AM J RESP CRIT CARE, V157, pS227, DOI 10.1164/ajrccm.157.6.mar4; Provost P, 1999, P NATL ACAD SCI USA, V96, P1881, DOI 10.1073/pnas.96.5.1881; RICH JB, 1995, NEUROLOGY, V45, P51, DOI 10.1212/WNL.45.1.51; Riddick CA, 1997, EUR J BIOCHEM, V246, P112, DOI 10.1111/j.1432-1033.1997.00112.x; ROHRIG U, 1995, FEBS LETT, V374, P284, DOI 10.1016/0014-5793(95)01130-7; Selmaoui B, 1999, LIFE SCI, V64, P2291, DOI 10.1016/S0024-3205(99)00180-0; Shetty AK, 1999, EXP NEUROL, V158, P491, DOI 10.1006/exnr.1999.7107; Silverman ES, 1998, BIOCHEM J, V336, P183, DOI 10.1042/bj3360183; SIMMET T, 1990, BRAIN RES, V515, P79, DOI 10.1016/0006-8993(90)90579-Z; STEINHILBER D, 1995, J BIOL CHEM, V270, P7037, DOI 10.1074/jbc.270.13.7037; Steinhilber D, 1999, CURR MED CHEM, V6, P71; Sugaya K, 1996, J NEUROSCI, V16, P3427; Uz T, 1999, J NEUROCHEM, V73, P693, DOI 10.1046/j.1471-4159.1999.0730693.x; Uz T, 1998, FASEB J, V12, P439, DOI 10.1096/fasebj.12.6.439; Uz T, 1997, J NEUROCHEM, V69, P2220; Uz T, 1998, NEUROREPORT, V9, P783, DOI 10.1097/00001756-199803300-00003; VACAS MI, 1987, NEUROENDOCRINOLOGY, V46, P412, DOI 10.1159/000124854; Wallace JL, 1999, TRENDS PHARMACOL SCI, V20, P4, DOI 10.1016/S0165-6147(98)01283-8; WALLIS RA, 1993, EUR J PHARMACOL, V238, P165, DOI 10.1016/0014-2999(93)90844-8; Wetterberg L, 1999, PSYCHONEUROENDOCRINO, V24, P209, DOI 10.1016/S0306-4530(98)00076-6; Wiesenberg I, 1998, RESTOR NEUROL NEUROS, V12, P143; Winking M, 1996, J CEREBR BLOOD F MET, V16, P737, DOI 10.1097/00004647-199607000-00026; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	62	94	102	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2000	14	10					1464	1469		10.1096/fj.14.10.1464	http://dx.doi.org/10.1096/fj.14.10.1464			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877840				2022-12-28	WOS:000087932200022
J	Geymayer, S; Doppler, W				Geymayer, S; Doppler, W			Activation of NF-kappa B p50/p65 is regulated in the developing mammary gland and inhibits STAT5-mediated beta-casein gene expression	FASEB JOURNAL			English	Article						TNF-alpha; prolactin; milk protein gene transcription; tyrosine phosphorylation	TUMOR-NECROSIS-FACTOR; GLUCOCORTICOID RECEPTOR; SYNERGISTIC ACTIVATION; ALPHA DEGRADATION; EPITHELIAL-CELLS; IMMUNE-RESPONSES; BREAST-CANCER; PROLACTIN; STAT5; MICE	The NF-kappa B family of transcription factors regulates diverse cellular functions such as immune response and cell growth and development, and has been reported to be constitutively active in a variety of mammary carcinoma cell lines. However, its role in normal mammary gland development has not been addressed. In our study, we detected developmentally regulated NF-kappa B activity in the mammary gland of mice. During pregnancy, DNA binding activity of NF-kappa B p50/p65 increased until day 16 postcoitum and decreased with the onset of lactation, most likely due to reduced p50 and p65 protein levels in the nucleus. Cotransfection experiments performed with 293 cells revealed an inhibition of the prolactin receptor/JAK2/STAT5 pathway by NF-kappa B. In HC11 cells, NF-kappa B p50/p65 activity was inversely correlated with prolactin-induced STAT5 tyrosine phosphorylation, expression of endogenous beta-casein gene, and of a transfected beta-casein gene promoter reporter construct. This indicates a negative cross talk between NF-kappa B and the prolactin receptor/JAK2/STAT5 activation pathway, which occurs at the level of STAT5 tyrosine phosphorylation. Our results provide evidence for a role of NF-kappa B in normal mammary gland development, and indicate its function as a negative regulator of beta-casein gene expression during pregnancy by interfering with STATS tyrosine phosphorylation.-Geymayer, S., Doppler, W. Activation of NF-kappa B p50/p65 is regulated in the developing mammary gland and inhibits STATS-mediated beta-casein gene expression.	Univ Innsbruck, Inst Med Chem & Biochem, A-6020 Innsbruck, Austria	University of Innsbruck	Doppler, W (corresponding author), Univ Innsbruck, Inst Med Chem & Biochem, Fritz Pregl Str 3, A-6020 Innsbruck, Austria.	Wolfgang.Doppler@uibk.ac.at.osupersub						BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baichwal V. R., 1997, CURR BIOL, V7, P94; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; BASOLO F, 1993, INT J CANCER, V55, P926, DOI 10.1002/ijc.2910550609; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; Cheshire JL, 1997, MOL CELL BIOL, V17, P6746, DOI 10.1128/MCB.17.11.6746; Delfino F, 1998, MOL ENDOCRINOL, V12, P1696, DOI 10.1210/me.12.11.1696; Dumont A, 1998, TRENDS BIOCHEM SCI, V23, P233, DOI 10.1016/S0968-0004(98)01212-2; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hehner SP, 1998, J BIOL CHEM, V273, P1288, DOI 10.1074/jbc.273.3.1288; Hennighausen L, 1998, GENE DEV, V12, P449, DOI 10.1101/gad.12.4.449; Horwitz BH, 1997, IMMUNITY, V6, P765, DOI 10.1016/S1074-7613(00)80451-3; Lechner J, 1997, J BIOL CHEM, V272, P20954, DOI 10.1074/jbc.272.33.20954; Luetteke NC, 1999, DEVELOPMENT, V126, P2739; Mayr S, 1998, EUR J BIOCHEM, V258, P784, DOI 10.1046/j.1432-1327.1998.2580784.x; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; NAUMANN M, 1999, IN PRESS ONCOGENE; SchmidtUllrich R, 1996, DEVELOPMENT, V122, P2117; Shen CH, 1998, MOL CELL BIOL, V18, P3395, DOI 10.1128/MCB.18.6.3395; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Starr R, 1999, BIOESSAYS, V21, P47, DOI 10.1002/(SICI)1521-1878(199901)21:1<47::AID-BIES6>3.0.CO;2-N; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Storz P, 1998, FEBS LETT, V440, P41, DOI 10.1016/S0014-5793(98)01421-5; STREULI CH, 1995, J BIOL CHEM, V270, P21639, DOI 10.1074/jbc.270.37.21639; Sun L, 1998, ONCOGENE, V16, P2095, DOI 10.1038/sj.onc.1201731; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; Varela LM, 1996, ENDOCRINOLOGY, V137, P4915, DOI 10.1210/en.137.11.4915; Weih F, 1997, J EXP MED, V185, P1359, DOI 10.1084/jem.185.7.1359; WELTE T, 1994, EUR J BIOCHEM, V223, P997, DOI 10.1111/j.1432-1033.1994.tb19078.x; WELTE T, 1994, MOL ENDOCRINOL, V8, P1091, DOI 10.1210/me.8.8.1091; Winklehner-Jennewein P, 1998, GENE, V217, P127, DOI 10.1016/S0378-1119(98)00380-1	34	64	66	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2000	14	9					1159	1170		10.1096/fasebj.14.9.1159	http://dx.doi.org/10.1096/fasebj.14.9.1159			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834938				2022-12-28	WOS:000087427300013
J	Han, ZQ; Ni, J; Smits, P; Underhill, CB; Xie, B; Chen, YX; Liu, NF; Tylzanowski, P; Parmelee, D; Feng, P; Ding, I; Gao, F; Gentz, R; Huylebroeck, D; Merregaert, J; Zhang, LR				Han, ZQ; Ni, J; Smits, P; Underhill, CB; Xie, B; Chen, YX; Liu, NF; Tylzanowski, P; Parmelee, D; Feng, P; Ding, I; Gao, F; Gentz, R; Huylebroeck, D; Merregaert, J; Zhang, LR			Extracellular matrix protein 1 (ECM1) has angiogenic properties and is expressed by breast tumor cells	FASEB JOURNAL			English	Article						angiogenesis; breast cancer; ECM1; endothelial cells	DEVELOPMENTAL EXPRESSION; ALPHA-FETOPROTEIN; BINDING; PROLIFERATION; INHIBITOR; ALBUMIN; CLONING; FAMILY; CANCER; MOUSE	Tumor growth and metastasis are critically dependent on the formation of new blood vessels. The present study found that extracelluIar matrix protein 1 (ECM1), a newly described secretory glycoprotein, promotes angiogenesis. This was initially suggested by itt situ hybridization studies of mouse embryos indicating that the ECM1 message was associated with blood vessels and its expression pattern was similar to that of flk-1, a recognized marker for endothelium. More direct evidence for the role of ECM1 in angiogenesis was provided by the fact that highly purified recombinant ECM1 stimulated the proliferation of cultured endothelial cells and promoted blood vessel formation in the chorioallantoic membrane of chicken embryos. Immunohistochemical staining with specific antibodies indicated that ECM1 was expressed by the human breast cancer cell lines MDA-435 and LCC15, both of which are highly tumorigenic. In addition, staining of tissue sections from patients with breast cancer revealed that ECM1 was present in a significant proportion of primary and secondary tumors. Collectively, the results of this study suggest that ECM1 possesses angiogenic properties that may promote tumor progression.	Georgetown Univ, Med Ctr, Dept Oncol, Washington, DC 20007 USA; Human Genome Sci, Rockville, MD 20850 USA; Univ Rochester, Med Ctr, Dept Radiol, Rochester, NY 14642 USA; Xiamen Univ, Dept Biol, Xiamen, Peoples R China; Katholieke Univ Leuven VIB, Mol Biol Lab, Celgen, Louvain, Belgium; Katholieke Univ Leuven VIB, Dept Cell Growth Differentiat & Dev, Louvain, Belgium; Univ Instelling Antwerp, Dept Biochem, Lab Mol Biotechnol, B-2610 Antwerp, Belgium	Georgetown University; GlaxoSmithKline; Human Genome Sciences Inc; University of Rochester; Xiamen University; Flanders Institute for Biotechnology (VIB); KU Leuven; Flanders Institute for Biotechnology (VIB); KU Leuven; University of Antwerp	Zhang, LR (corresponding author), Georgetown Univ, Med Ctr, Dept Oncol, 3970 Reservoir Rd NW, Washington, DC 20007 USA.	zhangl@georgetown.edu	Tylzanowski, Przemko/G-8881-2013; Chen, YX/G-3937-2010	Tylzanowski, Przemko/0000-0003-0769-559X; Huylebroeck, Danny/0000-0003-4862-1079	NCI NIH HHS [R29 CA71545] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA071545] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUSPRUNK DH, 1977, MICROVASC RES, V14, P53, DOI 10.1016/0026-2862(77)90141-8; BHALERAO J, 1995, J BIOL CHEM, V270, P16385, DOI 10.1074/jbc.270.27.16385; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; DECKERS MML, IN PRESS BONE; DEWULF N, 1995, ENDOCRINOLOGY, V136, P2652, DOI 10.1210/en.136.6.2652; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Hoffmann A, 1996, DEV DYNAM, V207, P332, DOI 10.1002/(SICI)1097-0177(199611)207:3<332::AID-AJA10>3.0.CO;2-6; JACOB F, 1983, CIBA F SYMP, V96, P4; Johnson MR, 1997, MATRIX BIOL, V16, P289, DOI 10.1016/S0945-053X(97)90017-2; KEW M, 1974, GUT, V15, P814, DOI 10.1136/gut.15.10.814; KRAGHHANSEN U, 1990, DAN MED BULL, V37, P57; MATHIEU E, 1994, J BONE MINER RES, V9, P903; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Nguyen M, 1997, INVEST NEW DRUG, V15, P29, DOI 10.1023/A:1005766511385; Ni J, 1998, J BIOL CHEM, V273, P24797, DOI 10.1074/jbc.273.38.24797; Ni J, 1997, J BIOL CHEM, V272, P10853; POLVERINI PJ, 1984, LAB INVEST, V51, P635; Smits P, 1997, GENOMICS, V45, P487, DOI 10.1006/geno.1997.4918; Smits P, 2000, J INVEST DERMATOL, V114, P718, DOI 10.1046/j.1523-1747.2000.00916.x; Sung V, 1998, EXP CELL RES, V241, P273, DOI 10.1006/excr.1998.4029; Thomas KA, 1996, J BIOL CHEM, V271, P603, DOI 10.1074/jbc.271.2.603; YACHNIN S, 1978, ANN CLIN LAB SCI, V8, P84; YANG F, 1985, P NATL ACAD SCI USA, V82, P7994, DOI 10.1073/pnas.82.23.7994	23	107	121	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2001	15	6					988	994		10.1096/fj.99-0934com	http://dx.doi.org/10.1096/fj.99-0934com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292659				2022-12-28	WOS:000167959300013
J	Nauenburg, S; Zwerschke, W; Jansen-Durr, P				Nauenburg, S; Zwerschke, W; Jansen-Durr, P			Induction of apoptosis in cervical carcinoma cells by peptide aptamers that bind to the HPV-16 E7 oncoprotein	FASEB JOURNAL			English	Article									Tiroler Krebsforschungsins, A-6020 Innsbruck, Austria; Austrian Acad Sci, Inst Biomed Alternsforsch, A-6020 Innsbruck, Austria; Deutsch Krebsforschungszentrum, Forschungsschewerpunket Angew Tumorvirol, D-69120 Heidelberg, Germany	Austrian Academy of Sciences; Helmholtz Association; German Cancer Research Center (DKFZ)	Zwerschke, W (corresponding author), Tiroler Krebsforschungsins, Innrain 66, A-6020 Innsbruck, Austria.		Jansen-Dürr, Pidder/ABG-2466-2020	Jansen-Dürr, Pidder/0000-0001-7771-3429; Zwerschke, Werner/0000-0003-1137-2953					0	39	45	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					592	594						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259377				2022-12-28	WOS:000167419500015
J	Tegeder, I; Niederberger, E; Israr, E; Guhring, H; Brune, K; Euchenhofer, C; Grosch, S; Geisslinger, G				Tegeder, I; Niederberger, E; Israr, E; Guhring, H; Brune, K; Euchenhofer, C; Grosch, S; Geisslinger, G			Inhibition of NF-KB and AP-1 activation by R- and S-flurbiprofen	FASEB JOURNAL			English	Article									Goethe Univ Frankfurt, Ctr Pharmacol, D-60590 Frankfurt, Germany; Univ Erlangen Nurnberg, Inst Expt Pharmakol & Toxikol, D-91054 Erlangen, Germany	Goethe University Frankfurt; University of Erlangen Nuremberg	Geisslinger, G (corresponding author), Goethe Univ Frankfurt, Ctr Pharmacol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	geisslinger@em.uni-frankfurt.de	Tegeder, Irmgard/AAM-2266-2020; Tegeder, Irmgard/AAM-2246-2020; Groesch, Sabine/H-4251-2018	Tegeder, Irmgard/0000-0001-7524-8025; Tegeder, Irmgard/0000-0001-7524-8025; Groesch, Sabine/0000-0002-7262-6307					0	48	50	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2001	15	3					595	597		10.1096/fasebj.15.3.595	http://dx.doi.org/10.1096/fasebj.15.3.595			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11291649				2022-12-28	WOS:000167419500016
J	Misasi, R; Sorice, M; Di Marzio, L; Campana, WM; Molinari, S; Cifone, MG; Pavan, A; Pontieri, GM; O'Brien, JS				Misasi, R; Sorice, M; Di Marzio, L; Campana, WM; Molinari, S; Cifone, MG; Pavan, A; Pontieri, GM; O'Brien, JS			Prosaposin treatment induces PC12 entry in the S phase of the cell cycle and prevents apoptosis: activation of ERKs and sphingosine kinase	FASEB JOURNAL			English	Article						signal-regulated protein kinase; BrdU; S-1-P; PC12 cells	NERVE GROWTH-FACTOR; PROTEIN-DEPENDENT MECHANISM; SIGNAL-TRANSDUCTION; SCHWANN-CELLS; NEUROTROPHIC FACTOR; IN-VIVO; PROSAPTIDE; CERAMIDE; PATHWAY; SPHINGOSINE-1-PHOSPHATE	We report that prosaposin treatment induced extracellular signal-regulated kinases (ERKs) and sphingosine kinase activity, increased DNA synthesis, and prevented cell apoptosis. Prosaposin treatment induced pheochromocytoma cells (PC12) to enter the S phase of the cell cycle; this effect was inhibited by the MEK inhibitor PD98059, indicating that prosaposin-induced ERK phosphorylation is required for stimulation of DNA synthesis. The prosaposin effect was also inhibited by pertussis toxin, indicating that the prosaposin receptor is a G-protein-coupled receptor. Prosaposin rescued PC12 cells from apoptosis induced by staurosporine or ceramide. Sphingosine kinase activity was increased by prosaposin treatment. We propose that this effect is a mechanism underlying the proliferative and anti-apoptotic functions of prosaposin. Prosaposin appears to be a key regulatory factor in the ceramide-S-l-P rheostat, which regulates cell fate.	Univ Rome La Sapienza, Dipartimento Med Sperimentale & Patol, Policlin Umberto I, I-00161 Rome, Italy; Univ LAquila, Dipartimento Med Sperimentale, Laquila, Italy; Univ Calif San Diego, Dept Neurosci, Sch Med, Ctr Mol Genet, La Jolla, CA 92093 USA	Sapienza University Rome; University Hospital Sapienza Rome; University of L'Aquila; University of California System; University of California San Diego	Misasi, R (corresponding author), Univ Rome La Sapienza, Dipartimento Med Sperimentale & Patol, Policlin Umberto I, Viale Regina Elena 324, I-00161 Rome, Italy.		Sousa, Maria/HCI-9642-2022; Cifone, Maria Grazia/ABH-1984-2021; Di Marzio, Luisa/H-9969-2012; Di Marzio, Luisa/AAF-8052-2021; Sorice, Maurizio/Q-5079-2019; Cifone, Maria Grazia/I-3750-2019	Di Marzio, Luisa/0000-0002-2518-7188; Cifone, Maria Grazia/0000-0002-9923-5445; Sorice, Maurizio/0000-0003-3534-1502				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; AZUMA N, 1994, ARCH BIOCHEM BIOPHYS, V311, P354, DOI 10.1006/abbi.1994.1248; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; Campana WM, 1999, J NEUROSCI RES, V57, P332; Campana WM, 1996, BIOCHEM BIOPH RES CO, V229, P706, DOI 10.1006/bbrc.1996.1869; Campana WM, 1998, FASEB J, V12, P307, DOI 10.1096/fasebj.12.3.307; Campana WM, 1998, NEUROTOXICOLOGY, V19, P237; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; COLIGAN JE, 1990, CURRENT PROTOCOLS IM, V2; CONNOLLY JL, 1979, J CELL BIOL, V82, P820, DOI 10.1083/jcb.82.3.820; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; FU Q, 1994, J MOL NEUROSCI, V5, P59, DOI 10.1007/BF02736694; GAVRIELI Y, 1992, J CELL BIOL, V119, P494; GREENE L, 1976, P NATL ACAD SCI USA, V3, P2424; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; Hartfield PJ, 1997, FEBS LETT, V401, P148, DOI 10.1016/S0014-5793(96)01460-3; HINENO T, 1991, BIOCHEM BIOPH RES CO, V176, P668, DOI 10.1016/S0006-291X(05)80236-0; HIRAIWA M, 1993, ARCH BIOCHEM BIOPHYS, V304, P110, DOI 10.1006/abbi.1993.1328; Hiraiwa M, 1997, P NATL ACAD SCI USA, V94, P4778, DOI 10.1073/pnas.94.9.4778; Hiraiwa M, 1997, BIOCHEM BIOPH RES CO, V240, P415, DOI 10.1006/bbrc.1997.7673; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; KISHIMOTO Y, 1992, J LIPID RES, V33, P1255; Kotani Y, 1996, J NEUROCHEM, V66, P2019; Kruman I, 1998, J NEUROSCI RES, V51, P293, DOI 10.1002/(SICI)1097-4547(19980201)51:3<293::AID-JNR3>3.0.CO;2-B; LINDENBOIM L, 1995, CANCER RES, V55, P1242; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OBRIEN JS, 1995, FASEB J, V9, P681, DOI 10.1096/fasebj.9.8.7768361; OBRIEN JS, 1994, P NATL ACAD SCI USA, V91, P9593, DOI 10.1073/pnas.91.20.9593; OBRIEN JS, 1991, FASEB J, V5, P301, DOI 10.1096/fasebj.5.3.2001789; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PUSHKAREVA M, 1995, IMMUNOL TODAY, V16, P294, DOI 10.1016/0167-5699(95)80184-7; Qi XY, 1996, J BIOL CHEM, V271, P6874, DOI 10.1074/jbc.271.12.6874; RIBONI L, 1995, J BIOL CHEM, V270, P26868, DOI 10.1074/jbc.270.45.26868; SANO A, 1994, BIOCHEM BIOPH RES CO, V204, P994, DOI 10.1006/bbrc.1994.2558; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Spiegel S, 1999, J LEUKOCYTE BIOL, V65, P341, DOI 10.1002/jlb.65.3.341; SUGITA M, 1975, BIOCHIM BIOPHYS ACTA, V398, P125, DOI 10.1016/0005-2760(75)90176-9; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Tsuboi K, 1998, DEV BRAIN RES, V110, P249, DOI 10.1016/S0165-3806(98)00109-6; vanEchtenDeckert G, 1997, J BIOL CHEM, V272, P15825, DOI 10.1074/jbc.272.25.15825; vanGrunsven LA, 1996, ONCOGENE, V12, P855; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; Xia P, 1998, P NATL ACAD SCI USA, V95, P14196, DOI 10.1073/pnas.95.24.14196; Yan LZ, 2000, NEUROSCI LETT, V278, P120, DOI 10.1016/S0304-3940(99)00902-7; YOUNG IT, 1977, J HISTOCHEM CYTOCHEM, V25, P935, DOI 10.1177/25.7.894009; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	49	46	51	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					467	474		10.1096/fj.00-0217com	http://dx.doi.org/10.1096/fj.00-0217com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156962				2022-12-28	WOS:000166872900028
J	Scherpereel, A; Wiewrodt, R; Christofidou-Solomidou, M; Gervais, R; Murciano, JC; Albelda, SM; Muzykantov, VR				Scherpereel, A; Wiewrodt, R; Christofidou-Solomidou, M; Gervais, R; Murciano, JC; Albelda, SM; Muzykantov, VR			Cell-selective intracellular delivery of a foreign enzyme to endothelium in vivo using vascular immunotargeting	FASEB JOURNAL			English	Article						drug targeting; lung; PECAM-1; beta-galactosidase; streptavidin	HUMAN PECAM-1 CD31; ADHESION MOLECULE-1; MONOCLONAL-ANTIBODY; TRANSDUCTION; PROTEINS; STRATEGY; LUNGS	Vascular immunotargeting, the administration of drugs conjugated with antibodies to endothelial surface antigens, has the potential for drug delivery to the endothelium. Our previous cell culture studies showed that biotinylated antibodies to PECAM-1 (a highly expressed endothelial surface antigen) coupled with streptavidin (SA, a cross-linking protein that facilitates anti-PECAM internalization and targeting) may provide a carrier for the intracellular delivery of therapeutic enzymes. This paper describes the PECAM-directed vascular immunotargeting of a reporter enzyme (beta -galactosidase, beta -Gal) in intact animals. Intravenous injection of [(125)I]SA-beta -Gal conjugated with either anti-PECAM or IgG led to a high (125)I uptake in liver and spleen, yet beta -Gal activity in these organs rapidly declined to the background levels, suggesting rapid degradation of the conjugates. In contrast, anti-PECAM/[(125)I]SA-B-Gal, but not IgG/[(125)I]SA-beta -Gal, accumulated in the lungs (36.0+/-1.3 vs. 3.9+/-0.6% injected dose/g) and induced a marked elevation of beta -Gal activity in the lung tissue persisting for up to 8 h after injection (10-fold elevation 4 h postinjection). Using histochemical detection, the beta -Gal activity in the lungs was detected in the endothelial cells of capillaries and large vessels. The anti-PECAM carrier also provided (125)I uptake and beta -Gal activity in the renal glomeruli. Predominant intracellular localization of anti-PECAM/SA-beta -Gal was documented in the PECAM-expressing cells in culture by confocal microscopy and in the pulmonary endothelium by electron microscopy. Therefore, vascular immunotargeting is a feasible strategy for cell-selective, intracellular delivery of an active foreign enzyme to endothelial cells in vivo, and thus may be potentially useful for the treatment of acute pulmonary or vascular diseases.	Univ Penn, Med Ctr, Inst Environm Med, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Med, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Muzykantov, VR (corresponding author), Univ Penn, Med Ctr, Inst Environm Med, 1 John Morgan Bldg,36th St & Hamilton Walk, Philadelphia, PA 19104 USA.	muzykant@mail.med.upenn.edu	Murciano, Juan Carlos/AAG-6253-2021	Murciano, Juan Carlos/0000-0002-4894-046X	NHLBI NIH HHS [HL 60290] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060290] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Atochina EN, 1998, AM J PHYSIOL-LUNG C, V275, pL806, DOI 10.1152/ajplung.1998.275.4.L806; Christofidou-Solomidou M, 2000, AM J PHYSIOL-LUNG C, V278, pL794, DOI 10.1152/ajplung.2000.278.4.L794; DANILOV SM, 1991, LAB INVEST, V64, P118; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; GOW A, 2000, AM J PHYSIOL, V277, pL271; Gurubhagavatula I, 1998, J CLIN INVEST, V101, P212, DOI 10.1172/JCI269; KUCHARCZUK JC, 1995, ANN THORAC SURG, V60, P593, DOI 10.1016/0003-4975(95)00507-H; Liu XY, 1996, P NATL ACAD SCI USA, V93, P11819, DOI 10.1073/pnas.93.21.11819; MARUYAMA K, 1990, P NATL ACAD SCI USA, V87, P5744, DOI 10.1073/pnas.87.15.5744; Muzykantov VR, 1999, P NATL ACAD SCI USA, V96, P2379, DOI 10.1073/pnas.96.5.2379; Muzykantov VR, 1996, P NATL ACAD SCI USA, V93, P5213, DOI 10.1073/pnas.93.11.5213; Muzykantov VR, 1998, PATHOPHYSIOLOGY, V5, P15; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Newman PJ, 1997, J CLIN INVEST, V99, P3, DOI 10.1172/JCI119129; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Spragg DD, 1997, P NATL ACAD SCI USA, V94, P8795, DOI 10.1073/pnas.94.16.8795; VAPORCIYAN AA, 1993, SCIENCE, V262, P1580, DOI 10.1126/science.8248808; Wiewredt R, 1999, AM J RESP CRIT CARE, V159, pA347; YAN HC, 1995, CELL ADHES COMMUN, V3, P45, DOI 10.3109/15419069509081277	19	49	49	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					416	426		10.1096/fj.00-0022com	http://dx.doi.org/10.1096/fj.00-0022com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156957				2022-12-28	WOS:000166872900023
J	Zhou, ZHL; Han, YL; Wei, T; Aras, S; Chaturvedi, P; Tyler, S; Rani, MRS; Ransohoff, RM				Zhou, ZHL; Han, YL; Wei, T; Aras, S; Chaturvedi, P; Tyler, S; Rani, MRS; Ransohoff, RM			Regulation of monocyte chemoattractant protein (MCP)-1 transcription by interferon-gamma (IFN-gamma) in human astrocytoma cells: postinduction refractory state of the gene, governed by its upstream elements	FASEB JOURNAL			English	Article						chemokine; gene expression; interferons; STAT factors; Sp1 transcriptions factor	MULTIPLE-SCLEROSIS LESIONS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; IN-SITU HYBRIDIZATION; MESSENGER-RNA; GROWTH-FACTOR; JE GENE; EXPRESSION; INDUCTION; CHEMOKINES; MCP-1	Monocyte chemoattractant protein (MCP)-1 is expressed by astrocytes in diverse inflammatory states and is a key regulator of monocyte recruitment to the central nervous system (CNS). In the current study, we addressed mechanisms by which transcription of the human MCP-I. gene (hMCP-1) was terminated, after induction by interferon (IFN)-gamma. Our results demonstrated that IFN-gamma -induced transcription of hMCP-1 was followed by a refractory state, during which hMCP-1 was resistant to restimulation by either IFN-gamma or heterologous activators such as TNF-alpha. This refractory state affected the hMCP-1 gene selectively, as other IFN-gamma -inducible genes remained responsive to restimulation. The IFN-gamma -induced hMCP-1 refractory state was governed at the transcriptional level and was sensitive to protein synthesis inhibitors, suggesting a requirement for newly expressed components, A minimal 213 base pair hMCP-1 regulatory element directed both IFN-gamma -mediated transcription and the subsequent refractory state, We previously demonstrated that IFN-gamma treatment resulted in coordinate protein occupancy in vivo of two hMCP-1 promoter elements, a gamma-activated site (GAS) and a GC-rich element. During the refractory state, IFN-gamma treatment failed to induce protection of either the hMCP-1 GAS element or the GC box. These results furnish insight into the expression of hMCP-1 during CNS inflammation and provide the first delineation of an IFN-gamma -induced transcriptional refractory state.-Zhou, Z.-H. L., Han, Y., Wei, T., Aras, S., Chaturvedi, P., Tyler, S., Rani, M. R. S., Ransohoff, R. M. Regulation of monocyte chemoattractant protein (MCP)-1 transcription by interferon-gamma (IFN-gamma) in human astrocytoma cells: postinduction refractory state of the gene, governed by its upstream elements.	Cleveland Clin Fdn, Dept Neurosci, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Mellen Ctr Multiple Sclerosis Treatment & Res, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Neurol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Ransohoff, RM (corresponding author), Cleveland Clin Fdn, Dept Neurosci, Lerner Res Inst, 9500 Euclid Ave,NC30, Cleveland, OH 44195 USA.		Aras, Sumer/ABG-1206-2021		NCI NIH HHS [2PO1-CA62220] Funding Source: Medline; NINDS NIH HHS [2RO1-NS32151] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA062220] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032151] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARNA BP, 1989, J NEUROIMMUNOL, V23, P45, DOI 10.1016/0165-5728(89)90072-6; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; Conant K, 1998, P NATL ACAD SCI USA, V95, P3117, DOI 10.1073/pnas.95.6.3117; FRETER RR, 1992, MOL CELL BIOL, V12, P5288, DOI 10.1128/MCB.12.12.5288; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; Glabinski AR, 1996, J IMMUNOL, V156, P4363; GOODBOURN S, 1988, P NATL ACAD SCI USA, V85, P1447, DOI 10.1073/pnas.85.5.1447; Gosling J, 1999, J CLIN INVEST, V103, P773, DOI 10.1172/JCI5624; Gourmala NG, 1997, J NEUROIMMUNOL, V74, P35, DOI 10.1016/S0165-5728(96)00203-2; Gu L, 2000, NATURE, V404, P407, DOI 10.1038/35006097; Gu L, 1997, J LEUKOCYTE BIOL, V62, P577, DOI 10.1002/jlb.62.5.577; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; LARNER AC, 1986, J BIOL CHEM, V261, P453; LI YS, 1993, MOL CELL BIOCHEM, V126, P61, DOI 10.1007/BF01772208; Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601; Majumder S, 1998, J IMMUNOL, V161, P4736; Majumder S, 1996, J NEUROSCI RES, V45, P758, DOI 10.1002/(SICI)1097-4547(19960915)45:6<758::AID-JNR12>3.0.CO;2-S; MANIATIS T, 1992, TRANSCRIPTIONAL REGU, P1193; McManus C, 1998, J NEUROIMMUNOL, V86, P20, DOI 10.1016/S0165-5728(98)00002-2; MUELLER PR, 1994, CURRENT PROTOCOLS MO, V2; NEISH AS, 1995, J BIOL CHEM, V270, P28903, DOI 10.1074/jbc.270.48.28903; Nicholson SE, 1998, J LEUKOCYTE BIOL, V63, P665, DOI 10.1002/jlb.63.6.665; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; Ping DS, 2000, J BIOL CHEM, V275, P1708, DOI 10.1074/jbc.275.3.1708; Ping DS, 1996, IMMUNITY, V4, P455, DOI 10.1016/S1074-7613(00)80412-4; Ping DS, 1999, J BIOL CHEM, V274, P31909, DOI 10.1074/jbc.274.45.31909; RANSOHOFF RM, 1991, J NEUROIMMUNOL, V33, P103, DOI 10.1016/0165-5728(91)90054-B; Ransohoff RM, 1997, J LEUKOCYTE BIOL, V62, P645, DOI 10.1002/jlb.62.5.645; RANSOHOFF RM, 1993, FASEB J, V7, P592, DOI 10.1096/fasebj.7.6.8472896; Ransohoff RM, 1998, TRENDS NEUROSCI, V21, P154, DOI 10.1016/S0166-2236(97)01198-3; Rollins B, 1999, CHEMOKINES CANC; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; ROLLINS BJ, 1989, MOL CELL BIOL, V9, P4687, DOI 10.1128/MCB.9.11.4687; Rollins BJ, 1996, MOL MED TODAY, V2, P198, DOI 10.1016/1357-4310(96)88772-7; Sakamoto H, 1998, BLOOD, V92, P1668, DOI 10.1182/blood.V92.5.1668.417k09_1668_1676; Simpson JE, 1998, J NEUROIMMUNOL, V84, P238, DOI 10.1016/S0165-5728(97)00208-7; Song MM, 1998, J BIOL CHEM, V273, P35056, DOI 10.1074/jbc.273.52.35056; Starr R, 1998, INT J BIOCHEM CELL B, V30, P1081, DOI 10.1016/S1357-2725(98)00067-3; Tani M, 1996, AM J PATHOL, V148, P889; Van der Voorn P, 1999, AM J PATHOL, V154, P45, DOI 10.1016/S0002-9440(10)65249-2; Zhou ZHL, 1998, J IMMUNOL, V160, P3908	42	21	22	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					383	392		10.1096/fj.00-0373com	http://dx.doi.org/10.1096/fj.00-0373com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156954				2022-12-28	WOS:000166872900020
J	Huang, ZZ; Chen, CJ; Zeng, ZH; Yang, HP; Oh, J; Chen, LX; Lu, SC				Huang, ZZ; Chen, CJ; Zeng, ZH; Yang, HP; Oh, J; Chen, LX; Lu, SC			Mechanism and significance of increased glutathione level in human hepatocellular carcinoma and liver regeneration	FASEB JOURNAL			English	Article									Univ So Calif, Sch Med, Dept Med,USC Liver Dis Res Ctr, Div Gastrointestinal & Liver Dis, Los Angeles, CA 90033 USA	University of Southern California	Lu, SC (corresponding author), Univ So Calif, Sch Med, Dept Med,USC Liver Dis Res Ctr, Div Gastrointestinal & Liver Dis, HMR Bldg,415,2011 Zonal Ave, Los Angeles, CA 90033 USA.	shellylu@hsc.usc.edu			NIDDK NIH HHS [DK-45334, DK48522] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045334, R29DK045334, R56DK045334, P30DK048522] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Marinho HS, 1997, BBA-MOL BASIS DIS, V1360, P157, DOI 10.1016/S0925-4439(96)00075-0	1	155	167	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2001	15	1					19	21		10.1096/fj.00-0445fje	http://dx.doi.org/10.1096/fj.00-0445fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11099488				2022-12-28	WOS:000166312400007
J	Muller, M; Fleischmann, BK; Selbert, S; Ji, GJ; Endl, E; Middeler, G; Muller, OJ; Schlenke, P; Frese, S; Wobus, AM; Hescheler, J; Katus, HA; Franz, WM				Muller, M; Fleischmann, BK; Selbert, S; Ji, GJ; Endl, E; Middeler, G; Muller, OJ; Schlenke, P; Frese, S; Wobus, AM; Hescheler, J; Katus, HA; Franz, WM			Selection of ventricular-like cardiomyocytes from ES cells in vitro	FASEB JOURNAL			English	Article						embryoid body; cardiac; green fluorescent protein; in vitro differentiation	EMBRYONIC STEM-CELLS; IN-VITRO; TRANSCRIPTION FACTOR; MYOCARDIAL TISSUE; TRANSGENIC MICE; GENE-EXPRESSION; IONIC CURRENTS; RETINOIC ACID; MUSCLE-CELLS; CA2+ CHANNEL	Ischemic disorders of the heart can cause an irreversible loss of cardiomyocytes resulting cause an irreversible loss of cardiomyocytes resulting in a substantial decrease of cardiac output. The therapy of choice is heart transplantation, a technique that is hampered by the low number of donor organs. in the present study, we describe the specific labeling, rapid but gentle purification and characterization of cardiomyocytes derived from mouse pluripotent embryonic stem (ES) cells. To isolate the subpopulation of ventricular-like cardiomyocytes, ES cells were stable transfected with the enhanced green fluorescent protein (EGFP) under transcriptional control of the ventricular-specific 2.1 kb myosin light chain-2v (MLC-2v) promoter and the 0.5 kb enhancer element of the cytomegalovirus (CMVenh.). First fluorescent cells were detected at day 6 + 8 of differentiation within EBs. Four weeks after initiation of differentiation 25% of the cardiomyocyte population displayed fluorescence. Immunohistochemistry revealed the exclusive cardiomyogenic nature of EGFP-positive cells. This was further corroborated by electrophysiological studies where preferentially ventricular phenotypes, but no pacemaker-like cardiomyocytes, were detected among the EGFP-positive population. The enzymatic digestion of EBs, followed by Percoll gradient centrifugation and fluorescence-activated cell sorting, resulted in a 97% pure population of cardiomyocytes. Based on this study, ventricular-like cardiomyocytes can be generated in vitro from EBs and labeled using CMVenh./MLC-2V-driven marker genes facilitating an efficient purification. This method may become an important tool for future cell replacement therapy of ischemic cardiomyopathy especially after the proof of somatic differentiation of human ES cells in vitro.	Med Univ Lubeck, Med Klin 2, D-23538 Lubeck, Germany; Univ Cologne, Inst Neurophysiol, D-50931 Cologne, Germany; Res Ctr, Div Mol Immunol, D-23845 Borstel, Germany; Inst Plant Genet & Crop Plant Res, D-06466 Gatersleben, Germany; Med Univ Lubeck, Dept Immunol, D-23538 Lubeck, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Lubeck; University of Cologne; Forschungszentrum Borstel; Leibniz Institut fur Pflanzengenetik und Kulturpflanzenforschung; University of Lubeck	Franz, WM (corresponding author), Med Univ Lubeck, Med Klin 2, Ratzeburger Allee 160, D-23538 Lubeck, Germany.	franz@medinf.mu-luebeck.de	Müller, Oliver J./H-4739-2016; Müller, Oliver/AAA-4399-2021	Müller, Oliver/0000-0001-8223-2638; Muller, Mathias/0000-0002-7879-3552				ANVERSA P, 1991, CIRC RES, V69, P1159, DOI 10.1161/01.RES.69.4.1159; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; BOUVAGNET P, 1984, CIRC RES, V55, P794, DOI 10.1161/01.RES.55.6.794; BUGAISKY LB, 1989, CIRC RES, V64, P493, DOI 10.1161/01.RES.64.3.493; DANGOOR M, 1990, J MUSCLE RES CELL M, V11, P216, DOI 10.1007/BF01843575; DELCARPIO JB, 1991, CIRC RES, V69, P1591, DOI 10.1161/01.RES.69.6.1591; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Drab M, 1997, FASEB J, V11, P905, DOI 10.1096/fasebj.11.11.9285489; FRANZ WM, 1993, CIRC RES, V73, P629, DOI 10.1161/01.RES.73.4.629; Grepin C, 1997, DEVELOPMENT, V124, P2387; HAMILL OP, 1981, NATURE, V294, P462, DOI 10.1038/294462a0; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; Ji GJ, 1999, FASEB J, V13, P313, DOI 10.1096/fasebj.13.2.313; KATZ EB, 1992, AM J PHYSIOL, V262, pH1867, DOI 10.1152/ajpheart.1992.262.6.H1867; Klug MG, 1996, J CLIN INVEST, V98, P216, DOI 10.1172/JCI118769; KOH GY, 1995, J CLIN INVEST, V96, P2034, DOI 10.1172/JCI118251; Kolossov E, 1998, J CELL BIOL, V143, P2045, DOI 10.1083/jcb.143.7.2045; LEE KJ, 1992, J BIOL CHEM, V267, P15875; Leor J, 1996, CIRCULATION, V94, P332; Li RK, 1996, CARDIOVASC RES, V32, P362, DOI 10.1016/0008-6363(96)00079-X; Li RK, 1997, CIRCULATION, V96, P179; Makino S, 1999, J CLIN INVEST, V103, P697, DOI 10.1172/JCI5298; MALTSEV VA, 1994, CIRC RES, V75, P233, DOI 10.1161/01.RES.75.2.233; Maltsev VA, 1999, CIRC RES, V84, P136, DOI 10.1161/01.RES.84.2.136; METZGER JM, 1994, J CELL BIOL, V126, P701, DOI 10.1083/jcb.126.3.701; MILLERHANCE WC, 1993, J BIOL CHEM, V268, P25244; OBRIEN TX, 1993, P NATL ACAD SCI USA, V90, P5157, DOI 10.1073/pnas.90.11.5157; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447; ROHWEDEL J, 1994, DEV BIOL, V164, P87, DOI 10.1006/dbio.1994.1182; Rothmann T, 1996, GENE THER, V3, P919; Schwarz ER, 1998, Z KARDIOL, V87, P1, DOI 10.1007/s003920050147; SEN A, 1988, J BIOL CHEM, V263, P19132; Shamblott MJ, 1998, P NATL ACAD SCI USA, V95, P13726, DOI 10.1073/pnas.95.23.13726; SOONPAA MH, 1994, SCIENCE, V264, P98, DOI 10.1126/science.8140423; STRUBING C, 1995, MECH DEVELOP, V53, P275, DOI 10.1016/0925-4773(95)00446-8; Taylor DA, 1998, NAT MED, V4, P929, DOI 10.1038/nm0898-929; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Wartenberg M, 1998, LAB INVEST, V78, P1301; Watanabe E, 1998, CELL TRANSPLANT, V7, P239, DOI 10.1016/S0963-6897(98)00011-6; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Wobus AM, 1997, J MOL CELL CARDIOL, V29, P1525, DOI 10.1006/jmcc.1997.0433; WOBUS AM, 1991, DIFFERENTIATION, V48, P173, DOI 10.1111/j.1432-0436.1991.tb00255.x; ZEHELEIN J, 1993, Z KARDIOL S1, V82, P155	43	227	267	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2000	14	15					2540	2548		10.1096/fj.00-0002com	http://dx.doi.org/10.1096/fj.00-0002com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099473				2022-12-28	WOS:000165723400025
J	Rossmeisl, M; Syrovy, I; Baumruk, F; Flachs, P; Janovska, P; Kopecky, J				Rossmeisl, M; Syrovy, I; Baumruk, F; Flachs, P; Janovska, P; Kopecky, J			Decreased fatty acid synthesis due to mitochondrial uncoupling in adipose tissue	FASEB JOURNAL			English	Article						UCP; lipogenesis; C57BL/6J mice; 3T3-L1; obesity	MESSENGER-RNA EXPRESSION; BROWN ADIPOCYTES; WHITE ADIPOCYTES; PROTEIN HOMOLOG; GENE-EXPRESSION; METABOLIC-RATE; OBESITY; HUMANS; LIPOGENESIS; INSULIN	Synthesis of fatty acid (FA) in adipose tissue requires cooperation of mitochondrial and cytoplasmic enzymes, Mitochondria are required for the production of ATP and they also support the formation of acetyl-CoA and NADPH in cytoplasm, Since cellular levels of all these metabolites depend on the efficiency of mitochondrial energy conversion, mitochondrial proton leak via uncoupling proteins (UCPs) could modulate FA synthesis. In 3T3-L1 adipocytes, 2,4-dinitrophenol depressed the synthesis of FA 4-fold while increasing FA oxidation 1.5-fold and the production of lactate 14-fold. Inhibition of FA synthesis in 3T3-L1 adipocytes was proportional to the decrease in mitochondrial membrane potential, FA synthesis from D-[U-C-14] glucose was reduced up to fourfold by ectopic UCP1 in the white fat of transgenic aP2-Ucp1 mice, reflecting the magnitude of UCP1 expression in different fat depots and the reduction of adiposity, Transcript levels for Lipogenic enzymes were lower in the white fat of the transgenic mice than in the control animals. Our results show that uncoupling of oxidative phosphorylation depresses FA synthesis in white fat, Reduction of adiposity via mitochondrial uncoupling in white fat not only reflects increased energy expenditure, but also decreased in situ lipogenesis.	Acad Sci Czech Republ, Inst Physiol, Dept Adipose Tissue Biol, CZ-14220 Prague, Czech Republic	Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences	Kopecky, J (corresponding author), Acad Sci Czech Republ, Inst Physiol, Dept Adipose Tissue Biol, Videnska 1083, CZ-14220 Prague, Czech Republic.	kopecky@biomed.cas.cz	Kopecky, Jan/B-8244-2012; Rossmeisl, Martin/CAF-0060-2022; Janovska, Petra/E-7160-2013; Flachs, Pavel/A-5341-2012; Rossmeisl, Martin/C-1892-2012	Kopecky, Jan/0000-0001-8072-2035; Rossmeisl, Martin/0000-0001-8534-4002; Janovska, Petra/0000-0002-6154-2175; Rossmeisl, Martin/0000-0001-8534-4002				ARNER P, 1987, AM J PHYSIOL, V253, pE193, DOI 10.1152/ajpendo.1987.253.2.E193; BARBER MC, 1991, HORM METAB RES, V23, P143, DOI 10.1055/s-2007-1003636; BASHAN N, 1993, AM J PHYSIOL, V264, pC430, DOI 10.1152/ajpcell.1993.264.2.C430; Baumruk F, 1999, FEBS LETT, V444, P206, DOI 10.1016/S0014-5793(99)00053-8; BELFIORE F, 1976, METABOLISM, V25, P483, DOI 10.1016/0026-0495(76)90001-9; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; Bouchard C, 1997, HUM MOL GENET, V6, P1887, DOI 10.1093/hmg/6.11.1887; BUCKLEY MG, 1987, BIOCHEM J, V243, P437, DOI 10.1042/bj2430437; CHASCIONE C, 1987, AM J PHYSIOL, V253, pE664, DOI 10.1152/ajpendo.1987.253.6.E664; Digby JE, 1998, DIABETES, V47, P138, DOI 10.2337/diabetes.47.1.138; EVANS RM, 1977, BIOCHIM BIOPHYS ACTA, V489, P48, DOI 10.1016/0005-2760(77)90230-2; FLATT JP, 1970, J LIPID RES, V11, P131; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Gimble JM, 1996, MOL PHARMACOL, V50, P1087; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; Guerra C, 1998, J CLIN INVEST, V102, P412, DOI 10.1172/JCI3155; Iritani N, 1996, J BIOCHEM, V120, P242, DOI 10.1093/oxfordjournals.jbchem.a021405; Jaburek M, 1999, J BIOL CHEM, V274, P26003, DOI 10.1074/jbc.274.37.26003; KATZ J, 1974, BIOCHIM BIOPHYS ACTA, V337, P313, DOI 10.1016/0005-2760(74)90105-2; Klingenberg M, 1999, BBA-BIOMEMBRANES, V1415, P271, DOI 10.1016/S0005-2736(98)00232-6; Kopecky J, 1995, J CLIN INVEST, V96, P2914, DOI 10.1172/JCI118363; Kopecky J, 1996, AM J PHYSIOL-ENDOC M, V270, pE768, DOI 10.1152/ajpendo.1996.270.5.E768; Kopecky J, 1996, AM J PHYSIOL-ENDOC M, V270, pE776, DOI 10.1152/ajpendo.1996.270.5.E776; KOPECKY J, 1997, KEYST S AD CELL PARK, P18; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Lee FYJ, 1999, HEPATOLOGY, V29, P677, DOI 10.1002/hep.510290320; MARTIN BR, 1971, BIOCHEM J, V125, P105, DOI 10.1042/bj1250105; Millet L, 1997, J CLIN INVEST, V100, P2665, DOI 10.1172/JCI119811; Oberkofler H, 1997, J LIPID RES, V38, P2125; Oberkofler H, 1998, DIABETOLOGIA, V41, P940, DOI 10.1007/s001250051011; PATEL MS, 1970, J BIOL CHEM, V245, P1302; PORTER RK, 1993, NATURE, V362, P628, DOI 10.1038/362628a0; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; ROGNSTAD R, 1969, BIOCHEM J, V111, P431, DOI 10.1042/bj1110431; SAGGERSON ED, 1988, BIOCHEM J, V251, P701, DOI 10.1042/bj2510701; SHILLABEER G, 1990, J LIPID RES, V31, P623; SIBILLE B, 1995, EUR J BIOCHEM, V231, P498, DOI 10.1111/j.1432-1033.1995.tb20724.x; Soloveva V, 1997, MOL ENDOCRINOL, V11, P27, DOI 10.1210/me.11.1.27; STANSBIE D, 1976, BIOCHEM J, V160, P413, DOI 10.1042/bj1600413; Stefl B, 1998, AM J PHYSIOL-ENDOC M, V274, pE527, DOI 10.1152/ajpendo.1998.274.3.E527; Surwit RS, 1998, P NATL ACAD SCI USA, V95, P4061, DOI 10.1073/pnas.95.7.4061; Valverde AM, 1998, ENDOCRINOLOGY, V139, P1229, DOI 10.1210/en.139.3.1229; Vidal-Puig A, 1999, OBES RES, V7, P133, DOI 10.1002/j.1550-8528.1999.tb00694.x; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; Yoshida T, 1998, AM J PHYSIOL-ENDOC M, V274, pE469, DOI 10.1152/ajpendo.1998.274.3.E469; Yoshida T, 1999, INT J OBESITY, V23, P570, DOI 10.1038/sj.ijo.0800870; Zhou YT, 1999, P NATL ACAD SCI USA, V96, P2391, DOI 10.1073/pnas.96.5.2391; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P6386, DOI 10.1073/pnas.94.12.6386	51	71	73	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2000	14	12					1793	1800		10.1096/fj.99-0965com	http://dx.doi.org/10.1096/fj.99-0965com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973929				2022-12-28	WOS:000089212400019
J	Wang, YX; Dhulipala, PK; Kotlikoff, MI				Wang, YX; Dhulipala, PK; Kotlikoff, MI			Hypoxia inhibits the Na+/Ca2+ exchanger pulmonary artery smooth muscle cells	FASEB JOURNAL			English	Article						smooth muscle; ion channel; cytosolic calcium; reverse transcriptase polymerase chain reaction hypoxic pulmonary vasoconstriction	SODIUM-CALCIUM EXCHANGE; TISSUE-SPECIFIC EXPRESSION; SINGLE VENTRICULAR CELLS; NA+-CA2+ EXCHANGER; RAT PULMONARY; GUINEA-PIG; CA2+ RELEASE; SARCOPLASMIC-RETICULUM; ION CHANNELS; K+ CHANNELS	The cellular mechanisms underlying hypoxic pulmonary vasoconstriction are not fully understood. We examined the effect of hypoxia on Ca2+ efflux from the cytosol in single Fura-2-loaded pulmonary artery myocytes, During mild hypoxia (pO(2)=50-60 Torr), peak [Ca2+](i) was increased and the rate of Ca2+ removal from the cytosol was markedly slowed after stimuli that elevated [Ca2+](i), Removal of extracellular Na+ potentiated the peak [Ca2+](i) rise and slowed the Ca2+ decay rate in cells recorded under normoxic conditions; it did not further slow the Ca2+ decay rate or potentiate the [Ca2+](i) increase in hypoxic cells. An Na+/Ca2+ exchange current was recorded in isolated pulmonary artery myocytes, Switching from Li+ to Na+ (130 mM) revealed an inward current with reversal potential consistent with the Na+/Ca2+ exchange current in cells in which [Ca2+](i) was clamped at 1 mu M; similar currents, although smaller, were observed with normal resting [Ca2+](i) using the perforated patch clamp technique. The Na+/Ca2+ exchange current was markedly inhibited in myocytes exposed to mild hypoxia, RT-PCR revealed the expression of specific alternatively spliced RNAs of NCX1 in rat pulmonary arteries. These findings provide an enhanced understanding of the molecular mechanisms underlying hypoxic sensing in pulmonary arteries.	Univ Penn, Dept Anim Biol, Sch Vet Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Kotlikoff, MI (corresponding author), Univ Penn, Dept Anim Biol, Sch Vet Med, 3800 Spruce St, Philadelphia, PA 19104 USA.	mik@vet.upenn.edu			NHLBI NIH HHS [HL41084, HL64043, HL45239] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041084, R01HL064043, R01HL045239, R29HL041084] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARCHER SL, 1993, CIRC RES, V73, P1100, DOI 10.1161/01.RES.73.6.1100; Archer SL, 1998, J CLIN INVEST, V101, P2319, DOI 10.1172/JCI333; Archer SL, 1996, CIRC RES, V78, P431, DOI 10.1161/01.RES.78.3.431; ASHIDA T, 1987, J PHYSIOL-LONDON, V392, P617, DOI 10.1113/jphysiol.1987.sp016800; BLAUSTEIN MP, 1992, JPN J PHARMACOL, V58, pP107; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; BRIGHT RT, 1995, AM J PHYSIOL-LUNG C, V269, pL203, DOI 10.1152/ajplung.1995.269.2.L203; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOERING AE, 1993, J PHYSIOL-LONDON, V466, P481; EARM YE, 1986, JPN HEART J, V27, P153; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; Gelband CH, 1997, CIRCULATION, V96, P3647; Jabr RI, 1997, BRIT J PHARMACOL, V122, P21, DOI 10.1038/sj.bjp.0701326; Juhaszova M, 1996, ANN NY ACAD SCI, V779, P318, DOI 10.1111/j.1749-6632.1996.tb44804.x; KIMURA J, 1987, J PHYSIOL-LONDON, V384, P199, DOI 10.1113/jphysiol.1987.sp016450; KOZLOWSKI RZ, 1995, CARDIOVASC RES, V30, P318; LEE SL, 1994, J BIOL CHEM, V269, P14849; LI ZP, 1994, J BIOL CHEM, V269, P17434; MADDEN JA, 1992, AM J PHYSIOL, V263, pL384, DOI 10.1152/ajplung.1992.263.3.L384; Marin J, 1998, LIFE SCI, V64, P279, DOI 10.1016/S0024-3205(98)00393-2; NAKASAKI Y, 1993, J BIOCHEM-TOKYO, V114, P528, DOI 10.1093/oxfordjournals.jbchem.a124211; Nazer MA, 1998, CELL CALCIUM, V24, P275, DOI 10.1016/S0143-4160(98)90051-3; Nazer MA, 1998, AM J PHYSIOL-HEART C, V274, pH123, DOI 10.1152/ajpheart.1998.274.1.H123; Nicoll DA, 1996, J BIOL CHEM, V271, P24914, DOI 10.1074/jbc.271.40.24914; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; Orallo F, 1996, PHARMACOL THERAPEUT, V69, P153, DOI 10.1016/0163-7258(95)02042-X; Perez GJ, 1999, J GEN PHYSIOL, V113, P229, DOI 10.1085/jgp.113.2.229; Perez-Garcia MT, 1999, J GEN PHYSIOL, V113, P897, DOI 10.1085/jgp.113.6.897; POST JM, 1995, CIRC RES, V77, P131, DOI 10.1161/01.RES.77.1.131; POST JM, 1992, AM J PHYSIOL, V262, pC882, DOI 10.1152/ajpcell.1992.262.4.C882; Quednau BD, 1997, AM J PHYSIOL-CELL PH, V272, pC1250, DOI 10.1152/ajpcell.1997.272.4.C1250; SALVATERRA CG, 1989, AM REV RESPIR DIS, V139, P933, DOI 10.1164/ajrccm/139.4.933; SEKI S, 1995, AM J PHYSIOL-HEART C, V268, pH1045, DOI 10.1152/ajpheart.1995.268.3.H1045; Shigematsu S, 1999, J MOL CELL CARDIOL, V31, P895, DOI 10.1006/jmcc.1998.0929; SLAUGHTER RS, 1989, BIOCHEMISTRY-US, V28, P3995, DOI 10.1021/bi00435a055; Slodzinski MK, 1998, AM J PHYSIOL-CELL PH, V275, pC251, DOI 10.1152/ajpcell.1998.275.1.C251; SLODZINSKI MK, 1995, AM J PHYSIOL-CELL PH, V269, pC1340, DOI 10.1152/ajpcell.1995.269.5.C1340; VADULA MS, 1993, AM J PHYSIOL, V265, pL591, DOI 10.1152/ajplung.1993.265.6.L591; VANBREEMEN C, 1995, TRENDS PHARMACOL SCI, V16, P98, DOI 10.1016/S0165-6147(00)88990-7; Vandier C, 1998, AM J PHYSIOL-LUNG C, V275, pL145, DOI 10.1152/ajplung.1998.275.1.L145; VOELKEL NF, 1981, J CLIN INVEST, V67, P238, DOI 10.1172/JCI110019; Wang J, 1997, J CLIN INVEST, V100, P2347, DOI 10.1172/JCI119774; Wang Q, 1997, AM J PHYSIOL-CELL PH, V273, pC520, DOI 10.1152/ajpcell.1997.273.2.C520; Wang YX, 1997, P NATL ACAD SCI USA, V94, P14918, DOI 10.1073/pnas.94.26.14918; Weir EK, 1998, CHEST, V114, p17S, DOI 10.1378/chest.114.1_Supplement.17S-a; YUAN XJ, 1994, AM J PHYSIOL, V267, pL52, DOI 10.1152/ajplung.1994.267.1.L52; YUAN XJ, 1993, AM J PHYSIOL, V264, pL116, DOI 10.1152/ajplung.1993.264.2.L116; ZHU ZM, 1994, AM J PHYSIOL, V266, pC794, DOI 10.1152/ajpcell.1994.266.3.C794	48	35	35	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2000	14	12					1731	1740		10.1096/fj.99-0859com	http://dx.doi.org/10.1096/fj.99-0859com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973922				2022-12-28	WOS:000089212400012
J	Van Leeuwen, FW; Hol, EM; Hermanussen, BWH; Sonnemans, MAF; Moraal, E; Fischer, DF; Evans, DAP; Chooi, KF; Burbach, JPH; Murphy, D				Van Leeuwen, FW; Hol, EM; Hermanussen, BWH; Sonnemans, MAF; Moraal, E; Fischer, DF; Evans, DAP; Chooi, KF; Burbach, JPH; Murphy, D			Molecular misreading in non-neuronal cells	FASEB JOURNAL			English	Article						RNA errors; dinucleotide deletions; frame-shifted proteins	HOMOZYGOUS BRATTLEBORO RAT; RNA SURVEILLANCE; VASOPRESSIN; MUTATIONS; PROTEIN; TRANSCRIPTS; ALZHEIMERS; DISEASE; DECAY	+1 Frame-shifted proteins such as amyloid precursor protein(+1) and ubiquitin-B+1 have been identified in the neuropathological hallmarks of Alzheimer's disease. These frameshifts are caused by dinucleotide deletions in GAGAG motifs of messenger RNA encoded by genes that have maintained the unchanged wild-type DNA sequence. This process is termed 'molecular misreading'. A key question is whether this process is confined to neurons or whether it could also occur in non-neuronal cells. A transgenic mouse line (MV-B) carrying multiple copies of a rat vasopressin minigene as a reporter driven by the MMTV-LTR promotor was used to screen non-neuronal tissues for molecular misreading by means of detection of the rat vasopressin(+1) protein and mutated mRNA. Molecular misreading was demonstrated to occur in several organs (e.g., epididymis and the parotid gland) where transgenic vasopressin expression is abundant, but its penetrance is variable both between and within tissues. This implies that non-neural tissues too, could be affected by cellular derangements caused by molecular misreading.	Netherlands Inst Brain Res, Res Grp Mol Misreading, NL-1105 AZ Amsterdam, Netherlands; Natl Univ Singapore, Inst Mol & Cell Biol, Neuropeptide Lab, Singapore 117548, Singapore; Univ Bristol, Bristol Royal Infirm, Dept Med, Mol Neuroendocrinol Res Grp, Bristol BS2 8HW, Avon, England; Univ Utrecht, Mol Neurosci Sect, Rudolf Magnus Inst Neurosci, Dept Med Pharmacol, Utrecht, Netherlands	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Bristol Royal Infirmary; University of Bristol; Utrecht University; Utrecht University Medical Center	Van Leeuwen, FW (corresponding author), Netherlands Inst Brain Res, Res Grp Mol Misreading, Meibergdreef 33, NL-1105 AZ Amsterdam, Netherlands.	f.van.leeuwen@nih.knaw.nl	Hol, Elly M/F-1891-2013; Hol, Elly/J-2025-2019; Murphy, David/C-3967-2012	Hol, Elly M/0000-0001-5604-2603; Hol, Elly/0000-0001-5604-2603; Murphy, David/0000-0003-2946-0353; Fischer, David/0000-0002-6690-0197				ABE K, 1983, ARCH HISTOL JAPON, V46, P51, DOI 10.1679/aohc.46.51; Applequist SE, 1997, NUCLEIC ACIDS RES, V25, P814, DOI 10.1093/nar/25.4.814; Benne R, 1996, CURR OPIN GENET DEV, V6, P221, DOI 10.1016/S0959-437X(96)80054-2; Bridges BA, 1999, SCIENCE, V284, P62, DOI 10.1126/science.284.5411.62; Cali BM, 1998, MOL GEN GENET, V260, P176, DOI 10.1007/s004380050883; CHOOI KF, 1994, CANCER RES, V54, P6434; Clermont Y, 1970, Biology Reprod., V3, P283; Denny PC, 1997, CRIT REV ORAL BIOL M, V8, P51, DOI 10.1177/10454411970080010301; DEVRIES GJ, 1985, J COMP NEUROL, V233, P236, DOI 10.1002/cne.902330206; EVANS DAP, 1994, P NATL ACAD SCI USA, V91, P6059, DOI 10.1073/pnas.91.13.6059; Finch CE, 1997, TRENDS NEUROSCI, V20, P501; Frischmeyer PA, 1999, HUM MOL GENET, V8, P1893, DOI 10.1093/hmg/8.10.1893; Hamilton D.W., 1975, HDB PHYSIOLOGY     7, P259; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; Herb A, 1996, P NATL ACAD SCI USA, V93, P1875, DOI 10.1073/pnas.93.5.1875; IVELL R, 1984, P NATL ACAD SCI-BIOL, V81, P2006, DOI 10.1073/pnas.81.7.2006; Korpelainen EI, 1998, J CELL BIOL, V143, P1705, DOI 10.1083/jcb.143.6.1705; Metzgar D, 2000, GENOME RES, V10, P72; NEWMAN AJ, 1994, CURR OPIN GENET DEV, V4, P298, DOI 10.1016/S0959-437X(05)80057-7; SCHATZ DG, 1992, ANNU REV IMMUNOL, V10, P359, DOI 10.1146/annurev.iy.10.040192.002043; Schwartz AL, 1999, ANNU REV MED, V50, P57; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; Sonnemans MAF, 1996, NEUROSCIENCE, V72, P225, DOI 10.1016/0306-4522(95)00550-1; van Leeuwen FW, 1998, SCIENCE, V279, P242, DOI 10.1126/science.279.5348.242; van Leeuwen FW, 1998, TRENDS NEUROSCI, V21, P331, DOI 10.1016/S0166-2236(98)01280-6; VANLEEUWEN F, 1989, P NATL ACAD SCI USA, V86, P6417, DOI 10.1073/pnas.86.16.6417; VANLEEUWEN FW, 1994, BRAIN RES, V635, P328, DOI 10.1016/0006-8993(94)91456-7; VERBALIS JG, 1991, J NEUROENDOCRINOL, V3, P267, DOI 10.1111/j.1365-2826.1991.tb00274.x	28	23	24	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2000	14	11					1595	1602		10.1096/fj.14.11.1595	http://dx.doi.org/10.1096/fj.14.11.1595			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CN	10928994				2022-12-28	WOS:000088627800014
J	Goukassian, D; Gad, F; Yaar, M; Eller, MS; Nehal, US; Gilchrest, BA				Goukassian, D; Gad, F; Yaar, M; Eller, MS; Nehal, US; Gilchrest, BA			Mechanisms and implications of the age-associated decrease in DNA repair capacity	FASEB JOURNAL			English	Article						aging; DNA damage repair; DNA photoproducts; nucleotide excision repair	NUCLEOTIDE EXCISION-REPAIR; CYCLOBUTANE PYRIMIDINE DIMERS; REPLICATION PROTEIN-A; NONMELANOMA SKIN-CANCER; ULTRAVIOLET-B RADIATION; BASAL-CELL CARCINOMA; NERVE GROWTH-FACTOR; UV-RADIATION; P53 PROTEIN; TRANSCRIPTIONAL ACTIVITY	Skin cancer incidence is clearly linked to UV irradiation and increases exponentially with age, We studied the rate of removal of thymine dimers and (6-4) photoproducts in UV-irradiated human dermal fibroblasts derived from donors of different ages. There was a significant decrease with aging in the repair rates of both thymine dimers and (6-4) photoproducts. (P<0.001). In addition, there was an age-associated decrease in the protein levels of ERCC3, PCNA, RPA, XPA, and p53 that participate in nucleotide excision repair. Moreover, the mRNA levels of XPA, ERCC3, and PCNA were significantly reduced with aging, suggesting that these decreases are often regulated at the mRNA level. Furthermore, with age induction of p53 after UV irradiation was significantly reduced. Taken together, our data suggest that the age-associated decrease in the repair of UV-induced DNA damage results at least in part from decreased levels of proteins that participate in the repair process.	Boston Univ, Sch Med, Dept Dermatol, Boston, MA 02118 USA	Boston University	Gilchrest, BA (corresponding author), Boston Univ, Sch Med, Dept Dermatol, 609 Albany St, Boston, MA 02118 USA.	bgilchre@bu.edu		Goukassian, David/0000-0001-5270-5270	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007562] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000115] Funding Source: NIH RePORTER; NIAMS NIH HHS [5T32AR07562] Funding Source: Medline; NIA NIH HHS [T32AG00115] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abramova NA, 1997, P NATL ACAD SCI USA, V94, P7186, DOI 10.1073/pnas.94.14.7186; ALCALAY J, 1990, J INVEST DERMATOL, V95, P506, DOI 10.1111/1523-1747.ep12504707; Balajee AS, 1998, MUTAT RES-FUND MOL M, V404, P3, DOI 10.1016/S0027-5107(98)00088-8; BERG RJW, 1995, CARCINOGENESIS, V16, P2455, DOI 10.1093/carcin/16.10.2455; Berton TR, 1997, J INVEST DERMATOL, V109, P340, DOI 10.1111/1523-1747.ep12335984; BRASH DE, 1988, PHOTOCHEM PHOTOBIOL, V48, P59; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Brush GS, 1996, P NATL ACAD SCI USA, V93, P15075, DOI 10.1073/pnas.93.26.15075; CARR AM, 1995, TRENDS CELL BIOL, V5, P32, DOI 10.1016/S0962-8924(00)88934-5; CLEAVER JE, 1987, MOL CELL BIOL, V7, P3353, DOI 10.1128/MCB.7.9.3353; CLEAVER JE, 1994, CELL, V76, P1, DOI 10.1016/0092-8674(94)90165-1; Crowley DJ, 1998, J BACTERIOL, V180, P3345, DOI 10.1128/JB.180.13.3345-3352.1998; Dumaz N, 1998, CARCINOGENESIS, V19, P1701, DOI 10.1093/carcin/19.9.1701; Dumaz N, 1997, MOL CARCINOGEN, V20, P340, DOI 10.1002/(SICI)1098-2744(199712)20:4<340::AID-MC3>3.0.CO;2-N; ELLER MS, 1992, EXP CELL RES, V198, P328, DOI 10.1016/0014-4827(92)90387-N; Eller MS, 1997, P NATL ACAD SCI USA, V94, P12627, DOI 10.1073/pnas.94.23.12627; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; GILCHREST BA, 1983, J INVEST DERMATOL, V81, pS184, DOI 10.1111/1523-1747.ep12541084; GILCHREST BA, 1993, J INVEST DERMATOL, V101, P666, DOI 10.1111/1523-1747.ep12371673; Gilchrest BA, 1997, FASEB J, V11, P322, DOI 10.1096/fasebj.11.5.9141498; GILCHREST BA, 1980, J GERONTOL, V35, P537, DOI 10.1093/geronj/35.4.537; GILCHREST BA, IN PRESS ROLE DNA DA; Goukassian DA, 1999, J INVEST DERMATOL, V112, P25, DOI 10.1046/j.1523-1747.1999.00468.x; Grossman L, 1997, ENVIRON HEALTH PERSP, V105, P927, DOI 10.2307/3433305; GROSSMAN L, 1995, CLIN CHEM, V41, P1854; Guo ZM, 1998, EXP CELL RES, V245, P228, DOI 10.1006/excr.1998.4269; HALL PA, 1993, ONCOGENE, V8, P203; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; JEEVES WP, 1986, CARCINOGENESIS, V7, P381, DOI 10.1093/carcin/7.3.381; JIN DJ, 1988, J MOL BIOL, V202, P245, DOI 10.1016/0022-2836(88)90455-X; KASTAN MB, 1991, CANCER RES, V51, P6304; KENNY MK, 1990, J BIOL CHEM, V265, P769; KING CM, 1994, MUTAT RES-DNAGING G, V316, P79, DOI 10.1016/0921-8734(94)90010-8; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kobayashi T, 1998, NUCLEIC ACIDS RES, V26, P4662, DOI 10.1093/nar/26.20.4662; KOCHEVAR IE, 1993, DERMATOLOGY GEN MED, P1627; KRAEMER KH, 1994, ARCH DERMATOL, V130, P1018, DOI 10.1001/archderm.130.8.1018; LAMBERT B, 1979, CANCER RES, V39, P2792; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li G, 1998, BRIT J DERMATOL, V139, P3; LI L, 1995, MOL CELL BIOL, V15, P5396; Lu X, 1996, ONCOGENE, V13, P413; LYTLE CD, 1976, MUTAT RES, V36, P257, DOI 10.1016/0027-5107(76)90235-9; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MEDRANO EE, 1995, CANCER RES, V55, P4047; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; Mitchell David L., 1993, P345; MITCHELL DL, 1990, J INVEST DERMATOL, V95, P55, DOI 10.1111/1523-1747.ep12873312; MITCHELL DL, 1992, NUCLEIC ACIDS RES, V20, P225, DOI 10.1093/nar/20.2.225; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; Moriwaki SI, 1996, MUTAT RES-DNA REPAIR, V364, P117, DOI 10.1016/0921-8777(96)00029-8; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; MULLAART E, 1988, J INVEST DERMATOL, V90, P346, DOI 10.1111/1523-1747.ep12456316; MULLENDERS LHF, 1993, MUTAT RES, V299, P271, DOI 10.1016/0165-1218(93)90103-K; NETTE EG, 1984, MECH AGEING DEV, V24, P283; Nocentini S, 1997, J BIOL CHEM, V272, P22991, DOI 10.1074/jbc.272.37.22991; PATRICK MH, 1977, PHOTOCHEM PHOTOBIOL, V25, P357, DOI 10.1111/j.1751-1097.1977.tb07355.x; PFEIFER GP, 1990, P NATL ACAD SCI USA, V87, P8252, DOI 10.1073/pnas.87.21.8252; PLAZA S, 1991, PHOTOCHEM PHOTOBIOL, V53, P217, DOI 10.1111/j.1751-1097.1991.tb03926.x; Reenstra WR, 1996, EXP CELL RES, V227, P252, DOI 10.1006/excr.1996.0274; ROBINSON DR, 1994, MUTAT RES-ENVIR MUTA, V313, P227, DOI 10.1016/0165-1161(94)90053-1; ROSENSTEIN BS, 1991, RADIAT RES, V126, P338, DOI 10.2307/3577923; RUVEN HJT, 1993, CANCER RES, V53, P1642; RUVEN HJT, 1994, ONCOGENE, V9, P3427; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; Sancar Gwendolyn B., 1996, Mutation Research, V362, P127, DOI 10.1016/0921-8777(95)00029-1; SCOTTO J, 1981, US DEP HLTH HUMAN SE; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SMITH ML, 1995, ONCOGENE, V10, P1053; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Smith ML, 1997, P NATL ACAD SCI USA, V94, P12255, DOI 10.1073/pnas.94.23.12255; SUQUET C, 1995, J BIOL CHEM, V270, P16507, DOI 10.1074/jbc.270.28.16507; SZYMKOWSKI DE, 1993, P NATL ACAD SCI USA, V90, P9823, DOI 10.1073/pnas.90.21.9823; Tron V A, 1998, J Cutan Med Surg, V3, P16; Ueda M, 1996, PHOTODERMATOL PHOTO, V12, P22, DOI 10.1111/j.1600-0781.1996.tb00239.x; Van Remmen Holly, 1995, P171; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WEI QY, 1995, J INVEST DERMATOL, V104, P933, DOI 10.1111/1523-1747.ep12606207; WERNINGHAUS K, 1991, PHOTODERMATOL PHOTO, V8, P236; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; YAAR M, 1994, J CLIN INVEST, V94, P1550, DOI 10.1172/JCI117496; YAAR M, 1991, J CELL BIOL, V115, P821, DOI 10.1083/jcb.115.3.821; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; Young AR, 1996, J INVEST DERMATOL, V106, P1307, DOI 10.1111/1523-1747.ep12349031; YUAN JL, 1995, CARCINOGENESIS, V16, P2295, DOI 10.1093/carcin/16.10.2295; ZDZIENICKA MZ, 1992, MUTAT RES, V273, P73, DOI 10.1016/0921-8777(92)90051-4; Zeng L, 1997, GENE THER, V4, P1077, DOI 10.1038/sj.gt.3300495; ZernikKobak M, 1997, J BIOL CHEM, V272, P23896, DOI 10.1074/jbc.272.38.23896; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	95	163	171	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2000	14	10					1325	1334		10.1096/fj.14.10.1325	http://dx.doi.org/10.1096/fj.14.10.1325			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877825				2022-12-28	WOS:000087932200007
J	Cuzzocrea, S; Misko, TP; Costantino, G; Mazzon, E; Micali, A; Caputi, AP; MacArthur, H; Salvemini, D				Cuzzocrea, S; Misko, TP; Costantino, G; Mazzon, E; Micali, A; Caputi, AP; MacArthur, H; Salvemini, D			Beneficial effects of peroxynitrite decomposition catalyst in a rat model of splanchnic artery occlusion and reperfusion	FASEB JOURNAL			English	Article						SAO; polymorphonuclear leukocyte; cytokine; nitrate	ADHESION MOLECULE-1 ICAM-1; NITRIC-OXIDE PRODUCTION; ADP-RIBOSE SYNTHETASE; TIME-COURSE; MYOCARDIAL-ISCHEMIA; ENDOTHELIAL DYSFUNCTION; INTESTINAL ISCHEMIA; ENDOTOXIC-SHOCK; INJURY; INFLAMMATION	The aim of the present study was to investigate the protective effect of the peroxynitrite decomposition catalyst 5,10,15,20-tetrakis(2,4,6-trimethyl-3,5-disulfonatophenyl)-porphyrinato iron (III) (FeTMPS) in a model of splanchnic artery occlusion shock (SAO). SAO shock was induced in rats by clamping both the superior mesenteric artery and the celiac trunk for 45 min, followed by release of the clamp (reperfusion). At 60 min after reperfusion, animals were killed for histological examination and biochemical studies. There was a marked increase in the oxidation of dihydrorhodamine 123 to rhodamine (a marker of peroxynitrite-induced oxidative processes) in the plasma of the SAO-shocked rats after reperfusion, but not during ischemia alone. Immunohistochemica1 examination demonstrated a marked increase in the immunoreactivity to nitrotyrosine, an index of nitrogen species such as peroxynitrite, in the necrotic ileum in shocked rats. SAG-shocked rats developed a significant increase of tissue myeloperoxidase and malonaldehyde activity, and marked histological injury to the distal ileum. SAO shock was also associated with a significant mortality (0% survival at 2 h after reperfusion). Reperfused ileum tissue sections from SAG-shocked rats showed positive staining for P-selectin localized mainly in the vascular endothelial cells. Ileum tissue sections obtained from SAO-shocked rats and stained with antibody to ICAM-1 showed a diffuse staining. Administration of FeTMPS significantly reduced ischemia/reperfusion injury in the bowel, and reduced lipid and the production of peroxynitrite during reperfusion. Treatment with PN catalyst also markedly reduced the intensity and degree of P-selectin and ICAM-1 staining in tissue sections from SAG-shocked rats and improved survival. Our results clearly demonstrate that peroxynitrite decomposition catalysts exert a protective effect in SAO and that this effect may be due to inhibition of the expression of adhesion molecules and the tissue damage associated with peroxynitrite-related pathways.-Cuzzocrea S., Misko, T. P., Costantino, C., Mazzon, E., Micali, A., Caputi, A. P., Macarthur, H., Salvemini, D. Beneficial effects of peroxynitrite decomposition catalyst in a rat model of splanchnic artery occlusion and reperfusion.	Univ Messina, Inst Pharmacol, I-98100 Messina, Italy; Univ Messina, Sch Med, Dept Biomorphol, I-98100 Messina, Italy; Discovery Pharmacol, St Louis, MO 63167 USA; St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA; Metaphore Pharmaceut, St Louis, MO 63110 USA	University of Messina; University of Messina; Saint Louis University	Cuzzocrea, S (corresponding author), Univ Messina Policlin, Sch Med, Inst Pharmacol, Via C Valeria Gazzi, I-98100 Messina, Italy.	salvator@www.unime.it	Mazzon, Emanuela/AAL-4334-2020	mazzon, emanuela/0000-0002-5073-717X; Micali, Antonio/0000-0003-0826-1910				Adams DH, 1997, BRIT J CANCER, V75, P1421, DOI 10.1038/bjc.1997.245; ALTURA BM, 1985, MICROCIRC ENDOTH LYM, V2, P3; AzMa T, 1996, BRIT J PHARMACOL, V119, P455, DOI 10.1111/j.1476-5381.1996.tb15694.x; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; BITTERMAN H, 1988, P SOC EXP BIOL MED, V188, P265; BOYD AW, 1988, P NATL ACAD SCI USA, V85, P3095, DOI 10.1073/pnas.85.9.3095; BRONER CW, 1988, CRIT CARE MED, V16, P848, DOI 10.1097/00003246-198809000-00006; BUTCHER EC, 1992, ADV EXP MED BIOL, V323, P181; BUTCHER EC, 1993, RES IMMUNOL, V144, P695, DOI 10.1016/S0923-2494(93)80053-2; CAPUTI AP, 1980, J PHARMACOL EXP THER, V215, P309; CAREY C, 1992, CIRC SHOCK, V38, P209; CAZEVIEILLE C, 1993, FREE RADICAL BIO MED, V14, P389, DOI 10.1016/0891-5849(93)90088-C; Clark WM, 1995, MOL CHEM NEUROPATHOL, V26, P213, DOI 10.1007/BF02815139; Crow J P, 1995, Curr Top Microbiol Immunol, V196, P57; Cuzzocrea S, 1998, FREE RADICAL BIO MED, V24, P450, DOI 10.1016/S0891-5849(97)00280-3; Cuzzocrea S, 1998, LIFE SCI, V63, P789, DOI 10.1016/S0024-3205(98)00334-8; Cuzzocrea S, 1997, BRIT J PHARMACOL, V121, P1065, DOI 10.1038/sj.bjp.0701234; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DOUGHERTY GJ, 1988, EUR J IMMUNOL, V18, P35, DOI 10.1002/eji.1830180107; DREYER WJ, 1991, CIRCULATION, V84, P400, DOI 10.1161/01.CIR.84.1.400; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; FARHOOD A, 1995, J LEUKOCYTE BIOL, V57, P368, DOI 10.1002/jlb.57.3.368; Fukuyama N, 1997, FREE RADICAL BIO MED, V22, P771, DOI 10.1016/S0891-5849(96)00401-7; GAUTHIER TW, 1994, AM J PHYSIOL-GASTR L, V267, pG562, DOI 10.1152/ajpgi.1994.267.4.G562; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GRANGER DN, 1981, GASTROENTEROLOGY, V81, P22; Granger DN, 1997, AM J PHYSIOL-GASTR L, V273, pG982, DOI 10.1152/ajpgi.1997.273.5.G982; HENSON PM, 1987, J CLIN INVEST, V79, P669, DOI 10.1172/JCI112869; Johnson K J, 1992, Immunol Ser, V57, P1; KANWAR S, 1994, CIRC SHOCK, V42, P135; KOOY NW, 1995, AM J RESP CRIT CARE, V151, P1250; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEFER AM, 1993, ANNU REV PHARMACOL, V33, P71, DOI 10.1146/annurev.pa.33.040193.000443; LORANT DE, 1991, J CELL BIOL, V115, P223, DOI 10.1083/jcb.115.1.223; MA TT, 1995, GASTROENTEROLOGY, V108, P463, DOI 10.1016/0016-5085(95)90075-6; MA XL, 1993, CIRC RES, V72, P403, DOI 10.1161/01.RES.72.2.403; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; Misko TP, 1998, J BIOL CHEM, V273, P15646, DOI 10.1074/jbc.273.25.15646; MULLANE KM, 1988, ANN NY ACAD SCI, V524, P103, DOI 10.1111/j.1749-6632.1988.tb38534.x; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; RATYCH RE, 1987, SURGERY, V102, P122; Salvemini D, 1999, BRIT J PHARMACOL, V127, P685, DOI 10.1038/sj.bjp.0702604; Salvemini D, 1996, BRIT J PHARMACOL, V118, P829, DOI 10.1111/j.1476-5381.1996.tb15475.x; Salvemini D, 1998, P NATL ACAD SCI USA, V95, P2659, DOI 10.1073/pnas.95.5.2659; Salvemini D, 1998, DRUG NEWS PERSPECT, V11, P204; SALVEMINI D, 1995, J CLIN INVEST, V96, P301, DOI 10.1172/JCI118035; SCHRAUFSTATTER IU, 1986, J CLIN INVEST, V77, P1312, DOI 10.1172/JCI112436; SHREENIWAS R, 1992, J CLIN INVEST, V90, P2333, DOI 10.1172/JCI116122; Stern MK, 1996, J AM CHEM SOC, V118, P8735, DOI 10.1021/ja961279f; Szabo C, 1997, J CLIN INVEST, V100, P723, DOI 10.1172/JCI119585; Thiemermann C, 1997, P NATL ACAD SCI USA, V94, P679, DOI 10.1073/pnas.94.2.679; TSAO PS, 1990, CIRCULATION, V82, P1402, DOI 10.1161/01.CIR.82.4.1402; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WHITE CR, 1994, P NATL ACAD SCI USA, V91, P1044, DOI 10.1073/pnas.91.3.1044; YU L, 1994, P NATL ACAD SCI USA, V91, P1691, DOI 10.1073/pnas.91.5.1691; ZIMMERMANN BJ, 1993, PATHOPHYSIOLOGY SHOC, P322; Zingarelli B, 1997, CARDIOVASC RES, V36, P205, DOI 10.1016/S0008-6363(97)00137-5; Zingarelli B, 1997, BRIT J PHARMACOL, V120, P259, DOI 10.1038/sj.bjp.0700872; ZINGARELLI B, 1992, EUR J PHARMACOL, V222, P13, DOI 10.1016/0014-2999(92)90456-E	61	91	92	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2000	14	9					1061	1072		10.1096/fasebj.14.9.1061	http://dx.doi.org/10.1096/fasebj.14.9.1061			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834927				2022-12-28	WOS:000087427300002
J	Tonini, R; Ferroni, A; Valenzuela, SM; Warton, K; Campbell, TJ; Breit, SN; Mazzanti, M				Tonini, R; Ferroni, A; Valenzuela, SM; Warton, K; Campbell, TJ; Breit, SN; Mazzanti, M			Functional characterization of the NCC27 nuclear protein in stable transfected CHO-K1 cells	FASEB JOURNAL			English	Article						single-channel currents; NCC27; ion channel	MOLECULAR-CLONING; CHLORIDE CHANNEL; ION CHANNELS; P64	NCC27 belongs to a family of small, highly conserved, organellar ion channel proteins. It is constitutively expressed by native CHO-K1 and dominantly localized to the nucleus and nuclear membrane. When CHO-K1 cells are transfected with NCC27-expressing constructs, synthesized proteins spill over into the cytoplasm and ion channel activity can then be detected on the plasma as well as nuclear membrane. This provided a unique opportunity to directly compare electrophysiological characteristics of the one cloned channel, both on the nuclear and cytoplasmic membranes. At the same time, as NCC27 is unusually small for an ion channel protein, we wished to directly determine whether it is a membrane-resident channel in its own right. In CHO-K1 cells transfected with epitope-tagged NCC27 constructs, we have demonstrated that the NCC27 conductance is chloride dependent and that the electrophysiological characteristics of the channels are essentially identical whether expressed on plasma or nuclear membranes. In addition, we show that a monoclonal antibody directed at an epitope tag added to NCC27 rapidly inhibits the ability of the expressed protein to conduct chloride, but only when the antibody has access to the tag epitope. By selectively tagging either the amino or carboxyl terminus of NCC27 and varying the side of the membrane from which we record channel activity, we have demonstrated conclusively that NCC27 is a transmembrane protein that directly forms part of the ion channel and, further, that the amino terminus projects outward and the carboxyl terminus inward. We conclude that despite its relatively small size, NCC27 must form an integral part of an ion channel complex.-Tonini, R., Ferroni, A., Valenzuela, S. M., Warton, K., Campbell, T. J., Breit, S. N., Mazzanti, M. Functional characterization of the NCC27 nuclear protein in stable transfected CHO-K1 cells.	Univ Rome La Sapienza, Dipartimento Biol Cellulare & Sviluppo, I-00185 Rome, Italy; Univ Milan 1, Dipartimento Fisiol & Biochim Gen, I-20133 Milan, Italy; St Vincents Hosp, Ctr Immunol, Sydney, NSW 2010, Australia; Univ New S Wales, Dept Med, Sydney, NSW 2010, Australia; Univ New S Wales, Victor Chang Cardiac Res Inst, Sydney, NSW 2010, Australia	Sapienza University Rome; St Vincents Hospital Sydney; University of New South Wales Sydney; University of New South Wales Sydney; Victor Chang Cardiac Research Institute	Mazzanti, M (corresponding author), Univ Rome La Sapienza, Dipartimento Biol Cellulare & Sviluppo, Piazzale Aldo Moro 5, I-00185 Rome, Italy.		Mazzanti, Michele/A-8941-2011; Valenzuela, Stella/R-6387-2019; Tonini, Raffaella/J-2960-2012	Valenzuela, Stella/0000-0001-5934-6047; Campbell, Terry/0000-0003-0055-4137; Mazzanti, Michele/0000-0002-1819-3811; TONINI, Raffaella/0000-0003-1652-4709				BUSTAMANTE JO, 1992, PFLUG ARCH EUR J PHY, V421, P473, DOI 10.1007/BF00370259; BUSTAMANTE JO, 1995, J MEMBRANE BIOL, V146, P239; INNOCENTI B, 1993, J MEMBRANE BIOL, V131, P137, DOI 10.1007/BF02791322; LANDRY D, 1993, J BIOL CHEM, V268, P14948; MAK DOD, 1994, J BIOL CHEM, V269, P29375; MATZKE AJM, 1990, FEBS LETT, V271, P161, DOI 10.1016/0014-5793(90)80397-2; MAZZANTI M, 1990, NATURE, V343, P764, DOI 10.1038/343764a0; Nilius B, 1996, GEN PHARMACOL-VASC S, V27, P1131, DOI 10.1016/S0306-3623(96)00061-4; Qian ZJ, 1999, J BIOL CHEM, V274, P1621, DOI 10.1074/jbc.274.3.1621; Rousseau E, 1996, BIOPHYS J, V70, P703, DOI 10.1016/S0006-3495(96)79610-8; Szewczyk A, 1998, MOL MEMBR BIOL, V15, P49, DOI 10.3109/09687689809027518; TONINI R, 1999, FASEB J, V14; Tulk BM, 1998, AM J PHYSIOL-RENAL, V274, pF1140, DOI 10.1152/ajprenal.1998.274.6.F1140; Valenzuela SM, 1997, J BIOL CHEM, V272, P12575, DOI 10.1074/jbc.272.19.12575	14	92	95	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2000	14	9					1171	1178		10.1096/fasebj.14.9.1171	http://dx.doi.org/10.1096/fasebj.14.9.1171			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834939				2022-12-28	WOS:000087427300014
J	Langen, RCJ; Schols, AMWJ; Kelders, MCJM; Wouters, EFM; Janssen-Heininger, MW				Langen, RCJ; Schols, AMWJ; Kelders, MCJM; Wouters, EFM; Janssen-Heininger, MW			Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor-kappa B	FASEB JOURNAL			English	Article						cachexia; muscle wasting; TNF-alpha; NF-kappa B; myogenic differentiation	TUMOR-NECROSIS-FACTOR; OBSTRUCTIVE PULMONARY-DISEASE; APOPTOSIS-RELATED PROTEINS; CHRONIC HEART-FAILURE; FACTOR-ALPHA; TRANSCRIPTION FACTORS; SKELETAL-MUSCLE; RHEUMATOID-ARTHRITIS; GENE-EXPRESSION; PROSTATE-CANCER	Muscle wasting is often associated with chronic inflammation, Because tumor necrosis factor alpha (TNF-alpha) has been implicated as a major mediator of cachexia, its effects on C2C12 myocytes were examined, TNF-alpha activated nuclear factor-kappaB (NF-kappaB) and interfered with the expression of muscle proteins in differentiating myoblasts, Introduction of a mutant form of inhibitory protein kappaB alpha (I kappaB alpha) restored myogenic differentiation in myoblasts treated with TNF-alpha or interleukin 1 beta, Conversely, activation of NF-kappaB by overexpression of I kappaB kinase was sufficient to block myogenesis, illustrating the causal link between NF-kappaB activation and inhibition of myogenic differentiation. The inhibitory effects of TNF-alpha on myogenic differentiation were reversible, indicating that the effects of the cytokine were not due to nonspecific toxicity, Treatment of differentiated myotubes with TNF-alpha did not result in a striking loss of muscle-specific proteins, which shows that myogenesis was selectively affected in the myoblast stage by TNF-alpha, An important finding was that NF-kappaB was activated to the same extent in differentiating and differentiated cells, illustrating that once myocytes have differentiated they become refractory to the effects of NF-kappaB activation, These results demonstrate that inflammatory cytokines may contribute to muscle wasting through the inhibition of myogenic differentiation via a NF-kappaB-dependent pathway.	Univ Vermont, Dept Pathol, Burlington, VT 05405 USA; Maastricht Univ, Dept Pulmonol, Maastricht, Netherlands	University of Vermont; Maastricht University	Janssen-Heininger, MW (corresponding author), Univ Vermont, Dept Pathol, Med Alumni Bldg A143, Burlington, VT 05405 USA.		Wouters, Emiel/ABD-6200-2021					Anker SD, 1997, LANCET, V349, P1050, DOI 10.1016/S0140-6736(96)07015-8; Anker SD, 1997, LANCET, V349, P1258; Argiles JM, 1999, MED RES REV, V19, P223, DOI 10.1002/(SICI)1098-1128(199905)19:3<223::AID-MED3>3.0.CO;2-N; BELEC L, 1995, J ACQ IMMUN DEF SYND, V8, P212; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buck M, 1996, EMBO J, V15, P1753, DOI 10.1002/j.1460-2075.1996.tb00524.x; COONEY R, 1994, AM J PHYSIOL-ENDOC M, V267, pE636, DOI 10.1152/ajpendo.1994.267.5.E636; CORNELIUS P, 1991, J BIOL CHEM, V266, P4023; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; DIFRANCIA M, 1994, AM J RESP CRIT CARE, V150, P1453, DOI 10.1164/ajrccm.150.5.7952575; FONG Y, 1989, AM J PHYSIOL, V256, pR659, DOI 10.1152/ajpregu.1989.256.3.R659; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Janssen YMW, 1997, AM J PHYSIOL-LUNG C, V273, pL789, DOI 10.1152/ajplung.1997.273.4.L789; Ji SQ, 1998, J INTERF CYTOK RES, V18, P879, DOI 10.1089/jir.1998.18.879; Kaliman P, 1999, J BIOL CHEM, V274, P17437, DOI 10.1074/jbc.274.25.17437; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; KIRCHBERGER M, 1991, PHYSL BASIS MED PRAC, P62; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; KOTLER DP, 1989, AM J CLIN NUTR, V50, P444, DOI 10.1093/ajcn/50.3.444; Layne MD, 1999, EXP CELL RES, V249, P177, DOI 10.1006/excr.1999.4465; Lehtinen SK, 1996, BIOCHEM BIOPH RES CO, V229, P36, DOI 10.1006/bbrc.1996.1754; Li YP, 1998, FASEB J, V12, P871, DOI 10.1096/fasebj.12.10.871; LLOVERA M, 1994, FEBS LETT, V338, P311, DOI 10.1016/0014-5793(94)80290-4; MacLachlan TK, 1998, J CELL BIOCHEM, V71, P461, DOI 10.1002/(SICI)1097-4644(19981215)71:4<461::AID-JCB1>3.0.CO;2-0; MILLER SC, 1988, MOL CELL BIOL, V8, P2295, DOI 10.1128/MCB.8.6.2295; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; MORRISON WL, 1988, CLIN SCI, V75, P415, DOI 10.1042/cs0750415; Nakashima J, 1998, CLIN CANCER RES, V4, P1743; NAKASHIMA J, 1995, CANCER RES, V55, P4881; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; ROUBENOFF R, 1992, J RHEUMATOL, V19, P1505; Schols AMWJ, 1998, AM J RESP CRIT CARE, V157, P1791, DOI 10.1164/ajrccm.157.6.9705017; Sugiura T, 1999, ARTHRITIS RHEUM, V42, P291, DOI 10.1002/1529-0131(199902)42:2<291::AID-ANR11>3.0.CO;2-1; Szalay K, 1997, EUR J CELL BIOL, V74, P391; SZASZ G, 1976, CLIN CHEM, V22, P650; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; Tews DS, 1997, NEUROPATH APPL NEURO, V23, P331, DOI 10.1046/j.1365-2990.1997.5998059.x; Tews DS, 1997, J NEUROPATH EXP NEUR, V56, P150, DOI 10.1097/00005072-199702000-00005; Thaloor D, 1999, AM J PHYSIOL-CELL PH, V277, pC320, DOI 10.1152/ajpcell.1999.277.2.C320; Vary TC, 1996, SHOCK, V6, P13, DOI 10.1097/00024382-199607000-00004; VREUGDENHIL G, 1992, EUR J CLIN INVEST, V22, P488, DOI 10.1111/j.1365-2362.1992.tb01495.x; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wang YJ, 2000, MOL CELL BIOL, V20, P4505, DOI 10.1128/MCB.20.13.4505-4512.2000; WILSON DO, 1989, AM REV RESPIR DIS, V139, P1435, DOI 10.1164/ajrccm/139.6.1435; WINTER B, 1993, J BIOL CHEM, V268, P9869; YABLONKAREUVENI Z, 1995, MICROSC RES TECHNIQ, V30, P366, DOI 10.1002/jemt.1070300504; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Zhao SP, 1997, INT J CARDIOL, V58, P257, DOI 10.1016/S0167-5273(96)02873-2; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	52	317	323	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1169	1180		10.1096/fj.00-0463	http://dx.doi.org/10.1096/fj.00-0463			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344085				2022-12-28	WOS:000168655200007
J	Marsche, G; Levak-Frank, S; Quehenberger, O; Heller, R; Sattler, W; Malle, E				Marsche, G; Levak-Frank, S; Quehenberger, O; Heller, R; Sattler, W; Malle, E			Identification of the human analog of SR-BI and LOX-1 as receptors for hypochlorite-modified high density lipoprotein on human umbilical venous endothelial cells	FASEB JOURNAL			English	Editorial Material									Karl Franzens Univ Graz, Inst Med Biochem, A-8010 Graz, Austria; Univ Calif, Dept Med, La Jolla, CA USA; Friedrich Schiller Univ Jena, Ctr Vasc Biol & Med, Erfurt, Germany	University of Graz; University of California System; University of California San Diego; Friedrich Schiller University of Jena	Malle, E (corresponding author), Karl Franzens Univ Graz, Inst Med Biochem, Harrachgasse 21, A-8010 Graz, Austria.	malle@kfunigraz.ac.at	Malle, Ernst/D-3071-2013	Marsche, Gunther/0000-0002-2422-5381	DFG [HE 2304/1-1]; OENB [8778, 8127]; FWF [P14109, P14186]	DFG(German Research Foundation (DFG)); OENB; FWF(Austrian Science Fund (FWF))	The authors are grateful to Dr. M. Krieger (MIT) providing ldlA[mSR-BI] and ldlA7 cells. The expert technical assistance of B. Hirschmugl is appreciated. This work was supported by the DFG (HE 2304/1-1), OENB (8778 and 8127), and the FWF (P14109 and P14186).		0	60	62	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2001	15	6					1095	1097		10.1096/fj.00-0532fje	http://dx.doi.org/10.1096/fj.00-0532fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292679				2022-12-28	WOS:000167959300024
J	Debat, H; Avalle, B; Chose, O; Sarde, CO; Friboulet, A; Thomas, D				Debat, H; Avalle, B; Chose, O; Sarde, CO; Friboulet, A; Thomas, D			Overpassing an aberrant V kappa gene to sequence an anti-idiotypic abzyme with beta-lactamase-like activity that could have a linkage with autoimmune diseases	FASEB JOURNAL			English	Article						catalytic antibody; autoantibody; aberrant kappa chain	VASOACTIVE-INTESTINAL-PEPTIDE; POLYMERASE CHAIN-REACTION; CATALYTIC ANTIBODIES; VARIABLE REGIONS; LIGHT-CHAIN; HYBRIDOMA CELLS; MESSENGER-RNA; ANTIIDIOTYPIC ANTIBODIES; IMMUNOGLOBULIN GENES; PCR AMPLIFICATION	A monoclonal antibody 9G4H9 that exhibits a beta -lactamase-like activity was previously obtained in accordance with the idiotypic network theory, This abzyme presents the most catalytic efficiency in amidase activity described in literature (k(cat) = 0.9 min(-1)). Some reports have demonstrated that functionality as complex as catalysis may be mimicked in this way. Comparison of the catalytic properties of both enzyme and abzyme previously allowed us to obtain better knowledge about 9G4H9 abzymatic machinery. ln attempt to characterize this abzyme, the variable regions of kappa and heavy chain were cloned. We present a 'universal' method to clone the correct V kappa gene to bypass aberrant V kappa (abV kappa) produced by MOPC-21-derived hybridomas, Sequences obtained are compared in the GenBank database. The VH and V kappa genes present some important sequence homology with autoantibodies suggesting a direct relationship between catalytic anti-idiotypic antibody and autoimmunity.	Univ Technol Compiegne, UPRES A 6022 Genie Enzymat & Cellulaire, F-60205 Compiegne, France	Picardie Universites; Universite de Technologie de Compiegne	Debat, H (corresponding author), Univ Technol Compiegne, UPRES A 6022 Genie Enzymat & Cellulaire, BP 20529, F-60205 Compiegne, France.			DEBAT, Helene/0000-0003-0020-2748				Asakura K, 1998, MULT SCLER, V4, P217, DOI 10.1177/135245859800400324; Avalle B, 1998, FASEB J, V12, P1055, DOI 10.1096/fasebj.12.11.1055; Avalle B, 2000, APPL BIOCHEM BIOTECH, V83, P163, DOI 10.1385/ABAB:83:1-3:163; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BAKKUS MHC, 1992, BLOOD, V80, P2326; Barbas CF, 1997, SCIENCE, V278, P2085, DOI 10.1126/science.278.5346.2085; BOWDISH K, 1991, J BIOL CHEM, V266, P11901; BRIGIDO MM, 1993, J IMMUNOL, V150, P469; BRONSHTEIN IB, 1992, FEBS LETT, V314, P259, DOI 10.1016/0014-5793(92)81484-4; Bronstein IB, 1996, ONCOL RES, V8, P17; Buchbinder JL, 1998, J MOL BIOL, V282, P1033, DOI 10.1006/jmbi.1998.2025; CABILLY S, 1985, GENE, V40, P157, DOI 10.1016/0378-1119(85)90037-X; CALCUTT MJ, 1993, GENE, V137, P77, DOI 10.1016/0378-1119(93)90254-Z; CARROLL WL, 1988, MOL IMMUNOL, V25, P991, DOI 10.1016/0161-5890(88)90005-3; Charbonnier JB, 1997, SCIENCE, V275, P1140, DOI 10.1126/science.275.5303.1140; CHENG HL, 1988, MOL IMMUNOL, V25, P33, DOI 10.1016/0161-5890(88)90087-9; CHONCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; Cochet O, 1999, BIOTECHNIQUES, V26, P818, DOI 10.2144/99265bm04; COLOMA MJ, 1991, BIOTECHNIQUES, V11, P152; CZERWINSKI M, 1994, MOL IMMUNOL, V31, P279, DOI 10.1016/0161-5890(94)90125-2; DEBAT H, 2000, INT J BIOCHROMATOGR, V5, P91; DONISKELLER H, 1979, NUCLEIC ACIDS RES, V7, P179, DOI 10.1093/nar/7.1.179; DUAN LX, 1994, NUCLEIC ACIDS RES, V22, P5433, DOI 10.1093/nar/22.24.5433; Fitzsimons MM, 1997, J AM SOC NEPHROL, V8, pA2112; Friboulet A, 1999, IMMUNOL TODAY, V20, P474, DOI 10.1016/S0167-5699(99)01528-5; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GAO QS, 1994, J BIOL CHEM, V269, P32389; GAO QS, 1995, J BIOL CHEM, V270, P20870; Gigant B, 1997, EUR J BIOCHEM, V246, P471, DOI 10.1111/j.1432-1033.1997.t01-1-00471.x; HAYNES MR, 1994, SCIENCE, V263, P646, DOI 10.1126/science.8303271; Heine A, 1998, SCIENCE, V279, P1934, DOI 10.1126/science.279.5358.1934; IZADYAR L, 1993, P NATL ACAD SCI USA, V90, P8876, DOI 10.1073/pnas.90.19.8876; JAUME JC, 1994, ENDOCRINOLOGY, V135, P16, DOI 10.1210/en.135.1.16; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; JONES ST, 1991, BIO-TECHNOL, V9, P88, DOI 10.1038/nbt0191-88; JONES ST, 1991, BIO-TECHNOL, V9, P579; Jovelin F, 1996, BIOTECHNIQUES, V21, P576; JOVELIN F, 1995, BIOTECHNIQUES, V19, P378; Kabat EA, 1991, SEQUENCES PROTEINS I; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; KOFLER R, 1988, J CLIN INVEST, V82, P852, DOI 10.1172/JCI113689; KOHLER G, 1976, EUR J IMMUNOL, V6, P511, DOI 10.1002/eji.1830060713; Kolesnikov AV, 2000, P NATL ACAD SCI USA, V97, P13526, DOI 10.1073/pnas.200360497; Krebber A, 1997, J IMMUNOL METHODS, V201, P35, DOI 10.1016/S0022-1759(96)00208-6; LARRICK JW, 1989, BIOCHEM BIOPH RES CO, V160, P1250, DOI 10.1016/S0006-291X(89)80138-X; LEFEVRE S, 2001, IN PRESS FEBS LETT; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEUNG SO, 1993, BIOTECHNIQUES, V15, P286; MEI S, 1991, J BIOL CHEM, V266, P15571; NICHOLLS PJ, 1993, J IMMUNOL METHODS, V165, P81, DOI 10.1016/0022-1759(93)90109-K; ORLANDI R, 1989, P NATL ACAD SCI USA, V86, P3833, DOI 10.1073/pnas.86.10.3833; Ostermeier C, 1996, NUCLEIC ACIDS RES, V24, P1979, DOI 10.1093/nar/24.10.1979; Patten PA, 1996, SCIENCE, V271, P1086, DOI 10.1126/science.271.5252.1086; PAUL S, 1995, J BIOL CHEM, V270, P15257, DOI 10.1074/jbc.270.25.15257; PAUL S, 1989, SCIENCE, V244, P1158, DOI 10.1126/science.2727702; Retter MW, 1998, J EXP MED, V188, P1231, DOI 10.1084/jem.188.7.1231; Romesberg FE, 1998, SCIENCE, V279, P1929, DOI 10.1126/science.279.5358.1929; Sahota SS, 1997, BLOOD, V89, P219, DOI 10.1182/blood.V89.1.219.219_219_226; Sahota SS, 1996, BLOOD, V87, P746, DOI 10.1182/blood.V87.2.746.bloodjournal872746; Sambrook J., 2002, MOL CLONING LAB MANU; SHLOMCHIK MJ, 1987, NATURE, V328, P805, DOI 10.1038/328805a0; Song KM, 2000, J EXP MED, V191, P1095, DOI 10.1084/jem.191.7.1095; STEWART JD, 1995, METHOD ENZYMOL, V249, P507; Takahashi N, 2000, J IMMUNOL METHODS, V235, P113, DOI 10.1016/S0022-1759(99)00224-0; TAWFIK DS, 1995, P NATL ACAD SCI USA, V92, P2145, DOI 10.1073/pnas.92.6.2145; Thayer MM, 1999, J MOL BIOL, V291, P329, DOI 10.1006/jmbi.1999.2960; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tyutyulkova S, 1996, BBA-MOL BASIS DIS, V1316, P217, DOI 10.1016/0925-4439(96)00028-2; WADE WS, 1993, J AM CHEM SOC, V115, P4906, DOI 10.1021/ja00064a068; ZHOU GW, 1994, SCIENCE, V265, P1059, DOI 10.1126/science.8066444; Zhu D, 1998, IMMUNOLOGY, V93, P162, DOI 10.1046/j.1365-2567.1998.00428.x	71	23	29	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					815	822		10.1096/fj.00-0410com	http://dx.doi.org/10.1096/fj.00-0410com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259400				2022-12-28	WOS:000167419500039
J	Suh, JH; Shigeno, ET; Morrow, JD; Cox, B; Rocha, AE; Frei, B; Hagen, TM				Suh, JH; Shigeno, ET; Morrow, JD; Cox, B; Rocha, AE; Frei, B; Hagen, TM			Oxidative stress in the aging rat heart is reversed by dietary supplementation with (R)-alpha-lipoic acid	FASEB JOURNAL			English	Article						aging; cardiac myocytes; oxidative stress; lipoic acid	LIPID-PEROXIDATION; ELECTROCHEMICAL DETECTION; PYRUVATE-DEHYDROGENASE; ALPHA-TOCOPHEROL; ASCORBIC-ACID; LIPOIC ACID; VITAMIN-E; OLD RATS; MYOCYTES; MITOCHONDRIA	Oxidative stress has been implicated as a causal factor in the aging process of the heart and other tissues. To determine the extent of age-related myocardial oxidative stress, oxidant production, antioxidant status, and oxidative DNA damage were measured in hearts of young (2 months) and old (28 months) male Fischer 344 rats. Cardiac myocytes isolated from old rats showed a nearly threefold increase in the rate of oxidant production compared to young rats, as measured by the rates of 2,7-dichlorofluorescin diacetate oxidation, Determination of myocardial antioxidant status revealed a significant twofold decline in the levels of ascorbic acid (P = 0.03), but not alpha -tocopherol, A significant age-related increase (P = 0.05) in steady-state levels of oxidative DNA damage was observed, as monitored by 8-oxo-2'-deoxyguanosine levels. To investigate whether dietary supplementation with (R)-alpha -lipoic acid (LA) was effective at reducing oxidative stress, young and old rats were fed an AIN-93M diet with or without 0.2% (w/w) LA for 2 wk before death. Cardiac myocytes from old, LA-supplemented rats exhibited a markedly lower rate of oxidant production that was no longer significantly different from that in cells from unsupplemented, young rats. Lipoic acid supplementation also restored myocardial ascorbic acid levels and reduced oxidative DNA damage, Our data indicate that the aging rat heart is under increased mitochondrial-induced oxidative stress, which is significantly attenuated by lipoic acid supplementation.-Suh, J. H., Shigeno, E. T., Merrow, J. D., Cox, B., Rocha, A. E., Frei, B., Hagen, T. M. Oxidative stress in the aging rat heart is reversed by dietary supplementation with (R)-alpha -lipoic acid.	Oregon State Univ, Linus Pauling Inst, Corvallis, OR 97331 USA; Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37212 USA	Oregon State University; Oregon State University; Vanderbilt University	Hagen, TM (corresponding author), Oregon State Univ, Linus Pauling Inst, 571 Weniger Hall, Corvallis, OR 97331 USA.				NCI NIH HHS [P01 CA077839, CA77839] Funding Source: Medline; NIA NIH HHS [R01 AG017141, RIAG17141A] Funding Source: Medline; NIDDK NIH HHS [R01 DK048831, P30 DK026657, DK26657, DK48831] Funding Source: Medline; NIGMS NIH HHS [R01 GM042056, GM42056, P50 GM015431, R37 GM042056, P01 GM015431, GM15431] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA077839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026657, R01DK048831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042056, R37GM042056, P50GM015431, P01GM015431] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017141] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AWAD JA, 1994, J NUTR, V124, P810, DOI 10.1093/jn/124.6.810; BUETTNER GR, 1993, ARCH BIOCHEM BIOPHYS, V300, P535, DOI 10.1006/abbi.1993.1074; CHOU PP, 1985, CLIN CHEM, V31, P880; Cohn JN, 1997, CIRCULATION, V95, P766; FARMER BB, 1983, LIFE SCI, V33, P1, DOI 10.1016/0024-3205(83)90706-3; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; FROLKIS VV, 1988, GERONTOLOGY, V34, P64, DOI 10.1159/000212932; Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064; Hagen TM, 1998, P NATL ACAD SCI USA, V95, P9562, DOI 10.1073/pnas.95.16.9562; Han D, 1997, BIOFACTORS, V6, P321, DOI 10.1002/biof.5520060303; Hansford RG, 1997, J BIOENERG BIOMEMBR, V29, P89, DOI 10.1023/A:1022420007908; Haramaki N, 1997, FREE RADICAL BIO MED, V22, P535, DOI 10.1016/S0891-5849(96)00400-5; Helbock HJ, 1998, P NATL ACAD SCI USA, V95, P288, DOI 10.1073/pnas.95.1.288; HOCH FL, 1992, BIOCHIM BIOPHYS ACTA, V1113, P71, DOI 10.1016/0304-4157(92)90035-9; Humphries KM, 1998, BIOCHEMISTRY-US, V37, P15835, DOI 10.1021/bi981512h; KATZ AM, 1991, HOSP PRACT, V26, P78; Kozlov AV, 1999, ARCH BIOCHEM BIOPHYS, V363, P148, DOI 10.1006/abbi.1998.1064; Lodge JK, 1998, FREE RADICAL BIO MED, V25, P287, DOI 10.1016/S0891-5849(98)00048-3; Lykkesfeldt J, 1998, FASEB J, V12, P1183, DOI 10.1096/fasebj.12.12.1183; MORGAN JP, 1990, CIRCULATION, V81, P21; Morrow JD, 1998, ARCH BIOCHEM BIOPHYS, V353, P160, DOI 10.1006/abbi.1998.0645; MORROW JD, 1992, J CLIN INVEST, V90, P2502, DOI 10.1172/JCI116143; NAKAGAWA Y, 1991, BIOCHEM PHARMACOL, V42, P883, DOI 10.1016/0006-2952(91)90049-B; Nakai N, 1997, LIFE SCI, V60, P2309, DOI 10.1016/S0024-3205(97)00286-5; NEGRETTI N, 1993, CARDIOVASC RES, V27, P1826, DOI 10.1093/cvr/27.10.1826; NOHL H, 1978, EUR J BIOCHEM, V82, P563, DOI 10.1111/j.1432-1033.1978.tb12051.x; Roy Sashwati, 1998, Biofactors, V7, P263; SAWADA M, 1987, MECH AGEING DEV, V41, P125, DOI 10.1016/0047-6374(87)90057-1; SIRI FM, 1991, AM J PHYSIOL, V261, pH514, DOI 10.1152/ajpheart.1991.261.2.H514; SOHAL RS, 1994, MECH AGEING DEV, V74, P121, DOI 10.1016/0047-6374(94)90104-X; Souza-Pinto NC, 1999, NUCLEIC ACIDS RES, V27, P1935, DOI 10.1093/nar/27.8.1935; TYTGAT J, 1994, CARDIOVASC RES, V28, P280, DOI 10.1093/cvr/28.2.280; WANG Z, 1995, J PHARMACOL EXP THER, V363, P148	33	96	104	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					700	706		10.1096/fj.00-0176com	http://dx.doi.org/10.1096/fj.00-0176com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259388	Green Accepted			2022-12-28	WOS:000167419500027
J	Brunetti, A; Manfioletti, G; Chiefari, E; Goldfine, ID; Foti, D				Brunetti, A; Manfioletti, G; Chiefari, E; Goldfine, ID; Foti, D			Transcriptional regulation of human insulin receptor gene by the high-mobility group protein HMGI(Y)	FASEB JOURNAL			English	Article						insulin receptor promoter; transcription factors; CAT reporter gene	FIBROBLAST GROWTH-FACTOR; DNA-BINDING PROTEINS; IFN-BETA GENE; CULTURED LYMPHOCYTES; MOLECULAR MECHANISMS; PROMOTER REGION; MAMMALIAN-CELLS; VIRUS INDUCTION; BREAST-CANCER; EXPRESSION	We have previously identified two closely related nuclear binding proteins that specifically interact with two unique functional AT-rich sequences of the 5' regulatory region of the human insulin receptor gene, Expression of these nuclear binding proteins increases during myocyte and adipocyte differentiation, and in other tissues appears to correlate with insulin receptor content. We have hypothesized, therefore, that insulin receptor expression in the insulin target tissues is regulated at least in part by these nuclear proteins. Here we show data on purification and biochemical characterization of these DNA binding proteins. Using a conventional chromatographic purification procedure combined with electrophoresis mobility shift assay and immunoblot analyses, a unique similar to 15 kDa protein, either identical to or highly related to the architectural transcription factor HMGI(Y), has now been identified, suggesting an essential role for HMGI(Y) in regulating insulin receptor gene transcription. Direct evidence of HMGI(Y) insulin receptor promoter interactions is provided by functional analysis with the GAT reporter gene and by hormone binding studies in cells expressing HMGI(Y) antisense RNA. In these experiments, antisense HMGI(Y) specifically inhibits insulin receptor promoter function and insulin receptor protein expression, indicating that HMGI(Y) is required for proper transcription of insulin receptor gene, Moreover, our data consistently support the hypothesis that a putative defect in this nuclear binding protein may cause insulin receptor dysfunction with subsequent impairment of insulin signaling and action.	Policlin Mater Domini, Cattedra Endocrinol, Dipartimento Med Sperimentale & Clin G Salvatore, I-88100 Catanzaro, Italy; Univ Trieste, Dipartimento Biochim Biofis & Chim Macromol, Trieste, Italy; Univ Calif San Francisco, Dept Med, Div Diabet & Endocrine Res, Mt Zion Med Ctr, San Francisco, CA 94120 USA; Univ Catanzaro Magna Graecia, Cattedra Med Interna, Dipartimento Med Sperimentale & Clin G Salvatore, Catanzaro, Italy	University of Trieste; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Medical Center at Mount Zion; Magna Graecia University of Catanzaro	Brunetti, A (corresponding author), Policlin Mater Domini, Cattedra Endocrinol, Dipartimento Med Sperimentale & Clin G Salvatore, Via T Campanella 115, I-88100 Catanzaro, Italy.		Brunetti, Antonio/K-7756-2016; Chiefari, Eusebio/Y-2558-2019; Foti, Daniela P/K-8038-2016	Chiefari, Eusebio/0000-0001-5329-3124; Brunetti, Antonio/0000-0003-1533-8779; MANFIOLETTI, GUIDALBERTO/0000-0001-7913-2601; Foti, Daniela/0000-0002-9536-5736	Fondazione Telethon Funding Source: Custom; Telethon [E.0613, GGP04245] Funding Source: Medline	Fondazione Telethon(Fondazione Telethon); Telethon(Fondazione Telethon)		Allemann RK, 1997, CHEM BIOL, V4, P643, DOI 10.1016/S1074-5521(97)90218-0; AMFO K, 1995, ONCOGENE, V11, P351; ARAKI E, 1987, J BIOL CHEM, V262, P16186; Bergmann U, 1996, BIOCHEM BIOPH RES CO, V220, P886, DOI 10.1006/bbrc.1996.0500; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BRUNETTI A, 1989, J CLIN INVEST, V83, P192, DOI 10.1172/JCI113858; BRUNETTI A, 1990, MOL ENDOCRINOL, V4, P880, DOI 10.1210/mend-4-6-880; BRUNETTI A, 1990, J BIOL CHEM, V265, P5960; BRUNETTI A, 1993, J CLIN INVEST, V92, P1288, DOI 10.1172/JCI116702; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CHLAPPETTA G, 1995, ONCOGENE, V10, P1307; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FOX SR, 1990, MOL ENDOCRINOL, V4, P1069, DOI 10.1210/mend-4-7-1069; GARTENBERG MR, 1991, J MOL BIOL, V219, P217, DOI 10.1016/0022-2836(91)90563-L; GOLDFINE ID, 1987, ENDOCR REV, V8, P235, DOI 10.1210/edrv-8-3-235; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAWLEY DM, 1989, J BIOL CHEM, V264, P2438; HOYER D, 1999, ANN NY ACAD SCI, V893, P301; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAHN CR, 1985, ANNU REV MED, V36, P429; LEE JK, 1992, J BIOL CHEM, V267, P4638; LEVY JR, 1993, DIABETES, V42, P66, DOI 10.2337/diabetes.42.1.66; Longo VD, 1999, NEUROBIOL AGING, V20, P479, DOI 10.1016/S0197-4580(99)00089-5; MAMULA PW, 1990, DIABETES CARE, V13, P288, DOI 10.2337/diacare.13.3.288; MAMULA PW, 1989, DIABETES, V37, P1241; Mantovani F, 1998, NUCLEIC ACIDS RES, V26, P1433, DOI 10.1093/nar/26.6.1433; MCDONALD AR, 1988, J CLIN INVEST, V81, P499, DOI 10.1172/JCI113347; MCKEON C, 1990, MOL ENDOCRINOL, V4, P647, DOI 10.1210/mend-4-4-647; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; OLEFSKY JM, 1981, DIABETES, V30, P148, DOI 10.2337/diab.30.2.148; PAPA V, 1990, J CLIN INVEST, V86, P1503, DOI 10.1172/JCI114868; Pellacani A, 1999, J BIOL CHEM, V274, P1525, DOI 10.1074/jbc.274.3.1525; PETRUZZELLI L, 1986, P NATL ACAD SCI USA, V83, P4710, DOI 10.1073/pnas.83.13.4710; PODSKALNY JM, 1985, EUR J BIOCHEM, V150, P401, DOI 10.1111/j.1432-1033.1985.tb09034.x; Polonsky KS, 1996, NEW ENGL J MED, V334, P777, DOI 10.1056/NEJM199603213341207; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; ROUILLER DG, 1985, J CLIN INVEST, V76, P645, DOI 10.1172/JCI112017; RUSSELL DW, 1983, NATURE, V304, P652, DOI 10.1038/304652a0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLEIF R, 1988, SCIENCE, V241, P1182, DOI 10.1126/science.2842864; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; Shain DH, 1998, NUCLEIC ACIDS RES, V26, P1019, DOI 10.1093/nar/26.4.1019; SIBLEY E, 1989, P NATL ACAD SCI USA, V86, P9732, DOI 10.1073/pnas.86.24.9732; STANDAERT ML, 1984, J BIOL CHEM, V259, P2337; STRUHL K, 1985, P NATL ACAD SCI USA, V82, P8419, DOI 10.1073/pnas.82.24.8419; SUNG CK, 1992, BIOCHEMISTRY-US, V31, P168, DOI 10.1021/bi00116a025; TAYLOR SI, 1992, DIABETES, V41, P1473, DOI 10.2337/diabetes.41.11.1473; Taylor SI, 1999, CELL, V97, P9, DOI 10.1016/S0092-8674(00)80709-6; TEWARI DS, 1989, J BIOL CHEM, V264, P16238; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TRISCHITTA V, 1989, J BIOL CHEM, V264, P5041; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Webster NJG, 1996, CANCER RES, V56, P2781; WEBSTER NJG, 1994, DIABETES, V43, P305, DOI 10.2337/diabetes.43.2.305; WHITE MF, 1994, J BIOL CHEM, V269, P1; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209	62	81	87	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					492	500		10.1096/fj.00-0190com	http://dx.doi.org/10.1096/fj.00-0190com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156965				2022-12-28	WOS:000166872900031
J	Sitte, N; Merker, K; Von Zglinicki, T; Grune, T; Davies, KJA				Sitte, N; Merker, K; Von Zglinicki, T; Grune, T; Davies, KJA			Protein oxidation and degradation during cellular senescence of human BJ fibroblasts: part I - effects of proliferative senescence	FASEB JOURNAL			English	Article						aging; cross-linked proteins; lysosomes; protein oxidation; protein turnover; proteolysis; proteasome; senescence	CROSS-LINKED PROTEIN; OXIDIZED PROTEINS; MULTICATALYTIC PROTEASE; GLUTAMINE-SYNTHETASE; GENE-EXPRESSION; CELLS; PROTEOLYSIS; STRESS; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; HYDROPHOBICITY	Oxidized and cross-linked proteins tend to accumulate in aging cells. Declining activity of proteolytic enzymes, particularly the proteasome, has been proposed as a possible explanation for this phenomenon, and direct inhibition of the proteasome by oxidized and cross-linked proteins has been demonstrated in vitro. We have further examined this hypothesis during both proliferative senescence (this paper) and postmitotic senescence (see the accompanying paper, ref 1) of human BJ fibroblasts. During proliferative senescence, we found a marked decline in all proteasome activities (trypsin-like activity, chymotrypsin-like activity, and peptidyl-glutamyl-hydrolyzing activity) and in lysosomal cathepsin activity. Despite the loss of proteasome activity, there was no concomitant change in cellular levels of actual proteasome protein (immunoassays) or in the steady-state levels of mRNAs for essential proteasome subunits. The decline in proteasome activities and lysosomal cathepsin activities was accompanied by dramatic increases in the accumulation of oxidized and cross-linked proteins. Furthermore, as proliferation stage increased, cells exhibited a decreasing ability to degrade the oxidatively damaged proteins generated by an acute, experimentally applied oxidative stress. Thus, oxidized and cross-linked proteins accumulated rapidly in cells of higher proliferation stages. Our data are consistent with the hypothesis that proteasome is progressively inhibited by small accumulations of oxidized and cross-linked proteins during proliferative senescence until late proliferation stages, when so much proteasome activity has been lost that oxidized proteins accumulate at ever-increasing rates. Lysosomes attempt to deal with the accumulating oxidized and cross-linked proteins, but declining lysosomal cathepsin activity apparently limits their effectiveness. This hypothesis, which may explain the progressive intracellular accumulation of oxidized and cross-linked proteins in aging, is further explored during postmitotic senescence in the accompanying paper (1).	Univ So Calif, Ethel Percy Andrus Gerontol Ctr, Los Angeles, CA 90089 USA; Univ So Calif, Div Mol Biol, Los Angeles, CA 90089 USA; Humboldt Univ, Fac Med Charite, Clin Phys Med, D-10098 Berlin, Germany; Humboldt Univ, Fac Med Charite, Clin Rehabil, D-10098 Berlin, Germany; Humboldt Univ, Fac Med Charite, Inst Pathol, D-10098 Berlin, Germany	University of Southern California; University of Southern California; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Davies, KJA (corresponding author), Univ So Calif, Ethel Percy Andrus Gerontol Ctr, 3715 McClintock Ave,Room 306, Los Angeles, CA 90089 USA.			Davies, Kelvin/0000-0001-7790-3003; von Zglinicki, Thomas/0000-0002-5939-0248; Grune, Tilman/0000-0003-4775-9973	NIEHS NIH HHS [ES03598] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003598, R23ES003598, R56ES003598] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AGARWAL S, 1994, MECH AGEING DEV, V75, P11, DOI 10.1016/0047-6374(94)90024-8; AGARWAL S, 1994, ARCH BIOCHEM BIOPHYS, V309, P24, DOI 10.1006/abbi.1994.1078; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BRADLEY MO, 1976, J BIOL CHEM, V251, P3521; Buss H, 1997, FREE RADICAL BIO MED, V23, P361, DOI 10.1016/S0891-5849(97)00104-4; CARNEY JM, 1991, P NATL ACAD SCI USA, V88, P3633, DOI 10.1073/pnas.88.9.3633; Chao CC, 1997, P NATL ACAD SCI USA, V94, P2969, DOI 10.1073/pnas.94.7.2969; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; FRIGUET B, 1994, ARCH BIOCHEM BIOPHYS, V311, P168, DOI 10.1006/abbi.1994.1222; Friguet B, 1997, FEBS LETT, V405, P21, DOI 10.1016/S0014-5793(97)00148-8; FRIGUET B, 1994, J BIOL CHEM, V269, P21639; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; Grune T, 1996, J BIOL CHEM, V271, P15504, DOI 10.1074/jbc.271.26.15504; Grune T, 1998, J BIOL CHEM, V273, P10857, DOI 10.1074/jbc.273.18.10857; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; GUILIVI C, 1994, ARCH BIOCHEM BIOPHYS, V311, P329; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; INUBUSHI T, 1994, J BIOCHEM-TOKYO, V116, P282, DOI 10.1093/oxfordjournals.jbchem.a124520; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; LIU AYC, 1989, J BIOL CHEM, V264, P12037; MELLMAN WJ, 1972, EXP CELL RES, V73, P399, DOI 10.1016/0014-4827(72)90064-X; Nakamura T, 1998, BBA-GENE STRUCT EXPR, V1399, P93, DOI 10.1016/S0167-4781(98)00105-5; OLIVER CN, 1987, J BIOL CHEM, V262, P5488; PACIFICI RE, 1993, J BIOL CHEM, V268, P15405; Reinheckel T, 1998, BIOCHEM J, V335, P637, DOI 10.1042/bj3350637; RIVETT AJ, 1985, J BIOL CHEM, V260, P2600; RIVETT AJ, 1985, J BIOL CHEM, V260, P300; Saretzki G, 1998, J GERONTOL A-BIOL, V53, pB438, DOI 10.1093/gerona/53A.6.B438; Sitte N, 2000, FASEB J, V14, P2503, DOI 10.1096/fj.00-0210com; Sitte N, 1998, FEBS LETT, V440, P399, DOI 10.1016/S0014-5793(98)01495-1; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; SOMMERBURG O, 1993, MEDIAT INFLAMM, V2, P27, DOI 10.1155/S0962935193000031; Stadtman E R, 1988, Basic Life Sci, V49, P331; Stadtman E R, 1992, EXS, V62, P64; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STARKEREED PE, 1989, ARCH BIOCHEM BIOPHYS, V275, P559, DOI 10.1016/0003-9861(89)90402-5; Von Zglinicki T, 1998, ANN NY ACAD SCI, V854, P318; vonZglinicki T, 1995, GERONTOLOGY, V41, P95; WONG SHY, 1987, CLIN CHEM, V33, P214; Yin DZ, 1996, FREE RADICAL BIO MED, V21, P871, DOI 10.1016/0891-5849(96)00175-X	43	179	183	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2495	2502		10.1096/fj.00-0209com	http://dx.doi.org/10.1096/fj.00-0209com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099467				2022-12-28	WOS:000165723400019
J	Sitte, N; Merker, K; Von Zglinicki, T; Davies, KJA; Grune, T				Sitte, N; Merker, K; Von Zglinicki, T; Davies, KJA; Grune, T			Protein oxidation and degradation during cellular senescence of human BJ fibroblasts: part II - aging of nondividing cells	FASEB JOURNAL			English	Article						aging; cross-linked proteins; lysosomes; proteasome; protein oxidation; proteolysis; protein turnover; senescence	CROSS-LINKED PROTEIN; RED BLOOD-CELLS; OXYGEN RADICALS; OXIDIZED PROTEINS; MULTICATALYTIC PROTEASE; LIPOFUSCIN PIGMENTS; ALZHEIMER-DISEASE; EPITHELIAL-CELLS; AGE; DAMAGE	Oxidized/cross-linked intracellular protein materials, known as ceroid pigment, age pigment, or lipofuscin, accumulate in postmitotic tissues. It is unclear, however, whether diminishing proteolytic capacities play a role in the accumulation of such oxidized intracellular proteins. Previous studies revealed that the proteasome is responsible for the degradation of most oxidized soluble cytoplasmic and nuclear proteins and, we propose, for the prevention of such damage accumulations. The present investigation was undertaken to test the changes in protein turnover, proteasome activity, lysosome activity, and protein oxidation status during the aging of nondividing cells. Since the companion paper shows that both proteasome activity and the overall protein turnover decline during proliferative senescence whereas the accumulation of oxidized proteins increases significantly, we decided to use the same human BJ fibroblasts, this time at confluency, at different PD levels (including those that are essentially postmitotic) to investigate the same parameters under conditions where cells do not divide. We find that the activity of the cytosolic proteasome declines dramatically during senescence of nondividing BJ fibroblasts. The peptidyl-glutamyl-hydrolyzing activity was particularly affected. This decline in proteasome activity was accompanied by a decrease in the overall turnover of short-lived (radiolabeled) proteins in the nondividing BJ fibroblasts. On the other hand, no decrease in the actual cellular proteasome content, as judged by immunoblots, was found. The decline in the activity of the proteasome was also accompanied by an increased accumulation of oxidized proteins, especially of oxidized and cross-linked material. Unlike the loss of lysosomal function seen in our accompanying studies of proliferative senescence (1), however, the present study of hyperoxic senescence in nondividing cells actually revealed marked increases in lysosomal cathepsin activity in all but the very 'oldest' postmitotic cells. Our comparative studies of proliferating (1)and nonproliferating (this paper) human BJ fibroblasts reveal a good correlation between the accumulation of oxidized/cross-linked proteins and the decline in proteasome activity and overall cellular protein turnover during in vitro senescence, which may predict a causal relationship during actual cellular aging.	Univ So Calif, Ethel Percy Andrus Gerontol Ctr, Los Angeles, CA 90089 USA; Univ So Calif, Div Mol Biol, Los Angeles, CA 90089 USA; Humboldt Univ, Fac Med Charite, Clin Phys Med, D-10098 Berlin, Germany; Humboldt Univ, Fac Med Charite, Clin Rehabil, D-10098 Berlin, Germany; Humboldt Univ, Fac Med Charite, Inst Pathol, D-10098 Berlin, Germany	University of Southern California; University of Southern California; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Davies, KJA (corresponding author), Univ So Calif, Ethel Percy Andrus Gerontol Ctr, 3715 McClintock Ave,Room 306, Los Angeles, CA 90089 USA.			Grune, Tilman/0000-0003-4775-9973; Davies, Kelvin/0000-0001-7790-3003; von Zglinicki, Thomas/0000-0002-5939-0248	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R23ES003598, R56ES003598, R01ES003598] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES03598] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AGARWAL S, 1994, MECH AGEING DEV, V75, P11, DOI 10.1016/0047-6374(94)90024-8; Andersen JK, 1996, J NEUROCHEM, V67, P2164; Anselmi B, 1998, J GERONTOL A-BIOL, V53, pB173, DOI 10.1093/gerona/53A.3.B173; Buss H, 1997, FREE RADICAL BIO MED, V23, P361, DOI 10.1016/S0891-5849(97)00104-4; CAO C, 1995, ARCH BIOCHEM BIOPHYS, V320, P106; CAO GH, 1995, ARCH BIOCHEM BIOPHYS, V320, P195, DOI 10.1006/abbi.1995.1359; CARNEY JM, 1991, P NATL ACAD SCI USA, V88, P3633, DOI 10.1073/pnas.88.9.3633; CATALDO AM, 1994, BRAIN RES, V640, P68, DOI 10.1016/0006-8993(94)91858-9; Conconi M, 1997, MOL BIOL REP, V24, P45, DOI 10.1023/A:1006852506884; Conconi M, 1996, ARCH BIOCHEM BIOPHYS, V331, P232, DOI 10.1006/abbi.1996.0303; DAVIES K J A, 1986, Journal of Free Radicals in Biology and Medicine, V2, P155, DOI 10.1016/S0748-5514(86)80066-6; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DAVIES KJA, 1987, J BIOL CHEM, V262, P8220; DAVIES KJA, 1987, J BIOL CHEM, V262, P9908; DAVIES KJA, 1987, J BIOL CHEM, V262, P9902; DAVIES KJA, 1987, J BIOL CHEM, V262, P9914; DAVIES KJA, 1987, J BIOL CHEM, V262, P8227; FRIGUET B, 1994, ARCH BIOCHEM BIOPHYS, V311, P168, DOI 10.1006/abbi.1994.1222; Friguet B, 1997, FEBS LETT, V405, P21, DOI 10.1016/S0014-5793(97)00148-8; FRIGUET B, 1994, J BIOL CHEM, V269, P21639; GIULIVI C, 1990, J BIOL CHEM, V265, P19453; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; Grune T, 1996, J BIOL CHEM, V271, P15504, DOI 10.1074/jbc.271.26.15504; Grune T, 1998, J BIOL CHEM, V273, P10857, DOI 10.1074/jbc.273.18.10857; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; GUILIVI C, 1994, ARCH BIOCHEM BIOPHYS, V311, P329; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; Horie K, 1997, BIOCHEM BIOPH RES CO, V236, P327, DOI 10.1006/bbrc.1997.6944; INUBUSHI T, 1994, J BIOCHEM-TOKYO, V116, P282, DOI 10.1093/oxfordjournals.jbchem.a124520; JAHNGENHODGE J, 1997, J BIOL CHEM, V272, P28211; Kato Y, 1998, FEBS LETT, V439, P231, DOI 10.1016/S0014-5793(98)01372-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; OLIVER CN, 1987, J BIOL CHEM, V262, P5488; PACIFICI RE, 1993, J BIOL CHEM, V268, P15405; PACIFICI RE, 1989, FREE RADICAL BIO MED, V7, P521, DOI 10.1016/0891-5849(89)90028-2; PORTA EA, 1991, ARCH GERONTOL GERIAT, V12, P303, DOI 10.1016/0167-4943(91)90036-P; PORTAL J, 1995, ORIENTAL ART, V41, P2; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROMERO MT, 1994, NEUROSCIENCE, V58, P217, DOI 10.1016/0306-4522(94)90169-4; SAHAKIAN JA, 1995, ARCH BIOCHEM BIOPHYS, V318, P411, DOI 10.1006/abbi.1995.1248; SHANG F, 1995, BIOCHEM J, V307, P297, DOI 10.1042/bj3070297; Shang F, 1997, J BIOL CHEM, V272, P23086, DOI 10.1074/jbc.272.37.23086; Sitte N, 2000, FASEB J, V14, P2495, DOI 10.1096/fj.00-0209com; Sitte N, 1998, FEBS LETT, V440, P399, DOI 10.1016/S0014-5793(98)01495-1; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; Stadtman E R, 1992, EXS, V62, P64; Terman A, 1995, GERONTOLOGY, V41, P319; Terman A, 1998, APMIS, V106, P265, DOI 10.1111/j.1699-0463.1998.tb01346.x; Ullrich O, 1999, P NATL ACAD SCI USA, V96, P6223, DOI 10.1073/pnas.96.11.6223; vonZglinicki T, 1995, GERONTOLOGY, V41, P95; Yin DZ, 1996, FREE RADICAL BIO MED, V21, P871, DOI 10.1016/0891-5849(96)00175-X	53	129	133	2	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2503	2510		10.1096/fj.00-0210com	http://dx.doi.org/10.1096/fj.00-0210com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099468				2022-12-28	WOS:000165723400020
J	Jiang, JC; Jaruga, E; Repnevskaya, MV; Jazwinski, SM				Jiang, JC; Jaruga, E; Repnevskaya, MV; Jazwinski, SM			An intervention resembling caloric restriction prolongs life span and retards aging in yeast	FASEB JOURNAL			English	Article									Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Jazwinski, SM (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1901 Perdido St,Box P7-2, New Orleans, LA 70112 USA.								0	266	275	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2135	2137						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11024000				2022-12-28	WOS:000165190800003
J	Bienengraeber, M; Alekseev, AE; Abraham, MR; Carrasco, AJ; Moreau, C; Vivaudou, M; Dzeja, PP; Terzic, A				Bienengraeber, M; Alekseev, AE; Abraham, MR; Carrasco, AJ; Moreau, C; Vivaudou, M; Dzeja, PP; Terzic, A			ATPase activity of the sulfonylurea receptor: a catalytic function for the K-ATP channel complex	FASEB JOURNAL			English	Article						ATP-sensitive K+ channels; enzyme; ABC proteins; nucleotide binding domains; potassium channel openers; Kir6.2; SUR	TRANSMEMBRANE CONDUCTANCE REGULATOR; NUCLEOTIDE-BINDING DOMAIN; SENSITIVE POTASSIUM CHANNELS; P-GLYCOPROTEIN; ADENYLATE KINASE; HYPOXIA-REOXYGENATION; PHYSICAL ASSOCIATION; DISTINCT FUNCTIONS; INSULIN-SECRETION; SUR1	ATP-sensitive K+ (K-ATP) channels are unique metabolic sensors formed by association of Kir6.2, an inwardly rectifying K+ channel, and the sulfonylurea receptor SUR, an ATP binding cassette protein. We identified an ATPase activity in immunoprecipitates of cardiac K-ATP channels and in purified fusion proteins containing nucleotide binding domains NBD1 and NBD2 of the cardiac SUR2A isoform. NBD2 hydrolyzed ATP with a twofold higher rate compared to NBD1, The ATPase required Mg2+ and was insensitive to ouabain, oligomycin, thapsigargin, or levamisole, K1348A and D1469N mutations in NBD2 reduced ATPase activity and produced channels with increased sensitivity to ATP. K-ATP channel openers, which bind to SUR, promoted ATPase activity in purified sarcolemma. At higher concentrations, openers reduced ATPase activity, possibly through stabilization of MgADP at the channel site, K1348A and D1469N mutations attenuated the effect of openers on K-ATP channel activity. Opener-induced channel activation was also inhibited by the creatine kinase/creatine phosphate system that removes ADP from the channel complex, Thus, the K-ATP channel complex functions not only as a K+ conductance, but also as an enzyme regulating nucleotide-dependent channel gating through an intrinsic ATPase activity of the SUR subuniT. Modulation of the channel ATPase activity and/or scavenging the product of the ATPase reaction provide novel means to regulate cellular functions associated with K-ATP channel opening.	Mayo Clin & Mayo Fdn, Dept Med, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Mol Pharmacol & Expt Therapeut, Div Cardiovasc Dis, Rochester, MN 55905 USA; CEA, DBMS, Lab Biophys Mol Cellulaire, F-38054 Grenoble, France	Mayo Clinic; Mayo Clinic; CEA	Terzic, A (corresponding author), Mayo Clin & Mayo Fdn, Dept Med, Div Cardiovasc Dis, Guggenheim 7,200 1st St SW, Rochester, MN 55905 USA.		MOREAU, Christophe/AAC-7912-2020; Vivaudou, Michel/C-5338-2008; MOREAU, Christophe J/D-3736-2009; Alekseev, Alexey/I-5346-2013	MOREAU, Christophe/0000-0002-5463-9593; Vivaudou, Michel/0000-0002-9777-3127; MOREAU, Christophe J/0000-0002-5463-9593; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064822] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM019567] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07111, HL64822] Funding Source: Medline; NIGMS NIH HHS [GM19567] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham MR, 1999, FASEB J, V13, P1901; ABRAHAM MR, 1999, PHYSIOLOGIST, V42, pA5; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Alekseev AE, 1998, J GEN PHYSIOL, V111, P381, DOI 10.1085/jgp.111.2.381; Alekseev AE, 1997, J MEMBRANE BIOL, V159, P161, DOI 10.1007/s002329900279; Aparicio G, 1996, FEMS MICROBIOL LETT, V141, P157, DOI 10.1111/j.1574-6968.1996.tb08378.x; Ashcroft FM, 1998, TRENDS NEUROSCI, V21, P288, DOI 10.1016/S0166-2236(98)01225-9; BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Bryan J, 1999, BBA-BIOMEMBRANES, V1461, P285, DOI 10.1016/S0005-2736(99)00164-9; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; D'Hahan N, 1999, MOL PHARMACOL, V56, P308, DOI 10.1124/mol.56.2.308; D'hahan N, 1999, P NATL ACAD SCI USA, V96, P12162, DOI 10.1073/pnas.96.21.12162; Dzeja PP, 1999, CIRC RES, V84, P1137, DOI 10.1161/01.RES.84.10.1137; Dzeja PP, 1999, MOL CELL BIOCHEM, V201, P33, DOI 10.1023/A:1007016703229; Dzeja PP, 1998, FASEB J, V12, P523, DOI 10.1096/fasebj.12.7.523; DZEJA PP, 1999, PHYSIOLOGIST, V42, pA3; ElvirMairena JR, 1996, J BIOL CHEM, V271, P31903, DOI 10.1074/jbc.271.50.31903; Gribble FM, 1997, EMBO J, V16, P1145, DOI 10.1093/emboj/16.6.1145; Gribble FM, 1998, P NATL ACAD SCI USA, V95, P7185, DOI 10.1073/pnas.95.12.7185; Gross GJ, 1999, CIRC RES, V84, P973, DOI 10.1161/01.RES.84.9.973; Hambrock A, 1999, MOL PHARMACOL, V55, P832; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hille B, 1999, NAT MED, V5, P1105, DOI 10.1038/13415; Hiromura M, 1998, J BIOL CHEM, V273, P5435, DOI 10.1074/jbc.273.10.5435; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; Jovanovic A, 1998, LAB INVEST, V78, P1101; Jovanovic A, 1998, CIRCULATION, V98, P1548, DOI 10.1161/01.CIR.98.15.1548; Jovanovic N, 1999, FASEB J, V13, P923, DOI 10.1096/fasebj.13.8.923; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; Loffler-Walz C, 1998, BRIT J PHARMACOL, V123, P1395, DOI 10.1038/sj.bjp.0701756; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; Lorenz E, 1998, MOL CELL BIOL, V18, P1652, DOI 10.1128/MCB.18.3.1652; Lorenz E, 1999, J MOL CELL CARDIOL, V31, P425, DOI 10.1006/jmcc.1998.0876; Matsuo M, 1999, J BIOL CHEM, V274, P37479, DOI 10.1074/jbc.274.52.37479; MILLER C, 1992, SCIENCE, V258, P240, DOI 10.1126/science.1384128; NICHOLS CG, 1990, J PHYSIOL-LONDON, V423, P91, DOI 10.1113/jphysiol.1990.sp018013; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; Randak C, 1997, FEBS LETT, V410, P180, DOI 10.1016/S0014-5793(97)00574-7; Schultz BD, 1996, J MEMBRANE BIOL, V151, P63, DOI 10.1007/s002329900058; Schwanstecher M, 1998, EMBO J, V17, P5529, DOI 10.1093/emboj/17.19.5529; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; Senior AE, 1997, SEMIN CANCER BIOL, V8, P143, DOI 10.1006/scbi.1997.0065; Sharma N, 1999, J BIOL CHEM, V274, P20628, DOI 10.1074/jbc.274.29.20628; SHARMA S, 1995, J BIOL CHEM, V270, P14085, DOI 10.1074/jbc.270.23.14085; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; Shyng SL, 1997, J GEN PHYSIOL, V110, P643, DOI 10.1085/jgp.110.6.643; SNABES MC, 1981, J BIOL CHEM, V256, P6291; TERZIC A, 1994, NEURON, V12, P1049, DOI 10.1016/0896-6273(94)90313-1; TERZIC A, 1994, J PHARMACOL EXP THER, V268, P818; Terzic A, 1999, CLIN PHARMACOL THER, V66, P105, DOI 10.1053/cp.1999.v66.99991; TERZIC A, 1994, CARDIOVASC RES, V28, P746, DOI 10.1093/cvr/28.6.746; TERZIC A, 1995, AM J PHYSIOL, V38, pC525; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Ueda K, 1999, BBA-BIOMEMBRANES, V1461, P305, DOI 10.1016/S0005-2736(99)00157-1; Ueda K, 1997, J BIOL CHEM, V272, P22983, DOI 10.1074/jbc.272.37.22983; Uhde I, 1999, J BIOL CHEM, V274, P28079, DOI 10.1074/jbc.274.40.28079; Urbatsch IL, 1998, BIOCHEMISTRY-US, V37, P4592, DOI 10.1021/bi9728001; VENKATESH N, 1992, CIRC RES, V71, P1324, DOI 10.1161/01.RES.71.6.1324; Wang C, 1999, BIOCHEM J, V338, P77, DOI 10.1042/0264-6021:3380077; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	66	122	123	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2000	14	13					1943	1952		10.1096/fj.00-0027com	http://dx.doi.org/10.1096/fj.00-0027com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023978				2022-12-28	WOS:000089634400013
J	Cozzi, PJ; Malhotra, S; Mcauliffe, P; Kooby, DA; Federoff, HJ; Huryk, B; Johnson, P; Scardino, PT; Heston, WDW; Fong, Y				Cozzi, PJ; Malhotra, S; Mcauliffe, P; Kooby, DA; Federoff, HJ; Huryk, B; Johnson, P; Scardino, PT; Heston, WDW; Fong, Y			Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model	FASEB JOURNAL			English	Article									Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, George M OBrien Urol Res Ctr, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Urol, New York, NY 10021 USA; Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA; NeuroVir Therapeut Inc, Vancouver, BC, Canada	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Rochester; University of Rochester	Fong, Y (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10021 USA.								0	68	76	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1306	1308		10.1096/fj.00-0533fje	http://dx.doi.org/10.1096/fj.00-0533fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344122				2022-12-28	WOS:000168655200044
J	Deigner, HP; Claus, R; Bonaterra, GA; Gehrke, C; Bibak, N; Blaess, M; Cantz, M; Metz, J; Kinscherf, R				Deigner, HP; Claus, R; Bonaterra, GA; Gehrke, C; Bibak, N; Blaess, M; Cantz, M; Metz, J; Kinscherf, R			Ceramide induces aSMase expression: implications for oxLDL-induced apoptosis	FASEB JOURNAL			English	Article						acid sphingomyelinase; macrophages; Niemann-Pick; programmed cell death; C-6-ceramide	LOW-DENSITY-LIPOPROTEIN; MANGANESE SUPEROXIDE-DISMUTASE; RADIATION-INDUCED APOPTOSIS; THERAPY-INDUCED APOPTOSIS; CELL-DEATH; ACID SPHINGOMYELINASE; ENDOTHELIAL-CELLS; SIGNAL-TRANSDUCTION; HUMAN LYMPHOBLASTS; DNA-BINDING	Sphingomyelinase (SMase) stimulation and subsequent ceramide generation are suggested to be involved in signal transduction of stress-induced apoptosis, We now show that apoptosis of human macrophages (M phi) and fibroblasts initiated by oxidized low density lipoproteins (minimally modified LDL, mmLDL) is associated with an increase in acid SMase (aSMase, E.C, 3.1.4.12) expression and ceramide concentration. Application of a novel, potent, and specific inhibitor of aSMase expression (NB6) diminished the effects of mmLDL and C-6-ceramide treatment by inhibiting transcription via Sp1 and AP-2. Moreover, apoptosis was abolished after mmLDL and C-6-ceramide treatment of hereditary aSMase-deficient fibroblasts (from Niemann-Pick patients), We suggest that in mmLDL-initiated apoptosis 1) enhanced ceramide generation via aSMase appears to be required as well as 2) a positive feedback control of aSMase expression by the increase in intracellular ceramide concentration.	Univ Jena, Clin Anaesthesiol, D-07740 Jena, Germany; Univ Jena, Clin Intens Care Med, D-07740 Jena, Germany; Univ Jena, Inst Pharmaceut Chem, D-07740 Jena, Germany; Univ Heidelberg, Dept Anat & Cell Biol 3, D-69120 Heidelberg, Germany; Univ Heidelberg, Inst Pathochem & Neurochem, D-69120 Heidelberg, Germany	Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Deigner, HP (corresponding author), Univ Jena, Clin Anaesthesiol, D-07740 Jena, Germany.		Blaess, Markus/AAU-9572-2021; Kinscherf, Ralf/AAV-7164-2021; Claus, Ralf A./Q-4035-2016	Claus, Ralf A./0000-0001-7232-4088; Blaess, Markus/0000-0002-5860-2878				Auge N, 1998, J BIOL CHEM, V273, P12893, DOI 10.1074/jbc.273.21.12893; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Chatelut M, 1998, FEBS LETT, V426, P102, DOI 10.1016/S0014-5793(98)00325-1; CHEN GL, 1986, ARCH BIOCHEM BIOPHYS, V245, P66, DOI 10.1016/0003-9861(86)90190-6; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; Claus R, 1996, BIOCHEMISTRY-US, V35, P4911, DOI 10.1021/bi952036n; Claus R., 2000, Current Drug Targets, V1, P185, DOI 10.2174/1389450003349272; Deigner HP, 1999, CURR MED CHEM, V6, P399; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; ELSAADANI M, 1989, J LIPID RES, V30, P627; Farina F, 2000, J HISTOCHEM CYTOCHEM, V48, P57, DOI 10.1177/002215540004800106; FOSSEL ET, 1994, CANCER RES, V54, P1240; GEHLER J, 1974, HUMANGENETIK, V23, P149; Grassme H, 1997, CELL, V91, P605, DOI 10.1016/S0092-8674(00)80448-1; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Harada-Shiba M, 1998, J BIOL CHEM, V273, P9681, DOI 10.1074/jbc.273.16.9681; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Heinrich M, 1999, EMBO J, V18, P5252, DOI 10.1093/emboj/18.19.5252; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; HIMBER J, 1995, INT J VITAM NUTR RES, V65, P137; Huang Y, 1998, BIOCHEM BIOPH RES CO, V249, P307, DOI 10.1006/bbrc.1998.9139; Hueber AO, 2000, NAT CELL BIOL, V2, pE23, DOI 10.1038/35000092; IDZIOREK T, 1995, J IMMUNOL METHODS, V185, P249, DOI 10.1016/0022-1759(95)00172-7; Jaffrezou JP, 1998, FASEB J, V12, P999, DOI 10.1096/fasebj.12.11.999; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; Kinscherf R, 1997, FEBS LETT, V405, P55, DOI 10.1016/S0014-5793(97)00157-9; Kinscherf R, 1998, FASEB J, V12, P461, DOI 10.1096/fasebj.12.6.461; Kinscherf R, 1997, J LEUKOCYTE BIOL, V62, P719, DOI 10.1002/jlb.62.6.719; Kockx MM, 2000, CARDIOVASC RES, V45, P736, DOI 10.1016/S0008-6363(99)00235-7; Langmann T, 1999, J LIPID RES, V40, P870; Lepple-Wienhues A, 1999, P NATL ACAD SCI USA, V96, P13795, DOI 10.1073/pnas.96.24.13795; MAOR I, 1994, J LIPID RES, V35, P803; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Pena LA, 2000, CANCER RES, V60, P321; Perry DK, 1999, TRENDS BIOCHEM SCI, V24, P226, DOI 10.1016/S0968-0004(99)01407-3; Perry DK, 1998, BBA-MOL CELL BIOL L, V1436, P233, DOI 10.1016/S0005-2760(98)00145-3; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; REID VC, 1993, J PATHOL, V171, P321, DOI 10.1002/path.1711710413; Sandhoff K., 1999, ANGEW CHEM GER ED, V111, P1632, DOI [10.1002/(SICI)1521-3757(19990601)111:113.0.CO;2-A, DOI 10.1002/(SICI)1521-3757(19990601)111:113.0.CO;2-A]; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Separovic D, 1999, BIOCHEM BIOPH RES CO, V258, P506, DOI 10.1006/bbrc.1999.0670; Seve M, 1999, ARCH BIOCHEM BIOPHYS, V361, P165, DOI 10.1006/abbi.1998.0942; Simon CG, 1999, BIOCHEMISTRY-US, V38, P14676, DOI 10.1021/bi991537w; Strelow A, 2000, J EXP MED, V192, P601, DOI 10.1084/jem.192.5.601; SUZUKI YJ, 1994, J IMMUNOL, V153, P5008; Tanaka T, 2000, ARTERIOSCL THROM VAS, V20, P392, DOI 10.1161/01.ATV.20.2.392; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Watson AD, 1995, J CLIN INVEST, V96, P2882, DOI 10.1172/JCI118359; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; Yuan XM, 2000, FREE RADICAL BIO MED, V28, P208, DOI 10.1016/S0891-5849(99)00220-8	52	79	81	1	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					807	814		10.1096/fj.15.3.807	http://dx.doi.org/10.1096/fj.15.3.807			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259399				2022-12-28	WOS:000167419500038
J	Ray, PS; Martin, JL; Swanson, EA; Otani, H; Dillmann, WH; Das, DK				Ray, PS; Martin, JL; Swanson, EA; Otani, H; Dillmann, WH; Das, DK			Transgene overexpression of alpha B crystallin confers simultaneous protection against cardiomyocyte apoptosis and necrosis during myocardial ischemia and reperfusion	FASEB JOURNAL			English	Article						alpha B crystallin; transgenic; ischemia/reperfusion; oxidative stress	HEAT-SHOCK-PROTEIN; RAT-HEART; RABBIT CARDIOMYOCYTES; OXIDATIVE STRESS; MOUSE HEART; INJURY; EXPRESSION; TISSUE; INDUCTION; HSP27	We investigated whether enhanced expression of alphaB crystallin, a stress-inducible molecular chaperone of the small heat shock family, can protect myocardial contractile apparatus against ischemia reperfusion (I/R) injury. Transgenic mice overexpressing alphaB crystallin were generated using the 0.76 kb rat alphaB crystallin cDNA cloned into a pCAGGS plasmid driven by a human cytomegalovirus expression system. Southern analysis confirmed transgene integration and Northern and Western blotting characterized expression (3.1-fold and 6.9-fold elevations in myocardial mRNA and protein levels, respectively). Extent of functional recovery over a 3 h reperfusion period following a 20 min ischemic period in transgenic and wild-type mouse hearts was assessed using an ex vivo work-performing heart preparation. The transgenic group displayed significantly higher values of DP at R45 min (29.14+/-1.9 mm Hg vs. 17.6+/-0.7 mm Hg), R60 min (31.56+/-1.7 mm Hg vs. 17.8+/-0.8 mm Hg), and R75 min (32.5+/-2.2 mm Hg vs. 16.9+/-0.9 mm Hg), and of dLVP/dt at R45 min (1740.2+/-111.5 mm Hg.s(-1) vs. 548.7+/-82.2 mm Hg.s(-1)) and R60 min (1199.8+/-104.6 mm Hg.s(-1) vs. 466.9+/-61.1 mm Hg.s(-1)). The transgenic group also displayed development of less oxidative stress, decreased extent of infarction, and attenuated cardiomyocyte apoptotic cell death. Transgene overexpression of alphaB crystallin was therefore successful in diminishing the independent contributory effects of both necrosis and apoptosis on I/R-induced cell death.	Univ Connecticut, Ctr Hlth, Dept Surg, Cardiovasc Res Ctr, Farmington, CT 06030 USA; Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA	University of Connecticut; University of California System; University of California San Diego	Das, DK (corresponding author), Univ Connecticut, Ctr Hlth, Dept Surg, Cardiovasc Res Ctr, 263 Farmington Ave, Farmington, CT 06030 USA.				NHLBI NIH HHS [HL 49434, HL 34360, HL22559] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022559, R01HL034360, R01HL049434, R37HL049434] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AOYAMA A, 1993, MOL CELL BIOL, V13, P1824, DOI 10.1128/MCB.13.3.1824; Armstrong SC, 1999, J MOL CELL CARDIOL, V31, P555, DOI 10.1006/jmcc.1998.0891; ASIMAKIS GK, 1992, AM J PHYSIOL, V263, pH887, DOI 10.1152/ajpheart.1992.263.3.H887; Barbato R, 1996, CIRC RES, V78, P821, DOI 10.1161/01.RES.78.5.821; Benjamin IJ, 1997, DEV DYNAM, V208, P75; BENNARDINI F, 1992, CIRC RES, V71, P288, DOI 10.1161/01.RES.71.2.288; BLUHM JF, 1998, AM J PHYSIOL, V275, pH2243; Bluhm WF, 1998, AM J PHYSIOL, V275, P2243; CHIEN KR, 1981, CIRC RES, V48, P711, DOI 10.1161/01.RES.48.5.711; CORDIS GA, 1995, J MOL CELL CARDIOL, V27, P1645, DOI 10.1016/S0022-2828(95)90656-8; Das DK, 1998, BIOLOGICAL OXIDANTS AND ANTIOXIDANTS: MOLECULAR MECHANISMS AND HEALTH EFFECTS, P165; Das DK, 1999, MOL CELL BIOCHEM, V196, P59, DOI 10.1023/A:1006966128795; DAS DK, 1994, METHOD ENZYMOL, V233, P601; DONNELLY TJ, 1992, CIRCULATION, V85, P769, DOI 10.1161/01.CIR.85.2.769; DUBLIN RA, 1989, MOL CELL BIOL, V9, P1083; Fliss H, 1996, CIRC RES, V79, P949, DOI 10.1161/01.RES.79.5.949; Gauthier NS, 1998, J MOL CELL CARDIOL, V30, P453, DOI 10.1006/jmcc.1997.0610; Golenhofen N, 1998, AM J PHYSIOL-HEART C, V274, pH1457, DOI 10.1152/ajpheart.1998.274.5.H1457; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; GRUPP IL, 1993, AM J PHYSIOL, V265, pH1401, DOI 10.1152/ajpheart.1993.265.4.H1401; HEAD MW, 1994, J CELL PHYSIOL, V159, P41, DOI 10.1002/jcp.1041590107; HEIKKILA JJ, 1993, DEV GENET, V14, P87, DOI 10.1002/dvg.1020140202; Hogan B., 1986, MANIPULATING MOUSE E, P332; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; IWAKI T, 1994, J CELL BIOL, V125, P1385, DOI 10.1083/jcb.125.6.1385; Kajstura J, 1996, LAB INVEST, V74, P86; KANTOROW M, 1994, P NATL ACAD SCI USA, V91, P3112, DOI 10.1073/pnas.91.8.3112; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1074, P201, DOI 10.1016/0304-4165(91)90062-L; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; LI GC, 1990, CIRCULATION, V82, P609, DOI 10.1161/01.CIR.82.2.609; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; Martin JL, 1997, CIRCULATION, V96, P4343; MAULIK N, 1995, CIRCULATION, V92, P381, DOI 10.1161/01.CIR.92.9.381; Maulik N, 1998, AM J PHYSIOL-HEART C, V274, pH242, DOI 10.1152/ajpheart.1998.274.1.H242; Maulik N, 1998, FREE RADICAL BIO MED, V24, P869, DOI 10.1016/S0891-5849(97)00388-2; Maulik N, 1999, MOL CELL BIOCHEM, V196, P13, DOI 10.1023/A:1006905910140; MAULIK N, 1993, CIRCULATION, V88, P387; MAULIK N, 1999, HEART FAIL REV, V4, P165; Maulik N, 1998, AM J PHYSIOL, V275, P1857; MESTRIL R, 1994, J CLIN INVEST, V93, P759, DOI 10.1172/JCI117030; MIYAMAE M, 1996, AM J PHYSIOL, V271, pH1245; Neufer PD, 1998, AM J PHYSIOL-CELL PH, V274, pC341, DOI 10.1152/ajpcell.1998.274.2.C341; Qian YZ, 1999, AM J PHYSIOL-HEART C, V276, pH224, DOI 10.1152/ajpheart.1999.276.1.H224; SAGE MD, 1988, AM J PATHOL, V133, P327; Sharov VG, 1996, AM J PATHOL, V148, P141; van de Klundert FAJM, 1998, EUR J CELL BIOL, V75, P38, DOI 10.1016/S0171-9335(98)80044-7	46	199	211	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					393	402		10.1096/fj.00-0199com	http://dx.doi.org/10.1096/fj.00-0199com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156955				2022-12-28	WOS:000166872900021
J	Koegel, H; Alzheimer, C				Koegel, H; Alzheimer, C			Expression and biological significance of Ca2+-activated ion channels in human keratinocytes	FASEB JOURNAL			English	Article						ATP-evoked change of membrane potential; P2Y2 receptor and intracellular Ca2+ release; Ca2+-activated Cl- channels; hSK4 proliferation and differentiation of keratinocytes	CULTURED HUMAN KERATINOCYTES; K+ CHANNELS; INTRACELLULAR CALCIUM; POTASSIUM CHANNELS; CHLORIDE TRANSPORT; EXTRACELLULAR ATP; CL SECRETION; DIFFERENTIATION; PROLIFERATION; CELLS	In whole-cell recording from HaCaT keratinocytes, ATP, bradykinin, and histamine caused a biphasic change of the membrane potential consisting of an initial transient depolarization, followed by a pronounced and long-lasting hyperpolarization. Flash photolysis of caged IP3 mimicked the agonist-induced voltage response, suggesting that intracellular Ca2+ release and subsequent opening of Ca2+-activated ion channels serve as the common transduction mechanism. In contrast, cAMP- and PKC-dependent pathways were not involved in the electrophysiological effects of the extracellular signaling molecules. The depolarization was predominantly mediated by a DIDS- and niflumic acid-sensitive Cl- current, whereas a charybdotoxin- and clotrimazole-sensitive K+ current underlay the prominent hyperpolarization. Consistent with the electrophysiological data, RT-PCR showed that HaCaT keratinocytes express two types of Ca2+-activated Cl- channels, CaCC2 and CaCC3 (CLCA2), as well as the Ca2+-activated K+ channel hSK4. That the pronounced hSK4-mediated hyperpolarization bears significance on the growth and differentiation properties of keratinocytes is suggested by RNase protection assays showing that hSK4 mRNA expression is strongly down-regulated under conditions that allow keratinocyte differentiation, hSK4 might thus play a role in linking changes in membrane potential to the biological fate of keratinocytes.	Univ Munich, Dept Physiol, D-80336 Munich, Germany	University of Munich	Alzheimer, C (corresponding author), Univ Munich, Dept Physiol, Pettenkoferstr 12, D-80336 Munich, Germany.							Agnel M, 1999, FEBS LETT, V455, P295, DOI 10.1016/S0014-5793(99)00891-1; Biro T, 1998, ARCH DERMATOL RES, V290, P270, DOI 10.1007/s004030050303; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Chan HC, 1997, J MEMBRANE BIOL, V156, P45; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOK PW, 1995, J INVEST DERMATOL, V104, P976, DOI 10.1111/1523-1747.ep12606228; DeRoos ADG, 1997, J CELL PHYSIOL, V170, P166, DOI 10.1002/(SICI)1097-4652(199702)170:2<166::AID-JCP8>3.0.CO;2-M; Devor DC, 1996, AM J PHYSIOL-LUNG C, V271, pL775, DOI 10.1152/ajplung.1996.271.5.L775; Dixon CJ, 1999, BRIT J PHARMACOL, V127, P1680, DOI 10.1038/sj.bjp.0702653; FUCHS E, 1988, TRENDS GENET, V4, P277, DOI 10.1016/0168-9525(88)90169-2; GALIETTA LJV, 1991, PFLUG ARCH EUR J PHY, V418, P18, DOI 10.1007/BF00370447; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; Gruber AD, 1999, AM J PHYSIOL-CELL PH, V276, pC1261; Gruber AD, 1998, HISTOCHEM CELL BIOL, V110, P43, DOI 10.1007/s004180050263; Gruber AD, 1998, GENOMICS, V54, P200, DOI 10.1006/geno.1998.5562; Huber SM, 1999, PFLUG ARCH EUR J PHY, V438, P53, DOI 10.1007/s004240050879; Jensen BS, 1998, AM J PHYSIOL-CELL PH, V275, pC848, DOI 10.1152/ajpcell.1998.275.3.C848; Joiner WJ, 1997, P NATL ACAD SCI USA, V94, P11013, DOI 10.1073/pnas.94.20.11013; JONES KT, 1994, EXP CELL RES, V212, P409, DOI 10.1006/excr.1994.1161; KAM E, 1987, EXP CELL RES, V173, P431, DOI 10.1016/0014-4827(87)90283-7; KANSEN M, 1992, BIOCHIM BIOPHYS ACTA, V1139, P49, DOI 10.1016/0925-4439(92)90081-W; Khanna R, 1999, J BIOL CHEM, V274, P14838, DOI 10.1074/jbc.274.21.14838; KYROZIS A, 1995, J NEUROSCI METH, V57, P27, DOI 10.1016/0165-0270(94)00116-X; Marty Alain, 1995, P31; MASTROCOLA T, 1991, BIOCHIM BIOPHYS ACTA, V1097, P275, DOI 10.1016/0925-4439(91)90081-J; Mauro T, 1997, J INVEST DERMATOL, V108, P864, DOI 10.1111/1523-1747.ep12292585; MAURO TM, 1990, J CELL PHYSIOL, V143, P13, DOI 10.1002/jcp.1041430103; MAURO TM, 1993, J MEMBRANE BIOL, V132, P201; NILIUS B, 1995, AM J PHYSIOL-CELL PH, V269, pC376, DOI 10.1152/ajpcell.1995.269.2.C376; Nilius B, 1997, J PHYSIOL-LONDON, V498, P381, DOI 10.1113/jphysiol.1997.sp021865; NILIUS B, 1994, NEWS PHYSIOL SCI, V9, P105; PILLAI S, 1992, J CLIN INVEST, V90, P42, DOI 10.1172/JCI115854; Ralevic V, 1998, PHARMACOL REV, V50, P413; ROSENBACH T, 1993, ARCH DERMATOL RES, V285, P393, DOI 10.1007/BF00372131; RYLE CM, 1989, DIFFERENTIATION, V40, P42, DOI 10.1111/j.1432-0436.1989.tb00812.x; Strobaek D, 1996, AM J PHYSIOL-CELL PH, V271, pC1463, DOI 10.1152/ajpcell.1996.271.5.C1463; SUTER MM, 1991, J INVEST DERMATOL, V97, P223, DOI 10.1111/1523-1747.ep12480162; TALWAR HS, 1989, J INVEST DERMATOL, V93, P241, DOI 10.1111/1523-1747.ep12277581; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; WHITE MM, 1990, MOL PHARMACOL, V37, P720; Wonderlin WF, 1996, J MEMBRANE BIOL, V154, P91, DOI 10.1007/s002329900135; ZegarraMoran O, 1997, J MEMBRANE BIOL, V156, P297, DOI 10.1007/s002329900209	42	41	46	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2001	15	1					145	154		10.1096/fj.00-0055com	http://dx.doi.org/10.1096/fj.00-0055com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149902				2022-12-28	WOS:000166312400023
J	Mechtcheriakova, D; Schabbauer, G; Lucerna, M; Clauss, M; De Martin, R; Binder, BR; Hofer, E				Mechtcheriakova, D; Schabbauer, G; Lucerna, M; Clauss, M; De Martin, R; Binder, BR; Hofer, E			Specificity, diversity, and convergence in VEGF and TNF-alpha signaling events leading to tissue factor up-regulation via EGR-1 in endothelial cells	FASEB JOURNAL			English	Article						endothelium; tissue factor; MAP kinases; inflammatory cytokines; angiogenic growth factors	NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; TUMOR-NECROSIS-FACTOR; COLONY-STIMULATING FACTOR; RECEPTOR TYROSINE KINASES; GROWTH-FACTOR; MAP KINASE; TRANSCRIPTION FACTOR; NUCLEAR-FACTOR; FACTOR GENE	Tissue factor (TF) has been shown to be up-regulated in endothelial cells by the inflammatory cytokine tumor necrosis factor alpha (TNF-alpha) as well as by the main angiogenic factor VEGF. Since both stimuli induce the transcription factor EGR-1, which is critically involved in TF gene regulation, we used EGR-1-dependent TF induction as a model to identify potential cross-talks between the various signal transduction cascades initiated by VEGF and TNF-alpha. The data show that at the MAP kinase level, VEGF mainly activates ERK1/2 and p38 MAP kinases in human endothelial cells. TNF-alpha is able to activate all three MAP kinase cascades as well as the classical inflammatory I kappaB/NF kappaB pathway. Furthermore, the MEK-ERK module of MAP kinases appears to act as the convergence point of VEGF- and TNF-alpha -initiated signaling cascades, which lead to the activation of EGR-1 and subsequent TF expression, whereas the upstream signals are distinct. We found that induction of TF by VEGF via EGR-1 is strongly PKC dependent. The TNF-alpha -initiated MEK/ERK cascade connected to EGR-1 and TF expression is clearly less sensitive to PKC inhibition. TNF-ol-mediated activation of MEK/ERK and EGR-1 can be blocked by adenoviral expression of a dominant negative mutant of IKK2, whereas the VEGF signaling pathway is unaffected. Thus, our data demonstrate a new link between the classical inflammatory IKK/I kappaB and the MEK/ERK cascades triggered by TNF-alpha. The additional finding that EGF induces ERK and EGR-1 in a PKC- independent manner and that this signal is not sufficient to up-regulate TF emphasizes the importance of a VEGF-specific signaling pattern for the induction of TF.	Univ Vienna, VIRCC, Dept Vasc Biol & Thrombosis Res, A-1235 Vienna, Austria; Max Planck Inst Physiol & Clin Res, Dept Mol Cell Biol, D-61231 Bad Nauheim, Germany	University of Vienna; Max Planck Society	Hofer, E (corresponding author), Univ Vienna, VIRCC, Dept Vasc Biol & Thrombosis Res, Brunnerstr 59, A-1235 Vienna, Austria.	erhard.hofer@univie.ac.at		Mechtcheriakova, Diana/0000-0002-8737-3592; Clauss, Matthias/0000-0001-5180-3899; Schabbauer, Gernot/0000-0002-7490-8009				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Anda T, 1997, NEUROL RES, V19, P369, DOI 10.1080/01616412.1997.11758599; Armesilla AL, 1999, MOL CELL BIOL, V19, P2032; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Basu A, 1996, CELL GROWTH DIFFER, V7, P1507; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; BUDWORTH J, 1995, FEBS LETT, V362, P139, DOI 10.1016/0014-5793(95)00227-Z; CAO XM, 1992, J BIOL CHEM, V267, P1345; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Cines DB, 1998, BLOOD, V91, P3527; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; Clauss M, 1996, FEBS LETT, V390, P334, DOI 10.1016/0014-5793(96)00690-4; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; Cohen P, 1996, Adv Pharmacol, V36, P15, DOI 10.1016/S1054-3589(08)60574-8; Contrino J, 1996, NAT MED, V2, P209, DOI 10.1038/nm0296-209; Corbit KC, 1999, MOL CELL BIOL, V19, P4209; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; deMartin R, 1997, GENE THER, V4, P493, DOI 10.1038/sj.gt.3300408; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; Hofer E, 1999, NATO ADV SCI I A-LIF, V308, P3; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; JAMIESON GA, 1989, J CELL PHYSIOL, V139, P262, DOI 10.1002/jcp.1041390207; KELLER JR, 1989, J IMMUNOL, V143, P4025; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lim CP, 1998, ONCOGENE, V16, P2915, DOI 10.1038/sj.onc.1201834; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MACKMAN N, 1995, FASEB J, V9, P883, DOI 10.1096/fasebj.9.10.7615158; Mark KS, 1999, LIFE SCI, V64, P1941, DOI 10.1016/S0024-3205(99)00139-3; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Mechtcheriakova D, 1999, BLOOD, V93, P3811, DOI 10.1182/blood.V93.11.3811.411k40_3811_3823; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MOLL T, 1995, J BIOL CHEM, V270, P3849, DOI 10.1074/jbc.270.8.3849; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; OKUDA K, 1992, BLOOD, V79, P2880; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; Ott I, 1998, J CELL BIOL, V140, P1241, DOI 10.1083/jcb.140.5.1241; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Petrova TV, 1999, EXP CELL RES, V253, P117, DOI 10.1006/excr.1999.4707; QIU ZH, 1994, J BIOL CHEM, V269, P19480; Qu ZC, 1998, J CELL BIOL, V142, P1075, DOI 10.1083/jcb.142.4.1075; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RUF W, 1994, FASEB J, V8, P385, DOI 10.1096/fasebj.8.6.8168689; SAKAMOTO KM, 1994, MOL CELL BIOL, V14, P5975, DOI 10.1128/MCB.14.9.5975; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; WOLFF B, 1995, EXP CELL RES, V217, P31, DOI 10.1006/excr.1995.1060; Yabkowitz R, 1999, BLOOD, V93, P1969, DOI 10.1182/blood.V93.6.1969.406k14_1969_1979; Yan SF, 1999, J BIOL CHEM, V274, P15030, DOI 10.1074/jbc.274.21.15030; Yoshiji H, 1999, CANCER RES, V59, P4413; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; ZHANG YM, 1994, J CLIN INVEST, V94, P1320, DOI 10.1172/JCI117451	74	173	186	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2001	15	1					230	242		10.1096/fj.00-0247com	http://dx.doi.org/10.1096/fj.00-0247com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149911				2022-12-28	WOS:000166312400032
J	Stitt, AW; Burke, GA; Chen, F; McMullen, CBT; Vlassara, H				Stitt, AW; Burke, GA; Chen, F; McMullen, CBT; Vlassara, H			Advanced glycation end-product receptor interactions on microvascular cells occur within caveolin-rich membrane domains	FASEB JOURNAL			English	Article									Queens Univ Belfast, Dept Ophthalmol, Belfast BT7 1NN, Antrim, North Ireland; Mt Sinai Med Ctr, Dept Geriatr, New York, NY 10029 USA	Queens University Belfast; Icahn School of Medicine at Mount Sinai	Stitt, AW (corresponding author), Queens Univ Belfast, Royal Victoria Hosp, Dept Ophthalmol, Belfast BT12 6BA, Antrim, North Ireland.		Stitt, Alan/A-9842-2009	Stitt, Alan/0000-0002-8647-9918; Moore, Tara/0000-0002-7659-9326					0	45	46	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2390	2392						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11024005				2022-12-28	WOS:000165723400007
J	Andoh, T; Lee, SY; Chiueh, CC				Andoh, T; Lee, SY; Chiueh, CC			Preconditioning regulation of bcl-2 and p66(shc) by human NOS1 enhances tolerance to oxidative stress	FASEB JOURNAL			English	Article									NIMH, Ctr Clin, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH National Institute of Mental Health (NIMH)	Chiueh, CC (corresponding author), NIMH, Ctr Clin, NIH, NIH Bldg 10,Room 3D-41, Bethesda, MD 20892 USA.			Lee, Sang/0000-0003-3911-8316	NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH002648] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))			0	71	71	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2144	2146						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11023998				2022-12-28	WOS:000165190800006
J	Murphy, KL; Dennis, AP; Rosen, JM				Murphy, KL; Dennis, AP; Rosen, JM			A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53-null mammary epithelial cell model	FASEB JOURNAL			English	Article						mutant p53; apoptosis; aneuploidy; centrosome abnormalities	INTRACHROMOSOMAL HOMOLOGOUS RECOMBINATION; SISTER-CHROMATID EXCHANGES; DNA-REPAIR; GENETIC INSTABILITY; TRANSGENIC MICE; MAMMALIAN-CELLS; BINDING PROTEIN; MUTATIONS; EXPRESSION; CANCER	Approximately 40% of human breast cancers contain alterations in the tumor suppressor p53, The p53 172R-H gain-of-function mutant (equivalent to the common 175R-H human breast cancer mutant) has been shown to promote aneuploidy and tumorigenesis in the mammary gland in transgenic mice and may affect genomic stability in part by causing centrosome abnormalities, The precise mechanism of action of these gain-of-function mutants is not well understood, and has been studied primarily in fibroblast cell lines. A novel p53-null mouse mammary epithelial cell line developed from p53-null mice has been used in adenovirus-mediated transient transfection experiments to study the properties of this p53 mutant, Marked centrosome amplification and an increased frequency of aberrant mitoses were observed within 72 h of introduction of p53 172R-H. However, few cells with aberrant centrosome numbers were observed in cells stably expressing the p53 172R-H mutant. Furthermore, stable expression of this p53 mutant reduced both basal and DNA damage-induced apoptosis, This result may be mediated in part through abrogation of p73 function. The p53 172R-H mutant, therefore, appears to influence tumorigenesis at the molecular level in two distinct ways: promoting the development of aneuploidy in cells while also altering their apoptotic response after DNA damage,-Murpby, K. L., Dennis, A. P., Rosen, J. M. A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53-null mammary epithelial cell model.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Rosen, JM (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Pl, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA016303, R37CA016303] Funding Source: NIH RePORTER; NCI NIH HHS [CA16303] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; Agapova LS, 1996, MUTAT RES-FUND MOL M, V354, P129, DOI 10.1016/0027-5107(96)00062-0; Allgood VE, 1997, BIOCHEMISTRY-US, V36, P224, DOI 10.1021/bi961125c; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BAYNA EM, 1990, NUCLEIC ACIDS RES, V18, P2977, DOI 10.1093/nar/18.10.2977; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; Brinkley BR, 1998, CELL MOTIL CYTOSKEL, V41, P281, DOI 10.1002/(SICI)1097-0169(1998)41:4<281::AID-CM1>3.0.CO;2-C; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; Brown JM, 1999, CANCER RES, V59, P1391; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donehower LA, 1997, CANCER SURV, V29, P329; Fang L, 1999, J CELL BIOL, V147, P823, DOI 10.1083/jcb.147.4.823; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Gersten KM, 1997, NAT GENET, V17, P378, DOI 10.1038/ng1297-378; Gong JG, 1999, NATURE, V399, P806; Grombacher T, 1998, ONCOGENE, V17, P845, DOI 10.1038/sj.onc.1202000; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; Hadsell DL, 2000, ONCOGENE, V19, P889, DOI 10.1038/sj.onc.1203386; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Honma M, 1997, MOL CELL BIOL, V17, P4774, DOI 10.1128/MCB.17.8.4774; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KITTRELL FS, 1992, CANCER RES, V52, P1924; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LATT SA, 1981, MUTAT RES, V87, P17, DOI 10.1016/0165-1110(81)90003-8; Li BL, 1997, MOL CELL BIOL, V17, P3155, DOI 10.1128/MCB.17.6.3155; Li BL, 1998, ONCOGENE, V16, P997, DOI 10.1038/sj.onc.1201621; Li G, 1996, AM J PATHOL, V148, P1113; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; MCNALLY A, 1983, CYTOBIOS, V38, P159; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; Merdes A, 1997, J CELL BIOL, V138, P953, DOI 10.1083/jcb.138.5.953; Miyazaki M, 1999, CANCER RES, V59, P5283; Murphy KL, 2000, ONCOGENE, V19, P1045, DOI 10.1038/sj.onc.1203274; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; OSBORNE RJ, 1991, CANCER RES, V51, P6194; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Pihan GA, 1999, SEMIN CANCER BIOL, V9, P289, DOI 10.1006/scbi.1999.0131; RAUGHT B, 1995, MOL ENDOCRINOL, V9, P1223, DOI 10.1210/me.9.9.1223; RING D, 1982, J CELL BIOL, V94, P549, DOI 10.1083/jcb.94.3.549; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; SANDS AT, 1995, P NATL ACAD SCI USA, V92, P8517, DOI 10.1073/pnas.92.18.8517; SMITH ML, 1995, ONCOGENE, V10, P1053; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Tebbs RS, 1999, DEV BIOL, V208, P513, DOI 10.1006/dbio.1999.9232; Wang CN, 1998, APPL ACOUST, V53, P35, DOI 10.1016/S0003-682X(97)00042-X; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	58	77	82	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2291	2302		10.1096/fj.00-0128com	http://dx.doi.org/10.1096/fj.00-0128com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053251				2022-12-28	WOS:000165190800023
J	Gardiner, EM; Baldock, PA; Thomas, GP; Sims, NA; Henderson, NK; Hollis, B; White, CP; Sunn, KL; Morrison, NA; Walsh, WR; Eisman, JA				Gardiner, EM; Baldock, PA; Thomas, GP; Sims, NA; Henderson, NK; Hollis, B; White, CP; Sunn, KL; Morrison, NA; Walsh, WR; Eisman, JA			Increased formation and decreased resorption of bone in mice with elevated vitamin D receptor in mature cells of the osteoblastic lineage	FASEB JOURNAL			English	Article						osteoclast; osteocyte; periosteum; uncoupling; turnover	OSTEOCALCIN GENE-EXPRESSION; POSTMENOPAUSAL OSTEOPOROSIS; OSTEOCLAST DIFFERENTIATION; MOUSE; 1,25-DIHYDROXYVITAMIN-D; CALCITRIOL; MATRIX; RAT; RADIOIMMUNOASSAY; RESPONSIVENESS	The microarchitecture of bone is regulated by complex interactions between the bone-forming and resorbing cells, and several compounds regulate both actions. For example, vitamin D, which is required for bone mineralization, also stimulates bone resorption. Transgenic mice overexpressing the vitamin D receptor solely in mature cells of the osteoblastic bone-forming lineage were generated to test the potential therapeutic value of shifting the balance of vitamin D activity in favor of bone formation. Cortical bone was 5% wider and 15% stronger in these mice due to a doubling of periosteal mineral apposition rate without altered body weight or calcium homeostatic hormone levels. A 20% increase in trabecular bone volume in transgenic vertebrae was also observed, unexpectedly associated with a 30% reduction in resorption surface rather than greater bone formation. These findings indicate anabolic vitamin D activity in bone and identify a previously unknown pathway from mature osteoblastic cells to inhibit osteoclastic bone resorption, counterbalancing the known stimulatory action through immature osteoblastic cells. A therapeutic approach that both stimulates cortical anabolic and inhibits trabecular resorptive pathways would be ideal for treatment of osteoporosis and other osteopenic disorders.	Garvan Inst Med Res, Bone & Mineral Res Program, Sydney, NSW 2010, Australia; Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA; Prince Wales Hosp, Dept Orthopaed, Sydney, NSW, Australia	Garvan Institute of Medical Research; Medical University of South Carolina	Gardiner, EM (corresponding author), Garvan Inst Med Res, Bone & Mineral Res Program, 384 Victoria St, Sydney, NSW 2010, Australia.	e.gardiner@ganan.unsw.edu.au	White, Christopher/K-8262-2019; Eisman, John A/C-2886-2014; Thomas, Gethin P/A-3624-2011; Baldock, Paul/B-3840-2012; Morrison, Nigel A/F-4082-2012; Sims, Natalie Ann/A-7192-2012	White, Christopher/0000-0002-7732-2206; Morrison, Nigel A/0000-0003-4774-3808; Sims, Natalie Ann/0000-0003-1421-8468; Briffa, Kathy/0000-0002-0731-4112; Walsh, William/0000-0002-5023-6148; Thomas, Gethin/0000-0001-9081-3686	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043421] Funding Source: NIH RePORTER; NIAMS NIH HHS [1RO1AR43421] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAK B, 1992, BONE, V13, P289, DOI 10.1016/8756-3282(92)90073-6; Candeliere GA, 1996, MOL CELL BIOL, V16, P584; Corral DA, 1998, P NATL ACAD SCI USA, V95, P13835, DOI 10.1073/pnas.95.23.13835; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; GALLAGHER JC, 1990, ANN INTERN MED, V113, P649, DOI 10.7326/0003-4819-113-9-649; Gerstenfeld LC, 1999, J BONE MINER RES, V14, P850, DOI 10.1359/jbmr.1999.14.6.850; GUNDBERG CM, 1992, ENDOCRINOLOGY, V130, P1909, DOI 10.1210/en.130.4.1909; Hollis BW, 1996, CLIN CHEM, V42, P586; Horwood NJ, 1998, ENDOCRINOLOGY, V139, P4743, DOI 10.1210/en.139.11.4743; INAOKA T, 1995, BIOCHEM BIOPH RES CO, V217, P264, DOI 10.1006/bbrc.1995.2773; ISHIDA H, 1993, ENDOCRINOLOGY, V132, P61, DOI 10.1210/en.132.1.61; Kartsogiannis V, 1999, J BONE MINER RES, V14, pS361; Lian JB, 1997, ENDOCRINOLOGY, V138, P2117, DOI 10.1210/en.138.5.2117; Lips P, 1996, ANN INTERN MED, V124, P400, DOI 10.7326/0003-4819-124-4-199602150-00003; MAJESKA RJ, 1982, CALCIFIED TISSUE INT, V34, P59, DOI 10.1007/BF02411210; MARIE PJ, 1985, METABOLISM, V34, P777, DOI 10.1016/0026-0495(85)90030-7; MARTIN TJ, 1994, J CELL BIOCHEM, V56, P357, DOI 10.1002/jcb.240560312; McClung MR, 1996, BONE, V19, pS195, DOI 10.1016/S8756-3282(96)90165-9; MCDONNELL DP, 1989, MOL ENDOCRINOL, V3, P635, DOI 10.1210/mend-3-4-635; Murakami T, 1998, BIOCHEM BIOPH RES CO, V252, P747, DOI 10.1006/bbrc.1998.9723; Nijweide P. J., 1996, P115; OTT SM, 1989, ANN INTERN MED, V110, P267, DOI 10.7326/0003-4819-110-4-267; OWEN TA, 1991, ENDOCRINOLOGY, V128, P1496, DOI 10.1210/endo-128-3-1496; PAGE KM, 1977, THEORY PRACTICE HIST, P223; PARFITT AM, 1983, J CLIN INVEST, V72, P1396, DOI 10.1172/JCI111096; PARFITT AM, 1995, J BONE MINER RES, V10, P466; PIERCE EA, 1987, J BIOL CHEM, V262, P17092; PRICE PA, 1982, P NATL ACAD SCI-BIOL, V79, P7734, DOI 10.1073/pnas.79.24.7734; REEVES PG, 1993, J NUTR, V123, P1939, DOI 10.1093/jn/123.11.1939; Rico H, 1997, CALCIFIED TISSUE INT, V61, P431, DOI 10.1007/s002239900361; Sims NA, 1997, MOL ENDOCRINOL, V11, P1695, DOI 10.1210/me.11.11.1695; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Terai K, 1999, J BONE MINER RES, V14, P839, DOI 10.1359/jbmr.1999.14.6.839; Thomsen JS, 1996, BONE, V19, P505, DOI 10.1016/S8756-3282(96)00231-1; TILYARD MW, 1992, NEW ENGL J MED, V326, P357, DOI 10.1056/NEJM199202063260601; TUOHIMAA P, 1992, J STEROID BIOCHEM, V43, P649, DOI 10.1016/0960-0760(92)90290-Y; UhlandSmith A, 1996, J BONE MINER RES, V11, P1921; Vedi S, 1996, BONE, V19, P535, DOI 10.1016/S8756-3282(96)00227-X; Westerlind KC, 1997, P NATL ACAD SCI USA, V94, P4199, DOI 10.1073/pnas.94.8.4199; Yasuda H, 1999, BONE, V25, P109, DOI 10.1016/S8756-3282(99)00121-0; Zhang R, 1997, J BIOL CHEM, V272, P110, DOI 10.1074/jbc.272.1.110; Zhou H, 1999, J BONE MINER RES, V14, pS361; Zhou H, 1999, J BONE MINER RES, V14, pS198	43	121	128	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2000	14	13					1908	1916		10.1096/fj.99-1075com	http://dx.doi.org/10.1096/fj.99-1075com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023975				2022-12-28	WOS:000089634400010
J	Dell'Angelica, EC; Mullins, C; Caplan, S; Bonifacino, JS				Dell'Angelica, EC; Mullins, C; Caplan, S; Bonifacino, JS			Lysosome-related organelles	FASEB JOURNAL			English	Review						melanosome; lytic granule; MIIC; platelet-dense granule; basophil granule; azurophil granule; pigment granule; Chediak-Higashi syndrome; Griscelli syndrome; Hermansky-Pudlak syndrome; protein trafficking	HERMANSKY-PUDLAK-SYNDROME; CHEDIAK-HIGASHI-SYNDROME; BASOPHILIC LEUKEMIA-CELLS; CLASS-II COMPARTMENTS; AP-3 ADAPTER COMPLEX; TYROSINASE-RELATED PROTEIN; INTEGRAL MEMBRANE-PROTEIN; STORAGE POOL DEFICIENCY; DENSE GRANULE MEMBRANES; NATURAL-KILLER-CELLS	Lysosomes are membrane-bound cytoplasmic organelles involved in intracellular protein degradation, They contain an assortment of soluble acid-dependent hydrolases and a set of highly glycosylated integral membrane proteins, Most of the properties of lysosomes are shared with a group of cell type-specific compartments referred to as 'lysosome-related organelles', which include melanosomes, lytic granules, MHC class II compartments, platelet-dense granules, basophil granules, azurophil granules, and Drosophila pigment granules. In addition to lysosomal proteins, these organelles contain cell type-specific components that are responsible for their specialized functions. Abnormalities in both lysosomes and lysosome-related organelles have been observed in human genetic diseases such as the Chediak-Higashi and Hermansky-Pudlak syndromes, further demonstrating the close relationship between these organelles. Identification of genes mutated in these human diseases, as well as in mouse and Drosophila pigmentation mutants, is beginning to shed light on the molecular machinery involved in the biogenesis of lysosomes and lysosome-related organelles.	NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Bonifacino, JS (corresponding author), NICHHD, Cell Biol & Metab Branch, NIH, Bldg 18T,Room 101,18 Lib Dr,MSC 5430, Bethesda, MD 20892 USA.	juan@helix.nih.gov		Bonifacino, Juan S./0000-0002-5673-6370	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001607] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001607] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Baram D, 1999, J EXP MED, V189, P1649, DOI 10.1084/jem.189.10.1649; Barbosa MDFS, 1996, NATURE, V382, P262, DOI 10.1038/382262a0; Bauerfeind R, 1993, CURR OPIN CELL BIOL, V5, P628, DOI 10.1016/0955-0674(93)90132-A; BENTFELDBARKER ME, 1980, J HISTOCHEM CYTOCHEM, V28, P1055, DOI 10.1177/28.10.7419898; Boissy RE, 1997, PIGM CELL RES, V10, P12, DOI 10.1111/j.1600-0749.1997.tb00461.x; Boissy RE, 1998, LAB INVEST, V78, P1037; BONIFACINO JS, 1989, J CELL SCI, V92, P701; BONIFACINO JS, 1986, J CELL BIOL, V102, P516, DOI 10.1083/jcb.102.2.516; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Bossi G, 1999, NAT MED, V5, P90, DOI 10.1038/4779; BROWN JA, 1985, J CELL BIOL, V100, P1894, DOI 10.1083/jcb.100.6.1894; CAGAN RL, 1989, DEV BIOL, V136, P346, DOI 10.1016/0012-1606(89)90261-3; Calvo PA, 1999, J BIOL CHEM, V274, P12780, DOI 10.1074/jbc.274.18.12780; CAPLAN S, 2000, IN PRESS IMMUNOL LET; CHAM BP, 1994, AM J PATHOL, V144, P1369; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Cieutat AM, 1998, BLOOD, V91, P1044, DOI 10.1182/blood.V91.3.1044.1044_1044_1058; Copier J, 1996, J IMMUNOL, V157, P1017; Cowles CR, 1997, CELL, V91, P109, DOI 10.1016/S0092-8674(01)80013-1; Cuervo AM, 1998, J MOL MED-JMM, V76, P6, DOI 10.1007/s109-1998-8099-y; DAHLGREN C, 1995, BIOCHEM J, V311, P667, DOI 10.1042/bj3110667; de Saint-Vis B, 1998, IMMUNITY, V9, P325, DOI 10.1016/S1074-7613(00)80615-9; DEAN GE, 1984, J BIOL CHEM, V259, P9569; DEDUVE C, 1963, LYSOSOMES, P1; Dell'Angelica EC, 2000, J BIOL CHEM, V275, P1300, DOI 10.1074/jbc.275.2.1300; Dell'Angelica EC, 1999, MOL CELL, V3, P11, DOI 10.1016/S1097-2765(00)80170-7; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; Detter JC, 2000, P NATL ACAD SCI USA, V97, P4144, DOI 10.1073/pnas.080517697; DUVE CD, 1975, SCIENCE, V189, P186, DOI 10.1126/science.1138375; ELEJALDE BR, 1979, AM J MED GENET, V3, P65, DOI 10.1002/ajmg.1320030112; Faigle W, 1998, J CELL BIOL, V141, P1121, DOI 10.1083/jcb.141.5.1121; Feng GH, 1997, HUM MOL GENET, V6, P793, DOI 10.1093/hmg/6.5.793; Feng LJ, 1999, HUM MOL GENET, V8, P323, DOI 10.1093/hmg/8.2.323; FITTSCHEN C, 1994, J CLIN INVEST, V93, P247, DOI 10.1172/JCI116952; Frank DW, 1999, MOL BIOL CELL, V10, p224A; GARAY SM, 1979, AM J MED, V66, P737, DOI 10.1016/0002-9343(79)91111-2; GARDNER JM, 1992, SCIENCE, V257, P1121, DOI 10.1126/science.257.5073.1121; Gardner JM, 1997, P NATL ACAD SCI USA, V94, P9238, DOI 10.1073/pnas.94.17.9238; Geuze HJ, 1998, IMMUNOL TODAY, V19, P282, DOI 10.1016/S0167-5699(98)01269-9; GLICKMAN JN, 1993, J CELL BIOL, V123, P99, DOI 10.1083/jcb.123.1.99; Griffiths G M, 1995, Curr Top Microbiol Immunol, V198, P39; GRIFFITHS GM, 1993, J CELL BIOL, V120, P885, DOI 10.1083/jcb.120.4.885; GRISCELLI C, 1978, AM J MED, V65, P691, DOI 10.1016/0002-9343(78)90858-6; Gullberg U, 1997, EUR J HAEMATOL, V58, P137; Gwynn B, 1997, GENOMICS, V42, P532, DOI 10.1006/geno.1997.4764; Harding CV, 1996, CRIT REV IMMUNOL, V16, P13, DOI 10.1615/CritRevImmunol.v16.i1.20; HARDING CV, 1993, J IMMUNOL, V151, P3988; HARFI HA, 1992, ALLERGY PROC, V13, P321, DOI 10.2500/108854192778816933; Hazelwood S, 1997, AM J HUM GENET, V61, P1088, DOI 10.1086/301611; Heilker R, 1999, BIOESSAYS, V21, P558, DOI 10.1002/(SICI)1521-1878(199907)21:7<558::AID-BIES4>3.0.CO;2-R; HERMANSKY F, 1959, BLOOD, V14, P162, DOI 10.1182/blood.V14.2.162.162; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; Huang LP, 1999, NAT GENET, V23, P329, DOI 10.1038/15507; Hunziker W, 1996, BIOESSAYS, V18, P379, DOI 10.1002/bies.950180508; Israels SJ, 1996, THROMB HAEMOSTASIS, V75, P623; ISRAELS SJ, 1992, BLOOD, V80, P143; JACKSON IJ, 1988, P NATL ACAD SCI USA, V85, P4392, DOI 10.1073/pnas.85.12.4392; Kantheti P, 1998, NEURON, V21, P111, DOI 10.1016/S0896-6273(00)80519-X; Kjeldsen L, 1998, J LEUKOCYTE BIOL, V64, P72, DOI 10.1002/jlb.64.1.72; Kleijmeer MJ, 1997, J CELL BIOL, V139, P639, DOI 10.1083/jcb.139.3.639; KORNER A, 1982, SCIENCE, V217, P1163, DOI 10.1126/science.6810464; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KULIAWAT R, 1992, J CELL BIOL, V118, P521, DOI 10.1083/jcb.118.3.521; Le Borgne R, 1998, J BIOL CHEM, V273, P29451, DOI 10.1074/jbc.273.45.29451; LESCH KP, 1993, J NEUROCHEM, V60, P2319, DOI 10.1111/j.1471-4159.1993.tb03522.x; Liljedahl M, 1996, EMBO J, V15, P4817, DOI 10.1002/j.1460-2075.1996.tb00862.x; Lloyd V, 1998, TRENDS CELL BIOL, V8, P257, DOI 10.1016/S0962-8924(98)01270-7; MARKS MS, 1995, J CELL BIOL, V131, P351, DOI 10.1083/jcb.131.2.351; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; Marone G, 1997, INT ARCH ALLERGY IMM, V114, P207, DOI 10.1159/000237670; MASSON D, 1990, BIOCHEMISTRY-US, V29, P11229, DOI 10.1021/bi00503a011; McNicol A, 1999, THROMB RES, V95, P1, DOI 10.1016/S0049-3848(99)00015-8; Medley QG, 1996, P NATL ACAD SCI USA, V93, P685, DOI 10.1073/pnas.93.2.685; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; Mullins C, 1999, MOL GEN GENET, V262, P401, DOI 10.1007/s004380051099; MULLINS C, 2000, IN PRESS MOL GEN GEN; Nagle DL, 1996, NAT GENET, V14, P307, DOI 10.1038/ng1196-307; Oh J, 2000, HUM MOL GENET, V9, P375, DOI 10.1093/hmg/9.3.375; Oh J, 1996, NAT GENET, V14, P300, DOI 10.1038/ng1196-300; Oh J, 1998, AM J HUM GENET, V62, P593, DOI 10.1086/301757; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; Ooi CE, 1997, EMBO J, V16, P4508; ORLOW SJ, 1995, J INVEST DERMATOL, V105, P3, DOI 10.1111/1523-1747.ep12312291; Pastural E, 1999, NAT GENET, V23, P373, DOI 10.1038/15565; Pastural E, 1997, NAT GENET, V16, P289, DOI 10.1038/ng0797-289; Perou CM, 1996, NAT GENET, V13, P303, DOI 10.1038/ng0796-303; Perou CM, 1997, J BIOL CHEM, V272, P29790, DOI 10.1074/jbc.272.47.29790; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PETERS PJ, 1991, J EXP MED, V173, P1099, DOI 10.1084/jem.173.5.1099; Pierre P, 1996, IMMUNITY, V4, P229, DOI 10.1016/S1074-7613(00)80431-8; Prekeris R, 1998, J CELL BIOL, V143, P957, DOI 10.1083/jcb.143.4.957; Raposo G, 1997, MOL BIOL CELL, V8, P2631, DOI 10.1091/mbc.8.12.2631; Rehling P, 1999, NAT CELL BIOL, V1, P346, DOI 10.1038/14037; RENDU F, 1983, AM J PATHOL, V111, P307; Rieder SE, 1997, MOL BIOL CELL, V8, P2307, DOI 10.1091/mbc.8.11.2307; RINCHIK EM, 1993, NATURE, V361, P72, DOI 10.1038/361072a0; Rodriguez A, 1997, J CELL BIOL, V137, P93, DOI 10.1083/jcb.137.1.93; SAITO N, 1991, AM J PATHOL, V139, P1053; SANDERSON F, 1994, SCIENCE, V266, P1566, DOI 10.1126/science.7985027; Schiaffino MV, 1999, NAT GENET, V23, P108, DOI 10.1038/12715; SCHWARTZ LB, 1980, J INVEST DERMATOL, V74, P349, DOI 10.1111/1523-1747.ep12543620; SETIADI H, 1995, J BIOL CHEM, V270, P26818, DOI 10.1074/jbc.270.45.26818; Sevrioukov EA, 1999, MOL CELL, V4, P479, DOI 10.1016/S1097-2765(00)80199-9; Shestopal SA, 1997, MOL GEN GENET, V253, P642; SILVERSTEIN RL, 1992, BLOOD, V80, P1470; Simmen T, 1999, J CELL SCI, V112, P45; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; Spritz RA, 1999, CLIN GENET, V55, P309, DOI 10.1034/j.1399-0004.1999.550503.x; Stepp JD, 1997, J CELL BIOL, V139, P1761, DOI 10.1083/jcb.139.7.1761; Stinchcombe JC, 1999, J CELL BIOL, V147, P1, DOI 10.1083/jcb.147.1.1; SUAREZQUIAN CA, 1987, TISSUE CELL, V19, P495, DOI 10.1016/0040-8166(87)90043-7; Thompson CB, 1997, IMMUNITY, V7, P445, DOI 10.1016/S1074-7613(00)80366-0; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; vanHam SM, 1997, CURR BIOL, V7, P950, DOI 10.1016/S0960-9822(06)00414-3; VANSMIT NP, 1993, BIOCHIM BIOPHYS ACTA, V1181, P1; VIJAYASARADHI S, 1995, J CELL BIOL, V130, P807, DOI 10.1083/jcb.130.4.807; Warner TS, 1998, GENOME, V41, P236, DOI 10.1139/gen-41-2-236; Wu XF, 1998, J CELL BIOL, V143, P1899, DOI 10.1083/jcb.143.7.1899; Youssefian T, 1997, BLOOD, V89, P4047, DOI 10.1182/blood.V89.11.4047; ZHOU BK, 1994, P NATL ACAD SCI USA, V91, P7076, DOI 10.1073/pnas.91.15.7076	125	402	414	6	62	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2000	14	10					1265	1278		10.1096/fj.14.10.1265	http://dx.doi.org/10.1096/fj.14.10.1265			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877819				2022-12-28	WOS:000087932200001
J	Bae, SS; Perry, DK; Oh, YS; Choi, JH; Galadari, SH; Ghayur, T; Ryu, SH; Hannun, YA; Suh, PG				Bae, SS; Perry, DK; Oh, YS; Choi, JH; Galadari, SH; Ghayur, T; Ryu, SH; Hannun, YA; Suh, PG			Proteolytic cleavage of phospholipase C-gamma 1 during apoptosis in Molt-4 cells	FASEB JOURNAL			English	Article						PLC-gamma 1; proteolysis; tyrosine phosphorylation	CYTOCHROME-C; FOCAL ADHESION; CASPASE FAMILY; SH3 DOMAIN; DEATH; PROTEIN; ACTIVATION; PHOSPHORYLATION; BCL-2; ELEGANS	Apoptosis is a cell suicide mechanism that requires the activation of cellular death proteases for its induction. We examined whether the progress of apoptosis involves cleavage of phospholipase C-gamma 1 (PLC-gamma 1), which plays a pivotal role in mitogenic signaling pathway. Pretreatment of T leukemic Molt-4 cells with PLC inhibitors such as U-73122 or ET-18-OCH3 potentiated etoposide-induced apoptosis in these cells. PLC-gamma 1 was fragmented when Molt-4 cells were treated with several apoptotic stimuli such as etoposide, ceramides, and tumor necrosis factor alpha. Cleavage of PLC-gamma 1 was blocked by overexpression of Bcl-2 and by specific inhibitors of caspases such as Z-DEVD-CH2F and YVAD-cmk. Purified caspase-3 and caspase-7, group II caspases, cleaved PLC-gamma 1 in vitro and generated a cleavage product of the same size as that observed in vivo, suggesting that PLC-gamma 1 is cleaved by group II caspases in vivo. From point mutagenesis studies, Ala-Glu-Pro-Asp(770) was identified to be a cleavage site within PLC-gamma 1. Epidermal growth factor receptor (EGFR) -induced tyrosine phosphorylation of PLC-gamma 1 resulted in resistance to cleavage by caspase-3 in vitro. Furthermore, cleaved PLC-gamma 1 could not be tyrosine-phosphorylated by EGFR in vitro. In addition, tyrosine-phosphorylated PLC-gamma 1 was not significantly cleaved during etoposide-induced apoptosis in Molt-4 cells. This suggests that the growth factor-induced tyrosine phosphorylation may suppress apoptosis-induced fragmentation of PLC-gamma 1. We provide evidence for the biochemical relationship between PLC-gamma 1-mediated signal pathway and apoptotic signal pathway, indicating that the defect of PLC-gamma 1-mediated signaling pathway can facilitate an apoptotic progression.-Bae, S. S., Ferry, D. K., Oh, Y. S., Choi, J. H., Galadari, S. H., Ghayur, T., Ryu, S. H., Hannun, Y. A., Suh, P.-G. Proteolytic cleavage of phospholipase C-gamma 1 during apoptosis in Molt-4 cells.	Pohang Univ Sci & Technol, Div Mol & Life Sci, Dept Signal Transduct, Nam Gu, Pohang 790784, South Korea; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; United Arab Emirates Univ, Fac Med & Hlth Sci, Dept Biochem, Al Ain, U Arab Emirates; BASF Biores Corp, Worcester, MA 01605 USA	Pohang University of Science & Technology (POSTECH); Medical University of South Carolina; United Arab Emirates University; BASF	Suh, PG (corresponding author), Pohang Univ Sci & Technol, Div Mol & Life Sci, Dept Signal Transduct, Nam Gu, San 31 Hyoja Dong, Pohang 790784, South Korea.		Suh, Pann-Ghill/F-3610-2010; Galadari, Sehamuddin/AAK-6039-2020; Choi, Jang Hyun/B-3055-2012	Ryu, Sung Ho/0000-0003-0913-3048; Oh, Yong-Seok/0000-0002-9039-2014				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Barkett M, 1997, J BIOL CHEM, V272, P29419, DOI 10.1074/jbc.272.47.29419; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; Chang JS, 1997, CANCER RES, V57, P5465; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DIETRICH A, 1992, FEBS LETT, V313, P220, DOI 10.1016/0014-5793(92)81195-R; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; FERNALD AW, 1994, BIOCHEM J, V302, P503, DOI 10.1042/bj3020503; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUANG PS, 1995, FEBS LETT, V358, P287, DOI 10.1016/0014-5793(94)01453-8; Jarpe MB, 1998, ONCOGENE, V17, P1475, DOI 10.1038/sj.onc.1202183; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; Oh WK, 1997, BIOCHEM BIOPH RES CO, V235, P794, DOI 10.1006/bbrc.1997.6875; Perry DK, 1997, CELL DEATH DIFFER, V4, P29, DOI 10.1038/sj.cdd.4400200; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Santoro MF, 1998, J BIOL CHEM, V273, P13119, DOI 10.1074/jbc.273.21.13119; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SUH PG, 1988, J BIOL CHEM, V263, P14497; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Xue D, 1997, NATURE, V390, P305, DOI 10.1038/36889; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YANG LJ, 1994, J BIOL CHEM, V269, P7156; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	47	64	66	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2000	14	9					1083	1092		10.1096/fasebj.14.9.1083	http://dx.doi.org/10.1096/fasebj.14.9.1083			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834929				2022-12-28	WOS:000087427300004
J	Cui, JK; Holmes, EH; Greene, TG; Liu, PK				Cui, JK; Holmes, EH; Greene, TG; Liu, PK			Oxidative DNA damage precedes DNA fragmentation after experimental stroke in rat brain	FASEB JOURNAL			English	Article						hydroxyl radicals; oxidative DNA damage; neurotoxicity; reactive oxygen species; stroke	FOCAL CEREBRAL-ISCHEMIA; AMYOTROPHIC-LATERAL-SCLEROSIS; EXCITOTOXICITY IN-VIVO; CELL-DEATH; C-FOS; ANTISENSE OLIGODEOXYNUCLEOTIDE; SUPEROXIDE-DISMUTASE; LIPID-PEROXIDATION; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE	Experimental stroke using a focal cerebral ischemia and reperfusion (FCIR) model was induced in male Long Evans rats by a bilateral occlusion of both common carotid arteries and the right middle cerebral artery for 30-90 min, followed by various periods of reperfusion, Oxidative DNA lesions in the ipsilateral cortex were demonstrated using Escherichia coli formamidopyrimidine DNA N-glycosylase (Fpg protein)-sensitive sites (FPGSS), as labeled in situ using digoxigenin-dUTP and detected using antibodies against digoxigenin. Because Fpg protein removes 8-hydroxy-2'-deoxyguanine (oh8dG) and other lesions in DNA, FPGSS measure oxidative DNA damage. The number of FPGSS-positive cells in the cortex from the sham-operated control group was 3 +/- 3 (mean +/- SD per mm(2)), In animals that received 90 min occlusion and 15 min of reperfusion (FCIR 90/15), FPGSS-positive cells were significantly increased by 200-fold. Oxidative DNA damage was confirmed by using monoclonal antibodies against 8-hydroxy-guanosine (oh8G) and oh8dG, A pretreatment of RNase A (100 mu g/ml) to the tissue reduced, but did not abolish, the oh8dG signal, The number of animals with positive FPGSS or oh8dG was significantly (P<0.01) higher in the FCIR group than in the sham-operated control group. We detected few FPGSS of oh8dG-positive cells in the animals treated with FCIR of 90/60, No terminal UTP nicked-end labeling (TUNEL)-positive cells, as a detection of cell death, were detected at this early reperfusion time. Our data suggest that early oxidative DNA lesions elicited by experimental stroke could be repaired. Therefore, the oxidative DNA lesions observed in the nuclear and mitochondrial DNA of the brain are different from the DNA fragmentation detected using TUNEL.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Cardiovasc Program, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; NW Hosp, Pacific NW Canc Fdn, Seattle, WA 98125 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Liu, PK (corresponding author), Baylor Coll Med, Dept Neurosurg, Suite 944,6560 Fannin, Houston, TX 77030 USA.	philipl@bcm.tmc.edu			NCI NIH HHS [CA67163] Funding Source: Medline; NINDS NIH HHS [NS34810, R01 NS034810-04, R01 NS034810-04S1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R43CA067163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034810] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akins PT, 1996, STROKE, V27, P1682, DOI 10.1161/01.STR.27.9.1682; AN G, 1993, ANN NEUROL, V33, P457, DOI 10.1002/ana.410330508; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; Chen J, 1997, J NEUROCHEM, V69, P232; CHEN ST, 1986, STROKE, V17, P738, DOI 10.1161/01.STR.17.4.738; CHO BP, 1991, NUCLEIC ACIDS RES, V19, P1041, DOI 10.1093/nar/19.5.1041; CHO BP, 1990, CHEM RES TOXICOL, V3, P445, DOI 10.1021/tx00017a010; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Croteau DL, 1997, J BIOL CHEM, V272, P27338, DOI 10.1074/jbc.272.43.27338; Cui JK, 1999, J NEUROSCI, V19, P1335; Cui JK, 1999, J NEUROCHEM, V73, P1164, DOI 10.1046/j.1471-4159.1999.0731164.x; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; Du C, 1996, J CEREBR BLOOD F MET, V16, P195, DOI 10.1097/00004647-199603000-00003; Eliasson MJL, 1999, J NEUROSCI, V19, P5910, DOI 10.1523/JNEUROSCI.19-14-05910.1999; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Epe B, 1996, NUCLEIC ACIDS RES, V24, P4105, DOI 10.1093/nar/24.21.4105; ERLANGER BF, 1964, P NATL ACAD SCI USA, V52, P68, DOI 10.1073/pnas.52.1.68; FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P172; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gobbel GT, 1998, J NEUROSCI, V18, P147; GUTTERIDGE JMC, 1983, ACTA NEUROL SCAND, V68, P365, DOI 10.1111/j.1600-0404.1983.tb04845.x; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HENNER WD, 1982, J BIOL CHEM, V257, P1750; Huang DY, 2000, FASEB J, V14, P407, DOI 10.1096/fasebj.14.2.407; IKEDA Y, 1990, NEUROSURGERY, V27, P1; Jaruga P, 1996, NUCLEIC ACIDS RES, V24, P1389, DOI 10.1093/nar/24.8.1389; JENNER P, 1992, ANN NEUROL, V32, pS82, DOI 10.1002/ana.410320714; KamathLoeb AS, 1997, EUR J BIOCHEM, V250, P492, DOI 10.1111/j.1432-1033.1997.0492a.x; Kamii H, 1996, J CEREBR BLOOD F MET, V16, P1153, DOI 10.1097/00004647-199611000-00009; KINUTA Y, 1989, J NEUROSURG, V71, P421, DOI 10.3171/jns.1989.71.3.0421; Kisby GE, 1997, NEUROREPORT, V8, P1337, DOI 10.1097/00001756-199704140-00004; KORNBERG A, 1980, DNA REPLICATION, P324; Kumura E, 1996, AM J PHYSIOL-CELL PH, V270, pC748, DOI 10.1152/ajpcell.1996.270.3.C748; LaPlaca MC, 1999, J NEUROCHEM, V73, P205, DOI 10.1046/j.1471-4159.1999.0730205.x; Lin LH, 2000, J NEUROCHEM, V74, P1098; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Liu PK, 1999, STROKE THERAPY, P299; LIU PK, 1993, MUTAT RES, V288, P229, DOI 10.1016/0027-5107(93)90089-X; LIU PK, 1994, ANN NEUROL, V36, P566, DOI 10.1002/ana.410360405; Liu PK, 1996, J NEUROSCI, V16, P6795; LIU TH, 1989, AM J PHYSIOL, V256, pH589, DOI 10.1152/ajpheart.1989.256.2.H589; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MALINSKI T, 1993, J CEREBR BLOOD F MET, V13, P355, DOI 10.1038/jcbfm.1993.48; MECOCCI P, 1993, ANN NEUROL, V34, P609, DOI 10.1002/ana.410340416; Neve RL, 1996, TRENDS NEUROSCI, V19, P371, DOI 10.1016/S0166-2236(96)30011-8; Nunomura A, 1999, J NEUROSCI, V19, P1959; ONeill MJ, 1996, EUR J PHARMACOL, V310, P115, DOI 10.1016/0014-2999(96)00387-1; PARK EM, 1992, P NATL ACAD SCI USA, V89, P3375, DOI 10.1073/pnas.89.8.3375; Parshad R, 1996, P NATL ACAD SCI USA, V93, P5146, DOI 10.1073/pnas.93.10.5146; PERRY TL, 1982, NEUROSCI LETT, V33, P305, DOI 10.1016/0304-3940(82)90390-1; ROSENTHAL RE, 1992, FREE RADICAL BIO MED, V12, P29, DOI 10.1016/0891-5849(92)90055-L; SCHULZ JB, 1995, J NEUROCHEM, V64, P2239; Schulz JB, 1995, J NEUROSCI, V15, P8419; Smith MA, 1996, NATURE, V382, P120, DOI 10.1038/382120b0; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Solenski NJ, 1997, STROKE, V28, P2545, DOI 10.1161/01.STR.28.12.2545; Spencer JPE, 1996, BIOCHEM BIOPH RES CO, V224, P17, DOI 10.1006/bbrc.1996.0977; Wilson DM, 1998, CONT CANC RES, P29; Won MH, 1999, BRAIN RES, V836, P70, DOI 10.1016/S0006-8993(99)01611-X; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; YOSHIDA T, 1994, J CEREBR BLOOD F MET, V14, P924, DOI 10.1038/jcbfm.1994.123; ZHANG ZG, 1995, J NEUROL SCI, V128, P22, DOI 10.1016/0022-510X(94)00216-B	65	134	147	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2000	14	7					955	967						13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	309CG	10783150				2022-12-28	WOS:000086749500014
J	Kawai, S; Vora, S; Das, S; Gachie, E; Becker, B; Neufeld, AH				Kawai, S; Vora, S; Das, S; Gachie, E; Becker, B; Neufeld, AH			Modeling of risk factors for the degeneration of retinal ganglion cells after ischemia/reperfusion in rats: effects of age, caloric restriction, diabetes, pigmentation, and glaucoma	FASEB JOURNAL			English	Article									Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA	Washington University (WUSTL)	Neufeld, AH (corresponding author), Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, Box 8096,660 S Euclid Ave, St Louis, MO 63110 USA.								0	59	59	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1285	1287		10.1096/fj.00-0666fje	http://dx.doi.org/10.1096/fj.00-0666fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344115				2022-12-28	WOS:000168655200037
J	Botchkareva, NV; Khlgatian, M; Longley, BJ; Botchkarev, VA; Gilchrest, BA				Botchkareva, NV; Khlgatian, M; Longley, BJ; Botchkarev, VA; Gilchrest, BA			SCF/c-kit signaling is required for cyclic regeneration of the hair pigmentation unit	FASEB JOURNAL			English	Article						melanocyte; stem cell; hair follicle; hair cycle	STEM-CELL FACTOR; FOLLICLE REGRESSION CATAGEN; TYROSINASE-RELATED PROTEIN; C57BL/6 MOUSE SKIN; C-KIT; GROWTH-FACTOR; MELANOCYTE DEVELOPMENT; TRANSCRIPTION FACTOR; NEUROTROPHIC FACTOR; KINASE RECEPTOR	Hair graying, an age-associated process of unknown etiology, is characterized by a reduced number and activity of hair follicle (HF) melanocytes, Stem cell factor (SCF) and its receptor c-kit are important for melanocyte survival during development, and mutations in these genes result in unpigmented hairs. Here we show that during cyclic HF regeneration in C57BL/6 mice, proliferating, differentiating, and melanin-producing melanocytes express c-kit, whereas presumptive melanocyte precursors do not, SCF overexpression in HF epithelium significantly increases the number and proliferative activity of melanocytes, During the induced hair cycle in C57BL/6 mice, administration of anti-c-kit antibody dose-dependently decreases hair pigmentation and leads to partially depigmented (gray) or fully depigmented (white) hairs, associated with significant decreases in melanocyte proliferation and differentiation, as determined by immunostaining and confocal microscopy, However, in the next hair cycle, the previously treated animals grow fully pigmented hairs with the normal number and distribution of melanocytes, This suggests that melanocyte stem cells are not dependent on SCF/c-kit and when appropriately stimulated can generate melano-genically active melanocytes, Therefore, the blockade of c-kit signaling offers a fully reversible model for hair depigmentation, which might be used for the studies of hair pigmentation disorders.-Botchkareva, N. V., Khlgatian, M., Longley, B. J., Botchkarev, V. A., and Gilchrest, B. A. SCF/c-kit signaling is required for cyclic regeneration of the hair pigmentation unit.	Boston Univ, Sch Med, Dept Dermatol, Boston, MA 02118 USA; Columbia Univ, Dept Dermatol, New York, NY 10027 USA	Boston University; Columbia University	Gilchrest, BA (corresponding author), Boston Univ, Sch Med, Dept Dermatol, 609 Albany St, Boston, MA 02118 USA.			Botchkarev, Vladimir/0000-0002-5212-5353				BEERMANN F, 1990, EMBO J, V9, P2819, DOI 10.1002/j.1460-2075.1990.tb07470.x; Bertolotto C, 1998, MOL CELL BIOL, V18, P694, DOI 10.1128/MCB.18.2.694; Botchkarev VA, 1998, AM J PATHOL, V153, P785, DOI 10.1016/S0002-9440(10)65621-0; Botchkarev VA, 1997, J COMP NEUROL, V386, P379, DOI 10.1002/(SICI)1096-9861(19970929)386:3<379::AID-CNE4>3.0.CO;2-Z; Botchkarev VA, 1999, FASEB J, V13, P395, DOI 10.1096/fasebj.13.2.395; Botchkarev VA, 1999, ANN NY ACAD SCI, V885, P433; Botchkarev VA, 1999, LAB INVEST, V79, P557; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHASE HB, 1954, PHYSIOL REV, V34, P113, DOI 10.1152/physrev.1954.34.1.113; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; Ermak G, 1997, J INVEST DERMATOL, V108, P160, DOI 10.1111/1523-1747.ep12332925; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; GERDES J, 1990, EUR J CELL BIOL S43, V72, P88; Gilchrest BA, 1996, PHOTOCHEM PHOTOBIOL, V63, P1, DOI 10.1111/j.1751-1097.1996.tb02988.x; Grichnik JM, 1998, J INVEST DERMATOL, V111, P233, DOI 10.1046/j.1523-1747.1998.00272.x; Halaban R, 2000, PIGM CELL RES, V13, P4, DOI 10.1034/j.1600-0749.2000.130103.x; HALL PA, 1993, ONCOGENE, V8, P203; HARA M, 1995, J INVEST DERMATOL, V105, P744, DOI 10.1111/1523-1747.ep12325522; HEARING VJ, 1991, FASEB J, V5, P2902, DOI 10.1096/fasebj.5.14.1752358; Hearing VJ, 1999, J INVEST DERM SYMP P, V4, P24, DOI 10.1038/sj.jidsp.5640176; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; Hibberts NA, 1996, BIOCHEM BIOPH RES CO, V222, P401, DOI 10.1006/bbrc.1996.0756; Ito M, 1999, J INVEST DERMATOL, V112, P796, DOI 10.1046/j.1523-1747.1999.00552.x; JACKSON I, 1994, ANNU REV GENET, V28, P198; JACKSON IJ, 1988, P NATL ACAD SCI USA, V85, P4392, DOI 10.1073/pnas.85.12.4392; JACKSON K, 1992, SIGHT SOUND, V2, P11; JIMBOW K, 1999, FITZPATRICKS DERMATO, V1, P192; JIMENEZ M, 1988, P NATL ACAD SCI USA, V85, P3830, DOI 10.1073/pnas.85.11.3830; JIMENEZ M, 1991, J BIOL CHEM, V266, P1147; Kos L, 1999, PIGM CELL RES, V12, P13, DOI 10.1111/j.1600-0749.1999.tb00503.x; Kunisada T, 1998, DEVELOPMENT, V125, P2915; Kunisada T, 1998, J EXP MED, V187, P1565, DOI 10.1084/jem.187.10.1565; LECOIN L, 1998, MOL BASIS EPITHELIAL, P131; Lindner G, 1997, AM J PATHOL, V151, P1601; LUO D, 1995, MELANOMA RES, V5, P303, DOI 10.1097/00008390-199510000-00002; Lyle S, 1998, J CELL SCI, V111, P3179; MacKenzie MAF, 1997, DEV BIOL, V192, P99, DOI 10.1006/dbio.1997.8738; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; OKURA M, 1995, J INVEST DERMATOL, V105, P322, DOI 10.1111/1523-1747.ep12319939; Park HY, 1999, CELL MOL BIOL, V45, P919; Paus R, 1999, J INVEST DERMATOL, V113, P523, DOI 10.1046/j.1523-1747.1999.00740.x; PAUS R, 1990, BRIT J DERMATOL, V122, P777, DOI 10.1111/j.1365-2133.1990.tb06266.x; Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; PAUS R, 1996, J INVEST DERMATOL, V106, P889; PAUS R, 1996, ARCH DERMATOL RES, V290, P311; Paus Ralf, 1998, Journal of Dermatology (Tokyo), V25, P793; Schallreuter K, 1998, EXP DERMATOL, V7, P143, DOI 10.1111/j.1600-0625.1998.tb00315.x; Shindler KS, 1996, J HISTOCHEM CYTOCHEM, V44, P1331, DOI 10.1177/44.11.8918908; Slominski A, 1998, BBA-MOL CELL RES, V1448, P147, DOI 10.1016/S0167-4889(98)00124-4; Slominski A, 1996, J INVEST DERMATOL, V106, P1203, DOI 10.1111/1523-1747.ep12348479; SLOMINSKI A, 1994, J INVEST DERMATOL, V102, P862, DOI 10.1111/1523-1747.ep12382606; SLOMINSKI A, 1993, J INVEST DERMATOL, V101, pS90, DOI 10.1111/1523-1747.ep12362991; SLOMINSKI A, 1991, J INVEST DERMATOL, V96, P172, DOI 10.1111/1523-1747.ep12460956; STARICCO RG, 1960, J INVEST DERMATOL, V35, P185; STEEL KP, 1992, DEVELOPMENT, V115, P1111; SUGIYAMA S, 1979, J ULTRA MOL STRUCT R, V67, P40, DOI 10.1016/S0022-5320(79)80016-7; Sugiyama Sadao, 1995, Journal of Dermatology (Tokyo), V22, P396; Suzuki T, 1997, J HISTOCHEM CYTOCHEM, V45, P49, DOI 10.1177/002215549704500107; Tobin DJ, 1996, PIGM CELL RES, V9, P304, DOI 10.1111/j.1600-0749.1996.tb00122.x; Tobin DJ, 1998, J INVEST DERMATOL, V111, P941, DOI 10.1046/j.1523-1747.1998.00417.x; Tobin DJ, 1999, J INVEST DERM SYMP P, V4, P323, DOI 10.1038/sj.jidsp.5640239; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; WINDER A, 1994, CELL MOL BIOL RES, V40, P613; Wu M, 2000, GENE DEV, V14, P301; YAAR M, 1994, J CLIN INVEST, V94, P1550, DOI 10.1172/JCI117496; Yasumoto K, 1997, J BIOL CHEM, V272, P503; Yoshida H, 1996, DEVELOPMENT, V122, P1207; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	68	184	202	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					645	658		10.1096/fj.00-0368com	http://dx.doi.org/10.1096/fj.00-0368com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259383				2022-12-28	WOS:000167419500022
J	Longoni, B; Boschi, E; Demontis, GC; Ratto, GM; Mosca, F				Longoni, B; Boschi, E; Demontis, GC; Ratto, GM; Mosca, F			Apoptosis and adaptive responses to oxidative stress in human endothelial cells exposed to cyclosporin A correlate with BCL-2 expression levels	FASEB JOURNAL			English	Article						confocal microscopy; reactive oxygen species; antioxidants; dihydrorhodamine 123; melatonin; transplantation	GLIOMA-CELLS; COMPLEX; NEPHROTOXICITY; MITOCHONDRIA; ATTENUATION; CALCINEURIN; INHIBITION; RELAXATION; MECHANISMS; MELATONIN	Treatment of transplanted patients with cyclosporin A (CSA) may cause adverse effects such as nephrotoxicity and hypertension, As CSA is kn1own to induce oxidative stress in several tissues, it may cause vascular problems by triggering oxidative stress in endothelial cells (EC), However, oxidative stress has been reported for acute exposure to CSA concentrations exceeding its clinical range, whereas immunosuppression requires life-long treatment with therapeutic concentrations. We therefore compared the effects of 21 h pharmacological (200 muM) vs. 8 days clinical (0.5-2.5 muM) doses of CSA on cultured human EC. Pharmacological doses of CSA cause a decrease in cell density via apoptosis and a down-regulation of the antiapoptotic protein Bcl-2. However, these effects are independent of CSA-induced oxidative stress. In contrast, therapeutic concentrations of CSA cause Bcl-2 up-regulation and modification of EC morphology, both effects blocked by antioxidants, Therefore, a low level of oxidants may act in EC as second messengers that up-regulate Bcl-2, thus promoting survival of impaired EC, Our data suggest that the oxidative stress induced by clinical concentrations of CSA may be involved in the adverse effects of the drug on the vascular system of transplanted patients via an adaptive response involving Bcl-2 up-regulation rather than an apoptotic process.-Longoni, B., Boschi, E., Demontis, G. C., Ratto, C. M., Mosca, F. Apoptosis and adaptive responses to oxidative stress in human endothelial cells exposed to cyclosporin A correlate with BCL-2 expression levels.	Univ Pisa, Dept Oncol Transplants & Adv Technol Med, Sch Med, I-56124 Pisa, Italy; Univ Pisa, Dept Physiol & Biochem, Sch Med, I-56124 Pisa, Italy; Univ Pisa, Dept Psychiat & Neurobiol, Sch Med, I-56124 Pisa, Italy; CNR, Inst Neurophysiol, I-56100 Pisa, Italy	University of Pisa; University of Pisa; University of Pisa; Consiglio Nazionale delle Ricerche (CNR)	Longoni, B (corresponding author), Univ Pisa, Dept Oncol Transplants & Adv Technol Med, Sch Med, Via Paradisa 2, I-56124 Pisa, Italy.	biancam@dfb.unipi.it	Demontis, Gian Carlo A.G./K-6963-2016; Ratto, Gian Michele/AAX-8514-2020; Ratto, Gian Michele/AAB-8719-2021	Demontis, Gian Carlo A.G./0000-0001-7641-0426; Ratto, Gian Michele/0000-0001-9632-7769				Armitage P., 1971, STAT METHODS MED RES, V1; Baliga R, 1999, DRUG METAB REV, V31, P971, DOI 10.1081/DMR-100101947; Bergmeyer HU, 1974, METHODS ENZYMATIC AN; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CLARDY J, 1995, P NATL ACAD SCI USA, V92, P56, DOI 10.1073/pnas.92.1.56; CROMPTON M, 1988, BIOCHEM J, V255, P357; Davies KJA, 1999, IUBMB LIFE, V48, P41, DOI 10.1080/152165499307404; DIEDERICH D, 1994, HYPERTENSION, V23, P957, DOI 10.1161/01.HYP.23.6.957; Durak I, 1998, NEPHRON, V78, P207, DOI 10.1159/000044912; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; FURCHGOTT RF, 1984, J CARDIOVASC PHARM, V6, pS336, DOI 10.1097/00005344-198406002-00008; GERKENS JF, 1989, J PHARMACOL EXP THER, V250, P1105; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GRIFFITH TM, 1984, NATURE, V308, P645, DOI 10.1038/308645a0; Hiroyasu S, 1999, J SURG RES, V84, P204, DOI 10.1006/jsre.1999.5644; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jansen B, 1998, NAT MED, V4, P232, DOI 10.1038/nm0298-232; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kumar KV, 1999, TRANSPLANTATION, V67, P1065, DOI 10.1097/00007890-199904150-00022; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Longoni B, 1999, BIOCHEM BIOPH RES CO, V260, P522, DOI 10.1006/bbrc.1999.0928; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Mosieniak G, 1997, J NEUROCHEM, V68, P1142; MYERS BD, 1988, TRANSPLANTATION, V46, P694, DOI 10.1097/00007890-198811000-00014; MYERS BD, 1988, KIDNEY INT, V33, P590, DOI 10.1038/ki.1988.38; PFLUGL G, 1993, NATURE, V361, P91, DOI 10.1038/361091a0; POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x; Pyrzynska B, 2000, J NEUROCHEM, V74, P42, DOI 10.1046/j.1471-4159.2000.0740042.x; REGO A, 1990, J PHARMACOL EXP THER, V252, P165; Reiter RJ, 1999, ADV EXP MED BIOL, V467, P379; Schechner JS, 2000, P NATL ACAD SCI USA, V97, P9191, DOI 10.1073/pnas.150242297; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; STEPHAN D, 1995, J CARDIOVASC PHARM, V26, P859, DOI 10.1097/00005344-199512000-00003; SWANSON SKH, 1992, P NATL ACAD SCI USA, V89, P3741, DOI 10.1073/pnas.89.9.3741; THERIAULT Y, 1993, NATURE, V361, P88, DOI 10.1038/361088a0; Thom SR, 2000, P NATL ACAD SCI USA, V97, P1305, DOI 10.1073/pnas.97.3.1305; WANG CY, 1995, KIDNEY INT, V47, P927, DOI 10.1038/ki.1995.138; WANG CY, 1994, TRANSPLANTATION, V58, P940, DOI 10.1097/00007890-199410270-00014; Wolf A, 1997, J PHARMACOL EXP THER, V280, P1328; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZOJA C, 1986, LAB INVEST, V55, P455	43	49	49	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2001	15	3					731	740		10.1096/fj.00-0163com	http://dx.doi.org/10.1096/fj.00-0163com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259391				2022-12-28	WOS:000167419500030
J	St-Amand, J; Okamura, K; Matsumoto, K; Shimizu, S; Sogawa, Y				St-Amand, J; Okamura, K; Matsumoto, K; Shimizu, S; Sogawa, Y			Characterization of control and immobilized skeletal muscle: an overview from genetic engineering	FASEB JOURNAL			English	Article						muscle atrophy; mRNA; serial analysis of gene expression (SAGE); sarcopenia; gene regulation	EXPRESSED SEQUENCE TAGS; MESSENGER-RNA; SERIAL ANALYSIS; CHROMOSOMAL LOCALIZATION; SELENOPROTEIN-W; CDNA LIBRARY; HUMAN-GENOME; CELL-CYCLE; RAT; ATROPHY	To elucidate the molecular basis of muscle atrophy, we have performed the serial analysis of gene expression (SAGE) method with control and immobilized muscles of 10 rats. The genes that expressed >0.5% in muscle are involved in the following three functions: I) contraction (troponin I, C and T; myosin light chain 1-3; actin; tropomyosin; and parvalbumin), 2) energy metabolism (cytochrome c oxidase I and III, creatine kinase, glyceraldehyde-3-phosphate-dehydrogenase, phosphoglycerate mutase, ATPase 6, and aldolase A), and 3) housekeeping (lens epithelial protein). Muscle atrophy appears to be caused by changes in mRNA levels of specific regulators of proteolysis, protein synthesis, and contractile apparatus assembling, such as polyubiquitin, elongation factor 2, and nebulin. Immobilization has produced a decrease more than threefold in gene expression of enzymes involved in energy metabolism, especially ATPase, cytochrome c oxidase, NADH dehydrogenase, and protein phosphatase 1. Differential gene expressions of selenoprotein W and uroporphyrinogen decarboxylase, which can be involved in oxidative stress, were also observed. Other genes with various functions, such as cholesterol metabolism and growth factors, were also differentially expressed. Moreover, novel genes regulated by immobilization were discovered. Thus, the current study allows a better understanding of global muscle characteristics and the molecular mechanisms of sedentarity and sarcopenia.-St-Amand, J., Okamura, IC, Matsumoto, K., Shimizu, S., Sogawa, Y. Characterization of control and immobilized skeletal muscle: an overview from genetic engineering.	Otsuka Pharmaceut Co Ltd, Saga Res Inst, Saga 8420195, Japan	Otsuka Pharmaceutical	St-Amand, J (corresponding author), Louisiana State Univ, Pennington Biomed Res Ctr, Human Genom Lab, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.			St-Amand, Jonny/0000-0002-2595-6127				ADAMS GR, 1995, J CELL PHYSL, V79, P368; APPELL HJ, 1990, SPORTS MED, V10, P42, DOI 10.2165/00007256-199010010-00005; Appell HJ, 1997, INT J SPORTS MED, V18, P157; Argyropoulos G, 1998, J LIPID RES, V39, P1870; Baldwin KM, 1996, MED SCI SPORT EXER, V28, P983, DOI 10.1097/00005768-199608000-00008; Beilstein MA, 1996, J INORG BIOCHEM, V61, P117, DOI 10.1016/0162-0134(95)00045-3; Booth FW, 1996, J APPL PHYSIOL, V81, P1941, DOI 10.1152/jappl.1996.81.5.1941; BOUCHARD C, 1993, ANNU REV NUTR, V13, P337, DOI 10.1146/annurev.nu.13.070193.002005; BREITBART RE, 1986, J MOL BIOL, V188, P313, DOI 10.1016/0022-2836(86)90157-9; Chen HX, 1998, J EXP MED, V188, P1657, DOI 10.1084/jem.188.9.1657; CHEN MJG, 1993, J BIOL CHEM, V268, P20327; CHOMYN A, 1986, SCIENCE, V234, P614, DOI 10.1126/science.3764430; Collins FS, 1999, NEW ENGL J MED, V341, P28, DOI 10.1056/NEJM199907013410106; Cros N, 1999, AM J PHYSIOL-REG I, V276, pR308, DOI 10.1152/ajpregu.1999.276.2.R308; Datson NA, 1999, NUCLEIC ACIDS RES, V27, P1300, DOI 10.1093/nar/27.5.1300; EPSTEIN P, 1986, J BIOL CHEM, V261, P5886; EVANS WJ, 1995, J GERONTOL A-BIOL, V50, P5, DOI 10.1093/gerona/50A.Special_Issue.5; Gonzalez-Zulueta M, 1998, J NEUROSCI, V18, P2040; HERBISON GJ, 1978, ARCH PHYS MED REHAB, V59, P301; Holben DH, 1999, J AM DIET ASSOC, V99, P836, DOI 10.1016/S0002-8223(99)00198-4; Horne MC, 1996, J BIOL CHEM, V271, P6050, DOI 10.1074/jbc.271.11.6050; HOULGATTE R, 1995, GENOME RES, V5, P272, DOI 10.1101/gr.5.3.272; HWANG DM, 1995, GENOMICS, V30, P293, DOI 10.1006/geno.1995.9874; INOUE C, 1988, BIOCHEM BIOPH RES CO, V150, P1302, DOI 10.1016/0006-291X(88)90771-1; JABS EW, 1994, HUM GENET, V93, P600; Jankala H, 1997, J APPL PHYSIOL, V82, P977, DOI 10.1152/jappl.1997.82.3.977; Kenzelmann M, 1999, NUCLEIC ACIDS RES, V27, P917, DOI 10.1093/nar/27.3.917; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; KONDO H, 1993, AM J PHYSIOL, V265, pE839, DOI 10.1152/ajpendo.1993.265.6.E839; Lanfranchi G, 1996, GENOME RES, V6, P35, DOI 10.1101/gr.6.1.35; Lecker SH, 1999, J NUTR, V129, p227S, DOI 10.1093/jn/129.1.227S; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Lenka N, 1998, PROG NUCLEIC ACID RE, V61, P309, DOI 10.1016/S0079-6603(08)60830-2; Leung MK, 1999, GENOMICS, V61, P307, DOI 10.1006/geno.1999.5970; LOPEZFERNANDEZ LA, 1995, BBA-GENE STRUCT EXPR, V1263, P10, DOI 10.1016/0167-4781(95)00065-O; MCKNIGHT GL, 1992, J BIOL CHEM, V267, P12131; MEDINA R, 1995, BIOCHEM J, V307, P631, DOI 10.1042/bj3070631; MURPHY WI, 1975, J MOL BIOL, V99, P809, DOI 10.1016/S0022-2836(75)80187-2; MURRAY RK, 1993, HARPERS BIOCH, P647; NISHIO Y, 1994, FASEB J, V8, P103, DOI 10.1096/fasebj.8.1.8299882; OJALA D, 1981, NATURE, V290, P470, DOI 10.1038/290470a0; Pennisi E, 1999, SCIENCE, V286, P449, DOI 10.1126/science.286.5439.449; PERIASAMY M, 1984, J BIOL CHEM, V259, P3595; POEHLMAN ET, 1992, METABOLISM, V41, P1351, DOI 10.1016/0026-0495(92)90107-L; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; RUIZOPAZO N, 1987, J BIOL CHEM, V262, P4755; Sanchez JC, 1997, ELECTROPHORESIS, V18, P150, DOI 10.1002/elps.1150180127; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; SCHLERF A, 1988, EMBO J, V7, P2387, DOI 10.1002/j.1460-2075.1988.tb03083.x; Schwaller B, 1999, AM J PHYSIOL-CELL PH, V276, pC395, DOI 10.1152/ajpcell.1999.276.2.C395; SHIMOMURA Y, 1984, J BIOL CHEM, V259, P4059; SIMONEAU JA, 1989, AM J PHYSIOL, V257, pE567, DOI 10.1152/ajpendo.1989.257.4.E567; St-Amand J, 1999, MED SCI SPORT EXER, V31, P692, DOI 10.1097/00005768-199905000-00011; TZAGOLOFF A, 1986, ANNU REV BIOCHEM, V55, P249, DOI 10.1146/annurev.bi.55.070186.001341; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; VENDELAND SC, 1995, P NATL ACAD SCI USA, V92, P8749, DOI 10.1073/pnas.92.19.8749; Welle S, 1999, GENOME RES, V9, P506; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	61	81	83	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					684	692		10.1096/fj.00-0150com	http://dx.doi.org/10.1096/fj.00-0150com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259386				2022-12-28	WOS:000167419500025
J	Greiwe, JS; Cheng, B; Rubin, DC; Yarasheski, KE; Semenkovich, CF				Greiwe, JS; Cheng, B; Rubin, DC; Yarasheski, KE; Semenkovich, CF			Resistance exercise decreases skeletal muscle tumor necrosis factor alpha in frail elderly humans	FASEB JOURNAL			English	Article						cytokines; sarcopenia; aging; lipoprotein lipase	PROTEIN-SYNTHESIS RATE; NF-KAPPA-B; LIPOPROTEIN-LIPASE; BODY-COMPOSITION; ADIPOSE-TISSUE; TNF-ALPHA; MEN; METABOLISM; EXPRESSION; WOMEN	Skeletal muscle protein and function decline with advancing age but the underlying pathophysiology is poorly understood. To test the hypothesis that the catabolic cytokine tumor necrosis factor alpha (TNF-alpha) contributes to this process, we studied the effects of aging and resistance exercise on TNF-alpha expression in human muscle. Using in situ hybridization, TNF-ar message was localized to myocytes in sections of skeletal muscle from elderly humans. Both TNF-alpha mRNA and protein levels were elevated in skeletal muscle from frail elderly (81+/-1 year) as com pared to healthy young (23+/-1 year) men and women. To determine whether resistance exercise affects TNF-alpha expression, frail elderly men and women were randomly assigned to a training group or to a nonexercising control group. Muscle biopsies were performed before and after 3 months. Muscle TNF-alpha mRNA and protein levels decreased in the exercise group but did nor change in the control group. Muscle protein synthesis rate in the exercise group was inversely related to levels of TNF-ol protein. These data suggest that TNF-alpha contributes to age-associated muscle wasting and that resistance exercise may attenuate this process by suppressing skeletal muscle TNF-alpha expression.	Washington Univ, Sch Med, Claude D Pepper Older Amer Independence Ctr, Ctr Cardiovasc Res,Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Claude D Pepper Older Amer Independence Ctr, Ctr Cardiovasc Res,Dept Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Semenkovich, CF (corresponding author), Washington Univ, Sch Med, Claude D Pepper Older Amer Independence Ctr, Ctr Cardiovasc Res,Dept Med, Box 8046,660 S Euclid Ave, St Louis, MO 63110 USA.		Yarasheski, Kevin E/A-3025-2008; Yarasheski, Kevin/AAC-7450-2021	Yarasheski, Kevin/0000-0001-5436-2451; Rubin, Deborah/0000-0002-4192-909X; Semenkovich, Clay/0000-0003-1163-1871	NCRR NIH HHS [P41 RR000954] Funding Source: Medline; NIA NIH HHS [AG14658, AG13629, P60 AG013629] Funding Source: Medline; NIDDK NIH HHS [DK53198] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P60AG013629, R01AG014658] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AHMAD S, 1994, LIFE SCI, V55, P1383, DOI 10.1016/0024-3205(94)00752-7; Akama KT, 2000, J BIOL CHEM, V275, P7918, DOI 10.1074/jbc.275.11.7918; Baumgartner RN, 1998, AM J EPIDEMIOL, V147, P755, DOI 10.1093/oxfordjournals.aje.a009520; Baumgartner RN, 1999, AM J EPIDEMIOL, V149, P1161; BEUTLER B, 1985, J EXP MED, V161, P984, DOI 10.1084/jem.161.5.984; Borisov AB, 2000, ANAT RECORD, V258, P305; Bruunsgaard H, 1999, J GERONTOL A-BIOL, V54, pM357, DOI 10.1093/gerona/54.7.M357; Cheema IR, 1999, CYTOBIOS, V97, P133; Cohen HJ, 1997, J GERONTOL A-BIOL, V52, pM201, DOI 10.1093/gerona/52A.4.M201; DINNEEN S, 1992, NEW ENGL J MED, V327, P707, DOI 10.1056/NEJM199209033271007; ESPAT NJ, 1994, SURG ONCOL, V3, P255, DOI 10.1016/0960-7404(94)90027-2; Frost RA, 1997, ENDOCRINOLOGY, V138, P4153, DOI 10.1210/en.138.10.4153; FUKAGAWA NK, 1990, AM J PHYSIOL, V259, pE233, DOI 10.1152/ajpendo.1990.259.2.E233; GARCIAMARTINEZ C, 1993, MOL CELL BIOCHEM, V125, P11, DOI 10.1007/BF00926829; GOODMAN MN, 1991, AM J PHYSIOL, V260, pE727, DOI 10.1152/ajpendo.1991.260.5.E727; HAGER K, 1994, NEUROBIOL AGING, V15, P771, DOI 10.1016/0197-4580(94)90066-3; Hambrecht R, 1999, J AM COLL CARDIOL, V33, P174, DOI 10.1016/S0735-1097(98)00531-2; KERN PA, 1995, J CLIN INVEST, V95, P2111, DOI 10.1172/JCI117899; Kohrt WM, 1998, J APPL PHYSIOL, V84, P372, DOI 10.1152/jappl.1998.84.1.372; Ledgerwood EC, 1999, LAB INVEST, V79, P1041; Li YP, 1998, FASEB J, V12, P871, DOI 10.1096/fasebj.12.10.871; LITHELL H, 1981, DIABETES, V30, P19, DOI 10.2337/diabetes.30.1.19; McArdle A, 1999, LAB INVEST, V79, P1069; Migheli A, 1997, NEUROGENETICS, V1, P81, DOI 10.1007/s100480050012; Morin CL, 1997, J GERONTOL A-BIOL, V52, pB190, DOI 10.1093/gerona/52A.4.B190; Paolisso G, 1998, AM J PHYSIOL-ENDOC M, V275, pE294, DOI 10.1152/ajpendo.1998.275.2.E294; POEHLMAN ET, 1995, ARCH INTERN MED, V155, P2443, DOI 10.1001/archinte.155.22.2443; REUBEN DB, 1992, J GERONTOL, V47, pM106, DOI 10.1093/geronj/47.4.M106; REUBEN DB, 1990, J AM GERIATR SOC, V38, P1105, DOI 10.1111/j.1532-5415.1990.tb01373.x; Rooyackers OE, 1996, P NATL ACAD SCI USA, V93, P15364, DOI 10.1073/pnas.93.26.15364; Saghizadeh M, 1996, J CLIN INVEST, V97, P1111, DOI 10.1172/JCI118504; Sakurai Y, 1996, AM J PHYSIOL-ENDOC M, V270, pE864, DOI 10.1152/ajpendo.1996.270.5.E864; Seip RL, 1997, AM J PHYSIOL-ENDOC M, V272, pE255; SEIP RL, 1995, AM J PHYSIOL-ENDOC M, V268, pE229, DOI 10.1152/ajpendo.1995.268.2.E229; Short K R, 2000, Curr Opin Clin Nutr Metab Care, V3, P39, DOI 10.1097/00075197-200001000-00007; Spencer NFL, 1997, INT IMMUNOL, V9, P1581, DOI 10.1093/intimm/9.10.1581; TESSITORE L, 1993, FASEB J, V12, P871; Yarasheski KE, 1999, AM J PHYSIOL-ENDOC M, V277, pE118, DOI 10.1152/ajpendo.1999.277.1.E118; YARASHESKI KE, 1993, AM J PHYSIOL, V265, pE210, DOI 10.1152/ajpendo.1993.265.2.E210; ZURLO F, 1994, METABOLISM, V43, P481, DOI 10.1016/0026-0495(94)90081-7; [No title captured]	41	333	343	0	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					475	482		10.1096/fj.00-0274com	http://dx.doi.org/10.1096/fj.00-0274com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156963				2022-12-28	WOS:000166872900029
J	Bruzzone, S; Guida, L; Zocchi, E; Franco, L; De Flora, A				Bruzzone, S; Guida, L; Zocchi, E; Franco, L; De Flora, A			Connexin 43 hemi channels mediate Ca2+-regulated transmembrane NAD(+) fluxes in intact cells	FASEB JOURNAL			English	Article									Univ Genoa, Dept Expt Med, Biochem Sect, I-16132 Genoa, Italy; Univ Naples Federico II, CNR, Biocrystallog Ctr, I-80134 Naples, Italy	University of Genoa; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II	De Flora, A (corresponding author), Univ Genoa, Dept Expt Med, Biochem Sect, Viale Benedetto XV 1, I-16132 Genoa, Italy.		Bruzzone, Santina/A-4264-2015	Bruzzone, Santina/0000-0003-2034-3716					0	390	396	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2001	15	1					10	12						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11099492				2022-12-28	WOS:000166312400004
J	Hiltunen, MO; Turunen, MP; Turunen, AM; Rissanen, TT; Laitinen, M; Kosma, VM; Yla-Herttuala, S				Hiltunen, MO; Turunen, MP; Turunen, AM; Rissanen, TT; Laitinen, M; Kosma, VM; Yla-Herttuala, S			Biodistribution of adenoviral vector to nontarget tissues after local in vivo gene transfer to arterial wall using intravascular and periadventitial gene delivery methods	FASEB JOURNAL			English	Article						adenovirus; biodistribution; vascular gene therapy	CAROTID-ARTERY; RECOMBINANT ADENOVIRUS; RETROVIRUSES; COMPLEXES; INVIVO	Expression of transgene other than in the target tissue may cause side effects and safety problems in gene therapy. We analyzed biodistribution of transgene expression after intravascular and periadventitial gene delivery methods using the first generation nuclear-targeted lacZ adenovirus. RT-PCR and X-Gal stainings were used to study transgene expression 14 days after the gene transfer. After intravascular catheter-mediated gene transfer to rabbit aorta mimicking angioplasty procedure, the target vessel showed 1.1% +/- 0.5 gene transfer efficiency. Other tissues showed varying lacZ gene expression indicating a systemic leakage of the vector with the highest transfection efficiency in hepatocytes (0.7% +/- 0.5). X-Gal staining of blood cells 24 h after the intravascular gene transfer indicated that a significant portion (1.8% +/- 0.8) of circulating monocytes was transfected. X-Gal-positive cells were also found in testis. After periadventitial gene transfer using a closed silicon capsule placed around the artery, 0.1% +/- 0.1 lacZ-positive cells were detected in the artery wall. Positive cells were also found in the liver and testis (<0.01%), indicating that the virus escapes even from the periadventitial space, although less extensively than during the intravascular application. We conclude that catheter-mediated intravascular and, to a lesser extent, periadventitial gene transfer lead to leakage of adenovirus to systemic circulation, followed by expression of the transgene in several tissues. Possible consequences of the ectopic expression of the transgene should be evaluated in gene therapy trials even if local gene delivery methods are used.	Univ Kuopio, AI Virtanen Inst, Dept Mol Med, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Med, FIN-70211 Kuopio, Finland; Univ Kuopio, Gene Therapy Unit, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Pathol & Forens Med, FIN-70211 Kuopio, Finland	Finland National Institute for Health & Welfare; University of Eastern Finland; University of Eastern Finland; University of Eastern Finland; University of Eastern Finland	Yla-Herttuala, S (corresponding author), Univ Kuopio, AI Virtanen Inst, Dept Mol Med, FIN-70211 Kuopio, Finland.			Rissanen, Tuomas/0000-0002-1914-2282; Yla-Herttuala, Seppo/0000-0001-7593-2708				BARR E, 1994, GENE THER, V1, P51; *CELL GEN THER PRO, US PHARM, pCH104; HERMANN KL, 1988, LAB DIAGNOSIS INFECT, V2, P82; Laitinen M, 1998, HUM GENE THER, V9, P1481, DOI 10.1089/hum.1998.9.10-1481; Laitinen M, 1997, HUM GENE THER, V8, P1737, DOI 10.1089/hum.1997.8.15-1737; Laitinen M, 1997, HUM GENE THER, V8, P1645, DOI 10.1089/hum.1997.8.14-1645; Lehrman S, 1999, NATURE, V401, P517, DOI 10.1038/43977; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; Palasis M, 2000, HUM GENE THER, V11, P237, DOI 10.1089/10430340050015987; Puumalainen AM, 1998, HUM GENE THER, V9, P1769, DOI 10.1089/hum.1998.9.12-1769; SOMA MR, 1993, ARTERIOSCLER THROMB, V13, P571, DOI 10.1161/01.ATV.13.4.571; STEG PG, 1994, CIRCULATION, V90, P1648, DOI 10.1161/01.CIR.90.4.1648; Turunen MP, 1999, GENE THER, V6, P6, DOI 10.1038/sj.gt.3300800; van der Eb MM, 1998, GENE THER, V5, P451, DOI 10.1038/sj.gt.3300637; VanPut DJM, 1995, EUR J PHARMACOL, V294, P753, DOI 10.1016/0014-2999(95)00635-4; WILLARD JE, 1994, CIRCULATION, V89, P2190, DOI 10.1161/01.CIR.89.5.2190; Ye XH, 1998, HUM GENE THER, V9, P2135, DOI 10.1089/hum.1998.9.14-2135; Yla-Herttuala S, 2000, LANCET, V355, P213, DOI 10.1016/S0140-6736(99)04180-X; YLAHERTTUALA S, 1995, J CLIN INVEST, V95, P2692, DOI 10.1172/JCI117971	19	77	77	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2230	2236		10.1096/fj.00-0145com	http://dx.doi.org/10.1096/fj.00-0145com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053244				2022-12-28	WOS:000165190800016
J	Durante, W; Liao, L; Reyna, SV; Peyton, KJ; Schafer, AI				Durante, W; Liao, L; Reyna, SV; Peyton, KJ; Schafer, AI			Physiological cyclic stretch directs L-arginine transport and metabolism to collagen synthesis in vascular smooth muscle	FASEB JOURNAL			English	Article						biomechanical strain; L-proline; cationic amino acid transporter; arginase; vascular cells	NITRIC-OXIDE SYNTHASE; AMINO-ACID TRANSPORTER; NECROSIS-FACTOR-ALPHA; RAT-LIVER ARGINASE; GENE-EXPRESSION; GROWTH-FACTOR; MECHANICAL STIMULATION; CELL-PROLIFERATION; ANGIOTENSIN-II; INDUCTION	Application of cyclic stretch (10% at 1 hertz) to vascular smooth muscle cells (SMC) increased L-arginine uptake and this was associated with a specific increase in cationic amino acid transporter-2 (CAT-2) mRNA. In addition, cyclic stretch stimulated L-arginine metabolism by inducing arginase I mRNA and arginase activity. In contrast, cyclic stretch inhibited the catabolism of L-arginine to nitric oxide (NO) by blocking inducible NO synthase expression. Exposure of SMC to cyclic stretch markedly increased the capacity of SMC to generate L-proline from L-arginine while inhibiting the formation of polyamines. The stretch-mediated increase in L-proline production was reversed by methyl-L-arginine, a competitive inhibitor of L-arginine transport, by hydroxy-L-arginine, an arginase inhibitor, or by the ornithine aminotransferase inhibitor L-canaline. Finally, cyclic stretch stimulated collagen synthesis and the accumulation of type I collagen, which was inhibited by L-canaline. These results demonstrate that cyclic stretch coordinately stimulates L-proline synthesis by regulating the genes that modulate the transport and metabolism of L-arginine. In addition, they show that stretch-stimulated collagen production is dependent on L-proline formation. The ability of hemodynamic forces to up-regulate L-arginine transport and direct its metabolism to L-proline may play an important role in stabilizing vascular lesions by promoting SMC collagen synthesis.	Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Durante, W (corresponding author), Vet Adm Med Ctr, Bldg 109,Room 130,2002 Holcombe Blvd, Houston, TX 77030 USA.	wdurante@bcm.tmc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062467, R01HL059976, R01HL036045] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-36045, HL-62467, HL-59976] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; AWOLESI MA, 1995, J CLIN INVEST, V96, P1449, DOI 10.1172/JCI118181; BENES AJ, 1985, J CELL SCI, V75, P35; BUNTIN CM, 1990, ANN BIOMED ENG, V18, P549, DOI 10.1007/BF02364617; BUSSE R, 1990, FEBS LETT, V275, P87, DOI 10.1016/0014-5793(90)81445-T; Chapman GB, 2000, AM J PHYSIOL-HEART C, V278, pH748, DOI 10.1152/ajpheart.2000.278.3.H748; CLOSS EI, 1993, J BIOL CHEM, V268, P20796; CLOSS EI, 1993, J BIOL CHEM, V268, P7538; DAGHIGH F, 1994, BIOCHEM BIOPH RES CO, V202, P174, DOI 10.1006/bbrc.1994.1909; DARTSCH PC, 1986, EUR J CELL BIOL, V41, P339; Dethlefsen SM, 1996, J VASC RES, V33, P405, DOI 10.1159/000159169; DIZIKES GJ, 1986, BIOCHEM BIOPH RES CO, V141, P53, DOI 10.1016/S0006-291X(86)80333-3; DOBRIN PB, 1978, PHYSIOL REV, V58, P397, DOI 10.1152/physrev.1978.58.2.397; Durante W, 1996, CIRC RES, V78, P1075, DOI 10.1161/01.RES.78.6.1075; DURANTE W, 1995, AM J PHYSIOL-HEART C, V268, pH1158; DURANTE W, 1993, AM J PHYSIOL, V264, pH617, DOI 10.1152/ajpheart.1993.264.2.H617; Durante W, 1996, P ASSOC AM PHYSICIAN, V108, P356; Durante W, 1996, J BIOL CHEM, V271, P11838, DOI 10.1074/jbc.271.20.11838; Durante W, 1998, CIRC RES, V83, P217, DOI 10.1161/01.RES.83.2.217; Durante W, 1997, J BIOL CHEM, V272, P30154, DOI 10.1074/jbc.272.48.30154; ENDEAN ED, 1991, J SURG RES, V50, P634, DOI 10.1016/0022-4804(91)90054-P; Geng YJ, 1996, ARTERIOSCL THROM VAS, V16, P19, DOI 10.1161/01.ATV.16.1.19; Gill DJ, 1996, J BIOL CHEM, V271, P11280, DOI 10.1074/jbc.271.19.11280; Gotoh T, 1996, FEBS LETT, V395, P119, DOI 10.1016/0014-5793(96)01015-0; Hosokawa H, 1997, J BIOL CHEM, V272, P8717, DOI 10.1074/jbc.272.13.8717; Iwashina M, 1998, CIRCULATION, V98, P1212, DOI 10.1161/01.CIR.98.12.1212; Jenkinson CP, 1996, COMP BIOCHEM PHYS B, V114, P107, DOI 10.1016/0305-0491(95)02138-8; JONES ME, 1985, J NUTR, V115, P509, DOI 10.1093/jn/115.4.509; KAWAMOTO S, 1987, J BIOL CHEM, V262, P6280; KIM HR, 1994, ANAL BIOCHEM, V223, P205, DOI 10.1006/abio.1994.1574; KITO K, 1978, J BIOCHEM-TOKYO, V83, P201, DOI 10.1093/oxfordjournals.jbchem.a131892; KOLPAKOV V, 1995, CIRC RES, V76, P305, DOI 10.1161/01.RES.76.2.305; KULIK TJ, 1993, J CELL PHYSIOL, V157, P615, DOI 10.1002/jcp.1041570322; Lee RT, 1997, ARTERIOSCL THROM VAS, V17, P1859, DOI 10.1161/01.ATV.17.10.1859; LEUNG DYM, 1976, SCIENCE, V191, P475; Li Q, 1998, J VASC RES, V35, P93, DOI 10.1159/000025570; LOW BC, 1995, J BIOL CHEM, V270, P27577, DOI 10.1074/jbc.270.46.27577; LOW BC, 1993, J CELL PHYSIOL, V156, P626, DOI 10.1002/jcp.1041560323; MACLEOD CL, 1990, MOL CELL BIOL, V10, P3663, DOI 10.1128/MCB.10.7.3663; Mills I, 1997, J CELL PHYSIOL, V170, P228, DOI 10.1002/(SICI)1097-4652(199703)170:3<228::AID-JCP2>3.0.CO;2-Q; PETERKOFSKY B, 1971, BIOCHEMISTRY-US, V10, P988, DOI 10.1021/bi00782a009; Reusch P, 1996, CIRC RES, V79, P1046, DOI 10.1161/01.RES.79.5.1046; SPECTOR EB, 1994, INT J DEV NEUROSCI, V12, P337, DOI 10.1016/0736-5748(94)90083-3; STRECKER HJ, 1965, J BIOL CHEM, V240, P1225; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; THYBERG J, 1987, EXP CELL RES, V170, P160, DOI 10.1016/0014-4827(87)90125-X; WHITE MF, 1985, BIOCHIM BIOPHYS ACTA, V822, P355, DOI 10.1016/0304-4157(85)90015-2; WILSON E, 1993, J CELL BIOL, V123, P741, DOI 10.1083/jcb.123.3.741; Wu GY, 1998, BIOCHEM J, V336, P1, DOI 10.1042/bj3360001; Yamamoto K, 1998, J BIOL CHEM, V273, P11862, DOI 10.1074/jbc.273.19.11862; Yang JH, 1998, J BIOL CHEM, V273, P6550, DOI 10.1074/jbc.273.11.6550	51	65	66	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2000	14	12					1775	1783		10.1096/fj.99-0960com	http://dx.doi.org/10.1096/fj.99-0960com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973927				2022-12-28	WOS:000089212400017
J	Magdinier, F; Billard, LM; Wittmann, G; Frappart, L; Benchaib, M; Lenoir, GM; Guerin, JF; Dante, R				Magdinier, F; Billard, LM; Wittmann, G; Frappart, L; Benchaib, M; Lenoir, GM; Guerin, JF; Dante, R			Regional methylation of the 5 ' end CpG island of BRCA1 is associated with reduced gene expression in human somatic cells	FASEB JOURNAL			English	Article						DNA methylation; oocytes; spermatozoa; breast cancer	SPORADIC BREAST-CANCER; HISTONE DEACETYLASE COMPLEX; DNA METHYLATION; BINDING-PROTEIN; TRANSCRIPTIONAL REPRESSOR; PROMOTER REGION; MECP2; LOCALIZATION; CHROMATIN; LINES	In mammalians, demethylation of specific promoter regions often correlates with gene activation; inversely, dense methylation of CpG islands leads to gene silencing, probably mediated by methyl-CpG binding proteins. In cell Lines and cancers, inhibition of tissue-specific genes and tumor suppressor genes expression seems to be related to such hypermethylation. The 5' end of the breast cancer predisposition gene BRCA1 is embedded in a large CpG island of similar to 2.7 kb in length. In human sporadic breast cancers, the down-regulation of BRCA1 does not seem to be related to BRCA1 gene alterations. Southern blot analysis and the bisulfite sequencing method indicate that the BRCA1 CpG island is regionally methylated in all human tissues analyzed and unmethylated in the gametes, suggesting a role for DNA methylation in the control of gene expression. We have therefore investigated the potential role of methyl-CpG binding proteins in the regulation of BRCA1 gene expression. In vitro, partial methylation of constructs containing this region strongly inhibits gene expression in the presence of MeCP2 protein. Moreover, iu the five human cell lines analyzed, chemically induced hypomethylation is associated with BRCA1 gene activation. These data suggest that methyl-CpG binding proteins might be associated with the control of BRCA1 gene expression and that methyl-DNA binding proteins may participate in the regulation of gene expression in mammalian cells.	UCBL1, UMR 5641, Genet Lab, F-69373 Lyon 08, France; UCBL1, Lab Biol Reprod & Dev, F-69373 Lyon, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Dante, R (corresponding author), UCBL1, UMR 5641, Genet Lab, Domaine Rockefeller,8 Ave Rockefeller, F-69373 Lyon 08, France.		Magdinier, Frederique/I-4735-2016; , Benchaib/AAE-7278-2020; Benchaib, Mehdi/AAO-2976-2021	Magdinier, Frederique/0000-0002-0159-9559; 				ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; Baylin Stephen B., 1997, V72, P141; Blackshear PE, 1998, ONCOGENE, V16, P61, DOI 10.1038/sj.onc.1201506; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; Chambers JA, 1996, GENOMICS, V38, P305, DOI 10.1006/geno.1996.0633; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Constancia M, 1998, GENOME RES, V8, P881, DOI 10.1101/gr.8.9.881; Dobrovic A, 1997, CANCER RES, V57, P3347; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; Magdinier F, 1999, ONCOGENE, V18, P4039, DOI 10.1038/sj.onc.1202780; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; Martin V, 1997, J CELL BIOCHEM, V65, P95, DOI 10.1002/(SICI)1097-4644(199704)65:1<95::AID-JCB10>3.0.CO;2-G; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; NAN X, 1997, CELL, V88, P1; Nan XS, 1996, MOL CELL BIOL, V16, P414; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Ribieras S, 1997, INT J CANCER, V73, P715, DOI 10.1002/(SICI)1097-0215(19971127)73:5<715::AID-IJC17>3.0.CO;2-4; Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086; Sambrook J., 2002, MOL CLONING LAB MANU; SMITH AP, 1992, HDB HUMAN PERFORMANC, V2, P1; Smith TM, 1996, GENOME RES, V6, P1029, DOI 10.1101/gr.6.11.1029; Suen TC, 1999, J BIOL CHEM, V274, P31297, DOI 10.1074/jbc.274.44.31297; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Thakur S, 1999, J BIOL CHEM, V274, P8837, DOI 10.1074/jbc.274.13.8837; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; TOH Y, 1994, J BIOL CHEM, V269, P22958; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; XU C, 1997, J BIOL CHEM, V34, P20994; Xu CF, 1997, HUM MOL GENET, V6, P1057, DOI 10.1093/hmg/6.7.1057; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743	43	60	70	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2000	14	11					1585	1594		10.1096/fj.14.11.1585	http://dx.doi.org/10.1096/fj.14.11.1585			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CN	10928993	Green Submitted			2022-12-28	WOS:000088627800013
J	Fanciulli, M; Bruno, T; Di Padova, M; De Angelis, R; Iezzi, S; Iacobini, C; Floridi, A; Passananti, C				Fanciulli, M; Bruno, T; Di Padova, M; De Angelis, R; Iezzi, S; Iacobini, C; Floridi, A; Passananti, C			Identification of a novel partner of RNA polymerase II subunit 11, Che-1, which interacts with and affects the growth suppression function of Rb	FASEB JOURNAL			English	Article						RNA polymerase II; hRPB11; Che-1; retinoblastoma susceptibility gene	RETINOBLASTOMA GENE-PRODUCT; LARGE T-ANTIGEN; HISTONE DEACETYLASE; REPRESS TRANSCRIPTION; COMPLEX-FORMATION; NUCLEAR-RECEPTOR; STRESS SURVIVAL; ALPHA-SUBUNIT; PROTEIN; BINDING	hRPB11 is a core submit of RNA polymerase II (pol II) specifically down-regulated on doxorubicin (dox) treatment. Levels of this protein profoundly affect cell differentiation, cell proliferation, and tumorigenicity in vivo. Here we describe Che-1, a novel human protein that interacts with hRPB11. Che-1 possesses a domain of high homology with Escherichia coli RNA polymerase sigma-factor 70 and SV40 large T antigen. In addition, we report that Che-l interacts with the retinoblastoma susceptibility gene (Rb) by two distinct domains. Functionally, we demonstrate that Che-1 represses the growth suppression function of Rb, counteracting the inhibitory action of Rb on the trans-activation function of E2F1. These results identify a novel protein that binds Rb and the core of pol II, and suggest that Che-l may be part of transcription regulatory complex.	Regina Elena Canc Inst, Cell Metab & Pharmacokinet Lab, I-00158 Rome, Italy; Univ Aquila, Dept Expt Med, I-67100 Laquila, Italy; CNR, Ist Tecnol Biomed, I-00137 Rome, Italy	University of L'Aquila; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR)	Fanciulli, M (corresponding author), Regina Elena Canc Inst, Cell Metab & Pharmacokinet Lab, Via Messi Doro 156, I-00158 Rome, Italy.		Iezzi, Simona/AAA-3275-2021; Passananti, Claudio/K-9593-2016; fanciulli, maurizio/ABH-6745-2020; bruno, tiziana/AAC-4913-2022	Iezzi, Simona/0000-0002-7484-5861; bruno, tiziana/0000-0003-0352-4523; PASSANANTI, CLAUDIO/0000-0002-9288-5736; DI PADOVA, Monica/0000-0003-3808-7159	Telethon [A.063] Funding Source: Medline	Telethon(Fondazione Telethon)		Acker J, 1997, J BIOL CHEM, V272, P16815, DOI 10.1074/jbc.272.27.16815; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Bruno T, 1998, FEBS LETT, V427, P241, DOI 10.1016/S0014-5793(98)00432-3; CHODER M, 1993, J BACTERIOL, V175, P6358, DOI 10.1128/JB.175.19.6358-6363.1993; CHODER M, 1993, MOL CELL BIOL, V13, P6984, DOI 10.1128/MCB.13.11.6984; Dorjsuren D, 1998, MOL CELL BIOL, V18, P7546, DOI 10.1128/MCB.18.12.7546; EBRIGHT RH, 1995, CURR OPIN GENET DEV, V5, P197, DOI 10.1016/0959-437X(95)80008-5; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; Fanciulli M, 1998, FEBS LETT, V427, P236, DOI 10.1016/S0014-5793(98)00431-1; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; FRANCIULLI M, 1996, FEBS LETT, V384, P48; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KHAZAK V, 1995, MOL BIOL CELL, V6, P759, DOI 10.1091/mbc.6.7.759; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Kimura M, 1997, J BIOL CHEM, V272, P25851, DOI 10.1074/jbc.272.41.25851; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; Korobko IV, 1997, GENE, V185, P1, DOI 10.1016/S0378-1119(96)00626-9; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; PATI UK, 1994, GENE, V145, P289, DOI 10.1016/0378-1119(94)90022-1; QIN XQ, 1995, MOL CELL BIOL, V15, P742; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; RUSSO FD, 1992, J BIOL CHEM, V267, P14515; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Ulmasov T, 1996, J BIOL CHEM, V271, P5085, DOI 10.1074/jbc.271.9.5085; Woychik Nancy A., 1993, Gene Expression, V3, P77	37	73	76	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2000	14	7					904	912		10.1096/fasebj.14.7.904	http://dx.doi.org/10.1096/fasebj.14.7.904			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	309CG	10783144				2022-12-28	WOS:000086749500008
J	Metwali, A; Blum, AM; Li, J; Elliott, DE; Weinstock, JV				Metwali, A; Blum, AM; Li, J; Elliott, DE; Weinstock, JV			IL-4 regulates VIP receptor subtype 2 mRNA (VPAC2) expression in T cells in murine schistosomiasis	FASEB JOURNAL			English	Article						Th1; Th2; CD4(+); T cells; VIP receptor; VPAC2; schistosomiasis	VASOACTIVE-INTESTINAL-PEPTIDE; SELECTIVE EXPRESSION; INFECTED MICE; MESSENGER-RNA; LYMPHOCYTES; GRANULOMAS; MANSONI; INTERLEUKIN-4; MODULATION; RESPONSES	In murine schistosomiasis, granuloma T cells express VPAC2 mRNA, whereas there is none in splenocytes, This suggests that T cell VPAC2 mRNA is inducible, To address this issue, splenocytes from schistosome-infected mice were incubated with anti-CD3 to induce VPAC2 mRNA, which only appeared when cell cultures also contained anti-IL-4 mAb, Granuloma cells expressed VPAC2 mRNA, This natural expression decreased substantially when cells were cultured 3 days in vitro, However, granuloma cells cultured with anti-IL-4 mAb strongly expressed VPAC2 mRNA. IL-4 KO mice were examined to further address the importance of IL-4 in VPAC2 regulation, Splenocytes and dispersed granuloma cells from IL-4 KO animals had substantially more VPAC2 mRNA than those in wild-type controls. VPAC2 mRNA content decreased when cells were cultured with rIL-4. VPAC2 mRNA localized to CD4+ T cells, Th1 cell lines expressed VPAC2 mRNA much stronger than Th2 cells. Anti-IL4 mAb, increased VPAC2 mRNA expression in Th2 cells cultured in vitro. However, rIL-4 could not suppress VPAC2 mRNA expression in Th1 cells. Thus, VPAC2 is an inducible CD4+ T cell receptor, and IL-4 down-modulates VPAC2 mRNA expression in Th2 cells.	Univ Iowa, Dept Internal Med, Div Gastroenterol Hepatol, Iowa City, IA 52242 USA	University of Iowa	Weinstock, JV (corresponding author), Univ Iowa, Dept Internal Med, Div Gastroenterol Hepatol, 200 Hawkins Dr,4607 JCP, Iowa City, IA 52242 USA.			Elliott, David/0000-0002-5359-7125	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002428, R01DK038327, P30DK025295] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK25295, DK38327, DK02428] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLUM AM, 1992, J NEUROIMMUNOL, V39, P101, DOI 10.1016/0165-5728(92)90179-O; Dewit D, 1998, IMMUNOL LETT, V60, P57, DOI 10.1016/S0165-2478(97)00129-6; ELLIOTT DE, 1994, J IMMUNOL, V153, P1180; ELLIOTT DE, 1996, IMMUNOMETHODS, V9, P255; Fujieda S, 1996, J CLIN INVEST, V98, P1527, DOI 10.1172/JCI118944; Goetzl EJ, 1998, ANN NY ACAD SCI, V840, P540, DOI 10.1111/j.1749-6632.1998.tb09593.x; Huang H, 1998, J EXP MED, V187, P1305, DOI 10.1084/jem.187.8.1305; Martinez C, 1996, J IMMUNOL, V156, P4128; MATHEW RC, 1992, J IMMUNOL, V148, P3572; Metwali A, 1996, J IMMUNOL, V157, P4546; Metwali A, 1996, J IMMUNOL, V157, P265; METWALI A, 1993, CELL IMMUNOL, V149, P11, DOI 10.1006/cimm.1993.1132; Miura S, 1997, AM J PHYSIOL-GASTR L, V272, pG92, DOI 10.1152/ajpgi.1997.272.1.G92; Nakamura T, 1997, J IMMUNOL, V158, P2090; OTTAWAY CA, 1984, J IMMUNOL, V132, P417; Rogge L, 1997, J EXP MED, V185, P825, DOI 10.1084/jem.185.5.825; ROLAPLESZCZYNSKI M, 1985, J IMMUNOL, V135, P2569; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; SANDOR M, 1995, J IMMUNOL, V155, P275; SANDOR M, 1992, IMMUNOBIOLOGY, V185, P268, DOI 10.1016/S0171-2985(11)80645-5; Shimozato T, 1997, J IMMUNOL, V158, P5178; Tang H, 1996, ANN NY ACAD SCI, V805, P768; Ulrich CD, 1998, GASTROENTEROLOGY, V114, P382, DOI 10.1016/S0016-5085(98)70491-3; WEINSTOCK JV, 1990, CELL IMMUNOL, V125, P291, DOI 10.1016/0008-8749(90)90085-6; WILLIAMS ME, 1993, EUR J IMMUNOL, V23, P1910, DOI 10.1002/eji.1830230827; Xia MH, 1996, J IMMUNOL, V157, P1132; Xin ZC, 1997, REGUL PEPTIDES, V72, P41, DOI 10.1016/S0167-0115(97)01028-8; Xu D, 1998, J EXP MED, V187, P787, DOI 10.1084/jem.187.5.787	28	17	18	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2000	14	7					948	954		10.1096/fasebj.14.7.948	http://dx.doi.org/10.1096/fasebj.14.7.948			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	309CG	10783149				2022-12-28	WOS:000086749500013
J	Chatterjee, PK; Zacharowski, K; Cuzzocrea, S; Otto, M; Thiemermann, C				Chatterjee, PK; Zacharowski, K; Cuzzocrea, S; Otto, M; Thiemermann, C			Inhibitors of poly (ADP-ribose) synthetase reduce renal ischemia-reperfusion injury in the anesthetized rat in vivo	FASEB JOURNAL			English	Article						kidney; proximal tubule; reactive oxygen species; reperfusion injury; poly (ADP-ribose) synthetase inhibitors	DNA STRAND-BREAKS; POLY(ADP-RIBOSE) SYNTHETASE; LIPID-PEROXIDATION; HYDROGEN-PEROXIDE; RABBIT KIDNEYS; CELLS; POLYMERASE; ACTIVATION; DEPLETION; 3-AMINOBENZAMIDE	The activation of poly (ADP-ribose) synthetase (PARS) subsequent to DNA damage caused by reactive oxygen or nitrogen species has been implicated in several pathophysiological conditions, including ischemia-reperfusion injury and shock. The aim of this study was to investigate whether PARS inhibitors could provide protection against renal ischemia-reperfusion injury in the rat in vivo. Male Wistar rats were subjected to 45 min bilateral clamping of the renal pedicles, followed by 6 h reperfusion (control animals). Animals were administered the PARS inhibitors 3-aminobenzamide, 1,5-dihydroxyisoquinoline, or nicotinamide during the reperfusion period. Ischemia, followed by reperfusion, produced significant increases in plasma concentrations of urea, creatinine, and fractional excretion of Na+ (FENa) and produced a significant reduction in glomerular filtration rate (GFR). However, administration of the PARS inhibitors significantly reduced urea and creatinine concentrations, suggesting improved renal function. The PARS inhibitors also significantly increased GFR and reduced FENa, suggesting the recovery of both glomerular and tubular function, respectively, with a more pronounced recovery of tubular function. In kidneys from control animals, histological examination revealed severe renal damage and immunohistochemical localization demonstrated PARS activation in the proximal tubule. Both renal damage and PARS activation were attenuated by administration of PARS inhibitors during reperfusion. Therefore, we propose that PARS activation contributes to renal reperfusion injury and that PARS inhibitors may be beneficial in renal disorders associated with oxidative stress-mediated injury.-Chatterjee, P. K., Zacharowski, K., Cuzzocrea, S., Otto, M., Thiemermann, C. Inhibitors of poly (ADP-ribose) synthetase reduce renal ischemia-reperfusion injury in the anesthetized rat in vivo.	St Bartholomews & Royal London Sch Med & Dent, William Harvey Res Inst, London EC1M 6BQ, England; Univ Messina, Inst Pharmacol, I-98123 Messina, Italy; Johannes Gutenberg Univ Mainz, Inst Pathol, D-55101 Mainz, Germany	University of London; Queen Mary University London; University of Messina; Johannes Gutenberg University of Mainz	Chatterjee, PK (corresponding author), St Bartholomews & Royal London Sch Med & Dent, William Harvey Res Inst, Charterhouse Sq, London EC1M 6BQ, England.	p.k.chatterjee@mds.qmw.ac.uk		Thiemermann, Christoph/0000-0003-4228-9722				Alcazar JM, 1997, CURR OPIN NEPHROL HY, V6, P157, DOI 10.1097/00041552-199703000-00009; BANASIK M, 1992, J BIOL CHEM, V267, P1569; Baum N, 1975, Urology, V5, P583; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; CARSON DA, 1986, EXP CELL RES, V164, P273, DOI 10.1016/0014-4827(86)90028-5; Chatterjee PK, 1999, KIDNEY INT, V56, P973, DOI 10.1046/j.1523-1755.1999.00644.x; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; DIERENFELDT SM, 1987, BIOCHEM MED METAB B, V38, P88, DOI 10.1016/0885-4505(87)90066-1; GREEN CJ, 1986, COMP BIOCHEM PHYS B, V85, P113, DOI 10.1016/0305-0491(86)90230-0; GREEN CJ, 1986, CRYOBIOLOGY, V23, P358, DOI 10.1016/0011-2240(86)90040-4; HELLER B, 1995, J BIOL CHEM, V270, P11176, DOI 10.1074/jbc.270.19.11176; Hottendorf G.H, 1984, ACUTE RENAL FAILURE, P419; HYSLOP PA, 1988, J BIOL CHEM, V263, P1665; IKAI K, 1983, J HISTOCHEM CYTOCHEM, V31, P1261, DOI 10.1177/31.11.6311893; Kadkhodaee M, 1998, NEPHROLOGY, V4, P163, DOI 10.1046/j.1440-1797.1998.d01-25.x; Kim SY, 1998, KIDNEY INT, V54, P1786; KLONER RA, 1989, CIRCULATION, V80, P1115, DOI 10.1161/01.CIR.80.5.1115; Lieberthal W, 1996, AM J PHYSIOL-RENAL, V271, pF477, DOI 10.1152/ajprenal.1996.271.3.F477; MCCOY RN, 1988, KIDNEY INT, V33, P812, DOI 10.1038/ki.1988.72; MCLAREN J, 1994, TOXICOLOGY, V88, P101, DOI 10.1016/0300-483X(94)90113-9; Oei S L, 1997, Rev Physiol Biochem Pharmacol, V131, P127; PALLER MS, 1994, J INVEST MED, V42, P632; Paller MS, 1994, MECH INJURY RENAL DI, P3; Pozzilli P, 1998, DIABETES METAB REV, V14, P69, DOI 10.1002/(SICI)1099-0895(199803)14:1<69::AID-DMR203>3.0.CO;2-E; RANKIN PW, 1989, J BIOL CHEM, V264, P4312; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SCHRAUFSTATTER IU, 1986, P NATL ACAD SCI USA, V83, P4908, DOI 10.1073/pnas.83.13.4908; SCHRAUFSTATTER IU, 1986, J CLIN INVEST, V77, P1312, DOI 10.1172/JCI112436; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; Szabo C, 1997, AM J RESP CELL MOL, V16, P105, DOI 10.1165/ajrcmb.16.2.9032115; Szabo C, 1996, P NATL ACAD SCI USA, V93, P1753, DOI 10.1073/pnas.93.5.1753; Thadhani R, 1996, NEW ENGL J MED, V334, P1448, DOI 10.1056/NEJM199605303342207; Thiemermann C, 1997, P NATL ACAD SCI USA, V94, P679, DOI 10.1073/pnas.94.2.679; THIES RL, 1991, ARCH BIOCHEM BIOPHYS, V286, P353, DOI 10.1016/0003-9861(91)90051-J; UCHIDA K, 1988, JPN J CANCER RES, V79, P1094, DOI 10.1111/j.1349-7006.1988.tb01532.x; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; VAMVAKAS S, 1992, BIOCHEM PHARMACOL, V44, P1131, DOI 10.1016/0006-2952(92)90377-U; WATSON AJM, 1995, GASTROENTEROLOGY, V109, P472, DOI 10.1016/0016-5085(95)90335-6; Weight SC, 1996, BRIT J SURG, V83, P162, DOI 10.1002/bjs.1800830206; Williams P, 1997, J PHARMACOL TOX MET, V37, P1, DOI 10.1016/S1056-8719(96)00141-4; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; Zingarelli B, 1997, CARDIOVASC RES, V36, P205, DOI 10.1016/S0008-6363(97)00137-5	42	100	101	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2000	14	5					641	651		10.1096/fasebj.14.5.641	http://dx.doi.org/10.1096/fasebj.14.5.641			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301DH	10744621				2022-12-28	WOS:000086292700002
J	Chen, SH; Arany, I; Apisarnthanarax, N; Rajaraman, S; Tyring, SK; Horikoshi, T; Brysk, H; Brysk, MM				Chen, SH; Arany, I; Apisarnthanarax, N; Rajaraman, S; Tyring, SK; Horikoshi, T; Brysk, H; Brysk, MM			Response of keratinocytes from normal and psoriatic epidermis to interferon-gamma differs in the expression of zinc-alpha(2)-glycoprotein and cathepsin D	FASEB JOURNAL			English	Article						interferon-gamma receptors; interferon regulatory factor; interferon signal transducer and activator; epidermal differentiation; apoptosis; bcl-2	PROGRAMMED CELL-DEATH; NORMAL HUMAN SKIN; HUMAN ZN-ALPHA(2)-GLYCOPROTEIN; TERMINAL DIFFERENTIATION; CULTURED KERATINOCYTES; IFN-GAMMA; IN-VIVO; ACTIVATION; RIBONUCLEASE; RECEPTOR	Psoriasis is a T cell-mediated inflammatory disease characterized by hyperproliferation and by aberrant differentiation. We found cathepsin D and zinc-alpha(2)-glycoprotein, two catalytic enzymes associated with apoptosis and desquamation, to be present in the stratum corneum of the normal epidermis but absent from the psoriatic plaque. Psoriasis is characterized by an altered response to interferon-gamma (IFN-gamma), including the induction of apoptosis in normal but not in psoriatic keratinocytes, often with opposite effects on gene expression of suprabasal proteins. We found that IFN-gamma binding and signaling were attenuated in psoriasis: The IFN-gamma receptor, the signal transducer and activator of transcription STAT-1, and the interferon regulatory factor IRF-1 were strongly up-regulated by IFN-gamma in normal keratinocytes, but not in psoriatic ones. IFN-gamma strongly up-regulated the expression of the catalytic enzymes cathepsin D and zinc-alpha(2)-glycoprotein in normal keratinocytes but down-regulated them in psoriatic ones; the reverse was true of the apoptotic suppressor bcl-2. We believe that the aberrant response to IFN-gamma plays a central role in the pathophysiology of psoriasis, particularly the disruption of apoptosis and desquamation.	Univ Texas, Med Branch, Dept Dermatol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Pathol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Kanebo Ltd, Basic Res Lab, Kanagawa 250002, Japan	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Brysk, MM (corresponding author), Univ Texas, Med Branch, Dept Dermatol, Galveston, TX 77555 USA.							Arany I, 1996, J INTERF CYTOK RES, V16, P453, DOI 10.1089/jir.1996.16.453; Bach EA, 1996, MOL CELL BIOL, V16, P3214; BAKER BS, 1988, SCAND J IMMUNOL, V28, P735, DOI 10.1111/j.1365-3083.1988.tb01507.x; BARKER J N W N, 1991, Journal of Dermatological Science, V2, P106, DOI 10.1016/0923-1811(91)90019-T; BARKER JNWN, 1993, AM J PATHOL, V142, P1091; Barrett A, 1977, PROTEINASES MAMMALIA, P209; BATACSORGO Z, 1993, J EXP MED, V178, P1271, DOI 10.1084/jem.178.4.1271; BERNARD BA, 1988, J INVEST DERMATOL, V90, P801, DOI 10.1111/1523-1747.ep12462014; BIANCHI L, 1994, J INVEST DERMATOL, V103, P829, DOI 10.1111/1523-1747.ep12413590; BRYSK MM, 1992, PROG HISTOCHEM CYTOC, V25, P1; BRYSK MM, 1994, EXP CELL RES, V214, P22, DOI 10.1006/excr.1994.1229; Brysk MM, 1999, CANCER LETT, V137, P117, DOI 10.1016/S0304-3835(98)00347-4; Brysk MM, 1997, ANTICANCER RES, V17, P3387; BRYSK MM, 1991, EXP CELL RES, V197, P140, DOI 10.1016/0014-4827(91)90415-Q; BRYSK MM, 1988, CELL TISSUE RES, V253, P657; Brysk MM, 1995, J INTERF CYTOK RES, V15, P1029, DOI 10.1089/jir.1995.15.1029; Carroll JM, 1997, J INVEST DERMATOL, V108, P412, DOI 10.1111/1523-1747.ep12289702; Darnell JE, 1998, J INTERF CYTOK RES, V18, P549, DOI 10.1089/jir.1998.18.549; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; DIEZITZA I, 1993, EUR J CANCER, V29A, P1256, DOI 10.1016/0959-8049(93)90068-Q; DOVER R, 1987, J INVEST DERMATOL, V89, P349, DOI 10.1111/1523-1747.ep12471751; FIERLBECK G, 1990, ARCH DERMATOL, V126, P351, DOI 10.1001/archderm.126.3.351; FREIJE JP, 1993, GENOMICS, V18, P575, DOI 10.1016/S0888-7543(05)80359-3; GIESELMANN V, 1985, J BIOL CHEM, V260, P3215; GRIFFITHS CEM, 1989, J AM ACAD DERMATOL, V20, P617, DOI 10.1016/S0190-9622(89)70073-6; GULNIK S, 1992, J MOL BIOL, V227, P265, DOI 10.1016/0022-2836(92)90696-H; HASILIK A, 1980, J BIOL CHEM, V255, P4937; Heim MH, 1999, J RECEPT SIGNAL TR R, V19, P75, DOI 10.3109/10799899909036638; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Horikoshi T, 1999, BRIT J DERMATOL, V141, P453; Horikoshi T, 1998, BIOCHIMIE, V80, P605, DOI 10.1016/S0300-9084(98)80013-8; Jackson M, 1999, FASEB J, V13, P495, DOI 10.1096/fasebj.13.3.495; JUNG V, 1987, P NATL ACAD SCI USA, V84, P4151, DOI 10.1073/pnas.84.12.4151; Kalvakolanu DV, 1996, CANCER INVEST, V14, P25, DOI 10.3109/07357909609018435; KANEKO F, 1990, Journal of Dermatological Science, V1, P425, DOI 10.1016/0923-1811(90)90012-3; KANITAKIS J, 1988, VIRCHOWS ARCH A, V412, P375, DOI 10.1007/BF00750265; KARASEK J, 1988, J INVEST DERMATOL, V91, P243, DOI 10.1111/1523-1747.ep12470372; LACCETTI P, 1992, CANCER RES, V52, P4582; Lei G, 1998, ARCH BIOCHEM BIOPHYS, V355, P160, DOI 10.1006/abbi.1998.0735; Lei G, 1997, J CELL BIOCHEM, V67, P216, DOI 10.1002/(SICI)1097-4644(19971101)67:2<216::AID-JCB6>3.0.CO;2-#; NEGI M, 1981, J INVEST DERMATOL, V77, P389, DOI 10.1111/1523-1747.ep12494561; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; NICKOLOFF BJ, 1984, LAB INVEST, V51, P697; NOVELLI F, 1994, J IMMUNOL, V152, P496; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pestka Sidney, 1997, Seminars in Oncology, V24, P18; RASHIDBAIGI A, 1986, P NATL ACAD SCI USA, V83, P384, DOI 10.1073/pnas.83.2.384; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; ROSSMAN MD, 1990, CELL IMMUNOL, V126, P268, DOI 10.1016/0008-8749(90)90320-Q; SAUNDERS NA, 1994, J BIOL CHEM, V269, P2016; SCHEYNIUS A, 1992, J INVEST DERMATOL, V98, P255, DOI 10.1111/1523-1747.ep12556086; SCHROEDER WT, 1992, J INVEST DERMATOL, V99, P27, DOI 10.1111/1523-1747.ep12611394; SCHWARTZ MK, 1995, CLIN CHIM ACTA, V237, P67, DOI 10.1016/0009-8981(95)06065-L; Selvanayagam P, 1998, J CELL BIOCHEM, V68, P74, DOI 10.1002/(SICI)1097-4644(19980101)68:1<74::AID-JCB7>3.0.CO;2-T; Shibata M, 1998, BIOCHEM BIOPH RES CO, V251, P199, DOI 10.1006/bbrc.1998.9422; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; STEINERT PM, 1981, P NATL ACAD SCI-BIOL, V78, P4097, DOI 10.1073/pnas.78.7.4097; TADA T, 1991, J HISTOCHEM CYTOCHEM, V39, P1221, DOI 10.1177/39.9.1918940; Taniguchi T, 1997, BBA-REV CANCER, V1333, pM9, DOI 10.1016/S0304-419X(97)00014-0; TAYLOR CB, 1993, P NATL ACAD SCI USA, V90, P5118, DOI 10.1073/pnas.90.11.5118; UEYAMA H, 1993, BIOCHEMISTRY-US, V32, P12968, DOI 10.1021/bi00211a004; VANDENOORD JJ, 1995, PATHOL RES PRACT, V191, P530, DOI 10.1016/S0344-0338(11)80872-1; WATT FM, 1987, ARCH DERMATOL RES, V279, P335, DOI 10.1007/BF00431227; Wormser U, 1997, ARCH DERMATOL RES, V289, P686, DOI 10.1007/s004030050262; WRONESMITH T, 1995, AM J PATHOL, V146, P1079; WroneSmith T, 1997, AM J PATHOL, V151, P1321; WU YN, 1993, J BIOL CHEM, V268, P10686	67	47	48	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2000	14	3					565	571		10.1096/fasebj.14.3.565	http://dx.doi.org/10.1096/fasebj.14.3.565			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	291TJ	10698972				2022-12-28	WOS:000085751900016
J	Pirkkala, L; Nykanen, P; Sistonen, L				Pirkkala, L; Nykanen, P; Sistonen, L			Roles of the heat shock transcription factors in regulation of the heat shock response and beyond	FASEB JOURNAL			English	Review						heat shock element; hsps; HSF family; knockout and transgenic HSF models	DNA-BINDING DOMAIN; EMBRYONAL CARCINOMA-CELLS; UBIQUITIN-PROTEASOME PATHWAY; FACTOR-I; STRESS-RESPONSE; GENE-EXPRESSION; MOLECULAR CHAPERONES; NUCLEAR-LOCALIZATION; NEGATIVE REGULATION; ACTIVATION DOMAIN	The heat shock response, characterized by increased expression of heat shock proteins (Hsps) is induced by exposure of cells and tissues to extreme conditions that cause acute or chronic stress. Hsps function as molecular chaperones in regulating cellular homeostasis and promoting survival. If the stress is too severe, a signal that leads to programmed cell death, apoptosis, is activated, thereby providing a finely tuned balance between survival and death, In addition to extracellular stimuli, several nonstressful conditions induce Hsps during normal cellular growth and development. The enhanced heat shock gene expression in response to various stimuli is regulated by heat shock transcription factors (HSFs), After the discovery of the family of HSFs (i.e., murine and human HSF1, 2, and 4 and a unique avian HSF3), the functional relevance of distinct HSFs is now emerging. HSF1, an HSF prototype, and HSF3 are responsible for heat-induced Hsp expression, whereas HSF2 is refractory to classical stressors, HSF4 is expressed in a tissue-specific manner; similar to HSF1 and HSF2, alternatively spliced isoforms add further complexity to its regulation. Recently developed powerful genetic models have provided evidence for both cooperative and specific functions of HSFs that expand beyond the heat shock response. Certain specialized functions of HSFs may even include regulation of novel target genes in response to distinct stimuli.	Univ Turku, Turku Ctr Biotechnol, Turku 20521, Finland; Abo Akad Univ, Dept Biol, SF-20500 Turku, Finland	University of Turku; Abo Akademi University	Sistonen, L (corresponding author), Univ Turku, Turku Ctr Biotechnol, Tykistokaty 6B, Turku 20521, Finland.	lea.sistonen@btk.utu.fi		Ostling, Paivi/0000-0001-5501-466X; Sistonen, Lea/0000-0003-1341-2867				ABRAVAYA K, 1991, MOL CELL BIOL, V11, P586, DOI 10.1128/MCB.11.1.586; Alastalo TP, 1998, EXP CELL RES, V240, P16, DOI 10.1006/excr.1997.3926; Ali A, 1998, MOL CELL BIOL, V18, P4949, DOI 10.1128/MCB.18.9.4949; Arrigo AP, 1998, BIOL CHEM, V379, P19; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; BENSAUDE O, 1983, NATURE, V305, P331, DOI 10.1038/305331a0; BENSAUDE O, 1983, EMBO J, V2, P173, DOI 10.1002/j.1460-2075.1983.tb01401.x; Bharadwaj S, 1999, MOL CELL BIOL, V19, P8033; BOSCH TCG, 1988, P NATL ACAD SCI USA, V85, P7927, DOI 10.1073/pnas.85.21.7927; Brennecke T, 1998, EUR J BIOCHEM, V255, P703, DOI 10.1046/j.1432-1327.1998.2550703.x; Bush KT, 1997, J BIOL CHEM, V272, P9086; Cahill CM, 1996, J BIOL CHEM, V271, P24874; Chen CM, 1997, J BIOL CHEM, V272, P26803, DOI 10.1074/jbc.272.43.26803; Christians E, 2000, NATURE, V407, P693, DOI 10.1038/35037669; Christians E, 1997, MOL CELL BIOL, V17, P778, DOI 10.1128/MCB.17.2.778; Chu BY, 1998, J BIOL CHEM, V273, P18640, DOI 10.1074/jbc.273.29.18640; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; Cotto JJ, 1997, J CELL SCI, V110, P2925; Cotto JJ, 1996, J BIOL CHEM, V271, P3355; Dai RJ, 2000, J BIOL CHEM, V275, P18210, DOI 10.1074/jbc.M000958200; DAMBERGER FF, 1994, PROTEIN SCI, V3, P1806, DOI 10.1002/pro.5560031020; Eddy EM, 1998, J EXP ZOOL, V282, P261, DOI 10.1002/(SICI)1097-010X(199809/10)282:1/2&lt;261::AID-JEZ28&gt;3.0.CO;2-V; Eriksson M, 2000, INT J DEV BIOL, V44, P471; Farkas T, 1998, MOL CELL BIOL, V18, P906, DOI 10.1128/MCB.18.2.906; FIORENZA MT, 1995, NUCLEIC ACIDS RES, V23, P467, DOI 10.1093/nar/23.3.467; GALLO GJ, 1993, MOL CELL BIOL, V13, P749, DOI 10.1128/MCB.13.2.749; GOODSON ML, 1995, J BIOL CHEM, V270, P2447, DOI 10.1074/jbc.270.6.2447; GOODSON ML, 1995, MOL CELL BIOL, V15, P5288; GREEN M, 1995, MOL CELL BIOL, V15, P3354; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; He B, 1998, MOL CELL BIOL, V18, P6624, DOI 10.1128/MCB.18.11.6624; Hofmann GE, 2000, J EXP BIOL, V203, P2331; Holbrook NJ, 1994, BIOL HEAT SHOCK PROT, P577; Holmberg CI, 2000, CELL STRESS CHAPERON, V5, P219, DOI 10.1379/1466-1268(2000)005<0219:FONHGV>2.0.CO;2; Hong YL, 1999, J BIOL CHEM, V274, P12967, DOI 10.1074/jbc.274.19.12967; Hong YL, 2000, BIOCHEM BIOPH RES CO, V272, P84, DOI 10.1006/bbrc.2000.2733; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; JAKOBSEN BK, 1991, EMBO J, V10, P369, DOI 10.1002/j.1460-2075.1991.tb07958.x; JAKOBSEN BK, 1988, MOL CELL BIOL, V8, P5040, DOI 10.1128/MCB.8.11.5040; Jedlicka P, 1997, EMBO J, V16, P2452, DOI 10.1093/emboj/16.9.2452; Johnson MS, 1996, METHOD ENZYMOL, V266, P575; JOHNSON MS, 1993, J MOL BIOL, V233, P716, DOI 10.1006/jmbi.1993.1548; Jolly C, 1997, J CELL SCI, V110, P2935; Jolly C, 1999, P NATL ACAD SCI USA, V96, P6769, DOI 10.1073/pnas.96.12.6769; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; KaneiIshii C, 1997, SCIENCE, V277, P246, DOI 10.1126/science.277.5323.246; Kawazoe Y, 1999, EUR J BIOCHEM, V265, P688, DOI 10.1046/j.1432-1327.1999.00762.x; Kawazoe Y, 1998, EUR J BIOCHEM, V255, P356, DOI 10.1046/j.1432-1327.1998.2550356.x; Kim D, 1999, BIOCHEM BIOPH RES CO, V254, P264, DOI 10.1006/bbrc.1998.9840; Kim Y, 1997, J CELL BIOCHEM, V67, P43, DOI 10.1002/(SICI)1097-4644(19971001)67:1<43::AID-JCB5>3.0.CO;2-W; Kline MP, 1997, MOL CELL BIOL, V17, P2107, DOI 10.1128/MCB.17.4.2107; Knauf U, 1996, GENE DEV, V10, P2782, DOI 10.1101/gad.10.21.2782; KROEGER PE, 1994, MOL CELL BIOL, V14, P7592, DOI 10.1128/MCB.14.11.7592; KROEGER PE, 1993, MOL CELL BIOL, V13, P3370, DOI 10.1128/MCB.13.6.3370; LEE BS, 1995, P NATL ACAD SCI USA, V92, P7207, DOI 10.1073/pnas.92.16.7207; Leppa S, 1997, J BIOL CHEM, V272, P15293, DOI 10.1074/jbc.272.24.15293; Leppa S, 1997, J BIOL CHEM, V272, P30400, DOI 10.1074/jbc.272.48.30400; Leppa S, 1997, ANN MED, V29, P73, DOI 10.3109/07853899708998745; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Liu XD, 1997, EMBO J, V16, P6466, DOI 10.1093/emboj/16.21.6466; Manuel M, 1999, GENE, V232, P115, DOI 10.1016/S0378-1119(99)00092-X; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; Mathew A, 1998, MOL CELL BIOL, V18, P5091, DOI 10.1128/MCB.18.9.5091; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; MEZGER V, 1994, DEV BIOL, V166, P819, DOI 10.1006/dbio.1994.1361; MEZGER V, 1994, DEV BIOL, V165, P627, DOI 10.1006/dbio.1994.1281; MEZGER V, 1989, MOL CELL BIOL, V9, P3888, DOI 10.1128/MCB.9.9.3888; MORANGE M, 1984, MOL CELL BIOL, V4, P730, DOI 10.1128/MCB.4.4.730; Morano KA, 1999, GENE EXPRESSION, V7, P271; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; MURPHY SP, 1994, MOL CELL BIOL, V14, P5309, DOI 10.1128/MCB.14.8.5309; Nakai A, 2000, J BIOL CHEM, V275, P34665, DOI 10.1074/jbc.M005302200; Nakai A, 1997, MOL CELL BIOL, V17, P469, DOI 10.1128/MCB.17.1.469; Nakai A, 1999, CELL STRESS CHAPERON, V4, P86, DOI 10.1054/csac.1998.0002; Nakai A, 2000, EMBO J, V19, P1545, DOI 10.1093/emboj/19.7.1545; NAKAI A, 1993, MOL CELL BIOL, V13, P1983, DOI 10.1128/MCB.13.4.1983; NAKAI A, 1995, MOL CELL BIOL, V15, P5268; Never L, 1996, CELL STRESS CHAPERON, V1, P215, DOI 10.1379/1466-1268(1996)001<0215:THWCAP>2.3.CO;2; Newton EM, 1996, MOL CELL BIOL, V16, P839; Pirkkala L, 1999, FASEB J, V13, P1089, DOI 10.1096/fasebj.13.9.1089; Pirkkala L, 2000, MOL CELL BIOL, V20, P2670, DOI 10.1128/MCB.20.8.2670-2675.2000; PLUMIER JCL, 1995, J CLIN INVEST, V95, P1854, DOI 10.1172/JCI117865; Rabergh CMI, 2000, J EXP BIOL, V203, P1817; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; RABINDRAN SK, 1994, MOL CELL BIOL, V14, P6552, DOI 10.1128/MCB.14.10.6552; Radford NB, 1996, P NATL ACAD SCI USA, V93, P2339, DOI 10.1073/pnas.93.6.2339; Rallu M, 1997, P NATL ACAD SCI USA, V94, P2392, DOI 10.1073/pnas.94.6.2392; RITOSSA F, 1962, EXPERIENTIA, V18, P571, DOI 10.1007/BF02172188; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1994, BIOL REPROD, V50, P1334, DOI 10.1095/biolreprod50.6.1334; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; Satyal SH, 1998, GENE DEV, V12, P1962, DOI 10.1101/gad.12.13.1962; SCHARF KD, 1990, EMBO J, V9, P4495, DOI 10.1002/j.1460-2075.1990.tb07900.x; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; Schultheiss J, 1996, EUR J BIOCHEM, V236, P911, DOI 10.1111/j.1432-1033.1996.00911.x; SHELDON LA, 1993, GENE DEV, V7, P1549, DOI 10.1101/gad.7.8.1549; Singh IS, 2000, J BIOL CHEM, V275, P9841, DOI 10.1074/jbc.275.13.9841; SINGH MK, 1984, NATURE, V309, P631, DOI 10.1038/309631a0; SISTONEN L, 1994, MOL CELL BIOL, V14, P2087, DOI 10.1128/MCB.14.3.2087; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; STUMP DG, 1995, GENE, V160, P207, DOI 10.1016/0378-1119(95)00176-7; Tanabe M, 1998, EMBO J, V17, P1750, DOI 10.1093/emboj/17.6.1750; Tanabe M, 1999, J BIOL CHEM, V274, P27845, DOI 10.1074/jbc.274.39.27845; Tanabe M, 1997, J BIOL CHEM, V272, P15389, DOI 10.1074/jbc.272.24.15389; Tanikawa J, 2000, J BIOL CHEM, V275, P15578, DOI 10.1074/jbc.M000372200; THEODORAKIS NG, 1989, MOL CELL BIOL, V9, P3166, DOI 10.1128/MCB.9.8.3166; VUISTER GW, 1994, NAT STRUCT BIOL, V1, P605, DOI 10.1038/nsb0994-605; WIEDERRECHT G, 1988, CELL, V54, P841, DOI 10.1016/S0092-8674(88)91197-X; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Xiao XZ, 1999, EMBO J, V18, P5943, DOI 10.1093/emboj/18.21.5943; Yoshima T, 1998, GENE, V214, P139, DOI 10.1016/S0378-1119(98)00208-X; Yoshima T, 1997, BIOCHEM BIOPH RES CO, V240, P228, DOI 10.1006/bbrc.1997.7662; Yoshima T, 1998, NUCLEIC ACIDS RES, V26, P2580, DOI 10.1093/nar/26.11.2580; Zhong M, 1998, MOL CELL, V2, P101, DOI 10.1016/S1097-2765(00)80118-5; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557; ZUO JR, 1995, MOL CELL BIOL, V15, P4319	125	789	838	1	121	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2001	15	7					1118	1131		10.1096/fj00-0294rev	http://dx.doi.org/10.1096/fj00-0294rev			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344080				2022-12-28	WOS:000168655200002
J	Sindram, D; Porte, RJ; Hoffman, MR; Bentley, RC; Clavien, PA				Sindram, D; Porte, RJ; Hoffman, MR; Bentley, RC; Clavien, PA			Synergism between platelets and leukocytes in inducing endothelial cell apoptosis in the cold ischemic rat liver: a Kupffer cell-mediated injury	FASEB JOURNAL			English	Article									Duke Univ, Med Ctr, Dept Surg, Hepatobiliary & Liver Transplant Lab, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; Univ Zurich, Dept Visceral & Transplantat Surg, CH-8006 Zurich, Switzerland	Duke University; Duke University; University of Zurich	Clavien, PA (corresponding author), Univ Zurich Hosp, Dept Visceral & Transplantat Surg, CH-8091 Zurich, Switzerland.			Hoffman, Maureane/0000-0001-7123-0100					0	96	108	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1230	1232		10.1096/fj.00-0554fje	http://dx.doi.org/10.1096/fj.00-0554fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344097				2022-12-28	WOS:000168655200019
J	Cheng, CM; Cohen, M; Wang, J; Bondy, CA				Cheng, CM; Cohen, M; Wang, J; Bondy, CA			Estrogen augments glucose transporter and IGF1 expression in primate cerebral cortex	FASEB JOURNAL			English	Article						estradiol; menopause; hormone replacement therapy; Alzheimer's disease; neurodegeneration	GROWTH-FACTOR-I; BLOOD-BRAIN-BARRIER; CENTRAL-NERVOUS-SYSTEM; POSITRON-EMISSION TOMOGRAPHY; GENE-EXPRESSION; ALZHEIMERS-DISEASE; RAT-BRAIN; MESSENGER-RNA; FACTOR RECEPTOR; SPINE DENSITY	Estrogen has many positive effects on neural tissue in experimental model systems, including stimulation of neurite growth and neurotransmitter synthesis and protection against diverse types of neural injury. In humans, estrogen treatment is reputed to protect against Alzheimer's disease. To investigate potential mediators of estrogen's action and determine whether selective estrogen receptor modulators (SERMs) such as tamoxifen have estrogen-like effects in the primate brain, we evaluated the expression of glucose transporters and insulin-like growth factor 1 (IGF1) and its receptor in the frontal cortex of ovariectomized rhesus monkeys. We treated one group for 3 days with vehicle, another with 17 beta estradiol (E2), and a third with tamoxifen. The expression of facilitative glucose transporters (Gluts) 1, 3, and 4 was investigated using in situ hybridization, immunohistochemistry, and immunoblot analysis. Gluts 3 and 4 were concentrated in cortical neurons and Glut1 in capillaries and glial cells. E2 treatment induced two- to fourfold increases in Glut3 and Glut4 mRNA levels and lesser but significant increases in Glut3 and 4 protein levels. E2 treatment induced an similar to 70% increase in parenchymal Glut1 mRNA levels, but did not appreciably affect vascular Glut1 gene expression. IGF1 and IGF1 receptor mRNAs were concentrated in cortical neurons in a distribution similar to Gluts 3 and 4. IGF1 mRNA levels were significantly increased in E2-treated animals but IGF1 receptor mRNA levels were not altered by hormone treatment. Tamoxifen increased cerebral cortical Glut3 and 4 mRNA levels, but did not affect Glut1, IGF1, or IGF1 receptor expression. This study provides novel data showing that Gluts 3 and 4 and IGF1 are coexpressed by primate cerebral cortical neurons, where their expression is enhanced by estrogen. These findings suggest that up-regulation of glucose transporter and IGF1 expression may contribute to estrogen's salutary effects on neural tissue. Tamoxifen, an antiestrogen at the breast, is shown to have estrogen-like effects on higher brain centers in the monkey, suggesting that some SERMs may share estrogen's neuroprotective potential for menopausal women.	NICHD, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Bondy, CA (corresponding author), NICHD, Dev Endocrinol Branch, NIH, Bldg 10-10N262,10 Ctr Dr, Bethesda, MD 20892 USA.	bondyc@exchange.nih.gov			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000628] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000628] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adesanya OO, 1999, P NATL ACAD SCI USA, V96, P3287, DOI 10.1073/pnas.96.6.3287; Adesanya OO, 1996, J CLIN ENDOCR METAB, V81, P1967, DOI 10.1210/jc.81.5.1967; Apelt J, 1999, J NEUROSCI RES, V57, P693, DOI 10.1002/(SICI)1097-4547(19990901)57:5<693::AID-JNR11>3.0.CO;2-X; Azcoitia I, 1999, J NEUROSCI RES, V58, P815, DOI 10.1002/(SICI)1097-4547(19991215)58:6<815::AID-JNR8>3.0.CO;2-R; BARKER KL, 1966, ENDOCRINOLOGY, V79, P1069, DOI 10.1210/endo-79-6-1069; BARTLETT WP, 1991, DEV BIOL, V147, P239, DOI 10.1016/S0012-1606(05)80021-1; BAXTER LR, 1987, PSYCHIAT RES, V21, P237, DOI 10.1016/0165-1781(87)90028-X; Berman KF, 1997, P NATL ACAD SCI USA, V94, P8836, DOI 10.1073/pnas.94.16.8836; Birge SJ, 1997, NEUROLOGY, V48, pS36, DOI 10.1212/WNL.48.5_Suppl_7.36S; BOADO RJ, 1990, BIOCHEM BIOPH RES CO, V166, P174, DOI 10.1016/0006-291X(90)91927-K; BONDY CA, 1991, J NEUROSCI, V11, P3442; BONDY CA, 1993, ANN NY ACAD SCI, V692, P33; BONDY CA, 1992, MOL CELL NEUROSCI, V3, P305, DOI 10.1016/1044-7431(92)90027-Y; Bonnefort AB, 1998, FEBS LETT, V441, P220, DOI 10.1016/S0014-5793(98)01552-X; BOULWARE SD, 1992, AM J PHYSIOL, V262, P130; CASCIERI MA, 1986, BIOCHIM BIOPHYS ACTA, V886, P491, DOI 10.1016/0167-4889(86)90186-2; Chen H, 1997, J BIOL CHEM, V272, P8026, DOI 10.1074/jbc.272.12.8026; Chen J, 1998, NEUROSCIENCE, V87, P817, DOI 10.1016/S0306-4522(98)00198-5; Cheng CM, 1998, J NEUROSCI, V18, P5673; CHIN E, 1993, J CLIN INVEST, V91, P1810, DOI 10.1172/JCI116392; Cornford EM, 1998, J NEUROPATH EXP NEUR, V57, P699, DOI 10.1097/00005072-199807000-00007; CZECH MP, 1995, ANNU REV NUTR, V15, P441, DOI 10.1146/annurev.nu.15.070195.002301; DEMEYTS P, 1994, HORM RES, V42, P152, DOI 10.1159/000184188; Dore S, 1997, TRENDS NEUROSCI, V20, P326; DUFFY KR, 1987, BRAIN RES, V420, P32, DOI 10.1016/0006-8993(87)90236-8; Fisher B, 2000, EUR J CANCER, V36, P142, DOI 10.1016/S0959-8049(99)00269-5; GERHART DZ, 1992, P NATL ACAD SCI USA, V89, P733, DOI 10.1073/pnas.89.2.733; Gibbs RB, 1998, EXP NEUROL, V151, P289, DOI 10.1006/exnr.1998.6789; Greene RA, 2000, FERTIL STERIL, V73, P143; HARIK SI, 1990, J NEUROSCI, V10, P3862, DOI 10.1523/JNEUROSCI.10-12-03862.1990; Inestrosa NC, 1998, MOL NEUROBIOL, V17, P73, DOI 10.1007/BF02802025; Kobayashi M, 1996, NEUROSCI LETT, V213, P103, DOI 10.1016/0304-3940(96)12845-7; KUMAGAI AK, 1994, BBA-BIOMEMBRANES, V1193, P24, DOI 10.1016/0005-2736(94)90328-X; LEE WH, 1993, ENDOCRINOLOGY, V133, P2540, DOI 10.1210/en.133.6.2540; Leloup C, 1996, MOL BRAIN RES, V38, P45, DOI 10.1016/0169-328X(95)00306-D; Levenson AS, 1999, EUR J CANCER, V35, P1974, DOI 10.1016/S0959-8049(99)00297-X; MacGregor JI, 1998, PHARMACOL REV, V50, P151; MAHER F, 1992, BIOCHEM BIOPH RES CO, V182, P703, DOI 10.1016/0006-291X(92)91789-S; McCall AL, 1996, J CEREBR BLOOD F MET, V16, P69, DOI 10.1097/00004647-199601000-00008; Mcewen BS, 1999, ENDOCR REV, V20, P279, DOI 10.1210/er.20.3.279; Murphy DD, 1998, J NEUROSCI, V18, P2550; MURPHY LJ, 1991, J STEROID BIOCHEM, V40, P223, DOI 10.1016/0960-0760(91)90186-9; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; NAGAMATSU S, 1992, J BIOL CHEM, V267, P467; NAMBA H, 1984, BRAIN RES, V291, P391, DOI 10.1016/0006-8993(84)91276-9; NEHLIG A, 1985, J CEREBR BLOOD F MET, V5, P393, DOI 10.1038/jcbfm.1985.54; Patrone C, 1999, P NATL ACAD SCI USA, V96, P10905, DOI 10.1073/pnas.96.19.10905; Pike CJ, 1999, J NEUROCHEM, V72, P1552, DOI 10.1046/j.1471-4159.1999.721552.x; Pozzo-Miller LD, 1999, J NEUROPHYSIOL, V81, P1404, DOI 10.1152/jn.1999.81.3.1404; Reiman EM, 1996, HUM REPROD, V11, P2799; REINHARDT RR, 1994, ENDOCRINOLOGY, V135, P1753, DOI 10.1210/en.135.5.1753; SALDARINI RJ, 1968, ENDOCRINOLOGY, V82, P511, DOI 10.1210/endo-82-3-511; Sawada H, 1998, J NEUROSCI RES, V54, P707, DOI 10.1002/(SICI)1097-4547(19981201)54:5<707::AID-JNR16>3.0.CO;2-T; Shi J, 1997, AM J PHYSIOL-ENDOC M, V272, pE1016, DOI 10.1152/ajpendo.1997.272.6.E1016; SIMPSON IA, 1994, ANN NEUROL, V35, P546, DOI 10.1002/ana.410350507; Simpson IA, 1999, J NEUROCHEM, V72, P238, DOI 10.1046/j.1471-4159.1999.0720238.x; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; Vannucci SJ, 1998, BRAIN RES, V797, P1, DOI 10.1016/S0006-8993(98)00103-6; Vedder H, 1999, J NEUROCHEM, V72, P2531, DOI 10.1046/j.1471-4159.1999.0722531.x; Welch RD, 1999, ENDOCRINOLOGY, V140, P3602, DOI 10.1210/en.140.8.3602; WERNER H, 1989, ENDOCRINOLOGY, V125, P314, DOI 10.1210/endo-125-1-314; Woolley CS, 1999, CURR OPIN NEUROBIOL, V9, P349, DOI 10.1016/S0959-4388(99)80051-8; Xu HX, 1998, NAT MED, V4, P447, DOI 10.1038/nm0498-447; YANO H, 1991, BIOCHEM BIOPH RES CO, V174, P470, DOI 10.1016/0006-291X(91)91440-N; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YOUNG WS, 1986, NEUROPEPTIDES, V8, P401; YOUNG WS, 1986, NEUROPEPTIDES, V8, P93, DOI 10.1016/0143-4179(86)90035-1; Yu S, 1998, BRAIN RES, V797, P65, DOI 10.1016/S0006-8993(98)00372-2; ZHOU J, 1993, J CLIN INVEST, V91, P845, DOI 10.1172/JCI116305; ZHOU J, 2000, IN PRESS J INVEST ME	70	91	94	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2001	15	6					907	915		10.1096/fj.00-0398com	http://dx.doi.org/10.1096/fj.00-0398com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292650				2022-12-28	WOS:000167959300004
J	Iljin, K; Karkkainen, MJ; Lawrence, EC; Kimak, MA; Uutela, M; Taipale, J; Pajusola, K; Alhonen, L; Halmekyto, M; Finegold, DN; Ferrell, RE; Alitalo, K				Iljin, K; Karkkainen, MJ; Lawrence, EC; Kimak, MA; Uutela, M; Taipale, J; Pajusola, K; Alhonen, L; Halmekyto, M; Finegold, DN; Ferrell, RE; Alitalo, K			VEGFR3 gene structure, regulatory region, and sequence polymorphisms	FASEB JOURNAL			English	Article						FLT4; receptor tyrosine kinase; promoter; endothelial cell; lymphangiogenesis	ENDOTHELIAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; VASCULAR-PERMEABILITY FACTOR; TRANSGENIC MICE; BINDING-SITES; HUMAN TISSUES; ORF VIRUS; IN-VIVO; EXPRESSION; FLT4	Vascular endothelial growth factor receptor 3 (VEGFR-3) is required for cardiovascular development during embryogenesis. In adults, this receptor is expressed in lymphatic endothelial cells, and mutant VEGFR3 alleles have been implicated in human hereditary lymphedema. To better understand the basis of its specific endothelial lineage-restricted expression, we have characterized the I VEGFR3 gene and its regulatory 5' flanking region. The human gene contains 31 exons, of which exons 30a and 30b are alternatively spliced. The VEGFR3 proximal promoter is TATA-less and contains stretches of sequences homologous with the mouse Vegfr3 promoter region. In transfection experiments of cultured cells, the Vegfr3 promoter was shown to control endothelial cell-specific transcription of downstream reporter genes. This result was further confirmed in vivo; in a subset of transgenic mouse embryos, a 1.6 kb Vegfr3 promoter fragment directed weak lymphatic endothelial expression of the LacZ marker gem. This suggests that endothelial cell-specific elements occur in the proximal promoter, although further enhancer elements are probably located elsewhere. The sequence, organization, and variation in the VEGFR3 gene and its regulatory region provide important tools for the molecular genetic analysis of the lymphatic system and its disorders.	Univ Helsinki, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland; Univ Helsinki, Ludwig Inst Canc Res, Haartman Inst, FIN-00014 Helsinki, Finland; Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA 15261 USA; Univ Kuopio, AI Virtanen Inst Mol Sci, FIN-70211 Kuopio, Finland	University of Helsinki; Ludwig Institute for Cancer Research; University of Helsinki; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Eastern Finland	Alitalo, K (corresponding author), Univ Helsinki, Mol Canc Biol Lab, POB 21,Haartmaninkatu 3, FIN-00014 Helsinki, Finland.	Kari.Alitalo@Helsinki.FI	Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902; Iljin, Kristiina/0000-0002-5161-0584; Finegold, David/0000-0001-9901-2578	NHLBI NIH HHS [HL35174, HL54526] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL054526, U10HL054526, R01HL035174] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; AIRD WC, 1995, P NATL ACAD SCI USA, V92, P4567, DOI 10.1073/pnas.92.10.4567; APRELIKOVA O, 1992, CANCER RES, V52, P746; ARMSTRONG E, 1993, GENE CHROMOSOME CANC, V7, P144, DOI 10.1002/gcc.2870070306; Cowan PJ, 1996, TRANSPLANTATION, V62, P155, DOI 10.1097/00007890-199607270-00002; Cowan PJ, 1998, J BIOL CHEM, V273, P11737, DOI 10.1074/jbc.273.19.11737; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fong GH, 1999, DEVELOPMENT, V126, P3015; GALLAND F, 1992, GENOMICS, V13, P475, DOI 10.1016/0888-7543(92)90277-Y; Gory S, 1998, J BIOL CHEM, V273, P6750, DOI 10.1074/jbc.273.12.6750; Guan JZ, 1999, BLOOD, V94, P3405, DOI 10.1182/blood.V94.10.3405.422k28_3405_3412; Iljin K, 1999, FASEB J, V13, P377, DOI 10.1096/fasebj.13.2.377; Irrthum A, 2000, AM J HUM GENET, V67, P295, DOI 10.1086/303019; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1996, EMBO J, V15, P290; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kappel A, 1999, BLOOD, V93, P4284, DOI 10.1182/blood.V93.12.4284.412k25_4284_4292; Karkkainen MJ, 2000, NAT GENET, V25, P153, DOI 10.1038/75997; Kondo K, 1998, GENE, V208, P297, DOI 10.1016/S0378-1119(98)00006-7; KORHONEN J, 1994, ONCOGENE, V9, P395; KORHONEN J, 1995, BLOOD, V86, P1828, DOI 10.1182/blood.V86.5.1828.bloodjournal8651828; Kukk E, 1996, DEVELOPMENT, V122, P3829; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; Nettelbeck DM, 1998, GENE THER, V5, P1656, DOI 10.1038/sj.gt.3300778; Ogawa S, 1998, J BIOL CHEM, V273, P31273, DOI 10.1074/jbc.273.47.31273; Oh SJ, 1997, DEV BIOL, V188, P96, DOI 10.1006/dbio.1997.8639; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PAJUSOLA K, 1994, ONCOGENE, V9, P3545; PAJUSOLA K, 1993, ONCOGENE, V8, P2931; Partanen TA, 2000, FASEB J, V14, P2087, DOI 10.1096/fj.99-1049com; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sabin FR, 1912, ANAT REC, V6, P335; Sarao R, 1998, TRANSGENIC RES, V7, P421, DOI 10.1023/A:1008837410485; Schlaeger TM, 1997, P NATL ACAD SCI USA, V94, P3058, DOI 10.1073/pnas.94.7.3058; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; TERMAN BI, 1991, ONCOGENE, V6, P1677; Valtola R, 1999, AM J PATHOL, V154, P1381, DOI 10.1016/S0002-9440(10)65392-8; Veikkola T, 2000, CANCER RES, V60, P203; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Wise LM, 1999, P NATL ACAD SCI USA, V96, P3071, DOI 10.1073/pnas.96.6.3071; WITTE MH, 1997, LYMPHANGIOGENESIS ME, P65; Yin LY, 1998, MAMM GENOME, V9, P408, DOI 10.1007/s003359900783; Yla-Herttuala S, 2000, LANCET, V355, P213, DOI 10.1016/S0140-6736(99)04180-X	52	56	66	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2001	15	6					1028	1036		10.1096/fj.00-0383com	http://dx.doi.org/10.1096/fj.00-0383com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292664				2022-12-28	WOS:000167959300018
J	Deaglio, S; Mallone, R; Baj, G; Donati, D; Giraudo, G; Corno, F; Bruzzone, S; Guena, M; Ausiello, C; Malavasi, F				Deaglio, S; Mallone, R; Baj, G; Donati, D; Giraudo, G; Corno, F; Bruzzone, S; Guena, M; Ausiello, C; Malavasi, F			Human CD38 and its ligand CD31 define a unique lamina propria T lymphocyte signaling pathway	FASEB JOURNAL			English	Article									Univ Turin, Sch Med, Dept Genet Biol & Biochem, Immunogenet Lab, I-10126 Turin, Italy; Univ Turin, Sch Med, Surg Clin 1, I-10126 Turin, Italy; Univ Turin, Sch Med, IRCC, Clin Immunol Lab, I-10126 Turin, Italy; Univ Genoa, Dept Expt Med, Biochem Sect, Genoa, Italy; Natl Inst Hlth, ISS, Rome, Italy	University of Turin; University of Turin; University of Turin; University of Genoa; Istituto Superiore di Sanita (ISS)	Malavasi, F (corresponding author), Univ Turin, Sch Med, Dept Genet Biol & Biochem, Immunogenet Lab, Via Santena 19, I-10126 Turin, Italy.		Bruzzone, Santina/A-4264-2015; Ausiello, Clara/G-3232-2011; Mallone, Roberto/H-4430-2013	Bruzzone, Santina/0000-0003-2034-3716; Mallone, Roberto/0000-0002-9846-8861; MALAVASI, Fabio/0000-0002-1844-174X; Geuna, Massimo/0000-0002-6475-5547	Telethon [E.0662] Funding Source: Medline	Telethon(Fondazione Telethon)			0	31	32	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					580	582						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259373				2022-12-28	WOS:000167419500011
J	Quinlivan, EP; McPartlin, J; Weir, DG; Scott, J				Quinlivan, EP; McPartlin, J; Weir, DG; Scott, J			Mechanism of the antimicrobial drug trimethoprim revisited	FASEB JOURNAL			English	Article						folate catabolism; folic acid; antifolate; dihydrofolate reductase	METABOLISM	We tested the hypothesis that the mechanism of action of the antifolate drug trimethoprim is through accumulation of bacterial dihydrofolate resulting in depletion of tetrahydrofolate coenzymes required for purine and pyrimidine biosynthesis. The folate pool of a strain of Escherichia coli (NCIMB 8879) was prelabeled with the folate biosynthetic precursor [H-3]-p-aminobenzoic acid before treatment with trimethoprim. Folates in untreated E. coli were present as tetrahydrofolate coenzymes. In trimethoprim-treated cells, however, a rapid transient accumulation of dihydrofolate occurred, followed by complete conversion of all forms of folate to cleaved catabolites (pteridines and para-aminobenzoylglutamate) and the stable nonreduced form of the vitamin, folic acid. Both para-aminobenzoylglutamate and folic acid were present in the cell in the form of polyglutamates. Removal of trimethoprim resulted in the reconversion of the accumulated folic acid to tetrahydrofolate cofactors for subsequent participation in the one-carbon cycle. Whereas irreversible catabolism is probably bactericidal, conversion to folic acid may constitute a bacteriostatic mechanism since, as we show, folic acid can be used by the bacteria and proliferation is resumed once trimethoprim is removed. Thus, the clinical effectiveness of this important drug may depend on the extent to which the processes of either catabolism or folic acid production occur in different bacteria or during different therapeutic regimes.	Univ Dublin Trinity Coll, Dept Clin Med, Dublin 2, Ireland; Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland	Trinity College Dublin; Trinity College Dublin	McPartlin, J (corresponding author), St James Hosp, Sir Patrick Duns Trinity Coll Lab, Vitamin Res Lab, Dublin 8, Ireland.	jmcprtln@tcd.ie	Quinlivan, Eoin/AAJ-1979-2021; Quinlivan, Eoin P/B-8454-2008	Quinlivan, Eoin/0000-0002-0908-1762; Quinlivan, Eoin P/0000-0002-0908-1762				BLAKLEY RL, 1969, BIOCH FOLIC ACID REL, P477; BLAKLEY RL, 1969, BIOCH FOLIC ACID REL, P489; BROWN JP, 1974, J GEN MICROBIOL, V84, P163, DOI 10.1099/00221287-84-1-163; BRUMFITT W, 1980, BRIT J HOSP MED, V23, P281; BUSHBY SRM, 1968, BRIT J PHARMACOL, V33, P72, DOI 10.1111/j.1476-5381.1968.tb00475.x; HITCHINGS GH, 1989, IN VITRO CELL DEV B, V25, P303; LUKIENKO PI, 1985, FARMAKOL TOKSIKOL, V48, P53; MCNULTY H, 1995, J NUTR, V125, P99; MCPARTLIN J, 1993, LANCET, V341, P148, DOI 10.1016/0140-6736(93)90007-4; MINI E, 1990, J CHEMOTHERAPY, V2, P17; Mitchell HK, 1941, J AM CHEM SOC, V63, P2284, DOI 10.1021/ja01853a512; Molloy AM, 1997, METHOD ENZYMOL, V281, P43; MURPHY M, 1976, BRIT J HAEMATOL, V84, P211; OLIVEIRA MBM, 1989, CELL BIOCHEM FUNCT, V7, P135, DOI 10.1002/cbf.290070209; Richards RME, 1996, J PHARM PHARMACOL, V48, P981, DOI 10.1111/j.2042-7158.1996.tb06017.x; SHANE B, 1989, VITAM HORM, V45, P263; THEN RL, 1993, J CHEMOTHERAPY, V5, P361, DOI 10.1080/1120009X.1993.11741082	17	45	47	1	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2000	14	15					2519	2524		10.1096/fj.99-1037com	http://dx.doi.org/10.1096/fj.99-1037com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099470				2022-12-28	WOS:000165723400022
J	Bujnicki, JM				Bujnicki, JM			Phylogenomic analysis of 16S rRNA :(guanine-N2) methyltransferases suggests new family members and reveals highly conserved motifs and a domain structure similar to other nucleic acid amino-methyltransferases	FASEB JOURNAL			English	Article						RNA modification; sequence alignment; molecular evolution; structure prediction	ADENOSYLMETHIONINE-DEPENDENT METHYLTRANSFERASES; S-ADENOSYLMETHIONINE; DNA METHYLTRANSFERASES; SEQUENCE ALIGNMENT; ESCHERICHIA-COLI; RNA; PROTEIN; IDENTIFICATION; GENERATION; ENZYMES	The sequences of known Escherichia coli 16S rRNA:m(2)G1207 methyltransferase (MTase) RsmC and hypothetical 168 rRNA:m(2)G966 MTase encoded by the ygjo open reading frame were used to carry out a database search of other putative m(2)G-generating enzymes in finished and unfinished genomic sequences. Sequence comparison and phylogenetic analysis of 21 close homologs of RsmC and YgjO revealed the presence of the third paralogous lineage in E. coli and other gamma -Proteobacteria, which might correspond to the subfamily of MTases specific for G1516 in 16S rRNA. In addition, the comparative sequence analysis supported by sequence/structure threading suggests that rRNA:m(2)G MTases are very closely related to RNA and DNA:m(6)A MTases and that these two enzyme families share common architecture of the active site and presumably a similar mechanism of methyl group transfer onto the exocyclic amino group of their target bases.-Bujnicki, J. M. Phylogenomic analysis of 16S rRNA (guanine-N2) methyltransferases suggests new family members and reveals highly conserved motifs and a domain structure similar to other nucleic acid amino-methyltransferases.	Int Inst Mol & Cell Biol, Bioinformat Unit, PL-02109 Warsaw, Poland; Henry Ford Hlth Syst, Mol Biol Res Program, Detroit, MI 48202 USA	Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej; Henry Ford Health System; Henry Ford Hospital	Bujnicki, JM (corresponding author), Int Inst Mol & Cell Biol, Bioinformat Unit, Ul Ks Trojdena 4, PL-02109 Warsaw, Poland.							Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bujnicki Janusz M., 1999, Acta Microbiologica Polonica, V48, P19; Bujnicki JM, 1999, IUBMB LIFE, V48, P247, DOI 10.1080/713803519; Bujnicki JM, 1999, NUCLEIC ACIDS RES, V27, P4501, DOI 10.1093/nar/27.22.4501; BUJNICKI JM, 1999, SILICO BIOL, V1, P1; Cheng X, 1999, S ADENOSYLMETHIONINE; FAUMAN EB, 1999, S ADENOSYLMETHIONINE, P1, DOI DOI 10.1142/9789812813077_0001; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Grosjean H, 1998, MODIFICATION EDITING, P21; Grosjean H., 1998, MODIFICATION EDITING, DOI [10.1128/9781555818296, DOI 10.1128/9781555818296]; Gustafsson C, 1996, NUCLEIC ACIDS RES, V24, P3756, DOI 10.1093/nar/24.19.3756; INGROSSO D, 1989, J BIOL CHEM, V264, P20131; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; LABAHN J, 1994, P NATL ACAD SCI USA, V91, P10957, DOI 10.1073/pnas.91.23.10957; MALONE T, 1995, J MOL BIOL, V253, P618, DOI 10.1006/jmbi.1995.0577; Motorin Y, 1999, RNA, V5, P1105, DOI 10.1017/S1355838299982201; OGARA M, 1995, GENE, V157, P135, DOI 10.1016/0378-1119(94)00669-J; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; Radlinska M, 1999, PROTEINS, V37, P717, DOI 10.1002/(SICI)1097-0134(19991201)37:4<717::AID-PROT20>3.0.CO;2-P; Reid R, 1999, NUCLEIC ACIDS RES, V27, P3138, DOI 10.1093/nar/27.15.3138; Rychlewski L, 2000, PROTEIN SCI, V9, P232, DOI 10.1110/ps.9.2.232; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SCHLUCKEBIER G, 1995, GENE, V157, P131, DOI 10.1016/0378-1119(94)00690-T; Schluckebier G, 1998, BIOL CHEM, V379, P389; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tscherne JS, 1999, J BIOL CHEM, V274, P924, DOI 10.1074/jbc.274.2.924; Yu LP, 1997, NAT STRUCT BIOL, V4, P483, DOI 10.1038/nsb0697-483	28	39	39	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2365	2368		10.1096/fj.00-0076com	http://dx.doi.org/10.1096/fj.00-0076com			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053259				2022-12-28	WOS:000165190800031
J	Venuti, A; Salani, D; Manni, V; Poggiali, F; Bagnato, A				Venuti, A; Salani, D; Manni, V; Poggiali, F; Bagnato, A			Expression of endothelin 1 and endothelin A receptor in HPV-associated cervical carcinoma: new potential targets for anticancer therapy	FASEB JOURNAL			English	Article						ETAR antagonists; genital tumors; tumor growth; papillomavirus; autocrine loop	GROWTH-FACTOR RECEPTOR; HUMAN-PAPILLOMAVIRUS; HUMAN KERATINOCYTES; OVARIAN-CARCINOMA; PROSTATE-CANCER; E5 ONCOPROTEIN; CELL-GROWTH; TUMOR; SUBTYPE	Human papillomaviruses (HPV) are associated with cervical cancer and interact with growth factors that may enhance malignant transformation of cervical carcinoma cells. Endothelin-1 (ET-1) is released from HPV transfected keratinocytes and induces increased growth response in these cell lines in comparison with normal cells. In the present study several cervical carcinoma cell Lines have been analyzed to investigate the expression of ET-1 and its receptors as well as their involvement in tumor growth, All HPV-positive cancer cells secreted ET-1 and expressed mRNA for ET-1 and its receptors, whereas a HPV-negative carcinoma cell line expressed only the ETBR mRNA and didn't secrete ET-1, Binding studies showed that HPV-associated cells expressed an increased number of functional ETAR. ET-1 stimulated a marked dose-dependent increase in [H-3]-thymidine incorporation with respect to the normal cells whereas ET-3 and ETBR agonists had no effect, In HPV-positive cancer cells, a specific antagonist of ETAR inhibited the proliferation induced by ET-1 and substantially reduced the basal growth rate of unstimulated cervical tumor cells, whereas the ETBR antagonist had no effect, These results demonstrate that ET-1 participates in the progression of neoplastic growth in HPV-associated carcinoma, in which ETAR are increased and could be targeted for antitumor therapy.-Venuti, A., Salani, D., Manni, V., Poggiali, F., Bagnato, A. Expression of endothelin 1 and endothelin A receptor in HPV-associated cervical carcinoma: new potential targets for anticancer therapy.	Regina Elena Canc Inst, Virol Lab, I-00158 Rome, Italy; Regina Elena Canc Inst, Lab Mol Pathol & Ultrastruct, I-00158 Rome, Italy		Venuti, A (corresponding author), Regina Elena Canc Inst, Virol Lab, Via Messi Oro 156, I-00158 Rome, Italy.		Bagnato, Anna/G-9747-2016; Venuti, Aldo/K-9637-2016	Bagnato, Anna/0000-0002-7269-9522; Venuti, Aldo/0000-0003-2322-6857				BAGNATO A, 1995, BIOCHEM BIOPH RES CO, V209, P80, DOI 10.1006/bbrc.1995.1473; Bagnato A, 1999, CANCER RES, V59, P720; Bagnato A, 1998, TRENDS ENDOCRIN MET, V9, P378, DOI 10.1016/S1043-2760(98)00094-0; Bagnato A, 1995, CLIN CANCER RES, V1, P1059; Bagnato A, 1997, CANCER RES, V57, P1306; BATTISTINI B, 1993, PEPTIDES, V14, P385, DOI 10.1016/0196-9781(93)90057-N; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DIMARCO E, 1991, J BIOL CHEM, V266, P21718; FRANCO EL, 1995, JNCI-J NATL CANCER I, V87, P779, DOI 10.1093/jnci/87.11.779; FUKAHIRO T, 1994, BIOCHEM BIOPH RES CO, V199, P1461; HALABAN R, 1988, J CELL BIOL, V107, P1611, DOI 10.1083/jcb.107.4.1611; LANG RA, 1990, IMMUNOL TODAY, V11, P244, DOI 10.1016/0167-5699(90)90098-T; Nelson JB, 1996, CANCER RES, V56, P663; NELSON JB, 1995, NAT MED, V1, P944, DOI 10.1038/nm0995-944; Nelson JB, 1998, NAT MED, V4, P1011, DOI 10.1038/1998; PEKONEN F, 1995, BRIT J CANCER, V71, P59, DOI 10.1038/bjc.1995.12; PISANI P, 1993, INT J CANCER, V55, P891, DOI 10.1002/ijc.2910550604; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SIZEMORE N, 1993, CANCER RES, V53, P4511; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; Venuti A, 1998, VIROLOGY, V248, P1, DOI 10.1006/viro.1998.9227; Venuti A, 1997, J VIROL, V71, P6898, DOI 10.1128/JVI.71.9.6898-6904.1997; YAMASHITA J, 1992, CANCER RES, V52, P4046; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; zurHausen H, 1996, J CANCER RES CLIN, V122, P3	26	51	53	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2277	2283		10.1096/fj.00-0024com	http://dx.doi.org/10.1096/fj.00-0024com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053249				2022-12-28	WOS:000165190800021
J	Deshpande, SS; Angkeow, P; Kuang, JP; Ozaki, M; Irani, K				Deshpande, SS; Angkeow, P; Kuang, JP; Ozaki, M; Irani, K			Rac1 inhibits TNF-alpha-induced endothelial cell apoptosis: dual regulation by reactive oxygen species	FASEB JOURNAL			English	Article						apoptosis; ROS; Rac1; nuclear factor-kappa B; caspase-3	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; SMOOTH-MUSCLE CELLS; NADPH OXIDASE; NITRIC-OXIDE; SIGNAL-TRANSDUCTION; PROTEIN-SYNTHESIS; ANGIOTENSIN-II; ACTIVATION; PATHWAY	Reactive oxygen species (ROS) have been implicated as mediators of tumor necrosis factor-alpha (TNF) -induced apoptosis. In addition to leading to cell death, ROS can also promote cell growth and/or survival. We investigated these two roles of ROS in TNF-induced endothelial cell apoptosis. Human umbilical vein endothelial cells (HUVECs) stimulated with TNF produced an intracellular burst of ROS. Adenoviral-mediated gene transfer of a dominant negative form of the small GTPase Rad (Rac1N17) partially suppressed the TNF-induced oxidative burst without affecting TNF-induced mitochondrial ROS production. HUVECs were protected from TNF-induced apoptosis. Expression of Rac1N17 blocked TNF-induced activation of nuclear factor-kappa B (NF-kappa B), increased activity of caspase-3, and markedly augmented endothelial cell susceptibility to TNF-induced apoptosis. Direct inhibition of NF-kappa B through adenoviral expression of the super repressor form of inhibitor of kappa B alpha (I-kappa B S32/36A) also increased susceptibility of HUVECs to TNF-induced apoptosis. Rotenone, a mitochondrial electron transport chain inhibitor, suppressed TNF-induced mitochondrial ROS production, proteolytic cleavage of procaspase-3, and apoptosis. These findings show that Rad is an important regulator of TNF-induced ROS production in endothelial cells. Moreover, they suggest that Rad-dependent ROS, directly or indirectly, lead to protection against TNF-induced death, whereas mitochondrial-derived ROS promote TNF-induced apoptosis.	Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21205 USA	Johns Hopkins University	Irani, K (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Ross 1023,720 Rutland Ave, Baltimore, MD 21205 USA.		Ozaki, Michitaka/A-4549-2012	Irani, Kaikobad/0000-0001-9194-7387				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BELLAS RE, 1995, J CLIN INVEST, V96, P2521, DOI 10.1172/JCI118313; Bombeli T, 1997, BLOOD, V89, P2429, DOI 10.1182/blood.V89.7.2429; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Clement MV, 1996, EMBO J, V15, P216, DOI 10.1002/j.1460-2075.1996.tb00352.x; COLLINS T, 1993, LAB INVEST, V68, P499; Crawford LE, 1996, J BIOL CHEM, V271, P26863, DOI 10.1074/jbc.271.43.26863; DAVIES MJ, 1988, BRIT HEART J, V60, P459; Del Bello B, 1999, FASEB J, V13, P69; FENG L, 1995, J CLIN INVEST, V95, P1669, DOI 10.1172/JCI117842; FRIEDL HP, 1989, FASEB J, V3, P2512, DOI 10.1096/fasebj.3.13.2806779; GENG YJ, 1995, AM J PATHOL, V147, P251; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; Gulbins E, 1996, J BIOL CHEM, V271, P26389, DOI 10.1074/jbc.271.42.26389; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hu XL, 1998, BLOOD, V92, P2759, DOI 10.1182/blood.V92.8.2759.420k29_2759_2765; Iimuro Y, 1998, J CLIN INVEST, V101, P1541; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; Krieg RM, 1995, J URBAN TECHNOL, V3, P1; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Li DY, 1998, AM J PHYSIOL-HEART C, V275, pH568, DOI 10.1152/ajpheart.1998.275.2.H568; Li JR, 1999, J BIOL CHEM, V274, P17325, DOI 10.1074/jbc.274.24.17325; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; MATTHEWS N, 1987, IMMUNOLOGY, V62, P153; MEIER B, 1993, BIOCHEM J, V289, P481, DOI 10.1042/bj2890481; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Ozes ON, 1999, NATURE, V401, P82; POHLMAN TH, 1989, CELL IMMUNOL, V119, P41, DOI 10.1016/0008-8749(89)90222-0; POLUNOVSKY VA, 1994, EXP CELL RES, V214, P584, DOI 10.1006/excr.1994.1296; Pracyk JB, 1998, J CLIN INVEST, V102, P929, DOI 10.1172/JCI2552; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; RICHARDSON BC, 1994, EUR J IMMUNOL, V24, P2640, DOI 10.1002/eji.1830241111; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROTHE G, 1991, J IMMUNOL METHODS, V138, P133, DOI 10.1016/0022-1759(91)90074-P; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	50	199	214	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2000	14	12					1705	1714		10.1096/fj.99-0910com	http://dx.doi.org/10.1096/fj.99-0910com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973919				2022-12-28	WOS:000089212400009
J	Kingwell, BA				Kingwell, BA			Nitric oxide-mediated metabolic regulation during exercise: effects of training in health and cardiovascular disease	FASEB JOURNAL			English	Review						coronary disease; glucose uptake; hypercholesterolemia; hypertension; vascular reactivity	CHRONIC HEART-FAILURE; ENDOTHELIUM-DEPENDENT VASODILATION; SPONTANEOUSLY HYPERTENSIVE RATS; SKELETAL-MUSCLE FIBERS; BLOOD-FLOW CONTROL; CORONARY-ARTERIES; MITOCHONDRIAL RESPIRATION; GLUCOSE-TRANSPORT; RELAXING FACTOR; CONSCIOUS DOGS	Accumulating data suggest that nitric oxide (NO) is important for both coronary and peripheral hemodynamic control and metabolic regulation during exercise. Although still controversial, NO of endothelial origin may potentiate exercise-induced hyperemia. Mechanisms of release include both acetylcholine derived from the neuromuscular junction and elevation in vascular shear stress. A splice variant of neuronal nitric oxide synthase (NOS), nNOS mu, is expressed in human skeletal muscle, In addition to being a potential modulator of blood flow, NO from skeletal muscle regulates muscle contraction and metabolism. In particular, recent human data indicate that NO plays a role in muscle glucose uptake during exercise independently of blood flow. Exercise training in healthy individuals elevates NO bioavailability through a variety of mechanisms including increased NOS enzyme expression and activity. Such adaptations likely contribute to increased exercise capacity and cardiovascular protection. Cardiovascular risk factors including hypercholesterolemia, hypertension, diabetes, and smoking as well as established disease are associated with impairment of the various NO systems. Given that NO is an important signaling mechanism during exercise, such impairment may contribute to limitations in exercise capacity through inadequate coronary or peripheral perfusion and via metabolic effects. Exercise training in individuals with elevated cardiovascular risk or established disease can increase NO bioavailability and may represent an important mechanism by which exercise training conveys benefit in the setting of secondary prevention.	Baker Med Res Inst, Alfred & Baker Med Unit, Melbourne, Vic 8008, Australia	Baker Heart and Diabetes Institute	Kingwell, BA (corresponding author), Baker Med Res Inst, Alfred & Baker Med Unit, Commercial Rd, Prahran, Vic 3181, Australia.	b.kingwell@alfred.org.au	Kingwell, Bronwyn A/B-1183-2009					Adachi H, 1997, AM HEART J, V134, P196, DOI 10.1016/S0002-8703(97)70124-8; Adams V, 1997, BIOCHEM MOL MED, V61, P152, DOI 10.1006/bmme.1997.2598; Augier T, 1996, J CARDIOVASC PHARM, V27, P752, DOI 10.1097/00005344-199605000-00020; BALON TW, 1994, J APPL PHYSIOL, V77, P2519, DOI 10.1152/jappl.1994.77.6.2519; Balon TW, 1997, J APPL PHYSIOL, V82, P359, DOI 10.1152/jappl.1997.82.1.359; Bank A J, 1998, J Card Fail, V4, P193, DOI 10.1016/S1071-9164(98)80006-7; Bernstein, 1996, CIRC RES, V79, P1218; Bernstein RD, 1996, CIRC RES, V79, P840, DOI 10.1161/01.RES.79.4.840; Bode-Boger S M, 1994, J Cardiovasc Risk, V1, P173; Bradley SJ, 1999, DIABETES, V48, P1815, DOI 10.2337/diabetes.48.9.1815; Brown GC, 1999, BBA-BIOENERGETICS, V1411, P351, DOI 10.1016/S0005-2728(99)00025-0; BROWN GC, 1995, FEBS LETT, V369, P136, DOI 10.1016/0014-5793(95)00763-Y; CAMERON JD, 1994, AM J PHYSIOL, V266, pH693, DOI 10.1152/ajpheart.1994.266.2.H693; Chao DS, 1996, METHOD ENZYMOL, V268, P488; Chen HI, 1996, AM J PHYSIOL-HEART C, V271, pH977, DOI 10.1152/ajpheart.1996.271.3.H977; Clarkson P, 1999, J AM COLL CARDIOL, V33, P1379, DOI 10.1016/S0735-1097(99)00036-4; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; Depre C, 1998, AM J PHYSIOL-HEART C, V274, pH1443, DOI 10.1152/ajpheart.1998.274.5.H1443; DUNCKER DJ, 1993, CIRCULATION, V88, P1245, DOI 10.1161/01.CIR.88.3.1245; DUNCKER DJ, 1995, J CLIN INVEST, V95, P285, DOI 10.1172/JCI117653; DYKE CK, 1995, J PHYSIOL-LONDON, V488, P259, DOI 10.1113/jphysiol.1995.sp020964; El-Dwairi Q, 1998, AM J PHYSIOL-CELL PH, V274, pC770, DOI 10.1152/ajpcell.1998.274.3.C770; Eriksson KF, 1996, DIABETOLOGIA, V39, P573, DOI 10.1007/BF00403304; Etgen GJ, 1997, DIABETES, V46, P1915, DOI 10.2337/diabetes.46.11.1915; Flesch M, 1999, J AM COLL CARDIOL, V33, P1062, DOI 10.1016/S0735-1097(98)00660-3; Frandsen U, 1996, BIOCHEM BIOPH RES CO, V227, P88, DOI 10.1006/bbrc.1996.1472; Fujii Y, 1998, J APPL PHYSIOL, V85, P2330, DOI 10.1152/jappl.1998.85.6.2330; GAGE JE, 1986, CIRCULATION, V73, P865, DOI 10.1161/01.CIR.73.5.865; GILLIGAN DM, 1994, CIRCULATION, V90, P2853, DOI 10.1161/01.CIR.90.6.2853; GONZALEZ JL, 1987, BRAIN RES, V412, P148, DOI 10.1016/0006-8993(87)91450-8; GORDON JB, 1989, J CLIN INVEST, V83, P1946, DOI 10.1172/JCI114103; Grozdanovic Z, 1999, HISTOL HISTOPATHOL, V14, P243, DOI 10.14670/HH-14.243; Habib FM, 1996, LANCET, V347, P1151, DOI 10.1016/S0140-6736(96)90610-8; Hambrecht R, 1998, CIRCULATION, V98, P2709, DOI 10.1161/01.CIR.98.24.2709; Hambrecht R, 1999, J AM COLL CARDIOL, V33, P174, DOI 10.1016/S0735-1097(98)00531-2; HASKELL WL, 1993, CIRCULATION, V87, P1076, DOI 10.1161/01.CIR.87.4.1076; Hayashi T, 1997, AM J PHYSIOL-ENDOC M, V273, pE1039, DOI 10.1152/ajpendo.1997.273.6.E1039; Hickner RC, 1997, AM J PHYSIOL-HEART C, V273, pH405, DOI 10.1152/ajpheart.1997.273.1.H405; Higashi Y, 1999, HYPERTENSION, V33, P591, DOI 10.1161/01.HYP.33.1.591; Higashi Y, 1999, CIRCULATION, V100, P1194, DOI 10.1161/01.CIR.100.11.1194; Hornig B, 1996, CIRCULATION, V93, P210, DOI 10.1161/01.CIR.93.2.210; Hu CT, 1997, BRIT J PHARMACOL, V122, P1237, DOI 10.1038/sj.bjp.0701496; IKEDA C, 1994, BRAIN RES, V655, P147, DOI 10.1016/0006-8993(94)91608-X; Ishibashi Y, 1997, J CARDIOVASC PHARM, V30, P374, DOI 10.1097/00005344-199709000-00016; Ishibashi Y, 1998, CIRC RES, V82, P346, DOI 10.1161/01.RES.82.3.346; IWAMOTO J, 1994, RESP PHYSIOL, V97, P333, DOI 10.1016/0034-5687(94)90069-8; JENNINGS G, 1986, CIRCULATION, V73, P30, DOI 10.1161/01.CIR.73.1.30; Jonsdottir IH, 1998, ACTA PHYSIOL SCAND, V162, P149; Kaasik A, 1999, FEBS LETT, V444, P75, DOI 10.1016/S0014-5793(99)00033-2; Katoh J, 1996, J INT MED RES, V24, P209, DOI 10.1177/030006059602400205; Katz SD, 1997, J APPL PHYSIOL, V82, P1488, DOI 10.1152/jappl.1997.82.5.1488; KING CE, 1994, J APPL PHYSIOL, V76, P1166, DOI 10.1152/jappl.1994.76.3.1166; KINGWELL BA, 1993, MED J AUSTRALIA, V158, P234, DOI 10.5694/j.1326-5377.1993.tb121740.x; Kingwell BA, 1998, NUTR METAB CARDIOVAS, V8, P173; Kingwell BA, 1997, AM J PHYSIOL-HEART C, V273, pH2186, DOI 10.1152/ajpheart.1997.273.5.H2186; Kingwell BA, 1996, AM J PHYSIOL-HEART C, V270, pH2008, DOI 10.1152/ajpheart.1996.270.6.H2008; Kingwell BA, 1997, AM J PHYSIOL-HEART C, V272, pH1070, DOI 10.1152/ajpheart.1997.272.3.H1070; KOBZIK L, 1995, BIOCHEM BIOPH RES CO, V211, P375, DOI 10.1006/bbrc.1995.1824; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; Koelling TM, 1998, AM J CARDIOL, V81, P1494, DOI 10.1016/S0002-9149(98)00214-8; Kojda G, 1999, CARDIOVASC RES, V41, P514, DOI 10.1016/S0008-6363(98)00314-9; KOLLER A, 1991, AM J PHYSIOL, V260, pH862, DOI 10.1152/ajpheart.1991.260.3.H862; Kubota T, 1997, JPN CIRC J, V61, P471, DOI 10.1253/jcj.61.471; Lau KS, 1998, FEBS LETT, V431, P71, DOI 10.1016/S0014-5793(98)00728-5; Lewis TV, 1999, ARTERIOSCL THROM VAS, V19, P2782, DOI 10.1161/01.ATV.19.11.2782; LIN C, 1998, BIOCHEM BIOPH RES CO, V18, P388; LINDSAY DC, 1992, CARDIOVASC RES, V26, P694, DOI 10.1093/cvr/26.7.694; Madar Z, 1997, DIABETES, V46, P93; MAROUN MJ, 1995, J APPL PHYSIOL, V79, P1219, DOI 10.1152/jappl.1995.79.4.1219; Martin CM, 1996, AM J PHYSIOL-HEART C, V270, pH442, DOI 10.1152/ajpheart.1996.270.2.H442; Maxwell AJ, 1998, CIRCULATION, V98, P369, DOI 10.1161/01.CIR.98.4.369; McAllister RM, 1997, J APPL PHYSIOL, V82, P1438, DOI 10.1152/jappl.1997.82.5.1438; Meszaros LG, 1996, FEBS LETT, V380, P49, DOI 10.1016/0014-5793(96)00003-8; Mills PC, 1999, RES VET SCI, V66, P135, DOI 10.1053/rvsc.1998.0258; Mohr S, 1996, J BIOL CHEM, V271, P4209; Mombouli JV, 1996, BRIT J PHARMACOL, V117, P413, DOI 10.1111/j.1476-5381.1996.tb15206.x; Morrison RJ, 1996, J APPL PHYSIOL, V80, P1065, DOI 10.1152/jappl.1996.80.3.1065; NABEL EG, 1990, CIRCULATION, V81, P850, DOI 10.1161/01.CIR.81.3.850; NICHOLS CG, 1991, AM J PHYSIOL, V261, pH1675, DOI 10.1152/ajpheart.1991.261.6.H1675; Niebauer J, 1999, AM J PHYSIOL-HEART C, V276, pH1346; Node K, 1998, J AM COLL CARDIOL, V32, P63, DOI 10.1016/S0735-1097(98)00196-X; Okubo T, 1999, FUNDAM CLIN PHARM, V13, P34, DOI 10.1111/j.1472-8206.1999.tb00318.x; OLTMAN CL, 1995, J APPL PHYSIOL, V79, P33, DOI 10.1152/jappl.1995.79.1.33; Owlya R, 1997, CIRCULATION, V96, P3897; Parker JL, 1997, J APPL PHYSIOL, V83, P434, DOI 10.1152/jappl.1997.83.2.434; Radegran G, 1999, AM J PHYSIOL-HEART C, V276, pH1951, DOI 10.1152/ajpheart.1999.276.6.H1951; Reid MB, 1998, ACTA PHYSIOL SCAND, V162, P401, DOI 10.1046/j.1365-201X.1998.0303f.x; Reinheimer T, 1998, N-S ARCH PHARMACOL, V358, pR87; Roberts CK, 1997, AM J PHYSIOL-ENDOC M, V273, pE220, DOI 10.1152/ajpendo.1997.273.1.E220; Roberts CK, 1999, AM J PHYSIOL-ENDOC M, V277, pE390, DOI 10.1152/ajpendo.1999.277.2.E390; Rodriguez-Plaza L G, 1997, J Cardiovasc Risk, V4, P367, DOI 10.1097/00043798-199710000-00009; Sakamoto S, 1998, DIABETES, V47, P82, DOI 10.2337/diabetes.47.1.82; SEGAL SS, 1994, HYPERTENSION, V23, P1113, DOI 10.1161/01.HYP.23.6.1113; Segal SS, 1999, J PHYSIOL-LONDON, V516, P283, DOI 10.1111/j.1469-7793.1999.283aa.x; SEGAL SS, 1995, MED SCI SPORT EXER, V27, P1158; SEN CK, 1995, J APPL PHYSIOL, V79, P675, DOI 10.1152/jappl.1995.79.3.675; SESSA W, 1994, CIRC RES, V73, P829; SHEN WQ, 1994, CIRC RES, V75, P1086, DOI 10.1161/01.RES.75.6.1086; VANHOUTTE PM, 1989, AM J MED, V87, pS1, DOI 10.1016/0002-9343(89)90496-8; VANHOUTTE PM, 1981, PHYSIOL REV, V61, P151, DOI 10.1152/physrev.1981.61.1.151; WATANABE H, 1993, J AM COLL CARDIOL, V21, P1497, DOI 10.1016/0735-1097(93)90330-4; Wei CM, 1996, MAYO CLIN PROC, V71, P346, DOI 10.4065/71.4.346; WILSON JR, 1993, J APPL PHYSIOL, V75, P2740, DOI 10.1152/jappl.1993.75.6.2740; Xu KY, 1999, P NATL ACAD SCI USA, V96, P657, DOI 10.1073/pnas.96.2.657; YEN MH, 1995, LIFE SCI, V57, P2205, DOI 10.1016/0024-3205(95)02127-5; Young ME, 1998, BIOCHEM J, V329, P73; Zhao G, 1997, CIRC RES, V80, P868	107	181	190	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2000	14	12					1685	1696		10.1096/fj.99-0896rev	http://dx.doi.org/10.1096/fj.99-0896rev			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973917	Bronze			2022-12-28	WOS:000089212400007
J	Jacobs, MG; Robinson, PJ; Bletchly, C; Mackenzie, JM; Young, PR				Jacobs, MG; Robinson, PJ; Bletchly, C; Mackenzie, JM; Young, PR			Dengue virus nonstructural protein 1 is expressed in a glycosyl-phosphatidylinositol-linked form that is capable of signal transduction	FASEB JOURNAL			English	Article						flavivirus; dengue; viral nonstructural proteins; GPI; antibody	YELLOW-FEVER VIRUS; T-CELL ACTIVATION; ANCHORED MEMBRANE-PROTEINS; DECAY-ACCELERATING FACTOR; BORNE ENCEPHALITIS-VIRUS; HEMORRHAGIC-FEVER; MONOCLONAL-ANTIBODIES; NUCLEOTIDE-SEQUENCE; STRUCTURAL PROTEINS; ENDOTHELIAL-CELLS	Dengue virus nonstructural protein I (NS1) is expressed on the surface of infected cells and is a target of human antibody responses to dengue virus infection. We show here that dengue virus uses the cellular glycosyl-phosphatidylinositol (GPI) linkage pathway to express a GPI-anchored form of NS1 and that GPI anchoring imparts a capacity for signal transduction in response to binding of NS1-specific antibody. This study is the first to identify GPI linkage of a virus-encoded protein. The GPI anchor addition signal for NS1 was identified, by transfection of HeLa cells with dengue cDNA constructs, as a downstream hydrophobic domain in NS2A, GPI linkage of NS1 in both transfected and infected cells was demonstrated by cleavage of NS1 from the surface by PI-specific phospholipase C and by metabolic incorporation of the GPI-specific components ethanolamine and inositol. In common with other GPI-anchored proteins, addition of specific antibody resulted in signal transduction, as evidenced by tyrosine phosphorylation of cellular proteins. Antibody-induced signal transduction by GPI-linked NS1 suggests a mechanism of cellular activation that may contribute to the pathogenesis of human dengue disease. Signal transduction by a GPI-anchored viral antigen interacting with a specific antibody that it induces is a new concept in the pathogenesis of viral disease.	Univ Queensland, SASVRC, Dept Microbiol & Parasitol, St Lucia, Qld 4072, Australia; Imperial Coll, Sch Med, Dept Paediat, London W2 1PG, England; Imperial Coll, Sch Med, MRC, Ctr Clin Sci, London W12 0NN, England; Royal Childrens Hosp, Sir Albert Sakzewski Virus Res Ctr, Brisbane, Qld 4029, Australia	University of Queensland; Imperial College London; Imperial College London; Royal Children's Hospital Brisbane	Young, PR (corresponding author), Univ Queensland, SASVRC, Dept Microbiol & Parasitol, St Lucia, Qld 4072, Australia.		Mackenzie, Jason/H-5632-2019; Young, Paul R/A-6176-2010	Mackenzie, Jason/0000-0001-6613-8350; Young, Paul R/0000-0002-2040-5190				Anderson R, 1997, J VIROL, V71, P4226, DOI 10.1128/JVI.71.6.4226-4232.1997; CAHOUR A, 1992, J VIROL, V66, P1535, DOI 10.1128/JVI.66.3.1535-1542.1992; CARAS IW, 1991, J CELL BIOL, V113, P77, DOI 10.1083/jcb.113.1.77; CHAMBERS TJ, 1990, P NATL ACAD SCI USA, V87, P8898, DOI 10.1073/pnas.87.22.8898; CHURDBOONCHART V, 1991, AM J TROP MED HYG, V44, P481, DOI 10.4269/ajtmh.1991.44.481; Eisenhaber B, 1998, PROTEIN ENG, V11, P1155, DOI 10.1093/protein/11.12.1155; FALCONAR AKI, 1991, J GEN VIROL, V72, P961, DOI 10.1099/0022-1317-72-4-961; FALGOUT B, 1989, J VIROL, V63, P1852, DOI 10.1128/JVI.63.5.1852-1860.1989; FALGOUT B, 1991, J VIROL, V65, P2467, DOI 10.1128/JVI.65.5.2467-2475.1991; FALGOUT B, 1995, J VIROL, V69, P7232, DOI 10.1128/JVI.69.11.7232-7243.1995; FALKLER WA, 1973, J IMMUNOL, V111, P1804; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; HAHN YS, 1988, VIROLOGY, V162, P167, DOI 10.1016/0042-6822(88)90406-0; HALSTEAD SB, 1980, B WORLD HEALTH ORGAN, V58, P1; HALSTEAD SB, 1988, SCIENCE, V239, P476, DOI 10.1126/science.3277268; HALSTEAD SB, 1989, REV INFECT DIS, V11, pS830; HIROSE S, 1995, METHOD ENZYMOL, V250, P582; Huang JH, 1999, J MED VIROL, V57, P1, DOI 10.1002/(SICI)1096-9071(199901)57:1&lt;1::AID-JMV1&gt;3.0.CO;2-T; Ilangumaran S, 1996, TRENDS CELL BIOL, V6, P163, DOI 10.1016/0962-8924(96)20012-1; KAPOOR M, 1995, J BIOL CHEM, V270, P19100, DOI 10.1074/jbc.270.32.19100; KOOYMAN DL, 1995, SCIENCE, V269, P89, DOI 10.1126/science.7541557; KUNO G, 1990, J MED VIROL, V32, P102, DOI 10.1002/jmv.1890320207; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEBLOIS H, 1995, J GEN VIROL, V76, P979, DOI 10.1099/0022-1317-76-4-979; LEBLOIS H, 1993, NUCLEIC ACIDS RES, V21, P1668, DOI 10.1093/nar/21.7.1668; Lindenbach BD, 1999, J VIROL, V73, P4611, DOI 10.1128/JVI.73.6.4611-4621.1999; Lindenbach BD, 1997, J VIROL, V71, P9608, DOI 10.1128/JVI.71.12.9608-9617.1997; Low M.G., 1992, LIPID MODIFICATION P, P117; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; LUNDJOHANSEN F, 1993, EUR J IMMUNOL, V23, P2782, DOI 10.1002/eji.1830231110; Mackenzie JM, 1996, VIROLOGY, V220, P232, DOI 10.1006/viro.1996.0307; MARKOFF L, 1989, J VIROL, V63, P3345, DOI 10.1128/JVI.63.8.3345-3352.1989; Mason JC, 1996, J IMMUNOL, V157, P874; MASON PW, 1989, VIROLOGY, V169, P354, DOI 10.1016/0042-6822(89)90161-X; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MEDOF ME, 1985, P NATL ACAD SCI USA, V82, P2980, DOI 10.1073/pnas.82.9.2980; MONATH TP, 1994, P NATL ACAD SCI USA, V91, P2395, DOI 10.1073/pnas.91.7.2395; Morozova OV, 1997, VIRUS RES, V49, P9, DOI 10.1016/S0168-1702(96)01433-5; NOWAK T, 1989, VIROLOGY, V169, P365, DOI 10.1016/0042-6822(89)90162-1; OSULLIVAN MA, 1994, J GEN VIROL, V75, P2387, DOI 10.1099/0022-1317-75-9-2387; Reed KE, 1998, J VIROL, V72, P6199, DOI 10.1128/JVI.72.7.6199-6206.1998; RICE CM, 1985, SCIENCE, V229, P726, DOI 10.1126/science.4023707; Robinson PJ, 1997, ADV EXP MED BIOL, V419, P365; ROBINSON PJ, 1989, NATURE, V342, P85, DOI 10.1038/342085a0; ROBINSON PJ, 1991, IMMUNOL TODAY, V12, P35, DOI 10.1016/0167-5699(91)90110-F; Rothman AL, 1999, VIROLOGY, V257, P1, DOI 10.1006/viro.1999.9656; SHENOYSCARIA AM, 1992, J IMMUNOL, V149, P3535; Stadler K, 1997, J VIROL, V71, P8475, DOI 10.1128/JVI.71.11.8475-8481.1997; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; SU B, 1991, J CELL BIOL, V112, P377, DOI 10.1083/jcb.112.3.377; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; VANDENBERG CW, 1995, J CELL BIOL, V131, P669, DOI 10.1083/jcb.131.3.669; *WHO, 1996, 117 WHO; WINKLER G, 1988, VIROLOGY, V162, P187, DOI 10.1016/0042-6822(88)90408-4; WINKLER G, 1989, VIROLOGY, V171, P302, DOI 10.1016/0042-6822(89)90544-8	55	117	121	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2000	14	11					1603	1610		10.1096/fj.14.11.1603	http://dx.doi.org/10.1096/fj.14.11.1603			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CN	10928995				2022-12-28	WOS:000088627800015
J	Kim, HS; Park, CH; Cha, SH; Lee, JH; Lee, S; Kim, Y; Rah, JC; Jeong, SJ; Suh, YH				Kim, HS; Park, CH; Cha, SH; Lee, JH; Lee, S; Kim, Y; Rah, JC; Jeong, SJ; Suh, YH			Carboxyl-terminal fragment of Alzheimer's APP destabilizes calcium homeostasis and renders neuronal cells vulnerable to excitotoxicity	FASEB JOURNAL			English	Article						amyloid precursor protein; intracellular free calcium concentration; Alzheimer's disease; glutamate; beta-sheet conformation	AMYLOID PRECURSOR PROTEIN; BETA-PROTEIN; SELECTIVE NEUROTOXICITY; RAT-BRAIN; DISEASE; PEPTIDE; MICE; EXPRESSION; CHANNELS; TOXICITY	Numerous lines of evidence indicate that some of the neurotoxicity associated with Alzheimer's disease (AD) is due to proteolytic fragments of the amyloid precursor protein (APP). Most research has focused on the amyloid beta peptide (A beta). However, the possible role of other cleaved products of APP is less clear. We have previously shown that a recombinant carboxy-terminal 105 amino acid fragment (CT 105) of APP induced strong nonselective inward currents in Xenopus oocyte; it also revealed neurotoxicity in PC12 cells and primary cortical neurons, blocked later phase of long-term potentiation in rat hippocampus in vivo, and induced memory deficits and neuropathological changes in mice. We report here that the pretreatment with CT 105 for 24 h at a 10 mu M concentration increases intracellular calcium concentration by about twofold in SK-N-SH and PC 12 cells, but not in U251 cells, originated from human glioblastoma. In addition, the calcium increase and toxicity induced by CT 105 were reduced by cholesterol and MK 801 in SK-N-SH and PC 12 cells, whereas the toxicity of A beta(1-42) was attenuated by nifedipine and verapamil. CT 105 rendered SK-N-SH cells and rat primary cortical neurons more vulnerable to glutamate-induced excitotoxicity, Also, conformational studies using circular dichroism experiments showed that CT 105 has similar to 15% of beta-sheet content in phosphate buffer and aqueous 2,2,2-trifluoroethanol solutions. However, the content of beta-sheet conformation in dodecyl phosphocholine micelle or in the negatively charged vesicles, is increased to 22%-23%. The results of this study showed that CT 105 disrupts calcium homeostasis and renders neuronal cells more vulnerable to glutamate-induced excitotoxicity, and that some portion of CT 105 has partial beta-sheet conformation in various environments, which may be related to the self-aggregation and toxicity. This may be significantly possibly involved in inducing the neurotoxicity characteristic of AD.	Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul 110799, South Korea; Seoul Natl Univ, Dept Mol Pharmacol, Neurosci Res Inst, MRC, Seoul 110799, South Korea; Kyorin Univ, Sch Med, Dept Pharmacol & Toxicol, Tokyo 181, Japan; Konkuk Univ, Coll Nat Sci, Dept Chem, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Kyorin University; Konkuk University	Suh, YH (corresponding author), Seoul Natl Univ, Coll Med, Dept Pharmacol, 28 Chongno Ku, Seoul 110799, South Korea.	yhsuh@plaza.snu.ac.kr	Suh, Yoo-Hun/J-2761-2012; Kim, Hye Sun/J-2752-2012	Rah, Jong-Cheol/0000-0003-3780-0522				ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; ARISPE N, 1993, P NATL ACAD SCI USA, V90, P10573, DOI 10.1073/pnas.90.22.10573; Arters J., 1995, Society for Neuroscience Abstracts, V21, P1483; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BARROW CJ, 1991, SCIENCE, V253, P179, DOI 10.1126/science.1853202; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Buchet R, 1996, BBA-MOL BASIS DIS, V1315, P40, DOI 10.1016/0925-4439(95)00102-6; BURDICK D, 1992, J BIOL CHEM, V267, P546; CHONG YH, 1994, LIFE SCI, V54, P1259; CLAUDIO S, 1996, BIOCHEM J, V314, P701; COLVIN RA, 1991, BRAIN RES, V543, P139, DOI 10.1016/0006-8993(91)91056-7; DYRKS T, 1992, J BIOL CHEM, V267, P18210; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; EINSTEIN G, 1994, J NEUROSCI, V14, P5077; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Fraser SP, 1996, J NEUROCHEM, V66, P2034; FRAUTSCHY SA, 1991, P NATL ACAD SCI USA, V88, P8362, DOI 10.1073/pnas.88.19.8362; FUKUCHI K, 1993, NEUROSCI LETT, V154, P145, DOI 10.1016/0304-3940(93)90192-N; FUKUCHI K, 1992, MOL BRAIN RES, V16, P37, DOI 10.1016/0169-328X(92)90191-D; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HARRIS ME, 1995, EXP NEUROL, V131, P193, DOI 10.1016/0014-4886(95)90041-1; Hartell NA, 2000, J NEUROCHEM, V74, P1112; KAMETANI F, 1994, FEBS LETT, V351, P165, DOI 10.1016/0014-5793(94)00851-5; KAMMESHEIDT A, 1992, P NATL ACAD SCI USA, V89, P10857, DOI 10.1073/pnas.89.22.10857; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kim HJ, 1999, NEUROREPORT, V10, P1427, DOI 10.1097/00001756-199905140-00008; Kim HS, 1998, NEUROREPORT, V9, P3875, DOI 10.1097/00001756-199812010-00020; Kim HS, 1999, NEUROREPORT, V10, P113, DOI 10.1097/00001756-199901180-00022; Kim SH, 1996, J NEUROCHEM, V67, P1172; KOO EH, 1994, J BIOL CHEM, V269, P17386; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MARUYAMA K, 1990, NATURE, V347, P566, DOI 10.1038/347566a0; MATSUMOTO A, 1991, BIOCHEM BIOPH RES CO, V175, P361, DOI 10.1016/0006-291X(91)91572-T; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; McPhie DL, 1997, J BIOL CHEM, V272, P24743, DOI 10.1074/jbc.272.40.24743; Nalbantoglu J, 1997, NATURE, V387, P500, DOI 10.1038/387500a0; NICOTERA P, 1994, CELL CALCIUM, V16, P279, DOI 10.1016/0143-4160(94)90091-4; OsterGranite ML, 1996, J NEUROSCI, V16, P6732; PFREUNDSCHUH M, 1978, P NATL ACAD SCI USA, V75, P5122, DOI 10.1073/pnas.75.10.5122; PIKE CJ, 1993, J NEUROSCI, V13, P1676; POLISNY MB, 1993, AM J PATHOL, V142, P17; RUSH RB, 1992, QUAL PROG, V25, P13; Salomon AR, 1996, BIOCHEMISTRY-US, V35, P13568, DOI 10.1021/bi9617264; SATO C, 1995, NEUROSCI LETT, V200, P105, DOI 10.1016/0304-3940(95)12089-M; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; Song DK, 1998, J NEUROCHEM, V71, P875; Suh YH, 1997, J NEUROCHEM, V68, P1781; Tjernberg LO, 1999, J BIOL CHEM, V274, P12619, DOI 10.1074/jbc.274.18.12619; Ueda K, 1997, J NEUROCHEM, V68, P265; WAITE J, 1992, NEUROBIOL AGING, V13, P595, DOI 10.1016/0197-4580(92)90062-3; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	57	77	78	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2000	14	11					1508	1517		10.1096/fj.14.11.1508	http://dx.doi.org/10.1096/fj.14.11.1508			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CN	10928985				2022-12-28	WOS:000088627800005
J	Obrosova, IG; Van Huysen, C; Fathallah, L; Cao, XH; Stevens, MJ; Greene, DA				Obrosova, IG; Van Huysen, C; Fathallah, L; Cao, XH; Stevens, MJ; Greene, DA			Evaluation of alpha 1-adrenoceptor antagonist on diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense	FASEB JOURNAL			English	Review						motor nerve conduction; peripheral diabetic neuropathy; nerve blood flow; prazosin	ALDOSE REDUCTASE INHIBITOR; ENDONEURIAL BLOOD-FLOW; ESSENTIAL FATTY-ACIDS; ALPHA-LIPOIC ACID; RAT SCIATIC-NERVE; SORBITOL DEHYDROGENASE; CONDUCTION-VELOCITY; OXIDATIVE STRESS; ENERGY-METABOLISM; NITRIC-OXIDE	The role for nerve blood flow (NBF) vs. other factors in motor nerve conduction (MNC) slowing in short-term diabetes was assessed by evaluating alpha(1)-adrenoceptor antagonist prazosin on NBF, MNC, as well as metabolic imbalances and oxidative stress in the neural tissue. Control and diabetic rats were treated with or without prazosin (5 mg.kg(-1).d(-1) for 3 wk), NBF was measured by hydrogen clearance. Both endoneurial vascular conductance and MNC velocity were decreased in diabetic rats vs. controls, and this decrease was prevented by prazosin, Free NAD(+):NADH ratios in mitochondrial cristae, matrix, and cytosol assessed by metabolite indicator method, as well as phosphocreatine levels and phosphocreatine/creatine ratios, were decreased in diabetic rats, and this reduction was ameliorated by prazosin, Neither diabetes-induced accumulation of two major glycation agents, glucose and fructose, as well as sorbitol and total malondialdehyde plus 4-hydroxyalkenals nor depletion of myo-inositol, GSH, and taurine or decrease in (Na/K)-ATP-ase activity were affected by prazosin, In conclusion, decreased NBF, but not metabolic imbalances or oxidative stress in the neural tissue, is a key mechanism of MNC slowing in short-term diabetes. Further experiments are needed to estimate whether preservation of NBF is sufficient for prevention of nerve dysfunction and morphological abnormalities in long-standing diabetes or whether the aforementioned metabolic imbalances closely associated with impaired neurotropism are of greater importance in advanced than in early diabetic neuropathy.	Univ Michigan, Ctr Med, Dept Internal Med, Div Endocrinol & Metab, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Obrosova, IG (corresponding author), Univ Michigan, Ctr Med, Dept Internal Med, Div Endocrinol & Metab, 1150 W Med Ctr Dr,MSRB II,Rm 5570, Ann Arbor, MI 48109 USA.	iobrosso@umich.edu						Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; BROWNLEE M, 1992, DIABETES CARE, V15, P1835, DOI 10.2337/diacare.15.12.1835; Calcutt NA, 1998, METABOLISM, V47, P650, DOI 10.1016/S0026-0495(98)90025-7; CAMERON NE, 1992, DIABETOLOGIA, V35, P12, DOI 10.1007/BF00400846; Cameron NE, 1996, J DIABETES COMPLICAT, V10, P43, DOI 10.1016/1056-8727(94)00076-X; Cameron NE, 1999, DIABETOLOGIA, V42, P1120, DOI 10.1007/s001250051280; CAMERON NE, 1994, DIABETOLOGIA, V37, P651, DOI 10.1007/s001250050160; CAMERON NE, 1991, DIABETES, V40, P1652, DOI 10.2337/diabetes.40.12.1652; CAMERON NE, 1994, DIABETOLOGIA, V37, P449, DOI 10.1007/s001250050131; Cameron NE, 1997, DIABETOLOGIA, V40, P271, DOI 10.1007/s001250050674; CAMERON NE, 1995, J CLIN INVEST, V96, P1159, DOI 10.1172/JCI118104; Cameron NE, 1998, DIABETOLOGIA, V41, P390, DOI 10.1007/s001250050921; Cameron NE, 1996, METABOLISM, V45, P1147, DOI 10.1016/S0026-0495(96)90015-3; Cameron NE, 1997, EUR J PHARMACOL, V319, P239, DOI 10.1016/S0014-2999(96)00844-8; Cameron NE, 1998, DIABETES, V47, pA137; CAMERON NE, 1995, N-S ARCH PHARMACOL, V352, P685; CARRINGTON AL, 1993, EUR J PHARMACOL, V237, P257, DOI 10.1016/0014-2999(93)90277-O; Chang K, 1997, AM J PHYSIOL-ENDOC M, V273, pE164, DOI 10.1152/ajpendo.1997.273.1.E164; CHANH PH, 1987, PROSTAG LEUKOTR ESS, V28, P243; Chellan P, 1999, ARCH BIOCHEM BIOPHYS, V368, P98, DOI 10.1006/abbi.1999.1291; Chen JJ, 1998, BBA-GEN SUBJECTS, V1380, P336, DOI 10.1016/S0304-4165(98)00002-6; Clerk A, 1998, BIOCHEM J, V333, P581, DOI 10.1042/bj3330581; COTTER MA, 1995, DIABETOLOGIA, V38, P1285; Cotter MA, 1998, EUR J PHARMACOL, V343, P217, DOI 10.1016/S0014-2999(97)01533-1; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Dewhurst M, 1997, BRIT J PHARMACOL, V120, P593, DOI 10.1038/sj.bjp.0700946; Dines KC, 1999, J NEUROL SCI, V163, P17, DOI 10.1016/S0022-510X(99)00013-1; DOSS DJ, 1997, J PERIPHER NERV SYST, V2, P1; DYCK PJ, 1988, NEW ENGL J MED, V319, P542, DOI 10.1056/NEJM198809013190904; Erdelmeier I, 1998, CHEM RES TOXICOL, V11, P1184, DOI 10.1021/tx970180z; Eriksson UJ, 1998, DIABETES, V47, P1960, DOI 10.2337/diabetes.47.12.1960; Fernyhough P, 1999, DIABETES, V48, P881, DOI 10.2337/diabetes.48.4.881; Greene DA, 1999, EUR J PHARMACOL, V375, P217, DOI 10.1016/S0014-2999(99)00356-8; GREENE DA, 1982, DIABETES, V31, P573, DOI 10.2337/diabetes.31.7.573; GREENE DA, 1983, J CLIN INVEST, V72, P1058, DOI 10.1172/JCI111030; GREENE DA, 1984, AM J PHYSIOL, V246, pE311, DOI 10.1152/ajpendo.1984.246.4.E311; GREENE DA, 1985, DIABETES CARE, V8, P290, DOI 10.2337/diacare.8.3.290; GREENE DA, 1992, DIABETES CARE, V15, P1902, DOI 10.2337/diacare.15.12.1902; HALE PJ, 1987, DIABETOLOGIA, V30, P464, DOI 10.1007/BF00279613; HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2; Hotta N, 1996, DIABETES, V45, P361, DOI 10.2337/diabetes.45.3.361; Hotta N, 1996, J PHARMACOL EXP THER, V276, P49; Hounsom L, 1998, DIABETOLOGIA, V41, P839, DOI 10.1007/s001250050996; Ido Y, 1997, SCIENCE, V277, P563, DOI 10.1126/science.277.5325.563; JONES BN, 1981, J LIQ CHROMATOGR, V4, P565, DOI 10.1080/01483918108059956; KADOR PF, 1988, MED RES REV, V8, P325, DOI 10.1002/med.2610080302; Kalichman MW, 1998, BRAIN RES, V810, P130, DOI 10.1016/S0006-8993(98)00898-1; Kalichman MW, 1998, ACTA NEUROPATHOL, V95, P47, DOI 10.1007/s004010050764; KARASU C, 1995, DIABETOLOGIA, V38, P129, DOI 10.1007/s001250050262; KIHARA M, 1994, AM J PHYSIOL, V266, pE980, DOI 10.1152/ajpendo.1994.266.6.E980; KIHARA M, 1991, P NATL ACAD SCI USA, V88, P6107, DOI 10.1073/pnas.88.14.6107; KINOSHITA JH, 1988, DIABETES METAB REV, V4, P323, DOI 10.1002/dmr.5610040403; LAL S, 1995, ARCH BIOCHEM BIOPHYS, V318, P191, DOI 10.1006/abbi.1995.1220; Lal S, 1997, ARCH BIOCHEM BIOPHYS, V342, P254, DOI 10.1006/abbi.1997.0117; LANGEVELD CH, 1995, FREE RADICAL BIO MED, V19, P209, DOI 10.1016/0891-5849(95)00014-O; LI YP, 1991, J NEUROCHEM, V56, P1747, DOI 10.1111/j.1471-4159.1991.tb02076.x; Love A, 1996, EUR J PHARMACOL, V31, P433; LOW PA, 1988, EXP NEUROL, V99, P201, DOI 10.1016/0014-4886(88)90139-2; LOW PA, 1985, AM J PHYSIOL, V248, pE457, DOI 10.1152/ajpendo.1985.248.4.E457; Low PA, 1997, DIABETES, V46, pS38, DOI 10.2337/diab.46.2.S38; LOW PA, 1986, AM J PHYSIOL, V250, pE94, DOI 10.1152/ajpendo.1986.250.1.E94; MASUDA T, 1990, J BIOL CHEM, V265, P20321; Maulik N, 1998, FEBS LETT, V429, P365, DOI 10.1016/S0014-5793(98)00632-2; Mizisin AP, 1998, ACTA NEUROPATHOL, V95, P171, DOI 10.1007/s004010050783; Mizisin AP, 1997, J NEUROPATH EXP NEUR, V56, P1290, DOI 10.1097/00005072-199712000-00004; Monnier VM, 1999, DIABETES, V48, P870, DOI 10.2337/diabetes.48.4.870; NAGAMATSU M, 1995, DIABETES CARE, V18, P1160, DOI 10.2337/diacare.18.8.1160; Ng DTF, 1998, DIABETES, V47, P961, DOI 10.2337/diabetes.47.6.961; Niwa T, 1999, J CHROMATOGR B, V731, P23, DOI 10.1016/S0378-4347(99)00113-9; Obrosova I, 1998, DIABETOLOGIA, V41, P1442, DOI 10.1007/s001250051090; Obrosova IG, 1999, INVEST OPHTH VIS SCI, V40, P680; Obrosova IG, 1999, DIABETOLOGIA, V42, P1187, DOI 10.1007/s001250051290; OGAWA S, 1986, ARCH BIOCHEM BIOPHYS, V248, P43, DOI 10.1016/0003-9861(86)90399-1; Passonneau J.V., 1972, FLEXIBLE SYSTEM ENZY; PHILLIPS SA, 1993, BIOCHEM PHARMACOL, V46, P805, DOI 10.1016/0006-2952(93)90488-I; Pop-Busui R, 1998, DIABETES, V47, pA137; Pop-Busui R, 1999, DIABETES, V48, pA148; ROBERTSON S, 1992, DIABETOLOGIA, V35, P1113, DOI 10.1007/BF00401363; Ryle C, 1997, MUSCLE NERVE, V20, P577, DOI 10.1002/(SICI)1097-4598(199705)20:5<577::AID-MUS6>3.0.CO;2-6; Sasaki H, 1997, ACTA NEUROPATHOL, V93, P118, DOI 10.1007/s004010050592; Schmidt RE, 1998, J NEUROPATH EXP NEUR, V57, P1175, DOI 10.1097/00005072-199812000-00010; Sima AAF, 1999, DIABETOLOGIA, V42, P773, DOI 10.1007/s001250051227; Song ZT, 1999, DIABETES, V48, pA66; Stansberry KB, 1996, DIABETES CARE, V19, P715, DOI 10.2337/diacare.19.7.715; STEVENS EJ, 1994, J PHYSIOL-LONDON, V475P, pP68; STEVENS MJ, 1993, DIABETOLOGIA, V36, P608, DOI 10.1007/BF00404069; STEVENS MJ, 1994, J CLIN INVEST, V94, P853, DOI 10.1172/JCI117406; STEVENS MJ, IN PRESS DIABETES; SUNDKVST G, 1999, J PERIPHER NERV SYST, V4, P195; SUZUKI E, 1994, J LAB CLIN MED, V124, P627; TILTON RG, 1995, DIABETES, V44, P234, DOI 10.2337/diabetes.44.2.234; Tomlinson DR, 1999, DIABETOLOGIA, V42, P1271, DOI 10.1007/s001250051439; TOMLINSON DR, 1985, EXP NEUROL, V89, P420, DOI 10.1016/0014-4886(85)90101-3; TUCK RR, 1984, BRAIN, V107, P935, DOI 10.1093/brain/107.3.935; Van Dam PS, 1999, METABOLISM, V48, P442; vanDam PS, 1998, FREE RADICAL BIO MED, V24, P18, DOI 10.1016/S0891-5849(97)00122-6; VEECH RL, 1969, BIOCHEM J, V115, P609, DOI 10.1042/bj1150609a; WILLIAMSON DH, 1967, BIOCHEM J, V103, P514, DOI 10.1042/bj1030514; WILLIAMSON JR, 1993, DIABETES, V42, P801, DOI 10.2337/diabetes.42.6.801; ZHU X, 1993, BIOCHIM BIOPHYS ACTA, V1168, P1, DOI 10.1016/0005-2760(93)90259-C; Zhuang HX, 1997, J PHARMACOL EXP THER, V283, P366	101	49	54	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2000	14	11					1548	1558		10.1096/fj.14.11.1548	http://dx.doi.org/10.1096/fj.14.11.1548			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CN	10928989				2022-12-28	WOS:000088627800009
J	Blackshaw, S; Sawa, A; Sharp, AH; Ross, CA; Snyder, SH; Khan, AA				Blackshaw, S; Sawa, A; Sharp, AH; Ross, CA; Snyder, SH; Khan, AA			Type 3 inositol 1,4,5-trisphosphate receptor modulates cell death	FASEB JOURNAL			English	Article						nerve growth factor; dorsal root ganglia; PCD; IP(3)R3 expression	SIGNAL-TRANSDUCTION; DNA FRAGMENTATION; ANTIGEN RECEPTOR; NERVOUS-SYSTEM; APOPTOSIS; EXPRESSION; COMMITMENT; ACTIVATION; CALCIUM	Mechanisms accounting for the cellular entry of calcium that mediates cellular proliferation and apoptosis have been obscure. Previously we reported selective augmentation of type 3 inositol (1,4,5) trisphosphate receptors (IP(3)R3) in lymphocytes undergoing programmed cell death, which was prevented by antisense constructs to IP(3)R3. We now report increases in mRNA and protein levels for IP(3)R3 associated with cell death in several apoptotic paradigms in diverse tissues. Elevations of IP,RS occur during developmental apoptosis in early postnatal cerebellar granule cells, dorsal root gang-lia, embryonic hair follicles, and intestinal villi. Neurotoxic damage elicited by the glutamate agonist kainate is also associated with IP(3)R3 augmentation. In chick dorsal root ganglia neurons undergoing apoptosis due to deprivation of nerve growth factor, levels of IP(3)R3 are selectively increased and cell death is selectively prevented by antisense oligonucleotides to IP(3)R3. Thus, IP(3)R3 appears to participate actively in cell death in a diversity of tissues.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Snyder, SH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 725 N Wolfe St, Baltimore, MD 21205 USA.	ssnyder@jhmi.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH018501, R37MH018501] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-00074] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Blackshaw S, 1997, J NEUROSCI, V17, P8074; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; CAMPAGNE MV, 1995, EUR J NEUROSCI, V7, P1627; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; DAVIES AM, 1987, DEVELOPMENT, V101, P185; DeLisle S, 1996, AM J PHYSIOL-CELL PH, V270, pC1255; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOLDSMITH MA, 1988, SCIENCE, V240, P1029, DOI 10.1126/science.3259335; GOLDSTEIN RS, 1993, J NEUROBIOL, V24, P1121, DOI 10.1002/neu.480240810; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kruman II, 1999, J NEUROCHEM, V72, P529, DOI 10.1046/j.1471-4159.1999.0720529.x; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MINAMIDE S, 1995, HISTOCHEM CELL BIOL, V103, P339, DOI 10.1007/BF01457808; Miyakawa T, 1999, EMBO J, V18, P1303, DOI 10.1093/emboj/18.5.1303; Nicotera P, 1998, CELL CALCIUM, V23, P173, DOI 10.1016/S0143-4160(98)90116-6; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Sanders EJ, 1995, INT REV CYTOL, V163, P105, DOI 10.1016/S0074-7696(08)62210-X; Sawa A, 1999, NAT MED, V5, P1194, DOI 10.1038/13518; Sawa A, 1997, P NATL ACAD SCI USA, V94, P11669, DOI 10.1073/pnas.94.21.11669; Sharp AH, 1999, J COMP NEUROL, V406, P207; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; WOOD KA, 1993, NEURON, V11, P621, DOI 10.1016/0896-6273(93)90074-2; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	30	75	77	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2000	14	10					1375	1379		10.1096/fj.14.10.1375	http://dx.doi.org/10.1096/fj.14.10.1375			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877830				2022-12-28	WOS:000087932200012
J	Leroy, A; Lauwaet, T; De Bruyne, G; Cornelissen, M; Mareel, M				Leroy, A; Lauwaet, T; De Bruyne, G; Cornelissen, M; Mareel, M			Entamoeba histolytica disturbs the tight junction complex in human enteric T84 cell layers	FASEB JOURNAL			English	Article						invasion; transepithelial electrical resistance; paracellular permeability; ZO proteins; amebiasis	ZONULA OCCLUDENS TOXIN; EPITHELIAL-CELLS; TYROSINE PHOSPHORYLATION; PERIPHERAL COMPONENT; POSSIBLE INVOLVEMENT; IN-VITRO; PROTEIN; PERMEABILITY; LECTIN; ZO-1	Entamoeba (E.) histolytica trophozoites initiate amebiasis through invasion into the enteric mucosa. It was our aim to understand the molecular interactions between amebic trophozoites and enterocytes during the early steps of invasion. Trophozoites of E. histolytica strain HM1:IMSS were seeded on the apical side of enteric T84 cell layers, which were established on filters in two-compartment culture chambers. Cocultures were analyzed for paracellular permeability by measurement of transepithelial electrical resistance (TER) and for the tight junction proteins ZO-1, ZO-2, occludin, and cingulin by immunocytochemistry and immunoprecipitation, On direct contact with the apical side of the enteric cells, trophozoites caused an increase in paracellular permeability as evidenced by a decrease of TER associated with all increase in [H-3]mannitol flux. Immunoprecipitation of cocultures revealed dephosphorylation of ZO-2, loss of ZO-1 from ZO-2, and degradation of ZO-1 but less so of ZO-2 and none of occludin or E-cadherin. In conclusion, trophozoite-associated increase in paracellular permeability of enteric cell layers is ascribed to disturbance of the molecular organization of tight junction proteins.-Leroy, A., Lauwaet, T., De Bruyne, G., Cornelissen, M., Marcel, M. Entamoeba histolytica disturbs the tight junction complex in human enteric T84 cell layers.	State Univ Ghent Hosp, Dept Radiotherapy & Nucl Med, Expt Cancerol Lab, B-9000 Ghent, Belgium; State Univ Ghent, Dept Anat Histol & Embryol, B-9000 Ghent, Belgium	Ghent University; Ghent University Hospital; Ghent University	Mareel, M (corresponding author), State Univ Ghent Hosp, Dept Radiotherapy & Nucl Med, Expt Cancerol Lab, De Pintelaan 185, B-9000 Ghent, Belgium.							CITI S, 1995, J CELL SCI, V108, P2917; CITI S, 1988, NATURE, V333, P272, DOI 10.1038/333272a0; DIAMOND LS, 1978, T ROY SOC TROP MED H, V72, P431, DOI 10.1016/0035-9203(78)90144-X; Fasano A, 1997, GASTROENTEROLOGY, V112, P839, DOI 10.1053/gast.1997.v112.pm9041245; FASANO A, 1995, J CLIN INVEST, V96, P710, DOI 10.1172/JCI118114; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; GRIFFITHS JK, 1994, INFECT IMMUN, V62, P4506, DOI 10.1128/IAI.62.10.4506-4514.1994; GUMBINER B, 1991, P NATL ACAD SCI USA, V88, P3460, DOI 10.1073/pnas.88.8.3460; GUMBINER B, 1986, J CELL BIOL, V102, P457, DOI 10.1083/jcb.102.2.457; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; HECHT G, 1992, GASTROENTEROLOGY, V102, P416, DOI 10.1016/0016-5085(92)90085-D; HECHT G, 1994, AM J PHYSIOL, V266, pG214, DOI 10.1152/ajpgi.1994.266.2.G214; Keon BH, 1996, J CELL BIOL, V134, P1003, DOI 10.1083/jcb.134.4.1003; Leippe M, 1997, PARASITOL TODAY, V13, P178, DOI 10.1016/S0169-4758(97)01038-7; LEROY A, 1995, INFECT IMMUN, V63, P4253, DOI 10.1128/IAI.63.11.4253-4260.1995; LEROY A, 1994, INVAS METAST, V14, P177; Leroy A, 1997, BIOCHEM SOC T, V25, P228, DOI 10.1042/bst0250228; Leroy Ancy, 1997, Invasion and Metastasis, V17, P138; LI E, 1994, INFECT IMMUN, V62, P5112, DOI 10.1128/IAI.62.11.5112-5119.1994; MADARA JL, 1986, J CELL BIOL, V102, P2125, DOI 10.1083/jcb.102.6.2125; Madara JL, 1998, ANNU REV PHYSIOL, V60, P143, DOI 10.1146/annurev.physiol.60.1.143; MADARA JL, 1987, J MEMBRANE BIOL, V100, P149, DOI 10.1007/BF02209147; MARTINEZPALOMO A, 1985, J PROTOZOOL, V32, P166, DOI 10.1111/j.1550-7408.1985.tb03033.x; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Moll T, 1998, J CELL BIOL, V140, P403, DOI 10.1083/jcb.140.2.403; PETRI WA, 1987, J CLIN INVEST, V80, P1238, DOI 10.1172/JCI113198; PETRI WA, 1991, ASM NEWS, V57, P299; Petri William A. Jr, 1993, Seminars in Cell Biology, V4, P305, DOI 10.1006/scel.1993.1037; Que X, 1997, PARASITOL TODAY, V13, P190, DOI 10.1016/S0169-4758(97)01043-0; RAVDIN JI, 1989, INFECT IMMUN, V57, P2179, DOI 10.1128/IAI.57.7.2179-2186.1989; SAFFER LD, 1991, INFECT IMMUN, V59, P4681, DOI 10.1128/IAI.59.12.4681-4683.1991; Sakakibara A, 1997, J CELL BIOL, V137, P1393, DOI 10.1083/jcb.137.6.1393; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; STADDON JM, 1995, J CELL SCI, V108, P609; Tsukamoto T, 1999, AM J PHYSIOL-RENAL, V276, pF737, DOI 10.1152/ajprenal.1999.276.5.F737; vanHengel J, 1997, J CELL BIOL, V137, P1103, DOI 10.1083/jcb.137.5.1103; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Wong V, 1997, J CELL BIOL, V136, P399, DOI 10.1083/jcb.136.2.399; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785; ZHONG Y, 1993, J CELL BIOL, V120, P477, DOI 10.1083/jcb.120.2.477	42	65	66	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2000	14	9					1139	1146		10.1096/fasebj.14.9.1139	http://dx.doi.org/10.1096/fasebj.14.9.1139			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834936				2022-12-28	WOS:000087427300011
J	Toulouse, A; Loubeau, M; Morin, J; Pappas, JJ; Wu, JP; Bradley, WEC				Toulouse, A; Loubeau, M; Morin, J; Pappas, JJ; Wu, JP; Bradley, WEC			RAR beta involvement in enhancement of lung tumor cell immunogenicity revealed by array analysis	FASEB JOURNAL			English	Article						lung cancer; retinoic acid receptor beta; tumor suppression; cDNA array	ACID-RECEPTOR-BETA; BREAST-CANCER CELLS; RETINOIC-ACID; CARCINOMA-CELLS; EXPRESSION; RNA; CHEMOPREVENTION; TRANSGENE; RAPAMYCIN; INDUCTION	The retinoid receptors (RARs and RXRs) ape mediators of the multiple effects of retinoic acid. Of these, the retinoic acid receptor beta 2 (RAR beta 2) has frequently been shown to be the principal mediator of the growth and tumor suppressive effects of retinoic acid; this gene is inactivated in many epithelial tumors and their derived cell lines. We have searched for genes that are regulated by this isoform and are potentially involved in tumor suppression. Using the Atlas human cDNA array I, we identified 27 genes (not counting RAR beta itself) that are regulated, directly or indirectly, by RAR beta 2 when it is transfected into Calu-1, a lung tumor-derived line that does not normally express RAR beta. Several of the affected genes code for proteins whose functions would augment the process of apoptosis and/or the host's immune response. The latter group included ICAM-1 and MHC class I heavy chain, whose protein products play particularly important roles in the mounting of an effective antitumor response. We then confirmed by flow cytometry that the observed increases in message levels were reflected in increased cell surface protein levels for ICAM-1 and MHC class I in RAR beta 2 transfectants of two RAR beta-deficient lines, Calu-1 and the epidermoid lung cancer-derived line SKMES. Finally, we showed that RAR beta 2 transfection of Calu-1 cells enhanced the heterologous CTL response in both the induction and the effector phases by up to threefold. These results support the hypothesis that down-regulation of these genes (and possibly others) in RAR beta-deficient tumor cells contributes to immune system evasion, and suggest a novel therapeutic approach for this disease.-Toulouse, A., Loubeau, M., Morin, Pappas, J. J., Wu, J., Bradley W. E. C. RAR beta involvement in enhancement of lung tumor cell immunogenicity revealed by array analysis.	CHUM, Inst Canc Montreal, Montreal, PQ H2L 4M1, Canada; CHUM, Ctr Rech, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Dept Med, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Surg, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal; McGill University; McGill University	Toulouse, A (corresponding author), Montreal Gen Hosp, Res Inst, Rm L12-132,1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.	mbem@musica.mcgill.ca	Toulouse, Andre/A-3159-2009	Loubeau, Martine/0000-0003-4629-7850; Toulouse, Andre/0000-0002-4045-8265				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; Ayoub J, 1999, J CLIN ONCOL, V17, P3546, DOI 10.1200/JCO.1999.17.11.3546; Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; BERARD J, 1994, EMBO J, V13, P5570, DOI 10.1002/j.1460-2075.1994.tb06894.x; Bookman MA, 1998, SEMIN ONCOL, V25, P381; BOUILLON M, 1991, BIOCHIM BIOPHYS ACTA, V1097, P95, DOI 10.1016/0925-4439(91)90091-M; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEN HF, 1994, J IMMUNOL, V152, P3107; Coligan JKA, 1991, CURRENT PROTOCOLS IM; Garrido F, 1995, ADV CANCER RES, V67, P155, DOI 10.1016/S0065-230X(08)60713-7; GEBERT JF, 1991, ONCOGENE, V6, P1859; GRAHAM S, 1984, JNCI-J NATL CANCER I, V73, P1423; Herman JG, 1996, CANCER RES, V56, P722; HOULE B, 1991, GENE CHROMOSOME CANC, V3, P358, DOI 10.1002/gcc.2870030506; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; JARROUS N, 1994, J BIOL CHEM, V269, P23141; Jen Y, 1996, DEV DYNAM, V207, P235; Liu Y, 1996, MOL CELL BIOL, V16, P1138; LUO H, 1993, CLIN EXP IMMUNOL, V94, P371; Norton JD, 1998, MOL CELL BIOL, V18, P2371, DOI 10.1128/MCB.18.4.2371; REARICK JI, 1989, ENVIRON HEALTH PERSP, V80, P229, DOI 10.2307/3430748; Rishi AK, 1999, NUCLEIC ACIDS RES, V27, P3111, DOI 10.1093/nar/27.15.3111; ROMAN SD, 1992, CANCER RES, V52, P2236; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SEGARS JH, 1993, MOL CELL BIOL, V13, P6157, DOI 10.1128/MCB.13.10.6157; Shang YF, 1999, J BIOL CHEM, V274, P18005, DOI 10.1074/jbc.274.25.18005; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P33; Toulouse A, 1998, RESP PHARM & PHARMAC, P193; vandeStolpe A, 1996, J MOL MED, V74, P13, DOI 10.1007/BF00202069; WELSH J, 1992, NUCLEIC ACIDS RES, V20, P4965, DOI 10.1093/nar/20.19.4965; Widschwendter M, 1997, CANCER RES, V57, P4158; Xu XC, 1999, J NATL CANCER I, V91, P1317, DOI 10.1093/jnci/91.15.1317; Xu XC, 1997, JNCI-J NATL CANCER I, V89, P624, DOI 10.1093/jnci/89.9.624; Xu XC, 1997, CANCER RES, V57, P4992	34	24	27	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2000	14	9					1224	1232		10.1096/fasebj.14.9.1224	http://dx.doi.org/10.1096/fasebj.14.9.1224			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834944				2022-12-28	WOS:000087427300019
J	Papassotiriou, J; Kohler, R; Prenen, J; Krause, H; Akbar, M; Eggermont, J; Paul, M; Distler, A; Nilius, B; Hoyer, J				Papassotiriou, J; Kohler, R; Prenen, J; Krause, H; Akbar, M; Eggermont, J; Paul, M; Distler, A; Nilius, B; Hoyer, J			Endothelial K+ channel lacks the Ca2+ sensitivity-regulating beta subunit	FASEB JOURNAL			English	Article						endothelium; Slo; maxi K; channel subunit; patch-clamp; beta subunit expression	ACTIVATED POTASSIUM CHANNELS; SMOOTH-MUSCLE CELLS; LARGE-CONDUCTANCE; ION CHANNELS; VASCULAR ENDOTHELIUM; NONSELECTIVE CATION; MESENTERIC-ARTERY; HYPERTENSIVE RATS; HUMAN BRAIN; EXPRESSION	Hyperpolarizing large-conductance, Ca2+-activated K+ channels (BK) are important modulators of vascular smooth muscle and endothelial cell function. In vascular smooth muscle cells, BK are composed of pore-forming cy subunits and modulatory beta subunits. However, expression, composition, and function of BK subunits in endothelium have not been studied so far. In patch-clamp experiments we identified BK (283 pS) in intact endothelium of porcine aortic tissue slices. The BK opener DHS-I (0.05-0.3 mu mol/l), stimulating BK activity only in the presence of beta subunits, had no effect on BK in endothelium whereas the alpha subunit selective BK opener NS1619 (20 mu mol/l) markedly increased channel activity. Correspondingly, mRNA expression of the beta subunit was undetectable in endothelium, whereas alpha subunit expression was demonstrated. To investigate the functional role of beta subunits, we transfected the beta subunit into a human endothelial cell line (EA.hy 926). beta subunit expression resulted in an increased Ca2+ sensitivity of BK activity: the potential of half-maximal activation (V-1/2) shifted from 73.4 mV to 49.6 mV at 1 mu mol/l [Ca2+](i) and an decrease of the EC50 value for [Ca2+], by 1 mu M at +60 mV was observed. This study demonstrates that BK channels in endothelium are composed of alpha subunits without association to beta subunits. The lack of the beta subunit indicates a substantially different channel regulation in endothelial cells compared to vascular smooth muscle cells.	Free Univ Berlin, Klinikum Benjamin Franklin, Med Klin & Poliklin, Abt Allg Innere Med & Nephrol, D-12200 Berlin, Germany; Free Univ Berlin, Klinikum Benjamin Franklin, Urol Abt, D-12200 Berlin, Germany; Free Univ Berlin, Klinikum Benjamin Franklin, Inst Klin Pharmakol, D-12200 Berlin, Germany; Katholieke Univ Leuven, Fysiol Lab, B-3000 Louvain, Belgium	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; KU Leuven	Hoyer, J (corresponding author), Free Univ Berlin, Klinikum Benjamin Franklin, Med Klin & Poliklin, Abt Allg Innere Med & Nephrol, Hindenburgdamm 30, D-12200 Berlin, Germany.	hoy@zedat.fu-berlin.de	Hoyer, Joachim/GQB-1090-2022; Paul, Martin/K-5425-2015	Eggermont, Jan/0000-0002-8497-1159; Krause, Hans/0000-0001-8713-8229; Kohler, Ralf/0000-0001-9563-2913				Ahring PK, 1997, FEBS LETT, V415, P67, DOI 10.1016/S0014-5793(97)01096-X; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; Baron A, 1996, J PHYSIOL-LONDON, V493, P691, DOI 10.1113/jphysiol.1996.sp021415; BENHAM CD, 1986, J PHYSIOL-LONDON, V371, P45, DOI 10.1113/jphysiol.1986.sp015961; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; COOKE JP, 1991, J CLIN INVEST, V88, P1663, DOI 10.1172/JCI115481; Dworetzky SI, 1996, J NEUROSCI, V16, P4543; DWORETZKY SI, 1994, MOL BRAIN RES, V27, P189, DOI 10.1016/0169-328X(94)90203-8; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; GARCIACALVO M, 1994, J BIOL CHEM, V269, P676; GIANGIACOMO KM, 1995, BIOCHEMISTRY-US, V34, P15849, DOI 10.1021/bi00048a031; Gribkoff VK, 1996, MOL PHARMACOL, V50, P206; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hardy P, 1998, CIRC RES, V83, P721, DOI 10.1161/01.RES.83.7.721; Hoyer J, 1998, FASEB J, V12, P359, DOI 10.1096/fasebj.12.3.359; Hoyer J, 1996, P NATL ACAD SCI USA, V93, P11253, DOI 10.1073/pnas.93.20.11253; Hoyer J, 1997, HYPERTENSION, V30, P112, DOI 10.1161/01.HYP.30.1.112; Kohler R, 1998, J HYPERTENS, V16, P1149, DOI 10.1097/00004872-199816080-00011; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; LEE K, 1995, EUR J PHARMACOL, V280, P215, DOI 10.1016/0014-2999(95)00251-F; MCMANUS OB, 1993, BIOCHEMISTRY-US, V32, P6128, DOI 10.1021/bi00075a002; MCMANUS OB, 1995, NEURON, V14, P645, DOI 10.1016/0896-6273(95)90321-6; Meera P, 1996, FEBS LETT, V382, P84, DOI 10.1016/0014-5793(96)00151-2; Mistry DK, 1998, J MEMBRANE BIOL, V164, P125, DOI 10.1007/s002329900399; NELSON MT, 1995, AM J PHYSIOL-CELL PH, V268, pC799, DOI 10.1152/ajpcell.1995.268.4.C799; NILIUS B, 1990, GEN PHYSIOL BIOPHYS, V9, P89; Nilius B, 1997, ANNU REV PHYSIOL, V59, P145, DOI 10.1146/annurev.physiol.59.1.145; OLESEN SP, 1994, EUR J PHARMACOL, V251, P53, DOI 10.1016/0014-2999(94)90442-1; Onu A, 1997, J IMMUNOL, V158, P255; POPP R, 1992, J PHYSIOL-LONDON, V454, P435, DOI 10.1113/jphysiol.1992.sp019272; Rae JL, 1998, CURR EYE RES, V17, P264, DOI 10.1076/ceyr.17.3.264.5224; SANSOM SC, 1994, AM J PHYSIOL, V266, pC1182; Tanaka Y, 1997, J PHYSIOL-LONDON, V502, P545, DOI 10.1111/j.1469-7793.1997.545bj.x; Trouet D, 1997, PFLUG ARCH EUR J PHY, V434, P632, DOI 10.1007/s004240050445; TsengCrank J, 1996, P NATL ACAD SCI USA, V93, P9200, DOI 10.1073/pnas.93.17.9200; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; Tytgat J, 1996, FEBS LETT, V390, P280, DOI 10.1016/0014-5793(96)00674-6; Vogalis F, 1996, AM J PHYSIOL-GASTR L, V271, pG629, DOI 10.1152/ajpgi.1996.271.4.G629	39	62	63	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2000	14	7					885	894		10.1096/fasebj.14.7.885	http://dx.doi.org/10.1096/fasebj.14.7.885			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	309CG	10783142				2022-12-28	WOS:000086749500006
J	Mitani, Y; Zaidi, SHE; Dufourcq, P; Thompson, K; Rabinovitch, H				Mitani, Y; Zaidi, SHE; Dufourcq, P; Thompson, K; Rabinovitch, H			Nitric oxide reduces vascular smooth muscle cell elastase activity through cGMP-mediated suppression of ERK phosphorylation and AML1B nuclear partitioning	FASEB JOURNAL			English	Article						transcription factors; proteinases; intracellular signaling; pulmonary hypertension	MONOCROTALINE PULMONARY-HYPERTENSION; ELASTOLYTIC ACTIVITY; GROWTH-FACTOR; GENE-EXPRESSION; DNA-BINDING; TENASCIN-C; TRANSCRIPTION; RECEPTOR; RATS; FIBRONECTIN	Nitric oxide (NO) reduces the severity of pulmonary vascular disease in rats as do elastase inhibitors. We therefore hypothesized that NO inhibits elastase by suppressing mitogen-activated protein kinases that trans-activate AML1B, a transcription factor for elastase. We used cultured pulmonary artery smooth muscle cells in which serum-treated elastin (STE) induces a > threefold increase in elastase activity as evaluated by solubilization of [H-3]-elastin. NO donors (SNAP and DETA NONO-ate) inhibited elastase in a dose-dependent manner as did a cGMP mimetic (8-pCPT-cGMP). SNAP inhibition of elastase was reversed by coadministration of a cGMP-PKG inhibitor (Rp-8-pCPT-cGMP). The STE-induced increase in phospho-ERK was suppressed by NO donors and the cGMP mimetic, and reversed by cGMP-PKG inhibitor, as was expression of AML1B and DNA binding in nuclear extracts. A concomitant increase in p38 phosphorylation was also inhibited by SNAP, but whereas MEK inhibitor (PD98059) suppressed elastase and AML1B-DNA binding, a p38 inhibitor (SB202190) did not. Our study uniquely links NO with inhibition of elastase-dependent matrix remodeling in vascular disease by suggesting a cGMP-PKG-related mechanism suppressing ERK-mediated partitioning of AML1B in nuclear extracts.	Univ Toronto, Hosp Sick Children, Div Cardiovasc Res, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Rabinovitch, H (corresponding author), Univ Toronto, Hosp Sick Children, Div Cardiovasc Res, Dept Lab Med & Pathobiol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	mr@sickkids.on.ca	Dufourcq, Pascale/ABH-6412-2020; Dufourcq, Pascale/A-2665-2012	Dufourcq, Pascale/0000-0002-9244-1879; 				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Assoian RK, 1997, J CLIN INVEST, V100, pS15; Banerjee C, 1996, P NATL ACAD SCI USA, V93, P4968, DOI 10.1073/pnas.93.10.4968; BOTNEY MD, 1992, AM J PATHOL, V140, P357; Clancy RM, 1997, J CLIN INVEST, V100, P1789, DOI 10.1172/JCI119706; Cowan B, 1996, J CLIN INVEST, V97, P2452, DOI 10.1172/JCI118692; Cowan KN, 2000, J CLIN INVEST, V105, P21, DOI 10.1172/JCI6539; Cowan KN, 1999, CIRC RES, V84, P1223, DOI 10.1161/01.RES.84.10.1223; Dey NB, 1998, CIRC RES, V82, P139; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Goebeler M, 1999, BLOOD, V93, P857, DOI 10.1182/blood.V93.3.857.403k03_857_865; HE P, 1998, AM J PHYSIOL, pH1865; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; Higenbottam TW, 1998, CHEST, V114, p72S, DOI 10.1378/chest.114.1_Supplement.72S; Hinek A, 1996, EXP CELL RES, V225, P122, DOI 10.1006/excr.1996.0163; Hinek Aleksander, 1997, Archivum Immunologiae et Therapiae Experimentalis, V45, P15; Jones PL, 1997, AM J PATHOL, V150, P1349; Jones PL, 1997, J CELL BIOL, V139, P279, DOI 10.1083/jcb.139.1.279; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; KOBAYASHI J, 1994, J CELL PHYSIOL, V160, P121, DOI 10.1002/jcp.1041600115; Kumar A, 1998, J BIOL CHEM, V273, P15742, DOI 10.1074/jbc.273.25.15742; Kurokawa M, 1996, ONCOGENE, V12, P883; Liu JQ, 1997, MOL CELL BIOL, V17, P5275, DOI 10.1128/MCB.17.9.5275; LoCoco F, 1997, HAEMATOLOGICA, V82, P364; Mancini MG, 1999, J CELL BIOCHEM, V72, P322, DOI 10.1002/(SICI)1097-4644(19990301)72:3<322::AID-JCB2>3.3.CO;2-0; MARUYAMA K, 1991, AM J PHYSIOL, V261, pH1716, DOI 10.1152/ajpheart.1991.261.6.H1716; Menconi MJ, 1998, BBA-GEN SUBJECTS, V1425, P189, DOI 10.1016/S0304-4165(98)00072-5; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Mitani Y, 1997, CIRCULATION, V96, P689; Moncada S, 1997, ANN NY ACAD SCI, V811, P60, DOI 10.1111/j.1749-6632.1997.tb51989.x; Moroi M, 1998, J CLIN INVEST, V101, P1225, DOI 10.1172/JCI1293; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; O'Blenes SB, 1998, CIRCULATION, V98, P319; Robert L, 1998, ATHEROSCLEROSIS, V140, P281, DOI 10.1016/S0021-9150(98)00171-3; ROSENBERG HC, 1988, AM J PHYSIOL, V255, pH1484, DOI 10.1152/ajpheart.1988.255.6.H1484; Saura M, 1999, IMMUNITY, V10, P21, DOI 10.1016/S1074-7613(00)80003-5; Stenoien D, 1998, J CELL BIOCHEM, V70, P213, DOI 10.1002/(SICI)1097-4644(19980801)70:2<213::AID-JCB7>3.0.CO;2-R; Steudel W, 1998, J CLIN INVEST, V101, P2468, DOI 10.1172/JCI2356; TAKAHASHI S, 1973, BIOCHIM BIOPHYS ACTA, V327, P138, DOI 10.1016/0005-2744(73)90111-3; Tanaka T, 1996, MOL CELL BIOL, V16, P3967; TARPEY MM, 1995, FEBS LETT, V364, P314, DOI 10.1016/0014-5793(95)00413-4; Thompson K, 1998, J CELL PHYSIOL, V174, P78; Thompson K, 1996, J CELL PHYSIOL, V166, P495, DOI 10.1002/(SICI)1097-4652(199603)166:3<495::AID-JCP4>3.0.CO;2-K; Thompson K. E., 1996, Molecular Biology of the Cell, V7, p588A; TODOROVICHHUNTER L, 1992, AM REV RESPIR DIS, V146, P213, DOI 10.1164/ajrccm/146.1.213; Tsao PS, 1997, CIRCULATION, V96, P934; Wigle DA, 1998, CIRC RES, V83, P252, DOI 10.1161/01.RES.83.3.252; YE CL, 1991, AM J PHYSIOL, V261, pH1255, DOI 10.1152/ajpheart.1991.261.4.H1255; Yu SM, 1997, CIRCULATION, V95, P1269; Zaidi SHE, 1998, MOL BIOL CELL, V9, p6A; Zeng CM, 1998, P NATL ACAD SCI USA, V95, P1585, DOI 10.1073/pnas.95.4.1585; Zeng CM, 1997, P NATL ACAD SCI USA, V94, P6746, DOI 10.1073/pnas.94.13.6746; ZHU L, 1994, J CLIN INVEST, V94, P1163, DOI 10.1172/JCI117432; ZHU XJ, 1994, MOL CELL BIOL, V14, P8051, DOI 10.1128/MCB.14.12.8051; ZHU XJ, 1995, MOL CELL BIOL, V15, P1136	55	42	43	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2000	14	5					805	814		10.1096/fasebj.14.5.805	http://dx.doi.org/10.1096/fasebj.14.5.805			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301DH	10744637				2022-12-28	WOS:000086292700018
J	Hu, VW; Heikka, DS				Hu, VW; Heikka, DS			Radiolabeling revisited: metabolic labeling with S-35-methionine inhibits cell cycle progression, proliferation, and survival	FASEB JOURNAL			English	Article						metabolic radiolabeling; beta emitters; cell cycle arrest; apoptosis	DNA-DAMAGE; HUMAN FIBROBLASTS; MAMMALIAN-CELLS; GROWTH ARREST; P53; APOPTOSIS; PHOSPHORYLATION; RADIOTOXICITY; IRRADIATION	Metabolic labeling of cells with low-energy beta-emitting radioisotopes such as [S-35]methionine is often used to follow the biosynthesis, maturation, and degradation of proteins in vivo, Such techniques have generally been assumed to be relatively nonperturbing to the cell. The results presented here indicate that metabolic labeling of cells with [S-35]methionine under standard experimental conditions can inhibit cell progression into mitosis, cause cell cycle arrest, inhibit cell proliferation in both short-term and colony-forming assays, alter cell morphology, and induce apoptosis over the course of several days. These results thus suggest the need for caution in interpretation of studies using such methods, especially if the experiments rely on the normal progression of the cell cycle or are intended to monitor events occurring in a normally proliferating cell.	George Washington Univ, Sch Med & Hlth Sci, Dept Biochem & Mol Biol, Washington, DC 20037 USA	George Washington University	Hu, VW (corresponding author), George Washington Univ, Sch Med & Hlth Sci, Dept Biochem & Mol Biol, Ross Hall,Room 526,2300 Eye St, Washington, DC 20037 USA.	bcmvwh@gwumc.edu		Hu, Valerie/0000-0002-3357-0777				AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DOVER R, 1994, J CELL SCI, V107, P1181; GUILLOUF C, 1995, ONCOGENE, V10, P2263; HERZINGER T, 1995, ONCOGENE, V11, P2151; HOFER KG, 1971, RADIAT RES, V47, P94, DOI 10.2307/3573291; KASSIS AI, 1980, RADIAT RES, V84, P407, DOI 10.2307/3575480; LEMOTTE PK, 1982, P NATL ACAD SCI-BIOL, V79, P7763, DOI 10.1073/pnas.79.24.7763; Linke SP, 1997, CANCER RES, V57, P1171; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Oda Y, 1999, P NATL ACAD SCI USA, V96, P6591, DOI 10.1073/pnas.96.12.6591; Poon RYC, 1997, CANCER RES, V57, P5168; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; POWELL SN, 1995, CANCER RES, V55, P1643; SHAPIRO J, 1972, RAD PROTECTION GUIDE, P54; Singh J, 1998, ONCOL REP, V5, P1307; SOLARY E, 1992, EXP CELL RES, V203, P495, DOI 10.1016/0014-4827(92)90027-6; SPECTOR DL, 1997, CELLS LAB MANUAL, V1, pCH14; STEWART N, 1995, ONCOGENE, V10, P109; XIE HQ, 1994, GWUMC DEPT, P223; YEARGIN J, 1995, CURR BIOL, V5, P423, DOI 10.1016/S0960-9822(95)00083-2; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	22	29	31	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2000	14	3					448	454		10.1096/fasebj.14.3.448	http://dx.doi.org/10.1096/fasebj.14.3.448			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	291TJ	10698959				2022-12-28	WOS:000085751900003
J	Nghiem, HO; Bettendorff, L; Changeux, JP				Nghiem, HO; Bettendorff, L; Changeux, JP			Specific phosphorylation of Torpedo 43K rapsyn by endogenous kinase(s) with thiamine triphosphate as the phosphate donor	FASEB JOURNAL			English	Article						nicotinic acetylcholine receptor (nAChR); cytoskeleton; neuromuscular junction (NMJ); synapse; phosphohistidine	NICOTINIC ACETYLCHOLINE-RECEPTOR; PROTEIN-HISTIDINE KINASES; MARMORATA ELECTRIC ORGAN; ZINC-FINGER DOMAIN; POSTSYNAPTIC MEMBRANES; POLYPHOSPHATE KINASE; TYROSINE PHOSPHORYLATION; NEUROMUSCULAR-JUNCTION; SIGNAL-TRANSDUCTION; PHOSPHOAMINO ACIDS	43K rapsyn is a peripheral protein specifically associated with the nicotinic acetylcholine receptor (nAChR) present in the postsynaptic membrane of the neuromuscular junction and of the electrocyte, and is essential for its clustering, Here, we demonstrate a novel specific phosphorylation of 43K rapsyn by endogenous protein kinase(s) present in Torpedo electrocyte nAChR-rich membranes and identify thiamine triphosphate (TTP) as the phosphate donor. In the presence of Mg2+ and [gamma-P-32]- TTP, 43K rapsyn is specifically phosphorylated with a P-32-half-maximal incorporation at similar to 5-25 mu M TTP. The presence of TTP in the cytosol and of 43K rapsyn at the cytoplasmic face of the postsynaptic membrane, together with TIE-dependent phosphorylation of 43K rapsyn without added exokinases, suggests that TTP-dependent-43K-rapsyn phosphorylation may occur in vivo, In addition, phosphoamino acid and chemical stability analysis suggests that the residues phosphorylated are predominantly histidines. Inhibition of phosphorylation by Zn2+ suggests a possible control of 43K rapsyn phosphorylation state by its zinc finger domain, Endogenous kinase(s) present in rodent brain membranes can also use [gamma-P-32]-TTP as a phosphodonor. The use of a phosphodonor (TTP) belonging to the thiamine family but not to the classical (ATP, GTP) purine triphosphate family represents a novel phosphorylation pathway possibly important for synaptic proteins.	Inst Pasteur, CNRS, UA D 1284, F-75724 Paris, France; Univ Liege, Ctr Rech Neurobiol Cellulaire & Mol, B-4000 Liege, Belgium	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Liege	Nghiem, HO (corresponding author), Inst Pasteur, CNRS, UA D 1284, 25-28 Rue Dr Roux, F-75724 Paris, France.	honghiem@pasteur.fr						ALEX LA, 1994, TRENDS GENET, V10, P133, DOI 10.1016/0168-9525(94)90215-1; APEL ED, 1995, NEURON, V15, P115, DOI 10.1016/0896-6273(95)90069-1; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BALDWIN TJ, 1988, DEVELOPMENT, V104, P557; BETTENDORFF L, 1991, ANAL BIOCHEM, V198, P52, DOI 10.1016/0003-2697(91)90505-N; BETTENDORFF L, 1989, J NEUROCHEM, V53, P80, DOI 10.1111/j.1471-4159.1989.tb07297.x; BETTENDORFF L, 1994, METAB BRAIN DIS, V9, P183, DOI 10.1007/BF01991194; BETTENDORFF L, 1987, J NEUROCHEM, V49, P495, DOI 10.1111/j.1471-4159.1987.tb02891.x; BETTENDORFF L, 1993, J NEUROCHEM, V60, P423, DOI 10.1111/j.1471-4159.1993.tb03168.x; Bezakova G, 1998, MOL CELL NEUROSCI, V11, P274, DOI 10.1006/mcne.1998.0688; Buckel A, 1996, GENOMICS, V35, P613, DOI 10.1006/geno.1996.0409; Burns AL, 1997, J NEUROSCI, V17, P5016; CARR C, 1987, BIOCHEMISTRY-US, V26, P7090, DOI 10.1021/bi00396a034; COHEN P, 1992, BIOCHEM SOC T, V20, P671, DOI 10.1042/bst0200671; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COOPER JR, 1979, NEUROCHEM RES, V4, P223, DOI 10.1007/BF00964146; CORTAY JC, 1986, EUR J BIOCHEM, V159, P227, DOI 10.1111/j.1432-1033.1986.tb09858.x; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; EDER L, 1980, J NEUROCHEM, V35, P1278, DOI 10.1111/j.1471-4159.1980.tb08999.x; EGI Y, 1986, BIOCHEM INT, V12, P385; FERNS MJ, 1992, CELL, V70, P1, DOI 10.1016/0092-8674(92)90525-H; FRAIL DE, 1988, J BIOL CHEM, V263, P15602; FRAIL DE, 1987, P NATL ACAD SCI USA, V84, P6302, DOI 10.1073/pnas.84.17.6302; FROEHNER SC, 1981, P NATL ACAD SCI-BIOL, V78, P5230, DOI 10.1073/pnas.78.8.5230; Gautam M, 1996, CELL, V85, P525, DOI 10.1016/S0092-8674(00)81253-2; GAUTAM M, 1995, NATURE, V377, P232, DOI 10.1038/377232a0; Gillespie SKH, 1996, NEURON, V16, P953, DOI 10.1016/S0896-6273(00)80118-X; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; Glass DJ, 1997, CURR OPIN NEUROBIOL, V7, P379, DOI 10.1016/S0959-4388(97)80066-9; GRANDFILS C, 1988, ANAL BIOCHEM, V169, P274, DOI 10.1016/0003-2697(88)90285-0; HILL JA, 1991, BIOCHEMISTRY-US, V30, P5579, DOI 10.1021/bi00236a034; HOPFIELD JF, 1988, NATURE, V336, P677, DOI 10.1038/336677a0; Huang EP, 1997, P NATL ACAD SCI USA, V94, P13386, DOI 10.1073/pnas.94.25.13386; HUGANIR RL, 1983, P NATL ACAD SCI-BIOL, V80, P1130, DOI 10.1073/pnas.80.4.1130; HUGANIR RL, 1984, P NATL ACAD SCI-BIOL, V81, P6968, DOI 10.1073/pnas.81.22.6968; HUGANIR RL, 1990, NEURON, V5, P555, DOI 10.1016/0896-6273(90)90211-W; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KATO J, 1993, GENE, V137, P237, DOI 10.1016/0378-1119(93)90013-S; Kawasaki T., 1992, MODERN CHROMATOGRAPH, P319; KNEEGIPUU A, 1999, NUCLEIC ACIDS RES, V27, P237; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; KRIKORIAN JG, 1992, J BIOL CHEM, V267, P9118; Kumble KD, 1996, P NATL ACAD SCI USA, V93, P14391, DOI 10.1073/pnas.93.25.14391; MATTHEWS HR, 1995, PHARMACOL THERAPEUT, V67, P323, DOI 10.1016/0163-7258(95)00020-8; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; Mesnildrey S, 1998, J BIOL CHEM, V273, P4436, DOI 10.1074/jbc.273.8.4436; Miles E W, 1977, Methods Enzymol, V47, P431; Nauti A, 1997, METAB BRAIN DIS, V12, P145; NEUBIG RR, 1979, P NATL ACAD SCI USA, V76, P690, DOI 10.1073/pnas.76.2.690; NGHIEM HO, 1988, J IMMUNOL METHODS, V111, P137; NGHIEM HO, 1991, DEVELOPMENT, V113, P1059; NGHIEM HO, 1983, P NATL ACAD SCI-BIOL, V80, P6403, DOI 10.1073/pnas.80.20.6403; NGHIEM HO, 1999, GUIDEBOOK EXTRACELLU, P67; Nghiem Hoang-Oanh, 1993, P95; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; QU ZC, 1990, NEURON, V4, P367, DOI 10.1016/0896-6273(90)90049-L; Qu ZC, 1996, MOL CELL NEUROSCI, V8, P171, DOI 10.1006/mcne.1996.0055; Ramarao MK, 1998, P NATL ACAD SCI USA, V95, P4007, DOI 10.1073/pnas.95.7.4007; Roche Katherine W., 1994, Current Opinion in Neurobiology, V4, P383, DOI 10.1016/0959-4388(94)90100-7; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SAFRAN A, 1987, J BIOL CHEM, V262, P10506; SCOTLAND PB, 1993, J CELL BIOL, V123, P719, DOI 10.1083/jcb.123.3.719; SEALOCK R, 1984, J CELL BIOL, V98, P2239, DOI 10.1083/jcb.98.6.2239; Smith R A, 1978, Methods Cell Biol, V19, P153; SOBEL A, 1977, EUR J BIOCHEM, V80, P215, DOI 10.1111/j.1432-1033.1977.tb11874.x; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; SWOPE SL, 1993, J BIOL CHEM, V268, P25152; TINSLEY CR, 1995, INFECT IMMUN, V63, P1624, DOI 10.1128/IAI.63.5.1624-1630.1995; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURNER AM, 1986, J GEN MICROBIOL, V132, P3433; WALLACE BG, 1991, NEURON, V6, P869, DOI 10.1016/0896-6273(91)90227-Q; WALLACE BG, 1994, J CELL BIOL, V125, P661, DOI 10.1083/jcb.125.3.661; WALSH DA, 1991, PHYSIOL REV, V71, P285, DOI 10.1152/physrev.1991.71.1.285; Wang ZZ, 1999, J NEUROSCI, V19, P1998; WEI YF, 1991, METHOD ENZYMOL, V200, P388; YAMASHITA H, 1993, NEUROSCI LETT, V158, P229, DOI 10.1016/0304-3940(93)90271-L; Yang SH, 1997, MOL CELL NEUROSCI, V8, P430, DOI 10.1006/mcne.1997.0597	79	65	67	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2000	14	3					543	554		10.1096/fasebj.14.3.543	http://dx.doi.org/10.1096/fasebj.14.3.543			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	291TJ	10698970				2022-12-28	WOS:000085751900014
J	Zouki, C; Ouellet, S; Filep, JG				Zouki, C; Ouellet, S; Filep, JG			The anti-inflammatory peptides, antiflammins, regulate the expression of adhesion molecules on human leukocytes and prevent neutrophil adhesion to endothelial cells	FASEB JOURNAL			English	Article						lipocortin-1-derived peptides; L-selectin; integrin; neutrophil recruitment; inflammation	PLATELET-ACTIVATING-FACTOR; L-SELECTIN; LIPOCORTIN-I; INTERCELLULAR-ADHESION; ANTIINFLAMMATORY ACTIVITY; PHOSPHOLIPASE-A2 ACTIVITY; MYOCARDIAL-ISCHEMIA; UTEROGLOBIN; MECHANISM; RECEPTOR	Antiflammin-1 and antiflammin-2 are nonapeptides corresponding to the region of highest similarity between glucocorticoid-inducible proteins lipocortin-1 and uteroglobin. We have studied whether antiflammins could affect expression of adhesion molecules on human leukocytes and coronary artery endothelial cells (HCAEC) and binding of neutrophils (PMNs) to HCAEC. Although neither antiflammin-1 nor antiflammin-2 affected expression of adhesion molecules on resting PMNs, monocytes, and lymphocytes in whole blood, they attenuated changes in L-selectin and CD11/CD18 expression evoked by platelet-activating factor or interleukin-8 with IC50 values of 4-20 mu mol/l. The maximum inhibition was similar to those seen with human recombinant lipocortin-1 (100 mu g/ml). Unlike,dexamethasone (100 nnol/l), the antiflammins had little effect on LPS-stimulated expression of E-selectin and ICAM-1 on HCAEC. Consistently, culture of HCAEC with dexamethasone, but not with antiflammins, decreased PMN binding to endothelial cells. Preincubation of PMNs with antiflammins markedly decreased their adhesion to LPS-activated HCAEC. Inhibition of adhesion was additive with function blocking anti-E-selectin and anti-L-selectin antibodies, but was not additive with anti-CD18 antibody. These results show that antiflammins inhibit PMN adhesion to HCAEC by attenuating. activation-induced upregulation of CD11/CD18 expression on leukocytes, and suggest that antiflammins may represent a novel therapeutic approach in blocking leukocyte trafficking in host defense and inflammation.	Hop Maison Neuve Rosemont, Res Ctr, Montreal, PQ H1T 2M4, Canada; Univ Montreal, Dept Med, Montreal, PQ H1T 2M4, Canada	Universite de Montreal; Universite de Montreal	Filep, JG (corresponding author), Hop Maison Neuve Rosemont, Res Ctr, 5415 Blvd Assompt, Montreal, PQ H1T 2M4, Canada.							BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CABRE F, 1992, BIOCHEM PHARMACOL, V44, P519, DOI 10.1016/0006-2952(92)90444-N; CAMUSSI G, 1990, J EXP MED, V171, P913, DOI 10.1084/jem.171.3.913; CHAN CC, 1991, ARCH OPHTHALMOL-CHIC, V109, P278, DOI 10.1001/archopht.1991.01080020124058; CHEN AJ, 1995, J EXP MED, V182, P519, DOI 10.1084/jem.182.2.519; CRONSTEIN BN, 1992, P NATL ACAD SCI USA, V89, P9991, DOI 10.1073/pnas.89.21.9991; Cuzzocrea S, 1997, J IMMUNOL, V159, P5089; DIAZGONZALEZ F, 1995, J CLIN INVEST, V95, P1756, DOI 10.1172/JCI117853; ENTMAN ML, 1991, FASEB J, V5, P2529, DOI 10.1096/fasebj.5.11.1868978; FACCHIANO A, 1991, LIFE SCI, V48, P453, DOI 10.1016/0024-3205(91)90501-2; Filep JG, 1997, CIRCULATION, V96, P295; FLOWER RJ, 1994, TRENDS PHARMACOL SCI, V15, P71, DOI 10.1016/0165-6147(94)90281-X; GOULDING NJ, 1990, LANCET, V335, P1416, DOI 10.1016/0140-6736(90)91445-G; GOULDING NJ, 1993, BIOCHEM BIOPH RES CO, V192, P351, DOI 10.1006/bbrc.1993.1422; GROYER A, 1987, NATURE, V328, P624, DOI 10.1038/328624a0; Haribabu B, 1997, J BIOL CHEM, V272, P13961, DOI 10.1074/jbc.272.21.13961; JOHNSON BA, 1993, ARTHRITIS RHEUM, V36, P137, DOI 10.1002/art.1780360203; Kahn J, 1998, CELL, V92, P809, DOI 10.1016/S0092-8674(00)81408-7; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KISHIMOTO TK, 1990, P NATL ACAD SCI USA, V87, P805; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; LEEUWENBERG JFM, 1990, J IMMUNOL, V145, P2110; LEVIN SW, 1986, LIFE SCI, V38, P1813, DOI 10.1016/0024-3205(86)90135-9; Loftus JC, 1997, J CLIN INVEST, V100, pS77; MA XL, 1991, J CLIN INVEST, V88, P1237, DOI 10.1172/JCI115427; MANCUSO F, 1995, J IMMUNOL, V155, P377; MARKI F, 1990, FEBS LETT, V264, P171, DOI 10.1016/0014-5793(90)80241-A; McDowall A, 1998, J BIOL CHEM, V273, P27396, DOI 10.1074/jbc.273.42.27396; MIELE L, 1988, NATURE, V335, P726, DOI 10.1038/335726a0; MIGAKI GI, 1995, J EXP MED, V182, P549, DOI 10.1084/jem.182.2.549; MONTGOMERY KF, 1991, P NATL ACAD SCI USA, V88, P6523, DOI 10.1073/pnas.88.15.6523; Moreno JJ, 1996, EUR J PHARMACOL, V314, P129, DOI 10.1016/S0014-2999(96)00521-3; PEPINSKY RB, 1988, J BIOL CHEM, V263, P10799; PERRETTI M, 1993, J IMMUNOL, V151, P4306; Perretti M, 1996, NAT MED, V2, P1259, DOI 10.1038/nm1196-1259; Rainger GE, 1997, AM J PHYSIOL-HEART C, V272, pH114, DOI 10.1152/ajpheart.1997.272.1.H114; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; TEDDER TF, 1995, J EXP MED, V181, P2259, DOI 10.1084/jem.181.6.2259; VANBINSBERGEN J, 1989, FEBS LETT, V247, P293, DOI 10.1016/0014-5793(89)81355-9; VOSTAL JG, 1989, BIOCHEM BIOPH RES CO, V165, P27, DOI 10.1016/0006-291X(89)91029-2; WALLNER BP, 1986, NATURE, V320, P77, DOI 10.1038/320077a0; ZIMMERMAN GA, 1990, J CELL BIOL, V110, P529, DOI 10.1083/jcb.110.2.529; Zouki C, 1997, J CLIN INVEST, V100, P522, DOI 10.1172/JCI119561	44	58	65	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2000	14	3					572	580		10.1096/fasebj.14.3.572	http://dx.doi.org/10.1096/fasebj.14.3.572			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	291TJ	10698973				2022-12-28	WOS:000085751900017
J	Gurevitz, M; Gordon, D; Ben-Natan, S; Turkov, M; Froy, O				Gurevitz, M; Gordon, D; Ben-Natan, S; Turkov, M; Froy, O			Diversification of neurotoxins by C-tail 'wiggling': a scorpion recipe for survival	FASEB JOURNAL			English	Article						toxic polypeptides; scorpion neurotoxin; bioactive surface	ANDROCTONUS-AUSTRALIS HECTOR; NUCLEAR-MAGNETIC-RESONANCE; TOXINS AFFECTING SODIUM; ALPHA-LIKE TOXIN; CHANNELS; POTASSIUM; SITE; DENDROTOXINS; EVOLUTION	The structure of bioactive surfaces of proteins is a subject of intensive research, yet the mechanisms by which such surfaces have evolved are largely unknown. Polypeptide toxins produced by venomous animals such as sea anemones, cone snails, scorpions, and snakes show multiple routes for active site diversification, each maintaining a typical con served scaffold. Comparative analysis of an array of genetically related scorpion polypeptide toxins that modulate sodium channels in neuronal membranes suggests a unique route of toxic site diversification. This premise is based on recent identification of bioactive surfaces of toxin representative of three distinct pharmacological groups and a comparison of their 3-dimensional structures, Despite their similar scaffold, the bioactive surfaces of the various toxins vary considerably, but always coincide with the molecular exterior onto which the C-tail is anchored. Superposition of the toxin structures indicates that the C-tails diverge from a common structural start point, which suggests that the pharmacological versatility displayed by these toxins might have been achieved along evolution via structural reconfiguration of the C-tail, leading to reshaping of new bioactive surfaces.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Plant Sci, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel	Tel Aviv University; Tel Aviv University	Gurevitz, M (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Plant Sci, Britania Bldg,Rm 506, IL-69978 Tel Aviv, Israel.		Froy, Oren/C-3550-2009					Benkhalifa R, 1997, LIFE SCI, V61, P819, DOI 10.1016/S0024-3205(97)00564-X; BERNDT KD, 1992, J MOL BIOL, V227, P757, DOI 10.1016/0022-2836(92)90222-6; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; DARBON H, 1991, BIOCHEMISTRY-US, V30, P1836, DOI 10.1021/bi00221a016; Duda TF, 1999, P NATL ACAD SCI USA, V96, P6820, DOI 10.1073/pnas.96.12.6820; FONTECILLACAMPS JC, 1988, P NATL ACAD SCI USA, V85, P7443, DOI 10.1073/pnas.85.20.7443; Froy O, 1998, FASEB J, V12, P1793, DOI 10.1096/fasebj.12.15.1793; Froy O, 1999, J BIOL CHEM, V274, P5769, DOI 10.1074/jbc.274.9.5769; Froy O, 1999, J MOL EVOL, V48, P187, DOI 10.1007/PL00006457; Gasparini S, 1998, J BIOL CHEM, V273, P25393, DOI 10.1074/jbc.273.39.25393; Gilles N, 1999, J NEUROSCI, V19, P8730, DOI 10.1523/JNEUROSCI.19-20-08730.1999; GORDON D, 1992, BIOCHEMISTRY-US, V31, P7622, DOI 10.1021/bi00148a025; Gordon D, 1998, J TOXICOL-TOXIN REV, V17, P131, DOI 10.3109/15569549809009247; Gordon D, 1997, TOXINS SIGNAL TRANSD, P119; Harvey AL, 1997, GEN PHARMACOL-VASC S, V28, P7, DOI 10.1016/S0306-3623(96)00173-5; Krimm I, 1999, J MOL BIOL, V285, P1749, DOI 10.1006/jmbi.1998.2418; Kuby J, 1994, IMMUNOLOGY, V2nd ed., P109; Landon C, 1997, PROTEINS, V28, P360, DOI 10.1002/(SICI)1097-0134(199707)28:3&lt;360::AID-PROT6&gt;3.0.CO;2-G; Martin-Eauclaire M. F., 1995, Handbook of neurotoxicology., P683; Menez A, 1998, TOXICON, V36, P1557, DOI 10.1016/S0041-0101(98)00148-2; Norton RS, 1998, TOXICON, V36, P1573, DOI 10.1016/S0041-0101(98)00149-4; NORTON RS, 1991, TOXICON, V29, P1051, DOI 10.1016/0041-0101(91)90205-6; Ohno M, 1998, PROG NUCLEIC ACID RE, V59, P307; OLIVERA BM, 1991, J BIOL CHEM, V266, P22067; Oren DA, 1998, STRUCTURE, V6, P1095, DOI 10.1016/S0969-2126(98)00111-7; Pintar A, 1999, J MOL BIOL, V287, P359, DOI 10.1006/jmbi.1999.2611; Possani LD, 1999, EUR J BIOCHEM, V264, P287, DOI 10.1046/j.1432-1327.1999.00625.x; Tugarinov V, 1997, BIOCHEMISTRY-US, V36, P2414, DOI 10.1021/bi961497l; Turkov M, 1997, PROTEIN EXPRES PURIF, V10, P123, DOI 10.1006/prep.1997.0724; VITA C, 1995, P NATL ACAD SCI USA, V92, P6404, DOI 10.1073/pnas.92.14.6404; Zilberberg N, 1997, J BIOL CHEM, V272, P14810, DOI 10.1074/jbc.272.23.14810; Zilberberg N, 1996, BIOCHEMISTRY-US, V35, P10215, DOI 10.1021/bi9528309; ZLOTKIN E, 1997, TOXINS SIGNAL TRANSD, P95	33	59	61	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1201	1205		10.1096/fj.00-0571hyp	http://dx.doi.org/10.1096/fj.00-0571hyp			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344088				2022-12-28	WOS:000168655200010
J	Schipke, CG; Ohlemeyer, C; Matyash, M; Nolte, C; Kettenmann, H; Kirchhoff, F				Schipke, CG; Ohlemeyer, C; Matyash, M; Nolte, C; Kettenmann, H; Kirchhoff, F			Astrocytes of the mouse neocortex express functional N-methyl-D-aspartate receptors	FASEB JOURNAL			English	Article									Max Planck Inst Expt Med, D-37075 Gottingen, Germany; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	Max Planck Society; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Kirchhoff, F (corresponding author), Max Planck Inst Expt Med, Hermann Rein Str 3, D-37075 Gottingen, Germany.		Kirchhoff, Frank/B-9335-2008; Kettenmann, Helmut/AAJ-5142-2021	Kirchhoff, Frank/0000-0002-2324-2761; Kettenmann, Helmut/0000-0001-8208-0291; Nolte, Christiane/0000-0001-5398-3440					0	151	157	2	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1270	1272		10.1096/fj.00-0439fje	http://dx.doi.org/10.1096/fj.00-0439fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344110				2022-12-28	WOS:000168655200032
J	Bussolino, DF; Guido, ME; Gil, GA; Borioli, GA; Renner, ML; Grabois, VR; Conde, CB; Caputto, BL				Bussolino, DF; Guido, ME; Gil, GA; Borioli, GA; Renner, ML; Grabois, VR; Conde, CB; Caputto, BL			c-Fos associates with the endoplasmic reticulum and activates phospholipid metabolism	FASEB JOURNAL			English	Article									Univ Nacl Cordoba, Fac Ciencias Quim, Dept Quim Biol, CIQUIBIC, RA-5000 Cordoba, Argentina	National University of Cordoba	Caputto, BL (corresponding author), Univ Nacl Cordoba, Fac Ciencias Quim, Dept Quim Biol, CIQUIBIC, Pabellon Argentina,Ciudad Univ, RA-5000 Cordoba, Argentina.		GIL, GERMAN A./T-3018-2019; Renner, Marianne/H-5315-2011	GIL, GERMAN A./0000-0001-6714-2693; Conde, Cecilia/0000-0002-5103-6391; Renner, Marianne/0000-0002-8727-6581					0	56	56	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					556	558						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259365				2022-12-28	WOS:000167419500003
J	Yakmovych, I; Ten Dijke, P; Heldin, CH; Souchelnytskyi, S				Yakmovych, I; Ten Dijke, P; Heldin, CH; Souchelnytskyi, S			Regulation of Smad signaling by protein kinase C	FASEB JOURNAL			English	Article									Ludwig Inst Canc Res, Biomed Ctr, S-75124 Uppsala, Sweden; Natl Acad Sci Ukraine, Inst Biochem, Lviv, Ukraine; Netherlands Canc Inst, NL-1066 CX Amsterdam, Netherlands	Ludwig Institute for Cancer Research; National Academy of Sciences Ukraine; Netherlands Cancer Institute	Souchelnytskyi, S (corresponding author), Ludwig Inst Canc Res, Biomed Ctr, Box 595,Husargatan Str 3, S-75124 Uppsala, Sweden.		Souchelnytskyi, Serhiy/J-9446-2014; Dijke, Peter ten/AAG-4660-2021; Souchelnytskyi, Serhiy/G-6491-2011	Dijke, Peter ten/0000-0002-7234-342X; Souchelnytskyi, Serhiy/0000-0001-8243-9276					0	149	157	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					553	555						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259364				2022-12-28	WOS:000167419500002
J	Salemi, M; Strimmer, K; Hall, WW; Duffy, M; Delaporte, E; Mboup, S; Peeters, M; Vandamme, AM				Salemi, M; Strimmer, K; Hall, WW; Duffy, M; Delaporte, E; Mboup, S; Peeters, M; Vandamme, AM			Dating the common ancestor of SIVcpz and HIV-1 group M and the origin of HIV-1 subtypes using a new method to uncover clock-like molecular evolution	FASEB JOURNAL			English	Article									Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium; Max Planck Inst Biochem, GSF, MIPS, D-82152 Martinsried, Germany; Natl Univ Ireland Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Dept Med Microbiol, Dublin 4, Ireland; IRD, Retrovirus Lab, Montpellier, France	KU Leuven; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Max Planck Society; University College Dublin; Institut de Recherche pour le Developpement (IRD)	Vandamme, AM (corresponding author), Katholieke Univ Leuven, Rega Inst Med Res, Minderbroedersstr 10, B-3000 Louvain, Belgium.	annemie.vandamme@uz.kuleuven.ac.be	Strimmer, Korbinian/C-1522-2009; Vandamme, Anne-Mieke/I-4127-2012; Delaporte, Eric/J-5397-2018	Strimmer, Korbinian/0000-0001-7917-2056; Vandamme, Anne-Mieke/0000-0002-6594-2766; Delaporte, Eric/0000-0002-1822-9853					0	101	107	1	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					276	278		10.1096/fj.00-0449fje	http://dx.doi.org/10.1096/fj.00-0449fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156935				2022-12-28	WOS:000166872900001
J	Comhair, SAA; Bhathena, PR; Farver, C; Thunnissen, FBJM; Erzurum, SC				Comhair, SAA; Bhathena, PR; Farver, C; Thunnissen, FBJM; Erzurum, SC			Extracellular glutathione peroxidase induction in asthmatic lungs: evidence for redox regulation of expression in human airway epithelial cells	FASEB JOURNAL			English	Article						reactive oxygen species; asthma; lung; nitrotyrosine	NITRIC-OXIDE SYNTHASE; PLASMA GLUTATHIONE; SUPEROXIDE-DISMUTASE; LINING FLUID; EXHALED AIR; ANTIOXIDANT; GENE; OXIDATION; OXIDANTS; DEXAMETHASONE	A critical first-line antioxidant defense on the airway epithelial surface against reactive oxygen and nitrogen species (ROS and RNS) is extracellular glutathione peroxidase (eGPx). Little is known about the regulation of eGPx or its role in ROS-mediated lung diseases such as asthma. Here we show that eGPx is increased in the asthmatic airway in comparison to healthy controls. Higher levels of eGPx mRNA in asthmatic airway epithelium verified bronchial epithelial cells as the source for the increased eGPx, The eGPx mRNA in bronchial epithelial cells in vitro increased eightfold after exposure to ROS and glutathione, an essential cofactor for eGPx activity. Alterations in intracellular and extracellular oxidized and reduced glutathione were temporally associated with eGPx induction, further supporting redox mechanisms in gene expression, Overexpression of superoxide dismutase, but not catalase, inhibited induction and identified superoxide as a key intermediary. The eGPx mRNA half-life was not affected by ROS, suggesting a transcriptional mechanism for eGPx regulation. Fusion genes of deletion fragments of the eGPx gene 5' flanking region driving a reporter gene conclusively identified the ROS-responsive region, which contained the consensus DNA binding site for the redox-regulated transcription factor, activator protein 1.	Cleveland Clin Fdn, Dept Pulm & Crit Care Med, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Pathol, Lerner Res Inst, Cleveland, OH 44195 USA; Canisius Wilhelmina Hosp, Dept Pathol, NL-6500 GS Nijmegen, Netherlands	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Canisius-Wilhelmina Hospital	Erzurum, SC (corresponding author), Cleveland Clin Fdn, Dept Pulm & Crit Care Med, Lerner Res Inst, 9500 Euclid Ave,A90, Cleveland, OH 44195 USA.	erzurus@ccf.org		Thunnissen, Erik/0000-0001-5355-8508	NHLBI NIH HHS [HL 60917] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060917, R37HL060917] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS JD, 1983, J PHARMACOL EXP THER, V227, P749; Arteel GE, 1999, FEBS LETT, V445, P226, DOI 10.1016/S0014-5793(99)00073-3; ASAHI M, 1995, J BIOL CHEM, V270, P21035, DOI 10.1074/jbc.270.36.21035; Asahi M, 1997, J BIOL CHEM, V272, P19152, DOI 10.1074/jbc.272.31.19152; Avissar N, 1996, AM J PHYSIOL-LUNG C, V270, pL173, DOI 10.1152/ajplung.1996.270.2.L173; AVISSAR N, 1991, J NUTR, V121, P1243, DOI 10.1093/jn/121.8.1243; AVISSAR N, 1994, AM J PHYSIOL, V266, pC367, DOI 10.1152/ajpcell.1994.266.2.C367; CALHOUN WJ, 1992, AM REV RESPIR DIS, V145, P317, DOI 10.1164/ajrccm/145.2_Pt_1.317; CANTIN AM, 1987, J APPL PHYSIOL, V63, P152, DOI 10.1152/jappl.1987.63.1.152; Cheng WH, 1999, FASEB J, V13, P1467, DOI 10.1096/fasebj.13.11.1467; CHU FF, 1992, BLOOD, V79, P3233; Comhair SAA, 1999, AM J RESP CRIT CARE, V159, P1824, DOI 10.1164/ajrccm.159.6.9810044; Comhair SAA, 2000, AM J RESP CELL MOL, V23, P350, DOI 10.1165/ajrcmb.23.3.4076; Comhair SAA, 2000, LANCET, V355, P624, DOI 10.1016/S0140-6736(99)04736-4; Danel C, 1998, HUM GENE THER, V9, P1487, DOI 10.1089/hum.1998.9.10-1487; DENEKE SM, 1989, AM J PHYSIOL, V257, pL163, DOI 10.1152/ajplung.1989.257.4.L163; DeRaeve HR, 1997, AM J PHYSIOL-LUNG C, V272, pL148, DOI 10.1152/ajplung.1997.272.1.L148; Guo FH, 1997, J CLIN INVEST, V100, P829, DOI 10.1172/JCI119598; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; Hou YC, 1996, BIOCHEM BIOPH RES CO, V228, P88, DOI 10.1006/bbrc.1996.1620; HOWIE AF, 1995, BIOCHEM J, V308, P713, DOI 10.1042/bj3080713; Jobsis Q, 1997, EUR RESPIR J, V10, P519; Kaminsky DA, 1999, J ALLERGY CLIN IMMUN, V104, P747, DOI 10.1016/S0091-6749(99)70283-6; KANAZAWA H, 1991, CHEST, V100, P1319, DOI 10.1378/chest.100.5.1319; KELLY FJ, 1999, LANCET, V354, P9177; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; Kingsley PD, 1998, MOL REPROD DEV, V49, P343, DOI 10.1002/(SICI)1098-2795(199804)49:4<343::AID-MRD1>3.3.CO;2-T; Klatt P, 1999, FASEB J, V13, P1481, DOI 10.1096/fasebj.13.12.1481; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MARKLUND S, 1974, EUR J BIOCHEM, V47, P469; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Misso NLA, 2000, FREE RADICAL BIO MED, V28, P934, DOI 10.1016/S0891-5849(00)00177-5; *NAT ASTHM ED PREV, 1997, PUBL NAT ASTHM ED PR, V97, P7809; Pietarinen-Runtti P, 1998, AM J RESP CELL MOL, V19, P286, DOI 10.1165/ajrcmb.19.2.2836; Pinkus R, 1996, J BIOL CHEM, V271, P13422, DOI 10.1074/jbc.271.23.13422; Polito AJ, 1998, J ALLERGY CLIN IMMUN, V102, P714, DOI 10.1016/S0091-6749(98)70008-9; Rahman I, 1998, AM J PHYSIOL-LUNG C, V275, pL80, DOI 10.1152/ajplung.1998.275.1.L80; Rahman I, 1999, J BIOL CHEM, V274, P5088, DOI 10.1074/jbc.274.8.5088; Ren B, 1997, J MOL BIOL, V268, P869, DOI 10.1006/jmbi.1997.1005; Saleh D, 1998, FASEB J, V12, P929, DOI 10.1096/fasebj.12.11.929; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SIEST J, 1997, J BIOL CHEM, V44; Smith L. J., 1996, FOLDING DESIGN, V1, pR95; SMITH LJ, 1993, AM REV RESPIR DIS, V147, P1461, DOI 10.1164/ajrccm/147.6_Pt_1.1461; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; Tham DM, 1998, AM J PHYSIOL-GASTR L, V275, pG1463, DOI 10.1152/ajpgi.1998.275.6.G1463; THOMAS EL, 1988, J BIOL CHEM, V263, P2178; van der Vliet A, 1999, AM J RESP CRIT CARE, V160, P1; WINTERBOURN CC, 1989, BIOCHEM PHARMACOL, V38, P271, DOI 10.1016/0006-2952(89)90037-3; WINTERBOURN CC, 1993, FREE RADICAL BIO MED, V14, P85, DOI 10.1016/0891-5849(93)90512-S; YOSHIMURA S, 1994, GENE, V145, P293	51	130	133	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2001	15	1					70	78		10.1096/fj.00-0085com	http://dx.doi.org/10.1096/fj.00-0085com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149894				2022-12-28	WOS:000166312400015
J	Faber-Elmann, A; Grabovsky, V; Dayan, M; Sela, M; Alon, R; Mozes, E				Faber-Elmann, A; Grabovsky, V; Dayan, M; Sela, M; Alon, R; Mozes, E			An altered peptide ligand inhibits the activities of matrix metalloproteinase-9 and phospholipase C, and inhibits T cell interactions with VCAM-1 induced in vivo by a myasthenogenic T cell epitope	FASEB JOURNAL			English	Article						autoimmune myasthenia gravis; T cell receptor; immunomodulation; T cell adhesiveness	LYMPHOCYTE ANTIGEN RECEPTORS; ACETYLCHOLINE-RECEPTOR; AUTOIMMUNE-RESPONSE; SIGNAL-TRANSDUCTION; ADHESION MOLECULES; INTEGRIN VLA-4; ALPHA-SUBUNIT; GRAVIS; ANALOGS; FLOW	Myasthenia gravis (MG) is a T cell-regulated, antibody-mediated autoimmune disease. Immunization with two myasthenogenic peptides, p195-212 and p259-271, which are sequences of the human acetylcholine receptor, resulted in MG-associated immune responses. A dual altered peptide ligand (APL) composed of the two APLs of the myasthenogenic peptides inhibited, in vitro and in vivo, those responses. This study was aimed at understanding the mechanism(s) underlying the in vivo inhibitory properties of the dual APL. To this end, we analyzed T cells of mice that were immunized with p259-271 for their adhesiveness toward vascular cell adhesion molecule 1, for the activity of their secreted matrix metalloproteinases (MMPs), and for their intracellular phospholipase C (PLC) activity. Immunization with p259-271 triggered the above three activities and in vivo administration of the dual APL inhibited the latter. Thus, treatment of mice with the dual APL interferes with functions required for T cells to migrate and interact with the self-AChR. This is the first indication that very late antigen 4, MMP-9, and PLC are targets for immunomodulation of autoreactive T cells by altered peptide ligands.	Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Mozes, E (corresponding author), Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel.	edna.mozes@weizmann.ac.il	ALON, RONEN/GRX-6987-2022	Alon, Ronen/0000-0001-9161-6369				AlberolaIla J, 1997, ANNU REV IMMUNOL, V15, P125, DOI 10.1146/annurev.immunol.15.1.125; ALON R, 1995, J CELL BIOL, V128, P1243, DOI 10.1083/jcb.128.6.1243; Anzai N, 1999, BLOOD, V93, P3317, DOI 10.1182/blood.V93.10.3317.410k12_3317_3326; Archelos JJ, 1997, MOL MED TODAY, V3, P310, DOI 10.1016/S1357-4310(97)01066-6; AXELROD O, 1986, IMMUNOBIOLOGY, V172, P99, DOI 10.1016/S0171-2985(86)80056-0; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; BROCKE S, 1990, IMMUNOLOGY, V69, P495; BROCKE S, 1988, J CLIN INVEST, V82, P1894, DOI 10.1172/JCI113807; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; Chen C, 1999, J IMMUNOL, V162, P1084; CONTITRONCONI BM, 1994, CRIT REV BIOCHEM MOL, V29, P69, DOI 10.3109/10409239409086798; DRACHMAN DB, 1994, NEW ENGL J MED, V330, P1797, DOI 10.1056/NEJM199406233302507; EVAVOLD BD, 1993, IMMUNOL TODAY, V14, P602, DOI 10.1016/0167-5699(93)90200-5; Faber-Elmann A, 1998, P NATL ACAD SCI USA, V95, P14320, DOI 10.1073/pnas.95.24.14320; FABERELMANN A, 2000, IN PRESS INT IMMUNOL, V12; FUCHS S, 1976, NATURE, V263, P329, DOI 10.1038/263329a0; Goetzl EJ, 1996, J IMMUNOL, V156, P1; Gross J., 1981, CELL BIOL EXTRACELLU; HEMLER ME, 1990, IMMUNOL REV, V114, P45, DOI 10.1111/j.1600-065X.1990.tb00561.x; KASSNER PD, 1995, MOL BIOL CELL, V6, P661, DOI 10.1091/mbc.6.6.661; Katz-Levy Y, 1998, J NEUROIMMUNOL, V85, P78, DOI 10.1016/S0165-5728(97)00265-8; KatzLevy Y, 1997, P NATL ACAD SCI USA, V94, P3200, DOI 10.1073/pnas.94.7.3200; Kirshner SL, 1996, SCAND J IMMUNOL, V44, P512, DOI 10.1046/j.1365-3083.1996.d01-330.x; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LINDSTROM J, 1988, ADV IMMUNOL, V42, P233, DOI 10.1016/S0065-2776(08)60847-0; LOBB RR, 1994, J CLIN INVEST, V94, P1722, DOI 10.1172/JCI117519; Madri JA, 1996, BIOCHEM CELL BIOL, V74, P749, DOI 10.1139/o96-082; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; McMurray RW, 1996, SEMIN ARTHRITIS RHEU, V25, P215, DOI 10.1016/S0049-0172(96)80034-5; Mobley JL, 1996, J IMMUNOL, V156, P948; Paas-Rozner M, 2000, P NATL ACAD SCI USA, V97, P2168, DOI 10.1073/pnas.040554597; PICKER LJ, 1994, CURR OPIN IMMUNOL, V6, P394, DOI 10.1016/0952-7915(94)90118-X; RIIKONEN T, 1995, J BIOL CHEM, V270, P13548, DOI 10.1074/jbc.270.22.13548; ROMANIC AM, 1994, J CELL BIOL, V125, P1165, DOI 10.1083/jcb.125.5.1165; SANCHEZMADRID F, 1998, J IMMUNOL, V161, P65; Shingleton WD, 1996, BIOCHEM CELL BIOL, V74, P759, DOI 10.1139/o96-083; SLOANLANCASTER J, 1995, CURR OPIN IMMUNOL, V7, P103, DOI 10.1016/0952-7915(95)80035-2; SloanLancaster J, 1996, ANNU REV IMMUNOL, V14, P1, DOI 10.1146/annurev.immunol.14.1.1; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Zisman E, 1996, P NATL ACAD SCI USA, V93, P4492, DOI 10.1073/pnas.93.9.4492	43	9	12	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2001	15	1					187	194		10.1096/fj.99-0976com	http://dx.doi.org/10.1096/fj.99-0976com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149906				2022-12-28	WOS:000166312400027
J	Erickson, JD; Varoqui, H				Erickson, JD; Varoqui, H			Molecular analysis of vesicular amine transporter function and targeting to secretory organelles	FASEB JOURNAL			English	Review						CAD; PC12; biogenic amines; acetylcholine; small synaptic vesicle; large dense core vesicle; synaptic-like microvesicle; trafficking; quantal release	SYNAPTIC-LIKE MICROVESICLES; DENSE CORE VESICLES; MIDBRAIN DOPAMINERGIC-NEURONS; CHOLINERGIC NERVE-TERMINALS; PROTEIN-KINASE-C; ACETYLCHOLINE TRANSPORTER; MONOAMINE TRANSPORTER; PC12 CELLS; SUBSTRATE RECOGNITION; CHROMAFFIN GRANULE	Vesicular transporters are responsible for the loading of neurotransmitters into specialized secretory organelles in neurons and neuroendocrine cells to make them available for regulated neurosecretion. The exocytotic release of neurotransmitter therefore depends on the functional activity of the vesicular transporters and their efficient sorting to these secretory organelles. Molecular analysis of vesicular transport proteins has revealed important information regarding structural domains responsible for their functional properties, including substrate specificity and trafficking to various classes of secretory vesicles. These studies have established the existence of an important functional relationship between transporter activity and presynaptic quantal neurosecretion.	Louisiana State Univ, Ctr Hlth Sci, Ctr Neurosci, New Orleans, LA 70112 USA; Louisiana State Univ, Ctr Hlth Sci, Dept Pharmacol, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University System	Erickson, JD (corresponding author), Louisiana State Univ, Ctr Hlth Sci, Ctr Neurosci, 2020 Gravier St,Suite D, New Orleans, LA 70112 USA.				NINDS NIH HHS [NS36936] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036936] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AGOSTON DV, 1988, EXP BRAIN RES, V72, P535; Ahnert-Hilger G, 1998, EMBO J, V17, P406, DOI 10.1093/emboj/17.2.406; ALLGAIER C, 1988, BRIT J PHARMACOL, V93, P525, DOI 10.1111/j.1476-5381.1988.tb10307.x; Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; Barbosa J, 1997, J NEUROCHEM, V69, P2608; BAUERFEIND R, 1995, P NATL ACAD SCI USA, V92, P7342, DOI 10.1073/pnas.92.16.7342; BAUERFEIND R, 1993, NEURON, V11, P105, DOI 10.1016/0896-6273(93)90275-V; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CHO GW, 2000, IN PRESS J BIOL CHEM; Clarizia AD, 1999, NEUROREPORT, V10, P2783, DOI 10.1097/00001756-199909090-00016; CLIFTOGRADY L, 1990, J CELL BIOL, V110, P1693, DOI 10.1083/jcb.110.5.1693; CUTLER DF, 1990, J CELL BIOL, V110, P721, DOI 10.1083/jcb.110.3.721; DARCHEN F, 1989, BIOCHEMISTRY-US, V28, P1692, DOI 10.1021/bi00430a040; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; Eiden LE, 1998, J NEUROCHEM, V70, P2227; Erickson J D, 1998, Adv Pharmacol, V42, P227; ERICKSON JD, 1993, J NEUROCHEM, V61, P2314, DOI 10.1111/j.1471-4159.1993.tb07476.x; Erickson JD, 1996, P NATL ACAD SCI USA, V93, P5166, DOI 10.1073/pnas.93.10.5166; Faundez V, 1998, CELL, V93, P423, DOI 10.1016/S0092-8674(00)81170-8; Finn JP, 1998, METHOD ENZYMOL, V296, P144; Finn JP, 1998, J BIOL CHEM, V273, P3943, DOI 10.1074/jbc.273.7.3943; Finn JP, 1997, J BIOL CHEM, V272, P16301, DOI 10.1074/jbc.272.26.16301; Fon EA, 1997, NEURON, V19, P1271, DOI 10.1016/S0896-6273(00)80418-3; FRERKING M, 1995, NEURON, V15, P885, DOI 10.1016/0896-6273(95)90179-5; Gilmor ML, 1996, J NEUROSCI, V16, P2179; GRACZ LM, 1988, BIOCHEMISTRY-US, V27, P5268, DOI 10.1021/bi00414a048; GROTE E, 1995, CELL, V81, P581, DOI 10.1016/0092-8674(95)90079-9; HEERINGA MJ, 1995, J NEUROCHEM, V65, P192; HENRY JP, 1989, BIOCHEM PHARMACOL, V38, P2395, DOI 10.1016/0006-2952(89)90082-8; Holtje M, 2000, J NEUROSCI, V20, P2131; Kim MH, 1999, J BIOL CHEM, V274, P673, DOI 10.1074/jbc.274.2.673; Kitamoto T, 2000, J NEUROBIOL, V42, P161, DOI 10.1002/(SICI)1097-4695(20000205)42:2<161::AID-NEU1>3.0.CO;2-P; KNOTH J, 1981, BIOCHEMISTRY-US, V20, P6625, DOI 10.1021/bi00526a016; KOSHIMURA K, 1990, J NEUROCHEM, V54, P533, DOI 10.1111/j.1471-4159.1990.tb01904.x; Krantz DE, 2000, J CELL BIOL, V149, P379, DOI 10.1083/jcb.149.2.379; Krantz DE, 1997, J BIOL CHEM, V272, P6752, DOI 10.1074/jbc.272.10.6752; Leitner B, 1999, J NEUROCHEM, V72, P1110, DOI 10.1046/j.1471-4159.1999.0721110.x; Li JY, 1998, NEUROCHEM INT, V32, P457, DOI 10.1016/S0197-0186(97)00122-8; Liu GS, 1999, NEURON, V22, P395, DOI 10.1016/S0896-6273(00)81099-5; Liu YJ, 1997, ANNU REV NEUROSCI, V20, P125; LIU YJ, 1994, J CELL BIOL, V127, P1419, DOI 10.1083/jcb.127.5.1419; Liu YJ, 1997, J CELL BIOL, V139, P907, DOI 10.1083/jcb.139.4.907; MERICKEL A, 1995, J BIOL CHEM, V270, P25798, DOI 10.1074/jbc.270.43.25798; Merickel A, 1997, J BIOL CHEM, V272, P5403, DOI 10.1074/jbc.272.9.5403; Nguyen ML, 1998, BIOCHEMISTRY-US, V37, P13400, DOI 10.1021/bi9802263; NIRENBERG MJ, 1995, P NATL ACAD SCI USA, V92, P8773, DOI 10.1073/pnas.92.19.8773; Nirenberg MJ, 1996, J NEUROSCI, V16, P4135; Nirenberg MJ, 1997, SYNAPSE, V26, P194; NJUS D, 1986, BIOCHIM BIOPHYS ACTA, V853, P237, DOI 10.1016/0304-4173(87)90003-6; PARSONS SM, 1993, INT REV NEUROBIOL, V35, P279, DOI 10.1016/S0074-7742(08)60572-3; Partoens P, 1998, J CELL SCI, V111, P681; Peter D, 1996, J BIOL CHEM, V271, P2979, DOI 10.1074/jbc.271.6.2979; PETER D, 1994, J BIOL CHEM, V269, P7231; Pothos E, 1996, J NEUROCHEM, V66, P629; Prior C, 1995, PHARMACOL RES, V32, P345, DOI 10.1016/S1043-6618(05)80039-8; Qi YP, 1997, J NEUROSCI, V17, P1217; Rand JB, 1998, METHOD ENZYMOL, V296, P529; RAND JB, 1984, GENETICS, V106, P227; REGNIERVIGOUROUX A, 1991, EMBO J, V10, P3589, DOI 10.1002/j.1460-2075.1991.tb04925.x; RUDNICK G, 1990, BIOCHEMISTRY-US, V29, P603, DOI 10.1021/bi00455a002; SALTON SRJ, 1995, FEBS LETT, V360, P106, DOI 10.1016/0014-5793(95)00086-O; SALVATERRA PM, 1985, J NEUROSCI, V5, P903; Schmidt A, 1997, J CELL BIOL, V137, P445, DOI 10.1083/jcb.137.2.445; SCHULDINER S, 1993, J BIOL CHEM, V268, P29; Shi GY, 1998, J CELL BIOL, V143, P947, DOI 10.1083/jcb.143.4.947; SHIRVAN A, 1994, FEBS LETT, V356, P145, DOI 10.1016/0014-5793(94)01252-0; SILVA NL, 1988, EUR J PHARMACOL, V149, P307, DOI 10.1016/0014-2999(88)90661-9; Song HJ, 1997, NEURON, V18, P815, DOI 10.1016/S0896-6273(00)80320-7; SteinerMordoch S, 1996, J BIOL CHEM, V271, P13048, DOI 10.1074/jbc.271.22.13048; Strasser JE, 1999, MOL BIOL CELL, V10, P2619, DOI 10.1091/mbc.10.8.2619; SULZER D, 1990, NEURON, V5, P797, DOI 10.1016/0896-6273(90)90339-H; Takei K, 1996, J CELL BIOL, V133, P1237, DOI 10.1083/jcb.133.6.1237; Tan PK, 1998, J BIOL CHEM, V273, P17351, DOI 10.1074/jbc.273.28.17351; Tao-Cheng J H, 1998, Adv Pharmacol, V42, P250; THURESONKLEIN A, 1983, NEUROSCIENCE, V10, P245, DOI 10.1016/0306-4522(83)90132-X; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; ULUS IH, 1989, BRAIN RES, V484, P217, DOI 10.1016/0006-8993(89)90364-8; VANDERKLOOT W, 1992, PFLUG ARCH EUR J PHY, V420, P336, DOI 10.1007/BF00374467; VANDERKLOOT W, 1991, J NEUROBIOL, V22, P204, DOI 10.1002/neu.480220210; Varoqui H, 1998, J BIOL CHEM, V273, P9094, DOI 10.1074/jbc.273.15.9094; Varoqui H, 1997, MOL NEUROBIOL, V15, P165, DOI 10.1007/BF02740633; Varoqui H, 1996, J BIOL CHEM, V271, P27229, DOI 10.1074/jbc.271.44.27229; Varoqui H, 1998, J PHYSIOLOGY-PARIS, V92, P141, DOI 10.1016/S0928-4257(98)80152-6; Varoqui H, 1998, METHOD ENZYMOL, V296, P84; VIZI ES, 1989, BRIT J PHARMACOL, V98, P898, DOI 10.1111/j.1476-5381.1989.tb14619.x; Weihe E, 1996, P NATL ACAD SCI USA, V93, P3547, DOI 10.1073/pnas.93.8.3547; Winkler H, 1997, NEUROCHEM RES, V22, P921, DOI 10.1023/A:1022410506476	87	53	53	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2450	2458		10.1096/fj.00-0206rev	http://dx.doi.org/10.1096/fj.00-0206rev			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099462				2022-12-28	WOS:000165723400014
J	Ferrari, D; La Sala, A; Chiozzi, P; Morelli, A; Falzoni, S; Girolomoni, G; Idzko, M; Dichmann, S; Norgauer, J; Di Virgilio, F				Ferrari, D; La Sala, A; Chiozzi, P; Morelli, A; Falzoni, S; Girolomoni, G; Idzko, M; Dichmann, S; Norgauer, J; Di Virgilio, F			The P2 purinergic receptors of human dendritic cells: identification and coupling to cytokine release	FASEB JOURNAL			English	Article						extracellular nucleotides; nucleotide receptors; IL-1 beta; TNF-alpha; inflammation	EPIDERMAL LANGERHANS CELLS; EXTRACELLULAR ATP; MICROGLIAL CELLS; PLASMA-MEMBRANE; GATED CHANNELS; MACROPHAGES; LYMPHOCYTES; MODULATION; ADENOSINE; MECHANISM	We investigated the expression of purinoceptors in human dendritic cells, providing functional, pharmacological, and biochemical evidence that immature and mature cells express P2Y and P2X subtypes, coupled to increase in the intracellular Ca2+ membrane depolarization, and secretion of inflammatory cytokines. The ATP-activated Ca2+ change was biphasic, with a fast release from intracellular stores and a delayed influx across the plasma membrane. A prolonged exposure to ATP was toxic to dendritic cells that swelled, lost typical dendrites, became phase lucent, detached from the substrate, and eventually died. These changes were highly suggestive of expression of the cytotoxic receptor P2X(7), as confirmed by ability of dendritic cells to become permeant to membrane impermeant dyes such as Lucifer yellow or ethidium bromide. The P2X(7) receptor ligand 2',3'-(4benzoyl-benzoyl)-ATP was a better agonist then ATP for Ca2+ increase and plasma membrane depolarization. Oxidized ATP, a covalent blocker of P2X receptors, and the selective P2X(7) antagonist KN-62 inhibited both permeabilization and Ca2+ changes induced by ATP. The following purinoceptors were expressed by immature and mature dendritic cells: P2Y(1), P2Y(2), P2Y(5), P2Y(11) and P2X(1), P2X(4), P2X(7). Finally, stimulation of LPS-matured cells with ATP triggered release of IL-1 beta and TNF-alpha. Purinoceptors may provide a new avenue to modulation of dendritic cells function.	Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, I-44100 Ferrara, Italy; Univ Ferrara, Ctr Biotechnol, I-44100 Ferrara, Italy; IRCCS, Immunol Lab, Ist Dermopat Immacolata, Rome, Italy; Univ Freiburg, Dept Pneumol, Freiburg, Germany; Univ Freiburg, Dept Dermatol, Freiburg, Germany	University of Ferrara; University of Ferrara; IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Freiburg; University of Freiburg	Ferrari, D (corresponding author), Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, Via L Borsari 46, I-44100 Ferrara, Italy.		GIROLOMONI, Giampiero/AAC-3405-2022; la Sala, Andrea/A-3228-2009; Di Virgilio, Francesco/J-3754-2018; DI VIRGILIO, Francesco/O-4634-2019; Ferrari, Davide/F-5644-2015	la Sala, Andrea/0000-0003-1268-6516; Di Virgilio, Francesco/0000-0003-3566-1362; DI VIRGILIO, Francesco/0000-0003-3566-1362; Ferrari, Davide/0000-0002-5727-9204; Chiozzi, Paola/0000-0003-4952-334X; Falzoni, Simonetta/0000-0002-6594-0357	Telethon [961] Funding Source: Medline	Telethon(Fondazione Telethon)		ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; APASOV S, 1995, IMMUNOL REV, V146, P5, DOI 10.1111/j.1600-065X.1995.tb00680.x; Apasov SG, 1997, J IMMUNOL, V158, P5095; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Baricordi OR, 1996, BLOOD, V87, P682, DOI 10.1182/blood.V87.2.682.bloodjournal872682; Baricordi OR, 1999, J BIOL CHEM, V274, P33206, DOI 10.1074/jbc.274.47.33206; BERGMEYER HU, 1983, METHOD ENZYMAT AN, V3, P118; Buell G, 1998, BLOOD, V92, P3521, DOI 10.1182/blood.V92.10.3521.422k50_3521_3528; CHAKER MB, 1984, J INVEST DERMATOL, V82, P496, DOI 10.1111/1523-1747.ep12261031; Chvatchko Y, 1996, IMMUNITY, V5, P275, DOI 10.1016/S1074-7613(00)80322-2; Cotrina ML, 1998, P NATL ACAD SCI USA, V95, P15735, DOI 10.1073/pnas.95.26.15735; Coutinho-Silva R, 1999, AM J PHYSIOL-CELL PH, V276, pC1139, DOI 10.1152/ajpcell.1999.276.5.C1139; Di Virgilio F, 1998, CELL DEATH DIFFER, V5, P191; Dichmann S, 2000, BLOOD, V95, P973, DOI 10.1182/blood.V95.3.973.003k47_973_978; DIVIRGILIO F, 1989, J IMMUNOL, V143, P1955; DIVIRGILIO F, 1995, IMMUNOL TODAY, V16, P524, DOI 10.1016/0167-5699(95)80045-X; DIVIRGILIO F, 2000, IN PRESS BLOOD; DIVIRGILIO F, 2000, IN PRESS HDB EXPT PH; ELMOATASSIM C, 1992, J BIOL CHEM, V267, P23664; FALZONI S, 1995, J CLIN INVEST, V95, P1207, DOI 10.1172/JCI117770; Ferrari D, 1997, NEUROPHARMACOLOGY, V36, P1295, DOI 10.1016/S0028-3908(97)00137-8; Ferrari D, 1996, J IMMUNOL, V156, P1531; Ferrari D, 1997, J EXP MED, V185, P579, DOI 10.1084/jem.185.3.579; Ferrari D, 1997, J IMMUNOL, V159, P1451; FERRARI D, 1994, AM J PHYSIOL-CELL PH, V267, pC886, DOI 10.1152/ajpcell.1994.267.4.C886; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; Gargett CE, 1997, BRIT J PHARMACOL, V120, P1483, DOI 10.1038/sj.bjp.0701081; GIROLOMONI G, 1993, J INVEST DERMATOL, V100, P282, DOI 10.1111/1523-1747.ep12469769; Hart DNJ, 1997, BLOOD, V90, P3245, DOI 10.1182/blood.V90.9.3245; HICKMAN SE, 1994, BLOOD, V84, P2452; HOGQUIST KA, 1991, J IMMUNOL, V147, P2181; Hu Y, 1998, J BIOL CHEM, V273, P27170, DOI 10.1074/jbc.273.42.27170; Humphreys BD, 1998, J LEUKOCYTE BIOL, V64, P265, DOI 10.1002/jlb.64.2.265; Jiang QS, 1998, J CELL BIOL, V143, P645, DOI 10.1083/jcb.143.3.645; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; Liu QH, 1999, FEBS LETT, V445, P402, DOI 10.1016/S0014-5793(99)00161-1; Ma WY, 1999, NATURE, V400, P894, DOI 10.1038/23743; Mitchell CH, 1998, P NATL ACAD SCI USA, V95, P7174, DOI 10.1073/pnas.95.12.7174; MURGIA M, 1993, J BIOL CHEM, V268, P8199; Mutini C, 1999, J IMMUNOL, V163, P1958; North RA, 1997, CURR OPIN NEUROBIOL, V7, P346, DOI 10.1016/S0959-4388(97)80062-1; PERREGAUX D, 1992, J IMMUNOL, V149, P1294; PERREGAUX D, 1994, J BIOL CHEM, V269, P15195; Perregaux DG, 1998, J IMMUNOL, V160, P2469; Ralevic V, 1998, PHARMACOL REV, V50, P413; Robson SC, 1997, J EXP MED, V185, P153, DOI 10.1084/jem.185.1.153; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Sikora A, 1999, J IMMUNOL, V163, P558; Solini A, 1999, J CELL SCI, V112, P297; Soto F, 1997, J MEMBRANE BIOL, V160, P91, DOI 10.1007/s002329900298; STEINBERG TH, 1987, J BIOL CHEM, V262, P8884; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; SUPRENANT A, 1996, SCIENCE, V272, P735; Virginio C, 1999, NAT NEUROSCI, V2, P315, DOI 10.1038/7225	54	124	131	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2466	2476		10.1096/fj.00-0031com	http://dx.doi.org/10.1096/fj.00-0031com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099464				2022-12-28	WOS:000165723400016
J	Scalia, R; Coyle, KM; Levine, BJ; Booth, G; Lefer, AM				Scalia, R; Coyle, KM; Levine, BJ; Booth, G; Lefer, AM			C-peptide inhibits leukocyte-endothelium interaction in the microcirculation during acute endothelial dysfunction	FASEB JOURNAL			English	Article						intravital microscopy; inflammation; rat; diabetes; nitric oxide synthase	DEPENDENT DIABETIC-PATIENTS; NITRIC-OXIDE; P-SELECTIN; ISCHEMIA-REPERFUSION; MYOCARDIAL-ISCHEMIA; CELL-ADHESION; BIOLOGICAL-ACTIVITY; GLUCOSE-UTILIZATION; IDDM PATIENTS; INSULIN	C-peptide is a cleavage product that comes from processing proinsulin to insulin that induces nitric oxide (NO) -mediated vasodilation, NO modulates leukocyte-endothelium interaction. We hypothesized that C-peptide might inhibit leukocyte-endothelium interaction via increased release of endothelial NO, Using intravital microscopy of the rat mesentery, we measured leukocyte-endothelium interactions after administration of C-peptide to the rat. Superfusion of the rat mesentery with either thrombin or L-NAME consistently and significantly increased the number of rolling, adhering, and transmigrated leukocytes, C-peptide significantly attenuated either thrombin- or L-NAME-induced leukocyte-endothelium interactions in rat mesenteric venules. A control scrambled sequence of C-peptide characterized by the same amino acid composition in a randomized sequence failed to inhibit leukocyte-endothelium interactions. These effects of C-peptide were associated with decreased surface expression of the cell adhesion molecules P-selectin and ICAM-1 on the microvascular endothelium. Endothelial nitric oxide synthase (eNOS) mRNA levels were increased in rats injected with C-peptide. This enhanced eNOS expression was associated with a marked increase in basal NO release from the aorta of C-peptide-treated rats. We conclude that C-peptide is a potent inhibitor of leukocyte-endothelium interaction and that this effect is specifically related to inhibition of endothelial cell adhesion molecules via maintenance of NO release from the vascular endothelium.-Scalia, R., Coyle, K. M., Levine, B, J., Booth, G., Lefer, A. M. C-peptide inhibits leukocyte-endothelium interaction in the microcirculation during acute endothelial dysfunction.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Physiol, Philadelphia, PA 19107 USA	Jefferson University	Scalia, R (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Physiol, 1020 Locust St, Philadelphia, PA 19107 USA.			Scalia, Rosario/0000-0002-1829-943X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T35HL007845] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-07599, HL-07845] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AOKI N, 1990, AM J PHYSIOL, V258, pG275, DOI 10.1152/ajpgi.1990.258.2.G275; BARROSOARANDA J, 1988, CIRC RES, V63, P437, DOI 10.1161/01.RES.63.2.437; BORDERS JL, 1984, MICROVASC RES, V27, P117, DOI 10.1016/0026-2862(84)90047-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVENPECK KL, 1994, GASTROENTEROLOGY, V107, P1050, DOI 10.1016/0016-5085(94)90229-1; DE CR, 1995, J CLIN INVEST, V96, P60; ENTMAN ML, 1990, J CLIN INVEST, V85, P1497, DOI 10.1172/JCI114596; Forst T, 1998, EXP CLIN ENDOCR DIAB, V106, P270, DOI 10.1055/s-0029-1212190; Forst T, 1998, J CLIN INVEST, V101, P2036, DOI 10.1172/JCI2147; Fox-Robichaud A, 1998, J CLIN INVEST, V101, P2497, DOI 10.1172/JCI2736; GAUTHIER TW, 1994, AM J PHYSIOL-GASTR L, V267, pG562, DOI 10.1152/ajpgi.1994.267.4.G562; GAUTHIER TW, 1995, ARTERIOSCL THROM VAS, V15, P1652, DOI 10.1161/01.ATV.15.10.1652; GRANGER DN, 1989, AM J PHYSIOL, V257, pG683, DOI 10.1152/ajpgi.1989.257.5.G683; GRANGER DN, 1994, J LEUKOCYTE BIOL, V55, P662, DOI 10.1002/jlb.55.5.662; Guo JP, 1996, J APPL PHYSIOL, V81, P774, DOI 10.1152/jappl.1996.81.2.774; Hickey MJ, 1997, EXP PHYSIOL, V82, P339, DOI 10.1113/expphysiol.1997.sp004029; Ido Y, 1997, SCIENCE, V277, P563, DOI 10.1126/science.277.5325.563; Jensen ME, 1999, AM J PHYSIOL-HEART C, V276, pH1223, DOI 10.1152/ajpheart.1999.276.4.H1223; JOHANSSON BL, 1992, DIABETOLOGIA, V35, P1151, DOI 10.1007/BF00401369; JOHANSSON BL, 1992, DIABETOLOGIA, V35, P121, DOI 10.1007/BF00402543; Johansson BL, 1996, DIABETOLOGIA, V39, P687; JOHNSON G, 1991, CRIT CARE MED, V19, P244, DOI 10.1097/00003246-199102000-00021; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; KUROSE I, 1993, HEPATOLOGY, V18, P380, DOI 10.1002/hep.1840180223; Lefer AM, 1996, CARDIOVASC RES, V32, P743, DOI 10.1016/0008-6363(96)00073-9; LEFER AM, 1993, J CARDIOVASC PHAR S7, V22, P27; LORANT DE, 1993, J CLIN INVEST, V92, P559, DOI 10.1172/JCI116623; McEver Rodger P., 1992, Current Opinion in Cell Biology, V4, P840, DOI 10.1016/0955-0674(92)90109-P; MCEVER RP, 1994, ANN NY ACAD SCI, V714, P185, DOI 10.1111/j.1749-6632.1994.tb12043.x; Minchenko AG, 1999, ENDOTHELIUM-NEW YORK, V6, P303, DOI 10.3109/10623329909078497; OSBORNE JA, 1989, AM J PHYSIOL, V256, P591; Pieper GM, 1998, HYPERTENSION, V31, P1047, DOI 10.1161/01.HYP.31.5.1047; Rigler R, 1999, P NATL ACAD SCI USA, V96, P13318, DOI 10.1073/pnas.96.23.13318; Rojas A, 2000, CIRC RES, V86, pE50, DOI 10.1161/01.RES.86.3.e50; Scalia R, 1997, P NATL ACAD SCI USA, V94, P9967, DOI 10.1073/pnas.94.18.9967; Scalia R, 1999, FASEB J, V13, P1039, DOI 10.1096/fasebj.13.9.1039; SIEGFRIED MR, 1992, J PHARMACOL EXP THER, V260, P668; Tung DKL, 1997, J LEUKOCYTE BIOL, V62, P163, DOI 10.1002/jlb.62.2.163; Wakelin MW, 1996, J EXP MED, V184, P229, DOI 10.1084/jem.184.1.229; WEYRICH AS, 1995, J LEUKOCYTE BIOL, V57, P45, DOI 10.1002/jlb.57.1.45; WEYRICH AS, 1994, CIRC RES, V75, P692, DOI 10.1161/01.RES.75.4.692; WEYRICH AS, 1993, J CLIN INVEST, V91, P2620, DOI 10.1172/JCI116501	43	78	82	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2357	2364		10.1096/fj.00-0183com	http://dx.doi.org/10.1096/fj.00-0183com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053258				2022-12-28	WOS:000165190800030
J	Blagosklonny, MV				Blagosklonny, MV			p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect	FASEB JOURNAL			English	Review						prion; dysfunction; cancer therapy; trans-activating function	WILD-TYPE P53; TUMOR-SUPPRESSOR P53; CELL-CYCLE ARREST; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVATION; COLORECTAL TUMORIGENESIS; SV40-TRANSFORMED CELLS; APOPTOTIC FUNCTION; CANCER-THERAPY; FEEDBACK LOOP	Increasing the complexity of their models, p53s are stabilized either in order to function (wt p53) or due to the loss of function (mutant p53) with acquiring a mysterious prion-like ability to drive the normal p53 into the abnormal conformation to gain new functions. As already recognized, the loss of trans-activating function leads to a stabilization of mutant p53 because of the disappearance of the p53-inducible proteins, which otherwise directly (Mdm-2) or indirectly (p21) target p53 for degradation. Simplifying further, I will discuss that the loss of function results in a dominant-negative effect and gain-of-function (a dominant-positive effect). Thus, mutant p53 lacking trans-activation function nevertheless may retain the ability to repress transcription due to its competition with numerous transcription factors for their coactivators. When mutant p53 competes with wt p53, the inhibition of the wt p53-dependent transcription is perceived as a dominant-negative effect. Just like trans-repression, a dominant-negative effect requires an excess of p53 and, therefore, a 'dominant'-negative effect is not dominant. Furthermore, the stabilization of an endogenous mt p53 due to the loss of wt functions cannot occur in the presence of the wt p53 allele. Given the inability of mutant p53 to accumulate in the presence of wt p53, a dominant-negative effect does not naturally occur and, not surprisingly, heterozygous mt/wt cells are rare. The detection of a dominant-negative effect simply indicates that mutant p53 indeed has lost its function. Last, since mutant p53 loses some or most but not all activities and accumulates in the absence of wt allele, gain-of-function can be considered as an exaggeration of the remaining functions. Applications to cancer therapy are discussed.	NCI, Med Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Blagosklonny, MV (corresponding author), NCI, Med Branch, NIH, Bldg 10,Room 13 N 226, Bethesda, MD 20892 USA.	mikhailb@box-m.nih.gov						Albor A, 1998, CANCER RES, V58, P2091; An WG, 1997, CANCER CHEMOTH PHARM, V40, P60, DOI 10.1007/s002800050626; An WG, 1998, EXP CELL RES, V244, P54, DOI 10.1006/excr.1998.4193; Arriola EL, 1999, ONCOGENE, V18, P1081, DOI 10.1038/sj.onc.1202391; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BAKER SJ, 1990, CANCER RES, V50, P7717; BHATIA K, 1993, FASEB J, V7, P951, DOI 10.1096/fasebj.7.10.8344493; Blagosklonny MV, 2000, J CLIN INVEST, V105, P533, DOI 10.1172/JCI8625; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Blagosklonny MV, 1997, ONCOGENE, V15, P1889, DOI 10.1038/sj.onc.1201374; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; Chene P, 1998, J MOL BIOL, V281, P205, DOI 10.1006/jmbi.1998.1897; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; Davis P, 1996, ONCOGENE, V13, P1315; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Epstein CB, 1998, ONCOGENE, V16, P2115, DOI 10.1038/sj.onc.1201734; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; FREBOURG T, 1994, CANCER RES, V54, P878; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Giannakakou P, 2000, ONCOGENE, V19, P3078, DOI 10.1038/sj.onc.1203642; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Haupt Ygal, 1997, Leukemia (Basingstoke), V11, P337; Joers A, 1998, ONCOGENE, V17, P2351, DOI 10.1038/sj.onc.1202146; KAELBLING M, 1992, LANCET, V340, P140, DOI 10.1016/0140-6736(92)93214-8; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KNUDSON AG, 1975, P NATL ACAD SCI USA, V72, P5116, DOI 10.1073/pnas.72.12.5116; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; LUNA RMD, 1995, NATURE, V378, P203; Maki CG, 1996, CANCER RES, V56, P2649; Marutani M, 1999, CANCER RES, V59, P4765; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; MIYASHITA T, 1995, CELL, V80, P293; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nagata Y, 1999, ONCOGENE, V18, P6037, DOI 10.1038/sj.onc.1202978; OConnor PM, 1997, CANCER RES, V57, P4285; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; PARK DJ, 1994, ONCOGENE, V9, P1899; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Ravi R, 1998, CANCER RES, V58, P4531; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Sheikh MS, 1999, ONCOGENE, V18, P4153, DOI 10.1038/sj.onc.1202763; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; SRIVASTAVA S, 1992, ONCOGENE, V7, P987; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SUN Y, 1993, FASEB J, V7, P944, DOI 10.1096/fasebj.7.10.8344492; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747; Venot C, 1999, ONCOGENE, V18, P2405, DOI 10.1038/sj.onc.1202539; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; WILLIAMS AC, 1995, ONCOGENE, V11, P141; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517	91	139	149	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2000	14	13					1901	1907		10.1096/fj.99-1078rev	http://dx.doi.org/10.1096/fj.99-1078rev			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023974				2022-12-28	WOS:000089634400009
J	Zainal, TA; Oberley, TD; Allison, DB; Szweda, LI; Weindruch, R				Zainal, TA; Oberley, TD; Allison, DB; Szweda, LI; Weindruch, R			Caloric restriction of rhesus monkeys lowers oxidative damage in skeletal muscle	FASEB JOURNAL			English	Article						aging; free radicals; immunogold; lipid peroxidation; reactive oxygen species; sarcopenia	PROTEIN-TURNOVER; DIETARY RESTRICTION; SARCOPLASMIC-RETICULUM; TYROSINE NITRATION; SERCA2A ISOFORM; NITRIC-OXIDE; CA-ATPASE; RAT; GROWTH; ANTIOXIDANT	In laboratory rodents, caloric restriction (CR) retards several age-dependent physiological and biochemical changes in skeletal muscle, including increased steady-state levels of oxidative damage to lipids, DNA, and proteins. We used immunogold electron microscopic (EM) techniques with antibodies raised against 4-hydroxy-2-nonenal (HNE) -modified proteins, dinitrophenol, and nitrotyrosine to quantify and localize the age-dependent accrual of oxidative damage in rhesus monkey vastus lateralis skeletal muscle, Using immunogold EM analysis of muscle from rhesus monkeys ranging in age from 2 to 34 years old, a fourfold maximal increase in levels of HNE-modified proteins was observed. Likewise, carbonyl levels increased twofold with aging, Comparing 17- to 23-year-old normally fed to age-matched monkeys subjected to CR for 10 years, levels of HNE-modified proteins, carbonyls, and nitrotyrosine in skeletal muscle from the CR group were significantly less than control group values. Oxidative damage largely localized to myofibrils, with lesser labeling in other subcellular compartments. Accumulation of lipid peroxidation-derived aldehydes, such as malondialdehyde and 4-hydroxy-2-alkenals, and protein carbonyls were measured biochemically and confirmed the morphological data. Our study is the first to quantify morphologically and localize the age-dependent accrual of oxidative damage in mammalian skeletal muscle and to demonstrate that oxidative damage in primates is lowered by CR.	William S Middleton Mem Vet Hosp, Pathol & Lab Med Serv, Madison, WI 53705 USA; William S Middleton Mem Vet Hosp, Ctr Geriatr Res Educ & Clin, Madison, WI 53705 USA; Univ Wisconsin, Dept Nutr Sci, Madison, WI 53705 USA; Univ Wisconsin, Dept Lab Med & Pathol, Madison, WI 53705 USA; Univ Wisconsin, Dept Med, Madison, WI 53705 USA; Univ Wisconsin, Wisconsin Reg Primate Res Ctr, Madison, WI 53705 USA; Columbia Univ Coll Phys & Surg, St Lukes Roosevelt Hosp, Obes Res Ctr, New York, NY 10032 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Columbia University; Mount Sinai St. Luke's; Mount Sinai West; Case Western Reserve University	Oberley, TD (corresponding author), William S Middleton Mem Vet Hosp, Pathol & Lab Med Serv, 2500 Overlook Terrace,Room A35, Madison, WI 53705 USA.			Allison, David/0000-0003-3566-9399				Aspnes LE, 1997, FASEB J, V11, P573, DOI 10.1096/fasebj.11.7.9212081; Balagopal P, 1997, AM J PHYSIOL-ENDOC M, V273, pE790, DOI 10.1152/ajpendo.1997.273.4.E790; BATES PC, 1983, BIOCHEM J, V214, P587, DOI 10.1042/bj2140587; Chambon-Savanovitch C, 1999, EUR J CLIN INVEST, V29, P504, DOI 10.1046/j.1365-2362.1999.00469.x; Dutta C, 1997, J NUTR, V127, pS992, DOI 10.1093/jn/127.5.992S; ELHAJ AJ, 1986, COMP BIOCHEM PHYS A, V85, P281, DOI 10.1016/0300-9629(86)90251-3; Felgines C, 1999, JPEN-PARENTER ENTER, V23, P32, DOI 10.1177/014860719902300132; Ferrington DA, 1998, J BIOL CHEM, V273, P5885, DOI 10.1074/jbc.273.10.5885; Fruhbeck G, 1996, J PHYSIOL BIOCHEM, V52, P207; GOLDSPINK DF, 1987, EXP GERONTOL, V22, P67, DOI 10.1016/0531-5565(87)90016-7; GOLDSPINK DF, 1986, CARDIOVASC RES, V20, P672, DOI 10.1093/cvr/20.9.672; Gorsuch R., 1983, FACTOR ANAL; HOLLOSZY JO, 1995, J GERONTOL A-BIOL, V50, P1; INGRAM DK, 1990, J GERONTOL, V45, P148; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; JI LL, 1990, AM J PHYSIOL, V258, pR918, DOI 10.1152/ajpregu.1990.258.4.R918; KELLY FJ, 1984, MUSCLE NERVE, V7, P235, DOI 10.1002/mus.880070309; KEMNITZ JW, 1993, J GERONTOL, V48, pB17, DOI 10.1093/geronj/48.1.B17; KEMNITZ JW, 1994, AM J PHYSIOL, V266, pE540, DOI 10.1152/ajpendo.1994.266.4.E540; Lass A, 1998, FREE RADICAL BIO MED, V25, P1089, DOI 10.1016/S0891-5849(98)00144-0; LAWLER JM, 1993, AM J PHYSIOL, V265, pR1344, DOI 10.1152/ajpregu.1993.265.6.R1344; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Leeuwenburgh C, 1997, ARCH BIOCHEM BIOPHYS, V346, P74, DOI 10.1006/abbi.1997.0297; LEEUWENBURGH C, 1994, AM J PHYSIOL, V267, pR439, DOI 10.1152/ajpregu.1994.267.2.R439; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; LEWIS SEM, 1985, EXP GERONTOL, V20, P253, DOI 10.1016/0531-5565(85)90050-6; LEWIS SEM, 1984, BIOCHEM J, V217, P517, DOI 10.1042/bj2170517; Marechal G, 1999, CELL MOL LIFE SCI, V55, P1088, DOI 10.1007/s000180050359; Mecocci P, 1999, FREE RADICAL BIO MED, V26, P303, DOI 10.1016/S0891-5849(98)00208-1; Millward DJ, 1997, AM J CLIN NUTR, V66, P774, DOI 10.1093/ajcn/66.4.774; Pansarasa O, 1999, FREE RADICAL BIO MED, V27, P617, DOI 10.1016/S0891-5849(99)00108-2; PURI ML, 1969, ANN MATH STAT, V40, P1325, DOI 10.1214/aoms/1177697505; Reid MB, 1998, ACTA PHYSIOL SCAND, V162, P401, DOI 10.1046/j.1365-201X.1998.0303f.x; Smith K, 1996, BAILLIERE CLIN ENDOC, V10, P469, DOI 10.1016/S0950-351X(96)80651-3; Smith MA, 1998, J HISTOCHEM CYTOCHEM, V46, P731, DOI 10.1177/002215549804600605; Smith MA, 1996, NATURE, V382, P120, DOI 10.1038/382120b0; SOHAL RS, 1994, MECH AGEING DEV, V74, P121, DOI 10.1016/0047-6374(94)90104-X; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; SOHAL RS, 1994, MECH AGEING DEV, V76, P215, DOI 10.1016/0047-6374(94)91595-4; STARNES JW, 1989, J APPL PHYSIOL, V67, P69, DOI 10.1152/jappl.1989.67.1.69; Toothaker LE, 1991, MULTIPLE COMP RES; UAUY R, 1978, J GERONTOL, V33, P663, DOI 10.1093/geronj/33.5.663; UCHIDA K, 1993, P NATL ACAD SCI USA, V90, P8742, DOI 10.1073/pnas.90.18.8742; Uchida K, 1995, ARCH BIOCHEM BIOPHYS, V324, P241, DOI 10.1006/abbi.1995.0036; Viera L, 1999, METHOD ENZYMOL, V301, P373; Viner RI, 1997, BBA-BIOMEMBRANES, V1329, P321, DOI 10.1016/S0005-2736(97)00125-9; Viner RI, 1996, FEBS LETT, V379, P286, DOI 10.1016/0014-5793(95)01530-2; Viner RI, 1999, BIOCHEM J, V340, P657, DOI 10.1042/0264-6021:3400657; Waterlow J. C., 1978, PROTEIN TURNOVER MAM; WEINDRUCH R, 1995, J GERONTOL A-BIOL, V50, P157; WEINDRUCH R, 1988, RETARDATION AGING DI; WELLE S, 1993, AM J PHYSIOL, V264, pE693, DOI 10.1152/ajpendo.1993.264.5.E693; YARASHESKI KE, 1993, AM J PHYSIOL, V265, pE210, DOI 10.1152/ajpendo.1993.265.2.E210; Ye YZ, 1996, METHOD ENZYMOL, V269, P201; Yu BP, 1996, FREE RADICAL BIO MED, V21, P651, DOI 10.1016/0891-5849(96)00162-1; Zainal TA, 1999, FREE RADICAL BIO MED, V26, P1181, DOI 10.1016/S0891-5849(98)00312-8	56	159	169	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2000	14	12					1825	1836		10.1096/fj.99-0881com	http://dx.doi.org/10.1096/fj.99-0881com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973932				2022-12-28	WOS:000089212400022
J	Schulte, R; Grassl, GA; Preger, S; Fessele, S; Jacobi, CA; Schaller, M; Nelson, PJ; Autenrieth, IB				Schulte, R; Grassl, GA; Preger, S; Fessele, S; Jacobi, CA; Schaller, M; Nelson, PJ; Autenrieth, IB			Yersinia enterocolitica invasin protein triggers IL-8 production in epithelial cells via activation of Rel p65-p65 homodimers	FASEB JOURNAL			English	Article						bacteria; chemokine; transcription; NF-kappa B	NF-KAPPA-B; INTERLEUKIN-8 GENE-EXPRESSION; OUTER-MEMBRANE PROTEIN; PSEUDOTUBERCULOSIS INVASIN; TRANSCRIPTION FACTOR; HELICOBACTER-PYLORI; MAMMALIAN-CELLS; IN-VITRO; TYROSINE PHOSPHORYLATION; INFLAMMATORY CYTOKINES	Enteropathogenic Yersinia bacteria trigger the production of the proinflammatory chemokine IL-8, an important chemokine for the recruitment of polymorphonuclear leukocytes (PMN). Yersinia is resistant to phagocytosis by PMN, and the recruitment of these cells is thought to be part of a pathogenic strategy of Yersinia to establish infection by allowing the pathogen to gain access to, and disseminate within, host tissue. We report here that Yersinia expressing the outer membrane protein invasin triggers IL-8 production in epithelial cells. The 195 carboxyl-terminal amino acids of invasin when linked to latex beads are sufficient to trigger IL-8 production. By means of IL-8 promoter reporter gene assays and electrophoretic mobility shift assay experiments, the minimal optimal region of the IL-8 promoter responsive to invasin was identified and invasin-responsive control elements were characterized. Invasin-induced activation of the IL-8 promoter tvas found to be mediated through a previously identified NF-kappa B element. This NF-kappa B binding site preferentially binds Rel p65-p65 homodimers as well as some p50-p65 heterodimers in response to stimulation by invasin. Invasin-induced NF-kappa B activation col-related with degradation of I kappa B alpha. and the inhibition of NF-kappa B by specific inhibitors of I kappa B activation blocked invasin-induced IL-8 secretion. Invasin-triggered IL-8 production does not depend on invasin-triggered uptake of bacteria, and is independent of a functional PI3-kinase. This report is the first to demonstrate the molecular basis of IL-8 production triggered by enteropathogenic bacteria. Together, these data elucidate the possible early pathomechanisms operating in Yersinia infection and may have implications for the design of novel therapeutics directed against this enteropathogen.	Univ Munich, Max Von Pettenkofer Inst Hyg & Med Microbiol, D-80336 Munich, Germany; Univ Munich, Med Poliklin, D-80336 Munich, Germany; Univ Munich, Klin Dermatol & Allergol, D-80337 Munich, Germany	University of Munich; University of Munich; University of Munich	Autenrieth, IB (corresponding author), Univ Munich, Max Von Pettenkofer Inst Hyg & Med Microbiol, Petterkoferstr 9A, D-80336 Munich, Germany.	Autenrieth@m304.mpk.med.uni-muenchen.de	Grassl, Guntram/B-3559-2010	Fessele, Sabine/0000-0002-5399-3574				Autenrieth IB, 1996, INFECT IMMUN, V64, P1357, DOI 10.1128/IAI.64.4.1357-1368.1996; Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; BLISKA JB, 1993, INFECT IMMUN, V61, P3914, DOI 10.1128/IAI.61.9.3914-3921.1993; BOTTONE EJ, 1977, CRC CR REV MICROBIOL, V5, P211, DOI 10.3109/10408417709102312; BRETT SJ, 1993, EUR J IMMUNOL, V23, P1608, DOI 10.1002/eji.1830230732; Clark MA, 1998, INFECT IMMUN, V66, P1237, DOI 10.1128/IAI.66.3.1237-1243.1998; Cornelis G R, 1994, Curr Top Microbiol Immunol, V192, P243; Cornelis GR, 1998, J BACTERIOL, V180, P5495, DOI 10.1128/JB.180.21.5495-5504.1998; COVER TL, 1989, NEW ENGL J MED, V321, P16, DOI 10.1056/NEJM198907063210104; DELOR I, 1990, INFECT IMMUN, V58, P2983, DOI 10.1128/IAI.58.9.2983-2988.1990; Dersch P, 1999, EMBO J, V18, P1199, DOI 10.1093/emboj/18.5.1199; Eaves-Pyles T, 1999, INFECT IMMUN, V67, P800, DOI 10.1128/IAI.67.2.800-804.1999; ECKMANN L, 1993, GASTROENTEROLOGY, V105, P1689, DOI 10.1016/0016-5085(93)91064-O; ECKMANN L, 1993, INFECT IMMUN, V61, P4569, DOI 10.1128/IAI.61.11.4569-4574.1993; Eckmann Lars, 1995, Trends in Microbiology, V3, P118, DOI 10.1016/S0966-842X(00)88894-0; Elewaut D, 1999, J IMMUNOL, V163, P1457; EMSDY L, 1989, J BACTERIOL, V171, P6674; Forsberg Ake, 1994, Trends in Microbiology, V2, P14, DOI 10.1016/0966-842X(94)90339-5; Grisham MB, 1999, METHOD ENZYMOL, V300, P345; Hamburger ZA, 1999, SCIENCE, V286, P291, DOI 10.1126/science.286.5438.291; Hauf N, 1997, P NATL ACAD SCI USA, V94, P9394, DOI 10.1073/pnas.94.17.9394; HEESEMANN J, 1987, FEMS MICROBIOL LETT, V40, P37, DOI 10.1016/0378-1097(87)90512-X; HEESEMANN J, 1983, J BACTERIOL, V155, P761, DOI 10.1128/JB.155.2.761-767.1983; Hoch RC, 1996, J LAB CLIN MED, V128, P134, DOI 10.1016/S0022-2143(96)90005-0; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; ISBERG RR, 1989, MOL MICROBIOL, V3, P1449, DOI 10.1111/j.1365-2958.1989.tb00128.x; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; JUNG HC, 1995, J CLIN INVEST, V95, P55, DOI 10.1172/JCI117676; Keates S, 1997, GASTROENTEROLOGY, V113, P1099, DOI 10.1053/gast.1997.v113.pm9322504; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; KUNSCH C, 1994, J IMMUNOL, V153, P153; LEE WH, 1977, CAN J MICROBIOL, V23, P1714, DOI 10.1139/m77-247; LEONG JM, 1990, EMBO J, V9, P1979, DOI 10.1002/j.1460-2075.1990.tb08326.x; LIN TH, 1995, J BIOL CHEM, V270, P16189, DOI 10.1074/jbc.270.27.16189; Lundgren E, 1996, INFECT IMMUN, V64, P829, DOI 10.1128/IAI.64.3.829-835.1996; Mastronarde JG, 1996, J INFECT DIS, V174, P262, DOI 10.1093/infdis/174.2.262; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; McCormick BA, 1997, INFECT IMMUN, V65, P1414, DOI 10.1128/IAI.65.4.1414-1421.1997; MILLER VL, 1989, INFECT IMMUN, V57, P121, DOI 10.1128/IAI.57.1.121-131.1989; MILLER VL, 1988, INFECT IMMUN, V56, P1242, DOI 10.1128/IAI.56.5.1242-1248.1988; MILLER VL, 1988, CURR TOP MICROBIOL, V138, P15; Monack DM, 1998, J EXP MED, V188, P2127, DOI 10.1084/jem.188.11.2127; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MUKAIDA N, 1994, J LEUKOCYTE BIOL, V56, P554, DOI 10.1002/jlb.56.5.554; Munzenmaier A, 1997, J IMMUNOL, V159, P6140; NAKAMURA H, 1991, J BIOL CHEM, V266, P19611; NHIEU GTV, 1991, J BIOL CHEM, V266, P24367; PAI CH, 1978, INFECT IMMUN, V19, P908, DOI 10.1128/IAI.19.3.908-911.1978; PEPE JC, 1990, J BACTERIOL, V172, P3780, DOI 10.1128/jb.172.7.3780-3789.1990; PEPE JC, 1993, P NATL ACAD SCI USA, V90, P6473, DOI 10.1073/pnas.90.14.6473; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; ROSENSHINE I, 1992, INFECT IMMUN, V60, P2211, DOI 10.1128/IAI.60.6.2211-2217.1992; Ruckdeschel K, 1996, INFECT IMMUN, V64, P724, DOI 10.1128/IAI.64.3.724-733.1996; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Savkovic SD, 1997, AM J PHYSIOL-CELL PH, V273, pC1160, DOI 10.1152/ajpcell.1997.273.4.C1160; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schulte R, 1998, MED MICROBIOL IMMUN, V187, P53, DOI 10.1007/s004300050074; Schulte R, 1996, INFECT IMMUN, V64, P2106, DOI 10.1128/IAI.64.6.2106-2113.1996; Schulte R, 1998, INFECT IMMUN, V66, P1216, DOI 10.1128/IAI.66.3.1216-1224.1998; SCHULZ L, 1993, PAPIER, V47, P1; Sharma SA, 1998, J IMMUNOL, V160, P2401; SKURNIK M, 1989, MOL MICROBIOL, V3, P517, DOI 10.1111/j.1365-2958.1989.tb00198.x; STRALEY SC, 1993, INFECT IMMUN, V61, P3105, DOI 10.1128/IAI.61.8.3105-3110.1993; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506; YOUNG VB, 1990, MOL MICROBIOL, V4, P1119, DOI 10.1111/j.1365-2958.1990.tb00686.x; YOUNG VB, 1992, J CELL BIOL, V116, P197, DOI 10.1083/jcb.116.1.197; YUROCHKO AD, 1992, P NATL ACAD SCI USA, V89, P9034, DOI 10.1073/pnas.89.19.9034	70	55	63	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2000	14	11					1471	1484		10.1096/fj.14.11.1471	http://dx.doi.org/10.1096/fj.14.11.1471			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CN	10928981				2022-12-28	WOS:000088627800001
J	Borlongan, CV; Yamaoto, M; Takei, N; Kumazaki, M; Ungsuparkorn, C; Hida, H; Sanberg, PR; Nishino, H				Borlongan, CV; Yamaoto, M; Takei, N; Kumazaki, M; Ungsuparkorn, C; Hida, H; Sanberg, PR; Nishino, H			Glial cell survival is enhanced during melatonin-induced neuroprotection against cerebral ischemia	FASEB JOURNAL			English	Article						stroke; gliosis; astrocytes; cell death; free radicals	MIDBRAIN DOPAMINERGIC-NEURONS; TRANSIENT FOREBRAIN ISCHEMIA; PROTECTS PRIMARY CULTURES; CENTRAL-NERVOUS-SYSTEM; RAT-BRAIN; 3-NITROPROPIONIC ACID; REGIONAL DIFFERENCES; NEUROTROPHIC FACTOR; PARKINSONS-DISEASE; IN-VITRO	The role of glial cells in neuronal death has become a major research interest. Glial cell activation has been demonstrated to accompany cerebral ischemia. However, there is disagreement whether such gliosis is a cell death or a neuroprotective response. In the present study, we examined alterations in glial cell responses to the reported neuroprotective action of the free radical scavenger, melatonin, against cerebral ischemia. Adult male Wistar rats were given oral injections of either melatonin (26 mu mol/rat) or saline just prior to 1 h occlusion of the middle cerebral artery (MCA), then once daily for 11 or 19 consecutive days. At 11 and 19 days after reperfusion of the MCA, randomly selected animals were killed and their brains removed for immunohistochemical assays. Melatonin significantly enhanced survival of glial cells (as revealed by glial cell specific markers, glial fibrillary acidic protein and aquaporin-4 immunostaining) at both time periods postischemia, and the preservation of these glial cells in the ischemic penumbra corresponded with a markedly reduced area of infarction (detected by immunoglobulin G and hematoxylin-eosin staining), as well as increased neuronal survival. The ischemia-induced locomotor deficits were partially ameliorated in melatonin-treated animals. In vitro replications of ischemia by serum deprivation or by exposure to free radical-producing toxins (sodium nitroprusside and 3-nitropropionic acid) revealed that melatonin (10 mu g/ml or 100 mu M) treatment of pure astrocytic cultures significantly reduced astrocytic cell death. These results suggest a potential strategy directed at enhancing glial cell survival as an alternative protective approach against ischemic damage.	NIDA, Cellular Neurobiol Branch, NIH, Baltimore, MD 21224 USA; Univ S Florida, Coll Med, Dept Neurol Surg, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Program Neurosci, Tampa, FL 33612 USA; Nagoya City Univ, Sch Med, Dept Physiol, Nagoya, Aichi 467, Japan	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA); State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Nagoya City University	Borlongan, CV (corresponding author), NIDA, Cellular Neurobiol Branch, NIH, 5500 Nathan Shock Dr, Baltimore, MD 21224 USA.		Borlongan, Cesar/I-5696-2012	Borlongan, Cesar/0000-0002-2966-9782				AIHARA N, 1994, BRAIN RES BULL, V33, P483, DOI 10.1016/0361-9230(94)90072-8; Blanc EM, 1998, J NEUROCHEM, V70, P958; Borlongan CV, 1998, EXP NEUROL, V149, P310, DOI 10.1006/exnr.1997.6730; Borlongan CV, 1998, EXP NEUROL, V151, P203, DOI 10.1006/exnr.1998.6790; Borlongan CV, 1998, NEUROREPORT, V9, P3615, DOI 10.1097/00001756-199811160-00012; Borlongan CV, 1997, NEUROSCI BIOBEHAV R, V21, P289, DOI 10.1016/S0149-7634(96)00027-9; Bronstein DM, 1995, BRAIN RES, V704, P112, DOI 10.1016/0006-8993(95)01189-7; CAGNOLI CM, 1995, J PINEAL RES, V18, P222, DOI 10.1111/j.1600-079X.1995.tb00163.x; Cazevieille C, 1997, BRAIN RES, V768, P120, DOI 10.1016/S0006-8993(97)00611-2; CHENG HW, 1994, NEUROSCIENCE, V62, P425, DOI 10.1016/0306-4522(94)90377-8; Cho S, 1997, BRAIN RES, V755, P335, DOI 10.1016/S0006-8993(97)00188-1; Colombo JA, 1996, INT J DEV NEUROSCI, V14, P497, DOI 10.1016/0736-5748(95)00104-2; Cuzzocrea S, 1998, J PINEAL RES, V25, P78, DOI 10.1111/j.1600-079X.1998.tb00543.x; DAVIS AA, 1994, NATURE, V372, P263, DOI 10.1038/372263a0; Deacon T, 1997, NAT MED, V3, P350, DOI 10.1038/nm0397-350; Diamond JS, 1998, NEURON, V21, P425, DOI 10.1016/S0896-6273(00)80551-6; DIEMER NH, 1977, ACTA NEUROPATHOL, V39, P59, DOI 10.1007/BF00690386; Eclancher F, 1996, BRAIN RES, V737, P201, DOI 10.1016/0006-8993(96)00732-9; Fawcett JW, 1998, TRENDS NEUROSCI, V21, P179, DOI 10.1016/S0166-2236(98)01241-7; Fiorina P, 1996, LANCET, V347, P692, DOI 10.1016/S0140-6736(96)91246-5; Fisher M, 1997, STROKE, V28, P866, DOI 10.1161/01.STR.28.4.866; Fukuda A, 1998, NEUROSCIENCE, V87, P497, DOI 10.1016/S0306-4522(98)00139-0; GIUSTI P, 1995, EXP NEUROL, V131, P39, DOI 10.1016/0014-4886(95)90005-5; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; HANSSON E, 1995, FASEB J, V9, P343, DOI 10.1096/fasebj.9.5.7534736; Hirata H, 1998, SYNAPSE, V30, P150, DOI 10.1002/(SICI)1098-2396(199810)30:2<150::AID-SYN4>3.0.CO;2-B; HOFFER BJ, 1994, NEUROSCI LETT, V182, P107, DOI 10.1016/0304-3940(94)90218-6; Horellou P, 1997, MOL NEUROBIOL, V15, P241, DOI 10.1007/BF02740636; Iacovitti L, 1997, BRAIN RES, V768, P317, DOI 10.1016/S0006-8993(97)00668-9; ISACSON O, 1995, NAT MED, V1, P1189, DOI 10.1038/nm1195-1189; Joo JY, 1998, RESTOR NEUROL NEUROS, V13, P185; Kilic E, 1999, J CEREBR BLOOD F MET, V19, P511, DOI 10.1097/00004647-199905000-00005; LANGEVELD CH, 1995, NEUROSCI LETT, V192, P13, DOI 10.1016/0304-3940(95)11596-O; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Lehrmann E, 1998, GLIA, V24, P437, DOI 10.1002/(SICI)1098-1136(199812)24:4<437::AID-GLIA9>3.0.CO;2-X; LEROUX PD, 1995, NEUROSCI LETT, V198, P5, DOI 10.1016/0304-3940(95)11946-T; LEROUX PD, 1995, J NEUROBIOL, V27, P97, DOI 10.1002/neu.480270110; Lin JHC, 1998, NAT NEUROSCI, V1, P494, DOI 10.1038/2210; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Luscher C, 1998, NEURON, V21, P435, DOI 10.1016/S0896-6273(00)80552-8; Manev H, 1996, FASEB J, V10, P1546, DOI 10.1096/fasebj.10.13.8940301; Matuszak Z, 1997, FREE RADICAL BIO MED, V23, P367, DOI 10.1016/S0891-5849(96)00614-4; Mawatari C, 1996, NEUROSCIENCE, V73, P201, DOI 10.1016/0306-4522(96)00025-5; MELCHIORRI D, 1995, FASEB J, V9, P1205, DOI 10.1096/fasebj.9.12.7672513; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Miller JW, 1996, FREE RADICAL BIO MED, V21, P241, DOI 10.1016/0891-5849(96)00033-0; Muramatsu K, 1997, STROKE, V28, P2281, DOI 10.1161/01.STR.28.11.2281; Nielsen S, 1997, J NEUROSCI, V17, P171; Nishino H, 1998, NEUROSCI RES, V30, P303, DOI 10.1016/S0168-0102(98)00010-8; Nishino Hitoo, 1994, Neurobiology (Budapest), V2, P223; Pantoni L, 1996, STROKE, V27, P1641, DOI 10.1161/01.STR.27.9.1641; Pappolla MA, 1997, J NEUROSCI, V17, P1683; Peinado MA, 1997, ANAT REC, V247, P420; PENG MT, 1979, GERONTOLOGY, V25, P205, DOI 10.1159/000212341; Petito CK, 1998, J NEUROPATH EXP NEUR, V57, P231, DOI 10.1097/00005072-199803000-00004; Reiter RJ, 1998, PROG NEUROBIOL, V56, P359, DOI 10.1016/S0301-0082(98)00052-5; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; SIESJO BK, 1992, J NEUROSURG, V77, P337, DOI 10.3171/jns.1992.77.3.0337; SOCHOCKA E, 1994, BRAIN RES, V638, P21, DOI 10.1016/0006-8993(94)90628-9; Svendsen CN, 1997, EXP NEUROL, V148, P135, DOI 10.1006/exnr.1997.6634; Tan DX, 1993, ENDOCR J, V1, P57; TERRY RD, 1987, ANN NEUROL, V21, P530, DOI 10.1002/ana.410210603; Vernadakis A, 1996, PROG NEUROBIOL, V49, P185, DOI 10.1016/S0301-0082(96)00012-3; Wang Y, 1997, J NEUROSCI, V17, P4341; WHITE HS, 1992, CAN J PHYSIOL PHARM, V70, pS263, DOI 10.1139/y92-271; Zhang HW, 1999, CHEM RES TOXICOL, V12, P526, DOI 10.1021/tx980243t; Zoli M, 1997, STROKE, V28, P1049, DOI 10.1161/01.STR.28.5.1049	67	122	137	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2000	14	10					1307	1317		10.1096/fj.14.10.1307	http://dx.doi.org/10.1096/fj.14.10.1307			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877823				2022-12-28	WOS:000087932200005
J	Lin, ZC; Itokawa, M; Uhl, GR				Lin, ZC; Itokawa, M; Uhl, GR			Dopamine transporter proline mutations influence dopamine uptake, cocaine analog recognition, and expression	FASEB JOURNAL			English	Article						affinity; translocation; ion gradients; turnover rate; plasma membrane targeting	NOREPINEPHRINE TRANSPORTERS; STRUCTURAL DOMAINS; PROTEINS; RESIDUES; 1-METHYL-4-PHENYLPYRIDINIUM; INHIBITION; SUBSTRATE; CLONING; HELICES	Analyses of mutation effects can aid in understanding how large proteins act, The dopamine transporter (DAT) mediates complex actions in recognizing cocaine and in recognizing and translocating dopamine, sodium, and chloride. DAT proline residues, especially those in transmembrane (TM) domains, are good candidates for involvement in these DAT actions. We now report production of mutants substituting alanine and/or glycine residues for 16 prolines located in or near putative DAT TM domains. We examine effects of these modifications on DAT expression, dopamine uptake, and cocaine analog binding. Mutants in prolines located in five DAT TM domains and four connecting loops alter apparent DAT membrane targeting, Five mutations decrease dopamine affinities more than threefold without significantly decreasing cocaine analog affinities. One decreases cocaine analog affinity without decreasing dopamine affinity. Two mutations decrease affinities for both dopamine and cocaine analog. P101 is especially implicated in dopamine uptake. Alanine substitution for this proline yields dopamine V-max values of less than 3% of wild-type values despite dopamine affinities more than fourfold higher than wild-type and normal Na+ and Cl- dependence. These DAT proline mutants identify DAT regions likely for dopamine translocation and for recognition of dopamine and cocaine.-Lin, Z., Itokawa, M., Uhl, G, R. Dopamine transporter proline mutations influence dopamine uptake, cocaine analog recognition, and expression.	NIDA, Mol Neurobiol Branch, IRP, NIH, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA); Johns Hopkins University; Johns Hopkins University	Uhl, GR (corresponding author), NIDA, Mol Neurobiol Branch, IRP, NIH, 5500 Nathan Shock Dr, Baltimore, MD 21224 USA.							AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BERGMAN J, 1989, J PHARMACOL EXP THER, V251, P150; BOJA JW, 1994, DOPAMINE RECEPTORS T, P611; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; Buck KJ, 1995, MOL PHARMACOL, V48, P1030; BUCK KJ, 1994, P NATL ACAD SCI USA, V91, P12584, DOI 10.1073/pnas.91.26.12584; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DUNKER AK, 1982, J THEOR BIOL, V97, P95, DOI 10.1016/0022-5193(82)90281-8; FREED C, 1995, J COMP NEUROL, V359, P340, DOI 10.1002/cne.903590211; GIROS B, 1994, J BIOL CHEM, V269, P15985; Gunasekaran K, 1998, J MOL BIOL, V275, P917, DOI 10.1006/jmbi.1997.1505; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; KITAYAMA S, 1992, ANN NEUROL, V32, P109, DOI 10.1002/ana.410320120; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; Lin ZC, 1999, MOL PHARMACOL, V56, P434, DOI 10.1124/mol.56.2.434; PIFL C, 1993, J NEUROSCI, V13, P4246, DOI 10.1523/jneurosci.13-10-04246.1993; Rassendren F, 1997, EMBO J, V16, P3446, DOI 10.1093/emboj/16.12.3446; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; ROTHSCHILD KJ, 1989, P NATL ACAD SCI USA, V86, P9832, DOI 10.1073/pnas.86.24.9832; SANKARARAMAKRISHNAN R, 1989, J BIOMOL STRUCT DYN, V7, P187, DOI 10.1080/07391102.1989.10507760; SANSOM MSP, 1992, PROTEIN ENG, V5, P53, DOI 10.1093/protein/5.1.53; SELF DW, 1995, ANNU REV NEUROSCI, V18, P463, DOI 10.1146/annurev.neuro.18.1.463; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; UHL GR, 1994, J EXP BIOL, V196, P229; VAUGHAN RA, 1993, MOL CELL NEUROSCI, V4, P209, DOI 10.1006/mcne.1993.1025; VILSEN B, 1989, J BIOL CHEM, V264, P21024; VONHEIJNE G, 1991, J MOL BIOL, V218, P499, DOI 10.1016/0022-2836(91)90695-3; WITKIN JM, 1994, NEUROSCI BIOBEHAV R, V18, P121, DOI 10.1016/0149-7634(94)90042-6; WOOLVERTON WL, 1992, TRENDS PHARMACOL SCI, V13, P193, DOI 10.1016/0165-6147(92)90063-C	33	54	54	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2000	14	5					715	728		10.1096/fasebj.14.5.715	http://dx.doi.org/10.1096/fasebj.14.5.715			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301DH	10744628				2022-12-28	WOS:000086292700009
J	Ikemoto, M; Nikawa, T; Takeda, S; Watanabe, C; Kitano, T; Baldwin, KM; Izumi, R; Nonaka, I; Towatari, T; Teshima, S; Rokutan, K; Kishi, K				Ikemoto, M; Nikawa, T; Takeda, S; Watanabe, C; Kitano, T; Baldwin, KM; Izumi, R; Nonaka, I; Towatari, T; Teshima, S; Rokutan, K; Kishi, K			Space shuttle flight (STS-90) enhances degradation of rat myosin heavy chain in association with activation of ubiquitin-proteasome pathway	FASEB JOURNAL			English	Article									Univ Tokushima, Sch Med, Dept Nutr, Tokushima 7708503, Japan; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Tokyo 1878502, Japan; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Natl Space Dev Agcy Japan, Tokyo 1050013, Japan; Natl Ctr Neurol & Psychiat, Dept Neuromuscular Res, Tokyo 1878551, Japan; Univ Tokushima, Inst Enzyme Res, Div Enzyme Chem, Tokushima 7708503, Japan	Tokushima University; National Center for Neurology & Psychiatry - Japan; University of California System; University of California Irvine; Japan Aerospace Exploration Agency (JAXA); National Center for Neurology & Psychiatry - Japan; Tokushima University	Nikawa, T (corresponding author), Univ Tokushima, Sch Med, Dept Nutr, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.			Ikemoto-Uezumi, Madoka/0000-0003-2771-9851					0	127	132	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1279	1281		10.1096/fj.00-0629fje	http://dx.doi.org/10.1096/fj.00-0629fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344113	Bronze			2022-12-28	WOS:000168655200035
J	Menegazzi, M; Tedeschi, E; Dussin, D; De Prati, AC; Cavalieri, E; Mariotto, S; Suzuki, H				Menegazzi, M; Tedeschi, E; Dussin, D; De Prati, AC; Cavalieri, E; Mariotto, S; Suzuki, H			Anti-interferon gamma action of epigallocatechin-3-gallate mediated by specific inhibition of STAT1 activation	FASEB JOURNAL			English	Article									Univ Verona, Dept Neurosci & Vis, Biochem Sect, I-37134 Verona, Italy	University of Verona	Suzuki, H (corresponding author), Univ Verona, Dept Neurosci & Vis, Biochem Sect, Str Grazie 8, I-37134 Verona, Italy.		mariotto, sofia/AAH-5473-2019; Menegazzi, Marta/AAE-7079-2019	Menegazzi, Marta/0000-0003-1310-9227					0	62	64	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1309	1311		10.1096/fj.00-0519fje	http://dx.doi.org/10.1096/fj.00-0519fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344123				2022-12-28	WOS:000168655200045
J	Yan, MS; Qiang, WN; Liu, N; Shen, JJ; Lynn, WS; Wong, PKY				Yan, MS; Qiang, WN; Liu, N; Shen, JJ; Lynn, WS; Wong, PKY			The ataxia-telangiectasia gene product may modulate DNA turnover and control cell fate by regulating cellular redox in lymphocytes	FASEB JOURNAL			English	Article						ATM protein kinase; differentiation; thiol; cellular redox activity; DNA turnover	ATM-DEFICIENT MICE; IONIZING-RADIATION; V(D)J RECOMBINATION; INDUCED APOPTOSIS; OXIDATIVE DAMAGE; PROTEIN; CHECKPOINT; PATHWAYS; DEPLETION; RESCUE	The ATM kinase, when activated postnatally, exerts multiple functions to prevent the onset of ataxia-telangiectasia (AT), Using freshly isolated thymocytes from Atm-/- mice that were under stress during postnatal differentiation, we noted that thiol redox activity, as indicated by reduction of the tebrazolium MTS, and DNA turnover activity, as indicated by incorporation of [H-3]thymidine into DNA, were both greatly increased compared with activities in thymocytes from Atm+/+ mice, This increased thymidine incorporation could be suppressed by the thiol N-acetylcysteine, In primary noncycling splenocytes, mitogens proportionally increased both the rate of [H-3]thymidine incorporation and the rate of reduction of MTS, The mitogen-induced activities in splenocytes were not affected by ATM but were suppressed by the calcineurin-dependent inhibitor FK-506, which has no effect on these activities in thymocytes, These findings suggest that increased [H-3]thymidine incorporation and reducing power indicate increased cell cycling in mitogenically stimulated splenocytes, whereas these two indicators represent increased FK-506-independent DNA turnover activities in thymocytes, Thus, a primary function of ATM is to activate the redox-sensitive checkpoint required for down-regulation of DNA turnover activities in developing lymphocytes, Cell-cycling checkpoints in undamaged quiescent lymphocytes are not activated by ATM with mitogenic stimulation. ATM may suppress abnormal DNA turnover and the resultant oncogenesis by regulating cellular thiol redox pathways.	Univ Texas, MD Anderson Canc Ctr, Div Res, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Wong, PKY (corresponding author), Univ Texas, MD Anderson Canc Ctr, Div Res, Sci Pk,POB 389, Smithville, TX 78957 USA.	pwong@sprdl.mdacc.tmc.edu	Qiang, Wenan/AAA-7633-2021	Qiang, Wenan/0000-0001-5068-7128	NCI NIH HHS [CA16672] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Barlow C, 1999, P NATL ACAD SCI USA, V96, P9915, DOI 10.1073/pnas.96.17.9915; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Barlow C, 1997, NAT GENET, V17, P462, DOI 10.1038/ng1297-462; Barlow C, 1998, NAT GENET, V18, P298, DOI 10.1038/ng0398-298b; Barlow C, 1997, NAT GENET, V17, P453, DOI 10.1038/ng1297-453; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Brown KD, 1999, AM J HUM GENET, V64, P46, DOI 10.1086/302223; Colussi C, 2000, FASEB J, V14, P2266, DOI 10.1096/fj.00-0074com; Costanzo V, 2000, MOL CELL, V6, P649, DOI 10.1016/S1097-2765(00)00063-0; DANSKA JS, 1994, SCIENCE, V266, P450, DOI 10.1126/science.7524150; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; GOODWIN CJ, 1995, J IMMUNOL METHODS, V179, P95, DOI 10.1016/0022-1759(94)00277-4; Hande MP, 2001, HUM MOL GENET, V10, P519, DOI 10.1093/hmg/10.5.519; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Huang STJ, 1999, FASEB J, V13, P467, DOI 10.1096/fasebj.13.3.467; Kim GD, 1999, J BIOL CHEM, V274, P31127, DOI 10.1074/jbc.274.44.31127; Lee Y, 2000, GENE DEV, V14, P2576, DOI 10.1101/gad.837100; Liao MJ, 1999, GENE DEV, V13, P1246, DOI 10.1101/gad.13.10.1246; Liyanage M, 2000, BLOOD, V96, P1940, DOI 10.1182/blood.V96.5.1940.h8001940_1940_1946; Lynn WS, 1997, NEUROIMMUNOMODULAT, V4, P277, DOI 10.1159/000097348; MEYN MS, 1995, CANCER RES, V55, P5991; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; Plug AW, 1997, NAT GENET, V17, P457, DOI 10.1038/ng1297-457; Rolig RL, 2000, TRENDS NEUROSCI, V23, P417, DOI 10.1016/S0166-2236(00)01625-8; Rotman G, 1997, CANCER SURV, V29, P285; Rybczynska M, 1996, BBA-LIPID LIPID MET, V1302, P231, DOI 10.1016/0005-2760(96)00067-7; SAHA K, 1993, VIROLOGY, V195, P211, DOI 10.1006/viro.1993.1362; Tanaka T, 1997, LAB INVEST, V77, P145; Vit JP, 2000, INT J RADIAT BIOL, V76, P841, DOI 10.1080/09553000050029002; Watters D, 1999, J BIOL CHEM, V274, P34277, DOI 10.1074/jbc.274.48.34277	31	28	29	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2001	15	7					1132	1138		10.1096/fj.00-0601com	http://dx.doi.org/10.1096/fj.00-0601com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344081				2022-12-28	WOS:000168655200003
J	Gounni, AS; Lamkhioued, B; Koussih, L; Ra, C; Renzi, PM; Hamid, Q				Gounni, AS; Lamkhioued, B; Koussih, L; Ra, C; Renzi, PM; Hamid, Q			Human neutrophils express the high-affinity receptor for immunoglobulin E (Fc epsilon RI): role in asthma	FASEB JOURNAL			English	Article						allergic diseases; IgE receptors; interleukin 8	COLONY-STIMULATING FACTOR; MAST-CELLS; POLYMORPHONUCLEAR NEUTROPHILS; BRONCHOALVEOLAR LAVAGE; CHEMOTACTIC FACTOR; HUMAN PLATELETS; T-LYMPHOCYTES; BETA-SUBUNIT; IN-VITRO; IGE	Polymorphonuclear neutrophils (PMNs) are important effector cells in host defense and the inflammatory response to antigen. The involvement of PMNs in inflammation is mediated mainly by the Fc receptor family, including IgE receptors. Recently, PMNs were shown to express two IgE receptors (CD23/Fc epsilon RII and galectin-3). In allergic diseases, the dominant role of IgE has been mainly ascribed to its high-affinity receptor, Fc epsilon RI. We have examined the expression of Fc epsilon RI by PMNs. mRNA and cell surface expression of Fc epsilon RI alpha chain was identified on PMNs from asthmatic subjects. Furthermore, preincubation with human IgE Fc fragment blocks completely the binding of anti-Fc epsilon RI alpha chain (mAb15-1) to human PMNs. Conversely, preincubation of PMNs with mAb15-1 inhibits significantly the binding of IgE Fc fragment to PMNs, indicating that IgE bound to the cell surface of PMNs mainly via the Fc epsilon RI. Peripheral blood and bronchoalveolar lavage (BAL) PMNs from asthmatic subjects also express intracellular Fc epsilon RI alpha and beta chain immunoreactivity. Engagement of Fc epsilon RI induces the release of IL-8 by PMNs. Collectively, these observations provide new evidence that PMNs express the Fc epsilon RI and suggest that these cells may play a role in allergic inflammation through an IgE-dependent activation mechanism.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; Univ Montreal, Notre Dame Hosp, Res Ctr, CHUM, Montreal, PQ H2L 4M1, Canada; Juntendo Univ, Sch Med, Tokyo 113, Japan	McGill University; Universite de Montreal; Juntendo University	Gounni, AS (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.	Abdel@meakins.lan.mcgill.ca	Gounni, Abdelilah Soussi/AAH-3456-2020; LAMKHIOUED, Bouchaib/AAL-4201-2021	Soussi Gounni, Abdelilah/0000-0002-7282-0388; Gounni, Abdelilah/0000-0003-1265-6560				[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; BOSHETTO P, 1989, EUR RESPIR J, V6, P456; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; BRUSASCO V, 1990, J APPL PHYSIOL, V69, P2209, DOI 10.1152/jappl.1990.69.6.2209; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; Carulli G, 1997, HAEMATOLOGICA, V82, P606; Dale DC, 1998, AM J HEMATOL, V57, P7, DOI 10.1002/(SICI)1096-8652(199801)57:1<7::AID-AJH2>3.0.CO;2-0; Dombrowicz D, 1996, J IMMUNOL, V157, P1645; Dombrowicz D, 1998, IMMUNITY, V8, P517, DOI 10.1016/S1074-7613(00)80556-7; DRIVER AG, 1991, AM REV RESPIR DIS, V143, P1002, DOI 10.1164/ajrccm/143.5_Pt_1.1002; FABBRI LM, 1987, AM REV RESPIR DIS, V136, P36, DOI 10.1164/ajrccm/136.1.36; FAHY JV, 1995, J ALLERGY CLIN IMMUN, V95, P843, DOI 10.1016/S0091-6749(95)70128-1; FISCHKOFF SA, 1988, LEUKEMIA RES, V12, P679, DOI 10.1016/0145-2126(88)90103-8; FUJISAWA T, 1990, AM REV RESPIR DIS, V141, P689, DOI 10.1164/ajrccm/141.3.689; Girard D, 1997, BIOCHEM J, V325, P147, DOI 10.1042/bj3250147; GORDON JR, 1991, J EXP MED, V174, P103, DOI 10.1084/jem.174.1.103; GOSSELIN EJ, 1993, J IMMUNOL, V151, P1482; GOUNNI AS, 1994, NATURE, V367, P183, DOI 10.1038/367183a0; GOUNNI AS, 1998, INT IMMUNOL, V10, P395; HALLAHAN AR, 1990, EUR RESPIR J, V3, P554; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; Hasegawa S, 1999, BLOOD, V93, P2543, DOI 10.1182/blood.V93.8.2543.408k14_2543_2551; Joseph M, 1997, EUR J IMMUNOL, V27, P2212, DOI 10.1002/eji.1830270914; KAY AB, 1987, ALLERGY INFLAMMATION, P203; Kraft S, 1998, J IMMUNOL, V161, P1000; KUROSAKI T, 1992, J EXP MED, V175, P447, DOI 10.1084/jem.175.2.447; KUSTER H, 1990, J BIOL CHEM, V265, P6448; LEE TH, 1982, J CLIN INVEST, V69, P889, DOI 10.1172/JCI110528; LEHRER RI, 1988, ANN INTERN MED, V109, P127, DOI 10.7326/0003-4819-109-2-127; LLYOLD AR, 1992, IMMUNOL TODAY, V13, P169; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; Maurer D, 1996, J IMMUNOL, V157, P607; MAURER D, 1994, J EXP MED, V179, P745, DOI 10.1084/jem.179.2.745; METZGER WJ, 1986, CHEST, V89, P477, DOI 10.1378/chest.89.4.477; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; RA C, 1993, INT IMMUNOL, V5, P47, DOI 10.1093/intimm/5.1.47; RA C, 1989, J BIOL CHEM, V264, P15323; RAVETCH JV, 1994, NAT GENET, V7, P117, DOI 10.1038/ng0694-117; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHEN L, 1987, J IMMUNOL, V139, P534; SHIRAKAWA T, 1994, NAT GENET, V7, P125, DOI 10.1038/ng0694-125; SIBILLE Y, 1990, AM REV RESPIR DIS, V141, P471, DOI 10.1164/ajrccm/141.2.471; SMITH HR, 1992, J ALLERGY CLIN IMMUN, V89, P1076, DOI 10.1016/0091-6749(92)90291-9; SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0; Taub DD, 1996, J CLIN INVEST, V97, P1931, DOI 10.1172/JCI118625; Terada N, 1995, J ALLERGY CLIN IMMUN, V96, P1161, DOI 10.1016/S0091-6749(95)70201-6; TRUONG MJ, 1993, J EXP MED, V177, P243, DOI 10.1084/jem.177.1.243; VARINBLANK N, 1990, J BIOL CHEM, V265, P15685; VENGE P, 1990, J ALLERGY CLIN IMMUN, V85, P498, DOI 10.1016/0091-6749(90)90161-V; VIRCHOW JC, 1995, AM J RESP CRIT CARE, V151, P960; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353; WUYTS A, 1998, CYTOKINE HDB, P185; Yamamoto F, 1996, NUCL MED BIOL, V23, P479, DOI 10.1016/0969-8051(96)00025-X; Ying S, 1998, IMMUNOLOGY, V93, P281, DOI 10.1046/j.1365-2567.1998.00418.x	54	99	106	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2001	15	6					940	949		10.1096/fj.00-0378com	http://dx.doi.org/10.1096/fj.00-0378com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292654				2022-12-28	WOS:000167959300008
J	Schild, L; Keilhoff, G; Augustin, W; Reiser, G; Striggow, F				Schild, L; Keilhoff, G; Augustin, W; Reiser, G; Striggow, F			Distinct Ca2+ thresholds determine cytochrome c release or permeability transition pore opening in brain mitochondria	FASEB JOURNAL			English	Article									Univ Magdeburg, Inst Clin Chem & Pathol Biochem, Dept Pathol Biochem, D-39120 Magdeburg, Germany; Univ Magdeburg, Inst Med Neurobiol, D-39120 Magdeburg, Germany; Univ Magdeburg, Fac Med, Inst Neurobiochem, D-39120 Magdeburg, Germany	Otto von Guericke University; Otto von Guericke University; Otto von Guericke University	Schild, L (corresponding author), Univ Magdeburg, Inst Clin Chem & Pathol Biochem, Dept Pathol Biochem, Leipziger Str 44, D-39120 Magdeburg, Germany.								0	77	87	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					565	567						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259368				2022-12-28	WOS:000167419500006
J	Andrade, FH; Reid, MB; Westerblad, H				Andrade, FH; Reid, MB; Westerblad, H			Contractile response of skeletal muscle to low peroxide concentrations: myofibrillar calcium sensitivity as a likely target for redox-modulation	FASEB JOURNAL			English	Article									Univ Hosp Cleveland, Res Inst, Cleveland, OH 44106 USA; Karolinska Inst, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden; Case Western Reserve Univ, Dept Neurol, Cleveland, OH 44106 USA; Baylor Coll Med, Pulm & Crit Care Med Sect, Houston, TX 77030 USA	University Hospitals of Cleveland; Karolinska Institutet; Case Western Reserve University; Baylor College of Medicine	Andrade, FH (corresponding author), Univ Hosp Cleveland, Res Inst, Wearn 650,11100 Euclid Ave, Cleveland, OH 44106 USA.		Andrade, Francisco H/F-1258-2011	Andrade, Francisco H/0000-0002-2460-5798; Westerblad, Hakan/0000-0002-8180-3029					0	137	140	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					309	311						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156946				2022-12-28	WOS:000166872900012
J	Pescarolo, MP; Bagnasco, L; Malacarne, D; Melchiori, A; Valente, P; Millo, E; Bruno, S; Basso, S; Parodi, S				Pescarolo, MP; Bagnasco, L; Malacarne, D; Melchiori, A; Valente, P; Millo, E; Bruno, S; Basso, S; Parodi, S			A retro-inverso peptide homologous to helix 1 of c-Myc is a potent and specific inhibitor of proliferation in different cellular systems	FASEB JOURNAL			English	Article									Natl Inst Canc Res, Expt Oncol Lab, I-16132 Genoa, Italy; Univ Genoa, Dept Expt Med, Biochem Sect, Genoa, Italy; Univ Genoa, Dept Expt Med, Sect Human Anat, Genoa, Italy; Adv Biotechnol Ctr, Immunopharmacol Sect, Genoa, Italy; Univ Genoa, Dept Oncol Biol & Genet, I-16132 Genoa, Italy	University of Genoa; IRCCS AOU San Martino IST; University of Genoa; University of Genoa; University of Genoa	Parodi, S (corresponding author), Natl Inst Canc Res, Expt Oncol Lab, Largo R Benzi 10, I-16132 Genoa, Italy.		Millo, Enrico/K-3218-2018; Bruno, Silvia/B-8980-2013	Millo, Enrico/0000-0002-4019-0051; bruno, silvia/0000-0001-8799-8325					0	39	45	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2001	15	1					31	33						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11099487				2022-12-28	WOS:000166312400011
J	Jeong, SJ; Kim, HS; Chang, KA; Geum, DH; Park, CH; Seo, JH; Rah, JC; Lee, JH; Choi, SH; Lee, SG; Kim, K; Suh, YH				Jeong, SJ; Kim, HS; Chang, KA; Geum, DH; Park, CH; Seo, JH; Rah, JC; Lee, JH; Choi, SH; Lee, SG; Kim, K; Suh, YH			Subcellular localization of presenilins during mouse preimplantation development	FASEB JOURNAL			English	Article						preimplantation embryos; nucleus; centrosome-kinetochore microtubule; cell division	FAMILIAL ALZHEIMERS-DISEASE; ENDOPLASMIC-RETICULUM; MISSENSE MUTATIONS; BETA-CATENIN; CELL-CYCLE; EXPRESSION; PROTEASOME; GENE; CLONING; MUTANT	The genes defective hi familial Alzheimer's disease encode the proteins presenilin 1 and 2 (PS1 and 2). Expression of presenilins (PSs) and their proteolytic processing are regulated during neuronal development. Even though these proteins are detected and regulated mainly in Golgi and endoplasmic reticulum, their subcellular distribution during the development is not known. The present study aimed to investigate the localization of PSs and their role during early developmental stage using mouse embryo model. At preimplantation stage, PSs were detected not only in cytoplasm, but also in the nucleus from oocyte to 2.5 dpc (day postcoitum), then disappeared in the nucleus at blastocyst stage (3.5 dpc). Antisense against PS1 and PS2 decreased the transition to blastocyst stage, whereas each antisense alone had no effect. Treatment with lactacystin (26S proteosome inhibitor), which arrest cell cycle at M phase, redistributed PSs into centrosome-kinetochore microtubule. PS2 overexpression in HEK 293 cell arrested cell cycle at S phase. These data suggest that PSs play key roles in cell division and differentiation during early development.	Seoul Natl Univ, Coll Med, Dept Pharmacol, Chongno Gu, Seoul 110799, South Korea; Seoul Natl Univ, Med Res Ctr, Neurosci Res Inst, Seoul 110799, South Korea; Korea Natl Inst Hlth, Biomed Brain Res Ctr, Seoul 110799, South Korea; Seoul Natl Univ, Coll Nat Sci, Dept Mol Biol, Seoul 151742, South Korea; Seoul Natl Univ, Coll Nat Sci, Cell Differentiat Res Ctr, Seoul 151742, South Korea	Seoul National University (SNU); Seoul National University (SNU); Korea Centers for Disease Control & Prevention (KCDC); Korea National Institute of Health (KNIH); Seoul National University (SNU); Seoul National University (SNU)	Suh, YH (corresponding author), Seoul Natl Univ, Coll Med, Dept Pharmacol, Chongno Gu, 28 Yongon Dong, Seoul 110799, South Korea.		Kim, Hye Sun/J-2752-2012; Suh, Yoo-Hun/J-2761-2012	Rah, Jong-Cheol/0000-0003-3780-0522				BRYAN J, 1971, P NATL ACAD SCI USA, V68, P1762, DOI 10.1073/pnas.68.8.1762; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Dix DJ, 1998, MOL REPROD DEV, V51, P373, DOI 10.1002/(SICI)1098-2795(199812)51:4&lt;373::AID-MRD3&gt;3.0.CO;2-E; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; FISHER S, 1991, P NATL ACAD SCI USA, V88, P1779, DOI 10.1073/pnas.88.5.1779; Fraser PE, 1998, NEUROBIOL AGING, V19, pS19, DOI 10.1016/S0197-4580(98)00029-3; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Honda T, 1999, J NEUROCHEM, V72, P255, DOI 10.1046/j.1471-4159.1999.0720255.x; Janicki SM, 1999, AM J PATHOL, V155, P135, DOI 10.1016/S0002-9440(10)65108-5; Kim TW, 1997, J BIOL CHEM, V272, P11006; Lee MK, 1996, J NEUROSCI, V16, P7513, DOI 10.1523/jneurosci.16-23-07513.1996; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li JH, 1997, CELL, V90, P917, DOI 10.1016/S0092-8674(00)80356-6; Li JH, 1995, P NATL ACAD SCI USA, V92, P12180, DOI 10.1073/pnas.92.26.12180; LUDUENA RF, 1977, J BIOL CHEM, V252, P7006; Mattson MP, 1998, J NEUROCHEM, V70, P1; Mengual E, 1996, J NEUROSCI, V16, P6331; Mothes W, 1997, CELL, V89, P523, DOI 10.1016/S0092-8674(00)80234-2; Murayama M, 1998, FEBS LETT, V433, P73, DOI 10.1016/S0014-5793(98)00886-2; Ohsugi M, 1996, DEV DYNAM, V206, P391, DOI 10.1002/(SICI)1097-0177(199608)206:4<391::AID-AJA5>3.0.CO;2-D; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Oyama F, 1998, J NEUROCHEM, V71, P313; Pederson T, 1998, NUCLEIC ACIDS RES, V26, P3871, DOI 10.1093/nar/26.17.3871; Ray WJ, 1999, P NATL ACAD SCI USA, V96, P3263, DOI 10.1073/pnas.96.6.3263; RIVETT AJ, 1993, BIOCHEM J, V291, P1; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Smith MA, 1998, INT REV NEUROBIOL, V42, P1, DOI 10.1016/S0074-7742(08)60607-8; Takahashi H, 1996, NEUROSCI LETT, V206, P113, DOI 10.1016/S0304-3940(96)12449-6; Takashima A, 1998, P NATL ACAD SCI USA, V95, P9637, DOI 10.1073/pnas.95.16.9637; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tsark EC, 1997, MOL REPROD DEV, V47, P271, DOI 10.1002/(SICI)1098-2795(199707)47:3&lt;271::AID-MRD6&gt;3.0.CO;2-I; Tsujimura A, 1997, BIOCHEM BIOPH RES CO, V231, P392, DOI 10.1006/bbrc.1996.6043; Ye YH, 1998, MECH DEVELOP, V79, P199, DOI 10.1016/S0925-4773(98)00169-5; Zhang WJ, 1998, J NEUROSCI, V18, P914	36	16	16	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2171	2176		10.1096/fj.99-1068com	http://dx.doi.org/10.1096/fj.99-1068com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053237				2022-12-28	WOS:000165190800009
J	Stochaj, U; Rassadi, R; Chiu, J				Stochaj, U; Rassadi, R; Chiu, J			Stress-mediated inhibition of the classical nuclear protein import pathway and nuclear accumulation of the small GTPase Gsp1p	FASEB JOURNAL			English	Article									McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada	McGill University	Stochaj, U (corresponding author), McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada.	stochaj@med.mcgill.ca	stochaj, ursula/AAC-1865-2021						0	67	68	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2000	14	14					2130	2132		10.1096/fj.99-0751fje	http://dx.doi.org/10.1096/fj.99-0751fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11024003				2022-12-28	WOS:000165190800001
J	Zsembery, A; Strazzabosco, M; Graf, J				Zsembery, A; Strazzabosco, M; Graf, J			Ca2+-activated Cl- channels can substitute for CFTR in stimulation of pancreatic duct bicarbonate secretion	FASEB JOURNAL			English	Article						cystic fibrosis; anion exchange; purinergic stimulation; K+ channel function	TRANSMEMBRANE CONDUCTANCE REGULATOR; VASOACTIVE-INTESTINAL-PEPTIDE; ADENOCARCINOMA CELL-LINE; CYSTIC-FIBROSIS PATIENTS; EPITHELIAL-CELLS; CHLORIDE CONDUCTANCE; MEMBRANE VOLTAGE; SODIUM-CHANNELS; CFPAC-1 CELLS; ATP	This study addresses the mechanisms by which a defect in CFTR impairs pancreatic duct bicarbonate secretion in cystic fibrosis, We used control (PANC-1) and CFTR-deficient (CEPAC-1; Delta F508 mutation) cell lines and measured HCO3- extrusion by the rate of recovery of intracellular pH after an alkaline load and recorded whole cell membrane currents using patch clamp techniques. 1) In PANC-1 cells, cAMP causes parallel activation of Cl- channels and of HCO3- extrusion by DIDS-sensitive and Na+-independent Cl-/HCO3- exchange, both effects being inhibited by Cl- channel blockers NPPB and glibenclamide, 2) In CFPAC-1 cells, cAMP fails to stimulate Cl-/HCO3- exchange and Cl- channels, except after promoting surface expression of Delta F508-CFTR by glycerol treatment. Instead, raising intracellular Ca concentration to 1 mu mol/l or stimulating purinergic receptors with ATP (10 and 100 mu mol/l) leads to parallel activation of Cl- channels and HCO3- extrusion, 3) K+ channel function is required for coupling cAMP- and Ca2+-dependent Cl- channel activation to effective stimulation of Cl-/HCO3- exchange in control and CF cells, respectively. It is concluded that stimulation of pancreatic duct bicarbonate secretion via Cl-/HCO3- exchange is directly correlated to activation of apical membrane Cl- channels. Reduced bicarbonate secretion in cystic fibrosis results from defective cAMP-activated Cl- channels, This defect is partially compensated for by an increased sensitivity of CF cells to purinergic stimulation and by alternative activation of Ca2+-dependent Cl- channels, mechanisms of interest with respect to possible treatment of cystic fibrosis and of related chronic pancreatic diseases.Zsembery, A., Strazzabosco, M., Graf, J, Ca2+-activated Cl- channels can substitute for CFTR in stimulation of pancreatic duct bicarbonate secretion.	Univ Vienna, Dept Gen & Expt Pathol, A-1090 Vienna, Austria; Univ Azienda Osped Padova, Ist Med Interna, Padua, Italy; Semmelweis Univ, Fac Med, Dept Pathophysiol, H-1085 Budapest, Hungary	University of Vienna; University of Padua; Azienda Ospedaliera - Universita di Padova; Semmelweis University	Graf, J (corresponding author), Univ Vienna, Dept Gen & Expt Pathol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	juerg.graf@univie.ac.at			Telethon [E.0873] Funding Source: Medline	Telethon(Fondazione Telethon)		ALAWQATI Q, 1995, SCIENCE, V269, P805, DOI 10.1126/science.7543697; AlNakkash L, 1996, INT J PANCREATOL, V19, P39; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; Argent B. E., 1994, P1473; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BARO I, 1994, J PHYSIOL-LONDON, V478, P469, DOI 10.1113/jphysiol.1994.sp020266; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; Bennett WD, 1996, AM J RESP CRIT CARE, V153, P1796, DOI 10.1164/ajrccm.153.6.8665037; Boron WF, 1992, KIDNEY PHYSL PATHOPH, P219; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC844, DOI 10.1152/ajpcell.1988.255.6.C844; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; Brown CR, 1996, CELL STRESS CHAPERON, V1, P117, DOI 10.1379/1466-1268(1996)001<0117:CCCTMP>2.3.CO;2; CASAVOLA V, 1995, AM J PHYSIOL-CELL PH, V269, pC226, DOI 10.1152/ajpcell.1995.269.1.C226; Chan HC, 1996, AM J PHYSIOL-CELL PH, V271, pC469, DOI 10.1152/ajpcell.1996.271.2.C469; Chan HC, 1997, J MEMBRANE BIOL, V156, P241, DOI 10.1007/s002329900204; CHAO AC, 1995, J CLIN INVEST, V96, P1794, DOI 10.1172/JCI118225; Dray-Charier N, 1999, HEPATOLOGY, V29, P1624, DOI 10.1002/hep.510290634; DURIE PR, 1989, J ROY SOC MED, V82, P2; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; ELGAVISH A, 1991, BIOCHEM BIOPH RES CO, V180, P342, DOI 10.1016/S0006-291X(05)81298-7; FULLER CM, 1992, AM J PHYSIOL, V263, pC267, DOI 10.1152/ajpcell.1992.263.2.C267; GALIETTA LJV, 1994, PFLUG ARCH EUR J PHY, V426, P534, DOI 10.1007/BF00378531; GASKIN KJ, 1982, PEDIATR RES, V16, P554, DOI 10.1203/00006450-198207000-00012; GRAY MA, 1994, AM J PHYSIOL, V266, pC213, DOI 10.1152/ajpcell.1994.266.1.C213; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hogan DL, 1997, AM J PHYSIOL-GASTR L, V272, pG872, DOI 10.1152/ajpgi.1997.272.4.G872; Hyde K, 1999, BIOCHEM BIOPH RES CO, V263, P315, DOI 10.1006/bbrc.1999.1367; Ismailov II, 1996, J BIOL CHEM, V271, P4725; Jiang SP, 1997, CANCER RES, V57, P1475; KOPELMAN H, 1993, J CLIN INVEST, V91, P1253, DOI 10.1172/JCI116289; KOPELMAN HR, 1988, GASTROENTEROLOGY, V98, P349; Lee MG, 1999, J BIOL CHEM, V274, P3414, DOI 10.1074/jbc.274.6.3414; Lindblad A, 1998, HEPATOLOGY, V27, P166, DOI 10.1002/hep.510270126; Loussouarn G, 1996, AM J PHYSIOL-CELL PH, V271, pC1565, DOI 10.1152/ajpcell.1996.271.5.C1565; MADDEN ME, 1988, PANCREAS, V5, P512; MARINO CR, 1991, J CLIN INVEST, V88, P712, DOI 10.1172/JCI115358; MARINO CR, 1992, GASTROENTEROLOGY, V103, P681, DOI 10.1016/0016-5085(92)90866-W; MCGILL J, 1996, GASTROENTEROLOGY, V107, P236; McNicholas CM, 1996, P NATL ACAD SCI USA, V93, P8083, DOI 10.1073/pnas.93.15.8083; Nguyen TD, 1998, AM J PHYSIOL-GASTR L, V275, pG76, DOI 10.1152/ajpgi.1998.275.1.G76; Nguyen TD, 1998, AM J PHYSIOL-GASTR L, V275, pG104, DOI 10.1152/ajpgi.1998.275.1.G104; NOVAK I, 1993, PFLUG ARCH EUR J PHY, V425, P272, DOI 10.1007/BF00374178; NOVAK I, 1988, PFLUG ARCH EUR J PHY, V411, P58, DOI 10.1007/BF00581647; O'Reilly CM, 1998, BRIT J PHARMACOL, V124, P1597, DOI 10.1038/sj.bjp.0701990; PAHL C, 1993, PFLUG ARCH EUR J PHY, V424, P315, DOI 10.1007/BF00384358; Poulsen JH, 1996, PFLUG ARCH EUR J PHY, V432, P546, DOI 10.1007/s004240050168; RIORDAN JR, 1989, SCIENCE, V245, P1066; Rubenstein Ronald C., 1998, Current Opinion in Pediatrics, V10, P250, DOI 10.1097/00008480-199806000-00005; RUGOLO M, 1993, J BIOL CHEM, V268, P24779; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; Schreiber R, 1997, PFLUG ARCH EUR J PHY, V434, P841, DOI 10.1007/s004240050473; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; Sharer N, 1998, NEW ENGL J MED, V339, P645, DOI 10.1056/NEJM199809033391001; SHEPPARD DN, 1993, ANN NY ACAD SCI, V707, P275, DOI 10.1111/j.1749-6632.1993.tb38058.x; Shumaker H, 1999, AM J PHYSIOL-CELL PH, V276, pC16, DOI 10.1152/ajpcell.1999.276.1.C16; SLIMAK GG, 1993, PANCREAS, V8, P212, DOI 10.1097/00006676-199303000-00012; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; Tauc M, 1996, J MEMBRANE BIOL, V150, P255, DOI 10.1007/s002329900049; VEEZE HJ, 1994, J CLIN INVEST, V93, P461, DOI 10.1172/JCI116993; VILLANGER O, 1995, GASTROENTEROLOGY, V108, P850, DOI 10.1016/0016-5085(95)90460-3; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WARTH R, 1993, CELL PHYSIOL BIOCHEM, V3, P2, DOI 10.1159/000154663; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; Winpenny JP, 1998, PFLUG ARCH EUR J PHY, V435, P796, DOI 10.1007/s004240050586; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111; Zeng WZ, 1997, AM J PHYSIOL-CELL PH, V273, pC442, DOI 10.1152/ajpcell.1997.273.2.C442; ZHAO H, 1994, J GEN PHYSIOL, V104, P57, DOI 10.1085/jgp.104.1.57	68	49	50	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2345	2356		10.1096/fj.99-0509com	http://dx.doi.org/10.1096/fj.99-0509com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053257				2022-12-28	WOS:000165190800029
J	D'Amico, M; Di Filippo, C; La, M; Solito, E; McLean, PG; Flower, RJ; Oliani, SM; Perretti, M				D'Amico, M; Di Filippo, C; La, M; Solito, E; McLean, PG; Flower, RJ; Oliani, SM; Perretti, M			Lipocortin 1 reduces myocardial ischemia-reperfusion injury by affecting local leukocyte recruitment	FASEB JOURNAL			English	Article									William Harvey Res Inst, Dept Biochem Pharmacol, London EC1M 6BQ, England; Univ Naples 2, Inst Pharmacol & Toxicol, I-80138 Naples, Italy; Inst Cochin Genet Mol, INSERM, U332, F-75014 Paris, France; UNESP, IBILCE, Dept Biol, Sao Paulo, Brazil	University of London; Queen Mary University London; Universita della Campania Vanvitelli; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universidade Estadual Paulista	Perretti, M (corresponding author), William Harvey Res Inst, Dept Biochem Pharmacol, Charterhouse Sq, London EC1M 6BQ, England.		Oliani, Sonia Maria/E-3476-2012	Oliani, Sonia Maria/0000-0003-0918-2130; d'amico, michele/0000-0002-6899-0595; Solito, Egle/0000-0001-5279-0049					0	79	80	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2000	14	13					1867	1869						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023969				2022-12-28	WOS:000089634400004
J	Gitter, AH; Bendfeldt, K; Schulzke, JD; Fromm, M				Gitter, AH; Bendfeldt, K; Schulzke, JD; Fromm, M			Leaks in the epithelial barrier caused by spontaneous and TNF-alpha-induced single-cell apoptosis	FASEB JOURNAL			English	Article						cell death; conductance scanning; intestine; tight junction; permeability	TUMOR-NECROSIS-FACTOR; INFLAMMATORY BOWEL-DISEASE; SMALL-INTESTINE; GASTROINTESTINAL-TRACT; TIGHT JUNCTIONS; HUMAN COLON; TRANSPORT; PERMEABILITY; CONDUCTANCE; MAINTENANCE	Current opinion assumes epithelial integrity during spontaneous apoptotic cell death. We measured, for the first time, the local conductances associated with apoptoses and show leaks of up to 280 nS (mean 48 +/- 19 nS) in human intestinal epithelium, The results disprove the dogma that isolated cell apoptosis occurs without affecting the epithelial cell permeability barrier, After induction by tumor necrosis factor alpha (TNF-alpha) the apoptotic leaks were dramatically enhanced: not only was the frequency increased by threefold, but the mean conductance also increased by 12-fold (597+/-98 nS), Thus, apoptosis accounted for about half (56%) of the TNF-alpha-induced permeability increase whereas the other half was caused by degradation of tight junctions in nonapoptotic areas. Hence, spontaneous and induced apoptosis hollow out the intestinal barrier and may facilitate loss of solutes and uptake of noxious agents.	Free Univ Berlin, Klinikum Benjamin Franklin, Inst Klin Physiol, D-12200 Berlin, Germany; Free Univ Berlin, Univ Hosp Benjamin Franklin, Inst Clin Physiol, D-1000 Berlin, Germany; Free Univ Berlin, Univ Hosp Benjamin Franklin, Dept Gastroenterol, D-1000 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Gitter, AH (corresponding author), Free Univ Berlin, Klinikum Benjamin Franklin, Inst Klin Physiol, D-12200 Berlin, Germany.	gitter@medizin.fu-berlin.de	bendfeldt, kerstin/AAZ-2197-2020; Fromm, Michael/K-6203-2013	Fromm, Michael/0000-0003-4497-7983				ANDERSON JM, 1995, AM J PHYSIOL-GASTR L, V269, pG467, DOI 10.1152/ajpgi.1995.269.4.G467; BARON DA, 1990, J ELECTRON MICR TECH, V16, P15, DOI 10.1002/jemt.1060160104; BREESE EJ, 1994, GASTROENTEROLOGY, V106, P1455, DOI 10.1016/0016-5085(94)90398-0; FROMTER E, 1972, NATURE-NEW BIOL, V235, P9, DOI 10.1038/newbio235009a0; Gitter AH, 1997, PFLUG ARCH EUR J PHY, V434, P830, DOI 10.1007/s004240050472; Goodenough DA, 1999, P NATL ACAD SCI USA, V96, P319, DOI 10.1073/pnas.96.2.319; HALL PA, 1994, J CELL SCI, V107, P3569; HEYMAN M, 1994, GASTROENTEROLOGY, V106, P1514, DOI 10.1016/0016-5085(94)90405-7; HUDSPETH AJ, 1975, P NATL ACAD SCI USA, V72, P2711, DOI 10.1073/pnas.72.7.2711; HUDSPETH AJ, 1982, EXP CELL RES, V138, P331, DOI 10.1016/0014-4827(82)90182-3; IWANAGA T, 1993, GASTROENTEROLOGY, V105, P1089, DOI 10.1016/0016-5085(93)90953-A; JINGUJI Y, 1992, CELL STRUCT FUNCT, V17, P27, DOI 10.1247/csf.17.27; Jones BA, 1997, AM J PHYSIOL-GASTR L, V273, pG1174, DOI 10.1152/ajpgi.1997.273.6.G1174; KANDIL HM, 1994, GUT, V35, P934, DOI 10.1136/gut.35.7.934; KOTLER DP, 1993, DIGEST DIS SCI, V38, P1119, DOI 10.1007/BF01295730; KREUSEL KM, 1991, AM J PHYSIOL, V261, pC574, DOI 10.1152/ajpcell.1991.261.4.C574; Ksontini R, 1998, ARCH SURG-CHICAGO, V133, P558, DOI 10.1001/archsurg.133.5.558; Kunstle G, 1997, IMMUNOL LETT, V55, P5, DOI 10.1016/S0165-2478(96)02642-9; LASTER SM, 1988, J IMMUNOL, V141, P2629; MADARA JL, 1990, J MEMBRANE BIOL, V116, P177, DOI 10.1007/BF01868675; Marano CW, 1998, J MEMBRANE BIOL, V161, P263, DOI 10.1007/s002329900333; Mayhew TM, 1999, HISTOL HISTOPATHOL, V14, P257, DOI 10.14670/HH-14.257; McKay DM, 1997, J IMMUNOL, V159, P2382; MERRITT AJ, 1994, CANCER RES, V54, P614; MULLIN JM, 1992, AM J PHYSIOL, V263, pF915, DOI 10.1152/ajprenal.1992.263.5.F915; MURCH SH, 1993, GUT, V34, P1705, DOI 10.1136/gut.34.12.1705; Potten CS, 1997, AM J PHYSIOL-GASTR L, V273, pG253, DOI 10.1152/ajpgi.1997.273.2.G253; RODRIGUEZ P, 1995, CYTOKINE, V7, P441, DOI 10.1006/cyto.1995.0060; RUGGIERO V, 1986, J IMMUNOL, V136, P2445; RUSSELL RG, 1993, J INFECT DIS, V168, P210, DOI 10.1093/infdis/168.1.210; SANDLE GI, 1990, GASTROENTEROLOGY, V99, P97, DOI 10.1016/0016-5085(90)91235-X; SARTOR RB, 1994, GASTROENTEROLOGY, V106, P533, DOI 10.1016/0016-5085(94)90614-9; Sategna-Guidetti Carla, 1993, Recenti Progressi in Medicina, V84, P93; Schmitz H, 1996, AM J PHYSIOL-GASTR L, V271, pG669, DOI 10.1152/ajpgi.1996.271.4.G669; Schmitz H, 1999, J CELL SCI, V112, P137; Soler AP, 1996, AM J PHYSIOL-RENAL, V270, pF869, DOI 10.1152/ajprenal.1996.270.5.F869	36	214	222	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2000	14	12					1749	1753		10.1096/fj.99-0898com	http://dx.doi.org/10.1096/fj.99-0898com			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973924				2022-12-28	WOS:000089212400014
J	Block, K; Kardana, A; Igarashi, P; Taylor, HS				Block, K; Kardana, A; Igarashi, P; Taylor, HS			In utero diethylstilbestrol (DES) exposure alters Hox gene expression in the developing mullerian system	FASEB JOURNAL			English	Article						genes; homeobox; teratogens; fetal development; estrogens	NUCLEAR RECEPTOR COACTIVATORS; RETINOIC ACID; ESTROGEN-RECEPTOR; SEX STEROIDS; MICE; ENDOMETRIUM; MECHANISMS; TAMOXIFEN; MUTATION; MOUSE	Diethylstilbestrol (DES) was widely used to treat pregnant women through 1971, The reproductive tracts of their female offspring exposed to DES in utero are characterized by anatomic abnormalities, Here we show that DES administered to mice in utero produces changes in the expression pattern of several Hox genes that are involved in patterning of the reproductive tract. DES produces posterior shifts in Hox gene expression and homeotic anterior transformations of the reproductive tract. In human uterine or cervical cell cultures, DES induces HOXA9 or HOXA10 gene expression, respectively, to levels approximately twofold that induced by estradiol, The DES-induced expression is not inhibited by cyclohexamide, Estrogens are novel morphogens that directly regulate the expression pattern of posterior Hox genes in a manner analogous to retinoic acid regulation of anterior Hox genes. Alterations in HOX gene expression are a molecular mechanism by which DES affects reproductive tract development. Changes in Hox gene expression are a potential marker for the effects of in utero drug use that may become apparent only at late stages of development.-Block, K., Kardana, A., Igarashi, P., Taylor, H. S. In utero diethylstilbestrol (DES) exposure alters Hox gene expression in the developing mullerian system.	Yale Univ, Sch Med, Dept Obstet & Gynecol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA	Yale University; Yale University	Taylor, HS (corresponding author), Yale Univ, Sch Med, Dept Obstet & Gynecol, 333 Cedar St, New Haven, CT 06520 USA.			Igarashi, Peter/0000-0001-8698-1185				BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Benson GV, 1996, DEVELOPMENT, V122, P2687; BONCINELLI E, 1991, TRENDS GENET, V7, P329, DOI 10.1016/0168-9525(91)90423-N; DECHERNEY AH, 1981, FERTIL STERIL, V36, P741; Duboule D, 1991, CURR OPIN GENET DEV, V1, P211, DOI 10.1016/S0959-437X(05)80072-3; Gendron RL, 1997, BIOL REPROD, V56, P1097, DOI 10.1095/biolreprod56.5.1097; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gradishar WJ, 1997, J CLIN ONCOL, V15, P840, DOI 10.1200/JCO.1997.15.2.840; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; HSIEHLI HM, 1995, DEVELOPMENT, V121, P1373; Jordan VC, 1998, J NATL CANCER I, V90, P967, DOI 10.1093/jnci/90.13.967; KALDAS RS, 1989, REPROD TOXICOL, V3, P81, DOI 10.1016/0890-6238(89)90042-7; KORACH KS, 1994, SCIENCE, V266, P1524, DOI 10.1126/science.7985022; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; MABLY TA, 1992, TOXICOL APPL PHARM, V114, P118, DOI 10.1016/0041-008X(92)90103-Y; Manzanares M, 1997, NATURE, V387, P191, DOI 10.1038/387191a0; MARSHALL H, 1994, NATURE, V370, P567, DOI 10.1038/370567a0; MARSHALL H, 1992, NATURE, V360, P737, DOI 10.1038/360737a0; MCLACHLAN JA, 1980, CANCER RES, V40, P3988; Mortlock DP, 1997, NAT GENET, V15, P179, DOI 10.1038/ng0297-179; NOLLER KL, 1974, MED CLIN N AM, V58, P739; NOMURA T, 1977, CANCER RES, V37, P1099; SATOKATA I, 1995, NATURE, V374, P46; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604; Tanenbaum DM, 1998, P NATL ACAD SCI USA, V95, P5998, DOI 10.1073/pnas.95.11.5998; Taylor HS, 1998, J CLIN INVEST, V101, P1379, DOI 10.1172/JCI1057; Taylor HS, 1999, J CLIN ENDOCR METAB, V84, P1129, DOI 10.1210/jc.84.3.1129; Taylor HS, 1997, BIOL REPROD, V57, P1338, DOI 10.1095/biolreprod57.6.1338; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; WALTERS LM, 1993, REPROD TOXICOL, V7, P599, DOI 10.1016/0890-6238(93)90036-7; Warot X, 1997, DEVELOPMENT, V124, P4781	34	193	203	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2000	14	9					1101	1108		10.1096/fasebj.14.9.1101	http://dx.doi.org/10.1096/fasebj.14.9.1101			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834931				2022-12-28	WOS:000087427300006
J	Offer, T; Russo, A; Samuni, A				Offer, T; Russo, A; Samuni, A			The pro-oxidative activity of SOD and nitroxide SOD mimics	FASEB JOURNAL			English	Article						papain; hydrogen peroxide; superoxide; oxidative damage; thiol	SUPEROXIDE-DISMUTASE; HYDROGEN-PEROXIDE; LIPID-PEROXIDATION; CU,ZN-SUPEROXIDE DISMUTASE; RADICAL PRODUCTION; TOXICITY; CELLS; H2O2; INACTIVATION; MECHANISM	Native Cu,Zn-SOD and synthetic SOD mimics sometimes demonstrate an apparently anomalous bell-shaped dose-response relationship when protecting various biological systems from oxidative stress. Several mechanisms have been proposed to account for such an effect, including: overproduction of H2O2, peroxidative activity of SOD, and opposing roles played by O-2(.-) in both initiation and termination of radical chain reactions. In the present study, ferrocyanide and thiols, which are susceptible to one-electron and two-electron oxidation, respectively, were subjected to a flux of superoxide in the presence and absence of SOD or SOD mimics. The results show that 1) either O-2(.-)/HO2. or H2O2 alone partially inactivates papain, whereas when combined they act synergistically; 2) nitroxide SOD mimics, but not SOD, exhibit a bell-shaped dose-response relationship in protecting papain from inactivation; 3) SOD, which at low dose inhibits superoxide-induced oxidation of ferrocyanide, loses its antioxidative effect as its concentration increases, These findings offer an additional explanation for the pro-oxidative activity of SOD and SOD mimics without invoking any dual activity of O-2(.-) or a combined effect of SOD and H2O2. The most significant outcome of an increase in SOD level is a decrease of [O-2(.-)](steady state), rather than any notable elevation of [H2O2](steady state). As a result, the reaction kinetics of the high oxidation state of each catalyst is altered. In the presence of ultra-low [O-2(.-)](steady state), the oxidized form of SOD [Cu(II),Zn-SOD] or SOD mimic (oxoammonium cation) does not react with O-2(.-) but rather oxidizes the target molecule that it was supposed to have protected. Consequently, these catalysts exert an anti- or pro-oxidative effect depending on their concentration.-Offer, T., Russo, A., Samuni, A. The pro-oxidative activity of SOD and nitroxide SOD mimics.	Hebrew Univ Jerusalem, Hadassah Med Sch, Fac Med, IL-91120 Jerusalem, Israel; NCI, Radiat Biol Branch, NIH, Bethesda, MD 20892 USA	Hebrew University of Jerusalem; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Offer, T (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Fac Med, IL-91120 Jerusalem, Israel.							ARMSTRONG DA, 1978, PHOTOCHEM PHOTOBIOL, V28, P743, DOI 10.1111/j.1751-1097.1978.tb07011.x; BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; BERNIER M, 1989, AM J PHYSIOL, V256, pH1344, DOI 10.1152/ajpheart.1989.256.5.H1344; BEYER WF, 1991, ARCH BIOCHEM BIOPHYS, V285, P60, DOI 10.1016/0003-9861(91)90328-G; BLOUGH NV, 1988, ENVIRON SCI TECHNOL, V22, P77, DOI 10.1021/es00166a008; DEGRAFF WG, 1992, ENVIRON MOL MUTAGEN, V19, P21, DOI 10.1002/em.2850190105; ELROYSTEIN O, 1986, EMBO J, V5, P615, DOI 10.1002/j.1460-2075.1986.tb04255.x; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; FRIDOVICH I, 1986, ARCH BIOCHEM BIOPHYS, V247, P1, DOI 10.1016/0003-9861(86)90526-6; GALLEZ B, 1992, TOXICOL LETT, V63, P35, DOI 10.1016/0378-4274(92)90105-S; Gariboldi MB, 1998, FREE RADICAL BIO MED, V24, P913, DOI 10.1016/S0891-5849(97)00372-9; Goss SPA, 1999, J BIOL CHEM, V274, P28233, DOI 10.1074/jbc.274.40.28233; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5299, DOI 10.1021/bi00695a011; ISHII T, 1991, FREE RADICAL RES COM, V14, P187, DOI 10.3109/10715769109088948; Jewett SL, 1999, FREE RADICAL BIO MED, V26, P905, DOI 10.1016/S0891-5849(98)00274-3; KEDZIORA J, 1988, FREE RADICAL BIO MED, V4, P317, DOI 10.1016/0891-5849(88)90052-4; KRISHNA MC, 1992, P NATL ACAD SCI USA, V89, P5537, DOI 10.1073/pnas.89.12.5537; Krishna MC, 1996, J BIOL CHEM, V271, P26018, DOI 10.1074/jbc.271.42.26018; LIN WS, 1975, RADIAT RES, V62, P438, DOI 10.2307/3574138; Liochev SI, 1997, ARCH BIOCHEM BIOPHYS, V346, P263, DOI 10.1006/abbi.1997.0298; LIOCHEV SI, 1992, ARCH BIOCHEM BIOPHYS, V294, P138, DOI 10.1016/0003-9861(92)90147-O; MAO GD, 1993, J BIOL CHEM, V268, P416; MCCORD JM, 1995, P SOC EXP BIOL MED, V209, P112; MCCORD JM, 1998, OXIDAT STRESS DIS, V1, P1; Meara JP, 1996, J MED CHEM, V39, P3357, DOI 10.1021/jm950445b; MITCHELL JB, 1990, BIOCHEMISTRY-US, V29, P2802, DOI 10.1021/bi00463a024; MIURA Y, 1995, FREE RADICAL RES, V22, P209, DOI 10.3109/10715769509147540; Monti E, 1996, FREE RADICAL BIO MED, V21, P463, DOI 10.1016/0891-5849(96)00124-4; Muller A, 1997, EXP EYE RES, V64, P637, DOI 10.1006/exer.1996.0277; NELSON SK, 1994, FREE RADICAL BIO MED, V16, P195, DOI 10.1016/0891-5849(94)90143-0; NILSSON UA, 1989, J BIOL CHEM, V264, P11131; NORRIS KH, 1990, MUTAT RES, V237, P95, DOI 10.1016/0921-8734(90)90015-J; Offer T, 1998, FREE RADICAL BIO MED, V25, P832, DOI 10.1016/S0891-5849(98)00162-2; OMAR BA, 1990, FREE RADICAL BIO MED, V9, P465, DOI 10.1016/0891-5849(90)90123-Z; OMAR BA, 1990, FREE RADICAL BIO MED, V9, P473, DOI 10.1016/0891-5849(90)90124-2; RACHMILEWITZ D, 1994, GUT, V35, P1181, DOI 10.1136/gut.35.9.1181; ROTILIO G, 1973, BIOCHIM BIOPHYS ACTA, V302, P229, DOI 10.1016/0005-2744(73)90151-4; SAMUNI A, 1991, BIOCHEMISTRY-US, V30, P555, DOI 10.1021/bi00216a033; SAMUNI A, 1988, J BIOL CHEM, V263, P17921; SAMUNI A, 1991, J CLIN INVEST, V87, P1526, DOI 10.1172/JCI115163; Sankarapandi S, 1999, J BIOL CHEM, V274, P34576, DOI 10.1074/jbc.274.49.34576; SCOTT MD, 1989, J BIOL CHEM, V264, P2498; SCOTT MD, 1987, J BIOL CHEM, V262, P3640; SEIS H, 1986, ARCH BIOCHEM BIOPHYS, V251, P393; SLATER AFG, 1995, BIOCHEM J, V306, P771, DOI 10.1042/bj3060771; SLEDZINSKI Z, 1995, INT J PANCREATOL, V18, P153; Subramainam R, 1996, BIOCHEM ARCH, V12, P105; VAIDYANATHAN VV, 1993, MOL CELL BIOCHEM, V129, P57, DOI 10.1007/BF00926576; VOEST EE, 1992, BIOCHIM BIOPHYS ACTA, V1136, P113, DOI 10.1016/0167-4889(92)90245-7; YIM MB, 1990, P NATL ACAD SCI USA, V87, P5006, DOI 10.1073/pnas.87.13.5006	50	95	101	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2000	14	9					1215	1223		10.1096/fasebj.14.9.1215	http://dx.doi.org/10.1096/fasebj.14.9.1215			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834943				2022-12-28	WOS:000087427300018
J	Pedersen, WA; Luo, H; Kruman, I; Kasarskis, E; Mattson, MP				Pedersen, WA; Luo, H; Kruman, I; Kasarskis, E; Mattson, MP			The prostate apoptosis response-4 protein participates in motor neuron degeneration in amyotrophic lateral sclerosis	FASEB JOURNAL			English	Article						NSC-19; oxidative stress; spinal cord; superoxide dismutase; transgenic mice	LIPID-PEROXIDATION PRODUCT; AMYLOID BETA-PEPTIDE; TRANSGENIC MOUSE MODEL; SUPEROXIDE-DISMUTASE MUTATION; METHYL-D-ASPARTATE; OXIDATIVE STRESS; SPINAL-CORD; GLUTAMATE TRANSPORTER; FAMILIAL ALS; MITOCHONDRIAL DYSFUNCTION	Prostate apoptosis response-4 (Par-4), a protein containing a leucine zipper domain within a death domain, is up-regulated in prostate cancer cells and hippocampal neurons induced to undergo apoptosis, Here, we report higher Par-4 levels in lumbar spinal cord samples from patients with amyotrophic lateral sclerosis (ALS) than in lumbar spinal cord samples from neurologically normal patients, We also compared the levels of Par-4 in lumbar spinal cord samples from wild-type and transgenic mice expressing the human Cu/Zn-superoxide dismutase gene with a familial ALS mutation. Relative to control samples, higher Par-4 levels were observed in lumbar spinal cord samples prepared from the transgenic mice at a time when they had hind-limb paralysis, Immunohistochemical analyses of human and mouse lumbar spinal cord sections revealed that Par-4 is localized to motor neurons in the ventral horn region. In culture studies, exposure of primary mouse spinal cord motor neurons or NSC-19 motor neuron cells to oxidative insults resulted in a rapid and large increase in Par-4 levels that preceded apoptosis, Pretreatment of the motor neuron cells with a Par-4 antisense oligonucleotide prevented oxidative stress-induced apoptosis and reversed oxidative stress-induced mitochondrial dysfunction that preceded apoptosis, Collectively, these data suggest a role for Par-4 in models of motor neuron injury relevant to ALS.	NIA, Neurosci Lab, Baltimore, MD 21224 USA; Univ Kentucky, Sanders Brown Res Ctr Aging, Lexington, KY 40536 USA; Univ Kentucky, Dept Neurol, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Kentucky; University of Kentucky; University of Kentucky	Mattson, MP (corresponding author), NIA, Neurosci Lab, GRC 4F01,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		Mattson, Mark P/F-6038-2012		NIA NIH HHS [AG14554] Funding Source: Medline; NINDS NIH HHS [NS35253] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035253] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000313, R01AG014554] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aguirre T, 1998, ANN NEUROL, V43, P452, DOI 10.1002/ana.410430407; Andrus PK, 1998, J NEUROCHEM, V71, P2041; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Beal MF, 1997, ANN NEUROL, V42, P644, DOI 10.1002/ana.410420416; BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; Blanc EM, 1998, GLIA, V22, P149, DOI 10.1002/(SICI)1098-1136(199802)22:2<149::AID-GLIA6>3.0.CO;2-2; Bogdanov MB, 1998, J NEUROCHEM, V71, P1321; Boghaert ER, 1997, CELL GROWTH DIFFER, V8, P881; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Bristol LA, 1996, ANN NEUROL, V39, P676, DOI 10.1002/ana.410390519; BROWN RH, 1995, CELL, V80, P687, DOI 10.1016/0092-8674(95)90346-1; Browne SE, 1998, J NEUROCHEM, V71, P281; BRUCE AJ, 1997, PATHOGENESIS, V1, P15; Bruijn LI, 1997, P NATL ACAD SCI USA, V94, P7606, DOI 10.1073/pnas.94.14.7606; Canton T, 1998, NEUROREPORT, V9, P775, DOI 10.1097/00001756-199803300-00001; Carriedo SG, 1996, J NEUROSCI, V16, P4069; CASHMAN NR, 1992, DEV DYNAM, V194, P209, DOI 10.1002/aja.1001940306; Chan SL, 1999, J NEUROCHEM, V73, P502, DOI 10.1046/j.1471-4159.1999.0730502.x; Cudkowicz ME, 1997, ANN NEUROL, V41, P210, DOI 10.1002/ana.410410212; DALCANTO MC, 1995, BRAIN RES, V676, P25, DOI 10.1016/0006-8993(95)00063-V; Diaz-Meco MT, 1999, J BIOL CHEM, V274, P19606, DOI 10.1074/jbc.274.28.19606; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; Duan WZ, 1999, J NEUROCHEM, V72, P2312, DOI 10.1046/j.1471-4159.1999.0722312.x; Dugan LL, 1997, P NATL ACAD SCI USA, V94, P9434, DOI 10.1073/pnas.94.17.9434; Ferrante RJ, 1997, ANN NEUROL, V42, P326, DOI 10.1002/ana.410420309; Ferrante RJ, 1997, J NEUROCHEM, V69, P2064; Friedlander RM, 1997, NATURE, V388, P31, DOI 10.1038/40299; Ghadge GD, 1997, J NEUROSCI, V17, P8756; Guo Q, 1998, NAT MED, V4, P957, DOI 10.1038/nm0898-957; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Gurney ME, 1996, ANN NEUROL, V39, P147, DOI 10.1002/ana.410390203; Hall ED, 1998, J NEUROSCI RES, V53, P66, DOI 10.1002/(SICI)1097-4547(19980701)53:1<66::AID-JNR7>3.3.CO;2-K; HAVERKAMP LJ, 1995, BRAIN, V118, P707, DOI 10.1093/brain/118.3.707; Keller JN, 1997, J NEUROCHEM, V69, P273; Kostic V, 1997, SCIENCE, V277, P559, DOI 10.1126/science.277.5325.559; Kruman I, 1997, J NEUROSCI, V17, P5089; Kruman I, 1998, J NEUROSCI RES, V51, P293, DOI 10.1002/(SICI)1097-4547(19980201)51:3<293::AID-JNR3>3.0.CO;2-B; Kruman II, 1999, EXP NEUROL, V160, P28, DOI 10.1006/exnr.1999.7190; Lin CLG, 1998, NEURON, V20, P589, DOI 10.1016/S0896-6273(00)80997-6; Liu RG, 1998, ANN NEUROL, V44, P763, DOI 10.1002/ana.410440510; MARK RJ, 1995, J NEUROSCI, V15, P6239; Mark RJ, 1997, J NEUROSCI, V17, P1046; Mark RJ, 1997, J NEUROCHEM, V68, P255; Mattson M.P., 1996, MOL MECH DEMENTIA, P103; Mattson MP, 1998, TRENDS NEUROSCI, V21, P53, DOI 10.1016/S0166-2236(97)01188-0; Mitsumoto H., 1997, NEUROLOGY S4, V48, P2, DOI DOI 10.1212/WNL.48.4_SUPPL_4.2S; Mu XJ, 1996, ANN NEUROL, V40, P379, DOI 10.1002/ana.410400307; NADLER JV, 1980, J COMP NEUROL, V192, P333, DOI 10.1002/cne.901920209; NITATORI T, 1995, J NEUROSCI, V15, P1001; OLNEY JW, 1979, BRAIN RES, V176, P91, DOI 10.1016/0006-8993(79)90872-2; Pasinelli P, 1998, P NATL ACAD SCI USA, V95, P15763, DOI 10.1073/pnas.95.26.15763; Pedersen WA, 1998, ANN NEUROL, V44, P819, DOI 10.1002/ana.410440518; Pedersen WA, 1999, EXP NEUROL, V155, P1, DOI 10.1006/exnr.1998.6890; Qin ZH, 1996, BRAIN RES, V725, P166, DOI 10.1016/S0006-8993(96)00200-4; RABIZADEH S, 1995, P NATL ACAD SCI USA, V92, P3024, DOI 10.1073/pnas.92.7.3024; Rangnekar VM, 1998, APOPTOSIS, V3, P61, DOI 10.1023/A:1009666705875; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; ROTHSTEIN JD, 1993, P NATL ACAD SCI USA, V90, P6591, DOI 10.1073/pnas.90.14.6591; ROTHSTEIN JD, 1992, NEW ENGL J MED, V326, P1464, DOI 10.1056/NEJM199205283262204; ROTHSTEIN JD, 1990, ANN NEUROL, V28, P18, DOI 10.1002/ana.410280106; ROTHSTEIN JD, 1995, ANN NEUROL, V38, P73, DOI 10.1002/ana.410380114; Sells SF, 1997, MOL CELL BIOL, V17, P3823, DOI 10.1128/MCB.17.7.3823; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; Smith RG, 1998, ANN NEUROL, V44, P696, DOI 10.1002/ana.410440419; Tu PH, 1996, P NATL ACAD SCI USA, V93, P3155, DOI 10.1073/pnas.93.7.3155; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Yim MB, 1996, P NATL ACAD SCI USA, V93, P5709, DOI 10.1073/pnas.93.12.5709; YOSHIYAMA Y, 1994, ACTA NEUROPATHOL, V88, P207	69	61	67	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2000	14	7					913	924		10.1096/fasebj.14.7.913	http://dx.doi.org/10.1096/fasebj.14.7.913			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	309CG	10783145				2022-12-28	WOS:000086749500009
J	Saber-Lichtenberg, Y; Brix, K; Schmitz, A; Heuser, JE; Wilson, JH; Lorand, L; Herzog, V				Saber-Lichtenberg, Y; Brix, K; Schmitz, A; Heuser, JE; Wilson, JH; Lorand, L; Herzog, V			Covalent cross-linking of secreted bovine thyroglobulin by transglutaminase	FASEB JOURNAL			English	Article							URCHIN FERTILIZATION ENVELOPE; THYROID EPITHELIAL-CELLS; CDNA LIBRARIES; TISSUE TRANSGLUTAMINASE; EXTRACELLULAR STORAGE; MESSENGER-RNAS; PROTEINS; CLONING; FIBRINOGEN; TRANSPORT	Extracellular storage of thyroglobulin (TG) is a prerequisite for maintaining constant levels of thyroid hormones in vertebrates. Storage: of TG within the follicle lumen is achieved by compactation and by the formation of covalent cross-links between TG molecules. In bovine thyroids, similar to 75% of the cross-links are other than disulfide bonds (J. Cell Biol, 180, 1071-1081), We have now shown that polymeric TG contains a large number of N-epsilon(gamma-glutamyl)lysine cross-links and that only traces of these can be found in the soluble form of TG. Because such isopeptide bridges are generated usually by the action of a transglutaminase, it is reasonable to propose that the covalent polymerization of TG in the g-lobules is under the control of this enzyme. Soluble TG was shown to be a substrate for transglutaminase in vitro; moreover, the presence of transglutaminase was demonstrated by immunofluorescence and by immunoblotting in freshly isolated bovine thyroid globules. With immunoelectron microscopy, transglutaminase was detected in the cytoplasm of thyrocytes, but not in compartments of the secretory pathway. Only one messenger RNA for transglutaminase was found by Northern blotting. Sequencing of the cloned gene failed to reveal a secretory signal, which supports the notion that the thyroid transglutaminase is the cytosolic type.. Apparently, the enzyme reaches the lumen of the follicle by an as yet unknown pathway to catalyze the covalent cross-linking of thyroid globules in this extracellular compartment.	Univ Bonn, Inst Zellbiol, D-53121 Bonn, Germany; Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA; Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA	University of Bonn; Washington University (WUSTL); Northwestern University	Herzog, V (corresponding author), Univ Bonn, Inst Zellbiol, Ulrich Haberland Str 61A, D-53121 Bonn, Germany.		Heuser, John/H-5940-2012; Brix, Klaudia/F-5072-2013	Brix, Klaudia/0000-0002-4476-0357	NHLBI NIH HHS [HL-02212] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APTE AN, 1993, BIOTECHNIQUES, V15, P890; Baudry N, 1998, BIOCHEM BIOPH RES CO, V242, P292, DOI 10.1006/bbrc.1997.7952; BELYAVSKY A, 1989, NUCLEIC ACIDS RES, V17, P2919, DOI 10.1093/nar/17.8.2919; Berndorfer U, 1996, J CLIN ENDOCR METAB, V81, P1918, DOI 10.1210/jc.81.5.1918; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brix K, 1996, ENDOCRINOLOGY, V137, P1963, DOI 10.1210/en.137.5.1963; CARIELLO L, 1984, BIOCHEMISTRY-US, V23, P6843, DOI 10.1021/bi00321a087; CORTESE F, 1976, EUR J BIOCHEM, V68, P121, DOI 10.1111/j.1432-1033.1976.tb10770.x; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; EYRE DR, 1984, ANNU REV BIOCHEM, V53, P717, DOI 10.1146/annurev.bi.53.070184.003441; FINK ML, 1980, P NATL ACAD SCI-BIOL, V77, P4564, DOI 10.1073/pnas.77.8.4564; FOERDER CA, 1977, P NATL ACAD SCI USA, V74, P4214, DOI 10.1073/pnas.74.10.4214; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; FRY SC, 1982, BIOCHEM J, V204, P449, DOI 10.1042/bj2040449; HALL HG, 1978, CELL, V15, P343, DOI 10.1016/0092-8674(78)90003-X; HAYDEN LJ, 1970, PFLUG ARCH EUR J PHY, V321, P173, DOI 10.1007/BF00586371; HERZOG V, 1992, J CELL BIOL, V118, P1071, DOI 10.1083/jcb.118.5.1071; HERZOG V, 1983, METHOD ENZYMOL, V98, P447; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; HEUSER J, 1989, J CELL BIOL, V108, P401, DOI 10.1083/jcb.108.2.401; Kohn L. D., 1994, THYROID DIS BASIC SC, P59; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lemansky P, 1998, EUR J CELL BIOL, V76, P53, DOI 10.1016/S0171-9335(98)80017-4; LISSITZKY S, 1984, J ENDOCRINOL INVEST, V7, P65, DOI 10.1007/BF03348380; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; LU S, 1995, J BIOL CHEM, V270, P9748, DOI 10.1074/jbc.270.17.9748; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MERCKEN L, 1985, NATURE, V316, P647, DOI 10.1038/316647a0; MOORE S, 1948, J BIOL CHEM, V176, P367; MOZINGO NM, 1991, DEV BIOL, V146, P148, DOI 10.1016/0012-1606(91)90455-C; MURTHY SNP, 1991, P NATL ACAD SCI USA, V88, P10601, DOI 10.1073/pnas.88.23.10601; NAKANISHI K, 1991, EUR J BIOCHEM, V202, P15, DOI 10.1111/j.1432-1033.1991.tb16338.x; Oswald A., 1899, Z PHYSL CHEM, V27, P14; RALL JE, 1974, PERSPECT BIOL MED, V17, P218; ROBBINS J, 1980, METABOLIC CONTROL DI, P1325; ROUSSET B, 1989, J BIOL CHEM, V264, P12620; SCHNEIDER PB, 1964, ENDOCRINOLOGY, V74, P973, DOI 10.1210/endo-74-6-973; SIEBENLIST KR, 1994, J BIOL CHEM, V269, P28414; SIMON M, 1985, CELL, V40, P677, DOI 10.1016/0092-8674(85)90216-8; SMEDS S, 1972, ENDOCRINOLOGY, V91, P1300, DOI 10.1210/endo-91-5-1300; STEINHOFF M, 1994, EUR J CELL BIOL, V65, P49; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WILLIAMS.HG, 1972, P NATL ACAD SCI USA, V69, P2322, DOI 10.1073/pnas.69.8.2322; WOLLMAN SH, 1980, THYROID GLAND, P1; WOLLMAN SH, 1969, LYSOSOMES BIOLOGY PA, V2, P483; ZELIGS JD, 1977, J CELL BIOL, V72, P584, DOI 10.1083/jcb.72.3.584	47	32	32	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2000	14	7					1005	1014		10.1096/fasebj.14.7.1005	http://dx.doi.org/10.1096/fasebj.14.7.1005			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	309CG	10783156				2022-12-28	WOS:000086749500020
J	Landini, G; Iannaccone, PM				Landini, G; Iannaccone, PM			Modeling of mosaic patterns in chimeric liver and adrenal cortex: algorithmic organogenesis?	FASEB JOURNAL			English	Article						chimeras; cell division; fractals; computer model	BUD SITE SELECTION; FRACTAL GEOMETRY; YEAST	If organogenesis were a completely deterministic process, then the amount of information required to store the spatial position and fate of every cell in vertebrate organisms would be larger than the total information that could be contained in their genomes, This suggests that the instructions of developmental mechanisms involved in organogenesis, coded iu DNA, must be at least in part procedural or algorithmically based. Chimeric mosaic patterns in rat livers have been shown to be isotropic and to have fractal profiles (D similar to 1.3) whereas adrenal gland mosaics show a less irregular radial pattern, with lower fractal dimension (D similar to 1.2) than in the liver. These findings suggested a possible model of parenchyma generation, We propose that during organogenesis in both liver and adrenal cortex, the same basic mechanism is directed to organ mass enlargement, whereas the differences observed in mosaic patterns between the organs could be due to the control of a single parameter, namely, a form of contact inhibition. Computer simulations in two dimensions returned comparable results in both the fractal dimension value of mosaic patches and appearance of the mosaic 'tissues', as observed histologically in chimeras. This suggests that position information and locomotion of cells would not be required to produce the mosaic pattern observed in chimeras.	Univ Birmingham, Oral Pathol Unit, Sch Dent, Birmingham B4 6NN, W Midlands, England; Northwestern Univ, Sch Med, Dept Pediat, Chicago, IL 60614 USA; Northwestern Univ, Sch Med, Childrens Mem Inst Educ & Res, Chicago, IL 60614 USA; Childrens Mem Hosp, Chicago, IL 60614 USA	University of Birmingham; Northwestern University; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago	Landini, G (corresponding author), Univ Birmingham, Oral Pathol Unit, Sch Dent, St Chads Queensway, Birmingham B4 6NN, W Midlands, England.			Landini, Gabriel/0000-0002-9689-0989				BODENSTEIN L, 1987, CURR TOP DEV BIOL, V21, P1; BODENSTEIN L, 1986, CELL DIFFER DEV, V19, P19, DOI 10.1016/0045-6039(86)90022-9; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; Freeman H., 1974, Computing Surveys, V6, P57, DOI 10.1145/356625.356627; Freeman H., 1961, IRE T ELECT COMPUT, V10, P260, DOI [10.1109/TEC.1961.5219197, DOI 10.1109/TEC.1961.5219197]; Graham GS, 1916, J MED RES, V34, P241; Iannaccone P, 1998, FRACTALS AND BEYOND, P53; IANNACCONE PM, 1987, J EXP ZOOL, V243, P217, DOI 10.1002/jez.1402430207; IANNACCONE PM, 1990, FASEB J, V4, P1508, DOI 10.1096/fasebj.4.5.2307328; IANNACCONE PM, 1989, J THEOR BIOL, V141, P363, DOI 10.1016/S0022-5193(89)80119-5; KHOKHA MK, 1994, DEV BIOL, V165, P545, DOI 10.1006/dbio.1994.1274; LANDINI G, 1996, FRACTAL GEOMETRY BIO, P205; Landini G, 1993, FRACTALS, V1, P239, DOI 10.1142/S0218348X93000241; Mandelbrot B.B., 1982, FRACTAL GEOMETRY NAT, P480; MANDELBROT BB, 1984, NATURE, V308, P721, DOI 10.1038/308721a0; Morley SD, 1996, MOL ENDOCRINOL, V10, P585, DOI 10.1210/me.10.5.585; NG YK, 1992, DEV BIOL, V151, P419, DOI 10.1016/0012-1606(92)90182-G; NG YK, 1992, CURR TOP DEV BIOL, V27, P235, DOI 10.1016/S0070-2153(08)60536-0; Nurse P, 1998, NAT MED, V4, P1103, DOI 10.1038/2594; RANSOM R, 1981, COMPUTERS EMBRYOS MO, pCH7; SUNG KLP, 1992, J CELL SCI, V103, P259; Thie M, 1998, HUM REPROD, V13, P3211, DOI 10.1093/humrep/13.11.3211; WEINBERG WC, 1985, SCIENCE, V227, P524, DOI 10.1126/science.3966159	24	12	12	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2000	14	5					823	827		10.1096/fasebj.14.5.823	http://dx.doi.org/10.1096/fasebj.14.5.823			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301DH	10744639				2022-12-28	WOS:000086292700020
J	Arredondo, M; Munoz, P; Mura, CV; Nunez, MT				Arredondo, M; Munoz, P; Mura, CV; Nunez, MT			HFE inhibits apical iron uptake by intestinal epithelial (Caco-2) cells	FASEB JOURNAL			English	Article									Univ Chile, Fac Ciencias, Dept Biol, Santiago, Chile; Univ Chile, Inst Nutr & Tecnol Alimentos, Santiago 11, Chile; Univ Chile, Millennium Inst Adv Studies Cell Biol & Biotechno, Santiago, Chile	Universidad de Chile; Universidad de Chile; Universidad de Chile	Nunez, MT (corresponding author), Univ Chile, Fac Ciencias, Dept Biol, Casilla 653, Santiago, Chile.		Nunez, Marco/H-6348-2014	Nunez, Marco/0000-0002-1967-8570					0	32	33	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1276	1278		10.1096/fj.00-0578fje	http://dx.doi.org/10.1096/fj.00-0578fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344112				2022-12-28	WOS:000168655200034
J	Kress, M; Fickenscher, H				Kress, M; Fickenscher, H			Infection by human varicella-zoster virus confers norepinephrine sensitivity to sensory neurons from rat dorsal root ganglia	FASEB JOURNAL			English	Article						DRG cells; norepinephrine; postherpetic neuralgia; sensory neurons	HERPES-ZOSTER; ADULT-RAT; ACCUMULATION; ATTENUATION; LATENCY; STRAIN; CELLS; MODEL; PAIN; DNA	Varicella-zoster virus (VZV) is a widespread human herpes virus causing chicken pox on primary infection and persisting in sensory neurons. Reactivation causes shingles, which are characterized by severe pain and often lead to postherpetic neuralgia, To elucidate the mechanisms of VZV-associated hyperalgesia, we elaborated an in vitro model for the VZV infection of sensory neurons from rat dorsal root ganglia. Between 35 and 50% of the neurons showed strong expression of the immediate-early virus antigens IE62 and IE63 and the late glycoprotein gE. When the intracellular calcium concentration was monitored microfluorometrically for individual cells after infection, the sensitivity to GABA or capsaicin was similar in controls and in VZV-infected neurons. However, the baseline calcium concentration was increased. Neurons became de novo sensitive to adrenergic stimulation after VZV infection, Norepinephrine-responsive neurons were more frequent and calcium responses to norepinephrine were significantly higher after infection with wild-type isolates than with the attenuated vaccine strain OKA. The adrenergic agonists phenylephrine and isoproterenol had similar efficacy. We suggest that the infection with wild-type VZV isolates confers norepinephrine sensitivity to sensory neurons by using alpha (1)-and/or beta (1)-adrenergic receptors providing a model for the pathophysiology of the severe pain associated with the acute reactivation of VZV.	Univ Erlangen Nurnberg, Inst Physiol & Expt Pathophysiol, D-91054 Erlangen, Germany; Univ Erlangen Nurnberg, Inst Klin & Mol Virol, D-91054 Erlangen, Germany	University of Erlangen Nuremberg; University of Erlangen Nuremberg	Kress, M (corresponding author), Univ Erlangen Nurnberg, Inst Physiol & Expt Pathophysiol, Univ Str 17, D-91054 Erlangen, Germany.	kress@physiologie1.uni-erlangen.de	Fickenscher, Helmut/J-9655-2019; Fickenscher, Helmut/A-3004-2010	Fickenscher, Helmut/0000-0003-0043-1153; Kress, Michaela/0000-0002-8921-7470				Abdulla FA, 1997, J NEUROSCI, V17, P1633; ALEXANDER SPH, 1999, TRENDS PHARMACOL SCI, V20, P11; Ali Z, 1999, J NEUROPHYSIOL, V81, P455, DOI 10.1152/jn.1999.81.2.455; Annunziato P, 1998, J INFECT DIS, V178, pS48, DOI 10.1086/514261; [Anonymous], 1999, MMWR Recomm Rep, V48, P1; Arvin AM, 1996, ANNU REV MICROBIOL, V50, P59, DOI 10.1146/annurev.micro.50.1.59; Choi B, 1997, PAIN, V69, P55, DOI 10.1016/S0304-3959(96)03245-9; CROEN KD, 1988, P NATL ACAD SCI USA, V85, P9773, DOI 10.1073/pnas.85.24.9773; DAVISON AJ, 1986, J GEN VIROL, V67, P1759, DOI 10.1099/0022-1317-67-9-1759; Dittert I, 1998, J NEUROSCI METH, V82, P195, DOI 10.1016/S0165-0270(98)00051-X; Dong SJ, 1999, ADV BIOSENS, V4, P1; Fleetwood-Walker SM, 1999, J GEN VIROL, V80, P2433, DOI 10.1099/0022-1317-80-9-2433; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HENKEN DB, 1991, J NEUROL SCI, V105, P29, DOI 10.1016/0022-510X(91)90114-M; Kennedy PGE, 1998, P NATL ACAD SCI USA, V95, P4658, DOI 10.1073/pnas.95.8.4658; KINCHINGTON PR, 1990, J VIROL, V64, P4540, DOI 10.1128/JVI.64.9.4540-4548.1990; KRAUSE PR, 1995, J PEDIATR-US, V127, P518, DOI 10.1016/S0022-3476(95)70106-0; Kress M, 1999, J NEUROPHYSIOL, V81, P2612, DOI 10.1152/jn.1999.81.6.2612; LaGuardia JJ, 1999, J VIROL, V73, P8571, DOI 10.1128/JVI.73.10.8571-8577.1999; Martinez E, 1998, CLIN INFECT DIS, V27, P1510, DOI 10.1086/515019; MAYER ML, 1986, J NEUROSCI, V6, P391; MCLACHLAN EM, 1993, NATURE, V363, P543, DOI 10.1038/363543a0; MERVILLELOUIS MP, 1989, J VIROL, V63, P3155, DOI 10.1128/JVI.63.7.3155-3160.1989; Moffat JF, 1998, J VIROL, V72, P965, DOI 10.1128/JVI.72.2.965-974.1998; MYERS MG, 1991, J INFECT DIS, V163, P746, DOI 10.1093/infdis/163.4.746; OLIVIER M, 1992, J IMMUNOL, V148, P1188; Petersen M, 1996, PAIN, V67, P391, DOI 10.1016/0304-3959(96)03146-6; SADZOTDELVAUX C, 1995, J GEN VIROL, V76, P2875, DOI 10.1099/0022-1317-76-11-2875; SADZOTDELVAUX C, 1990, J NEUROSCI RES, V26, P83, DOI 10.1002/jnr.490260110; SadzotDelvaux C, 1995, NEUROLOGY, V45, pS18, DOI 10.1212/WNL.45.12_Suppl_8.S18; SATO J, 1991, SCIENCE, V251, P1608, DOI 10.1126/science.2011742; STEFANINI M, 1967, NATURE, V216, P173, DOI 10.1038/216173a0; WAYMAN GA, 1995, J BIOL CHEM, V270, P24108, DOI 10.1074/jbc.270.41.24108; WELLER TH, 1992, J INFECT DIS, V166, pS1; WOOD JN, 1988, J NEUROSCI, V8, P3208; Wu CL, 2000, PAIN, V87, P121, DOI 10.1016/S0304-3959(00)00230-X; Zeilhofer HU, 1996, J NEUROPHYSIOL, V76, P2834, DOI 10.1152/jn.1996.76.5.2834	37	23	25	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2001	15	6					1037	1043		10.1096/fj.00-0440com	http://dx.doi.org/10.1096/fj.00-0440com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292665				2022-12-28	WOS:000167959300019
J	Bezombes, C; Segui, B; Cuvillier, O; Bruno, AP; Uro-Coste, E; Gouaze, V; Andrieu-Abadie, N; Carpentier, S; Laurent, G; Salvayre, R; Jaffrezou, JP; Levade, T				Bezombes, C; Segui, B; Cuvillier, O; Bruno, AP; Uro-Coste, E; Gouaze, V; Andrieu-Abadie, N; Carpentier, S; Laurent, G; Salvayre, R; Jaffrezou, JP; Levade, T			Lysosomal sphingomyelinase is not solicited for apoptosis signaling	FASEB JOURNAL			English	Article									CHU Rangueil, Lab Biochim Med, INSERM, U466, F-31403 Toulouse, France; Inst Claudius Regaud, INSERM, E9910, F-31052 Toulouse, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud	Levade, T (corresponding author), CHU Rangueil, Lab Biochim Med, INSERM, U466, 1 Ave Jean Poulhes, F-31403 Toulouse, France.		Levade, Thierry/O-8948-2014; Gouaze-Andersson, Valerie/O-9180-2014; Bezombes, Christine/AAC-1724-2020; Andrieu-Abadie, Nathalie/N-6793-2013; Ségui, Bruno/O-8957-2014; CUVILLIER, Olivier/B-2567-2009; CUVILLIER, Olivier/S-1631-2019; Bezombes, Christine/G-2743-2017; Bezombes, christine/X-8479-2019	Gouaze-Andersson, Valerie/0000-0002-1797-515X; Andrieu-Abadie, Nathalie/0000-0003-2698-1970; Ségui, Bruno/0000-0002-6119-1889; CUVILLIER, Olivier/0000-0003-3346-375X; CUVILLIER, Olivier/0000-0003-3346-375X; Bezombes, christine/0000-0003-4079-4872					0	49	51	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					297	299						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156942				2022-12-28	WOS:000166872900008
J	Blander, G; Zalle, N; Leal, JFM; Bar-Or, RL; Yu, CE; Oren, M				Blander, G; Zalle, N; Leal, JFM; Bar-Or, RL; Yu, CE; Oren, M			The Warner syndrome protein contributes to induction of p53 by DNA damage	FASEB JOURNAL			English	Article									Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Vet Affairs Med Ctr, Seattle, WA 98108 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Neurol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	Weizmann Institute of Science; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Oren, M (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.		Leal, Juan F Martinez/N-6328-2013	Leal, Juan F Martinez/0000-0002-7538-0875; Oren, Moshe/0000-0003-4311-7172					0	32	34	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2000	14	14					2138	2140						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11023999				2022-12-28	WOS:000165190800004
J	Orpiszewski, J; Schormann, N; Kluve-Beckerman, B; Liepnieks, JJ; Benson, MD				Orpiszewski, J; Schormann, N; Kluve-Beckerman, B; Liepnieks, JJ; Benson, MD			Protein aging hypothesis of Alzheimer disease	FASEB JOURNAL			English	Article						amyloid; beta-protein; succinimide; isoaspartate; amyloidosis	AMYLOID-BETA-PEPTIDE; L-ISOASPARTYL METHYLTRANSFERASE; IN-VITRO; AMINOSUCCINYL PEPTIDES; SUCCINIMIDE FORMATION; BOND ISOMERIZATION; HAIRPIN FORMATION; TRANSGENIC MICE; MAMMALIAN BRAIN; NEUROTOXICITY	Alzheimer disease (AD), the most common form of aging-related neurodegenerative disorders, is associated with formation of fibrillar deposits of amyloid beta-protein (A beta), While the direct involvement of A beta in AD has been well documented, the relations between AP production, amyloid formation, and neurodegeneration remain unknown. We propose that AD is initiated by a protein aging-related structural transformation in soluble A beta. We hypothesize that spontaneous chemical modification of aspartyl residues in A beta to transient succinimide induces a non-native conformation in a fraction of soluble A beta, rendering it amyloidogenic and neurotoxic, Conformationally altered A beta is characterized by increased stability in solution and the presence of a nonnative p-turn that determines folding of A beta in solution and the structure of A beta subunits incorporated into amyloid fibrils, While the soluble 'non-native' A beta is both the factor triggering the neurodegenerative cascade and the precursor of amyloid plaques, these two events result from interaction of A beta with different sets of cellular components and need not coincide in space and time. Extensive literature data and experimental evidence are provided in support of this hypothesis.-Orpiszewski, J., Schormann, N., Kluve-Beckerman, B., Liepnieks, J. J., Benson, M. D. Protein aging hypothesis of Alzheimer disease.	Aprot Corp, Carmel, IN 46082 USA; Indiana Univ, Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA; Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center	Orpiszewski, J (corresponding author), Aprot Corp, POB 3813, Carmel, IN 46082 USA.	aprot@excite.com						Aswad DW, 1995, CRC SERIES ANAL BIOT; Baldwin RL, 1999, TRENDS BIOCHEM SCI, V24, P77, DOI 10.1016/S0968-0004(98)01345-0; Blanco F, 1998, CURR OPIN STRUC BIOL, V8, P107, DOI 10.1016/S0959-440X(98)80017-1; Brovia V, 1996, J NEUROCHEM, V67, P382; CAPASSO S, 1992, ACTA CRYSTALLOGR B, V48, P285, DOI 10.1107/S010876819101368X; Capasso S, 1995, CHIRALITY, V7, P605, DOI 10.1002/chir.530070808; CAPASSO S, 1984, ACTA CRYSTALLOGR C, V43, P1607; Chui DH, 1999, NAT MED, V5, P560, DOI 10.1038/8438; CLARKE S, 1987, INT J PEPT PROT RES, V30, P808, DOI 10.1111/j.1399-3011.1987.tb03390.x; Coles M, 1998, BIOCHEMISTRY-US, V37, P11064, DOI 10.1021/bi972979f; David CL, 1998, J BIOL CHEM, V273, P32063, DOI 10.1074/jbc.273.48.32063; DEALBA E, 1996, FOLDING DESIGN, V26, P133; DYSON HJ, 1995, FASEB J, V9, P37, DOI 10.1096/fasebj.9.1.7821757; FABIAN H, 1994, EUR J BIOCHEM, V221, P959, DOI 10.1111/j.1432-1033.1994.tb18811.x; Fersht AR, 1997, CURR OPIN STRUC BIOL, V7, P3, DOI 10.1016/S0959-440X(97)80002-4; Fonseca MI, 1999, EXP NEUROL, V157, P277, DOI 10.1006/exnr.1999.7058; Fukuda H, 1999, BIOORG MED CHEM LETT, V9, P953, DOI 10.1016/S0960-894X(99)00121-3; GarzonRodriguez W, 1997, J BIOL CHEM, V272, P21037, DOI 10.1074/jbc.272.34.21037; Ghetti B, 1996, BRAIN PATHOL, V6, P127, DOI 10.1111/j.1750-3639.1996.tb00796.x; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Haque TS, 1997, J AM CHEM SOC, V119, P2303, DOI 10.1021/ja963653h; HAQUE TS, 1994, J AM CHEM SOC, V116, P4105, DOI 10.1021/ja00088a067; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Hui JO, 1998, ARCH BIOCHEM BIOPHYS, V358, P377, DOI 10.1006/abbi.1998.0884; JOHNSON BA, 1991, NEUROBIOL AGING, V12, P19, DOI 10.1016/0197-4580(91)90034-H; JOHNSON BA, 1985, J NEUROCHEM, V45, P1119, DOI 10.1111/j.1471-4159.1985.tb05531.x; Kim E, 1997, P NATL ACAD SCI USA, V94, P6132, DOI 10.1073/pnas.94.12.6132; Kortemme T, 1998, SCIENCE, V281, P253, DOI 10.1126/science.281.5374.253; Kuo YM, 1998, BBA-MOL BASIS DIS, V1406, P291, DOI 10.1016/S0925-4439(98)00014-3; Kuo YM, 1996, J BIOL CHEM, V271, P4077; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; LOWENSON JD, 1994, TRENDS CARDIOVAS MED, V4, P3, DOI 10.1016/1050-1738(94)90019-1; MAY PC, 1997, ALZHEIMERS DIS REV, V2, P15; Moechars D, 1999, NEUROSCIENCE, V91, P819, DOI 10.1016/S0306-4522(98)00599-5; MORI H, 1994, TOHOKU J EXP MED, V174, P251, DOI 10.1620/tjem.174.251; Munoz V, 1997, NATURE, V390, P196, DOI 10.1038/36626; Najbauer J, 1996, BIOCHEMISTRY-US, V35, P5183, DOI 10.1021/bi953063g; Neira JL, 1996, FOLD DES, V1, P231, DOI 10.1016/S1359-0278(96)00034-X; Neve RL, 1998, TRENDS NEUROSCI, V21, P15, DOI 10.1016/S0166-2236(97)01168-5; Noguchi S, 1998, J MOL BIOL, V278, P231, DOI 10.1006/jmbi.1998.1674; Orpiszewski J, 1999, J MOL BIOL, V289, P413, DOI 10.1006/jmbi.1999.2768; Orpiszewski J, 1996, J BIOL CHEM, V271, P22965, DOI 10.1074/jbc.271.38.22965; PARANANDI MV, 1995, BIOCHEM BIOPH RES CO, V212, P442, DOI 10.1006/bbrc.1995.1989; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; POTTER SM, 1993, PROTEIN SCI, V2, P1648, DOI 10.1002/pro.5560021011; RamirezAlvarado M, 1996, NAT STRUCT BIOL, V3, P604, DOI 10.1038/nsb0796-604; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; ROHER AE, 1993, J BIOL CHEM, V268, P3072; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; SHAPIRA R, 1988, J NEUROCHEM, V50, P69, DOI 10.1111/j.1471-4159.1988.tb13231.x; Sharman GJ, 1997, CHEM COMMUN, P1955; SIBANDA BL, 1985, NATURE, V316, P170, DOI 10.1038/316170a0; Small DH, 1998, NEUROCHEM RES, V23, P795, DOI 10.1023/A:1022471729291; Solomon B, 1997, P NATL ACAD SCI USA, V94, P4109, DOI 10.1073/pnas.94.8.4109; SZENDREI GI, 1994, EUR J BIOCHEM, V226, P917, DOI 10.1111/j.1432-1033.1994.t01-1-00917.x; Szendrei GI, 1996, INT J PEPT PROT RES, V47, P289; TAM J P, 1988, Peptide Research, V1, P6; TOMIYAMA T, 1994, J BIOL CHEM, V269, P10205; Valazquez P, 1997, NAT MED, V3, P77, DOI 10.1038/nm0197-77; Valle, 1995, METABOLIC BASIS INHE, P4159; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; WOOD SJ, 1995, BIOCHEMISTRY-US, V34, P724, DOI 10.1021/bi00003a003; Yan SD, 1997, NATURE, V389, P689; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Yang AS, 1996, J MOL BIOL, V259, P873, DOI 10.1006/jmbi.1996.0364; Zhou HXX, 1996, NAT STRUCT BIOL, V3, P446, DOI 10.1038/nsb0596-446	69	46	50	2	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2000	14	9					1255	1263		10.1096/fasebj.14.9.1255	http://dx.doi.org/10.1096/fasebj.14.9.1255			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834947				2022-12-28	WOS:000087427300022
J	Zemel, MB; Shi, H; Greer, B; Dirienzo, D; Zemel, PC				Zemel, MB; Shi, H; Greer, B; Dirienzo, D; Zemel, PC			Regulation of adiposity by dietary calcium	FASEB JOURNAL			English	Article						human adipocytes; lipolysis; agouti; PTH	CYTOSOLIC-FREE CALCIUM; INSULIN-RESISTANCE; HUMAN ADIPOCYTES; RAT ADIPOCYTES; AGOUTI GENE; HYPERTENSION; OBESITY; MECHANISMS	Recent data from this laboratory demonstrate that increasing adipocyte intracellular Ca2+ results in a coordinated stimulation of lipogenesis and inhibition of lipolysis. We have also noted that increasing dietary calcium of obese patients for 1 year resulted in a 4.9 kg loss of body fat (P<0.01). Accordingly, we tested the possibility that calcitrophic hormones may act on adipocytes to increase Ca2+ and lipid metabolism by measuring the effects of 1,25(OH)(2)-D in primary cultures of human adipocytes, and found significant, sustained increases in intracellular Ca2+ and a corresponding marked inhibition of lipolysis (EC50 similar to 50 pM; P<0.001), suggesting that dietary calcium could reduce adipocyte mass by suppressing 1,25-(OH)(2)-D. To test this hypothesis, we placed transgenic mice expressing the agouti gene specifically in adipocytes on a low (0.4%) Ca/high fat/high sucrose diet either unsupplemented or with 25 or 50% of the protein replaced by non-fat dry milk or supplemented to 1.2% Ca with CaCO3 for 6 wk. Weight gain and fat pad mass were reduced by 26-39% by the three high calcium diets (P<0.001). The high calcium diets exerted a corresponding 51% inhibition of adipocyte fatty acid synthase expression and activity (P<0.002) and stimulation of lipolysis by 3.4- to 5.2-fold (P<0.015). This concept of calcium modulation of adiposity was further evaluated epidemiologically in the NHANES III data set. After controlling for energy intake, relative risk of being in the highest quartile of body fat was set to 1.00 for the lowest quartile of Ca intake and was reduced to 0.75, 0.40, and 0.16 for the second, third, and fourth quartiles, respectively, of calcium intake for women (n=380;P<0.0009); a similar inverse relationship was also noted in men (n=7114; P<0.0006). Thus, increasing dietary calcium suppresses adipocyte intracellular Ca2+ and thereby modulates energy metabolism and attenuates obesity risk.	Univ Tennessee, Dept Nutr, Knoxville, TN 37996 USA; Natl Dairy Council, Rosemont, IL 60018 USA	University of Tennessee System; University of Tennessee Knoxville	Zemel, MB (corresponding author), Univ Tennessee, Dept Nutr, 1215 W Cumberland Ave,Room 229, Knoxville, TN 37996 USA.	mzemel@utk.edu		Zemel, Michael/0000-0003-4104-5750				Barbagallo M, 1997, J CLIN ENDOCR METAB, V82, P1761, DOI 10.1210/jc.82.6.1761; BOOBIS LH, 1983, CLIN CHIM ACTA, V132, P173, DOI 10.1016/0009-8981(83)90245-0; BYYNY RL, 1992, AM J HYPERTENS, V5, P459, DOI 10.1093/ajh/5.7.459; DRAZNIN B, 1988, J CLIN INVEST, V82, P1848, DOI 10.1172/JCI113801; DRAZNIN B, 1987, J BIOL CHEM, V262, P14385; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Jones BH, 1996, AM J PHYSIOL-ENDOC M, V270, pE192, DOI 10.1152/ajpendo.1996.270.1.E192; Kim JH, 1997, AM J PHYSIOL-ENDOC M, V272, pE379, DOI 10.1152/ajpendo.1997.272.3.E379; Kim JH, 1996, FASEB J, V10, P1646, DOI 10.1096/fasebj.10.14.9002558; MANNE J, 1995, P NATL ACAD SCI USA, V92, P4721, DOI 10.1073/pnas.92.11.4721; Moustaid N, 1996, J NUTR, V126, P865, DOI 10.1093/jn/126.4.865; Mynatt RL, 1997, P NATL ACAD SCI USA, V94, P919, DOI 10.1073/pnas.94.3.919; National Center for Health Statistics, 1994, PLAN OP 3 NAT HLTH N; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Resnick L, 1999, PROG CARDIOVASC DIS, V42, P1, DOI 10.1016/S0033-0620(99)70006-X; RESNICK LM, 1991, HYPERTENSION, V17, P951, DOI 10.1161/01.HYP.17.6.951; SEGAL KR, 1988, AM J CLIN NUTR, V47, P7, DOI 10.1093/ajcn/47.1.7; Shah BV, 1996, SUDAAN USERS MANUAL; SHAN J, 1993, AM J HYPERTENS, V6, P983, DOI 10.1093/ajh/6.12.983; SHI H, 1999, IN PRESS FASEB J; Summerbell CD, 1998, BRIT MED J, V317, P1487, DOI 10.1136/bmj.317.7171.1487; Tebar F, 1996, ENDOCRINOLOGY, V137, P4181, DOI 10.1210/en.137.10.4181; WILLARD DH, 1995, BIOCHEMISTRY-US, V34, P12341, DOI 10.1021/bi00038a030; Xue BZ, 1998, FASEB J, V12, P1391, DOI 10.1096/fasebj.12.13.1391; ZEMEL MB, 1995, P NATL ACAD SCI USA, V92, P4733, DOI 10.1073/pnas.92.11.4733; ZEMEL MB, 1999, FASEB J, V13; ZEMEL MB, 1995, OBES RES, V3, pS338	27	704	759	1	50	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2000	14	9					1132	1138		10.1096/fasebj.14.9.1132	http://dx.doi.org/10.1096/fasebj.14.9.1132			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834935				2022-12-28	WOS:000087427300010
J	Garcia-Ruiz, C; Colell, A; Paris, R; Fernandez-Checa, JC				Garcia-Ruiz, C; Colell, A; Paris, R; Fernandez-Checa, JC			Direct interaction of GD3 ganglioside with mitochondria generates reactive oxygen species followed by mitochondrial permeability transition, cytochrome c release, and caspase activation	FASEB JOURNAL			English	Article						oxidative stress; apoptosis; necrosis; glutathione	TUMOR-NECROSIS-FACTOR; CERAMIDE-INDUCED APOPTOSIS; ELECTRON-TRANSPORT CHAIN; RAT HEPATOCYTES; CANCER-CELLS; GLUTATHIONE; BCL-2; ACCUMULATION; REQUIREMENT; INHIBITION	Glycosphingolipids, including gangliosides, are emerging as signaling intermediates of extracellular stimuli. Because mitochondria play a key role in the orchestration of death signals, we assessed the interaction of GD3 ganglioside (GD3) with mitochondria and the subsequent cascade of events that culminate in cell death. In vitro studies with isolated mitochondria from rat liver demonstrate that GD3 elicited a burst of peroxide production within 15-30 min, which preceded the opening of the mitochondrial permeability transition, followed by cytochrome c (cyt c) release. These effects were mimicked by lactosylceramide and N-acetyl-sphingosine but not by sphinganine or sphingosine and were prevented by cyclosporin A and butylated hydroxytoluene (BHT). Reconstitution of mitochondria pre-exposed to GD3 with cytosol from rat liver in a cell-free system resulted in the proteolytic processing of procaspase 3 and subsequent caspase 3 activation. Intact hepatocytes or U937 cells selectively depleted of glutathione in mitochondria by 3-hydroxyl-4-pentenoate (HP) with the sparing of cytosol reduced glutathione (GSH) were sensitized to GD3, manifested as an apoptotic death. Inhibition of caspase 3 prevented the apoptotic phenotype of HP-treated cells caused by GD3 without affecting cell survival; in contrast, BHT fully protected HP-treated cells to GD3 treatment. Treatment of cells with tumor necrosis factor increased the level of GD3, whereas blockers of mitochondrial respiration at complex I and II protected sensitized cells to GD3 treatment. Thus, the effect of GD3 as a lipid death effector is determined by its interaction with mitochondria leading to oxidant-dependent caspase activation. Mitochondrial glutathione plays a key role in controlling cell survival through modulation of the oxidative stress induced by glycosphingolipids.	CSIC, Hosp Clin & Prov, Liver Unit, Inst Invest Biomed August Pi Suner,Dept Med, Barcelona, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Fernandez-Checa, JC (corresponding author), CSIC, Hosp Clin & Prov, Liver Unit, Inst Invest Biomed August Pi Suner,Dept Med, Villarroel 170, Barcelona, Spain.	checa@medicina.ub.es	Fernández-Checa, José Carlos/L-8342-2014; Colell, Anna/N-8710-2014; Garcia-Ruiz, Carmen/L-8211-2014	Fernández-Checa, José Carlos/0000-0003-3422-2990; Colell, Anna/0000-0001-5236-1834; Garcia-Ruiz, Carmen/0000-0002-2652-6102	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009526, P50AA011999] Funding Source: NIH RePORTER; NIAAA NIH HHS [P50 AA11999, AA 09526] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Bhunia AK, 1998, J BIOL CHEM, V273, P34349, DOI 10.1074/jbc.273.51.34349; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Braun JS, 1999, NAT MED, V5, P298, DOI 10.1038/6514; Colell A, 1998, GASTROENTEROLOGY, V115, P1541, DOI 10.1016/S0016-5085(98)70034-4; Cursio R, 1999, FASEB J, V13, P253, DOI 10.1096/fasebj.13.2.253; De Maria R, 1998, J EXP MED, V187, P897, DOI 10.1084/jem.187.6.897; Degli Esposti M, 1998, FEBS LETT, V430, P338, DOI 10.1016/S0014-5793(98)00688-7; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; ECHTEN G, 1993, J BIOL CHEM, V268, P5341; FARISS MW, 1987, METHOD ENZYMOL, V143, P101; Fernandez-Checa JC, 1998, SEMIN LIVER DIS, V18, P389, DOI 10.1055/s-2007-1007172; FERNANDEZCHECA JC, 1997, AM J PHYSIOL, V273, pF7; Garcia-Ruiz C, 1999, HEPATOLOGY, V30, p411A; GARCIARUIZ C, 1995, MOL PHARMACOL, V48, P825; GARCIARUIZ C, 1994, J CLIN INVEST, V94, P193, DOI 10.1172/JCI117306; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gudz TI, 1997, J BIOL CHEM, V272, P24154, DOI 10.1074/jbc.272.39.24154; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; Ishisaka R, 1998, FEBS LETT, V435, P233, DOI 10.1016/S0014-5793(98)01080-1; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Kristal BS, 1999, J BIOL CHEM, V274, P23169, DOI 10.1074/jbc.274.33.23169; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Lavie Y, 1997, J BIOL CHEM, V272, P1682, DOI 10.1074/jbc.272.3.1682; Lavie Y, 1996, J BIOL CHEM, V271, P19530, DOI 10.1074/jbc.271.32.19530; Lemasters JJ, 1999, AM J PHYSIOL-GASTR L, V276, pG1, DOI 10.1152/ajpgi.1999.276.1.G1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; MATYAS GR, 1987, BIOCHIM BIOPHYS ACTA, V921, P599, DOI 10.1016/0005-2760(87)90089-0; Morales A, 1998, INT J RADIAT ONCOL, V42, P191, DOI 10.1016/S0360-3016(98)00185-0; Morales A, 1997, J BIOL CHEM, V272, P30371, DOI 10.1074/jbc.272.48.30371; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Samali A, 1998, FEBS LETT, V431, P167, DOI 10.1016/S0014-5793(98)00740-6; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; SHAN XQ, 1993, CHEM RES TOXICOL, V6, P75, DOI 10.1021/tx00031a012; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Testi R, 1996, TRENDS BIOCHEM SCI, V21, P468, DOI 10.1016/S0968-0004(96)10056-6; Veldman RJ, 1998, BIOCHEM J, V331, P563, DOI 10.1042/bj3310563; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	50	158	160	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2000	14	7					847	858		10.1096/fasebj.14.7.847	http://dx.doi.org/10.1096/fasebj.14.7.847			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	309CG	10783138				2022-12-28	WOS:000086749500002
J	Tan, NS; Ho, B; Ding, JL				Tan, NS; Ho, B; Ding, JL			High-affinity LPS binding domain(s) in recombinant factor C of a horseshoe crab neutralizes LPS-induced lethality	FASEB JOURNAL			English	Article						Carcinoscorpius rotundicauda; novel secretory signal; endotoxin binding and neutralization	EPIDERMAL GROWTH-FACTOR; CARCINOSCORPIUS-ROTUNDICAUDA; LIMULUS AMEBOCYTE; PICHIA-PASTORIS; HUMAN BLOOD; LIPID-A; ENDOTOXIN; EXPRESSION; LIPOPOLYSACCHARIDES; LACTOFERRIN	SSCrFCES is a biologically active, recombinant fragment of factor C, which is the endotoxin-sensitive serine protease of the LAL coagulation cascade. The similar to 38 kDa protein represents the LPS binding domain of factor C. A novel secretory signal directs the secretion of SSCrFCES into the culture supernatant of Drosophila cells, and hence it is readily purified. By differential ultrafiltration followed by preparative isoelectric membrane electrophoresis, SSCrFCES was purified as an isoelectrically homogeneous and stable monomeric protein. The ability of SSCrFCES to bind lipid A was analyzed using an ELISA-based assay as well as surface plasmon resonance. SSCrFCES exhibits high positive cooperativity of binding to two or three lipid A molecules, with a Hill's coefficient of 2.2. The 50% endotoxin-neutralizing concentration of SSCrFCES against 200 EU of endotoxin is similar to 0.069 mu M, suggesting that SSCrFCES is an effective inhibitor of LAL coagulation cascade. Although partially attenuated by human serum, as little as 1 mu M of,SSCrFCES inhibits the LPS-induced secretion of hTNF-alpha and hIL-8 by THP-1 and human peripheral blood mononuclear cells with greater potency than polymyxin B. SSCrFCES is noncytotoxic, with a clearance rate of 4.7 ml/min. The L.D.(90) of SSCrFCES for LPS lethality is achieved at 2 mu M. These results demonstrate the endotoxin-neutralizing capability of SSCrFCES in vitro and in vivo and its potential use for the treatment of endotoxin-induced septic shock.	Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore; Natl Univ Singapore, Dept Microbiol, Singapore 117543, Singapore	National University of Singapore; National University of Singapore	Ding, JL (corresponding author), Natl Univ Singapore, Dept Biol Sci, 10 Kent Ridge Crescent, Singapore 117543, Singapore.		Tan, Nguan Soon/A-2220-2011; Ding, Jeak/H-8057-2012	Tan, Nguan Soon/0000-0003-0136-7341; 				[Anonymous], 1994, J ENDOTOXIN RES, DOI DOI 10.1177/096805199400100407; APPELMELK BJ, 1994, INFECT IMMUN, V62, P2628, DOI 10.1128/IAI.62.6.2628-2632.1994; ARMSTRONG PB, 1982, EXP CELL RES, V140, P15, DOI 10.1016/0014-4827(82)90150-1; CLARE JJ, 1991, GENE, V105, P205, DOI 10.1016/0378-1119(91)90152-2; CORY AH, 1991, CANCER COMMUN, V3, P207, DOI 10.3727/095535491820873191; Ding Jeak L., 1995, Molecular Marine Biology and Biotechnology, V4, P90; FOWLER VM, 1984, J BIOL CHEM, V259, P5978; GALANOS C, 1979, P NATL ACAD SCI USA, V76, P5939, DOI 10.1073/pnas.76.11.5939; Hill A.V, 1910, J PHYSL, V40, piv, DOI DOI 10.1113/JPHYSIOL.1910.SP001386; Hussein AS, 1999, J BIOL CHEM, V274, P9312, DOI 10.1074/jbc.274.14.9312; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Karima R, 1999, MOL MED TODAY, V5, P123, DOI 10.1016/S1357-4310(98)01430-0; Kreutz M, 1997, IMMUNOLOGY, V92, P396, DOI 10.1046/j.1365-2567.1997.00365.x; LARRAMENDY ML, 1995, REV BRAS GENET, V18, P63; Laub PB, 1996, J PHARM SCI, V85, P393, DOI 10.1021/js9503744; LEHMANN V, 1987, J EXP MED, V165, P657, DOI 10.1084/jem.165.3.657; LEVIN J, 1970, J LAB CLIN MED, V75, P903; MARRA MN, 1990, J IMMUNOL, V144, P662; Muta T., 1996, Progress in Molecular and Subcellular Biology, V15, P154; MUTA T, 1991, J BIOL CHEM, V266, P6554; NAKAO A, 1995, EUR SURG RES, V27, P216, DOI 10.1159/000129402; ORIORDAN JF, 1983, ADV EXP MED BIOL, V159, P435; Pui AWM, 1997, J ENDOTOXIN RES, V4, P391, DOI 10.1177/096805199700400602; Ried C, 1996, J BIOL CHEM, V271, P28120, DOI 10.1074/jbc.271.45.28120; RIGHETTI PG, 1994, ELECTROPHORESIS, V15, P1040, DOI 10.1002/elps.11501501155; RISS RTL, 1992, MOL BIOL CELL S, V3, pA184; Roopashree SD, 1996, MOL MAR BIOL BIOTECH, V5, P334; ROOPASHREE SD, 1995, BIOCHEM MOL BIOL INT, V35, P841; SAMBROOK J, 1989, MOL CLONING LAB MANA; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; Tracey K J, 1990, Adv Surg, V23, P21; TSUCHIYA S, 1982, CANCER RES, V42, P1530; WARREN HS, 1992, INFECT IMMUN, V60, P2506, DOI 10.1128/IAI.60.6.2506-2513.1992; ZAHRINGER U, 1994, ADV CARBOHYD CHEM BI, V50, P211, DOI 10.1016/S0065-2318(08)60152-3; Zhang GH, 1999, INFECT IMMUN, V67, P1353, DOI 10.1128/IAI.67.3.1353-1358.1999	35	56	66	2	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2000	14	7					859	870		10.1096/fasebj.14.7.859	http://dx.doi.org/10.1096/fasebj.14.7.859			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	309CG	10783139				2022-12-28	WOS:000086749500003
J	Koushik, SV; Wang, J; Rogers, R; Moskophidis, D; Lambert, NA; Creazzo, TL; Conway, SJ				Koushik, SV; Wang, J; Rogers, R; Moskophidis, D; Lambert, NA; Creazzo, TL; Conway, SJ			Targeted inactivation of the sodium-calcium exchanger (Ncx1) results in the lack of a heartbeat and abnormal myofibrillar organization	FASEB JOURNAL			English	Article									Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA; Med Coll Georgia, Augusta Vet Affairs Med Ctr, Augusta, GA 30912 USA; Med Coll Georgia, Dept Cell Biol & Anat, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University	Conway, SJ (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, 1120 15th St,CB2803, Augusta, GA 30912 USA.								0	188	195	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1209	1211		10.1096/fj.00-0696fje	http://dx.doi.org/10.1096/fj.00-0696fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344090				2022-12-28	WOS:000168655200012
J	Schmidt-Ott, KM; Xu, AD; Tuschick, S; Liefeldt, L; Kresse, W; Verkhratsky, A; Kettenmann, H; Paul, M				Schmidt-Ott, KM; Xu, AD; Tuschick, S; Liefeldt, L; Kresse, W; Verkhratsky, A; Kettenmann, H; Paul, M			Hypoxia reverses dibutyryl-cAMP-induced stellation of cultured astrocytes via activation of the endothelin system	FASEB JOURNAL			English	Article									Free Univ Berlin, Benjamin Franklin Med Ctr, Inst Clin Pharmacol & Toxicol, D-14195 Berlin, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany; Jinan Univ, Dept Neurol, Guangzhou, Peoples R China	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Jinan University	Paul, M (corresponding author), Free Univ Berlin, Benjamin Franklin Med Ctr, Inst Clin Pharmacol & Toxicol, Garystr 5, D-14195 Berlin, Germany.		Schmidt-Ott, Kai/F-4588-2011; Kettenmann, Helmut/AAJ-5142-2021; Verkhratsky, Alexei/J-4527-2013; Paul, Martin/K-5425-2015	Schmidt-Ott, Kai/0000-0002-7700-7142; Verkhratsky, Alexei/0000-0003-2592-9898; Liefeldt, Lutz/0000-0002-3964-4685; Kettenmann, Helmut/0000-0001-8208-0291; Xu, An-Ding/0000-0003-3154-0985					0	10	10	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1227	1229		10.1096/fj.00-0625fje	http://dx.doi.org/10.1096/fj.00-0625fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344096				2022-12-28	WOS:000168655200018
J	Rosenthal, R; Thieme, H; Strauss, O				Rosenthal, R; Thieme, H; Strauss, O			Fibroblast growth factor receptor 2 (FGFR2) in brain neurons and retinal pigment epithelial cells act via stimulation of neuroendocrine L-type channels (Ca(v)1,3)	FASEB JOURNAL			English	Article						RPE; bek; flg; Ca2+ channels; bFGF	SENSITIVE CALCIUM CHANNELS; PROTEIN-KINASE-C; POTASSIUM CURRENTS; GENE-EXPRESSION; CULTURED RAT; CREB PHOSPHORYLATION; TYROSINE KINASE; PHOTORECEPTORS; ACTIVATION; RELEASE	In contrast to the fibroblast growth factor receptor 1 (FGFR1), little is known about intracellular signaling of FGFR2, The signaling cascade of FGFR2 was studied using the perforated patch configuration of the patch-clamp technique in cultured rat retinal pigment epithelial (RPE) cells that express both FGFR1 and FGFR2, Interaction of signaling proteins was studied using immunoprecipitation techniques with membrane proteins from RPE cells and freshly isolated rat brain, When Ba2+ currents through L-type channels were studied, extracellular application of bFGF (10 ng/ml) led to a shift of the steady-state activation to more negative values. In 50% of cells, an additional increase in maximal current amplitude was observed, This effect was blocked by the tyrosine kinase inhibitor lavendustin A (10(-5) M) but was not influenced by the FGFR1 blocker SU5402 (2x10(-5) M) or by the blocker for src-kinase herbimycin A (10(-5) M). Immunoprecipitation of FGFR2 led to coprecipitation of alpha 1D Ca2+ channel subunits and precipitation of alpha 1D subunits led to coprecipitation of FGFR2, Immunoprecipitation of FGFR1 did not result in the coprecipitation with alpha 1D Ca2+ channel subunits, The coprecipitation results were comparable when using brain tissue and RPE cells. The alpha 1D subunit-specific band were stained with antiphosphotyrosine antibodies, We conclude that FGFR2 acts via a different signaling cascade than FGFR1, This cascade involves an src-kinase-independent, close functional interaction of FGFR2 and the alpha subunit of neuroendocrine L-type channels.	Free Univ Berlin, Klinikum Benjamin Franklin, Inst Klin Physiol, D-12200 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Strauss, O (corresponding author), Free Univ Berlin, Klinikum Benjamin Franklin, Inst Klin Physiol, Hindenburgdamm 30, D-12200 Berlin, Germany.	strauss@ukbf.fu-berlin.de	Strauss, Olaf/AAA-6485-2019	Strauss, Olaf/0000-0002-6272-8596				AHLIJANIAN MK, 1990, NEURON, V4, P819, DOI 10.1016/0896-6273(90)90135-3; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; BOST LM, 1992, EXP EYE RES, V55, P727, DOI 10.1016/0014-4835(92)90177-T; CAMPOCHIARO PA, 1994, J CELL SCI, V107, P2459; Catterall WA, 1998, CELL CALCIUM, V24, P307, DOI 10.1016/S0143-4160(98)90055-0; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; EDWARDS RB, 1977, IN VITRO CELL DEV B, V13, P301; FAKTOROVICH EG, 1992, J NEUROSCI, V12, P3554; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; Guillonneau X, 1997, EXP CELL RES, V233, P198, DOI 10.1006/excr.1997.3542; HUGHES BA, 1990, J PHYSIOL-LONDON, V428, P273, DOI 10.1113/jphysiol.1990.sp018212; ISHIGOOKA H, 1993, INVEST OPHTH VIS SCI, V34, P2813; Klint Peter, 1999, Frontiers in Bioscience, V4, pD165, DOI 10.2741/Klint; KOIKE H, 1993, NEUROSCI LETT, V150, P57, DOI 10.1016/0304-3940(93)90107-V; KURIYAMA S, 1991, INVEST OPHTH VIS SCI, V32, P2882; LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249; Liu XP, 1998, OPHTHALMIC RES, V30, P302, DOI 10.1159/000055489; Mergler S, 1998, FASEB J, V12, P1125, DOI 10.1096/fasebj.12.12.1125; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; MURPHY TH, 1991, NEURON, V7, P625, DOI 10.1016/0896-6273(91)90375-A; PURO DG, 1991, J NEUROSCI, V11, P1873; ROSEN LB, 1995, ADV SEC MESS PHOSPH, V30, P225; STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526; STRAUSS O, 1993, BIOCHEM BIOPH RES CO, V191, P775, DOI 10.1006/bbrc.1993.1284; Strauss O, 1997, FASEB J, V11, P859, DOI 10.1096/fasebj.11.11.9285484; STRAUSS O, 1994, J CELL PHYSIOL, V160, P89, DOI 10.1002/jcp.1041600111; STRAUSS O, 1994, COMP BIOCHEM PHYS A, V109, P975, DOI 10.1016/0300-9629(94)90246-1; Tanihara H, 1997, PROG RETIN EYE RES, V16, P271, DOI 10.1016/S1350-9462(96)00028-6; TANIHARA H, 1993, INVEST OPHTH VIS SCI, V34, P413; TAO Q, 1994, J MEMBRANE BIOL, V141, P123; UEDA Y, 1995, INVEST OPHTH VIS SCI, V36, P373; UEDA Y, 1993, INVEST OPHTH VIS SCI, V34, P3408; WEN R, 1993, J PHYSIOL-LONDON, V465, P121, DOI 10.1113/jphysiol.1993.sp019669; WESTENBROEK RE, 1990, NATURE, V347, P281, DOI 10.1038/347281a0; WILLIAMS EJ, 1994, DEVELOPMENT, V120, P1685; YOSHIDA M, 1992, BIOCHEM BIOPH RES CO, V189, P66, DOI 10.1016/0006-291X(92)91526-V; ZHU DL, 1994, J CARDIOVASC PHARM, V23, P395, DOI 10.1097/00005344-199423030-00006	38	36	38	1	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2001	15	6					970	977		10.1096/fj.00-0188com	http://dx.doi.org/10.1096/fj.00-0188com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292657				2022-12-28	WOS:000167959300011
J	Herrera, B; Alvarez, AM; Sanchez, A; Fernandez, M; Roncero, C; Benito, M; Fabregat, I				Herrera, B; Alvarez, AM; Sanchez, A; Fernandez, M; Roncero, C; Benito, M; Fabregat, I			Reactive oxygen species (ROS) mediates the mitochondrial-dependent apoptosis induced by transforming growth factor beta in fetal hepatocytes	FASEB JOURNAL			English	Article						cytochrome c; caspases; Bcl-x	CYTOCHROME-C RELEASE; FACTOR BETA(1)-INDUCED APOPTOSIS; PERMEABILITY TRANSITION PORE; RAT HEPATOCYTES; CASPASE ACTIVATION; HYDROGEN-PEROXIDE; TGF-BETA; BAX; BCL-2; EXPRESSION	Treatment of fetal rat hepatocytes with transforming growth factor beta (TGF-beta) is followed by apoptotic cell death, Analysis of radical oxygen species (ROS) content and mitochondrial transmembrane potential (Delta Psi (m)), using specific fluorescent probes in FACScan and confocal microscopy, showed that TGF-beta mediates ROS production that precedes the loss of Delta Psi (m), the release of cytochrome c, and the activation of caspase 3. TGF-beta induces a decrease in the protein and mRNA levels of bcl-x(L), an antiapoptotic member of the Bcl-2 family. In contrast, there is no change in the expression and/or translocation of Bax, a proapoptotic member of the same family. EGF maintains Bcl-x(L), preventing Delta Psi (m) collapse and release of cytochrome c, The presence of radical scavengers blocks the decrease in bcl-x(L) levels, Delta Psi (m) collapse, cytochrome c release, and activation of caspase 3; in contrast, the presence of glutathione synthesis inhibitors such as BSO accentuated the effect. The incubation of fetal hepatocytes in the presence of ter-butyl-hydroperoxide alone produces a decrease in bcl-x(L). These results indicate that during the apoptosis mediated by TGF-beta in fetal hepatocytes, ROS may be responsible for the decrease in bcl-x(L) mRNA levels that precedes the loss of Delta Psi (m), the release of cytochrome c, and the activation of caspase 3, culminating in cell death.	Univ Complutense Madrid, Dept Bioquim & Biol Mol, Fac Farm,Inst Bioquim, CSIC,Ctr Mixto, E-28040 Madrid, Spain; Univ Complutense Madrid, Ctr Citometria Flujo & Microscopia Confocal, Fac Farm, E-28040 Madrid, Spain	Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Complutense University of Madrid	Fabregat, I (corresponding author), Univ Complutense Madrid, Dept Bioquim & Biol Mol, Fac Farm,Inst Bioquim, CSIC,Ctr Mixto, E-28040 Madrid, Spain.	isabelf@eucmax.sim.ucm.es	Roncero, Cesáreo/H-9039-2015; Sánchez, Aránzazu/H-7810-2015; Alvarez-Barrientos, Alberto/L-9299-2014; Herrera, Blanca/K-1803-2014; Fernández, Margarita/H-9077-2015; Benito, Manuel/J-5637-2014; Fabregat, Isabel/H-7038-2015	Roncero, Cesáreo/0000-0001-7608-8553; Sánchez, Aránzazu/0000-0001-9145-6633; Alvarez-Barrientos, Alberto/0000-0003-4761-0212; Herrera, Blanca/0000-0002-2415-2055; Fernández, Margarita/0000-0001-7207-2028; Benito, Manuel/0000-0002-7218-406X; Fabregat, Isabel/0000-0003-0136-8440				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Byrne AM, 1999, HEPATOLOGY, V29, P1523, DOI 10.1002/hep.510290521; CARACENI P, 1995, BBA-MOL CELL RES, V1268, P249, DOI 10.1016/0167-4889(95)00077-6; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Christensen JG, 1998, CELL GROWTH DIFFER, V9, P815; Constantini P., 1996, J BIOL CHEM, V271, P6746; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Fabregat I, 1996, FEBS LETT, V384, P14, DOI 10.1016/0014-5793(96)00266-9; Fadeel B, 1999, FASEB J, V13, P1647, DOI 10.1096/fasebj.13.13.1647; Fan GS, 1996, ONCOGENE, V12, P1909; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Garcia-Ruiz C, 2000, FASEB J, V14, P847, DOI 10.1096/fasebj.14.7.847; Garcia-Trevijano ER, 1999, HEPATOLOGY, V29, P960, DOI 10.1002/hep.510290346; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hildeman DA, 1999, IMMUNITY, V10, P735, DOI 10.1016/S1074-7613(00)80072-2; InayatHussain SH, 1997, HEPATOLOGY, V25, P1516, DOI 10.1002/hep.510250634; Jacobs-Helber SM, 1998, MOL CELL BIOL, V18, P3699, DOI 10.1128/MCB.18.7.3699; Karbowski M, 1999, FREE RADICAL BIO MED, V26, P396, DOI 10.1016/S0891-5849(98)00209-3; KAYANOKI Y, 1994, J BIOL CHEM, V269, P15488; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lafon C, 1996, CELL GROWTH DIFFER, V7, P1095; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LOWERSON SA, 1992, ANAL BIOCHEM, V205, P372, DOI 10.1016/0003-2697(92)90453-E; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Massague J, 2000, GENE DEV, V14, P627; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Patel T, 1998, SEMIN LIVER DIS, V18, P105, DOI 10.1055/s-2007-1007147; Pitot HC, 1998, HEPATOLOGY, V28, P1, DOI 10.1002/hep.510280101; Rodrigues CMP, 1999, CELL DEATH DIFFER, V6, P842, DOI 10.1038/sj.cdd.4400560; RONCERO C, 1989, BIOCHIM BIOPHYS ACTA, V1012, P320, DOI 10.1016/0167-4889(89)90115-8; Saltzman A, 1998, EXP CELL RES, V242, P244, DOI 10.1006/excr.1998.4096; Sanchez A, 1999, EXP CELL RES, V252, P281, DOI 10.1006/excr.1999.4624; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; SANCHEZ A, 1995, J CELL PHYSIOL, V165, P398, DOI 10.1002/jcp.1041650221; Sanchez A, 1997, HEPATOLOGY, V26, P935, DOI 10.1002/hep.510260420; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Shima Y, 1999, HEPATOLOGY, V30, P1215, DOI 10.1002/hep.510300503; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Silva M, 1999, J BIOL CHEM, V274, P22165, DOI 10.1074/jbc.274.32.22165; Simon AR, 1998, AM J PHYSIOL-CELL PH, V275, pC1640, DOI 10.1152/ajpcell.1998.275.6.C1640; Stoll SW, 1998, ONCOGENE, V16, P1493, DOI 10.1038/sj.onc.1201657; Teramoto T, 1998, BIOCHEM BIOPH RES CO, V251, P56, DOI 10.1006/bbrc.1998.9411; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; Thorgeirsson SS, 1998, SEMIN LIVER DIS, V18, P115, DOI 10.1055/s-2007-1007148; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Yamamoto M, 1998, HEPATOLOGY, V27, P959, DOI 10.1002/hep.510270410; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	55	272	283	0	22	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2001	15	3					741	751		10.1096/fj.00-0267com	http://dx.doi.org/10.1096/fj.00-0267com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259392				2022-12-28	WOS:000167419500031
J	Qu, XW; Wang, H; De Plaen, IG; Rozenfeld, RA; Hsueh, W				Qu, XW; Wang, H; De Plaen, IG; Rozenfeld, RA; Hsueh, W			Neuronal nitric oxide synthase (NOS) regulates the expression of inducible NOS in rat small intestine via modulation of nuclear factor kappa B	FASEB JOURNAL			English	Article						NO; gene regulation; transcription factor	PLATELET-ACTIVATING-FACTOR; CELL-ADHESION MOLECULE-1; MESSENGER-RNA; ENDOTHELIAL-CELLS; GENE-EXPRESSION; DNA-BINDING; INHIBITION; ALPHA; INFLAMMATION; SUPEROXIDE	We previously reported that neuronal nitric oxide synthase (nNOS) is the predominant NOS in the intestine. Inducible NOS (iNOS), an enzyme involved in the inflammatory response, is regulated by cytokines via the transcriptional factor NF-kappaB. We examined a new mechanism of intestinal iNOS regulation with respect to the role of nNOS and its effect on NF-kappaB. Young Sprague-Dawley rats were treated for 4 days with 1) saline, 2) 7-nitroindazole (7-NI, specific nNOS inhibitor), 3) 7-NI + pyrrolidine dithiocarbamate (PDTC, NF-kappaB inhibitor), or 4) PDTC. Intestinal iNOS mRNA, NF-kappaB activity, and the tissue content of the regulatory I kappaB alpha were examined. We found that 7-NI-treated animals had higher intestinal NF-kappaB (p50-p65) activity, lower I kappaB alpha content, and increased intestinal iNOS mRNA, iNOS protein, and iNOS activity compared with controls. All of these changes were abolished when PDTC was given together with 7-NI. PDTC alone had no effect. 7-NI induces a delayed increase in intestinal myeloperoxidase activity (after elevation in NF-kappaB and iNOS), which could be abrogated by PDTC, We conclude that in normal rat small intestine, nNOS suppresses the gene expression of iNOS through NF-kappaB down-regulation and that nNOS suppression leads to I kappaB alpha degradation, NF-kappaB activation, and iNOS expression.	Northwestern Univ, Sch Med, Childrens Mem Med Ctr, Dept Pathol, Chicago, IL 60614 USA; Northwestern Univ, Sch Med, Childrens Mem Med Ctr, Dept Pediat, Chicago, IL 60614 USA	Northwestern University; Northwestern University	Hsueh, W (corresponding author), Childrens Mem Hosp, Dept Pathol, 2300 Childrens Plaza, Chicago, IL 60614 USA.	w-hsueh@nwu.edu		De Plaen, Isabelle G/0000-0002-1742-2926				ANGGARD E, 1994, LANCET, V343, P1199, DOI 10.1016/S0140-6736(94)92405-8; Baeuerle PA, 1998, CELL, V95, P729, DOI 10.1016/S0092-8674(00)81694-3; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BOHLEN HG, 1992, AM J PHYSIOL, V262, pH813, DOI 10.1152/ajpheart.1992.262.3.H813; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Chandrasekar B, 1999, CIRCULATION, V99, P427, DOI 10.1161/01.CIR.99.3.427; CHARTRAIN NA, 1994, J BIOL CHEM, V269, P6765; CHEN CC, 1995, J IMMUNOL, V155, P3538; Chen K, 1996, BIOCHEM BIOPH RES CO, V224, P703, DOI 10.1006/bbrc.1996.1087; CLANCY RM, 1992, J CLIN INVEST, V90, P1116, DOI 10.1172/JCI115929; Colasanti M, 1997, J BIOL CHEM, V272, P7582, DOI 10.1074/jbc.272.12.7582; COLASANTI M, 1995, J BIOL CHEM, V270, P26731, DOI 10.1074/jbc.270.45.26731; De Plaen IG, 1998, BBA-LIPID LIPID MET, V1392, P185, DOI 10.1016/S0005-2760(98)00024-1; DECATERINA R, 1995, J CLIN INVEST, V96, P60, DOI 10.1172/JCI118074; DERYCKERE F, 1994, BIOTECHNIQUES, V16, P405; DiazGuerra MJM, 1996, J BIOL CHEM, V271, P30114, DOI 10.1074/jbc.271.47.30114; DIEDERICH D, 1990, AM J PHYSIOL, V258, pH445, DOI 10.1152/ajpheart.1990.258.2.H445; GABOURY J, 1993, AM J PHYSIOL, V265, pH862, DOI 10.1152/ajpheart.1993.265.3.H862; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Haas M, 1998, J LEUKOCYTE BIOL, V63, P395, DOI 10.1002/jlb.63.3.395; Holzer P, 1997, J PHARMACOL EXP THER, V280, P154; Khan BV, 1996, P NATL ACAD SCI USA, V93, P9114, DOI 10.1073/pnas.93.17.9114; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; KUBES P, 1993, AM J PHYSIOL, V264, pG143, DOI 10.1152/ajpgi.1993.264.1.G143; LEVIN J, 1970, J LAB CLIN MED, V75, P903; MACNAUL KL, 1993, BIOCHEM BIOPH RES CO, V196, P1330, DOI 10.1006/bbrc.1993.2398; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; McCafferty DM, 1997, GASTROENTEROLOGY, V112, P1022, DOI 10.1053/gast.1997.v112.pm9041266; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; MILLER MJS, 1993, SCAND J GASTROENTERO, V28, P149, DOI 10.3109/00365529309096062; MYERS PR, 1995, AM J PHYSIOL-HEART C, V268, pH955, DOI 10.1152/ajpheart.1995.268.3.H955; Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782; NICHOLS K, 1993, GASTROENTEROLOGY, V105, P1651, DOI 10.1016/0016-5085(93)91060-U; Park SK, 1997, BIOCHEM J, V322, P609, DOI 10.1042/bj3220609; PARK SK, 1994, BIOCHEM BIOPH RES CO, V201, P762, DOI 10.1006/bbrc.1994.1766; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; Peng HB, 1998, J IMMUNOL, V161, P1970; Perko MJ, 1998, J PHYSIOL-LONDON, V513, P907, DOI 10.1111/j.1469-7793.1998.907ba.x; Qu XW, 1999, BBA-MOL CELL RES, V1451, P211, DOI 10.1016/S0167-4889(99)00076-2; Qu XW, 1999, CRIT CARE MED, V27, P356, DOI 10.1097/00003246-199902000-00043; Qu XW, 1999, GUT, V44, P203, DOI 10.1136/gut.44.2.203; REMICK DG, 1990, AM J PATHOL, V136, P49; SCHULZ JB, 1995, J NEUROCHEM, V64, P936, DOI 10.1046/j.1471-4159.1995.64020936.x; Spiecker M, 1998, J LEUKOCYTE BIOL, V63, P732, DOI 10.1002/jlb.63.6.732; SUZUKI N, 1994, EUR J PHARMACOL, V251, P221, DOI 10.1016/0014-2999(94)90403-0; Szabo C, 1996, SHOCK, V6, P25, DOI 10.1097/00024382-199607000-00006; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Togashi H, 1997, P NATL ACAD SCI USA, V94, P2676, DOI 10.1073/pnas.94.6.2676; Wang Y, 1995, Curr Opin Nephrol Hypertens, V4, P12, DOI 10.1097/00041552-199501000-00003; Weisbrodt NW, 1996, AM J PHYSIOL-GASTR L, V271, pG454, DOI 10.1152/ajpgi.1996.271.3.G454; Xia Y, 1997, P NATL ACAD SCI USA, V94, P6954, DOI 10.1073/pnas.94.13.6954; YANCEY SL, 1993, J APPL PHYSIOL, V75, P1334, DOI 10.1152/jappl.1993.75.3.1334; YOSHIZUMI M, 1993, CIRC RES, V73, P205, DOI 10.1161/01.RES.73.1.205; ZHU L, 1992, ARCH BIOCHEM BIOPHYS, V298, P452, DOI 10.1016/0003-9861(92)90434-X	54	59	60	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2001	15	2					439	446		10.1096/fj.99-0343com	http://dx.doi.org/10.1096/fj.99-0343com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156959				2022-12-28	WOS:000166872900025
J	Krynetskaia, NF; Cai, XJ; Nitiss, JL; Krynetski, EY; Relling, MV				Krynetskaia, NF; Cai, XJ; Nitiss, JL; Krynetski, EY; Relling, MV			Thioguanine substitution alters DNA cleavage mediated by topoisomerase II	FASEB JOURNAL			English	Article						thioguanylated oligodeoxyribonucleotides etoposide; thiopurine; leukemogenesis	ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; BLOOD LEUKOCYTE DNA; SECONDARY LEUKEMIA; MISMATCH REPAIR; ETOPOSIDE; TUMORS; 6-THIOGUANINE; CHILDREN; THERAPY	Thiopurines and topoisomerase II-targeted drugs (e.g., etoposide) are widely used anticancer drugs. However, topoisomerase Ii-targeted drugs can cause acute myeloid leukemia, with the risk of this secondary leukemia linked to a genetic defect in thiopurine catabolism. Chronic thiopurines result in thioguanine substitution in DNA. The effect of these substitutions on DNA topoisomerase II activity is not known. Our goal was to determine whether deoxthio-guanosine substitution alters DNA cleavage stabilized by human topoisomerase If. We studied four variations of a 40 mer oligonucleotide with a topoisomerase II cleavage site, each with a single deoxythioguanosine in a different position relative to the cleavage site (-1 or +2 in the top and +2 or +4 in the bottom strand). Deoxythioguanosine substitution caused position-dependent quantitative effects on cleavage. With the -1 or +2 top and +2 or +4 bottom substitutions, mean topoisomerase II-induced cleavage was 0.6-, 2.0-, 1.1-, and 3.3-fold that with the wild-type substrate (P=0.011, < 0.008, 0.51, and < 0.001, respectively). In the presence of 100 muM etoposide, cleavage was enhanced for wild-type and all thioguanosin-modified substrates relative to no etoposide, with the +4 bottom substitution showing greater etoposide-induced cleavage than the wild-type substrate (P=0.015). We conclude that thioguanine incorporation alters the DNA cleavage induced by topoisomerase II in the presence and absence of etoposide, providing new insights to the mechanism of thiopurine effect and on the leukemogenesis of thiopurines, with or without topoisomerase inhibitors.-Krynetskaia, N. F., Cai, X., Nitiss, J. L., Krynetski, E. Y., Relling, M. V. Thioguanine substitution alters DNA cleavage mediated by topoisomerase II.	St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; Univ Tennessee, Memphis, TN 38105 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Relling, MV (corresponding author), St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale St, Memphis, TN 38105 USA.	mary.relling@stjude.org	Nitiss, John/E-9974-2010	Nitiss, John/0000-0002-1013-4972	NATIONAL CANCER INSTITUTE [R01CA082313, R37CA036401, R01CA036401, R01CA052814] Funding Source: NIH RePORTER; NCI NIH HHS [CA52814, CA36401, CA82313] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bigioni M, 1996, BIOCHEMISTRY-US, V35, P153, DOI 10.1021/bi951736p; BOSHOFF C, 1995, ANN ONCOL, V6, P35, DOI 10.1093/oxfordjournals.annonc.a059037; Budavari S., 1989, MERCK INDEX; CHEN GL, 1984, J BIOL CHEM, V259, P3560; Cuffari C, 1996, CAN J PHYSIOL PHARM, V74, P580, DOI 10.1139/cjpp-74-5-580; ELSEA SH, 1995, J BIOL CHEM, V270, P1913, DOI 10.1074/jbc.270.4.1913; FELIX CA, 1995, CANCER RES, V55, P4287; FRIEDBERG EC, 1995, TRENDS BIOCHEM SCI, V20, P381, DOI 10.1016/S0968-0004(00)89082-9; Gantchev TG, 1997, ANTI-CANCER DRUG, V8, P164, DOI 10.1097/00001813-199702000-00007; Glaab WE, 1998, CARCINOGENESIS, V19, P1931, DOI 10.1093/carcin/19.11.1931; Hsieh T, 1990, CURR OPIN CELL BIOL, V2, P461, DOI 10.1016/0955-0674(90)90128-2; Kingma PS, 1997, BIOCHEMISTRY-US, V36, P5934, DOI 10.1021/bi970507v; Kingma PS, 1997, J BIOL CHEM, V272, P7488, DOI 10.1074/jbc.272.11.7488; Kollmannsberger C, 1998, J CLIN ONCOL, V16, P3386, DOI 10.1200/JCO.1998.16.10.3386; Krynetskaia NF, 1999, MOL PHARMACOL, V56, P841; Kushner BH, 1998, J CLIN ONCOL, V16, P3016, DOI 10.1200/JCO.1998.16.9.3016; LING YH, 1992, MOL PHARMACOL, V42, P802; Nitiss JL, 1998, BBA-GENE STRUCT EXPR, V1400, P63, DOI 10.1016/S0167-4781(98)00128-6; Nitiss JL, 1996, MOL PHARMACOL, V50, P1095; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P4303, DOI 10.1021/bi00388a018; Pedersen-Bjergaard J, 1998, J CLIN ONCOL, V16, P1897, DOI 10.1200/JCO.1998.16.5.1897; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; PUI CH, 1991, NEW ENGL J MED, V325, P1682, DOI 10.1056/NEJM199112123252402; RATAIN MJ, 1992, ANN ONCOL, V3, P107, DOI 10.1093/oxfordjournals.annonc.a058121; Relling MV, 1998, LEUKEMIA, V12, P346, DOI 10.1038/sj.leu.2400928; Relling MV, 1999, LANCET, V354, P34, DOI 10.1016/S0140-6736(98)11079-6; SANDER M, 1983, J BIOL CHEM, V258, P8421; Smith MA, 1999, J CLIN ONCOL, V17, P569, DOI 10.1200/JCO.1999.17.2.569; Smith MA, 1996, JNCI-J NATL CANCER I, V88, P407, DOI 10.1093/jnci/88.7.407; SPITZLEY T, 1989, RATIO, V2, P63, DOI 10.1111/j.1467-9329.1989.tb00127.x; Stine KC, 1997, J CLIN ONCOL, V15, P1583, DOI 10.1200/JCO.1997.15.4.1583; Strissel PL, 1998, BLOOD, V92, P3793, DOI 10.1182/blood.V92.10.3793.422a24_3793_3803; Swann PF, 1996, SCIENCE, V273, P1109, DOI 10.1126/science.273.5278.1109; Thomsen JB, 1999, CANCER-AM CANCER SOC, V86, P1080, DOI 10.1002/(SICI)1097-0142(19990915)86:6<1080::AID-CNCR26>3.0.CO;2-5; WARREN DJ, 1995, CANCER RES, V55, P1670; WINICK NJ, 1993, J CLIN ONCOL, V11, P209, DOI 10.1200/JCO.1993.11.2.209; WORLAND ST, 1989, J BIOL CHEM, V264, P4412	37	40	40	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2000	14	14					2339	2344		10.1096/fj.00-0089com	http://dx.doi.org/10.1096/fj.00-0089com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053256				2022-12-28	WOS:000165190800028
J	Lefterov, IM; Koldamova, RP; Lazo, JS				Lefterov, IM; Koldamova, RP; Lazo, JS			Human bleomycin hydrolase regulates the secretion of amyloid precursor protein	FASEB JOURNAL			English	Article						Alzheimer disease; protease; beta-amyloid	FAMILIAL ALZHEIMERS-DISEASE; BETA-PROTEIN; CYSTEINE PROTEASE; ENDOPLASMIC-RETICULUM; CRYSTAL-STRUCTURE; GENE; PEPTIDE; CLEAVAGE; CELLS; BINDS	Human bleomycin hydrolase (hBH) is a neutral cysteine protease genetically associated with increased risk for Alzheimer disease, We show here that ectopic expression of hBH in 293APPwt and CHOAPPsw cells altered the processing of amyloid precursor protein (APP) and increased significantly the release of its proteolytic fragment, beta amyloid (A beta), We also found that hBH interacted and colocalized with APP as determined by subcellular fractionation, in vitro binding assay, and confocal immunolocalization. Metabolic labeling and pulse-chase experiments showed that ectopic hBH expression increased secretion of soluble APP alpha/beta products without changing the half-life of cellular APP, We also observed that this increased A beta secretion was independent of hBH isoforms, Our finding suggest a regulatory role for hBH in APP processing pathways.	Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lazo, JS (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol, Biomed Sci Tower E1340, Pittsburgh, PA 15261 USA.		Lefterov, Iliya/B-4767-2008	Lefterov, Iliya/0000-0002-0249-0280; Koldamova, Radosveta/0000-0002-6761-0984	NATIONAL CANCER INSTITUTE [R01CA043917] Funding Source: NIH RePORTER; NCI NIH HHS [CA43917] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM C R, 1990, Peptide Research, V3, P211; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Chang TE, 1996, ANN NY ACAD SCI, V777, P183, DOI 10.1111/j.1749-6632.1996.tb34417.x; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Emilien G, 2000, ARCH NEUROL-CHICAGO, V57, P176, DOI 10.1001/archneur.57.2.176; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Farrer LA, 1998, ANN NEUROL, V44, P808, DOI 10.1002/ana.410440515; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Greenfield JP, 1999, P NATL ACAD SCI USA, V96, P742, DOI 10.1073/pnas.96.2.742; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1994, J BIOL CHEM, V269, P17741; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; HSIAO KK, 1995, NEURON, V15, P1203, DOI 10.1016/0896-6273(95)90107-8; Ikezu T, 1998, J BIOL CHEM, V273, P10485, DOI 10.1074/jbc.273.17.10485; JOSHUATOR L, 1995, SCIENCE, V269, P945, DOI 10.1126/science.7638617; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; Koldamova RP, 1998, MOL PHARMACOL, V54, P954, DOI 10.1124/mol.54.6.954; Koldamova RP, 1998, BIOCHEMISTRY-US, V37, P2282, DOI 10.1021/bi9722204; Koldamova RP, 1999, BIOCHEMISTRY-US, V38, P7111, DOI 10.1021/bi990135l; MAGDOLEN U, 1993, BIOCHIM BIOPHYS ACTA, V1171, P299, DOI 10.1016/0167-4781(93)90069-P; Masliah E, 1996, J NEUROSCI, V16, P5795; Montoya SE, 1998, NAT GENET, V18, P211, DOI 10.1038/ng0398-211; Namba Y, 1999, BRAIN RES, V830, P200, DOI 10.1016/S0006-8993(99)01435-3; O'Farrell PA, 1999, STRUCT FOLD DES, V7, P619, DOI 10.1016/S0969-2126(99)80083-5; Raina AK, 1999, NEUROREPORT, V10, P1355, DOI 10.1097/00001756-199904260-00036; Sabo SL, 1999, J BIOL CHEM, V274, P7952, DOI 10.1074/jbc.274.12.7952; Sambamurti K, 1999, J BIOL CHEM, V274, P26810, DOI 10.1074/jbc.274.38.26810; Sastre M, 1998, J BIOL CHEM, V273, P22351, DOI 10.1074/jbc.273.35.22351; SEBTI SM, 1987, BIOCHEMISTRY-US, V26, P4213, DOI 10.1021/bi00388a006; SEBTI SM, 1988, PHARMACOL THERAPEUT, V38, P321, DOI 10.1016/0163-7258(88)90009-5; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Skern T, 1998, J GEN VIROL, V79, P301, DOI 10.1099/0022-1317-79-2-301; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; Thome J, 1999, NEUROSCI LETT, V274, P37, DOI 10.1016/S0304-3940(99)00662-X; Turner RS, 1996, J BIOL CHEM, V271, P8966, DOI 10.1074/jbc.271.15.8966; VAN BROECKHOVEN C, 1990, SCIENCE, V248, P1120, DOI 10.1126/science.1971458; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Zhang JM, 1998, J BIOL CHEM, V273, P12436, DOI 10.1074/jbc.273.20.12436; Zhang W, 1997, BBA-MOL CELL RES, V1359, P110, DOI 10.1016/S0167-4889(97)00082-7; Zheng WJ, 1998, CELL, V93, P103, DOI 10.1016/S0092-8674(00)81150-2	49	31	31	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2000	14	12					1837	1847		10.1096/fj.99-0938com	http://dx.doi.org/10.1096/fj.99-0938com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	352JU	10973933				2022-12-28	WOS:000089212400023
J	Sitte, N; Huber, M; Grune, T; Ladhoff, A; Doecke, WD; Von Zglinicki, T; Davies, KJA				Sitte, N; Huber, M; Grune, T; Ladhoff, A; Doecke, WD; Von Zglinicki, T; Davies, KJA			Proteasome inhibition by lipofuscin/ceroid during postmitotic aging of fibroblasts	FASEB JOURNAL			English	Article						ceroid pigment; protein turnover; lysosome; oxidative stress; free radicals	MULTICATALYTIC PROTEINASE COMPLEX; OXIDATIVE STRESS; OXIDIZED PROTEINS; AMBIENT OXYGEN; CELLS; ACCUMULATION; DEGRADATION; LIPOFUSCINOGENESIS; PROTEOLYSIS; BRAIN	We have studied the effects of hyperoxia and of cell loading with artificial lipofuscin or ceroid pigment on the postmitotic aging of human lung fibroblast cell cultures. Normobaric hyperoxia (40% oxygen) caused an irreversible senescence-like growth arrest after about 4 wk and shortened postmitotic life span from 1-1/2 years down to 3 months, During the first 8 wk of hyperoxria-induced 'aging', overall protein degradation (breakdown of [S-35]methionine metabolically radiolabeled cell proteins increased somewhat, but by 12 wk and thereafter overall proteolysis was significantly depressed, in contrast, protein synthesis rates were unaffected by 12 wk of hyperoxia. Lysosomal cathepsin-specific activity (using the fluorogenic substrate z-FR-MCA) and cytoplasmic proteasome-specific activity (measured with suc-LLVY-MCA) both declined by 80% or more over 12 wk. Hyperoxia also caused a remarkable increase iu lipofuscin/ceroid formation and accumulation over 12 wk, as judged by both fluorescence measurements and FACscan methods. To test whether the association between lipofuscin/ceroid accumulation and decreased proteolysis might be causal, we next exposed cells to lipofuscin/ceroid loading under normoxic conditions. Lipofuscin/ceroid-loaded cells indeed exhibited a gradual decrease in overall protein degradation over 4 wk of treatment, whereas protein synthesis was unaffected. Proteasome specific activity decreased by 25% over this period, which is important since proteasome is normally responsible for degrading oxidized cell proteins. In contrast, an apparent increase in lysosomal cathepsin activity was actually caused by a large increase in the number of lysosomes per cell. To test whether Lipofuscin/ceroid could in fact directly inhibit proteasome activity, thus causing oxidized proteins to accumulate, we incubated purified proteasome with lipofuscin/ceroid preparations in vitro. We found that proteasome is directly inhibited by lipofuscin/ceroid. Our results indicate that an accumulation of oxidized proteins land lipids) such as lipofuscin/ceroid may actually cause further increases in damage accumulation during aging by inhibiting the proteasome.	Univ So Calif, Ethel Percy Andrus Gerontol Ctr, Los Angeles, CA 90089 USA; Humboldt Univ, Inst Pathol, Bereich Med Charite, Berlin, Germany; Humboldt Univ, Clin Phys Med & Rehabil, Bereich Med Charite, Berlin, Germany; Univ So Calif, Div Mol Biol, Los Angeles, CA 90089 USA	University of Southern California; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Southern California	Davies, KJA (corresponding author), Univ So Calif, Ethel Percy Andrus Gerontol Ctr, 3715 McClintock Ave,Room 306, Los Angeles, CA 90089 USA.	kelvin@usc.edu		Davies, Kelvin/0000-0001-7790-3003; von Zglinicki, Thomas/0000-0002-5939-0248; Grune, Tilman/0000-0003-4775-9973	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003598, R23ES003598, R56ES003598] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 03598] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; BRUNK U, 1988, APMIS, V96, P3, DOI 10.1111/j.1699-0463.1988.tb05261.x; BRUNK UT, 1992, MUTAT RES, V275, P395, DOI 10.1016/0921-8734(92)90042-N; CAO GH, 1995, ARCH BIOCHEM BIOPHYS, V320, P106, DOI 10.1006/abbi.1995.1347; CAO GH, 1995, ARCH BIOCHEM BIOPHYS, V320, P195, DOI 10.1006/abbi.1995.1359; CARNEY JM, 1991, P NATL ACAD SCI USA, V88, P3633, DOI 10.1073/pnas.88.9.3633; Conconi M, 1996, ARCH BIOCHEM BIOPHYS, V331, P232, DOI 10.1006/abbi.1996.0303; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DAVIES KJA, 1993, BIOCHEM SOC T, V21, P346, DOI 10.1042/bst0210346; Eldred GE, 1995, GERONTOLOGY, V41, P15; ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0; FRIGUET B, 1994, ARCH BIOCHEM BIOPHYS, V311, P168, DOI 10.1006/abbi.1994.1222; FRIGUET B, 1994, J BIOL CHEM, V269, P21639; GAO GX, 1994, MECH AGEING DEV, V73, P79, DOI 10.1016/0047-6374(94)90040-X; GILLE JJP, 1992, MUTAT RES, V275, P405, DOI 10.1016/0921-8734(92)90043-O; Grune T, 1997, BIOFACTORS, V6, P165, DOI 10.1002/biof.5520060210; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; Grune T, 1996, J BIOL CHEM, V271, P15504, DOI 10.1074/jbc.271.26.15504; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x; INUBUSHI T, 1994, J BIOCHEM-TOKYO, V116, P282, DOI 10.1093/oxfordjournals.jbchem.a124520; IVY GO, 1991, MECH AGEING DEV, V57, P213, DOI 10.1016/0047-6374(91)90048-5; IVY GO, 1984, SCIENCE, V226, P985, DOI 10.1126/science.6505679; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; MARZABADI MR, 1991, APMIS, V99, P416, DOI 10.1111/j.1699-0463.1991.tb05170.x; Nakano M, 1995, GERONTOLOGY, V41, P69; Nilsson E, 1997, MECH AGEING DEV, V99, P61, DOI 10.1016/S0047-6374(97)00091-2; PACIFICI RE, 1993, J BIOL CHEM, V268, P15405; PACIFICI RE, 1989, FREE RADICAL BIO MED, V7, P521, DOI 10.1016/0891-5849(89)90028-2; PACIFICI RE, 1991, GERONTOLOGY, V37, P166; Sitte N, 1998, FREE RADICAL BIO MED, V24, P885, DOI 10.1016/S0891-5849(97)00363-8; SOHAL RS, 1989, FREE RADICAL BIO MED, V6, P23, DOI 10.1016/0891-5849(89)90155-X; SOHAL RS, 1986, ADV FREE RADICAL BIO, V2, P117, DOI 10.1016/S8755-9668(86)80026-6; STARKEREED PE, 1989, ARCH BIOCHEM BIOPHYS, V275, P559, DOI 10.1016/0003-9861(89)90402-5; STREHLER BERNARD L., 1964, ADVANCE GERONTOL RES, V1, P343; vonZglinicki T, 1995, GERONTOLOGY, V41, P95; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; VONZGLINICKI T, 1993, Z GERONTOL, V26, P215	40	270	277	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2000	14	11					1490	1498		10.1096/fj.14.11.1490	http://dx.doi.org/10.1096/fj.14.11.1490			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	342CN	10928983				2022-12-28	WOS:000088627800003
J	Ippoliti, R; Lendaro, E; Benedetti, PA; Torrisi, MR; Belleudi, F; Carpani, D; Soria, MR; Fabbrini, MS				Ippoliti, R; Lendaro, E; Benedetti, PA; Torrisi, MR; Belleudi, F; Carpani, D; Soria, MR; Fabbrini, MS			Endocytosis of a chimera between human pro-urokinase and the plant toxin saporin: an unusual internalization mechanism	FASEB JOURNAL			English	Article						plasminogen activator; ribsome-inactivating proteins; receptors; ligand-passing; cancer	RIBOSOME-INACTIVATING PROTEINS; RECEPTOR-RELATED-PROTEIN; PLASMINOGEN-ACTIVATOR; CELL-SURFACE; SIGNAL-TRANSDUCTION; INHIBITOR COMPLEX; SERPIN COMPLEXES; TRANSPORT; SYSTEM; CANCER	A fluorescent derivative of a chimeric toxin between human pro-urokinase and the plant ribosome-inactivating protein saporin (p-uPA-Sap(TRITC)), has been prepared in order to study the endocytosis of this potentially antimetastatic conjugate in the murine model cell line LB6 clone19 (Cl19) transfected with the human urokinase receptor gene. The physiological internalization of urokinase-inhibitor complexes is triggered by the interaction of plasminogen inhibitors (PAIs) with receptors belonging to the low density lipoprotein-related receptor protein (LRP) family, and involves a macro-quaternary structure including uPAR, LRP, and PAIs. However, in contrast to this mechanism, we observed a two-step process: first, the urokinase receptor (uPAR) acts as the anchoring factor on the plasma membrane; subsequently, LRP acts as the endocytic trigger. Once the chimera is bound to the plasma membrane by interaction with uPAR, we suggest that a possible exchange may occur to transfer the toxin to LRP via the saporin moiety and begin the internalization. So an unusual endocytic process is described, where the toxin enters the cell via a receptor different from that used to bind the plasma membrane.	Univ Rome La Sapienza, Dept Biochem Sci, I-00185 Rome, Italy; CNR, Inst Biophys, I-56100 Pisa, Italy; Univ Rome La Sapienza, Dept Expt Med & Pathol, Rome, Italy; San Raffaele Sci Inst, DIBIT, Dept Biol & Technol Res, I-20132 Milan, Italy	Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR); Sapienza University Rome; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Ippoliti, R (corresponding author), Univ Rome La Sapienza, Dept Biochem Sci, P Aldo Moro 5, I-00185 Rome, Italy.			IPPOLITI, RODOLFO/0000-0003-0652-3470				ANDREASEN PA, 1994, FEBS LETT, V338, P239, DOI 10.1016/0014-5793(94)80276-9; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; BARBIERI L, 1993, BIOCHIM BIOPHYS ACTA, V1154, P237, DOI 10.1016/0304-4157(93)90002-6; Besser D, 1996, FIBRINOLYSIS, V10, P215, DOI 10.1016/S0268-9499(96)80018-X; BLASI F, 1987, J CELL BIOL, V104, P801, DOI 10.1083/jcb.104.4.801; BLASI F, 1998, BIOCHIM BIOPHYS ACTA, V1423, pR35; CAVALLARO U, 1993, J BIOL CHEM, V268, P23186; CAVALLARO U, 1995, EUR J BIOCHEM, V232, P165, DOI 10.1111/j.1432-1033.1995.tb20795.x; CONESE M, 1995, BIOL CHEM H-S, V376, P143; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; DEVRIES TJ, 1995, J PATHOL, V175, P59, DOI 10.1002/path.1711750110; ENDO Y, 1987, J BIOL CHEM, V262, P5908; Fabbrini MS, 1997, FASEB J, V11, P1169, DOI 10.1096/fasebj.11.13.9367352; Fabbrini MS, 1997, BIOCHEM J, V322, P719, DOI 10.1042/bj3220719; Fabbrini MS, 2000, FASEB J, V14, P391, DOI 10.1096/fasebj.14.2.391; Flavell DJ, 1998, CURR TOP MICROBIOL, V234, P57; GrondahlHansen J, 1995, CLIN CANCER RES, V1, P1079; HEEGAARD CW, 1995, J BIOL CHEM, V270, P20855, DOI 10.1074/jbc.270.35.20855; IPPOLITI R, 1995, FASEB J, V9, P1220, DOI 10.1096/fasebj.9.12.7672515; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; Konakova M, 1998, EUR J BIOCHEM, V253, P421, DOI 10.1046/j.1432-1327.1998.2530421.x; Lord JM, 1998, J CELL BIOL, V140, P733; MOESTRUP SK, 1994, BBA-REV BIOMEMBRANES, V1197, P197, DOI 10.1016/0304-4157(94)90005-1; MYOHANEN HT, 1993, J HISTOCHEM CYTOCHEM, V41, P1291; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; NYKJAER A, 1994, J BIOL CHEM, V269, P25668; OKADA SS, 1995, EXP CELL RES, V217, P180, DOI 10.1006/excr.1995.1077; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; Pinckard JK, 1997, J BIOL CHEM, V272, P10784; Reiter Y, 1998, TRENDS BIOTECHNOL, V16, P513, DOI 10.1016/S0167-7799(98)01226-8; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SLEIGHT RG, 1984, J CELL BIOL, V99, P742, DOI 10.1083/jcb.99.2.742; STAHL A, 1995, J CELL BIOL, V129, P335, DOI 10.1083/jcb.129.2.335; VERSPAGET HW, 1995, EUR J CANCER, V31A, P1105, DOI 10.1016/0959-8049(95)00170-N; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107	39	36	36	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2000	14	10					1335	1344		10.1096/fj.14.10.1335	http://dx.doi.org/10.1096/fj.14.10.1335			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877826				2022-12-28	WOS:000087932200008
J	Jagla, W; Wiede, A; Dietzmann, K; Rutkowski, K; Hoffmann, W				Jagla, W; Wiede, A; Dietzmann, K; Rutkowski, K; Hoffmann, W			Co-localization of TFF3 peptide and oxytocin in the human hypothalamus	FASEB JOURNAL			English	Article						pituitary; TFF-domain; neuropeptide; oxytocin; vasopressin; epithelial cell migration; anxiolytic	INTESTINAL TREFOIL FACTOR; PANCREATIC SPASMOLYTIC POLYPEPTIDE; PARAVENTRICULAR NUCLEUS; MAGNOCELLULAR NEURONS; PS2 GENE; IMMUNOCYTOCHEMICAL LOCALIZATION; NEUROHYPOPHYSEAL HORMONES; RECEPTOR-BINDING; MOUSE ASTROCYTES; LACTATING RATS	TFF-peptides (formerly P domain peptides, trefoil factors) are typical secretory products of many mucous epithelial cells. TFF3 is also synthesized in the hypothalamus and has anxiolytic or anxiogenic activities when injected into the rat amygdala. Here we show by immunohistochemistry that TFF3 is localized to a distinct population of neurons of the human hypothalamic paraventricular and supraoptic nuclei. Generally, TFF3-positive cells are co-localized in oxytocin-producing cells and not in vasopressin-producing cells. Relatively large amounts of TFF3-but not TFF1 and TFE2-are present in the posterior lobe of the human pituitary, where it is probably released into the bloodstream. Furthermore, TFF3 was also detectable in human postmortem cerebrospinal fluid.-Jagla, W., Wiede, A, Dietzmann, K, Rutkowski, IC, Hoffmann, W. Go-localization of TFF3 peptide and oxytocin in the human hypothalamus.	Otto Von Guericke Univ, Inst Mol Med & Med Chem, D-39120 Magdeburg, Germany; Otto Von Guericke Univ, Inst Neuropathol, D-39120 Magdeburg, Germany	Otto von Guericke University; Otto von Guericke University	Hoffmann, W (corresponding author), Univ Klinikum Magdeburg, Inst Mol Biol & Med Chem, Leipziger Str 44, D-39120 Magdeburg, Germany.	Werner.Hoffmann@Medizin.Uni-Magdeburg.de	Hoffmann, Werner/AAY-9182-2020	Hoffmann, Werner/0000-0003-0031-9540				BENBARAK Y, 1985, J NEUROSCI, V5, P81; BUIJS RM, 1979, CELL TISSUE RES, V204, P355; BUIJS RM, 1978, CELL TISSUE RES, V192, P423, DOI 10.1007/bf00224932; CARTER CS, 1992, NEUROSCI BIOBEHAV R, V16, P131, DOI 10.1016/S0149-7634(05)80176-9; CHINERY R, 1993, EUR J BIOCHEM, V212, P557, DOI 10.1111/j.1432-1033.1993.tb17693.x; CHINERY R, 1995, PEPTIDES, V16, P749, DOI 10.1016/0196-9781(95)00045-L; CHINERY R, 1995, BRIT J PHARMACOL, V115, P77, DOI 10.1111/j.1476-5381.1995.tb16322.x; DICRICKX K, 1979, CELL TISSUE RES, V196, P203; Dierickx K, 1980, Int Rev Cytol, V62, P119; DIERICKX K, 1977, CELL TISSUE RES, V184, P15, DOI 10.1007/BF00220524; FODOR M, 1992, NEUROSCIENCE, V46, P891, DOI 10.1016/0306-4522(92)90192-5; Forsling ML, 1998, EXP PHYSIOL, V83, P409, DOI 10.1113/expphysiol.1998.sp004124; FRANDSEN EK, 1988, REGUL PEPTIDES, V20, P45, DOI 10.1016/0167-0115(88)90056-0; FRANDSEN EK, 1986, REGUL PEPTIDES, V16, P291, DOI 10.1016/0167-0115(86)90028-5; HIROTA M, 1994, BIOCHEM MOL BIOL INT, V33, P515; HIROTA M, 1994, NEUROSCI LETT, V171, P49, DOI 10.1016/0304-3940(94)90601-7; HIROTA M, 1995, BIOCHEM MOL BIOL INT, V35, P1079; HOFFMANN W, 1993, TRENDS BIOCHEM SCI, V18, P239, DOI 10.1016/0968-0004(93)90170-R; Ishunina TA, 1999, J CLIN ENDOCR METAB, V84, P4637, DOI 10.1210/jc.84.12.4637; Jagla W, 1998, CELL TISSUE RES, V291, P13; Jagla W, 1999, CELL TISSUE RES, V298, P161, DOI 10.1007/s004419900087; KIYAMA H, 1990, J NEUROENDOCRINOL, V2, P257, DOI 10.1111/j.1365-2826.1990.tb00401.x; KONIGSTORFER A, 1989, J BIOL CHEM, V264, P13689; Landry M, 1997, J ENDOCRINOL, V155, P467, DOI 10.1677/joe.0.1550467; Langer G, 1999, INVEST OPHTH VIS SCI, V40, P2220; Lefebvre O, 1996, SCIENCE, V274, P259, DOI 10.1126/science.274.5285.259; LUDWIG M, 1995, AM J PHYSIOL-ENDOC M, V268, pE537, DOI 10.1152/ajpendo.1995.268.4.E537; Mashimo H, 1996, SCIENCE, V274, P262, DOI 10.1126/science.274.5285.262; MEZEY E, 1991, ENDOCRINOLOGY, V129, P1814, DOI 10.1210/endo-129-4-1814; MORTON A, 1969, J COMP NEUROL, V136, P143, DOI 10.1002/cne.901360203; OKADO N, 1982, ANAT RECORD, V202, P117, DOI 10.1002/ar.1092020114; Podolsky DK, 1997, J GASTROENTEROL, V32, P122, DOI 10.1007/BF01213309; Poulsen SS, 1998, GUT, V43, P240, DOI 10.1136/gut.43.2.240; POW DV, 1989, NEUROSCIENCE, V32, P435, DOI 10.1016/0306-4522(89)90091-2; PROBST JC, 1995, MOL BRAIN RES, V33, P269, DOI 10.1016/0169-328X(95)00137-H; Probst JC, 1996, FASEB J, V10, P1518, DOI 10.1096/fasebj.10.13.8940297; Purba JS, 1996, ARCH GEN PSYCHIAT, V53, P137; Russell JA, 1998, J ENDOCRINOL, V157, P343, DOI 10.1677/joe.0.1570343; Schwarzberg H, 1999, PHARMACOL BIOCHEM BE, V62, P173, DOI 10.1016/S0091-3057(98)00137-3; SILVERMAN AJ, 1983, ANNU REV NEUROSCI, V6, P357, DOI 10.1146/annurev.ne.06.030183.002041; SOFRONIEW MV, 1983, TRENDS NEUROSCI, V6, P467, DOI 10.1016/0166-2236(83)90221-7; SOFRONIEW MV, 1980, J HISTOCHEM CYTOCHEM, V28, P475, DOI 10.1177/28.5.7381192; Swaab DF, 1998, PROG BRAIN RES, V119, P577; SWAAB DF, 1995, J CLIN ENDOCR METAB, V80, P573, DOI 10.1210/jc.80.2.573; SWAAB DF, 1997, HAND CHEM N, V13, P39; Tan XD, 1999, BIOCHEM J, V338, P745, DOI 10.1042/0264-6021:3380745; Tan XD, 1997, BIOCHEM BIOPH RES CO, V237, P673, DOI 10.1006/bbrc.1997.7144; THEODOSIS DT, 1992, ANN NY ACAD SCI, V652, P303, DOI 10.1111/j.1749-6632.1992.tb34363.x; TOMASETTO C, 1990, EMBO J, V9, P407, DOI 10.1002/j.1460-2075.1990.tb08125.x; Tomasetto C, 2000, GASTROENTEROLOGY, V118, P70, DOI 10.1016/S0016-5085(00)70415-X; WANG H, 1995, NEUROSCIENCE, V68, P1179, DOI 10.1016/0306-4522(95)00186-M; Wiede A, 1999, AM J RESP CRIT CARE, V159, P1330, DOI 10.1164/ajrccm.159.4.9804149; Wong WM, 1999, GUT, V44, P890, DOI 10.1136/gut.44.6.890; Wright NA, 1997, FEBS LETT, V408, P121, DOI 10.1016/S0014-5793(97)00424-9	54	66	70	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2000	14	9					1126	1131		10.1096/fasebj.14.9.1126	http://dx.doi.org/10.1096/fasebj.14.9.1126			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834934				2022-12-28	WOS:000087427300009
J	Daugas, E; Susin, SA; Zamzami, N; Ferri, KF; Irinopoulou, T; Larochette, N; Prevost, MC; Leber, B; Andrews, D; Penninger, J; Kroemer, G				Daugas, E; Susin, SA; Zamzami, N; Ferri, KF; Irinopoulou, T; Larochette, N; Prevost, MC; Leber, B; Andrews, D; Penninger, J; Kroemer, G			Mitochondrio-nuclear translocation of AIF in apoptosis and necrosis	FASEB JOURNAL			English	Article						antioncogene; mitochondrial transmembrane potential; oncogene; permeability transition; programmed cell death	PERMEABILITY TRANSITION PORE; CYTOCHROME-C RELEASE; CELL-DEATH; T-CELLS; BCL-2; DNA; BAX; ACTIVATION; PROTEASES; FRAGMENTATION	Apoptosis inducing factor (AIF) is a novel apoptotic effector protein that induces chromatin condensation and large-scale (similar to 50 kbp) DNA fragmentation when added to purified nuclei in vitro. Confocal and electron microscopy reveal that, in normal cells, ATF is strictly confined to mitochondria and thus colocalizes with heat shock protein 60 (hsp60). On induction of apoptosis by staurosporin, c-Myc, etoposide, or ceramide, AIF (but not hsp60) translocates to the nucleus. This suggests that only the outer mitochondrial membrane (which retains AIF in the intermembrane space) but not the inner membrane (which retains hsp60 in the matrix) becomes protein permeable. The mitochondrio-nuclear redistribution of AIF is prevented by a Bcl-2 protein specifically targeted to mitochondrial membranes. The pan-caspase inhibitor Z-VAD.fmk does not prevent the staurosporin-induced translocation of ATF, although it does inhibit oligonucleosomal DNA fragmentation and arrests chromatin condensation at an early stage. ATP depletion is sufficient to cause AIF translocation to the nucleus, and this phenomenon is accelerated by the apoptosis inducer staurosporin. However, in conditions in which both glycolytic and respiratory ATP generation is inhibited, cells fail to manifest any sign of chromatin condensation and advanced DNA fragmentation, thus manifesting a 'necrotic' phenotype. Both in the presence of Z-VAD.fmk and in conditions of ATP depletion, AIF translocation correlates with the appearance of large-scale DNA fragmentation. Altogether, these data are compatible with the hypothesis that AIF is a caspase-independent mitochondrial death effector responsible for partial chromatinolysis.-Daugas, E., Susin, S. A., Zamzami, N., Ferri, K., Irinopoulou, T., Larochette, N., Prevost, RI.-C., Leber, B., Andrews, D., Penninger, J., Kroemer, G. Mitochondria nuclear translocation of AIF in apoptosis and necrosis.	CNRS, UPR420, F-94801 Villejuif, France; Assistance Publ Hop, Serv Nephrol B, Hop Tenon, F-75020 Paris, France; Inst Pasteur, Unite Oncol Virale, F-75724 Paris, France; McMaster Univ, Med Ctr, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada; Hop Broussais, Lab Anatomopathol, F-75014 Paris, France; Hop Broussais, INSERM, U430, F-75014 Paris, France; Univ Toronto, Amgen Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Ontario Canc Inst, Dept Med Biophys & Immunol, Toronto, ON M5G 2C1, Canada	Centre National de la Recherche Scientifique (CNRS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; McMaster University; McMaster University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Kroemer, G (corresponding author), 19 Rue Guy Moquet,BP 8, F-94801 Villejuif, France.		KROEMER, Guido/B-4263-2013; Penninger, Josef M/I-6860-2013; LAROCHETTE, Nathanael/R-4298-2017; Kroemer, Guido/AAY-9859-2020; Susin, Santos A/Q-6754-2017	KROEMER, Guido/0000-0002-9334-4405; Penninger, Josef M/0000-0002-8194-3777; LAROCHETTE, Nathanael/0000-0002-7936-678X; Susin, Santos A/0000-0002-3366-1628; DAUGAS, Eric/0000-0001-7256-7979; Andrews, David/0000-0002-9266-7157; Leber, Brian/0000-0001-5502-1480				Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; BROWN DG, 1993, J BIOL CHEM, V268, P3037; Deas O, 1998, J IMMUNOL, V161, P3375; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Eguchi Y, 1997, CANCER RES, V57, P1835; Eguchi Y, 1999, CANCER RES, V59, P2174; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GONZALO JA, 1993, J EXP MED, V177, P1239, DOI 10.1084/jem.177.5.1239; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Jutila A, 1998, MOL PHARMACOL, V54, P722; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201; LIU AK, 1995, GLOBAL ATMOSPHERE OC, V3, P175; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Macho A, 1996, CYTOMETRY, V25, P333, DOI 10.1002/(SICI)1097-0320(19961201)25:4<333::AID-CYTO4>3.0.CO;2-E; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; Petit PX, 1998, FEBS LETT, V426, P111, DOI 10.1016/S0014-5793(98)00318-4; Saikumar P, 1998, ONCOGENE, V17, P3401, DOI 10.1038/sj.onc.1202590; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Salamon Z, 1997, J BIOENERG BIOMEMBR, V29, P211, DOI 10.1023/A:1022401825287; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 1996, ONCOGENE, V12, P2045; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZHOU H, 1997, CELL, V90, P405; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	42	685	716	0	48	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2000	14	5					729	739		10.1096/fasebj.14.5.729	http://dx.doi.org/10.1096/fasebj.14.5.729			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301DH	10744629				2022-12-28	WOS:000086292700010
J	Grewal, TS; Genever, PG; Brabbs, AC; Birch, M; Skerry, TM				Grewal, TS; Genever, PG; Brabbs, AC; Birch, M; Skerry, TM			Best5: a novel interferon-inducible gene expressed during bone formation	FASEB JOURNAL			English	Article						osteoblasts; differentiation; cytokines; osteoporosis; mechanical loading	TUMOR NECROSIS FACTOR; NEONATAL MOUSE CALVARIA; MARROW STROMAL CELLS; COLLAGEN-SYNTHESIS; GAMMA-INTERFERON; FACTOR-ALPHA; IN-VIVO; RESORPTION; INHIBITION; CULTURES	Regulation of bone formation is important in the pathogenesis of many conditions such as osteoporosis, fracture healing, and loosening of orthopedic implants. We have recently identified a novel rat cDNA (best5) by differential display PCR that is regulated during osteoblast differentiation and bone formation in vitro and in vivo, Expression of best5 mRNA is induced in cultures of osteoblasts by both interferon-alpha (IFN-alpha) or IFN-gamma. Whereas IFN-alpha induced a rapid, transient induction of best5 expression peaking at 4-6 h poststimulation, IFN-gamma elicited a more prolonged induction of best5 expression, which remained elevated 48 h poststimulation, A polyclonal antibody generated to a peptide derived from the best5 coding region recognized a 27 kDa protein on Western blot analysis of osteoblast lysates. We localized BEST5 protein in osteoblast progenitor cells and mature osteoblasts in sections of rat tibiae and in sections of bones loaded in vivo to induce adaptive bone formation. Best5 may therefore be a fundamental intermediate in the response of osteoblasts to stimuli that modulate proliferation/ differentiation, such as interferons or mechanical loading. These findings highlight the close interactions between the immune system and bone cells and may open new therapeutic avenues in modulating bone mass.	Univ York, Dept Biol, Bone & Joint Biol Res Grp, York YO10 5YW, N Yorkshire, England	University of York - UK	Grewal, TS (corresponding author), Univ York, Dept Biol, Bone & Joint Biol Res Grp, York YO10 5YW, N Yorkshire, England.		Birch, Mark/B-7051-2009	Skerry, Timothy/0000-0003-1319-5575; Genever, Paul/0000-0002-5730-8976				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aman MJ, 1996, EXP HEMATOL, V24, P863; AMAN MJ, 1994, BLOOD, V84, P4142, DOI 10.1182/blood.V84.12.4142.bloodjournal84124142; ARONOW MA, 1990, J CELL PHYSIOL, V143, P213, DOI 10.1002/jcp.1041430203; BERESFORD JN, 1990, EUR J BIOCHEM, V193, P589, DOI 10.1111/j.1432-1033.1990.tb19377.x; BROXMEYER HE, 1983, J IMMUNOL, V131, P1300; BUCHAN G, 1988, CLIN EXP IMMUNOL, V71, P295; Corpet F, 1999, NUCLEIC ACIDS RES, V27, P263, DOI 10.1093/nar/27.1.263; FIRESTEIN GS, 1990, J IMMUNOL, V144, P3347; GALVANI DW, 1990, LEUKEMIA RES, V14, P525, DOI 10.1016/0145-2126(90)90004-S; GOLDRING MB, 1986, J BIOL CHEM, V261, P9049; GOLLNER G, 1995, BRIT J HAEMATOL, V91, P8; GOWEN M, 1988, ARTHRITIS RHEUM, V31, P1500, DOI 10.1002/art.1780311206; GOWEN M, 1986, J BONE MINER RES, V1, P469; HILLAM RA, 1995, J BONE MINER RES, V10, P683; HOFFMANN O, 1987, BIOCHEM BIOPH RES CO, V143, P38, DOI 10.1016/0006-291X(87)90626-7; HOPKINS SJ, 1988, CLIN EXP IMMUNOL, V73, P88; KURIHARA N, 1990, J INTERFERON RES, V10, P541, DOI 10.1089/jir.1990.10.541; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; LEVY DE, 1995, SEMIN VIROL, V6, P181, DOI 10.1006/smvy.1995.0023; MANN GN, 1994, ENDOCRINOLOGY, V135, P1077, DOI 10.1210/en.135.3.1077; NAKANO T, 1993, EXP HEMATOL, V21, P1498; Nii A, 1997, VET PATHOL, V34, P431, DOI 10.1177/030098589703400507; Oreffo ROC, 1999, J CELL BIOCHEM, V74, P372, DOI 10.1002/(SICI)1097-4644(19990901)74:3<372::AID-JCB6>3.0.CO;2-H; PETERLIK M, 1985, FEBS LETT, V185, P287, DOI 10.1016/0014-5793(85)80924-8; REVEL M, 1986, TRENDS BIOCHEM SCI, V11, P166, DOI 10.1016/0968-0004(86)90134-9; Sharrock WJ, 1998, J BONE MINER RES, V13, P537, DOI 10.1359/jbmr.1998.13.4.537; SMITH DD, 1987, ENDOCRINOLOGY, V120, P2494, DOI 10.1210/endo-120-6-2494; STEPHENSON ML, 1985, FEBS LETT, V180, P43, DOI 10.1016/0014-5793(85)80227-1; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; YOSHIHARA R, 1990, LYMPHOKINE RES, V9, P59; Zhu H, 1997, P NATL ACAD SCI USA, V94, P13985, DOI 10.1073/pnas.94.25.13985	32	43	49	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2000	14	3					523	531		10.1096/fasebj.14.3.523	http://dx.doi.org/10.1096/fasebj.14.3.523			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	291TJ	10698968				2022-12-28	WOS:000085751900012
J	Robinson, GS; Ju, M; Shih, SC; Xu, X; McMahon, G; Caldwell, RB; Smith, LEH				Robinson, GS; Ju, M; Shih, SC; Xu, X; McMahon, G; Caldwell, RB; Smith, LEH			Nonvascular role for VEGF: VEGFR-1, 2 activity is critical for neural retinal development	FASEB JOURNAL			English	Article									Harvard Univ, Childrens Hosp, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA; SUGEN Inc, S San Francisco, CA USA; Med Coll Georgia, Augusta, GA 30912 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Pfizer; University System of Georgia; Augusta University	Smith, LEH (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Dept Ophthalmol, 300 Longwood Ave, Boston, MA 02115 USA.			Caldwell, Ruth/0000-0003-0168-0354					0	129	140	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1215	1217		10.1096/fj.00-0598fje	http://dx.doi.org/10.1096/fj.00-0598fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344092				2022-12-28	WOS:000168655200014
J	Huber-Lang, MS; Sarma, JV; McGuire, SR; Lu, KT; Guo, RF; Padgaonkar, VA; Younkin, EM; Laudes, IJ; Riedemann, NC; Younger, JG; Ward, PA				Huber-Lang, MS; Sarma, JV; McGuire, SR; Lu, KT; Guo, RF; Padgaonkar, VA; Younkin, EM; Laudes, IJ; Riedemann, NC; Younger, JG; Ward, PA			Protective effects of anti-C5a peptide antibodies in experimental sepsis	FASEB JOURNAL			English	Article									Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Emergency Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Ward, PA (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 1301 Catherine Rd, Ann Arbor, MI 48109 USA.		Huber-Lang, Markus/AAJ-2209-2020	Younger, John/0000-0002-0820-0635					0	104	114	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					568	570						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259369				2022-12-28	WOS:000167419500007
J	Loeffler, M; Daugas, E; Susin, SA; Zamzami, N; Metivier, D; Nieminen, AL; Brothers, G; Penninger, JM; Kroemer, G				Loeffler, M; Daugas, E; Susin, SA; Zamzami, N; Metivier, D; Nieminen, AL; Brothers, G; Penninger, JM; Kroemer, G			Dominant cell death induction by extramitochondrially targeted apoptosis-inducing factor	FASEB JOURNAL			English	Article						AIF; apoptosis; Bcl-2; caspases; cytochrome c	MITOCHONDRIAL INTERMEMBRANE SPACE; CYTOCHROME-C; ADENYLATE KINASE; GD3 GANGLIOSIDE; FACTOR AIF; BCL-2; RELEASE; ACTIVATION; PROTEINS; REQUIREMENT	The complete AIF cDNA comprising the amino-terminal mitochondrial localization sequence (MLS) and the oxidoreductase domain has been fused in its carboxyl terminus to enhanced green fluorescent protein (GFP), thereby engineering an AIF-GFP fusion protein that is selectively targeted to the mitochondrial intermembrane space. Upon induction of apoptosis, the AIF-GFP protein translocates together with cytochrome c (Cyt-c) to the extramitochondrial compartment. Microinjection of recombinant AIF leads to the release of AIF-GFP and Cyt-c-GFP, indicating that ectopic AIF can favor permeabilization of the outer mitochondrial membrane. These mitochondrial effects of AIF are caspase independent, whereas the Cyt-c-microinjection induced translocation of AIF-GFP and Cyt-c-GFP is suppressed by the pan-caspase inhibitor Z-VAD.fmk. Upon prolonged culture, transfection-enforced overexpression of AIF results in spontaneous translocation of AIF-GFP from mitochondria, nuclear chromatin condensation, and cell death. These effects are caspase independent and do not rely on the oxidoreductase function of AIF. Spontaneous AIF-GFP translocation and subsequent nuclear apoptosis can be retarded by overexpression of a Bcl-2 protein selectively targeted to mitochondria, but not by a Bcl-2 protein targeted to the endoplasmic reticulum. Overexpression of a mutant AIF protein in which the MLS has been deleted (AIF Delta 1-100) results in the primary cytosolic accumulation of AIF. AIF Delta 1-100-induced cell death is suppressed by neither Z-VAD.fmk or by Bcl-2. Thus, extramitochondrially targeted AIF is a dominant cell death inducer.	Inst Gustave Roussy, CNRS, UMR 1599, F-94805 Villejuif, France; Hop Tenon, Assistance Publ Hop Paris, Serv Nephrol B, F-75020 Paris, France; Case Western Reserve Univ, Sch Med, Dept Anat, Cleveland, OH 44106 USA; Univ Toronto, Amgen Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Ontario Canc Inst, Dept Med Biophys & Immunol, Toronto, ON M5G 2C1, Canada	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; Case Western Reserve University; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR 1599, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Kroemer, Guido/AAY-9859-2020; KROEMER, Guido/B-4263-2013; Penninger, Josef M/I-6860-2013; Susin, Santos A/Q-6754-2017	KROEMER, Guido/0000-0002-9334-4405; Penninger, Josef M/0000-0002-8194-3777; Susin, Santos A/0000-0002-3366-1628; DAUGAS, Eric/0000-0001-7256-7979				BEASLEY EM, 1993, EMBO J, V12, P2303, DOI 10.1002/j.1460-2075.1993.tb05884.x; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Coves J, 1999, BIOCHEM J, V342, P465, DOI 10.1042/0264-6021:3420465; Daugas E, 2000, FEBS LETT, V476, P118, DOI 10.1016/S0014-5793(00)01731-2; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; Kohler C, 1999, FEBS LETT, V447, P10, DOI 10.1016/S0014-5793(99)00251-3; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Lorenzo HK, 1999, CELL DEATH DIFFER, V6, P516, DOI 10.1038/sj.cdd.4400527; MAJANDER A, 1994, J BIOL CHEM, V269, P21037; ODONNELL VB, 1993, BIOCHEM J, V290, P41, DOI 10.1042/bj2900041; Patterson SD, 2000, CELL DEATH DIFFER, V7, P137, DOI 10.1038/sj.cdd.4400640; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Samejima K, 1998, J CELL BIOL, V143, P225, DOI 10.1083/jcb.143.1.225; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; Single B, 1998, CELL DEATH DIFFER, V5, P1001, DOI 10.1038/sj.cdd.4400462; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	33	194	208	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2001	15	3					758	767		10.1096/fj.00-0388com	http://dx.doi.org/10.1096/fj.00-0388com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259394				2022-12-28	WOS:000167419500033
J	Pervaiz, S				Pervaiz, S			Reactive oxygen-dependent production of novel photochemotherapeutic agents	FASEB JOURNAL			English	Article						PDT; photodynamic reaction; photosensitizer; mitochondrial permeability	SINGLET MOLECULAR-OXYGEN; CYTOCHROME-C RELEASE; PHOTODYNAMIC THERAPY; TUMOR-CELLS; HEMATOPOIETIC-CELLS; FLASH-PHOTOLYSIS; MEROCYANINE 540; LYMPHOMA-CELLS; PROTEIN DAMAGE; HUMAN LEUKEMIA	The reactive nature of species derived from oxygen, such as singlet oxygen and hydrogen peroxide, has been exploited in the clinical setting for targeting bacteria, viruses, and tumor cells by photodynamic excitation of a variety of chromophores, This modality, termed photodynamic therapy (PDT), is currently being used to treat some forms of cancer. However, the applicability of conventional PDT is limited due to the absolute dependence on simultaneous exposure of the target to the photoactive com pound and light, In 1990, we demonstrated that the need for simultaneous exposure of the biological target to light and photosensitizer could be circumvented by prior exposure (activation) of the sensitizer molecule to light and its subsequent use as any other anti-cancer or and-viral drug. By dint of the nature of the protocol, this process was termed preactivation. Since then, the generation of biologically active molecules in vitro by preactivation has been validated using a variety of chromophores, such as merocyanine 540, Photofrin II, and naphthalimide. Here we briefly review the role of reactive oxygen species in the photodynamic effect, and provide an explanation for the mechanism of preactivation. We propose that photo-oxidation not only provides a novel means for the generation of biologically active molecules, but could also explain, at least in part the mechanism of conventional PDT, It is Likely that the light-dependent breakdown of the chromophore to generate novel active compounds, in addition to reactive oxygen species, also contributes to the photodynamic damage observed on simultaneous exposure of the chromophore and target tissue to light during PDT.-Pervaiz, S. Reactive oxygen-dependent production of novel photochemotherapeutic agents.	Natl Univ Singapore, Dept Physiol, Singapore 117597, Singapore	National University of Singapore	Pervaiz, S (corresponding author), Natl Univ Singapore, Dept Physiol, 2 Med Dr, Singapore 117597, Singapore.	phssp@nus.edu.sg	Pervaiz, Shazib/C-4188-2015					AGARWAL ML, 1991, CANCER RES, V51, P5993; Anderson C, 1997, PHOTOCHEM PHOTOBIOL, V65, P895, DOI 10.1111/j.1751-1097.1997.tb01940.x; BARRETT AJ, 1990, J PHOTOCH PHOTOBIO B, V6, P309, DOI 10.1016/1011-1344(90)85101-2; Blum H.F., 1941, PHOTODYNAMIC ACTION; CHAN PJ, 1991, ARCH ANDROLOGY, V27, P103, DOI 10.3109/01485019108987660; CHANH TC, 1992, J ACQ IMMUN DEF SYND, V5, P188; CHANH TC, 1994, ANTIVIR RES, V25, P133, DOI 10.1016/0166-3542(94)90102-3; Dahle J, 1999, PHOTOCHEM PHOTOBIOL, V70, P363, DOI 10.1111/j.1751-1097.1999.tb08150.x; DAS M, 1985, CANCER RES, V45, P6328; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DAVILA J, 1991, PHOTOCHEM PHOTOBIOL, V53, P1, DOI 10.1111/j.1751-1097.1991.tb08460.x; Delaey E, 2000, J PHOTOCH PHOTOBIO B, V55, P27, DOI 10.1016/S1011-1344(00)00021-X; DIWU ZJ, 1994, PHARMACOL THERAPEUT, V63, P1, DOI 10.1016/0163-7258(94)90054-X; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; DOUGHERTY TJ, 1987, PHOTOCHEM PHOTOBIOL, V45, P879, DOI 10.1111/j.1751-1097.1987.tb07898.x; FRANCK B, 1992, PHOTOCHEM PHOTOBIOL, V56, P271, DOI 10.1111/j.1751-1097.1992.tb02157.x; FREEMAN BA, 1984, FREE RADICALS MOL BI; FREITAS I, 1990, J PHOTOCH PHOTOBIO B, V7, P359, DOI 10.1016/1011-1344(90)85169-W; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; Garbo GM, 1996, J PHOTOCH PHOTOBIO B, V34, P109, DOI 10.1016/1011-1344(96)07343-5; GOMER CJ, 1989, RADIAT RES, V120, P1, DOI 10.2307/3577632; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GULLIYA KS, 1990, EUR J CANCER, V26, P551, DOI 10.1016/0277-5379(90)90072-2; GULLIYA KS, 1990, PHOTOCHEM PHOTOBIOL, V52, P831, DOI 10.1111/j.1751-1097.1990.tb08689.x; GULLIYA KS, 1989, BLOOD, V73, P1059; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x; Hirpara JL, 2000, BLOOD, V95, P1773, DOI 10.1182/blood.V95.5.1773.005k17_1773_1780; Hsi RA, 1999, DRUGS, V57, P725, DOI 10.2165/00003495-199957050-00005; HUANG SK, 1992, CANCER RES, V52, P6774; ITOH T, 1993, BONE MARROW TRANSPL, V12, P191; JESIONEK A, 1903, MUENCH MED WOCHSCHS, V47, P20420; Jori G, 1996, J PHOTOCH PHOTOBIO B, V36, P87, DOI 10.1016/S1011-1344(96)07352-6; KALYANARAMAN B, 1987, P NATL ACAD SCI USA, V84, P2999, DOI 10.1073/pnas.84.9.2999; KANG Q, 1992, PHOTOCHEM PHOTOBIOL, V56, P489, DOI 10.1111/j.1751-1097.1992.tb02192.x; Kessel D, 1999, CELL DEATH DIFFER, V6, P28, DOI 10.1038/sj.cdd.4400446; KESSEL D, 1995, PHOTOCHEM PHOTOBIOL, V62, P875; Kessel D, 1998, J PHOTOCH PHOTOBIO B, V42, P89, DOI 10.1016/S1011-1344(97)00127-9; KESSEL D, 1992, ONCOL RES, V4, P219; KESSEL D, 1995, J PHOTOCH PHOTOBIO B, V28, P13, DOI 10.1016/1011-1344(94)07085-3; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; LIPSON RL, 1961, J NATL CANCER I, V26, P1; Mayer LD, 1997, J PHARMACOL EXP THER, V280, P1406; Mayer LD, 1998, CANCER METAST REV, V17, P211, DOI 10.1023/A:1006070906949; MEAGHER RC, 1989, CANCER RES, V49, P3637; MOAN J, 1991, PHOTOCHEM PHOTOBIOL, V53, P549, DOI 10.1111/j.1751-1097.1991.tb03669.x; MULRONEY CM, 1994, SEMIN ONCOL, V21, P24; Nauta JM, 1996, EUR J ORAL SCI, V104, P69, DOI 10.1111/j.1600-0722.1996.tb00049.x; Ochsner M, 1997, J PHOTOCH PHOTOBIO B, V39, P1, DOI 10.1016/S1011-1344(96)07428-3; Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816; PANDEY RK, 1991, PHOTOCHEM PHOTOBIOL, V53, P65, DOI 10.1111/j.1751-1097.1991.tb08468.x; PATHAK MA, 1982, JNCI-J NATL CANCER I, V69, P163, DOI 10.1093/jnci/69.1.163; Peng Q, 1996, ULTRASTRUCT PATHOL, V20, P109, DOI 10.3109/01913129609016306; Pervaiz S, 1998, CANCER LETT, V128, P11, DOI 10.1016/S0304-3835(98)00021-4; Pervaiz S, 1999, BLOOD, V93, P4096, DOI 10.1182/blood.V93.12.4096.412k44_4096_4108; PERVAIZ S, 1992, FREE RADICAL BIO MED, V12, P389, DOI 10.1016/0891-5849(92)90088-X; PERVAIZ S, 1993, CANCER CHEMOTH PHARM, V31, P467, DOI 10.1007/BF00685037; Raab O, 1900, Z BIOL-MUNICH, V39, P524; RICCHELLI F, 1993, PHOTOCHEM PHOTOBIOL, V58, P53, DOI 10.1111/j.1751-1097.1993.tb04903.x; SCHLEGEL RA, 1980, CELL, V20, P321, DOI 10.1016/0092-8674(80)90618-2; SCHWARTZ S, 1955, U MINNESOTA MED B, V7, P7; SIEBER F, 1987, LEUKEMIA RES, V11, P43, DOI 10.1016/0145-2126(87)90104-4; SIEBER F, 1987, PHOTOCHEM PHOTOBIOL, V46, P1035, DOI 10.1111/j.1751-1097.1987.tb04890.x; SINGH RJ, 1992, PHOTOCHEM PHOTOBIOL, V55, P483, DOI 10.1111/j.1751-1097.1992.tb04268.x; SINGH RJ, 1991, PHOTOCHEM PHOTOBIOL, V53, P493, DOI 10.1111/j.1751-1097.1991.tb03661.x; SMITH OM, 1991, EXP HEMATOL, V19, P785; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VALINSKY JE, 1978, CELL, V13, P487, DOI 10.1016/0092-8674(78)90322-7; Vandenbogaerde AL, 1997, J PHOTOCH PHOTOBIO B, V38, P136, DOI 10.1016/S1011-1344(96)07446-5; Vantieghem A, 1998, FEBS LETT, V440, P19, DOI 10.1016/S0014-5793(98)01416-1; VERMEERSCH G, 1991, PHOTOCHEM PHOTOBIOL, V54, P661, DOI 10.1111/j.1751-1097.1991.tb02072.x; Villanueva A, 1999, ONCOL RES, V11, P447; VOGELMANN E, 1976, PHOTOCHEM PHOTOBIOL, V24, P595, DOI 10.1111/j.1751-1097.1976.tb06878.x; Von Tappeiner H., 1904, DEUT ARCH KLIN MED, V80, P427	74	53	61	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2001	15	3					612	617		10.1096/fj.00-0555rev	http://dx.doi.org/10.1096/fj.00-0555rev			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259379				2022-12-28	WOS:000167419500018
J	Gilroy, DW; Saunders, MA; Sansores-Garcia, L; Matijevic-Aleksic, N; Wu, KK				Gilroy, DW; Saunders, MA; Sansores-Garcia, L; Matijevic-Aleksic, N; Wu, KK			Cell cycle-dependent expression of cyclooxygenase-2 in human fibroblasts	FASEB JOURNAL			English	Article									Univ Texas, Sch Med, Vasc Biol Res Ctr, Houston, TX 77030 USA; Univ Texas, Sch Med, Div Hematol, Dept Med, Houston, TX 77030 USA; Acad Sinica, Inst Biomed Sci, Vasc Biol Program, Taipei, Taiwan	University of Texas System; University of Texas System; Academia Sinica - Taiwan	Wu, KK (corresponding author), Univ Texas, Sch Med, Vasc Biol Res Ctr, 6431 Fannin,MSB 5-016, Houston, TX 77030 USA.		Wu, Kenneth Kun-Yu/B-1070-2010; Gilroy, Derek W/C-2588-2009; Gilroy, Derek/AAP-7227-2020	Gilroy, Derek/0000-0003-3476-0844; Sansores-Garcia, Leticia/0000-0003-2510-225X					0	33	36	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					288	290						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156939				2022-12-28	WOS:000166872900005
J	Tavernier, B; Li, JM; El-Omar, AM; Lanone, S; Yang, ZK; Trayer, IP; Mebazaa, A; Shah, AM				Tavernier, B; Li, JM; El-Omar, AM; Lanone, S; Yang, ZK; Trayer, IP; Mebazaa, A; Shah, AM			Cardiac contractile impairment associated with increased phosphorylation of troponin I in endotoxemic rats	FASEB JOURNAL			English	Article									Kings Coll London, GKT Sch Med, Dept Cardiol, London SE5 9PJ, England; Hop Lariboisiere, Dept Anesthesiol, F-75475 Paris, France; Cardiff Univ, Dept Cardiol, Cardiff CF4 4XN, S Glam, Wales; Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	University of London; King's College London; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Cardiff University; University of Birmingham	Shah, AM (corresponding author), Kings Coll London, GKT Sch Med, Dept Cardiol, Denmark Hill Campus,Bessemer Rd, London SE5 9PJ, England.	ajay.shah@kcl.ac.uk	Lanone, Sophie/I-4042-2016	Lanone, Sophie/0000-0003-2509-8799; Shah, Ajay/0000-0002-6547-0631					0	69	69	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					294	296		10.1096/fj.00-0433fje	http://dx.doi.org/10.1096/fj.00-0433fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156941				2022-12-28	WOS:000166872900007
J	Wanagat, J; Cao, ZJ; Pathare, P; Aiken, JM				Wanagat, J; Cao, ZJ; Pathare, P; Aiken, JM			Mitochondrial DNA deletion mutations colocalize with segmental electron transport system abnormalities, muscle fiber atrophy, fiber splitting, and oxidative damage in sarcopenia	FASEB JOURNAL			English	Article						aging; skeletal muscle; laser capture microdissection	AGING SKELETAL-MUSCLE; RAGGED-RED FIBERS; CONTRACTILE PROPERTIES; CALORIC RESTRICTION; SOLEUS MUSCLE; HUMAN HEARTS; WILD-TYPE; AGE; RATS; NUMBER	The in vivo cellular impact of age-associated mitochondrial DNA mutations is unknown, We hypothesized that mitochondrial DNA deletion mutations contribute to the fiber atrophy and loss that cause sarcopenia, the age-related decline of muscle mass and function. We examined 82,713 rectus femoris muscle fibers from Fischer 344 x Brown Norway F-1 hybrid rats of ages 5, 18, and 38 months through 1000 microns by serial cryosectioning and histochemical staining for cytochrome c oxidase and succinate dehydrogenase, Between 5 and 38 months of age, the rectus femoris muscle in the hybrid rat demonstrated a 33% decrease in mass concomitant with a 30% decrease in total fibers at the muscle mid-belly, We observed significant increases in the number of mitochondrial abnormalities with age from 289 +/- 8 ETS abnormal fibers in the entire 5-month-old rectus femoris to 1094 +/- 126 in the 38-month-old as calculated from the volume density of these abnormalities. Segmental mitochondrial abnormalities contained mitochondrial DNA deletion mutations as revealed by laser capture microdissection and whole mitochondrial genome amplification, Muscle fibers harboring mitochondrial deletions often displayed atrophy, splitting and increased steady-state levels of oxidative nucleic damage. These data suggest a causal role for age-associated mitochondrial DNA deletion mutations in sarcopenia.	Univ Wisconsin, Dept Anim Hlth & Biomed Sci, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Med Scientist Training Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Aiken, JM (corresponding author), Univ Wisconsin, Dept Anim Hlth & Biomed Sci, 1656 Linden Dr, Madison, WI 53706 USA.		Wanagat, Jonathan/B-2856-2009	Aiken, Judd/0000-0001-6119-4521; Wanagat, Jonathan/0000-0002-8460-8616	NIA NIH HHS [P01 AG11915, R01 AG11604, T32 AG00213] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [T32AG000213, R01AG011604, P01AG011915] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALNAQEEB MA, 1987, J ANAT, V153, P31; ANSVED T, 1989, J NEUROL SCI, V93, P105, DOI 10.1016/0022-510X(89)90165-2; ANSVED T, 1995, ACTA PHYSIOL SCAND, V154, P291, DOI 10.1111/j.1748-1716.1995.tb09913.x; ASPNES LE, 1997, FASEB J, V11, P673; BENJAMIN IJ, 1989, CIRC RES, V65, P657, DOI 10.1161/01.RES.65.3.657; BENZI G, 1992, NEUROBIOL AGING, V13, P361, DOI 10.1016/0197-4580(92)90109-B; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; Brierley EJ, 1996, QJM-MON J ASSOC PHYS, V89, P251; BROWN LM, 1982, MUSCLE NERVE, V5, P645, DOI 10.1002/mus.880050810; BROWN M, 1987, AGE AGEING, V16, P244, DOI 10.1093/ageing/16.4.244; BYRNE E, 1992, MUTAT RES, V275, P125, DOI 10.1016/0921-8734(92)90017-J; Chariot P, 1996, ACTA NEUROPATHOL, V91, P530, DOI 10.1007/s004010050462; Croteau DL, 1999, MUTAT RES-DNA REPAIR, V434, P137, DOI 10.1016/S0921-8777(99)00025-7; Desai VG, 1996, ARCH BIOCHEM BIOPHYS, V333, P145, DOI 10.1006/abbi.1996.0375; Dubowitz V., 1985, MUSCLE BIOPSY PRACTI; ENRIGHT HU, 1992, NUCLEIC ACIDS RES, V20, P3341, DOI 10.1093/nar/20.13.3341; EVANS WJ, 1995, J GERONTOL A-BIOL, V50, P5, DOI 10.1093/gerona/50A.Special_Issue.5; Fernandes G, 1997, J CLIN IMMUNOL, V17, P85, DOI 10.1023/A:1027344730553; Fiori MG, 1996, CLIN NEUROPATHOL, V15, P240; FUJISAWA K, 1974, J NEUROL SCI, V22, P353, DOI 10.1016/0022-510X(74)90006-9; GONYEA W, 1977, ACTA PHYSIOL SCAND, V99, P105, DOI 10.1111/j.1748-1716.1977.tb10358.x; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HAYAKAWA M, 1991, BIOCHEM BIOPH RES CO, V179, P1023, DOI 10.1016/0006-291X(91)91921-X; HAYAKAWA M, 1993, MOL CELL BIOCHEM, V119, P95, DOI 10.1007/BF00926859; HAYAKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P979, DOI 10.1016/0006-291X(92)92300-M; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; HOLLOSZY JO, 1991, MECH AGEING DEV, V60, P199, DOI 10.1016/0047-6374(91)90131-I; Howard C, 1998, UNBIASED STEREOLOGY; Khrapko K, 1999, NUCLEIC ACIDS RES, V27, P2434, DOI 10.1093/nar/27.11.2434; Kwong LK, 2000, ARCH BIOCHEM BIOPHYS, V373, P16, DOI 10.1006/abbi.1999.1495; LARSSON L, 1986, J NEUROL SCI, V76, P69, DOI 10.1016/0022-510X(86)90143-7; Lass A, 1998, FREE RADICAL BIO MED, V25, P1089, DOI 10.1016/S0891-5849(98)00144-0; Lee CM, 1998, FREE RADICAL BIO MED, V25, P964, DOI 10.1016/S0891-5849(98)00185-3; Lee HC, 1998, FEBS LETT, V441, P292, DOI 10.1016/S0014-5793(98)01564-6; LEXELL J, 1988, J NEUROL SCI, V84, P275, DOI 10.1016/0022-510X(88)90132-3; LJUNGMAN M, 1992, MOL CARCINOGEN, V5, P264, DOI 10.1002/mc.2940050406; LOPEZ ME, 1999, EXERCISE OXYGEN TOXI, P831; LOPEZ ME, 2000, IN PRESS MUTAT RES; MECOCCI P, 1993, ANN NEUROL, V34, P609, DOI 10.1002/ana.410340416; Mita S, 1998, MUSCLE NERVE, V21, P490, DOI 10.1002/(SICI)1097-4598(199804)21:4<490::AID-MUS7>3.0.CO;2-4; Moraes C T, 1996, Methods Enzymol, V264, P522, DOI 10.1016/S0076-6879(96)64046-4; Mueller-Hoecker J., 1992, Mutation Research, V275, P115; Mueller-Hoecker J., 1993, Virchows Archiv A Pathological Anatomy and Histopathology, V422, P7; Mueller-Hoecker J., 1996, Mechanisms of Ageing and Development, V86, P197; Mueller-Hoecker J., 1992, Pathology Research and Practice, V188, P701; MUELLER-HOECKER J, 1990, Journal of the Neurological Sciences, V100, P14; MUELLER-HOECKER J, 1989, American Journal of Pathology, V134, P1167; Mueller-Hoecker Josef, 1997, Hepatology, V26, P709; OH SJ, 1992, ANN NEUROL, V32, P253; Ozawa M, 1998, J NEUROL SCI, V159, P170, DOI 10.1016/S0022-510X(98)00152-X; PINZ KG, 1995, J BIOL CHEM, V270, P9202, DOI 10.1074/jbc.270.16.9202; Porteous WK, 1998, EUR J BIOCHEM, V257, P192, DOI 10.1046/j.1432-1327.1998.2570192.x; RICHTER C, 1992, MUTAT RES, V275, P249, DOI 10.1016/0921-8734(92)90029-O; RIFAI Z, 1995, ANN NEUROL, V37, P24, DOI 10.1002/ana.410370107; Rosenberg IH, 1997, J NUTR, V127, pS990, DOI 10.1093/jn/127.5.990S; SADEH M, 1988, J NEUROL SCI, V87, P67, DOI 10.1016/0022-510X(88)90055-X; SCHULTZ E, 1994, REV PHYSL BIOCH PHAR, V123, P214; SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13; SELIGMAN AM, 1968, J CELL BIOL, V38, P1, DOI 10.1083/jcb.38.1.1; Sheehan D.C., 1980, THEORY PRACTICE HIST; Short K. R., 1999, Journal of Endocrinological Investigation, V22, P95; SHOUBRIDGE EA, 1990, CELL, V62, P43, DOI 10.1016/0092-8674(90)90238-A; SOHAL RS, 1994, MECH AGEING DEV, V76, P215, DOI 10.1016/0047-6374(94)91595-4; SUGIYAMA S, 1993, BIOCHEM MOL BIOL INT, V30, P937	64	284	288	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					322	332		10.1096/fj.00-0320com	http://dx.doi.org/10.1096/fj.00-0320com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156948				2022-12-28	WOS:000166872900014
J	Jones, SA; Horiuchi, S; Topley, N; Yamamoto, N; Fuller, GM				Jones, SA; Horiuchi, S; Topley, N; Yamamoto, N; Fuller, GM			The soluble interleukin 6 receptor: mechanisms of production and implications in disease	FASEB JOURNAL			English	Review						cytokines; soluble receptors; interleukin 6; inflammation; shedding	C-REACTIVE PROTEIN; LEUKEMIA INHIBITORY FACTOR; NECROSIS-FACTOR-ALPHA; BLOOD MONONUCLEAR-CELLS; IL-6 SIGNAL TRANSDUCER; ACUTE-PHASE RESPONSE; SERUM AMYLOID-A; ONCOSTATIN-M; PROTEOLYTIC CLEAVAGE; RHEUMATOID-ARTHRITIS	Interleukin 6 (IL-6) performs a prominent role during disease and has been described as both a pro- and anti-inflammatory cytokine. A key feature in the regulation of IL-6 responses has been the identification of a soluble interleukin 6 receptor (sIL-6R), which forms a ligand-receptor complex with IL-6 that is capable of stimulating a variety of cellular responses including proliferation, differentiation and activation of inflammatory processes. Elevated sIL-6R levels have been documented in numerous clinical conditions indicating that its production is coordinated as part of a disease response. Thus, sIL-6R has the potential to regulate both local and systemic IL-6-mediated events. This review will outline the central role of sIL-6R in the coordination of IL-6 responses, Details relating to the mechanisms of sIL-6R production will be provided, while the potential significance of sIL-6R during the development of clinical conditions will be emphasized. We want to convey, therefore, that when thinking about the inflammatory capability of IL-6, it is essential to consider not only the action of IL-6 itself, but also the effect sIL-6R may have on cellular processes.	Cardiff Univ, Cardiff Sch Biosci, Cardiff CF10 3US, S Glam, Wales; Tokyo Med & Dent Univ, Dept Microbiol, Tokyo 113, Japan; Cardiff Univ, Inst Nephrol, Cardiff CF14 4XN, S Glam, Wales; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA	Cardiff University; Tokyo Medical & Dental University (TMDU); Cardiff University; University of Alabama System; University of Alabama Birmingham	Jones, SA (corresponding author), Cardiff Univ, Cardiff Sch Biosci, Biomed Sci Bldg,Museum Ave,POB 911, Cardiff CF10 3US, S Glam, Wales.	JonesSA@cf.ac.uk	Jones, Simon Arnett/Q-7017-2018	Jones, Simon Arnett/0000-0001-7297-9711				Alonzi T, 1998, J EXP MED, V187, P461, DOI 10.1084/jem.187.4.461; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Atreya R, 2000, NAT MED, V6, P583, DOI 10.1038/75068; Bank U, 1999, J INTERF CYTOK RES, V19, P1277, DOI 10.1089/107999099312957; Banning U, 1998, IMMUNOL INVEST, V27, P47, DOI 10.3109/08820139809070889; Barber MD, 1999, CLIN SCI, V96, P83, DOI 10.1042/CS19980185; BARTON BE, 1993, INFECT IMMUN, V61, P1496, DOI 10.1128/IAI.61.4.1496-1499.1993; BAUMANN H, 1991, J BIOL CHEM, V266, P20424; Bennett TA, 1996, J IMMUNOL, V156, P3093; Bharadwaj D, 1999, J EXP MED, V190, P585, DOI 10.1084/jem.190.4.585; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Boe A, 1999, CYTOKINE, V11, P1057, DOI 10.1006/cyto.1999.0502; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; Champagne B, 1998, J IMMUNOL, V161, P6398; Cheng JG, 1997, J NEUROCHEM, V69, P2278; Cichy J, 1997, J IMMUNOL, V159, P5648; Cichy J, 1996, BIOCHEM BIOPH RES CO, V227, P318, DOI 10.1006/bbrc.1996.1507; Coeshott C, 1999, P NATL ACAD SCI USA, V96, P6261, DOI 10.1073/pnas.96.11.6261; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DEBENEDETTI F, 1991, ARTHRITIS RHEUM, V34, P1158, DOI 10.1002/art.1780340912; Dempsey PJ, 1997, J CELL BIOL, V138, P747, DOI 10.1083/jcb.138.4.747; Desgeorges A, 1997, J RHEUMATOL, V24, P1510; Diamant M, 1997, FEBS LETT, V412, P379, DOI 10.1016/S0014-5793(97)00750-3; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; ESCARY JL, 1993, NATURE, V363, P361, DOI 10.1038/363361a0; FILEP J, 1989, LIFE SCI, V44, P517, DOI 10.1016/0024-3205(89)90613-9; Franchimont N, 1997, J BIOL CHEM, V272, P12144, DOI 10.1074/jbc.272.18.12144; FRIELING JTM, 1995, J INFECT DIS, V171, P469, DOI 10.1093/infdis/171.2.469; Frieling JTM, 1996, CRIT CARE MED, V24, P1801, DOI 10.1097/00003246-199611000-00007; Gaillard JP, 1997, EUR J IMMUNOL, V27, P3332, DOI 10.1002/eji.1830271232; GAILLARD JP, 1993, EUR J IMMUNOL, V23, P820, DOI 10.1002/eji.1830230408; GANAPATHI MK, 1988, BIOCHEM BIOPH RES CO, V157, P271, DOI 10.1016/S0006-291X(88)80043-3; GEARING DP, 1991, CELL, V66, P9, DOI 10.1016/0092-8674(91)90131-H; GEISTERFER M, 1995, CYTOKINE, V7, P503, DOI 10.1006/cyto.1995.0068; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; Guerne PA, 1999, MATRIX BIOL, V18, P253, DOI 10.1016/S0945-053X(99)00021-9; GUERNE PA, 1989, J CLIN INVEST, V83, P585, DOI 10.1172/JCI113921; GUILLEN I, 1995, AM J PHYSIOL-REG I, V269, pR229, DOI 10.1152/ajpregu.1995.269.2.R229; HACK CE, 1989, BLOOD, V74, P1704; Haggiag S., 1999, FEBS LETT, V2, P1; Hampel H, 1998, BRAIN RES, V780, P356, DOI 10.1016/S0006-8993(97)01355-3; Hans VHJ, 1999, NEUROREPORT, V10, P409; HARDIN J, 1994, BLOOD, V84, P3063; Hargreaves PG, 1998, BRIT J HAEMATOL, V101, P694, DOI 10.1046/j.1365-2141.1998.00754.x; Hasegawa M, 1999, RHEUMATOLOGY, V38, P612, DOI 10.1093/rheumatology/38.7.612; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HERMANN E, 1989, CLIN EXP RHEUMATOL, V7, P411; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; Hirota H, 1996, J EXP MED, V183, P2627, DOI 10.1084/jem.183.6.2627; HIROTA H, 1995, P NATL ACAD SCI USA, V92, P4862, DOI 10.1073/pnas.92.11.4862; HONDA M, 1992, J IMMUNOL, V148, P2175; HORII Y, 1989, J IMMUNOL, V143, P3949; HORIUCHI S, 1994, EUR J IMMUNOL, V24, P1945, DOI 10.1002/eji.1830240837; Horiuchi S, 1998, IMMUNOLOGY, V95, P360, DOI 10.1046/j.1365-2567.1998.00622.x; HOUSSIAU FA, 1988, ARTHRITIS RHEUM, V31, P784, DOI 10.1002/art.1780310614; Jablonska E, 1998, CYTOKINE, V10, P540, DOI 10.1006/cyto.1997.0327; Jacobson SH, 1998, NEPHRON, V80, P401, DOI 10.1159/000045211; JAKOBSEN PH, 1994, INFECT IMMUN, V62, P4374, DOI 10.1128/IAI.62.10.4374-4379.1994; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; Jones SA, 1998, EUR J IMMUNOL, V28, P3514, DOI 10.1002/(SICI)1521-4141(199811)28:11<3514::AID-IMMU3514>3.3.CO;2-K; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; Keul R, 1998, CYTOKINE, V10, P729, DOI 10.1006/cyto.1997.0343; KEW RR, 1990, J LAB CLIN MED, V115, P339; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; Klouche M, 1999, J IMMUNOL, V163, P4583; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Kotake S, 1996, J BONE MINER RES, V11, P88; KUMAR G, 1994, J IMMUNOL, V153, P4436; Kyriakou D, 1997, INT J HEMATOL, V66, P367; Kyrtsonis MC, 1996, BRIT J HAEMATOL, V93, P398, DOI 10.1046/j.1365-2141.1996.4721018.x; Le-Barillec K, 1999, J CLIN INVEST, V103, P1039, DOI 10.1172/JCI5779; LUDWIG H, 1991, BLOOD, V77, P2794; LUST JA, 1992, CYTOKINE, V4, P96, DOI 10.1016/1043-4666(92)90043-Q; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MACKIEWICZ A, 1992, FEBS LETT, V306, P257, DOI 10.1016/0014-5793(92)81012-B; MAES M, 1995, J PSYCHIAT RES, V29, P141, DOI 10.1016/0022-3956(94)00049-W; Maes M, 1999, BIOL PSYCHIAT, V45, P833, DOI 10.1016/S0006-3223(98)00131-0; Maione D, 1998, EMBO J, V17, P5588, DOI 10.1093/emboj/17.19.5588; Martinez ME, 1997, CANCER EPIDEM BIOMAR, V6, P1; Marz P, 1998, P NATL ACAD SCI USA, V95, P3251, DOI 10.1073/pnas.95.6.3251; MASU Y, 1993, NATURE, V365, P27, DOI 10.1038/365027a0; MATSUDA T, 1994, BLOOD, V83, P3457; MATSUDA T, 1995, J BIOL CHEM, V270, P11037, DOI 10.1074/jbc.270.19.11037; MATSUMOTO T, 1995, INT J ANTIMICROB AG, V6, P85, DOI 10.1016/0924-8579(95)00024-0; Matsumura M, 1999, LIFE SCI, V65, pPL129, DOI 10.1016/S0024-3205(99)00368-9; MIHARA M, 1995, BRIT J RHEUMATOL, V34, P321; MITSUYAMA K, 1995, GUT, V36, P45, DOI 10.1136/gut.36.1.45; MODRELL B, 1994, GROWTH FACTORS, V11, P81, DOI 10.3109/08977199409001050; Modur V, 1997, J CLIN INVEST, V100, P2752, DOI 10.1172/JCI119821; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; MonteroJulian FA, 1997, CLIN CANCER RES, V3, P1443; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MULLBERG J, 1994, J IMMUNOL, V152, P4958; MULLBERG J, 1993, EUR J IMMUNOL, V23, P473, DOI 10.1002/eji.1830230226; MULLBERG J, 1995, J IMMUNOL, V155, P5198; MULLBERG J, 1993, FEBS LETT, V332, P174, DOI 10.1016/0014-5793(93)80507-Q; MULLBERG J, 1992, BIOCHEM BIOPH RES CO, V189, P794, DOI 10.1016/0006-291X(92)92272-Y; Muller-Newen G, 1998, J IMMUNOL, V161, P6347; MullerNewen G, 1996, EUR J BIOCHEM, V236, P837, DOI 10.1111/j.1432-1033.1996.00837.x; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; MurakamiMori K, 1996, INT IMMUNOL, V8, P595, DOI 10.1093/intimm/8.4.595; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NARAZAKI M, 1993, BLOOD, V82, P1120, DOI 10.1182/blood.V82.4.1120.bloodjournal8241120; Neddermann P, 1996, J BIOL CHEM, V271, P30986, DOI 10.1074/jbc.271.48.30986; NOVICK D, 1989, J EXP MED, V170, P1409, DOI 10.1084/jem.170.4.1409; Ogata A, 1997, J IMMUNOL, V159, P2212; Oh JW, 1998, J IMMUNOL, V161, P4992; Oh JW, 1999, J NEUROVIROL, V5, P82, DOI 10.3109/13550289909029749; Oh JW, 1996, CYTOKINE, V8, P401, DOI 10.1006/cyto.1996.0055; Ohshima S, 1998, P NATL ACAD SCI USA, V95, P8222, DOI 10.1073/pnas.95.14.8222; OHTANI K, 1995, BRIT J HAEMATOL, V91, P116, DOI 10.1111/j.1365-2141.1995.tb05255.x; Ozbek S, 1998, J BIOL CHEM, V273, P21374, DOI 10.1074/jbc.273.33.21374; Padberg F, 1999, J NEUROIMMUNOL, V99, P218, DOI 10.1016/S0165-5728(99)00120-4; PATTERSON PH, 1994, P NATL ACAD SCI USA, V91, P7833, DOI 10.1073/pnas.91.17.7833; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; PEPYS MB, 1983, ADV IMMUNOL, V34, P141, DOI 10.1016/S0065-2776(08)60379-X; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Peters M, 1997, J IMMUNOL, V159, P1474; Peters M, 1996, J EXP MED, V183, P1399, DOI 10.1084/jem.183.4.1399; Peters M, 1998, BLOOD, V92, P3495, DOI 10.1182/blood.V92.10.3495.422k47_3495_3504; Peters M, 1997, J EXP MED, V185, P755, DOI 10.1084/jem.185.4.755; Petrinovic-Doresic J, 1999, OCUL IMMUNOL INFLAMM, V7, P75, DOI 10.1076/ocii.7.2.75.4017; Pflanz S, 1999, FEBS LETT, V454, P172, DOI 10.1016/S0014-5793(99)00659-6; Pflanz S, 1999, FEBS LETT, V450, P117, DOI 10.1016/S0014-5793(99)00477-9; POLI G, 1990, J EXP MED, V172, P151, DOI 10.1084/jem.172.1.151; Pulkki K, 1996, BRIT J HAEMATOL, V92, P370, DOI 10.1046/j.1365-2141.1996.d01-1470.x; Rebouissou C, 1998, BLOOD, V91, P4727, DOI 10.1182/blood.V91.12.4727.412k35_4727_4737; Robak T, 1998, MEDIAT INFLAMM, V7, P347, DOI 10.1080/09629359890875; Romano M, 1997, IMMUNITY, V6, P315, DOI 10.1016/S1074-7613(00)80334-9; Romas E, 1996, J EXP MED, V183, P2581, DOI 10.1084/jem.183.6.2581; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; Rosendahl MS, 1997, J BIOL CHEM, V272, P24588, DOI 10.1074/jbc.272.39.24588; SAITO M, 1992, J IMMUNOL, V148, P4066; Salvi M, 1996, J CLIN ENDOCR METAB, V81, P2976, DOI 10.1210/jc.81.8.2976; SCHINDLER R, 1990, BLOOD, V75, P40; Schirmacher P, 1998, AM J PATHOL, V153, P639, DOI 10.1016/S0002-9440(10)65605-2; SCHOBITZ B, 1995, FASEB J, V9, P659, DOI 10.1096/fasebj.9.8.7768358; Schroder W., 1996, Clinical and Experimental Obstetrics and Gynecology, V23, P10; Senaldi G, 1999, P NATL ACAD SCI USA, V96, P11458, DOI 10.1073/pnas.96.20.11458; Silacci P, 1998, J BIOL CHEM, V273, P13625, DOI 10.1074/jbc.273.22.13625; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Stubner S, 1999, NEUROSCI LETT, V259, P145, DOI 10.1016/S0304-3940(98)00916-1; Sui XW, 1999, BLOOD, V93, P2525, DOI 10.1182/blood.V93.8.2525.408k11_2525_2532; SUI XW, 1995, P NATL ACAD SCI USA, V92, P2859, DOI 10.1073/pnas.92.7.2859; SZEKANECZ Z, 1994, AGENTS ACTIONS, V42, P159, DOI 10.1007/BF01983484; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; Tajima S, 1996, J EXP MED, V184, P1357, DOI 10.1084/jem.184.4.1357; Takagi N, 1998, ARTHRITIS RHEUM, V41, P2117, DOI 10.1002/1529-0131(199812)41:12<2117::AID-ART6>3.3.CO;2-G; Takayanagi H, 1999, J CLIN INVEST, V104, P137, DOI 10.1172/JCI6093; TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924; THARBARD W, 1999, CLIN CANCER RES, V5, P2693; TILG H, 1994, BLOOD, V83, P113; UDAGAWA N, 1995, J EXP MED, V182, P1461, DOI 10.1084/jem.182.5.1461; ULICH TR, 1991, AM J PATHOL, V138, P1097; Van Wagoner NJ, 1999, J NEUROSCI, V19, P5236; VanRiet J, 1997, LEUKEMIA, V11, P284, DOI 10.1038/sj.leu.2400564; Vollmer P, 1996, INFECT IMMUN, V64, P3646, DOI 10.1128/IAI.64.9.3646-3651.1996; Vollmer P, 1996, J IMMUNOL METHODS, V199, P47, DOI 10.1016/S0022-1759(96)00163-9; Wagner JA, 1996, J EXP MED, V183, P2417, DOI 10.1084/jem.183.6.2417; Walcheck B, 1996, NATURE, V380, P720, DOI 10.1038/380720a0; Walev I, 1996, P NATL ACAD SCI USA, V93, P7882, DOI 10.1073/pnas.93.15.7882; WENDLING D, 1993, J RHEUMATOL, V20, P259; Xing Z, 1998, J CLIN INVEST, V101, P311, DOI 10.1172/JCI1368; Yamamoto M, 2000, J IMMUNOL, V164, P4878, DOI 10.4049/jimmunol.164.9.4878; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YOKOYAMA A, 1995, CLIN EXP IMMUNOL, V100, P325; Yokoyama A, 1997, AM J RESP CRIT CARE, V156, P1688, DOI 10.1164/ajrccm.156.5.9610070; Yoshida A, 1996, ASSIST REPROD REV, V67, P93; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407; Zhou YW, 1998, MICROBIOL IMMUNOL, V42, P109, DOI 10.1111/j.1348-0421.1998.tb02258.x; Zouki C, 1997, J CLIN INVEST, V100, P522, DOI 10.1172/JCI119561	177	465	488	1	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2001	15	1					43	58		10.1096/fj.99-1003rev	http://dx.doi.org/10.1096/fj.99-1003rev			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149892				2022-12-28	WOS:000166312400013
J	Kasinsky, HE; Lewis, JD; Dacks, JB; Ausio, J				Kasinsky, HE; Lewis, JD; Dacks, JB; Ausio, J			Origin of H1 linker histones	FASEB JOURNAL			English	Review						histone H1; evolution; protists; bacteria	COMPLETE GENOME SEQUENCE; CRYSTAL-STRUCTURE; GLOBULAR DOMAIN; DNA-BINDING; PROTEIN; EVOLUTION; VARIANTS; CONTAIN; FOLD; H-1	In which taxa did H1 linker histones appear in the course of evolution? Detailed comparative analysis of the histone H1 and histone H1-related sequences available to date suggests that the origin of histone H1 can be traced to bacteria. The data also reveal that the sequence corresponding to the 'winged helix' motif of the globular structural domain, a domain characteristic of all metazoan histone H1 molecules, is evolutionarily conserved and appears separately in several divergent lines of protists. Some protists, however, appear to have only a lysine-rich basic protein, which has compositional similarity to some of the histone H1-like proteins from eubacteria and to the carboxy-terminal domain of the H1 linker histones from animals and plants. No lysine-rich basic proteins have been described in archaebacteria, The data presented in this review provide the surprising conclusion that whereas DNA-condensing H1-related histones may have arisen early in evolution in eubacteria, the appearance of the sequence motif corresponding to the globular domain of metazoan H1s occurred much later in the protists, after and independently of the appearance of the chromosomal core histones in archaebacteria.	Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada; Univ British Columbia, Dept Zool, Vancouver, BC V6T 1Z4, Canada; Dalhousie Univ, Dept Biochem & Mol Biol, Canadian Inst Adv Res, Program Evolut Biol, Halifax, NS B3H 4H7, Canada	University of Victoria; University of British Columbia; Canadian Institute for Advanced Research (CIFAR); Dalhousie University	Ausio, J (corresponding author), Univ Victoria, Dept Biochem & Microbiol, Petch Bldg,Room 220, Victoria, BC V8W 3P6, Canada.	jausio@uvic.ca	Dacks, Joel/AAE-3308-2021	Dacks, Joel/0000-0003-4520-5694				ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; ALLAN RN, 1986, IEEE T POWER SYST, V1, P1, DOI 10.1109/TPWRS.1986.4335006; Arenhovel H., 1991, Few-Body Systems Supplementum, P1, DOI 10.1007/978-3-7091-6701-4_1; ARENTS G, 1995, P NATL ACAD SCI USA, V92, P11170, DOI 10.1073/pnas.92.24.11170; Ausio J, 1999, J BIOL CHEM, V274, P31115, DOI 10.1074/jbc.274.44.31115; Barra JL, 2000, MOL CELL BIOL, V20, P61, DOI 10.1128/MCB.20.1.61-69.2000; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; BURRI M, 1993, PARASITOL RES, V79, P649, DOI 10.1007/BF00932507; CAPLAN EB, 1975, BIOCHIM BIOPHYS ACTA, V407, P109, DOI 10.1016/0005-2787(75)90028-3; CHARLESWORTH MC, 1977, EUR J BIOCHEM, V75, P241, DOI 10.1111/j.1432-1033.1977.tb11523.x; CHURCHILL MEA, 1991, TRENDS BIOCHEM SCI, V16, P92, DOI 10.1016/0968-0004(91)90040-3; COLEMAN C C, 1984, Seminars in Interventional Radiology, V1, P24; Dacks J, 1999, J MOL EVOL, V48, P779, DOI 10.1007/PL00013156; Dacks JB, 1999, COMP BIOCHEM PHYS A, V124, P287, DOI 10.1016/S1095-6433(99)00117-8; Doolittle WF, 1999, SCIENCE, V284, P2124, DOI 10.1126/science.284.5423.2124; DUSCHAK VG, 1990, BIOCHIM BIOPHYS ACTA, V1040, P159, DOI 10.1016/0167-4838(90)90071-M; EICKBUSH TH, 1978, BIOCHEMISTRY-US, V17, P4955, DOI 10.1021/bi00616a016; Faguy DM, 1999, CURR BIOL, V9, pR883; HACKSTADT T, 1991, P NATL ACAD SCI USA, V88, P3937, DOI 10.1073/pnas.88.9.3937; HANSEN JC, 1992, TRENDS BIOCHEM SCI, V17, P187, DOI 10.1016/0968-0004(92)90264-A; Hausmann K., 1996, PROTOZOOLOGY; HAYASHI T, 1987, J BIOCHEM-TOKYO, V102, P369, DOI 10.1093/oxfordjournals.jbchem.a122063; ISENBERG I, 1978, CELL NUCLEUS, P135; IWAI K, 1964, NUCLEOHISTONES, P59; JARDINE NJ, 1978, BIOCHEM J, V169, P103, DOI 10.1042/bj1690103; JOHNS EW, 1971, HISTONES NUCLEOHISTO, P1; Kawarabayasi Y, 1999, DNA Res, V6, P83, DOI 10.1093/dnares/6.2.83; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Landsman D, 1996, TRENDS BIOCHEM SCI, V21, P287, DOI 10.1016/S0968-0004(96)30030-3; LENNARD AC, 1985, EMBO J, V4, P3455, DOI 10.1002/j.1460-2075.1985.tb04104.x; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MENDE LM, 1983, BIOCHEMISTRY-US, V22, P38, DOI 10.1021/bi00270a006; Morris RL, 1999, J EUKARYOT MICROBIOL, V46, P648, DOI 10.1111/j.1550-7408.1999.tb05142.x; NEELIN JM, 1964, CAN J BIOCHEM PHYS, V42, P1743, DOI 10.1139/o64-185; Patterton HG, 1998, J BIOL CHEM, V273, P7268, DOI 10.1074/jbc.273.13.7268; Ramakrishnan V, 1997, CRIT REV EUKAR GENE, V7, P215, DOI 10.1615/CritRevEukarGeneExpr.v7.i3.20; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; Ramon A, 2000, MOL MICROBIOL, V35, P223, DOI 10.1046/j.1365-2958.2000.01702.x; RIZZO PJ, 1985, BIOCHEMISTRY-US, V24, P1727, DOI 10.1021/bi00328a024; SALAROVIRA M, 1991, CHROMOSOMA, V100, P510, DOI 10.1007/BF00352201; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Stiller JW, 1999, MOL BIOL EVOL, V16, P1270, DOI 10.1093/oxfordjournals.molbev.a026217; SUBIRANA JA, 1990, BIOPOLYMERS, V29, P1351, DOI 10.1002/bip.360291003; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TORO GC, 1988, EXP CELL RES, V174, P16, DOI 10.1016/0014-4827(88)90137-1; Ushinsky SC, 1997, YEAST, V13, P151, DOI 10.1002/(SICI)1097-0061(199702)13:2<151::AID-YEA94>3.0.CO;2-5; van Holde K. E., 1989, CHROMATIN, P1; VERNET G, 1990, BIOCHIM BIOPHYS ACTA, V1048, P281, DOI 10.1016/0167-4781(90)90068-D; WELLS D, 1991, NUCLEIC ACIDS RES, V19, P2173, DOI 10.1093/nar/19.suppl.2173; WU M, 1994, MOL CELL BIOL, V14, P10, DOI 10.1128/MCB.14.1.10; Zhou YB, 1998, NATURE, V395, P402, DOI 10.1038/26521; ZLANOTOVA J, 1998, FASEB J, V12, P421	54	169	176	2	22	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2001	15	1					34	42		10.1096/fj.00-0237rev	http://dx.doi.org/10.1096/fj.00-0237rev			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149891				2022-12-28	WOS:000166312400012
J	Goepfert, TM; McCarthy, M; Kittrell, FS; Stephens, C; Ullrich, RL; Brinkley, BR; Medina, D				Goepfert, TM; McCarthy, M; Kittrell, FS; Stephens, C; Ullrich, RL; Brinkley, BR; Medina, D			Progesterone facilitates chromosome instability (aneuploidy) in p53 null normal mammary epithelial cells	FASEB JOURNAL			English	Article						estrogen; aneuploidy; centrosomes; steroid hormone	BREAST-CANCER-CELLS; IN-SITU; GENETIC INSTABILITY; BALB/C MICE; RECEPTOR; TUMORS; GLAND; ESTROGEN; DIFFERENTIATION; CARCINOGENESIS	Mammary epithelial cells from p53 null mice have been shown recently to exhibit an increased risk for tumor development, Hormonal stimulation markedly increased tumor development in p53 null mammary cells. Here we demonstrate that mammary tumors arising in p53 null mammary cells are highly aneuploid, with greater than 70% of the tumor cells containing altered chromosome number and a mean chromosome number of 56, Normal mammary cells of p53 null genotype and aged less than 14 wk do not exhibit aneuploidy in primary cell culture, Significantly, the hormone progesterone, but not estrogen, increases the incidence of aneuploidy in morphologically normal p53 null mammary epithelial cells. Such cells exhibited 40% aneuploidy and a mean chromosome number of 54, The increase in aneuploidy measured in p53 null tumor cells or hormonally stimulated normal p53 null cells was not accompanied by centrosome amplification. These results suggest that normal levels of progesterone can facilitate chromosomal instability in the absence of the tumor suppressor gene, p53, The results support the emerging hypothesis based both on human epidemiological and animal model studies that progesterone markedly enhances mammary tumorigenesis.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Univ Texas, Med Branch, Dept Radiat Therapy, Galveston, TX 77550 USA; Univ Texas, MD Anderson Canc Ctr, Dept Vet Med & Surg, Houston, TX 77030 USA	Baylor College of Medicine; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; UTMD Anderson Cancer Center	Medina, D (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza,MS 112A, Houston, TX 77030 USA.	dmedina@bcm.tmc.edu			NATIONAL CANCER INSTITUTE [R37CA041424, R01CA043322, R01CA041424, P01CA064255] Funding Source: NIH RePORTER; NCI NIH HHS [CA43322, CA41424, CA64255] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aardema MJ, 1997, CANCER GENET CYTOGEN, V96, P140, DOI 10.1016/S0165-4608(96)00301-9; ALDAZ CM, 1995, CANCER RES, V55, P3976; ALLRED DC, 2000, DIS BREAST, P355; ALLRED DC, 1997, DUCTAL CARCINOMA IN, P37; BARDON S, 1987, CANCER RES, V47, P1441; BARRETT JC, 1987, MECHANISMS ENV CARCI, V2, P73; BERARDO MD, 1996, HORMONE DEPENDENT CA, P1; Bocchinfuso WP, 1997, J MAMMARY GLAND BIOL, V2, P323, DOI 10.1023/A:1026339111278; Brinkley BR, 1998, CELL MOTIL CYTOSKEL, V41, P281, DOI 10.1002/(SICI)1097-0169(1998)41:4<281::AID-CM1>3.0.CO;2-C; BUTEL JS, 1977, CANCER RES, V37, P1892; Cardiff RD, 1999, J MAMMARY GLAND BIOL, V4, P105, DOI 10.1023/A:1018712905244; CHRISTOV K, 1993, CARCINOGENESIS, V14, P2019, DOI 10.1093/carcin/14.10.2019; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donehower LA, 1996, PROG CLIN BIOL RES, V395, P1; ETHIER SP, 1993, CANCER RES, V53, P627; ETHIER SP, 1982, CANCER RES, V42, P1753; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukatsu K, 1997, SEN-I GAKKAISHI, V53, P15, DOI 10.2115/fiber.53.15; GANTT R, 1978, P NATL ACAD SCI USA, V75, P3809, DOI 10.1073/pnas.75.8.3809; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Greendale GA, 1999, ANN INTERN MED, V130, P262, DOI 10.7326/0003-4819-130-4_Part_1-199902160-00003; Guzman RC, 1999, P NATL ACAD SCI USA, V96, P2520, DOI 10.1073/pnas.96.5.2520; HORWITZ KB, 1985, ENDOCRINOLOGY, V116, P2236, DOI 10.1210/endo-116-6-2236; Imagawa Walter, 1994, P1033; Jerry DJ, 2000, ONCOGENE, V19, P1052, DOI 10.1038/sj.onc.1203270; Jerry DJ, 1998, ONCOGENE, V17, P2305, DOI 10.1038/sj.onc.1202157; JULL JW, 1954, J PATHOL BACTERIOL, V68, P547, DOI 10.1002/path.1700680227; KITTRELL FS, 1992, CANCER RES, V52, P1924; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LENGAUER C, 1977, NATURE, V386, P623; LI ML, 1995, J CELL PHYSIOL, V164, P1, DOI 10.1002/jcp.1041640102; Lingle WL, 1999, AM J PATHOL, V155, P1941, DOI 10.1016/S0002-9440(10)65513-7; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Lydon JP, 1999, CANCER RES, V59, P4276; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; MEDINA D, 1996, MAMMARY TUMOR CELL C, P37; MEDINA D, 2000, IN PRESS J MANNARY G, V5; Medina D, 1996, J MAMMARY GLAND BIOL, V1, P5, DOI 10.1007/BF02096299; Mendelin J, 1999, LAB INVEST, V79, P387; Meyn RE, 1996, INT J CANCER, V65, P466, DOI 10.1002/(SICI)1097-0215(19960208)65:4<466::AID-IJC13>3.0.CO;2-8; MITELMAN F, 1981, HEREDITAS, V95, P79; O'Connell P, 1998, JNCI-J NATL CANCER I, V90, P697, DOI 10.1093/jnci/90.9.697; OSHIMURA M, 1986, ENVIRON MUTAGEN, V8, P129, DOI 10.1002/em.2860080112; Pihan GA, 1999, SEMIN CANCER BIOL, V9, P289, DOI 10.1006/scbi.1999.0131; Pihan GA, 1998, CANCER RES, V58, P3974; Plaut K, 1999, J CELL PHYSIOL, V180, P298, DOI 10.1002/(SICI)1097-4652(199908)180:2<298::AID-JCP17>3.0.CO;2-V; Ponnaiya B, 1997, RADIAT RES, V147, P121, DOI 10.2307/3579411; Prives C, 1999, J PATHOL, V187, P112; Rasnick D, 1999, BIOCHEM J, V340, P621, DOI 10.1042/0264-6021:3400621; Ross RK, 2000, JNCI-J NATL CANCER I, V92, P328, DOI 10.1093/jnci/92.4.328; Schairer C, 2000, JAMA-J AM MED ASSOC, V283, P485, DOI 10.1001/jama.283.4.485; Shyamala G, 1997, TRENDS ENDOCRIN MET, V8, P34, DOI 10.1016/S1043-2760(96)00207-X; Silberstein GB, 1996, CELL GROWTH DIFFER, V7, P945; Sivaraman L, 1998, CARCINOGENESIS, V19, P1573, DOI 10.1093/carcin/19.9.1573; TSUKADA T, 1993, ONCOGENE, V8, P3313; VISSCHER DW, 1993, J CELL BIOCHEM, P114; Wang CN, 1998, APPL ACOUST, V53, P35, DOI 10.1016/S0003-682X(97)00042-X; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	59	66	69	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2000	14	14					2221	2229		10.1096/fj.00-0165com	http://dx.doi.org/10.1096/fj.00-0165com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	371QZ	11053243				2022-12-28	WOS:000165190800015
J	Vassileva, G; Huwyler, L; Poirier, K; Agellon, LB; Toth, MJ				Vassileva, G; Huwyler, L; Poirier, K; Agellon, LB; Toth, MJ			The intestinal fatty acid binding protein is not essential for dietary fat absorption in mice	FASEB JOURNAL			English	Article						intestine; gene targeting; mouse; I-FABP	INSULIN-RESISTANCE; ESCHERICHIA-COLI; GENE; EXPRESSION; POLYMORPHISM; REFINEMENT; ADIPOCYTE; MEMBRANES; PALMITATE; CODON-54	The intestinal fatty acid binding protein (I-FABP) belongs to a family of 15 kDa clamshell-like proteins that are found in many different tissues. So far, nine types have been identified. Their primary structures are highly conserved between species but somewhat less so among the different types. The function of these proteins, many of which are highly expressed, is not web understood. Their ability to bind lipid ligands suggests a role in lipid metabolism, but direct evidence for this idea is still lacking. We tested the hypothesis that I-FABP serves an essential role in the assimilation of dietary fatty acids by disrupting its gene (Fabpi) in the mouse. We discovered that Fabpi(-/-) mice are viable, but they display alterations in body weight and are hyperinsulinemic. Male Fabpi(-/-) mice had elevated plasma triacylglycerols and weighed more regardless of the dietary fat content. In contrast, female Fabpi(-/-) mice gained less weight in response to a high-fat diet. The results clearly demonstrate that I-FABP is not essential for dietary fat absorption. We propose that I-FABP functions as a lipid-sensing component of energy homeostasis that alters body weight gain in a gender-specific fashion.	Novartis Inst Biomed Res, Summit, NJ 07901 USA; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada	Novartis; University of Alberta	Toth, MJ (corresponding author), Novartis Inst Biomed Res, 130-2265,556 Morris Ave, Summit, NJ 07901 USA.		Vassileva, Galya/A-6807-2009					Agren JJ, 1998, ARTERIOSCL THROM VAS, V18, P1606, DOI 10.1161/01.ATV.18.10.1606; BAIER LJ, 1995, J CLIN INVEST, V95, P1281, DOI 10.1172/JCI117778; Bernlohr DA, 1997, ANNU REV NUTR, V17, P277, DOI 10.1146/annurev.nutr.17.1.277; Binas B, 1999, FASEB J, V13, P805, DOI 10.1096/fasebj.13.8.805; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; Coe NR, 1999, J LIPID RES, V40, P967; Corsico B, 1998, P NATL ACAD SCI USA, V95, P12174, DOI 10.1073/pnas.95.21.12174; Darimont C, 2000, J LIPID RES, V41, P84; Glatz JFC, 1996, PROG LIPID RES, V35, P243, DOI 10.1016/S0163-7827(96)00006-9; GREEN RP, 1992, DNA CELL BIOL, V11, P31, DOI 10.1089/dna.1992.11.31; Hodsdon ME, 1996, J MOL BIOL, V264, P585, DOI 10.1006/jmbi.1996.0663; Hogan B., 1994, MANIPULATING MOUSE E, P296; Hohoff C, 1998, FETT-LIPID, V100, P252; Hotamisligil GS, 1996, SCIENCE, V274, P1377, DOI 10.1126/science.274.5291.1377; Hsu KT, 1996, J BIOL CHEM, V271, P13317, DOI 10.1074/jbc.271.23.13317; KNOWLER WC, 1990, DIABETES METAB REV, V6, P1, DOI 10.1002/dmr.5610060101; LOWE JB, 1987, J BIOL CHEM, V262, P5931; Pihlajamaki J, 1997, ARTERIOSCL THROM VAS, V17, P1039, DOI 10.1161/01.ATV.17.6.1039; Richieri GV, 1996, J BIOL CHEM, V271, P11291, DOI 10.1074/jbc.271.19.11291; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; SCAPIN G, 1992, J BIOL CHEM, V267, P4253; SWEETSER DA, 1987, ANNU REV NUTR, V7, P337, DOI 10.1146/annurev.nu.07.070187.002005; SWEETSER DA, 1987, J BIOL CHEM, V262, P16060	24	134	139	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2000	14	13					2040	2046		10.1096/fj.99-0959com	http://dx.doi.org/10.1096/fj.99-0959com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023988				2022-12-28	WOS:000089634400023
J	Yao, X; Kwan, HY; Chan, FL; Chan, NWK; Huang, Y				Yao, X; Kwan, HY; Chan, FL; Chan, NWK; Huang, Y			A protein kinase G-sensitive channel mediates flow-induced Ca2+ entry into vascular endothelial cells	FASEB JOURNAL			English	Article						blood flow; shear stress; nonselective cation channel; endothelium	ACTIVATED ION CHANNELS; NITRIC-OXIDE RELEASE; SHEAR-STRESS; INTRACELLULAR CALCIUM; POTASSIUM CHANNEL; CATION CHANNEL; MEMBRANE; STORES; BLOCK	The hemodynamic force generated by blood flow is considered to be the physiologically most important stimulus for the release of nitric oxide (NO) and prostacyclin (PGI(2)) from vascular endothelial cells (1). NO and PGI(2) then act on the underlying smooth muscle cells, causing vasodilation and thus lowering blood pressure (2, 3). One critical early event occurring in this now-induced regulation of vascular tone is that blood flow induces Ca2+ entry into vascular endothelial cells, which in turn leads to the formation of NO (4, 5). Here we report a mechanosensitive Ca2+-permeable channel in vascular endothelial cells. The activity of the channel was inhibited by 8-Br-cGMP, a membrane-permeant activator of protein kinase G (PKG), in cell-attached membrane patches. The inhibition could be reversed by PKG inhibitor KT5823 or H-8. A direct application of active PKG in inside-out patches blocked the channel activity. Gd3+, Ni2+, or SK&F-96365 also inhibited the channel activity. A study of fluorescent Ca2+ entry revealed a striking pharmacological similarity between the Ca2+ entry elicited by flow and the mechanosensitive Ca2+-permeable channel we identified, suggesting that this channel is the primary pathway mediating flow-induced Ca2+ entry into vascular endothelial cells.	Chinese Univ Hong Kong, Fac Med, Dept Physiol, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Fac Med, Dept Anat, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong	Yao, X (corresponding author), Chinese Univ Hong Kong, Fac Med, Dept Physiol, 319 BMSB, Shatin, Hong Kong, Peoples R China.		Huang, Yu/K-2866-2017; Yao, Xiaoqiang/I-5413-2016; Chan, Franky L./M-1043-2018	Huang, Yu/0000-0002-1277-6784; Yao, Xiaoqiang/0000-0002-0687-8186; Chan, Franky L./0000-0003-0567-2052; KWAN, Hiu Yee/0000-0002-6088-7323				ADAMS DJ, 1989, FASEB J, V3, P2389, DOI 10.1096/fasebj.3.12.2477294; Ando Joji, 1993, Frontiers of Medical and Biological Engineering, V5, P17; BEEBE SJ, 1986, ENZYMES, V17, P43; Bevan JA, 1997, INT J MICROCIRC, V17, P248, DOI 10.1159/000179237; CABELLO OA, 1993, BIOCHEM J, V295, P357, DOI 10.1042/bj2950357; COHEN RA, 1995, CIRCULATION, V92, P3337, DOI 10.1161/01.CIR.92.11.3337; COOKE JP, 1991, J CLIN INVEST, V88, P1663, DOI 10.1172/JCI115481; Davies PF, 1995, FLOW DEPENDENT REGUL, P46; GRIDER JR, 1993, AM J PHYSIOL, V264, pG334, DOI 10.1152/ajpgi.1993.264.2.G334; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hamill OP, 1996, PHARMACOL REV, V48, P231; HECKER M, 1993, AM J PHYSIOL, V265, pH828, DOI 10.1152/ajpheart.1993.265.3.H828; HIMMEL HM, 1993, HYPERTENSION, V21, P112, DOI 10.1161/01.HYP.21.1.112; Hutcheson IR, 1997, BRIT J PHARMACOL, V122, P117, DOI 10.1038/sj.bjp.0701340; KANAI AJ, 1995, CIRC RES, V77, P284, DOI 10.1161/01.RES.77.2.284; LANSMAN JB, 1987, NATURE, V325, P811, DOI 10.1038/325811a0; LEWIS CA, 1979, J PHYSIOL-LONDON, V286, P417, DOI 10.1113/jphysiol.1979.sp012629; Lipowsky HH, 1995, FLOW DEPENDENT REGUL; LIPOWSKY HH, 1995, FLOW DEPENDENT REGUL, P46; OHNO M, 1993, CIRCULATION, V88, P193, DOI 10.1161/01.CIR.88.1.193; PEARSON JD, 1978, BIOCHEM J, V170, P265, DOI 10.1042/bj1700265; POPP R, 1992, BIOCHIM BIOPHYS ACTA, V1108, P59, DOI 10.1016/0005-2736(92)90114-2; RUBANYI GM, 1986, AM J PHYSIOL, V250, P1145, DOI 10.1152/ajpheart.1986.250.6.H1145; WINEGAR BD, 1991, J GEN PHYSIOL, V97, P351, DOI 10.1085/jgp.97.2.351; YAMAMOTO Y, 1992, J PHYSIOL-LONDON, V450, P395, DOI 10.1113/jphysiol.1992.sp019133; YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333; Yao XQ, 1996, J CLIN INVEST, V97, P2525, DOI 10.1172/JCI118700; Yao XQ, 1999, LIFE SCI, V65, P55, DOI 10.1016/S0024-3205(99)00218-0	28	53	56	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2000	14	7					932	938		10.1096/fasebj.14.7.932	http://dx.doi.org/10.1096/fasebj.14.7.932			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	309CG	10783147				2022-12-28	WOS:000086749500011
J	Mancini, R; Fagioli, C; Fra, AM; Maggioni, C; Sitia, R				Mancini, R; Fagioli, C; Fra, AM; Maggioni, C; Sitia, R			Degradation of unassembled soluble Ig subunits by cytosolic proteasomes: evidence that retrotranslocation and degradation are coupled events	FASEB JOURNAL			English	Article						IgM; quality control; redox regulation; secretion	ENDOPLASMIC-RETICULUM; PROTEIN-DEGRADATION; QUALITY-CONTROL; ER MEMBRANE; J-CHAIN; HEAVY-CHAINS; RAT-LIVER; B-CELLS; TRANSLOCATION; PATHWAY	Many aberrant or unassembled proteins synthesized in the endoplasmic reticulum (ER) are degraded by cytosolic proteasomes. To investigate how soluble glycoproteins destined for degradation are retrotranslocated across the ER membrane, we analyzed the fate of two IgM subunits, mu and J, retained in the ER by myeloma cells that do not synthesize light chains. Degradation of mu, and J is prevented by proteasome inhibitors, suggesting that both chains are retrotranslocated to be disposed of by proteasomes. Indeed, when proteasomes are inhibited, some deglycosylated J chains that no longer contain intrachain disulfide bonds accumulate in the cytosol. However, abundant glycosylated J chains are still present in the ER at time points in which degradation would have been almost complete in the absence of proteasome inhibitors, suggesting that retrotranslocation and degradation are coupled events. This was confirmed by protease protection and cell fractionation assays, which revealed that virtually all mu chains are retained in the ER lumen in a glycosylated state when proteasomes are inhibited. Association with calnexin correlated with the failure of mu chains to dislocate to the cytosol. Taken together, these results suggest that active proteasomes are required for the extraction of Ig subunits from the ER, though the requirements for retrotranslocation may differ among individual substrates.	Ist Sci San Raffaele, Dept Mol Pathol & Med, DIBIT, I-20132 Milan, Italy	Vita-Salute San Raffaele University	Sitia, R (corresponding author), Ist Sci San Raffaele, Dept Mol Pathol & Med, DIBIT, Via Olgettina 58, I-20132 Milan, Italy.	r.sitia@hsr.it	Fra, Annamaria/I-5532-2012; Sitia, Roberto/AAB-5005-2019; Fagioli, Claudio/AAN-4147-2020	Fra, Annamaria/0000-0002-4327-3004; Sitia, Roberto/0000-0001-7086-4152; Fagioli, Claudio/0000-0001-9889-4695				Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; Bush KT, 1997, J BIOL CHEM, V272, P9086; Cresswell P, 1997, CURR BIOL, V7, pR552, DOI 10.1016/S0960-9822(06)00279-X; de Virgilio M, 1998, J BIOL CHEM, V273, P9734, DOI 10.1074/jbc.273.16.9734; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DEVIRGILIO M, 1999, IN PRESS MOL BIOL CE; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; FRA AM, 1993, EMBO J, V12, P4755, DOI 10.1002/j.1460-2075.1993.tb06164.x; FRUTIGER S, 1992, BIOCHEMISTRY-US, V31, P12643, DOI 10.1021/bi00165a014; Glas R, 1998, NATURE, V392, P618, DOI 10.1038/33443; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; Hamman BD, 1997, CELL, V89, P535, DOI 10.1016/S0092-8674(00)80235-4; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Hebert DN, 1997, J CELL BIOL, V139, P613, DOI 10.1083/jcb.139.3.613; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Hughes EA, 1997, P NATL ACAD SCI USA, V94, P1896, DOI 10.1073/pnas.94.5.1896; Huppa JB, 1997, IMMUNITY, V7, P113, DOI 10.1016/S1074-7613(00)80514-2; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; KAJI H, 1974, NATURE, V249, P45, DOI 10.1038/249045a0; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KNITTLER MR, 1995, P NATL ACAD SCI USA, V92, P1764, DOI 10.1073/pnas.92.5.1764; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Lord JM, 1996, CURR BIOL, V6, P1067, DOI 10.1016/S0960-9822(02)70666-0; Matlack KES, 1999, CELL, V97, P553, DOI 10.1016/S0092-8674(00)80767-9; Mayer TU, 1998, EMBO J, V17, P3251, DOI 10.1093/emboj/17.12.3251; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; Obin M, 1998, FASEB J, V12, P561, DOI 10.1096/fasebj.12.7.561; OOI CE, 1992, CELL, V71, P87, DOI 10.1016/0092-8674(92)90268-H; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; RANDALL TD, 1992, J BIOL CHEM, V267, P18002; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; RIVETT AJ, 1992, J HISTOCHEM CYTOCHEM, V40, P1165, DOI 10.1177/40.8.1619280; ROTH RA, 1987, BIOCHEMISTRY-US, V26, P4179, DOI 10.1021/bi00388a001; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; SITIA R, 1987, EMBO J, V6, P3969, DOI 10.1002/j.1460-2075.1987.tb02739.x; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; SUZUKI T, 1994, J BIOL CHEM, V269, P17611; Tortorella D, 1998, J CELL BIOL, V142, P365, DOI 10.1083/jcb.142.2.365; VALETTI C, 1994, MOL BIOL CELL, V5, P1311, DOI 10.1091/mbc.5.12.1311; VALETTI C, 1991, J CELL BIOL, V115, P983, DOI 10.1083/jcb.115.4.983; VERNER K, 1988, SCIENCE, V241, P1307, DOI 10.1126/science.2842866; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Weng S, 1997, BIOCHEM J, V322, P655, DOI 10.1042/bj3220655; Werner ED, 1996, P NATL ACAD SCI USA, V93, P13797, DOI 10.1073/pnas.93.24.13797; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800	51	87	87	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2000	14	5					769	778		10.1096/fasebj.14.5.769	http://dx.doi.org/10.1096/fasebj.14.5.769			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301DH	10744633				2022-12-28	WOS:000086292700014
J	Goldman, E; Korus, M; Mandecki, W				Goldman, E; Korus, M; Mandecki, W			Efficiencies of translation in three reading frames of unusual non-ORF sequences isolated from phage display	FASEB JOURNAL			English	Article						E. coli protein synthesis; recoding; programmed translational frameshifts; readthrough of UGA codons	ESCHERICHIA-COLI; TRANSFER-RNA; PEPTIDE LIBRARY; STOP CODON; PROTEIN; GENE; SELENOCYSTEINE; READTHROUGH; ELONGATION; ACCURACY	An unusual nucleotide sequence, called H10, was previously isolated by biopanning with a random peptide Library on filamentous phage. The sequence encoded a peptide that bound to the growth hormone binding protein. Despite the fact that the H10 sequence can be expressed in Escherichia coli as a fusion to the gene III minor coat protein of the M13 phage, the sequence contained two TGA stop codons in the zero frame. Several mutant derivatives of the H10 sequence carried not only a stop codon, but also showed frameshifts, either +1 or -1 in individual isolates, between the H10 start and the gene III sequences. In this work, we have subcloned the H10 sequence and three of its derivatives tone requiring a +1 reading frameshift for expression, one requiring a -1 reading frameshift, and one open reading frame) in gene fusions to a reporter beta-galactosidase gene. These sequences have been cloned in all three reading frames relative to the reporter. The non-open reading frame constructs gave (surprisingly) high expression of the reporter (10-40% of control vector expression levels) in two out of the three frames. A site-directed mutant of the TGA stop codon (to TTA) in the +1 shifter greatly reduced the frameshift and gave expression primarily in the zero frame. By contrast, a site-directed mutant of the TGA in the -1 shifter had little effect on the pattern of expression, and alteration of the first TGA (of two) in H10 itself paradoxically reduced expression by half. We believe these phenomena to reflect a translational recoding mechanism in which ribosomes switch reading frames or read past stop codons upon encountering a signal encoded in the nucleotide sequence of the mRNA, because both the open reading frame derivative (which has six nucleotide changes from parental H10) and the site-directed mutant of the +1 shifter, primarily expressed the reporter only in the zero frame.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol, Newark, NJ 07103 USA; PharmaSeq Inc, Monmouth Junct, NJ 08852 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Goldman, E (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol, 185 S Orange Ave, Newark, NJ 07103 USA.							ADHIN MR, 1990, J MOL BIOL, V213, P811, DOI 10.1016/S0022-2836(05)80265-7; ATKINS JF, 1990, CELL, V62, P413, DOI 10.1016/0092-8674(90)90007-2; ATKINS JF, 1991, ANNU REV GENET, V25, P201; BOCK A, 1991, MOL MICROBIOL, V5, P515, DOI 10.1111/j.1365-2958.1991.tb00722.x; BRIERLEY I, 1995, J GEN VIROL, V76, P1885, DOI 10.1099/0022-1317-76-8-1885; Carcamo J, 1998, P NATL ACAD SCI USA, V95, P11146, DOI 10.1073/pnas.95.19.11146; CHEN GFT, 1993, J BIOL CHEM, V268, P23128; CHEN GT, 1992, MOL MICROBIOL, V6, P781, DOI 10.1111/j.1365-2958.1992.tb01528.x; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; CURRAN JF, 1986, P NATL ACAD SCI USA, V83, P6538, DOI 10.1073/pnas.83.17.6538; CURRAN JF, 1988, J MOL BIOL, V203, P75, DOI 10.1016/0022-2836(88)90092-7; DESMIT MH, 1994, GENE, V143, P43, DOI 10.1016/0378-1119(94)90602-5; Dinman JD, 1997, RNA, V3, P870; Farabaugh PJ, 1996, ANNU REV GENET, V30, P507, DOI 10.1146/annurev.genet.30.1.507; Farabaugh PJ, 1996, MICROBIOL REV, V60, P103, DOI 10.1128/MMBR.60.1.103-134.1996; Gallant JA, 1998, P NATL ACAD SCI USA, V95, P13771, DOI 10.1073/pnas.95.23.13771; GAO WW, 1995, J MOL BIOL, V251, P210, DOI 10.1006/jmbi.1995.0428; Gesteland RF, 1996, ANNU REV BIOCHEM, V65, P741, DOI 10.1146/annurev.bi.65.070196.003521; HOFSTETTER H, 1974, BIOCHIM BIOPHYS ACTA, V374, P238, DOI 10.1016/0005-2787(74)90366-9; HUANG WM, 1988, SCIENCE, V239, P1005, DOI 10.1126/science.2830666; JACKS T, 1988, CELL, V55, P447, DOI 10.1016/0092-8674(88)90031-1; KANE JF, 1992, NUCLEIC ACIDS RES, V20, P6707, DOI 10.1093/nar/20.24.6707; Larsen B, 1997, J MOL BIOL, V271, P47, DOI 10.1006/jmbi.1997.1162; LINDSLEY D, 1993, P NATL ACAD SCI USA, V90, P5469, DOI 10.1073/pnas.90.12.5469; Lovett PS, 1996, MICROBIOL REV, V60, P366, DOI 10.1128/MMBR.60.2.366-385.1996; MANLEY JL, 1978, J MOL BIOL, V125, P449, DOI 10.1016/0022-2836(78)90310-8; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; Ravera MW, 1998, ONCOGENE, V16, P1993, DOI 10.1038/sj.onc.1201717; Sambrook J., 2002, MOL CLONING LAB MANU; SHARP PA, 1981, CELL, V23, P643, DOI 10.1016/0092-8674(81)90425-6; SIPLEY J, 1993, P NATL ACAD SCI USA, V90, P2315, DOI 10.1073/pnas.90.6.2315; Stuart K, 1997, MICROBIOL MOL BIOL R, V61, P105, DOI 10.1128/.61.1.105-120.1997; Tsai FC, 1998, RNA, V4, P1514, DOI 10.1017/S1355838298981274; TSUCHIHASHI Z, 1991, NUCLEIC ACIDS RES, V19, P2457, DOI 10.1093/nar/19.9.2457; ULLMANN A, 1984, GENE, V29, P27, DOI 10.1016/0378-1119(84)90162-8; Weiss R B, 1990, Prog Nucleic Acid Res Mol Biol, V39, P159, DOI 10.1016/S0079-6603(08)60626-1; WEISS RB, 1987, COLD SPRING HARB SYM, V52, P687, DOI 10.1101/SQB.1987.052.01.078; Wenthzel AMK, 1998, FEBS LETT, V421, P237, DOI 10.1016/S0014-5793(97)01570-6; ZHANG SP, 1991, GENE, V105, P61, DOI 10.1016/0378-1119(91)90514-C	39	24	27	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2000	14	3					603	611		10.1096/fasebj.14.3.603	http://dx.doi.org/10.1096/fasebj.14.3.603			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	291TJ	10698976				2022-12-28	WOS:000085751900020
J	Clark, AF; Kawase, K; English-Wright, S; Lane, D; Steely, HT; Yamamoto, T; Kitazawa, Y; Kwon, YH; Fingert, JH; Swiderski, RE; Mullins, RF; Hageman, GS; Alward, WLM; Sheffield, VC; Stone, EM				Clark, AF; Kawase, K; English-Wright, S; Lane, D; Steely, HT; Yamamoto, T; Kitazawa, Y; Kwon, YH; Fingert, JH; Swiderski, RE; Mullins, RF; Hageman, GS; Alward, WLM; Sheffield, VC; Stone, EM			Expression of the glaucoma gene myocilin (MYOC) in the human optic nerve head	FASEB JOURNAL			English	Article									Alcon Res Ltd, Glaucoma Res R2 41, Ft Worth, TX 76134 USA; Gifu Univ, Dept Ophthalmol, Gifu, Japan; Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA USA; Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; Univ Iowa, Howard Hughes Med Inst, Iowa City, IA 52242 USA	Novartis; Alcon; Gifu University; University of Iowa; University of Iowa; Howard Hughes Medical Institute; University of Iowa	Clark, AF (corresponding author), Alcon Res Ltd, Glaucoma Res R2 41, 6201 S Freeway, Ft Worth, TX 76134 USA.		Mullins, Robert F/I-6717-2013; Alward, Wallace/AAY-4149-2020; Fingert, John/AAX-4750-2021	Fingert, John/0000-0002-0377-0479; Mullins, Robert/0000-0002-5006-0891; Sheffield, Val/0000-0002-6282-0835; Kwon, Young/0000-0002-1116-8250; Stone, Edwin M./0000-0003-3343-4414; Alward, Wallace/0000-0001-6368-9018					0	43	48	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1251	1253		10.1096/fj.00-0663fje	http://dx.doi.org/10.1096/fj.00-0663fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344104				2022-12-28	WOS:000168655200026
J	Moller, P; Loft, S; Lundby, C; Olsen, NV				Moller, P; Loft, S; Lundby, C; Olsen, NV			Acute hypoxia and hypoxic exercise induce DNA strand breaks and oxidative DNA damage in humans	FASEB JOURNAL			English	Article						FPG; high-intensity exercise; ENDO III; reactive oxygen species	TUMOR-NECROSIS-FACTOR; INTERLEUKIN-1 RECEPTOR ANTAGONIST; MODERATE-ALTITUDE; HYPOBARIC HYPOXIA; GENE-EXPRESSION; STRESS; CELLS; ADHESION; MARKERS; MUSCLE	The present study investigated the effect of a single bout of exhaustive exercise on the generation of DNA strand breaks and oxidative DNA damage under normal conditions and at high-altitude hypoxia (4559 meters for 3 days). Twelve healthy subjects performed a maximal bicycle exercise test; lymphocytes were isolated for analysis of DNA strand breaks and oxidatively altered nucleotides, detected by endonuclease III and formamidipyridine glycosylase (FPG) enzymes. Urine was collected for 24 h periods for analysis of 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG), a marker of oxidative DNA damage. Urinary excretion of 8-oxodG increased during the first day in altitude hypoxia, and there were more endonuclease III-sensitive sites on day 3 at high altitude. The subjects had more DNA strand breaks in altitude hypoxia than at sea level. The level of DNA strand breaks further increased immediately after exercise in altitude hypoxia, Exercise-induced generation of DNA strand breaks was not seen at sea level. In both environments, the level of FPG and endonuclease III-sensitive sites remained unchanged immediately after exercise. DNA strand breaks and oxidative DNA damage are probably produced by reactive oxygen species, generated by leakage of the mitochondrial respiration or during a hypoxia-induced inflammation, Furthermore, the presence of DNA strand breaks may play an important role in maintaining hypoxia-induced inflammation processes. Hypoxia seems to deplete the antioxidant system of its capacity to withstand oxidative stress produced by exhaustive exercise.	Univ Copenhagen, Panum Inst, Dept Pharmacol, Inst Publ Hlth, DK-2200 Copenhagen N, Denmark; Copenhagen Univ Hosp, Neurosci Ctr, Dept Neuroanaesthesia, DK-2200 Copenhagen N, Denmark	University of Copenhagen; University of Copenhagen	Moller, P (corresponding author), Univ Copenhagen, Panum Inst, Dept Pharmacol, Inst Publ Hlth, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.	fipm@farmakol.ku.dk		Loft, Steffen/0000-0001-9552-8518				Brenner IKM, 1999, EUR J APPL PHYSIOL O, V80, P452, DOI 10.1007/s004210050617; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; CHANG SW, 1989, LUNG, V167, P269, DOI 10.1007/BF02714956; Chao WH, 1999, J NUTR, V129, P2009, DOI 10.1093/jn/129.11.2009; Collins A, 1997, ENVIRON MOL MUTAGEN, V30, P139, DOI 10.1002/(SICI)1098-2280(1997)30:2<139::AID-EM6>3.0.CO;2-I; Dempsey JA, 1999, J APPL PHYSIOL, V87, P1997, DOI 10.1152/jappl.1999.87.6.1997; Drenth JPH, 1998, EUR J CLIN INVEST, V28, P866; Duranteau J, 1998, J BIOL CHEM, V273, P11619, DOI 10.1074/jbc.273.19.11619; Espersen GT, 1996, SCAND J MED SCI SPOR, V6, P156; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GHEZZI P, 1991, CYTOKINE, V3, P189, DOI 10.1016/1043-4666(91)90015-6; GINIS I, 1993, J CELL PHYSIOL, V157, P569, DOI 10.1002/jcp.1041570317; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; HARTMANN A, 1994, MUTAGENESIS, V9, P269, DOI 10.1093/mutage/9.3.269; Hartmann A, 1998, FREE RADICAL BIO MED, V24, P245, DOI 10.1016/S0891-5849(97)00249-9; Hartmann G, 2000, CYTOKINE, V12, P246, DOI 10.1006/cyto.1999.0533; Hempel SL, 1996, AM J RESP CELL MOL, V14, P170, DOI 10.1165/ajrcmb.14.2.8630267; KARAKURUM M, 1994, J CLIN INVEST, V93, P1564, DOI 10.1172/JCI117135; Klausen T, 1997, EUR J APPL PHYSIOL, V76, P480, DOI 10.1007/s004210050278; Kleger GR, 1996, J APPL PHYSIOL, V81, P1917, DOI 10.1152/jappl.1996.81.5.1917; KLOKKER M, 1993, J APPL PHYSIOL, V74, P1100, DOI 10.1152/jappl.1993.74.3.1100; KLOKKER M, 1995, J APPL PHYSIOL, V78, P709; Kubo K, 1996, THORAX, V51, P739, DOI 10.1136/thx.51.7.739; Kumar D, 1999, INT J BIOMETEOROL, V42, P201, DOI 10.1007/s004840050105; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Loft S, 1999, METHOD ENZYMOL, V300, P166; Moller P, 1996, CHEM-BIOL INTERACT, V102, P17, DOI 10.1016/0009-2797(96)03729-5; Moller P, 1998, MUTAT RES-DNA REPAIR, V407, P25, DOI 10.1016/S0921-8777(97)00057-8; Natelson BH, 1996, INT J SPORTS MED, V17, P299, DOI 10.1055/s-2007-972850; Niess AM, 1996, INT J SPORTS MED, V17, P397, DOI 10.1055/s-2007-972868; Pavlicek V, 2000, EUR J APPL PHYSIOL, V81, P497, DOI 10.1007/s004210050074; Pfeiffer JM, 1999, WILD ENVIRON MED, V10, P66, DOI 10.1580/1080-6032(1999)010[0066:EOASOU]2.3.CO;2; Poulsen HE, 1999, P NUTR SOC, V58, P1007, DOI 10.1017/S0029665199001329; Poulsen HE, 1996, J SPORT SCI, V14, P343, DOI 10.1080/02640419608727720; Radak Z, 1999, FREE RADICAL BIO MED, V26, P1059, DOI 10.1016/S0891-5849(98)00309-8; Richardson RS, 1999, AM J PHYSIOL-HEART C, V277, pH2247, DOI 10.1152/ajpheart.1999.277.6.H2247; Roach R, 1993, HYPOXIA MOL MED; Roach RC, 2000, J APPL PHYSIOL, V88, P581, DOI 10.1152/jappl.2000.88.2.581; SEN CK, 1994, J APPL PHYSIOL, V76, P2570, DOI 10.1152/jappl.1994.76.6.2570; SHREENIWAS R, 1992, J CLIN INVEST, V90, P2333, DOI 10.1172/JCI116122; SIMONSCHNASS I, 1988, INT J VITAM NUTR RES, V58, P49; Tuo JS, 1999, FREE RADICAL BIO MED, V26, P801, DOI 10.1016/S0891-5849(98)00267-6; VANOTTEREN GM, 1995, AM J RESP CELL MOL, V13, P399, DOI 10.1165/ajrcmb.13.4.7546769; Vasankari TJ, 1997, EUR J APPL PHYSIOL O, V75, P396, DOI 10.1007/s004210050178; Wood JG, 1999, J APPL PHYSIOL, V87, P1734, DOI 10.1152/jappl.1999.87.5.1734	45	181	189	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2001	15	7					1181	1186		10.1096/fj.00-0703com	http://dx.doi.org/10.1096/fj.00-0703com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344086				2022-12-28	WOS:000168655200008
J	Poot, M; Yom, JS; Whang, SH; Kato, JT; Gollahon, KA; Rabinovitch, PS				Poot, M; Yom, JS; Whang, SH; Kato, JT; Gollahon, KA; Rabinovitch, PS			Werner syndrome cells are sensitive to DNA crosslinking drugs	FASEB JOURNAL			English	Article									Univ Washington, Dept Pathol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Poot, M (corresponding author), Univ Washington, Dept Pathol, 1959 NE Pacific Ave,Hlth Sci Bldg,Room K-081, Seattle, WA 98195 USA.		Poot, Martin/F-9427-2010	Yom, Sue/0000-0002-0779-7476					0	125	125	2	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1224	1226		10.1096/fj.00-0611fje	http://dx.doi.org/10.1096/fj.00-0611fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344095				2022-12-28	WOS:000168655200017
J	Varani, K; Rigamonti, D; Sipione, S; Camurri, A; Borea, PA; Cattabeni, F; Abbracchio, MP; Cattaneo, E				Varani, K; Rigamonti, D; Sipione, S; Camurri, A; Borea, PA; Cattabeni, F; Abbracchio, MP; Cattaneo, E			Aberrant amplification of A(2A) receptor signaling in striatal cells expressing mutant huntingtin	FASEB JOURNAL			English	Article									Univ Milan, Dept Pharmacol Sci, I-20133 Milan, Italy; Univ Ferrara, Dipartimento Med Clin Sperimentale, I-44100 Ferrara, Italy	University of Milan; University of Ferrara	Abbracchio, MP (corresponding author), Univ Milan, Dept Pharmacol Sci, Via Balzaretti 9, I-20133 Milan, Italy.		Abbracchio, Maria Pia/B-9342-2014	Abbracchio, Maria Pia/0000-0002-7833-3388; CATTANEO, ELENA/0000-0002-0755-4917	Telethon [E.0840, E.1116] Funding Source: Medline	Telethon(Fondazione Telethon)			0	72	73	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2001	15	7					1245	1247		10.1096/fj.00-0730fje	http://dx.doi.org/10.1096/fj.00-0730fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	431WR	11344102				2022-12-28	WOS:000168655200024
J	Donahue, RJ; Razmara, M; Hoek, JB; Knudsen, TB				Donahue, RJ; Razmara, M; Hoek, JB; Knudsen, TB			Direct influence of the p53 tumor suppressor on mitochondrial biogenesis and function	FASEB JOURNAL			English	Article						16S rRNA; PK11195; peripheral benzodiazepine receptor	WILD-TYPE P53; BENZODIAZEPINE RECEPTOR; DNA MUTATIONS; CELL-LINE; APOPTOSIS; PROTEIN; MOUSE; IDENTIFICATION; LOCALIZATION; GENES	Mitochondrial localization of p53 has been observed in several cell systems, but an understanding of its organelle-based physiological activity remains incomplete. The purpose of the present study was to investigate the mitochondrial DNA genomic response to dominant-negative p53 mutant miniprotein (p53DD) fused to a mitochondrial import signal. Constructs were generated to express mitochondrial targeted enhanced green fluorescent protein (mEGFP) or dominant-negative mutant p53 miniprotein (m53DD) by in-frame fusion to the signal peptide sequence of murine Cox8l. Control cytosolic vectors (cEGFP, c53DD) had the signal sequence placed in antisense orientation. NIH 3T3 cells were transiently transfected with these vectors in various combinations. Mitochondrial 16S ribosomal RNA (16S rRNA) expression and fluorochrome staining with Mitotracker Red CMXRos (Delta Psim) were decreased in cells expressing m53DD, Both alterations were specific for mitochondrial import competence (e.g., m53DD vs. c53DD) as well as the passenger protein (e.g., m53DD vs. mEGFP). The normal functional state of mitochondria was restored with PK11195, a specific ligand of the mitochondrial peripheral-type benzodiazepine receptor. Negative dominance of m53DD on 16S rRNA expression and CMXRos staining, and rescue of these parameters with PK11195, imply a direct positive effect of p53 on mitochondrial biogenesis and function.-Donahue, R. J., Razmara, M., Hock, J. B., Knudsen, T. B. Direct influence of the p53 tumor suppressor on mitochondrial biogenesis and function.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Jefferson University	Knudsen, TB (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Pathol Anat & Cell Biol, 1020 Locust St, Philadelphia, PA 19107 USA.			Hoek, Jan/0000-0001-7127-4218	NIEHS NIH HHS [R01 ES09120, T32 ES07282] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009120, T32ES007282] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AUSUBELL FM, 1989, CURRENT PROTOCOLS MO; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; Bonsing BA, 1997, CYTOMETRY, V28, P11, DOI 10.1002/(SICI)1097-0320(19970501)28:1<11::AID-CYTO2>3.3.CO;2-H; Bourdon JC, 1997, ONCOGENE, V14, P85, DOI 10.1038/sj.onc.1200804; Bowman T, 1996, GENE DEV, V10, P826, DOI 10.1101/gad.10.7.826; CAHILL A, 1995, ANAL BIOCHEM, V232, P47, DOI 10.1006/abio.1995.9962; Castedo M, 1995, EUR J IMMUNOL, V25, P3277, DOI 10.1002/eji.1830251212; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Choi J, 1999, CELL MOL LIFE SCI, V55, P38, DOI 10.1007/s000180050268; Crawford DR, 1997, FREE RADICAL BIO MED, V22, P551, DOI 10.1016/S0891-5849(96)00380-2; Demonacos CV, 1996, STEROIDS, V61, P226, DOI 10.1016/0039-128X(96)00019-0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDIERY WS, 1992, NAT GENET, V1, P45; Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GOGLIA F, 1989, MOL CELL ENDOCRINOL, V62, P41, DOI 10.1016/0303-7207(89)90111-1; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Hirsch T, 1998, EXP CELL RES, V241, P426, DOI 10.1006/excr.1998.4084; Ibrahim MM, 1998, BBA-MOL CELL RES, V1403, P254, DOI 10.1016/S0167-4889(98)00066-4; IGLESIAS T, 1995, BIOCHEM BIOPH RES CO, V210, P995, DOI 10.1006/bbrc.1995.1755; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; KASTAN MB, 1991, CANCER RES, V51, P6304; Kato MV, 1999, LEUKEMIA LYMPHOMA, V33, P181, DOI 10.3109/10428199909093740; Katsumoto T, 1995, BIOL CELL, V84, P167, DOI 10.1016/0248-4900(96)89426-3; Knudsen TB, 2000, TERATOLOGY, V62, P238; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Lill R, 1996, CURR OPIN CELL BIOL, V8, P505, DOI 10.1016/S0955-0674(96)80028-7; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Liu YA, 1998, MOL BIOL CELL, V9, P15, DOI 10.1091/mbc.9.1.15; MAKRIS GJ, 1995, BIOCHIM BIOPHYS ACTA, V1308, P197; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Marchetti P, 1996, CANCER RES, V56, P2033; McLure KG, 1996, ONCOGENE, V13, P1297; Merrick BA, 1996, BBA-PROTEIN STRUCT M, V1297, P57; MIYASHITA T, 1995, CELL, V80, P293; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Okamura S, 1999, ONCOL RES, V11, P281; Pastorino JG, 1996, J BIOL CHEM, V271, P29792, DOI 10.1074/jbc.271.47.29792; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; Prives C, 1999, J PATHOL, V187, P112; RIZZUTO R, 1995, CURR BIOL, V5, P635, DOI 10.1016/S0960-9822(95)00128-X; Sabapathy K, 1997, EMBO J, V16, P6217, DOI 10.1093/emboj/16.20.6217; SHAULIAN E, 1992, MOL CELL BIOL, V12, P581; SHAY JW, 1987, MUTAT RES, V186, P149, DOI 10.1016/0165-1110(87)90028-5; Smalheiser NR, 1996, MOL BIOL CELL, V7, P1003, DOI 10.1091/mbc.7.7.1003; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wright G, 1999, EXP CELL RES, V246, P443, DOI 10.1006/excr.1998.4331	51	56	57	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					635	644		10.1096/fj.00-0262com	http://dx.doi.org/10.1096/fj.00-0262com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259382				2022-12-28	WOS:000167419500021
J	Tohka, S; Laukkanen, ML; Jalkanen, S; Salmi, M				Tohka, S; Laukkanen, ML; Jalkanen, S; Salmi, M			Vascular adhesion protein 1 (VAP-1) functions as a molecular brake during granulocyte rolling and mediates recruitment in vivo	FASEB JOURNAL			English	Article						inflammation; rolling; extravasation; migration; monoamine oxidases	P-SELECTIN; IN-VIVO; TRANSENDOTHELIAL MIGRATION; LEUKOCYTE ACCUMULATION; LYMPHOCYTE BINDING; ENDOTHELIAL-CELLS; MICE DEFICIENT; SHEAR; PECAM-1; VENULES	Granulocyte extravasation from the blood into tissues is a prerequisite for a proper inflammatory response. It is regulated by a multistep adhesion cascade consisting of successive contacts between leukocyte surface receptors and their endothelial ligands on vessels. Vascular adhesion protein 1 (VAP-1) is an endothelial surface glycoprotein with two functions. It is an enzyme (monoamine oxidase) and an adhesion molecule for lymphocytes, Its function in binding of granulocytes or in leukocyte trafficking into sites of inflammation in vivo has remained unknown. Here we show that treatment of rabbits with anti-VAP-1 monoclonal antibodies abrogates similar to 70% of granulocyte extravasation into a site of an experimental inflammation, Using intravital microscopy, VAP-1 blockade is shown to increase the velocity of the rolling granulocytes and the frequency of their jerky skippings during the rolling. In addition, the number of firmly bound leukocytes decreased by 44% when VAP-1 was rendered nonfunctional, Our results suggest that VAP-1 functions as a molecular brake early in the adhesion cascade and consequently decreases the firm adherence; it may also directly influence the transmigration step. These data elucidate a new interplayer in the granulocyte extravasation process and provide a novel physiological function for a member of the monoamine oxidase family.	Turku Univ, MediCity Res Lab, FIN-20520 Turku, Finland; Natl Publ Hlth Inst, Turku, Finland; VTT Biotechnol & Food Res, Espoo, Finland	University of Turku; Finland National Institute for Health & Welfare; VTT Technical Research Center Finland	Salmi, M (corresponding author), Turku Univ, MediCity Res Lab, Tykistokatu 6A, FIN-20520 Turku, Finland.							Alon R, 1996, J CELL BIOL, V135, P849, DOI 10.1083/jcb.135.3.849; ARFORS KE, 1987, BLOOD, V69, P338; Armour KL, 1999, EUR J IMMUNOL, V29, P2613, DOI 10.1002/(SICI)1521-4141(199908)29:08<2613::AID-IMMU2613>3.0.CO;2-J; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Bianchi E, 1997, IMMUNOL TODAY, V18, P586, DOI 10.1016/S0167-5699(97)01162-6; BOSSE R, 1994, EUR J IMMUNOL, V24, P3019, DOI 10.1002/eji.1830241215; BULLARD DC, 1995, J CLIN INVEST, V95, P1782, DOI 10.1172/JCI117856; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Chen SQ, 1999, J CELL BIOL, V144, P185, DOI 10.1083/jcb.144.1.185; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; Duncan GS, 1999, J IMMUNOL, V162, P3022; Frenette PS, 1996, CELL, V84, P563, DOI 10.1016/S0092-8674(00)81032-6; Jaakkola K, 1999, AM J PATHOL, V155, P1953, DOI 10.1016/S0002-9440(10)65514-9; JALKANEN S, 1987, J CELL BIOL, V105, P983, DOI 10.1083/jcb.105.2.983; Jung U, 1998, J CLIN INVEST, V102, P1526, DOI 10.1172/JCI119893; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; KETTLEBOROUGH CA, 1993, EUR J IMMUNOL, V23, P206, DOI 10.1002/eji.1830230132; KLINMAN JP, 1994, ANNU REV BIOCHEM, V63, P299, DOI 10.1146/annurev.bi.63.070194.001503; Kunkel EJ, 1996, CIRC RES, V79, P1196, DOI 10.1161/01.RES.79.6.1196; Kurkijarvi R, 1998, J IMMUNOL, V161, P1549; Ley K, 1998, CIRC RES, V83, P287, DOI 10.1161/01.RES.83.3.287; LEY K, 1991, CIRC RES, V69, P1034, DOI 10.1161/01.RES.69.4.1034; Lyles GA, 1996, INT J BIOCHEM CELL B, V28, P259, DOI 10.1016/1357-2725(95)00130-1; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; Newman PJ, 1997, J CLIN INVEST, V99, P3, DOI 10.1172/JCI119129; OLOFSSON AM, 1994, BLOOD, V84, P2749, DOI 10.1182/blood.V84.8.2749.bloodjournal8482749; Salmi M, 1997, ADV IMMUNOL, V64, P139, DOI 10.1016/S0065-2776(08)60889-5; SALMI M, 1992, SCIENCE, V257, P1407, DOI 10.1126/science.1529341; Salmi M, 1996, J EXP MED, V183, P569, DOI 10.1084/jem.183.2.569; Salmi M, 1997, J EXP MED, V186, P589, DOI 10.1084/jem.186.4.589; SLIGH JE, 1993, P NATL ACAD SCI USA, V90, P8529, DOI 10.1073/pnas.90.18.8529; Smith DJ, 1998, J EXP MED, V188, P17, DOI 10.1084/jem.188.1.17; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STEWART M, 1995, CURR OPIN CELL BIOL, V7, P690, DOI 10.1016/0955-0674(95)80111-1; VONANDRIAN UH, 1992, AM J PHYSIOL, V263, pH1034, DOI 10.1152/ajpheart.1992.263.4.H1034; Wakelin MW, 1996, J EXP MED, V184, P229, DOI 10.1084/jem.184.1.229; Walcheck B, 1996, J CLIN INVEST, V98, P1081, DOI 10.1172/JCI118888; Wilmot CM, 1999, SCIENCE, V286, P1724, DOI 10.1126/science.286.5445.1724	39	74	78	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					373	382		10.1096/fj.00-0240com	http://dx.doi.org/10.1096/fj.00-0240com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156953				2022-12-28	WOS:000166872900019
J	Dedio, J; Konig, P; Wohlfart, P; Schroeder, C; Kummer, W; Muller-Esterl, W				Dedio, J; Konig, P; Wohlfart, P; Schroeder, C; Kummer, W; Muller-Esterl, W			NOSIP, a novel modulator of endothelial nitric oxide synthase activity	FASEB JOURNAL			English	Article						eNOS; yeast two-hybrid system; protein-protein interaction; subcellular trafficking	INDUCIBLE NO SYNTHASE; IN-VIVO; CAVEOLAE; CELLS; PROTEIN; PALMITOYLATION; TRANSLOCATION; CALMODULIN; RECEPTOR; DOMAIN	Production of nitric oxide (NO) in endothelial cells is regulated by direct interactions of endothelial nitric oxide synthase (eNOS) with effector proteins such as Ca2+-calmodulin, by posttranslational modifications such as phosphorylation via protein kinase B, and by translocation of the enzyme from the plasma membrane caveolae to intracellular compartments. Reversible acylation of eNOS is thought to contribute to the intracellular trafficking of the enzyme; however, protein factor(s) that govern the translocation of the enzyme are still unknown, Here we have used the yeast two-hybrid system and identified a novel 34 kDa protein, termed NOSIP (eNOS interacting protein), which avidly binds to the carboxyl-terminal region of the eNOS oxygenase domain. Coimmunoprecipitation studies demonstrated the specific interaction of eNOS and NOSIP in vitro and in vivo, and complex formation was inhibited by a synthetic peptide of the caveolin-1 scaffolding domain. NO production was significantly reduced in eNOS-expressing CHO cells (CHO-eNOS) that transiently overexpressed NOSIP, Stimulation with the calcium ionophore A23187 induced the reversible translocation of eNOS from the detergent-insoluble to the detergent-soluble fractions of CHO-eNOS, and this translocation was completely prevented by transient coexpression of NOSIP in CHO-eNOS, Immunofluorescence studies revealed a prominent plasma membrane staining for eNOS in CHO-eNOS that aas abolished in the presence of NOSIP. Subcellular fractionation studies identified eNOS in the caveolin-rich membrane fractions of CHO-eNOS, and coexpression of NOSIP caused a shift of eNOS to intracellular compartments, We conclude that NOSIP is a novel type of modulator that promotes translocation of eNOS from the plasma membrane to intracellular sites, thereby uncoupling eNOS from plasma membrane caveolae and inhibiting NO synthesis.	Johannes Gutenberg Univ Mainz, Inst Physiol Chem & Pathobiochem, D-55099 Mainz, Germany; Univ Hosp, Inst Biochem 2, Frankfurt, Germany; Univ Giessen, Inst Anat & Cell Biol, D-35385 Giessen, Germany; Aventis, Dis Grp Cardiovasc Agents, D-65926 Frankfurt, Germany	Johannes Gutenberg University of Mainz; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Justus Liebig University Giessen; Sanofi-Aventis	Muller-Esterl, W (corresponding author), Univ Hosp, Inst Biochem 2, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	wme@biochem2.de	König, Peter/AAK-2021-2020	Kummer, Wolfgang/0000-0002-3946-0683				Beck KF, 1999, J EXP BIOL, V202, P645; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Brown GC, 1999, BBA-BIOENERGETICS, V1411, P351, DOI 10.1016/S0005-2728(99)00025-0; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; Forstermann U, 1998, FASEB J, V12, P773; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Gath I, 1996, FASEB J, V10, P1614, DOI 10.1096/fasebj.10.14.9002553; Ghosh S, 1998, J BIOL CHEM, V273, P22267, DOI 10.1074/jbc.273.35.22267; Goetz RM, 1999, P NATL ACAD SCI USA, V96, P2788, DOI 10.1073/pnas.96.6.2788; GOLEMIS EA, 1993, CURRENT PROTOCOLS MO, V3; GUO FH, 1995, P NATL ACAD SCI USA, V92, P7809, DOI 10.1073/pnas.92.17.7809; Ju H, 1998, J BIOL CHEM, V273, P24025, DOI 10.1074/jbc.273.37.24025; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Liu JW, 1997, J CELL BIOL, V137, P1525, DOI 10.1083/jcb.137.7.1525; Liu JW, 1996, BIOCHEMISTRY-US, V35, P13277, DOI 10.1021/bi961720e; LUNDSTROM K, 1995, J RECEPT SIGNAL TR R, V15, P23, DOI 10.3109/10799899509045204; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Prabhakar P, 1998, J BIOL CHEM, V273, P27383, DOI 10.1074/jbc.273.42.27383; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Sowa G, 1999, J BIOL CHEM, V274, P22524, DOI 10.1074/jbc.274.32.22524; Wohlfart P, 1997, J PHARMACOL EXP THER, V280, P1109	34	134	142	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2001	15	1					79	89		10.1096/fj.00-0078com	http://dx.doi.org/10.1096/fj.00-0078com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149895				2022-12-28	WOS:000166312400016
J	Khubchandani, KR; Snyder, JM				Khubchandani, KR; Snyder, JM			Surfactant protein A (SP-A): the alveolus and beyond	FASEB JOURNAL			English	Review						lectins; cystic fibrosis; extra-alveolar sites; innate immunity	HUMAN-FETAL LUNG; RESPIRATORY-DISTRESS-SYNDROME; MEDIATES ENHANCED PHAGOCYTOSIS; BRONCHOALVEOLAR LAVAGE FLUIDS; IDIOPATHIC PULMONARY FIBROSIS; EUSTACHIAN-TUBE FUNCTION; GENE-EXPRESSION; CYSTIC-FIBROSIS; AMNIOTIC-FLUID; CRYPTOCOCCUS-NEOFORMANS	Surfactant protein A (SP-A) is the major protein component of pulmonary surfactant, a material secreted by the alveolar type II cell that reduces surface tension at the alveolar air-liquid interface, The function of SP-A in the alveolus is to facilitate the surface tension-lowering properties of surfactant phospholipids, regulate surfactant phospholipid synthesis, secretion, and recycling, and counteract the inhibitory effects of plasma proteins released during lung injury on surfactant function. It has also been shown that SP-A modulates host response to microbes and particulates at the level of the alveolus. More recently, several investigators have reported that pulmonary surfactant phospholipids and SP-A are present in nonalveolar pulmonary sites as well as in other organs of the body. We describe the structure and possible functions of alveolar SP-A as well as the sites of extra-alveolar SP-A expression and the possible functions of SP-A in these sites.	Univ Iowa, Coll Med, Dept Anat & Cell Biol, Iowa City, IA 52242 USA	University of Iowa	Snyder, JM (corresponding author), Univ Iowa, Coll Med, Dept Anat & Cell Biol, 1-550 Bowen Sci Bldg, Iowa City, IA 52242 USA.	jeanne-snyder@uiowa.edu						ACARREGUI MJ, 1990, ENDOCRINOLOGY, V127, P1105, DOI 10.1210/endo-127-3-1105; ACARREGUI MJ, 1993, AM J PHYSIOL, V264, pL465, DOI 10.1152/ajplung.1993.264.5.L465; Alcorn JL, 1999, AM J PHYSIOL-LUNG C, V277, pL349, DOI 10.1152/ajplung.1999.277.2.L349; Awasthi S, 1999, AM J RESP CRIT CARE, V160, P942, DOI 10.1164/ajrccm.160.3.9806061; BALLARD PL, 1990, AM J RESP CELL MOL, V2, P137, DOI 10.1165/ajrcmb/2.2.137; BALLARD PL, 1986, P NATL ACAD SCI USA, V83, P9527, DOI 10.1073/pnas.83.24.9527; BAUGHMAN RP, 1993, AM REV RESPIR DIS, V147, P653, DOI 10.1164/ajrccm/147.3.653; Benne CA, 1997, EUR J IMMUNOL, V27, P886, DOI 10.1002/eji.1830270413; BENNE CA, 1995, J INFECT DIS, V171, P335, DOI 10.1093/infdis/171.2.335; Bernhard W, 1997, AM J RESP CELL MOL, V17, P41, DOI 10.1165/ajrcmb.17.1.2594; BLAU H, 1994, AM J PHYSIOL, V266, pL148, DOI 10.1152/ajplung.1994.266.2.L148; Blau H, 1997, AM J PHYSIOL-LUNG C, V272, pL1198, DOI 10.1152/ajplung.1997.272.6.L1198; CHITNIS SN, 1990, FEMS MICROBIOL LETT, V72, P281, DOI 10.1016/0378-1097(90)90317-J; Chroneos ZC, 1996, J BIOL CHEM, V271, P16375, DOI 10.1074/jbc.271.27.16375; COCKSHUTT AM, 1990, BIOCHEMISTRY-US, V29, P8424, DOI 10.1021/bi00488a032; Creuwels LAJM, 1997, LUNG, V175, P1, DOI 10.1007/PL00007554; Crouch EC, 1998, AM J RESP CELL MOL, V19, P177, DOI 10.1165/ajrcmb.19.2.140; DEMELLO DE, 1989, AM J PATHOL, V134, P1285; Dobbie JW, 1996, PERITON DIALYSIS INT, V16, P574; DOYLE IR, 1995, AM J RESP CRIT CARE, V152, P307, DOI 10.1164/ajrccm.152.1.7599839; Dutton JM, 1999, ANN OTO RHINOL LARYN, V108, P915, DOI 10.1177/000348949910801001; Eliakim R, 1997, AM J PHYSIOL-GASTR L, V272, pG425, DOI 10.1152/ajpgi.1997.272.3.G425; ENDO H, 1991, EARLY HUM DEV, V25, P149, DOI 10.1016/0378-3782(91)90111-F; FLOROS J, 1986, J BIOL CHEM, V261, P9029; GAYNOR CD, 1995, J IMMUNOL, V155, P5343; Goss KL, 1998, AM J RESP CELL MOL, V19, P613, DOI 10.1165/ajrcmb.19.4.3155; HAAGSMAN HP, 1987, J BIOL CHEM, V262, P13877; HALLMAN M, 1988, AM J OBSTET GYNECOL, V158, P531, DOI 10.1016/0002-9378(88)90019-1; HAMM H, 1994, CHEST, V106, P1766, DOI 10.1378/chest.106.6.1766; Harrod KS, 1999, AM J PHYSIOL-LUNG C, V277, pL580, DOI 10.1152/ajplung.1999.277.3.L580; Hartshorn KL, 1998, AM J PHYSIOL-LUNG C, V274, pL958, DOI 10.1152/ajplung.1998.274.6.L958; Hickling TP, 1998, MOL MED, V4, P266, DOI 10.1007/BF03401923; Hickman-Davis J, 1999, P NATL ACAD SCI USA, V96, P4953, DOI 10.1073/pnas.96.9.4953; Hills BA, 1998, PERITON DIALYSIS INT, V18, P157; HILLS BA, 1992, AUST NZ J MED, V22, P441, DOI 10.1111/j.1445-5994.1992.tb02167.x; HILLS BA, 1984, ARCH OTOLARYNGOL, V110, P3; HILLS BA, 1983, AM J PHYSIOL, V244, pG561, DOI 10.1152/ajpgi.1983.244.5.G561; Hills BA, 1998, BRIT J RHEUMATOL, V37, P143; HOLM BA, 1988, CHEM PHYS LIPIDS, V49, P49, DOI 10.1016/0009-3084(88)90063-1; HONDA Y, 1993, CHEST, V103, P496, DOI 10.1378/chest.103.2.496; HOROWITZ S, 1991, AM J RESP CELL MOL, V5, P511, DOI 10.1165/ajrcmb/5.6.511; Hull J, 1997, AM J RESP CRIT CARE, V156, P161, DOI 10.1164/ajrccm.156.1.9609090; Ikegami M, 1998, AM J PHYSIOL-LUNG C, V275, pL247, DOI 10.1152/ajplung.1998.275.2.L247; IKEGAMI M, 1986, BIOL NEONATE, V50, P121; Kabha K, 1997, AM J PHYSIOL-LUNG C, V272, pL344, DOI 10.1152/ajplung.1997.272.2.L344; Kala P, 1998, PEDIATR RES, V43, P169, DOI 10.1203/00006450-199802000-00003; KATYAL SL, 1992, AM J RESP CELL MOL, V6, P446, DOI 10.1165/ajrcmb/6.4.446; KATYAL SL, 1984, AM J OBSTET GYNECOL, V148, P48, DOI 10.1016/S0002-9378(84)80031-9; KHOOR A, 1993, J HISTOCHEM CYTOCHEM, V41, P1311, DOI 10.1177/41.9.8354874; KHUBCHANDANI KR, 2000, PEDIAT PATHOL MOL ME; KING RJ, 1975, J APPL PHYSIOL, V39, P735, DOI 10.1152/jappl.1975.39.5.735; KOBAYASHI K, 1992, ANN OTO RHINOL LARYN, V101, P491, DOI 10.1177/000348949210100608; Korfhagen TR, 1996, P NATL ACAD SCI USA, V93, P9594, DOI 10.1073/pnas.93.18.9594; Koziel H, 1998, AM J RESP CELL MOL, V18, P834, DOI 10.1165/ajrcmb.18.6.3059; Kremlev SG, 1997, AM J PHYSIOL-LUNG C, V272, pL1070, DOI 10.1152/ajplung.1997.272.6.L1070; KREMLEV SG, 1994, AM J PHYSIOL-LUNG C, V267, pL357, DOI 10.1152/ajplung.1994.267.4.L357; KREMLEV SG, 1994, AM J PHYSIOL-LUNG C, V267, pL712, DOI 10.1152/ajplung.1994.267.6.L712; Kremlev SG, 1997, AM J PHYSIOL-LUNG C, V272, pL996, DOI 10.1152/ajplung.1997.272.5.L996; Kresch MJ, 1996, BBA-LIPID LIPID MET, V1299, P39, DOI 10.1016/0005-2760(95)00186-7; Kumar AR, 1998, AM J PHYSIOL-LUNG C, V274, pL177, DOI 10.1152/ajplung.1998.274.2.L177; KUROKI Y, 1993, AM REV RESPIR DIS, V147, P723, DOI 10.1164/ajrccm/147.3.723; Kuroki Y, 1998, BBA-MOL BASIS DIS, V1408, P334, DOI 10.1016/S0925-4439(98)00079-9; KUROKI Y, 1991, J BIOL CHEM, V266, P3068; LeVine AM, 1997, J IMMUNOL, V158, P4336; LeVine AM, 1998, AM J RESP CELL MOL, V19, P700, DOI 10.1165/ajrcmb.19.4.3254; LeVine AM, 1999, J CLIN INVEST, V103, P1015, DOI 10.1172/JCI5849; LeVine AM, 1996, CRIT CARE MED, V24, P1062, DOI 10.1097/00003246-199606000-00029; LIAU DF, 1987, AM REV RESPIR DIS, V136, P395, DOI 10.1164/ajrccm/136.2.395; Lu JH, 1997, BIOESSAYS, V19, P509, DOI 10.1002/bies.950190610; Madan T, 1997, CLIN EXP IMMUNOL, V110, P241; MANZKEINKE H, 1992, EUR J CELL BIOL, V57, P95; Mariencheck WI, 1999, AM J PHYSIOL-LUNG C, V277, pL777, DOI 10.1152/ajplung.1999.277.4.L777; MCCORMACK FX, 1991, AM REV RESPIR DIS, V144, P160, DOI 10.1164/ajrccm/144.1.160; McIntosh JC, 1996, AM J RESP CELL MOL, V15, P509, DOI 10.1165/ajrcmb.15.4.8879185; McIntosh JC, 1996, AM J PHYSIOL-LUNG C, V271, pL310, DOI 10.1152/ajplung.1996.271.2.L310; MENDELSON CR, 1986, J BIOL CHEM, V261, P9938; MOSS RB, 1995, CLIN INFECT DIS, V21, P839, DOI 10.1093/clinids/21.4.839; Nepomuceno RR, 1997, IMMUNITY, V6, P119, DOI 10.1016/S1074-7613(00)80419-7; ODOM MJ, 1987, ENDOCRINOLOGY, V121, P1155, DOI 10.1210/endo-121-3-1155; OHMERSCHROCK D, 1995, J CELL SCI, V108, P3695; OHMERSCHROCK D, 1993, MICROSC RES TECHNIQ, V26, P374, DOI 10.1002/jemt.1070260505; OREILLY MA, 1988, BIOCHIM BIOPHYS ACTA, V970, P194, DOI 10.1016/0167-4889(88)90179-6; Paananen R, 1999, FEBS LETT, V452, P141, DOI 10.1016/S0014-5793(99)00602-X; PERSSON A, 1988, BIOCHEMISTRY-US, V27, P8576, DOI 10.1021/bi00423a011; PHELPS DS, 1991, AM REV RESPIR DIS, V143, P1072, DOI 10.1164/ajrccm/143.5_Pt_1.1072; PIKAAR JC, 1995, J INFECT DIS, V172, P481, DOI 10.1093/infdis/172.2.481; Postle AD, 1999, AM J RESP CELL MOL, V20, P90, DOI 10.1165/ajrcmb.20.1.3253; POULAIN FR, 1992, AM J PHYSIOL, V262, pL730, DOI 10.1152/ajplung.1992.262.6.L730; PRYHUBER GS, 1990, J BIOL CHEM, V265, P20822; RAPPORT PN, 1975, ARCH OTOLARYNGOL, V101, P305; RICE WR, 1987, J APPL PHYSIOL, V63, P692, DOI 10.1152/jappl.1987.63.2.692; RUBIO S, 1995, J BIOL CHEM, V270, P12162, DOI 10.1074/jbc.270.20.12162; Saitoh H, 1998, AM J RESP CELL MOL, V19, P202, DOI 10.1165/ajrcmb.19.2.3239; SCHELENZ S, 1995, INFECT IMMUN, V63, P3360, DOI 10.1128/IAI.63.9.3360-3366.1995; SNYDER JM, 1987, ENDOCRINOLOGY, V120, P1250, DOI 10.1210/endo-120-4-1250; SNYDER JM, 1988, PEDIATR RES, V24, P728, DOI 10.1203/00006450-198812000-00016; Sugahara K, 1996, LAB INVEST, V74, P209; SUPER M, 1989, LANCET, V2, P1236; TENNER AJ, 1989, J BIOL CHEM, V264, P13923; Tino MJ, 1996, AM J PHYSIOL-LUNG C, V270, pL677, DOI 10.1152/ajplung.1996.270.4.L677; VANGOLDE LMG, 1995, BIOL NEONATE, V67, P2; VANIWAARDEN F, 1990, AM J RESP CELL MOL, V2, P91, DOI 10.1165/ajrcmb/2.1.91; VANIWAARDEN JF, 1995, BIOCHEM J, V309, P551, DOI 10.1042/bj3090551; VANIWAARDEN JF, 1994, BIOCHEM J, V303, P407, DOI 10.1042/bj3030407; VANIWAARDEN JF, 1992, J BIOL CHEM, V267, P25039; VOSS T, 1991, AM J RESP CELL MOL, V4, P88, DOI 10.1165/ajrcmb/4.1.88; Walenkamp AME, 1999, EUR J CLIN INVEST, V29, P83, DOI 10.1046/j.1365-2362.1999.00429.x; WEAVER TE, 1991, BIOCHEM J, V273, P249, DOI 10.1042/bj2730249; Weikert LF, 1997, AM J PHYSIOL-LUNG C, V272, pL989, DOI 10.1152/ajplung.1997.272.5.L989; WHITE P, 1989, AM J OTOLARYNG, V10, P301, DOI 10.1016/0196-0709(89)90103-8; WHITE RT, 1985, NATURE, V317, P361, DOI 10.1038/317361a0; WHITSETT JA, 1987, J BIOL CHEM, V262, P7908; WHITSETT JA, 1987, J BIOL CHEM, V262, P5256; WISPE JR, 1990, J CLIN INVEST, V86, P1954, DOI 10.1172/JCI114929; WRIGHT JR, 1995, AM J PHYSIOL-LUNG C, V268, pL772, DOI 10.1152/ajplung.1995.268.5.L772; WRIGHT JR, 1987, J BIOL CHEM, V262, P2888; Wright JR, 1997, PHYSIOL REV, V77, P931, DOI 10.1152/physrev.1997.77.4.931; YAMANAKA N, 1991, ANN OTO RHINOL LARYN, V100, P835, DOI 10.1177/000348949110001009	118	94	98	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2001	15	1					59	69		10.1096/fj.00-0318rev	http://dx.doi.org/10.1096/fj.00-0318rev			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149893				2022-12-28	WOS:000166312400014
J	Yegutkin, GG; Henttinen, T; Jalkanen, S				Yegutkin, GG; Henttinen, T; Jalkanen, S			Extracellular ATP formation on vascular endothelial cells is mediated by ecto-nucleotide kinase activities via phosphotransfer reactions	FASEB JOURNAL			English	Article						adenine nucleotides; ecto-enzymes; hydrolysis; interconversion; vasculature	SMOOTH-MUSCLE CELLS; ADENINE-NUCLEOTIDES; DIPHOSPHOHYDROLASE; SYNTHASE; SURFACE; CD39; IDENTIFICATION; LYMPHOCYTES; EXPRESSION; HYDROLYSIS	Cell surface ecto-nucleotidases are considered the major effector system for inactivation of extracellular adenine nucleotides, whereas the alternative possibility of ATP synthesis has received little attention, Using a TLC assay, we investigated the main exchange activities of H-3-labeled adenine nucleotides on the cultured human umbilical vein endothelial cells, Stepwise nucleotide degradation to adenosine occurred when a particular nucleotide was present alone, whereas combined cell treatment with ATP and either [H-3]AMP or [H-3]ADP caused unexpected phosphorylation of H-3-nucleotides via the backward reactions AMP --> ADP --> ATP. The following two groups of nucleotide-converting ecto-enzymes were identified based on inhibition and substrate specificity studies: 1) ecto-nucleotidases, ATP-diphosphohydrolase, and 5'-nucleotidase; 2) ecto-nucleotide kinases, adenylate kinase, and nucleoside diphosphate kinase. Ecto-nucleoside diphosphate kinase possessed the highest activity, as revealed by comparative kinetic analysis, and was capable of using both adenine and nonadenine nucleotides as phosphate donors and acceptors. The transphosphorylation mechanism was confirmed by direct transfer of the gamma -phosphate from [gamma-P-32]ATP to AMP or nucleoside diphosphates and by measurement of extracellular ATP synthesis using luciferin-luciferase luminometry, The data demonstrate the coexistence of opposite, ATP-consuming and ATP-generating, pathways on the cell surface and provide a novel mechanism for regulating the duration and magnitude of purinergic signaling in the vasculature.	Univ Turku, MediCity Res Lab, FIN-20520 Turku, Finland; Natl Publ Hlth Inst, FIN-20520 Turku, Finland	University of Turku; Finland National Institute for Health & Welfare	Yegutkin, GG (corresponding author), Univ Turku, MediCity Res Lab, Tykistokatu 6A, FIN-20520 Turku, Finland.		Yegutkin, Gennady G./K-3815-2014	Yegutkin, Gennady G./0000-0001-6684-7982				AGREN G, 1974, J CELL PHYSIOL, V83, P91, DOI 10.1002/jcp.1040830113; Airas L, 1997, J CELL BIOL, V136, P421, DOI 10.1083/jcb.136.2.421; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Burnstock G, 1997, NEUROPHARMACOLOGY, V36, P1127, DOI 10.1016/S0028-3908(97)00125-1; Clifford EE, 1997, AM J PHYSIOL-CELL PH, V273, pC973, DOI 10.1152/ajpcell.1997.273.3.C973; DAS B, 1994, J EXP MED, V180, P273, DOI 10.1084/jem.180.1.273; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; Dzeja PP, 1998, FASEB J, V12, P523, DOI 10.1096/fasebj.12.7.523; Enjyoji K, 1999, NAT MED, V5, P1010, DOI 10.1038/12447; Goding JW, 1998, IMMUNOL REV, V161, P11, DOI 10.1111/j.1600-065X.1998.tb01568.x; GORDON EL, 1989, J BIOL CHEM, V264, P18986; Grobben B, 1999, J NEUROCHEM, V72, P826, DOI 10.1046/j.1471-4159.1999.0720826.x; Harden TK, 1999, PROG BRAIN RES, V120, P135; HARDEN TK, 1995, ANNU REV PHARMACOL, V35, P541, DOI 10.1146/annurev.pharmtox.35.1.541; Ilangumaran S, 2000, IMMUNOL TODAY, V21, P2, DOI 10.1016/S0167-5699(99)01494-2; Kaczmarek E, 1996, J BIOL CHEM, V271, P33116, DOI 10.1074/jbc.271.51.33116; Koziak K, 1999, THROMB HAEMOSTASIS, V82, P1538; Lazarowski ER, 1997, J BIOL CHEM, V272, P20402, DOI 10.1074/jbc.272.33.20402; LAZAROWSKI ER, 2000, 2 INT WORKSH ECT REL, P283; Marcus AJ, 1997, J CLIN INVEST, V99, P1351, DOI 10.1172/JCI119294; MEGHJI P, 1995, BIOCHEM J, V308, P725, DOI 10.1042/bj3080725; Moser TL, 1999, P NATL ACAD SCI USA, V96, P2811, DOI 10.1073/pnas.96.6.2811; NORMAN GA, 1974, J CHROMATOGR, V90, P105, DOI 10.1016/S0021-9673(01)94779-X; PEARSON JD, 1980, BIOCHEM J, V190, P421, DOI 10.1042/bj1900421; Piacentini L, 1996, MOL CELL BIOCHEM, V157, P59; PLESNER L, 1995, INT REV CYTOL, V158, P141; Postel EH, 1998, INT J BIOCHEM CELL B, V30, P1291, DOI 10.1016/S1357-2725(98)00087-9; Ralevic V, 1998, PHARMACOL REV, V50, P413; Resta R, 1998, IMMUNOL REV, V161, P95, DOI 10.1111/j.1600-065X.1998.tb01574.x; ROBSON S, 2000, EMERGING THER TARGET, V4, P155; RONQUIST G, 1968, ACTA PHYSIOL SCAND, V74, P594, DOI 10.1111/j.1748-1716.1968.tb04270.x; Wang TF, 1996, J BIOL CHEM, V271, P9898, DOI 10.1074/jbc.271.17.9898; Yan HG, 1999, ADV ENZYMOL RAMB, V73, P103, DOI 10.1002/9780470123195.ch4; Yegutkin G, 2000, BRIT J PHARMACOL, V129, P921, DOI 10.1038/sj.bjp.0703136; Yegutkin GG, 1998, BBA-BIOMEMBRANES, V1373, P227, DOI 10.1016/S0005-2736(98)00108-4; ZIMMER AM, 1992, ANTIBODY IMMUNOCONJ, V5, P285; Zimmermann H, 1999, TRENDS PHARMACOL SCI, V20, P231, DOI 10.1016/S0165-6147(99)01293-6; Zimmermann H, 1996, PROG NEUROBIOL, V49, P589, DOI 10.1016/0301-0082(96)00026-3	38	104	105	2	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2001	15	1					251	260		10.1096/fj.00-0268com	http://dx.doi.org/10.1096/fj.00-0268com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149913				2022-12-28	WOS:000166312400034
J	Eiden, LE				Eiden, LE			The vesicular neurotransmitter transporters: current perspectives and future prospects	FASEB JOURNAL			English	Review							CHOLINERGIC GENE LOCUS; CAENORHABDITIS-ELEGANS; ACETYLCHOLINE TRANSPORTER; MONOAMINE TRANSPORTER; CHROMAFFIN GRANULES; SYNAPTIC VESICLES; MOLECULAR-BIOLOGY; RELEASE; STORAGE; GABA		NIMH, Mol Neurosci Sect, Lab Cellular & Mol Regulat, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Eiden, LE (corresponding author), NIMH, Mol Neurosci Sect, Lab Cellular & Mol Regulat, 9000 Rockville Pike,Bldg 36,Rm 2A-11, Bethesda, MD 20892 USA.			Eiden, Lee/0000-0001-7524-944X	NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH002386, ZIAMH002386] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALFONSO A, 1994, J MOL BIOL, V241, P627, DOI 10.1006/jmbi.1994.1538; ALFONSO A, 1993, SCIENCE, V261, P617, DOI 10.1126/science.8342028; ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H; Bellocchio EE, 2000, SCIENCE, V289, P957, DOI 10.1126/science.289.5481.957; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; Bonisch H, 1998, Adv Pharmacol, V42, P149; Brose N, 1999, NEURON, V24, P766, DOI 10.1016/S0896-6273(00)81023-5; Chalfie M, 1998, TRENDS GENET, V14, P506, DOI 10.1016/S0168-9525(98)01623-0; Crowder KM, 1999, P NATL ACAD SCI USA, V96, P15268, DOI 10.1073/pnas.96.26.15268; Duerr JS, 1999, J NEUROSCI, V19, P72, DOI 10.1523/JNEUROSCI.19-01-00072.1999; Edwards R H, 1992, Curr Opin Neurobiol, V2, P586, DOI 10.1016/0959-4388(92)90023-E; Efange SMN, 2000, FASEB J, V14, P2401, DOI 10.1096/fj.00-0204rev; Eiden LE, 1998, J NEUROCHEM, V70, P2227; ERICKSON JD, 1994, J BIOL CHEM, V269, P21929; Erickson JD, 2000, FASEB J, V14, P2450, DOI 10.1096/fj.00-0206rev; Fon EA, 1997, NEURON, V19, P1271, DOI 10.1016/S0896-6273(00)80418-3; GOEDERT JJ, 1984, LANCET, V2, P711; Goridis C, 1999, CURR OPIN NEUROBIOL, V9, P47, DOI 10.1016/S0959-4388(99)80006-3; HENRY JP, 1994, J EXP BIOL, V196, P251; HILLARP NA, 1958, ACTA PHYSIOL SCAND, V43, P82, DOI 10.1111/j.1748-1716.1958.tb01579.x; ISRAEL M, 1993, PROG BRAIN RES, V98, P219; Janz R, 1999, NEURON, V24, P1003, DOI 10.1016/S0896-6273(00)81046-6; JOHNSON RG, 1988, PHYSIOL REV, V68, P232, DOI 10.1152/physrev.1988.68.1.232; Krantz DE, 2000, J CELL BIOL, V149, P379, DOI 10.1083/jcb.149.2.379; Kuhl DE, 1996, ANN NEUROL, V40, P399, DOI 10.1002/ana.410400309; Liu YJ, 1999, TRENDS CELL BIOL, V9, P356, DOI 10.1016/S0962-8924(99)01605-0; MAYCOX PR, 1990, TRENDS NEUROSCI, V13, P83, DOI 10.1016/0166-2236(90)90178-D; McIntire SL, 1997, NATURE, V389, P870, DOI 10.1038/39908; MCINTIRE SL, 1993, NATURE, V364, P334, DOI 10.1038/364334a0; PARSONS SM, 1993, INT REV NEUROBIOL, V35, P279, DOI 10.1016/S0074-7742(08)60572-3; Parsons SM, 2000, FASEB J, V14, P2423, DOI 10.1096/fj.00-0203rev; Rand JB, 2000, FASEB J, V14, P2414, DOI 10.1096/fj.00-0313rev; Sagne C, 1997, FEBS LETT, V417, P177, DOI 10.1016/S0014-5793(97)01279-9; SCHULDINER S, 1994, J NEUROCHEM, V62, P2067; SCHULDINER S, 1995, PHYSIOL REV, V75, P369, DOI 10.1152/physrev.1995.75.2.369; Takahashi N, 1997, MOL BRAIN RES, V49, P7, DOI 10.1016/S0169-328X(97)00116-2; Takamori S, 2000, NATURE, V407, P189, DOI 10.1038/35025070; Tao-Cheng J H, 1998, Adv Pharmacol, V42, P250; Uhl GR, 2000, FASEB J, V14, P2459, DOI 10.1096/fj.00-0205rev; USDIN TB, 1995, TRENDS NEUROSCI, V18, P218, DOI 10.1016/0166-2236(95)93906-E; Wang YM, 1997, NEURON, V19, P1285, DOI 10.1016/S0896-6273(00)80419-5; Weihe E, 2000, FASEB J, V14, P2435, DOI 10.1096/fj.00-0202rev; WHITTAKER VP, 1988, HDB EXPT PHARM, V86; WIRZJUSTICE A, 1988, EXPERIENTIA, V44, P145, DOI 10.1007/BF01952199	45	65	68	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2396	2400		10.1096/fj.00-0817rev	http://dx.doi.org/10.1096/fj.00-0817rev			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099457				2022-12-28	WOS:000165723400009
J	Cherepanov, P; Pluymers, W; Claeys, A; Proost, P; De Clercq, E; Debyser, Z				Cherepanov, P; Pluymers, W; Claeys, A; Proost, P; De Clercq, E; Debyser, Z			High-level expression of active HIV-1 integrase from a synthetic gene in human cells	FASEB JOURNAL			English	Article						complementation; expression; human immunodeficiency virus type 1	IMMUNODEFICIENCY-VIRUS TYPE-1; RETROVIRAL DNA INTEGRATION; NONDIVIDING CELLS; PREINTEGRATION COMPLEXES; MESSENGER-RNA; NUCLEAR-LOCALIZATION; CDNA INTEGRATION; PROTEIN INVITRO; MATRIX PROTEIN; SARCOMA VIRUS	A synthetic gene encoding for HIV-1 integase was designed to circumvent the intrinsic instability and the repressor elements present in the wild-type gene. High-level expression of HIV-1 integrase was obtained in various human cell lines independently of viral accessory proteins. A human 293T cell line was selected that stably expresses HIV-1 integrase and has growth kinetics comparable to the parental cell line. The enzyme was localized in the nucleus and remained stably associated with the chromosomes during mitosis. Lentiviral vector particles carrying the inactivating D64V mutation in the integase gene were capable of stably transducing 293T cells when complemented in the producer cells with integrase expressed from the synthetic gene. When the cell line that stably expresses integase was infected with the defective viral particles, complementation of integrase activity was detected as well. Expression of active HIV-1 integase in human cells will facilitate the study of the interplay between host and viral factors during integation.	Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium	KU Leuven	Debyser, Z (corresponding author), Katholieke Univ Leuven, Rega Inst Med Res, Minderbroedersstr 10, B-3000 Louvain, Belgium.		Proost, Paul/V-3052-2017; Cherepanov, Peter P/F-6859-2010	Proost, Paul/0000-0002-0133-5545; Cherepanov, Peter P/0000-0002-0634-538X; De Clercq, Erik/0000-0002-2985-8890				Abdallah B, 1996, HUM GENE THER, V7, P1947, DOI 10.1089/hum.1996.7.16-1947; BRAY M, 1994, P NATL ACAD SCI USA, V91, P1256, DOI 10.1073/pnas.91.4.1256; Brown P. O., 1997, P161; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; BUKRINSKY MI, 1992, P NATL ACAD SCI USA, V89, P6580, DOI 10.1073/pnas.89.14.6580; BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144; BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428; BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339; Carteau S, 1998, J VIROL, V72, P4005, DOI 10.1128/JVI.72.5.4005-4014.1998; Caumont AB, 1996, CURR GENET, V29, P503; Cherepanov P, 1999, NUCLEIC ACIDS RES, V27, P2202, DOI 10.1093/nar/27.10.2202; COCHRANE AW, 1991, J VIROL, V65, P5305, DOI 10.1128/JVI.65.10.5305-5313.1991; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; Daniel R, 1999, SCIENCE, V284, P644, DOI 10.1126/science.284.5414.644; Day DA, 1998, J ENDOCRINOL, V157, P361, DOI 10.1677/joe.0.1570361; DECLERCQ E, 1995, J MED CHEM, V38, P2491, DOI 10.1021/jm00014a001; ENGELMAN A, 1993, EMBO J, V12, P3269, DOI 10.1002/j.1460-2075.1993.tb05996.x; ENGELMAN A, 1994, J VIROL, V68, P5911, DOI 10.1128/JVI.68.9.5911-5917.1994; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; Farnet CM, 1997, CELL, V88, P483, DOI 10.1016/S0092-8674(00)81888-7; Faust EA, 1995, BIOCHEM MOL BIOL INT, V36, P745; Fletcher TM, 1997, EMBO J, V16, P5123, DOI 10.1093/emboj/16.16.5123; GALLAY P, 1995, CELL, V80, P379, DOI 10.1016/0092-8674(95)90488-3; Gallay P, 1997, P NATL ACAD SCI USA, V94, P9825, DOI 10.1073/pnas.94.18.9825; Gaur M, 1998, J VIROL, V72, P4678, DOI 10.1128/JVI.72.6.4678-4685.1998; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Haas J, 1996, CURR BIOL, V6, P315, DOI 10.1016/S0960-9822(02)00482-7; Hennigan AN, 1996, MOL CELL BIOL, V16, P3833; Jarzembowski J A, 1997, Prog Mol Subcell Biol, V18, P141; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Kukolj G, 1997, J VIROL, V71, P843, DOI 10.1128/JVI.71.1.843-847.1997; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LAFEMINA RL, 1992, J VIROL, V66, P7414, DOI 10.1128/JVI.66.12.7414-7419.1992; Leavitt AD, 1996, J VIROL, V70, P721, DOI 10.1128/JVI.70.2.721-728.1996; Lee MS, 1998, P NATL ACAD SCI USA, V95, P1528, DOI 10.1073/pnas.95.4.1528; Miller MD, 1997, J VIROL, V71, P5382, DOI 10.1128/JVI.71.7.5382-5390.1997; MORRISVASIOS C, 1989, J VIROL, V62, P349; MUMM SR, 1992, VIROLOGY, V189, P500, DOI 10.1016/0042-6822(92)90574-9; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; NASIOULAS G, 1994, J VIROL, V68, P2986, DOI 10.1128/JVI.68.5.2986-2993.1994; OSTLING O, 1984, BIOCHEM BIOPH RES CO, V123, P291, DOI 10.1016/0006-291X(84)90411-X; Petit C, 1999, J VIROL, V73, P5079, DOI 10.1128/JVI.73.6.5079-5088.1999; Pluymers W, 1999, VIROLOGY, V258, P327, DOI 10.1006/viro.1999.9727; Pommier Y, 1997, ANTIVIR CHEM CHEMOTH, V8, P463, DOI 10.1177/095632029700800601; Popov S, 1998, EMBO J, V17, P909, DOI 10.1093/emboj/17.4.909; SAKAI H, 1993, J VIROL, V67, P1169, DOI 10.1128/JVI.67.3.1169-1174.1993; SCHIAVI SC, 1994, J BIOL CHEM, V269, P3441; Schneider R, 1997, J VIROL, V71, P4892, DOI 10.1128/JVI.71.7.4892-4903.1997; SCHWARTZ S, 1992, J VIROL, V66, P150, DOI 10.1128/JVI.66.1.150-159.1992; SHERMAN PA, 1990, P NATL ACAD SCI USA, V87, P5119, DOI 10.1073/pnas.87.13.5119; Tabernero C, 1996, J VIROL, V70, P5998, DOI 10.1128/JVI.70.9.5998-6011.1996; VANGENT DC, 1993, EMBO J, V12, P3261, DOI 10.1002/j.1460-2075.1993.tb05995.x; VINK C, 1993, NUCLEIC ACIDS RES, V21, P1419, DOI 10.1093/nar/21.6.1419; Zheng RL, 1996, P NATL ACAD SCI USA, V93, P13659, DOI 10.1073/pnas.93.24.13659	55	56	59	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2000	14	10					1389	1399		10.1096/fj.14.10.1389	http://dx.doi.org/10.1096/fj.14.10.1389			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877832				2022-12-28	WOS:000087932200014
J	Parsons, M; Young, L; Lee, JE; Jacobson, KA; Liang, BT				Parsons, M; Young, L; Lee, JE; Jacobson, KA; Liang, BT			Distinct cardioprotective effects of adenosine mediated by differential coupling of receptor subtypes to phospholipases C and D	FASEB JOURNAL			English	Article						ischemia; ventricular myocyte; PKC activity; cardioprotection	SENSITIVE POTASSIUM CHANNELS; CARDIAC MYOCYTES; A(3) RECEPTORS; RABBIT HEART; ISCHEMIA; STIMULATION; ACTIVATION; PROTECTION; MUSCLE; INJURY	Adenosine released during cardiac ischemia exerts a marked protective effect in the heart that is mediated by the A(1) and A(3) subtypes of adenosine receptors, The signaling pathways activated by these adenosine receptors have now been characterized in a chick embryo ventricular myocyte culture model of cardioprotection against ischemia. Selective A(1) and A(3) receptor agonists were shown to activate phospholipases C and D, respectively, to achieve their distinct cardioprotective effects. The specificity of the A(3) receptor-phospholipase D interaction was also demonstrated in chick embryo atrial myocytes (which do not express endogenous A(3) receptors) that had been transfected with a vector encoding the human A(3) receptor. Activation of both endogenous A(1) and A(3) receptors in ventricular myocytes resulted in a protective response greater than that induced by stimulation of either receptor alone, Agonists that activate both adenosine A(1) and A(3) receptors may thus prove beneficial for the treatment of myocardial ischemia.	Univ Penn, Med Ctr, Dept Med, Div Cardiovasc, Philadelphia, PA 19104 USA; NIDDKD, Mol Recognit Sect, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA	University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Liang, BT (corresponding author), Univ Penn, Med Ctr, Dept Med, Div Cardiovasc, 956 BRBII-III,421 Curie Blvd, Philadelphia, PA 19104 USA.		Jacobson, Kenneth Alan/A-1530-2009	Jacobson, Kenneth Alan/0000-0001-8104-1493	Intramural NIH HHS [Z01 DK031117-20] Funding Source: Medline; NHLBI NIH HHS [R01 HL48225, R01 HL048225] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048225] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK031117, Z01DK031116] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ali H, 1996, J PHARMACOL EXP THER, V276, P837; Auchampach JA, 1997, CIRC RES, V80, P800; BARNETT JV, 1990, BIOCHEM J, V271, P437, DOI 10.1042/bj2710437; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Carr CS, 1997, CARDIOVASC RES, V36, P52, DOI 10.1016/S0008-6363(97)00160-0; Cohen MV, 1996, CIRCULATION, V94, P1713, DOI 10.1161/01.CIR.94.7.1713; Dougherty C, 1998, FASEB J, V12, P1785, DOI 10.1096/fasebj.12.15.1785; DOWNEY JM, 1992, TRENDS CARDIOVAS MED, V2, P170, DOI 10.1016/1050-1738(92)90045-T; ELY SW, 1992, CIRCULATION, V85, P893, DOI 10.1161/01.CIR.85.3.893; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; GROSS GJ, 1995, BASIC RES CARDIOL, V90, P85, DOI 10.1007/BF00789438; GROVER GJ, 1992, CIRCULATION, V86, P1310, DOI 10.1161/01.CIR.86.4.1310; KIM HO, 1994, J MED CHEM, V37, P3614, DOI 10.1021/jm00047a018; LI GC, 1990, CIRCULATION, V82, P609, DOI 10.1161/01.CIR.82.2.609; Liang BT, 1996, AM J PHYSIOL-HEART C, V271, pH1769, DOI 10.1152/ajpheart.1996.271.5.H1769; Liang BT, 1998, P NATL ACAD SCI USA, V95, P6995, DOI 10.1073/pnas.95.12.6995; Liang BT, 1997, AM J PHYSIOL-HEART C, V273, pH847, DOI 10.1152/ajpheart.1997.273.2.H847; MARTINSON EA, 1990, J BIOL CHEM, V265, P22282; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; MURTHY KS, 1995, MOL PHARMACOL, V48, P293; Podrasky E, 1997, AM J PHYSIOL-HEART C, V273, pH2380, DOI 10.1152/ajpheart.1997.273.5.H2380; Stambaugh K, 1997, AM J PHYSIOL-HEART C, V273, pH501; Strickler J, 1996, J CLIN INVEST, V98, P1773, DOI 10.1172/JCI118976; Tracey WR, 1997, CARDIOVASC RES, V33, P410, DOI 10.1016/S0008-6363(96)00240-4; XU H, 1992, NUCLEIC ACIDS RES, V20, P6425, DOI 10.1093/nar/20.23.6425	26	78	79	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2000	14	10					1423	1431		10.1096/fj.14.10.1423	http://dx.doi.org/10.1096/fj.14.10.1423			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877835	Green Accepted			2022-12-28	WOS:000087932200017
J	Polly, P; Herdick, M; Moehren, U; Baniahmad, A; Heinzel, T; Carlberg, C				Polly, P; Herdick, M; Moehren, U; Baniahmad, A; Heinzel, T; Carlberg, C			VDR-Alien: a novel, DNA-selective vitamin D-3 receptor-corepressor partnership	FASEB JOURNAL			English	Article						gene regulation; repression; NCoR	NUCLEAR HORMONE-RECEPTOR; LIGAND-BINDING DOMAIN; STIMULATING FACTOR GENE; RETINOIC ACID; THYROID-HORMONE; TRANSCRIPTIONAL REPRESSION; CO-REPRESSOR; FUNCTIONAL-CHARACTERIZATION; BASAL TRANSCRIPTION; SIGNALING PATHWAYS	The vitamin D receptor (VDR) is a transcription factor that transmits incoming 1,25-dihydroxyvitamin D-3 (1 alpha,25(OH)(2)D-3) signaling via combined contact with coactivator proteins and specific DNA binding sites (VDREs), which ultimately results in activation of transcription. In contrast, the mechanisms of transcriptional repression via the VDR are less well understood. This study documents VDR-dependent transcriptional repression largely via histone deacetylase (HDAC) activity. Direct, ligand-sensitive protein-protein interaction of the VDR with the nuclear receptor corepressor (NCoR) and a novel corepressor, called Alien, was demonstrated to be comparable but independent of the VDR AF-2 transactivation domain. Functional assays indicated that Alien, but not NCoR, displays selectivity for different VDRE structures for transferring these repressive effects into gene regulatory activities. Moreover, superrepression via Alien was found to be affected only in part by HDAC inhibitors such as trichostatin A. Finally, for a dissociation of VDR-Alien complexes in vitro and in vivo, higher ligand concentrations were needed than for a dissociation of VDR-NCoR complexes. This suggests that Alien and NCoR are using different interfaces for interaction with the VDR and different pathways for mediating superrepression, which in turn characterizes Alien as a representative of a new class of corepressors. Taken together, association of the VDR with corepressor proteins provides a further level of transcriptional regulation, which is emerging as a complex network of protein-protein interaction-mediated control.	Univ Dusseldorf, Inst Physiol Chem 1, D-40001 Dusseldorf, Germany; Univ Giessen, Genet Inst, D-35392 Giessen, Germany	Heinrich Heine University Dusseldorf; Justus Liebig University Giessen	Carlberg, C (corresponding author), Univ Dusseldorf, Inst Physiol Chem 1, Postfach 10 10 07, D-40001 Dusseldorf, Germany.		Carlberg, Carsten/C-9075-2011; Heinzel, Thorsten/B-1013-2015	Carlberg, Carsten/0000-0003-2633-0684; 				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ALROY I, 1995, MOL CELL BIOL, V15, P5789; Baniahmad A, 1997, MOL CELL BIOL, V17, P4259, DOI 10.1128/MCB.17.8.4259; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Burke LJ, 1998, MOL ENDOCRINOL, V12, P248, DOI 10.1210/me.12.2.248; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; Carlberg C, 1998, CRIT REV EUKAR GENE, V8, P19, DOI 10.1615/CritRevEukarGeneExpr.v8.i1.20; Carlberg C, 1996, ENDOCRINE, V4, P91, DOI 10.1007/BF02782754; CARLBERG C, 1995, EUR J BIOCHEM, V231, P517, DOI 10.1111/j.1432-1033.1995.0517d.x; Carlberg C., 1997, P 10 INT VIT D WORKS, P268; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Dressel U, 1999, MOL CELL BIOL, V19, P3383; Dwivedi PP, 1998, J MOL ENDOCRINOL, V20, P327, DOI 10.1677/jme.0.0200327; GarciaVillalba P, 1996, MOL CELL BIOL, V16, P318; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JANAGI Y, 1999, J BIOL CHEM, V274, P12971; Jenster G, 1998, MOL CELL ENDOCRINOL, V143, P1, DOI 10.1016/S0303-7207(98)00145-2; Jimenez-Lara AM, 1999, ENDOCRINOLOGY, V140, P2898, DOI 10.1210/en.140.6.2898; Kahlen JP, 1996, BIOCHEM BIOPH RES CO, V218, P882, DOI 10.1006/bbrc.1996.0157; Koszewski NJ, 1999, MOL ENDOCRINOL, V13, P455, DOI 10.1210/me.13.3.455; Kremer R, 1996, J BIOL CHEM, V271, P16310, DOI 10.1074/jbc.271.27.16310; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; Li Q, 1999, TRENDS ENDOCRIN MET, V10, P157, DOI 10.1016/S1043-2760(98)00141-6; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; MORRISON J, 1989, ANN CLIN PSYCHIATRY, V1, P25; Muscat GEO, 1998, NUCLEIC ACIDS RES, V26, P2899, DOI 10.1093/nar/26.12.2899; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nayeri S, 1996, NUCLEIC ACIDS RES, V24, P4513, DOI 10.1093/nar/24.22.4513; Ordentlich P, 1999, P NATL ACAD SCI USA, V96, P2639, DOI 10.1073/pnas.96.6.2639; OZONO K, 1990, J BIOL CHEM, V265, P21881; Polly P, 1997, J CELL BIOCHEM, V67, P287, DOI 10.1002/(SICI)1097-4644(19971201)67:3<287::AID-JCB1>3.0.CO;2-S; Quack M, 1998, NUCLEIC ACIDS RES, V26, P5372, DOI 10.1093/nar/26.23.5372; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; Schrader M, 1997, BIOCHEM BIOPH RES CO, V230, P646, DOI 10.1006/bbrc.1996.6025; SCHRADER M, 1993, J BIOL CHEM, V268, P17830; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; Tagami T, 1998, BIOCHEM BIOPH RES CO, V253, P358, DOI 10.1006/bbrc.1998.9799; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Towers TL, 1998, J BIOL CHEM, V273, P10338, DOI 10.1074/jbc.273.17.10338; Towers TL, 1999, MOL CELL BIOL, V19, P4191; Wong CW, 1998, MOL CELL BIOL, V18, P5500, DOI 10.1128/MCB.18.9.5500; Zamir I, 1997, P NATL ACAD SCI USA, V94, P14400, DOI 10.1073/pnas.94.26.14400	47	149	151	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2000	14	10					1455	1463		10.1096/fj.14.10.1455	http://dx.doi.org/10.1096/fj.14.10.1455			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877839				2022-12-28	WOS:000087932200021
J	Guppy, M; Reeves, DC; Bishop, T; Withers, P; Buckingham, JA; Brand, MD				Guppy, M; Reeves, DC; Bishop, T; Withers, P; Buckingham, JA; Brand, MD			Intrinsic metabolic depression in cells isolated from the hepatopancreas of estivating snails	FASEB JOURNAL			English	Article						oxygen consumption; metabolic hysteresis; pH; oxygen conformance; estivation	DIGESTIVE GLAND; OTALA-LACTEA; ENVIRONMENTAL-STRESS; ARTEMIA-FRANCISCANA; PROTEIN-SYNTHESIS; INTRACELLULAR PH; HELIX-ASPERSA; LAND SNAILS; IN-VITRO; HEPATOCYTES	Many animals across the phylogenetic scale are routinely capable of depressing their metabolic rate to 5-15% of that at rest, remaining in this state sometimes for years, However, despite its widespread occurrence, the biochemical process;es associated with metabolic depression remain obscure, We demonstrate here the development of an isolated cell. model for the study of metabolic depression, The isolated cells from the hepatopancreas; (digestive gland) of the land snail (Helix aspersa) are oxygen conformers; i,e,, their rate of respiration depends on pO(2) Cells isolated from estivating snails show a stable metabolic depression to 30% of control (despite the long and invasive process; of cell isolation) when metabolic rate at the physiological pH and pO(2) of the hemolymph of estivating snails is compared with metabolic rate at the physiological pH and pO(2) of the hemolymph of control snails. When the extrinsic effects of pH and pO(2) are excluded, the intrinsic metabolic depression of the cells from estivating snails is still to below 50% of control snails. The in vitro effect of pO(2) on metabolic rate is independent of pH and state (awake or estivating), but the effects of pH and state significantly interact, This suggests that pH and state change affect metabolic depression by similar mechanisms but that the metabolic depression by hypoxia involves a separate mechanism.	Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England	University of Cambridge	Guppy, M (corresponding author), Univ Western Australia, Dept Biochem, Nedlands, WA 6907, Australia.		Brand, Martin D/A-9423-2012; Withers, Philip Carew/A-3005-2013	Brand, Martin D/0000-0003-4418-6153; Bishop, Tammie/0000-0003-3308-9139; Withers, Philip/0000-0002-4854-4088				BARNHART MC, 1988, J EXP BIOL, V138, P289; BARNHART MC, 1986, J COMP PHYSIOL B, V156, P347, DOI 10.1007/BF01101097; BAYNE CJ, 1981, ADV CELL CULT, P297; BROOKS SPJ, 1995, MOL CELL BIOCHEM, V143, P7, DOI 10.1007/BF00925921; BUCK LT, 1993, AM J PHYSIOL, V265, pR49, DOI 10.1152/ajpregu.1993.265.1.R49; BUCK LT, 1993, AM J PHYSIOL, V265, pR1020, DOI 10.1152/ajpregu.1993.265.5.R1020; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; CHIARANDINI DJ, 1964, LIFE SCI, V3, P1513, DOI 10.1016/0024-3205(64)90098-0; CORNELLBELL AH, 1982, J EXP ZOOL, V219, P293, DOI 10.1002/jez.1402190305; FARRIS VK, 1968, SCIENCE, V160, P1245, DOI 10.1126/science.160.3833.1245; Fuery CJ, 1998, COMP BIOCHEM PHYS A, V119, P469, DOI 10.1016/S1095-6433(97)00453-4; GUPPY M, 1994, COMP BIOCHEM PHYS B, V109, P175, DOI 10.1016/0305-0491(94)90001-9; Guppy M, 1999, BIOL REV, V74, P1, DOI 10.1017/S0006323198005258; Hand SC, 1996, ANNU REV PHYSIOL, V58, P539, DOI 10.1146/annurev.ph.58.030196.002543; Hand SC, 1998, J EXP BIOL, V201, P1233; Hardewig I, 1996, MOL CELL BIOCHEM, V158, P139; HOFMANN GE, 1994, P NATL ACAD SCI USA, V91, P8492, DOI 10.1073/pnas.91.18.8492; KRUMSCHNABEL G, 1994, EXPERIENTIA, V50, P483, DOI 10.1007/BF01920752; Kwast KE, 1996, J BIOL CHEM, V271, P7313, DOI 10.1074/jbc.271.13.7313; LAND SC, 1995, P NATL ACAD SCI USA, V92, P7505, DOI 10.1073/pnas.92.16.7505; Pedler S, 1996, J COMP PHYSIOL B, V166, P375, DOI 10.1007/BF02336920; Porcel D, 1996, COMP BIOCHEM PHYS A, V115, P11, DOI 10.1016/0300-9629(95)02069-1; Reipschlager A, 1996, J EXP BIOL, V199, P1801; REYNAFARJE B, 1985, ANAL BIOCHEM, V145, P406, DOI 10.1016/0003-2697(85)90381-1; Robledo Y, 1997, EUR J CELL BIOL, V72, P362; SCHUMACKER PT, 1993, AM J PHYSIOL, V265, pL395, DOI 10.1152/ajplung.1993.265.4.L395; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Smith RW, 1996, AM J PHYSIOL-REG I, V271, pR897, DOI 10.1152/ajpregu.1996.271.4.R897; Stuart JA, 1998, AM J PHYSIOL-REG I, V275, pR1977, DOI 10.1152/ajpregu.1998.275.6.R1977; SUMNER AT, 1965, Q J MICROSC SCI, V106, P173	30	34	34	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2000	14	7					999	1004		10.1096/fasebj.14.7.999	http://dx.doi.org/10.1096/fasebj.14.7.999			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	309CG	10783155				2022-12-28	WOS:000086749500019
J	Mullins, RF; Russell, SR; Anderson, DH; Hageman, GS				Mullins, RF; Russell, SR; Anderson, DH; Hageman, GS			Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease	FASEB JOURNAL			English	Review						retina; retinal pigmented epithelium; amyloid; vitronectin; soft drusen	RETINAL-PIGMENT EPITHELIUM; GLOMERULONEPHRITIS TYPE-II; APOLIPOPROTEIN-E IMMUNOREACTIVITY; BASAL LAMINAR DEPOSIT; BRUCHS MEMBRANE; P-COMPONENT; ALZHEIMERS-DISEASE; IMMUNOHISTOCHEMICAL LOCALIZATION; S-PROTEIN; MESANGIOCAPILLARY GLOMERULONEPHRITIS	Age-related macular degeneration (AMD), a blinding disorder that compromises central vision, is characterized by the accumulation of extracellular deposits, termed drusen, between the retinal pigmented epithelium and the choroid. Recent studies in this laboratory revealed that vitronectin is a major component of drusen. Because vitronectin is also a constituent of abnormal deposits associated with a variety of diseases, drusen from human donor eyes were examined for compositional similarities with other extracellular disease deposits. Thirty-four antibodies to 29 different proteins or protein complexes were tested for immunoreactivity with hard and soft drusen phenotypes. These analyses provide a partial profile of the molecular composition of drusen. Serum amyloid P component, apolipoprotein E, immunoglobulin light chains, Factor X, and complement proteins (C5 and C5b-9 complex) were identified in all drusen phenotypes. Transcripts encoding some of these molecules were also found to be synthesized by the retina, retinal pigmented epithelium, and/or choroid. The compositional similarity between drusen and other disease deposits may be significant in view of the recently established correlation between AMD and atherosclerosis. This study suggests that similar pathways may be involved in the etiologies of AMD and other age-related diseases.	Univ Iowa, Dept Ophthalmol & Visual Sci, Ctr Macular Degenerat, Iowa City, IA 52240 USA; Univ Calif Santa Barbara, Neurosci Res Inst, Ctr Study Macular Degenerat, Santa Barbara, CA 93106 USA	University of Iowa; University of California System; University of California Santa Barbara	Hageman, GS (corresponding author), Univ Iowa, Dept Ophthalmol & Visual Sci, Ctr Macular Degenerat, 11190E PFP,200 Hawkins Dr, Iowa City, IA 52240 USA.	gregory-hageman@uiowa.edu	Mitchell, Paul/P-1498-2014; Mullins, Robert F/I-6717-2013	Russell, Stephen/0000-0003-3776-1367; Mullins, Robert/0000-0002-5006-0891	NATIONAL EYE INSTITUTE [R01EY011515, R01EY011521] Funding Source: NIH RePORTER; NEI NIH HHS [EY06463, EY11521, EY11515] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AKIYAMA H, 1991, J NEUROIMMUNOL, V32, P19, DOI 10.1016/0165-5728(91)90067-H; ANDERSON D, 1999, IN PRESS INVEST OPHT; BABAEV VR, 1990, ATHEROSCLEROSIS, V85, P239, DOI 10.1016/0021-9150(90)90116-Z; BIRD A, 1992, AGE RELATED MACULAR, pCH3; BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552; BOBRYSHEV YV, 1995, ATHEROSCLEROSIS, V118, P9, DOI 10.1016/0021-9150(95)05588-N; BOCAN TMA, 1988, ARTERIOSCLEROSIS, V8, P499, DOI 10.1161/01.ATV.8.5.499; Bradt BM, 1998, J EXP MED, V188, P431, DOI 10.1084/jem.188.3.431; BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035; BUYUKBABANI N, 1994, J PATHOL, V172, P199, DOI 10.1002/path.1711720207; Camejo G, 1998, ATHEROSCLEROSIS, V139, P205, DOI 10.1016/S0021-9150(98)00107-5; CASTANO EM, 1995, J BIOL CHEM, V270, P17610, DOI 10.1074/jbc.270.29.17610; CORIA F, 1988, LAB INVEST, V58, P454; DAHLBACK K, 1988, ACTA DERM-VENEREOL, V68, P107; DAHLBACK K, 1990, J INVEST DERMATOL, V94, P284, DOI 10.1111/1523-1747.ep12874430; DAHLBACK K, 1993, J INVEST DERMATOL, V100, P166, DOI 10.1111/1523-1747.ep12462792; DAHLBACK K, 1989, J INVEST DERMATOL, V92, P727, DOI 10.1111/1523-1747.ep12721619; DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045; DUVALL J, 1985, ARCH OPHTHALMOL-CHIC, V103, P694, DOI 10.1001/archopht.1985.01050050086024; DUVALLYOUNG J, 1989, BRIT J OPHTHALMOL, V73, P297, DOI 10.1136/bjo.73.4.297; Ermilov V V, 1995, Vestn Oftalmol, V111, P24; Fariss RN, 1997, AM J PATHOL, V150, P323; FARKAS TG, 1971, AM J OPHTHALMOL, V71, P1206, DOI 10.1016/0002-9394(71)90964-0; FIGUEROA MS, 1994, RETINA-J RET VIT DIS, V14, P391, DOI 10.1097/00006982-199414050-00001; FRENNESSON C, 1995, DOC OPHTHALMOL, V90, P377, DOI 10.1007/BF01268123; FRENNESSON IC, 1995, BRIT J OPHTHALMOL, V79, P905, DOI 10.1136/bjo.79.10.905; GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206; Gorin MB, 1999, MOL VIS, V5, pU31; GURNE DH, 1991, OPHTHALMOLOGY, V98, P602; Guyton JR, 1996, ARTERIOSCL THROM VAS, V16, P4, DOI 10.1161/01.ATV.16.1.4; Hageman GS, 1999, MOL VIS, V5; Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477; HALE IL, 1993, METHOD CELL BIOL, V38, P289; HASHIMOT.K, 1967, J INVEST DERMATOL, V48, P405, DOI 10.1038/jid.1967.66; HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106; HINTNER H, 1988, J INVEST DERMATOL, V91, P22, DOI 10.1111/1523-1747.ep12463283; Holz F G, 1995, Ger J Ophthalmol, V4, P336; HOQUE M, 1993, JPN J NEPHROL, V35, P365; HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629; ISHIBASHI T, 1986, AM J OPHTHALMOL, V101, P342, DOI 10.1016/0002-9394(86)90830-5; JANSEN JH, 1993, AM J PATHOL, V143, P1356; JAWOROWSKI A, 1995, BBA-GEN SUBJECTS, V1245, P121, DOI 10.1016/0304-4165(95)00079-Q; JOH K, 1993, ACTA PATHOL JAPON, V43, P552; KIDA E, 1994, NEUROSCI LETT, V167, P73, DOI 10.1016/0304-3940(94)91030-8; KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86; KIVELA T, 1994, INVEST OPHTH VIS SCI, V35, P3759; KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025; KLIFFEN M, 1994, INVEST OPHTH VIS SCI, V35, P2901; KLIFFEN M, 1995, LAB INVEST, V73, P267; Kliffen M, 1996, ARCH OPHTHALMOL-CHIC, V114, P1009, DOI 10.1001/archopht.1996.01100140217021; KLIGMAN AM, 1969, J AMER MED ASSOC, V210, P2377, DOI 10.1001/jama.210.13.2377; LEWIS H, 1986, OPHTHALMOLOGY, V93, P1098; LEYS A, 1991, GRAEF ARCH CLIN EXP, V229, P406, DOI 10.1007/BF00166300; LEYS A, 1990, GRAEF ARCH CLIN EXP, V228, P499, DOI 10.1007/BF00918479; LI JJ, 1984, SCAND J IMMUNOL, V20, P219, DOI 10.1111/j.1365-3083.1984.tb00995.x; LI XA, 1995, ARTERIOSCL THROM VAS, V15, P252, DOI 10.1161/01.ATV.15.2.252; LIEM ATA, 1992, AM J OPHTHALMOL, V114, P149, DOI 10.1016/S0002-9394(14)73978-9; Loeffler KU, 1997, GRAEF ARCH CLIN EXP, V235, P248, DOI 10.1007/BF00941767; LOFFLER KU, 1995, INVEST OPHTH VIS SCI, V36, P24; Luna L. G., 1968, MANUAL HISTOLOGICAL, V3rd; MEHREGAN A, 1991, PINKUS GUIDE DERMATO, P369; MIDENA E, 1994, DOC OPHTHALMOL, V88, P179, DOI 10.1007/BF01204616; MUDA AO, 1988, VIRCHOWS ARCH A, V413, P529; Mullins RF, 1999, J HISTOCHEM CYTOCHEM, V47, P1533, DOI 10.1177/002215549904701205; Mullins RF, 1997, OPHTHALMOLOGY, V104, P288, DOI 10.1016/S0161-6420(97)30322-4; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; NEWSOME DA, 1987, AM J OPHTHALMOL, V104, P373, DOI 10.1016/0002-9394(87)90227-3; NEWSOME DA, 1987, CURR EYE RES, V6, P1211, DOI 10.3109/02713688709025231; NEWSOME DA, 1988, RETINAL DYSTROPHIES, P271; NICULESCU F, 1987, ATHEROSCLEROSIS, V65, P1, DOI 10.1016/0021-9150(87)90002-5; NICULESCU F, 1989, ATHEROSCLEROSIS, V78, P197, DOI 10.1016/0021-9150(89)90223-2; OPPENHEIM J, 1989, HUMAN MONOCYTES; Osusky R, 1997, OCUL IMMUNOL INFLAMM, V5, P43, DOI 10.3109/09273949709085049; Ozaki S, 1999, BIOCHEM BIOPH RES CO, V258, P524, DOI 10.1006/bbrc.1999.0672; PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548; PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X; Penfold PL, 1997, INVEST OPHTH VIS SCI, V38, P2125; PENFOLD PL, 1986, INVEST OPHTH VIS SCI, V27, P364; PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948; PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033; PEPYS M, 1992, P NATL ACAD SCI USA, V91, P5602; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; PUCHTLER H, 1962, J HISTOCHEM CYTOCHEM, V10, P355, DOI 10.1177/10.3.355; REBLIN T, 1995, ATHEROSCLEROSIS, V113, P179, DOI 10.1016/0021-9150(94)05445-O; SARKS S, 1989, RETINA, V2; SARKS SH, 1980, AUST J OPHTHALMOL, V8, P117, DOI 10.1111/j.1442-9071.1980.tb01670.x; Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0; SIGELMAN J, 1991, OPHTHALMOLOGY, V98, P1379; SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138; SNOW AD, 1992, J HISTOCHEM CYTOCHEM, V40, P105, DOI 10.1177/40.1.1370306; Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022; STANGOS N, 1995, OPHTHALMOLOGICA, V209, P194, DOI 10.1159/000310612; STARY HC, 1995, CIRCULATION, V92, P1355, DOI 10.1161/01.CIR.92.5.1355; STENSTAD T, 1993, CLIN EXP IMMUNOL, V94, P189; STONE E, 1993, MOL GENETICS INHERIT; STRITTMATTER WJ, 1995, P NATL ACAD SCI USA, V92, P4725, DOI 10.1073/pnas.92.11.4725; TAN SY, 1994, HISTOPATHOLOGY, V25, P403, DOI 10.1111/j.1365-2559.1994.tb00001.x; TARNAWSKI R, 1995, ATHEROSCLEROSIS, V115, P27, DOI 10.1016/0021-9150(94)05496-6; THORNER P, 1982, ARCH PATHOL LAB MED, V106, P628; VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278; VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657; VANDERSCHAFT TL, 1994, GRAEF ARCH CLIN EXP, V232, P40, DOI 10.1007/BF00176436; VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648; Wetzig P C, 1988, Trans Am Ophthalmol Soc, V86, P276; YANAGIHARA M, 1985, J CUTAN PATHOL, V12, P110, DOI 10.1111/j.1600-0560.1985.tb01611.x; YANG GCH, 1992, AM J PATHOL, V141, P409	106	683	744	1	49	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2000	14	7					835	846		10.1096/fasebj.14.7.835	http://dx.doi.org/10.1096/fasebj.14.7.835			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	309CG	10783137				2022-12-28	WOS:000086749500001
J	Thum, T; Haverich, A; Borlak, J				Thum, T; Haverich, A; Borlak, J			Cellular dedifferentiation of endothelium is linked to activation and silencing of certain nuclear transcription factors: implications for endothelial dysfunction and vascular biology	FASEB JOURNAL			English	Article						endothelial cells; hepatocytes; gene expression; PECAM-1	ADHESION MOLECULE-1 PROMOTER; CELLS; EXPRESSION; CULTURE; GENE; HEPATOCYTES; INHIBITOR; INDUCTION; CLONING; ELEMENT	We investigated the gene expression of the nuclear transcription factors c/EBP alpha, GATA-2, and the silencer Oct-1 in conjunction with the gene expression of all major cytochrome P450 genes and of eNOS in cultures of endothelial cells of the rat. The purity of cultured endothelial cells was also confirmed by flow cytometry measurements of PECAM-1, a surface antigen of endothelial cells. Taken collectively, the gene expression and flow cytometry studies provide strong evidence for c/EBP alpha, GATA-2, and Oct-1 to play a key role in the cellular dedifferentiation of endothelial cells; gene expression of eight individual CYP genes in conjunction with protein activity could be significantly increased upon treatment with Aroclor 1254, a well-documented chemical inducer of a battery of genes. Nevertheless, the gene expression of c/EBP alpha, GATA-2, and most of the CW genes was dramatically reduced (up to 90%) in cell cultures lacking PECAM-1 expression; in strong contrast, expression of the silencer Oct-1 was massively increased (similar to 14 fold). We thus conclude activation of the silencer Oct-1 to be strongly correlated with loss of PECAM-1 and eNOS gene expression, e.g., loss of cellular differentiation and endothelial function; in conjunction, gene expression of all major P450 isoforms was dramatically reduced in cultures of dedifferentiated endothelial cells. This process of cellular dedifferentiation and endothelial dysfunction was accompanied by down-regulation of endothelial specific transcription factors.	Fraunhofer Inst Toxicol & Aerosol Res, Dept Mol Toxicol & Pharmacokinet, D-30659 Hannover, Germany; Hannover Med Sch, Klin Thoraz Herz & Gefass Chirurg, D-3000 Hannover, Germany	Fraunhofer Gesellschaft; Hannover Medical School	Borlak, J (corresponding author), Fraunhofer Inst Toxicol & Aerosol Res, Dept Mol Toxicol & Pharmacokinet, Nicolai Fuchs Str 1, D-30659 Hannover, Germany.	Borlak@ita.fhg.de		Thum, Thomas/0000-0003-4360-1511				Adeagbo ASO, 1997, AM J HYPERTENS, V10, P763, DOI 10.1016/S0895-7061(97)00057-5; ALBELDA SM, 1991, J CELL BIOL, V114, P1059, DOI 10.1083/jcb.114.5.1059; Almendro N, 1996, J IMMUNOL, V157, P5411; Bujan J, 1999, J VASC RES, V36, P106, DOI 10.1159/000025632; CARY DA, 1987, MOL CELL ENDOCRINOL, V53, P103, DOI 10.1016/0303-7207(87)90196-1; CASTELLOT JJ, 1981, J CELL BIOL, V90, P372, DOI 10.1083/jcb.90.2.372; Chat M, 1997, LIFE SCI, V62, P151, DOI 10.1016/S0024-3205(97)01061-8; COCEANI F, 1998, BRIT J PHARMACOL, V117, P1586; Cowan PJ, 1998, J BIOL CHEM, V273, P11737, DOI 10.1074/jbc.273.19.11737; DUNN JCY, 1989, FASEB J, V3, P174, DOI 10.1096/fasebj.3.2.2914628; FARIN FM, 1994, TOXICOL APPL PHARM, V124, P1, DOI 10.1006/taap.1994.1001; FREIMAN PC, 1986, CIRC RES, V58, P783, DOI 10.1161/01.RES.58.6.783; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GRAIER WF, 1995, J PHYSIOL-LONDON, V482, P259, DOI 10.1113/jphysiol.1995.sp020515; GRANT MH, 1987, BIOCHEM PHARMACOL, V36, P2311, DOI 10.1016/0006-2952(87)90596-X; Griendling KK, 1996, FASEB J, V10, P283, DOI 10.1096/fasebj.10.2.8641561; Gumina RJ, 1997, BLOOD, V89, P1260, DOI 10.1182/blood.V89.4.1260; KAWANA M, 1995, MOL CELL BIOL, V15, P4225; Li CG, 1996, BRIT J PHARMACOL, V118, P57, DOI 10.1111/j.1476-5381.1996.tb15366.x; MINOR RL, 1990, J CLIN INVEST, V86, P2109, DOI 10.1172/JCI114949; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; Oike Y, 1999, BLOOD, V93, P2771; POBER JS, 1991, LAB INVEST, V64, P301; SATO T, 1987, EXP MOL PATHOL, V47, P202, DOI 10.1016/0014-4800(87)90075-X; Schwachtgen JL, 1998, BLOOD, V92, P1247, DOI 10.1182/blood.V92.4.1247.416k08_1247_1258; SEGLEN PO, 1979, J TOXICOL ENV HEALTH, V5, P551, DOI 10.1080/15287397909529766; Sheibani N, 1997, MOL BIOL CELL, V8, P1329, DOI 10.1091/mbc.8.7.1329; SHEN Y, 1998, AM J PHYSIOL, V275, P479; STEGEMAN JJ, 1995, MOL PHARMACOL, V47, P296; STEGEMAN JJ, 1989, MOL PHARMACOL, V36, P723; Sterling K, 1996, MOL PHARMACOL, V49, P329; STEWARD AR, 1985, ARCH BIOCHEM BIOPHYS, V241, P494, DOI 10.1016/0003-9861(85)90575-2; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; ZHANG R, 1995, J BIOL CHEM, V270, P15320, DOI 10.1074/jbc.270.25.15320	34	59	59	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2000	14	5					740	751		10.1096/fasebj.14.5.740	http://dx.doi.org/10.1096/fasebj.14.5.740			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	301DH	10744630				2022-12-28	WOS:000086292700011
J	Notaro, R; Afolayan, A; Luzzatto, L				Notaro, R; Afolayan, A; Luzzatto, L			Human mutations in glucose 6-phosphate dehydrogenase reflect evolutionary history	FASEB JOURNAL			English	Article						G6PD deficiency; G6PD variants; housekeeping genes; human mutants; evolution	HUMAN GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; PLASMODIUM-FALCIPARUM; G6PD DEFICIENCY; NITRIC-OXIDE; PROTEIN; GENE; SEQUENCE; PROMOTER; MALARIA; MODEL	Glucose 6-phosphate dehydrogenase (G6PD) is a cytosolic enzyme encoded by a housekeeping X-linked gene whose main function is to produce NADPH, a key electron donor in the defense against oxidizing agents and in reductive biosynthetic reactions. Inherited G6PD deficiency is associated with either episodic hemolytic anemia (triggered by fava beans or other agents) or life-long hemolytic anemia. We show here that an evolutionary analysis is a key to understanding the biology of a housekeeping gene, From the alignment of the amino acid (aa) sequence of 52 glucose 6-phosphate dehydrogenase (G6PD) species from 42 different organisms, we found a striking correlation between the aa replacements that cause G6PD deficiency in humans and the sequence conservation of G6PD: two-thirds of such replacements are in highly and moderately conserved (50-99%) aa; relatively few are in fully conserved aa (where they might be lethal) or in poorly conserved aa, where presumably they simply would not cause G6PD deficiency, This: is consistent with the notion that all human mutants have residual enzyme activity and that null mutations are lethal at some stage of development, Comparing the distribution of mutations in a human housekeeping gene with evolutionary conservation is a useful tool for pinpointing amino acid residues important for the stability or the function of the corresponding protein. In view of the current explosive increase in full genome sequencing projects, this tool will become rapidly available for numerous other genes.	Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA; Obafemi Awolowo Univ, Dept Biochem, Ile Ife, Nigeria	Memorial Sloan Kettering Cancer Center; Obafemi Awolowo University	Luzzatto, L (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Human Genet, 1275 York Ave, New York, NY 10021 USA.		Notaro, Rosario/J-7293-2016	Notaro, Rosario/0000-0002-9087-9404	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL059312] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL 59312] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Au SWN, 1999, ACTA CRYSTALLOGR D, V55, P826, DOI 10.1107/S0907444999000827; BAUTISTA JM, 1995, FEBS LETT, V366, P61, DOI 10.1016/0014-5793(95)00474-N; BEUTLER E, 1991, NEW ENGL J MED, V324, P169; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; DAYHOFF MO, 1979, ATLAS PROTEIN SEQ S3, V5; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Goldman N, 1998, GENETICS, V149, P445; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HINO Y, 1982, J BIOL CHEM, V257, P2563; Krawczak M, 1997, TRENDS GENET, V13, P121, DOI 10.1016/S0168-9525(97)01068-8; Longo L., 1997, Blood, V90, p408A; LUZZATTO L, 1979, BLOOD, V54, P961; LUZZATTO L, 1985, ADV HUM GENET, V14, P217; LUZZATTO L, 1995, METABOLIC MOL BASES, P3367; MARTINI G, 1986, EMBO J, V5, P1849, DOI 10.1002/j.1460-2075.1986.tb04436.x; Mason PJ, 1996, BRIT J HAEMATOL, V94, P585, DOI 10.1111/j.1365-2141.1996.tb00001.x; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Naylor CE, 1996, BLOOD, V87, P2974, DOI 10.1182/blood.V87.7.2974.bloodjournal8772974; Nicholas HBJ, 1997, GENEDOC; NICHOLAS K, 1997, ANAL VISUALIZATION G; OBRIEN E, 1994, MOL BIOCHEM PARASIT, V64, P313, DOI 10.1016/0166-6851(94)00028-X; OZOLS J, 1993, P NATL ACAD SCI USA, V90, P5302, DOI 10.1073/pnas.90.11.5302; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; PANDOLFI PP, 1995, EMBO J, V14, P5209, DOI 10.1002/j.1460-2075.1995.tb00205.x; PERSICO MG, 1986, NUCLEIC ACIDS RES, V14, P2511, DOI 10.1093/nar/14.6.2511; PHILIPPE M, 1994, EUR J BIOCHEM, V226, P377, DOI 10.1111/j.1432-1033.1994.tb20062.x; ROWLAND P, 1994, STRUCTURE, V2, P1073, DOI 10.1016/S0969-2126(94)00110-3; RUWENDE C, 1995, NATURE, V376, P246, DOI 10.1038/376246a0; Scopes DA, 1997, MOL MICROBIOL, V23, P847, DOI 10.1046/j.1365-2958.1997.2621629.x; SMITH RF, 1990, P NATL ACAD SCI USA, V87, P118, DOI 10.1073/pnas.87.1.118; STRAUS D, 1985, MOL CELL BIOL, V5, P3497, DOI 10.1128/MCB.5.12.3497; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; TATUSOV RL, 1998, NATURAL SYSTEM GENE; TAYLOR WR, 1986, J THEOR BIOL, V119, P205, DOI 10.1016/S0022-5193(86)80075-3; Tsai KJ, 1998, FEBS LETT, V436, P411, DOI 10.1016/S0014-5793(98)01174-0; URSINI MV, 1990, BIOCHEM BIOPH RES CO, V170, P1203, DOI 10.1016/0006-291X(90)90521-N; Vulliamy T, 1997, BLOOD CELL MOL DIS, V23, P302, DOI 10.1006/bcmd.1997.0147; Warburg O, 1932, BIOCHEM Z, V254, P438; WARBURG OTTO, 1931, BIOCHEM ZEITSCHR, V242, P206	39	48	48	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2000	14	3					485	494		10.1096/fasebj.14.3.485	http://dx.doi.org/10.1096/fasebj.14.3.485			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	291TJ	10698963				2022-12-28	WOS:000085751900007
J	Wheeler, M; Stachlewitz, RF; Yamashina, S; Ikejima, K; Morrow, AL; Thurman, RG				Wheeler, M; Stachlewitz, RF; Yamashina, S; Ikejima, K; Morrow, AL; Thurman, RG			Glycine-gated chloride channels in neutrophils attenuate calcium influx and superoxide production	FASEB JOURNAL			English	Article						glycine; strychnine; intracellular calcium; lipopolysaccharide; formyl-methionine-leucine-phenylalanine	SIGNAL-TRANSDUCTION; LIVER-INJURY; RECEPTOR; ENDOTOXEMIA; MECHANISMS; STRYCHNINE	Recently, it was demonstrated that liver injury and TNF-alpha production as a result of endotoxin (lipopolysaccharide, LPS) were attenuated by feeding animals a diet enriched with glycine. This phenomenon was shown to be a result of, at least in part, activation of a chloride channel in Kupffer cells by glycine, which hyperpolarizes the cell membrane and blunts increases in intracellular calcium concentrations ([Ca(2+)](i)) similar to its action in the neuron. It is well known that hepatotoxicity due to LPS has a neutrophil-mediated component and that activation of neutrophils is dependent on increases in [Ca(2+)](i). Therefore, the purpose of this study was to determine if glycine affected agonist-induced increases in [Ca(2+)](i) in rat neutrophils. The effect of glycine on increases in [Ca(2+)](i) elicited either by the bacterial-derived peptide formyl-methionine-leucine-phenylalanine (FMLP) or LPS was studied in individual neutrophils using Fura-2 and fluorescence microscopy, Both FMLP and LPS caused dose-dependent increases in [Ca(2+)](i), which were maximal at 1 mu M FMLP and 100 mu g/ml LPS, respectively. LPS increased intracellular calcium in the presence and absence of extracellular calcium. Glycine blunted increases in [Ca(2+)](i) in a dose-dependent manner with an IC(50) of similar to 0.3 mM, values only slightly higher than plasma levels. Glycine was unable to prevent agonist-induced increases in [Ca(2+)](i) in chloride-free buffer. Moreover, strychnine (1 mu M), an antagonist of the glycine-gated chloride channel in the central nervous system, reversed the effects of glycine (1 mM) on FMLP- or LPS-stimulated increases in [Ca(2+)](i). To provide hard evidence for a glycine-gated chloride channel in the neutrophil, the effect of glycine on radioactive chloride uptake was determined. Glycine caused a dose-dependent increase in chloride uptake into neutrophils with an ED(50) of similar to 0.4 mM, an effect also prevented by 1 mu M strychnine. Glycine also significantly reduced the production of superoxide anion from FMLP-stimulated neutrophils. Taken together, these data provide clear evidence that neutrophils contain a glycine-gated chloride channel that can attenuate increases in [Ca(2+)](i) and diminish oxidant production by this important leukocyte.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Alcohol Studies, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Thurman, RG (corresponding author), Univ N Carolina, Dept Pharmacol, CB 7365 Mary Ellen Jones Bldg, Chapel Hill, NC 27599 USA.	thurman@med.unc.edu	Morrow, Ardythe/GQO-8482-2022		NIAAA NIH HHS [AA07573, AA05551] Funding Source: Medline; NIGMS NIH HHS [GM 07040-20] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007040] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [F31AA005551] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BETZ H, 1991, ADV EXP MED BIOL, P421; BODE C, 1987, J HEPATOL, V4, P8, DOI 10.1016/S0168-8278(87)80003-X; DENBUTTER G, 1993, TRANSPLANTATION, V56, P817; GYRNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hailman E, 1996, J IMMUNOL, V156, P4384; HEWETT JA, 1992, LAB INVEST, V66, P347; HIJIOKA T, 1992, MOL PHARMACOL, V41, P435; Ikejima K, 1997, AM J PHYSIOL-GASTR L, V272, pG1581, DOI 10.1152/ajpgi.1997.272.6.G1581; Ikejima K, 1996, AM J PHYSIOL-GASTR L, V271, pG97, DOI 10.1152/ajpgi.1996.271.1.G97; IRITA K, 1986, BIOCHEM PHARMACOL, V35, P3465, DOI 10.1016/0006-2952(86)90613-1; ITO S, 1991, J PHYSIOL-LONDON, V440, P67, DOI 10.1113/jphysiol.1991.sp018696; JACONI MEE, 1988, J BIOL CHEM, V263, P10557; JAESCHKE H, 1990, FASEB J, V4, P3355, DOI 10.1096/fasebj.4.15.2253850; KRAUSE KH, 1993, BLOOD CELLS, V19, P165; LANGOSCH D, 1990, EUR J BIOCHEM, V194, P1, DOI 10.1111/j.1432-1033.1990.tb19419.x; LEMASTERS JJ, 1991, HEPATOLOGY ELSEWHERE, V14, P952; Lovry O.H., 1951, J BIOL CHEM, V193, P265; Mak DOD, 1997, J GEN PHYSIOL, V109, P571, DOI 10.1085/jgp.109.5.571; MALECH HL, 1987, NEW ENGL J MED, V317, P687, DOI 10.1056/NEJM198709103171107; MARGOLIASH E, 1959, BIOCHEM J, V71, P570, DOI 10.1042/bj0710570; MILLER GW, 1994, TOXICOL APPL PHARM, V125, P192, DOI 10.1006/taap.1994.1064; MORROW AL, 1988, J NEUROCHEM, V50, P302, DOI 10.1111/j.1471-4159.1988.tb13264.x; OFLAHERTY JT, 1991, BIOCHEM J, V277, P705, DOI 10.1042/bj2770705; Rajendra S, 1997, PHARMACOL THERAPEUT, V73, P121, DOI 10.1016/S0163-7258(96)00163-5; ROSSE RB, 1989, CLIN NEUROPHARMACOL, V12, P416, DOI 10.1097/00002826-198910000-00006; SCHWARTZ RD, 1986, DCLIN NEUROPHARMACOL, V9, P389; SKLAR LA, 1985, J BIOL CHEM, V260, P1468; STACHLEWITZ RF, 1995, HEPATOLOGY, V22, P1105; Stachlewitz RF, 1999, HEPATOLOGY, V29, P737, DOI 10.1002/hep.510290335; THELEN M, 1993, PHYSIOL REV, V73, P797, DOI 10.1152/physrev.1993.73.4.797; VANDEVENTER SJH, 1988, GASTROENTEROLOGY, V94, P825, DOI 10.1016/0016-5085(88)90261-2; VARANI J, 1989, AM J PATHOL, V135, P435; Wheeler MD, 1999, AM J PHYSIOL-LUNG C, V277, pL952, DOI 10.1152/ajplung.1999.277.5.L952; WHEELER MD, IN PRESS CELL MOL LI; WHEELER MD, 1999, CELLS HEPATIC SINUSO; Yin M, 1998, J PHARMACOL EXP THER, V286, P1014; Zhong Z, 1996, AM J PHYSIOL-GASTR L, V270, pG332, DOI 10.1152/ajpgi.1996.270.2.G332	38	103	116	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2000	14	3					476	484		10.1096/fasebj.14.3.476	http://dx.doi.org/10.1096/fasebj.14.3.476			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	291TJ	10698962				2022-12-28	WOS:000085751900006
J	Blum, AM; Metwali, A; Crawford, C; Li, J; Qadir, K; Elliott, DE; Weinstock, JV				Blum, AM; Metwali, A; Crawford, C; Li, J; Qadir, K; Elliott, DE; Weinstock, JV			Interleukin 12 and antigen independently induce substance P receptor expression in T cells in murine schistosomiasis mansoni	FASEB JOURNAL			English	Article						schistosomiasis; substance P; substance P receptor; IL-12; schistosome egg antigen	IFN-GAMMA PRODUCTION; NK-1 RECEPTOR; NEUROKININ-1 RECEPTOR; MACROPHAGES; ANTAGONIST; GRANULOMAS; MICE; SOMATOSTATIN; LOCALIZATION; LYMPHOCYTES	Substance P (SP) regulates interferon-gamma (IFN-gamma) production through interaction with the SP receptor NK1 (SPr) on T cells at sites of inflammation. Using murine schistosomiasis, we evaluated whether SPr expression was subject to immunoregulation. Splenocytes from schistosome-infected mice cultured for less than or equal to 18 h did not express SPr, as determined by quantitative polymerase chain reaction assay. However, exposure to schistosome egg antigen (SEA) for less than or equal to4 h induced strong receptor expression. Experiments using splenocytes fractionated with antibody-coupled, paramagnetic beads showed that induction localized exclusively to T cells. Receptor protein expression was confirmed with Western blot. Interleukin 12 (IL-12) also induced strong T-cell SPr expression. Both SEA and IL-12 remained strong inducers of T-cell SPr in lymphocytes from the IL-12 (p40) and IFN-gammaR doublel-knockout mouse, which suggested that SEA did not require IL-12 to induce SPr and that both worked independently of IFN-gamma. Splenocytes from wild-type mice cultured with SEA and neutralizing anti-IL-12 monoclonal antibody (mAb) also showed SPr induction. However, anti-Ia mAb inhibited SEA. induction of SPr. Thus, SPr is inducible on T cells. SEA induces SPr through interaction with T-cell receptor (TCR), independently of IL-12 and IFN-gamma. IL-12 induces SPr independently of TCR activation and IFN-gamma expression. SP and its receptor, which regulate IFN-gamma production, are probably part of the IL-12-Th1 circuit.	Univ Iowa, Dept Internal Med, Div Gastroenterol Hepatol, Iowa City, IA 52242 USA	University of Iowa	Weinstock, JV (corresponding author), Univ Iowa Hosp & Clin, Div Gastroenterol, 4607 JCP,200 Hawkins Dr, Iowa City, IA 52242 USA.	joelweinstock@uiowa.edu		Elliott, David/0000-0002-5359-7125	NIDDK NIH HHS [DK25295, DK38327] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295, R01DK038327] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahluwalia AA, 1998, BRIT J PHARMACOL, V124, P1013, DOI 10.1038/sj.bjp.0701978; BAI TR, 1995, AM J PHYSIOL, V269, P309; Blum A, 1996, J NEUROIMMUNOL, V66, P1, DOI 10.1016/0165-5728(95)00163-8; Blum AM, 1999, J IMMUNOL, V162, P6080; BLUM AM, 1993, J IMMUNOL, V151, P225; BLUM AM, 1993, J IMMUNOL, V151, P6994; Bozic CR, 1996, SCIENCE, V273, P1722, DOI 10.1126/science.273.5282.1722; Castagliuolo I, 1998, J CLIN INVEST, V101, P1547, DOI 10.1172/JCI2039; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOK GA, 1994, J IMMUNOL, V152, P1830; Elliott David E., 1996, Methods (Orlando), V9, P255, DOI 10.1006/meth.1996.0032; Goode T, 1998, J IMMUNOL, V161, P2232; GREENO EW, 1993, J EXP MED, V177, P1269, DOI 10.1084/jem.177.5.1269; Ho WZ, 1997, J IMMUNOL, V159, P5654; Kennedy PGE, 1997, P NATL ACAD SCI USA, V94, P4167, DOI 10.1073/pnas.94.8.4167; KincyCain T, 1996, J IMMUNOL, V157, P255; Maggi CA, 1997, REGUL PEPTIDES, V70, P75, DOI 10.1016/S0167-0115(97)00029-3; MANTYH CR, 1995, GASTROENTEROLOGY, V109, P850, DOI 10.1016/0016-5085(95)90394-1; Marriott I, 1998, CELL IMMUNOL, V183, P113, DOI 10.1006/cimm.1998.1248; Marriott I, 2000, J IMMUNOL, V165, P182, DOI 10.4049/jimmunol.165.1.182; McCormack RJ, 1996, NEUROIMMUNOMODULAT, V3, P35, DOI 10.1159/000097225; OHKUBO H, 1991, ANN NY ACAD SCI, V632, P53, DOI 10.1111/j.1749-6632.1991.tb33094.x; Okamura H, 1998, CURR OPIN IMMUNOL, V10, P259, DOI 10.1016/S0952-7915(98)80163-5; Rakasz E, 1998, J IMMUNOL, V160, P4994; Trinchieri G, 1999, CURR TOP MICROBIOL, V238, P57; WEINSTOCK JV, 1988, J IMMUNOL, V141, P961; Weinstock JV, 1998, ANN NY ACAD SCI, V840, P532, DOI 10.1111/j.1749-6632.1998.tb09592.x	27	23	24	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2001	15	6					950	957		10.1096/fj.00-0379	http://dx.doi.org/10.1096/fj.00-0379			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292655				2022-12-28	WOS:000167959300009
J	Untergasser, G; Rumpold, H; Plas, E; Madersbacher, S; Berger, P				Untergasser, G; Rumpold, H; Plas, E; Madersbacher, S; Berger, P			A low-molecular-weight fraction of human seminal plasma activates adenylyl cyclase and induces caspase 3-independent apoptosis in prostatic epithelial cells by decreasing mitochondrial potential and Bcl-2/Bax ratio	FASEB JOURNAL			English	Article						SMP; aging; HPLC analysis; cAMP; mitochondria; Par-4; p53	HUMAN-SEMEN; CANCER; HYPERPLASIA; INVOLVEMENT; PROLACTIN; LINE	The majority of elderly men are affected by benign and malign diseases of the prostate that are governed by endocrine factors and local stromal/epithelial and luminal/epithelial interactions. Prostate epithelial cells secrete numerous factors into the seminal plasma (SMP) that are thought to be responsible for nutrition, accurate pH, and ionic environment of sperm. Our hypothesis assumes that prostatic factors responsible for optimal fertility might have retrograde influences on epithelial cell growth, differentiation, and function. SMP was analyzed for proteins and other biologically active substances by size exclusion highperformance liquid chromatography. Each fraction was investigated for its effect on cell growth and death. A low molecular mass fraction (2-4 kDa) was responsible for inducing apoptosis in proliferating prostate epithelial cells. Signal transduction was mediated by the production of cAMP; no significant changes in tyrosine phosphorylation of membrane receptors were observed. Mechanisms of apoptosis, i.e., caspase- and mitochondria-dependent pathways, were investigated in prostate epithelial cells by caspase activity assays, annexin/propidium iodide staining, changes in mitochondrial potential, p53, Par-4, Bax, and Bcl-2 protein levels. SMP induced p53- and Bcl-2-dependent apoptosis without activation of caspase-3. Obviously, SMP contains protective factors that help eliminate degenerated cells and control epithelial renewal. Age-related changes in the composition of SMP or the susceptibility of epithelial cells might, therefore, contribute to proliferative prostatic diseases.-untergasser, G., Rumpold, H., Plas, E., Madersbacher, S., Berger, P. A low molecular weight fraction of human seminal plasma activates adenylyl cyclase and induces caspase 3-independent apoptosis in prostatic epithelial cells by decreasing mitochondrial potential and Bcl-2/Bax ratio.	Austrian Acad Sci, Inst Biomed Aging Res, A-6020 Innsbruck, Austria; Ludwig Boltzmann Inst Androl & Urol, Vienna, Austria; Univ Vienna, Dept Urol, A-1010 Vienna, Austria	Austrian Academy of Sciences; Ludwig Boltzmann Institute; University of Vienna	Berger, P (corresponding author), Austrian Acad Sci, Inst Biomed Aging Res, Rennweg 10, A-6020 Innsbruck, Austria.			Rumpold, Holger/0000-0002-4118-0111				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Aumuller G, 1990, Int Rev Cytol, V121, P127, DOI 10.1016/S0074-7696(08)60660-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTER BS, 1990, PROSTATE, V16, P187, DOI 10.1002/pros.2990160302; Claus S, 1997, J UROLOGY, V158, P217, DOI 10.1097/00005392-199707000-00074; COCKLE SM, 1994, BBA-MOL BASIS DIS, V1227, P60, DOI 10.1016/0925-4439(94)90107-4; COCKLE SM, 1989, J ENDOCRINOL, V120, P31, DOI 10.1677/joe.0.1200031; Colao A, 1998, J CLIN ENDOCR METAB, V83, P775, DOI 10.1210/jc.83.3.775; COSTELLO LC, 1994, PROSTATE, V24, P162, DOI 10.1002/pros.2990240311; DONDI D, 1994, CANCER RES, V54, P4091; EDWARDS JJ, 1981, CLIN CHEM, V27, P1335; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HAYWARD SW, 1995, IN VITRO CELL DEV-AN, V31, P14; KELLY RW, 1991, CLIN EXP IMMUNOL, V86, P550; Mantzoros CS, 1997, BRIT J CANCER, V76, P1115, DOI 10.1038/bjc.1997.520; Marcelli M, 1999, J CLIN ENDOCR METAB, V84, P3463, DOI 10.1210/jc.84.10.3463; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Molinari M, 1996, ONCOGENE, V13, P2077; *NAT KIDN UR DIS A, 1990, LONG RANG PLAN WIND; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Perlman H, 1999, CELL DEATH DIFFER, V6, P48, DOI 10.1038/sj.cdd.4400453; Sells SF, 1997, MOL CELL BIOL, V17, P3823, DOI 10.1128/MCB.17.7.3823; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; Shapiro E, 1996, TXB BENIGN PROSTATIC, P17; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Untergasser G, 1999, EXP GERONTOL, V34, P275, DOI 10.1016/S0531-5565(98)00063-1; Wennbo H, 1997, ENDOCRINOLOGY, V138, P4410, DOI 10.1210/en.138.10.4410	27	22	23	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2001	15	3					673	683		10.1096/fj.00-0270com	http://dx.doi.org/10.1096/fj.00-0270com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11259385				2022-12-28	WOS:000167419500024
J	Ilan, N; Mohsenin, A; Cheung, L; Madri, JA				Ilan, N; Mohsenin, A; Cheung, L; Madri, JA			PECAM-1 shedding during apoptosis generates a membrane-anchored truncated molecule with unique signaling characteristics	FASEB JOURNAL			English	Article						platelet-endothelial cell adhesion molecule (CD31); endothelium; apoptosis; shedding; cleavage	CELL-ADHESION MOLECULE-1; RECEPTOR TYROSINE KINASE; ACTIVATED PROTEIN-KINASE; BETA-CATENIN; TRANSENDOTHELIAL MIGRATION; EXTRACELLULAR-MATRIX; ECTODOMAIN CLEAVAGE; ENDOTHELIAL-CELLS; CYCLIN D1; IN-VITRO	Shedding of cell surface molecules, including growth factor receptors, provides a mechanism by which cells regulate signal transduction events. Here we show that platelet-endothelial cell adhesion molecule (PECAM)-1 is shed from the endothelial cell surface during apoptosis and accumulates in the culture medium as a similar to 100 kDa soluble protein. The cleavage mediating the shedding is matrix metalloproteinase (MMP) dependent, as GM6001, a broad-spectrum MMP inhibitor, inhibits PECAM-1 accumulation in the culture medium in a dose-responsive manner. In addition to the 100 kDa soluble fragment, PECAM-1 cleavage generates the formation of a truncated (Tr.) similar to 28 kDa molecule, composed of the transmembrane and the cytoplasmic PECAM-1 domains. Transfections of the full-length (F1) and the Tr. PECAM-1 gene constructs into endothelial and nonendothelial cells were performed. We found 1) significantly more gamma -catenin and SHP-2 bound to the truncated than to the full-length PECAM-1; 2) stable expression of the truncated PECAM-1 in SW480 colon carcinoma cells resulted in a dramatic decrease in cell proliferation, whereas expression of comparable levels of the full-length PECAM-1 had no effect; 3) the decrease observed in cell proliferation is due, in part, to an increase in programmed cell death (apoptosis) and correlated with continuous caspase 8 cleavage and p38/JNK phosphorylation. These results support the intimate involvement of PECAM-1 in signal transduction cascades and also suggest that caspase substrates (e.g., PECAM-1) may possess distinct and unique functions on cleavage.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA	Yale University	Madri, JA (corresponding author), Yale Univ, Sch Med, Dept Pathol, 310 Cedar St,POB 208023, New Haven, CT 06520 USA.	joseph.madri@yale.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL028373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038979] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37-HL28373] Funding Source: Medline; NIDDK NIH HHS [P01-DK38979] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Bird IN, 1999, J CELL SCI, V112, P1989; Brancolini C, 1997, J CELL BIOL, V139, P759, DOI 10.1083/jcb.139.3.759; Bratton SB, 2000, EXP CELL RES, V256, P27, DOI 10.1006/excr.2000.4835; Cabrera N, 1996, J CELL BIOL, V132, P427, DOI 10.1083/jcb.132.3.427; Chaudhary PM, 1999, J BIOL CHEM, V274, P19211, DOI 10.1074/jbc.274.27.19211; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Duncan GS, 1999, J IMMUNOL, V162, P3022; Feehan C, 1996, J BIOL CHEM, V271, P7019, DOI 10.1074/jbc.271.12.7019; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Galan A, 2000, J BIOL CHEM, V275, P11418, DOI 10.1074/jbc.275.15.11418; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Ilan N, 1998, J CELL SCI, V111, P3621; Ilan N, 2000, J BIOL CHEM, V275, P21435, DOI 10.1074/jbc.M001857200; Ilan N, 1999, J CELL SCI, V112, P3005; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Jackson DE, 1997, J BIOL CHEM, V272, P6986, DOI 10.1074/jbc.272.11.6986; Kim CS, 1998, LAB INVEST, V78, P583; Kito M, 1999, BIOCHEM BIOPH RES CO, V257, P771, DOI 10.1006/bbrc.1999.0497; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Liao F, 1999, J IMMUNOL, V163, P5640; Liao F, 1997, J EXP MED, V185, P1349, DOI 10.1084/jem.185.7.1349; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Losy J, 1999, J NEUROIMMUNOL, V99, P169, DOI 10.1016/S0165-5728(99)00092-2; Lu TT, 1997, J BIOL CHEM, V272, P14442, DOI 10.1074/jbc.272.22.14442; Lu TT, 1996, P NATL ACAD SCI USA, V93, P11808, DOI 10.1073/pnas.93.21.11808; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; McCarthy MJ, 1999, LAB INVEST, V79, P889; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Meredith JE, 1997, TRENDS CELL BIOL, V7, P146, DOI 10.1016/S0962-8924(97)01002-7; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; OBESO J, 1990, LAB INVEST, V63, P259; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Pinter E, 1997, AM J PATHOL, V150, P1523; Reinhard C, 1997, EMBO J, V16, P1080, DOI 10.1093/emboj/16.5.1080; ROSKELLEY CD, 1994, P NATL ACAD SCI USA, V91, P12378, DOI 10.1073/pnas.91.26.12378; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schwager SLU, 1999, BIOCHEMISTRY-US, V38, P10388, DOI 10.1021/bi990357j; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tlsty TD, 1998, CURR OPIN CELL BIOL, V10, P647, DOI 10.1016/S0955-0674(98)80041-0; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; VAPORCIYAN AA, 1993, SCIENCE, V262, P1580, DOI 10.1126/science.8248808; Vecchi M, 1997, J CELL BIOL, V139, P995, DOI 10.1083/jcb.139.4.995; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Wilson DJ, 1996, EUR J IMMUNOL, V26, P989, DOI 10.1002/eji.1830260505; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yabkowitz R, 1999, BLOOD, V93, P1969, DOI 10.1182/blood.V93.6.1969.406k14_1969_1979	65	108	113	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2001	15	2					362	372		10.1096/fj.00-0372com	http://dx.doi.org/10.1096/fj.00-0372com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156952				2022-12-28	WOS:000166872900018
J	Neuzil, J; Weber, T; Schroder, A; Lu, M; Ostermann, G; Gellert, N; Mayne, GC; Olejnicka, B; Negre-Salvayre, A; Sticha, M; Coffey, RJ; Weber, C				Neuzil, J; Weber, T; Schroder, A; Lu, M; Ostermann, G; Gellert, N; Mayne, GC; Olejnicka, B; Negre-Salvayre, A; Sticha, M; Coffey, RJ; Weber, C			Induction of cancer cell apoptosis by alpha-tocopheryl succinate: molecular pathways and structural requirements	FASEB JOURNAL			English	Article						vitamin E succinate; protein kinase C; programmed cell death; colon cancer	PROTEIN-KINASE-C; CHOLESTERYL HEMISUCCINATE; MEDIATED APOPTOSIS; OXIDATIVE STRESS; PHOSPHATASE 2A; VITAMIN-E; INHIBITION; ACTIVATION; EXPRESSION; PHOSPHORYLATION	The vitamin E analog alpha -tocopheryl succinate (alpha -TOS) can induce apoptosis. We show that the proapoptotic activity of alpha -TOS in hematopoietic and cancer cell lines involves inhibition of protein kinase C (PKC), since phorbol myristyl acetate prevented alpha -TOS-triggered apoptosis. More selective effecters indicated that alpha -TOS reduced PKC alpha isotype activity by increasing protein phosphatase 2A (PP2A) activity. The role of PKC alpha inhibition in alpha -TOS-induced apoptosis was confirmed using antisense oligonucleotides or PKC alpha overexpression. Gain- or loss-of-function bcl-2 mutants implied modulation of bcl-2 activity by PKC/PP2A as a mitochondrial target of alpha -TOS-induced proapoptotic signals. Structural analogs revealed that alpha -tocopheryl and succinyl moieties are both required for maximizing these effects. In mice with colon cancer xenografts, alpha -TOS suppressed tumor growth by 80%. This epitomizes cancer cell killing by a pharmacologically relevant compound without known side effects.	Univ Munich, Inst Prevent Cardiovasc Dis, D-80336 Munich, Germany; Univ Munich, Med Policlin, D-80336 Munich, Germany; Vanderbilt Univ, Med Ctr N, Nashville, TN USA; Flinders Univ S Australia, Adelaide, SA 5001, Australia; Linkoping Univ Hosp, Dept Pathol 2, Linkoping, Sweden; INSERM, Dept Biochem, Toulouse, France; Charles Univ, Fac Sci, Prague, Czech Republic	University of Munich; University of Munich; Vanderbilt University; Flinders University South Australia; Linkoping University; Institut National de la Sante et de la Recherche Medicale (Inserm); Charles University Prague	Neuzil, J (corresponding author), Univ Munich, Inst Prevent Cardiovasc Dis, Pettenkoferstr 9, D-80336 Munich, Germany.		Olejnicka, Beata/AAY-6457-2021; Sticha, Martin/E-6158-2017; Neuzil, Jiri/H-7204-2014; Weber, Christian/AAW-2153-2020	Sticha, Martin/0000-0001-8008-7668; Neuzil, Jiri/0000-0002-2478-2460; Weber, Christian/0000-0003-4610-8714; Negre-Salvayre, Anne/0000-0003-2136-5706				BURTON GW, 1990, ANNU REV NUTR, V10, P357, DOI [10.1146/annurev.nu.10.070190.002041, 10.1146/annurev.nutr.10.1.357]; Cachia O, 1998, J BIOL CHEM, V273, P32801, DOI 10.1074/jbc.273.49.32801; Chandra J, 1997, BLOOD, V90, P3673, DOI 10.1182/blood.V90.9.3673; Chen CY, 1999, J BIOL CHEM, V274, P15320, DOI 10.1074/jbc.274.22.15320; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; Devaraj S, 1998, CURR OPIN LIPIDOL, V9, P11, DOI 10.1097/00041433-199802000-00004; DEVERAJ S, 1996, J CLIN INVEST, V98, P756; Djuric Z, 1997, CANCER LETT, V111, P133, DOI 10.1016/S0304-3835(96)04522-3; Erl W, 1999, CIRC RES, V84, P668, DOI 10.1161/01.RES.84.6.668; Erl W, 1997, AM J PHYSIOL-HEART C, V273, pH634, DOI 10.1152/ajpheart.1997.273.2.H634; FARISS MW, 1994, CANCER RES, V54, P3346; Ferraris C, 1997, EXP CELL RES, V234, P37, DOI 10.1006/excr.1997.3601; Frey MR, 1997, J BIOL CHEM, V272, P9424; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Israel K, 2000, NUTR CANCER, V36, P90, DOI 10.1207/S15327914NC3601_13; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Jha MN, 1999, NUTR CANCER, V35, P189, DOI 10.1207/S15327914NC352_14; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Keaney JF, 1996, J CLIN INVEST, V98, P386, DOI 10.1172/JCI118804; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Krohn AJ, 1998, J NEUROSCI, V18, P8186; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; Li Q, 1999, J BIOL CHEM, V274, P3764, DOI 10.1074/jbc.274.6.3764; Livneh E, 1997, EUR J BIOCHEM, V248, P1, DOI 10.1111/j.1432-1033.1997.t01-4-00001.x; LU Y, 1994, J IMMUNOL, V153, P1495; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Mayne GC, 1998, J BIOL CHEM, V273, P24115, DOI 10.1074/jbc.273.37.24115; McKay RA, 1999, J BIOL CHEM, V274, P1715, DOI 10.1074/jbc.274.3.1715; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Neuzil J, 1999, FEBS LETT, V445, P295, DOI 10.1016/S0014-5793(99)00141-6; Neuzil J, 1997, FREE RADICAL BIO MED, V22, P57, DOI 10.1016/S0891-5849(96)00224-9; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OLLINGER K, 1995, FREE RADICAL BIO MED, V19, P565, DOI 10.1016/0891-5849(95)00062-3; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Qian M, 1997, ONCOGENE, V15, P223, DOI 10.1038/sj.onc.1201181; Ricciarelli R, 1998, ARCH BIOCHEM BIOPHYS, V355, P197, DOI 10.1006/abbi.1998.0732; Ricciarelli R, 1998, BIOCHEM J, V334, P243, DOI 10.1042/bj3340243; Roberg K, 1998, AM J PATHOL, V152, P1151; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; Santoro MF, 1998, J BIOL CHEM, V273, P13119, DOI 10.1074/jbc.273.21.13119; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Shao RG, 1997, J BIOL CHEM, V272, P31321, DOI 10.1074/jbc.272.50.31321; Singh I, 1998, J BIOL CHEM, V273, P20354, DOI 10.1074/jbc.273.32.20354; Slater SJ, 1998, J BIOL CHEM, V273, P23160, DOI 10.1074/jbc.273.36.23160; Suzuki Y, 1998, FEBS LETT, V425, P209, DOI 10.1016/S0014-5793(98)00228-2; SUZUKI YJ, 1993, BIOCHEM MOL BIOL INT, V31, P693; Tasinato A, 1995, P NATL ACAD SCI USA, V92, P12190, DOI 10.1073/pnas.92.26.12190; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Wang RX, 1998, J IMMUNOL, V161, P2201; WAYS DK, 1995, J CLIN INVEST, V95, P1906, DOI 10.1172/JCI117872; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zhang CH, 1996, J IMMUNOL, V157, P3980	56	247	269	1	32	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2001	15	2					403	415		10.1096/fj.00-0251com	http://dx.doi.org/10.1096/fj.00-0251com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	400LK	11156956				2022-12-28	WOS:000166872900022
J	Huwiler, A; Johansen, B; Skarstad, A; Pfeilschifter, J				Huwiler, A; Johansen, B; Skarstad, A; Pfeilschifter, J			Ceramide binds to the CaLB domain of cytosolic phospholipase A(2) and facilitates its membrane docking and arachidonic acid release	FASEB JOURNAL			English	Article									Univ Frankfurt Klinikum, Inst Pharmacol & Toxicol, Zentrum Pharmakol, D-60590 Frankfurt, Germany; Norwegian Univ Sci & Technol, Dept Bot, UNIGEN Ctr Mol Biol, N-7491 Trondheim, Norway	Goethe University Frankfurt; Goethe University Frankfurt Hospital; Norwegian University of Science & Technology (NTNU)	Pfeilschifter, J (corresponding author), Univ Frankfurt Klinikum, Inst Pharmacol & Toxicol, Zentrum Pharmakol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.								0	108	109	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2001	15	1					7	9						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11099485				2022-12-28	WOS:000166312400003
J	Kamynina, E; Debonneville, C; Bens, M; Vandewalle, A; Staub, O				Kamynina, E; Debonneville, C; Bens, M; Vandewalle, A; Staub, O			A novel mouse Nedd4 protein suppresses the activity of the epithelial Na+ channel	FASEB JOURNAL			English	Article						Liddle's syndrome; hypertension; Na+ transport; ubiquitination; HECT domain; ENaC; protein-protein interaction; WW domain; isoform	SODIUM-CHANNEL; LIDDLES-SYNDROME; BETA-SUBUNIT; WW DOMAINS; PY MOTIF; PSEUDOHYPOALDOSTERONISM TYPE-1; HUMAN HYPERTENSION; MISSENSE MUTATION; MEMBRANE TOPOLOGY; GAMMA-SUBUNIT	Liddle's syndrome is a form of inherited hypertension linked to mutations in the genes encoding the epithelial Na+ channel (ENaC). These mutations alter or delete PY motifs involved in protein-protein interactions with a ubiquitin-protein ligase, Nedd4. Here we show that Na+ transporting cells, derived from mouse cortical collecting duct, express two Nedd4 proteins with different structural organization and characteristics of ENaC regulation: 1) the classical Nedd4 therein referred to as Nedd4-1) containing one amino-terminal C2, three WW, and one HECT-ubiquitin protein ligase domain and 2) a novel Nedd4 protein (Nedd4-2), homologous to Xenopus Nedd4 and comprising four WW, one HECT, yet lacking a C2 domain, Nedd4-2, but not Nedd4-1, inhibits ENaC activity when coexpressed in Xenopus oocytes and this property correlates with the ability to bind to ENaC, as only Nedd4-2 coimmunoprecipitates with ENaC. Furthermore, this interaction depends on the presence of at least one PY motif in the ENaC complex and on WW domains 3 and 4 in Nedd4-2, Thus, these results suggest that the novel suppressor protein Nedd4-2 is the regulator of ENaC and hence a potential susceptibility gene for arterial hypertension.	Univ Lausanne, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland; Univ Paris 07, Inst Federatif Rech 02, U478, INSERM, F-75870 Paris 18, France	University of Lausanne; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Staub, O (corresponding author), Univ Lausanne, Inst Pharmacol & Toxicol, Rue du Bugnon 27, CH-1005 Lausanne, Switzerland.	olivier.staub@ipharm.unil.ch						Abriel H, 1999, J CLIN INVEST, V103, P667, DOI 10.1172/JCI5713; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bens M, 1999, J AM SOC NEPHROL, V10, P923; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Dinudom A, 1998, P NATL ACAD SCI USA, V95, P7169, DOI 10.1073/pnas.95.12.7169; Farr TJ, 2000, BIOCHEM J, V345, P503, DOI 10.1042/0264-6021:3450503; Felley-Bosco E, 1999, ELECTROPHORESIS, V20, P3508, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3508::AID-ELPS3508>3.0.CO;2-7; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Goulet CC, 1998, J BIOL CHEM, V273, P30012, DOI 10.1074/jbc.273.45.30012; HANSSON JH, 1995, P NATL ACAD SCI USA, V92, P11495, DOI 10.1073/pnas.92.25.11495; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; Harvey KF, 1999, J BIOL CHEM, V274, P12525, DOI 10.1074/jbc.274.18.12525; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Inoue J, 1998, J CLIN ENDOCR METAB, V83, P2210, DOI 10.1210/jc.83.6.2210; Inoue T, 1998, EUR J ENDOCRINOL, V138, P691, DOI 10.1530/eje.0.1380691; Ishikawa T, 1998, J GEN PHYSIOL, V111, P825, DOI 10.1085/jgp.111.6.825; Kanelis V, 1998, BIOCHEM CELL BIOL, V76, P341, DOI 10.1139/bcb-76-2-3-341; Koepf EK, 1999, BIOCHEMISTRY-US, V38, P14338, DOI 10.1021/bi991105l; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; Kumar S, 1997, GENOMICS, V40, P435, DOI 10.1006/geno.1996.4582; LIDDLE GW, 1963, T ASSOC AM PHYSICIAN, V76, P199; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Puoti A, 1997, P NATL ACAD SCI USA, V94, P5949, DOI 10.1073/pnas.94.11.5949; Rebhun JF, 1998, DNA SEQUENCE, V9, P295, DOI 10.3109/10425179809008468; RENARD S, 1994, J BIOL CHEM, V269, P12981; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Strautnieks SS, 1996, NAT GENET, V13, P248, DOI 10.1038/ng0696-248; Tamura H, 1996, J CLIN INVEST, V97, P1780, DOI 10.1172/JCI118606; Warnock DG, 1998, KIDNEY INT, V53, P18, DOI 10.1046/j.1523-1755.1998.00728.x	46	235	241	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2001	15	1					204	214		10.1096/fj.00-0191com	http://dx.doi.org/10.1096/fj.00-0191com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	11149908				2022-12-28	WOS:000166312400029
J	Kovala, AT; Harvey, KA; McGlynn, P; Boguslawski, G; Garcia, JGN; English, D				Kovala, AT; Harvey, KA; McGlynn, P; Boguslawski, G; Garcia, JGN; English, D			High-efficiency transient transfection of endothelial cells for functional analysis	FASEB JOURNAL			English	Article						FACS sorting; chemotaxis; heterotrimeric G-protein beta gamma subunits	GREEN FLUORESCENT PROTEIN; GENE-TRANSFER; SPHINGOSINE 1-PHOSPHATE; SIGNALING PATHWAY; RECEPTOR KINASE; ANGIOGENESIS; MIGRATION; CHEMOTAXIS; ACTIVATION; MECHANISMS	The definition of signaling pathways in endothelial cells has been hampered by the difficulty of transiently transfecting these cells with high efficiency. This investigation was undertaken to develop an efficient technique for the transfection of endothelial cells for functional analyses. Cells cotransfected with plasmid expressing green fluorescent protein (GFP) and the plasmid of interest were isolated by fluorescence-activated cell sorting (FACS) based on GFP expression. In the sorted cell population, a 2.5-fold enhancement in the number of cells expressing the gene of interest was observed, as confirmed by FAGS analysis and Western blotting. Sorted cells retained functional properties, as demonstrated by chemotaxis to the agonist sphingosine l-phosphate (SPP). To demonstrate the usefulness of this method for defining cellular signaling pathways, cells were cotransfected with plasmids encoding GFP and the carboxyl-terminal domain of the beta -adrenergic receptor kinase (beta ARKct), which inhibits signaling through the beta gamma dimer of heterotrimeric G-proteins. SPP-induced chemotaxis in sorted cells coexpressing beta ARKct was inhibited by 80%, demonstrating that chemotaxis was driven by a beta gamma -dependent pathway. However, no significant inhibition was observed in cells transfected with beta ARKct but not enriched by sorting. Thus, we have developed a method for enriching transfected cells that allows the elucidation of crucial mechanisms of endothelial cell activation and function. This method should find wide applicability in studies designed to define pathways responsible for regulation of motility and other functions in these dynamic cells.	Clarian Hlth Partners Inc, Methodist Res Inst, Expt Cell Res Program, Indianapolis, IN 46202 USA; Johns Hopkins Univ, Sch Med, Dept Pulm & Crit Care Med, Baltimore, MD 21224 USA; Indiana Univ, Sch Med, Dept Physiol & Biophys, Indianapolis, IN 46202 USA	Indiana University System; Johns Hopkins University; Indiana University System; Indiana University-Purdue University Indianapolis	English, D (corresponding author), Methodist Res Inst, Expt Cell Res Program, 1701 N Senate Ave, Indianapolis, IN 46219 USA.		Garcia, Joe GN/E-8862-2010	Kovala, A. Thomas/0000-0002-2908-5613	NHLBI NIH HHS [P01 HL 50864] Funding Source: Medline; PHS HHS [R01 61751] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Arai H, 1997, P NATL ACAD SCI USA, V94, P14495, DOI 10.1073/pnas.94.26.14495; Bussolino F, 1997, TRENDS BIOCHEM SCI, V22, P251, DOI 10.1016/S0968-0004(97)01074-8; CLAPMAN DE, 1995, NATURE, V365, P403; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Delerive P, 1999, CIRC RES, V85, P394, DOI 10.1161/01.RES.85.5.394; Edgell CJS, 1998, BIOTECHNIQUES, V25, P264, DOI 10.2144/98252gt01; English D, 1999, J HEMATOTH STEM CELL, V8, P627, DOI 10.1089/152581699319795; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Harvey KA, 1996, BRIT J HAEMATOL, V93, P515, DOI 10.1046/j.1365-2141.1996.d01-1706.x; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Jin T, 2000, SCIENCE, V287, P1034, DOI 10.1126/science.287.5455.1034; Keith MBA, 2000, BIOTECHNIQUES, V28, P148, DOI 10.2144/00281rr03; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Lascombe I, 1996, BIOTECHNIQUES, V20, P88; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Lundell A, 1999, CIRCULATION, V100, P2018, DOI 10.1161/01.CIR.100.19.2018; Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657; Merrick AF, 1996, TRANSPLANTATION, V62, P1085, DOI 10.1097/00007890-199610270-00011; Neptune ER, 1997, P NATL ACAD SCI USA, V94, P14489, DOI 10.1073/pnas.94.26.14489; Niebauer J, 1999, J AM COLL CARDIOL, V34, P1201, DOI 10.1016/S0735-1097(99)00304-6; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Tanner FC, 1997, CARDIOVASC RES, V35, P522, DOI 10.1016/S0008-6363(97)00151-X; Teifel M, 1997, ENDOTHELIUM-J ENDOTH, V5, P21, DOI 10.3109/10623329709044156; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Wrighton CJ, 1996, J EXP MED, V183, P1013, DOI 10.1084/jem.183.3.1013; WU LJ, 1995, J CELL BIOL, V129, P1667, DOI 10.1083/jcb.129.6.1667; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407	33	31	32	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2486	2494		10.1096/fj.00-0147com	http://dx.doi.org/10.1096/fj.00-0147com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11099466				2022-12-28	WOS:000165723400018
J	Viedt, C; Hansch, GM; Brandes, RP; Kubler, W; Kreuzer, J				Viedt, C; Hansch, GM; Brandes, RP; Kubler, W; Kreuzer, J			The terminal complement complex C5b-9 stimulates interleukin-6 production in human smooth muscle cells through activation of transcription factors NF-kappa B and AP-1	FASEB JOURNAL			English	Article									Univ Heidelberg, Inst Immunol, D-69115 Heidelberg, Germany; Univ Frankfurt, Inst Kardiovaskulare Physiol, D-6000 Frankfurt, Germany	Ruprecht Karls University Heidelberg; Goethe University Frankfurt	Kreuzer, J (corresponding author), Univ Heidelberg, Inst Immunol, Bergheimer Str 58, D-69115 Heidelberg, Germany.		Brandes, Ralf P/L-3058-2017	Brandes, Ralf P/0000-0002-8035-0048					0	76	84	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	2000	14	15					2370	2372						3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	380VD	11024008				2022-12-28	WOS:000165723400001
J	Janosch, P; Kieser, A; Eulitz, M; Lovric, J; Sauer, G; Reichert, M; Gounari, F; Buscher, D; Baccarini, M; Mischak, H; Kolch, W				Janosch, P; Kieser, A; Eulitz, M; Lovric, J; Sauer, G; Reichert, M; Gounari, F; Buscher, D; Baccarini, M; Mischak, H; Kolch, W			The Raf-1 kinase associates with vimentin kinases and regulates the structure of vimentin filaments	FASEB JOURNAL			English	Article						Raf; phosphorylation; cytoskeleton; casein kinase 2	DEPENDENT PROTEIN-KINASE; NIH 3T3 CELLS; INTERMEDIATE FILAMENTS; SIGNAL-TRANSDUCTION; IN-VITRO; V-RAF; PLASMA-MEMBRANE; PHOSPHORYLATION; ACTIVATION; DIFFERENTIATION	Using immobilized GST-Raf-1 as bait, we have isolated the intermediate filament protein vimentin as a Raf-1-associated protein. Vimentin coimmunoprecipitated and colocalized with Raf-1 in fibroblasts, Vimentin was not a Raf-1 substrate, but was phosphorylated by Raf-1-associated vimentin kinases, We provide evidence for at least two Raf-1-associated vimentin kinases and identified one as casein kinase 2. They are regulated by Raf-1, since the activation status of Raf-1 correlated with the phosphorylation of vimentin. Vimentin phosphorylation by Raf-1 preparations interfered with its polymerization in vitro. A subset of tryptic vimentin phosphopeptides induced by Raf-1. in vitro matched the vimentin phosphopeptides isolated from v-raf-transfected cells labeled with orthophosphoric acid, indicating that Raf-1 also induces vimentin phosphorylation in intact cells. In NIH 3T3 fibroblasts, the selective activation of an estrogen-regulated Raf-1 mutant induced a rearrangement and depolymerization of the reticular vimentin scaffold similar to the changes elicited by serum treatment. The rearrangement of the vimentin network occurred independently of the MEK/ERK pathway. These data identify a new branch point in Raf-1 signaling, which links Raf-1 to changes in the cytoskeletal architecture.	Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; GSF Forschungszentrum Umwelt & Gesundheit, Inst Klin Mol Biol & Tumorgenet, D-81377 Munich, Germany; Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland; Dana Farber Canc Inst, Boston, MA 02115 USA; Salk Inst Biol Studies, La Jolla, CA 92037 USA; Vienna Bioctr, Inst Microbiol & Genet, A-1030 Vienna, Austria; Hannover Med Sch, Dept Nephrol, D-30625 Hannover, Germany	Beatson Institute; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Lausanne; Harvard University; Dana-Farber Cancer Institute; Salk Institute; Vienna Biocenter (VBC); Hannover Medical School	Janosch, P (corresponding author), Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	pjanosch@beatson.gla.ac.uk	Admin, SBI/HGB-2738-2022; Baccarini, Manuela/B-6481-2014; Mischak, Harald/E-8685-2011; Kieser, Arnd/M-4616-2014; Kolch, Walter/ABF-2102-2021	Baccarini, Manuela/0000-0002-3033-391X; Kieser, Arnd/0000-0003-0783-1950; Kolch, Walter/0000-0001-5777-5016; Mischak, Harald/0000-0003-0323-0306; Lovric, Josip/0000-0002-0338-6581				ANDO S, 1989, BIOCHEMISTRY-US, V28, P2974, DOI 10.1021/bi00433a035; ANDO S, 1991, BIOCHEM BIOPH RES CO, V175, P955, DOI 10.1016/0006-291X(91)91658-Y; ANDO S, 1993, BIOCHEM BIOPH RES CO, V195, P837, DOI 10.1006/bbrc.1993.2121; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BAI WL, 1993, ONCOGENE, V8, P2207; BERTRAND F, 1994, AM J PHYSIOL, V266, pC611, DOI 10.1152/ajpcell.1994.266.3.C611; CAPETANAKI Y, 1989, J CELL BIOL, V109, P1653, DOI 10.1083/jcb.109.4.1653; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; CHOU YH, 1991, J BIOL CHEM, V266, P7325; CHOU YH, 1989, P NATL ACAD SCI USA, V86, P1885, DOI 10.1073/pnas.86.6.1885; CHOU YH, 1989, P NATL ACAD SCI USA, V86, P3214; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DENT P, 1995, MOL CELL BIOL, V15, P4125; EIDEN MV, 1991, MOL CELL BIOL, V11, P5321, DOI 10.1128/MCB.11.10.5321; ERIKSSON J E, 1992, Current Opinion in Cell Biology, V4, P99, DOI 10.1016/0955-0674(92)90065-K; ESCRIBANO J, 1988, J CELL PHYSIOL, V137, P223, DOI 10.1002/jcp.1041370204; Evans RM, 1998, BIOESSAYS, V20, P79, DOI 10.1002/(SICI)1521-1878(199801)20:1<79::AID-BIES11>3.3.CO;2-I; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GARD DL, 1982, MOL CELL BIOL, V2, P1104, DOI 10.1128/MCB.2.9.1104; GEISLER N, 1989, EUR J BIOCHEM, V183, P441, DOI 10.1111/j.1432-1033.1989.tb14947.x; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HEINS S, 1994, CURR OPIN CELL BIOL, V6, P25, DOI 10.1016/0955-0674(94)90112-0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; INAGAKI M, 1987, NATURE, V328, P649, DOI 10.1038/328649a0; Inagaki M, 1996, BIOESSAYS, V18, P481, DOI 10.1002/bies.950180610; Janosch P, 1996, J BIOL CHEM, V271, P13868, DOI 10.1074/jbc.271.23.13868; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KLYMKOWSKY MW, 1995, CURR OPIN CELL BIOL, V7, P46, DOI 10.1016/0955-0674(95)80044-1; Kolch W, 1996, ONCOGENE, V13, P1305; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KONDOH SK, 1993, FEBS LETT, V336, P255; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; KOUKLIS PD, 1993, J CELL SCI, V106, P919; KVRIAKIS JM, 1992, NATURE, V358, P417; LAMB NJC, 1989, J CELL BIOL, V108, P2409, DOI 10.1083/jcb.108.6.2409; LAZARIDES E, 1980, NATURE, V283, P249, DOI 10.1038/283249a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Lovric J, 1998, J BIOL CHEM, V273, P22848; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MISCHAK H, 1990, ONCOGENE, V5, P1377; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; NGAI J, 1984, J CELL BIOL, V99, P306, DOI 10.1083/jcb.99.1.306; OCONNOR CM, 1981, CELL, V23, P135, DOI 10.1016/0092-8674(81)90278-6; PAPAMARCAKI T, 1991, J BIOL CHEM, V266, P21247; PORRAS A, 1994, J BIOL CHEM, V269, P12741; Porras A, 1996, INT J OBESITY, V20, pS43; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SATOH Y, 1994, MUTAT RES, V316, P25, DOI 10.1016/0921-8734(94)90005-1; SHEA TB, 1993, J NEUROSCI RES, V36, P66, DOI 10.1002/jnr.490360108; SINGLETARY K, 1989, In Vivo (Attiki), V3, P173; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Takai Y, 1996, J CELL BIOL, V133, P141, DOI 10.1083/jcb.133.1.141; TRAUB P, 1994, INT REV CYTOL, V154, P1, DOI 10.1016/S0074-7696(08)62198-1; Turowski P, 1999, MOL BIOL CELL, V10, P1997, DOI 10.1091/mbc.10.6.1997; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WILLIAMS NG, 1994, CANCER METAST REV, V13, P105, DOI 10.1007/BF00690421; WYATT TA, 1991, J BIOL CHEM, V266, P21274; YEUNG K, 2000, IN PRESS MOL CELL BI; ZEH AK, 1997, NATURE, V385, P544	71	55	56	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2000	14	13					2008	2021		10.1096/fj.99-0883com	http://dx.doi.org/10.1096/fj.99-0883com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023985				2022-12-28	WOS:000089634400020
J	Miranda, SRP; He, XX; Simonaro, CM; Gatt, S; Dagan, A; Desnick, RJ; Schuchman, EH				Miranda, SRP; He, XX; Simonaro, CM; Gatt, S; Dagan, A; Desnick, RJ; Schuchman, EH			Infusion of recombinant human acid sphingomyelinase into Niemann-Pick disease mice leads to visceral, but not neurological, correction of the pathophysiology	FASEB JOURNAL			English	Article						lysosomal storage disease; enzyme therapy; animal models	INHERITED ENZYME DEFICIENCY; HAMSTER OVARY CELLS; MACROPHAGE-TARGETED GLUCOCEREBROSIDASE; REPLACEMENT THERAPY; NUCLEOTIDE-SEQUENCE; GAUCHERS-DISEASE; MAMMALIAN-CELLS; GENE; MUCOPOLYSACCHARIDOSIS; TRANSPLANTATION	An inherited deficiency of acid sphingomyelinase (ASM) activity results in the Type A and B forms of Niemann-Pick disease (NPD). Using the ASM-deficient mouse model (ASMKO) of NPD, we evaluated the efficacy of enzyme replacement therapy (ERT) for the treatment of this disorder. Recombinant human ASM (rhASM) was purified from the media of overexpressing Chinese Hamster ovary cells and i.v. injected into 16 five-month-old ASMKO mice at doses of 0.3, 1, 3, or 10 mg/kg every other day for 14 days (7 injections). On day 16, the animals were killed and the tissues were analyzed for their sphingomyelin (SPM) content. Notably, the SPM levels were markedly reduced in the hearts, livers, and spleens of these animals, and to a lesser degree in the lungs. Little or no substrate depletion was found in the kidneys or brains. Based on these results, three additional 5-month-old ASMKO animals were injected every other day with 5 mg/kg for 8 days (4 injections) and killed on day 10 for histological analysis. Consistent with the biochemical results, marked histological improvements were observed in the livers, spleens, and lungs, indicating a reversal of the disease pathology. A group of 10 ASMKO mice were then i.v. injected once a week with 1 mg/kg rhASM for 15 wk, starting at 3 wk of age. Although anti-rhASM antibodies were produced in these mice, the antibodies were not neutralizing and no adverse effects were observed from this treatment. Weight gain and rota-rod performance were slightly improved in the treated animals as compared with ASMKO control animals, but significant neurological deficits were still observed and their life span was not extended by ERT. In contrast with these CNS results, striking histological and biochemical improvements were found in the reticuloendothelial system organs (livers, spleens, and lungs). These studies indicate that ERT should be an effective therapeutic approach for Type B NPD, but is unlikely to prevent the severe neurodegeneration associated with Type A NPD.	Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Mt Sinai Sch Med, Inst Gene Therapy & Mol Med, New York, NY 10029 USA; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-92710 Jerusalem, Israel	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Hebrew University of Jerusalem	Schuchman, EH (corresponding author), Mt Sinai Sch Med, Dept Human Genet, 1425 Madison Ave,14-20A, New York, NY 10029 USA.				NCRR NIH HHS [RR0071] Funding Source: Medline; NICHD NIH HHS [HD28607, HD32654] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD028607] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028607, P01HD032654] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; BEUTLER E, 1995, BLOOD CELL MOL DIS, V21, P86, DOI 10.1006/bcmd.1995.0012; Bielicki J, 1999, J BIOL CHEM, V274, P36335, DOI 10.1074/jbc.274.51.36335; BRADY RO, 1974, NEW ENGL J MED, V291, P989, DOI 10.1056/NEJM197411072911901; BRADY RO, 1966, P NATL ACAD SCI USA, V55, P366, DOI 10.1073/pnas.55.2.366; BRADY RO, 1973, NEW ENGL J MED, V289, P9, DOI 10.1056/NEJM197307052890103; DEAN MF, 1973, NATURE-NEW BIOL, V243, P143, DOI 10.1038/newbio243143a0; DESNICK RJ, 1976, PHYSIOL REV, V56, P57, DOI 10.1152/physrev.1976.56.1.57; DESNICK RJ, 1979, P NATL ACAD SCI USA, V76, P5326, DOI 10.1073/pnas.76.10.5326; DIFERRANTE N, 1971, P NATL ACAD SCI USA, V68, P303; DINUR T, 1992, HUM GENE THER, V3, P633, DOI 10.1089/hum.1992.3.6-633; DUNHAM NM, 1957, J AM PHARM ASS, V46; He XX, 1999, BBA-PROTEIN STRUCT M, V1432, P251, DOI 10.1016/S0167-4838(99)00069-2; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; IOANNOU YA, 1992, J CELL BIOL, V119, P1137, DOI 10.1083/jcb.119.5.1137; JONES BJ, 1968, J PHARM PHARMACOL, V20, P302, DOI 10.1111/j.2042-7158.1968.tb09743.x; Kakkis ED, 1996, BIOCHEM MOL MED, V58, P156, DOI 10.1006/bmme.1996.0044; KAKKIS ED, 1994, PROTEIN EXPRES PURIF, V5, P225, DOI 10.1006/prep.1994.1035; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P537, DOI 10.1016/0076-6879(90)85044-O; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; Kikuchi T, 1998, J CLIN INVEST, V101, P827, DOI 10.1172/JCI1722; Matsuura F, 1998, GLYCOBIOLOGY, V8, P329, DOI 10.1093/glycob/8.4.329; Miranda SRP, 1998, TRANSPLANTATION, V65, P884, DOI 10.1097/00007890-199804150-00005; Miranda SRP, 1997, BLOOD, V90, P444; Neufeld E F, 1980, Birth Defects Orig Artic Ser, V16, P77; NEUFELD EF, 1975, ANNU REV BIOCHEM, V44, P357, DOI 10.1146/annurev.bi.44.070175.002041; O'Connor LH, 1998, J CLIN INVEST, V101, P1394, DOI 10.1172/JCI1773; OTTERBACH B, 1995, CELL, V81, P1053, DOI 10.1016/S0092-8674(05)80010-8; QUINTERN LE, 1989, EMBO J, V8, P2469, DOI 10.1002/j.1460-2075.1989.tb08382.x; ROSENTHAL DI, 1995, PEDIATRICS, V96, P629; ROUSSEAU A, 1986, ARCH BIOCHEM BIOPHYS, V244, P838, DOI 10.1016/0003-9861(86)90653-3; Schissel SL, 1998, J BIOL CHEM, V273, P18250, DOI 10.1074/jbc.273.29.18250; Schissel SL, 1996, J BIOL CHEM, V271, P18431, DOI 10.1074/jbc.271.31.18431; SCHNEIDER PB, 1967, J LIPID RES, V8, P202; SCHUCHMAN EH, 1992, GENOMICS, V12, P197, DOI 10.1016/0888-7543(92)90366-Z; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; Schuchman EHDR, 1995, METABOLIC MOL BASIS, V7th, P2601; STEIN S, 1973, ARCH BIOCHEM BIOPHYS, V155, P202, DOI 10.1016/S0003-9861(73)80022-0; Verderese C L, 1993, J Neurosci Nurs, V25, P296	39	96	111	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	OCT	2000	14	13					1988	1995		10.1096/fj.00-0014com	http://dx.doi.org/10.1096/fj.00-0014com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023983	Green Submitted			2022-12-28	WOS:000089634400018
J	Partanen, TA; Arola, J; Saaristo, A; Jussila, L; Ora, A; Miettinen, M; Stacker, SA; Achen, MG; Alitalo, K				Partanen, TA; Arola, J; Saaristo, A; Jussila, L; Ora, A; Miettinen, M; Stacker, SA; Achen, MG; Alitalo, K			VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues	FASEB JOURNAL			English	Article						growth substance; receptor tyrosine kinase; vascular endothelium	ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; LYMPHATIC ENDOTHELIUM; TYROSINE KINASES; FACTOR FAMILY; IN-VITRO; TUMORS; ANGIOGENESIS; PATTERN; BINDING	Recently, vascular endothelial growth factor receptor 3 (VEGFR-3) has been shown to provide a specific marker for lymphatic endothelia in certain human tissues. In this study, we have investigated the expression of VEGFR-3 and its ligands VEGF-C and VEGF-D in fetal and adult tissues. VEGFR-3 was consistently detected in the endothelium of lymphatic vessels such as the thoracic duct, but fenestrated capillaries of several organs including the bone marrow, splenic and hepatic sinusoids, kidney glomeruli and endocrine glands also expressed this receptor. VEGF-C and VEGF-D, which bind both VEGFR-2 and VEGFR-3 were expressed in vascular smooth muscle cells. In addition, intense cytoplasmic staining for VEGF-C was observed in neuroendocrine cells such as the alpha cells of the islets of Langerhans, prolactin secreting cells of the anterior pituitary, adrenal medullary cells, and dispersed neuroendocrine cells of the gastrointestinal tract. VEGF-D was observed in the innermost zone of the adrenal cortex and in certain dispersed neuroendocrine cells. These results suggest that VEGF-C and VEGF-D have a paracrine function and perhaps a role in peptide release from secretory granules of certain neuroendocrine cells to surrounding capillaries.	Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland; Univ Helsinki, Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland; Armed Forces Inst Pathol, Dept Soft Tissue Pathol, Washington, DC 20306 USA; Royal Melbourne Hosp, Melbourne Tumour Biol Branch, Ludwig Inst Canc Res, Angiogenesis Lab, Parkville, Vic 3050, Australia	University of Helsinki; University of Helsinki; United States Department of Defense; Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Alitalo, K (corresponding author), Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, Haartmaninkatu 3, FIN-00014 Helsinki, Finland.	Kari.Alitalo@Helsinki.fi	ora, ari/P-5180-2015; Alitalo, Kari K/J-5013-2014; Broth, Taina/M-2397-2019	Alitalo, Kari K/0000-0002-7331-0902; Achen, Marc/0000-0002-3791-803X; Stacker, Steven/0000-0003-4096-9273				Achen MG, 2000, EUR J BIOCHEM, V267, P2505, DOI 10.1046/j.1432-1327.2000.01257.x; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Avantaggiato V, 1998, MECH DEVELOP, V73, P221, DOI 10.1016/S0925-4773(98)00049-5; Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; Breiteneder-Geleff S, 1999, AM J PATHOL, V154, P385, DOI 10.1016/S0002-9440(10)65285-6; BreitenederGeleff S, 1997, AM J PATHOL, V151, P1141; Cao YH, 1996, J BIOL CHEM, V271, P3154, DOI 10.1074/jbc.271.6.3154; CHRISTY AA, 1995, VIB SPECTROSC, V9, P1, DOI 10.1016/0924-2031(95)90021-7; Damsky CH, 1998, CURR OPIN CELL BIOL, V10, P660, DOI 10.1016/S0955-0674(98)80043-4; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; Esser S, 1998, J CELL BIOL, V140, P947, DOI 10.1083/jcb.140.4.947; Farnebo F, 1999, BIOCHEM BIOPH RES CO, V257, P891, DOI 10.1006/bbrc.1999.0562; FERRARA N, 1991, METHOD ENZYMOL, V198, P391; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; Guy L, 1998, BRIT J UROL, V82, P738; Jabbour HN, 1997, MOL CELL ENDOCRINOL, V134, P91, DOI 10.1016/S0303-7207(97)00158-5; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Joukov V, 1998, J BIOL CHEM, V273, P6599, DOI 10.1074/jbc.273.12.6599; Joukov V, 1996, EMBO J, V15, P290; Jussila L, 1998, CANCER RES, V58, P1599; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kukk E, 1996, DEVELOPMENT, V122, P3829; KURODA M, 1995, J CLIN ENDOCR METAB, V80, P3196, DOI 10.1210/jc.80.11.3196; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; Lymboussaki A, 1998, AM J PATHOL, V153, P395, DOI 10.1016/S0002-9440(10)65583-6; Marconcini L, 1999, P NATL ACAD SCI USA, V96, P9671, DOI 10.1073/pnas.96.17.9671; Orlandini M, 1996, P NATL ACAD SCI USA, V93, P11675, DOI 10.1073/pnas.93.21.11675; Partanen TA, 1999, CANCER-AM CANCER SOC, V86, P2406, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2406::AID-CNCR31>3.3.CO;2-5; PLATE KH, 1994, BRAIN PATHOL, V4, P207, DOI 10.1111/j.1750-3639.1994.tb00835.x; Ross MH., 1995, HISTOLOGY TEXT ATLAS, V3; Sabin FR, 1902, AM J ANAT, V1, P367, DOI 10.1002/aja.1000010310; Salven P, 1998, AM J PATHOL, V153, P103, DOI 10.1016/S0002-9440(10)65550-2; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Simon M, 1998, J AM SOC NEPHROL, V9, P1032; Terris B, 1998, HISTOPATHOLOGY, V32, P133; Tsurusaki T, 1999, BRIT J CANCER, V80, P309, DOI 10.1038/sj.bjc.6690356; Valtola R, 1999, AM J PATHOL, V154, P1381, DOI 10.1016/S0002-9440(10)65392-8; Vuorela P, 1997, BIOL REPROD, V56, P489, DOI 10.1095/biolreprod56.2.489; Wigle JT, 1999, CELL, V98, P769, DOI 10.1016/S0092-8674(00)81511-1; Wilting J, 1997, CELL TISSUE RES, V288, P207, DOI 10.1007/s004410050807; Witzenbichler B, 1998, AM J PATHOL, V153, P381, DOI 10.1016/S0002-9440(10)65582-4; Yamada Y, 1997, GENOMICS, V42, P483, DOI 10.1006/geno.1997.4774	44	263	292	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2000	14	13					2087	2096		10.1096/fj.99-1049com	http://dx.doi.org/10.1096/fj.99-1049com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	359WE	11023993				2022-12-28	WOS:000089634400028
J	Sengenes, C; Berlan, M; De Glisezinski, I; Lafontan, M; Galitzky, J				Sengenes, C; Berlan, M; De Glisezinski, I; Lafontan, M; Galitzky, J			Natriuretic peptides: a new lipolytic pathway in human adipocytes	FASEB JOURNAL			English	Article						human fat cells; ANP; BNP; lipolysis; microdialysis	FAT-CELL FUNCTION; ADIPOSE-TISSUE; CLEARANCE RECEPTOR; PROTEIN-KINASE; CYCLIC-AMP; PHOSPHODIESTERASES; INSULIN; LOCALIZATION; ACTIVATION; EXPRESSION	Atrial natriuretic peptide (ANP) receptors have been described on rodent adipocytes and expression of their mRNA is found in human adipose tissue. However, no biological effects associated with the stimulation of these receptors have been reported in this tissue. A putative lipolytic effect of natriuretic peptides was investigated in human adipose tissue. On isolated fat cells, ANP and brain natriuretic peptide (BNP) stimulated lipolysis as much as isoproterenol, a nonselective beta-adrenergic receptor agonist, whereas C-type natriuretic peptide (CNP) had the lowest lipolytic effect. In situ microdialysis experiments confirmed the potent lipolytic effect of ANP in abdominal s.c. adipose tissue of healthy subjects. A high level of ANP binding sites was identified in human adipocytes. The potency order defined in lipolysis (ANP > BNP > CNP) and the ANP-induced cGMP production sustained the presence of type A natriuretic peptide receptor in human fat cells. Activation or inhibition of cGMP-inhibited phosphodiesterase (PDE-3B) (using insulin and OPC 3911, respectively) did not modify ANP-induced lipolysis whereas the isoproterenol effect was decreased or increased. Moreover, inhibition of adenylyl cyclase activity (using a mixture of alpha(2)-adrenergic and adenosine A1 agonists receptors) did not change ANP- but suppressed isoproterenol-induced lipolysis. The noninvolvement of the PDE-3B was finally confirmed by measuring its activity under ANP stimulation. Thus, we demonstrate that natriuretic peptides are a new pathway controlling human adipose tissue lipolysis operating via a cGMP-dependent pathway that does not involve PDE-3B inhibition and cAMP production.	Fac Med Toulouse, INSERM, U317, Lab Pharmacol Med & Clin, F-31073 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Galitzky, J (corresponding author), Fac Med Toulouse, INSERM, U317, Lab Pharmacol Med & Clin, 37 Allees Jules Guesde, F-31073 Toulouse, France.	galizky@cict.fr	Sengenes, Coralie/GSN-0709-2022; Galitzky, Jean/R-6599-2017	de Glisezinski, Isabelle/0000-0002-3166-549X; Sengenes, Coralie/0000-0002-4820-6660				ANANDSRIVASTAVA MB, 1990, J BIOL CHEM, V265, P8566; ATHONSEN MW, 1998, J BIOL CHEM, V273, P215; BERLAN M, 1980, J PHYSIOL-PARIS, V76, P133; BRADLEY DC, 1989, ANAL BIOCHEM, V180, P11, DOI 10.1016/0003-2697(89)90081-X; DEBOLD AJ, 1981, LIFE SCI, V28, P89, DOI 10.1016/0024-3205(81)90370-2; Degerman E, 1997, J BIOL CHEM, V272, P6823, DOI 10.1074/jbc.272.11.6823; Degerman E, 1996, BIOCHEM SOC T, V24, P1010, DOI 10.1042/bst0241010; DELEON H, 1995, CIRC RES, V77, P64, DOI 10.1161/01.RES.77.1.64; GSKE R, 1989, BIOMED RES, V10, P463; JEANDEL L, 1989, MOL CELL ENDOCRINOL, V62, P69, DOI 10.1016/0303-7207(89)90114-7; LAFONTAN M, 1993, J LIPID RES, V34, P1057; LAFONTAN M, 1995, ENDOCR REV, V16, P716, DOI 10.1210/er.16.6.716; LEVIN ER, 1993, AM J PHYSIOL, V264, pE483, DOI 10.1152/ajpendo.1993.264.4.E483; LONDOS C, 1980, P NATL ACAD SCI-BIOL, V77, P2551, DOI 10.1073/pnas.77.5.2551; Maack Thomas, 1995, P1001; MANGANIELLO V, 1988, METHOD ENZYMOL, V159, P504; MANGANIELLO VC, 1992, ADV SEC MESS PHOSPH, V25, P147; Manganiello VC, 1996, CURR TOP CELL REGUL, V34, P63, DOI 10.1016/S0070-2137(96)80003-3; Millet L, 1998, J APPL PHYSIOL, V85, P181, DOI 10.1152/jappl.1998.85.1.181; Pandey KN, 1996, ENDOCRINOLOGY VASCUL, P255, DOI [10.1007/978-1-4612-0231-8_19, DOI 10.1007/978-1-4612-0231-8_19]; Patel AI, 1997, J PHARMACOL EXP THER, V283, P894; RODBELL M, 1964, J BIOL CHEM, V239, P375; Sarzani R, 1996, J ENDOCRINOL INVEST, V19, P581; Sarzani R, 1995, J HYPERTENS, V13, P1241, DOI 10.1097/00004872-199511000-00004; SCAVONE C, 1995, J PHARMACOL EXP THER, V272, P1036; STRALFORS P, 1985, FEBS LETT, V180, P280, DOI 10.1016/0014-5793(85)81086-3; SUDOH T, 1990, BIOCHEM BIOPH RES CO, V168, P863, DOI 10.1016/0006-291X(90)92401-K; SUDOH T, 1988, NATURE, V332, P78, DOI 10.1038/332078a0; Thibault G, 1996, LIFE SCI, V58, P2345, DOI 10.1016/0024-3205(96)00235-4; UEHLINGER DE, 1986, J CARDIOVASC PHARM, V8, P1122, DOI 10.1097/00005344-198611000-00005	30	380	395	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2000	14	10					1345	1351		10.1096/fj.14.10.1345	http://dx.doi.org/10.1096/fj.14.10.1345			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	329WV	10877827				2022-12-28	WOS:000087932200009
J	Ullrich, O; Diestel, A; Bechmann, I; Homberg, M; Grune, T; Hass, R; Nitsch, R				Ullrich, O; Diestel, A; Bechmann, I; Homberg, M; Grune, T; Hass, R; Nitsch, R			Turnover of oxidatively damaged nuclear proteins in BV-2 microglial cells is linked to their activation state by poly(ADP-ribose)polymerase	FASEB JOURNAL			English	Article						oxidative stress; proteasome; protein degradation; tumor necrosis factor-alpha; antioxidative protection	ADHESION MOLECULE EXPRESSION; ADP-RIBOSE-POLYMERASE; OXIDIZED PROTEINS; INTERFERON-GAMMA; ASTROCYTES; PROTEASOME; 20S; DIFFERENTIATION; DEGRADATION; MODULATION	During neuroinflammation, activated microglial cells migrate to the sites of neuronal injury, phagocytose neighboring cells, and produce large amounts of oxygen free radicals, which might contribute to severe cell damage and death. It is interesting that microglial cells have withstood this cytotoxic action of free radicals, which indicates that there is an intracellular mechanism that apparently enables microglial cells to cope with such oxidative challenges. In this study, we investigated the capability of BV-2 murine microglial cells to cope with oxidatively damaged proteins by the proteasomal proteolytic system. To induce a highly activated state, we used the proinflammatory cytokine tumor necrosis factor-alpha, which acts as a priming signal for microglial superoxide radical production. We showed that activation of the nuclear enzyme poly(ADPribose)polymerase (PARP) enabled activated microglial cells to resist oxidative damage by an up-regulation of the nuclear proteasome. Activated microglial cells revealed an efficient recognition and degradation of oxidatively damaged proteins during an enhanced endogenous protein turnover. The impairment of PARP function by inhibitor or antisense experiments resulted in an accumulation of damaged proteins and subsequently cell death. In contrast, this was not the case in resting microglial cells. These findings demonstrate the crucial role of the PARP in microglial cell survival during activation and renders it a potential anti-inflammatory target.	Humboldt Univ, Fac Med Charite, Dept Cell & Neurobiol, Inst Anat, D-10098 Berlin, Germany; Humboldt Univ, Fac Med Charite, Neurosci Res Ctr, D-10098 Berlin, Germany; Hannover Med Sch, Oststadtkrankenhaus, Clin Obstet & Gynecol OE 6410, Dept Biochem & Tumor Biol, D-30659 Hannover, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Hannover Medical School	Ullrich, O (corresponding author), Humboldt Univ, Fac Med Charite, Inst Anat, Dept Cell & Neurobiol, Philippstr 12, D-10115 Berlin, Germany.	oliver.ullrich@charite.de	Nitsch, Robert/AAI-9129-2021; Hass, Ralf/F-3197-2012	Hass, Ralf/0000-0002-2481-7547; Gimsa, Ulrike/0000-0003-2248-5793; Grune, Tilman/0000-0003-4775-9973				AKIYAMA H, 1993, ACTA NEUROPATHOL, V85, P628, DOI 10.1007/BF00334673; Bechmann I, 1997, GLIA, V20, P145, DOI 10.1002/(SICI)1098-1136(199706)20:2<145::AID-GLIA6>3.0.CO;2-8; Bhatia M, 1996, CELL GROWTH DIFFER, V7, P91; Bruce-Keller AJ, 1999, J NEUROSCI RES, V58, P191, DOI 10.1002/(SICI)1097-4547(19991001)58:1<191::AID-JNR17>3.0.CO;2-E; CANTONI O, 1989, BIOCHIM BIOPHYS ACTA, V1014, P1, DOI 10.1016/0167-4889(89)90234-6; COLTON CA, 1987, FEBS LETT, V223, P284, DOI 10.1016/0014-5793(87)80305-8; DEMURCIA G, 1991, BIOESSAYS, V13, P455, DOI 10.1002/bies.950130905; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; EMIG S, 1995, J BIOL CHEM, V270, P13787, DOI 10.1074/jbc.270.23.13787; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; Grune T, 1997, BIOFACTORS, V6, P165, DOI 10.1002/biof.5520060210; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; Grune T, 1996, J BIOL CHEM, V271, P15504, DOI 10.1074/jbc.271.26.15504; Hailer NP, 1996, GLIA, V18, P319, DOI 10.1002/(SICI)1098-1136(199612)18:4<319::AID-GLIA6>3.0.CO;2-S; Hailer NP, 1997, HIPPOCAMPUS, V7, P341, DOI 10.1002/(SICI)1098-1063(1997)7:3<341::AID-HIPO8>3.0.CO;2-N; Heppner FL, 1998, GLIA, V22, P180, DOI 10.1002/(SICI)1098-1136(199802)22:2<180::AID-GLIA9>3.0.CO;2-B; HOUGH R, 1987, J BIOL CHEM, V262, P8303; HU SX, 1995, GLIA, V13, P45, DOI 10.1002/glia.440130106; Jeggo PA, 1998, CURR BIOL, V8, pR49, DOI 10.1016/S0960-9822(98)70032-6; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; KIRSTEN E, 1991, EXP CELL RES, V194, P1, DOI 10.1016/0014-4827(91)90122-B; Kleczkowska HE, 1996, MUTAT RES-FUND MOL M, V358, P215, DOI 10.1016/S0027-5107(96)00123-6; KREUTZBERG GW, 1995, ARZNEIMITTEL-FORSCH, V45-1, P357; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LEE SC, 1993, J IMMUNOL, V150, P594; Leist P, 1996, FREE RADICAL BIO MED, V21, P297, DOI 10.1016/0891-5849(96)00045-7; Lindenau J, 1998, GLIA, V24, P252, DOI 10.1002/(SICI)1098-1136(199810)24:2<252::AID-GLIA10>3.0.CO;2-Z; Lo EH, 1998, STROKE, V29, P830, DOI 10.1161/01.STR.29.4.830; Mayer-Kuckuk P, 1999, BIOCHEM BIOPH RES CO, V259, P576, DOI 10.1006/bbrc.1999.0824; MAZEN A, 1989, NUCLEIC ACIDS RES, V17, P4589; MESSMER UK, 1995, MOL PHARMACOL, V47, P757; NIETOSAMPEDRO M, 1985, BRAIN RES, V343, P320, DOI 10.1016/0006-8993(85)90750-4; NITSCH R, 1993, HIPPOCAMPUS, V3, P247; Noack H, 1998, GLIA, V23, P285, DOI 10.1002/(SICI)1098-1136(199808)23:4<285::AID-GLIA1>3.0.CO;2-2; Paris D, 2000, NEUROSCI LETT, V278, P5, DOI 10.1016/S0304-3940(99)00901-5; PERRY VH, 1993, GLIA, V7, P60, DOI 10.1002/glia.440070111; Reinheckel T, 2000, ARCH BIOCHEM BIOPHYS, V377, P65, DOI 10.1006/abbi.2000.1717; REZNICK AZ, 1994, METHOD ENZYMOL, V233, P357; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; Schubert P, 1998, ALZ DIS ASSOC DIS, V12, pS21; STEWARD O, 1993, EXP NEUROL, V124, P167, DOI 10.1006/exnr.1993.1187; Stohwasser R, 2000, GLIA, V29, P355, DOI 10.1002/(SICI)1098-1136(20000215)29:4<355::AID-GLIA6>3.0.CO;2-4; Sugaya K, 1997, NEUROREPORT, V8, P2241, DOI 10.1097/00001756-199707070-00030; Takahashi K, 1999, BRAIN RES, V829, P46, DOI 10.1016/S0006-8993(99)01335-9; TOMODA T, 1992, BIOCHIM BIOPHYS ACTA, V1135, P79, DOI 10.1016/0167-4889(92)90169-C; Ullrich O, 2000, FREE RADICAL BIO MED, V29, P995, DOI 10.1016/S0891-5849(00)00399-3; Ullrich O, 1999, ARCH BIOCHEM BIOPHYS, V362, P211, DOI 10.1006/abbi.1998.1031; Ullrich O, 1999, P NATL ACAD SCI USA, V96, P6223, DOI 10.1073/pnas.96.11.6223; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; ZIELASEK J, 1993, NEUROSCI LETT, V153, P136, DOI 10.1016/0304-3940(93)90306-6; ZWILLING S, 1995, EMBO J, V14, P1198, DOI 10.1002/j.1460-2075.1995.tb07103.x	51	102	103	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1460	+		10.1096/fj.00-0540fje	http://dx.doi.org/10.1096/fj.00-0540fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11292676				2022-12-28	WOS:000173705800009
